EP1957487A1 - Novel pyridopyrazines and their use as modulators of kinases - Google Patents

Novel pyridopyrazines and their use as modulators of kinases

Info

Publication number
EP1957487A1
EP1957487A1 EP06819385A EP06819385A EP1957487A1 EP 1957487 A1 EP1957487 A1 EP 1957487A1 EP 06819385 A EP06819385 A EP 06819385A EP 06819385 A EP06819385 A EP 06819385A EP 1957487 A1 EP1957487 A1 EP 1957487A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
heterocyclyl
group
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06819385A
Other languages
German (de)
French (fr)
Inventor
Eckhard Claus
Irene Seipelt
Eckhard Günther
Emmanuel Polymeropoulos
Michael Czech
Tilmann Schuster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Aeterna Zentaris GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05024693A external-priority patent/EP1785423A1/en
Application filed by Aeterna Zentaris GmbH filed Critical Aeterna Zentaris GmbH
Priority to EP06819385A priority Critical patent/EP1957487A1/en
Publication of EP1957487A1 publication Critical patent/EP1957487A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Definitions

  • Novel pyridopyrazines and their use as modulators of kinases are novel pyridopyrazines and their use as modulators of kinases.
  • the invention relates to kinase modulators of the pyrido [2,3-b] pyrazine type, to their preparation and use as medicaments for modulating misdirected cellular signal transduction processes, in particular for influencing the function of tyrosine, serine / threonine and lipid kinases and to Treatment of malignant or benign tumors and other diseases based on pathological cell proliferation diseases such.
  • the phosphorylation of proteins is generally initiated by extracellular signals and provides a universal mechanism for the control of various cellular events, such as cell proliferation. As metabolic processes, cell growth, cell migration, cell differentiation, membrane transport and apoptosis. For protein phosphorylation, the protein family of kinases is responsible. These enzymes catalyze the phosphate transfer to specific substrate proteins. Based on substrate specificity, the kinases are divided into three major classes, the tyrosine kinases, the serine / threonine kinases, and the lipid kinases.
  • Both the receptor tyrosine kinases and the cytoplasmic tyrosine, serine / threonine and lipid kinases are important proteins of the signal transduction of the cell. Overexpression or degeneration of these proteins plays an important role in disorders based on pathological cell proliferation. These include metabolic diseases, connective tissue and blood vessel diseases, as well as malignant and benign tumors. They occur in tumor development and development often as oncogenes, ie as aberrant, constitutively active kinase proteins. The consequences of this excessive Kinaseeducation ist are z. For example, uncontrolled cell growth and reduced cell death. The stimulation of tumor-induced growth factors can also be the cause of the overstimulation of kinases. The development of kinase modulators is therefore of particular interest for all pathogenic processes that are influenced by kinases.
  • diseases such as cancer, neurodegeneration and inflammatory diseases
  • the individual components of these signaling cascades represent important therapeutic targets for the intervention of the various disease processes (Weinstein-Oppenheimer CR et al 2000, Chang F. et al., 2003, Katso R. et al., 2001 and Lu Y. et al., 2003).
  • a variety of growth factors, cytokines and oncogenes transduce their growth-promoting signals via activation of G-protein coupled ras, which is used to activate the serine-threonine kinase Raf and to activate mitogen-activated protein kinase kinase 1 and 2 (MAPKK1 / 2 or Mek1 / 2) and in the phosphorylation and activation of MAPK 1 and 2 - also known as Extracellular Signal Regulated Kinase (Erk1 and 2).
  • G-protein coupled ras which is used to activate the serine-threonine kinase Raf and to activate mitogen-activated protein kinase kinase 1 and 2 (MAPKK1 / 2 or Mek1 / 2) and in the phosphorylation and activation of MAPK 1 and 2 - also known as Extracellular Signal Regulated Kinase (Erk1 and 2).
  • the ras-Raf-Mek-Erk pathway combines a large number of proto-oncogenes, including ligands, tyrosine kinase receptors, G proteins, kinases, and nuclear transcription factors.
  • Tyrosine kinases such as EGFR (Menelsohn J. et al., 2000) often mediate constitutive active signals to the downstream ras-Raf-Mek- Erk signaling pathway in tumors due to overexpression and mutation. Ras mutations are mutated in 30% of all human tumors (Khleif SN et al., 1999, Marshall C, 1999), the highest incidence being 90% in pancreatic carcinomas (Friess H.
  • Raf kinases also have Mek-Erk independent, anti-apoptotic functions, whose molecular steps are not yet fully described.
  • Ask1, Bcl-2, Akt and Bag1 have been described as possible interaction partners for the Mek-Erk-independent Raf activity (Chen J et al., 2001, Troppajier J. et al., 2003, Rapp UR et al., 2004, Gotz R. et al., 2005). It is now believed that both Mek-Erk-dependent and Mek-Erk-independent signal transduction mechanisms control the activation of the ras and Raf stimuli located above.
  • the isoenzymes of phosphatidylinositol 3-kinases function predominantly as lipid kinases and catalyze the D3 phosphorylation of second messenger lipids Ptdlns (phosphatidylinositol) to Ptdlns (3) P, Ptdlns (3,4) P 2 , Ptdlns (3,4 , 5) P 3 phosphatidylinositol phosphates.
  • the class I PI3Ks are structurally composed of the catalytic (pHOalpha, beta, gamma, delta) and regulatory (p85alpha, beta or p101gamma) subunits.
  • class II (PI3K-C2alpha, PI3K-C2beta) and class IN (Vps34p) enzymes belong to the family of PI3 kinases (Wymann MP et al., 1998, Van Haesebroeck B. et al., 2001).
  • the PIP increase triggered by PI3Ks activates the proliferative ras-Raf-Mek-Erk signaling pathway via the coupling of ras (Rodriguez-Viciana P.
  • PI3Ks fulfills at least 2 crucial mechanisms of tumorigenesis, namely the activation of cell growth and cell differentiation and the inhibition of apoptosis.
  • the PI3K also have protein-phosphorylating properties (Dhand et al., 1994, Bondeva T. et al., 1998, Bondev A. et al., 1999, Van Haesebroeck B.
  • PI3Ks also have kinase-independent, regulatory effector properties, for example in the control of cardiac contraction (Crackower - A -
  • PI3Kdelta and PI3Kgamma are specifically expressed on hematopoietic cells and thus potential targets for isoenzyme-specific PI3Kdelta and PI3Kgamma inhibitors in the treatment of inflammatory diseases such as rheumatism, asthma and allergies and in the treatment of B- and T- Cell lymphomas (Okkenhaug K. et al., 2003, Ali K. et al., 2004, Sujobert P. et al., 2005).
  • PI3Kalpha which has recently been identified as a proto-oncogene (Shayesteh L.
  • PI3K-related kinases include the serine / threonine kinases mTOR, ATM, ATR, h-SMG-1, and DNA-PK (Chiang G.G. et al., 2004).
  • PIKK PI3K-related kinases
  • Their catalytic domains have high sequence homology to the catalytic domain of the PI3Ks.
  • Phosphorylation contributes to the overactivation of Akt and its downstream cascade components, thus underlining the causal role of PI3K as a target for tumor therapy.
  • the kinase inhibitor Bay 43-9006 (WO 99/32111, WO 03/068223) already in clinical trials shows a relatively nonspecific inhibition pattern of serine / threonine and tyrosine kinases such as Raf, VEGFR2 / 3, Flt-3 , PDGFR, c-Kit and other kinases.
  • This inhibitor is of great importance in angiogenesis-induced advanced tumor diseases (eg in renal cell carcinoma) but also in melanomas with a high B-Raf mutation rate.
  • the clinical effect of Bay 43-9006 is currently also being investigated in patients with refractory solid tumors in combination with eg docetaxel. So far, mild side effects and promising anti-tumoral effects have been described. Inhibition of the kinases in the PI3K-Akt signaling pathway is not described or disclosed for Bay 43-9006.
  • the Mek1 / 2 inhibitor PD0325901 (WO 02/06213) is currently undergoing Phase I clinical trials.
  • the precursor CM 040 (WO 00/35435, WO 00/37141) was noted for its high Mek specificity and target affinity , However, this compound proved to be metabolically unstable in Phase I / II studies.
  • Clinical data of the current successor substance PD0325901 are pending. However, neither an interaction with Erk1 or Erk2, nor a PI3K-Akt signaling pathway inhibiting function or its simultaneous modulation is published or disclosed for this Mek inhibitor.
  • ICOS disclosed a PI3K inhibitor IC87114 with high PI3Kdelta isoenzyme specificity (WO 01/81346).
  • PI103 Yamanouchi / Piramed describe a selectivity versus the PI3Kalpha isoform.
  • a highly regarded research environment exists (see review R. Wetzker et al., 2004).
  • Inhibitors of the SAPK signaling pathway are described in the literature (Gum RJ., 1998, Bennett BL et al 2001, Davies SP et al 2000). However, for these SAPK inhibitors, no PI3Ks-inhibiting function and also no specific inhibition of Erk1 or Erk2 or simultaneous inhibition of SAPKs, Erk1, Erk2, or PI3Ks is disclosed. In the 6- or 7-position substituted pyrido [2,3-b] pyrazine derivatives are widely used as pharmacologically active compounds and as building blocks in pharmaceutical chemistry.
  • patents WO 04/104002 and WO 04/104003 describe pyrido [2,3-b] pyrazines, which may be substituted in the 6- or 7-position by urea, thiourea, amidine or guanidine groups. These compounds possess properties as inhibitors or modulators of kinases, in particular of tyrosine and serine / threonine kinases, and a use as medicaments is indicated. In contrast, a use of these compounds as modulators of lipid kinases, alone or in combination with tyrosine and serine / threonine kinases, is not described.
  • patent WO 99/17759 describes pyrido [2,3-b] pyrazines which carry, inter alia, alkyl, aryl and heteroaryl-substituted carbamates in the 6-position. These compounds will be used to modulate the function of serine-threonine protein kinases.
  • 6- and 7-position urea-substituted pyrido [2,3-b] pyrazines are given in the patent WO 05/056547 (Bemis et al.).
  • the compounds in this patent have additional carbonyl, sulfoxy, sulfonic or imine substitution in the 2- or 3-position, whereby the compounds are structurally distinct from the pyrido [2,3-b] pyrazines of the invention described in this invention differ.
  • the pyridopyrazines indicated in WO 05/056547 are described as inhibitors of protein kinases, in particular of GSK-3, Syk and JAK-3.
  • the invention is therefore directed to providing novel compounds which are useful as modulators of receptor tyrosine kinases, cytoplasmic tyrosine, serine / threonine kinases and lipid kinases. Since not all in dysregulated signal transduction cascades connected in series kinases - such. For example, in Raf-Mek-Erk or PI3K-Akt - must be present as oncogenic kinases or as constitutively active enzymes, in this invention, the non-active kinases are considered as therapeutic target proteins, i. The new compounds can bind to both active and non-active kinases, thereby influencing signal transduction.
  • the invention is further directed to providing novel compounds which possess as a modulator of receptor tyrosine kinases, cytoplasmic tyrosine, serine / threonine kinases and lipid kinases the property of both a single and two or more kinases, in particular Erk1 / 2 and PI3K, from one or several signal transduction cascades, in particular ras Raf Mek Erk and PI3K act to influence.
  • a dual mechanism, i. H. the simultaneous inhibition of two or more signal-induction cascades in comparison to the therapeutic attack of only one signal transduction pathway should lead to an increase in the effect in the treatment of all pathogenic processes which are influenced by kinases.
  • a first aspect of the present application describes novel compounds from the series of pyrido [2,3-b] pyrazines according to the general formula (I),
  • radicals Z3, Z4 or both radicals Z3, Z4 is independently “substituted aryl", where "substituted aryl" is substituted by at least one substituent, identical or different, selected from the group consisting of:
  • Substituted aryl is substituted with “heterocyclylalkyl", the other radical Z3 or Z4 is not “substituted or unsubstituted aryl", where optionally additionally one of the radicals Z3, Z4 or additionally both radicals Z3, Z4 can also be further substituted independently of one another with min. at least one substituent, identical or different, selected from the group consisting of:
  • X124, X125, X126, X127, X128, X129, X130, X131, X132, X133, X134, X135, X136, X137, X138, X139, X140, X141, X142, X143, X144, X145, X146, X147, X148, x149, X150, X151, X152, x153 are X154 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively, X109, X110 and / or X1 18, X119 and / or X131, X132 and / or X138, X139 and / or X147,
  • alkyl "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHX155, -NX156X157, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -
  • OS OS (O 2) -X177, -NHC (O) -XI78, -NX179C (O) -XI80, -NH-C (O) -O- X181, -NH-C (O) -NH-XI82, -NH -C (O) -NXI83X184, -NX185-C (O) - O-X186, -NX187-C (O) -NH-XI88, -NX189-C (O) -NXI90X191, - NHS (O 2) -X192 , -NX193S (O 2) -X194, -S-x195, -S (O) -XI96, -S (O 2) - X197, -S (O 2) NH-XI 98, -S (O 2) NXI 99X200, -S (O 2) O-X201, - P (O) (OX202) (OX203),
  • X187, X188, X189, X190, X191, X192, X193, X194, X195, X196, X197, X198, X199, X200, X201, X202, X203, X204, X205, X206 are independently selected from the group consisting of: alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X161,
  • X162 and / or X170, X171 and / or X183, X184 and / or X190, X191 and / or X199, X200 may together also form "heterocyclyl";
  • radicals Z3, Z4 or both radicals Z3, Z4 are independently "substituted aryl", where "substituted aryl" is substituted by at least one substituent, identical or different, selected from the group consisting of:
  • X217, X218, X219, X220, X221, X222, X223, X224, X225, X226, X227, X228, X229, X230, X231, X232, X233, X234, X235, X236, X237, X238, X239, X240, X241, X242, x243, X244, X245, X246, are x247, x248 independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X216, X217 and / or X221, X222 and / or X227, X228
  • X415, X416, X417, X418, X419, X420, X421, X422, X423, X424, X425, X426, X427, X428, X429, X430, X431, X432, X433, X434, X435, X436, X437, X438, X439, X440, X441, X442, X443, X444, X445, X446, X447, X448, X449, X450, X451, X452, X453, X454, X455, X456 independent are independently selected from the group consisting of: "(C 9 -C 3 o) alkyl, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary
  • Z3, Z4 or none of Z3, Z4 is independently selected from the group consisting of: (e) hydrogen;
  • alkyl (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHX509, -NX510X511, -NO 2 , -OH, -OCF 3 , -
  • X538, X539, X540, X541, X542, X543, X544, X545, X546, X547, X548, X549, X550, X551, X552, X553, X554, X555, X556, X557, X558, X559, X560 are independently selected the group consisting of: "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X515, X516 and / or X524, X525 and / or X537, X538 and / or X544, X545 and / or X553, X554 in each case also" heterocyclyl " can form;
  • substituents of the substituent group (ii) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
  • X652, X653, X654, X655, X656, X657, X658, X659, X660, X661, X662, are X663, X664 are independently selected from the group consisting of: "alkyl, (30 Cg-C) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X619, X620 and / or X628, X629 and / or
  • X641, X642 and / or X648, X649 and / or X657, X658 may together also form "heterocyclyl", where optionally substituents of the substituent group (i) above may be substituted independently of one another with at least one at least one substituent, the same or different, selected from the group consisting of:
  • X694, X695, X696, X697, X698, X699, X700, X701, X702, X703, X704, X705, X706, X707, X708, X709, X710, X711, X712, X713, X714, X715, X716 are independently selected consisting of the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively X671, X672 and / or X680, X681 and / or X693, X694 and / or X700, X701 and / or X709, X710 may together also form "heterocyclyl
  • X725, X726, X727, X728, X729, X730, X731, X732, X733, X734, X735, X736, X737, X738, X739, X740, X741, X742, X743, X744, X745, X746, X747, X748, X749, X750, X751, X752, X753, X754, X755, X756, X757, X758, X759, X760, X761, X762, X763, X764, X765, X766, X767, X768 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl
  • X762 together can also form "heterocyclyl"
  • heteroaryl radical may be substituted by at least one substituent, identical or different, selected from the group consisting of:
  • X808, X809, X810, X81 1, X812, X813, X814, X815, X816, X817, X818, X819, X820 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl , cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X775, X776 and / or X784, X785 and / or
  • X797, X798 and / or X804, X805 and / or X813, X814 may together also form "heterocyclyl", where optionally substituents of the substituent group (i) above may be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
  • X850, X851, X852, X853, X854, X855, X856, X857, X858, X859, X860, X861, X862, X863, X864, X865, X866, X867, X868, X869, X870, X871, X872 are independently selected consisting of the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cyclo-
  • alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
  • X881, X882, X883, X884, X885, X886, X887, X888, X889, X890, X891, X892, X893, X894, X895, X896, X897, X898, X899, X900, X901, X902, X903, X904, X905, X906, X907, X908, X909, X910, X91 1, X912, X913, X914, X915, X916, X917, X918, X919, X920, X921, X922, X923, X924 are independently selected from the group consisting of: "alkyl , (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, as heterocyclyl, heterocyclylalkyl, aryl, aryl
  • X918 may together also form "heterocyclyl"
  • Z6 is independently selected from the group consisting of: (i) "hydrogen, alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
  • X954, X955, X956, X957, X958, X959, X960, X961, X962, X963, X964, X965, X966, X967, X968, X969, X970, X971, X972, X973, X974, X975, X976 are independently selected from consisting of the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cyclo-
  • alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
  • X1019, X1020, X1021, X1022, X1023, X1024, X1025, X1026, X1027, X1028 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl , arylalkyl, heteroaryl, heteroarylalkyl "and alternatively, X983, X984 and / or X992, X993 and / or X1005, X1006 and / or X1012, X1013 and / or X1021, X1022 may each together also form" heterocyclyl ";
  • Z7 is independently selected from the group consisting of: "hydrogen, alkyl, (C” 9 " -C” 30 " ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl”; optionally wherein the above substituents of the substituent group ( i) may in turn be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
  • X1068, X1069, X1070, X1071, X1072, X1073, X1074, X1075, X1076, X1077, X1078, X1079, x1080 independently selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl,
  • X1035, X1036 and / or X1044, X1045 and / or X1057, X1058 and / or X1064, X1065 and / or X1073, X1074 may together also form "heterocyclyl" wherein optionally substituents of substituent group (ii) 25 optionally substituted independently of one another may be at least one substituent, the same or different, selected from the group consisting of:
  • alkyl "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
  • X1112, X1113, X1114, X1115, X1116, X1117, X1118, X1119, X1120, X1121, X1122, X1123, X1124, X1125, X1126, X1127, X1128, X1129, X1130, X1131, X1132 are independently selected from the group consisting of : "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively X1087, X1088 and / or X1096, X1097 and / or X1 109, X1 110 and / or X11 16, X11 17 and / or X1125, X1 126 may each together also form "heterocycly
  • NZ8Z9 wherein Z8, Z9 are independently selected from the group consisting of:
  • OSi (X1 158) (X1159) (X1160), -0S (0 2 ) -X1161, -NHC (O) -X1 162, -NX1 163C (O) -X1 164, -NH-C (O) -O- X1165, -N HC (O) -NH-X1 166, -NH-C (O) -NX1 167X1168, -NX1 169-C (O) -O-X1170, -NX1 171-C (O) -NH- X1172, -NX1 173-C (O) -NXI 174X1175, - NHS (0 2 ) -X 1 176, -NX 1 177S (O 2 ) -X 1178, -S-X 1 179, -S (O) -
  • X1 154, X1 155, X1 156, X1 157, X1158, X1159, X1160, X1161, X1 162, X1 163, X1 164, X1 165, X1166, X1167, X1168, X1169, X1 170, X1 171, X1 172, X1 173, X1174, X1175, X1176, X1177, X1 178, X1 179, X1 180, X1 181, X1182, X1183, X1184, X1185, X1 186, X1 187, X1 188, X1 189, X1190 are independently selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylal
  • alkyl "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I 1 1 CN CF 3, N 3, NH 2 , -NHX1 191, -NX1 192X1193, -NO 2 , -
  • one of Z3, Z4 or both Z3, Z4 are independently "substituted heteroaryl", wherein “substituted heteroaryl” is substituted with at least one substituent selected from the group consisting of: (a) "alkyl, cycloalkyl, heterocyclyl , aryl, heteroaryl, -NH-V1, -N (alkyl) 2 , -
  • Substituents the same or different, selected from the group consisting of: (i) "(C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, N 3 , -NH-cycloalkyl, -NH-cycloalkylalkyl, -NH-heteroaryl, -NH- heteroarylalkyl, -NH-arylalkyl, -NH-heterocyclyl, -NH-heterocyclylalkyl, -NV4V5, -S-cycloalkyl, -S-cycloalkylalkyl, -S-aryl, -S-arylalkyl, -S-heteroaryl, -S-heteroarylalkyl, -S-heteroarylalkyl, -
  • Z3, Z4 independently of one another may also be further substituted by at least one substituent, identical or different, selected from the group consisting of: (b) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclicalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2, -NHV53, -NV54V55, -NO 2, -OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2, - CHO, -COOH, -C (O) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) -V56, -C (O) O-V57, -C (O) NH-V58, -C (O) NV59V60
  • V80, V81, V82, V83, V84, V85, V86, V87, V88, V89, V90, V91, V92, V93, V94, V95, V96, V97, V98, V99, V100, V101, V102, V103, V104 are independent are selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V59, V60 and / or
  • V68, V69 and / or V81, V82 and / or V88, V89 and / or V97, V98 may together also form "heterocyclyl" wherein optional substituents above the substituent group (b) may be independently substituted with at least one substituent, the same or different, selected from the group consisting of:
  • V148, V149, V150, V151, V152, V153, V154, V155, V156 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl , heteroaryl, heteroarylalkyl "and wherein alternatively V1 11, V1 12 and / or V120, V121 and / or V133, V134 and / or V140, V141 and / or V149, V150 may together also form" heterocyclyl "; wherein optionally above substituents of the substituent group (i) and / or substituent group (ii) may be independently substituted with at least one substituent, same or different, selected from the group consisting of:
  • radicals Z3, Z4 or both radicals Z3, Z4 independently of one another are "substituted heteroaryl", where "substituted heteroaryl” is substituted by at least one substituent, identical or different, selected from the group consisting of:
  • V230, V231, V232, V233, V234, V235, V236, V237, V238, V239, V240, V241, V242, V243, V244, V245, V246, V247, V248, V249, V250, V251, V252 are selected independently the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V218,
  • V219 and / or V223, V224 and / or V229, V230 and / or V233, V234 and / or V238, V239 and / or V241, V242 may together also form "heterocyclyl", with the proviso that the substituents "- N (alkyl) 2 "," - C (O) N (alkyl) 2 ",” - C (O) N (cycloalkyl) 2 ",” - C (O) N (aryl) 2 ", C (O) N (heteroaryl) 2 "are further substituted by at least one substituent selected from sub-substituent group (i); wherein optionally substituted substituents of the substituent group (c) may in turn be independently substituted with at least one substituent, same or different, selected from the group consisting of:
  • V279 -NH-C (O) -NH-V280, -NH-C (O) -NV281V282, -NV283-C (O) -O-V284, -NV285-C (O) -NH-V286, -NV287 -C (O) -NV288V289, - NHS (O 2) -V290, -NV291S (O 2) -V292, -S-V293, -S (O) -V294, -S (O 2) - V295, -S (O 2) N H-V296, -S (O 2) NV297V298, -S (O 2) O-V299, - P (O) (OV300) (OV301), -Si (V302) (V303 ) (V304) "; wherein V253, V254, V255, V256, V257, V258, V259, V260, V261, V262, V263, V264, V26
  • V285, V286, V287, V288, V289, V290, V291, V292, V293, V294, V295, V296, V297, V298, V299, V300, V301, V302, V303, V304 are independently selected from the group consisting of: " alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively V259,
  • V260 and / or V268, V269 and / or V281, V282 and / or V288, V289 and / or V297, V298 may together also form "heterocyclyl", optionally additionally one of the radicals Z3, Z4 or additionally both radicals Z3, Z4 independently from each other can also be further substituted with at least one substituent, identical or different, selected from
  • V350 may also together form "heterocyclyl", where optionally substituted substituents of the substituent group (d) may in turn be substituted by at least one substituent, identical or different, selected from the group consisting of:
  • V367, V368, V369, V370, V371, V372, V373, V374, V375, V376, V377, V378, V379, V380, V381, V382, V383, V384, V385, V386, V387, V388, V389, V390, V391, V392, V393, V394, V395, V396, V397, V398, V399, V400, V401, V402, V403, V404, V405, V406, V407, V408 are independently selected from the group consisting of: "alkyl,
  • V430, V431, V432, V433, V434, V435, V436, V437, V438, V439, V440, V441, V442, V443, V444, V445, V446, V447, V448, V449, V450, V451, V452, V453, V454, V455, V456a, V456b, V456c, V456d, V456e are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and wherein alternatively V415, V416 and / or V424, V425 and / or V437, V438 and / or V444, V445 and / or V453, V454 may together also form "heterocyclyl";
  • Z3, Z4 or none of Z3, Z4 is independently selected from the group consisting of:
  • (g) unsubstituted or substituted alkyl or (Cg-C3o) alkyl may be optionally substituted with (C 9 -C 30 C) alkyl moiety of the alkyl or at least one substituent, identical or different, selected from the group-consisting of pe:
  • V463, V464 and /: are V506, V507, V508 independently selected from the group consisting of or V472, V473 and / or V485, V486 and / or V492, V493 and / or V501, V502 may each together also form "heterocyclyl"; optionally substituents of the substituent group (i) above may be substituted independently of one another with at least at least one substituent, the same or different, selected from the group consisting of:
  • V538, V539, V540, V541, V542, V543, V544, V545, V546, V547, V548, V549, V550, V551, V552, V553, V554, V555, V556, V557, V558, V559, V560 are independently selected from consisting of the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V515, V516 and / or V524, V525, and / or V537, V538 and / or V544, V545 and / or V553, V554 may together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent
  • V569, V570, V571, V572, V573, V574, V575, V576, V577, V578, V579, V580, V581, V582, V583, V584, V585, V586, V587, V588, V589, V590, V591, V592, V593, V594, V595, V596, V597, V598, V599, V600, V601, V602, V603, V604, V605, V606, V607, V608, V609, V610, V611, V612 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and, alternatively, V567, V568 and / or V576, V577 and / or V589, V5
  • V606 may together also form "heterocyclyl"
  • V662 V663 (V664) "; wherein V613, V614, V615, V616, V617, V618, V619, V620, V621, V622, V623, V624, V625, V626, V627, V628, V629, V630, V631 , V632, V633, V634, V635, V636, V637, V638, V639, V640, V641, V642, V643, V644, V645, V646, V647, V648, V649, V650, V651,
  • V652, V653, V654, V655, V656, V657, V658, V659, V660, V661, V662, V663, V664 are each independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, and wherein alternatively V619, V620 and / or V628, V629 and / or
  • V641, V642 and / or V648, V649 and / or V657, V658 may in each case also form "heterocyclyl", where optionally substituents of the substituent group (i) above may be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
  • V694, V695, V696, V697, V698, V699, V700, V701, V702, V703, V704, V705, V706, V707, V708, V709, V710, V71 1, V712, V713, V714, V715, V716 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cyclo-
  • V671, V672 and / or V680, V681 and / or V693, V694 and / or V700, V701 and / or V709, V710 also together also "heterocyclyl "can form; in which optional substituents of substituent group (ii) 20 may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
  • alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
  • V725, V726, V727, V728, V729, V730, V731, V732, V733, V734, V735, V736, V737, V738, V739, V740, V741, V742, V743, V744, V745, V746, V747, V748, V749, V750, V751, V752, V753, V754, V755, V756, V757, V758, V759, V760, V761, V762, V763, V764, V765, V766, V767, V768 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, as heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively V723, V724 and / or V732, V733 and / or V745, V7
  • V762 may together also form "heterocyclyl"
  • heteroaryl radical may be substituted by at least one substituent, identical or different, selected from the group consisting of:
  • V798, V799, V800, V801, V802, V803, V804, V805, V806, V807, V808, V809, V810, V811, V812, V813, V814, V815, V816, V817, V818, V819, V820 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- alkyl" and wherein alternatively V775, V776 and / or V784, V785 and or V797, V798 and / or V804, V805 and / or V813, V814 may together also form "heterocyclyl"; in which optionally above substituents of the substituent group (i) can in turn be substituted independently of one another with at least one substituent,
  • alkyl (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV821, -NV822V823, -NO 2 , -OH, -OCF 3 , -
  • alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl
  • V827, V828 and / or V836, V837 and / or V849, V850 and / or V856, V857 and / or V865, V866 may together also form "heterocyclyl";
  • substituents of the substituent group (ii) above may be substituted independently with at least one substituent, identical or different, selected from the group consisting of:
  • NV905-C O-NH-V906, -NV907-C (O) -NV908V909, - NHS (O 2) -V910, -NV911S (O 2) -V912, -S-V913, -S (O) - V914, -S (O 2) -V915, -S (O 2) NH-V916, -S (O 2) NV917V918, -S (O 2) O- V919, -P (O) (OV920) (OV921) , -Si (V922) (V923) (V924) ";
  • V881, V882, V883, V884, V885, V886, V887, V888, V889, V890, V891, V892, V893, V894, V895, V896, V897, V898, V899, V900, V901, V902, V903, V904, V905, V906, V907, V908, V909, V910, V911, V912, V913, V914, V915, V916, V917, V918, V919, V920, V921, V922, V923, V924 are independently selected from the group consisting of: "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl heteroaryl, heteroarylalkyl "and wherein alternatively V879, V880 and / or V888, V889 and / or V901, V902 and
  • alkyl (Cg-C 3 o) alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl
  • V931, V932 and / or V940, V941 and / or V953, V954 and / or V960, V961 and / or V969, V970 may together also form "heterocyclyl";
  • substituents of the substituent group (ii) above may be substituted independently with at least one substituent, identical or different, selected from the group consisting of:
  • V1025 30 P (O) (OVI 024) (OV1025), -Si (VI 026) (V1027) (V1028) "; wherein V977, V978, V979, V980, V981, V982, V983, V984, V985, V986, V987, V988, V989, V990, V991, V992, V993, V994, V995, V996, V997, V998, V999, V1000, V1001, V1002, V1003, V1004, V1005, V1006, V1007, V1008, V1009, V1010, V1011, V1012, V1013, V1014, V1015, V1016, V1017, V1018, V1019, V1020, V1021, V1022, V1023, V1024, V1025, V1026, V1027, V1028 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkyl
  • Z7 is independently selected from the group consisting of: "hydrogen, alkyl, (C” 9 " -C” 30 " ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl”; optionally wherein the above substituents of the substituent group ( i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
  • alkyl (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV1029, -NV1030V1031, -NO 2 , -OH, -
  • NV1044V1045 -OP (O) (OVI 046) (OV1047), - OSi (VI 048) (V1049) (V1050), -OS (O 2) -V1051, -N HC (O) -VI 052, - NV1053C ( O) -VI 054, -NH-C (O) -O-VI 055, -NH-C (O) -NH-V1056, -NH-C (O) -NVI 057V1058, -NV1059-C (O) - O-VI 060, - NV1061-C (O) -NH-VI 062, -NV1063-C (O) -NVI 064V1065, -
  • V1060 V1061, V1062, V1063, V1064, V1065, V1066, V1067,
  • alkyl (- C 30 9 C) alkyl, cycloalkyl, cycloalkylalkyl, "alkyl,: are V1068, V1069, V1070, V1071, V1072, V1073, V1074, V1075, V1076, V1077, V1078, V1079, V1080 independently selected from the group consisting of , heterocyclyl, heterocyclylalkyl, 10 aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively
  • V1035, V1036 and / or V1044, V1045 and / or V1057, V1058 and / or V1064, V1065 and / or V1073, V1074 may together also form "heterocyclyl" wherein optionally substituted substituents of substituent group (ii) 15 in turn independently substituted may be at least one substituent, the same or different, selected from the group consisting of:
  • alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
  • V1131 35 Si (VI 130) (V1131) (V1132) "; wherein V1081, V1082, V1083, V1084, V1085, V1086, V1087, V1088, V1089, V1090, V1091, V1092, V1093, V1094, V1095, V1096, V1097, V1098, V1099, V1100, V1101, V1102, V1103, V1104, V1105 , V1106, V1107, V1108, V1109, V1110, V1111, VII ⁇ 1 VIIIa 1 VIIU 1 VIIIS 1 VIIIe 1 VIIIy 1 VIIIe 1 VIIIg 1
  • V1120, V1121, V1122, V1123, V1124, V1125, V1126, V1127, V1128, V1129, V1130, V1131, V1132 are independently selected from the group consisting of: "alkyl, (C 9 - C 30 ) alkyl, cycloalkyl, cycloalkylalkyl , heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively V1087, V1088 and / or V1096, V1097 and / or V1109, V1110 and / or V1116, V1117 and / or V1125, V1126 also together also" heterocyclyl "can form;
  • V1180 -S (0 2) -V1 181, -S (O 2) NH-V1 182, -S (O 2) NVI 183V1184, - S (O 2) O-V1185, -P (O) (OV1186) (OV1 187), -Si (VI 188) (V1189) (V1190) ", wherein V1139, V1140, V1141, V1142, V1143, V1144, V1145,
  • V1186, V1187, V1188, V1 189 V1 190 are independently selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively, V1145, V1146 and / or V1 154, V1 155 and / or V1 167, V1 168
  • V1 174, V1 175 and / or V1 183, V1184 may together also also form "heterocyclyl", where optionally substituents of the substituent group (ii) above may be substituted independently with at least one substituent, identical or different - 30 selects from the group consisting of:
  • V1238, V1239, V1240, V1241 are, V1242 independently selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V1197, V1198 and / or V1206, V1207 and / or
  • V1219, V1220 and / or V1226, V1227 and / or V1235, V1236 may together also form "heterocyclyl";
  • one of the radicals Z3, Z4 or both radicals Z3, Z4 is independently "substituted alkyl", where "substituted alkyl” is substituted by at least one substituent selected from the group consisting of: (a) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2, -NHW1, -NW2W3, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP (O) (OH) 2, -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W 4, -C (O) (
  • W26, W27, W28, W29, W30, W31, W32, W33, W34, W35, W36, W37, W38, W39, W40, W41, W42, W43, W44, W45, W46, W47, W48, W49, W50, W51, W52 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl” and wherein alternatively W7, W8 and or W16, W17 and / or W29, W30 and / or W36, W37 and / or W45, W46 may together also form "heterocyclyl”; with the proviso that "--C (O) NH-aryl", "- C (O) NH-heteroaryl", "
  • W99, W100, W101, W102, W103, W104 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylal- kyl, heteroaryl, heteroarylalkyl and alternatively W59, W60 and / or W68, W69 and / or W81, W82 and / or W88, W89 and / or W97, W98 may together also form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
  • alkyl "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, - NHW105, -NW106W107, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2, -CHO, -COOH, -
  • W153, W154, W155, are W156 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively W1 11 , W1 12 and / or W120, W121 and / or W133, W134 and / or W140, W141 and / or W149, W150 may together also form "heterocyclyl";
  • Z3, Z4 or both radicals Z3, Z4 are independently "(C 9 -C 3 o) alkyl" are one another, wherein "(Cg-C 3 o) alkyl” may optionally be independently substituted with at least one substituent , the same or different, selected from the group consisting of:
  • alkyl (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylal- kyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 .
  • W176, W177, W178, W179, W180, W181, W182, W183, W184, W185, W186, W187, W188, W189, W190, W191, W192, W193, W194, W195, W196, W197, W198, W199, W200, W201, W202, W203, W204, W205, W206, W207, W208 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- rocyclyl, heterocyclylalkyl, aryl, arylalkyl heteroaryl, heteroarylalkyl "and alternatively W163, W164 and / or W172, W173 and / or W185, W186 and / or W192, W193 and / or W201, W202 may together also form" heterocyclyl "; in which optional substituents of the substituent group (i) may in
  • alkyl consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively W215, W216 and / or W224, W225 and / or W237, W238 and / or W244, W245 and / or W253, W254 can in each case together also form "heterocyclyl";
  • Z3, Z4 or none of Z3, Z4 is independently selected from the group consisting of:
  • alkyl or (Cg-C 3 o) alkyl group may be substituted with at least one substituent, identical or different, selected from the group consisting of: (i) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, - NHW457, -NW458W459, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (
  • W493, W494, W495, W496, W497, W498, W499, W500, W501, W502, W503, W504, W505, W506, W507, W508 are independently selected from the group consisting of: "alkyl, (Cg-C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively W463,
  • W464 and / or W472, W473 and / or W485, W486 and / or W492, W493 and / or W501, W502 may in each case also form "heterocyclyl", where optionally the above substituents of the substituent group (i) in turn are substituted independently of one another may be substituted by at least one substituent, the same or different, selected from the group consisting of:
  • alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW509, -NW510W511, -NO 2 , -OH, -OCF 3 ,
  • W553, W554, W555, W556, W557, W558, W559, W560 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl , arylalkyl, heteroaryl, heteroarylalkyl "and alternatively W515, W516 and / or W524, W525 and / or W537,
  • W538 and / or W544, W545 and / or W553, W554 may together also form "heterocyclyl", where optionally substituents of the substituent group (ii) above may be substituted independently with at least one substituent, identical or different, selected selects from the group consisting of:
  • alkyl "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW561, -NW562W563, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -
  • W577, W578, W579, W580, W581, W582, W583, W584, W585, W586, W587, W588, W589, W590, W591, W592, W593, W594, W595, W596, W597, W598, W599, W600, W601, W602, W603, W604, W605, W606, W607, W608, W609, W610, W61 1, W612 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl , heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively W567, W568 and / or W576, W577 and / or W589, W590 and / or W596, W597 and / or W605, W606 may each together
  • W640, W641, W642, W643, W644, W645, W646, W647, W648, W649, W650, W651, W652, W653, W654, W655, W656, W657, W658, W659, W660, W661, W662, W663, W664 independent are selected from the group consisting of: "alkyl, (C 9 - C 30 ) alkyl, cycloalkyl, cycloalkyl alkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively W619, W620 and / or W628, W629 and / or W641, W642 and / or W648, W649 and / or W657, W658 may each also together form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substitu
  • alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,
  • W709, W710, W71 1, W712, W713, W714, W715, W716 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl , arylalkyl, heteroaryl, heteroarylalkyl "and where 10 alternatively W671, W672 and / or W680, W681 and / or W693,
  • W694 and / or W700, W701 and / or W709, W710 may together also form "heterocyclyl", where optionally substituents of the substituent group (ii) above may be substituted independently of one another with
  • At least one substituent identical or different, selected from the group consisting of:
  • alkyl "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW717, -NW718W719, -NO 2 , -
  • OSi (W736) (W737) (W738), -OS (O2) -W739, -NHC (O) -W740, -NW741C (O) -W742, -NH-C (O) -O-W743, -NH -C (O) -NH-W744, -NHC (O) -N W745W746, -NW747-C (O) -O-W748, -NW749-C (O) -NH-W750, -NW751 -C (O ) -N W752W753, -
  • W757, W758, W759, W760, W761, W762, W763, W764 are, W765, W766, W767, W768 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively
  • W723, W724 and / or W732, W733 and / or W745, W746 and / or W752, W753 and / or W761, W762 may together also form "heterocyclyl";
  • heteroaryl radical may be substituted by at least one substituent, identical or different, selected from the group consisting of:
  • OSi (W788) (W789) (W790), -OS (O2) -W791, -NHC (O) -W792, - NW793C (O) -W794, -NH-C (O) -O-W795, -N HC (O) -NH-W796, -NHC (O) -N W797W798, -NW799-C (O) -O-W800, -NW801-C (O) -NH-W802, -NW803-C (O ) -NW804W805, -NHS (O2) -W806, - NW807S (O2) -W808, -S-W809, -S (0) -W810, -S (O2) -W81 1 -
  • W879, W880 and / or W888, W889 and / or W901, W902 and / or W908, W909 and / or W917, W918 may together also form "heterocyclyl";
  • alkyl (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW925, -NW926W927, -NO 2 , -OH, -OCF 3 ,
  • W970, W971, W972, W973, W974, W975, W976 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively 10 W931, W932 and / or W940, W941 and / or W953,
  • W954 and / or W960, W961 and / or W969, W970 may together also form "heterocyclyl", where optionally substituents of the substituent group (ii) above may be substituted independently of one another with
  • At least one substituent identical or different, selected from the group consisting of:
  • alkyl "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW977, -NW978W979, -NO 2 , -
  • OSi (W996) (W997) (W998), -OS (O2) -W999, -NHC (O) -WIOOO, -NW1001 C (O) -WI 002, -NH-C (O) -O-WI 003 , -NH-C (O) -NH-W1004, -NH-C (O) -NWI 005W1006, -NW1007-C (O) -O-W1008, -NW1009-C (O) -NH-WI 010, - NW1011-C (O) -
  • W1015, W1016, W1017, W1018, W1019, W1020, W1021, W1022, W1023, W1024, W1025, W1026, W1027, are W1028 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl , cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and, alternatively, W983, W984 and / or W992, W993 and / or W1005, W1006 and / or W1012, W1013 and / or W1021, W1022, respectively together may also form "heterocyclyl";
  • alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW1029, -NW1030W1031, -NO 2 , -OH, -
  • W1068, W1069, W1070, W1071, W1072, W1073, W1074, W1075, W1076, W1077, W1078, W1079, W1080 are independently selected from the group consisting of: "alkyl, alkyl, cycloalkyl, cycloalkylalkyl (Cg-C 30), heterocyclyl, heterocyclylalkyl,
  • W1035, W1036 and / or W1044, W1045 and / or W1057, W1058 and / or W1064, W1065 and / or W1073, W1074 may together also form "heterocyclyl" wherein optionally substituted substituents of substituent group (ii) 20 in turn independently substituted may be at least one substituent, the same or different, selected from the group consisting of:
  • alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
  • W1 108, W1109, W11 10, W1 11 1, W1 112, W11 13, W11 14, W1 115, W11 16, W11 17, W1 118, W1 119, W1120, W1121, W1 122, W1123, W1124, W1 125, W1 126, W1127, W1128, W1 129, W1130, W1131, W1 132 are independently selected from the group consisting of: "alkyl, (Cg-)
  • W1 170, W1171, W1172, W1 173, W1 174, W1175, W1176, W1 177, W1 178, W1179, W1180, W1 181, W1 182, W1183, W1184, W1 185, W1 186, W1187, W1188, W1 189, W1190 are independently selected from the group consisting of: "alkyl, (C 9 - C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively W1 145, W1146 and / or W1 154, W1155 and / or W1 167, W1 168 and / or W1174, W1 175 and / or W1 183, W1184 may together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn
  • alkyl (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I 1 CN 1 CF 3 , N 3 , NH 2 , -NHW 1 191, -NW 1192 W 1193, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C ( O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W 1194, -C (O) O-
  • W1239, W1240, W1241, W1242 are independently selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl” and wherein alternatively W1 197, W1 198 and / or W1206, W1207 and / or W1219, W1220 and / or W1226, W1227 and / or W1235, W1236 may together also form "heterocyclyl";
  • radicals Z3, Z4 or both radicals Z3, Z4 are independently selected from the group consisting of:
  • radicals Z10, Z11 or both radicals Z10, Z1 1 and radicals Z12, Z13 being selected independently of one another from the group consisting of:
  • Q26, Q27, Q28, Q29, Q30, Q31, Q32, Q33, Q34, Q35, Q36, Q37, Q38, Q39, Q40, Q41, Q42, Q43, Q44, Q45, Q46, Q47, Q48, Q49 are independently selected are selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively Q10, Q11 and / or Q23, Q24, and or Q27, Q28 and / or Q34, Q35 and / or Q47, Q48 may together also form "heterocyclyl"; in which optionally above substituents of the substituent group (a) and / or the substituent group (i) may in turn be independently substituted with at least one substitu
  • alkyl (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ50, -NQ51 Q52, -NO 2 , -OH, -OCF 3 , -
  • OSi (Q69) (Q70) (Q71), -OS (O 2) -Q72, -NHC (O) -Q73, - NQ74C (O) -Q75, -NH-C (O) -O-Q76, -N HC (O) -NH-Q77, -NH-C (O) -NQ78Q79, -NQ80-C (O) -O-Q81, -NQ82-C (O) -NH-Q83, -NQ84-C (O ) -NQ85Q86, -NHS (O 2 ) -Q87, -NQ88S (O 2 ) -Q89, -S- Q90, -S (0) -Q91, -S (O 2) -Q92, -S (O 2) NH-Q93, -S (O 2) NQ94Q95, -S (O 2) O-Q96, -P ( O) (OQ97)
  • Q85, Q86, Q87, Q88, Q89, Q90, Q91, Q92, Q93, Q94, Q95, Q96, Q97, Q98, Q99, Q100, Q101 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, and alternatively Q56, Q57 and / or Q65, Q66 and / or Q78, Q79 and / or Q85, Q86 and / or or Q94, Q95 may together also form "heterocyclyl"; in which optional substituents of substituent group (ii) 15 can in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
  • alkyl (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
  • Q146, Q147, Q148, Q149, Q150, Q151, Q152, Q153 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively Q108, Q109 and / or Q117, Q1 18 and / or Q130, Q131 and / or Q137, Q138 and / or Q146, Q147 can each also together form" heterocyclyl ";
  • Q209, Q210, Q21 1 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl” and wherein alternatively Q166 , Q167 and / or Q175, Q176 and / or Q188, Q189 and / or Q195, Q196 and / or Q204, Q205 may each together also form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
  • Q239, Q240, Q241, Q242, Q243, Q244, Q245, Q246, Q247, Q248, Q249, Q250, Q251, Q252, Q253, Q254, Q255, Q256, Q257, Q258, Q259, Q260, Q261, Q262, Q263 independent are selected from the group consisting of: "alkyl,
  • substituents of the substituent group (ii) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
  • Q290, Q291, Q292, Q293, Q294, Q295, Q296, Q297, Q298, Q299, Q300, Q301, Q302, Q303, Q304, Q305, Q306, Q307, Q308, Q309, Q310, Q31 1, Q312, Q313, Q314 are Q315 independently selected from the group consist- ing of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" and wherein alternatively Q270 , Q271 and / or Q279, Q280 and / or Q292, Q293 and / or Q299, Q300 and / or Q308, Q309 may together also form "heterocyclyl";
  • Z10, Z11 or none of Z10, Z11 is independently selected from the group consisting of:
  • Q361, Q362, Q363, Q364, Q365, Q366, Q367, Q368, Q369, Q370, Q371, Q372, Q373 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, and alternatively Q328, Q329 and / or Q337, Q338 and / or
  • Q350, Q351 and / or Q357, Q358 and / or Q366, Q367 may together also form "heterocyclyl", where optionally substituents of the substituent group (i) above may be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
  • Q401, Q402, Q403, Q404, Q405, Q406, Q407, Q408, Q409, Q410, Q411, Q412, Q413, Q414, Q415, Q416, Q417, Q418, Q419, Q420, Q421, Q422, Q423, Q424, Q425 independent are selected from the group consisting of: "alkyl,
  • substituents of the substituent group (ii) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
  • Q456e, Q456f, Q456g, Q456h, Q456i, Q456J, Q456k, Q456I, Q456m, Q456n, Q456o, Q456p, Q456q, Q456r, Q456s, Q456t, Q456u, Q456v are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively Q432, Q433 and / or Q441, Q442 and / or Q454, Q455 and / or Q456f, Q456g and / or Q456o, Q456p may together also form "heterocyclyl";
  • Z3, Z4 or none of Z3, Z4 is independently selected from the group consisting of:
  • alkyl (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3,
  • Q506, Q507, Q508 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- alkyl" and wherein alternatively Q463, Q464 and / or Q472, Q473 and / or Q485, Q486 and / or Q492, Q493 and / or Q501, Q502 may together also form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
  • Q545, Q546, Q547, Q548, Q549, Q550, Q551, Q552, Q553, Q554, Q555, Q556, Q557, Q558, Q559, Q560 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclic
  • alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
  • Q605, Q606, Q607, Q608, Q609, Q610, Q611 are, Q612 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- rocyclyl, heterocyclylalkyl, aryl, arylalkyl heteroaryl, heteroarylalkyl "and wherein alternatively Q567, Q568 and / or Q576, Q577 and / or Q589, Q590 and / or Q596, Q597 and / or Q605, Q606 may each together also form" heterocyclyl ";
  • Q642, Q643, Q644, Q645, Q646, Q647, Q648, Q649, Q650, Q651, Q652, Q653, Q654, Q655, Q656, Q657, Q658, Q659, Q660, Q661, Q662, Q663, Q664 are selected independently from each other consisting of the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- alkyl" and wherein alternatively Q619, Q620 and / or Q628, Q629 and / or Q641, Q642 and / or Q648, Q649 and / or Q657, Q658 may each together also form "heterocyclyl"; in which optionally above substituents of the substituent group (i) can in turn be substituted independently of one another with
  • alkyl (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ665, -NQ666Q667, -NO 2 , -OH, -OCF 3 ,
  • heteroaryl radical may be substituted by at least one substituent, identical or different, selected from the group consisting of:
  • Q788, Q789, Q790, Q791, Q792, Q793, Q794, Q795, Q796, Q797, Q798, Q799, Q800, Q801, Q802, Q803, Q804, Q805, Q806, Q807, Q808, Q809, Q810, Q81 1, Q812 , Q813, Q814, Q815, Q816, Q817, Q818, Q819, Q820 are independently selected from the A group consisting of: "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively Q775, Q776 and / or Q784, Q785 and / or Q797 , Q798 and / or Q804, Q805 and / or Q813, Q814 together can also form "heterocyclyl
  • Q830, Q831, Q832, Q833, Q834, Q835, Q836, Q837, Q838, Q839, Q840, Q841, Q842, Q843, Q844, Q845, Q846, Q847, Q848, Q849, Q850, Q851, Q852, Q853, Q854, Q855, Q856, Q857, Q858, Q859, Q860, Q861, Q862, Q863, Q864, Q865, Q866, Q867, Q868, Q869, Q870, Q871, Q872 are independently selected from the group consisting of: "alkyl, (Cg -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively Q827, Q828 and / or Q836, Q837 and / or Q849, Q850 and
  • alkyl "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHQ873, -NQ874Q875, -NO 2 , -OH,
  • OSi (Q892) (Q893) (Q894), -OS (O 2) -Q895, -NHC (O) -Q896, - NQ897C (O) -Q898, -NH-C (O) -O-Q899, -NH -C (O) -NH-Q900, -NH-C (O) -NQ901 Q902, -NQ903-C (O) -O-Q904, -NQ905-C (O) -NH-Q906, -NQ907-C ( O) -NQ908Q909, -
  • Q961, Q962, Q963, Q964, Q965, Q966, Q967, Q968, Q969, Q970, Q971, Q972, Q973, Q974, Q975, Q976 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and, alternatively, Q931, Q932 and / or Q940, Q941 and / or Q953, Q954 and / or Q960, Q961 and / or Q969, Q970 in each case together can also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
  • Q1009, Q1010, Q1011, Q1012, Q1013, Q1014, Q1015, Q1016, Q1017, Q1018, Q1019, Q1020, Q1021, Q1022, Q1023, Q1024, Q1025, Q1026, Q1027, Q1028 are independently selected from the group consisting of: "Alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl” and wherein alternatively Q983, Q984 and / or Q992, Q993 and / or Q1005, Q1006 and / or Q1012, Q1013 and / or Q1021, Q1022 may together also form "heterocyclyl";
  • substituent group (i) "hydrogen, alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wherein optionally above substituents of substituent group (i) in turn may be independently substituted with at least a substituent, the same or different, selected from the group consisting of:
  • C 30 alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and, alternatively, Q1035, Q1036 and / or Q1044, Q1045 and / or Q1057, Q1058 and / or Q1064, Q1065 and / or Q1073, Q1074 can together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
  • Q1130, Q1131 are, Q1132 independently selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, Cyc loalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, ary lalkyl, heteroaryl, heteroarylalkyl” and wherein alternatively Q1087 , Q1088 and / or Q1096, Q1097 and / or Q1 109, Q1 110 and / or Q1 116, Q1 117 and / or Q1 125, Q1 126 may together also form "heterocyclyl";
  • NZ8Z9 wherein Z8, Z9 are independently selected from the group consisting of:
  • OSi (QI 158) (Q1 159) (Q1 160), -0S (0 2 ) -Q1 161, -NHC (O) -Q1162, -NQ1 163C (O) -Q1 164, -NH-C (O) - O-Q1 165, -NH-C (O) -NH-Q1166, -NH-C (O) -NQ1 167Q1 168, -NQ1169-C (O) -O-Q1 170, -NQ1171 -C (O) - NH-Q1 172, -NQ1173-C (O) -NQ1174Q1 175, - 10 NHS (0 2) -Q1 176, -NQ1177S (O 2) -Q1178, -S-Q1179, -S (O) -
  • (Cg-C 30) alkyl, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and wherein alternatively: 20 Q1186, Q1187, Q1188, Q1189, Q1190 independently selected from the group consisting of Q1145, Q1146 and / or Q1154, Q1155 and / or Q1 167, Q1 168
  • Q1233, Q1234, Q1235, Q1236, Q1237, Q1238, Q1239, Q1240, Q1241, Q1242 are independently selected from the group consisting of: "alkyl, (Cg-C3o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl , arylalkyl, heteroaryl, heteroarylalkyl "and alternatively Q1 197,
  • Q1198 and / or Q1206, Q1207 and / or Q1219, Q1220 and / or Q1226, Q1227 and / or Q1235, Q1236 may together also form "heterocyclyl";
  • U100, U101, U 102, U103, U104 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, ary lalkyl, heteroaryl, heteroarylalkyl "and alternatively U59, U60 and / or U68, U69 and / or U81, U82 and / or U88, U89
  • U98 may in each case also form "heterocyclyl", where optionally substituted substituents of substituent group (ii) may in turn be substituted independently with at least one substituent, identical or different, selected from the group consisting of:
  • alkyl "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHU105, -NU106U107, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -
  • U151, -P (O) (OU152) (OU153), -Si (U154) (U155) (U156) ", where U105, U106, U107, U108, U10g, U110, U111, U112, U113, U114, U115, U116, U117, U118, U119, U120, U121, U122, U123, U124, U125, U126, U127, U128, U12g, U130, U131, U132, U133, U134, U135, U136, U137, U138, U139, U140, U141, U142, U143, U144, U145, U146, U147, U148, U149, U150, U151, U152, U153, U154, U155, U156 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl
  • heterocyclylalkyl aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively U1 11, U1 12 and / or U 120, U 121 and / or U133, U134 and / or U140, U141 and / or U149, U150 also together in each case" heterocyclyl "can form;
  • Z23 is independently selected from the group consisting of:
  • substitution group (a) "hydrogen, alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wherein above substituents of the substitution group (a) may be independently optionally substituted with at least a substituent, the same or different, selected from the group consisting of:
  • alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,
  • (Cg-C 3 o) alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl alkyl are U206, U207, U208 independently selected from the group consisting of , U 164 and / or U 172,
  • U202 may in each case also form "heterocyclyl", where optionally substituted substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
  • alkyl (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl
  • heterocyclylalkyl aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively U215, U216 and / or U224, U225 and / or U237, U238 and / or U244, U245 and / or U253, U254 may together also also form" heterocyclyl " ;
  • (ii) may in turn be independently substituted with at least one substituent, the same or different, selected from the group consisting of:
  • NU289U290 -NU291-C (O) -O-U292, -N11293-C (O) -NH- U294, -NU295-C (O) -NU296U297, -NHS (O 2) -U298, - NU299S (O 2 ) -U300, U301 -S, -S (O) -U302, -S (O 2) -U303, -S (O 2) NH-U304, -S (O 2) NU305U306, -S (O 2) O-U307, -
  • alkyl (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br,
  • U376, U377, U378, U379, U380, U381, U382, U383, U384, U385, U386, U387, U388, U389, U390, U391, U392, U393, U394, U395, U396, U397, U398, U399, U400, U401, U402, U403, U404, U405, U406, U407, U408, U409, U410, U411, U412, U413, U414, U415, U416, U417, U418, U419 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl , heteroaryl, heteroarylalkyl "and where
  • U397 and / or U403, U404 and / or U412, U413 may together also form "heterocyclyl", where optionally substituents of the substituent group (i) above may be substituted independently of one another with
  • At least one substituent identical or different, selected from the group consisting of:
  • alkyl (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHU420, -NU421 U422, -NO 2 ,
  • U464, U465 may together also form "heterocyclyl", where optionally substituents of the substituent group (ii) above may be substituted independently of one another
  • U479, U480, U481, U482, U483, U484, U485, U486, U487, U488, U489, U490, U491, U492, U493, U494, U495, U496, U497, U498, U499, U500, U501, U502, U503, U504, U505, U506, U507, U508, U509, U510, U511, U512, U513, U514, U515, U516, U517, U518, U519, U520, U521, U522, U523 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively U478, U479 and / or U487, U488 and / or U500,
  • Rest Z5 is independently selected from the group consisting of:
  • A44, A45, A46, A47, A48, A49, A50, A51, A52 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl , heteroaryl, het eroarylalkyl "and wherein alternatively A7, A8 and / or A16, A17 and / or A29, A30 and / or A36, A37 and / or A45, A46 may together also form" heterocyclyl "; wherein optionally substituents of the substituent group (i) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
  • A65, A66, A67, A68, A69, A70, A71, A72, A73, A74, A75, A76, A77, A78, A79, A80, A81, A82, A83, A84, A85, A86, A87, A88, A89, A90, A91, A92, A93, A94, A95, A96, A97, A98, A99, A100, A101, A102, A103, A104 are independently selected from the group consisting of: alkyl "alkyl, (Cg-C 30), cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively A59, A60 and / or A68, A69 and / or A81, A82 and / or A88, A89 and / or A97, A98 in each case together also "heterocyclyl"
  • A124, A125, A126, A127, A128, A129, A130, A131, A132, A133, A134, A135, A136, A137, A138, A139, A140, A141, A142, A143, A144, A145, A146, A147, A148, A149, A150, A151, A152, A153, A154, A155, A156 are independently selected from the group consisting of: alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl "heteroarylalkyl” and wherein alternatively A11 1, A1 12 and / or A120, A121 and / or A133, A134 and / or A140, A141 and / or A149, A150 may together also form "heterocyclyl";
  • one of the radicals Z1, Z2 or both radicals Z1, Z2 are independently selected from the group consisting of: (a) -NZ24Z25; with the proviso that one of the radicals Z24, Z25 or both radicals Z24, Z25 are selected independently of one another from the group consisting of: (1) ,, - C (O) -C (O) -TI, -S (O 2) -NT2T3 "; wherein T1, T2, T3 are independently selected from the group consisting of:
  • T4 T5, T6, T7, T8, T9, T10, T11, T12, T13, T14, T15, T16, T17, T18, T19, T20, T21, T22, T23, T24, T25, T26, T27, T28, T29, T30, T31, T32, T33, T34, T35, T36, T37, T38, T39, T40, T41, T42,
  • T43, T44, T45, T46, T47, T48, T49, T50, T51, T52, T53, T54, T55 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl , heterocyc IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively T10, T1 1 and / or T19, T20 and / or T32, T33 and / or T39, T40 and / or T48, T49 also together" terocyclyl "can form; wherein optionally substituted substituents of the substitution group (I) independently of one another can also be further substituted by at least one substituent, identical or different, selected from the group consisting of:
  • OSi T75) (T76) (T77), -OS (O 2) -T78, -NHC (O) -T79, -NT80C (O) - T81, -NH-C (O) -O-T82, -N HC (O) -NH-T83, -NH-C (O) -NT84T85, -NT86-C (O) -O-T87, -NT88-C (O) -NH-T89, -NT90-C (O ) -NT91T92, -NHS (O 2 ) -T93, -NT94S (O 2 ) -T95, -S-T96, -
  • T56 T57, T58, T59, T60, T61, T62, T63, T64, T65, T66, T67, T68, T69, T70, T71, T72, T73, T74, T75, T76, T77, T78, T79, T80, T81, T82, T83, T84, T85, T86, T87, T88, T89, T90,
  • T103, T104, T105, T106, T107 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively T62,
  • T101 may together also form "heterocyclyl", where optionally substituents of the substituent group (i) above may be substituted independently of one another With
  • At least one substituent identical or different, selected from the group consisting of:
  • alkyl (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, - NHT108, -NT109T110, -NO 2 , -
  • T153 may in each case also form "heterocyclyl", where optionally substituted substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
  • NT195T196 -NHS (O 2) -T197, -NT198S (O 2) -T199, -S- T200, -S (O) -T201, -S (O 2) -T202, -S (O 2) NH- T203, - S (O 2) NT204T205, -S (O 2) O-T206, - P (O) (OT207) (OT208), -Si (T209) (T210), (T211) "; wherein T160, T161, T162, T163, T164, T165, T166, T167,
  • T168, T169, T170, T171, T172, T173, T174, T175, T176, T177, T178, T179, T180, T181, T182, T183, T184, T185, T186, T187, T188, T189, T190, T191, T192, T193, T194, T195, T196, T197, T198, T199, T200, T201, T202, T203, T204, T205, T206, T207, T208, T209, T210, T21 1 are independently selected from the group consisting of: "alkyl , (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylal- kyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaromatics ryl, heteroarylalkyl "and wherein alternatively T166, T167 and / or T175, T176 and / or T188, T189, and / or
  • T195, T196 and / or T204, T205 may together also form “heterocyclyl”; alternatively, T2, T3 may together also form “heterocyclyl”;
  • Z24, Z25 or none of Z24, Z25 is also independently selected from the group consisting of:
  • T261, T262, T263 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl” and alternatively T218, T219 and or T227, T228 and / or T240, T241 and / or T247, T248 and / or T256, T257 may each together also form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
  • T293, T294, T295, T296, T297, T298, T299, T300, T301, T302, T303, T304, T305, T306, T307, T308, T309, T310, T311, T312, T313, T314, T315 are independently selected from consisting of the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, Cyc
  • T270, T271 and / or T279, T280 and / or T292, T293 and / or T299, T300 and / or T308, T309 also together in each case also Can form "heterocyclyl";
  • substituents of the substituent group (ii) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
  • T366 Si (T365) (T366) (T367) "; wherein T316, T317, T318, T319, T320, T321, T322, T323, T324, T325, T326, T327, T328, T329, T330, T331, T332, T333, T334 , T335, T336, T337, T338, T339, T340, T341, T342, T343, T344, T345, T346, T347, T348, T349, T350,
  • T351, T352, T353, T354, T355, T356, T357, T358, T359, T360, T361, T362, T363, T364, T365, T366, T367 are independently selected from the group consisting of: "alkyl, (Cg-C3o ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and where alternatively T322, T323 and / or T331, T332 and / or T344, T345 and / or T351, T352 and / or T360, T361 may together also form "heterocyclyl";
  • radicals Z26, Z27 or both radicals Z26, Z27 are independently selected from the group consisting of:
  • T377, T378, T379, T380, T381, T382, T383, T384, T385, T386, T387, T388, T389, T390, T391, T392, T393, T394, T395, T396, T397, T398, T399, T400, T401, T402, T403, T404 are independently selected from the group consisting of:
  • alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and wherein alternatively T374, T375 and / or T381, T382 and / or T391, T392 and or T398, T399 may together also form "heterocyclyl";
  • substituents of the substituent group (i) may in turn be further independently substituted with at least one substituent, identical or different, selected from the group consisting of:
  • NT437-C (O) -NH-T438, -NT439-C (O) -NT440T441, - NHS (O 2) -T442, -NT443S (O 2) -T444, -S-T445, -S (O) - T446, -S (O 2) -T447, -S (O 2) N H-T448, -S (O 2) NT449T450, - S (O 2) O-T451, -P (O) (OT452) (OT453), - Si (T454) (T455), (T456) "; wherein T405, T406, T407, T408, T409, T410, T411, T412 , T413, T414, T415, T416, T417, T418, T419, T420, T421,
  • T431, T432, T433, T434, T435, T436, T437, T438, T439, T440, T441, T442, T443, T444, T445, T446, T447, T448, T449, T450, T451, T452, T453, T454, T455, T456 are independently selected from the group consisting of
  • T41 1, T412 and / or T420, T421 and or T433, T434 and / or T440, T441 and / or T449, T450 may together also form "heterocyclyl";
  • (ii) may in turn be independently substituted with at least one substituent, the same or different, selected from the group consisting of:
  • T483, T484, T485, T486, T487, T488, T489, T490, T491, T492, T493, T494, T495, T496, T497, T498, T499, T500, T501, T502, T503, T504, T505, T506, T507, T508 are independently selected from the group con- sisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylal- kyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaromatics ryl, heteroarylalkyl" and wherein alternatively T463, T464 and / or T472, T473 and / or T485, T486 and / or T492, T493 and / or T501, T502 may together also form "heterocyclyl";
  • Z28, Z29 and at least one of Z30 is Z31 independently selected from the group consisting of: (II) "(Cg-C 3 o) alkyl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, -C (O) - (C 9 -C 30 ) alkyl, -C (O) -cycloalkyl, -C (O) -cycloalkylalkyl, -C (O) -arylalkyl, -C (O) -heteroarylalkyl, - C (O) -heterocyclyl, -C (O) - heterocyclylalkyl, -S (O 2) alkyl, -S (0 2) - (C 9 -C 3 O) alkyl, -S (O 2) - cycloalkyl, (2 O) -S cycloalkyl,
  • substitution group (II) may be independently further substituted with at least one substituent, same or different, selected from the group consisting of:
  • T587, T588, T589, T590, T591, T592, T593, T594, T595, T596, T597, T598, T599, T600, T601, T602, T603, T604, T605, T606, T607, T608, T609, T610, T611, T612 are independently selected from the group consisting of
  • T606 may each together also form "heterocyclyl";
  • (ii) may in turn be independently substituted with at least one substituent, the same or different, selected from the group consisting of:
  • T639, T640, T641, T642, T643, T644, T645, T646, T647, T648, T649, T650, T651, T652, T653, T654, T655, T656, T657, T658, T659, T660, T661, T662, T663, T664 are independently selected from the group con- sisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylal- kyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaromatics ryl, heteroarylalkyl" and wherein alternatively T619 , T620 and / or T628, T629 and / or T641, T642 and / or T648, T649 and / or T657, T658 may each together also form "heterocyclyl";
  • Z28, Z29 or none of Z28, Z29 and Z30, Z31 or none of Z30, Z31 and Z32 is independently selected from the group consisting of: (III) "hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C (O) -alkyl, -C (O) -aryl, -C (O) -heteroaryl ", where optionally above substituents of the substituent group (IM) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
  • T684, T685, T686, T687, T688, T689, T690, T691, T692, T693, T694, T695, T696, T697, T698, T699, T700, T701, T702, T703, T704, T705, T706, T707, T708, T709, T710, T71 1, T712, T713, T714, T715, T716 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively T671, T672 and / or T680, T681 and / or T693, T694 and / or T700, T701 and / or T709, T710 may together also also form" heterocyclyl "; optional
  • T734 T735, T736, T737, T738, T739, T740, T741, T742,
  • T743, T744, T745, T746, T747, T748, T749, T750, T751, T752, T753, T754, T755, T756, T757, T758, T759, T760, T761, T762, T763, T764, T765, T766, T767, T768 are independently selected from the group consisting of
  • alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and wherein alternatively T723, T724 and / or T732, T733 and / or T745, T746 and or T752, T753 and / or T761, T762 may together also form "heterocyclyl";
  • (ii) may in turn be independently substituted with at least one substituent, the same or different, selected from the group consisting of: (iii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, as heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl, F, Cl, Br, I, CN, CF 3, N 3 , NH 2 , -NHT769, - NT770T771, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, - OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -
  • OSi (T788) (T789), (T790), -OS (O 2) -T791, -NHC (O) -T792, -NT793C (O) -T794, -NH-C (O) -O-T795, -NH -C (O) -NH-T796, -NH-C (O) -NT797T798, -NT799-C (O) -O-T800, -NT801 -C (O) -NH-T802, -NT803-C ( O) - NT804T805, -NHS (O 2) -T806, -NT807S (O 2) -T808, -S-S-
  • NT836T837 -OP (O) (OT838) (OT839), -OSi (T840) (T814), (T842), -OS (O 2) -T843, -NHC (O) -T844, -NT845C (O) -T846 , -NH-C (O) -O-T847, -NHC (O) -NH-T848, -NH-C (O) -NT849T850, -NT851-C (O) -O-T852, -NT853- C (O) -NH-T854, -NT855- C (O) -NT856T857, -NHS (O 2) -T858, -NT859S (O 2) -T860, -S-S-
  • T870, T871, T872 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, Cyc loalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, hetero- aryl, heteroarylalkyl" and wherein alternatively T827, T828 and / or
  • T866 may together also form "heterocyclyl", wherein optionally substituents of the substituent group (i) above may also be further substituted independently of one another
  • alkyl (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT873, -NT874T875, -NO 2 , -
  • OSi T892 (T893), (T894), -OS (O 2) -T895, -NHC (O) -T896 - NT897C (O) -T898, -NH-C (O) -O-T899, -NH -C (O) -NH-T900, -NH-C (O) -NT901T902, -NT903-C (O) -O-T904, - NT905-C (O) -NH-T906, -NT907-C (O ) -NT908T909, -
  • T924 T873, T874, T875, T876, T877, T878, T879, T880, T881, T882, T883, T884, T885, T886, T887, T888, T889, T890, T891, T892, T893, T894, T895, T896, T897 , T898, T899, T900, T901, T902, T903, T904, T905, T906, T907, 5 T908, T909, T910, T911, T912, T913, T914, T915, T916,
  • T917, T918, T919, T920, T921, T922, T923, T924 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl
  • T879, T880 and / or T888, T889 and / or T901, T902 and / or T908, T909 and / or T917, T918 may together also form "heterocyclyl"; optionally substituents of the substituent group (ii) above may be substituted independently of one another
  • NEN having at least one substituent, the same or different, selected from the group consisting of:
  • alkyl "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT925, -
  • T969, T970, T971, T972, T973, T974, T975 are, T976 independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylal- kyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively T931, T932 and / or T940, T941 and / or T953, T954 and / or T960, T961 and / or T969, T970 can each also together form" heterocyclyl ";
  • radicals Z26, Z27 or none of the radicals Z26, Z27 independently of one another is also selected from the group consisting of:
  • alkyl "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- cyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C (O) -alkyl, -
  • OSi T996) (T997), (T998), -OS (O 2) -T999, -NHC (O) -TIOOO, - NT1001C (O) -TI002, -NH-C (O) -O-TI003, -NH -C (O) -NH-TI004, -NH-C (O) -NTI005T1006, -NT1007-C (O) -O-TI008, -NT1009-C (O) -NH-TIOIO 1 -NTIOII-C (O ) -NTIO ⁇ TIOIS 1 -NHS (O 2 ) - T 1014, -NT 10 15 S (O 2 ) -T 10 16, -S-T 10 17, -S (O) -TiO 18, -S (O 2 ) -
  • T1005, T1006, T1007, T1008, T1009, T1010, T1011, T1012, T1013, T1014, T1015, T1016, T1017, T1018, T1019, T1020, T1021, T1022, T1023, T1024, T1025, T1026, T1027, T1028 are independently selected are selected from the group consisting of: "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl” and alternatively T983, T984 and / or T992, T993 and / or T1005, T1006 and / or T1012, T1013 and / or T1021, T1022 may together also form "heterocyclyl"; in which optional substituents of substituent group (i) may in turn also be further substituted with at least one substituent
  • T1056 -NH-C (O) -NTI057T1058, -NT1059-C (O) -O-TI060, -NT1061-C (O) -NH-TI062, -NT1063-C (O) -NTI064T1065, -NHS (O 2) -T1066, -NT1067S (O 2) -T1068, -S-T1069, -S (O) - T1070, -S (O 2) -T1071, -S (O 2) NH-TI072, -S (O 2 ) NTI073T1074, -S (O 2 ) O-TI075, -P (O) (OTI076) (OT1077),
  • T1060, T1061, T1062, T1063, T1064, T1065, T1066, T1067, T1068, T1069, T1070, T1071, T1072, T1073, T1074, T1075, T1076, T1077, T1078, T1079, T1080 are independently selected from the group consisting of "Alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclicalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively T 1035, T 1036 and / or T 1044, T 1045 and / or T 1057, T 1058 and or T1064, T1065 and / or T1073, T1074 may together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of
  • alkyl "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT1081, -NT1082T1083, - NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Ti 084, -
  • T1 126 may together also form "heterocyclyl"; and one of the radicals Z1, Z2 or none of the radicals Z1, Z2 is independently selected from the group consisting of:
  • T1 172, T1173, T1 174, T1175, T1176, T1177, T1 178, T1179, T1 180, T1181, T1 182, T1 183, T1184 are independently selected from the group consisting of: "alkyl, (Cg -
  • T1 139, T1140 and / or T1148, T1 149 and / or T1 161, T1162 and / or T1168, T1 169 and T1177, T1 178 may together also form "heterocyclyl"; optionally optionally substituents of the substituent group (c) may be further independently substituted with at least one substituent, same or different, selected from the group consisting of: "Alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N
  • T1234 (T1235) (T1236) "where T1 185, T1186, T1 187, T1188, T1189, T1190, T1191, T1192, T1193, T1194, T1195, T1196, T1197, T1198, T1199, T1200, T1201, T1202, T1203, T1204, T1205, T1206, T1207, T1208, T1209, T1210, T1211, T1212, T1213, T1214, T1215, T1216, T1217, T1218, T1219,
  • T1220, T1221, T1222, T1223, T1224, T1225, T1226, T1227, T1228, T1229, T1230, T1231, T1232, T1233, T1234, T1235, T1236 are independently selected from the group consisting of: "alkyl, (C 9 - C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively
  • T1191, T1 192 and / or T1200, T1201 and / or T1213, T1214 and / or T1220, T1221 and / or T1229, T1230 may together also form "heterocyclyl", where optionally substituents of the substituent group (i) above are also independent may be substituted with at least one substituent, identical or different, selected from the group consisting of:
  • NT1269-C (O) -NH-T1270, -NT1271-C (O) -NT1272T1273, - NHS (O 2) -T1274, -NT1275S (O 2) -T1276, -S-T1277, -S (O) - T1278, -S (O 2) -T1279, -S (O 2) NH-T1280, -S (O 2) NT1281T1282, - S (O 2) O-TI283, -P (O) (OTI284) (OT1285) , Si (T1286) (T1287) (T1288) "; wherein T1237, T1238, T1239, T1240, T1241, T1242, T1243, T1244, T1245, T1246, T1247, T1248, T1249, T1250, T1251, T1252, T1253, T1254 , T1255, T1256, T1257, T1258, T1259, T1260, T126
  • T1277, T1278, T1279, T1280, T1281, T1282, T1283, T1284, T1285, T1286, T1287, T1288 independently selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively
  • T1243, T1244 and / or T1252, T1253 and / or T1265, T1266 and / or T1272, T1273 and / or T1281, T1282 may together also form "heterocyclyl";
  • OSi (T1308) (T1309) (T1310), - OS (O 2) -T1311, -NHC (O) -T1312, - NT1313C (O) -TI314, -NH-C (O) -O-TI315, -NH -C (O) -NH-T1316, -NH-C (O) -NTI317T1318, -NT1319-C (O) -O-TI320, -NT1321-C (O) -NH-T1322, -NT1323-C (O ) -NTI324T1325, - NHS (O 2 ) -T 1326, -NT 1327S (O 2 ) -T 1328, -S-T 1329, -S (O) -
  • T1304, T1305, T1306, T1307, T1308, T1309, T1310, T1311, T1312, T1313, T1314, T1315, T1316, T1317, T1318, T1319, T1320, T1321, T1322, T1323, T1324, T1325, T1326, T1327, T1328, are T1329, T1330, T1331, T1332, T1333, T1334, T1335, T1336, T1337, T1338, T1339, T1340 independently selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively T1295, T1296 and / or T1304, T1305 and / or T1317, T1318 and / or T1324, T1325 and
  • alkyl "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHT1341, -NT1342T1343, -NO 2 , -
  • alkyl "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, - NHT1393, -NT1394T1395,
  • NT1408T1409 -OP (O) (OTI410) (OTI411), - OSi (T1412) (T1413) (T1414), -OS (O 2) -T1415, -NHC (O) - T1416, -NT1417C (O) -T1418 , -NH-C (O) -O-TI419, -NH-C (O) -NH-TI420, -NH-C (O) -NT1421T1422, -NT1423-
  • T1400 T1401, T1402, T1403, T1404, T1405, T1406, T1407, T1408, T1409, T1410, T1411, T1412, T1413, T1414, T1415, T1416, T1417, T1418, T1419, T1420, T1421, T1422, T1423, T1424, T1425, T1426, T1427,
  • T1435, T1436, T1437, T1438, T1439, T1440, T1441, T1442, T1443, T1444 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively T1399, T1400 and / or T1408, T1409 and / or T1421, T1422 and / or T1428, T1429 and / or T1437, T1438 can in each case also form" heterocyclyl ";
  • T1445, T1446, T1447 are independently selected from the group consisting of: (I)" hydrogen , alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHT1448 , -NT1449T1450, - NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , - SO 3 H, -P (O) (OH) 2, -C
  • T1497 T1498) (T1499) "; wherein T1448, T1449, T1450, T1451, T1452, T1453, T1454, T1455, T1456, T1457, T1458, T1459, T1460, T1461, T1462, T1463, T1464, T1465, T1466 , T1467, T1468, T1469, T1470, T1471, T1472, T1473, T1474, T1475, T1476, T1477, T1478,
  • T1479, T1480, T1481, T1482, T1483, T1484, T1485, T1486, T1487, T1488, T1489, T1490, T1491, T1492, T1493, T1494, T1495, T1496, T1497, T1498, T1499 are independently selected from the group consisting of : "Alkyl, (Cg- C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively T1454, T1455 and / or T1463, T1464 and / or T1476, T1477 and / or T1483, T1484 and / or T1492 , T1493 together can also form 5 "heterocyclyl"; wherein optionally substituted substituents of the substitution group (I) may be independently further substituted with at least one substituent, same or different, selected from the
  • T1531, T1532, T1533, T1534, T1535, T1536, T1537, T1538, T1539, T1540, T1541, T1542, T1543, T1544, T1545, T1546, T1547, T1548, T1549, T1550, T1551 are independently selected from the group consisting of : "Alkyl, (Cg- C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and, alternatively, T1506, T1507 and / or T1515, T1516 and / or T1528, T1529 and / or T1535, T1536 and / or T1544, T1545 each may together also form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least
  • T1573, T1574, T1575, T1576, T1577, T1578, T1579, T1580, T1581, T1582, T1583, T1584, T1585, T1586, T1587, T1588, T1589, T1590, T1591, T1592, T1593, T1594, T1595, T1596, T1597, T1598, T1599, T1600, T1601, T1602, T1603 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alter-
  • T1580, T1581 and / or T1587, T1588 and / or T1596, T1597 may together also form "heterocyclyl", wherein optionally substituents of the substituent groups above
  • 10 pe (ii) may in turn be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
  • T1630 -NH-C (O) -NH-TI631, -NH-C (O) -NT1632T1633, -NT1634-C (O) -O-TI635, -NT1636-C (O) -NH-TI637, -NT1638 -C (O) -NTI639T1640, - NHS (O 2) -T1641, -NT1642S (O 2) -T1643, -S-T1644, -
  • T1604 T1605, T1606, T1607 , T1608, T1609, T1610, T1611, T1612, T1613, T1614, T1615, T1616, T1617, T1618, T1619, T1620, T1621, T1622, T1623, T1624, T1625, T1626, T1627, T1628, T1629, T1630, T1631, T1632, T1633, T1634, T1635, T1636, T1637, T1638, T1639, T1640, T1641, T1642, T1643, T1644, T1645, T1646, T1647, T1648, T1649, T1650, T1651,
  • T1652, T1653, T1654 is, T1655 independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" and wherein alternatively T1610, T161 1 and / or
  • T1619, T1620 and / or T1632, T1633 and / or T1639, T1640 and / or T1648, T1649 may each also together form "heterocyclyl", alternatively T1446, T1447 may together also form "heterocyclyl";
  • (I) is hydrogen, alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- alkyl, -C (O) alkyl, -C (0) - (C 9 -C 3 O) alkyl, -C (O) cycloalkyl, -C (O) - cycloalkylalkyl, -C (O) -aryl, -C (O) -arylalkyl, -C (O) -heteroaryl, -
  • alkyl (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
  • NHT1670 -O-C (O) -NTI 671 T1672, - OP (O) (OTI 673) (OT1674), -OSi (TI 675) (T1676) (T1677), - OS (O 2 ) -T1678, NHC (O) -TI 679, -NT1680C (O) -TI 681, -NH-C (O) -O-TI 682, -NH-C (O) -NH-TI 683, -NH-C (O) -
  • T1703, T1704, T1705, T1706, T1707 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and whereby
  • T1684, T1685 and / or T1691, T1692 and / or T1700, T1701 in each case together can also form "heterocyclyl", where optionally substituents of the substituent group (i) optionally substituted further independently of one another may be at least one substituent, the same or different, selected from the group consisting of:
  • alkyl (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,
  • T1743, T1744, T1745, T1746, T1747, T1748, T1749, T1750, T1751, T1752, T1753, T1754, T1755, T1756, T1757, T1758, T1759 are independently selected from the group consisting of: "alkyl, (C 9 - 30) C alkyl,
  • substituent group (ii) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
  • alkyl "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT1760, -NT1761T1762, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -
  • OSi (TI779) (T1780) (T1781), -OS (O 2) -T1782, - NHC (O) -TI783, -NT1784C (O) -TI785, -NH-C (O) -O- T1786, -NH -C (O) -NH-TI787, -NH-C (O) -NT1788T1789, -NT1790-C (O) -O-TI791, -NT1792-

Abstract

The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general formulae (I) and (II), their preparation and use as medicaments, in particular for the treatment of malignant and other disorders involving pathological cell proliferations.

Description

Neue Pyridopyrazine und deren Verwendung als Modulatoren von Kinasen Novel pyridopyrazines and their use as modulators of kinases
Beschreibungdescription
Technisches GebietTechnical area
Die Erfindung betrifft Kinase-Modulatoren vom Typ der Pyrido[2,3-b]pyrazine, deren Herstellung und Verwendung als Arzneimittel zur Modulation von fehlgeleiteten zellulären Signaltransduktionsprozessen, insbesondere zur Beeinflussung der Funktion von Tyrosin-, Serin-/Threonin- und Lipidkinasen und zur Behandlung von malignen bzw. benignen Tumorerkrankungen und anderen, auf pathologischen Zellproliferatio- nen beruhenden Erkrankungen, wie z. B. Restenose, Psoriasis, Arteriosklerose und Leberzirrhose.The invention relates to kinase modulators of the pyrido [2,3-b] pyrazine type, to their preparation and use as medicaments for modulating misdirected cellular signal transduction processes, in particular for influencing the function of tyrosine, serine / threonine and lipid kinases and to Treatment of malignant or benign tumors and other diseases based on pathological cell proliferation diseases such. B. restenosis, psoriasis, arteriosclerosis and cirrhosis.
Stand der Technik Die Aktivierung von Proteinkinasen ist ein zentrales Ereignis bei zellulärenBackground Art Activation of protein kinases is a pivotal event in cellular
Signaltransduktions-Prozessen. Eine aberrante Kinaseaktivierung wird bei diversen Krankheitszuständen beobachtet. Daher ist die gezielte Inhibition von Kinasen ein fundamentales therapeutisches Ziel.Signal transduction processes. An aberrant kinase activation is observed in various disease states. Therefore, targeted inhibition of kinases is a fundamental therapeutic target.
Die Phosphorylierung von Proteinen wird im Allgemeinen durch extrazelluläre Sig- nale initiiert und stellt einen universellen Mechanismus für die Kontrolle von verschiedenen zellulären Ereignissen, wie z. B. metabolischen Prozessen, Zellwachstum, Zellmigration, Zelldifferenzierung, Membrantransport und Apoptose dar. Für die Proteinphosphorylierung ist die Proteinfamilie der Kinasen verantwortlich. Diese Enzyme katalysieren den Phosphat-Transfer zu spezifischen Substratproteinen. Basierend auf der Substratspezifität werden die Kinasen in drei Hauptklassen, die Tyrosinkinasen, die Serin/Threonin-Kinasen und die Lipidkinasen unterteilt. Sowohl die Rezeptor- Tyrosinkinasen als auch die cytoplasmatischen Tyrosin-, Serin/Threonin- und Lipidkinasen sind wichtige Proteine der Signaltransduktion der Zelle. Eine Überexpression bzw. Entartung dieser Proteine spielt eine wichtige Rolle bei auf pathologischen Zellproliferationen beruhenden Erkrankungen. Dazu zählen unter anderem Stoffwechselerkrankungen, Erkrankung des Bindegewebes und der Blutgefäße, sowie maligne und benigne Tumorerkrankungen. Bei der Tumorentstehung und Entwicklung treten sie häufig als Onkogene d.h. als aberrante, konstitutiv aktive Kinaseproteine auf. Die Folgen dieser übermäßigen Kinaseaktivierung sind z. B. das unkontrollierte Zellwachstum und der reduzierte Zelltod. Auch die Stimulation von tumorinduzierten Wachstumsfaktoren kann Ursache für die Überstimulation von Kinasen sein. Die Entwicklung von Kinasemodulatoren ist daher von besonderem Interesse für alle pathogenen Prozesse, die durch Kinasen beeinflusst werden.The phosphorylation of proteins is generally initiated by extracellular signals and provides a universal mechanism for the control of various cellular events, such as cell proliferation. As metabolic processes, cell growth, cell migration, cell differentiation, membrane transport and apoptosis. For protein phosphorylation, the protein family of kinases is responsible. These enzymes catalyze the phosphate transfer to specific substrate proteins. Based on substrate specificity, the kinases are divided into three major classes, the tyrosine kinases, the serine / threonine kinases, and the lipid kinases. Both the receptor tyrosine kinases and the cytoplasmic tyrosine, serine / threonine and lipid kinases are important proteins of the signal transduction of the cell. Overexpression or degeneration of these proteins plays an important role in disorders based on pathological cell proliferation. These include metabolic diseases, connective tissue and blood vessel diseases, as well as malignant and benign tumors. They occur in tumor development and development often as oncogenes, ie as aberrant, constitutively active kinase proteins. The consequences of this excessive Kinaseaktivierung are z. For example, uncontrolled cell growth and reduced cell death. The stimulation of tumor-induced growth factors can also be the cause of the overstimulation of kinases. The development of kinase modulators is therefore of particular interest for all pathogenic processes that are influenced by kinases.
Die Signaltransduktionskaskaden ras-Raf-Mek-Erk und PI3K-Akt spielen eine zentrale Rolle bei Zellwachstum, Zeilproliferation, Apoptose, Adhäsion, Migration und GIu- kose Stoffwechsel. So ist die fundamentale Beteiligung an der Pathogenese von Erkrankungen wie Krebs, Neurodegeneration und endzündlichen Erkrankungen sowohl für den ras-Raf-Mek-Erk- als auch für den PI3K-Akt-Signalweg belegt. Daher stellen die Einzelkomponenten dieser Signalkaskaden wichtige therapeutische Angriffspunkte für die Intervention der verschiedenen Krankheitsprozesse dar (Weinstein- Oppenheimer CR. et al 2000, Chang F. et al 2003, Katso R. et al 2001 und Lu Y. et al 2003).The signal transduction cascades ras-Raf-Mek-Erk and PI3K-Akt play a central role in cell growth, cell proliferation, apoptosis, adhesion, migration and glucose metabolism. Thus, the fundamental involvement in the pathogenesis of diseases such as cancer, neurodegeneration and inflammatory diseases has been demonstrated for both ras-Raf-Mek-Erk and PI3K-Akt signaling pathways. Therefore, the individual components of these signaling cascades represent important therapeutic targets for the intervention of the various disease processes (Weinstein-Oppenheimer CR et al 2000, Chang F. et al., 2003, Katso R. et al., 2001 and Lu Y. et al., 2003).
Im Folgenden sind die molekularen und biochemischen Eigenschaften beider Signalwege zunächst gesondert beschrieben.The molecular and biochemical properties of both signaling pathways are described separately below.
Eine Vielzahl von Wachstumsfaktoren, Zytokinen und Onkogenen transduziert ihre wachstumsfördernden Signale über die Aktivierung von G-Protein gekuppeltem ras, welches zur Aktivierung der Serin-Threonin-Kinase Raf und zur Aktivierung der Mitogen aktivierten Protein Kinase Kinase 1 und 2 (MAPKK1/2 oder Mek1/2) führt und in der Phosphorylierung und Aktivierung der MAPK 1 und 2 - auch bekannt als Extrazel- lulär Signal Regulierte Kinase (Erk1 und 2) - resuliert. Verglichen mit anderen Signalwegen vereint der ras-Raf-Mek-Erk-Signalweg eine große Anzahl an Protoonkogenen, eingeschlossen Liganden, Tyrosinkinase-Rezeptoren, G-Proteinen, Kinasen und nuklearen Transkriptionsfaktoren. Tyrosin-Kinasen, wie z.B. der EGFR (Men- delsohn J. et al., 2000) vermitteln im Tumorgeschehen, bedingt durch Überexpression und Mutation, häufig konstitutiv aktive Signale an den nachgeschalteten ras-Raf-Mek- Erk-Signalweg. Ras Mutationen sind in 30% aller humanen Tumore mutiert (Khleif S. N. et al., 1999, Marshall C, 1999) wobei die höchste Inzidenz mit 90% bei Pankreaskarzi- nomen liegt (Friess H. et al., 1996, Sirivatanauksorn V. et al., 1998). Für c-Raf wurde bei verschiedenen Tumoren eine deregulierte Expression und/oder Aktivierung be- schrieben (Hoshino R. et al., 1999, McPhillips F. et al., 2001 ). B-Raf-Punktmutanten wurden in 66% aller humanen malignen Melanome, 14% ovarialen und 12% Kolonkarzinomen detektiert (Davies H. et al., 2002). Daher ist es nicht überraschend, dass Erk1/2 an vielen zellulären Prozessen wie Zellwachstum, Zeilproliferation und Zelldiffe- renzierung primär beteiligt ist (Lewis T. S. et al., 1998, Chang F. et al., 2003).A variety of growth factors, cytokines and oncogenes, transduce their growth-promoting signals via activation of G-protein coupled ras, which is used to activate the serine-threonine kinase Raf and to activate mitogen-activated protein kinase kinase 1 and 2 (MAPKK1 / 2 or Mek1 / 2) and in the phosphorylation and activation of MAPK 1 and 2 - also known as Extracellular Signal Regulated Kinase (Erk1 and 2). Compared with other signaling pathways, the ras-Raf-Mek-Erk pathway combines a large number of proto-oncogenes, including ligands, tyrosine kinase receptors, G proteins, kinases, and nuclear transcription factors. Tyrosine kinases, such as EGFR (Menelsohn J. et al., 2000) often mediate constitutive active signals to the downstream ras-Raf-Mek- Erk signaling pathway in tumors due to overexpression and mutation. Ras mutations are mutated in 30% of all human tumors (Khleif SN et al., 1999, Marshall C, 1999), the highest incidence being 90% in pancreatic carcinomas (Friess H. et al., 1996, Sirivatanauksorn V. et al., 1998). For c-Raf, deregulated expression and / or activation of various tumors has been reported. (Hoshino R. et al., 1999, McPhillips F. et al., 2001). B-Raf point mutants were detected in 66% of all human malignant melanomas, 14% ovarian and 12% colon cancers (Davies H. et al., 2002). Thus, it is not surprising that Erk1 / 2 is primarily involved in many cellular processes such as cell growth, cell proliferation, and cell differentiation (Lewis TS et al., 1998, Chang F. et al., 2003).
Darüberhinaus haben die Mitglieder der Raf-Kinasen auch Mek-Erk unabhängige, anti-apoptotische Funktionen, deren molekulare Schritte noch nicht vollständig beschrieben sind. Als mögliche Interaktionspartner für die Mek-Erk-unabhängige Raf- Aktivität wurden Ask1 , Bcl-2, Akt und Bag1 beschrieben (Chen J et al., 2001 , Tropp- maier J. et al., 2003, Rapp U.R. et al., 2004, Götz R. et al., 2005). Man geht heute davon aus, daß sowohl Mek-Erk-abhängige als auch Mek-Erk-unabhängige Signaltrans- duktions-Mechanismen die Aktivierung der oberhalb gelegenen Stimuli ras und Raf steuern.In addition, members of Raf kinases also have Mek-Erk independent, anti-apoptotic functions, whose molecular steps are not yet fully described. Ask1, Bcl-2, Akt and Bag1 have been described as possible interaction partners for the Mek-Erk-independent Raf activity (Chen J et al., 2001, Troppajier J. et al., 2003, Rapp UR et al., 2004, Gotz R. et al., 2005). It is now believed that both Mek-Erk-dependent and Mek-Erk-independent signal transduction mechanisms control the activation of the ras and Raf stimuli located above.
Die Isoenzyme der Phosphatidylinositol 3-Kinasen (PI3Ks) fungieren vorwiegend als Lipidkinasen und katalysieren die D3-Phosphorylierung der Second-Messenger Lipide Ptdlns (Phosphatidylinositol) zu Ptdlns(3)P, Ptdlns(3,4)P2, Ptdlns(3,4,5)P3 Phosphatidylinositolphosphaten. Die PI3Ks der Klasse I setzen sich strukturell aus der katalytischen (pHOalpha, beta, gamma, delta) und der regulatorischen (p85alpha, beta oder p101gamma) Untereinheit zusammen. Weiterhin gehören die Klasse II-(PI3K- C2alpha, PI3K-C2beta) und Klasse IN-(Vps34p)Enzyme zur Familie der PI3-Kinasen (Wymann M. P. et al., 1998, VanHaesebroeck B. et al., 2001 ). Der durch die PI3Ks ausgelöste PIP-Anstieg aktiviert einerseits den proliferativen ras-Raf-Mek-Erk Signalweg über die Kupplung von ras (Rodriguez-Viciana P. et al., 1994) und stimuliert ande- rerseits den anti-apoptotischen Signalweg durch Rekrutierung von Akt an die Zellmembran und folglicher Überaktivierung dieser Kinase (Alessi D. R. et al., 1996, Chang H.W. et al., 1997, Moore S. M. et al., 1998). Somit erfüllt die Aktivierung der PI3Ks mindestens 2 entscheidende Mechanismen der Tumorentstehung, nämlich die Aktivierung von Zellwachstum und Zelldifferenzierung und die Inhibition der Apoptose. Darüberhi- naus verfügen die PI3K auch über Protein-phosphorylierende Eigenschaften (Dhand et al., 1994, Bondeva T. et al., 1998, Bondev A. et al., 1999, VanHaesebroeck B. et al., 1999) die z.B. eine die PI3Ks intrinsisch regulierende Serin-Autophosphorylierung auslösen kann. Außerdem ist bekannt, dass PI3Ks auch Kinase-unabhängige, regulierende Effektor-Eigenschaften haben z.B. bei der Kontrolle der Herzkontraktion (Crackower - A -The isoenzymes of phosphatidylinositol 3-kinases (PI3Ks) function predominantly as lipid kinases and catalyze the D3 phosphorylation of second messenger lipids Ptdlns (phosphatidylinositol) to Ptdlns (3) P, Ptdlns (3,4) P 2 , Ptdlns (3,4 , 5) P 3 phosphatidylinositol phosphates. The class I PI3Ks are structurally composed of the catalytic (pHOalpha, beta, gamma, delta) and regulatory (p85alpha, beta or p101gamma) subunits. Furthermore, the class II (PI3K-C2alpha, PI3K-C2beta) and class IN (Vps34p) enzymes belong to the family of PI3 kinases (Wymann MP et al., 1998, Van Haesebroeck B. et al., 2001). On the one hand, the PIP increase triggered by PI3Ks activates the proliferative ras-Raf-Mek-Erk signaling pathway via the coupling of ras (Rodriguez-Viciana P. et al., 1994) and, on the other hand, stimulates the anti-apoptotic pathway by recruiting Act to the cell membrane and consequent overactivation of this kinase (Alessi DR et al., 1996, Chang HW et al., 1997, Moore SM et al., 1998). Thus, the activation of PI3Ks fulfills at least 2 crucial mechanisms of tumorigenesis, namely the activation of cell growth and cell differentiation and the inhibition of apoptosis. In addition, the PI3K also have protein-phosphorylating properties (Dhand et al., 1994, Bondeva T. et al., 1998, Bondev A. et al., 1999, Van Haesebroeck B. et al., 1999), eg which can trigger PI3Ks intrinsically regulating serine autophosphorylation. It is also known that PI3Ks also have kinase-independent, regulatory effector properties, for example in the control of cardiac contraction (Crackower - A -
M.A. et al., 2002, Patrucco et al., 2004). Ferner ist belegt, dass PI3Kdelta und PI3Kgamma auf hematopoietischen Zellen spezifisch exprimiert werden und damit potenzielle Angriffpunkte für Isoenzym-spezifische PI3Kdelta- und PI3Kgamma- Inhibitoren bei der Behandlung von inflammatorischen Erkrankungen wie Rheuma, Asthma und Allergien und bei der Behandlung von B- und T-Zelllymphomen (Okken- haug K. et al., 2003, Ali K. et al., 2004, Sujobert P. et al., 2005) darstellen. Die PI3Kalpha, welche kürzlich als Proto-Onkogen identifiziert wurde (Shayesteh L. et al., 1999, Ma Y.Y. et al., 2000, Samuels Y. et al., 2004, Campbell I.G. et al., 2004, Levine D.A., 2005) gilt als wichtiges Target bei der Therapie von Tumorerkrankungen. Die Bedeutung der PI3K-Spezies als Target für die Wirkstoffentwicklung ist daher äußerst vielfältig (Chang F. & Lee JT. et al, 2003).M.A. et al., 2002, Patrucco et al., 2004). Furthermore, it has been demonstrated that PI3Kdelta and PI3Kgamma are specifically expressed on hematopoietic cells and thus potential targets for isoenzyme-specific PI3Kdelta and PI3Kgamma inhibitors in the treatment of inflammatory diseases such as rheumatism, asthma and allergies and in the treatment of B- and T- Cell lymphomas (Okkenhaug K. et al., 2003, Ali K. et al., 2004, Sujobert P. et al., 2005). PI3Kalpha, which has recently been identified as a proto-oncogene (Shayesteh L. et al., 1999, Ma YY et al., 2000, Samuel's Y. et al., 2004, Campbell IG et al., 2004, Levine DA, 2005 ) is considered to be an important target in the treatment of tumor diseases. The importance of the PI3K species as a target for drug development is therefore extremely diverse (Chang F. & Lee JT et al., 2003).
Von ebenso großem Interesse sind die PI3K verwandten Kinasen (PIKK), welche die Serin/Threonin-Kinasen mTOR, ATM, ATR, h-SMG-1 und DNA-PK (Chiang G.G. et al 2004) einschließen. Ihre katalytischen Domänen haben eine hohe Sequenz- Homologie zur katalytische Domäne der PI3Ks.Also of great interest are the PI3K-related kinases (PIKK), which include the serine / threonine kinases mTOR, ATM, ATR, h-SMG-1, and DNA-PK (Chiang G.G. et al., 2004). Their catalytic domains have high sequence homology to the catalytic domain of the PI3Ks.
Überdies trägt der Verlust des Tumorsuppressor-Proteins PTEN (Li J. et al., 1997,Moreover, the loss of the tumor suppressor protein PTEN (Li J. et al., 1997,
Steck P.A. et al., 1997) - dessen Funktion die Reversion der durch die PI3K initiiertePlug P.A. et al., 1997) - the function of which is the reversion of those initiated by the PI3K
Phosphorylierung ist - zu einer Überaktivierung von Akt und deren abwärts gelegenen Kaskade-Komponenten bei und unterstreicht damit die kausale Bedeutung von PI3K als Zielmolekül für die Tumortherapie.Phosphorylation contributes to the overactivation of Akt and its downstream cascade components, thus underlining the causal role of PI3K as a target for tumor therapy.
Diverse Inhibitoren von Einzelkomponenten der ras-Raf-Mek-Erk und PI3K-Akt- Signalwege sind bereits publiziert und patentiert worden.Various inhibitors of individual components of ras-Raf-Mek-Erk and PI3K-Akt signaling pathways have already been published and patented.
Der gegenwärtige Entwicklungsstand auf dem Gebiet der Kinase-Inhibitoren, besonders des ras-Raf-Mek-Erk- und des PI3K-Akt-Weges wird in den Übersichten von J. S. Sebolt-Leopold et al., 2004, und R. Wetzker et al., 2004 dargestellt. In benannten Publikation finden sich umfassende Auflistungen der offengelegten Patentschriften, die die Synthese und Anwendung niedermolekularer ras-Raf-Mek-Erk- und PI3K-lnhibitoren beschreiben. Der bereits in klinischer Erprobung befindliche Kinaseinhibitor Bay 43-9006 (WO 99/321 11 , WO 03/068223) zeigt ein relativ unspezifisches Inhibitionsmuster von Se- rin/Threonin- und von Tyrosin-Kinasen wie Raf, VEGFR2/3, Flt-3, PDGFR, c-Kit und weiteren Kinasen. Diesem Inhibitor wird bei durch Angiogenese-induzierten fortgeschrittenen Tumorerkrankungen (z.B. beim Nierenzellkarzinom) aber auch bei Melanomen mit hoher B-Raf-Mutationsrate eine große Bedeutung zugemessen. Die klinische Wirkung von Bay 43-9006 wird zurzeit außerdem an Patienten mit refraktären soliden Tumoren in Kombination z.B. mit Docetaxel ermittelt. Bislang wurden milde Nebenwirkungen und vielversprechende anti-tumorale Effekte beschrieben. Eine Inhibition der Kinasen im PI3K-Akt- Signalweg ist für Bay 43-9006 nicht beschrieben oder offenbart.The current state of development in the field of kinase inhibitors, especially the ras-Raf-Mek-Erk and the PI3K-Akt pathway, is reviewed in reviews by JS Sebolt-Leopold et al., 2004, and R. Wetzker et al. , 2004. The named publication contains a comprehensive list of published patent specifications describing the synthesis and application of low molecular weight ras Raf Mek Erk and PI3K inhibitors. The kinase inhibitor Bay 43-9006 (WO 99/32111, WO 03/068223) already in clinical trials shows a relatively nonspecific inhibition pattern of serine / threonine and tyrosine kinases such as Raf, VEGFR2 / 3, Flt-3 , PDGFR, c-Kit and other kinases. This inhibitor is of great importance in angiogenesis-induced advanced tumor diseases (eg in renal cell carcinoma) but also in melanomas with a high B-Raf mutation rate. The clinical effect of Bay 43-9006 is currently also being investigated in patients with refractory solid tumors in combination with eg docetaxel. So far, mild side effects and promising anti-tumoral effects have been described. Inhibition of the kinases in the PI3K-Akt signaling pathway is not described or disclosed for Bay 43-9006.
Der Mek1/2-lnhibitor PD0325901 (WO 02/06213) befindet sich derzeit in klinischer Erprobung der Phase I. Die Vorläufersubstanz CM 040 (WO 00/35435, WO 00/37141 ) fiel durch ihre hohe Mek-Spezifität und Target-Affinität auf. Jedoch erwies sich diese Verbindung in Phase I/Il-Studien als metabolisch instabil. Klinische Daten der aktuellen Nachfolgersubstanz PD0325901 stehen noch aus. Jedoch ist für diesen Mek-Inhibitor weder eine Wechselwirkung mit Erk1 oder Erk2 noch eine den PI3K-Akt-Signalweg inhibierende Funktion oder deren gleichzeitige Modulation publiziert oder offenbart.The Mek1 / 2 inhibitor PD0325901 (WO 02/06213) is currently undergoing Phase I clinical trials. The precursor CM 040 (WO 00/35435, WO 00/37141) was noted for its high Mek specificity and target affinity , However, this compound proved to be metabolically unstable in Phase I / II studies. Clinical data of the current successor substance PD0325901 are pending. However, neither an interaction with Erk1 or Erk2, nor a PI3K-Akt signaling pathway inhibiting function or its simultaneous modulation is published or disclosed for this Mek inhibitor.
Die bislang publizierten PI3K-lnhibitoren befinden sich in präklinischer Erprobung.The previously published PI3K inhibitors are in preclinical testing.
ICOS offenbarte einen PI3K-lnhibitor IC87114 mit hoher PI3Kdelta Isoenzymspezifität (WO 01/81346). Für PI103 (WO 04/017950) beschreiben Yamanouchi/Piramed eine Selektivität versus der PI3Kalpha Isoform. In der frühen Entwicklung von PI3K-lnhibitoren existiert darüberhinaus ein stark beachtetes Forschungs-Umfeld (s. Übersicht R. Wetzker et al., 2004).ICOS disclosed a PI3K inhibitor IC87114 with high PI3Kdelta isoenzyme specificity (WO 01/81346). For PI103 (WO 04/017950) Yamanouchi / Piramed describe a selectivity versus the PI3Kalpha isoform. In addition, in the early development of PI3K inhibitors, a highly regarded research environment exists (see review R. Wetzker et al., 2004).
Inhibitoren des SAPK-Signalweges, entweder von Jnk oder von p38 sind in der Literatur beschrieben (Gum RJ. , 1998, Bennett B. L. et al 2001 , Davies S. P. et al 2000). Jedoch ist für diese SAPK-Inhibitoren keine die PI3Ks inhibierende Funktion und auch keine spezifische Inhibition der Erk1 oder Erk2 oder auch gleichzeitige Inhibition von SAPKs, Erk1 , Erk2, oder PI3Ks offenbart. In 6- oder 7-Position substituierte Pyrido[2,3-b]pyrazin-Derivate finden als pharmakologisch aktive Verbindungen und als Synthesebausteine in der pharmazeutischen Chemie vielfältige Verwendung.Inhibitors of the SAPK signaling pathway, either from Jnk or p38, are described in the literature (Gum RJ., 1998, Bennett BL et al 2001, Davies SP et al 2000). However, for these SAPK inhibitors, no PI3Ks-inhibiting function and also no specific inhibition of Erk1 or Erk2 or simultaneous inhibition of SAPKs, Erk1, Erk2, or PI3Ks is disclosed. In the 6- or 7-position substituted pyrido [2,3-b] pyrazine derivatives are widely used as pharmacologically active compounds and as building blocks in pharmaceutical chemistry.
Beispielsweise werden in den Patentschriften WO 04/104002 und WO 04/104003 Pyrido[2,3-b]pyrazine beschrieben, die in 6- oder 7-Position mit Harnstoff-, Thio- harnstoff-, Amidin- oder Guanidingruppen substituiert sein können. Diese Verbindungen besitzen Eigenschaften als Inhibitoren bzw. Modulatoren von Kinasen, insbesondere von Tyrosin- und Serin/Threoninkinasen und es ist eine Verwendung als Arzneimittel angegeben. Demgegenüber ist eine Verwendung dieser Verbindungen als Modu- latoren von Lipidkinasen, alleine oder in Kombination mit Tyrosin- und Serin/Threoninkinasen, nicht beschrieben.For example, the patents WO 04/104002 and WO 04/104003 describe pyrido [2,3-b] pyrazines, which may be substituted in the 6- or 7-position by urea, thiourea, amidine or guanidine groups. These compounds possess properties as inhibitors or modulators of kinases, in particular of tyrosine and serine / threonine kinases, and a use as medicaments is indicated. In contrast, a use of these compounds as modulators of lipid kinases, alone or in combination with tyrosine and serine / threonine kinases, is not described.
Weiterhin werden in der Patentschrift WO 99/17759 Pyrido[2,3-b]pyrazine beschrieben, die in 6-Position unter anderem Alkyl-, Aryl- und Heteroarylsubstituierte Carbamate tragen. Diese Verbindungen sollen dazu verwendet werden, die Funktion von Serin-Threonin-Proteinkinasen zu modulieren.Furthermore, the patent WO 99/17759 describes pyrido [2,3-b] pyrazines which carry, inter alia, alkyl, aryl and heteroaryl-substituted carbamates in the 6-position. These compounds will be used to modulate the function of serine-threonine protein kinases.
In der Patentschrift WO 05/007099 (Kawakami et al.) werden unter anderem auch Harnstoff-substituierte Pyrido[2,3-b]pyrazine als Inhibitoren der Serin/Threoninkinase PKB beschrieben. Allerdings ist in dieser Patentschrift der Rest R, der den Substituti- onsumfang am Harnstoff beschreiben soll, nicht weiter definiert und somit ist der Um- fang der Substitution am Harnstoff nicht eindeutig offenbart. Für diese Verbindungen wird eine Verwendung bei der Behandlung von Krebserkrankungen angegeben. Allerdings werden keine konkreten Beispiele von Harnstoff-substituierten Pyridopyrazinen mit diesen biologischen Eigenschaften aufgeführt. Zusätzlich unterscheiden sich die hier beschriebenen Pyridopyrazine strukturell deutlich von den in dieser Erfindung be- schriebenen erfindungsgemäßen Pyrido[2,3-b]pyrazinen.The patent specification WO 05/007099 (Kawakami et al.) Also describes urea-substituted pyrido [2,3-b] pyrazines as inhibitors of serine / threonine kinase PKB. However, in this patent specification, the radical R, which is intended to describe the extent of substitution on urea, is not further defined, and thus the extent of substitution on urea is not clearly disclosed. These compounds are indicated for use in the treatment of cancers. However, no concrete examples of urea-substituted pyridopyrazines having these biological properties are listed. In addition, the pyridopyrazines described here differ structurally distinctly from the pyrido [2,3-b] pyrazines according to the invention described in this invention.
Weitere Beispiele für in 6- und 7-Position Harnstoff-substitutierte Pyrido[2,3- b]pyrazine werden in der Patentschrift WO 05/056547 (Bemis et al.) angegeben. Die Verbindungen in dieser Patentschrift haben allerdings in 2- oder 3-Position zusätzliche Carbonyl-, Sulfoxy-, Sulfon- oder Imin-Substitution, wodurch sich die Verbindungen strukturell deutlich von den in dieser Erfindung beschriebenen erfindungsgemäßen Pyrido[2,3-b]pyrazine unterscheiden. Die in WO 05/056547 angegebenen Pyridopyrazine werden als Inhibitoren von Protein-Kinasen, insbesondere von GSK-3, Syk und JAK-3, beschrieben. Für diese Verbindungen wird unter anderem eine Verwendung bei der Behandlung von proliferativen Erkrankungen angegeben. Eine Verwendung dieser Verbindungen als Modulatoren von Lipidkinasen, alleine oder in Kombination mit Se- rin/Threoninkinasen, ist nicht beschrieben.Further examples of 6- and 7-position urea-substituted pyrido [2,3-b] pyrazines are given in the patent WO 05/056547 (Bemis et al.). However, the compounds in this patent have additional carbonyl, sulfoxy, sulfonic or imine substitution in the 2- or 3-position, whereby the compounds are structurally distinct from the pyrido [2,3-b] pyrazines of the invention described in this invention differ. The pyridopyrazines indicated in WO 05/056547 are described as inhibitors of protein kinases, in particular of GSK-3, Syk and JAK-3. Amongst others, a use in the treatment of proliferative disorders is given for these compounds. A use of this Compounds as modulators of lipid kinases, alone or in combination with serine / threonine kinases, are not described.
In dem Patent WO 04/005472 von White et al. werden unter anderem in 6-Position Carbamat-substituierte Pyrido[2,3-b]pyrazine beschrieben, die als antibakterielle Sub- stanzen das Wachstum von Bakterien hemmen. Eine Antitumorwirkung ist nicht beschrieben.In the patent WO 04/005472 of White et al. are described, inter alia, in 6-position carbamate-substituted pyrido [2,3-b] pyrazines, which inhibit the growth of bacteria as antibacterial substances. An antitumor effect is not described.
Bestimmte Diphenylchinoxaline und -pyrido[2,3-b]pyrazine mit speziellen Alkylpyr- rolidin-, Alkylpiperidin- oder Alkylsulfonamid-Resten an einem Phenylring, die zusätzlich auch Harnstoff- oder Carbamat-Substitutionen in 6- oder 7-Position tragen können, werden in den Patentschriften WO 03/084473 (Barnett et al.), WO 03/086394 (Bilodeau et al.) und WO 03/086403 (Lindsley et al.) als Inhibitoren der Aktivität der Se- rin/Threonin-Kinase Akt beschrieben. Für diese Verbindungen wird eine Verwendung bei der Behandlung von Krebserkrankungen angegeben. Für die dort beschriebenen Pyrido[2,3-b]pyrazin-Beispiel-Verbindungen ist kein definierter Hinweis auf eine biolo- gische Wirkung angegeben. Ausserdem besteht ein deutlicher struktureller Unterschied zu den in dieser Erfindung beschriebenen erfindungsgemäßen Pyrido[2,3-b]pyrazinen.Certain diphenylquinoxalines and -pyrido [2,3-b] pyrazines having special alkylpyrrolidine, alkylpiperidine or alkylsulfonamide radicals on a phenyl ring, which may additionally also carry urea or carbamate substitutions in the 6- or 7-position in WO 03/084473 (Barnett et al.), WO 03/086394 (Bilodeau et al.) and WO 03/086403 (Lindsley et al.) as inhibitors of the serine / threonine kinase Akt activity. These compounds are indicated for use in the treatment of cancers. For the pyrido [2,3-b] pyrazine example compounds described there, no definite indication of a biological effect is given. In addition, there is a marked structural difference with the pyrido [2,3-b] pyrazines of the invention described in this invention.
Weiterhin werden in dem Patent WO 03/024448 von Delorme et al. Amid- und Ac- rylamid-substituierte Pyrido[2,3-b]pyrazine beschrieben, die als zusätzliche Substituen- ten auch Carbamate enthalten und als Histon Deacetylase-Inhibitoren zur Behandlung von Zellproliferationserkrankungen verwendet werden können.Furthermore, in the patent WO 03/024448 Delorme et al. Amid- and acrylamide-substituted pyrido [2,3-b] pyrazines described which also contain carbamates as additional substituents and can be used as histone deacetylase inhibitors for the treatment of cell proliferation disorders.
In einer weiteren Publikation (C. Temple, Jr.; J. Med. Chem. 1990, 3044-3050) wird an einem Beispiel die Synthese eines 6-Ethylcarbamat-substituierten Pyrido[2,3- b]pyrazin-Derivates beschrieben. Eine Antitumorwirkung ist weder offenbart noch nahegelegt. Die Synthese von weiteren Derivaten des 6-Ethylcarbamat-substituierten Pyri- do[2,3-b]pyrazins wird in einer Veröffentlichung von R. D. Elliott beschrieben (J. Org. Chem. 1968, 2393-2397). Eine biologische Wirkung dieser Verbindungen ist weder beschrieben noch nahegelegt.In another publication (C. Temple, Jr, J. Med. Chem. 1990, 3044-3050), the synthesis of a 6-ethylcarbamate-substituted pyrido [2,3-b] pyrazine derivative is described by way of example. An anti-tumor effect is neither disclosed nor suggested. The synthesis of further derivatives of 6-ethylcarbamate-substituted pyrido [2,3-b] pyrazine is described in a publication by R. D. Elliott (J. Org. Chem. 1968, 2393-2397). A biological effect of these compounds is neither described nor suggested.
In der Publikation von C.Temple, Jr. J. Med. Chem. 1968,1216-1218 wird die Syn- these und Untersuchung von 6-Ethylcarbamat-substituierten Pyrido[2,3-b]pyrazinen als potentielle Antimalaria-Wirkstoffe beschrieben. Eine Antitumorwirkung ist weder offenbart noch nahegelegt. Darstellunq der ErfindungThe publication by C.Temple, Jr. J. Med. Chem. 1968, 1216-1218 describes the synthesis and study of 6-ethylcarbamate-substituted pyrido [2,3-b] pyrazines as potential antimalarial drugs. An anti-tumor effect is neither disclosed nor suggested. Darstellunq of the invention
Die Erfindung ist daher darauf ausgerichtet, neue Verbindungen zu schaffen, die als Modulatoren von Rezeptor-Tyrosinkinasen, von cytoplasmatischen Tyrosin-, Se- rin/Threoninkinasen und Lipidkinasen geeignet sind. Da nicht alle in fehlregulierten Signaltransduktionskaskaden hintereinander geschalteten Kinasen - wie z. B. bei Raf- Mek-Erk oder PI3K-Akt - als onkogene Kinasen bzw. als konstitutiv aktive Enzyme vorliegen müssen, werden in dieser Erfindung auch die nicht-aktiven Kinasen als therapeutische Zielproteine betrachtet, d.h. die neuen Verbindungen können sowohl an aktiven als auch an nicht-aktiven Kinasen binden und damit die Signaltransduktion be- einflussen.The invention is therefore directed to providing novel compounds which are useful as modulators of receptor tyrosine kinases, cytoplasmic tyrosine, serine / threonine kinases and lipid kinases. Since not all in dysregulated signal transduction cascades connected in series kinases - such. For example, in Raf-Mek-Erk or PI3K-Akt - must be present as oncogenic kinases or as constitutively active enzymes, in this invention, the non-active kinases are considered as therapeutic target proteins, i. The new compounds can bind to both active and non-active kinases, thereby influencing signal transduction.
Die Erfindung ist weiterhin darauf ausgerichtet, neue Verbindungen zu schaffen, die als Modulatoren von Rezeptor-Tyrosinkinasen, cytoplasmatischen Tyrosin-, Se- rin/Threoninkinasen und Lipidkinasen die Eigenschaft besitzen, sowohl eine einzelne als auch zwei oder mehrere Kinasen, insbesondere Erk1/2 und PI3K, aus einem oder verschiedenen Signaltransduktionskaskaden, insbesondere ras-Raf-Mek-Erk und PI3K-Akt, zu beeinflussen. Ein dualer Mechanismus, d. h. die gleichzeitige Inhibition von zwei oder mehreren Signaltansduktionskaskaden gegenüber dem therapeutischen Angriff von nur einem Signaltransduktionsweg sollte durch die additive Wirkung zu einer Steigerung des Effektes bei der Behandlung von allen pathogenen Prozessen füh- ren, die durch Kinasen beeinflusst werden.The invention is further directed to providing novel compounds which possess as a modulator of receptor tyrosine kinases, cytoplasmic tyrosine, serine / threonine kinases and lipid kinases the property of both a single and two or more kinases, in particular Erk1 / 2 and PI3K, from one or several signal transduction cascades, in particular ras Raf Mek Erk and PI3K act to influence. A dual mechanism, i. H. the simultaneous inhibition of two or more signal-induction cascades in comparison to the therapeutic attack of only one signal transduction pathway should lead to an increase in the effect in the treatment of all pathogenic processes which are influenced by kinases.
Es wurde jetzt überraschend gefunden, dass neue Verbindungen aus der Reihe der Pyrido[2,3-b]pyrazine, welche in 6- oder 7-Position z. B. mit Harnstoff- oder Thio- harnstoffgruppierungen substituiert sind, zur Herstellung von Arzneimitteln zur Modula- tion von fehlgeleiteten zellulären Signaltransduktionsprozessen, insbesondere zur Beeinflussung der Funktion von Rezeptor-Tyrosinkinasen, cytoplasmatischen Tyrosin-, Serin/Threonin- und Lipidkinasen und zur Behandlung von malignen bzw. benignen Tumorerkrankungen, wie z. B. der Brust, Prostata, Lunge, Haut, Eierstöcke und anderen, auf pathologischen Zellproliferationen beruhenden Erkrankungen geeignet sind.It has now surprisingly been found that new compounds from the series of pyrido [2,3-b] pyrazines, which in the 6- or 7-position z. Substituted with urea or thiourea groups for the preparation of medicaments for the modulation of aberrant cellular signal transduction processes, in particular for influencing the function of receptor tyrosine kinases, cytoplasmic tyrosine, serine / threonine and lipid kinases and for the treatment of malignant or benign tumors such. As the breast, prostate, lung, skin, ovaries and other diseases based on pathological cell proliferations are suitable.
Ein erster Aspekt der vorliegenden Anmeldung beschreibt neue Verbindungen aus der Reihe der Pyrido[2,3-b]pyrazine gemäß der allgemeinen Formel (I), A first aspect of the present application describes novel compounds from the series of pyrido [2,3-b] pyrazines according to the general formula (I),
woπn: (A) einer der Reste Z3, Z4 oder beide Reste Z3, Z4 unabhängig voneinander „substituiertes Aryl" sind, wobei „substituiertes Aryl" substituiert ist mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:where: (A) one of the radicals Z3, Z4 or both radicals Z3, Z4 is independently "substituted aryl", where "substituted aryl" is substituted by at least one substituent, identical or different, selected from the group consisting of:
(a) „alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NH-X1 , -N(alkyl)2, - NHC(O)-alkyl, -NHC(O)-cycloalkyl, -NHC(O)-heterocyclyl, -NHC(O)- aryl, -NHC(O)-heteroaryl, -NHC(O)-arylalkyl, -NHC(O)-heteroarylalkyl, -NHS(O2)-alkyl, -NHS(O2)-cycloalkyl, -NHS(O2)-heterocyclyl, - NHS(O2)-aryl, -NHS(O2)-heteroaryl, -NHS(O2)-arylalkyl, -NHS(O2)- heteroarylalkyl, -S-alkyl, -S-aryl, -S-heteroaryl, -0-X2, -OC(O)-alkyl, - OC(O)-cycloalkyl, -OC(O)-heterocyclyl, -OC(O)-aryl, -OC(O)- heteroaryl, -OC(O)-arylalkyl, -OC(O)-heteroarylalkyl, -OS(O2)-alkyl, - OS(O2)-cycloalkyl, -OS(O2)-heterocyclyl, -OS(O2)-aryl, -OS(O2)- heteroaryl, -OS(O2)-arylalkyl, -OS(O2)-heteroarylalkyl, -C(O)-alkyl, - C(O)-aryl, -C(O)-heteroaryl, -C(O)O-X3, -C(O)NH-X4, -C(O)N(alkyl)2, -C(O)N(cycloalkyl)2, -C(O)N(aryl)2, -C(O)N(heteroraryl)2, -S(O)-alkyl, -(a) "alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NH-X1, -N (alkyl) 2 , -NHC (O) -alkyl, -NHC (O) -cycloalkyl, -NHC (O) -heterocyclyl, -NHC (O) -aryl, -NHC (O) -heteroaryl, -NHC (O) -arylalkyl, -NHC (O) -heteroarylalkyl, -NHS (O 2 ) -alkyl, -NHS (O 2 ) -cycloalkyl, -NHS (O 2 ) -heterocyclyl, -NHS (O 2 ) -aryl, -NHS (O 2 ) -heteroaryl, -NHS (O 2 ) -arylalkyl, -NHS (O 2 ) -heteroarylalkyl, -S-alkyl, -S-aryl, -S-heteroaryl, -O-X2, -OC (O) -alkyl, - OC (O) -cycloalkyl, -OC (O) -heterocyclyl, -OC (O) -aryl, -OC ( O) - heteroaryl, -OC (O) -arylalkyl, -OC (O) -heteroarylalkyl, -OS (O 2 ) -alkyl, -OS (O 2 ) -cycloalkyl, -OS (O 2 ) -heterocyclyl, -OS (O 2 ) -aryl, -OS (O 2 ) -heteroaryl, -OS (O 2 ) -arylalkyl, -OS (O 2 ) -heteroarylalkyl, -C (O) -alkyl, - C (O) -aryl, -C (O) -heteroaryl, -C (O) O -X3, -C (O) NH-X4, -C (O) N (alkyl) 2 , -C (O) N (cycloalkyl) 2 , -C (O) N (aryl) 2 , -C (O) N (heteroaryl) 2 , -S (O) -alkyl,
S(O)-aryl, -S(O2)-alkyl, -S(O2)-aryl, -S(O2)NH-alkyl, -S(O2)NH-aryl, - S(O2)NH-heteroaryl, -S(O2)NH-arylalkyl, S(O2)O-alkyl, -S(O2)O-aryl, - S(O2)O-arylalkyl"; wobei X1 , X2, X3, X4 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; mit der Maßgabe, dass obige Substituenten der Substituentengruppe (a) unabhängig voneinander weiter substituiert sind mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe be- stehend aus: (i) „(Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylal- kyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, N3, -NH-cycloalkyl, - NH-cycloalkylalkyl, -NH-heteroaryl, -NH-heteroarylalkyl, -NH- arylalkyl, -NH-heterocyclyl, -NH-heterocyclylalkyl, -NX5X6, -S- cycloalkyl, -S-cycloalkylalkyl, -S-aryl, —S— arylalkyl, -S-heteroaryl, -S (O) -aryl, -S (O 2 ) -alkyl, -S (O 2 ) -aryl, -S (O 2 ) NH-alkyl, -S (O 2 ) -NH-aryl, -S (O 2 ) NH-heteroaryl, -S (O 2 ) NH-arylalkyl, S (O 2 ) O -alkyl, -S (O 2 ) O -aryl, -S (O 2 ) O -arylalkyl ", where X 1, X 2 , X3, X4 are independently selected from the group consisting of: "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; with the proviso that the above substituents of the substituent group (a) are independently further substituted by at least one substituent, identical or different, selected from the group consisting of: (i) "(C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, N 3 , -NH-cycloalkyl, -NH-cycloalkylalkyl, -NH-heteroaryl, NH-heteroarylalkyl, -NH-arylalkyl, -NH-heterocyclyl, -NH-heterocyclylalkyl, -NX5X6, -S-cycloalkyl, -S-cycloalkylalkyl, -S-aryl, -S-arylalkyl, -S-heteroaryl, -
S-heteroarylalkyl, -S-heterocyclyl, -S-heterocyclylalkyl, -O- cycloalkyl, -O-cycloalkylalkyl, -O-arylalkyl, -O-heteroaryl, -O- heteroarylalkyl, -O-heterocyclyl, -O-heterocyclylalkyl,-O(-X7-O)p- X8 (p = 1 , 2, 3, 4, 5), -OP(O)(OX9)(OX10), -C(O)O-XH 1 -C(O)NH2, -C(O)NH-XI 2, -C(O)NXI 3X14, -S(O2)-X15, -P(O)(OH)2, -S-heteroarylalkyl, -S-heterocyclyl, -S-heterocyclylalkyl, -O-cycloalkyl, -O-cycloalkylalkyl, -O-arylalkyl, -O-heteroaryl, -O-heteroarylalkyl, -O-heterocyclyl, -O-heterocyclylalkyl, - O (-X7-O) p - X8 (p = 1, 2, 3, 4, 5), -OP (O) (OX9) (OX10), -C (O) O-XH 1 -C (O) NH 2 , -C (O) NH-XI 2, -C (O) NXI 3 X 14, -S (O 2 ) -X 15, -P (O) (OH) 2 , -
P(O)(OXI 6)(0X17), -Si(XI 8)(X19)(X20), -O-Si(X21 )(X22)(X23), -O- C(O)-O-X24, -0-C(O)-N H-X25, -O-C(O)-NX26X27, -NH-C(O)- O-X28, -N H-C(O)-N H-X29, -NH-C(O)-NX30X31 , -NX32-C(O)-O- X33, -NX34-C(O)-NH-X35, -NX36-C(O)-NX37X38, -O-S(O2)-X39, -NH-C(O)-X40, -NX41-C(O)-X42, -C(O)-X43, -OC(O)-X44, -P (O) (OXI6) (OX17), -Si (XI8) (X19) (X20), -O-Si (X21) (X22) (X23), -O-C (O) -O-X24 , -O-C (O) -NH-X25, -OC (O) -NX26X27, -NH-C (O) -O-X28, -NHC (O) -NH-X29, -NH-C (O) -NX30X31, -NX32-C (O) -O- X33, -NX34-C (O) -NH-X35, -NX36-C (O) -NX37X38, -OS (O 2) -X39, - NH-C (O) -X40, -NX41-C (O) -X42, -C (O) -X43, -OC (O) -X44, -
S(O)-X45, -S(O2)-NHX46, -S(O2)-NX47X48, -S(O2)-OX49, -0(- X50-O)p-H (p = 1 , 2, 3, 4, 5)"; mit der weiteren Maßgabe, dass ,,-N(alkyl)2" weiter substituiert ist mit mindestens einem Substituenten ausgewählt aus der untigen Substi- tuentengruppe (b); wobei X5, X6, X7, X8, X9, X10, X1 1 , X12, X13, X14, X15, X16, X17, X18, X19, X20, X21 , X22, X23, X24, X25, X26, X27, X28, X29, X30, X31 , X32, X33, X34, X35, X36, X37, X38, X39, X40, X41 , X42, X43, X44, X45, X46, X47, X48, X49, X50 unabhängig voneinander ausge- wählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X13, X14 und/oder X26, X27 und/oder X30, X31 und/oder X37, X38 und/oder X47, X48 zusammen auch „heterocyclyl" bilden können; und mit der weiteren Maßgabe, dass wenn einer der Reste Z3 oder Z4S (O) -X45, -S (O 2) -NHX46, -S (O 2) -NX47X48, -S (O 2) -OX49, -0 (- X50-O) p -H (p = 1, 2, 3, 4, 5) "with the further proviso that" --N (alkyl) 2 "is further substituted by at least one substituent selected from the lower substituent group (b); where X5, X6, X7, X8, X9, X10, X1, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X22, X23, X24, X25, X26, X27, X28, X29, X30, X31, X32, X33, X34, X35, X36, X37, X38, X39, X40, X41, X42, X43, X44, X45, X46, X47, X48, X49, X50 are independently selected consisting of the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively X13, X14 and / or X26, X27 and / or X30 , X31 and / or X37, X38 and / or X47, X48 may together also form "heterocyclyl"; and with the further proviso that when one of Z3 or Z4
„substituiertes Aryl" substiuiert mit „heterocyclylalkyl" ist, der jeweils andere Rest Z3 oder Z4 nicht „substituiertes oder unsubstituiertes Aryl" ist; wobei optional zusätzlich einer der Reste Z3, Z4 oder zusätzlich beide Reste Z3, Z4 unabhängig voneinander auch weiter substituiert sein können mit min- destens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:"Substituted aryl" is substituted with "heterocyclylalkyl", the other radical Z3 or Z4 is not "substituted or unsubstituted aryl", where optionally additionally one of the radicals Z3, Z4 or additionally both radicals Z3, Z4 can also be further substituted independently of one another with min. at least one substituent, identical or different, selected from the group consisting of:
(b) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylal- kyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX51 , -NX52X53, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -(b) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylal- kyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHX51, -NX52X53, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -
CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X54, -C(O)O-X55, -C(O)NH-X56, -C(O)NX57X58, -O-X59, -O(-X60-O) -H (r = 1 , 2, 3, 4, 5), -O(-X61-O) -X62 (r = 1 , 2, 3, 4, 5), -OC(O)-X63, -OC(O)-O-X64, - OC(O)-N HX65, -O-C(O)-NX66X67, -OP(O)(OX68)(OX69), - OSi(X70)(X71 )(X72), -OS(O2)-X73, -NHC(O)-X74, -NX75C(O)-X76, -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X54, -C (O) O-X55, -C (O) NH-X56, -C (O) NX57X58, -O-X59, -O (-X60-O) -H (r = 1, 2, 3, 4, 5), -O (-X61-O) -X62 (r = 1, 2, 3, 4, 5), -OC (O) -X63, -OC (O) -O-X64, -OC (O) -N HX65, -OC (O) -NX66X67, OP (O) (OX68) (OX69), - OSi (X70) (X71) (X72), -OS (O 2) -X73, -NHC (O) -X74, -NX75C (O) -X76, -
NH-C(O)-O-X77, -N H-C(O)-N H-X78, -NH-C(O)-NX79X80, -NX81- C(O)-O-X82, -NX83-C(O)-NH-X84, -NX85-C(O)-NX86X87, -NHS(O2)- X88, -NX89S(O2)-X90, -S-X91 , -S(O)-X92, -S(O2)-X93, -S(O2)NH-X94, -S(O2)NX95X96, -S(O2)O-X97, -P(O)(OX98)(OX99), - Si(X100)(X101 )(X102)"; wobei X51 , X52, X53, X54, X55, X56, X57, X58, X59, X60, X61 , X62, X63, X64, X65, X66, X67, X68, X69, X70, X71 , X72, X73, X74, X75, X76, X77, X78, X79, X80, X81 , X82, X83, X84, X85, X86, X87, X88, X89, X90, X91 , X92, X93, X94, X95, X96, X97, X98, X99, X100, X101 , X102 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-NH-C (O) -O-X77, -NHC (O) -NH-X78, -NH-C (O) -NX79X80, -NX81-C (O) -O-X82, -NX83-C ( O) -NH-X84, -NX85-C (O) -NX86X87, -NHS (O 2) - X88, -NX89S (O 2) -X90, -S-X91, -S (O) -X92, -S (O 2) -X93, -S (O2) NH-X94, -S (O 2) NX95X96, -S (O2) O-X97, -P (O) (OX98) (OX99), - Si ( X100) (X101) (X102) "; wherein X51, X52, X53, X54, X55, X56, X57, X58, X59, X60, X61, X62, X63, X64, X65, X66, X67, X68, X69, X70 , X71, X72, X73, X74, X75, X76, X77, X78, X79, X80, X81, X82, X83, X84, X85, X86, X87, X88, X89, X90, X91, X92, X93, X94, X95 , X96, X97, X98, X99, X100, X101, X102 are independently selected from the group consisting of: "alkyl, (Cg-
C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X57, X58 und/oder X66, X67 und/oder X79, X80 und/oder X86, X87 und/oder X95, X96 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (b) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X57, X58 and / or X66, X67 and / or X79, X80 and / or X86, X87 and / or X95, X96 together can also form "heterocyclyl"; optionally optionally substituted substituents of the substituent group (b) may in turn be substituted with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3,(ii) "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 ,
NH2, -NHX103, -NX104X105, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- X106, -C(O)O-XI 07, -C(O)NH-XI 08, -C(O)NXI 09X1 10, -0-X1 11 , - 0(-X1 12-O)5-H (s = 1 , 2, 3, 4, 5), -0(-X113-0)s-X1 14 (s = 1 , 2, 3, 4, 5), -OC(O)-X115, -OC(O)-O-X116, -OC(O)-NHX117, -0-C(O)- NX118X119, -OP(O)(OXI20)(OX121), -OSi(XI22)(X123)(X124), - OS(O2)-X125, -NHC(O)-X126, -NX127C(O)-XI28, -NH-C(O)-O- X129, -NH-C(O)-NH-XI30, -NH-C(O)-NXI31X132, -NX133-C(O)- O-X134, -NX135-C(O)-NH-XI36, -NX137-C(O)-NXI38X139, -NH 2, -NHX103, -NX104X105, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP (O) (OH) 2, -CHO, -COOH, -C (O ) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X106, -C (O) O-XI 07, -C (O) NH-XI 08, -C ( O) NXI 09X1 10, -0-X1 11, - 0 (-X1 12-O) 5 -H (s = 1, 2, 3, 4, 5), -0 (-X113-0) s -X1 14 (s = 1, 2, 3, 4, 5), -OC (O) -X115, -OC (O) -O-X116, -OC (O) -NHX117, -O-C (O) -NX118X119, -OP (O) (OXI20) (OX121) , -OSi (XI22) (X123) (X124), - OS (O 2) -X125, -NHC (O) -X126, -NX127C (O) -XI28, -NH-C (O) -O- X129, -NH-C (O) -NH-XI30, -NH-C (O) -NXI31X132, -NX133-C (O) -O-X134, -NX135-C (O) -NH-XI36, -NX137-C (O) -NXI38X139, -
NHS(O2)-X140, -NX141S(O2)-X142, -S-X143, -S(O)-X144, -S(O2)- X145, -S(O2)NH-XI46, -S(O2)NXI47X148, -S(O2)O-XI49, - P(O)(OXI50)(OX151), -Si(XI52)(X153)(X154)"; wobei X103, X104, X105, X106, X107, X108, X109, X1 10, X1 11 , X1 12, X113, X1 14, X115, X1 16, X117, X118, X1 19, X120, X121 , X122, X123,NHS (O 2) -X140, -NX141S (O 2) -X142, -S-X143, -S (O) -X144, -S (O2) - X145, -S (O 2) NH-XI46, - wherein X106, X103, X104, X105, P (O) (OXI50) (OX151), -Si (XI52) (x153) (X154) "- S (O 2) NXI47X148, -S (O 2) O-XI49, , X107, X108, X109, X1 10, X1 11, X1 12, X113, X1 14, X115, X1 16, X117, X118, X1 19, X120, X121, X122, X123,
X124, X125, X126, X127, X128, X129, X130, X131 , X132, X133, X134, X135, X136, X137, X138, X139, X140, X141 , X142, X143, X144, X145, X146, X147, X148, X149, X150, X151 , X152, X153, X154 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X109, X110 und/oder X1 18, X119 und/oder X131 , X132 und/oder X138, X139 und/oder X147, X148 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) und/oder Substituentengruppe (ii) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:X124, X125, X126, X127, X128, X129, X130, X131, X132, X133, X134, X135, X136, X137, X138, X139, X140, X141, X142, X143, X144, X145, X146, X147, X148, x149, X150, X151, X152, x153 are X154 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively, X109, X110 and / or X1 18, X119 and / or X131, X132 and / or X138, X139 and / or X147, X148 may together also form "heterocyclyl"; wherein optionally above substituents of the substituent group (i) and / or substituent group (ii) may be independently substituted with at least one substituent, same or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX155, -NX156X157, -NO2, -OH, -OCF3, -SH, -0-SO3H, -(iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHX155, -NX156X157, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -
OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- X158, -C(O)O-XI59, -C(O)NH-XI60, -C(O)NXI61X162, -O-X163, - O(-X164-O)t-H (t = 1, 2, 3, 4, 5), -0(-X165-O)t-X166 (t = 1, 2, 3, 4, 5), -OC(O)-XI67, -OC(O)-O-XI68, -OC(O)-NHXI69, -0-C(O)- NX170X171 , -OP(O)(OXI72)(OX173), -OSi(XI74)(X175)(X176), -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X 158, -C (O ) O-XI59, -C (O) NH-XI60, -C (O) NXI61X162, -O-X163, -O (-X164-O) t -H (t = 1, 2, 3, 4, 5) , -O (-X165-O) t -X166 (t = 1, 2, 3, 4, 5), -OC (O) -XI67, -OC (O) -O-XI68, -OC (O) - NHXI69, -O-C (O) - NX170X171, -OP (O) (OXI72) (OX173), -OSi (XI74) (X175) (X176),
OS(O2)-X177, -NHC(O)-XI78, -NX179C(O)-XI80, -NH-C(O)-O- X181, -NH-C(O)-NH-XI82, -NH-C(O)-NXI83X184, -NX185-C(O)- O-X186, -NX187-C(O)-NH-XI88, -NX189-C(O)-NXI90X191, - NHS(O2)-X192, -NX193S(O2)-X194, -S-X195, -S(O)-XI96, -S(O2)- X197, -S(O2)NH-XI 98, -S(O2)NXI 99X200, -S(O2)O-X201 , - P(O)(OX202)(OX203), -Si(X204)(X205)(X206)"; wobei X155, X156, X157, X158, X159, X160, X161 , X162, X163, X164, X165, X166, X167, X168, X169, X170, X171 , X172, X173, X174, X175, X176, X177, X178, X179, X180, X181 , X182, X183, X184, X185, X186,OS (O 2) -X177, -NHC (O) -XI78, -NX179C (O) -XI80, -NH-C (O) -O- X181, -NH-C (O) -NH-XI82, -NH -C (O) -NXI83X184, -NX185-C (O) - O-X186, -NX187-C (O) -NH-XI88, -NX189-C (O) -NXI90X191, - NHS (O 2) -X192 , -NX193S (O 2) -X194, -S-x195, -S (O) -XI96, -S (O 2) - X197, -S (O 2) NH-XI 98, -S (O 2) NXI 99X200, -S (O 2) O-X201, - P (O) (OX202) (OX203), -Si (X204) ( X205) (X206) "; wherein X155, X156, X157, X158, X159, X160, X161, X162, X163, X164, X165, X166, X167, X168, X169, X170, X171, X172, X173, X174, X175, X176, X177, X178, X179, X180, X181, X182, X183, X184, X185, X186,
X187, X188, X189, X190, X191 , X192, X193, X194, X195, X196, X197, X198, X199, X200, X201 , X202, X203, X204, X205, X206 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X161 ,X187, X188, X189, X190, X191, X192, X193, X194, X195, X196, X197, X198, X199, X200, X201, X202, X203, X204, X205, X206 are independently selected from the group consisting of: alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X161,
X162 und/oder X170, X171 und/oder X183, X184 und/oder X190, X191 und/oder X199, X200 zusammen auch „heterocyclyl" bilden können;X162 and / or X170, X171 and / or X183, X184 and / or X190, X191 and / or X199, X200 may together also form "heterocyclyl";
oder einer der Reste Z3, Z4 oder beide Reste Z3, Z4 unabhängig voneinander „substituiertes Aryl" sind, wobei „substituiertes Aryl" substituiert ist mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:or one of the radicals Z3, Z4 or both radicals Z3, Z4 are independently "substituted aryl", where "substituted aryl" is substituted by at least one substituent, identical or different, selected from the group consisting of:
(C) „(C9-C3o)alkyl, -NX207X208, -NH-(C9-C30)alkyl, -NHC(O)-cycloalkylalkyl, - NHC(O)-heterocyclylalkyl, -NHC(O)-(C9-C30)alkyl, -NX209C(O)-X210, - NX21 1C(O)-(C9-C30)alkyl, -NHC(O)-OX212, -NX213C(O)-OX214, -(C) "(C 9 -C 3 o) alkyl, -NX207X208, -NH- (C 9 -C 30) alkyl, -NHC (O) cycloalkylalkyl, - NHC (O) -heterocyclylalkyl, -NHC (O) (C 9 -C 30 ) alkyl, -NX 2 O 9 C (O) -X 2 O, NX21 1C (O) - (C 9 -C 30 ) alkyl, -NHC (O) -OX 2 12, -NX 2 13C (O) -OX 2 14, -
N HC(O)-N HX215, -NHC(O)-NX216X217, -NX218C(O)-NHX219, - NX220C(O)-NX221X222, -NHS(O2)-cycloalkylalkyl, -NHS(O2)- heterocyclylalkyl, -NX223S(O2)-X224, -O-(C9-C30)alkyl, -S-cycloalkyl, -S- heterocyclyl, —S— arylalkyl, -S-heteroarylalkyl, -S-cycloalkylalkyl, -S- heterocyclylalkyl, -S-(C9-C30)alkyl, -OC(O)-cycloalkylalkyl, -OC(O)- heterocyclylalkyl, -OC(O)-(C9-C30)alkyl, -OS(O2)-cycloalkylalkyl, -OS(O2)- heterocyclylalkyl, -OS(O2)-(C9-C30)alkyl, -OC(O)-OX225, -OC(O)- NHX226, -OC(O)-NX227X228, -OP(O)(OX229)(OX230), -C(O)-cycloalkyl, -C(O)-heterocyclyl, -C(O)-arylalkyl, -C(O)-heteroarylalkyl, -C(O)- cycloalkylalkyl, -C(O)-heterocyclylalkyl, -C(O)-(C9-C30)alkyl, -C(O)O-(C9-N HC (O) -N HX215, -NHC (O) -NX216X217, -NX218C (O) -NHX219, - NX220C (O) -NX221X222, -NHS (O 2) cycloalkylalkyl, -NHS (O 2) - heterocyclylalkyl , -NX223S (O 2 ) -X224, -O- (C 9 -C 30 ) -alkyl, -S-cycloalkyl, -S-heterocyclyl, -S-arylalkyl, -S-heteroarylalkyl, -S-cycloalkylalkyl, -S- heterocyclylalkyl, -S- (C 9 -C 30 ) alkyl, -OC (O) -cycloalkylalkyl, -OC (O) -heterocyclylalkyl, -OC (O) - (C 9 -C 30 ) alkyl, -OS (O 2 ) -cycloalkylalkyl, -OS (O 2 ) -heterocyclylalkyl, -OS (O 2 ) - (C 9 -C 30 ) -alkyl, -OC (O) -OX225, -OC (O) -NHX226, -OC (O) -NX227X228, -OP (O) (OX229) (OX230), -C (O) -cycloalkyl, -C (O) -heterocyclyl, -C (O) -arylalkyl, -C (O) -heteroarylalkyl, -C ( O) - cycloalkylalkyl, -C (O) -heterocyclylalkyl, -C (O) - (C 9 -C 30 ) alkyl, -C (O) O- (C 9 -
C30)alkyl, -C(O)NH-(C9-C30)alkyl, -C(O)NX231X232, -C(O)NH-OX233, - C(O)NX234-OX235, -C(O)N H-NX236X237, -C(O)NX238-NX239X240, - S(O)-cycloalkyl, -S(O)-heterocyclyl, -S(O)-heteroaryl, -S(O)-arylalkyl, - S(O)-heteroarylalkyl, -S(O)-cycloalkylalkyl, -S(O)-heterocyclylalkyl, - S(0)-(C9-C3o)alkyl, -S(O2)-cycloalkyl, -S(O2)-heterocyclyl, -S(O2)- heteroaryl, -S(O2)-arylalkyl, -S(O2)-heteroarylalkyl, -S(O2)-cycloalkylalkyl, -S(O2)-heterocyclylalkyl, -S(02)-(C9-C3o)alkyl, -S(O2)NH-cycloalkyl, - S(O2)N H-heterocyclyl, -S(O2)NH-heteroarylalkyl, -S(O2)NH- cycloalkylalkyl, -S(O2)NH-heterocyclylalkyl, -S(02)NH-(C9-C3o)alkyl, -C 30) alkyl, C 9 -C 30) alkyl, -C (O) NH- (C, -C (O) NX231X232, -C (O) NH-OX233, - C (O) NX234-OX235, -C (O ) N H -NX236X237, -C (O) NX238-NX239X240, - S (O) -cycloalkyl, -S (O) -heterocyclyl, -S (O) -heteroaryl, -S (O) -arylalkyl, -S ( O) -heteroarylalkyl, -S (O) -cycloalkylalkyl, -S (O) -heterocyclylalkyl, - Arylalkyl heteroaryl, -S (O 2) - S (0) - (C 9 -C 3 o) alkyl, (O 2) cycloalkyl -S, -S (O 2) -heterocyclyl, -S (O 2) , -S (O 2) heteroarylalkyl, -S (O 2) cycloalkylalkyl, -S (O 2) -heterocyclylalkyl, -S (0 2) - (C 9 -C 3 O) alkyl, -S (O 2 ) NH-cycloalkyl, -S (O 2 ) N H -heterocyclyl, -S (O 2 ) NH-heteroarylalkyl, -S (O 2 ) NH -cycloalkylalkyl, -S (O 2 ) NH-heterocyclylalkyl, -S (0 2) NH- (C 9 -C 3 o) alkyl, -
S(O2)O-cycloalkyl, -S(O2)O-heterocyclyl, -S(O2)O-heteroaryl, -S(O2)O- heteroarylalkyl, -S(O2)O-cycloalkylalkyl, -S(O2)O-heterocyclylalkyl, - S(02)0-(C9-C3o)alkyl, -P(O)(OH)2, -P(O)(OX241 )(OX242), - Si(X243)(X244)(X245), -O-Si(X246)(X247)(X248)"; wobei X207, X208, X209, X210, X21 1 , X212, X213, X214, X215, X216,S (O 2 ) O -cycloalkyl, -S (O 2 ) O-heterocyclyl, -S (O 2 ) O-heteroaryl, -S (O 2 ) O-heteroarylalkyl, -S (O 2 ) O -cycloalkylalkyl, - S (O 2) O-heterocyclylalkyl, - S (0 2) 0- (C 9 -C 3 o) alkyl, -P (O) (OH) 2, -P (O) (OX241) (OX242), - Si (X243) (X244) (X245), -O-Si (X246) (X247) (X248) "; wherein X207, X208, X209, X210, X21 1, X212, X213, X214, X215, X216,
X217, X218, X219, X220, X221 , X222, X223, X224, X225, X226, X227, X228, X229, X230, X231 , X232, X233, X234, X235, X236, X237, X238, X239, X240, X241 , X242, X243, X244, X245, X246, X247, X248 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X216, X217 und/oder X221 , X222 und/oder X227, X228 und/oder X231 , X232 und/oder X236, X237 und/oder X239, X240 jeweils zusammen auch „heterocyclyl" bilden können; mit der Maßgabe, dass die Substituenten ,,-N(alkyl)2", ,,-C(O)N(alkyl)2", „-X217, X218, X219, X220, X221, X222, X223, X224, X225, X226, X227, X228, X229, X230, X231, X232, X233, X234, X235, X236, X237, X238, X239, X240, X241, X242, x243, X244, X245, X246, are x247, x248 independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X216, X217 and / or X221, X222 and / or X227, X228 and / or X231, X232 and / or X236, X237 and / or X239, X240 may each together also form" heterocyclyl "; with the proviso that the substituents "- N (alkyl) 2 ", "- C (O) N (alkyl) 2 ", "-
C(O)N(cycloalkyl)2", ,,-C(O)N(aryl)2", ,,-C(O)N(heteroraryl)2" weiter substituiert sind mit mindestens einem Substituenten ausgewählt aus der untigen Substituentengruppe (i); mit der weiteren Maßgabe, dass wenn einer der Reste Z3 oder Z4 „substitu- iertes Aryl" substituiert mit „heterocyclylalkyl" ist, der jeweils andere Rest Z3 oder Z4 nicht „unsubstituiertes oder substituiertes Aryl" ist; wobei optional obige Substituenten der Substituentengruppe (c) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:C (O) N (cycloalkyl) 2 "," - C (O) N (aryl) 2 "," - C (O) N (heteroaryl) 2 "are further substituted with at least one substituent selected from the same substituent group (i); with the further proviso that when one of Z3 or Z4 is "substituted aryl" substituted with "heterocyclylalkyl", each other of Z3 or Z4 is not "unsubstituted or substituted aryl"; wherein optionally above substituents of the substituent group (c) may in turn be independently substituted with at least one substituent, same or different, selected from the group consisting of:
(i) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX249, -NX250X251 , -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- X252, -C(O)O-X253, -C(O)NH-X254, -C(O)NX255X256, -O-X257, - O(-X258-O)u-H (u = 1 , 2, 3, 4, 5), -O(-X259-O)u-X260 (u = 1 , 2, 3, 4, 5), -OC(O)-X261 , -OC(O)-O-X262, -OC(O)-N HX263, -0-C(O)- NX264X265, -OP(O)(OX266)(OX267), -OSi(X268)(X269)(X270), - OS(O2)-X271 , -NHC(O)-X272, -NX273C(O)-X274, -NH-C(O)-O-(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHX249, -NX250X251, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP (O) (OH) 2, -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) - X252, -C (O) O -X253, -C (O) NH-X254, -C (O) NX255X256, -O-X257, -O (-X258-O) uH (u = 1, 2, 3, 4, 5), -O (-X259-O) u -X260 (u = 1, 2, 3, 4, 5), -OC (O) -X261, -OC (O) -O-X262, -OC (O) -N HX263, -0-C (O) - NX264X265, -OP (O) (OX266) (OX267), -OSi (X268) (X269) (X270), - OS (O 2) -X271, -NHC (O) -X272, -NX273C (O) -X274, -NH-C (O) -O-
X275, -N H-C(O)-N H-X276, -NH-C(O)-NX277X278, -NX279-C(O)- O-X280, -NX281 -C(O)-N H-X282, -NX283-C(O)-NX284X285, - NHS(O2)-X286, -NX287S(O2)-X288, -S-X289, -S(O)-X290, -S(O2)- X291 , -S(O2)N H-X292, -S(O2)NX293X294, -S(O2)O-X295, - P(O)(OX296)(OX297), -Si(X298)(X299)(X300)"; wobei X249, X250, X251 , X252, X253, X254, X255, X256, X257, X258, X259, X260, X261 , X262, X263, X264, X265, X266, X267, X268, X269, X270, X271 , X272, X273, X274, X275, X276, X277, X278, X279, X280, X281 , X282, X283, X284, X285, X286, X287, X288, X289, X290, X291 , X292, X293, X294, X295, X296, X297, X298, X299, X300 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X255, X256 und/oder X264, X265 und/oder X277, X278 und/oder X284, X285 und/oder X293, X294 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional zusätzlich einer der Reste Z3, Z4 oder zusätzlich beide Reste Z3, Z4 unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:X275, -NHC (O) -NH-X276, -NH-C (O) -NX277X278, -NX279-C (O) -O-X280, -NX281 -C (O) -NH-X282, - NX283-C (O) -NX284X285, - NHS (O 2) -X286, -NX287S (O 2) -X288, -S-X289, -S (O) -X290, -S (O2) - X291, - S (O 2) N H-X292, -S (O 2) NX293X294, -S (O2) O-X295, - P (O) (OX296) (OX297), -Si (X298) (X299) (X300 where X249, X250, X251, X252, X253, X254, X255, X256, X257, X258, X259, X260, X261, X262, X263, X264, X265, X266, X267, X268, X269, X270, X271, X272, X273, X274, X275, X276, X277, X278, X279, X280, X281, X282, X283, X284, X285, X286, X287, X288, X289, X290, X291, X292, X293, X294, X295, X296, X297, X298, are X299, X300 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively X255, X256 and / or X264, X265 and / or X277, X278 and / or X284, X285 and / or X293, X294 may in each case also together form "heterocyclyl"; in addition, one of the radicals Z3, Z4 or additionally both radicals Z3, Z4 can also be further independently substituted with at least one substituent, identical or different, selected from the group consisting of:
(d) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX301 , -NX302X303, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- X304, -C(O)O-X305, -C(O)NH-X306, -C(O)NX307X308, -O-X309, -0(-(d) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHX301, -NX302X303, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) - X304, -C (O) O-X305, -C (O) NH-X306, -C (O) NX307X308, -O-X309, -0 (-
X310-O)uu-H (uu = 1 , 2, 3, 4, 5), -O(-X311-O)uu-X312 (uu = 1 , 2, 3, 4, 5), -OC(O)-X313, -OC(O)-O-X314, -OC(O)-N HX315, -0-C(O)- NX316X317, -OP(O)(OX318)(OX319), -OSi(X320)(X321 )(X322), -OS(O2)- X323, -NHC(O)-X324, -NX325C(O)-X326, -NH-C(O)-O-X327, -NH- C(O)-NH-X328, -NH-C(O)-NX329X330, -NX331-C(O)-O-X332, - NX333-C(O)-NH-X334, -NX335-C(O)-NX336X337, -NHS(O2)-X338, - NX339S(O2)-X340, -S-X341 , -S(O)-X342, -S(O2)-X343, -S(O2)NH- X344, -S(O2)NX345X346, -S(O2)O-X347, -P(O)(OX348)(OX349), - Si(X350)(X351 )(X352)"; wobei X301 , X302, X303, X304, X305, X306, X307, X308, X309, X310, X31 1 , X312, X313, X314, X315, X316, X317, X318, X319, X320, X321 , X322, X323, X324, X325, X326, X327, X328, X329, X330, X331 , X332, X333, X334, X335, X336, X337, X338, X339, X340, X341 , X342, X343, X344, X345, X346, X347, X348, X349, X350, X351 , X352 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, ary- lalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X307, X308 und/oder X316, X317 und/oder X329, X330 und/oder X336, X337 und/oder X345, X346 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (d) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX353, -NX354X355, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- X356, -C(O)O-X357, -C(O)NH-X358, -C(O)NX359X360, -O-X361 , - O(-X362-O)v-H (v = 1 , 2, 3, 4, 5), -O(-X363-O)v-X364 (v = 1, 2, 3, 4,X310-O) uu -H (uu = 1, 2, 3, 4, 5), -O (-X311-O) uu -X312 (uu = 1, 2, 3, 4, 5), -OC (O ) -X313, -OC (O) -O-X314, -OC (O) -N HX315, -O-C (O) -NX316X317, -OP (O) (OX318) (OX319), -OSi (X320) (X321) (X322), -OS (O2) - X323, -NHC (O) -X324, -NX325C (O) -X326, -NH-C (O) -O-X327, -NH- C (O) -NH-X328, -NH-C (O) -NX329X330, -NX331-C (O) -O-X332, -NX333-C (O) -NH-X334, -NX335-C (O) -NX336X337, -NHS (O 2) -X338, - NX339S (O 2) -X340, -S-X341, -S (O) -X342, -S (O 2) -X343, -S (O 2) NH wherein X302 X301, - - X344, -S (O 2) NX345X346, -S (O2) O-X347, -P (O) (OX348) (OX349), -Si (X350) (X351) (X352) " , X303, X304, X305, X306, X307, X308, X309, X310, X31 1, X312, X313, X314, X315, X316, X317, X318, X319, X320, X321, X322, X323, X324, X325, X326, X327, X328, X329, X330, X331, X332, X333, X334, X335, X336, X337, X338, X339, X340, X341, X342, X343, X344, X345, X346, X347, X348, X349, X350, X351, X352 are independently selected from the group consisting of: "alkyl, (C 9 - C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively X307, X308 and / or X316, X317 and / or X329, X330 and / or X336, X337 and / or X345, X346 in each case can together also form "heterocyclyl", optionally optionally Sub substituents of the substituent group (d) independently may in turn be substituted with at least one substituent, same or different, selected from the group consisting of: (ii) alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl , aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHX353, -NX354X355, -NO2, -OH, -OCF3, -SH, -0 -SO 3 H, - OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) - X356, -C (O) O -X357, -C (O) NH-X358, -C (O) NX359X360, -O-X361, -O (-X362-O) v -H (v = 1, 2, 3, 4, 5), -O (-X363-O) v -X364 (v = 1, 2, 3, 4,
5), -OC(O)-X365, -OC(O)-O-X366, -OC(O)-NHX367, -0-C(O)- NX368X369, -OP(O)(OX370)(OX371), -OSi(X372)(X373)(X374), - OS(O2)-X375, -NHC(O)-X376, -NX377C(O)-X378, -NH-C(O)-O- X379, -NH-C(O)-NH-X380, -NH-C(O)-NX381X382, -NX383-C(O)- O-X384, -NX385-C(O)-NH-X386, -NX387-C(O)-NX388X389, -5), -OC (O) -X365, -OC (O) -O-X366, -OC (O) -NHX367, -O-C (O) -NX368X369, -OP (O) (OX370) (OX371) , -OSi (X372) (X373) (X374), - OS (O 2) -X375, -NHC (O) -X376, -NX377C (O) -X378, -NH-C (O) -O- X379, -NH-C (O) -NH-X380, -NH-C (O) -NX381X382, -NX383-C (O) -O-X384, -NX385-C (O) -NH-X386, -NX387-C (O) -NX388X389, -
NHS(O2)-X390, -NX391S(O2)-X392, -S-X393, -S(O)-X394, -S(O2)- X395, -S(O2)NH-X396, -S(O2)NX397X398, -S(O2)O-X399, - P(O)(OX400)(OX401), -Si(X402)(X403)(X404)"; wobei X353, X354, X355, X356, X357, X358, X359, X360, X361 , X362, X363, X364, X365, X366, X367, X368, X369, X370, X371 , X372, X373, X374, X375, X376, X377, X378, X379, X380, X381 , X382, X383, X384, X385, X386, X387, X388, X389, X390, X391 , X392, X393, X394, X395, X396, X397, X398, X399, X400, X401 , X402, X403, X404 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X359, X360 und/oder X368, X369 und/oder X381 , X382 und/oder X388, X389 und/oder X397, X398 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) und/oder Substituentengruppe (ii) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:NHS (O 2) -X390, -NX391S (O 2) -X392, -S-X393, -S (O) -X394, -S (O2) - X395, -S (O 2) NH-X396, - S (O 2) NX397X398, -S (O2) O-X399, - P (O) (OX400) (OX401), -Si (X402) (X403) (X404) "; where X353, X354, X355, X356, X357, X358, X359, X360, X361, X362, X363, X364, X365, X366, X367, X368, X369, X370, X371, X372, X373, X374, X375, X376, X377 , X378, X379, X380, X381, X382, X383, X384, X385, X386, X387, X388, X389, X390, X391, X392, X393, X394, X395, X396, X397, X398, X399, X400, X401, X402 are X403, X404 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively X359, X360 and / or X368, X369 and / or X381, X382 and / or X388, X389 and / or X397, X398 may each together also form "heterocyclyl"; wherein optionally above substituents of the substituent group (i) and / or substituent group (ii) may be independently substituted with at least one substituent, same or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX405, -NX406X407, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- X408, -C(O)O-X409, -C(O)NH-X410, -C(O)NX411X412, -O-X413, -(iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHX405, -NX406X407, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP (O) (OH) 2, -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X408, -C (O) O -X409, -C (O) NH-X410, -C (O) NX 4 11 X 412, O-X413, -
O(-X414-O)w-H (w = 1 , 2, 3, 4, 5), -O(-X415-O)w-X416 (w = 1 , 2, 3, 4, 5), -OC(O)-X417, -OC(O)-O-X418, -OC(O)-NHX419, -0-C(O)- NX420X421 , -OP(O)(OX422)(OX423), -OSi(X424)(X425)(X426), - OS(O2)-X427, -NHC(O)-X428, -NX429C(O)-X430, -NH-C(O)-O- X431 , -N H-C(O)-N H-X432, -NH-C(O)-NX433X434, -NX435-C(O)-O (-X414-O) w -H (w = 1, 2, 3, 4, 5), -O (-X415-O) w -X416 (w = 1, 2, 3, 4, 5), OC (O) -X417, -OC (O) -O-X418, -OC (O) -NHX419, -O-C (O) -NX420X421, -OP (O) (OX422) (OX423), -OSi ( X424) (X425) (X426), - OS (O 2) -X427, -NHC (O) -X428, -NX429C (O) -X430, -NH-C (O) -O- X431, -N HC ( O) -NH-X432, -NH-C (O) -NX433X434, -NX435-C (O) -
O-X436, -NX437-C(O)-NH-X438, -NX439-C(O)-NX440X441 , - NHS(O2)-X442, -NX443S(O2)-X444, -S-X445, -S(O)-X446, -S(O2)- X447, -S(O2)N H-X448, -S(O2)NX449X450, -S(O2)O-X451 , - P(O)(OX452)(OX453), -Si(X454)(X455)(X456)"; wobei X405, X406, X407, X408, X409, X410, X411, X412, X413, X414,O-X436, -NX437-C (O) -NH-X438, -NX439-C (O) -NX440X441, - NHS (O 2) -X442, -NX443S (O 2) -X444, -S-X445, - S (O) -X446, -S (O2) - X447, -S (O2) N H-X448, -S (O 2) NX449X450, -S (O2) O-X451, - P (O) (OX452) (OX453), -Si (X454) (X455) (X456) "; wherein X405, X406, X407, X408, X409, X410, X411, X412, X413, X414,
X415, X416, X417, X418, X419, X420, X421, X422, X423, X424, X425, X426, X427, X428, X429, X430, X431 , X432, X433, X434, X435, X436, X437, X438, X439, X440, X441 , X442, X443, X444, X445, X446, X447, X448, X449, X450, X451, X452, X453, X454, X455, X456 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X411 , X412 und/oder X420, X421 und/oder X433, X434 und/oder X440, X441 und/oder X449, X450 jeweils zusammen auch „heterocyclyl" bilden können;X415, X416, X417, X418, X419, X420, X421, X422, X423, X424, X425, X426, X427, X428, X429, X430, X431, X432, X433, X434, X435, X436, X437, X438, X439, X440, X441, X442, X443, X444, X445, X446, X447, X448, X449, X450, X451, X452, X453, X454, X455, X456 independent are independently selected from the group consisting of: "(C 9 -C 3 o) alkyl, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively X411, X412 and / or X420, X421 and / or X433, X434 and / or X440, X441 and / or X449, X450 may each together also form "heterocyclyl";
und einer der Reste Z3, Z4 oder keiner der Reste Z3, Z4 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus: (e) Wasserstoff;and one of Z3, Z4 or none of Z3, Z4 is independently selected from the group consisting of: (e) hydrogen;
(f) Halogen, F, Cl, Br, I;(f) halogen, F, Cl, Br, I;
(g) unsubstituiertes oder substituiertes Alkyl oder (C9-C30)Alkyl, wobei optional der Alkyl- oder (Cg-C3o)Alkylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Grup- pe bestehend aus:(g) unsubstituted or substituted alkyl or (C 9 -C 30 ) alkyl, wherein optionally the alkyl or (Cg-C 3 o) alkyl radical may be substituted by at least one substituent, identical or different, selected from the group consisting out:
(i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX457, -NX458X459, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X460, -C(O)O-X461 , -C(O)NH-X462, -C(O)NX463X464, -(i) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHX457, -NX458X459, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X460, -C (O) O-X 461, -C (O) NH-X 462, -C (O) NX463X464,
O-X465, -O(-X466-O)x-H (x = 1 , 2, 3, 4, 5), -O(-X467-O)x-X468 (x = 1 , 2, 3, 4, 5), -OC(O)-X469, -OC(O)-O-X470, -OC(O)-N HX471 , - O-C(O)-NX472X473, -OP(O)(OX474)(OX475), - OSi(X476)(X477)(X478), -OS(O2)-X479, -NHC(O)-X480, - NX481 C(O)-X482, -NH-C(O)-O-X483, -N H-C(O)-N H-X484, -NH-O-X465, -O (-X466-O) x -H (x = 1, 2, 3, 4, 5), -O (-X467-O) x -X468 (x = 1, 2, 3, 4 , 5), -OC (O) -X469, -OC (O) -O-X470, -OC (O) -N HX471, -OC (O) -NX472X473, -OP (O) (OX474) (OX475) , - OSi (X476) (X477) (X478), -OS (O 2) -X479, -NHC (O) -X480, - NX481 -C (O) -X482, -NH-C (O) -O-X483 , -NHC (O) -NH-X484, -NH-
C(O)-NX485X486, -NX487-C(O)-O-X488, -NX489-C(O)-NH- X490, -NX491-C(O)-NX492X493, -NHS(O2)-X494, -NX495S(O2)- X496, -S-X497, -S(O)-X498, -S(O2)-X499, -S(O2)N H-X500, - S(O2)NX501X502, -S(O2)O-X503, -P(O)(OX504)(OX505), - Si(X506)(X507)(X508)"; wobei X457, X458, X459, X460, X461, X462, X463, X464, X465, X466, X467, X468, X469, X470, X471, X472, X473, X474, X475, X476, X477, X478, X479, X480, X481, X482, X483, X484, X485, X486, X487, X488, X489, X490, X491 , X492, X493, X494, X495, X496, X497, X498, X499, X500, X501 , X502, X503, X504, X505, X506, X507, X508 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ X463, X464 und/oder X472, X473 und/oder X485, X486 und/oder X492, X493 und/oder X501 , X502 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wie- derum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:C (O) -NX485X486, -NX487-C (O) -O-X488, -NX489-C (O) -NH- X490, -NX491-C (O) -NX492X493, -NHS (O 2) -X494, -NX495S (O2) - X496, -S-X497, -S (O) -X498, -S (O 2) -X499, -S (O2) N H-X500, - S (O 2) NX501X502, -S (O 2 ) O -X503, -P (O) (OX504) (OX505), -Si (X506) (X507) (X508) "; wherein X457, X458, X459, X460, X461, X462, X463, X464, X465, X466, X467, X468, X469, X470, X471, X472, X473, X474, X475, X476, X477, X478, X479, X480, X481, X482, X483, X484, X485, X486, X487, X488, X489, X490, X491, X492, X493, X494, X495, X496, X497, X498, X499, X500, X501, X502, X503, X504, X505, X506, X507, X508 are independently selected consisting of the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- alkyl" and wherein alternatively X463, X464 and / or X472, X473 and / or X485, X486 and / or X492, X493 and / or X501, X502 may each together also form "heterocyclyl"; in which optionally above substituents of the substituent group (i) can in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX509, -NX510X511, -NO2, -OH, -OCF3, -(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHX509, -NX510X511, -NO 2 , -OH, -OCF 3 , -
SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X512, -C(O)O-X513, -C(O)NH-X514, - C(O)NX515X516, -O-X517, -O(-X518-O)y-H (y = 1, 2, 3, 4, 5), - O(-X519-O)y-X520 (y = 1, 2, 3, 4, 5), -OC(O)-X521, -OC(O)-O- X522, -OC(O)-NHX523, -O-C(O)-NX524X525, -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X512, -C (O) O -X513, -C (O) NH-X514, -C (O) NX515X516, -O-X517, -O (-X518-O) y -H (y = 1, 2, 3, 4, 5), - O (-X519-O) y -X520 (y = 1, 2, 3, 4, 5), -OC (O) -X521, -OC (O) - O-X522, -OC (O) -NHX523, -OC (O) -NX524X525, -
OP(O)(OX526)(OX527), -OSi(X528)(X529)(X530), -OS(O2)- X531, -NHC(O)-X532, -NX533C(O)-X534, -NH-C(O)-O-X535, -NH-C(O)-NH-X536, -NH-C(O)-NX537X538, -NX539-C(O)-O- X540, -NX541-C(O)-NH-X542, -NX543-C(O)-NX544X545, - NHS(O2)-X546, -NX547S(O2)-X548, -S-X549, -S(O)-X550, -OP (O) (OX526) (OX527), -OSi (X528) (X529) (X530), -OS (O2) - X531, -NHC (O) -X532, -NX533C (O) -X534, -NH -C (O) -O-X535, -NH-C (O) -NH-X536, -NH-C (O) -NX537X538, -NX539-C (O) -O-X540, -NX541-C (O ) -NH-X542, -NX543-C (O) -NX544X545, - NHS (O 2) -X546, -NX547S (O 2) -X548, -S-X549, -S (O) -X550, -
S(O2)-X551, -S(O2)NH-X552, -S(O2)NX553X554, -S(O2)O- X555, -P(O)(OX556)(OX557), -Si(X558)(X559)(X560)"; wobei X509, X510, X51 1 , X512, X513, X514, X515, X516, X517, X518, X519, X520, X521 , X522, X523, X524, X525, X526, X527, X528, X529, X530, X531 , X532, X533, X534, X535, X536, X537,S (O 2) -X551, -S (O2) NH-X552, -S (O 2) NX553X554, -S (O2) O- X555, -P (O) (OX556) (OX557), -Si (X558) (X559) (X560) "; wherein X509, X510, X51 1, X512, X513, X514, X515, X516, X517, X518, X519, X520, X521, X522, X523, X524, X525, X526, X527 , X528, X529, X530, X531, X532, X533, X534, X535, X536, X537,
X538, X539, X540, X541 , X542, X543, X544, X545, X546, X547, X548, X549, X550, X551 , X552, X553, X554, X555, X556, X557, X558, X559, X560 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X515, X516 und/oder X524, X525 und/oder X537, X538 und/oder X544, X545 und/oder X553, X554 jeweils zusammen auch „heterocyclyl" bilden können;X538, X539, X540, X541, X542, X543, X544, X545, X546, X547, X548, X549, X550, X551, X552, X553, X554, X555, X556, X557, X558, X559, X560 are independently selected the group consisting of: "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X515, X516 and / or X524, X525 and / or X537, X538 and / or X544, X545 and / or X553, X554 in each case also" heterocyclyl " can form;
5 wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:In which optionally substituents of the substituent group (ii) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he-(iii) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE
10 terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,10 terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
Br, I, CN, CF3, N3, NH2, -NHX561 , -NX562X563, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X564, -C(O)O-X565, - C(O)NH-X566, -C(O)NX567X568, -O-X569, -O(-X570-O)z-Br, I, CN, CF 3, N 3, NH 2, -NHX561, -NX562X563, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2 , -CHO, -COOH, - C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X564, -C (O) O-X 565, - C ( O) NH-X566, -C (O) NX567X568, -O-X569, -O (-X570-O) z -
15 H (z = 1 , 2, 3, 4, 5), -O(-X571-O)z-X572 (z = 1 , 2, 3, 4, 5), -15 H (z = 1, 2, 3, 4, 5), -O (-X571-O) z -X572 (z = 1, 2, 3, 4, 5),
OC(O)-X573, -OC(O)-O-X574, -OC(O)-N HX575, -0-C(O)- NX576X577, -OP(O)(OX578)(OX579), - OSi(X580)(X581 )(X582), -OS(O2)-X583, -NHC(O)-X584, - NX585C(O)-X586, -NH-C(O)-O-X587, -NH-C(O)-NH-OC (O) -X573, -OC (O) -O-X574, -OC (O) -N HX575, -O-C (O) -NX576X577, -OP (O) (OX578) (OX579), -OSi (X580) (X581) (x582), -OS (O 2) -X583, -NHC (O) -X584, - NX585C (O) -X586, -NH-C (O) -O-X587, -NH- C (O) -NH-
20 X588, -NH-C(O)-NX589X590, -NX591-C(O)-O-X592, -20 X588, -NH-C (O) -NX589X590, -NX591-C (O) -O-X592, -
NX593-C(O)-NH-X594, -NX595-C(O)-NX596X597, - NHS(O2)-X598, -NX599S(O2)-X600, -S-X601 , -S(O)-X602, -S(O2)-X603, -S(O2)N H-X604, -S(O2)NX605X606, -S(O2)O- X607, -P(O)(OX608)(OX609), -Si(X610)(X61 1 )(X612)";NX593-C (O) -NH-X594, -NX595-C (O) -NX596X597, - NHS (O 2) -X598, -NX599S (O 2) -X600, -S-X601, -S (O) - X602, -S (O 2) -X603, -S (O2) N H-X604, -S (O 2) NX605X606, -S (O2) O- X607, -P (O) (OX608) (OX609 ), -Si (X610) (X61 1) (X612) ";
25 wobei X561 , X562, X563, X564, X565, X566, X567, X568,25 where X561, X562, X563, X564, X565, X566, X567, X568,
X569, X570, X571 , X572, X573, X574, X575, X576, X577, X578, X579, X580, X581 , X582, X583, X584, X585, X586, X587, X588, X589, X590, X591 , X592, X593, X594, X595, X596, X597, X598, X599, X600, X601 , X602, X603, X604,X569, X570, X571, X572, X573, X574, X575, X576, X577, X578, X579, X580, X581, X582, X583, X584, X585, X586, X587, X588, X589, X590, X591, X592, X593, X594, X595, X596, X597, X598, X599, X600, X601, X602, X603, X604,
30 X605, X606, X607, X608, X609, X610, X61 1 , X612 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X567, X568 und/oder X576, X577 und/oder X589, X590 und/oder X596, X597 und/oder X605, X606 jeweils zusammen auch „heterocyclyl" bilden können;"Alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl: 30 X605, X606, X607, X608, X609, X610, X61 1, X612 are independently selected from the group consisting of , heteroaryl, heteroarylalkyl "and, alternatively, X567, X568 and / or X576, X577 and / or X589, X590 and / or X596, X597 and / or X605, X606 may each together also form "heterocyclyl";
(h) unsubstituiertes oder substituiertes Aryl, wobei optional der Arylrest sub- stituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(h) unsubstituted or substituted aryl, wherein optionally the aryl radical can be substituted by at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX613, -NX614X615, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2,(i) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHX613, -NX614X615, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O ) NH 2 , -SO 3 H, -P (O) (OH) 2 ,
-C(O)-X616, -C(O)O-X617, -C(O)NH-X618, -C(O)NX619X620, - O-X621 , -O(-X622-O)a-H (a = 1 , 2, 3, 4, 5), -O(-X623-O)a-X624 (a = 1 , 2, 3, 4, 5), -OC(O)-X625, -OC(O)-O-X626, -OC(O)-N HX627, - O-C(O)-NX628X629, -OP(O)(OX630)(OX631 ), - OSi(X632)(X633)(X634), -OS(O2)-X635, -NHC(O)-X636, --C (O) -X616, -C (O) O -X617, -C (O) NH-X618, -C (O) NX619X620, -O-X621, -O (-X622-O) a -H ( a = 1, 2, 3, 4, 5), -O (-X623-O) a -X624 (a = 1, 2, 3, 4, 5), -OC (O) -X625, -OC (O ) -O-X626, -OC (O) -N HX627, -OC (O) -NX628X629, -OP (O) (OX630) (OX631), -OSi (X632) (X633) (X634), -OS ( O 2 ) -X635, -NHC (O) -X636, -
NX637C(O)-X638, -NH-C(O)-O-X639, -N H-C(O)-N H-X640, -NH- C(O)-NX641X642, -NX643-C(O)-O-X644, -NX645-C(O)-NH- X646, -NX647-C(O)-NX648X649, -NHS(O2)-X650, -NX651 S(O2)- X652, -S-X653, -S(O)-X654, -S(O2)-X655, -S(O2)N H-X656, - S(O2)NX657X658, -S(O2)O-X659, -P(O)(OX660)(OX661 ), -NX637C (O) -X638, -NH-C (O) -O-X639, -NHC (O) -NH-X640, -NH-C (O) -NX641X642, -NX643-C (O) -O -X644, -NX645-C (O) -NH- X646, -NX647-C (O) -NX648X649, -NHS (O 2) -X650, -NX651 S (O 2) - X652, -S-X653, - S (O) -X654, -S (O 2) -X655, -S (O2) N H-X656, - S (O 2) NX657X658, -S (O2) O-X659, -P (O) (OX660) (OX661), -
Si(X662)(X663)(X664)"; wobei X613, X614, X615, X616, X617, X618, X619, X620, X621 , X622, X623, X624, X625, X626, X627, X628, X629, X630, X631 , X632, X633, X634, X635, X636, X637, X638, X639, X640, X641 , X642, X643, X644, X645, X646, X647, X648, X649, X650, X651 ,Si (X662) (X663) (X664) "; wherein X613, X614, X615, X616, X617, X618, X619, X620, X621, X622, X623, X624, X625, X626, X627, X628, X629, X630, X631 , X632, X633, X634, X635, X636, X637, X638, X639, X640, X641, X642, X643, X644, X645, X646, X647, X648, X649, X650, X651,
X652, X653, X654, X655, X656, X657, X658, X659, X660, X661 , X662, X663, X664 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ X619, X620 und/oder X628, X629 und/oderX652, X653, X654, X655, X656, X657, X658, X659, X660, X661, X662, are X663, X664 are independently selected from the group consisting of: "alkyl, (30 Cg-C) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X619, X620 and / or X628, X629 and / or
X641 , X642 und/oder X648, X649 und/oder X657, X658 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindes- tens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:X641, X642 and / or X648, X649 and / or X657, X658 may together also form "heterocyclyl", where optionally substituents of the substituent group (i) above may be substituted independently of one another with at least one at least one substituent, the same or different, selected from the group consisting of:
(ii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX665, -NX666X667, -NO2, -OH, -OCF3, -(ii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHX665, -NX666X667, -NO 2 , -OH, -OCF 3 , -
SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X668, -C(O)O-X669, -C(O)NH-X670, - C(O)NX671X672, -O-X673, -O(-X674-O)b-H (b = 1 , 2, 3, 4, 5), - O(-X675-O)b-X676 (b = 1 , 2, 3, 4, 5), -OC(O)-X677, -OC(O)-O- X678, -OC(O)-NHX679, -O-C(O)-NX680X681 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X668, -C (O) O -X669, -C (O) NH-X670, -C (O) NX671X672, -O-X673, -O (-X674-O) b -H (b = 1, 2, 3, 4, 5), - O (-X675-O) b -X676 (b = 1, 2, 3, 4, 5), -OC (O) -X677, -OC (O) - O-X678, -OC (O) -NHX679, -OC (O) -NX680X681, -
OP(O)(OX682)(OX683), -OSi(X684)(X685)(X686), -OS(O2)- X687, -NHC(O)-X688, -NX689C(O)-X690, -NH-C(O)-O-X691, -NH-C(O)-NH-X692, -NH-C(O)-NX693X694, -NX695-C(O)-O- X696, -NX697-C(O)-NH-X698, -NX699-C(O)-NX700X701, - NHS(O2)-X702, -NX703S(O2)-X704, -S-X705, -S(O)-X706, -OP (O) (OX682) (OX683), -OSi (X684) (X685) (X686), -OS (O2) - X687, -NHC (O) -X688, -NX689C (O) -X690, -NH -C (O) -O-X691, -NH-C (O) -NH-X692, -NH-C (O) -NX693X694, -NX695-C (O) -O-X696, -NX697-C (O ) -NH-X698, -NX699-C (O) -NX700X701, - NHS (O 2 ) -X702, -NX703S (O 2 ) -X704, -S-X705, -S (O) -X706, -
S(O2)-X707, -S(O2)NH-X708, -S(O2)NX709X710, -S(O2)O- X711,-P(O)(OX712)(OX713), -Si(X714)(X715)(X716)"; wobei X665, X666, X667, X668, X669, X670, X671, X672, X673, X674, X675, X676, X677, X678, X679, X680, X681 , X682, X683, X684, X685, X686, X687, X688, X689, X690, X691 , X692, X693,S (O 2) -X707, -S (O2) NH-X708, -S (O 2) NX709X710, -S (O2) O- X711, -P (O) (OX712) (OX713), -Si (X714) (X715) (X716) "; wherein X665, X666, X667, X668, X669, X670, X671, X672, X673, X674, X675, X676, X677, X678, X679, X680, X681, X682, X683, X684, X685, X686, X687, X688, X689, X690, X691, X692, X693,
X694, X695, X696, X697, X698, X699, X700, X701, X702, X703, X704, X705, X706, X707, X708, X709, X710, X711, X712, X713, X714, X715, X716 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X671 , X672 und/oder X680, X681 und/oder X693, X694 und/oder X700, X701 und/oder X709, X710 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:X694, X695, X696, X697, X698, X699, X700, X701, X702, X703, X704, X705, X706, X707, X708, X709, X710, X711, X712, X713, X714, X715, X716 are independently selected consisting of the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively X671, X672 and / or X680, X681 and / or X693, X694 and / or X700, X701 and / or X709, X710 may together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX717, -NX718X719, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X720, -C(O)O-X721 , - C(O)NH-X722, -C(O)NX723X724, -O-X725, -O(-X726-O)c- H (c = 1 , 2, 3, 4, 5), -O(-X727-O)c-X728 (c = 1 , 2, 3, 4, 5), -(iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHX717, -NX718X719, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X720, -C (O) O-X 721, -C (O) NH-X722, -C (O) NX723X724, -O-X725, -O (-X726-O) c - H (c = 1, 2, 3, 4, 5), -O (-X727- O) c -X728 (c = 1, 2, 3, 4, 5), -
OC(O)-X729, -OC(O)-O-X730, -OC(O)-N HX731 , -0-C(O)- NX732X733, -OP(O)(OX734)(OX735), - OSi(X736)(X737)(X738), -OS(O2)-X739, -NHC(O)-X740, - NX741 C(O)-X742, -NH-C(O)-O-X743, -NH-C(O)-NH- X744, -NH-C(O)-NX745X746, -NX747-C(O)-O-X748, -OC (O) -X729, -OC (O) -O-X730, -OC (O) -N HX731, -O-C (O) -NX732X733, -OP (O) (OX734) (OX735), -OSi (X736) (X737) (X738), -OS (O 2) -X739, -NHC (O) -X740, - NX741 -C (O) -X742, -NH-C (O) -O-X743, -NH -C (O) -NH-X744, -NH-C (O) -NX745X746, -NX747-C (O) -O-X748, -
NX749-C(O)-NH-X750, -NX751-C(O)-NX752X753, - NHS(O2)-X754, -NX755S(O2)-X756, -S-X757, -S(O)-X758, -S(O2)-X759, -S(O2)N H-X760, -S(O2)NX761X762, -S(O2)O- X763, -P(O)(OX764)(OX765), -Si(X766)(X767)(X768)"; wobei X717, X718, X719, X720, X721 , X722, X723, X724,NX749-C (O) -NH-X750, -NX751-C (O) -NX752X753, - NHS (O 2) -X754, -NX755S (O 2) -X756, -S-X757, -S (O) - X758, -S (O 2) -X759, -S (O2) N H-X760, -S (O 2) NX761X762, -S (O2) O- X763, -P (O) (OX764) (OX765 -Si (X766) (X767) (X768) "; wherein X717, X718, X719, X720, X721, X722, X723, X724,
X725, X726, X727, X728, X729, X730, X731 , X732, X733, X734, X735, X736, X737, X738, X739, X740, X741 , X742, X743, X744, X745, X746, X747, X748, X749, X750, X751 , X752, X753, X754, X755, X756, X757, X758, X759, X760, X761 , X762, X763, X764, X765, X766, X767, X768 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X723, X724 und/oder X732, X733 und/oder X745, X746 und/oder X752, X753 und/oder X761 ,X725, X726, X727, X728, X729, X730, X731, X732, X733, X734, X735, X736, X737, X738, X739, X740, X741, X742, X743, X744, X745, X746, X747, X748, X749, X750, X751, X752, X753, X754, X755, X756, X757, X758, X759, X760, X761, X762, X763, X764, X765, X766, X767, X768 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and where alternatively X 723, X 724 and / or X 732, X 733 and / or X 745, X 746 and / or X752, X753 and / or X761,
X762 jeweils zusammen auch „heterocyclyl" bilden können;X762 together can also form "heterocyclyl";
(j) unsubstituiertes oder substituiertes Heteroaryl, wobei optional der Hetero- arylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(j) unsubstituted or substituted heteroaryl, where optionally the heteroaryl radical may be substituted by at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX769, -NX770X771 , -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X772, -C(O)O-X773, -C(O)NH-X774, -C(O)NX775X776, - O-X777, -O(-X778-O)d-H (d = 1 , 2, 3, 4, 5), -O(-X779-O)d-X780 (d = 1 , 2, 3, 4, 5), -OC(O)-X781 , -OC(O)-O-X782, -OC(O)-N HX783, - O-C(O)-NX784X785, -OP(O)(OX786)(OX787), - OSi(X788)(X789)(X790), -OS(O2)-X791 , -NHC(O)-X792, -(i) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHX769, -NX770X771, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X772, -C (O) O -X773, -C (O) NH-X774, -C (O) NX775X776, -O-X777, -O (-X778-O) d -H ( d = 1, 2, 3, 4, 5), -O (-X779-O) d -X780 (d = 1, 2, 3, 4, 5), -OC (O) -X781, -OC (O ) -O-X782, -OC (O) -N HX783, - OC (O) -NX784X785, -OP (O) (OX786) (OX787), - OSi (X788) (X789) (X790), -OS ( O 2) -X791, -NHC (O) -X792, -
NX793C(O)-X794, -NH-C(O)-O-X795, -N H-C(O)-N H-X796, -NH- C(O)-NX797X798, -NX799-C(O)-O-X800, -NX801-C(O)-NH- X802, -NX803-C(O)-NX804X805, -NHS(O2)-X806, -NX807S(O2)- X808, -S-X809, -S(O)-X810, -S(O2)-X811 , -S(O2)N H-X812, - S(O2)NX813X814, -S(O2)O-X815, -P(O)(OX816)(OX817), -NX793C (O) -X794, -NH-C (O) -O-X795, -NHC (O) -NH-X796, -NH-C (O) -NX797X798, -NX799-C (O) -O -X800, -NX801-C (O) -NH- X802, -NX803-C (O) -NX804X805, -NHS (O 2) -X806, -NX807S (O2) - X808, -S-X809, -S (O) -X810, -S (O 2) -X811, -S (O2) N H-X812, - S (O 2) NX813X814, -S (O2) O-X815, -P (O) ( OX816) (OX817), -
Si(X818)(X819)(X820)"; wobei X769, X770, X771 , X772, X773, X774, X775, X776, X777, X778, X779, X780, X781 , X782, X783, X784, X785, X786, X787, X788, X789, X790, X791 , X792, X793, X794, X795, X796, X797, X798, X799, X800, X801 , X802, X803, X804, X805, X806, X807,Si (X818) (X819) (X820) "; wherein X769, X770, X771, X772, X773, X774, X775, X776, X777, X778, X779, X780, X781, X782, X783, X784, X785, X786, X787 , X788, X789, X790, X791, X792, X793, X794, X795, X796, X797, X798, X799, X800, X801, X802, X803, X804, X805, X806, X807,
X808, X809, X810, X81 1 , X812, X813, X814, X815, X816, X817, X818, X819, X820 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ X775, X776 und/oder X784, X785 und/oderAre X808, X809, X810, X81 1, X812, X813, X814, X815, X816, X817, X818, X819, X820 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl , cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X775, X776 and / or X784, X785 and / or
X797, X798 und/oder X804, X805 und/oder X813, X814 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindes- tens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:X797, X798 and / or X804, X805 and / or X813, X814 may together also form "heterocyclyl", where optionally substituents of the substituent group (i) above may be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX821 , -NX822X823, -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H,(ii) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, - NHX821, -NX822X823, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H,
-P(O)(OH)2, -C(O)-X824, -C(O)O-X825, -C(O)NH-X826, - C(O)NX827X828, -O-X829, -O(-X830-O)e-H (e = 1 , 2, 3, 4, 5), - O(-X831-O)e-X832 (e = 1 , 2, 3, 4, 5), -OC(O)-X833, -OC(O)-O- X834, -OC(O)-N HX835, -O-C(O)-NX836X837, - OP(O)(OX838)(OX839), -OSi(X840)(X841)(X842), -OS(O2)- X843, -NHC(O)-X844, -NX845C(O)-X846, -NH-C(O)-O-X847, -NH-C(O)-NH-X848, -NH-C(O)-NX849X850, -NX851-C(O)-O- X852, -NX853-C(O)-NH-X854, -NX855-C(O)-NX856X857, --P (O) (OH) 2 , -C (O) -X824, -C (O) O -X825, -C (O) NH-X826, -C (O) NX827X828, -O-X829, -O (-X830-O) e -H (e = 1, 2, 3, 4, 5), - O (-X831-O) e -X832 (e = 1, 2, 3, 4, 5), -OC (O) -X833, -OC (O) -O-X834, -OC (O) -N HX835, -OC (O) -NX836X837, - OP (O) (OX838) (OX839), -OSi (X840) (X841) (X842), -OS (O2) - X843, -NHC (O) -X844, -NX845C (O) -X846, -NH -C (O) -O-X847, -NH-C (O) -NH-X848, -NH-C (O) -NX849X850, -NX851-C (O) -O-X852, -NX853-C (O ) -NH-X854, -NX855-C (O) -NX856X857, -
5 NHS(O2)-X858, -NX859S(O2)-X860, -S-X861 , -S(O)-X862, -5 NHS (O 2) -X858, -NX859S (O 2) -X860, -S-X861, -S (O) -X862, -
S(O2)-X863, -S(O2)NH-X864, -S(O2)NX865X866, -S(O2)O- X867, -P(O)(OX868)(OX869), -Si(X870)(X871)(X872)"; wobei X821, X822, X823, X824, X825, X826, X827, X828, X829, X830, X831, X832, X833, X834, X835, X836, X837, X838, X839,S (O 2) -X863, -S (O2) NH-X864, -S (O 2) NX865X866, -S (O2) O- X867, -P (O) (OX868) (OX869), -Si (X870) (X871) (X872) "; wherein X821, X822, X823, X824, X825, X826, X827, X828, X829, X830, X831, X832, X833, X834, X835, X836, X837, X838, X839,
10 X840, X841, X842, X843, X844, X845, X846, X847, X848, X849,10 X840, X841, X842, X843, X844, X845, X846, X847, X848, X849,
X850, X851, X852, X853, X854, X855, X856, X857, X858, X859, X860, X861, X862, X863, X864, X865, X866, X867, X868, X869, X870, X871, X872 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cyclo-X850, X851, X852, X853, X854, X855, X856, X857, X858, X859, X860, X861, X862, X863, X864, X865, X866, X867, X868, X869, X870, X871, X872 are independently selected consisting of the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cyclo-
15 alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X827, X828 und/oder X836, X837 und/oder X849, X850 und/oder X856, X857 und/oder X865, X866 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) 20 wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:15 alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively X827, X828 and / or X836, X837 and / or X849, X850 and / or X856, X857 and / or X865, X866 in each case also" heterocyclyl "can form; in which optional substituents of substituent group (ii) 20 may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,(iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
25 Br, I, CN, CF3, N3, NH2, -NHX873, -NX874X875, -NO2, -OH,25 Br, I, CN, CF 3, N 3, NH 2, -NHX873, -NX874X875, -NO 2, -OH,
-OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X876, -C(O)O-X877, - C(O)NH-X878, -C(O)NX879X880, -O-X881 , -O(-X882-O)r- H (f = 1 , 2, 3, 4, 5), -O(-X883-O)f-X884 (f = 1 , 2, 3, 4, 5), --OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH ) 2 , -C (O) -X876, -C (O) O -X877, -C (O) NH-X878, -C (O) NX879X880, -O-X881, -O (-X882-O) r - H (f = 1, 2, 3, 4, 5), -O (-X883-O) f -X884 (f = 1, 2, 3, 4, 5), -
30 OC(O)-X885, -OC(O)-O-X886, -OC(O)-N HX887, -0-C(O)-30 OC (O) -X885, -OC (O) -O-X886, -OC (O) -N HX887, -O-C (O) -
NX888X889, -OP(O)(OX890)(OX891 ), - OSi(X892)(X893)(X894), -OS(O2)-X895, -NHC(O)-X896, - NX897C(O)-X898, -NH-C(O)-O-X899, -NH-C(O)-NH- X900, -NH-C(O)-NX901X902, -NX903-C(O)-O-X904, - NX905-C(O)-NH-X906, -NX907-C(O)-NX908X909, - NHS(O2)-X910, -NX91 1 S(O2)-X912, -S-X913, -S(O)-X914, -S(O2)-X915, -S(O2)NH-X916, -S(O2)NX917X918, -S(O2)O- X919, -P(O)(OX920)(OX921 ), -Si(X922)(X923)(X924)"; wobei X873, X874, X875, X876, X877, X878, X879, X880,NX888X889, -OP (O) (OX890) (OX891), - OSi (X892) (X893) (X894), -OS (O 2) -X895, -NHC (O) -X896, - NX897C (O) -X898 , -NH-C (O) -O-X899, -NH-C (O) -NH-X900, -NH-C (O) -NX901X902, -NX903-C (O) -O-X904, - NX905-C (O) -NH-X906, -NX907-C (O) -NX908X909, - NHS (O 2) -X910, -NX91 1 S (O 2) -X912, -S-X913, -S (O ) -X914, -S (O 2) -X915, -S (O2) NH-X916, -S (O 2) NX917X918, -S (O2) O- X919, -P (O) (OX920) ( OX921), -Si (X922) (X923) (X924) "; wherein X873, X874, X875, X876, X877, X878, X879, X880,
X881 , X882, X883, X884, X885, X886, X887, X888, X889, X890, X891 , X892, X893, X894, X895, X896, X897, X898, X899, X900, X901 , X902, X903, X904, X905, X906, X907, X908, X909, X910, X91 1 , X912, X913, X914, X915, X916, X917, X918, X919, X920, X921 , X922, X923, X924 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X879, X880 und/oder X888, X889 und/oder X901 , X902 und/oder X908, X909 und/oder X917,X881, X882, X883, X884, X885, X886, X887, X888, X889, X890, X891, X892, X893, X894, X895, X896, X897, X898, X899, X900, X901, X902, X903, X904, X905, X906, X907, X908, X909, X910, X91 1, X912, X913, X914, X915, X916, X917, X918, X919, X920, X921, X922, X923, X924 are independently selected from the group consisting of: "alkyl , (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, as heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X879, X880 and / or X888, X889 and / or X901, X902 and / or X908, X909 and / or X917,
X918 jeweils zusammen auch „heterocyclyl" bilden können;X918 may together also form "heterocyclyl";
(k) OZ6, wobei Z6 unabhängig ausgewählt ist aus der Gruppe bestehend aus: (i) „Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(k) OZ6, wherein Z6 is independently selected from the group consisting of: (i) "hydrogen, alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX925, -NX926X927, -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X928, -C(O)O-X929, -C(O)NH-X930, -(ii) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, - NHX925, -NX926X927, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X 928, -C (O) O-X 929, -C (O) NH-X 930, -
C(O)NX931X932, -O-X933, -O(-X934-O)g-H (g = 1 , 2, 3, 4, 5), - O(-X935-O)g-X936 (g = 1 , 2, 3, 4, 5), -OC(O)-X937, -OC(O)-O- X938, -OC(O)-NHX939, -O-C(O)-NX940X941 , - OP(O)(OX942)(OX943), -OSi(X944)(X945)(X946), -OS(O2)- X947, -NHC(O)-X948, -NX949C(O)-X950, -NH-C(O)-O-X951, -NH-C(O)-NH-X952, -NH-C(O)-NX953X954, -NX955-C(O)-O- X956, -NX957-C(O)-NH-X958, -NX959-C(O)-NX960X961, -C (O) NX931X932, -O-X933, -O (-X934-O) g -H (g = 1, 2, 3, 4, 5), - O (-X935-O) g -X936 (g = 1, 2, 3, 4, 5), -OC (O) -X937, -OC (O) -O-X938, -OC (O) -NHX939, -OC (O) -NX940X941, - OP (O) (OX942) (OX943), -OSi (X944) (X945) (X946), -OS (O2) - X947, -NHC (O) -X948, -NX949C (O) -X950, -NH -C (O) -O-X951, -NH-C (O) -NH-X952, -NH-C (O) -NX953X954, -NX955-C (O) -O-X956, -NX957-C (O ) -NH-X958, -NX959-C (O) -NX960X961, -
5 NHS(O2)-X962, -NX963S(O2)-X964, -S-X965, -S(O)-X966, -5 NHS (O 2) -X962, -NX963S (O 2) -X964, -S-X965, -S (O) -X966, -
S(O2)-X967, -S(O2)NH-X968, -S(O2)NX969X970, -S(O2)O- X971 , -P(O)(OX972)(OX973), -Si(X974)(X975)(X976)"; wobei X925, X926, X927, X928, X929, X930, X931, X932, X933, X934, X935, X936, X937, X938, X939, X940, X941 , X942, X943,S (O 2) -X967, -S (O2) NH-X968, -S (O 2) NX969X970, -S (O2) O- X971, -P (O) (OX972) (OX973), -Si (X974) (X975) (X976) "; wherein X925, X926, X927, X928, X929, X930, X931, X932, X933, X934, X935, X936, X937, X938, X939, X940, X941, X942, X943,
10 X944, X945, X946, X947, X948, X949, X950, X951 , X952, X953,10 X944, X945, X946, X947, X948, X949, X950, X951, X952, X953,
X954, X955, X956, X957, X958, X959, X960, X961, X962, X963, X964, X965, X966, X967, X968, X969, X970, X971, X972, X973, X974, X975, X976 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cyclo-X954, X955, X956, X957, X958, X959, X960, X961, X962, X963, X964, X965, X966, X967, X968, X969, X970, X971, X972, X973, X974, X975, X976 are independently selected from consisting of the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cyclo-
15 alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X931 , X932 und/oder X940, X941 und/oder X953, X954 und/oder X960, X961 und/oder X969, X970 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) 20 wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:15 alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively X931, X932 and / or X940, X941 and / or X953, X954 and / or X960, X961 and / or X969, X970 in each case also" heterocyclyl "can form; in which optional substituents of substituent group (ii) 20 may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,(iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
25 Br, I, CN, CF3, N3, NH2, -NHX977, -NX978X979, -NO2, -OH,25 Br, I, CN, CF 3, N 3, NH 2, -NHX977, -NX978X979, -NO 2, -OH,
-OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X980, -C(O)O-X981 , - C(O)NH-X982, -C(O)NX983X984, -O-X985, -O(-X986-O)h- H (h = 1 , 2, 3, 4, 5), -O(-X987-O)h-X988 (h = 1 , 2, 3, 4, 5), --OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH ) 2 , -C (O) -X980, -C (O) O -X981, -C (O) NH-X982, -C (O) NX983X984, -O-X985, -O (-X986-O) h - H (h = 1, 2, 3, 4, 5), -O (-X987-O) h -X988 (h = 1, 2, 3, 4, 5), -
30 OC(O)-X989, -OC(O)-O-X990, -OC(O)-N HX991 , -0-C(O)-30 OC (O) -X989, -OC (O) -O-X990, -OC (O) -N HX991, -O-C (O) -
NX992X993, -OP(O)(OX994)(OX995), - OSi(X996)(X997)(X998), -OS(O2)-X999, -NHC(O)-XI OOO, - NX1001 C(O)-XI 002, -NH-C(O)-O-XI 003, -NH-C(O)-NH- X1004, -NH-C(O)-NXI 005X1006, -NX1007-C(O)-O-XI 008, -NXI OO^(O)-NH-XI OI O1 -NXI 01 1^(0)^X1012X1013, - NHS(O2)-X1014, -NX1015S(O2)-X1016, -S-X1017, -S(O)- X1018, -S(O2)-X1019, -S(O2)NH-XI 020, - S(O2)NX1021X1022, -S(O2)O-XI 023, - P(O)(OXI 024)(OX1025), -Si(XI 026)(X1027)(X1028)"; wobei X977, X978, X979, X980, X981 , X982, X983, X984, X985, X986, X987, X988, X989, X990, X991 , X992, X993, X994, X995, X996, X997, X998, X999, X1000, X1001 , X1002, X1003, X1004, X1005, X1006, X1007, X1008, X1009, X1010, X101 1 , X1012, X1013, X1014, X1015, X1016, X1017, X1018,NX992X993, -OP (O) (OX994) (OX995), - OSi (X996) (X997) (X998), -OS (O 2) -X999, -NHC (O) -XI OOO, - NX1001 C (O) -XI 002, -NH-C (O) -O-XI 003, -NH-C (O) -NH-X1004, -NH-C (O) -NXI 005X1006, -NX1007-C (O) -O- XI 008, -NXI OO ^ (O) -NH-XI OI O 1 -NXI 01 1 ^ (0) ^ X1012X1013, - NHS (O 2 ) -X1014, -NX1015S (O 2 ) -X1016, -S-X1017, -S (O) - X1018, -S (O 2) -X1019, -S (O2) NH-XI 020, - S (O 2) NX1021X1022, -S (O 2) O-XI 023, - P (O) (OXI 024) (OX1025), -Si (XI 026) (X1027) (X1028) "; wherein X977, X978, X979, X980, X981, X982, X983, X984, X985, X986, X987, X988, X989, X990 , X991, X992, X993, X994, X995, X996, X997, X998, X999, X1000, X1001, X1002, X1003, X1004, X1005, X1006, X1007, X1008, X1009, X1010, X101 1, X1012, X1013, X1014, X1015, X1016, X1017, X1018,
X1019, X1020, X1021 , X1022, X1023, X1024, X1025, X1026, X1027, X1028 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X983, X984 und/oder X992, X993 und/oder X1005, X1006 und/oder X1012, X1013 und/oder X1021 , X1022 jeweils zusammen auch „heterocyclyl" bilden können;Are x1019, X1020, X1021, X1022, X1023, X1024, X1025, X1026, X1027, X1028 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl , arylalkyl, heteroaryl, heteroarylalkyl "and alternatively, X983, X984 and / or X992, X993 and / or X1005, X1006 and / or X1012, X1013 and / or X1021, X1022 may each together also form" heterocyclyl ";
, wobei Z7 unabhängig ausgewählt ist aus der Gruppe bestehend aus: „Wasserstoff, alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindes- tens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:wherein Z7 is independently selected from the group consisting of: "hydrogen, alkyl, (C" 9 " -C" 30 " ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; optionally wherein the above substituents of the substituent group ( i) may in turn be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX1029, -NXI OSOXI OSI 1 -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2,(ii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHX1029, -NXI OSOXI OSI 1 -NO 2 , -OH, - OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O ) NH 2 ,
-SO3H, -P(O)(OH)2, -C(O)-XI 032, -C(O)O-XI 033, -C(O)NH- X1034, -C(O)NXI 035X1036, -O-X1037, -0(-X1038-O)-H (i = 1 , 2, 3, 4, 5), -0(-X1039-O)1-XI 040 (i = 1 , 2, 3, 4, 5), -OC(O)- X1041 , -OC(O)-O-XI 042, -OC(O)-NHXI 043, -0-C(O)- NX1044X1045, -OP(O)(OXI 046)(OX1047), - OSi(XI 048)(X1049)(X1050), -0S(02)-X1051 , -N HC(O)-XI 052, - NX1053C(O)-XI 054, -NH-C(O)-O-XI 055, -N H-C(O)-N H--SO 3 H, -P (O) (OH) 2 , -C (O) -XI 032, -C (O) O -XlO33, -C (O) NH-X1034, -C (O) NXI 035X1036 , -O-X1037, -O (-X1038-O) -H (i = 1, 2, 3, 4, 5), -O (-X1039-O) 1 -XI 040 (i = 1, 2, 3 , 4, 5), -OC (O) - X1041, -OC (O) -O-XI 042, -OC (O) -NHXI 043, -O-C (O) -NX1044X1045, -OP (O) (OXI 046) (OX1047), -OSi (XI 048 ) (X1049) (X1050), -0S (0 2 ) -X1051, -NHC (O) -XI 052, -NX1053C (O) -XI 054, -NH-C (O) -O-XI 055, - N HC (O) -N H-
5 X1056, -NH-C(O)-NXI 057X1058, -NX1059-C(O)-O-XI 060, -5 X1056, -NH-C (O) -NXI 057X1058, -NX1059-C (O) -O-XI 060, -
NX1061-C(O)-NH-X1062, -NX1063-C(O)-NXI 064X1065, - NHS(O2)-X1066, -NX1067S(O2)-X1068, -S-X1069, -S(O)- X1070, -S(02)-X1071 , -S(O2)NH-XI 072, -S(O2)NXI 073X1074, - S(O2)O-XI 075, -P(O)(OXI 076)(OX1077), - 10 Si(XI 078)(X1079)(X1080)"; wobei X1029, X1030, X1031 , X1032, X1033, X1034, X1035, X1036, X1037, X1038, X1039, X1040, X1041 , X1042, X1043, X1044, X1045, X1046, X1047, X1048, X1049, X1050, X1051 , X1052, X1053, X1054, X1055, X1056, X1057, X1058, X1059,NX1061-C (O) -NH-X1062, -NX1063-C (O) -NXI 064X1065, - NHS (O 2) -X1066, -NX1067S (O 2) -X1068, -S-X1069, -S (O) - X1070, -S (O 2 ) -X1071, -S (O 2 ) NH-XI 072, -S (O 2 ) NXI 073X1074, -S (O 2 ) O-XI 075, -P (O) (OXI 076) (OX1077), 10 Si (XI 078) (X1079) (X1080) "; where X1029, X1030, X1031, X1032, X1033, X1034, X1035, X1036, X1037, X1038, X1039, X1040, X1041, X1042, X1043, X1044, X1045, X1046, X1047, X1048, X1049, X1050, X1051, X1052, X1053, X1054, X1055, X1056, X1057, X1058, X1059,
15 X1060, X1061 , X1062, X1063, X1064, X1065, X1066, X1067,15 X1060, X1061, X1062, X1063, X1064, X1065, X1066, X1067,
X1068, X1069, X1070, X1071 , X1072, X1073, X1074, X1075, X1076, X1077, X1078, X1079, X1080 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl,Are X1068, X1069, X1070, X1071, X1072, X1073, X1074, X1075, X1076, X1077, X1078, X1079, x1080 independently selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl,
20 aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ20 aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively
X1035, X1036 und/oder X1044, X1045 und/oder X1057, X1058 und/oder X1064, X1065 und/oder X1073, X1074 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) 25 wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:X1035, X1036 and / or X1044, X1045 and / or X1057, X1058 and / or X1064, X1065 and / or X1073, X1074 may together also form "heterocyclyl" wherein optionally substituents of substituent group (ii) 25 optionally substituted independently of one another may be at least one substituent, the same or different, selected from the group consisting of:
(iii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,(iii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
30 Br, I, CN, CF3, N3, NH2, -NHX1081 , -NX1082X1083, -NO2, -30 Br, I, CN, CF 3, N 3, NH 2, -NHX1081, -NX1082X1083, -NO 2, -
OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-XI 084, -C(O)O-XI 085, -C(O)NH-XI 086, -C(O)NXI 087X1088, -O-X1089, -O(- X1090-O)-H C = 1 , 2, 3, 4, 5), -O(-X1091-O)-X1092 (j = 1 , 2, 3, 4, 5), -OC(O)-XI 093, -OC(O)-O-XI 094, -OC(O)- NHX1095, -0-C(O)-NXI 096X1097, - OP(O)(OXI 098)(OX1099), -OSi(X1100)(X1101 )(X1102), - 0S(02)-X1103, -NHC(O)-X1104, -NX1105C(O)-X1106, - NH-C(O)-O-X1107, -NH-C(O)-NH-X1108, -NH-C(O)-OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Xl 084, -C (O) O -XlO85, -C (O) NH-XI 086, -C (O) NXI 087X1088, -O-X1089, -O ( - X1090-O) -HC = 1, 2, 3, 4, 5), -O (-X1091-O) -X1092 (j = 1, 2, 3, 4, 5), -OC (O) -XI 093, -OC (O) -O-XI 094, -OC (O) - NHX1095, -O-C (O) -NXI 096X1097, - OP (O) (OXI 098) (OX1099), -OSi (X1100) (X1101) (X1102), -0S (0 2 ) -X1103, -NHC (O) -X1104, -NX1105C (O) -X1106, -NH -C (O) -O-X1107, -NH-C (O) -NH-X1108, -NH-C (O) -
NX1 109X11 10, -NX1 11 1-C(O)-O-X1 112, -NX11 13-C(O)- NH-X1 114, -NX11 15-C(O)-NX1 116X11 17, -NHS(O2)- X1 118, -NX11 19S(O2)-X1120, -S-X1 121 , -S(O)-X1 122, - S(02)-X1123, -S(O2)NH-X1124, -S(O2)NX1 125X1126, - S(O2)O-X1127, -P(O)(OX1128)(OX1 129), -NX1 109X11 10, -NX1 11 1-C (O) -O-X1 112, -NX11 13-C (O) -NH-X1 114, -NX11 15-C (O) -NX1 116X11 17, -NHS (O 2 ) - X1 118, -NX11 19S (O 2 ) -X1120, -S-X1 121, -S (O) -X1 122, -S (0 2 ) -X1123, -S (O 2 ) NH-X1124, -S (O 2) NX1 125X1126, - S (O 2) O-X1127, -P (O) (OX1128) (OX1 129), -
Si(XI 130)(X1 131 )(X1 132)"; wobei X1081, X1082, X1083, X1084, X1085, X1086, X1087, X1088, X1089, X1090, X1091, X1092, X1093, X1094, X1095, X1096, X1097, X1098, X1099, X1100, X1101, X1102, X1103, X1104, X1105, X1106, X1107, X1108, X1109, X1110, X1111 ,Si (XI 130) (X1 131) (X1 132) ", wherein X1081, X1082, X1083, X1084, X1085, X1086, X1087, X1088, X1089, X1090, X1091, X1092, X1093, X1094, X1095, X1096, X1097, X1098, X1099, X1100, X1101, X1102, X1103, X1104, X1105, X1106, X1107, X1108, X1109, X1110, X1111,
X1112, X1113, X1114, X1115, X1116, X1117, X1118, X1119, X1120, X1121, X1122, X1123, X1124, X1125, X1126, X1127, X1128, X1129, X1130, X1131 , X1132 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X1087, X1088 und/oder X1096, X1097 und/oder X1 109, X1 110 und/oder X11 16, X11 17 und/oder X1125, X1 126 jeweils zusammen auch „heterocyclyl" bilden können;X1112, X1113, X1114, X1115, X1116, X1117, X1118, X1119, X1120, X1121, X1122, X1123, X1124, X1125, X1126, X1127, X1128, X1129, X1130, X1131, X1132 are independently selected from the group consisting of : "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively X1087, X1088 and / or X1096, X1097 and / or X1 109, X1 110 and / or X11 16, X11 17 and / or X1125, X1 126 may each together also form "heterocyclyl";
(m) NZ8Z9, wobei Z8, Z9 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:(m) NZ8Z9, wherein Z8, Z9 are independently selected from the group consisting of:
(i) „Wasserstoff, alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C(O)- X1 133, -C(O)O-X1134, -C(O)-NX1135X1136, -S(O2)-X1 137, -(i) "hydrogen, alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C (O) - X1 133, -C (O) O-X1134, -C (O) -NX1135X1136, -S (O 2 ) -X1 137, -
S(O2)O-X1138"; wobei X1133, X1134, X1135, X1136, X1 137, X1138 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X1 135, X1 136 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindes- tens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:S (O 2) O-X1138 "; wherein X1133, X1134, X1135, X1136, X1 137, X1138 are independently selected from the group consisting of: hydrogen, alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X1 135, X1 136 may together also form" heterocyclyl "; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX1 139, -NX1 140X1141 , -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2,(ii) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHX1 139, -NX1 140X1141, -NO 2 , -OH, - OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O ) NH 2 ,
-SO3H, -P(O)(OH)2, -C(O)-X1 142, -C(O)O-X1 143, -C(O)NH- X1 144, -C(O)NX1145X1 146, -0-X1147, -0(-X1 148-O)k-H (k = 1 , 2, 3, 4, 5), -0(-X1 149-O)k-X1 150 (k = 1 , 2, 3, 4, 5), -OC(O)- X1 151 , -OC(O)-O-X1 152, -OC(O)-NHX1 153, -0-C(O)- NX1 154X1155, -OP(O)(OX1156)(OX1 157), --SO 3 H, -P (O) (OH) 2, -C (O) -X1 142, -C (O) O-X1 143, -C (O) NH- X1 144, -C (O) NX1145X1 146, -0-X1147, -0 (-X1 148-O) k -H (k = 1, 2, 3, 4, 5), -0 (-X1 149-O) k -X1 150 (k = 1 , 2, 3, 4, 5), -OC (O) - X 1 151, -OC (O) -O-X 1 152, -OC (O) -NHX 1 153, -O-C (O) - NX 1 154 X 1155, -OP (O) (OX1156) (OX1 157), -
OSi(X1 158)(X1159)(X1160), -0S(02)-X1161 , -NHC(O)-X1 162, - NX1 163C(O)-X1 164, -NH-C(O)-O-X1165, -N H-C(O)-N H- X1 166, -NH-C(O)-NX1 167X1168, -NX1 169-C(O)-O-X1170, - NX1 171-C(O)-NH-X1172, -NX1 173-C(O)-NXI 174X1175, - NHS(02)-X1 176, -NX1 177S(O2)-X1178, -S-X1 179, -S(O)-OSi (X1 158) (X1159) (X1160), -0S (0 2 ) -X1161, -NHC (O) -X1 162, -NX1 163C (O) -X1 164, -NH-C (O) -O- X1165, -N HC (O) -NH-X1 166, -NH-C (O) -NX1 167X1168, -NX1 169-C (O) -O-X1170, -NX1 171-C (O) -NH- X1172, -NX1 173-C (O) -NXI 174X1175, - NHS (0 2 ) -X 1 176, -NX 1 177S (O 2 ) -X 1178, -S-X 1 179, -S (O) -
X1 180, -S(02)-X1 181 , -S(O2)NH-X1 182, -S(O2)NXI 183X1 184, - S(O2)O-X1185, -P(O)(OX1186)(OX1 187), - Si(XI 188)(X1 189)(X1 190)"; wobei X1139, X1140, X1141 , X1142, X1 143, X1144, X1 145, X1 146, X1 147, X1 148, X1149, X1150, X1151 , X1152, X1153,X1 180, -S (O 2 ) -X1 181, -S (O 2 ) NH-X1 182, -S (O 2 ) NXI 183X1 184, -S (O 2 ) O-X 1185, -P (O) ( OX1186) (OX1 187), -Si (XI 188) (X1 189) (X1 190) "; wherein X1139, X1140, X1141, X1142, X1 143, X1144, X1 145, X1 146, X1 147, X1 148, X1149 , X1150, X1151, X1152, X1153,
X1 154, X1 155, X1 156, X1 157, X1158, X1159, X1160, X1161 , X1 162, X1 163, X1 164, X1 165, X1166, X1167, X1168, X1169, X1 170, X1 171 , X1 172, X1 173, X1174, X1175, X1176, X1177, X1 178, X1 179, X1 180, X1 181 , X1182, X1183, X1184, X1185, X1 186, X1 187, X1 188, X1 189, X1190 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X1 145, X1 146 und/oder X1 154, X1155 und/oder X1167, X1168 und/oder X1 174, X1175 und/oder X1183, X1184 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mitX1 154, X1 155, X1 156, X1 157, X1158, X1159, X1160, X1161, X1 162, X1 163, X1 164, X1 165, X1166, X1167, X1168, X1169, X1 170, X1 171, X1 172, X1 173, X1174, X1175, X1176, X1177, X1 178, X1 179, X1 180, X1 181, X1182, X1183, X1184, X1185, X1 186, X1 187, X1 188, X1 189, X1190 are independently selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively X1 145, X1 146 and / or X1 154, X1155 and / or X1167, X1168 and / or X 1 174, X 1175 and / or X 1183, X 1184 may in each case also together form "heterocyclyl", where optionally substituents of the substituent group (ii) above may be substituted independently of one another
5 mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:5 at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I1 CN1 CF3, N3, NH2, -NHX1 191 , -NX1 192X1193, -NO2, -(iii) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I 1 1 CN CF 3, N 3, NH 2 , -NHX1 191, -NX1 192X1193, -NO 2 , -
10 OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -10 OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -
C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X1 194, -C(O)O-X1 195, -C(O)NH-X1 196, -C(O)NX1197X1198, -0-X1199, -0(- X1200-O),-H (I = 1 , 2, 3, 4, 5), -O(-X1201-O),-X1202 (1 = 1 , 2, 3, 4, 5), -OC(O)-XI 203, -OC(O)-O-XI 204, -OC(O)-C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X 1 194, -C (O) O -X 1 195, -C (O) NH-X 1 196 , -C (O) NX1197X1198, -O-X1199, -O (- X1200-O), - H (I = 1, 2, 3, 4, 5), -O (-X1201-O), - X1202 ( 1 = 1, 2, 3, 4, 5), -OC (O) -XI 203, -OC (O) -O-XI 204, -OC (O) -
15 NHX1205, -0-C(O)-NXI 206X1207, -15 NHX1205, -O-C (O) -NXI 206X1207, -
OP(O)(OX1208)(OX1209), -OSi(X1210)(X1211 )(X1212), - OS(O2)-X1213, -NHC(O)-X1214, -NX1215C(O)-X1216, - NH-C(O)-O-X1217, -NH-C(O)-NH-X1218, -NH-C(O)- NX1219X1220, -NX1221-C(O)-O-XI 222, -NX1223-C(O)-OP (O) (OX1208) (OX1209), -OSi (X1210) (X1211) (X1212), - OS (O 2) -X1213, -NHC (O) -X1214, -NX1215C (O) -X1216, - NH -C (O) -O-X1217, -NH-C (O) -NH-X 1218, -NH-C (O) - NX 1219 X 1220, -NX 1221-C (O) -O-XI 222, -NX 1223-C ( O)-
20 NH-X1224, -NX1225-C(O)-NXI 226X1227, -NHS(O2)-20 NH-X1224, -NX1225-C (O) -NXI 226X1227, -NHS (O 2 ) -
X1228, -NX1229S(O2)-X1230, -S-X1231 , -S(O)-XI 232, - S(O2)-X1233, -S(O2)NH-X1234, -S(O2)NXI 235X1236, - S(O2)O-XI 237, -P(O)(OXI 238)(OX1239), - Si(XI 240)(X1241 )(X1242)";X1228, -NX1229S (O 2) -X1230, -S-X1231, -S (O) -XI 232, - S (O 2) -X1233, -S (O 2) NH-X1234, -S (O 2) NXI 235X1236, -S (O 2 ) O-XI 237, -P (O) (OXI 238) (OX 1239), -Si (XI 240) (X 1241) (X 1242) ";
25 wobei X1191. X1192, X1193, X1194, X1 195, X1196, X1 197,25 where X1191. X1192, X1193, X1194, X1 195, X1196, X1 197,
X1 198, X1 199, X1200, X1201 , X1202, X1203, X1204, X1205, X1206, X1207, X1208, X1209, X1210, X1211 , X1212, X1213, X1214, X1215, X1216, X1217, X1218, X1219, X1220, X1221 , X1222, X1223, X1224, X1225, X1226, X1227, X1228, X1229,X1 198, X1 199, X1200, X1201, X1202, X1203, X1204, X1205, X1206, X1207, X1208, X1209, X1210, X1211, X1212, X1213, X1214, X1215, X1216, X1217, X1218, X1219, X1220, X1221, X1222, X1223, X1224, X1225, X1226, X1227, X1228, X1229,
30 X1230, X1231 , X1232, X1233, X1234, X1235, X1236, X1237,30 X1230, X1231, X1232, X1233, X1234, X1235, X1236, X1237,
X1238, X1239, X1240, X1241 , X1242 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei al- ternativ X1 197, X1 198 und/oder X1206, X1207 und/oder X1219, X1220 und/oder X1226, X1227 und/oder X1235, X1236 jeweils zusammen auch „heterocyclyl" bilden können;"(Cg-C 30) cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl alkyl, alkyl," and where: are X1238, X1239, X1240, X1241, X1242 are independently selected from the group consisting of al- Alternatively, X1 197, X1 198 and / or X1206, X1207 and / or X1219, X1220 and / or X1226, X1227 and / or X1235, X1236 may together also form "heterocyclyl";
oderor
(B) einer der Reste Z3, Z4 oder beide Reste Z3, Z4 unabhängig voneinander „substituiertes Heteroaryl" sind, wobei „substituiertes Heteroaryl" substituiert ist mit mindestens einem Substituenten ausgewählt aus der Gruppe bestehend aus: (a) „alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NH-V1 , -N(alkyl)2, -(B) one of Z3, Z4 or both Z3, Z4 are independently "substituted heteroaryl", wherein "substituted heteroaryl" is substituted with at least one substituent selected from the group consisting of: (a) "alkyl, cycloalkyl, heterocyclyl , aryl, heteroaryl, -NH-V1, -N (alkyl) 2 , -
NHC(O)-alkyl, -NHC(O)-cycloalkyl, -NHC(O)-heterocyclyl, -NHC(O)-aryl, -NHC(O)-heteroaryl, -NHC(O)-arylalkyl, -NHC(O)-heteroarylalkyl, - NHS(O2)-alkyl, -NHS(O2)-cycloalkyl, -NHS(O2)-heterocyclyl, -NHS(O2)- aryl, -NHS(O2)-heteroaryl, -NHS(O2)-arylalkyl, -NHS(O2)-heteroarylalkyl, -S-alkyl, -S-aryl, -S-heteroaryl, -O-alkyl, -O-cycloalkyl, -O- cycloalkylalkyl, -O-aryl, -O-arylalkyl, -O-heteroaryl, -O-heteroarylalkyl, - O-heterocyclylalkyl, -OC(O)-alkyl, -OC(O)-cycloalkyl, -OC(O)- heterocyclyl, -OC(O)-aryl, -OC(O)-heteroaryl, -OC(O)-arylalkyl, -OC(O)- heteroarylalkyl, -OS(O2)-alkyl, -OS(O2)-cycloalkyl, -OS(O2)-heterocyclyl, -OS(O2)-aryl, -OS(O2)-heteroaryl, -OS(O2)-arylalkyl, -OS(O2)- heteroarylalkyl, -C(O)-alkyl, -C(O)-aryl, -C(O)-heteroaryl, -C(O)O-V2, - C(O)NH-V3, -C(O)N(alkyl)2, -C(O)N(cycloalkyl)2, -C(O)N(aryl)2, - C(O)N(heteroraryl)2, -S(O2)N H-alkyl, -S(O2)N H-aryl, -S(O2)NH- heteroaryl, -S(O2)NH-arylalkyl, -S(O2)O-alkyl, -S(O2)O-aryl, -S(O2)O- arylalkyl"; wobei V1 , V2, V3 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; mit der Maßgabe, dass obige Substituenten der Substituentengruppe (a) unabhängig voneinander weiter substituiert sind mit mindestens einemNHC (O) -alkyl, -NHC (O) -cycloalkyl, -NHC (O) -heterocyclyl, -NHC (O) -aryl, -NHC (O) -heteroaryl, -NHC (O) -arylalkyl, -NHC ( O) -heteroarylalkyl, - NHS (O 2 ) -alkyl, -NHS (O 2 ) -cycloalkyl, -NHS (O 2 ) -heterocyclyl, -NHS (O 2 ) -aryl, -NHS (O 2 ) -heteroaryl, -NHS (O 2 ) -arylalkyl, -NHS (O 2 ) -heteroarylalkyl, -S-alkyl, -S-aryl, -S-heteroaryl, -O-alkyl, -O-cycloalkyl, -O-cycloalkylalkyl, -O -aryl, -O-arylalkyl, -O-heteroaryl, -O-heteroarylalkyl, - O-heterocyclylalkyl, -OC (O) -alkyl, -OC (O) -cycloalkyl, -OC (O) -heterocyclyl, -OC ( O) -aryl, -OC (O) -heteroaryl, -OC (O) -arylalkyl, -OC (O) -heteroarylalkyl, -OS (O 2 ) -alkyl, -OS (O 2 ) -cycloalkyl, -OS ( O 2 ) -heterocyclyl, -OS (O 2 ) -aryl, -OS (O 2 ) -heteroaryl, -OS (O 2 ) -arylalkyl, -OS (O 2 ) -heteroarylalkyl, -C (O) -alkyl, -C (O) -aryl, -C (O) -heteroaryl, -C (O) O-V2, -C (O) NH-V3, -C (O) N (alkyl) 2 , -C (O) N (cycloalkyl) 2 , -C (O) N (aryl) 2 , - C (O) N (heteroaryl) 2 , -S (O 2 ) N H -alkyl, -S (O 2 ) N H -aryl, -S (O 2) NH- heteroaryl, -S (O 2) NH-arylalkyl, -S (O 2) O-alkyl, -S (O 2) O-aryl, - S (O 2 ) O -arylalkyl "; wherein V1, V2, V3 are independently selected from the group consisting of: "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; with the proviso that the above substituents of the substituent group (a) independently further substituted with at least one
Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (i) „(Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, N3, -NH-cycloalkyl, -NH- cycloalkylalkyl, -NH-heteroaryl, -NH-heteroarylalkyl, -NH-arylalkyl, - NH-heterocyclyl, -NH-heterocyclylalkyl, -NV4V5, -S-cycloalkyl, -S- cycloalkylalkyl, -S-aryl, —S— arylalkyl, -S-heteroaryl, -S-heteroarylalkyl,Substituents, the same or different, selected from the group consisting of: (i) "(C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, N 3 , -NH-cycloalkyl, -NH-cycloalkylalkyl, -NH-heteroaryl, -NH- heteroarylalkyl, -NH-arylalkyl, -NH-heterocyclyl, -NH-heterocyclylalkyl, -NV4V5, -S-cycloalkyl, -S-cycloalkylalkyl, -S-aryl, -S-arylalkyl, -S-heteroaryl, -S-heteroarylalkyl,
-S-heterocyclyl, -S-heterocyclylalkyl, -O-cycloalkyl, -O- cycloalkylalkyl, —O— arylalkyl, -O-heteroaryl, -O-heteroarylalkyl, -O- heterocyclyl, -O-heterocyclylalkyl, -O(-V6-O)p-H (p = 1 , 2, 3, 4, 5), - O(-V7-O)p-V8 (p = 1 , 2, 3, 4, 5), -OP(O)(OV9)(OV10), -C(O)O-V1 1 , - C(O)NH2, -C(O)NH-V12, -C(O)NV13V14, -S(O2)-V15, -P(O)(OH)2, --S-heterocyclyl, -S-heterocyclylalkyl, -O-cycloalkyl, -O-cycloalkylalkyl, -O-arylalkyl, -O-heteroaryl, -O-heteroarylalkyl, -O-heterocyclyl, -O-heterocyclylalkyl, -O (-V6 -O) p -H (p = 1, 2, 3, 4, 5), - O (-V7-O) p -V8 (p = 1, 2, 3, 4, 5), -OP (O) (OV9) (OV10), -C (O) O-V1 1, - C (O) NH 2, -C (O) NH-V12, -C (O) NV13V14, -S (O 2) -V15, -P (O) (OH) 2 , -
P(O)(OVI 6)(0V17), -Si(VI 8)(V19)(V20), -O-Si(V21 )(V22)(V23), -O- C(O)-O-V24, -0-C(O)-N H-V25, -0-C(O)-N V26V27, -NH-C(O)-O- V28, -N H-C(O)-N H-V29, -N H-C(O)-N V30V31 , -NV32-C(O)-O-V33, -NV34-C(O)-NH-V35, -NV36-C(O)-NV37V38, -NV39-S(O2)-V40, - NH-S(O2)-V41 , -O-S(O2)-V42, -NH-C(O)-V43, -NV44-C(O)-V45, -P (O) (OVI6) (OV17), -Si (VI8) (V19) (V20), -O-Si (V21) (V22) (V23), -O-C (O) -O-V24 , -O-C (O) -NH-V25, -O-C (O) -N V26V27, -NH-C (O) -O-V28, -NHC (O) -NH-V29, - N HC (O) -N V30V31, -NV32-C (O) -O-V33, -NV34-C (O) -NH-V35, -NV36-C (O) -NV37V38, -NV39-S (O 2 ) -V40, - NH-S (O 2) -V41, -OS (O 2) -V42, -NH-C (O) -V43, -NV44-C (O) -V45, -
C(O)-V46, -OC(O)-V47, -S(O)-V48, -S(O2)-NHV49, -S(O2)- NV50V51 , -S(O2)-OV52"; mit der weiteren Maßgabe, dass ,,-N(alkyl)2" weiter substituiert ist mit mindestens einem Substituenten ausgewählt aus der untigen Substi- tuentengruppe (b); wobei V4, V5, V6, V7, V8, V9, V10, V11 , V12, V13, V14, V15, V16, V17, V18, V19, V20, V21 , V22, V23, V24, V25, V26, V27, V28, V29, V30, V31 , V32, V33, V34, V35, V36, V37, V38, V39, V40, V41 , V42, V43, V44, V45, V46, V47, V48, V49, V50, V51 , V52 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V13, V14 und/oder V26, V27 und/oder V30, V31 und/oder V37, V38 und/oder V50, V51 zusammen auch „heterocyclyl" bilden können; wobei optional zusätzlich einer der Reste Z3, Z4 oder zusätzlich beide ResteC (O) -V46, -OC (O) -V47, -S (O) -V48, -S (O 2) -NHV49, -S (O 2) - NV50V51, -S (O 2) -OV52 " with the further proviso that "--N (alkyl) 2 " is further substituted by at least one substituent selected from the lower substituent group (b); wherein V4, V5, V6, V7, V8, V9, V10, V11, V12, V13, V14, V15, V16, V17, V18, V19, V20, V21, V22, V23, V24, V25, V26, V27, V28 , V29, V30, V31, V32, V33, V34, V35, V36, V37, V38, V39, V40, V41, V42, V43, V44, V45, V46, V47, V48, V49, V50, V51, V52 are independent of each other "(C 9 -C 3 o) alkyl, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V13, V14 and / or V26, V27 and: are selected from the group consisting of or V30, V31 and / or V37, V38 and / or V50, V51 may together also form "heterocyclyl"; optionally additionally one of the radicals Z3, Z4 or additionally both radicals
Z3, Z4 unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (b) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylal- kyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV53, -NV54V55, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, - CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V56, -C(O)O-V57, -C(O)NH-V58, -C(O)NV59V60, -0-V61 , -O(-V62-O)r-H (r = 1 , 2, 3, 4, 5),Z3, Z4 independently of one another may also be further substituted by at least one substituent, identical or different, selected from the group consisting of: (b) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclicalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2, -NHV53, -NV54V55, -NO 2, -OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2, - CHO, -COOH, -C (O) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) -V56, -C (O) O-V57, -C (O) NH-V58, -C (O) NV59V60 , -O-V61, -O (-V62-O) r -H (r = 1, 2, 3, 4, 5),
-O(-V63-O)r-V64 (r = 1 , 2, 3, 4, 5), -OC(O)-V65, -OC(O)-O-V66, - OC(O)-NHV67, -O-C(O)-NV68V69, -OP(O)(OV70)(OV71 ), - OSi(V72)(V73)(V74), -OS(O2)-V75, -NHC(O)-V76, -NV77C(O)-V78, - NH-C(O)-O-V79, -N H-C(O)-N H-V80, -N H-C(O)-N V81V82, -NV83- C(O)-O-V84, -NV85-C(O)-NH-V86, -NV87-C(O)-NV88V89, -NHS(O2)--O (-V63-O) r -V64 (r = 1, 2, 3, 4, 5), -OC (O) -V65, -OC (O) -O-V66, -OC (O) -NHV67 , -OC (O) -NV68V69, -OP (O) (OV70) (OV71), - OSi (V72) (V73) (V74), -OS (O 2) -V75, -NHC (O) -V76, -NV77C (O) -V78, -NH-C (O) -O-V79, -NHC (O) -NH-V80, -NHC (O) -N V81V82, -NV83-C (O) - O-V84, -NV85-C (O) -NH-V86, -NV87-C (O) -NV88V89, -NHS (O 2) -
V90, -NV91 S(O2)-V92, -S-V93, -S(O)-V94, -S(O2)-V95, -S(O2)NH-V96, -S(O2)NV97V98, -S(O2)O-V99, -P(O)(OVI 00)(OV101 ), - Si(VI 02)(V103)(V104)"; wobei V53, V54, V55, V56, V57, V58, V59, V60, V61 , V62, V63, V64, V65, V66, V67, V68, V69, V70, V71 , V72, V73, V74, V75, V76, V77, V78, V79,V90, -NV91 S (O 2) -V92, -S-V93, -S (O) -V94, -S (O 2) -V95, -S (O 2) NH-V96, -S (O 2) NV97V98, -S (O 2) O-V99, -P (O) (OVI 00) (OV101), - Si (VI 02) (V103) (V104) "; wherein V53, V54, V55, V56, V57, V58, V59, V60, V61, V62, V63, V64, V65, V66, V67, V68, V69, V70, V71, V72, V73, V74, V75, V76, V77, V78, V79,
V80, V81 , V82, V83, V84, V85, V86, V87, V88, V89, V90, V91 , V92, V93, V94, V95, V96, V97, V98, V99, V100, V101 , V102, V103, V104 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, ary- lalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V59, V60 und/oderV80, V81, V82, V83, V84, V85, V86, V87, V88, V89, V90, V91, V92, V93, V94, V95, V96, V97, V98, V99, V100, V101, V102, V103, V104 are independent are selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V59, V60 and / or
V68, V69 und/oder V81 , V82 und/oder V88, V89 und/oder V97, V98 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (b) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:V68, V69 and / or V81, V82 and / or V88, V89 and / or V97, V98 may together also form "heterocyclyl" wherein optional substituents above the substituent group (b) may be independently substituted with at least one substituent, the same or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV105, -NV106V107, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-(ii) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, - NHV105, -NV106V107, -NO 2, -OH, -OCF3, -SH, -0-SO3H, - OP (O) (OH) 2, -CHO, -COOH, -C (O) NH 2, -SO 3 H, -P (O) (OH) 2 , -C (O) -
V108, -C(O)O-VI 09, -C(O)NH-V1 10, -C(O)NV11 1V112, -0-V113, - 0(-V1 14-O)5-H (s = 1 , 2, 3, 4, 5), -O(-V115-O)s-V116 (s = 1 , 2, 3, 4, 5), -OC(O)-V117, -OC(O)-O-V1 18, -OC(O)-NHV119, -0-C(O)- NV120V121 , -OP(O)(OVI 22)(OV123), -OSi(VI 24)(V125)(V126), - OS(O2)-V127, -NHC(O)-V128, -NV129C(O)-VI30, -NH-C(O)-O- V131, -NH-C(O)-NH-VI32, -NH-C(O)-NVI33V134, -NV135-C(O)- O-V136, -NV137-C(O)-NH-VI38, -NV139-C(O)-NVI40V141, - NHS(O2)-V142, -NV143S(O2)-V144, -S-V145, -S(O)-V146, -S(O2)- V147, -S(O2)NH-VI48, -S(O2)NVI49V150, -S(O2)O-VI51, -V108, -C (O) O-VI 09, -C (O) NH-V1 10, -C (O) NV11 1V112, -O-V113, -O (-V1 14-O) 5 -H (s = 1, 2, 3, 4, 5), -O (-V115-O) s -V116 (s = 1, 2, 3, 4, 5), -OC (O) -V117, -OC (O) - O-V1 18, -OC (O) -NHV119, -O-C (O) -NV120V121, -OP (O) (OVI 22) (OV123), -OSi (VI 24) (V125) (V126), OS (O 2) -V127, -NHC (O) -V128, -NV129C (O) -VI30, -NH-C (O) -O- V131, -NH-C (O) -NH-VI32, -NH -C (O) -NVI33V134, -NV135-C (O) - O-V136, -NV137-C (O) -NH-VI38, -NV139-C (O) -NVI40V141, - NHS (O 2) -V142 , -NV143S (O 2) -V144, -S-V145, -S (O) -V146, -S (O 2) - V147, -S (O 2) NH-VI48, -S (O 2) NVI49V150, -S (O 2 ) O-VI 51, -
P(O)(OVI52)(OV153), -Si(VI54)(V155)(V156)"; wobei V105, V106, V107, V108, V109, V110, V111 , V112, V113, V114, V115, V116, V117, V118, V119, V120, V121, V122, V123, V124, V125, V126, V127, V128, V129, V130, V131, V132, V133, V134, V135, V136, V137, V138, V139, V140, V141 , V142, V143, V144, V145, V146, V147,P (O) (OVI52) (OV153), -Si (VI54) (V155) (V156) "; wherein V105, V106, V107, V108, V109, V110, V111, V112, V113, V114, V115, V116, V117 , V118, V119, V120, V121, V122, V123, V124, V125, V126, V127, V128, V129, V130, V131, V132, V133, V134, V135, V136, V137, V138, V139, V140, V141, V142 , V143, V144, V145, V146, V147,
V148, V149, V150, V151 , V152, V153, V154, V155, V156 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V1 11 , V1 12 und/oder V120, V121 und/oder V133, V134 und/oder V140, V141 und/oder V149, V150 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) und/oder Substituentengruppe (ii) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Are V148, V149, V150, V151, V152, V153, V154, V155, V156 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl , heteroaryl, heteroarylalkyl "and wherein alternatively V1 11, V1 12 and / or V120, V121 and / or V133, V134 and / or V140, V141 and / or V149, V150 may together also form" heterocyclyl "; wherein optionally above substituents of the substituent group (i) and / or substituent group (ii) may be independently substituted with at least one substituent, same or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV157, -NV158V159, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- V160, -C(O)O-VI61, -C(O)NH-VI62, -C(O)NVI63V164, -O-V165, -(iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV157, -NV158V159, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -V160, -C (O) O-VI61, -C (O) NH-VI62, -C (O) NVI63V164, O-V165, -
O(-V166-O)t-H (t = 1, 2, 3, 4, 5), -0(-V167-O)t-V168 (t = 1, 2, 3, 4, 5), -OC(O)-VI69, -OC(O)-O-VI70, -OC(O)-NHV171, -0-C(O)- NV172V173, -OP(O)(OVI74)(OV175), -OSi(VI76)(V177)(V178), - OS(O2)-V179, -NHC(O)-VI80, -NV181C(O)-VI82, -NH-C(O)-O- V183, -NH-C(O)-NH-VI84, -NH-C(O)-NVI85V186, -NV187-C(O)-O (-V166-O) t -H (t = 1, 2, 3, 4, 5), -0 (-V167-O) t -V168 (t = 1, 2, 3, 4, 5), OC (O) -VI69, -OC (O) -O-VI70, -OC (O) -NHV171, -O-C (O) -VV172V173, -OP (O) (OVI74) (OV175), -OSi ( VI76) (V177) (V178), - OS (O 2) -V179, -NHC (O) -VI80, -NV181C (O) -VI82, -NH-C (O) -O- V183, -NH-C (O) -NH-VI84, -NH-C (O) -NVI85V186, -NV187-C (O) -
O-V188, -NV189-C(O)-NH-VI90, -NV191-C(O)-NVI92V193, - NHS(O2)-V194, -NV195S(O2)-V196, -S-V197, -S(O)-VI98, -S(O2)- V199, -S(O2)NH-V200, -S(O2)NV201V202, -S(O2)O-V203, - P(O)(OV204)(OV205),-Si(V206)(V207)(V208)"; wobei V157, V158, V159, V160, V161 , V162, V163, V164, V165, V166, V167, V168, V169, V170, V171 , V172, V173, V174, V175, V176, V177, V178, V179, V180, V181 , V182, V183, V184, V185, V186, V187, V188, V189, V190, V191 , V192, V193, V194, V195, V196, V197, V198, V199, V200, V201 , V202, V203, V204, V205, V206, V207, V208 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V163, V164 und/oder V172, V173 und/oder V185, V186 und/oder V192, V193 und/oder V201 , V202 zusammen auch „heterocyclyl" bilden können;O-V188, -NV189-C (O) -NH-VI90, -NV191-C (O) -NVI92V193, - NHS (O 2) -V194, -NV195S (O 2) -V196, -S-V197, - S (O) -VI98, -S (O 2) - V199, -S (O 2) NH-V200 -S (O 2) NV201V202, -S (O 2) O-V203 - P (O) ( OV204) (OV205), - Si (V206) (V207) (V208) "; where V157, V158, V159, V160, V161, V162, V163, V164, V165, V166, V167, V168, V169, V170, V171, V172, V173, V174, V175, V176, V177, V178, V179, V180, V181 , V182, V183, V184, V185, V186, V187, V188, V189, V190, V191, V192, V193, V194, V195, V196, V197, V198, V199, V200, V201, V202, V203, V204, V205, V206 are V207, V208 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V163, V164 and / or V172, V173 and / or V185, V186 and / or V192, V193 and / or V201, V202 may together also form "heterocyclyl";
oder einer der Reste Z3, Z4 oder beide Reste Z3, Z4 unabhängig voneinander voneinander „substituiertes Heteroaryl" sind, wobei voneinander „substituiertes Heteroaryl" substituiert ist mit mindestens einem Substituenten, gleich oder ver- schieden, ausgewählt aus der Gruppe bestehend aus:or one of the radicals Z3, Z4 or both radicals Z3, Z4 independently of one another are "substituted heteroaryl", where "substituted heteroaryl" is substituted by at least one substituent, identical or different, selected from the group consisting of:
(c) „(C9-C3o)alkyl, -NV209V210, -NH-(C9-C30)alkyl, -NHC(O)-cycloalkylalkyl, - NHC(O)-heterocyclylalkyl, -NHC(O)-(C9-C30)alkyl, -NV21 1C(O)-V212, - NV213C(O)-(C9-C30)alkyl, -NHC(O)-OV214, -NV215C(O)-OV216, - N HC(O)-N HV217, -NHC(O)-NV218V219, -NV220C(O)-NHV221 , - NV222C(O)-NV223V224, -NHS(O2)-cycloalkylalkyl, -NHS(O2)- heterocyclylalkyl, -NV225S(O2)-V226, -O-heterocyclyl, -O-(C9-C30)alkyl, - S-cycloalkyl, -S-heterocyclyl, —S— arylalkyl, -S-heteroarylalkyl, -S- cycloalkylalkyl, -S-heterocyclylalkyl, -S-(C9-C30)alkyl, -OC(O)- cycloalkylalkyl, -OC(O)-heterocyclylalkyl, -OC(O)-(C9-C30)alkyl, -OC(O)- OV227, -OC(O)-N H V228, -OC(O)-NV229V230, -OP(O)(OV231 )(OV232),(c) "(C 9 -C 3 o) alkyl, -NV209V210, -NH- (C 9 -C 30) alkyl, -NHC (O) cycloalkylalkyl, - NHC (O) -heterocyclylalkyl, -NHC (O) - (C 9 -C 30 ) alkyl, -NV 21 1C (O) -V 2 12, - NV 2 13 C (O) - (C 9 -C 30 ) alkyl, -NHC (O) -OV 2 14, -NV 2 15C (O) -OV 2 16, - N HC (O) -N HV217, -NHC (O) -NV218V219, -NV220C (O) -NHV221, - NV222C (O) -NV223V224, -NHS (O 2) cycloalkylalkyl, -NHS (O 2) - heterocyclylalkyl, -NV225S (O 2 ) -V226, -O-heterocyclyl, -O- (C 9 -C 30 ) -alkyl, -s-cycloalkyl, -S-heterocyclyl, -S-arylalkyl, -S-heteroarylalkyl, -S - cycloalkylalkyl, -S-heterocyclylalkyl, -S- (C 9 -C 30 ) alkyl, -OC (O) -cycloalkylalkyl, -OC (O) -heterocyclylalkyl, -OC (O) - (C 9 -C 30 ) alkyl , -OC (O) -OV227, -OC (O) -NH V228, -OC (O) -NV229V230, -OP (O) (OV231) (OV232),
-OS(O2)-cycloalkylalkyl, -OS(O2)-heterocyclylalkyl, -OS(O2)-(C9-C30)alkyl, -C(O)-cycloalkyl, -C(O)-heterocyclyl, -C(O)-arylalkyl, -C(O)- heteroarylalkyl, -C(O)-cycloalkylalkyl, -C(O)-heterocyclylalkyl, -C(O)-(C9- C30)alkyl, -C(O)O-(C9-C30)alkyl, -C(O)NH-(C9-C30)alkyl, -C(O)NV233V234, -C(O)N H-OV235, -C(O)N V236-OV237, -C(O)NH-NV238V239, --OS (O 2 ) -cycloalkylalkyl, -OS (O 2 ) -heterocyclylalkyl, -OS (O 2 ) - (C 9 -C 30 ) -alkyl, -C (O) -cycloalkyl, -C (O) -heterocyclyl, -C (O) -arylalkyl, -C (O) -heteroarylalkyl, -C (O) -cycloalkylalkyl, -C (O) -heterocyclylalkyl, -C (O) - (C 9 -C 30 ) alkyl, -C ( O) O- (C 9 -C 30 ) alkyl, -C (O) NH- (C 9 -C 30 ) alkyl, -C (O) NV 233 V 234, -C (O) N H -OV 235, -C (O ) N V236-OV237, -C (O) NH-NV238V239, -
C(O)NV240-NV241V242, -S(O)-V243, -S(O2)-V244, -S(O2)NH- cycloalkyl, -S(O2)NH-heterocyclyl, -S(O2)NH-heteroarylalkyl, -S(O2)NH- cycloalkylalkyl, -S(O2)NH-heterocyclylalkyl, -S(O2)NH-(C9-C30)alkyl, - S(O2)O-cycloalkyl, -S(O2)O-heterocyclyl, -S(O2)O-heteroaryl, -S(O2)O- heteroarylalkyl, -S(θ2)O-cycloalkylalkyl, -S(θ2)O-heterocyclylalkyl, - S(02)0-(C9-C3o)alkyl, -P(O)(OH)2, -P(O)(OV245)(OV246), - Si(V247)(V248)(V249), -O-Si(V250)(V251 )(V252)"; wobei V209, V210, V211 , V212, V213, V214, V215, V216, V217, V218, V219, V220, V221 , V222, V223, V224, V225, V226, V227, V228, V229,C (O) NV240-NV241V242, -S (O) -V243, -S (O 2) -V244, -S (O 2) NH- cycloalkyl, -S (O 2) NH-heterocyclyl, -S (O 2 ) NH-heteroarylalkyl, -S (O 2 ) NH-cycloalkylalkyl, -S (O 2 ) NH-heterocyclylalkyl, -S (O 2 ) NH- (C 9 -C 30 ) alkyl, - S (O 2 ) O- cycloalkyl, -S (O 2 ) O-heterocyclyl, -S (O 2 ) O-heteroaryl, -S (O 2 ) O- heteroarylalkyl, -S (θ 2) O-cycloalkylalkyl, -S (θ 2) O-heterocyclylalkyl, - S (0 2) 0- (C9-C 3 o) alkyl, -P (O) (OH) 2, - P (O) (OV245) (OV246), -Si (V247) (V248) (V249), -O-Si (V250) (V251) (V252) "; where V209, V210, V211, V212, V213, V214 , V215, V216, V217, V218, V219, V220, V221, V222, V223, V224, V225, V226, V227, V228, V229,
V230, V231 , V232, V233, V234, V235, V236, V237, V238, V239, V240, V241 , V242, V243, V244, V245, V246, V247, V248, V249, V250, V251 , V252 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V218,V230, V231, V232, V233, V234, V235, V236, V237, V238, V239, V240, V241, V242, V243, V244, V245, V246, V247, V248, V249, V250, V251, V252 are selected independently the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V218,
V219 und/oder V223, V224 und/oder V229, V230 und/oder V233, V234 und/oder V238, V239 und/oder V241 , V242 zusammen auch „heterocyclyl" bilden können; mit der Maßgabe, dass die Substituenten ,,-N(alkyl)2", ,,-C(O)N(alkyl)2", „- C(O)N(cycloalkyl)2", ,,-C(O)N(aryl)2", ,,-C(O)N(heteroraryl)2" weiter substituiert sind mit mindestens einem Substituenten ausgewählt aus untiger Sub- stituentengruppe (i); wobei optional obige Substituenten der Substituentengruppe (c) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Sub- stituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:V219 and / or V223, V224 and / or V229, V230 and / or V233, V234 and / or V238, V239 and / or V241, V242 may together also form "heterocyclyl", with the proviso that the substituents "- N (alkyl) 2 "," - C (O) N (alkyl) 2 "," - C (O) N (cycloalkyl) 2 "," - C (O) N (aryl) 2 ", C (O) N (heteroaryl) 2 "are further substituted by at least one substituent selected from sub-substituent group (i); wherein optionally substituted substituents of the substituent group (c) may in turn be independently substituted with at least one substituent, same or different, selected from the group consisting of:
(i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV253, -NV254V255, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-(i) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV253, -NV254V255, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -
V256, -C(O)O-V257, -C(O)NH-V258, -C(O)NV259V260, -O-V261 , - O(-V262-O)u-H (u = 1, 2, 3, 4, 5), -O(-V263-O)u-V264 (u = 1, 2, 3, 4, 5), -OC(O)-V265, -OC(O)-O-V266, -OC(O)-NHV267, -0-C(O)- NV268V269, -OP(O)(OV270)(OV271), -OSi(V272)(V273)(V274), - OS(O2)-V275, -NHC(O)-V276, -NV277C(O)-V278, -NH-C(O)-O-V256, -C (O) O-V257, -C (O) NH-V258, -C (O) NV259V260, -O-V261, -O (-V262-O) u -H (u = 1, 2, 3, 4, 5), -O (-V263-O) u -V264 (u = 1, 2, 3, 4, 5), -OC (O) -V265, -OC (O) -O-V266, -OC (O) -NHV267, -0-C (O) - NV268V269, -OP (O) (OV270) (OV271), -OSi (V272) (V273) (V274), - OS (O 2) -V275 , -NHC (O) -V276, -NV277C (O) -V278, -NH-C (O) -O-
V279, -NH-C(O)-NH-V280, -NH-C(O)-NV281V282, -NV283-C(O)- O-V284, -NV285-C(O)-NH-V286, -NV287-C(O)-NV288V289, - NHS(O2)-V290, -NV291S(O2)-V292, -S-V293, -S(O)-V294, -S(O2)- V295, -S(O2)N H-V296, -S(O2)NV297V298, -S(O2)O-V299, - P(O)(OV300)(OV301 ), -Si(V302)(V303)(V304)"; wobei V253, V254, V255, V256, V257, V258, V259, V260, V261 , V262, V263, V264, V265, V266, V267, V268, V269, V270, V271 , V272, V273, V274, V275, V276, V277, V278, V279, V280, V281 , V282, V283, V284,V279, -NH-C (O) -NH-V280, -NH-C (O) -NV281V282, -NV283-C (O) -O-V284, -NV285-C (O) -NH-V286, -NV287 -C (O) -NV288V289, - NHS (O 2) -V290, -NV291S (O 2) -V292, -S-V293, -S (O) -V294, -S (O 2) - V295, -S (O 2) N H-V296, -S (O 2) NV297V298, -S (O 2) O-V299, - P (O) (OV300) (OV301), -Si (V302) (V303 ) (V304) "; wherein V253, V254, V255, V256, V257, V258, V259, V260, V261, V262, V263, V264, V265, V266, V267, V268, V269, V270, V271, V272, V273, V274 , V275, V276, V277, V278, V279, V280, V281, V282, V283, V284,
V285, V286, V287, V288, V289, V290, V291 , V292, V293, V294, V295, V296, V297, V298, V299, V300, V301 , V302, V303, V304 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V259,V285, V286, V287, V288, V289, V290, V291, V292, V293, V294, V295, V296, V297, V298, V299, V300, V301, V302, V303, V304 are independently selected from the group consisting of: " alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively V259,
V260 und/oder V268, V269 und/oder V281 , V282 und/oder V288, V289 und/oder V297, V298 zusammen auch „heterocyclyl" bilden können; wobei optional zusätzlich einer der Reste Z3, Z4 oder zusätzlich beide Reste Z3, Z4 unabhängig voneinander auch weiter substituiert sein können mit min- destens einem Substituenten, gleich oder verschieden, ausgewählt aus derV260 and / or V268, V269 and / or V281, V282 and / or V288, V289 and / or V297, V298 may together also form "heterocyclyl", optionally additionally one of the radicals Z3, Z4 or additionally both radicals Z3, Z4 independently from each other can also be further substituted with at least one substituent, identical or different, selected from
Gruppe bestehend aus:Group consisting of:
(d) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV305, -NV306V307, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-(d) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV305, -NV306V307, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -
V308, -C(O)O-V309, -C(O)NH-V310, -C(O)NV311V312, -O-V313, -0(- V314-O)v-H (v = 1 , 2, 3, 4, 5), -O(-V315-O)v-V316 (v = 1 , 2, 3, 4, 5), - OC(O)-V317, -OC(O)-O-V318, -OC(O)-N HV319, -0-C(O)-N V320V321 , -OP(O)(OV322)(OV323), -OSi(V324)(V325)(V326), -OS(O2)-V327, - NHC(O)-V328, -NV329C(O)-V330, -NH-C(O)-O-V331 , -NH-C(O)-NH-V308, -C (O) O-V309, -C (O) NH-V310, -C (O) NV311V312, -O-V313, -O (- V314-O) v -H (v = 1, 2, 3, 4, 5), -O (-V315-O) v -V316 (v = 1, 2, 3, 4, 5), - OC (O) -V317, -OC (O) -O-V318, -OC (O) -N HV319, -0-C (O) -N V320V321, -OP (O) (OV322) (OV323), -OSi (V324) (V325) (V326), -OS (O 2) -V327, - NHC (O) -V328, -NV329C (O) -V330, -NH-C (O) -O-V331, -NH-C (O) -NH-
V332, -NH-C(O)-NV333V334, -NV335-C(O)-O-V336, -NV337-C(O)- NH-V338, -NV339-C(O)-NV340V341 , -NHS(O2)-V342, -NV343S(O2)- V344, -S-V345, -S(O)-V346, -S(O2)-V347, -S(O2)NH-V348, - S(O2)NV349V350, -S(O2)O-V351 , -P(O)(OV352)(OV353), - Si(V354)(V355)(V356)"; wobei V305, V306, V307, V308, V309, V310, V311, V312, V313, V314, V315, V316, V317, V318, V319, V320, V321, V322, V323, V324, V325, V326, V327, V328, V329, V330, V331 , V332, V333, V334, V335, V336, V337, V338, V339, V340, V341, V342, V343, V344, V345, V346, V347, V348, V349, V350, V351 , V352, V353, V354, V355, V356 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, ary- lalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V311 , V312 und/oder V320, V321 und/oder V333, V334 und/oder V340, V341 und/oder V349,V332, -NH-C (O) -NV333V334, -NV335-C (O) -O-V336, -NV337-C (O) -NH-V338, -NV339-C (O) -NV340V341, -NHS (O 2) -V342, -NV343S (O 2) - V344, V345 -S-, -S (O) -V346, -S (O 2) -V347, -S (O 2) NH-V348, - S (O 2) NV349V350, -S (O 2) O-V351, -P (O) (OV352) (OV353), - Si (V354) (V355) (V356) "; wherein V305, V306, V307, V308, V309, V310, V311, V312, V313, V314, V315, V316, V317, V318, V319, V320, V321, V322, V323, V324, V325, V326, V327, V328, V329, V330, V331, V332, V333, V334, V335, V336, V337, V338, V339, V340, V341, V342, V343, V344, V345, V346, V347, V348, V349, V350, V351, V352, V353, V354, V355, V356 are independently selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively V311, V312 and / or V320, V321 and / or V333, V334 and / or V340, V341 and / or V349,
V350 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (d) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe beste- hend aus:V350 may also together form "heterocyclyl", where optionally substituted substituents of the substituent group (d) may in turn be substituted by at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV357, -NV358V359, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- V360, -C(O)O-V361 , -C(O)NH-V362, -C(O)NV363V364, -O-V365, -(ii) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, - NHV357, -NV358V359, -NO 2, -OH, -OCF3, -SH, -0-SO3H, - OP (O) (OH) 2, -CHO, -COOH, -C (O) NH 2, -SO 3 H, -P (O) (OH) 2, --C (O) - V360, -C (O) O-V361, -C (O) NH-V362, -C (O) NV363V364, -O -V365, -
O(-V366-O)w-H (w = 1 , 2, 3, 4, 5), -O(-V367-O)w-V368 (w = 1 , 2, 3, 4, 5), -OC(O)-V369, -OC(O)-O-V370, -OC(O)-NHV371, -0-C(O)- NV372V373, -OP(O)(OV374)(OV375), -OSi(V376)(V377)(V378), - OS(O2)-V379, -NHC(O)-V380, -NV381C(O)-V382, -NH-C(O)-O- V383, -NH-C(O)-NH-V384, -NH-C(O)-NV385V386, -NV387-C(O)-O (-V366-O) w -H (w = 1, 2, 3, 4, 5), -O (-V367-O) w -V368 (w = 1, 2, 3, 4, 5), OC (O) -V369, -OC (O) -O-V370, -OC (O) -NHV371, -O-C (O) - NV372V373, -OP (O) (OV374) (OV375), -OSi ( V376) (V377) (V378), - OS (O 2) -V379, -NHC (O) -V380, -NV381C (O) -V382, -NH-C (O) -O- V383, -NH-C (O) -NH-V384, -NH-C (O) -NV385V386, -NV387-C (O) -
O-V388, -NV389-C(O)-NH-V390, -NV391-C(O)-NV392V393, - NHS(O2)-V394, -NV395S(O2)-V396, -S-V397, -S(O)-V398, -S(O2)- V399, -S(O2)NH-V400, -S(O2)NV401V402, -S(O2)O-V403, - P(O)(OV404)(OV405),-Si(V406)(V407)(V408)"; wobei V357, V358, V359, V360, V361 , V362, V363, V364, V365, V366,O-V388, -NV389-C (O) -NH-V390, -NV391-C (O) -NV392V393, - NHS (O 2) -V394, -NV395S (O 2) -V396, -S-V397, - S (O) -V398, -S (O 2) - V399, -S (O 2) NH-V400, -S (O 2) NV401V402, -S (O 2) O-V403, - P (O) ( OV404) (OV405), -Si (V406) (V407) (V408) "; wherein V357, V358, V359, V360, V361, V362, V363, V364, V365, V366,
V367, V368, V369, V370, V371 , V372, V373, V374, V375, V376, V377, V378, V379, V380, V381 , V382, V383, V384, V385, V386, V387, V388, V389, V390, V391 , V392, V393, V394, V395, V396, V397, V398, V399, V400, V401 , V402, V403, V404, V405, V406, V407, V408 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl,V367, V368, V369, V370, V371, V372, V373, V374, V375, V376, V377, V378, V379, V380, V381, V382, V383, V384, V385, V386, V387, V388, V389, V390, V391, V392, V393, V394, V395, V396, V397, V398, V399, V400, V401, V402, V403, V404, V405, V406, V407, V408 are independently selected from the group consisting of: "alkyl,
(C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V363, V364 und/oder V372, V373 und/oder V385, V386 und/oder V392, V393 und/oder V401 , V402 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) und/oder Substituentengruppe (ii) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV409, -NV410V41 1 , -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- V412, -C(O)O-V413, -C(O)NH-V414, -C(O)NV415V416, -O-V417, - 0(-V418-O)x-H (x = 1, 2, 3, 4, 5), -O(-V419-O)x-V420 (x = 1, 2, 3, 4,(C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively V363, V364 and / or V372, V373 and / or V385, V386 and / or V392, V393 and or V401, V402 together can also form "heterocyclyl"; wherein optionally above substituents of the substituent group (i) and / or substituent group (ii) may in turn independently be substituted with at least one substituent, same or different, selected from the group consisting of: (iii) alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV409, -NV410V41 1, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P ( O) (OH) 2 , -C (O) -V412, -C (O) O-V413, -C (O) NH-V414, -C (O) NV415V416, -O-V417, -O (-V418 -O) x -H (x = 1, 2, 3, 4, 5), -O (-V419-O) x -V420 (x = 1, 2, 3, 4,
5), -OC(O)-V421, -OC(O)-O-V422, -OC(O)-NHV423, -0-C(O)- NV424V425, -OP(O)(OV426)(OV427), -OSi(V428)(V429)(V430), - OS(O2)-V431, -NHC(O)-V432, -NV433C(O)-V434, -NH-C(O)-O- V435, -NH-C(O)-NH-V436, -NH-C(O)-NV437V438, -NV439-C(O)- O-V440, -NV441-C(O)-NH-V442, -NV443-C(O)-NV444V445, -5), -OC (O) -V421, -OC (O) -O-V422, -OC (O) -NHV423, -O-C (O) - NV424V425, -OP (O) (OV426) (OV427) , -OSi (V428) (V429) (V430), - OS (O 2) -V431, -NHC (O) -V432, -NV433C (O) -V434, -NH-C (O) -O- V435, -NH-C (O) -NH-V436, -NH-C (O) -NV437V438, -NV439-C (O) -O-V440, -NV441-C (O) -NH-V442, -NV443-C (O) -NV444V445, -
NHS(O2)-V446, -NV447S(O2)-V448, -S-V449, -S(O)-V450, -S(O2)- V451, -S(O2)NH-V452, -S(O2)NV453V454, -S(O2)O-V455, - P(O)(OV456a)(OV456b), -Si(V456c)(V456d)(V456e)"; wobei V409, V410, V411 , V412, V413, V414, V415, V416, V417, V418, V419, V420, V421 , V422, V423, V424, V425, V426, V427, V428, V429,NHS (O 2 ) -V 446, -NV 447S (O 2 ) -V448, -S-V 449, -S (O) -V 450, -S (O 2 ) -V 451, -S (O 2 ) NH-V 452, - S (O 2) NV453V454, -S (O 2) O-V455, - P (O) (OV456a) (OV456b), -Si (V456c) (V456d) (V456e) "; wherein V409, V410, V411, V412 , V413, V414, V415, V416, V417, V418, V419, V420, V421, V422, V423, V424, V425, V426, V427, V428, V429,
V430, V431 , V432, V433, V434, V435, V436, V437, V438, V439, V440, V441 , V442, V443, V444, V445, V446, V447, V448, V449, V450, V451 , V452, V453, V454, V455, V456a, V456b, V456c, V456d, V456e unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V415, V416 und/oder V424, V425 und/oder V437, V438 und/oder V444, V445 und/oder V453, V454 zusammen auch „heterocyclyl" bilden können;V430, V431, V432, V433, V434, V435, V436, V437, V438, V439, V440, V441, V442, V443, V444, V445, V446, V447, V448, V449, V450, V451, V452, V453, V454, V455, V456a, V456b, V456c, V456d, V456e are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and wherein alternatively V415, V416 and / or V424, V425 and / or V437, V438 and / or V444, V445 and / or V453, V454 may together also form "heterocyclyl";
und einer der Reste Z3, Z4 oder keiner der Reste Z3, Z4 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus:and one of Z3, Z4 or none of Z3, Z4 is independently selected from the group consisting of:
(e) Wasserstoff; (f) Halogen, F, Cl, Br, I;(e) hydrogen; (f) halogen, F, Cl, Br, I;
(g) unsubstituiertes oder substituiertes Alkyl oder (Cg-C3o)Alkyl, wobei optional der Alkyl- oder (C9-C30 )Alkylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Grup- pe bestehend aus:(g) unsubstituted or substituted alkyl or (Cg-C3o) alkyl, may be optionally substituted with (C 9 -C 30 C) alkyl moiety of the alkyl or at least one substituent, identical or different, selected from the group-consisting of pe:
(i) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV457, -NV458V459, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V460, -C(O)O-V461 , -C(O)NH-V462, -C(O)NV463V464, -(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV457, -NV458V459, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -V 460, -C (O) O-V 461, -C (O) NH-V 462, -C (O) NV 463 V464 , -
O-V465, -O(-V466-O)y-H (y = 1 , 2, 3, 4, 5), -O(-V467-O)y-V468 (y = 1 , 2, 3, 4, 5), -OC(O)-V469, -OC(O)-O-V470, -OC(O)-N H V471 , - 0-C(O)-N V472V473, -OP(O)(OV474)(OV475), - OSi(V476)(V477)(V478), -OS(O2)-V479, -NHC(O)-V480, - NV481C(O)-V482, -NH-C(O)-O-V483, -N H-C(O)-N H-V484, -NH-O-V465, -O (-V466-O) y -H (y = 1,2,3,4,5), -O (-V467-O) y -V468 (y = 1,2,3,4 , 5), -OC (O) -V469, -OC (O) -O-V470, -OC (O) -NH V471, -O-C (O) -N V472V473, -OP (O) (OV474) (OV475), - OSi (V476) (V477) (V478), -OS (O 2) -V479, -NHC (O) -V480, - NV481C (O) -V482, -NH-C (O) -O -V483, -N HC (O) -NH-V484, -NH-
C(O)-N V485V486, -NV487-C(O)-O-V488, -NV489-C(O)-NH- V490, -NV491 -C(O)-N V492V493, -NHS(O2)-V494, -NV495S(O2)- V496, -S-V497, -S(O)-V498, -S(O2)-V499, -S(O2)NH-V500, - S(O2)NV501V502, -S(O2)O-V503, -P(O)(OV504)(OV505), - Si(V506)(V507)(V508)"; wobei V457, V458, V459, V460, V461 , V462, V463, V464, V465, V466, V467, V468, V469, V470, V471 , V472, V473, V474, V475, V476, V477, V478, V479, V480, V481 , V482, V483, V484, V485, V486, V487, V488, V489, V490, V491 , V492, V493, V494, V495, V496, V497, V498, V499, V500, V501 , V502, V503, V504, V505,C (O) -N V485V486, -NV487-C (O) -O-V488, -NV489-C (O) -NH-V490, -NV491 -C (O) -N V492V493, -NHS (O 2 ) - V494, -NV495S (O 2) - V496, V497 -S-, -S (O) -V498, -S (O 2) -V499, -S (O 2) NH-V500, - S (O 2) NV501V502 , -S (O 2) O-V503, -P (O) (OV504) (OV505), - Si (V506) (V507) (V508) "; wherein V457, V458, V459, V460, V461, V462, V463 , V464, V465, V466, V467, V468, V469, V470, V471, V472, V473, V474, V475, V476, V477, V478, V479, V480, V481, V482, V483, V484, V485, V486, V487, V488 , V489, V490, V491, V492, V493, V494, V495, V496, V497, V498, V499, V500, V501, V502, V503, V504, V505,
V506, V507, V508 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V463, V464 und/oder V472, V473 und/oder V485, V486 und/oder V492, V493 und/oder V501 , V502 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindes- tens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:"(Cg-C 30) alkyl, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V463, V464 and /: are V506, V507, V508 independently selected from the group consisting of or V472, V473 and / or V485, V486 and / or V492, V493 and / or V501, V502 may each together also form "heterocyclyl"; optionally substituents of the substituent group (i) above may be substituted independently of one another with at least at least one substituent, the same or different, selected from the group consisting of:
(ii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV509, -NV510V511 , -NO2, -OH, -OCF3, -(ii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHV509, -NV510V511, -NO 2 , -OH, -OCF 3 , -
SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V512, -C(O)O-V513, -C(O)NH-V514, - C(O)NV515V516, -O-V517, -O(-V518-O)z-H (z = 1 , 2, 3, 4, 5), - O(-V519-O)z-V520 (z = 1 , 2, 3, 4, 5), -OC(O)-V521 , -OC(O)-O- V522, -OC(O)-N HV523, -O-C(O)-NV524V525, -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -V512, -C (O) O-V513, -C (O) NH-V514, -C (O) NV515V516, -O-V517, -O (-V518-O) z -H (z = 1, 2, 3, 4, 5), - O (-V519-O) z -V520 (z = 1, 2, 3, 4, 5), -OC (O) -V521, -OC (O) - O-V522, -OC (O) -N HV523, -OC (O) -NV524V525, -
OP(O)(OV526)(OV527), -OSi(V528)(V529)(V530), -OS(O2)- V531 , -NHC(O)-V532, -NV533C(O)-V534, -NH-C(O)-O-V535, -N H-C(O)-N H-V536, -N H-C(O)-N V537V538, -NV539-C(O)-O- V540, -NV541 -C(O)-N H-V542, -NV543-C(O)-NV544V545, - NHS(O2)-V546, -NV547S(O2)-V548, -S-V549, -S(O)-V550, -OP (O) (OV526) (OV527), -OSi (V528) (V529) (V530), -OS (O 2) - V531, -NHC (O) -V532, -NV533C (O) -V534, -NH -C (O) -O-V535, -NHC (O) -NH-V536, -NHC (O) -N V537V538, -NV539-C (O) -O-V540, -NV541 -C (O ) -N H-V542, -NV543-C (O) -NV544V545, - NHS (O 2) -V546, -NV547S (O 2) -V548, -S-V549, -S (O) -V550, -
S(O2)-V551 , -S(O2)NH-V552, -S(O2)NV553V554, -S(O2)O- V555, -P(O)(OV556)(OV557), -Si(V558)(V559)(V560)"; wobei V509, V510, V51 1 , V512, V513, V514, V515, V516, V517, V518, V519, V520, V521 , V522, V523, V524, V525, V526, V527, V528, V529, V530, V531 , V532, V533, V534, V535, V536, V537,S (O 2) -V551, -S (O 2) NH-V552, -S (O 2) NV553V554, -S (O 2) O- V555, -P (O) (OV556) (OV557), -Si (V558) (V559) (V560) "; wherein V509, V510, V51 1, V512, V513, V514, V515, V516, V517, V518, V519, V520, V521, V522, V523, V524, V525, V526, V527 , V528, V529, V530, V531, V532, V533, V534, V535, V536, V537,
V538, V539, V540, V541 , V542, V543, V544, V545, V546, V547, V548, V549, V550, V551 , V552, V553, V554, V555, V556, V557, V558, V559, V560 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V515, V516 und/oder V524, V525 und/oder V537, V538 und/oder V544, V545 und/oder V553, V554 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:V538, V539, V540, V541, V542, V543, V544, V545, V546, V547, V548, V549, V550, V551, V552, V553, V554, V555, V556, V557, V558, V559, V560 are independently selected from consisting of the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V515, V516 and / or V524, V525, and / or V537, V538 and / or V544, V545 and / or V553, V554 may together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV561 , -NV562V563, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V564, -C(O)O-V565, - C(O)N H-V566, -C(O)NV567V568, -O-V569, -O(-V570-O)a- H (a = 1 , 2, 3, 4, 5), -O(-V571-O)a-V572 (a = 1 , 2, 3, 4, 5), -(iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHV561, -NV562V563, -NO 2, -OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2 , -CHO, -COOH, - C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -V564, -C (O) O-V565, -C ( O) N H-V566, -C (O) NV567V568, -O-V569, -O (-V570-O) a - H (a = 1, 2, 3, 4, 5), -O (-V571- O) a -V572 (a = 1, 2, 3, 4, 5), -
OC(O)-V573, -OC(O)-O-V574, -OC(O)-N H V575, -0-C(O)- NV576V577, -OP(O)(OV578)(OV579), - OSi(V580)(V581 )(V582), -OS(O2)-V583, -NHC(O)-V584, - NV585C(O)-V586, -NH-C(O)-O-V587, -NH-C(O)-NH- V588, -N H-C(O)-N V589V590, -NV591-C(O)-O-V592, -OC (O) -V573, -OC (O) -O-V574, -OC (O) -NH V575, -O-C (O) - NV576V577, -OP (O) (OV578) (OV579), - OSi (V580) (V581) (V582), -OS (O 2) -V583, -NHC (O) -V584, - NV585C (O) -V586, -NH-C (O) -O-V587, -NH- C (O) -NH-V588, -NHC (O) -N V589V590, -NV591-C (O) -O-V592, -
NV593-C(O)-NH-V594, -NV595-C(O)-NV596V597, - NHS(O2)-V598, -NV599S(O2)-V600, -S-V601 , -S(O)-V602, -S(O2)-V603, -S(O2)N H-V604, -S(O2)NV605V606, -S(O2)O- V607, -P(O)(OV608)(OV609), -Si(V610)(V611 )(V612)"; wobei V561 , V562, V563, V564, V565, V566, V567, V568,NV593-C (O) -NH-V594, -NV595-C (O) -NV596V597, - NHS (O 2) -V598, -NV599S (O 2) -V600, -S-V601, -S (O) - V602, -S (O 2) -V603, -S (O 2) N H-V604, -S (O 2) NV605V606, -S (O 2) O- V607, -P (O) (OV608) (OV609 -Si (V610) (V611) (V612) "; wherein V561, V562, V563, V564, V565, V566, V567, V568,
V569, V570, V571 , V572, V573, V574, V575, V576, V577, V578, V579, V580, V581 , V582, V583, V584, V585, V586, V587, V588, V589, V590, V591 , V592, V593, V594, V595, V596, V597, V598, V599, V600, V601 , V602, V603, V604, V605, V606, V607, V608, V609, V610, V611 , V612 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V567, V568 und/oder V576, V577 und/oder V589, V590 und/oder V596, V597 und/oder V605,V569, V570, V571, V572, V573, V574, V575, V576, V577, V578, V579, V580, V581, V582, V583, V584, V585, V586, V587, V588, V589, V590, V591, V592, V593, V594, V595, V596, V597, V598, V599, V600, V601, V602, V603, V604, V605, V606, V607, V608, V609, V610, V611, V612 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and, alternatively, V567, V568 and / or V576, V577 and / or V589, V590 and / or V596, V597 and / or V605,
V606 jeweils zusammen auch „heterocyclyl" bilden können;V606 may together also form "heterocyclyl";
(h) unsubstituiertes oder substituiertes Aryl, wobei optional der Arylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder ver- schieden, ausgewählt aus der Gruppe bestehend aus:(h) unsubstituted or substituted aryl, wherein optionally the aryl radical may be substituted by at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV613, -NV614V615, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V616, -C(O)O-V617, -C(O)NH-V618, -C(O)NV619V620, - O-V621 , -O(-V622-O)b-H (b = 1 , 2, 3, 4, 5), -O(-V623-O)b-V624 (b = 1 , 2, 3, 4, 5), -OC(O)-V625, -OC(O)-O-V626, -OC(O)-N HV627, - 0-C(O)-N V628V629, -OP(O)(OV630)(OV631 ), - OSi(V632)(V633)(V634), -OS(O2)-V635, -NHC(O)-V636, -(i) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV613, -NV614V615, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -V616, -C (O) O-V617, -C (O) NH-V618, -C (O) NV619V620, -O-V621, -O (-V622-O) b -H ( b = 1, 2, 3, 4, 5), -O (-V623-O) b -V624 (b = 1, 2, 3, 4, 5), -OC (O) -V625, -OC (O ) -O-V626, -OC (O) -N HV627, -O-C (O) -N V628V629, -OP (O) (OV630) (OV631), -OSi (V632) (V633) (V634), -OS (O 2 ) -V635, -NHC (O) -V636, -
NV637C(O)-V638, -NH-C(O)-O-V639, -N H-C(O)-N H-V640, -NH- C(O)-NV641V642, -NV643-C(O)-O-V644, -NV645-C(O)-NH- V646, -NV647-C(O)-NV648V649, -NHS(O2)-V650, -NV651 S(O2)- V652, -S-V653, -S(O)-V654, -S(O2)-V655, -S(O2)N H-V656, - S(O2)NV657V658, -S(O2)O-V659, -P(O)(OV660)(OV661 ), -NV637C (O) -V638, -NH-C (O) -O-V639, -NHC (O) -NH-V640, -NH-C (O) -NV641V642, -NV643-C (O) -O -V644, -NV645-C (O) -NH- V646, -NV647-C (O) -NV648V649, -NHS (O 2) -V650, -NV651 S (O 2) - V652, -S-V653, - S (O) -V654, -S (O 2) -V655, -S (O 2) N H-V656, - S (O 2) NV657V658, -S (O 2) O-V659, -P (O) (OV660) (OV661),
Si(V662)(V663)(V664)"; wobei V613, V614, V615, V616, V617, V618, V619, V620, V621, V622, V623, V624, V625, V626, V627, V628, V629, V630, V631, V632, V633, V634, V635, V636, V637, V638, V639, V640, V641, V642, V643, V644, V645, V646, V647, V648, V649, V650, V651 ,Si (V662) (V663) (V664) "; wherein V613, V614, V615, V616, V617, V618, V619, V620, V621, V622, V623, V624, V625, V626, V627, V628, V629, V630, V631 , V632, V633, V634, V635, V636, V637, V638, V639, V640, V641, V642, V643, V644, V645, V646, V647, V648, V649, V650, V651,
V652, V653, V654, V655, V656, V657, V658, V659, V660, V661 , V662, V663, V664 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ V619, V620 und/oder V628, V629 und/oderV652, V653, V654, V655, V656, V657, V658, V659, V660, V661, V662, V663, V664 are each independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, and wherein alternatively V619, V620 and / or V628, V629 and / or
V641 , V642 und/oder V648, V649 und/oder V657, V658 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindes- tens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:V641, V642 and / or V648, V649 and / or V657, V658 may in each case also form "heterocyclyl", where optionally substituents of the substituent group (i) above may be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV665, -NV666V667, -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H,(ii) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, - NHV665, -NV666V667, -NO 2, -OH, -OCF3, - SH, -0-SO3H, -OP (O) (OH) 2, -CHO, -COOH, -C (O) NH 2, -SO 3 H,
-P(O)(OH)2, -C(O)-V668, -C(O)O-V669, -C(O)NH-V670, - C(O)NV671V672, -O-V673, -O(-V674-O)c-H (c = 1 , 2, 3, 4, 5), - O(-V675-O)c-V676 (c = 1 , 2, 3, 4, 5), -OC(O)-V677, -OC(O)-O- V678, -OC(O)-N HV679, -0-C(O)-N V680V681 , - OP(O)(OV682)(OV683), -OSi(V684)(V685)(V686), -OS(O2)- V687, -NHC(O)-V688, -NV689C(O)-V690, -NH-C(O)-O-V691 , -N H-C(O)-N H-V692, -NH-C(O)-NV693V694, -NV695-C(O)-O- V696, -NV697-C(O)-NH-V698, -NV699-C(O)-NV700V701 , --P (O) (OH) 2 , -C (O) -V668, -C (O) O -V669, -C (O) NH-V670, -C (O) NV671V672, -O-V673, -O (-V674-O) c -H (c = 1, 2, 3, 4, 5), - O (-V675-O) c -V676 (c = 1, 2, 3, 4, 5), -OC (O) -V677, -OC (O) -O-V678, -OC (O) -N HV679, -O-C (O) -N V680V681, - OP (O) (OV682) (OV683), -OSi (V684) (V685) (V686), -OS (O 2) - V687, -NHC (O) -V688, -NV689C (O) -V690, -NH -C (O) -O-V691, -NHC (O) -NH-V692, -NH-C (O) -NV693V694, -NV695-C (O) -O-V696, -NV697-C (O ) -NH-V698, -NV699-C (O) -NV700V701, -
5 NHS(O2)-V702, -NV703S(O2)-V704, -S-V705, -S(O)-V706, -5 NHS (O 2) -V702, -NV703S (O 2) -V704, -S-V705, -S (O) -V706, -
S(O2)-V707, -S(O2)NH-V708, -S(O2)NV709V710, -S(O2)O- V71 1 , -P(O)(OV712)(OV713), -Si(V714)(V715)(V716)"; wobei V665, V666, V667, V668, V669, V670, V671, V672, V673, V674, V675, V676, V677, V678, V679, V680, V681, V682, V683,S (O 2) -V707, -S (O 2) NH-V708, -S (O 2) NV709V710, -S (O 2) O- V71 1, -P (O) (OV712) (OV713) - Si (V714) (V715) (V716) "; wherein V665, V666, V667, V668, V669, V670, V671, V672, V673, V674, V675, V676, V677, V678, V679, V680, V681, V682, V683 .
10 V684, V685, V686, V687, V688, V689, V690, V691, V692, V693,10 V684, V685, V686, V687, V688, V689, V690, V691, V692, V693,
V694, V695, V696, V697, V698, V699, V700, V701 , V702, V703, V704, V705, V706, V707, V708, V709, V710, V71 1 , V712, V713, V714, V715, V716 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cyclo-V694, V695, V696, V697, V698, V699, V700, V701, V702, V703, V704, V705, V706, V707, V708, V709, V710, V71 1, V712, V713, V714, V715, V716 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cyclo-
15 alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V671 , V672 und/oder V680, V681 und/oder V693, V694 und/oder V700, V701 und/oder V709, V710 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) 20 wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:In which alternatively V671, V672 and / or V680, V681 and / or V693, V694 and / or V700, V701 and / or V709, V710 also together also "heterocyclyl "can form; in which optional substituents of substituent group (ii) 20 may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,(iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
25 Br, I, CN, CF3, N3, NH2, -NHV717, -NV718V719, -NO2, -OH,25 Br, I, CN, CF 3, N 3, NH 2, -NHV717, -NV718V719, -NO 2, -OH,
-OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V720, -C(O)O-V721 , - C(O)N H-V722, -C(O)NV723V724, -O-V725, -O(-V726-O)d- H (d = 1 , 2, 3, 4, 5), -O(-V727-O)d-V728 (d = 1 , 2, 3, 4, 5), --OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH ) 2 , -C (O) -V720, -C (O) O -V721, -C (O) N H -V722, -C (O) NV723V724, -O-V725, -O (-V726-O) d - H (d = 1, 2, 3, 4, 5), -O (-V727-O) d -V728 (d = 1, 2, 3, 4, 5),
30 OC(O)-V729, -OC(O)-O-V730, -OC(O)-N H V731 , -0-C(O)-30 OC (O) -V729, -OC (O) -O-V730, -OC (O) -NH V731, -O-C (O) -
NV732V733, -OP(O)(OV734)(OV735), - OSi(V736)(V737)(V738), -OS(O2)-V739, -NHC(O)-V740, - NV741C(O)-V742, -NH-C(O)-O-V743, -NH-C(O)-NH- V744, -N H-C(O)-N V745V746, -NV747-C(O)-O-V748, - NV749-C(O)-NH-V750, -NV751-C(O)-NV752V753, - NHS(O2)-V754, -NV755S(O2)-V756, -S-V757, -S(O)-V758, -S(O2)-V759, -S(O2)N H-V760, -S(O2)NV761V762, -S(O2)O- V763, -P(O)(OV764)(OV765), -Si(V766)(V767)(V768)"; wobei V717, V718, V719, V720, V721, V722, V723, V724,NV732V733, -OP (O) (OV734) (OV735), - OSi (V736) (V737) (V738), -OS (O 2) -V739, -NHC (O) -V740, - NV741C (O) -V742 , -NH-C (O) -O-V743, -NH-C (O) -NH-V744, -NHC (O) -N V745V746, -NV747-C (O) -O-V748, - NV749-C (O) -NH-V750, -NV751-C (O) -NV752V753, - NHS (O 2) -V754, -NV755S (O 2) -V756, -S-V757, -S (O) - V758, -S (O 2) -V759, -S (O 2) N H-V760, -S (O 2) NV761V762, -S (O 2) O- V763, -P (O) (OV764) (OV765 -Si (V766) (V767) (V768) "; wherein V717, V718, V719, V720, V721, V722, V723, V724,
V725, V726, V727, V728, V729, V730, V731 , V732, V733, V734, V735, V736, V737, V738, V739, V740, V741, V742, V743, V744, V745, V746, V747, V748, V749, V750, V751 , V752, V753, V754, V755, V756, V757, V758, V759, V760, V761 , V762, V763, V764, V765, V766, V767, V768 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V723, V724 und/oder V732, V733 und/oder V745, V746 und/oder V752, V753 und/oder V761 ,V725, V726, V727, V728, V729, V730, V731, V732, V733, V734, V735, V736, V737, V738, V739, V740, V741, V742, V743, V744, V745, V746, V747, V748, V749, V750, V751, V752, V753, V754, V755, V756, V757, V758, V759, V760, V761, V762, V763, V764, V765, V766, V767, V768 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, as heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively V723, V724 and / or V732, V733 and / or V745, V746 and / or V752 , V753 and / or V761,
V762 jeweils zusammen auch „heterocyclyl" bilden können;V762 may together also form "heterocyclyl";
(j) unsubstituiertes oder substituiertes Heteroaryl, wobei optional der Hetero- arylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(j) unsubstituted or substituted heteroaryl, where optionally the heteroaryl radical may be substituted by at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV769, -NV770V771 , -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V772, -C(O)O-V773, -C(O)NH-V774, -C(O)NV775V776, -(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV769, -NV770V771, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -V 772, -C (O) O-V773, -C (O) NH-V774, -C (O) NV 775 V 776,
O-V777, -O(-V778-O)e-H (e = 1 , 2, 3, 4, 5), -O(-V779-O)e-V780 (e = 1 , 2, 3, 4, 5), -OC(O)-V781 , -OC(O)-O-V782, -OC(O)-N HV783, - O-C(O)-NV784V785, -OP(O)(OV786)(OV787), - OSi(V788)(V789)(V790), -OS(O2)-V791 , -NHC(O)-V792, - NV793C(O)-V794, -NH-C(O)-O-V795, -N H-C(O)-N H-V796, -NH-O-V777, -O (-V778-O) e -H (e = 1, 2, 3, 4, 5), -O (-V779-O) e -V780 (e = 1, 2, 3, 4 , 5), -OC (O) -V781, -OC (O) -O-V782, -OC (O) -N HV783, -OC (O) -NV784V785, -OP (O) (OV786) (OV787) , - OSi (V788) (V789) (V790), -OS (O 2) -V791, -NHC (O) -V792, - NV793C (O) -V794, -NH-C (O) -O-V795, -NHC (O) -NH-V796, -NH-
C(O)-NV797V798, -NV799-C(O)-O-V800, -NV801 -C(O)-N H- V802, -NV803-C(O)-NV804V805, -NHS(O2)-V806, -NV807S(O2)- V808, -S-V809, -S(O)-V810, -S(O2)-V811 , -S(O2)N H-V812, - S(O2)NV813V814, -S(O2)O-V815, -P(O)(OV816)(OV817), - Si(V818)(V819)(V820)"; wobei V769, V770, V771 , V772, V773, V774, V775, V776, V777, V778, V779, V780, V781 , V782, V783, V784, V785, V786, V787, V788, V789, V790, V791 , V792, V793, V794, V795, V796, V797,C (O) -NV797V798, -NV799-C (O) -O-V800, -NV801 -C (O) -N H- V802, -NV803-C (O) -NV804V805, -NHS (O 2) -V806 , -NV807S (O 2) - V808, V809 -S-, -S (O) -V810, -S (O 2) -V811, -S (O 2) N H-V812, - S (O 2) NV813V814, -S (O 2) O-V815, -P (O) (OV816) (OV817), - Si (V818) (V819) (V820) "; wherein V769, V770, V771, V772 , V773, V774, V775, V776, V777, V778, V779, V780, V781, V782, V783, V784, V785, V786, V787, V788, V789, V790, V791, V792, V793, V794, V795, V796, V797 .
V798, V799, V800, V801 , V802, V803, V804, V805, V806, V807, V808, V809, V810, V81 1 , V812, V813, V814, V815, V816, V817, V818, V819, V820 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ V775, V776 und/oder V784, V785 und/oder V797, V798 und/oder V804, V805 und/oder V813, V814 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wie- derum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:V798, V799, V800, V801, V802, V803, V804, V805, V806, V807, V808, V809, V810, V811, V812, V813, V814, V815, V816, V817, V818, V819, V820 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- alkyl" and wherein alternatively V775, V776 and / or V784, V785 and or V797, V798 and / or V804, V805 and / or V813, V814 may together also form "heterocyclyl"; in which optionally above substituents of the substituent group (i) can in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV821 , -NV822V823, -NO2, -OH, -OCF3, -(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV821, -NV822V823, -NO 2 , -OH, -OCF 3 , -
SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V824, -C(O)O-V825, -C(O)NH-V826, - C(O)NV827V828, -O-V829, -O(-V830-O)^H (f = 1 , 2, 3, 4, 5), - O(-V831-O)^V832 (f = 1 , 2, 3, 4, 5), -OC(O)-V833, -OC(O)-O- V834, -OC(O)-NHV835, -0-C(O)-NV836V837, -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -V824, -C (O) O-V825, -C (O) NH-V826, -C (O) NV827V828, -O-V829, -O (-V830-O) ^ H (f = 1 , 2, 3, 4, 5), - O (-V831-O) ^ V832 (f = 1, 2, 3, 4, 5), -OC (O) -V833, -OC (O) -O- V834, -OC (O) -NHV835, -O-C (O) -NV836V837, -
OP(O)(OV838)(OV839), -OSi(V840)(V841)(V842), -OS(O2)- V843, -NHC(O)-V844, -NV845C(O)-V846, -NH-C(O)-O-V847, -NH-C(O)-NH-V848, -NH-C(O)-NV849V850, -NV851-C(O)-O- V852, -NV853-C(O)-NH-V854, -NV855-C(O)-NV856V857, - NHS(O2)-V858, -NV859S(O2)-V860, -S-V861, -S(O)-V862, -OP (O) (OV838) (OV839), -OSi (V840) (V841) (V842), -OS (O 2) - V843, -NHC (O) -V844, -NV845C (O) -V846, -NH -C (O) -O-V847, -NH-C (O) -NH-V848, -NH-C (O) -NV849V850, -NV851-C (O) -O-V852, -NV853-C (O ) -NH-V854, -NV855-C (O) -NV856V857, - NHS (O 2) -V858, -NV859S (O 2) -V860, -S-V861, -S (O) -V862, -
S(O2)-V863, -S(O2)NH-V864, -S(O2)NV865V866, -S(O2)O- V867, -P(O)(OV868)(OV869), -Si(V870)(V871)(V872)"; wobei V821, V822, V823, V824, V825, V826, V827, V828, V829, V830, V831, V832, V833, V834, V835, V836, V837, V838, V839, V840, V841 , V842, V843, V844, V845, V846, V847, V848, V849, V850, V851 , V852, V853, V854, V855, V856, V857, V858, V859, V860, V861 , V862, V863, V864, V865, V866, V867, V868, V869, V870, V871 , V872 unabhängig voneinander ausgewählt sind ausS (O 2) -V863, -S (O 2) NH-V864, -S (O 2) NV865V866, -S (O 2) O- V867, -P (O) (OV868) (OV869), -Si (V870) (V871) (V872) "; wherein V821, V822, V823, V824, V825, V826, V827, V828, V829, V830, V831, V832, V833, V834, V835, V836, V837, V838, V839, V840, V841, V842, V843, V844, V845, V846, V847, V848, V849, V850, V851, V852, V853, V854, V855, V856, V857, V858, V859, V860, V861, V862, V863, V864, V865, V866, V867, V868, V869, V870, V871, V872 are independently selected
5 der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V827, V828 und/oder V836, V837 und/oder V849, V850 und/oder V856, V857 und/oder V865, V866 jeweils zusammen auch „heterocyclyl" bilden können;5 of the group consisting of: "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V827, V828 and / or V836, V837 and / or V849, V850 and / or V856, V857 and / or V865, V866 may together also form "heterocyclyl";
10 wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:In which optionally substituents of the substituent group (ii) above may be substituted independently with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he-(iii) "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE
15 terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,15 terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
Br, I, CN, CF3, N3, NH2, -NHV873, -NV874V875, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V876, -C(O)O-V877, - C(O)NH-V878, -C(O)NV879V880, -O-V881 , -O(-V882-O)g-Br, I, CN, CF 3, N 3, NH 2, -NHV873, -NV874V875, -NO 2, -OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -V 876, -C (O) O-V 877, -C (O) NH-V878, -C (O) NV879V880, -O-V881, -O (-V882-O) g -
20 H (g = 1 , 2, 3, 4, 5), -O(-V883-O)g-V884 (g = 1 , 2, 3, 4, 5), -20 H (g = 1, 2, 3, 4, 5), -O (-V883-O) g -V884 (g = 1, 2, 3, 4, 5),
OC(O)-V885, -OC(O)-O-V886, -OC(O)-N HV887, -0-C(O)- NV888V889, -OP(O)(OV890)(OV891 ), - OSi(V892)(V893)(V894), -OS(O2)-V895, -NHC(O)-V896, - NV897C(O)-V898, -NH-C(O)-O-V899, -NH-C(O)-NH-OC (O) -V885, -OC (O) -O-V886, -OC (O) -N HV887, -O-C (O) - NV888V889, -OP (O) (OV890) (OV891), - OSi (V892) (V893) (V894), -OS (O 2) -V895, -NHC (O) -V896, - NV897C (O) -V898, -NH-C (O) -O-V899, -NH- C (O) -NH-
25 V900, -N H-C(O)-N V901V902, -NV903-C(O)-O-V904, -25 V900, -NH-C (O) -N V901V902, -NV903-C (O) -O-V904, -
NV905-C(O)-NH-V906, -NV907-C(O)-NV908V909, - NHS(O2)-V910, -NV911S(O2)-V912, -S-V913, -S(O)-V914, -S(O2)-V915, -S(O2)NH-V916, -S(O2)NV917V918, -S(O2)O- V919, -P(O)(OV920)(OV921 ), -Si(V922)(V923)(V924)";NV905-C (O) -NH-V906, -NV907-C (O) -NV908V909, - NHS (O 2) -V910, -NV911S (O 2) -V912, -S-V913, -S (O) - V914, -S (O 2) -V915, -S (O 2) NH-V916, -S (O 2) NV917V918, -S (O 2) O- V919, -P (O) (OV920) (OV921) , -Si (V922) (V923) (V924) ";
30 wobei V873, V874, V875, V876, V877, V878, V879, V880,30 where V873, V874, V875, V876, V877, V878, V879, V880,
V881 , V882, V883, V884, V885, V886, V887, V888, V889, V890, V891, V892, V893, V894, V895, V896, V897, V898, V899, V900, V901 , V902, V903, V904, V905, V906, V907, V908, V909, V910, V911, V912, V913, V914, V915, V916, V917, V918, V919, V920, V921 , V922, V923, V924 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V879, V880 und/oder V888, V889 und/oder V901 , V902 und/oder V908, V909 und/oder V917, V918 jeweils zusammen auch „heterocyclyl" bilden können;V881, V882, V883, V884, V885, V886, V887, V888, V889, V890, V891, V892, V893, V894, V895, V896, V897, V898, V899, V900, V901, V902, V903, V904, V905, V906, V907, V908, V909, V910, V911, V912, V913, V914, V915, V916, V917, V918, V919, V920, V921, V922, V923, V924 are independently selected from the group consisting of: "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl heteroaryl, heteroarylalkyl "and wherein alternatively V879, V880 and / or V888, V889 and / or V901, V902 and / or V908, V909 and / or V917, V918 may together also form" heterocyclyl ";
(k) OZ6, wobei Z6 unabhängig ausgewählt ist aus der Gruppe bestehend aus:(k) OZ6, wherein Z6 is independently selected from the group consisting of:
(i) „Wasserstoff, alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindes- tens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(i) "hydrogen, alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wherein optionally above substituents of substituent group (i) can in turn be substituted independently of one another having at least one substituent, the same or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV925, -NV926V927, -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H,(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV925, -NV926V927, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H,
-P(O)(OH)2, -C(O)-V928, -C(O)O-V929, -C(O)NH-V930, - C(O)NV931V932, -O-V933, -O(-V934-O)h-H (h = 1 , 2, 3, 4, 5), - O(-V935-O)h-V936 (h = 1 , 2, 3, 4, 5), -OC(O)-V937, -OC(O)-O- V938, -OC(O)-NHV939, -0-C(O)-NV940V941 , - OP(O)(OV942)(OV943), -OSi(V944)(V945)(V946), -OS(O2)--P (O) (OH) 2 , -C (O) -V928, -C (O) O-V929, -C (O) NH-V930, -C (O) NV931V932, -O-V933, -O (-V934-O) h -H (h = 1, 2, 3, 4, 5), - O (-V935-O) h -V936 (h = 1, 2, 3, 4, 5), -OC (O) -V937, -OC (O) -O-V938, -OC (O) -NHV939, -O-C (O) -NV940V941, -OP (O) (OV942) (OV943), -OSi (V944 ) (V945) (V946), -OS (O 2 ) -
V947, -NHC(O)-V948, -NV949C(O)-V950, -NH-C(O)-O-V951, -NH-C(O)-NH-V952, -NH-C(O)-NV953V954, -NV955-C(O)-O- V956, -NV957-C(O)-NH-V958, -NV959-C(O)-NV960V961, - NHS(O2)-V962, -NV963S(O2)-V964, -S-V965, -S(O)-V966, - S(O2)-V967, -S(O2)NH-V968, -S(O2)NV969V970, -S(O2)O-V947, -NHC (O) -V948, -NV949C (O) -V950, -NH-C (O) -O-V951, -NH-C (O) -NH-V952, -NH-C (O) - NV953V954, -NV955-C (O) -O- V956, -NV957-C (O) -NH-V958, -NV959-C (O) -NV960V961, - NHS (O 2) -V962, -NV963S (O 2 ) -V964, -S-V965, -S (O) -V 966, -S (O 2 ) -V 967, -S (O 2 ) NH-V 968, -S (O 2 ) NV 969 V 970, -S (O 2 ) O-
V971, -P(O)(OV972)(OV973), -Si(V974)(V975)(V976)"; wobei V925, V926, V927, V928, V929, V930, V931, V932, V933, V934, V935, V936, V937, V938, V939, V940, V941, V942, V943, V944, V945, V946, V947, V948, V949, V950, V951 , V952, V953, V954, V955, V956, V957, V958, V959, V960, V961 , V962, V963, V964, V965, V966, V967, V968, V969, V970, V971 , V972, V973, V974, V975, V976 unabhängig voneinander ausgewählt sind ausV971, -P (O) (OV972) (OV973), -Si (V974) (V975) (V976) "; wherein V925, V926, V927, V928, V929, V930, V931, V932, V933, V934, V935, V936, V937, V938, V939, V940, V941, V942, V943, V944, V945, V946, V947, V948, V949, V950, V951, V952, V953, V954, V955, V956, V957, V958, V959, V960, V961, V962, V963, V964, V965, V966, V967, V968, V969, V970, V971, V972, V973, V974, V975, V976 are independently selected from
5 der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V931 , V932 und/oder V940, V941 und/oder V953, V954 und/oder V960, V961 und/oder V969, V970 jeweils zusammen auch „heterocyclyl" bilden können;5 the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V931, V932 and / or V940, V941 and / or V953, V954 and / or V960, V961 and / or V969, V970 may together also form "heterocyclyl";
10 wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:In which optionally substituents of the substituent group (ii) above may be substituted independently with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he-(iii) "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE
15 terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,15 terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
Br, I, CN, CF3, N3, NH2, -NHV977, -NV978V979, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V980, -C(O)O-V981 , - C(O)N H-V982, -C(O)NV983V984, -O-V985, -O(-V986-O),-Br, I, CN, CF 3, N 3, NH 2, -NHV977, -NV978V979, -NO 2, -OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -V980, -C (O) O-V981, -C (O) N H -V982, -C (O) NV983V984, -O-V985, -O (-V986-O),
20 H (i = 1 , 2, 3, 4, 5), -O(-V987-O),-V988 (i = 1 , 2, 3, 4, 5), -20 H (i = 1, 2, 3, 4, 5), -O (-V987-O), - V988 (i = 1, 2, 3, 4, 5),
OC(O)-V989, -OC(O)-O-V990, -OC(O)-N H V991 , -0-C(O)- NV992V993, -OP(O)(OV994)(OV995), - OSi(V996)(V997)(V998), -OS(O2)-V999, -NHC(O)-VI OOO, - NV1001 C(O)-VI 002, -NH-C(O)-O-VI 003, -NH-C(O)-NH-OC (O) -V989, -OC (O) -O-V990, -OC (O) -NH V991, -O-C (O) - NV992V993, -OP (O) (OV994) (OV995), - OSi (V996) (V997) (V998), -OS (O 2) -V999, -NHC (O) -VI OOO, - NV1001 C (O) -VI 002, -NH-C (O) -O-VI 003 , -NH-C (O) -NH-
25 V1004, -NH-C(O)-NVI 005V1006, -NV1007-C(O)-O-VI 008,25 V1004, -NH-C (O) -NVI 005V1006, -NV1007-C (O) -O-VI 008,
-NVI OOg-C(O)-NH-VI OIO1 -NVI OI I-C(O)-NVIO^VI OI S, - NHS(O2)-V1014, -NV1015S(O2)-V1016, -S-V1017, -S(O)- V1018, -S(O2)-V1019, -S(O2)NH-VI 020, - S(O2)NVI 021 V1022, -S(O2)O-VI 023, --NVI OOg-C (O) -NH-VI OIO 1 -NVI OI IC (O) -NVIO ^ VI OI S, - NHS (O 2 ) -V1014, -NV1015S (O 2 ) -V 1016, -S-V1017 , -S (O) - V1018, -S (O 2) -V1019, -S (O 2) NH-VI 020, - S (O 2) NVI 021 V1022, -S (O 2) O-VI 023, -
30 P(O)(OVI 024)(OV1025), -Si(VI 026)(V1027)(V1028)"; wobei V977, V978, V979, V980, V981, V982, V983, V984, V985, V986, V987, V988, V989, V990, V991 , V992, V993, V994, V995, V996, V997, V998, V999, V1000, V1001, V1002, V1003, V1004, V1005, V1006, V1007, V1008, V1009, V1010, V1011, V1012, V1013, V1014, V1015, V1016, V1017, V1018, V1019, V1020, V1021, V1022, V1023, V1024, V1025, V1026, V1027, V1028 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V983, V984 und/oder V992, V993 und/oder V1005, V1006 und/oder V1012, V1013 und/oder V1021 , V1022 jeweils zusammen auch „heterocyclyl" bilden können;30 P (O) (OVI 024) (OV1025), -Si (VI 026) (V1027) (V1028) "; wherein V977, V978, V979, V980, V981, V982, V983, V984, V985, V986, V987, V988, V989, V990, V991, V992, V993, V994, V995, V996, V997, V998, V999, V1000, V1001, V1002, V1003, V1004, V1005, V1006, V1007, V1008, V1009, V1010, V1011, V1012, V1013, V1014, V1015, V1016, V1017, V1018, V1019, V1020, V1021, V1022, V1023, V1024, V1025, V1026, V1027, V1028 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively V983, V984 and / or V992, V993 and / or V1005, V1006 and / or V1012, V1013 and / or V1021, V1022 may together also form "heterocyclyl";
, wobei Z7 unabhängig ausgewählt ist aus der Gruppe bestehend aus: „Wasserstoff, alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei optional obige Substituenten der Substituentengruppe (i) wie- derum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:wherein Z7 is independently selected from the group consisting of: "hydrogen, alkyl, (C" 9 " -C" 30 " ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; optionally wherein the above substituents of the substituent group ( i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV1029, -NV1030V1031 , -NO2, -OH, -(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV1029, -NV1030V1031, -NO 2 , -OH, -
OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-VI 032, -C(O)O-VI 033, -C(O)NH- V1034, -C(O)NVI 035V1036, -O-V1037, -O(-V1038-O)-H (j = 1 , 2, 3, 4, 5), -O(-V1039-O)-V1040 (j = 1 , 2, 3, 4, 5), -OC(O)- V1041 , -OC(O)-O-VI 042, -OC(O)-NHVI 043, -0-C(O)-OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -VI 032, -C (O) O-VI 033, -C (O) NH-V1034, -C (O) NVI 035V1036, -O-V1037, -O (-V1038-O ) -H (j = 1, 2, 3, 4, 5), -O (-V1039-O) -V1040 (j = 1, 2, 3, 4, 5), -OC (O) - V1041, - OC (O) -O-VI 042, -OC (O) -NHVI 043, -O-C (O) -
NV1044V1045, -OP(O)(OVI 046)(OV1047), - OSi(VI 048)(V1049)(V1050), -OS(O2)-V1051 , -N HC(O)-VI 052, - NV1053C(O)-VI 054, -NH-C(O)-O-VI 055, -NH-C(O)-NH- V1056, -NH-C(O)-NVI 057V1058, -NV1059-C(O)-O-VI 060, - NV1061-C(O)-NH-VI 062, -NV1063-C(O)-NVI 064V1065, -NV1044V1045, -OP (O) (OVI 046) (OV1047), - OSi (VI 048) (V1049) (V1050), -OS (O 2) -V1051, -N HC (O) -VI 052, - NV1053C ( O) -VI 054, -NH-C (O) -O-VI 055, -NH-C (O) -NH-V1056, -NH-C (O) -NVI 057V1058, -NV1059-C (O) - O-VI 060, - NV1061-C (O) -NH-VI 062, -NV1063-C (O) -NVI 064V1065, -
NHS(O2)-V1066, -NV1067S(O2)-V1068, -S-V1069, -S(O)- V1070, -S(O2)-V1071 , -S(O2)NH-VI 072, -S(O2)NVI 073V1074, - S(O2)O-VI 075, -P(O)(OVI 076)(OV1077), - Si(VI 078)(V1079)(V1080)"; wobei V1029, V1030, V1031 , V1032, V1033, V1034, V1035, V1036, V1037, V1038, V1039, V1040, V1041 , V1042, V1043, V1044, V1045, V1046, V1047, V1048, V1049, V1050, V1051 , V1052, V1053, V1054, V1055, V1056, V1057, V1058, V1059,NHS (O 2 ) -V 1066, -NV 1067S (O 2 ) -V 1068, -S-V 1069, -S (O) -V 1070, -S (O 2 ) -V 1071, -S (O 2 ) NH-VI 072, -S (O 2) NVI 073V1074, - S (O 2) OVI 075, -P (O) (OVI 076) (OV1077), - Si (078 VI) (V1079) (V1080) "; where V1029, V1030, V1031, V1032, V1033, V1034, V1035, V1036, V1037, V1038, V1039, V1040, V1041, V1042, V1043, V1044, V1045, V1046, V1047, V1048, V1049, V1050, V1051, V1052, V1053 , V1054, V1055, V1056, V1057, V1058, V1059,
5 V1060, V1061 , V1062, V1063, V1064, V1065, V1066, V1067,5 V1060, V1061, V1062, V1063, V1064, V1065, V1066, V1067,
V1068, V1069, V1070, V1071 , V1072, V1073, V1074, V1075, V1076, V1077, V1078, V1079, V1080 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, 10 aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ(- C 30 9 C) alkyl, cycloalkyl, cycloalkylalkyl, "alkyl,: are V1068, V1069, V1070, V1071, V1072, V1073, V1074, V1075, V1076, V1077, V1078, V1079, V1080 independently selected from the group consisting of , heterocyclyl, heterocyclylalkyl, 10 aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively
V1035, V1036 und/oder V1044, V1045 und/oder V1057, V1058 und/oder V1064, V1065 und/oder V1073, V1074 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) 15 wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:V1035, V1036 and / or V1044, V1045 and / or V1057, V1058 and / or V1064, V1065 and / or V1073, V1074 may together also form "heterocyclyl" wherein optionally substituted substituents of substituent group (ii) 15 in turn independently substituted may be at least one substituent, the same or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,(iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
20 Br, I, CN, CF3, N3, NH2, -NHV1081 , -NV1082V1083, -NO2, -20 Br, I, CN, CF 3, N 3, NH 2, -NHV1081, -NV1082V1083, -NO 2, -
OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-VI 084, -C(O)O-VI 085, -C(O)NH-VI 086, -C(O)NVI 087V1088, -O-V1089, -0(- V1090-O)k-H (k = 1 , 2, 3, 4, 5), -O(-V1091-O)k-V1092 (k = 1 ,OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -VI 084, -C (O) O-VI 085, -C (O) NH-VI 086, -C (O) NVI 087V1088, -O-V1089, -O ( K -H (k = 1,2,3-O) k -V1092 (k = 1,
25 2, 3, 4, 5), -OC(O)-VI 093, -OC(O)-O-VI 094, -OC(O)-25 2, 3, 4, 5), -OC (O) -VI 093, -OC (O) -O-VI 094, -OC (O) -
NHV1095, -0-C(O)-NVI 096V1097, - OP(O)(OVI 098)(OV1099), -OSi(V1 100)(V1101 )(V1102), - OS(O2)-V1103, -NHC(O)-V1 104, -NV1105C(O)-V1 106, - NH-C(O)-O-V1107, -NH-C(O)-NH-V1 108, -NH-C(O)-NHV1095, -O-C (O) -NVI 096V1097, - OP (O) (OVI 098) (OV1099), -OSi (V1 100) (V1101) (V1102), - OS (O 2 ) -V1103, -NHC (O) -V1 104, -NV1105C (O) -V1 106, -NH-C (O) -O-V1107, -NH-C (O) -NH-V1 108, -NH-C (O) -
30 NV1109V11 10, -NV111 1-C(O)-O-V1112, -NV11 13-C(O)-30 NV1109V11 10, -NV111 1-C (O) -O-V1112, -NV11 13-C (O) -
NH-V1 114, -NV11 15-C(O)-NV1 116V11 17, -NHS(O2)- V11 18, -NV1 119S(O2)-V1 120, -S-V1121 , -S(O)-V1 122, - S(O2)-V1123, -S(O2)NH-V1124, -S(O2)NVI 125V1 126, - S(O2)O-V1127, -P(O)(OV1128)(OV1 129), -NH-V1 114, -NV11 15-C (O) -NV1 116V11 17, -NHS (O 2 ) -V11 18, -NV1 119S (O 2 ) -V1 120, -S-V1121, -S (O) - V1 122, -S (O 2 ) -V1123, -S (O 2 ) NH-V1124, -S (O 2 ) NVI 125V1 126, -S (O 2 ) O-V1127, -P (O) (OV1128) (OV1 129), -
35 Si(VI 130)(V1131 )(V1132)"; wobei V1081, V1082, V1083, V1084, V1085, V1086, V1087, V1088, V1089, V1090, V1091, V1092, V1093, V1094, V1095, V1096, V1097, V1098, V1099, V1100, V1101, V1102, V1103, V1104, V1105, V1106, V1107, V1108, V1109, V1110, V1111, VII^1VIIIa1VIIU1VIIIS1VIIIe1VIIIy1VIIIe1VIIIg1 35 Si (VI 130) (V1131) (V1132) "; wherein V1081, V1082, V1083, V1084, V1085, V1086, V1087, V1088, V1089, V1090, V1091, V1092, V1093, V1094, V1095, V1096, V1097, V1098, V1099, V1100, V1101, V1102, V1103, V1104, V1105 , V1106, V1107, V1108, V1109, V1110, V1111, VII ^ 1 VIIIa 1 VIIU 1 VIIIS 1 VIIIe 1 VIIIy 1 VIIIe 1 VIIIg 1
V1120, V1121, V1122, V1123, V1124, V1125, V1126, V1127, V1128, V1129, V1130, V1131 , V1132 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V1087, V1088 und/oder V1096, V1097 und/oder V1109, V1110 und/oder V1116, V1117 und/oder V1125, V1126 jeweils zusammen auch „heterocyclyl" bilden können;V1120, V1121, V1122, V1123, V1124, V1125, V1126, V1127, V1128, V1129, V1130, V1131, V1132 are independently selected from the group consisting of: "alkyl, (C 9 - C 30 ) alkyl, cycloalkyl, cycloalkylalkyl , heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively V1087, V1088 and / or V1096, V1097 and / or V1109, V1110 and / or V1116, V1117 and / or V1125, V1126 also together also" heterocyclyl "can form;
(m) NZ8Z9, wobei Z8, Z9 unabhängig voneinander ausgewählt sind aus der(m) NZ8Z9, wherein Z8, Z9 are independently selected from
Gruppe bestehend aus:Group consisting of:
(i) „Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C(O)- V1133, -C(O)O-V1134, -C(O)-NV1135V1136, -S(O2)-V1137, - S(O2)O-V1138"; wobei V1133, V1134, V1135, V1136, V1137, V1138 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: Wasserstoff, alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei al- ternativ V1135, V1136 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV1139, -NV1140V1141, -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V1 142, -C(O)O-V1 143, -C(O)NH- V1144, -C(O)NV1 145V1146, -O-V1 147, -O(-V1148-O)1-H (1 = 1 , 2, 3, 4, 5), -O(-V1 149-O)1-V1 150 (I = 1 , 2, 3, 4, 5), -OC(O)- V1151 , -OC(O)-O-V1 152, -OC(O)-NHV1 153, -0-C(O)- 5 NV1154V1155, -OP(O)(OV1156)(OV1 157), -(i) "hydrogen, alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C (O) -V 1133, -C (O) O-V 1134, -C (O) -NV1135V1136, -S (O 2) -V1137, - S (O 2) O-V1138 "; wherein V1133, V1134, V1135, V1136, V1137, V1138 independently selected from the group consisting of: Hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively V 1135, V 1136 may together also form" heterocyclyl ", where optionally the above-mentioned substituents of Substituent group (i) may in turn be independently substituted with at least one substituent, same or different, selected from the group consisting of: (ii) alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl , arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHV1139, -NV 1140V1141, -NO 2 , -OH, - OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2, -C (O) -V1 142, -C (O) O-V1 143, -C (O) NH- V1144, -C (O) NV1 145V1146 , -O-V1 147, -O (-V1148-O) 1 -H (1 = 1, 2, 3, 4, 5), -O (-V1 149-O) 1 -V1 150 (I = 1, 2, 3, 4, 5), -OC (O) -V1151, -OC (O) -O-V1 152, -OC (O) -NHV1 153, -O-C (O) -5 NV1154V1155, -OP (O) (OV1156) (OV1 157), -
OSi(V1 158)(V1 159)(V1160), -0S(02)-V1161 , -NHC(O)-V1 162, - NV1163C(O)-V1164, -NH-C(O)-O-V1165, -N H-C(O)-N H- V1166, -NH-C(O)-NV1 167V1168, -NV1 169-C(O)-O-V1 170, - NV1171-C(O)-N H-V1 172, -NV1173-C(O)-NVI 174V1175, - 10 NHS(02)-V1 176, -NV1177S(O2)-V1178, -S-V1 179, -S(O)-OSi (V1158) (V1159) (V1160), -0S (0 2 ) -V1161, -NHC (O) -V1 162, - NV1163C (O) -V1164, -NH-C (O) -O-V1165 , -NHC (O) -NH-V1166, -NH-C (O) -NV1 167V1168, -NV1 169-C (O) -O-V1 170, - NV1171-C (O) -NH-V1 172, -NV1173-C (O) -NVI 174V1175, - 10 NHS (0 2 ) -V1 176, -NV1177S (O 2 ) -V1178, -S-V1 179, -S (O) -
V1180, -S(02)-V1 181 , -S(O2)NH-V1 182, -S(O2)NVI 183V1184, - S(O2)O-V1185, -P(O)(OV1186)(OV1 187), - Si(VI 188)(V1189)(V1190)"; wobei V1139, V1140, V1141 , V1142, V1143, V1144, V1145,V1180, -S (0 2) -V1 181, -S (O 2) NH-V1 182, -S (O 2) NVI 183V1184, - S (O 2) O-V1185, -P (O) (OV1186) (OV1 187), -Si (VI 188) (V1189) (V1190) ", wherein V1139, V1140, V1141, V1142, V1143, V1144, V1145,
15 V1146, V1147, V1 148, V1 149, V1 150, V1 151 , V1 152, V1 153,15 V1146, V1147, V1 148, V1 149, V1 150, V1 151, V1 152, V1 153,
V1154, V1155, V1 156, V1 157, V1 158, V1 159, V1 160, V1 161 , V1162, V1163, V1 164, V1 165, V1 166, V1 167, V1 168, V1 169, V1170, V1171 , V1 172, V1 173, V1 174, V1 175, V1 176, V1 177, V1178, V1179, V1 180, V1 181 , V1 182, V1 183, V1 184, V1 185,V1154, V1155, V1 156, V1 157, V1 158, V1 159, V1 160, V1 161, V1162, V1163, V1 164, V1 165, V1 166, V1 167, V1 168, V1 169, V1170, V1171, V1 172 , V1 173, V1 174, V1 175, V1 176, V1 177, V1178, V1179, V1 180, V1 181, V1 182, V1 183, V1 184, V1 185,
20 V1186, V1187, V1188, V1 189, V1 190 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V1145, V1146 und/oder V1 154, V1 155 und/oder V1 167, V1 16820 V1186, V1187, V1188, V1 189 V1 190 are independently selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively, V1145, V1146 and / or V1 154, V1 155 and / or V1 167, V1 168
25 und/oder V1 174, V1 175 und/oder V1 183, V1184 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausge- 30 wählt aus der Gruppe bestehend aus:25 and / or V1 174, V1 175 and / or V1 183, V1184 may together also also form "heterocyclyl", where optionally substituents of the substituent group (ii) above may be substituted independently with at least one substituent, identical or different - 30 selects from the group consisting of:
(iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I1 CN1 CF3, N3, NH2, -NHV1191 , -NV1 192V1193, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V1194, -C(O)O-V1195, -C(O)NH-V1196, -C(O)NV1197V1198, -O-V1199, -O(- V1200-O)m-H (m = 1, 2, 3, 4, 5), -O(-V1201-O)m-V1202 (m = 1, 2, 3, 4, 5), -OC(O)-VI203, -OC(O)-O-VI204, -OC(O)- NHV1205, -0-C(O)-NVI206V1207, -(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I 1 CN 1 CF 3 , N 3 , NH 2 , -NHV1191, -NV1 192V1193, -NO 2 , - OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, - C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -V 1194, -C (O) O-V 1195, -C (O) NH-V1196, -C (O) NV1197V1198, -O-V1199, -O (-V1200-O) m -H (m = 1, 2, 3, 4, 5), -O (-V1201-O) m -V1202 (m = 1 , 2, 3, 4, 5), -OC (O) -VI203, -OC (O) -O-VI204, -OC (O) -NHV1205, -O-C (O) -NVI206V1207, -
OP(O)(OVI208)(OV1209), -OSi(V1210)(V1211)(V1212), - OS(O2)-V1213, -NHC(O)-VI214, -NV1215C(O)-V1216, - NH-C(O)-O-V1217, -NH-C(O)-NH-VI218, -NH-C(O)- NV1219V1220, -NV1221-C(O)-O-VI222, -NV1223-C(O)- NH-V1224, -NV1225-C(O)-NVI226V1227, -NHS(O2)-OP (O) (OVI208) (OV1209), -OSi (V1210) (V1211) (V1212), - OS (O 2) -V1213, -NHC (O) -VI214, -NV1215C (O) -V1216, - NH -C (O) -O-V1217, -NH-C (O) -NH-VI218, -NH-C (O) - NV1219V1220, -NV1221-C (O) -O-VI222, -NV1223-C (O ) - NH-V1224, -NV1225-C (O) -NVI226V1227, -NHS (O 2 ) -
V1228, -NV1229S(O2)-V1230, -S-V1231, -S(O)-VI232, - S(O2)-V1233, -S(O2)NH-V1234, -S(O2)NVI235V1236, - S(O2)O-VI237, -P(O)(OVI238)(OV1239), - Si(V1240)(V1241)(V1242)"; wobei V1191 , V1192, V1193, V1194, V1195, V1196, V1197,V1228, -NV1229S (O 2) -V1230, -S-V1231, -S (O) -VI232, - S (O 2) -V1233, -S (O 2) NH-V1234, -S (O 2) NVI235V1236 , -S (O 2 ) O -VI237, -P (O) (OVI238) (OV1239), -Si (V1240) (V1241) (V1242) ", wherein V1191, V1192, V1193, V1194, V1195, V1196, V1197 .
V1198, V1199, V1200, V1201 , V1202, V1203, V1204, V1205, V1206, V1207, V1208, V1209, V1210, V121 1 , V1212, V1213, V1214, V1215, V1216, V1217, V1218, V1219, V1220, V1221 , V1222, V1223, V1224, V1225, V1226, V1227, V1228, V1229, V1230, V1231 , V1232, V1233, V1234, V1235, V1236, V1237,V1198, V1199, V1200, V1201, V1202, V1203, V1204, V1205, V1206, V1207, V1208, V1209, V1210, V121 1, V1212, V1213, V1214, V1215, V1216, V1217, V1218, V1219, V1220, V1221, V1222 , V1223, V1224, V1225, V1226, V1227, V1228, V1229, V1230, V1231, V1232, V1233, V1234, V1235, V1236, V1237,
V1238, V1239, V1240, V1241 , V1242 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei al- ternativ V1197, V1198 und/oder V1206, V1207 und/oderV1238, V1239, V1240, V1241 are, V1242 independently selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V1197, V1198 and / or V1206, V1207 and / or
V1219, V1220 und/oder V1226, V1227 und/oder V1235, V1236 jeweils zusammen auch „heterocyclyl" bilden können;V1219, V1220 and / or V1226, V1227 and / or V1235, V1236 may together also form "heterocyclyl";
oderor
(C) einer der Reste Z3, Z4 oder beide Reste Z3, Z4 unabhängig voneinander „substituiertes Alkyl" sind, wobei „substituiertes Alkyl" substituiert ist mit mindestens einem Substituenten ausgewählt aus der Gruppe bestehend aus: (a) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW1 , -NW2W3, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(0)-W4, -C(0)0-W5, -C(0)NH-W6, -C(O)NW7W8, -0-W9, -0(-W10-O)r-H (r(C) one of the radicals Z3, Z4 or both radicals Z3, Z4 is independently "substituted alkyl", where "substituted alkyl" is substituted by at least one substituent selected from the group consisting of: (a) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2, -NHW1, -NW2W3, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP (O) (OH) 2, -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W 4, -C (O) O-W 5, -C (O) NH-W 6, -C (O) NW 7W 8 , -0-W9, -O (-W10-O) r -H (r
= 1 , 2, 3, 4, 5), -0(-W1 1-0)r-W12 (r = 1 , 2, 3, 4, 5), -OC(O)-WI 3, - 0C(0)-0-W14, -OC(O)-NHWI 5, -0-C(0)-NW16W17, - OP(O)(OWI 8)(0W19), -OSi(W20)(W21 )(W22), -OS(O2)-W23, - NHC(O)-W24, -NW25C(O)-W26, -NH-C(O)-O-W27, -NH-C(O)-NH- W28, -N H-C(O)-N W29W30, -NW31-C(O)-O-W32, -NW33-C(O)-NH-= 1, 2, 3, 4, 5), -0 (-W1 1-0) r -W12 (r = 1, 2, 3, 4, 5), -OC (O) -WI 3, - 0C ( 0) -0-W14, -OC (O) -NHWI5, -0-C (0) -NW16W17, - OP (O) (OWI8) (0W19), -OSi (W20) (W21) (W22) , -OS (O 2 ) -W23, -NHC (O) -W24, -NW25C (O) -W26, -NH-C (O) -O-W27, -NH-C (O) -NH-W28, -NHC (O) -N W29W30, -NW31-C (O) -O-W32, -NW33-C (O) -NH-
W34, -NW35-C(O)-NW36W37, -NHS(O2)-W38, -NW39S(O2)-W40, - S-W41 , -S(O)-W42, -S(O2)-W43, -S(O2)NH-W44, -S(O2)NW45W46, - S(O2)O-W47, -P(O)(OW48)(OW49), -Si(W50)(W51 )(W52)"; wobei W1 , W2, W3, W4, W5, W6, W7, W8, W9, W10, W1 1 , W12, W13, W14, W15, W16, W17, W18, W19, W20, W21 , W22, W23, W24, W25,W34, -NW35-C (O) -NW36W37, -NHS (O 2) -W38, -NW39S (O2) -W40, - S-W41, -S (O) -W42, -S (O 2) - W43, -S (O2) NH-W44, -S (O2) NW45W46, - S (O 2) O-W47, -P (O) (OW48) (OW49), -Si (W50) (W51) (W52) "where W1, W2, W3, W4, W5, W6, W7, W8, W9, W10, W1, W12, W13, W14, W15, W16, W17, W18, W19, W20, W21, W22 , W23, W24, W25,
W26, W27, W28, W29, W30, W31 , W32, W33, W34, W35, W36, W37, W38, W39, W40, W41 , W42, W43, W44, W45, W46, W47, W48, W49, W50, W51 , W52 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W7, W8 und/oder W16, W17 und/oder W29, W30 und/oder W36, W37 und/oder W45, W46 jeweils zusammen auch „heterocyclyl" bilden können; mit der Maßgabe, dass ,,-C(O)N H-aryl", ,,-C(O)N H-heteroaryl", „- C(O)NH-cycloalkyl", ,,-C(O)N H-heterocyclyl" weiter substituiert sind mit mindestens einem Substituenten ausgewählt aus untiger Substitutionsgruppe (i); wobei optional obige Substituenten der Substituentengruppe (a) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:W26, W27, W28, W29, W30, W31, W32, W33, W34, W35, W36, W37, W38, W39, W40, W41, W42, W43, W44, W45, W46, W47, W48, W49, W50, W51, W52 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively W7, W8 and or W16, W17 and / or W29, W30 and / or W36, W37 and / or W45, W46 may together also form "heterocyclyl"; with the proviso that "--C (O) NH-aryl", "- C (O) NH-heteroaryl", "- C (O) NH -cycloalkyl", "- C (O) N H-heterocyclyl "are further substituted by at least one substituent selected from inferior substitution group (i); in which optional substituents of the substituent group (a) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW53, -NW54W55, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, - C(O)-W56, -C(O)O-W57, -C(O)NH-W58, -C(O)NW59W60, -O- W61 , -O(-W62-O)s-H (s = 1 , 2, 3, 4, 5), -O(-W63-O)t-W64 (t = 1 , 2, 3, 4, 5), -OC(O)-W65, -OC(O)-O-W66, -OC(O)-NHW67, -0-C(O)- NW68W69, -OP(O)(OW70)(OW71 ), -OSi(W72)(W73)(W74), -(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW53, -NW54W55, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W 56, -C ( O) O-W57, -C (O) NH-W58, -C (O) NW59W60, -O-W61, -O (-W62-O) s -H (s = 1, 2, 3, 4, 5 ), -O (-W63-O) t -W64 (t = 1, 2, 3, 4, 5), -OC (O) -W65, -OC (O) -O-W66, -OC (O) -NHW67, -O-C (O) - NW68W69, -OP (O) (OW70) (OW71), -OSi (W72) (W73) (W74), -
OS(O2)-W75, -NHC(O)-W76, -NW77C(O)-W78, -NH-C(O)-O- W79, -N H-C(O)-N H-W80, -NH-C(O)-NW81W82, -NW83-C(O)-O- W84, -NW85-C(O)-NH-W86, -NW87-C(O)-NW88W89, -NHS(O2)- W90, -NW91S(O2)-W92, -S-W93, -S(O)-W94, -S(O2)-W95, - S(O2)NH-W96, -S(O2)NW97W98, -S(O2)O-W99, -OS (O 2) -W75, -NHC (O) -W76, -NW77C (O) -W78, -NH- C (O) -O- W79, -N HC (O) -N H-W80, -NH -C (O) -NW81W82, -NW83-C (O) -O- W84, -NW85-C (O) -NH-W86, -NW87-C (O) -NW88W89, -NHS (O 2) - W90 , -NW91S (O2) -W92, -S-W93, -S (O) -W94, -S (O2) -W95, - S (O 2) NH-W96, -S (O2) NW97W98, -S (O 2 ) O-W99, -
P(O)(OWI 00)(OW101 ), -Si(WI 02)(W103)(W104)"; wobei W53, W54, W55, W56, W57, W58, W59, W60, W61 , W62, W63, W64, W65, W66, W67, W68, W69, W70, W71 , W72, W73, W74, W75, W76, W77, W78, W79, W80, W81 , W82, W83, W84, W85, W86, W87, W88, W89, W90, W91 , W92, W93, W94, W95, W96, W97, W98,P (O) (OWI 00) (OW101), -Si (WI 02) (W103) (W104) "; wherein W53, W54, W55, W56, W57, W58, W59, W60, W61, W62, W63, W64 , W65, W66, W67, W68, W69, W70, W71, W72, W73, W74, W75, W76, W77, W78, W79, W80, W81, W82, W83, W84, W85, W86, W87, W88, W89 , W90, W91, W92, W93, W94, W95, W96, W97, W98,
W99, W100, W101 , W102, W103, W104 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylal- kyl, heteroaryl, heteroarylalkyl" und wobei alternativ W59, W60 und/oder W68, W69 und/oder W81 , W82 und/oder W88, W89 und/oder W97, W98 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindes- tens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:W99, W100, W101, W102, W103, W104 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylal- kyl, heteroaryl, heteroarylalkyl and alternatively W59, W60 and / or W68, W69 and / or W81, W82 and / or W88, W89 and / or W97, W98 may together also form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW105, -NW106W107, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -(ii) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, - NHW105, -NW106W107, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2, -CHO, -COOH, -
C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-WI 08, -C(0)0-W109, -C(O)N H-W110, -C(O)NW11 1 W1 12, -0-W113, -0(-W114- O)1-H (t = 1 , 2, 3, 4, 5), -0(-W1 15-0)t-W1 16 (t = 1 , 2, 3, 4, 5), -OC(O)-W1 17, -OC(O)-O-W1 18, -OC(O)-NHW1 19, -O- C(O)-NW120W121 , -OP(O)(OWI 22)(OW123), - OSi(W124)(W125)(W126), -OS(O2)-W127, -NHC(O)-W128, -NW129C(O)-WI 30, -N H-C(O)-O-WI 31 , -N H-C(O)-N KIWI 32, -NH-C(O)-NWI 33W134, -NW135-C(O)-O-WI 36, - NW137-C(O)-NH-WI 38, -NW139-C(O)-NWI 40W141 , -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Wi 08, -C (O) O-W109, -C (O) N H-W110, -C (O) NW11 1 W1 12, -0-W113, -0 (-W114-O) 1 -H (t = 1, 2, 3, 4, 5), -0 (-W1 15-0) t -W1 16 (t = 1, 2, 3, 4, 5), -OC (O) -W1 17, -OC (O) -O-W1 18, -OC (O) -NHW1 19, -O- C (O) -NW120W121, -OP (O) (OWI 22) (OW123), - OSi (W124) (W125) (W126), -OS (O2) -W127, -NHC (O) -W128, - NW129C (O) -WI 30, -N HC (O) -O-WI 31, -N HC (O) -N KIWI 32, -NH-C (O) -NWI 33W134, -NW135-C (O) - O-WI 36, -NW137-C (O) -NH-WI 38, -NW139-C (O) -NWI 40W141, -
NHS(O2)-W142, -NW143S(O2)-W144, -S-W145, -S(O)- W146, -S(O2)-W147, -S(O2)NH-W148, -S(O2)NWI 49W150, -S(O2)O-WI 51 , -P(O)(OWI 52)(OW153), - Si(WI 54)(W155)(W156)"; wobei W105, W106, W107, W108, W109, W110, W11 1 , W1 12,NHS (O 2) -W142, -NW143S (O2) -W144, -S-W145, -S (O) - W146, -S (O2) -W147, -S (O2) NH-W148, - S (O 2 ) NWI 49W150, -S (O 2 ) O-WI 51, -P (O) (OWI 52) (OW153), -Si (WI 54) (W155) (W156) ", where W105, W106 , W107, W108, W109, W110, W11 1, W1 12,
W1 13, W1 14, W115, W116, W1 17, W1 18, W119, W120, W121 , W122, W123, W124, W125, W126, W127, W128, W129, W130, W131 , W132, W133, W134, W135, W136, W137, W138, W139, W140, W141 , W142, W143, W144, W145, W146, W147, W148, W149, W150, W151 , W152,W1 13, W1 14, W115, W116, W1 17, W1 18, W119, W120, W121, W122, W123, W124, W125, W126, W127, W128, W129, W130, W131, W132, W133, W134, W135, W136, W137, W138, W139, W140, W141, W142, W143, W144, W145, W146, W147, W148, W149, W150, W151, W152,
W153, W154, W155, W156 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W1 11 , W1 12 und/oder W120, W121 und/oder W133, W134 und/oder W140, W141 und/oder W149, W150 jeweils zusammen auch „heterocyclyl" bilden können;W153, W154, W155, are W156 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively W1 11 , W1 12 and / or W120, W121 and / or W133, W134 and / or W140, W141 and / or W149, W150 may together also form "heterocyclyl";
oder einer der Reste Z3, Z4 oder beide Reste Z3, Z4 unabhängig voneinander voneinander „(C9-C3o)alkyl" sind; wobei „(Cg-C3o)alkyl" optional unabhängig voneinander substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:or one of Z3, Z4 or both radicals Z3, Z4 are independently "(C 9 -C 3 o) alkyl" are one another, wherein "(Cg-C 3 o) alkyl" may optionally be independently substituted with at least one substituent , the same or different, selected from the group consisting of:
(i) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylal- kyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2,(i) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylal- kyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 .
-NHW157, -NW158W159, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- W160, -C(0)0-W161 , -C(O)NH-WI 62, -C(O)NWI 63W164, -O-W165, - O(-W166-O)u-H (u = 1 , 2, 3, 4, 5), -0(-W167-O)u-W168 (u = 1 , 2, 3, 4, 5), -OC(O)-WI 69, -OC(O)-O-WI 70, -OC(O)-N H W171 , -0-C(O)- NW172W173, -OP(O)(OWI 74)(OW175), -OSi(WI 76)(W177)(W178), - OS(O2)-W179, -NHC(O)-WI 80, -NW181 C(O)-WI 82, -NH-C(O)-O- W183, -NH-C(O)-NH-WI 84, -NH-C(O)-NWI 85W186, -NW187-C(O)- O-W188, -NW189-C(O)-NH-WI 90, -NW191-C(O)-NWI 92W193, --NHW157, -NW158W159, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W160, -C (O) 0-W161, -C (O) NH-WI 62, -C (O) NWI 63W164 , -O-W165, -O (-W166-O) u -H (u = 1,2,3,4,5), -0 (-W167-O) u -W168 (u = 1,2,3 , 4, 5), -OC (O) -WI 69, -OC (O) -O-WI 70, -OC (O) -NH W171, -O-C (O) -NW172W173, -OP (O) (OWI 74) (OW175 ), -OSi (WI 76) (W177) (W178), - OS (O 2 ) -W 179, -NHC (O) -WI 80, -NW181 C (O) -WI 82, -NH-C (O) -O- W183, -NH-C (O) -NH-WI 84, -NH-C (O) -NWI 85W186, -NW187-C (O) -O-W188, -NW189-C (O) -NH -WI 90, -NW191-C (O) -NWI 92W193, -
NHS(O2)-W194, -NW195S(O2)-W196, -S-W197, -S(O)-WI 98, -S(O2)- W199, -S(O2)N H-W200, -S(O2)NW201W202, -S(O2)O-W203, - P(O)(OW204)(OW205), -Si(W206)(W207)(W208)"; wobei W157, W158, W159, W160, W161 , W162, W163, W164, W165, W166, W167, W168, W169, W170, W171 , W172, W173, W174, W175,NHS (O 2) -W194, -NW195S (O2) -W196, -S-W197, -S (O) -WI 98, -S (O 2) - W199, -S (O2) N H-W200 , -S (O 2) NW201W202, -S (O2) O-W203, - P (O) (OW204) (OW205), -Si (W206) (W207) (W208) "; wherein W157, W158, W159 W160 W161 W162 W163 W164 W165 W166 W167 W168 W169 W170 W171 W172 W173 W174 W175
W176, W177, W178, W179, W180, W181 , W182, W183, W184, W185, W186, W187, W188, W189, W190, W191 , W192, W193, W194, W195, W196, W197, W198, W199, W200, W201 , W202, W203, W204, W205, W206, W207, W208 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, hete- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W163, W164 und/oder W172, W173 und/oder W185, W186 und/oder W192, W193 und/oder W201 , W202 jeweils zusammen auch „he- terocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:W176, W177, W178, W179, W180, W181, W182, W183, W184, W185, W186, W187, W188, W189, W190, W191, W192, W193, W194, W195, W196, W197, W198, W199, W200, W201, W202, W203, W204, W205, W206, W207, W208 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- rocyclyl, heterocyclylalkyl, aryl, arylalkyl heteroaryl, heteroarylalkyl "and alternatively W163, W164 and / or W172, W173 and / or W185, W186 and / or W192, W193 and / or W201, W202 may together also form" heterocyclyl "; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3,(ii) "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 ,
NH2, -NHW209, -NW210W21 1 , -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- W212, -C(O)O-W213, -C(O)NH-W214, -C(O)NW215W216, -O- W217, -O(-W218-O)v-H (v = 1 , 2, 3, 4, 5), -O(-W219-O)v-W220 (v = 1 , 2, 3, 4, 5), -OC(O)-W221 , -OC(O)-O-W222, -OC(O)-N H W223, -NH 2, -NHW209, -NW210W21 1, -NO 2, -OH, -OCF3, -SH, -0-SO3H, - OP (O) (OH) 2, -CHO, -COOH, -C ( O) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) - W212, -C (O) O-W213, -C (O) NH-W214, -C (O ) NW215W216, -O-W217, -O (-W218-O) v -H (v = 1, 2, 3, 4, 5), -O (-W219-O) v -W220 (v = 1, 2 , 3, 4, 5), -OC (O) -W221, -OC (O) -O-W222, -OC (O) -NH W223, -
O-C(O)-NW224W225, -OP(O)(OW226)(OW227), - OSi(W228)(W229)(W230), -OS(O2)-W231 , -NHC(O)-W232, - NW233C(O)-W234, -NH-C(O)-O-W235, -N H-C(O)-N H-W236, -NH- C(O)-NW237W238, -NW239-C(O)-O-W240, -NW241 -C(O)-N H- W242, -NW243-C(O)-NW244W245, -NHS(O2)-W246, -NW247S(O2)- W248, -S-W249, -S(O)-W250, -S(O2)-W251 , -S(O2)N H-W252, - S(O2)N W253W254, -S(O2)O-W255, -P(O)(OW256)(OW257), - Si(W258)(W259)(W260)"; wobei W209, W210, W21 1 , W212, W213, W214, W215, W216, W217,OC (O) -NW224W225, -OP (O) (OW226) (OW227), - OSi (W228) (W229) (W230), -OS (O2) -W231, -NHC (O) -W232, - NW233C (O) -W234, -NH-C (O) -O-W235, -NHC (O) -NH-W236, -NH-C (O) -NW237W238, -NW239-C (O) -O- W240, -NW241 -C (O) -N H- W242, -NW243-C (O) -NW244W245, -NHS (O2) -W246, -NW247S (O2) - W248, -S-W249, -S (O) -W250, -S (O 2) - W251, -S (O2) N H-W252, - S (O 2) N W253W254, -S (O 2) O-W255, -P (O) (OW256) (OW257), - Si (W258) ( W259) (W260) ", where W209, W210, W21 1, W212, W213, W214, W215, W216, W217,
W218, W219, W220, W221 , W222, W223, W224, W225, W226, W227, W228, W229, W230, W231 , W232, W233, W234, W235, W236, W237, W238, W239, W240, W241 , W242, W243, W244, W245, W246, W247, W248, W249, W250, W251 , W252, W253, W254, W255, W256, W257, W258, W259, W260 unabhängig voneinander ausgewählt sind aus derW218, W219, W220, W221, W222, W223, W224, W225, W226, W227, W228, W229, W230, W231, W232, W233, W234, W235, W236, W237, W238, W239, W240, W241, W242, W243, W244, W245, W246, W247, W248, W249, W250, W251, W252, W253, W254, W255, W256, W257, W258, W259, W260 are independently selected from the
Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W215, W216 und/oder W224, W225 und/oder W237, W238 und/oder W244, W245 und/oder W253, W254 jeweils zu- sammen auch „heterocyclyl" bilden können;Group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively W215, W216 and / or W224, W225 and / or W237, W238 and / or W244, W245 and / or W253, W254 can in each case together also form "heterocyclyl";
und einer der Reste Z3, Z4 oder keiner der Reste Z3, Z4 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus:and one of Z3, Z4 or none of Z3, Z4 is independently selected from the group consisting of:
(b) Wasserstoff; (c) Halogen, F, Cl, Br, I;(b) hydrogen; (c) halogen, F, Cl, Br, I;
(d) unsubstituiertes oder substituiertes Alkyl oder (C9-C30)Alkyl, wobei optional der Alkyl- oder (Cg-C3o)Alkylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (i) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW457, -NW458W459, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-W460, -C(O)O-W461 , -C(O)N H-W462, -C(O)NW463W464, -O-W465, -O(-W466-O)x-H (x = 1 , 2, 3, 4, 5), -O(-W467-O)x-(d) unsubstituted or substituted alkyl or (C 9 -C 30) alkyl, optionally wherein said alkyl or (Cg-C 3 o) alkyl group may be substituted with at least one substituent, identical or different, selected from the group consisting of: (i) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, - NHW457, -NW458W459, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2, -C (O) -W460, -C (O) O-W461, -C (O) N H-W462, -C (O) NW463W464, - O-W465, -O (-W466-O) x -H (x = 1, 2, 3, 4, 5), -O (-W467-O) x -
W468 (x = 1 , 2, 3, 4, 5), -OC(O)-W469, -OC(O)-O-W470, -OC(O)- NHW471 , -O-C(O)-NW472W473, -OP(O)(OW474)(OW475), - OSi(W476)(W477)(W478), -OS(O2)-W479, -NHC(O)-W480, - NW481 C(O)-W482, -NH-C(O)-O-W483, -N H-C(O)-N H-W484, - N H-C(O)-N W485W486, -NW487-C(O)-O-W488, -NW489-C(O)- NH-W490, -NW491 -C(O)-N W492W493, -NHS(O2)-W494, - NW495S(O2)-W496, -S-W497, -S(O)-W498, -S(O2)-W499, - S(O2)NH-W500, -S(O2)NW501W502, -S(O2)O-W503, -W468 (x = 1, 2, 3, 4, 5), -OC (O) -W469, -OC (O) -O-W470, -OC (O) -NHW471, -OC (O) -NW472W473, - OP (O) (OW474) (OW475), - OSi (W476) (W477) (W478), -OS (O2) -W479, -NHC (O) -W480, - NW481 C (O) -W482, -NH-C (O) -O-W483, -NHC (O) -NH-W484, -NHC (O) -N W485W486, -NW487-C (O) - O-W488, -NW489-C (O) - NH-W490, -NW491 -C (O) -N W492W493, -NHS (O 2) -W494, - NW495S (O2) -W496, -S-W497, -S (O) -W498, -S (O2) -W499, - S (O 2) NH-W500, -S (O2) NW501W502, -S (O2) O-W503, -
P(O)(OW504)(OW505), -Si(W506)(W507)(W508)"; wobei W457, W458, W459, W460, W461 , W462, W463, W464, W465, W466, W467, W468, W469, W470, W471 , W472, W473, W474, W475, W476, W477, W478, W479, W480, W481 , W482, W483, W484, W485, W486, W487, W488, W489, W490, W491 , W492,P (O) (OW504) (OW505), -Si (W506) (W507) (W508) "; wherein W457, W458, W459, W460, W461, W462, W463, W464, W465, W466, W467, W468, W469 , W470, W471, W472, W473, W474, W475, W476, W477, W478, W479, W480, W481, W482, W483, W484, W485, W486, W487, W488, W489, W490, W491, W492,
W493, W494, W495, W496, W497, W498, W499, W500, W501 , W502, W503, W504, W505, W506, W507, W508 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, a- ryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W463,W493, W494, W495, W496, W497, W498, W499, W500, W501, W502, W503, W504, W505, W506, W507, W508 are independently selected from the group consisting of: "alkyl, (Cg-C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively W463,
W464 und/oder W472, W473 und/oder W485, W486 und/oder W492, W493 und/oder W501 , W502 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wie- derum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:W464 and / or W472, W473 and / or W485, W486 and / or W492, W493 and / or W501, W502 may in each case also form "heterocyclyl", where optionally the above substituents of the substituent group (i) in turn are substituted independently of one another may be substituted by at least one substituent, the same or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW509, -NW510W511 , -NO2, -OH, -OCF3,(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW509, -NW510W511, -NO 2 , -OH, -OCF 3 ,
-SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, - SO3H, -P(O)(OH)2, -C(O)-W512, -C(O)O-W513, -C(O)NH- W514, -C(O)NW515W516, -O-W517, -O(-W518-O)y-H (y = 1 , 2, 3, 4, 5), -O(-W519-O)y-W520 (y = 1 , 2, 3, 4, 5), -OC(O)- W521 , -OC(O)-O-W522, -OC(O)-N H W523, -0-C(O)--SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , - C (O) -W512, -C (O) O-W513, -C (O) NH-W514, -C (O) NW515W516, -O-W517, -O (-W518-O) y -H (y = 1, 2, 3, 4, 5), -O (-W519-O) y -W520 (y = 1, 2, 3, 4, 5), -OC (O) - W521, -OC (O) -O-W522, -OC (O) -NH W523, -O-C (O) -
NW524W525, -OP(O)(OW526)(OW527), - OSi(W528)(W529)(W530), -OS(O2)-W531 , -NHC(O)-W532, - NW533C(O)-W534, -NH-C(O)-O-W535, -N H-C(O)-N H-W536, -N H-C(O)-N W537W538, -NW539-C(O)-O-W540, -NW541- C(O)-NH-W542, -NW543-C(O)-NW544W545, -NHS(O2)-W546, -NW547S(O2)-W548, -S-W549, -S(O)-W550, -S(O2)-W551 , - S(O2)N H-W552, -S(O2)NW553W554, -S(O2)O-W555, - P(O)(OWSSe)(OWSSy)1 -Si(WSSS)(WSSg)(WSeO)";NW524W525, -OP (O) (OW526) (OW527), - OSi (W528) (W529) (W530), -OS (O2) -W531, -NHC (O) -W532, - NW533C (O) -W534 , -NH-C (O) -O-W535, -NHC (O) -NH-W536, -NHC (O) -N W537W538, -NW539-C (O) -O-W540, -NW541- C (O) -NH-W542, -NW543-C (O) -NW544W545, -NHS (O2) -W546, -NW547S (O2) -W548, -S-W549, -S (O) -W550, -S (O 2) -W551, - S (O 2) N H-W552, -S (O2) NW553W554, -S (O2) O-W555, - P (O) (OWSSe) (OWSSy) 1 -Si (WSSS) (WSSG) (WSeO) ";
5 wobei W509, W510, W511 , W512, W513, W514, W515, W516,5 wherein W509, W510, W511, W512, W513, W514, W515, W516,
W517, W518, W519, W520, W521 , W522, W523, W524, W525, W526, W527, W528, W529, W530, W531 , W532, W533, W534, W535, W536, W537, W538, W539, W540, W541 , W542, W543, W544, W545, W546, W547, W548, W549, W550, W551 , W552,W517, W518, W519, W520, W521, W522, W523, W524, W525, W526, W527, W528, W529, W530, W531, W532, W533, W534, W535, W536, W537, W538, W539, W540, W541, W542, W543, W544, W545, W546, W547, W548, W549, W550, W551, W552,
10 W553, W554, W555, W556, W557, W558, W559, W560 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W515, W516 und/oder W524, W525 und/oder W537,10 W553, W554, W555, W556, W557, W558, W559, W560 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl , arylalkyl, heteroaryl, heteroarylalkyl "and alternatively W515, W516 and / or W524, W525 and / or W537,
15 W538 und/oder W544, W545 und/oder W553, W554 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausge- 20 wählt aus der Gruppe bestehend aus:W538 and / or W544, W545 and / or W553, W554 may together also form "heterocyclyl", where optionally substituents of the substituent group (ii) above may be substituted independently with at least one substituent, identical or different, selected selects from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW561 , -NW562W563, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -(iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW561, -NW562W563, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -
25 C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-W564, -C(O)O-W565,25 C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W564, -C (O) O-W565,
-C(O)NH-W566, -C(O)NW567W568, -O-W569, -O(-W570- O)z-H (z = 1 , 2, 3, 4, 5), -O(-W571-O)z-W572 (z = 1 , 2, 3, 4, 5), -OC(O)-W573, -OC(O)-O-W574, -OC(O)-N H W575, -O- C(O)-NW576W577, -OP(O)(OW578)(OW579), --C (O) NH-W566, -C (O) NW567W568, -O-W569, -O (-W570-O) z -H (z = 1, 2, 3, 4, 5), -O (-) W571-O) z -W572 (z = 1, 2, 3, 4, 5), -OC (O) -W573, -OC (O) -O-W574, -OC (O) -NH W575, -O - C (O) -NW576W577, -OP (O) (OW578) (OW579),
30 OSi(W580)(W581 )(W582), -OS(O2)-W583, -NHC(O)-W584,30 OSi (W580) (W581) (W582), -OS (O2) -W583, -NHC (O) -W584,
-NW585C(O)-W586, -NH-C(O)-O-W587, -NH-C(O)-NH- W588, -NH-C(O)-NW589W590, -NW591-C(O)-O-W592, - NW593-C(O)-NH-W594, -NW595-C(O)-NW596W597, - NHS(O2)-W598, -NW599S(O2)-W600, -S-W601 , -S(O)- W602, -S(O2)-W603, -S(O2)N H-W604, -S(O2)NW605W606, -S(O2)O-W607, -P(O)(OW608)(OW609), - Si(W610)(W611 )(W612)"; wobei W561 , W562, W563, W564, W565, W566, W567, W568, W569, W570, W571 , W572, W573, W574, W575, W576,-NW585C (O) -W586, -NH-C (O) -O-W587, -NH-C (O) -NH-W588, -NH-C (O) -NW589W590, -NW591-C (O) - O-W592, - NW593-C (O) -NH-W594, -NW595-C (O) -NW596W597, - NHS (O2) -W598, -NW599S (O2) -W600, -S-W601, - SO)- W602, -S (O2) -W603, -S (O2) N H-W604, -S (O2) NW605W606, -S (O2) O-W607, -P (O) (OW608) (OW609 ), Si (W610) (W611) (W612) ", wherein W561, W562, W563, W564, W565, W566, W567, W568, W569, W570, W571, W572, W573, W574, W575, W576,
W577, W578, W579, W580, W581 , W582, W583, W584, W585, W586, W587, W588, W589, W590, W591 , W592, W593, W594, W595, W596, W597, W598, W599, W600, W601 , W602, W603, W604, W605, W606, W607, W608, W609, W610, W61 1 , W612 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W567, W568 und/oder W576, W577 und/oder W589, W590 und/oder W596, W597 und/oder W605, W606 jeweils zusammen auch „heterocyclyl" bilden können;W577, W578, W579, W580, W581, W582, W583, W584, W585, W586, W587, W588, W589, W590, W591, W592, W593, W594, W595, W596, W597, W598, W599, W600, W601, W602, W603, W604, W605, W606, W607, W608, W609, W610, W61 1, W612 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl , heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively W567, W568 and / or W576, W577 and / or W589, W590 and / or W596, W597 and / or W605, W606 may each together also form" heterocyclyl ";
(e) unsubstituiertes oder substituiertes Aryl, wobei optional der Arylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder ver- schieden, ausgewählt aus der Gruppe bestehend aus:(e) unsubstituted or substituted aryl, wherein optionally the aryl radical may be substituted by at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW613, -NW614W615, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-W616, -C(O)O-W617, -C(O)NH-W618, -C(O)NW619W620,(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW613, -NW614W615, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W616, -C (O) O-W 617, -C (O) NH-W 618, -C (O) NW 619W620,
-O-W621 , -O(-W622-O)a-H (a = 1 , 2, 3, 4, 5), -O(-W623-O)a- W624 (a = 1 , 2, 3, 4, 5), -OC(O)-W625, -OC(O)-O-W626, -OC(O)- NHW627, -O-C(O)-NW628W629, -OP(O)(OW630)(OW631 ), - OSi(W632)(W633)(W634), -OS(O2)-W635, -NHC(O)-W636, - NW637C(O)-W638, -NH-C(O)-O-W639, -N H-C(O)-N H-W640, --O-W621, -O (-W622-O) a -H (a = 1, 2, 3, 4, 5), -O (-W623-O) a - W624 (a = 1, 2, 3, 4, 5), -OC (O) -W625, -OC (O) -O-W626, -OC (O) -NHW627, -OC (O) -NW628W629, -OP (O) (OW630) (OW631) , - OSi (W632) (W633) (W634), -OS (O2) -W635, -NHC (O) -W636, - NW637C (O) -W638, -NH-C (O) -O-W639, -N HC (O) -N H-W640, -
N H-C(O)-N W641W642, -NW643-C(O)-O-W644, -NW645-C(O)- NH-W646, -NW647-C(O)-NW648W649, -NHS(O2)-W650, - NW651 S(O2)-W652, -S-W653, -S(O)-W654, -S(O2)-W655, - S(O2)NH-W656, -S(O2)NW657W658, -S(O2)O-W659, - P(O)(OW660)(OW661 ), -Si(W662)(W663)(W664)"; wobei W613, W614, W615, W616, W617, W618, W619, W620, W621 , W622, W623, W624, W625, W626, W627, W628, W629, W630, W631 , W632, W633, W634, W635, W636, W637, W638, W639,N HC (O) -N W641W642, -NW643-C (O) -O-W644, -NW645-C (O) -NH-W646, -NW647-C (O) -NW648W649, -NHS (O 2 ) - W650, - NW651 S (O 2) -W652, -S-W653, -S (O) -W654, -S (O2) -W655, - S (O 2) NH-W656, -S (O2) NW657W658, -S (O2) O-W659, - P (O) (OW660) (OW661), -Si (W662) (W663) (W664) W613, W614, W615, W616, W617, W618, W619, W620, W621, W622, W623, W624, W625, W626, W627, W628, W629, W630, W631, W632, W633, W634, W635, W636 , W637, W638, W639,
W640, W641 , W642, W643, W644, W645, W646, W647, W648, W649, W650, W651 , W652, W653, W654, W655, W656, W657, W658, W659, W660, W661 , W662, W663, W664 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C30)alkyl, cycloalkyl, cycloal kyl alkyl , heterocyclyl, heterocyclylalkyl, a- ryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W619, W620 und/oder W628, W629 und/oder W641 , W642 und/oder W648, W649 und/oder W657, W658 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:W640, W641, W642, W643, W644, W645, W646, W647, W648, W649, W650, W651, W652, W653, W654, W655, W656, W657, W658, W659, W660, W661, W662, W663, W664 independent are selected from the group consisting of: "alkyl, (C 9 - C 30 ) alkyl, cycloalkyl, cycloalkyl alkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively W619, W620 and / or W628, W629 and / or W641, W642 and / or W648, W649 and / or W657, W658 may each also together form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,
CN, CF3, N3, NH2, -NHW665, -NW666W667, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, - SO3H, -P(O)(OH)2, -C(O)-W668, -C(O)O-W669, -C(O)NH- W670, -C(O)NW671W672, -O-W673, -O(-W674-O)b-H (b = 1 , 2, 3, 4, 5), -O(-W675-O)b-W676 (b = 1 , 2, 3, 4, 5), -OC(O)-CN, CF 3, N 3, NH 2, -NHW665, -NW666W667, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2, -CHO , -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W668, -C (O) O-W669, -C (O) NH - W670, -C (O) NW671W672, -O-W673, -O (-W674-O) b -H (b = 1, 2, 3, 4, 5), -O (-W675-O) b - W676 (b = 1, 2, 3, 4, 5), -OC (O) -
W677, -OC(O)-O-W678, -OC(O)-N H W679, -0-C(O)- NW680W681 , -OP(O)(OW682)(OW683), - OSi(W684)(W685)(W686), -OS(O2)-W687, -NHC(O)-W688, - NW689C(O)-W690, -NH-C(O)-O-W691 , -N H-C(O)-N H-W692, -N H-C(O)-N W693W694, -NW695-C(O)-O-W696, -NW697-W677, -OC (O) -O-W678, -OC (O) -NH W679, -O-C (O) -NW680W681, -OP (O) (OW682) (OW683), -OSi (W684) (W685 ) (W686), -OS (O2) -W687, -NHC (O) -W688, - NW689C (O) -W690, -NH-C (O) -O-W691, -N HC (O) -N H-W692, -N HC (O) -N W693W694, -NW695-C (O) -O-W696, -NW697-
C(O)-N H-W698, -NW699-C(O)-NW700W701 , -NHS(O2)-W702, -NW703S(O2)-W704, -S-W705, -S(O)-W706, -S(O2)-W707, - S(O2)N H-W708, -S(O2)NW709W710, -S(O2)O-W711 , - P(0)(0W712)(OW713), -Si(W714)(W715)(W716)"; wobei W665, W666, W667, W668, W669, W670, W671 , W672, W673, W674, W675, W676, W677, W678, W679, W680, W681 , W682, W683, W684, W685, W686, W687, W688, W689, W690, W691 , W692, W693, W694, W695, W696, W697, W698, W699, 5 W700, W701 , W702, W703, W704, W705, W706, W707, W708,C (O) -N H-W698, -NW699-C (O) -NW700W701, -NHS (O2) -W702, -NW703S (O2) -W704, -S-W705, -S (O) -W706 , -S (O 2 ) -W 707, -S S (O 2 ) N H-W708, -S (O 2 ) NW709W710, -S (O 2 ) O-W 711, -P (0) (0W712) (OW713) , -Si (W714) (W715) (W716) "; wherein W665, W666, W667, W668, W669, W670, W671, W672, W673, W674, W675, W676, W677, W678, W679, W680, W681, W682, W683, W684, W685, W686, W687, W688, W689 , W690, W691, W692, W693, W694, W695, W696, W697, W698, W699, 5 W700, W701, W702, W703, W704, W705, W706, W707, W708,
W709, W710, W71 1 , W712, W713, W714, W715, W716 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei 10 alternativ W671 , W672 und/oder W680, W681 und/oder W693,W709, W710, W71 1, W712, W713, W714, W715, W716 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl , arylalkyl, heteroaryl, heteroarylalkyl "and where 10 alternatively W671, W672 and / or W680, W681 and / or W693,
W694 und/oder W700, W701 und/oder W709, W710 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mitW694 and / or W700, W701 and / or W709, W710 may together also form "heterocyclyl", where optionally substituents of the substituent group (ii) above may be substituted independently of one another with
15 mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:At least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW717, -NW718W719, -NO2, -(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW717, -NW718W719, -NO 2 , -
20 OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -20 OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -
C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-W720, -C(O)O-W721 , -C(O)N H-W722, -C(O)N W723W724, -O-W725, -O(-W726- O)c-H (c = 1 , 2, 3, 4, 5), -O(-W727-O)c-W728 (c = 1 , 2, 3, 4, 5), -OC(O)-W729, -OC(O)-O-W730, -OC(O)-N H W731 , -O-C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W 720, -C (O) O-W 721, -C (O) N H-W 722, - C (O) N W723W724, -O-W725, -O (-W726- O) c -H (c = 1, 2, 3, 4, 5), -O (-W727-O) c-W728 (c = 1, 2, 3, 4, 5), -OC (O) -W729, -OC (O) -O-W730, -OC (O) -NH W731, -O-
25 C(O)-NW732W733, -OP(O)(OW734)(OW735), -25 C (O) -NW732W733, -OP (O) (OW734) (OW735),
OSi(W736)(W737)(W738), -OS(O2)-W739, -NHC(O)-W740, -NW741C(O)-W742, -NH-C(O)-O-W743, -NH-C(O)-NH- W744, -N H-C(O)-N W745W746, -NW747-C(O)-O-W748, - NW749-C(O)-NH-W750, -NW751 -C(O)-N W752W753, -OSi (W736) (W737) (W738), -OS (O2) -W739, -NHC (O) -W740, -NW741C (O) -W742, -NH-C (O) -O-W743, -NH -C (O) -NH-W744, -NHC (O) -N W745W746, -NW747-C (O) -O-W748, -NW749-C (O) -NH-W750, -NW751 -C (O ) -N W752W753, -
30 NHS(O2)-W754, -NW755S(O2)-W756, -S-W757, -S(O)-30 NHS (O 2 ) -W754, -NW755S (O 2 ) -W756, -S-W757, -S (O) -
W758, -S(O2)-W759, -S(O2)N H-W760, -S(O2)NW761W762, -S(O2)O-W763, -P(O)(OW764)(OW765), - Si(W766)(W767)(W768)"; wobei W717, W718, W719, W720, W721 , W722, W723, W724, W725, W726, W727, W728, W729, W730, W731 , W732, W733, W734, W735, W736, W737, W738, W739, W740, W741 , W742, W743, W744, W745, W746, W747, W748, W749, W750, W751 , W752, W753, W754, W755, W756,W758, -S (O2) -W759, -S (O2) N H-W760, -S (O2) NW761W762, -S (O2) O-W763, -P (O) (OW764) (OW765 ), - Si (W766) (W767) (W768) "; wherein W717, W718, W719, W720, W721, W722, W723, W724, W725, W726, W727, W728, W729, W730, W731, W732, W733, W734, W735, W736, W737, W738, W739, W740, W741 , W742, W743, W744, W745, W746, W747, W748, W749, W750, W751, W752, W753, W754, W755, W756,
W757, W758, W759, W760, W761 , W762, W763, W764, W765, W766, W767, W768 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativW757, W758, W759, W760, W761, W762, W763, W764 are, W765, W766, W767, W768 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively
W723, W724 und/oder W732, W733 und/oder W745, W746 und/oder W752, W753 und/oder W761 , W762 jeweils zusammen auch „heterocyclyl" bilden können;W723, W724 and / or W732, W733 and / or W745, W746 and / or W752, W753 and / or W761, W762 may together also form "heterocyclyl";
(f) unsubstituiertes oder substituiertes Heteroaryl, wobei optional der Hetero- arylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(f) unsubstituted or substituted heteroaryl, where optionally the heteroaryl radical may be substituted by at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW769, -NW770W771 , -NO2, -OH, -OCF3, -SH, -O-(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW769, -NW770W771, -NO 2 , -OH, -OCF 3 , -SH, -O-
SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-W772, -C(O)O-W773, -C(O)N H-W774, -C(O)NW775W776, -O-W777, -O(-W778-O)d-H (d = 1 , 2, 3, 4, 5), -O(-W779-O)d- W780 (d = 1 , 2, 3, 4, 5), -OC(O)-W781 , -OC(O)-O-W782, -OC(O)- NHW783, -O-C(O)-NW784W785, -OP(O)(OW786)(OW787), -SO 3 H, -OP (O) (OH) 2, -CHO, -COOH, -C (O) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) -W772 , -C (O) O-W773, -C (O) N H-W774, -C (O) NW775W776, -O-W777, -O (-W778-O) d -H (d = 1, 2, 3, 4, 5), -O (-W779-O) d -W780 (d = 1, 2, 3, 4, 5), -OC (O) -W781, -OC (O) -O-W782, -OC (O) - NHW783, -OC (O) -NW784W785, -OP (O) (OW786) (OW787),
OSi(W788)(W789)(W790), -OS(O2)-W791 , -NHC(O)-W792, - NW793C(O)-W794, -NH-C(O)-O-W795, -N H-C(O)-N H-W796, - N H-C(O)-N W797W798, -NW799-C(O)-O-W800, -NW801-C(O)- NH-W802, -NW803-C(O)-NW804W805, -NHS(O2)-W806, - NW807S(O2)-W808, -S-W809, -S(0)-W810, -S(O2)-W81 1 , -OSi (W788) (W789) (W790), -OS (O2) -W791, -NHC (O) -W792, - NW793C (O) -W794, -NH-C (O) -O-W795, -N HC (O) -NH-W796, -NHC (O) -N W797W798, -NW799-C (O) -O-W800, -NW801-C (O) -NH-W802, -NW803-C (O ) -NW804W805, -NHS (O2) -W806, - NW807S (O2) -W808, -S-W809, -S (0) -W810, -S (O2) -W81 1 -
S(O2)NH-W812, -S(O2)NW813W814, -S(O2)O-W815, - P(0)(0W816)(OW817), -Si(W818)(W819)(W820)"; wobei W769, W770, W771 , W772, W773, W774, W775, W776, W777, W778, W779, W780, W781 , W782, W783, W784, W785, W786, W787, W788, W789, W790, W791 , W792, W793, W794, W795, W796, W797, W798, W799, W800, W801 , W802, W803, W804, W805, W806, W807, W808, W809, W810, W81 1 , W812, W813, W814, W815, W816, W817, W818, W819, W820 unabhängig vonein- ander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-S (O 2) NH-W812, -S (O2) NW813W814, -S (O2) O-W815, - P (0) (0W816) (OW817), -Si (W818) (W819) (W820) W769, W770, W771, W772, W773, W774, W775, W776, W777, W778, W779, W780, W781, W782, W783, W784, W785, W786, W787, W788, W789, W790, W791, W792, W793, W794, W795, W796, W797, W798, W799, W800, W801, W802, W803, W804, W805, W806, W807, W808, W809, W810, W81 1 , W812, W813, W814, W815, W816, W817, W818, W819, W820 are independently selected from the group consisting of: "alkyl, (Cg-
C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, a- ryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W775, W776 und/oder W784, W785 und/oder W797, W798 und/oder W804, W805 und/oder W813, W814 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW821 , -NW822W823, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, - SO3H, -P(O)(OH)2, -C(O)-W824, -C(O)O-W825, -C(O)NH- W826, -C(O)NW827W828, -O-W829, -O(-W830-O)e-H (e = 1 ,C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively W775, W776 and / or W784, W785 and / or W797, W798 and / or W804, W805 and / or W813, W814 may together also form "heterocyclyl"; in which optionally substituents of substituent group (i) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of: (ii) alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHW821, -NW822W823, -NO2, -OH, -OCF3, -SH , -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C ( O) -W824, -C (O) O-W825, -C (O) NH-W826, -C (O) NW827W828, -O-W829, -O (-W830-O) e -H (e = 1 .
2, 3, 4, 5), -O(-W831-O)e-W832 (e = 1 , 2, 3, 4, 5), -OC(O)- W833, -OC(O)-O-W834, -OC(O)-N H W835, -0-C(O)- NW836W837, -OP(O)(OW838)(OW839), - OSi(W840)(W841 )(W842), -OS(O2)-W843, -NHC(O)-W844, - NW845C(O)-W846, -NH-C(O)-O-W847, -N H-C(O)-N H-W848,2, 3, 4, 5), -O (-W831-O) e-W832 (e = 1, 2, 3, 4, 5), -OC (O) - W833, -OC (O) -O- W834, -OC (O) -NH W835, -O-C (O) -NW836W837, -OP (O) (OW838) (OW839), -OSi (W840) (W841) (W842), -OS (O 2 ) -W843, -NHC (O) -W844, -NW845C (O) -W846, -NH-C (O) -O-W847, -NHC (O) -NH-W848,
-N H-C(O)-N W849W850, -NW851-C(O)-O-W852, -NW853- C(O)-N H-W854, -NW855-C(O)-NW856W857, -NHS(O2)-W858, -NW859S(O2)-W860, -S-W861 , -S(O)-W862, -S(O2)-W863, - S(O2)N H-W864, -S(O2)NW865W866, -S(O2)O-W867, - P(O)(OW868)(OW869), -Si(W870)(W871 )(W872)"; wobei W821 , W822, W823, W824, W825, W826, W827, W828, W829, W830, W831 , W832, W833, W834, W835, W836, W837, W838, W839, W840, W841 , W842, W843, W844, W845, W846, W847, W848, W849, W850, W851 , W852, W853, W854, W855, W856, W857, W858, W859, W860, W861 , W862, W863, W864, W865, W866, W867, W868, W869, W870, W871 , W872 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete--NHC (O) -N W849W850, -NW851-C (O) -O-W852, -NW853-C (O) -NH-W854, -NW855-C (O) -NW856W857, -NHS (O 2 ) -W858, -NW859S (O2) -W860, -S-W861, -S (O) -W862, -S (O2) -W863, - S (O 2) N H-W864, -S (O 2) NW865W866, -S (O2) O-W867, - P (O) (OW868) (OW869), -Si (W870) (W871) (W872) "; wherein W821, W822, W823, W824, W825, W826, W827, W828, W829, W830, W831, W832, W833, W834, W838, W839, W840, W841, W842, W843, W844, W845, W846, W847, W848, W849, W850, W851, W852, W853, W854, W855, W856, W857, W858, W859, W860, W861, W862, W863, W864, W865, W866, W867, W868, W869, W870, W871, W872 are independently selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete
5 rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W827, W828 und/oder W836, W837 und/oder W849, W850 und/oder W856, W857 und/oder W865, W866 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) 10 wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:5 rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively W827, W828 and / or W836, W837 and / or W849, W850 and / or W856, W857 and / or W865, W866 can each also together form" heterocyclyl "; in which optional substituents of substituent group (ii) 10 may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,(iii) "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
15 Br, I, CN, CF3, N3, NH2, -NHW873, -NW874W875, -NO2, -15 Br, I, CN, CF 3, N 3, NH 2, -NHW873, -NW874W875, -NO2, -
OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-W876, -C(O)O-W877, -C(O)N H-W878, -C(O)N W879W880, -O-W881 , -O(-W882- O)^H (f = 1 , 2, 3, 4, 5), -O(-W883-OH/V884 (f = 1 , 2, 3, 4, 5),OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W876, -C (O) O-W877, -C (O) NH-W878, -C (O) N W879W880, -O-W881, -O (-W882 - O) ^ H (f = 1, 2, 3, 4, 5), -O (-W883-OH / V884 (f = 1, 2, 3, 4, 5),
20 -OC(O)-W885, -OC(O)-O-W886, -OC(O)-N H W887, -O-20 -OC (O) -W885, -OC (O) -O-W886, -OC (O) -NH W887, -O-
C(O)-NW888W889, -OP(O)(OW890)(OW891 ), - OSi(W892)(W893)(W894), -OS(O2)-W895, -NHC(O)-W896, -NW897C(O)-W898, -NH-C(O)-O-W899, -NH-C(O)-NH- W900, -N H-C(O)-N W901W902, -NW903-C(O)-O-W904, -C (O) -NW888W889, -OP (O) (OW890) (OW891), - OSi (W892) (W893) (W894), -OS (O2) -W895, -NHC (O) -W896, -NW897C (O) -W898, -NH-C (O) -O-W899, -NH-C (O) -NH-W900, -NHC (O) -N W901W902, -NW903-C (O) -O- W904, -
25 NW905-C(O)-NH-W906, -NW907-C(O)-NW908W909, -25 NW905-C (O) -NH-W906, -NW907-C (O) -NW908W909, -
NHS(O2)-W910, -NW91 1S(O2)-W912, -S-W913, -S(O)- W914, -S(O2)-W915, -S(O2)NH-W916, -S(O2)NW917W918, -S(O2)O-W919, -P(O)(OW920)(OW921 ), - Si(W922)(W923)(W924)";NHS (O 2) -W910, -NW91 1S (O 2) -W912, -S-W913, -S (O) - W914, -S (O2) -W915, -S (O2) NH-W916, -S (O 2) NW917W918, -S (O2) O-W919, -P (O) (OW920) (OW921), - Si (W922) (W923) (W924) ";
30 wobei W873, W874, W875, W876, W877, W878, W879, W880,30 wherein W873, W874, W875, W876, W877, W878, W879, W880,
W881 , W882, W883, W884, W885, W886, W887, W888, W889, W890, W891 , W892, W893, W894, W895, W896, W897, W898, W899, W900, W901 , W902, W903, W904, W905, W906, W907, W908, W909, W910, W91 1 , W912, W913, W914, W915, W916, W917, W918, W919, W920, W921 , W922, W923, W924 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativW881, W882, W883, W884, W885, W886, W887, W888, W889, W890, W891, W892, W893, W894, W895, W896, W897, W898, W899, W900, W901, W902, W903, W904, W905, W906, W907, W908, W909, W910, W91 1, W912, W913, W914, W915, W916, W917, W918, W919, W920, W921, W922, W923, are W924 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl , heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively
W879, W880 und/oder W888, W889 und/oder W901 , W902 und/oder W908, W909 und/oder W917, W918 jeweils zusammen auch „heterocyclyl" bilden können;W879, W880 and / or W888, W889 and / or W901, W902 and / or W908, W909 and / or W917, W918 may together also form "heterocyclyl";
(g) OZ6, wobei Z6 unabhängig ausgewählt ist aus der Gruppe bestehend aus:(g) OZ6, wherein Z6 is independently selected from the group consisting of:
(i) „Wasserstoff, alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei optional obige Substituenten der Substituentengruppe (i) wie- derum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl", wherein optionally above substituents of the substituent group (i) in turn are independently substituted may be substituted by at least one substituent, the same or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW925, -NW926W927, -NO2, -OH, -OCF3,(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW925, -NW926W927, -NO 2 , -OH, -OCF 3 ,
-SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, - SO3H, -P(O)(OH)2, -C(O)-W928, -C(O)O-W929, -C(O)NH- W930, -C(O)NW931W932, -O-W933, -O(-W934-O)g-H (g = 1 , 2, 3, 4, 5), -O(-W935-O)g-W936 (g = 1 , 2, 3, 4, 5), -OC(O)- W937, -OC(O)-O-W938, -OC(O)-N H W939, -0-C(O)--SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , - C (O) -W928, -C (O) O-W929, -C (O) NH- W930, -C (O) NW931W932, -O-W933, -O (-W934-O) g -H (g = 1, 2, 3, 4, 5), -O (-W935-O) g -W936 (g = 1, 2, 3, 4, 5), -OC (O) - W937, -OC (O) -O-W938, -OC (O) -NH W939, -O-C (O) -
NW940W941 , -OP(O)(OW942)(OW943), - OSi(W944)(W945)(W946), -OS(O2)-W947, -NHC(O)-W948, - NW949C(O)-W950, -NH-C(O)-O-W951 , -N H-C(O)-N H-W952, -N H-C(O)-N W953W954, -NW955-C(O)-O-W956, -NW957- C(O)-N H-W958, -NW959-C(O)-NW960W961 , -NHS(O2)-W962,NW940W941, -OP (O) (OW942) (OW943), - OSi (W944) (W945) (W946), -OS (O2) -W947, -NHC (O) -W948, - NW949C (O) -W950 , -NH-C (O) -O-W951, -NHC (O) -NH-W952, -NHC (O) -N W953W954, -NW955-C (O) -O-W956, -NW957- C (O) -N H-W958, -NW959-C (O) -NW960W961, -NHS (O2) -W962,
-NW963S(O2)-W964, -S-W965, -S(O)-W966, -S(O2)-W967, - S(O2)N H-W968, -S(O2)NW969W970, -S(O2)O-W971 , - P(O)(OW972)(OW973), -Si(W974)(W975)(W976)"; wobei W925, W926, W927, W928, W929, W930, W931 , W932, W933, W934, W935, W936, W937, W938, W939, W940, W941 , W942, W943, W944, W945, W946, W947, W948, W949, W950, W951 , W952, W953, W954, W955, W956, W957, W958, W959, 5 W960, W961 , W962, W963, W964, W965, W966, W967, W968,-NW963S (O2) -W964, -S-W965, -S (O) -W966, -S (O2) -W967, - S (O 2) N H-W968, -S (O2) NW969W970, -S (O 2 ) O-W 971, -P (O) (OW972) (OW973), -Si (W974) (W975) (W976) "; wherein W925, W926, W927, W928, W929, W930, W931, W932, W933, W934, W935, W936, W937, W938, W939, W940, W941, W942, W943, W944, W945, W946, W947, W948, W949 , W950, W951, W952, W953, W954, W955, W956, W957, W958, W959, 5 W960, W961, W962, W963, W964, W965, W966, W967, W968,
W969, W970, W971 , W972, W973, W974, W975, W976 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei 10 alternativ W931 , W932 und/oder W940, W941 und/oder W953,W969. W970, W971, W972, W973, W974, W975, W976 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively 10 W931, W932 and / or W940, W941 and / or W953,
W954 und/oder W960, W961 und/oder W969, W970 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mitW954 and / or W960, W961 and / or W969, W970 may together also form "heterocyclyl", where optionally substituents of the substituent group (ii) above may be substituted independently of one another with
15 mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:At least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW977, -NW978W979, -NO2, -(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW977, -NW978W979, -NO 2 , -
20 OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -20 OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -
C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-W980, -C(O)O-W981 , -C(O)N H-W982, -C(O)N W983W984, -O-W985, -O(-W986- O)h-H (h = 1 , 2, 3, 4, 5), -O(-W987-O)h-W988 (h = 1 , 2, 3, 4, 5), -OC(O)-W989, -OC(O)-O-W990, -OC(O)-N H W991 , -O-C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W 980, -C (O) O-W 981, -C (O) N H-W982, C (O) N W983W984, -O-W985, -O (-W986- O) h -H (h = 1, 2, 3, 4, 5), -O (-W987-O) h -W988 (h = 1, 2, 3, 4, 5), -OC (O) -W989, -OC (O) -O-W990, -OC (O) -NH W991, -O-
25 C(O)-NW992W993, -OP(O)(OW994)(OW995), -25 C (O) -NW992W993, -OP (O) (OW994) (OW995),
OSi(W996)(W997)(W998), -OS(O2)-W999, -NHC(O)-WIOOO, -NW1001 C(O)-WI 002, -NH-C(O)-O-WI 003, -NH-C(O)- NH-W1004, -NH-C(O)-NWI 005W1006, -NW1007-C(O)-O- W1008, -NW1009-C(O)-NH-WI 010, -NW1011-C(O)-OSi (W996) (W997) (W998), -OS (O2) -W999, -NHC (O) -WIOOO, -NW1001 C (O) -WI 002, -NH-C (O) -O-WI 003 , -NH-C (O) -NH-W1004, -NH-C (O) -NWI 005W1006, -NW1007-C (O) -O-W1008, -NW1009-C (O) -NH-WI 010, - NW1011-C (O) -
30 NW1012W1013, -NHS(O2)-W1014, -NW1015S(O2)-W1016,30 NW1012W1013, -NHS (O 2) -W1014, -NW1015S (O 2) -W1016,
-S-W1017, -S(O)-WI 018, -S(O2)-W1019, -S(O2)NH- W1020, -S(O2)NW1021W1022, -S(O2)O-WI 023, - P(O)(OWI 024)(OW1025), -Si(WI 026)(W1027)(W1028)"; wobei W977, W978, W979, W980, W981 , W982, W983, W984, W985, W986, W987, W988, W989, W990, W991 , W992, W993, W994, W995, W996, W997, W998, W999, W1000, W1001 , W1002, W1003, W1004, W1005, W1006, W1007, W1008, W1009, W1010, W101 1 , W1012, W1013, W1014,-S-W1017, -S (O) -WI 018, -S (O 2) -W1019, -S (O 2) NH- W1020, -S (O 2) NW1021W1022, -S (O 2) O-WI 023, - P (O) (OWI 024) (OW1025), -Si (WI 026) (W1027) (W1028) "; wherein W977, W978, W979, W980, W981, W982, W983, W984, W985, W986, W987, W988, W989, W990, W991, W992, W993, W994, W995, W996, W997, W998, W999, W1000, W1001 , W1002, W1003, W1004, W1005, W1006, W1007, W1008, W1009, W1010, W101 1, W1012, W1013, W1014,
W1015, W1016, W1017, W1018, W1019, W1020, W1021 , W1022, W1023, W1024, W1025, W1026, W1027, W1028 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, hete- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" und wobei alternativ W983, W984 und/oder W992, W993 und/oder W1005, W1006 und/oder W1012, W1013 und/oder W1021 , W1022 jeweils zusammen auch „heterocyc- IyI" bilden können;W1015, W1016, W1017, W1018, W1019, W1020, W1021, W1022, W1023, W1024, W1025, W1026, W1027, are W1028 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl , cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and, alternatively, W983, W984 and / or W992, W993 and / or W1005, W1006 and / or W1012, W1013 and / or W1021, W1022, respectively together may also form "heterocyclyl";
(h) SZ7, wobei Z7 unabhängig ausgewählt ist aus der Gruppe bestehend aus:(h) SZ7, wherein Z7 is independently selected from the group consisting of:
(i) „Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei optional obige Substituenten der Substituentengruppe (i) wie- derum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(i) "hydrogen, alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, as heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wherein optionally above substituents of substituent group (i), in turn, independently of one another may be substituted with at least one substituent, the same or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW1029, -NW1030W1031 , -NO2, -OH, -(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW1029, -NW1030W1031, -NO 2 , -OH, -
OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-WI 032, -C(O)O-WI 033, -C(O)NH- W1034, -C(O)NWI 035W1036, -O-W1037, -O(-W1038-O),-H (i = 1 , 2, 3, 4, 5), -0(-W1039-O)1-WI 040 (i = 1 , 2, 3, 4, 5), -OC(O)- W1041 , -OC(O)-O-WI 042, -OC(O)-NHWI 043, -0-C(O)-OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -WI 032, -C (O) O-WI 033, -C (O) NH-W1034, -C (O) NWI 035W1036, -O-W1037, -O (-W1038-O ), - H (i = 1, 2, 3, 4, 5), -O (-W1039-O) 1 -WI 040 (i = 1, 2, 3, 4, 5), -OC (O) - W1041, -OC (O) -O-WI 042, -OC (O) -NHWI 043, -O-C (O) -
NW1044W1045, -OP(O)(OWI 046)(OW1047), - OSi(WI 048)(W1049)(W1050), -OS(O2)-W1051 , -NHC(O)- W1052, -NW1053C(O)-WI 054, -NH-C(O)-O-WI 055, -NH- C(O)-NH-WI 056, -NH-C(O)-NWI 057W1058, -NW1059-C(O)- O-W1060, -NW1061-C(O)-NH-WI 062, -NW1063-C(O)- NW1064W1065, -NHS(O2)-W1066, -NW1067S(O2)-W1068, -S- W1069, -S(O)-WI 070, -S(O2)-W1071 , -S(O2)NH-WI 072, - S(O2)NWI 073W1074, -S(O2)O-WI 075, - 5 P(O)(OWI 076)(OW1077), -Si(WI 078)(W1079)(W1080)"; wobei W1029, W1030, W1031 , W1032, W1033, W1034, W1035, W1036, W1037, W1038, W1039, W1040, W1041 , W1042, W1043, W1044, W1045, W1046, W1047, W1048, W1049, W1050, W1051 , W1052, W1053, W1054, W1055, W1056, W1057, W1058, W1059,NW1044W1045, -OP (O) (OWI 046) (OW1047), - OSi (WI 048) (W1049) (W1050), -OS (O 2) -W1051, -NHC (O) - W1052, -NW1053C (O) -WI 054, -NH-C (O) -O-WI 055, -NH-C (O) -NH-WI 056, -NH-C (O) -NWI 057W1058, -NW1059-C (O) - O-W1060, -NW1061-C (O) -NH-WI 062, -NW1063-C (O) - NW1064W1065, -NHS (O 2) -W1066, -NW1067S (O 2) -W1068, -S- W1069, -S (O) -WI 070, -S (O 2) -W1071, -S (O 2) NH-WI 072, - S (O 2) NWI 073W1074, -S (O 2) O-WI 075 - 5 P (O) (OWI 076) (OW1077), -Si (WI 078) (W1079) (W1080) "; where W1029, W1030, W1031, W1032, W1033, W1034, W1035, W1036, W1037, W1038, W1039, W1040, W1041, W1042, W1043, W1044, W1045, W1046, W1047, W1048, W1049, W1050, W1051, W1052, W1053, W1054, W1055, W1056, W1057, W1058, W1059,
10 W1060, W1061 , W1062, W1063, W1064, W1065, W1066, W1067,10 W1060, W1061, W1062, W1063, W1064, W1065, W1066, W1067,
W1068, W1069, W1070, W1071 , W1072, W1073, W1074, W1075, W1076, W1077, W1078, W1079, W1080 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl,W1068, W1069, W1070, W1071, W1072, W1073, W1074, W1075, W1076, W1077, W1078, W1079, W1080 are independently selected from the group consisting of: "alkyl, alkyl, cycloalkyl, cycloalkylalkyl (Cg-C 30), heterocyclyl, heterocyclylalkyl,
15 aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ15 aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively
W1035, W1036 und/oder W1044, W1045 und/oder W1057, W1058 und/oder W1064, W1065 und/oder W1073, W1074 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) 20 wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:W1035, W1036 and / or W1044, W1045 and / or W1057, W1058 and / or W1064, W1065 and / or W1073, W1074 may together also form "heterocyclyl" wherein optionally substituted substituents of substituent group (ii) 20 in turn independently substituted may be at least one substituent, the same or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,(iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
25 Br, I, CN, CF3, N3, NH2, -NHW1081 , -NW1082W1083, -NO2,25 Br, I, CN, CF 3, N 3, NH 2, -NHW1081, -NW1082W1083, -NO 2,
-OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-W1084, -C(O)O- W1085, -C(O)NH-WI 086, -C(O)NWI 087W1088, -O-W1089, -O(-W1090-O)-H C = 1 , 2, 3, 4, 5), -O(-W1091 -O)-WI 092-OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O ) (OH) 2 , -C (O) -W1084, -C (O) O-W1085, -C (O) NH-WI 086, -C (O) NWI 087W1088, -O-W1089, -O (-) W1090-O) -HC = 1, 2, 3, 4, 5), -O (-W1091 -O) -WI 092
30 0 = 1 , 2, 3, 4, 5), -OC(O)-WI 093, -OC(O)-O-WI 094, -30 0 = 1, 2, 3, 4, 5), -OC (O) -WI 093, -OC (O) -O-WI 094, -
OC(O)-NHWI 095, -0-C(O)-NWI 096W1097, - OP(O)(OWI 098)(OW1099), -OSi(W1 100)(W1101 )(W1 102), - 0S(02)-W1 103, -NHC(O)-W1 104, -NW1 105C(O)-W1 106, - NH-C(O)-O-W1107, -NH-C(O)-NH-W1108, -NH-C(O)- NW1 109W1 110, -NW11 11-C(O)-O-W1 112, -NW1 113- C(O)-NH-W11 14, -NW11 15-C(O)-NW1 116W1 117, — NHS(02)-W11 18, -NW1 119S(O2)-W1120, -S-W1 121 , — S(O)-W1 122, -S(O2)-W1 123, -S(O2)NH-W1124, - S(O2)NW1 125W1 126, -S(O2)O-W1127, -OC (O) -NHWI 095, -O-C (O) -NWI 096W1097, - OP (O) (OWI 098) (OW1099), -OSi (W1 100) (W1101) (W1 102), -0S (0 2 ) -W1 103, -NHC (O) -W1 104, -NW1 105C (O) -W1 106, -NH-C (O) -O-W1107, -NH-C (O) -NH-W1108, - NH-C (O) - NW1 109W1 110, -NW11 11-C (O) -O-W1 112, -NW1 113- C (O) -NH-W11 14, -NW11 15-C (O) -NW1 116W1 117, -NHS (0 2 ) -W11 18, -NW1 119S (O 2 ) -W1120, -S-W1 121, -S (O) -W1 122, -S (O 2 ) -W 1 123, -S (O 2 ) NH-W1124, - S (O 2 ) NW 1 125W 1 126, -S (O 2 ) O-W 1 127, -
P(O)(OW1128)(OW1 129), -Si(W1130)(W1131 )(W1 132)"; wobei W1081 , W1082, W1083, W1084, W1085, W1086, W1087, W1088, W1089, W1090, W1091 , W1092, W1093, W1094, W1095, W1096, W1097, W1098, W1099, W1100, W1 101 , W1102, W1103, W1 104, W1 105, W1106, W1107,P (O) (OW1128) (OW1 129), -Si (W1130) (W1131) (W1 132) ", wherein W1081, W1082, W1083, W1084, W1085, W1086, W1087, W1088, W1089, W1090, W1091, W1092 , W1093, W1094, W1095, W1096, W1097, W1098, W1099, W1100, W1101, W1102, W1103, W1104, W1105, W1106, W1107,
W1 108, W1109, W11 10, W1 11 1 , W1 112, W11 13, W11 14, W1 115, W11 16, W11 17, W1 118, W1 119, W1120, W1121 , W1 122, W1123, W1124, W1 125, W1 126, W1127, W1128, W1 129, W1130, W1131 , W1 132 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-W1 108, W1109, W11 10, W1 11 1, W1 112, W11 13, W11 14, W1 115, W11 16, W11 17, W1 118, W1 119, W1120, W1121, W1 122, W1123, W1124, W1 125, W1 126, W1127, W1128, W1 129, W1130, W1131, W1 132 are independently selected from the group consisting of: "alkyl, (Cg-)
C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W1087, W1088 und/oder W1096, W1097 und/oder W1 109, W11 10 und/oder W1 116, W11 17 und/oder W1 125, W1 126 jeweils zusammen auch „heterocyclyl" bilden können;C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively W1087, W1088 and / or W1096, W1097 and / or W1 109, W11 10 and / or W1 116, W11 17 and / or W1 125, W1 126 may together also form "heterocyclyl";
(j) NZ8Z9, wobei Z8, Z9 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:(j) NZ8Z9, wherein Z8, Z9 are independently selected from the group consisting of:
(i) „Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C(O)-(i) "hydrogen, alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C (O) -
W1 133, -C(O)O-W1134, -C(O)-NW1135W1136, -S(02)-W1137, - S(O2)O-W1 138"; wobei W1133, W1 134, W1 135, W1136, W1137, W1 138 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: Was- serstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W1135, W1136 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW1139, -NW1 140W1 141 , -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-W1142, -C(O)O-W1143, -C(O)NH- W1 144, -C(O)NWI 145W1146, -0-W1 147, -O(-W1148-O)k-H (kW1 133, -C (O) O-W1134, -C (O) -NW1135W1136, -S (0 2) -W1137, - S (O 2) O-W1 138 "; wherein W1133, W1 134, M1 135, W1136, W1137, W1 138 are independently selected from the group consisting of: hydrogen, alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively W1135, W1136 together can also form "heterocyclyl"; in which optionally substituents of substituent group (i) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of: (ii) alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHW1139, -NW1 140W1 141, -NO 2, -OH, - OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W1142, -C (O) O-W1143, -C (O) NH-W1 144, -C (O) NWI 145W1146, -O-W1 147, -O (-W1148-O) k -H (k
= 1 , 2, 3, 4, 5), -O(-W1 149-O)k-W1 150 (k = 1 , 2, 3, 4, 5), - OC(O)-W1151 , -OC(O)-O-W1 152, -OC(O)-NHW1153, -O- C(O)-NW1154W1 155, -OP(O)(OW1 156)(OW1157), - OSi(W1158)(W1159)(W1 160), -0S(02)-W1161 , -NHC(O)- W1 162, -NW1 163C(O)-W1 164, -NH-C(O)-O-W1165, -NH-= 1, 2, 3, 4, 5), -O (-W1 149-O) k -W1 150 (k = 1, 2, 3, 4, 5), - OC (O) -W1151, -OC ( O) -O-W1 152, -OC (O) -NHW1153, -O-C (O) -NW1154W1 155, -OP (O) (OW1 156) (OW1157), -OSi (W1158) (W1159) (W1 160) -0S (0 2) -W1161, -NHC (O) - W1 162, -NW1 163C (O) -W1 164, -NH-C (O) -O-W1165, -NH-
C(O)-NH-W1166, -NH-C(O)-NW1167W1168, -NW1169-C(O)- O-W1 170, -NW1 171-C(O)-NH-W1172, -N W1173-C(O)- NW1 174W1175, -NHS(02)-W1 176, -NW1 177S(O2)-W1178, -S- W1 179, -S(O)-W1 180, -S(02)-W1 181 , -S(O2)NH-W1182, - S(O2)NW1 183W1 184, -S(O2)O-W1185, -C (O) -NH-W1166, -NH-C (O) -NW1167W1168, -NW1169-C (O) -O-W1 170, -NW1 171-C (O) -NH-W1172, -N W1173-C (O) - NW1 174W1175, -NHS (0 2 ) -W1 176, -NW1 177S (O 2 ) -W1178, -S-W1 179, -S (O) -W1 180, -S (0 2 ) -W1 181, -S (O 2) NH-W1182, - S (O 2) NW1 183W1 184, -S (O 2) O-W1185, -
P(0)(0W1186)(OW1 187), -Si(W1188)(W1189)(W1 190)"; wobei W1139, W1 140, W1 141 , W1142, W1 143, W1 144, W1145, W1 146, W1147, W1148, W1 149, W1 150, W1151 , W1152, W1 153, W1 154, W1155, W1156, W1 157, W1 158, W1159, W1160, W1 161 , W1 162, W1163, W1164, W1 165, W1 166, W1167, W1168, W1 169,P (0) (0W1186) (OW1 187), -Si (W1188) (W1189) (W1 190) ", wherein W1139, W1140, W1141, W1142, W1143, W1144, W1145, W1146, W1147, W1148, W1 149, W1 150, W1151, W1152, W1 153, W1 154, W1155, W1156, W1 157, W1 158, W1159, W1160, W1 161, W1 162, W1163, W1164, W1 165, W1 166, W1167, W1168, W1 169,
W1 170, W1171 , W1172, W1 173, W1 174, W1175, W1176, W1 177, W1 178, W1179, W1180, W1 181 , W1 182, W1183, W1184, W1 185, W1 186, W1187, W1188, W1 189, W1190 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W1 145, W1146 und/oder W1 154, W1155 und/oder W1 167, W1 168 und/oder W1174, W1 175 und/oder W1 183, W1184 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:W1 170, W1171, W1172, W1 173, W1 174, W1175, W1176, W1 177, W1 178, W1179, W1180, W1 181, W1 182, W1183, W1184, W1 185, W1 186, W1187, W1188, W1 189, W1190 are independently selected from the group consisting of: "alkyl, (C 9 - C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively W1 145, W1146 and / or W1 154, W1155 and / or W1 167, W1 168 and / or W1174, W1 175 and / or W1 183, W1184 may together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
5 (iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I1 CN1 CF3, N3, NH2, -NHW1 191 , -NW1192W1193, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-W1194, -C(O)O-5 (iii) alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I 1 CN 1 CF 3 , N 3 , NH 2 , -NHW 1 191, -NW 1192 W 1193, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C ( O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W 1194, -C (O) O-
10 W1 195, -C(O)NH-W1 196, -C(O)NW1197W1198, -0-W1199,10 W1 195, -C (O) NH-W1 196, -C (O) NW1197W1198, -0-W1199,
-0(-W1200-O)1-H (I = 1 , 2, 3, 4, 5), -0(-W1201 -O)1-WI 202 (I = 1 , 2, 3, 4, 5), -OC(O)-WI 203, -OC(O)-O-WI 204, - OC(O)-NHW1205, -0-C(0)-NW1206W1207, - OP(O)(OW1208)(OW1209), -OSi(W1210)(W1211 )(W1212), --0 (-W1200-O) 1 -H (I = 1,2,3,4,5), -0 (-W1201 -O) 1 -WI 202 (I = 1,2,3,4,5) , -OC (O) -WI 203, -OC (O) -O-WI 204, - OC (O) -NHW1205, -O-C (O) -NW1206W1207, -OP (O) (OW1208) (OW1209) , -OSi (W1210) (W1211) (W1212), -
15 OS(O2)-W1213, -NHC(O)-WI 214, -NW1215C(0)-W1216, -15 OS (O 2) -W1213, -NHC (O) -WI 214 -NW1215C (0) -W1216, -
N H-C(0)-0-W1217, -NH-C(O)-NH-W1218, -NH-C(O)- NW1219W1220, -NW1221-C(O)-O-W1222, -NW1223- C(O)-NH-W1224, -NW1225-C(O)-NWI 226W1227, - NHS(O2)-W1228, -NW1229S(O2)-W1230, -S-W1231 , -N HC (O) -O-W1217, -NH-C (O) -NH-W1218, -NH-C (O) -NW1219W1220, -NW1221-C (O) -O-W1222, -NW1223-C (O ) -NH-W1224, -NW1225-C (O) -NWI 226W1227, - NHS (O 2) -W1228, -NW1229S (O 2) -W1230, -S-W1231, -
20 S(O)-W1232, -S(O2)-W1233, -S(O2)NH-W1234, -20 S (O) -W1232, -S (O 2) -W1233, -S (O 2) NH-W1234, -
S(O2)NWI 235W1236, -S(O2)O-WI 237, - P(0)(0W1238)(OW1239), -Si(WI 240)(W1241 )(W1242)"; wobei W1191 , W1 192, W1 193, W1194, W1 195, W1 196, W1 197, W1198, W1199, W1200, W1201 , W1202, W1203,S (O 2 ) NWI 235W1236, -S (O 2 ) O-WI 237, -P (0) (0W1238) (OW1239), -Si (WI 240) (W1241) (W1242) ", where W1191, W1 192 , W1 193, W1194, W1 195, W1 196, W1 197, W1198, W1199, W1200, W1201, W1202, W1203,
25 W1204, W1205, W1206, W1207, W1208, W1209, W1210,25 W1204, W1205, W1206, W1207, W1208, W1209, W1210,
W121 1 , W1212, W1213, W1214, W1215, W1216, W1217, W1218, W1219, W1220, W1221 , W1222, W1223, W1224, W1225, W1226, W1227, W1228, W1229, W1230, W1231 , W1232, W1233, W1234, W1235, W1236, W1237, W1238,W121 1, W1212, W1213, W1214, W1215, W1216, W1217, W1218, W1219, W1220, W1221, W1222, W1223, W1224, W1225, W1226, W1227, W1228, W1229, W1230, W1231, W1232, W1233, W1234, W1235 , W1236, W1237, W1238,
30 W1239, W1240, W1241 , W1242 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W1 197, W1 198 und/oder W1206, W1207 und/oder W1219, W1220 und/oder W1226, W1227 und/oder W1235, W1236 jeweils zusammen auch „heterocyclyl" bilden können;30 W1239, W1240, W1241, W1242 are independently selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively W1 197, W1 198 and / or W1206, W1207 and / or W1219, W1220 and / or W1226, W1227 and / or W1235, W1236 may together also form "heterocyclyl";
oderor
(D) einer der Reste Z3, Z4 oder beide Reste Z3, Z4 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:(D) one of the radicals Z3, Z4 or both radicals Z3, Z4 are independently selected from the group consisting of:
(1 ) ,,-NZ10Z1 1 , -OZ12, -SZ13"; wobei einer der Reste Z10, Z11 oder beide Reste Z10, Z1 1 und Reste Z12, Z13 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:(1) ,, - NZ10Z1 1, -OZ12, -SZ13 ", one of the radicals Z10, Z11 or both radicals Z10, Z1 1 and radicals Z12, Z13 being selected independently of one another from the group consisting of:
(a) „Wasserstoff, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl"; mit der Maßgabe, dass nicht beide Reste Z10, Z11 gleichzeitig Wasserstoff sind; mit der weiteren Maßgabe, dass Rest Z12 nicht Wasserstoff ist; mit der weiteren Maßgabe, dass obige Substituenten der Substituen- tengruppe (a), wenn nicht Wasserstoff, unabhängig voneinander weiter substituiert sind mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (i) „(C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, N3, -NH-cycloalkyl, - NH-cycloalkylalkyl, -NH-heteroaryl, -NH-heteroarylalkyl, -NH- arylalkyl, -NH-heterocyclyl, -NH-heterocyclylalkyl, -NQ1Q2, -S- cycloalkyl, -S-cycloalkylalkyl, -S-aryl, —S— arylalkyl, -S-heteroaryl, - S-heteroarylalkyl, -S-heterocyclyl, -S-heterocyclylalkyl, -O- cycloalkyl, -O-cycloalkylalkyl, -O-arylalkyl, -O-heteroaryl, -O- heteroarylalkyl, -O-heterocyclyl, -O-heterocyclylalkyl, -O(-Q3-O)p- H (p = 1 , 2, 3, 4, 5), -O(-Q4-O)p-Q5 (p = 1 , 2, 3, 4, 5), - OP(O)(OQ6)(OQ7), -C(O)O-Q8, -C(O)NH2, -C(O)NH-Q9, - C(O)NQ10Q11 , -S(O2)-Q12, -P(O)(OH)2, -P(O)(OQI 3)(OQ14), -(a) "hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl"; with the proviso that both radicals Z10, Z11 are not simultaneously hydrogen, with the further proviso that radical Z12 is not hydrogen with the further proviso that the above substituents of the substituent group (a), if not hydrogen, are further independently substituted with at least one substituent, same or different, selected from the group consisting of: (i) "(C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, N 3 , -NH-cycloalkyl, - NH-cycloalkylalkyl, -NH-heteroaryl, -NH-heteroarylalkyl, -NH-arylalkyl , -NH-heterocyclyl, -NH-heterocyclylalkyl, -NQ1Q2, -S-cycloalkyl, -S-cycloalkylalkyl, -S-aryl, -S-arylalkyl, -S-heteroaryl, - S-heteroarylalkyl, -S-heterocyclyl, - S-heterocyclylalkyl, -O-cycloalkyl, -O-cycloalkylalkyl, -O-ar ylalkyl, -O-heteroaryl, -O-heteroarylalkyl, -O-heterocyclyl, -O-heterocyclylalkyl, -O (-Q3-O) p - H (p = 1, 2, 3, 4, 5), -O ( -Q4-O) p -Q5 (p = 1, 2, 3, 4, 5) - OP (O) (OQ6) (OQ7), -C (O) O-Q8, -C (O) NH 2 , -C (O) NH-Q9, - C (O) NQ10Q11, -S (O 2) -Q12, -P (O) (OH) 2, -P (O) (OQI 3) (OQ14) -
Si(QI 5)(Q16)(Q17), -O-Si(Q18)(Q19)(Q20), -O-C(O)-O-Q21 , -O- C(O)-NH-Q22, -0-C(O)-N Q23Q24, -NH-C(O)-O-Q25, -NH-C(O)- NH-Q26, -NH-C(O)-NQ27Q28, -NQ29-C(O)-O-Q30, -NQ31- C(O)-NH-Q32, -NQ33-C(O)-NQ34Q35, -NQ36-S(O2)-Q37, -NH- S(O2)-Q38, -O-S(O2)-Q39, -NH-C(O)-Q40, -NQ41-C(O)-Q42, - C(O)-Q43, -OC(O)-Q44, -S(O)-Q45, -S(O2)-NHQ46, -S(O2)- NQ47Q48, -S(O2)-OQ49"; mit der weiteren Maßgabe, dass ,,-N(alkyl)2" weiter substituiert ist mit mindestens einem Substituenten ausgewählt aus der untigen Substi- tuentengruppe (ii); wobei Q1 , Q2, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q10, Q11 , Q12, Q13, Q14, Q15, Q16, Q17, Q18, Q19, Q20, Q21 , Q22, Q23, Q24, Q25,Si (QI 5) (Q16) (Q17), -O-Si (Q18) (Q19) (Q20), -OC (O) -O-Q21, -O-C (O) -NH-Q22, -0 -C (O) -NQ23Q24, -NH-C (O) -O-Q25, -NH-C (O) - NH-Q26, -NH-C (O) -NQ27Q28, -NQ29-C (O) -O-Q30, -NQ31-C (O) -NH-Q32, -NQ33-C (O) -NQ34Q35, -NQ36 -S (O 2 ) -Q37, -NH-S (O 2 ) -Q38, -OS (O 2 ) -Q39, -NH-C (O) -Q40, -NQ41-C (O) -Q42, - C (O) -Q43, -OC (O) -Q44, -S (O) -Q45, -S (O 2) -NHQ46, -S (O 2) - NQ47Q48, -S (O 2) -OQ49 " with the further proviso that "--N (alkyl) 2 " is further substituted by at least one substituent selected from the lower substituent group (ii); where Q1, Q2, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q10, Q11, Q12, Q13, Q14, Q15, Q16, Q17, Q18, Q19, Q20, Q21, Q22, Q23, Q24, Q25 .
Q26, Q27, Q28, Q29, Q30, Q31 , Q32, Q33, Q34, Q35, Q36, Q37, Q38, Q39, Q40, Q41 , Q42, Q43, Q44, Q45, Q46, Q47, Q48, Q49 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q10, Q11 und/oder Q23, Q24 und/oder Q27, Q28 und/oder Q34, Q35 und/oder Q47, Q48 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (a) und/oder der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Q26, Q27, Q28, Q29, Q30, Q31, Q32, Q33, Q34, Q35, Q36, Q37, Q38, Q39, Q40, Q41, Q42, Q43, Q44, Q45, Q46, Q47, Q48, Q49 are independently selected are selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively Q10, Q11 and / or Q23, Q24, and or Q27, Q28 and / or Q34, Q35 and / or Q47, Q48 may together also form "heterocyclyl"; in which optionally above substituents of the substituent group (a) and / or the substituent group (i) may in turn be independently substituted with at least one substituent, same or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ50, -NQ51 Q52, -NO2, -OH, -OCF3, -(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ50, -NQ51 Q52, -NO 2 , -OH, -OCF 3 , -
SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q53, -C(O)O-Q54, -C(O)NH-Q55, - C(O)NQ56Q57, -O-Q58, -O(-Q59-O) -H (r = 1 , 2, 3, 4, 5), -0(- Q60-O) -Q61 (r = 1 , 2, 3, 4, 5), -OC(O)-Q62, -OC(O)-O-Q63, - OC(O)-NHQ64, -O-C(O)-NQ65Q66, -OP(O)(OQ67)(OQ68), -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q53, -C (O) O-Q54, -C (O) NH-Q55, -C (O) NQ56Q57, -O-Q58, -O (-Q59-O) -H (r = 1 , 2, 3, 4, 5), -0 (-Q60-O) -Q61 (r = 1, 2, 3, 4, 5), -OC (O) -Q62, -OC (O) -O- Q63, - OC (O) -NHQ64, -OC (O) -NQ65Q66, -OP (O) (OQ67) (OQ68),
OSi(Q69)(Q70)(Q71 ), -OS(O2)-Q72, -NHC(O)-Q73, - NQ74C(O)-Q75, -NH-C(O)-O-Q76, -N H-C(O)-N H-Q77, -NH- C(O)-NQ78Q79, -NQ80-C(O)-O-Q81 , -NQ82-C(O)-NH-Q83, - NQ84-C(O)-NQ85Q86, -NHS(O2)-Q87, -NQ88S(O2)-Q89, -S- Q90, -S(0)-Q91 , -S(O2)-Q92, -S(O2)NH-Q93, -S(O2)NQ94Q95, -S(O2)O-Q96, -P(O)(OQ97)(OQ98), -Si(Q99)(Q100)(Q101 )"; wobei Q50, Q51 , Q52, Q53, Q54, Q55, Q56, Q57, Q58, Q59, Q60, Q61 , Q62, Q63, Q64, Q65, Q66, Q67, Q68, Q69, Q70, Q71 , Q72,OSi (Q69) (Q70) (Q71), -OS (O 2) -Q72, -NHC (O) -Q73, - NQ74C (O) -Q75, -NH-C (O) -O-Q76, -N HC (O) -NH-Q77, -NH-C (O) -NQ78Q79, -NQ80-C (O) -O-Q81, -NQ82-C (O) -NH-Q83, -NQ84-C (O ) -NQ85Q86, -NHS (O 2 ) -Q87, -NQ88S (O 2 ) -Q89, -S- Q90, -S (0) -Q91, -S (O 2) -Q92, -S (O 2) NH-Q93, -S (O 2) NQ94Q95, -S (O 2) O-Q96, -P ( O) (OQ97) (OQ98), -Si (Q99) (Q100) (Q101) "; where Q50, Q51, Q52, Q53, Q54, Q55, Q56, Q57, Q58, Q59, Q60, Q61, Q62, Q63 , Q64, Q65, Q66, Q67, Q68, Q69, Q70, Q71, Q72,
5 Q73, Q74, Q75, Q76, Q77, Q78, Q79, Q80, Q81 , Q82, Q83, Q84,5 Q73, Q74, Q75, Q76, Q77, Q78, Q79, Q80, Q81, Q82, Q83, Q84,
Q85, Q86, Q87, Q88, Q89, Q90, Q91 , Q92, Q93, Q94, Q95, Q96, Q97, Q98, Q99, Q100, Q101 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloal- kyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, 10 heteroaryl, heteroarylalkyl" und wobei alternativ Q56, Q57 und/oder Q65, Q66 und/oder Q78, Q79 und/oder Q85, Q86 und/oder Q94, Q95 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) 15 wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Q85, Q86, Q87, Q88, Q89, Q90, Q91, Q92, Q93, Q94, Q95, Q96, Q97, Q98, Q99, Q100, Q101 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, and alternatively Q56, Q57 and / or Q65, Q66 and / or Q78, Q79 and / or Q85, Q86 and / or or Q94, Q95 may together also form "heterocyclyl"; in which optional substituents of substituent group (ii) 15 can in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
20 Br, I, CN, CF3, N3, NH2, -NHQ102, -NQ103Q104, -NO2, -OH,20 Br, I, CN, CF 3, N 3, NH 2, -NHQ102, -NQ103Q104, -NO 2, -OH,
-OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-QI 05, -C(O)O-QI 06, - C(O)NH-QI 07, -C(O)NQI 08Q109, -0-Q110, -0(-Q1 11 - O)5-H (s = 1 , 2, 3, 4, 5), -O(-Q1 12-O)s-Q1 13 (s = 1 , 2, 3, 4,-OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH ) 2 , -C (O) -QI 05, -C (O) O -QI 06, -C (O) NH-QI 07, -C (O) NQI 08Q109, -O-Q110, -0 (-Q1 11-O) 5 -H (s = 1, 2, 3, 4, 5), -O (-Q1 12-O) s -Q1 13 (s = 1, 2, 3, 4,
25 5), -OC(O)-Q114, -OC(O)-O-Q1 15, -OC(O)-NHQ116, -O-25 5), -OC (O) -Q114, -OC (O) -O-Q1 15, -OC (O) -NHQ116, -O-
C(O)-NQ1 17Q118, -OP(O)(OQ119)(OQ120), - OSi(Q121 )(Q122)(Q123), -OS(O2)-Q124, -NHC(O)-Q125, - NQ126C(O)-Q127, -NH-C(O)-O-Q128, -NH-C(O)-NH- Q129, -NH-C(O)-NQI 30Q131 , -NQ132-C(O)-O-QI 33, -C (O) -NQ1 17Q118, -OP (O) (OQ119) (OQ120), - OSi (Q121) (Q122) (Q123), -OS (O 2) -Q124, -NHC (O) -Q125, - NQ126C (O) -Q127, -NH-C (O) -O-Q128, -NH-C (O) -NH-Q129, -NH-C (O) -NQI 30Q131, -NQ132-C (O) - O-QI 33, -
30 NQ134-C(O)-NH-QI 35, -NQ136-C(O)-NQI 37Q138, -30 NQ134-C (O) -NH-QI 35, -NQ136-C (O) -NQI 37Q138, -
NHS(O2)-Q139, -NQ140S(O2)-Q141 , -S-Q142, -S(O)-Q143, -S(O2)-Q144, -S(O2)NH-QI 45, -S(O2)NQI 46Q147, - S(O2)O-QI 48, -P(O)(OQI 49)(OQ150), - Si(Q151 )(Q152)(Q153)"; wobei Q102, Q103, Q104, Q105, Q106, Q107, Q108, Q109, Q110, Q1 11 , Q112, Q1 13, Q1 14, Q115, Q1 16, Q117, Q1 18, Q119, Q120, Q121 , Q122, Q123, Q124, Q125, Q126, Q127, Q128, Q129, Q130, Q131 , Q132, Q133, Q134, Q135, Q136, Q137, Q138, Q139, Q140, Q141 , Q142, Q143, Q144, Q145,NHS (O 2) -Q139, -NQ140S (o 2) -Q141, -S-Q142, S (O) -Q143, -S (O2) -Q144, -S (O2) NH-QI 45, -S (O2) NQI 46Q147, - S (O 2) OQI 48, -P (O) (OQI 49) (OQ150), - Si (Q151) (Q152) (Q153) "; wherein Q102, Q103, Q104, Q105, Q106, Q107, Q108, Q109, Q110, Q1 11, Q112, Q1 13, Q1 14, Q115, Q1 16, Q117, Q1 18, Q119, Q120, Q121, Q122, Q123, Q124, Q125, Q126, Q127, Q128, Q129, Q130, Q131, Q132, Q133, Q134, Q135, Q136, Q137, Q138, Q139, Q140, Q141, Q142, Q143, Q144, Q145,
Q146, Q147, Q148, Q149, Q150, Q151 , Q152, Q153 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, hete- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" und wobei alternativ Q108, Q109 und/oder Q117, Q1 18 und/oder Q130, Q131 und/oder Q137, Q138 und/oder Q146, Q147 jeweils zusammen auch „heterocyclyl" bilden können;Are Q146, Q147, Q148, Q149, Q150, Q151, Q152, Q153 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively Q108, Q109 and / or Q117, Q1 18 and / or Q130, Q131 and / or Q137, Q138 and / or Q146, Q147 can each also together form" heterocyclyl ";
(b) „(C9-C3o)alkyl, -C(O)-QI 54, -C(O)O-QI 55, -C(O)-NQI 56Q157, -S(O2)- Q158, -S(O2)O-QI 59"; wobei Q154, Q155, Q156, Q157, Q158, Q159 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „Wasserstoff, alkyl, (Cg- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q156, Q157 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (b) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (i) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ160, -NQ161Q162, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-QI 63, -C(O)O-QI 64, -C(O)NH-QI 65, -C(O)NQI 66Q167, - 0-Q168, -0(-Q169-O)1-H (t = 1 , 2, 3, 4, 5), -0(-Q170-O)t-Q171 (t(b) "(C9-3 o) alkyl, -C (O) -qi 54, -C (O) O-QI 55, -C (O) -NQI 56Q157, -S (O 2) - Q158 , -S (O 2) O-QI 59 "; said Q154, Q155, Q156, Q157, Q158, Q159 are independently selected from the group consisting of" hydrogen, alkyl, (Cg-C 30) alkyl cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively Q156, Q157 may together also form" heterocyclyl "wherein optionally substituted substituents of substituent group (b) may in turn be independently substituted with at least one substituent, same or different, selected from the group consisting of: (i) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ160, -NQ161Q162, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH , -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -QI 63, -C (O) O-QI 64, -C ( O) NH-QI 65, -C (O) NQI 66Q167, -O-Q168, -O (-Q169-O) 1 -H (t = 1, 2, 3, 4, 5), -O (-Q170 -O) t -Q171 (t
= 1 , 2, 3, 4, 5), -OC(O)-QI 72, -OC(O)-O-QI 73, -OC(O)-NHQI 74, - 0-C(O)-NQI 75Q176, -OP(O)(OQI 77)(OQ178), - OSi(QI 79)(Q180)(Q181 ), -OS(O2)-Q182, -NHC(O)-QI 83, - NQ184C(O)-QI 85, -NH-C(O)-O-QI 86, -NH-C(O)-NH-QI 87, - NH-C(O)-NQI88Q189, -NQ190-C(O)-O-QI91, -NQ192-C(O)-NH- Q193, -NQ194-C(O)-NQI95Q196, -NHS(O2)-Q197, -NQ198S(O2)- Q199, -S-Q200, -S(O)-Q201, -S(O2)-Q202, -S(O2)NH-Q203, - S(O2)NQ204Q205, -S(O2)O-Q206, -P(O)(OQ207)(OQ208), - Si(Q209)(Q210)(Q211)"; wobei Q160, Q161, Q162, Q163, Q164, Q165, Q166, Q167, Q168, Q169, Q170, Q171, Q172, Q173, Q174, Q175, Q176, Q177, Q178, Q179, Q180, Q181, Q182, Q183, Q184, Q185, Q186, Q187, Q188, Q189, Q190, Q191, Q192, Q193, Q194, Q195, Q196, Q197, Q198, Q199, Q200, Q201, Q202, Q203, Q204, Q205, Q206, Q207, Q208,= 1, 2, 3, 4, 5), -OC (O) -QI 72, -OC (O) -O-QI 73, -OC (O) -NHQI 74, -O-C (O) -NQI 75Q176, -OP (O) (OQI 77) (OQ178), - OSi (QI 79) (Q180) (Q181), -OS (O 2) -Q182, -NHC (O) -qi 83 - NQ184C (O ) -QI 85, -NH-C (O) -O-QI 86, -NH-C (O) -NH-QI 87, - NH-C (O) -NQI88Q189, -NQ190-C (O) -O-QI91, -NQ192-C (O) -NH-Q193, -NQ194-C (O) -NQI95Q196, -NHS (O 2 ) - Q197, -NQ198S (O 2) - Q199, Q200 -S-, -S (O) -Q201, -S (O 2) -Q202, -S (O 2) NH-Q203, - S (O 2) NQ204Q205 , -S (O 2) O-Q206, -P (O) (OQ207) (OQ208), - Si (Q209) (Q210) (Q211) "; wherein Q160, Q161, Q162, Q163, Q164, Q165, Q166 , Q167, Q168, Q169, Q170, Q171, Q172, Q173, Q174, Q175, Q176, Q177, Q178, Q179, Q180, Q181, Q182, Q183, Q184, Q185, Q186, Q187, Q188, Q189, Q190, Q191 , Q192, Q193, Q194, Q195, Q196, Q197, Q198, Q199, Q200, Q201, Q202, Q203, Q204, Q205, Q206, Q207, Q208,
Q209, Q210, Q21 1 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ Q166, Q167 und/oder Q175, Q176 und/oder Q188, Q189 und/oder Q195, Q196 und/oder Q204, Q205 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Q209, Q210, Q21 1 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively Q166 , Q167 and / or Q175, Q176 and / or Q188, Q189 and / or Q195, Q196 and / or Q204, Q205 may each together also form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ212, -NQ213Q214, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, - SO3H, -P(O)(OH)2, -C(O)-Q215, -C(O)O-Q216, -C(O)NH-Q217,(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ212, -NQ213Q214, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q 2 15, -C (O) O-Q 2 16, -C (O) NH-Q 2 17,
-C(O)NQ218Q219, -O-Q220, -O(-Q221-O)u-H (u = 1 , 2, 3, 4, 5), -O(-Q222-O)u-Q223 (u = 1 , 2, 3, 4, 5), -OC(O)-Q224, - OC(O)-O-Q225, -OC(O)-NHQ226, -O-C(O)-NQ227Q228, - OP(O)(OQ229)(OQ230), -OSi(Q231 )(Q232)(Q233), -OS(O2)- Q234, -NHC(O)-Q235, -NQ236C(O)-Q237, -NH-C(O)-O-Q238,-C (O) NQ218Q219, -O-Q220, -O (-Q221-O) u -H (u = 1, 2, 3, 4, 5), -O (-Q222-O) u -Q223 (u = 1, 2, 3, 4, 5), -OC (O) -Q224, - OC (O) -O-Q225, -OC (O) -NHQ226, -OC (O) -NQ227Q228, - OP (O ) (OQ229) (OQ230), -OSi (Q231) (Q232) (Q233), -OS (O 2) - Q234, -NHC (O) -Q235, -NQ236C (O) -Q237, -NH-C ( O) -O-Q238,
-NH-C(O)-NH-Q239, -NH-C(O)-NQ240Q241 , -NQ242-C(O)- O-Q243, -NQ244-C(O)-NH-Q245, -NQ246-C(O)-NQ247Q248, -NHS(O2)-Q249, -NQ250S(O2)-Q251 , -S-Q252, -S(O)-Q253, - S(O2)-Q254, -S(O2)N H-Q255, -S(O2)NQ256Q257, -S(O2)O- Q258, -P(O)(OQ259)(OQ260), -Si(Q261 )(Q262)(Q263)"; wobei Q212, Q213, Q214, Q215, Q216, Q217, Q218, Q219, Q220, Q221 , Q222, Q223, Q224, Q225, Q226, Q227, Q228, Q229,-NH-C (O) -NH-Q239, -NH-C (O) -NQ240Q241, -NQ242-C (O) -O-Q243, -NQ244-C (O) -NH-Q245, -NQ246-C (O) -NQ247Q248, -NHS (O 2) -Q249, -NQ250S (O 2) -Q251, -S-Q252, -S (O) -Q253, - S (O 2) -Q254, -S (O 2) N H-Q255, -S (O 2) NQ256Q257, -S (O 2) O- Q258, -P (O) (OQ259) (OQ260) - Si (Q261) (Q262) (Q263) "; where Q212, Q213, Q214, Q215, Q216, Q217, Q218, Q219, Q220, Q221, Q222, Q223, Q224, Q225, Q226, Q227, Q228, Q229,
5 Q230, Q231 , Q232, Q233, Q234, Q235, Q236, Q237, Q238,5 Q230, Q231, Q232, Q233, Q234, Q235, Q236, Q237, Q238,
Q239, Q240, Q241 , Q242, Q243, Q244, Q245, Q246, Q247, Q248, Q249, Q250, Q251 , Q252, Q253, Q254, Q255, Q256, Q257, Q258, Q259, Q260, Q261 , Q262, Q263 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl,Q239, Q240, Q241, Q242, Q243, Q244, Q245, Q246, Q247, Q248, Q249, Q250, Q251, Q252, Q253, Q254, Q255, Q256, Q257, Q258, Q259, Q260, Q261, Q262, Q263 independent are selected from the group consisting of: "alkyl,
10 (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q218, Q219 und/oder Q227, Q228 und/oder Q240, Q241 und/oder Q247, Q248 und/oder Q256, Q257 jeweils zusammen auch „heterocyclyl" bilden können;10 (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively Q218, Q219 and / or Q227, Q228 and / or Q240, Q241 and / or Q247 , Q248 and / or Q256, Q257 may together also form "heterocyclyl";
15 wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:In which optionally substituents of the substituent group (ii) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he-(iii) "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE
20 terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,20 terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
Br, I, CN, CF3, N3, NH2, -NHQ264, -NQ265Q266, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q267, -C(O)O-Q268, - C(O)NH-Q269, -C(O)NQ270Q271 , -O-Q272, -O(-Q273-Br, I, CN, CF 3, N 3, NH 2, -NHQ264, -NQ265Q266, -NO 2, -OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q267, -C (O) O-Q268, -C (O) NH-Q269, -C (O) NQ270Q271, -O-Q272, -O (-Q273-
25 O)v-H (v = 1 , 2, 3, 4, 5), -O(-Q274-O)v-Q275 (v = 1 , 2, 3, 4,25 O) v -H (v = 1, 2, 3, 4, 5), -O (-Q274-O) v -Q275 (v = 1, 2, 3, 4,
5), -OC(O)-Q276, -OC(O)-O-Q277, -OC(O)-NHQ278, -O- C(O)-NQ279Q280, -OP(O)(OQ281 )(OQ282), - OSi(Q283)(Q284)(Q285), -OS(O2)-Q286, -NHC(O)-Q287, - NQ288C(O)-Q289, -NH-C(O)-O-Q290, -NH-C(O)-NH-5), -OC (O) -Q276, -OC (O) -O-Q277, -OC (O) -NHQ278, -O-C (O) -NQ279Q280, -OP (O) (OQ281) (OQ282) , - OSi (Q283) (Q284) (Q285), -OS (O 2) -Q286, -NHC (O) -Q287, - NQ288C (O) -Q289, -NH-C (O) -O-Q290, -NH-C (O) -NH-
30 Q291 , -NH-C(O)-NQ292Q293, -NQ294-C(O)-O-Q295, -30 Q291, -NH-C (O) -NQ292Q293, -NQ294-C (O) -O-Q295, -
NQ296-C(O)-NH-Q297, -NQ298-C(O)-NQ299Q300, - NHS(O2)-Q301 , -NQ302S(O2)-Q303, -S-Q304, -S(O)-Q305, -S(O2)-Q306, -S(O2)NH-Q307, -S(O2)NQ308Q309, - S(O2)O-Q310, -P(O)(OQ311 )(OQ312), - Si(Q313)(Q314)(Q315)"; wobei Q264, Q265, Q266, Q267, Q268, Q269, Q270, Q271 , Q272, Q273, Q274, Q275, Q276, Q277, Q278, Q279, Q280, Q281 , Q282, Q283, Q284, Q285, Q286, Q287, Q288, Q289,NQ296-C (O) -NH-Q297, -NQ298-C (O) -NQ299Q300, - NHS (O 2) -Q301, -NQ302S (O 2) -Q303, -S-Q304, -S (O) - Q305, -S (O 2) -Q306, -S (O 2) NH-Q307, -S (O 2) NQ308Q309, - S (O 2 ) O-Q310, -P (O) (OQ311) (OQ312), -Si (Q313) (Q314) (Q315) "; wherein Q264, Q265, Q266, Q267, Q268, Q269, Q270, Q271 , Q272, Q273, Q274, Q275, Q276, Q277, Q278, Q279, Q280, Q281, Q282, Q283, Q284, Q285, Q286, Q287, Q288, Q289,
Q290, Q291 , Q292, Q293, Q294, Q295, Q296, Q297, Q298, Q299, Q300, Q301 , Q302, Q303, Q304, Q305, Q306, Q307, Q308, Q309, Q310, Q31 1 , Q312, Q313, Q314, Q315 unabhängig voneinander ausgewählt sind aus der Gruppe beste- hend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, hete- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" und wobei alternativ Q270, Q271 und/oder Q279, Q280 und/oder Q292, Q293 und/oder Q299, Q300 und/oder Q308, Q309 jeweils zusammen auch „heterocyclyl" bilden können;Q290, Q291, Q292, Q293, Q294, Q295, Q296, Q297, Q298, Q299, Q300, Q301, Q302, Q303, Q304, Q305, Q306, Q307, Q308, Q309, Q310, Q31 1, Q312, Q313, Q314 are Q315 independently selected from the group consist- ing of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" and wherein alternatively Q270 , Q271 and / or Q279, Q280 and / or Q292, Q293 and / or Q299, Q300 and / or Q308, Q309 may together also form "heterocyclyl";
und einer der Reste Z10, Z11 oder keiner der Reste Z10, Z11 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:and one of Z10, Z11 or none of Z10, Z11 is independently selected from the group consisting of:
(c) „Wasserstoff, alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -C(O)-Q316, - C(O)O-Q317, -C(O)-NQ318Q319, -S(O2)-Q320, -S(O2)O-Q321"; wobei Q316, Q317, Q318, Q319, Q320, Q321 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „Wasserstoff, alkyl, (C9- C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q318, Q319 zu- sammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (c), wenn nicht Wasserstoff, wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ322, -NQ323Q324, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q325, -C(O)O-Q326, -C(O)NH-Q327, -C(O)NQ328Q329, - O-Q330, -O(-Q331-O)w-H (w = 1 , 2, 3, 4, 5), -O(-Q332-O)w-Q333 (w = 1 , 2, 3, 4, 5), -OC(O)-Q334, -OC(O)-O-Q335, -OC(O)- NHQ336, -O-C(O)-NQ337Q338, -OP(O)(OQ339)(OQ340), - OSi(Q341 )(Q342)(Q343), -OS(O2)-Q344, -NHC(O)-Q345, -(c) "hydrogen, alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -C (O) -Q316, - C (O) O-Q317 , -C (O) -NQ318Q319, -S (O 2) -Q320, -S (O 2) O-Q321 "; wherein Q316, Q317, Q318, Q319, Q320 are, Q321 independently selected from the group consisting of "is hydrogen, alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively Q318, Q319 to-gether can also form "heterocyclyl"; wherein optionally above substituents of substituent group (c), if not hydrogen, again independently of each other may be substituted with at least one substituent, identical or different, selected from the group consisting of: (i) "alkyl, (Cg-C 3 o) alkyl, cycloalkyl , cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ322, -NQ323Q324, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q325, -C (O) O -Q326, -C (O) NH-Q327, -C (O) NQ328Q329, -O-Q330, -O (-Q331-O) w -H ( w = 1, 2, 3, 4, 5), -O (-Q332-O) w -Q333 (w = 1, 2, 3, 4, 5), -OC (O) -Q334, -OC (O ) -O-Q335, -OC (O) -NHQ336, -OC (O) -NQ337Q338, -OP (O) (OQ339) (OQ340), -OSi (Q341) (Q342) (Q343), -OS (O 2 ) -Q344, -NHC (O) -Q345, -
NQ346C(O)-Q347, -NH-C(O)-O-Q348, -N H-C(O)-N H-Q349, - NH-C(O)-NQ350Q351 , -NQ352-C(O)-O-Q353, -NQ354-C(O)-NH- Q355, -NQ356-C(O)-NQ357Q358, -NHS(O2)-Q359, -NQ360S(O2)- Q361 , -S-Q362, -S(O)-Q363, -S(O2)-Q364, -S(O2)NH-Q365, - S(O2)NQ366Q367, -S(O2)O-Q368, -P(O)(OQ369)(OQ370), -NQ346C (O) -Q347, -NH-C (O) -O-Q348, -NHC (O) -NH-Q349, -NH-C (O) -NQ350Q351, -NQ352-C (O) -O -Q353, -NQ354-C (O) -NH- Q355, -NQ356-C (O) -NQ357Q358, -NHS (O 2) -Q359, -NQ360S (O 2) - Q361, Q362 -S-, -S (O) -Q363, -S (O 2) -Q364, -S (O 2) NH-Q365, - S (O 2) NQ366Q367, -S (O 2) O-Q368, -P (O) (OQ369 ) (OQ370), -
Si(Q371 )(Q372)(Q373)"; wobei Q322, Q323, Q324, Q325, Q326, Q327, Q328, Q329, Q330, Q331 , Q332, Q333, Q334, Q335, Q336, Q337, Q338, Q339, Q340, Q341 , Q342, Q343, Q344, Q345, Q346, Q347, Q348, Q349, Q350, Q351 , Q352, Q353, Q354, Q355, Q356, Q357, Q358, Q359, Q360,Si (Q371) (Q372) (Q373) "; where Q322, Q323, Q324, Q325, Q326, Q327, Q328, Q329, Q330, Q331, Q332, Q333, Q334, Q335, Q336, Q337, Q338, Q339, Q340 , Q341, Q342, Q343, Q344, Q345, Q346, Q347, Q348, Q349, Q350, Q351, Q352, Q353, Q354, Q355, Q356, Q357, Q358, Q359, Q360,
Q361 , Q362, Q363, Q364, Q365, Q366, Q367, Q368, Q369, Q370, Q371 , Q372, Q373 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ Q328, Q329 und/oder Q337, Q338 und/oderAre Q361, Q362, Q363, Q364, Q365, Q366, Q367, Q368, Q369, Q370, Q371, Q372, Q373 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, and alternatively Q328, Q329 and / or Q337, Q338 and / or
Q350, Q351 und/oder Q357, Q358 und/oder Q366, Q367 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindes- tens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Q350, Q351 and / or Q357, Q358 and / or Q366, Q367 may together also form "heterocyclyl", where optionally substituents of the substituent group (i) above may be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ374, -NQ375Q376, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -(ii) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, - NHQ374, -NQ375Q376, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -
SO3H, -P(O)(OH)2, -C(O)-Q377, -C(O)O-Q378, -C(O)NH-Q379, -C(O)NQ380Q381 , -O-Q382, -0(-0383-O)x-H (x = 1 , 2, 3, 4, 5), -O(-Q384-O)x-Q385 (x = 1 , 2, 3, 4, 5), -OC(O)-Q386, -OC(O)- O-Q387, -OC(O)-N HQ388, -O-C(O)-NQ389Q390, - OP(O)(OQ391 )(OQ392), -OSi(Q393)(Q394)(Q395), -OS(O2)- Q396, -NHC(O)-Q397, -NQ398C(O)-Q399, -NH-C(O)-O-Q400, -N H-C(O)-N H-Q401 , -NH-C(O)-NQ402Q403, -NQ404-C(O)- O-Q405, -NQ406-C(O)-NH-Q407, -NQ408-C(O)-NQ409Q410,SO 3 H, -P (O) (OH) 2, -C (O) -Q377, -C (O) O-Q378, -C (O) NH-Q379, -C (O) NQ380Q381, -O- Q382, -0 (-0383-O) x -H (x = 1, 2, 3, 4, 5), -O (-Q384-O) x -Q385 (x = 1, 2, 3, 4, 5 ), -OC (O) -Q386, -OC (O) -O-Q387, -OC (O) -N HQ388, -OC (O) -NQ389Q390, - OP (O) (OQ391) (OQ392), -OSi (Q393) (Q394) (Q395), -OS (O 2) - Q396, -NHC (O) -Q397, -NQ398C (O) -Q399, -NH -C (O) -O-Q400, -NHC (O) -NH-Q401, -NH-C (O) -NQ402Q403, -NQ404-C (O) -O-Q405, -NQ406-C (O -NH-Q407, -NQ408-C (O) -NQ409Q410,
5 -NHS(O2)-Q41 1 , -NQ412S(O2)-Q413, -S-Q414, -S(O)-Q415, -5 -NHS (O 2) -Q41 1, -NQ412S (O 2) -Q413, -S-Q414, -S (O) -Q415, -
S(O2)-Q416, -S(O2)NH-Q417, -S(O2)NQ418Q419, -S(O2)O- Q420, -P(O)(OQ421 )(OQ422), -Si(Q423)(Q424)(Q425)"; wobei Q374, Q375, Q376, Q377, Q378, Q379, Q380, Q381 , Q382, Q383, Q384, Q385, Q386, Q387, Q388, Q389, Q390, Q391 ,S (O 2) -Q416, -S (O 2) NH-Q417, -S (O 2) NQ418Q419, -S (O 2) O- Q420, -P (O) (OQ421) (OQ422), -Si (Q423) (Q424) (Q425) "; wherein Q374, Q375, Q376, Q377, Q378, Q379, Q380, Q381, Q382, Q383, Q384, Q385, Q386, Q387, Q388, Q389, Q390, Q391,
10 Q392, Q393, Q394, Q395, Q396, Q397, Q398, Q399, Q400,10 Q392, Q393, Q394, Q395, Q396, Q397, Q398, Q399, Q400,
Q401 , Q402, Q403, Q404, Q405, Q406, Q407, Q408, Q409, Q410, Q411 , Q412, Q413, Q414, Q415, Q416, Q417, Q418, Q419, Q420, Q421 , Q422, Q423, Q424, Q425 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl,Q401, Q402, Q403, Q404, Q405, Q406, Q407, Q408, Q409, Q410, Q411, Q412, Q413, Q414, Q415, Q416, Q417, Q418, Q419, Q420, Q421, Q422, Q423, Q424, Q425 independent are selected from the group consisting of: "alkyl,
15 (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q380, Q381 und/oder Q389, Q390 und/oder Q402, Q403 und/oder Q409, Q410 und/oder Q418, Q419 jeweils zusammen auch „heterocyclyl" bilden können;15 (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively Q380, Q381 and / or Q389, Q390 and / or Q402, Q403 and / or Q409 Q410 and / or Q418, Q419 may together also form "heterocyclyl";
20 wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:In which optionally substituents of the substituent group (ii) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he-(iii) "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he-
25 terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,25 terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
Br, I, CN, CF3, N3, NH2, -NHQ426, -NQ427Q428, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q429, -C(O)O-Q430, - C(O)NH-Q431 , -C(O)NQ432Q433, -O-Q434, -O(-Q435-Br, I, CN, CF 3, N 3, NH 2, -NHQ426, -NQ427Q428, -NO 2, -OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2, -CHO, -COOH, - C (O) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) -Q429, -C (O) O-Q430, - C (O) NH-Q431, -C (O) NQ432Q433, -O-Q434, -O (-Q435-
30 O)y-H (y = 1 , 2, 3, 4, 5), -O(-Q436-O)y-Q437 (y = 1 , 2, 3, 4,30 O) y -H (y = 1, 2, 3, 4, 5), -O (-Q436-O) y -Q437 (y = 1, 2, 3, 4,
5), -OC(O)-Q438, -OC(O)-O-Q439, -OC(O)-N HQ440, -O- C(O)-NQ441Q442, -OP(O)(OQ443)(OQ444), - OSi(Q445)(Q446)(Q447), -OS(O2)-Q448, -NHC(O)-Q449, - NQ450C(O)-Q451 , -NH-C(O)-O-Q452, -NH-C(O)-NH- Q453, -NH-C(O)-NQ454Q455, -NQ456a-C(O)-O-Q456b, - NQ456c-C(O)-NH-Q456d, -NQ456e-C(O)-NQ456fQ456g, - NHS(O2)-Q456h, -NQ456iS(O2)-Q456j, -S-Q456k, -S(O)- Q456I, -S(O2)-Q456m, -S(O2)NH-Q456n, - S(O2)NQ456oQ456p, -S(O2)O-Q456q, -5), -OC (O) -Q438, -OC (O) -O-Q439, -OC (O) -N HQ440, -O-C (O) -NQ441Q442, -OP (O) (OQ443) (OQ444 ), - OSi (Q445) (Q446) (Q447), -OS (O 2) -Q448, -NHC (O) -Q449, - NQ450C (O) -Q451, -NH-C (O) -O-Q452 , -NH-C (O) -NH- Q453, -NH-C (O) -NQ454Q455, -NQ456a-C (O) -O-Q456b, -NQ456c-C (O) -NH-Q456d, -NQ456e-C (O) -NQ456fQ456g, -NHS (O 2) -Q456h, -NQ456iS (O 2) -Q456j, -S-Q456k, -S (O) - Q456I, -S (O 2) -Q456m, -S (O 2) NH-Q456n, - S (O 2) NQ456oQ456p, -S (O 2) O-Q456q, -
P(O)(OQ456r)(OQ456s), -Si(Q456t)(Q456u)(Q456v)"; wobei Q426, Q427, Q428, Q429, Q430, Q431 , Q432, Q433, Q434, Q435, Q436, Q437, Q438, Q439, Q440, Q441 , Q442, Q443, Q444, Q445, Q446, Q447, Q448, Q449, Q450, Q451 , Q452, Q453, Q454, Q455, Q456a, Q456b, Q456c, Q456d,P (O) (OQ456r) (OQ456s), -Si (Q456t) (Q456u) (Q456v) "; where Q426, Q427, Q428, Q429, Q430, Q431, Q432, Q433, Q434, Q435, Q436, Q437, Q438 , Q439, Q440, Q441, Q442, Q443, Q444, Q445, Q446, Q447, Q448, Q449, Q450, Q451, Q452, Q453, Q454, Q455, Q456a, Q456b, Q456c, Q456d,
Q456e, Q456f, Q456g, Q456h, Q456i, Q456J, Q456k, Q456I, Q456m, Q456n, Q456o, Q456p, Q456q, Q456r, Q456s, Q456t, Q456u, Q456v unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q432, Q433 und/oder Q441 , Q442 und/oder Q454, Q455 und/oder Q456f, Q456g und/oder Q456o, Q456p jeweils zusammen auch „heterocyclyl" bilden können;Q456e, Q456f, Q456g, Q456h, Q456i, Q456J, Q456k, Q456I, Q456m, Q456n, Q456o, Q456p, Q456q, Q456r, Q456s, Q456t, Q456u, Q456v are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively Q432, Q433 and / or Q441, Q442 and / or Q454, Q455 and / or Q456f, Q456g and / or Q456o, Q456p may together also form "heterocyclyl";
und einer der Reste Z3, Z4 oder keiner der Reste Z3, Z4 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus:and one of Z3, Z4 or none of Z3, Z4 is independently selected from the group consisting of:
(d) Wasserstoff;(d) hydrogen;
(e) Halogen, F, Cl, Br, I; (f) unsubstituiertes oder substituiertes Alkyl oder (C9-C30)AI ky I, wobei optional der Alkyl- oder (Cg-C30 )Alkylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(e) halogen, F, Cl, Br, I; (f) unsubstituted or substituted alkyl or (C 9 -C 30 ) Al ky I, wherein optionally the alkyl or (Cg-C 30 ) alkyl may be substituted with at least one substituent, same or different, selected from the group consisting of :
(i) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3,(i) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3,
N3, NH2, -NHQ457, -NQ458Q459, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q460, -C(O)O-Q461 , -C(O)NH-Q462, -C(O)NQ463Q464, - O-Q465, -O(-Q466-O)z-H (z = 1 , 2, 3, 4, 5), -O(-Q467-O)z-Q468 (z = 1 , 2, 3, 4, 5), -OC(O)-Q469, -OC(O)-O-Q470, -OC(O)-N HQ471 , - O-C(O)-NQ472Q473, -OP(O)(OQ474)(OQ475), - OSi(Q476)(Q477)(Q478), -OS(O2)-Q479, -NHC(O)-Q480, - NQ481C(O)-Q482, -NH-C(O)-O-Q483, -N H-C(O)-N H-Q484, -N 3, NH 2, -NHQ457, -NQ458Q459, -NO 2, -OH, -OCF3, -SH, -O- SO3H, -OP (O) (OH) 2, -CHO, -COOH, - C (O) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) -Q460, -C (O) O-Q461, -C (O) NH-Q462, -C (O) NQ463Q464, - O-Q465, -O (-Q466-O) z -H (z = 1, 2, 3, 4, 5), -O (-Q467-O) z -Q468 (z = 1, 2, 3, 4 , 5), -OC (O) -Q469, -OC (O) -O-Q470, -OC (O) -N HQ471, -OC (O) -NQ472Q473, -OP (O) (OQ474) (OQ475) , - OSi (Q476) (Q477) (Q478), -OS (O 2) -Q479, -NHC (O) -Q480, - NQ481C (O) -Q482, -NH-C (O) -O-Q483, -N HC (O) -N H-Q484, -
NH-C(O)-NQ485Q486, -NQ487-C(O)-O-Q488, -NQ489-C(O)-NH- Q490, -NQ491-C(O)-NQ492Q493, -NHS(O2)-Q494, -NQ495S(O2)- Q496, -S-Q497, -S(O)-Q498, -S(O2)-Q499, -S(O2)NH-Q500, - S(O2)NQ501Q502, -S(O2)O-Q503, -P(O)(OQ504)(OQ505), - Si(Q506)(Q507)(Q508)"; wobei Q457, Q458, Q459, Q460, Q461 , Q462, Q463, Q464, Q465, Q466, Q467, Q468, Q469, Q470, Q471 , Q472, Q473, Q474, Q475, Q476, Q477, Q478, Q479, Q480, Q481 , Q482, Q483, Q484, Q485, Q486, Q487, Q488, Q489, Q490, Q491 , Q492, Q493, Q494, Q495, Q496, Q497, Q498, Q499, Q500, Q501 , Q502, Q503, Q504, Q505,NH-C (O) -NQ485Q486, -NQ487-C (O) -O-Q488, -NQ489-C (O) -NH-Q490, -NQ491-C (O) -NQ492Q493, -NHS (O 2 ) - Q494, -NQ495S (O 2) - Q496, Q497 -S-, -S (O) -Q498, -S (O 2) -Q499, -S (O 2) NH-Q500, - S (O 2) NQ501Q502 Q463 Q457 wherein, Q458, Q459, Q460, Q461, Q462,; -, -S (O 2) O-Q503, -P (O) (OQ504) (OQ505), Si (Q506) (Q507) (Q508) " , Q464, Q465, Q466, Q467, Q468, Q469, Q470, Q471, Q472, Q473, Q474, Q475, Q476, Q477, Q478, Q479, Q480, Q481, Q482, Q483, Q484, Q485, Q486, Q487, Q488 , Q489, Q490, Q491, Q492, Q493, Q494, Q495, Q496, Q497, Q498, Q499, Q500, Q501, Q502, Q503, Q504, Q505,
Q506, Q507, Q508 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ Q463, Q464 und/oder Q472, Q473 und/oder Q485, Q486 und/oder Q492, Q493 und/oder Q501 , Q502 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Are Q506, Q507, Q508 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- alkyl" and wherein alternatively Q463, Q464 and / or Q472, Q473 and / or Q485, Q486 and / or Q492, Q493 and / or Q501, Q502 may together also form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ509, -NQ510Q511 , -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, - SO3H, -P(O)(OH)2, -C(O)-Q512, -C(O)O-Q513, -C(O)NH-Q514,(ii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHQ509, -NQ510Q511, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2, - SO 3 H, -P (O) (OH) 2, -C (O) -Q512, -C (O) O-Q513, -C (O) NH-Q514,
-C(O)NQ515Q516, -O-Q517, -O (-0518-O)3-H (a = 1 , 2, 3, 4, 5), -O(-Q519-O)a-Q520 (a = 1 , 2, 3, 4, 5), -OC(O)-Q521 , - OC(O)-O-Q522, -OC(O)-NHQ523, -O-C(O)-NQ524Q525, - OP(O)(OQ526)(OQ527), -OSi(Q528)(Q529)(Q530), -OS(O2)- Q531 , -NHC(O)-Q532, -NQ533C(O)-Q534, -NH-C(O)-O-Q535, -NH-C(O)-NH-Q536, -NH-C(O)-NQ537Q538, -NQ539-C(O)- O-Q540, -NQ541 -C(O)-N H-Q542, -NQ543-C(O)-NQ544Q545, -NHS(O2)-Q546, -NQ547S(O2)-Q548, -S-Q549, -S(O)-Q550, - 5 S(O2)-Q551 , -S(O2)N H-Q552, -S(O2)NQ553Q554, -S(O2)O--C (O) NQ515Q516, -O-Q517, -O (-0518-O) 3 -H (a = 1, 2, 3, 4, 5), -O (-Q519-O) a -Q520 (a = 1, 2, 3, 4, 5), -OC (O) -Q521, - OC (O) -O-Q522, -OC (O) -NHQ523, -OC (O) -NQ524Q525, - OP (O ) (OQ526) (OQ527), -OSi (Q528) (Q529) (Q530), -OS (O 2 ) - Q531, -NHC (O) -Q532, -NQ533C (O) -Q534, -NH-C (O) -O-Q535, -NH-C (O) -NH-Q536, -NH-C (O) - NQ537Q538, -NQ539-C (O) - O-Q540, -NQ541 -C (O) -N H-Q542, -NQ543-C (O) -NQ544Q545, -NHS (O 2) -Q546, -NQ547S (O 2) -Q548, -S-Q549, -S (O) -Q550, - 5 S (O 2) -Q551, -S (O 2) N H-Q552, -S (O 2) NQ553Q554, -S ( O 2 ) O-
Q555, -P(O)(OQ556)(OQ557), -Si(Q558)(Q559)(Q560)"; wobei Q509, Q510, Q511 , Q512, Q513, Q514, Q515, Q516, Q517, Q518, Q519, Q520, Q521 , Q522, Q523, Q524, Q525, Q526, Q527, Q528, Q529, Q530, Q531 , Q532, Q533, Q534, Q535,Q555, -P (O) (OQ556) (OQ557), -Si (Q558) (Q559) (Q560) "where Q509, Q510, Q511, Q512, Q513, Q514, Q515, Q516, Q517, Q518, Q519, Q520, Q521, Q522, Q523, Q524, Q525, Q526, Q527, Q528, Q529, Q530, Q531, Q532, Q533, Q534, Q535,
10 Q536, Q537, Q538, Q539, Q540, Q541 , Q542, Q543, Q544,10 Q536, Q537, Q538, Q539, Q540, Q541, Q542, Q543, Q544,
Q545, Q546, Q547, Q548, Q549, Q550, Q551 , Q552, Q553, Q554, Q555, Q556, Q557, Q558, Q559, Q560 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly-Q545, Q546, Q547, Q548, Q549, Q550, Q551, Q552, Q553, Q554, Q555, Q556, Q557, Q558, Q559, Q560 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclic
15 lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q515, Q516 und/oder Q524, Q525 und/oder Q537, Q538 und/oder Q544, Q545 und/oder Q553, Q554 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) 20 wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:15 lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively Q515, Q516 and / or Q524, Q525 and / or Q537, Q538 and / or Q544, Q545 and / or Q553, Q554 may each together also form" heterocyclyl "; in which optional substituents of substituent group (ii) 20 may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,(iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
25 Br, I, CN, CF3, N3, NH2, -NHQ561 , -NQ562Q563, -NO2, -OH,25 Br, I, CN, CF 3, N 3, NH 2, -NHQ561, -NQ562Q563, -NO 2, -OH,
-OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q564, -C(O)O-Q565, - C(O)N H-Q566, -C(O)NQ567Q568, -O-Q569, -O(-Q570- O)b-H (b = 1 , 2, 3, 4, 5), -O(-Q571-O)b-Q572 (b = 1 , 2, 3, 4,-OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH ) 2 , -C (O) -Q564, -C (O) O-Q565, -C (O) NH-Q566, -C (O) NQ567Q568, -O-Q569, -O (-Q570-O) b -H (b = 1, 2, 3, 4, 5), -O (-Q571-O) b -Q572 (b = 1, 2, 3, 4,
30 5), -OC(O)-Q573, -OC(O)-O-Q574, -OC(O)-N HQ575, -O-30 5), -OC (O) -Q573, -OC (O) -O-Q574, -OC (O) -N HQ575, -O-
C(O)-NQ576Q577, -OP(O)(OQ578)(OQ579), - OSi(Q580)(Q581 )(Q582), -OS(O2)-Q583, -NHC(O)-Q584, - NQ585C(O)-Q586, -NH-C(O)-O-Q587, -NH-C(O)-NH- Q588, -NH-C(O)-NQ589Q590, -NQ591-C(O)-O-Q592, - NQ593-C(O)-NH-Q594, -NQ595-C(O)-NQ596Q597, - NHS(O2)-Q598, -NQ599S(O2)-Q600, -S-Q601 , -S(O)-Q602, -S(O2)-Q603, -S(O2)NH-Q604, -S(O2)NQ605Q606, - S(O2)O-Q607, -P(O)(OQ608)(OQ609), - Si(Q610)(Q611 )(Q612)"; wobei Q561 , Q562, Q563, Q564, Q565, Q566, Q567, Q568, Q569, Q570, Q571 , Q572, Q573, Q574, Q575, Q576, Q577, Q578, Q579, Q580, Q581 , Q582, Q583, Q584, Q585, Q586, Q587, Q588, Q589, Q590, Q591 , Q592, Q593, Q594, Q595, Q596, Q597, Q598, Q599, Q600, Q601 , Q602, Q603, Q604,C (O) -NQ576Q577, -OP (O) (OQ578) (OQ579), - OSi (Q580) (Q581) (Q582), -OS (O 2) -Q583, -NHC (O) -Q584, - NQ585C (O) -Q586, -NH-C (O) -O-Q587, -NH-C (O) -NH-Q588, -NH-C (O) -NQ589Q590, -NQ591-C (O) -O- Q592, - NQ593-C (O) -NH-Q594, -NQ595-C (O) -NQ596Q597, - NHS (O 2) -Q598, -NQ599S (O 2) -Q600, -S-Q601, -S (O) - Q602, -S (O 2) -Q603, -S (O 2) NH-Q604, -S (O 2) NQ605Q606, - S (O 2) O-Q607, -P (O) (OQ608) (OQ609) , Si (Q610) (Q611) (Q612) "; wherein Q561, Q562, Q563, Q564, Q565, Q566, Q567, Q568, Q569, Q570, Q571, Q572, Q573, Q574, Q575, Q576, Q577, Q578 , Q579, Q580, Q581, Q582, Q583, Q584, Q585, Q586, Q587, Q588, Q589, Q590, Q591, Q592, Q593, Q594, Q595, Q596, Q597, Q598, Q599, Q600, Q601, Q602, Q603 , Q604,
Q605, Q606, Q607, Q608, Q609, Q610, Q611 , Q612 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, hete- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" und wobei alternativ Q567, Q568 und/oder Q576, Q577 und/oder Q589, Q590 und/oder Q596, Q597 und/oder Q605, Q606 jeweils zusammen auch „heterocyclyl" bilden können;Q605, Q606, Q607, Q608, Q609, Q610, Q611 are, Q612 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- rocyclyl, heterocyclylalkyl, aryl, arylalkyl heteroaryl, heteroarylalkyl "and wherein alternatively Q567, Q568 and / or Q576, Q577 and / or Q589, Q590 and / or Q596, Q597 and / or Q605, Q606 may each together also form" heterocyclyl ";
(g) unsubstituiertes oder substituiertes Aryl, wobei optional der Arylrest sub- stituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(g) unsubstituted or substituted aryl, where optionally the aryl radical can be substituted by at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ613, -NQ614Q615, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2,(i) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ613, -NQ614Q615, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 ,
-C(O)-Q616, -C(O)O-Q617, -C(O)NH-Q618, -C(O)NQ619Q620, - O-Q621 , -O(-Q622-O)c-H (c = 1 , 2, 3, 4, 5), -O(-Q623-O)c-Q624 (c = 1 , 2, 3, 4, 5), -OC(O)-Q625, -OC(O)-O-Q626, -OC(O)-NHQ627, - O-C(O)-NQ628Q629, -OP(O)(OQ630)(OQ631 ), - OSi(Q632)(Q633)(Q634), -OS(O2)-Q635, -NHC(O)-Q636, --C (O) -Q616, -C (O) O-Q617, -C (O) NH-Q618, -C (O) NQ619Q620, -O-Q621, -O (-Q622-O) c -H ( c = 1, 2, 3, 4, 5), -O (-Q623-O) c -Q624 (c = 1, 2, 3, 4, 5), -OC (O) -Q625, -OC (O ) -O-Q626, -OC (O) -NHQ627, - OC (O) -NQ628Q629, -OP (O) (OQ630) (OQ631), - OSi (Q632) (Q633) (Q634), -OS (O 2 ) -Q635, -NHC (O) -Q636, -
NQ637C(O)-Q638, -NH-C(O)-O-Q639, -N H-C(O)-N H-Q640, - NH-C(O)-NQ641 Q642, -NQ643-C(O)-O-Q644, -NQ645-C(O)-NH- Q646, -NQ647-C(O)-NQ648Q649, -NHS(O2)-Q650, -NQ651 S(O2)- Q652, -S-Q653, -S(O)-Q654, -S(O2)-Q655, -S(O2)NH-Q656, - S(O2)NQ657Q658, -S(O2)O-Q659, -P(O)(OQ660)(OQ661 ), - Si(Q662)(Q663)(Q664)"; wobei Q613, Q614, Q615, Q616, Q617, Q618, Q619, Q620, Q621 , Q622, Q623, Q624, Q625, Q626, Q627, Q628, Q629, Q630, Q631 , Q632, Q633, Q634, Q635, Q636, Q637, Q638, Q639, Q640, Q641 ,NQ637C (O) -Q638, -NH-C (O) -O-Q639, -NHC (O) -NH-Q640, -NH-C (O) -NQ641Q642, -NQ643-C (O) - O-Q644, -NQ645-C (O) -NH- Q646, -NQ647-C (O) -NQ648Q649, -NHS (O 2) -Q650, -NQ651 S (O 2) - Q652, -S-Q653, -S (O) -Q654, -S (O 2) -Q655, -S (O 2) NH-Q656, - S (O 2) NQ657Q658, -S (O 2) O-Q659, -P (O) (OQ660) (OQ661), - Si (Q662) (Q663) (Q664) "; wherein Q613, Q614, Q615, Q616 , Q617, Q618, Q619, Q620, Q621, Q622, Q623, Q624, Q625, Q626, Q627, Q628, Q629, Q630, Q631, Q632, Q633, Q634, Q635, Q636, Q637, Q638, Q639, Q640, Q641 .
Q642, Q643, Q644, Q645, Q646, Q647, Q648, Q649, Q650, Q651 , Q652, Q653, Q654, Q655, Q656, Q657, Q658, Q659, Q660, Q661 , Q662, Q663, Q664 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ Q619, Q620 und/oder Q628, Q629 und/oder Q641 , Q642 und/oder Q648, Q649 und/oder Q657, Q658 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wie- derum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Q642, Q643, Q644, Q645, Q646, Q647, Q648, Q649, Q650, Q651, Q652, Q653, Q654, Q655, Q656, Q657, Q658, Q659, Q660, Q661, Q662, Q663, Q664 are selected independently from each other consisting of the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- alkyl" and wherein alternatively Q619, Q620 and / or Q628, Q629 and / or Q641, Q642 and / or Q648, Q649 and / or Q657, Q658 may each together also form "heterocyclyl"; in which optionally above substituents of the substituent group (i) can in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ665, -NQ666Q667, -NO2, -OH, -OCF3,(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ665, -NQ666Q667, -NO 2 , -OH, -OCF 3 ,
-SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, - SO3H, -P(O)(OH)2, -C(O)-Q668, -C(O)O-Q669, -C(O)NH-Q670, -C(O)NQ671 Q672, -O-Q673, -O(-Q674-O)d-H (d = 1 , 2, 3, 4, 5), -O(-Q675-O)d-Q676 (d = 1 , 2, 3, 4, 5), -OC(O)-Q677, - OC(O)-O-Q678, -OC(O)-NHQ679, -O-C(O)-NQ680Q681 , --SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , - C (O) -Q668, -C (O) O -Q669, -C (O) NH-Q670, -C (O) NQ671 Q672, -O-Q673, -O (-Q674-O) d -H ( d = 1, 2, 3, 4, 5), -O (-Q675-O) d -Q676 (d = 1, 2, 3, 4, 5), -OC (O) -Q677, -OC (O ) -O-Q678, -OC (O) -NHQ679, -OC (O) -NQ680Q681, -
OP(O)(OQ682)(OQ683), -OSi(Q684)(Q685)(Q686), -OS(O2)- Q687, -NHC(O)-Q688, -NQ689C(O)-Q690, -NH-C(O)-O-Q691 , -NH-C(O)-NH-Q692, -NH-C(O)-NQ693Q694, -NQ695-C(O)- O-Q696, -NQ697-C(O)-NH-Q698, -NQ699-C(O)-NQ700Q701 , -NHS(O2)-Q702, -NQ703S(O2)-Q704, -S-Q705, -S(O)-Q706, -OP (O) (OQ682) (OQ683), -OSi (Q684) (Q685) (Q686), -OS (O 2) - Q687, -NHC (O) -Q688, -NQ689C (O) -Q690, -NH -C (O) -O-Q691, -NH-C (O) -NH-Q692, -NH-C (O) -NQ693Q694, -NQ695-C (O) -O-Q696, -NQ697-C (O ) -NH-Q698, -NQ699-C (O) -NQ700Q701, -NHS (O 2) -Q702, -NQ703S (O 2) -Q704, -S-Q705, -S (O) -Q706, -
S(O2)-Q707, -S(O2)NH-Q708, -S(O2)NQ709Q710, -S(O2)O- Q71 1 , -P(O)(OQ712)(OQ713), -Si(Q714)(Q715)(Q716)"; wobei Q665, Q666, Q667, Q668, Q669, Q670, Q671 , Q672, Q673, Q674, Q675, Q676, Q677, Q678, Q679, Q680, Q681 , Q682, Q683, Q684, Q685, Q686, Q687, Q688, Q689, Q690, Q691 , Q692, Q693, Q694, Q695, Q696, Q697, Q698, Q699, Q700, Q701 , Q702, Q703, Q704, Q705, Q706, Q707, Q708, Q709, Q710, Q711 , Q712, Q713, Q714, Q715, Q716 unabhängig von-S (O 2) -Q707, -S (O 2) NH-Q708, -S (O 2) NQ709Q710, -S (O 2) O- Q71 1, -P (O) (OQ712) (OQ713) - Si (Q714) (Q715) (Q716) "; wherein Q665, Q666, Q667, Q668, Q669, Q670, Q671, Q672, Q673, Q674, Q675, Q676, Q677, Q678, Q679, Q680, Q681, Q682, Q683, Q684, Q685, Q686, Q687, Q688, Q689, Q690, Q691, Q692, Q693, Q694, Q695, Q696, Q697, Q698, Q699, Q700, Q701, Q702, Q703, Q704, Q705, Q706, Q707, Q708, Q709, Q710, Q711, Q712, Q713, Q714, Q715, Q716 regardless of-
5 einander ausgewählt sind aus der Gruppe bestehend aus: „alkyl,5 are selected from the group consisting of: "alkyl,
(C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q671 , Q672 und/oder Q680, Q681 und/oder Q693, Q694 und/oder Q700, Q701 und/oder Q709, Q710 jeweils zusammen 10 auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively Q671, Q672 and / or Q680, Q681 and / or Q693, Q694 and / or Q700 , Q701 and / or Q709, Q710 may together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
15 (iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ717, -NQ718Q719, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q720, -C(O)O-Q721 , -15 (iii) "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ 717, -NQ 718Q 719, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O ) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q 720, -C (O) O-Q 721,
20 C(O)N H-Q722, -C(O)NQ723Q724, -O-Q725, -O(-Q726-20 C (O) N H-Q722, -C (O) NQ723Q724, -O-Q725, -O (-Q726-
O)e-H (e = 1 , 2, 3, 4, 5), -O(-Q727-O)e-Q728 (e = 1 , 2, 3, 4, 5), -OC(O)-Q729, -OC(O)-O-Q730, -OC(O)-N HQ731 , -O- C(O)-NQ732Q733, -OP(O)(OQ734)(OQ735), - OSi(Q736)(Q737)(Q738), -OS(O2)-Q739, -NHC(O)-Q740, -O) e -H (e = 1, 2, 3, 4, 5), -O (-Q727-O) e -Q728 (e = 1, 2, 3, 4, 5), -OC (O) - Q729, -OC (O) -O-Q730, -OC (O) -N HQ731, -O-C (O) -NQ732Q733, -OP (O) (OQ734) (OQ735), -OSi (Q736) (Q737 ) (Q738), -OS (O 2 ) -Q739, -NHC (O) -Q740, -
25 NQ741C(O)-Q742, -NH-C(O)-O-Q743, -NH-C(O)-NH-25 NQ741C (O) -Q742, -NH-C (O) -O-Q743, -NH-C (O) -NH-
Q744, -NH-C(O)-NQ745Q746, -NQ747-C(O)-O-Q748, - NQ749-C(O)-NH-Q750, -NQ751-C(O)-NQ752Q753, - NHS(O2)-Q754, -NQ755S(O2)-Q756, -S-Q757, -S(O)-Q758, -S(O2)-Q759, -S(O2)NH-Q760, -S(O2)NQ761 Q762, -Q744, -NH-C (O) -NQ745Q746, -NQ747-C (O) -O-Q748, - NQ749-C (O) -NH-Q750, -NQ751-C (O) -NQ752Q753, - NHS (O 2) -Q754, -NQ755S (O 2) -Q756, -S-Q757, -S (O) -Q758, -S (O 2) -Q759, -S (O 2) NH-Q760, -S (O 2 ) NQ761 Q762, -
30 S(O2)O-Q763, -P(O)(OQ764)(OQ765), -30S (O 2 ) O-Q763, -P (O) (OQ764) (OQ765),
Si(Q766)(Q767)(Q768)"; wobei Q717, Q718, Q719, Q720, Q721 , Q722, Q723, Q724, Q725, Q726, Q727, Q728, Q729, Q730, Q731 , Q732, Q733, Q734, Q735, Q736, Q737, Q738, Q739, Q740, Q741 , Q742, Q743, Q744, Q745, Q746, Q747, Q748, Q749, Q750, Q751 , Q752, Q753, Q754, Q755, Q756, Q757, Q758, Q759, Q760, Q761 , Q762, Q763, Q764, Q765, Q766, Q767, Q768 unabhängig voneinander ausgewählt sind aus der Gruppe beste- hend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, hete- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" und wobei alternativ Q723, Q724 und/oder Q732, Q733 und/oder Q745, Q746 und/oder Q752, Q753 und/oder Q761 , Q762 jeweils zusammen auch „heterocyclyl" bilden können;Si (Q766) (Q767) (Q768) "; where Q717, Q718, Q719, Q720, Q721, Q722, Q723, Q724, Q725, Q726, Q727, Q728, Q729, Q730, Q731, Q732, Q733, Q734, Q735 , Q736, Q737, Q738, Q739, Q740, Q741, Q742, Q743, Q744, Q745, Q746, Q747, Q748, Q749, Q750, Q751, Q752, Q753, Q754, Q755, Q756, Q757, Q758, Q759, Q760, Q761, Q762, Q763, Q764, Q765, Q766, Q767, Q768 are independently selected from the group consist- ing of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" and wherein alternatively Q723, Q724 and / or Q732, Q733 and / or Q745, Q746 and / or Q752, Q753 and / or Q761, Q762 may together also form "heterocyclyl";
(h) unsubstituiertes oder substituiertes Heteroaryl, wobei optional der Hetero- arylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(h) unsubstituted or substituted heteroaryl, where optionally the heteroaryl radical may be substituted by at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3,(i) "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 ,
N3, NH2, -NHQ769, -NQ770Q771 , -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q772, -C(O)O-Q773, -C(O)NH-Q774, -C(O)NQ775Q776, - O-Q777, -O(-Q778-O)f-H (f = 1 , 2, 3, 4, 5), -O(-Q779-O)^Q780 (f = 1 , 2, 3, 4, 5), -OC(O)-Q781 , -OC(O)-O-Q782, -OC(O)-NHQ783, -N 3 , NH 2 , -NHQ769, -NQ770Q771, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, - C (O) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) -Q772, -C (O) O-Q773, -C (O) NH-Q774, -C (O) NQ775Q776, - O-Q777, -O (-Q778-O) f -H (f = 1, 2, 3, 4, 5), -O (-Q779-O) ^ Q780 (f = 1, 2, 3, 4, 5), -OC (O) -Q781, -OC (O) -O-Q782, -OC (O) -NHQ783, -
O-C(O)-NQ784Q785, -OP(O)(OQ786)(OQ787), - OSi(Q788)(Q789)(Q790), -OS(O2)-Q791 , -NHC(O)-Q792, - NQ793C(O)-Q794, -NH-C(O)-O-Q795, -N H-C(O)-N H-Q796, - NH-C(O)-NQ797Q798, -NQ799-C(O)-O-Q800, -NQ801 -C(O)-N H- Q802, -NQ803-C(O)-NQ804Q805, -NHS(O2)-Q806, -NQ807S(O2)-OC (O) -NQ784Q785, -OP (O) (OQ786) (OQ787), - OSi (Q788) (Q789) (Q790), -OS (O 2) -Q791, -NHC (O) -Q792, - NQ793C (O) -Q794, -NH-C (O) -O-Q795, -NHC (O) -NH-Q796, -NH-C (O) -NQ797Q798, -NQ799-C (O) -O- Q800, -NQ801 -C (O) -N H- Q802, -NQ803-C (O) -NQ804Q805, -NHS (O 2) -Q806, -NQ807S (O 2) -
Q808, -S-Q809, -S(O)-Q810, -S(O2)-Q811 , -S(O2)NH-Q812, - S(O2)NQ813Q814, -S(O2)O-Q815, -P(O)(OQ816)(OQ817), - Si(Q818)(Q819)(Q820)"; wobei Q769, Q770, Q771 , Q772, Q773, Q774, Q775, Q776, Q777, Q778, Q779, Q780, Q781 , Q782, Q783, Q784, Q785, Q786, Q787,Q808, Q809 -S-, -S (O) -Q810, -S (O 2) -Q811, -S (O 2) NH-Q812, - S (O 2) NQ813Q814, -S (O 2) O- Q815, -P (O) (OQ816) (OQ817), -Si (Q818) (Q819) (Q820) "; where Q769, Q770, Q771, Q772, Q773, Q774, Q775, Q776, Q777, Q778, Q779, Q780, Q781, Q782, Q783, Q784, Q785, Q786, Q787,
Q788, Q789, Q790, Q791 , Q792, Q793, Q794, Q795, Q796, Q797, Q798, Q799, Q800, Q801 , Q802, Q803, Q804, Q805, Q806, Q807, Q808, Q809, Q810, Q81 1 , Q812, Q813, Q814, Q815, Q816, Q817, Q818, Q819, Q820 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ Q775, Q776 und/oder Q784, Q785 und/oder Q797, Q798 und/oder Q804, Q805 und/oder Q813, Q814 jeweils zu- sammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ821 , -NQ822Q823, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, - SO3H, -P(O)(OH)2, -C(O)-Q824, -C(O)O-Q825, -C(O)NH-Q826, -C(O)NQ827Q828, -O-Q829, -O(-Q830-O)g-H (g = 1 , 2, 3, 4,Q788, Q789, Q790, Q791, Q792, Q793, Q794, Q795, Q796, Q797, Q798, Q799, Q800, Q801, Q802, Q803, Q804, Q805, Q806, Q807, Q808, Q809, Q810, Q81 1, Q812 , Q813, Q814, Q815, Q816, Q817, Q818, Q819, Q820 are independently selected from the A group consisting of: "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively Q775, Q776 and / or Q784, Q785 and / or Q797 , Q798 and / or Q804, Q805 and / or Q813, Q814 together can also form "heterocyclyl"; wherein optionally above substituents of substituent group (i) in turn may be independently substituted with at least one substituent, identical or different, selected from the group consisting of: (ii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl , heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHQ821, -NQ822Q823, -NO 2, -OH, -OCF 3, - SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q824, -C (O) O-Q825, -C (O) NH-Q826, -C (O) NQ827Q828, -O-Q829, -O (-Q830-O) g -H (g = 1, 2, 3, 4,
5), -O(-Q831-O)g-Q832 (g = 1 , 2, 3, 4, 5), -OC(O)-Q833, - OC(O)-O-Q834, -OC(O)-NHQ835, -O-C(O)-NQ836Q837, - OP(O)(OQ838)(OQ839), -OSi(Q840)(Q841 )(Q842), -OS(O2)- Q843, -NHC(O)-Q844, -NQ845C(O)-Q846, -NH-C(O)-O-Q847, -NH-C(O)-NH-Q848, -NH-C(O)-NQ849Q850, -NQ851-C(O)-5), -O (-Q831-O) g -Q832 (g = 1, 2, 3, 4, 5), -OC (O) -Q833, -OC (O) -O-Q834, -OC (O ) -NHQ835, -OC (O) -NQ836Q837, - OP (O) (OQ838) (OQ839), -OSi (Q840) (Q841) (Q842), -OS (O 2) - Q843, -NHC (O) -Q844, -NQ845C (O) -Q846, -NH-C (O) -O-Q847, -NH-C (O) -NH-Q848, -NH-C (O) -NQ849Q850, -NQ851-C ( O)-
O-Q852, -NQ853-C(O)-NH-Q854, -NQ855-C(O)-NQ856Q857, -NHS(O2)-Q858, -NQ859S(O2)-Q860, -S-Q861 , -S(O)-Q862, - S(O2)-Q863, -S(O2)N H-Q864, -S(O2)NQ865Q866, -S(O2)O- Q867, -P(O)(OQ868)(OQ869), -Si(Q870)(Q871 )(Q872)"; wobei Q821 , Q822, Q823, Q824, Q825, Q826, Q827, Q828, Q829,O-Q852, -NQ853-C (O) -NH-Q854, -NQ855-C (O) -NQ856Q857, -NHS (O 2) -Q858, -NQ859S (O 2) -Q860, -S-Q861, - S (O) -Q862, - S (O 2) -Q863, -S (O 2) N H-Q864, -S (O 2) NQ865Q866, -S (O 2) O- Q867, -P (O) (OQ868) (OQ869), -Si (Q870) (Q871) (Q872) "; where Q821, Q822, Q823, Q824, Q825, Q826, Q827, Q828, Q829,
Q830, Q831 , Q832, Q833, Q834, Q835, Q836, Q837, Q838, Q839, Q840, Q841 , Q842, Q843, Q844, Q845, Q846, Q847, Q848, Q849, Q850, Q851 , Q852, Q853, Q854, Q855, Q856, Q857, Q858, Q859, Q860, Q861 , Q862, Q863, Q864, Q865, Q866, Q867, Q868, Q869, Q870, Q871 , Q872 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q827, Q828 und/oder Q836, Q837 und/oder Q849, Q850 und/oder Q856, Q857 und/oder Q865, Q866 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mitQ830, Q831, Q832, Q833, Q834, Q835, Q836, Q837, Q838, Q839, Q840, Q841, Q842, Q843, Q844, Q845, Q846, Q847, Q848, Q849, Q850, Q851, Q852, Q853, Q854, Q855, Q856, Q857, Q858, Q859, Q860, Q861, Q862, Q863, Q864, Q865, Q866, Q867, Q868, Q869, Q870, Q871, Q872 are independently selected from the group consisting of: "alkyl, (Cg -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively Q827, Q828 and / or Q836, Q837 and / or Q849, Q850 and / or Q856, Q857 and / or Q865, Q866 may together also form "heterocyclyl" wherein optionally substituents of the substituent group (ii) above may be substituted independently of one another with
5 mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:5 at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ873, -NQ874Q875, -NO2, -OH,(iii) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHQ873, -NQ874Q875, -NO 2 , -OH,
10 -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -10 -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -
C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q876, -C(O)O-Q877, - C(O)NH-Q878, -C(O)NQ879Q880, -O-Q881 , -O(-Q882- O)h-H (h = 1 , 2, 3, 4, 5), -O(-Q883-O)h-Q884 (h = 1 , 2, 3, 4, 5), -OC(O)-Q885, -OC(O)-O-Q886, -OC(O)-NHQ887, -O-C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q876, -C (O) O-Q 877, -C (O) NH-Q878, -C (O) NQ879Q880, -O-Q881, -O (-Q882-O) h -H (h = 1, 2, 3, 4, 5), -O (-Q883-O) h -Q884 (h = 1 , 2, 3, 4, 5), -OC (O) -Q885, -OC (O) -O-Q886, -OC (O) -NHQ887, -O-
15 C(O)-NQ888Q889, -OP(O)(OQ890)(OQ891 ), -15 C (O) -NQ888Q889, -OP (O) (OQ890) (OQ891),
OSi(Q892)(Q893)(Q894), -OS(O2)-Q895, -NHC(O)-Q896, - NQ897C(O)-Q898, -NH-C(O)-O-Q899, -NH-C(O)-NH- Q900, -NH-C(O)-NQ901 Q902, -NQ903-C(O)-O-Q904, - NQ905-C(O)-NH-Q906, -NQ907-C(O)-NQ908Q909, -OSi (Q892) (Q893) (Q894), -OS (O 2) -Q895, -NHC (O) -Q896, - NQ897C (O) -Q898, -NH-C (O) -O-Q899, -NH -C (O) -NH-Q900, -NH-C (O) -NQ901 Q902, -NQ903-C (O) -O-Q904, -NQ905-C (O) -NH-Q906, -NQ907-C ( O) -NQ908Q909, -
20 NHS(O2)-Q910, -NQ911 S(O2)-Q912, -S-Q913, -S(O)-Q914,20 NHS (O 2) -Q910, -NQ911 S (O 2) -Q912, -S-Q913, -S (O) -Q914,
-S(O2)-Q915, -S(O2)NH-Q916, -S(O2)NQ917Q918, - S(O2)O-Q919, -P(O)(OQ920)(OQ921 ), - Si(Q922)(Q923)(Q924)"; wobei Q873, Q874, Q875, Q876, Q877, Q878, Q879, Q880,-S (O 2) -Q915, -S (O 2) NH-Q916, -S (O 2) NQ917Q918, - S (O 2) O-Q919, -P (O) (OQ920) (OQ921) - Si (Q922) (Q923) (Q924) ", where Q873, Q874, Q875, Q876, Q877, Q878, Q879, Q880,
25 Q881, Q882, Q883, Q884, Q885, Q886, Q887, Q888, Q889,25 Q881, Q882, Q883, Q884, Q885, Q886, Q887, Q888, Q889,
Q890, Q891, Q892, Q893, Q894, Q895, Q896, Q897, Q898, Q899, Q900, Q901, Q902, Q903, Q904, Q905, Q906, Q907, Q908, Q909, Q910, Q911, Q912, Q913, Q914, Q915, Q916, Q917, Q918, Q919, Q920, Q921, Q922, Q923, Q924 unab-Q905, Q891, Q892, Q893, Q894, Q895, Q896, Q897, Q898, Q899, Q900, Q901, Q902, Q903, Q904, Q905, Q906, Q907, Q908, Q909, Q910, Q911, Q912, Q913, Q914, Q915, Q916, Q917, Q918, Q919, Q920, Q921, Q922, Q923, Q924
30 hängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q879, Q880 und/oder Q888, Q889 und/oder Q901 , Q902 und/oder Q908, Q909 und/oder Q917, Q918 jeweils zusammen auch „heterocyclyl" bilden können;30 are selected from the group consisting of: "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively Q879, Q880 and / or Q888, Q889 and / or Q901, Q902 and / or Q908, Q909 and / or Q917, Q918 may together also form "heterocyclyl";
(j) OZ6, wobei Z6 unabhängig ausgewählt ist aus der Gruppe bestehend aus:(j) OZ6, wherein Z6 is independently selected from the group consisting of:
(i) „Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindes- tens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(i) "hydrogen, alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wherein optionally substituents of the substituent group (i) above may be independently substituted with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ925, -NQ926Q927, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ925, -NQ926Q927, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -
SO3H, -P(O)(OH)2, -C(O)-Q928, -C(O)O-Q929, -C(O)NH-Q930, -C(O)NQ931 Q932, -O-Q933, -O(-Q934-O),-H (i = 1 , 2, 3, 4, 5), -O(-Q935-O),-Q936 (i = 1 , 2, 3, 4, 5), -OC(O)-Q937, -OC(O)- O-Q938, -OC(O)-NHQ939, -O-C(O)-NQ940Q941 , - OP(O)(OQ942)(OQ943), -OSi(Q944)(Q945)(Q946), -OS(O2)-SO 3 H, -P (O) (OH) 2, -C (O) -Q928, -C (O) O-Q929, -C (O) NH-Q930, -C (O) NQ931 Q932, -O -Q933, -O (-Q934-O), - H (i = 1, 2, 3, 4, 5), -O (-Q935-O), - Q936 (i = 1, 2, 3, 4, 5), -OC (O) -Q937, -OC (O) -O-Q938, -OC (O) -NHQ939, -OC (O) -NQ940Q941, -OP (O) (OQ942) (OQ943), OSi (Q944) (Q945) (Q946), -OS (O 2 ) -
Q947, -NHC(O)-Q948, -NQ949C(O)-Q950, -NH-C(O)-O-Q951 , -N H-C(O)-N H-Q952, -NH-C(O)-NQ953Q954, -NQ955-C(O)- O-Q956, -NQ957-C(O)-NH-Q958, -NQ959-C(O)-NQ960Q961 , -NHS(O2)-Q962, -NQ963S(O2)-Q964, -S-Q965, -S(O)-Q966, - S(O2)-Q967, -S(O2)NH-Q968, -S(O2)NQ969Q970, -S(O2)O-Q947, -NHC (O) -Q948, -NQ949C (O) -Q950, -NH-C (O) -O-Q951, -NHC (O) -NH-Q952, -NH-C (O) - NQ953Q954, -NQ955-C (O) - O-Q956, -NQ957-C (O) -NH-Q958, -NQ959-C (O) -NQ960Q961, -NHS (O 2) -Q962, -NQ963S (O 2 ) -Q964, -S-Q965, -S (O) -Q966, - S (O 2) -Q967, -S (O 2) NH-Q968, -S (O 2) NQ969Q970, -S (O 2) O-
Q971 , -P(O)(OQ972)(OQ973), -Si(Q974)(Q975)(Q976)"; wobei Q925, Q926, Q927, Q928, Q929, Q930, Q931 , Q932, Q933, Q934, Q935, Q936, Q937, Q938, Q939, Q940, Q941 , Q942, Q943, Q944, Q945, Q946, Q947, Q948, Q949, Q950, Q951 , Q952, Q953, Q954, Q955, Q956, Q957, Q958, Q959, Q960,Q971, -P (O) (OQ972) (OQ973), -Si (Q974) (Q975) (Q976) "; where Q925, Q926, Q927, Q928, Q929, Q930, Q931, Q932, Q933, Q934, Q935, Q936, Q937, Q938, Q939, Q940, Q941, Q942, Q943, Q944, Q945, Q946, Q947, Q948, Q949, Q950, Q951, Q952, Q953, Q954, Q955, Q956, Q957, Q958, Q959, Q960,
Q961 , Q962, Q963, Q964, Q965, Q966, Q967, Q968, Q969, Q970, Q971 , Q972, Q973, Q974, Q975, Q976 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q931 , Q932 und/oder Q940, Q941 und/oder Q953, Q954 und/oder Q960, Q961 und/oder Q969, Q970 jeweils zusammen 5 auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Q961, Q962, Q963, Q964, Q965, Q966, Q967, Q968, Q969, Q970, Q971, Q972, Q973, Q974, Q975, Q976 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and, alternatively, Q931, Q932 and / or Q940, Q941 and / or Q953, Q954 and / or Q960, Q961 and / or Q969, Q970 in each case together can also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
10 (iii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ977, -NQ978Q979, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q980, -C(O)O-Q981 , -10 (iii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3 , NH 2 , -NHQ977, -NQ978Q979, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C ( O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q980, -C (O) O-Q981,
15 C(O)N H-Q982, -C(O)NQ983Q984, -O-Q985, -O(-Q986-O)-15 C (O) N H -Q982, -C (O) NQ983Q984, -O-Q985, -O (-Q986-O) -
H C = 1 , 2, 3, 4, 5), -O(-Q987-O)-Q988 G = 1 , 2, 3, 4, 5), - OC(O)-Q989, -OC(O)-O-Q990, -OC(O)-N HQ991 , -0-C(O)- NQ992Q993, -OP(O)(OQ994)(OQ995), - OSi(Q996)(Q997)(Q998), -OS(O2)-Q999, -NHC(O)-QIOOO, -HC = 1,2,3,4,5), -O (-Q987-O) -Q988 G = 1,2,3,4,5), - OC (O) -Q989, -OC (O) - O-Q990, -OC (O) -N HQ991, -O-C (O) -NQ992Q993, -OP (O) (OQ994) (OQ995), -OSi (Q996) (Q997) (Q998), -OS ( O 2 ) -Q999, -NHC (O) -QIOOO, -
20 NQ1001 C(O)-QI 002, -NH-C(O)-O-QI 003, -NH-C(O)-NH-20 NQ1001 C (O) -QI 002, -NH-C (O) -O-QI 003, -NH-C (O) -NH-
Q1004, -NH-C(O)-NQI 005Q1006, -NQ1007-C(O)-O- Q1008, -NQ1009-C(O)-NH-QI 010, -NQ1011-C(O)- NQ1012Q1013, -NHS(O2)-Q1014, -NQ1015S(O2)-Q1016, - S-Q1017, -S(O)-QI 018, -S(O2)-Q1019, -S(O2)NH-QI 020, -Q1004, -NH-C (O) -NQI 005Q1006, -NQ1007-C (O) -O-Q1008, -NQ1009-C (O) -NH-QI 010, -NQ1011-C (O) - NQ1012Q1013, -NHS (O 2) -Q1014, -NQ1015S (O 2) -Q1016, - S Q1017, -S (O) -qi 018, -S (O 2) -Q1019, -S (O 2) NH-QI 020, -
25 S(O2)NQI 021 Q1022, -S(O2)O-QI 023, -25 S (O 2 ) NQI 021 Q1022, -S (O 2 ) O-QI 023, -
P(O)(OQI 024)(OQ1025), -Si(QI 026)(Q1027)(Q1028)"; wobei Q977, Q978, Q979, Q980, Q981 , Q982, Q983, Q984, Q985, Q986, Q987, Q988, Q989, Q990, Q991 , Q992, Q993, Q994, Q995, Q996, Q997, Q998, Q999, Q1000, Q1001 ,P (O) (OQI 024) (OQ1025), -Si (QI 026) (Q1027) (Q1028) "; where Q977, Q978, Q979, Q980, Q981, Q982, Q983, Q984, Q985, Q986, Q987, Q988 , Q989, Q990, Q991, Q992, Q993, Q994, Q995, Q996, Q997, Q998, Q999, Q1000, Q1001,
30 Q1002, Q1003, Q1004, Q1005, Q1006, Q1007, Q1008,30 Q1002, Q1003, Q1004, Q1005, Q1006, Q1007, Q1008,
Q1009, Q1010, Q1011 , Q1012, Q1013, Q1014, Q1015, Q1016, Q1017, Q1018, Q1019, Q1020, Q1021 , Q1022, Q1023, Q1024, Q1025, Q1026, Q1027, Q1028 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q983, Q984 und/oder Q992, Q993 und/oder Q1005, Q1006 und/oder Q1012, Q1013 und/oder Q1021 , Q1022 jeweils zusammen auch „heterocyclyl" bilden können;Q1009, Q1010, Q1011, Q1012, Q1013, Q1014, Q1015, Q1016, Q1017, Q1018, Q1019, Q1020, Q1021, Q1022, Q1023, Q1024, Q1025, Q1026, Q1027, Q1028 are independently selected from the group consisting of: "Alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively Q983, Q984 and / or Q992, Q993 and / or Q1005, Q1006 and / or Q1012, Q1013 and / or Q1021, Q1022 may together also form "heterocyclyl";
(k) SZ7, wobei Z7 unabhängig ausgewählt ist aus der Gruppe bestehend aus:(k) SZ7, wherein Z7 is independently selected from the group consisting of:
(i) „Wasserstoff, alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(i) "hydrogen, alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wherein optionally above substituents of substituent group (i) in turn may be independently substituted with at least a substituent, the same or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,(ii) "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,
CN, CF3, N3, NH2, -NHQ1029, -NQ1030Q1031 , -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-QI 032, -C(O)O-QI 033, -C(O)NH- Q1034, -C(O)NQI 035Q1036, -O-Q1037, -O(-Q1038-O)k-H (k = 1 , 2, 3, 4, 5), -0(-Q1039-O)k-Q1040 (k = 1 , 2, 3, 4, 5), -OC(O)-CN, CF 3, N 3, NH 2, -NHQ1029, -NQ1030Q1031, -NO 2, -OH, - OCF 3, -SH, -0-SO3H, -OP (O) (OH) 2, -CHO , -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -QI 032, -C (O) O-QI 033, -C (O ) NH-Q1034, -C (O) NQI 035Q1036, -O-Q1037, -O (-Q1038-O) k -H (k = 1, 2, 3, 4, 5), -O (-Q1039-O ) k -Q1040 (k = 1, 2, 3, 4, 5), -OC (O) -
Q1041 , -OC(O)-O-QI 042, -OC(O)-NHQI 043, -0-C(O)- NQ1044Q1045, -OP(O)(OQI 046)(OQ1047), - OSi(QI 048)(Q1049)(Q1050), -OS(O2)-Q1051 , -NHC(O)-QI 052, -NQ1053C(O)-QI 054, -NH-C(O)-O-QI 055, -NH-C(O)-NH- Q1056, -NH-C(O)-NQI 057Q1058, -NQ1059-C(O)-O-QI 060, -Q1041, -OC (O) -O-QI 042, -OC (O) -NHQI 043, -O-C (O) -NQ1044Q1045, -OP (O) (OQI 046) (OQ1047), -OSi (QI 048 ) (Q1049) (Q1050), -OS (O 2) -Q1051, -NHC (O) -qi 052, -NQ1053C (O) -qi 054, -NH-C (O) -O-QI 055, -NH -C (O) -NH-Q1056, -NH-C (O) -NQI 057Q1058, -NQ1059-C (O) -O-QI 060, -
NQ1061-C(O)-NH-Q1062, -NQ1063-C(O)-NQI 064Q1065, - NHS(O2)-Q1066, -NQ1067S(O2)-Q1068, -S-Q1069, -S(O)- Q1070, -S(O2)-Q1071 , -S(O2)NH-QI 072, -S(O2)NQI 073Q1074, -S(O2)O-QI 075, -P(O)(OQI 076)(OQ1077), - Si(QI 078)(Q1079)(Q1080)"; wobei Q1029, Q1030, Q1031, Q1032, Q1033, Q1034, Q1035, Q1036, Q1037, Q1038, Q1039, Q1040, Q1041, Q1042, Q1043, Q1044, Q1045, Q1046, Q1047, Q1048, Q1049, Q1050, Q1051, Q1052, Q1053, Q1054, Q1055, Q1056, Q1057, Q1058, Q1059, Q1060, Q1061, Q1062, Q1063, Q1064, Q1065, Q1066, Q1067, Q1068, Q1069, Q1070, Q1071, Q1072, Q1073, Q1074, Q1075, Q1076, Q1077, Q1078, Q1079, Q1080 unabhängig voneinander 5 ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-NQ1061-C (O) -NH-Q1062, -NQ1063-C (O) -NQI 064Q1065, - NHS (O 2) -Q1066, -NQ1067S (O 2) -Q1068, -S-Q1069, -S (O) - Q1070, -S (O 2 ) -Q1071, -S (O 2 ) NH-QI 072, -S (O 2 ) NQI 073Q1074, -S (O 2 ) O-QI 075, -P (O) (OQI 076) (OQ1077), - Si (QI 078) (Q1079) (Q1080) "where Q1029, Q1030, Q1031, Q1032, Q1033, Q1034, Q1035, Q1036, Q1037, Q1038, Q1039, Q1040, Q1041, Q1042, Q1043 , Q1044, Q1045, Q1046, Q1047, Q1048, Q1049, Q1050, Q1051, Q1052, Q1053, Q1054, Q1055, Q1056, Q1057, Q1058, Q1059, Q1060, Q1061, Q1062, Q1063, Q1064, Q1065, Q1066, Q1067, Q1068, Q1069, Q1070, Q1071, Q1072, Q1073, Q1074, Q1075, Q1076, Q1077, Q1078, Q1079, Q1080 are independently selected from the group consisting of: "alkyl, (Cg-
C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q1035, Q1036 und/oder Q1044, Q1045 und/oder Q1057, Q1058 und/oder Q1064, Q1065 und/oder Q1073, Q1074 jeweils zusam- 10 men auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and, alternatively, Q1035, Q1036 and / or Q1044, Q1045 and / or Q1057, Q1058 and / or Q1064, Q1065 and / or Q1073, Q1074 can together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
15 (iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I1 CN1 CF3, N3, NH2, -NHQ1081 , -NQ1082Q1083, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-QI 084, -C(O)O-15 (iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I 1 CN 1 CF 3 , N 3 , NH 2 , -NHQ1081, -NQ1082Q1083, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -QI 084, -C (O) O-
20 Q1085, -C(O)NH-QI 086, -C(O)NQI 087Q1088, -O-Q1089, -20 Q1085, -C (O) NH-QI 086, -C (O) NQI 087Q1088, -O-Q1089, -
0(-Q1090-O)1-H (I = 1 , 2, 3, 4, 5), -0(-Q1091 -O)1-QI 092 (I = 1 , 2, 3, 4, 5), -OC(O)-QI 093, -OC(O)-O-QI 094, -OC(O)- NHQ1095, -O-C(O)-NQ1096Q1097, - OP(O)(OQI 098)(OQ1099), -OSi(Q1 100)(Q1 101 )(Q1102), -0 (-Q1090-O) 1 -H (I = 1, 2, 3, 4, 5), -0 (-Q1091 -O) 1 -QI 092 (I = 1, 2, 3, 4, 5), -OC (O) -QI 093, -OC (O) -O-QI 094, -OC (O) -NHQ1095, -OC (O) -NQ1096Q1097, -OP (O) (OQI 098) (OQ1099), OSi (Q1 100) (Q1 101) (Q1102),
25 OS(O2)-Q1103, -NHC(O)-Q1 104, -NQ1105C(O)-Q1106, -25 OS (O 2 ) -Q1103, -NHC (O) -Q 1 104, -NQ1105C (O) -Q1106, -
NH-C(O)-O-Q1107, -NH-C(O)-NH-Q1108, -NH-C(O)- NQ1109Q1 110, -NQ11 1 1-C(O)-O-Q1 112, -NQ11 13-C(O)- NH-Q1 114, -NQ11 15-C(O)-NQ1116Q1 117, -NHS(O2)- Q11 18, -NQ1 119S(O2)-Q1 120, -S-Q1121 , -S(O)-Q1 122, -NH-C (O) -O-Q1107, -NH-C (O) -NH-Q1108, -NH-C (O) -NQ1109Q1 110, -NQ11 1 1-C (O) -O-Q1 112, - NQ11 13-C (O) -NH-Q1 114, -NQ11 15-C (O) -NQ1116Q1 117, -NHS (O 2 ) -Q11 18, -NQ1 119S (O 2 ) -Q1 120, -S-Q1121 , -S (O) -Q1 122, -
30 S(O2)-Q1123, -S(O2)NH-Q1124, -S(O2)NQ1 125Q1126, -30 S (O 2) -Q1123, -S (O 2) NH-Q1124, -S (O 2) NQ1 125Q1126, -
S(O2)O-Q1127, -P(O)(OQ1128)(OQ1129), - Si(QI 130)(Q1131 )(Q1132)"; wobei Q1081, Q1082, Q1083, Q1084, Q1085, Q1086, Q1087, Q1088, Q1089, Q1090, Q1091, Q1092, Q1093, Q1094, Q1095, Q1096, Q1097, Q1098, Q1099, Q1100, Q1101, Q1102, Q1103, Q1104, Q1105, Q1106, Q1107, Q1108, Q1109, Q1110, Q1111, Q1112, Q1113, Q1114, Q1115, Q1116, Q1117, Q1118, Q1119, Q1120, Q1121.Q1122, Q1123, Q1124, Q1125, Q1126, Q1127, Q1128, Q1129,S (O 2 ) O-Q1127, -P (O) (OQ1128) (OQ1129), -Si (QI 130) (Q1131) (Q1132) "; where Q1081, Q1082, Q1083, Q1084, Q1085, Q1086, Q1087, Q1088, Q1089, Q1090, Q1091, Q1092, Q1093, Q1094, Q1095, Q1096, Q1097, Q1098, Q1099, Q1100, Q1101, Q1102, Q1103, Q1104, Q1105, Q1106, Q1107, Q1108, Q1109, Q1110, Q1111, Q1112, Q1113, Q1114, Q1115, Q1116, Q1117, Q1118, Q1119, Q1120, Q1121.Q1122, Q1123, Q1124, Q1125, Q1126, Q1127, Q1128, Q1129,
Q1130, Q1131 , Q1132 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C30)alkyl, cyc- loalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, ary- lalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q1087, Q1088 und/oder Q1096, Q1097 und/oder Q1 109, Q1 110 und/oder Q1 116, Q1 117 und/oder Q1 125, Q1 126 jeweils zusammen auch „heterocyclyl" bilden können;Q1130, Q1131 are, Q1132 independently selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, Cyc loalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, ary lalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively Q1087 , Q1088 and / or Q1096, Q1097 and / or Q1 109, Q1 110 and / or Q1 116, Q1 117 and / or Q1 125, Q1 126 may together also form "heterocyclyl";
NZ8Z9, wobei Z8, Z9 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:NZ8Z9, wherein Z8, Z9 are independently selected from the group consisting of:
(i) „Wasserstoff, alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C(O)- Q1133, -C(O)O-Q1134, -C(O)-NQ1 135Q1136, -S(O2)-Q1137, - S(O2)O-Q1138"; wobei Q1 133, Q1 134, Q1 135, Q1 136, Q1 137, Q1 138 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q1 135, Q1 136 zusammen auch „heterocyclyl" bilden kön- nen; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ1 139, -NQ1140Q1 141 , -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q1 142, -C(O)O-Q1 143, -C(O)NH- Q1144, -C(O)NQ1 145Q1146, -O-Q1147, -O(-Q1148-O)m-H (m = 1 , 2, 3, 4, 5), -O(-Q1149-O)m-Q1150 (m = 1 , 2, 3, 4, 5), - OC(O)-Q1151 , -OC(O)-O-Q1152, -OC(O)-NHQ1153, -O- 5 C(O)-NQ1 154Q1155, -OP(O)(OQ1 156)(OQ1 157), -(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C (O) -Q1133, -C (O) O-Q 1134, -C (O) -NQ1 135Q1136, -S (O 2) -Q1137, - S (O 2) O-Q1138 "; wherein Q1 133, Q1 134, Q1 135, Q1 136, Q1 137, Q1 138 independently selected are selected from the group consisting of: hydrogen, alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein together alternatively Q1 135, Q1 136,""form heterocyclyl optionally substituted substituents of the substituent group (i) may in turn be independently substituted with at least one substituent, identical or different, selected from the group consisting of: (ii) alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ 1 139, -NQ1140Q1 141, -NO 2 , -OH, - OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2, -C (O) -Q1 142, -C (O) O-Q1 143, -C (O) NH- Q1144, -C (O) NQ1 145Q1146 , -O-Q1147, -O (-Q1148-O) m -H (m = 1, 2, 3, 4, 5), -O (-Q1149-O) m -Q1150 (m = 1, 2, 3 , 4, 5), - OC (O) -Q1151, -OC (O) -O-Q1152, -OC (O) -NHQ1153, -O- 5 C (O) -NQ1 154Q1155, -OP (O) ( OQ1 156) (OQ1 157), -
OSi(QI 158)(Q1 159)(Q1 160), -0S(02)-Q1 161 , -NHC(O)-Q1162, -NQ1 163C(O)-Q1 164, -NH-C(O)-O-Q1 165, -NH-C(O)-NH- Q1166, -NH-C(O)-NQ1 167Q1 168, -NQ1169-C(O)-O-Q1 170, - NQ1171 -C(O)-NH-Q1 172, -NQ1173-C(O)-NQ1174Q1 175, - 10 NHS(02)-Q1 176, -NQ1177S(O2)-Q1178, -S-Q1179, -S(O)-OSi (QI 158) (Q1 159) (Q1 160), -0S (0 2 ) -Q1 161, -NHC (O) -Q1162, -NQ1 163C (O) -Q1 164, -NH-C (O) - O-Q1 165, -NH-C (O) -NH-Q1166, -NH-C (O) -NQ1 167Q1 168, -NQ1169-C (O) -O-Q1 170, -NQ1171 -C (O) - NH-Q1 172, -NQ1173-C (O) -NQ1174Q1 175, - 10 NHS (0 2) -Q1 176, -NQ1177S (O 2) -Q1178, -S-Q1179, -S (O) -
Q1180, -S(02)-Q1181 , -S(O2)NH-Q1 182, -S(O2)NQ1183Q1 184, -S(O2)O-Q1 185, -P(O)(OQI 186)(OQ1 187), - Si(QI 188)(Q1189)(Q1190)"; wobei Q1 139, Q1 140, Q1 141 , Q1 142, Q1 143, Q1 144, Q1 145,Q1180, -S (0 2) -Q1181, -S (O 2) NH-Q1 182, -S (O 2) NQ1183Q1 184, -S (O 2) O-Q1 185, -P (O) (OQI 186 ) (OQ1 187), -Si (QI 188) (Q1189) (Q1190) ", where Q1 139, Q1 140, Q1 141, Q1 142, Q1 143, Q1 144, Q1 145,
15 Q1146, Q1147, Q1148, Q1149, Q1150, Q1151 , Q1152, Q1153,15 Q1146, Q1147, Q1148, Q1149, Q1150, Q1151, Q1152, Q1153,
Q1154, Q1155, Q1156, Q1157, Q1158, Q1159, Q1160, Q1161 , Q1162, Q1163, Q1164, Q1165, Q1166, Q1167, Q1168, Q1169, Q1170, Q1171 , Q1172, Q1173, Q1174, Q1175, Q1176, Q1177, Q1178, Q1179, Q1180, Q1181 , Q1182, Q1183, Q1184, Q1185,Q1154, Q1155, Q1156, Q1157, Q1158, Q1159, Q1160, Q1161, Q1162, Q1163, Q1164, Q1165, Q1166, Q1167, Q1168, Q1169, Q1170, Q1171, Q1172, Q1173, Q1174, Q1175, Q1176, Q1177, Q1178, Q1179, Q1180, Q1181, Q1182, Q1183, Q1184, Q1185,
20 Q1186, Q1187, Q1188, Q1189, Q1190 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q1145, Q1146 und/oder Q1154, Q1155 und/oder Q1 167, Q1 168"(Cg-C 30) alkyl, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively: 20 Q1186, Q1187, Q1188, Q1189, Q1190 independently selected from the group consisting of Q1145, Q1146 and / or Q1154, Q1155 and / or Q1 167, Q1 168
25 und/oder Q1 174, Q1 175 und/oder Q1 183, Q1 184 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausge- 30 wählt aus der Gruppe bestehend aus:25 and / or Q1 174, Q1 175 and / or Q1 183, Q1 184 may in each case also form "heterocyclyl", where optionally the above substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I1 CN1 CF3, N3, NH2, -NHQ1191 , -NQ1 192Q1193, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q1194, -C(O)O- Q1195, -C(O)NH-Q1196, -C(O)NQ1197Q1198, -O-Q1199, - O(-Q1200-O)n-H (n = 1, 2, 3, 4, 5), -O(-Q1201-O)n-QI202 (n = 1, 2, 3, 4, 5), -OC(O)-QI203, -OC(O)-O-QI204, - OC(O)-NHQI205, -0-C(O)-NQI206Q1207, -(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I 1 CN 1 CF 3 , N 3 , NH 2 , -NHQ1191, -NQ1 192Q1193, -NO 2 , - OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, - C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q 1194, -C (O) O-Q 1195, -C (O) NH-Q 1196, -C (O) NQ1197Q1198, -O-Q1199, - O (-Q1200-O) n -H (n = 1, 2, 3, 4, 5), -O (-Q1201-O) n -QI202 (n = 1 , 2, 3, 4, 5), -OC (O) -QI203, -OC (O) -O-QI204, - OC (O) -NHQI205, -O-C (O) -NQI206Q1207, -
OP(O)(OQ1208)(OQ1209), -OSi(Q1210)(Q1211)(Q1212), - OS(O2)-Q1213, -NHC(O)-Q1214, -NQ1215C(O)-Q1216, - NH-C(O)-O-QI217, -NH-C(O)-NH-Q1218, -NH-C(O)- NQ1219Q1220, -NQ1221-C(O)-O-Q1222, -NQ1223-C(O)- NH-Q1224, -NQ1225-C(O)-NQI226Q1227, -NHS(O2)-OP (O) (OQ1208) (OQ1209), -OSi (Q1210) (Q1211) (Q1212), - OS (O 2) -Q1213, -NHC (O) -Q1214, -NQ1215C (O) -Q1216, - NH -C (O) -O-QI217, -NH-C (O) -NH-Q1218, -NH-C (O) -NQ1219Q1220, -NQ1221-C (O) -O-Q1222, -NQ1223-C (O ) - NH-Q1224, -NQ1225-C (O) -NQI226Q1227, -NHS (O 2 ) -
Q1228, -NQ1229S(O2)-Q1230, -S-Q1231, -S(O)-Q1232, - S(O2)-Q1233, -S(O2)NH-Q1234, -S(O2)NQ1235Q1236, - S(O2)O-Q1237, -P(O)(OQ1238)(OQ1239), - Si(Q1240)(Q1241)(Q1242)"; wobei Q1 191 , Q1 192, Q1 193, Q1 194, Q1 195, Q1 196, Q1 197,Q1228, -NQ1229S (O 2) -Q1230, -S-Q1231, -S (O) -Q1232, - S (O 2) -Q1233, -S (O 2) NH-Q1234, -S (O 2) NQ1235Q1236 , -S (O 2 ) O-Q 1237, -P (O) (OQ 1238) (OQ 1239), -Si (Q1240) (Q1241) (Q1242) ", where Q1 191, Q1 192, Q1 193, Q1 194, Q1 195, Q1 196, Q1 197,
Q1198, Q1199, Q1200, Q1201 , Q1202, Q1203, Q1204, Q1205, Q1206, Q1207, Q1208, Q1209, Q1210, Q1211 , Q1212, Q1213, Q1214, Q1215, Q1216, Q1217, Q1218, Q1219, Q1220, Q1221 , Q1222, Q1223, Q1224, Q1225, Q1226, Q1227, Q1228, Q1229, Q1230, Q1231 , Q1232,Q1198, Q1199, Q1200, Q1201, Q1202, Q1203, Q1204, Q1205, Q1206, Q1207, Q1208, Q1209, Q1210, Q1211, Q1212, Q1213, Q1214, Q1215, Q1216, Q1217, Q1218, Q1219, Q1220, Q1221, Q1222, Q1223, Q1224, Q1225, Q1226, Q1227, Q1228, Q1229, Q1230, Q1231, Q1232,
Q1233, Q1234, Q1235, Q1236, Q1237, Q1238, Q1239, Q1240, Q1241 , Q1242 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cyc- loalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, ary- lalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q1 197,Q1233, Q1234, Q1235, Q1236, Q1237, Q1238, Q1239, Q1240, Q1241, Q1242 are independently selected from the group consisting of: "alkyl, (Cg-C3o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl , arylalkyl, heteroaryl, heteroarylalkyl "and alternatively Q1 197,
Q1198 und/oder Q1206, Q1207 und/oder Q1219, Q1220 und/oder Q1226, Q1227 und/oder Q1235, Q1236 jeweils zusammen auch „heterocyclyl" bilden können;Q1198 and / or Q1206, Q1207 and / or Q1219, Q1220 and / or Q1226, Q1227 and / or Q1235, Q1236 may together also form "heterocyclyl";
undand
Reste Z1 , Z2 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „Wasserstoff, NZ14Z15"; mit der Maßgabe, dass wenn Z1 = H ist, Z2 = NZ14Z15 ist, und wenn Z1 = NZ14Z15 ist, Z2 = H ist; wobei Z14, Z15 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: (a) „Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C(Y1 )NZ16Z17, - C(=NZ18)-Z19, -C(Y2)NZ20-Y3-Z21 "; mit der Maßgabe, dass Z14, Z15 nicht gleichzeitig Wasserstoff oder „alkyl, (Cg- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylal- kyl, heteroaryl, heteroarylalkyl" sind; mit der weiteren Maßgabe, dass wenn einer der Reste Z14, Z15 Wasserstoff oder „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" ist, der jeweils andere Rest Z14, Z15 ,,-C(Y1 )NZ16Z17", ,,-C(=NZ18)-Z19" oder ,,-C(Y2)NZ20-Y3-Z21 " ist; wobei Y1 , Y2, Y3 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus „O, S, =NH, =NZ22"; wobei Z16, Z17, Z18, Z19, Z20, Z21 , Z22 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:Radicals Z1, Z2 are independently selected from the group consisting of: "hydrogen, NZ14Z15"; with the proviso that when Z1 = H, Z2 = NZ14Z15, and when Z1 = NZ14Z15, Z2 = H; wherein Z14, Z15 independently selected from the group consisting of: (a) "hydrogen, alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, - C (Y1) NZ16Z17, - C (= NZ18) -Z19, -C (Y2) Y3-NZ20 Z21-alkyl alkyl, (Cg-C 30), "with the proviso that Z14, Z15 do not simultaneously hydrogen or" cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "; with the further proviso that when one of Z14, Z15 hydrogen or "alkyl, (Cg-C 3 o) alkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl cycloalkyl", the in each case other radical Z14 , Z15 ,, -C (Y1) NZ16Z17 "," - C (= NZ18) -Z19 "or" - C (Y2) NZ20-Y3-Z21 "; wherein Y1, Y2, Y3 are independently selected from the group consisting of "O, S, = NH, = NZ22"; wherein Z16, Z17, Z18, Z19, Z20, Z21, Z22 are independently selected from the group consisting of :
(1 ) Wasserstoff (2) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl"; wobei obige Substituenten der Substitutionsgruppe (a) und/oder Substitutionsgruppe (2) unabhängig voneinander optional substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(1) Hydrogen (2) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl"; wherein the above substituents of the substitution group (a) and / or substitution group (2 ) independently of one another may optionally be substituted by at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHU1 , -NU2U3, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- U4, -C(O)O-U5, -C(O)NH-U6, -C(O)NU7U8, -0-U9, -O(-U10-O)r-(i) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, - NHU1, -NU2U3, -NO 2, -OH, -OCF3, -SH, -0-SO3H, - OP (O) (OH) 2, -CHO, -COOH, -C (O) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) - U4, -C (O) O-U5, -C (O) NH-U6, -C (O) NU7U8, -0 -U9, -O (-U10-O) r -
H (r = 1 , 2, 3, 4, 5), -0(-U1 1-0)r-U12 (r = 1 , 2, 3, 4, 5), -OC(O)-UI 3, -OC(O)-O-U14, -0C(0)-NHU15, -0-C(O)-N U 16U 17, - OP(O)(OU18)(OU19), -OSi(U20)(U21 )(U22), -OS(O2)-U23, - NHC(O)-U24, -NU25C(O)-U26, -NH-C(O)-O-U27, -NH-C(O)-NH- U28, -NH-C(O)-NU29U30, -NU31-C(O)-O-U32, -N 1133-C(O)-NH- U34, -NU35-C(O)-NU36U37, -NHS(O2)-U38, -NU39S(O2)-U40, - S-U41 , -S(O)-U42, -S(O2)-U43, -S(O2)NH-U44, -S(O2)NU45U46, -H (r = 1, 2, 3, 4, 5), -0 (-U1 1-0) r -U12 (r = 1, 2, 3, 4, 5), -OC (O) -UI 3, -OC (O) -O-U14, -0C (O) -NHU15, -O-C (O) -NU 16U 17, - OP (O) (OU18) (OU19), -OSi (U20) (U21) (U22), -OS (O 2) -U23, - NHC (O) -U24, -NU25C (O) -U26, -NH -C (O) -O-U27, -NH-C (O) -NH-U28, -NH-C (O) -NU29U30, -NU31-C (O) -O-U32, -N1133-C ( O) -NH- U34, -NU35-C (O) -NU36U37, -NHS (O 2) -U38, -NU39S (O 2) -U40, - S-U41, -S (O) -U42, -S (O 2) -U43, -S (O 2) NH-U44, -S (O 2) NU45U46, -
S(O2)O-U47, -P(O)(OU48)(OU49), -Si(U50)(U51 )(U52)"; wobei U1 , U2, U3, U4, U5, U6, U7, U8, U9, U10, U1 1 , U12, U13, U14, U15, U16, U17, U18, U19, U20, U21 , U22, U23, U24, U25, U26, U27, U28, U29, U30, U31 , U32, U33, U34, U35, U36, U37, U38, U39, U40, U41 , U42, U43, U44, U45, U46, U47, U48, U49, U50, U51 , U52 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ U7, U8 und/oder U16, U17 und/oder U29, U30 und/oder U36, U37 und/oder U45, U46 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:S (O 2 ) O-U47, -P (O) (OU48) (OU49), -Si (U50) (U51) (U52) "; where U1, U2, U3, U4, U5, U6, U7, U8 , U9, U10, U1 1, U12, U13, U14, U15, U16, U17, U18, U19, U20, U21, U22, U23, U24, U25, U26, U27, U28, U29, U30, U31, U32, U33, U34, U35, U36, U37, U38, U39, U40, U41, U42, U43, U44, U45, U46, U47, U48, U49, U50, U51, U52 are independently selected from the group consisting of: " alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively U7, U8 and / or U16, U17 and / or U29, U30 and / or U36, U37 and / or U45, U46 may together also also form "heterocyclyl", where optionally substituents of the substituent group (i) above may be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHU53, -NU54U55, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, - P(O)(OH)2, -C(O)-U56, -C(O)O-U57, -C(O)NH-U58, -(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2, -NHU53, -NU54U55, -NO 2, -OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2, -CHO, -COOH, -C (O) NH 2 , -SO 3 H, - P (O) (OH) 2 , -C (O) -U56, -C (O) O-U57, -C (O) NH-U 58,
C(O)NU59U60, -0-U61 , -O(-U62-O) -H (r = 1 , 2, 3, 4, 5), -0(- U63-O) -U64 (r = 1 , 2, 3, 4, 5), -OC(O)-U65, -OC(O)-O-U66, - OC(O)-NHU67, -O-C(O)-NU68U69, -OP(O)(OU70)(OU71 ), - OSi(U72)(U73)(U74), -OS(O2)-U75, -NHC(O)-U76, -NU77C(O)- U78, -NH-C(O)-O-U79, -NH-C(O)-NH-U80, -NH-C(O)-C (O) NU59U60, -0-U61, -O (-U62-O) -H (r = 1, 2, 3, 4, 5), -0 (- U63-O) -U64 (r = 1, 2, 3, 4, 5), -OC (O) -U65, -OC (O) -O-U66, -OC (O) -NHU67, -OC (O) -NU68U69, -OP (O) (OU70 ) (OU71), - OSi (U72) (U73) (U74), -OS (O 2) -U75, -NHC (O) -U76, -NU77C (O) - U78, -NH-C (O) - O-U79, -NH-C (O) -NH-U80, -NH-C (O) -
NU81 U82, -NU83-C(O)-O-U84, -NU85-C(O)-NH-U86, -NU87- C(O)-NU88U89, -NHS(O2)-U90, -NU91S(O2)-U92, -S-U93, - S(O)-U94, -S(O2)-U95, -S(O2)NH-U96, -S(O2)NU97U98, - S(O2)O-U99, -P(O)(OU I OO)(OU I OI ), -Si(UI 02)(U103)(U104)"; wobei U53, U54, U55, U56, U57, U58, U59, U60, U61 , U62, U63, U64, U65, U66, U67, U68, U69, U70, U71 , U72, U73, U74, U75, U76, U77, U78, U79, U80, U81 , U82, U83, U84, U85, U86, U87, U88, U89, U90, U91 , U92, U93, U94, U95, U96, U97, U98, U99,NU81 U82, -NU83-C (O) -O-U84, -NU85-C (O) -NH-U86, -NU87- C (O) -NU88U89, -NHS (O 2) -U90, -NU91S (O 2) -U92, -S-U93, - S (O) -U94, -S (O 2) -U95, -S (O 2) NH-U96, -S (O 2) NU97U98, - S (O 2 ) O-U99, -P (O) (OUIOO) (OUIOI), -Si (UIO2) (U103) (U104) "; wherein U53, U54, U55, U56, U57, U58, U59, U60, U61, U62, U63, U64, U65, U66, U67, U68, U69, U70, U71, U72, U73, U74, U75, U76, U77 , U78, U79, U80, U81, U82, U83, U84, U85, U86, U87, U88, U89, U90, U91, U92, U93, U94, U95, U96, U97, U98, U99,
5 U100, U101 , U 102, U103, U104 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, ary- lalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ U59, U60 und/oder U68, U69 und/oder U81 , U82 und/oder U88, U895 U100, U101, U 102, U103, U104 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, ary lalkyl, heteroaryl, heteroarylalkyl "and alternatively U59, U60 and / or U68, U69 and / or U81, U82 and / or U88, U89
10 und/oder U97, U98 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausge- 15 wählt aus der Gruppe bestehend aus:10 and / or U97, U98 may in each case also form "heterocyclyl", where optionally substituted substituents of substituent group (ii) may in turn be substituted independently with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHU105, -NU106U107, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -(iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHU105, -NU106U107, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -
20 C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-U108, -C(O)O-U109, -20 C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -U108, -C (O) O-U109, -
C(O)NH-U110, -C(O)NU111U112, -0-U113, -0(-U114-O)8- H (s = 1 , 2, 3, 4, 5), -0(-U115-O)8-Ui 16 (s = 1, 2, 3, 4, 5), - OC(O)-Um1-OC(O)-O-UIIS1-OC(O)-NHUIIg1-O-C(O)- NU120U121,-OP(O)(OU122)(OU123),-C (O) NH-U110, -C (O) NU111U112, -0-U113, -0 (-U114-O) 8 -H (s = 1, 2, 3, 4, 5), -0 (-U115 -O) 8 -Ui 16 (s = 1, 2, 3, 4, 5), - OC (O) -Um 1 -OC (O) -O-UIIS 1 -OC (O) -NHUIIg 1 -OC ( O) - NU120U121, -OP (O) (OU122) (OU123), -
25 OSi(U124)(U125)(U126), -OS(O2)-U127, -NHC(O)-U128, -25 OSi (U124) (U125), (U126), -OS (O 2) -U127, -NHC (O) -U128, -
NU^gC(O)-UISO1-NH-C(O)-O-UISI1-NH-C(O)-NH- U132, -NH-C(O)-NU133U134, -NU135-C(O)-O-U136, - NU137-C(O)-NH-UI38, -NU13g-C(O)-NU140U141, - NHS(O2)-U142, -NU143S(O2)-U144, -S-U145, -S(O)-U146,NU ^ gC (O) -UISO 1 -NH-C (O) -O-UISI 1 -NH-C (O) -NH- U132, -NH-C (O) -NU133U134, -NU135-C (O) -O-U136, - NU137-C (O) -NH-UI38, -NU13g-C (O) -NU140U141, - NHS (O 2) -U142, -NU143S (O 2) -U144, -S-U145, -S (O) -U146,
30 -S(O2)-U147, -S(O2)NH-U148, -S(O2)NU14gU150, -S(O2)O-30 -S (O 2) -U147, -S (O 2) NH-U148, -S (O 2) NU14gU150, -S (O 2) O-
U151, -P(O)(OU152)(OU153), -Si(U154)(U155)(U156)"; wobei U105, U106, U107, U108, U10g, U110, U111, U112, U113, U114, U115, U116, U117, U118, U119, U120, U121, U122, U123, U124, U125, U126, U127, U128, U12g, U130, U131, U132, U133, U134, U135, U136, U137, U138, U139, U140, U141, U142, U143, U144, U145, U146, U147, U148, U149, U150, U151, U152, U153, U154, U155, U156 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc-U151, -P (O) (OU152) (OU153), -Si (U154) (U155) (U156) ", where U105, U106, U107, U108, U10g, U110, U111, U112, U113, U114, U115, U116, U117, U118, U119, U120, U121, U122, U123, U124, U125, U126, U127, U128, U12g, U130, U131, U132, U133, U134, U135, U136, U137, U138, U139, U140, U141, U142, U143, U144, U145, U146, U147, U148, U149, U150, U151, U152, U153, U154, U155, U156 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl
IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ U1 11 , U1 12 und/oder U 120, U 121 und/oder U133, U134 und/oder U140, U141 und/oder U149, U150 jeweils zusammen auch „heterocyclyl" bilden können;IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively U1 11, U1 12 and / or U 120, U 121 and / or U133, U134 and / or U140, U141 and / or U149, U150 also together in each case" heterocyclyl "can form;
(3) -C(O)-Z23, wobei Z23 unabhängig ausgewählt ist aus der Gruppe bestehend aus:(3) -C (O) -Z23, wherein Z23 is independently selected from the group consisting of:
(a) „Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei obige Substituenten der Substitutionsgruppe (a) unabhängig voneinander optional substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(a) "hydrogen, alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wherein above substituents of the substitution group (a) may be independently optionally substituted with at least a substituent, the same or different, selected from the group consisting of:
(i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,(i) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,
CN, CF3, N3, NH2, -NHU157, -NU158U159, -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-U160, -C(O)O-U161, -C(O)NH-U162, - C(O)NUI63U164, -O-U165, -0(-U166-O)1-H (t = 1, 2, 3, 4, 5), - O(-U167-O)t-U168 (t = 1, 2, 3, 4, 5), -OC(O)-UI69, -OC(O)-O-CN, CF 3, N 3, NH 2, -NHU157, -NU158U159, -NO 2, -OH, -OCF3, - SH, -0-SO3H, -OP (O) (OH) 2, -CHO , -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -U160, -C (O) O-U161, -C (O) NH -U162, - C (O) NUI63U164, -O-U165, -O (-U166-O) 1 -H (t = 1, 2, 3, 4, 5), - O (-U167-O) t - U168 (t = 1, 2, 3, 4, 5), -OC (O) -UI69, -OC (O) -O-
U170, -OC(O)-NHU171, -O-C(O)-NU172U173, - OP(O)(OU174)(OU175), -OSi(U176)(U177)(U178), -OS(O2)- U179, -NHC(O)-U180, -NU181C(O)-U182, -NH-C(O)-O-UI83, -NH-C(O)-NH-U184, -NH-C(O)-NU185U186, -NU187-C(O)- O-U188, -NU189-C(O)-NH-U190, -NU191-C(O)-NU192U193,U170, -OC (O) -NHU171, -OC (O) -NU172U173, - OP (O) (OU174) (OU175), -OSi (U176) (U177), (U178), -OS (O 2) - U179 , -NHC (O) -U180, -NU181C (O) -U182, -NH-C (O) -O-UI83, -NH-C (O) -NH-U184, -NH-C (O) -NU185U186 , -NU187-C (O) -O-U188, -NU189-C (O) -NH-U190, -NU191-C (O) -NU192U193,
-NHS(O2)-U194, -NU195S(O2)-U196, -S-U197, -S(O)-U198, - S(O2)-U199, -S(O2)NH-U200, -S(O2)NU201U202, -S(O2)O- U203, -P(O)(OU204)(OU205), -Si(U206)(U207)(U208)"; wobei U157, U158, U159, U160, U161 , U162, U163, U164, U165, U166, U167, U168, U169, U170, U171 , U172, U173, U174, U175, U176, U177, U178, U179, U180, U181 , U182, U183, U184, U185, U186, U187, U188, U189, U190, U191 , U192, U193, U194, U195,-NHS (O 2) -U194, -NU195S (O 2) -U196, U197 -S, -S (O) -U198, - S (O 2) -U199, -S (O 2) NH-U200, -S (O 2) NU201U202, -S (O 2) O- U203, -P (O) (OU204) (OU205), -Si (U206) (U207), (U208) "; wherein U157, U158, U159, U160, U161, U162, U163, U164, U165, U166, U167, U168, U169, U170, U171, U172, U173, U174, U175, U176, U177, U178, U179, U180, U181 , U182, U183, U184, U185, U186, U187, U188, U189, U190, U191, U192, U193, U194, U195,
5 U196, U197, U198, U199, U200, U201 , U202, U203, U204, U205,5 U196, U197, U198, U199, U200, U201, U202, U203, U204, U205,
U206, U207, U208 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ U 163, U 164 und/oder U 172,"(Cg-C 3 o) alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl alkyl," and wherein alternatively U 163: are U206, U207, U208 independently selected from the group consisting of , U 164 and / or U 172,
10 U173 und/oder U185, U186 und/oder U192, U 193 und/oder U201 ,10 U173 and / or U185, U186 and / or U192, U193 and / or U201,
U202 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausge- 15 wählt aus der Gruppe bestehend aus:U202 may in each case also form "heterocyclyl", where optionally substituted substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHU209, -NU210U211 , -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHU209, -NU210U211, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -
20 C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-U212, -C(O)O-U213, -20 C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -U 2 12, -C (O) O-U 2 13, -
C(O)NH-U214, -C(O)NU215U216, -O-U217, -O(-U218-O)u- H (u = 1, 2, 3, 4, 5), -O(-U219-O)u-U220 (u = 1, 2, 3, 4, 5), - OC(O)-U221, -OC(O)-O-U222, -OC(O)-NHU223, -0-C(O)- NU224U225, -OP(O)(OU226)(OU227), -C (O) NH-U214, -C (O) NU215U216, -O-U217, -O (-U218-O) u -H (u = 1, 2, 3, 4, 5), -O (-U219 -O) u -U220 (u = 1, 2, 3, 4, 5), - OC (O) -U221, -OC (O) -O-U222, -OC (O) -NHU223, -O-C (O) - NU224U225, -OP (O) (OU226) (OU227), -
25 OSi(U228)(U229)(U230), -OS(O2)-U231, -NHC(O)-U232, -25 OSi (U228) (U229), (U230), -OS (O 2) -U231, -NHC (O) -U232, -
NU233C(O)-U234, -NH-C(O)-O-U235, -NH-C(O)-NH- U236, -NH-C(O)-NU237U238, -NU239-C(O)-O-U240, - NU241-C(O)-NH-U242, -NU243-C(O)-NU244U245, - NHS(O2)-U246, -NU247S(O2)-U248, -S-U249, -S(O)-U250,NU233C (O) -U234, -NH-C (O) -O-U235, -NH-C (O) -NH-U236, -NH-C (O) -NU237U238, -NU239-C (O) -O -U240, - NU241-C (O) -NH-U242, -NU243-C (O) -NU244U245, - NHS (O 2) -U246, -NU247S (O 2) -U248, -S-U249, -S (O) -U250,
30 -S(O2)-U251, -S(O2)NH-U252, -S(O2)NU253U254, -S(O2)O-30 -S (O 2) -U251, -S (O 2) NH-U252, -S (O 2) NU253U254, -S (O 2) O-
U255, -P(O)(OU256)(OU257), -Si(U258)(U259)(U260)"; wobei U209, U210, U211, U212, U213, U214, U215, U216, U217, U218, U219, U220, U221, U222, U223, U224, U225, U226, U227, U228, U229, U230, U231, U232, U233, U234, U235, U236, U237, U238, U239, U240, U241, U242, U243, U244, U245, U246, U247, U248, U249, U250, U251, U252, U253, U254, U255, U256, U257, U258, U259, U260 unabhängig voneinander ausgewählt sind aus der Gruppe bestehendU255, -P (O) (OU256) (OU257), -Si (U258) (U259) (U260) "; where U209, U210, U211, U212, U213, U214, U215, U216, U217, U218, U219, U220, U221, U222, U223, U224, U225, U226, U227, U228, U229, U230, U231, U232, U233, U234, U235, U236, U237, U238, U239, U240, U241, U242, U243, U244, U245, U246, U247, U248, U249, U250, U251, U252, U253, U254, U255, U256, U257, U258, U259, U260 are independently selected from the group consisting
5 aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc-5 of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl
IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ U215, U216 und/oder U224, U225 und/oder U237, U238 und/oder U244, U245 und/oder U253, U254 jeweils zusammen auch „heterocyclyl" bilden können;IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively U215, U216 and / or U224, U225 and / or U237, U238 and / or U244, U245 and / or U253, U254 may together also also form" heterocyclyl " ;
10 wobei optional obige Substituenten der SubstituentengruppeWherein optionally substituents of the substituent group above
(ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(ii) may in turn be independently substituted with at least one substituent, the same or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl,(iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl,
15 heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,15 heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,
F, Cl, Br, I, CN, CF3, N3, NH2, -NHU261, -NU262U263, - NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-U264, - C(O)O-U265, -C(O)NH-U266, -C(O)NU267U268, -O-F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHU261, -NU262U263, - NO 2, -OH, -OCF3, -SH, -0-SO3H, -OP (O ) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -U 264, -C (O) O- U265, -C (O) NH-U266, -C (O) NU267U268, -O-
20 U269, -O(-U270-O)v-H (v = 1 , 2, 3, 4, 5), -O(-U271-O)v-20 U269, -O (-U270-O) v -H (v = 1, 2, 3, 4, 5), -O (-U271-O) v -
U272 (v = 1, 2, 3, 4, 5), -OC(O)-U273, -OC(O)-O-U274, -OC(O)-NHU275, -O-C(O)-NU276U277, - OP(O)(OU278)(OU279), -OSi(U280)(U281)(U282), - OS(O2)-U283, -NHC(O)-U284, -NU285C(O)-U286, -NH-U272 (v = 1, 2, 3, 4, 5), -OC (O) -U273, -OC (O) -O-U274, -OC (O) -NHU275, -OC (O) -NU276U277, - OP (O) (OU278) (OU279), -OSi (U280) (U281), (U282), - OS (O 2) -U283, -NHC (O) -U284, -NU285C (O) -U286, -NH -
25 C(O)-O-U287, -NH-C(O)-NH-U288, -NH-C(O)-25 C (O) -O-U287, -NH-C (O) -NH-U288, -NH-C (O) -
NU289U290, -NU291-C(O)-O-U292, -N11293-C(O)-NH- U294, -NU295-C(O)-NU296U297, -NHS(O2)-U298, - NU299S(O2)-U300, -S-U301, -S(O)-U302, -S(O2)-U303, -S(O2)NH-U304, -S(O2)NU305U306, -S(O2)O-U307, -NU289U290, -NU291-C (O) -O-U292, -N11293-C (O) -NH- U294, -NU295-C (O) -NU296U297, -NHS (O 2) -U298, - NU299S (O 2 ) -U300, U301 -S, -S (O) -U302, -S (O 2) -U303, -S (O 2) NH-U304, -S (O 2) NU305U306, -S (O 2) O-U307, -
30 P(O)(OU308)(OU309), -Si(U310)(U311)(U312)"; wobei U261, U262, U263, U264, U265, U266, U267, U268, U269, U270, U271, U272, U273, U274, U275, U276, U277, U278, U279, U280, U281, U282, U283, U284, U285, U286, U287, U288, U289, U290, U291, U292, U293, U294, U295, U296, U297, U298, U299, U300, U301 , U302, U303, U304, U305, U306, U307, U308, U309, U310, U31 1 , U312 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ U267, U268 und/oder U276, U277 und/oder U289, U290 und/oder U296, U297 und/oder U305, U306 jeweils zusammen auch „heterocyclyl" bilden können;30 P (O) (OU308) (OU309), -Si (U310) (U311) (U312) ", where U261, U262, U263, U264, U265, U266, U267, U268, U269, U270, U271, U272, U273, U274, U275, U276, U277, U278, U279, U280, U281, U282, U283, U284, U285, U286, U287, U288, U289, U290, U291, U292, U293, U294, U295, U296, U297, U298, U299, U300, U301, U302, U303, U304, U305, U306, U307, U308, U309, U310, U31 1, U312 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively U267, U268 and / or U276, U277 and / or U289, U290 and / or U296, U297 and / or U305, U306 may together also form "heterocyclyl";
(4) Z16, Z17 unabhängig optional zusammen auch „heterocyclyl" bilden können";(4) Z16, Z17 independently optionally together can also form "heterocyclyl" ";
(5) ,,-C(O)-C(O)-U313, -S(O2)-NU314U315"; wobei U313, U314, U315 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:(5) ,, - C (O) -C (O) -U313, -S (O 2) -NU314U315 "; wherein U313, U314, U315 independently selected from the group consisting of:
(I) „Wasserstoff, alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHU316, -NU317U318, -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -(I) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2, -NHU316, -NU317U318, -NO 2, -OH, - OCF 3, -SH, -0-SO3H, -OP (O) (OH) 2, -CHO, -COOH, -C (O) NH 2 , -
SO3H, -P(O)(OH)2, -C(O)-U319, -C(O)O-U320, -C(O)NH-U321 , - C(O)NU322U323, -O-U324, -O(-U325-O)w-H (w = 1 , 2, 3, 4, 5), - O(-U326-O)w-U327 (w = 1 , 2, 3, 4, 5), -OC(O)-U328, -OC(O)-O- U329, -OC(O)-NHU330, -O-C(O)-NU331 U332, - OP(O)(OU333)(OU334), -OSi(U335)(U336)(U337), -OS(O2)-U338,SO 3 H, -P (O) (OH) 2, -C (O) -U319, -C (O) O-U320, -C (O) NH-U321, - C (O) NU322U323, -O- U324, -O (-U325-O) w -H (w = 1,2,3,4,5), - O (-U326-O) w -U327 (w = 1,2,3,4,5 ), -OC (O) -U328, -OC (O) -O-U329, -OC (O) -NHU330, -OC (O) -NU331U332, -OP (O) (OU333) (OU334), OSi (U335) (U336), (U337), -OS (O 2) -U338,
-NHC(O)-U339, -NU340C(O)-U341 , -NH-C(O)-O-U342, -NH- C(O)-NH-U343, -NH-C(O)-NU344U345, -NU346-C(O)-O-U347, -NU348-C(O)-NH-U349, -NU350-C(O)-NU351 U352, -NHS(O2)- U353, -NU354S(O2)-U355, -S-U356, -S(O)-U357, -S(O2)-U358, -S(O2)NH-U359, -S(O2)NU360U361 , -S(O2)O-U362, --NHC (O) -U339, -NU340C (O) -U341, -NH-C (O) -O-U342, -NH-C (O) -NH-U343, -NH-C (O) -NU344U345, -NU346-C (O) -O-U347, -NU348-C (O) -NH-U349, -NU350-C (O) -NU351 U352, -NHS (O 2) - U353, -NU354S (O 2) -U355, U356 -S, -S (O) -U357, -S (O 2) -U358, -S (O 2) NH-U359, -S (O 2) NU360U361, -S (O 2) O -U362, -
P(O)(OU363)(OU364), -Si(U365)(U366)(U367)"; wobei U316, U317, U318, U319, U320, U321 , U322, U323, U324, U325, U326, U327, U328, U329, U330, U331 , U332, U333, U334, U335, U336, U337, U338, U339, U340, U341 , U342, U343, U344, U345, U346, U347, U348, U349, U350, U351 , U352, U353, U354, U355, U356, U357, U358, U359, U360, U361 , U362, U363, U364, U365, U366, U367 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloal- kylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, he- teroarylalkyl" und wobei alternativ U322, U323 und/oder U331 , U332 und/oder U344, U345 und/oder U351 , U352 und/oder U360, U361 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substitutionsgruppe (I) unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:P (O) (OU363) (OU364), -Si (U365) (U366) (U367) "; wherein U316, U317, U318, U319, U320, U321, U322, U323, U324, U325, U326, U327, U328 , U329, U330, U331, U332, U333, U334, U335, U336, U337, U338, U339, U340, U341, U342, U343, U344, U345, U346, U347, U348, U349, U350, U351, U352, U353, U354, U355, U356, U357, U358, U359, U360, U361, U362, U363, U364, U365, U366, U367 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl heteroaryl, heteroarylalkyl "and where, alternatively, U322, U323 and / or U331, U332 and / or U344, U345 and / or U351, U352 and / or U360, U361 may each together also form" heterocyclyl "; wherein optionally substituted substituents of the substitution group (I) may be independently further substituted with at least one substituent, same or different, selected from the group consisting of:
(i) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br,(i) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br,
I, CN, CF3, N3, NH2, -NHU368, -NU369U370, -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-U371 , -C(O)O-U372, - C(O)NH-U373, -C(O)NU374U375, -O-U376, -0(-11377-O)x-H (x = 1 , 2, 3, 4, 5), -O(-U378-O)x-U379 (x = 1 , 2, 3, 4, 5), -I, CN, CF 3 , N 3 , NH 2 , -NHU368, -NU369U370, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -U371, -C (O) O-U372, -C (O ) NH-U373, -C (O) NU374U375, -O-U376, -O (-11377-O) x -H (x = 1, 2, 3, 4, 5), -O (-U378-O) x -U379 (x = 1, 2, 3, 4, 5), -
OC(O)-U380, -OC(O)-O-U381 , -OC(O)-NHU382, -0-C(O)- NU383U384, -OP(O)(OU385)(OU386), - OSi(U387)(U388)(U389), -OS(O2)-U390, -NHC(O)-U391 , - NU392C(O)-U393, -NH-C(O)-O-U394, -NH-C(O)-NH-U395, -NH-C(O)-NU396U397, -NU398-C(O)-O-U399, -NU400-OC (O) -U380, -OC (O) -O-U381, -OC (O) -NHU382, -O-C (O) -NU383U384, -OP (O) (OU385) (OU386), -OSi ( U387) (U388), (U389), -OS (O 2) -U390, -NHC (O) -U391, - NU392C (O) -U393, -NH-C (O) -O-U394, -NH-C (O) -NH-U395, -NH-C (O) -NU396U397, -NU398-C (O) -O-U399, -NU400-
C(O)-NH-U401 , -NU402-C(O)-NU403U404, -NHS(O2)-U405, -NU406S(O2)-U407, -S-U408, -S(O)-U409, -S(O2)-U410, - S(O2)NH-U411 , -S(O2)NU412U413, -S(O2)O-U414, - P(0)(0U415)(OU416), -Si(U417)(U418)(U419)"; wobei U368, U369, U370, U371 , U372, U373, U374, U375,C (O) -NH-U401, -NU402-C (O) -NU403U404, -NHS (O 2) -U405, -NU406S (O 2) -U407, U408 -S, -S (O) -U409, -S (O 2) -U410, - S (O 2) NH-U411, -S (O 2) NU412U413, -S (O 2) O-U414, - P (0) (0U415) (OU416) - Si (U417) (U418) (U419) "; wherein U368, U369, U370, U371, U372, U373, U374, U375,
U376, U377, U378, U379, U380, U381 , U382, U383, U384, U385, U386, U387, U388, U389, U390, U391 , U392, U393, U394, U395, U396, U397, U398, U399, U400, U401 , U402, U403, U404, U405, U406, U407, U408, U409, U410, U411 , U412, U413, U414, U415, U416, U417, U418, U419 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wo-U376, U377, U378, U379, U380, U381, U382, U383, U384, U385, U386, U387, U388, U389, U390, U391, U392, U393, U394, U395, U396, U397, U398, U399, U400, U401, U402, U403, U404, U405, U406, U407, U408, U409, U410, U411, U412, U413, U414, U415, U416, U417, U418, U419 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl , heteroaryl, heteroarylalkyl "and where
5 bei alternativ U374, U375 und/oder U383, U384 und/oder U396,5 with alternatively U374, U375 and / or U383, U384 and / or U396,
U397 und/oder U403, U404 und/oder U412, U413 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mitU397 and / or U403, U404 and / or U412, U413 may together also form "heterocyclyl", where optionally substituents of the substituent group (i) above may be substituted independently of one another with
10 mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:At least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHU420, -NU421 U422, -NO2,(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHU420, -NU421 U422, -NO 2 ,
15 -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -15 -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -
COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-U423, - C(O)O-U424, -C(O)NH-U425, -C(O)NU426U427, -O- U428, -O(-U429-O)y-H (y = 1, 2, 3, 4, 5), -O(-U430-O)y- U431 (y = 1 , 2, 3, 4, 5), -OC(O)-U432, -OC(O)-O-U433, -COOH, -C (O) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) -U423, - C (O) O-U424, -C (O) NH-U425 , -C (O) NU426U427, -O-U428, -O (-U429-O) y -H (y = 1, 2, 3, 4, 5), -O (-U430-O) y - U431 ( y = 1, 2, 3, 4, 5), -OC (O) -U432, -OC (O) -O-U433, -
20 OC(O)-NHU434, -O-C(O)-NU435U436, -20 OC (O) -NHU434, -O-C (O) -NU435U436, -
OP(O)(OU437)(OU438), -OSi(U439)(U440)(U441), - OS(O2)-U442, -NHC(O)-U443, -NU444C(O)-U445, -NH- C(O)-O-U446, -NH-C(O)-NH-U447, -NH-C(O)- NU448U449, -NU450-C(O)-O-U451, -N11452-C(O)-NH-OP (O) (OU437) (OU438), -OSi (U439) (U440), (U441), - OS (O 2) -U442, -NHC (O) -U443, -NU444C (O) -U445, -NH - C (O) -O-U446, -NH-C (O) -NH-U447, -NH-C (O) -NU448U449, -NU450-C (O) -O-U451, -N11452-C (O ) -NH-
25 U453, -NU454-C(O)-NU455U456, -NHS(O2)-U457, -25 U453, -NU454-C (O) -NU455U456, -NHS (O 2 ) -U457, -
NU458S(O2)-U459, -S-U460, -S(O)-U461, -S(O2)-U462, - S(O2)NH-U463, -S(O2)NU464U465, -S(O2)O-U466, - P(O)(OU467)(OU468), -Si(U469)(U470)(U471)"; wobei U420, U421, U422, U423, U424, U425, U426, U427,NU458S (O 2) -U459, U460 -S, -S (O) -U461, -S (O 2) -U462, - S (O 2) NH-U463, -S (O 2) NU464U465, -S (O 2 ) O-U466, -P (O) (OU467) (OU468), -Si (U469) (U470) (U471) "; where U420, U421, U422, U423, U424, U425, U426, U427,
30 U428, U429, U430, U431 , U432, U433, U434, U435, U436,30 U428, U429, U430, U431, U432, U433, U434, U435, U436,
U437, U438, U439, U440, U441, U442, U443, U444, U445, U446, U447, U448, U449, U450, U451, U452, U453, U454, U455, U456, U457, U458, U459, U460, U461, U462, U463, U464, U465, U466, U467, U468, U469, U470, U471 unab- hängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, he- terocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, hete- roarylalkyl" und wobei alternativ U426, U427 und/oder U435,U437, U438, U439, U440, U441, U442, U443, U444, U445, U446, U447, U448, U449, U450, U451, U452, U453, U454, U455, U456, U457, U458, U459, U460, U461, U462, U463, U464, U465, U466, U467, U468, U469, U470, U471 "(C 9 -C 3 o) alkyl, alkyl, cycloalkyl, cycloalkylalkyl, HE terocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, het- roarylalkyl" and wherein alternatively U426, U427 and: are pending selected from the group consisting of / or U435,
5 U436 und/oder U448, U449 und/oder U455, U456 und/oder5 U436 and / or U448, U449 and / or U455, U456 and / or
U464, U465 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein kön-U464, U465 may together also form "heterocyclyl", where optionally substituents of the substituent group (ii) above may be substituted independently of one another
10 nen mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:10 nen with at least one substituent, the same or different, selected from the group consisting of:
(iii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHU472, -(iii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHU472, -
15 NU473U474, -NO2, -OH, -OCF3, -SH, -0-SO3H, -15 NU473U474, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -
OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, - P(O)(OH)2, -C(O)-U475, -C(O)O-U476, -C(O)NH- U477, -C(O)NU478U479, -O-U480, -O(-U481-O)z-H (z = 1 , 2, 3, 4, 5), -O(-U482-O)z-U483 (z = 1 , 2, 3, 4, 5), -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -U475, -C (O ) O-U476, -C (O) NH-U477, -C (O) NU478U479, -O-U480, -O (-U481-O) z -H (z = 1, 2, 3, 4, 5) , -O (-U482-O) z -U483 (z = 1, 2, 3, 4, 5), -
20 OC(O)-U484, -OC(O)-O-U485, -OC(O)-N H U486, -O-20 OC (O) -U484, -OC (O) -O-U485, -OC (O) -NHU486, -O-
C(O)-NU487U488, -OP(O)(OU489)(OU490), - OSi(U491 )(U492)(U493), -OS(O2)-U494, -NHC(O)- U495, -NU496C(O)-U497, -NH-C(O)-O-U498, -NH- C(O)-NH-U499, -NH-C(O)-NU500U501 , -NU502-C (O) -NU487U488, -OP (O) (OU489) (OU490), - OSi (U491) (U492), (U493), -OS (O 2) -U494, -NHC (O) - U495, -NU496C (O) -U497, -NH-C (O) -O-U498, -NH-C (O) -NH-U499, -NH-C (O) -NU500U501, -NU502-
25 C(O)-O-U503, -NU504-C(O)-NH-U505, -NU506-25 C (O) -O-U503, -NU504-C (O) -NH-U505, -NU506-
C(O)-NU507U508, -NHS(O2)-U509, -NU51 OS(O2)- U511 , -S-U512, -S(O)-U513, -S(O2)-U514, -S(O2)NH- U515, -S(O2)NU516U517, -S(O2)O-U518, - P(O)(OU519)(OU520), -Si(U521 )(U522)(U523)";C (O) -NU507U508, -NHS (O 2) -U509, -NU51 OS (O 2) - U511, U512 -S-, -S (O) -U513, -S (O 2) -U514, -S (O 2) NH- U515, -S (O 2) NU516U517, -S (O 2) O-U518, - P (O) (OU519) (OU520), -Si (U521) (U522), (U523) ";
30 wobei U472, U473, U474, U475, U476, U477, U478,30 wherein U472, U473, U474, U475, U476, U477, U478,
U479, U480, U481 , U482, U483, U484, U485, U486, U487, U488, U489, U490, U491 , U492, U493, U494, U495, U496, U497, U498, U499, U500, U501 , U502, U503, U504, U505, U506, U507, U508, U509, U510, U511 , U512, U513, U514, U515, U516, U517, U518, U519, U520, U521 , U522, U523 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ U478, U479 und/oder U487, U488 und/oder U500, U501 und/oder U507, U508 und/oder U516, U517 jeweils zusammen auch „heterocyclyl" bilden können; und wobei alternativ U314, U315 zusammen auch „heterocyclyl" bilden können;U479, U480, U481, U482, U483, U484, U485, U486, U487, U488, U489, U490, U491, U492, U493, U494, U495, U496, U497, U498, U499, U500, U501, U502, U503, U504, U505, U506, U507, U508, U509, U510, U511, U512, U513, U514, U515, U516, U517, U518, U519, U520, U521, U522, U523 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively U478, U479 and / or U487, U488 and / or U500, U501 and / or U507, U508 and / or U516, U517 also together in each case" heterocyclyl "can form; and alternatively, U314, U315 may together also form "heterocyclyl";
undand
Rest Z5 unabhängig ausgewählt ist aus der Gruppe bestehend aus:Rest Z5 is independently selected from the group consisting of:
(i) „Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, het- erocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHA1 , -NA2A3, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(0)-A4, - C(0)0-A5, -C(O)NH-A6, -C(O)NA7A8, -0-A9, -O(-A10-O)r-H (r = 1 , 2, 3,(i) "hydrogen, alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2, -NHA1, -NA2A3, -NO 2, -OH, -OCF3, -SH, -0-SO3H, - OP (O) (OH) 2, -CHO, -COOH, -C ( O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -A 4, -C (O) 0 -A5, -C (O) NH-A 6, -C (O ) NA7A8, -O-A9, -O (-A10-O) r -H (r = 1, 2, 3,
4, 5), -0(-A11-0)r-A12 (r = 1 , 2, 3, 4, 5), -OC(O)-AI 3, -OC(O)-O-AI 4, - OC(O)-NHAI 5, -0-C(O)-NAI 6A17, -OP(O)(OAI 8)(0A19), - OSi(A20)(A21 )(A22), -OS(O2)-A23, -NHC(O)-A24, -NA25C(O)-A26, -NH- C(O)-O-A27, -N H-C(O)-N H-A28, -N H-C(O)-N A29A30, -NA31 -C(O)-O- A32, -NA33-C(O)-NH-A34, -NA35-C(O)-NA36A37, -NHS(O2)-A38, -4, 5), -O (-A11-0) r -A12 (r = 1, 2, 3, 4, 5), -OC (O) -Al 3, -OC (O) -O-Al 4, OC (O) -NHAI 5, -O-C (O) -NAI 6A17, -OP (O) (OAI 8) (0A19), -OSi (A20) (A21) (A22), -OS (O 2 ) -A23, -NHC (O) -A24, -NA25C (O) -A26, -NH-C (O) -O-A27, -NHC (O) -NH-A28, -NHC (O) N A29A30, -NA31-C (O) -O- A32, -NA33-C (O) -NH-A34, -NA35-C (O) -NA36A37, -NHS (O 2) -A38, -
NA39S(O2)-A40, -S-A41 , -S(O)-A42, -S(O2)-A43, -S(O2)NH-A44, - S(O2)NA45A46, -S(O2)O-A47, -P(O)(OA48)(OA49), -Si(A50)(A51 )(A52)"; wobei A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, A11, A12, A13, A14, A15,NA39S (O2) -A40, -S-A41, -S (O) -A42, -S (O2) -A43, -S (O2) NH-A44, - S (O 2) NA45A46, -S (O 2 ) O-A47, -P (O) (OA48) (OA49), -Si (A50) (A51) (A52) ", wherein A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, A11, A12, A13, A14, A15,
A16, A17, A18, A19, A20, A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A35, A36, A37, A38, A39, A40, A41, A42, A43,A16, A17, A18, A19, A20, A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A35, A36, A37, A38, A39, A40, A41, A42, A43,
A44, A45, A46, A47, A48, A49, A50, A51 , A52 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, het- eroarylalkyl" und wobei alternativ A7, A8 und/oder A16, A17 und/oder A29, A30 und/oder A36, A37 und/oder A45, A46 jeweils zusammen auch „hetero- cyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum un- abhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:A44, A45, A46, A47, A48, A49, A50, A51, A52 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl , heteroaryl, het eroarylalkyl "and wherein alternatively A7, A8 and / or A16, A17 and / or A29, A30 and / or A36, A37 and / or A45, A46 may together also form" heterocyclyl "; wherein optionally substituents of the substituent group (i) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHA53, -NA54A55, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-(ii) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHA53, -NA54A55, -NO 2, -OH, -OCF3, -SH, -0-SO3H, - OP (O) (OH) 2, -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -
A56, -C(O)O-A57, -C(O)NH-A58, -C(O)NA59A60, -0-A61 , -O(-A62- O)5-H (s = 1 , 2, 3, 4, 5), -O(-A63-O)t-A64 (t = 1 , 2, 3, 4, 5), -OC(O)- A65, -OC(O)-O-A66, -OC(O)-NHA67, -0-C(O)-N A68A69, - OP(O)(OA70)(OA71 ), -OSi(A72)(A73)(A74), -OS(O2)-A75, -NHC(O)- A76, -NA77C(O)-A78, -NH-C(O)-O-A79, -N H-C(O)-N H-A80, -NH-A56, -C (O) O-A57, -C (O) NH-A58, -C (O) NA59A60, -O-A61, -O (-A62-O) 5 -H (s = 1, 2, 3, 4, 5), -O (-A63-O) t -A64 (t = 1, 2, 3, 4, 5), -OC (O) -A65, -OC (O) -O-A66, -OC (O) -NHA67, -O-C (O) -N A68A69, - OP (O) (OA70) (OA71), -OSi (A72) (A73) (A74), -OS (O 2 ) - A75, -NHC (O) -A76, -NA77C (O) -A78, -NH-C (O) -O-A79, -NHC (O) -NH-A80, -NH-
C(O)-NA81A82, -NA83-C(O)-O-A84, -NA85-C(O)-NH-A86, -NA87- C(O)-NA88A89, -NHS(O2)-A90, -NA91 S(O2)-A92, -S-A93, -S(O)-A94, -S(O2)-A95, -S(O2)NH-A96, -S(O2)NA97A98, -S(O2)O-A99, - P(O)(OAI 00)(OA101 ), -Si(AI 02)(A103)(A104)"; wobei A53, A54, A55, A56, A57, A58, A59, A60, A61 , A62, A63, A64,C (O) -NA81A82, -NA83-C (O) -O-A84, -NA85-C (O) -NH-A86, -NA87- C (O) -NA88A89, -NHS (O 2) -A90, -NA91 S (O 2) -A92, -S-A93, -S (O) -A94, -S (O2) -A95, -S (O2) NH-A96, -S (O2) NA97A98, -S (O 2 ) O-A99, -P (O) (OAlO) O (OA101), -Si (AlO 2) (A103) (A104) ", where A53, A54, A55, A56, A57, A58, A59, A60, A61, A62, A63, A64,
A65, A66, A67, A68, A69, A70, A71 , A72, A73, A74, A75, A76, A77, A78, A79, A80, A81 , A82, A83, A84, A85, A86, A87, A88, A89, A90, A91 , A92, A93, A94, A95, A96, A97, A98, A99, A100, A101 , A102, A103, A104 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ A59, A60 und/oder A68, A69 und/oder A81 , A82 und/oder A88, A89 und/oder A97, A98 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einemA65, A66, A67, A68, A69, A70, A71, A72, A73, A74, A75, A76, A77, A78, A79, A80, A81, A82, A83, A84, A85, A86, A87, A88, A89, A90, A91, A92, A93, A94, A95, A96, A97, A98, A99, A100, A101, A102, A103, A104 are independently selected from the group consisting of: alkyl "alkyl, (Cg-C 30), cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively A59, A60 and / or A68, A69 and / or A81, A82 and / or A88, A89 and / or A97, A98 in each case together also "heterocyclyl" can form; optionally substituents of the substituent group (ii) above may be substituted independently with at least one
Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Substituents, the same or different, selected from the group consisting of:
(iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocy- clylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHA105, -NA106A107, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-AI 08, -C(O)O-AI 09, -C(O)NH-AH O, -C(O)NA1 11 A1 12, - 0-A113, -O(-A114-O)t-H (t = 1 , 2, 3, 4, 5), -O(-A115-O)t-A116 (t = 1 , 2, 3, 4, 5), -OC(O)-A1 17, -OC(O)-O-A118, -OC(O)-NHA1 19, -(iii) "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHA105, -NA106A107, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP (O) (OH) 2, -CHO, - COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Al 08, -C (O) O-Al 09, -C (O) NH -AHO, -C (O) NA 11 Al 12, 0-A113, -O (-A114-O) t -H (t = 1, 2, 3, 4, 5), -O (-A115- O) t -A116 (t = 1, 2, 3, 4, 5), -OC (O) -A1 17, -OC (O) -O-A118, -OC (O) -NHA1 19, -
0-C(O)-NAI 20A121 , -OP(O)(OAI 22)(OA123), - OSi(AI 24)(A125)(A126), -OS(O2)-A127, -NHC(O)-A128, - NA129C(O)-AI 30, -N H-C(O)-O-AI 31 , -N H-C(O)-NH-AI 32, -NH- C(O)-NAI 33A134, -NA135-C(O)-O-AI 36, -NA137-C(O)-N H- A138, -NA139-C(O)-NAI 40A141 , -NHS(O2)-A142, -NA143S(O2)-0-C (O) -NAI 20A121, -OP (O) (OAI 22) (OA123), - OSi (Al 24) (A125) (A126), -OS (O 2 ) -A127, -NHC (O) -A128, - NA129C (O) -AI 30, -NHC (O) -O-Al 31, -NHC (O) -NH-AI 32, -NH-C (O) -NAI 33A134, -NA 135- C (O) -O-AI 36, -NA137-C (O) -N H-A138, -NA139-C (O) -nai 40A141, -NHS (O 2) -A142, -NA143S (O 2) -
A144, -S-A145, -S(O)-AI 46, -S(O2)-A147, -S(O2)NH-AI 48, - S(O2)NAI 49A150, -S(O2)O-AI 51 , -P(O)(OAI 52)(OA153), - Si(AI 54)(A155)(A156)"; wobei A105, A106, A107, A108, A109, A1 10, A11 1 , A1 12, A113, A114. A115, A1 16. A117, A1 18. A119, A120. A121 , A122, A123,A144, -S-A145, -S (O) -AI 46, -S (O 2) -A147, -S (O 2) NH-AI 48, - S (O 2) NAI 49A150, -S (O 2 ) O-Al 51, -P (O) (OAl 52) (OA153), -Si (Al 54) (A155) (A156) ", where A105, A106, A107, A108, A109, A1 10, A11 1, A1 12, A113, A114, A115, A1, 16. A117, A1, 18. A119, A120, A121, A122, A123,
A124, A125, A126, A127, A128, A129, A130, A131 , A132, A133, A134, A135, A136, A137, A138, A139, A140, A141 , A142, A143, A144, A145, A146, A147, A148, A149, A150, A151 , A152, A153, A154, A155, A156 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ A11 1 , A1 12 und/oder A120, A121 und/oder A133, A134 und/oder A140, A141 und/oder A149, A150 jeweils zusammen auch „heterocyclyl" bilden können;A124, A125, A126, A127, A128, A129, A130, A131, A132, A133, A134, A135, A136, A137, A138, A139, A140, A141, A142, A143, A144, A145, A146, A147, A148, A149, A150, A151, A152, A153, A154, A155, A156 are independently selected from the group consisting of: alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl "heteroarylalkyl" and wherein alternatively A11 1, A1 12 and / or A120, A121 and / or A133, A134 and / or A140, A141 and / or A149, A150 may together also form "heterocyclyl";
oderor
(E) einer der Reste Z1 , Z2 oder beide Reste Z1 , Z2 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: (a) -NZ24Z25; mit der Maßgabe, dass einer der Reste Z24, Z25 oder beide Reste Z24, Z25 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: (1 ) ,,-C(O)-C(O)-TI , -S(O2)-NT2T3"; wobei T1 , T2, T3 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:(E) one of the radicals Z1, Z2 or both radicals Z1, Z2 are independently selected from the group consisting of: (a) -NZ24Z25; with the proviso that one of the radicals Z24, Z25 or both radicals Z24, Z25 are selected independently of one another from the group consisting of: (1) ,, - C (O) -C (O) -TI, -S (O 2) -NT2T3 "; wherein T1, T2, T3 are independently selected from the group consisting of:
(I) „Wasserstoff, alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F,(I) "hydrogen, alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F,
Cl, Br, I, CN, CF3, N3, NH2, -NHT4, -NT5T6, -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, - P(O)(OH)2, -C(0)-T7, -C(0)0-T8, -C(0)NH-T9, -C(O)NTI0T11, - 0-T12, -O(-T13-O)p-H (p = 1, 2, 3, 4, 5), -O(-T14-O)p-T15 (p = 1, 2, 3, 4, 5), -OC(O)-TI6, -OC(O)-O-TI7, -OC(O)-NHTI8, -O-Cl, Br, I, CN, CF 3, N 3, NH 2, -NHT4, -NT5T6, -NO 2, -OH, -OCF3, - SH, -0-SO3H, -OP (O) ( OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, - P (O) (OH) 2 , -C (O) -T 7, -C (O) 0-T 8, -C (O) NH-T9, -C (O) NTI0T11, -O-T12, -O (-T13-O) p -H (p = 1, 2, 3, 4, 5), -O (- T14-O) p -T15 (p = 1, 2, 3, 4, 5), -OC (O) -TI6, -OC (O) -O-TI7, -OC (O) -NHTI8, -O-
C(O)-NTI9T20, -OP(O)(OT21)(OT22), -OSi(T23)(T24)(T25), - OS(O2)-T26, -NHC(O)-T27, -NT28C(O)-T29, -NH-C(O)-O-T30, -NH-C(O)-NH-T31, -NH-C(O)-NT32T33, -NT34-C(O)-O-T35, - NT36-C(O)-NH-T37, -NT38-C(O)-NT39T40, -NHS(O2)-T41, - NT42S(O2)-T43, -S-T44, -S(O)-T45, -S(O2)-T46, -S(O2)NH-T47,C (O) -NTI9T20, -OP (O) (OT21) (OT22), -OSi (T23) (T24) (T25), - OS (O 2) -T26, -NHC (O) -T27, -NT28C (O) -T29, -NH-C (O) -O-T30, -NH-C (O) -NH-T31, -NH-C (O) -NT32T33, -NT34-C (O) -O- T35, - NT36-C (O) -NH-T37, -NT38-C (O) -NT39T40, -NHS (O 2) -T41, - NT42S (O 2) -T43, -S-T44, -S ( O) -T45, -S (O 2) -T46, -S (O 2) NH-T47,
-S(O2)NT48T49, -S(O2)O-T50, -P(O)(OT51)(OT52), - Si(T53)(T54)(T55)"; wobei T4, T5, T6, T7, T8, T9, T10, T11, T12, T13, T14, T15, T16, T17, T18, T19, T20, T21, T22, T23, T24, T25, T26, T27, T28, T29, T30, T31 , T32, T33, T34, T35, T36, T37, T38, T39, T40, T41 , T42,-S (O 2) NT48T49, -S (O 2) O-T50, -P (O) (OT51) (OT52), - Si (T53) (T54) (T55) "; wherein T4, T5, T6, T7, T8, T9, T10, T11, T12, T13, T14, T15, T16, T17, T18, T19, T20, T21, T22, T23, T24, T25, T26, T27, T28, T29, T30, T31, T32, T33, T34, T35, T36, T37, T38, T39, T40, T41, T42,
T43, T44, T45, T46, T47, T48, T49, T50, T51 , T52, T53, T54, T55 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T10, T1 1 und/oder T19, T20 und/oder T32, T33 und/oder T39, T40 und/oder T48, T49 jeweils zusammen auch „he- terocyclyl" bilden können; wobei optional obige Substituenten der Substitutionsgruppe (I) unabhängig voneinander auch weiter substituiert sein können mit min- destens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Are T43, T44, T45, T46, T47, T48, T49, T50, T51, T52, T53, T54, T55 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl , heterocyc IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively T10, T1 1 and / or T19, T20 and / or T32, T33 and / or T39, T40 and / or T48, T49 also together" terocyclyl "can form; wherein optionally substituted substituents of the substitution group (I) independently of one another can also be further substituted by at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT56, -NT57T58, -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, - SO3H, -P(O)(OH)2, -C(O)-T59, -C(O)O-T60, -C(0)NH-T61 , - C(O)NT62T63, -O-T64, -O(-T65-O)r-H (r = 1 , 2, 3, 4, 5), -0(- T66-O)r-T67 (r = 1 , 2, 3, 4, 5), -OC(O)-T68, -OC(O)-O-T69, - 5 OC(O)-NHT70, -O-C(O)-NT71T72, -OP(O)(OT73)(OT74), -(i) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT56, -NT57T58, -NO 2 , -OH, -OCF 3 , - SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T59, -C (O) O-T60, -C (O) NH-T61, -C (O) NT62T63, -O-T64, -O (-T65-O) r -H (r = 1, 2, 3, 4, 5), -0 (- T66-O) r -T67 (r = 1, 2, 3, 4, 5), -OC (O) -T68, -OC (O) - O-T69, 5 OC (O) -NHT70, -OC (O) -NT71T72, -OP (O) (OT73) (OT74),
OSi(T75)(T76)(T77), -OS(O2)-T78, -NHC(O)-T79, -NT80C(O)- T81 , -NH-C(O)-O-T82, -N H-C(O)-N H-T83, -NH-C(O)- NT84T85, -NT86-C(O)-O-T87, -NT88-C(O)-NH-T89, -NT90- C(O)-NT91T92, -NHS(O2)-T93, -NT94S(O2)-T95, -S-T96, -OSi (T75) (T76) (T77), -OS (O 2) -T78, -NHC (O) -T79, -NT80C (O) - T81, -NH-C (O) -O-T82, -N HC (O) -NH-T83, -NH-C (O) -NT84T85, -NT86-C (O) -O-T87, -NT88-C (O) -NH-T89, -NT90-C (O ) -NT91T92, -NHS (O 2 ) -T93, -NT94S (O 2 ) -T95, -S-T96, -
10 S(O)-T97, -S(O2)-T98, -S(O2)NH-T99, -S(O2)NTI 00T101 , -10 S (O) -T97, -S (O 2) -T98, -S (O 2) NH-T99, -S (O 2) NTI 00T101, -
S(O2)O-TI 02, -P(O)(OTI 03)(OT104), -Si(TI 05)(T106)(T107)"; wobei T56, T57, T58, T59, T60, T61 , T62, T63, T64, T65, T66, T67, T68, T69, T70, T71 , T72, T73, T74, T75, T76, T77, T78, T79, T80, T81 , T82, T83, T84, T85, T86, T87, T88, T89, T90,S (O 2 ) O-TI 02, -P (O) (OTI 03) (OT104), -Si (TI 05) (T106) (T107) "; wherein T56, T57, T58, T59, T60, T61, T62, T63, T64, T65, T66, T67, T68, T69, T70, T71, T72, T73, T74, T75, T76, T77, T78, T79, T80, T81, T82, T83, T84, T85, T86, T87, T88, T89, T90,
15 T91 , T92, T93, T94, T95, T96, T97, T98, T99, T100, T101 , T102,15 T91, T92, T93, T94, T95, T96, T97, T98, T99, T100, T101, T102,
T103, T104, T105, T106, T107 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T62,T103, T104, T105, T106, T107 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively T62,
20 T63 und/oder T71 , T72 und/oder T84, T85 und/oder T91 , T92 und/oder T100, T101 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit20 T63 and / or T71, T72 and / or T84, T85 and / or T91, T92 and / or T100, T101 may together also form "heterocyclyl", where optionally substituents of the substituent group (i) above may be substituted independently of one another With
25 mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:At least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT108, -NT109T110, -NO2, -(ii) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, - NHT108, -NT109T110, -NO 2 , -
30 OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH,30 OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH,
-C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-TH 1 , -C(O)O-T112, -C(O)NH-T1 13, -C(O)NT114T1 15, -0-T116, -0(-T1 17- O)5-H (s = 1 , 2, 3, 4, 5), -0(-T1 18-0)s-T1 19 (s = 1 , 2, 3, 4, 5), -OC(O)-T120, -OC(O)-O-TI 21 , -OC(O)-NHTI 22, -O- C(O)-NTI 23T124, -OP(O)(OTI 25)(OT126), - OSi(TI 27)(T128)(T129), -OS(O2)-T130, -NHC(O)-TI 31 , - NT132C(O)-TI 33, -NH-C(O)-O-TI 34, -NH-C(O)-NH- T135, -NH-C(O)-NTI 36T137, -NT138-C(O)-O-TI 39, - 5 NT140-C(O)-NH-TI 41 , -NT142-C(O)-NTI 43T144, --C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -TH 1, -C (O) O-T1 12, -C (O) NH-T1 13 , -C (O) NT114T1 15, -O-T116, -O (-T1 17-O) 5 -H (s = 1, 2, 3, 4, 5), -O (-T1 18-0) s -T1 19 (s = 1, 2, 3, 4, 5), -OC (O) -T120, -OC (O) -O-TI 21, -OC (O) -NHTI 22, -O- C (O) -NTI 23T124, -OP (O) (OTI 25) (OT126), - OSi (TI 27) (T128) (T129), -OS (O 2 ) -T130, -NHC (O) -TI 31, - NT132C (O) -TI 33, -NH-C (O) -O-TI 34, -NH-C (O) -NH-T135, -NH-C (O) -NTI 36T137, -NT138- C (O) -O-TI 39, - 5NT140-C (O) -NH-TI 41, -NT142-C (O) -NTI 43T144, -
NHS(O2)-T145, -NT146S(O2)-T147, -S-T148, -S(O)-T149, -S(O2)-T150, -S(O2)NH-TI 51 , -S(O2)NTI 52T153, - S(O2)O-TI 54, -P(O)(OTI 55)(OT156), - Si(TI 57)(T158)(T159)";NHS (O 2) -T145, -NT146S (O 2) -T147, -S-T148, -S (O) -T149, -S (O 2) -T150, -S (O 2) NH-TI 51, -S (O 2) NTI 52T153, - S (O 2) OTI 54, -P (O) (OTI 55) (OT156), - Si (TI 57) (T158), (T159) ";
10 wobei T108, T109, T110, T11 1 , T112, T113, T1 14, T1 15,10 where T108, T109, T110, T11 1, T112, T113, T1 14, T1 15,
T116, T1 17, T1 18, T1 19, T120, T121 , T122, T123, T124, T125, T126, T127, T128, T129, T130, T131 , T132, T133, T134, T135, T136, T137, T138, T139, T140, T141 , T142, T143, T144, T145, T146, T147, T148, T149, T150, T151 ,T116, T117, T118, T119, T120, T121, T122, T123, T124, T125, T126, T127, T128, T129, T130, T131, T132, T133, T134, T135, T136, T137, T138, T139 , T140, T141, T142, T143, T144, T145, T146, T147, T148, T149, T150, T151,
15 T152, T153, T154, T155, T156, T157, T158, T159 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" und wobei alternativ T114, T115 und/oder T123, T124(C 9 -C 3 o) "alkyl, alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl: 15 T152, T153, T154, T155, T156, T157, T158, T159 independently selected from the group consisting of , arylalkyl, heteroaryl, heteroarylalkyl "and alternatively T114, T115 and / or T123, T124
20 und/oder T136, T137 und/oder T143, T144 und/oder T152,20 and / or T136, T137 and / or T143, T144 and / or T152,
T153 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder ver- 25 schieden, ausgewählt aus der Gruppe bestehend aus:T153 may in each case also form "heterocyclyl", where optionally substituted substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT160, - NT161T162, -NO2, -OH, -OCF3, -SH, -0-SO3H, - 30 OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -(iii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHT160, -NT161T162, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -30 OP (O) (OH) 2 , -CHO, -COOH, -C ( O) NH 2 , -SO 3 H, -
P(O)(OH)2, -C(O)-TI 63, -C(O)O-TI 64, -C(O)NH-TI 65, -C(O)NTI 66T167, -O-T168, -0(-T169-O)1-H (t = 1 , 2, 3, 4, 5), -O(-T170-O)t-T171 (t = 1 , 2, 3, 4, 5), -OC(O)- T172, -OC(O)-O-TI 73, -OC(O)-NHTI 74, -0-C(O)- NT175T176, -OP(O)(OTI77)(OT178), - OSi(TI79)(T180)(T181), -OS(O2)-T182, -NHC(O)-TI83, -NT184C(O)-TI85, -NH-C(O)-O-TI86, -NH-C(O)- NH-T187, -NH-C(O)-NTI88T189, -NT190-C(O)-O- T191, -NT192-C(O)-NH-TI93, -NT194-C(O)-P (O) (OH) 2 , -C (O) -TI 63, -C (O) O-TI 64, -C (O) NH-TI 65, -C (O) NTI 66T167, -O-T168 , -O (-T169-O) 1 -H (t = 1, 2, 3, 4, 5), -O (-T170-O) t -T171 (t = 1, 2, 3, 4, 5) , -OC (O) -T172, -OC (O) -O-TI 73, -OC (O) -NHTI 74, -O-C (O) - NT175T176, -OP (O) (OTI77) (OT178), - OSi (TI79) (T180), (T181), -OS (O 2) -T182, -NHC (O) -TI83, -NT184C (O) -TI85 , -NH-C (O) -O-TI86, -NH-C (O) -NH-T187, -NH-C (O) -NTI88T189, -NT190-C (O) -O-T191, -NT192- C (O) -NH-TI93, -NT194-C (O) -
NT195T196, -NHS(O2)-T197, -NT198S(O2)-T199, -S- T200, -S(O)-T201 , -S(O2)-T202, -S(O2)NH-T203, - S(O2)NT204T205, -S(O2)O-T206, - P(O)(OT207)(OT208), -Si(T209)(T210)(T211)"; wobei T160, T161, T162, T163, T164, T165, T166, T167,NT195T196, -NHS (O 2) -T197, -NT198S (O 2) -T199, -S- T200, -S (O) -T201, -S (O 2) -T202, -S (O 2) NH- T203, - S (O 2) NT204T205, -S (O 2) O-T206, - P (O) (OT207) (OT208), -Si (T209) (T210), (T211) "; wherein T160, T161, T162, T163, T164, T165, T166, T167,
T168, T169, T170, T171, T172, T173, T174, T175, T176, T177, T178, T179, T180, T181, T182, T183, T184, T185, T186, T187, T188, T189, T190, T191, T192, T193, T194, T195, T196, T197, T198, T199, T200, T201, T202, T203, T204, T205, T206, T207, T208, T209, T210, T21 1 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylal- kyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroa- ryl, heteroarylalkyl" und wobei alternativ T166, T167 und/oder T175, T176 und/oder T188, T189 und/oderT168, T169, T170, T171, T172, T173, T174, T175, T176, T177, T178, T179, T180, T181, T182, T183, T184, T185, T186, T187, T188, T189, T190, T191, T192, T193, T194, T195, T196, T197, T198, T199, T200, T201, T202, T203, T204, T205, T206, T207, T208, T209, T210, T21 1 are independently selected from the group consisting of: "alkyl , (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylal- kyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaromatics ryl, heteroarylalkyl "and wherein alternatively T166, T167 and / or T175, T176 and / or T188, T189, and / or
T195, T196 und/oder T204, T205 jeweils zusammen auch „heterocyclyl" bilden können; wobei alternativ T2, T3 zusammen auch „heterocyclyl" bilden können;T195, T196 and / or T204, T205 may together also form "heterocyclyl"; alternatively, T2, T3 may together also form "heterocyclyl";
und einer der Reste Z24, Z25 oder keiner der Reste Z24, Z25 unabhängig voneinander auch ausgewählt ist aus der Gruppe bestehend aus:and one of Z24, Z25 or none of Z24, Z25 is also independently selected from the group consisting of:
(2) „Wasserstoff, alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei optional obige Substituenten der Substitutionsgruppe (2) unab- hängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- cyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT212, -NT213T214, -NO2, -OH, -OCF3, -SH, - 0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, - P(O)(OH)2, -C(O)-T215, -C(O)O-T216, -C(O)NH-T217, -"Alkyl hydrogen, alkyl, (Cg-C 30) cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" (2), wherein optionally above substituents of the substitution group (2) may be independently of one another also be further substituted may be substituted by at least one substituent, the same or different, selected from the group consisting of: "Alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , - NHT212, -NT213T214, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, - P (O) (OH) 2 , -C (O) -T215, -C (O) O-T216, -C (O) NH-T217, -
C(O)NT218T219, -O-T220, -O(-T221-O)u-H (u = 1 , 2, 3, 4, 5), - O(-T222-O)u-T223 (u = 1 , 2, 3, 4, 5), -OC(O)-T224, -OC(O)-O- T225, -OC(O)-NHT226, -O-C(O)-NT227T228, - OP(O)(OT229)(OT230), -OSi(T231 )(T232)(T233), -OS(O2)-T234, - NHC(O)-T235, -NT236C(O)-T237, -NH-C(O)-O-T238, -NH-C (O) NT218T219, -O-T220, -O (-T221-O) u -H (u = 1, 2, 3, 4, 5), - O (-T222-O) u -T223 (u = 1, 2, 3, 4, 5), -OC (O) -T224, -OC (O) -O-T225, -OC (O) -NHT226, -OC (O) -NT227T228, - OP (O) (OT229) (OT230), -OSi (T231) (T232), (T233), -OS (O 2) -T234, - NHC (O) -T235, -NT236C (O) -T237, -NH-C (O ) -O-T238, -NH-
C(O)-NH-T239, -NH-C(O)-NT240T241 , -NT242-C(O)-O-T243, - NT244-C(O)-NH-T245, -NT246-C(O)-NT247T248, -NHS(O2)- T249, -NT250S(O2)-T251 , -S-T252, -S(O)-T253, -S(O2)-T254, - S(O2)N H-T255, -S(O2)NT256T257, -S(O2)O-T258, - P(O)(OT259)(OT260), -Si(T261 )(T262)(T263)"; wobei T212, T213, T214, T215, T216, T217, T218, T219, T220, T221 , T222, T223, T224, T225, T226, T227, T228, T229, T230, T231 , T232, T233, T234, T235, T236, T237, T238, T239, T240, T241 , T242, T234, T244, T245, T246, T247, T248, T249, T250, T251 , T252, T253, T254, T255, T256, T257, T258, T259, T260,C (O) -NH-T239, -NH-C (O) -NT240T241, -NT242-C (O) -O-T243, -NT244-C (O) -NH-T245, -NT246-C (O) -NT247T248, -NHS (O 2) - T249, -NT250S (O 2) -T251, -S-T252, -S (O) -T253, -S (O 2) -T254, - S (O 2) N H-T255, -S (O 2) NT256T257, -S (O 2) O-T258, - P (O) (OT259) (OT260), -Si (T261) (T262), (T263) "; wherein T212, T213, T214, T215, T216, T217, T218, T219, T220, T221, T222, T223, T224, T225, T226, T227, T228, T229, T230, T231, T232, T233, T234, T235, T236, T237, T238, T239, T240, T241, T242, T234, T244, T245, T246, T247, T248, T249, T250, T251, T252, T253, T254, T255, T256, T257, T258, T259, T260,
T261 , T262, T263 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T218, T219 und/oder T227, T228 und/oder T240, T241 und/oder T247, T248 und/oder T256, T257 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:T261, T262, T263 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively T218, T219 and or T227, T228 and / or T240, T241 and / or T247, T248 and / or T256, T257 may each together also form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT264, -NT265T266, -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-T267, -C(O)O-T268, - C(O)NH-T269, -C(O)NT270T271, -O-T272, -O(-T273-O)v-H (v = 1, 2, 3, 4, 5), -O(-T274-O)v-T275 (v = 1 , 2, 3, 4, 5), - OC(O)-T276, -OC(O)-O-T277, -OC(O)-NHT278, -0-C(O)-(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT264, -NT265T266, -NO 2 , -OH, - OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, - C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T 267, -C (O) O-T 268, -C (O) NH-T 269, -C (O) NT270T271, -O-T272, -O (-T273-O) v -H (v = 1, 2, 3, 4, 5), -O (-T274-O) v -T275 (v = 1 , 2, 3, 4, 5), - OC (O) -T276, -OC (O) -O-T277, -OC (O) -NHT278, -O-C (O) -
5 NT279T280, -OP(O)(OT281)(OT282), -OSi(T283)(T284)(T285),5 NT279T280, -OP (O) (OT281) (OT282), -OSi (T283) (T284) (T285),
-OS(O2)-T286, -NHC(O)-T287, -NT288C(O)-T289, -NH- C(O)-O-T290, -NH-C(O)-NH-T291, -NH-C(O)-NT292T293, - NT294-C(O)-O-T295, -NT296-C(O)-NH-T297, -NT298- C(O)-NT299T300, -NHS(O2)-T301, -NT302S(O2)-T303, -S- 10 T304, -S(O)-T305, -S(O2)-T306, -S(O2)NH-T307, --OS (O 2) -T286, -NHC (O) -T287, -NT288C (O) -T289, -NH- C (O) -O-T290, -NH-C (O) -NH-T291, - NH-C (O) -NT292T293, -NT294-C (O) -O-T295, -NT296-C (O) -NH-T297, -NT298-C (O) -NT299T300, -NHS (O 2 ) - T301, -NT302S (O 2) -T303, -S- T304 10, -S (O) -T305, -S (O 2) -T306, -S (O 2) NH-T307, -
S(O2)NT308T309, -S(O2)O-T310, -P(O)(OT311)(OT312), - Si(T313)(T314)(T315)"; wobei T264, T265, T266, T267, T268, T269, T270, T271 , T272, T273, T274, T275, T276, T277, T278, T279, T280, T281, T282,S (O 2) NT308T309, -S (O 2) O-T310, -P (O) (OT311) (OT312), - Si (T313) (T314), (T315) "; wherein T264, T265, T266, T267 , T268, T269, T270, T271, T272, T273, T274, T275, T276, T277, T278, T279, T280, T281, T282,
15 T283, T284, T285, T286, T287, T288, T289, T290, T291, T292,15 T283, T284, T285, T286, T287, T288, T289, T290, T291, T292,
T293, T294, T295, T296, T297, T298, T299, T300, T301, T302, T303, T304, T305, T306, T307, T308, T309, T310, T311, T312, T313, T314, T315 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cyc-T293, T294, T295, T296, T297, T298, T299, T300, T301, T302, T303, T304, T305, T306, T307, T308, T309, T310, T311, T312, T313, T314, T315 are independently selected from consisting of the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, Cyc
20 loalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, hetero- aryl, heteroarylalkyl" und wobei alternativ T270, T271 und/oder T279, T280 und/oder T292, T293 und/oder T299, T300 und/oder T308, T309 jeweils zusammen auch „heterocyclyl" bilden können;And wherein alternatively T270, T271 and / or T279, T280 and / or T292, T293 and / or T299, T300 and / or T308, T309 also together in each case also Can form "heterocyclyl";
25 wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:In which optionally substituents of the substituent group (ii) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl,(iii) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl,
30 heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F,30 heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F,
Cl, Br, I, CN, CF3, N3, NH2, -NHT316, -NT317T318, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-T319, -C(O)O-T320, -C(O)NH-T321 , -C(O)NT322T323, -O-T324, -O(-T325- O)w-H (w = 1 , 2, 3, 4, 5), -O(-T326-O)w-T327 (w = 1 , 2, 3, 4, 5), -OC(O)-T328, -OC(O)-O-T329, -OC(O)-NHT330, - O-C(O)-NT331T332, -OP(O)(OT333)(OT334), - OSi(T335)(T336)(T337), -OS(O2)-T338, -NHC(O)-T339, - NT340C(O)-T341 , -NH-C(O)-O-T342, -N H-C(O)-N H-Cl, Br, I, CN, CF 3, N 3, NH 2, -NHT316, -NT317T318, -NO 2, - OH, -OCF3, -SH, -0-SO3H, -OP (O) ( OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T319, -C (O) O-T320, -C (O) NH-T321, -C (O) NT322T323, -O-T324, -O (-T325- O) w -H (w = 1, 2, 3, 4, 5), -O (-T326-O) w -T327 (w = 1, 2, 3, 4, 5), -OC (O) - T328, -OC (O) -O-T329, -OC (O) -NHT330, -OC (O) -NT331T332, -OP (O) (OT333) (OT334), -OSi (T335) (T336) (T337 ), -OS (O 2 ) -T338, -NHC (O) -T339, --NT340C (O) -T341, -NH-C (O) -O-T342, -NHC (O) -N H-
T343, -NH-C(O)-NT344T345, -NT346-C(O)-O-T347, - NT348-C(O)-NH-T349, -NT350-C(O)-NT351T352, - NHS(O2)-T353, -NT354S(O2)-T355, -S-T356, -S(O)-T357, -S(O2)-T358, -S(O2)NH-T359, -S(O2)NT360T361 , - S(O2)O-T362, -P(O)(OT363)(OT364), -T343, -NH-C (O) -NT344T345, -NT346-C (O) -O-T347, - NT348-C (O) -NH-T349, -NT350-C (O) -NT351T352, - NHS (O 2) -T353, -NT354S (O 2) -T355, -S-T356, -S (O) -T357, -S (O 2) -T358, -S (O 2) NH-T359, -S (O 2 ) NT360T361, -S (O 2 ) O-T362, -P (O) (OT363) (OT364),
Si(T365)(T366)(T367)"; wobei T316, T317, T318, T319, T320, T321, T322, T323, T324, T325, T326, T327, T328, T329, T330, T331, T332, T333, T334, T335, T336, T337, T338, T339, T340, T341, T342, T343, T344, T345, T346, T347, T348, T349, T350,Si (T365) (T366) (T367) "; wherein T316, T317, T318, T319, T320, T321, T322, T323, T324, T325, T326, T327, T328, T329, T330, T331, T332, T333, T334 , T335, T336, T337, T338, T339, T340, T341, T342, T343, T344, T345, T346, T347, T348, T349, T350,
T351 , T352, T353, T354, T355, T356, T357, T358, T359, T360, T361 , T362, T363, T364, T365, T366, T367 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" und wobei alternativ T322, T323 und/oder T331 , T332 und/oder T344, T345 und/oder T351 , T352 und/oder T360, T361 jeweils zusammen auch „heterocyclyl" bilden können;T351, T352, T353, T354, T355, T356, T357, T358, T359, T360, T361, T362, T363, T364, T365, T366, T367 are independently selected from the group consisting of: "alkyl, (Cg-C3o ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and where alternatively T322, T323 and / or T331, T332 and / or T344, T345 and / or T351, T352 and / or T360, T361 may together also form "heterocyclyl";
(b) -NZ26Z27, wobei einer der Reste Z26, Z27 oder beide Reste Z26, Z27 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:(b) -NZ26Z27, wherein one of the radicals Z26, Z27 or both radicals Z26, Z27 are independently selected from the group consisting of:
(1 ) ,,-C(Y4)NZ28Z29, -C(=NZ30)-Z31 "; wobei Y4 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus „O, S, =NH, =NZ32"; mit der Maßgabe, dass mindestens einer der Reste Z28, Z29 und mindestens einer der Reste Z30, Z31 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus: „alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O)-alkyl, -C(O)- aryl, -C(O)-heteroaryl"; mit der weiteren Maßgabe, dass obige Substituenten der Substituen- tengruppe (I) unabhängig voneinander weiter substituiert sind mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(1) ,, -C (Y4) NZ28Z29, -C (= NZ30) -Z31 "; wherein Y4 is independently selected from the group consisting of" O, S, = NH, = NZ32 "; with the proviso that at least one of Z28, Z29 and at least one of Z30, Z31 is independently selected from the group consisting of: "Alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C (O) -alkyl, -C (O) -aryl, -C (O) -heteroaryl"; with the further proviso that the above substituents of the substituent group (I ) are independently further substituted with at least one substituent, identical or different, selected from the group consisting of:
(i) „(Cg-C3o)alkyl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroa- rylalkyl, N3, -NT368T369, -NHC(O)-cycloalkylalkyl, -NHC(O)- heterocyclylalkyl, -NT370C(O)-T371 , -NH-C(O)-O-T372, - N H-C(O)-N H-T373, -NH-C(O)-NT374T375, -NT376-C(O)-(i) "(Cg-C 3 o) alkyl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroaromatics rylalkyl, N 3, -NT368T369, -NHC (O) cycloalkylalkyl, -NHC (O) - heterocyclylalkyl, -NT370C (O) -T371, -NH-C (O) -O-T372, -NHC (O) -NH-T373, -NH-C (O) -NT374T375, -NT376-C (O) -
O-T377, -NT378-C(O)-NH-T379, -NT380-C(O)-NT381T382, -NHS(O2)-cycloalkylalkyl, -NHS(O2)-heterocyclylalkyl, - NT383S(O2)-T384, -O-T385, -O(-T386-O)x-T387 (x = 1 , 2, 3, 4, 5), -O(-T388-O)x-H (x = 1 , 2, 3, 4, 5), -OC(O)- cycloalkylalkyl, -OC(O)-heterocyclylalkyl, -OC(O)-O-T389, -Cycloalkylalkyl-O T377, -NT378-C (O) -NH-T379, -NT380-C (O) -NT381T382, -NHS (O 2), (2 O) -heterocyclylalkyl -NHS, - NT383S (O 2) -T384, -O-T385, -O (-T386-O) x -T387 (x = 1, 2, 3, 4, 5), -O (-T388-O) x -H (x = 1, 2 , 3, 4, 5), -OC (O) -cycloalkylalkyl, -OC (O) -heterocyclylalkyl, -OC (O) -O-T389, -
OC(O)-NHT390, -O-C(O)-NT391T392, -OS(O2)- cycloalkylalkyl, -OS(O2)-heterocyclylalkyl, - OP(O)(OT393)(OT394), -OSi(T395)(T396)(T397), -CHO, - C(O)-cycloalkyl, -C(O)-heterocyclyl, -C(O)-cycloalkylalkyl, - C(O)-heterocyclylalkyl, -C(O)-arylalkyl, -C(O)-heteroarylalkyl,OC (O) -NHT390, -OC (O) -NT391T392, -OS (O 2) - cycloalkylalkyl, -OS (O 2) -heterocyclylalkyl, - OP (O) (OT393) (OT394), -OSi (T395) (T396) (T397), -CHO, - C (O) -cycloalkyl, -C (O) -heterocyclyl, -C (O) -cycloalkylalkyl, - C (O) -heterocyclylalkyl, -C (O) -arylalkyl, -C (O) heteroarylalkyl,
-S- cycloalkylalkyl, -S-heterocyclylalkyl, —S— arylalkyl, -S- heteroarylalkyl, -S(O)-cycloalkyl, -S(O)-heterocyclyl, -S(O)- heteroaryl, -S(O)-cycloalkylalkyl, -S(O)-heterocyclylalkyl, - S(O)-arylalkyl, -S(O)-heteroarylalkyl, -S(O2)-cycloalkyl, - S(O2)-heterocyclyl, -S(O2)-heteroaryl, -S(O2)-cycloalkylalkyl, --S-cycloalkylalkyl, -S-heterocyclylalkyl, -S-arylalkyl, -S-heteroarylalkyl, -S (O) -cycloalkyl, -S (O) -heterocyclyl, -S (O) -heteroaryl, -S (O) - cycloalkylalkyl, -S (O) -heterocyclylalkyl, - S (O) -arylalkyl, -S (O) -heteroarylalkyl, -S (O 2 ) -cycloalkyl, - S (O 2 ) -heterocyclyl, -S (O 2 ) -heteroaryl, -S (O 2 ) -cycloalkylalkyl, -
S(O2)-heterocyclylalkyl, -S(O2)-arylalkyl, -S(O2)- heteroarylalkyl, -S(O2)NH-cycloalkyl, -S(O2)NH-heterocyclyl, - S(O2)N H-cycloalkylalkyl, -S(O2)NH-heterocyclylalkyl, - S(O2)NH-heteroarylalkyl, -S(O2)NT398T399, -S(O2)O- cycloalkyl, -S(O2)O-heterocyclyl, -S(O2)O-heteroaryl, -S(O2)O- cycloalkylalkyl, -S(O2)O-heterocyclylalkyl, -S(O2)O- heteroarylalkyl, -P(O)(OH)2, -P(O)(OT400)(OT401 ), - Si(T402)(T403)(T404)"; mit der weiteren Maßgabe, dass ,,-N(alkyl)2", ,,-C(O)N(alkyl)2", „- C(O)N(cycloalkyl)2", ,,-C(O)N(Aryl)2", ,,-C(O)N(Heteroaryl)2" weiter substituiert sind mit mindestens einem Substituenten ausgewählt aus der untigen Substituentengruppe (ii);S (O 2) -heterocyclylalkyl, -S (O2) -arylalkyl, -S (O 2) - heteroarylalkyl, -S (O 2) NH-cycloalkyl, -S (O 2) NH-heterocyclyl, - S (O 2 ) N H -cycloalkylalkyl, -S (O 2 ) NH-heterocyclylalkyl, - S (O 2 ) NH-heteroarylalkyl, -S (O 2 )NT398T399, -S (O 2 ) O -cycloalkyl, -S (O 2 ) O-heterocyclyl, -S (O 2 ) O-heteroaryl, -S (O 2 ) O -cycloalkylalkyl, -S (O 2 ) O-heterocyclylalkyl, -S (O 2 ) O-heteroarylalkyl, -P (O) (OH) 2 , -P (O) (OT400) (OT401), -Si (T402) (T403) (T404) "; with the further proviso that "- N (alkyl) 2 ", "- C (O) N (alkyl) 2 ", "- C (O) N (cycloalkyl) 2 ", "-" C (O) N (aryl) 2 ", - C (O) N (heteroaryl) 2 " are further substituted with at least one substituent selected from the lower substituent group (ii);
5 wobei T368, T369, T370, T371 , T372, T373, T374, T375, T376,5 where T368, T369, T370, T371, T372, T373, T374, T375, T376,
T377, T378, T379, T380, T381 , T382, T383, T384, T385, T386, T387, T388, T389, T390, T391 , T392, T393, T394, T395, T396, T397, T398, T399, T400, T401 , T402, T403, T404 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:T377, T378, T379, T380, T381, T382, T383, T384, T385, T386, T387, T388, T389, T390, T391, T392, T393, T394, T395, T396, T397, T398, T399, T400, T401, T402, T403, T404 are independently selected from the group consisting of:
10 „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T374, T375 und/oder T381 , T382 und/oder T391 , T392 und/oder T398, T399 jeweils zusammen auch „heterocyclyl" bilden können;10 "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively T374, T375 and / or T381, T382 and / or T391, T392 and or T398, T399 may together also form "heterocyclyl";
15 wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:In which optional substituents of the substituent group (i) may in turn be further independently substituted with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl,(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl,
20 heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F,20 heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F,
Cl, Br, I, CN, CF3, N3, NH2, -NHT405, -NT406T407, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-T408, -C(O)O-T409, -C(O)NH-T410, -C(O)NT41 1T412, -O-T413, -O(-T414-Cl, Br, I, CN, CF 3, N 3, NH 2, -NHT405, -NT406T407, -NO 2, - OH, -OCF3, -SH, -0-SO3H, -OP (O) ( OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T 408, -C (O) O-T 409, -C (O) NH-T410, -C (O) NT41 1T412, -O-T413, -O (-T414-
25 O)y-H (y = 1 , 2, 3, 4, 5), -O(-T415-O)y-T416 (y = 1 , 2, 3, 4,25 O) y -H (y = 1, 2, 3, 4, 5), -O (-T415-O) y -T416 (y = 1, 2, 3, 4,
5), -OC(O)-T417, -OC(O)-O-T418, -OC(O)-N HT419, -O- C(O)-NT420T421 , -OP(O)(OT422)(OT423), - OSi(T424)(T425)(T426), -OS(O2)-T427, -NHC(O)-T428, - NT429C(O)-T430, -NH-C(O)-O-T431 , -N H-C(O)-N H-5), -OC (O) -T417, -OC (O) -O-T418, -OC (O) -NHT419, -O-C (O) -NT420T421, -OP (O) (OT422) (OT423 ), - OSi (T424) (T425), (T426), -OS (O 2) -T427, -NHC (O) -T428 - NT429C (O) -T430, -NH-C (O) -O-T431 , -N HC (O) -N H-
30 T432, -NH-C(O)-NT433T434, -NT435-C(O)-O-T436, -30 T432, -NH-C (O) -NT433T434, -NT435-C (O) -O-T436, -
NT437-C(O)-NH-T438, -NT439-C(O)-NT440T441 , - NHS(O2)-T442, -NT443S(O2)-T444, -S-T445, -S(O)-T446, -S(O2)-T447, -S(O2)N H-T448, -S(O2)NT449T450, - S(O2)O-T451 , -P(O)(OT452)(OT453), - Si(T454)(T455)(T456)"; wobei T405, T406, T407, T408, T409, T410, T411, T412, T413, T414, T415, T416, T417, T418, T419, T420, T421,NT437-C (O) -NH-T438, -NT439-C (O) -NT440T441, - NHS (O 2) -T442, -NT443S (O 2) -T444, -S-T445, -S (O) - T446, -S (O 2) -T447, -S (O 2) N H-T448, -S (O 2) NT449T450, - S (O 2) O-T451, -P (O) (OT452) (OT453), - Si (T454) (T455), (T456) "; wherein T405, T406, T407, T408, T409, T410, T411, T412 , T413, T414, T415, T416, T417, T418, T419, T420, T421,
5 T422, T423, T424, T425, T426, T427, T428, T429, T430,5 T422, T423, T424, T425, T426, T427, T428, T429, T430,
T431 , T432, T433, T434, T435, T436, T437, T438, T439, T440, T441 , T442, T443, T444, T445, T446, T447, T448, T449, T450, T451 , T452, T453, T454, T455, T456 unabhängig voneinander ausgewählt sind aus der Gruppe bestehendT431, T432, T433, T434, T435, T436, T437, T438, T439, T440, T441, T442, T443, T444, T445, T446, T447, T448, T449, T450, T451, T452, T453, T454, T455, T456 are independently selected from the group consisting
10 aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" und wobei alternativ T41 1 , T412 und/oder T420, T421 und/oder T433, T434 und/oder T440, T441 und/oder T449, T450 jeweils zusammen auch „heterocyclyl" bilden können;10 of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" and wherein alternatively T41 1, T412 and / or T420, T421 and or T433, T434 and / or T440, T441 and / or T449, T450 may together also form "heterocyclyl";
15 wobei optional obige Substituenten der SubstituentengruppeWherein optionally substituents of the substituent group above
(ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(ii) may in turn be independently substituted with at least one substituent, the same or different, selected from the group consisting of:
(iii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc-(iii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl
20 IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT457, - NT458T459, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, - P(O)(OH)2, -C(O)-T460, -C(O)O-T461 , -C(O)N H-T462,20 iyi, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHT457, - NT458T459, -NO 2, -OH, -OCF 3 , -SH, -O-SO 3 H, - OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, - P (O) (OH) 2 , -C (O) -T460, -C (O) O-T461, -C (O) NH-T462,
25 -C(O)NT463T464, -O-T465, -O(-T466-O)z-H (z = 1 , 2,25 -C (O) NT463T464, -O-T465, -O (-T466-O) z -H (z = 1, 2,
3, 4, 5), -O(-T467-O)z-T468 (z = 1 , 2, 3, 4, 5), -OC(O)- T469, -OC(O)-O-T470, -OC(O)-NHT471 , -0-C(O)- NT472T473, -OP(O)(OT474)(OT475), - OSi(T476)(T477)(T478), -OS(O2)-T479, -NHC(O)-T480,3, 4, 5), -O (-T467-O) z -T468 (z = 1, 2, 3, 4, 5), -OC (O) - T469, -OC (O) -O-T470, -OC (O) -NHT471, -0-C (O) - NT472T473, -OP (O) (OT474) (OT475), - OSi (T476) (T477), (T478), -OS (O 2) -T479 , -NHC (O) -T480,
30 -NT481C(O)-T482, -NH-C(O)-O-T483, -NH-C(O)-30 -NT481C (O) -T482, -NH-C (O) -O-T483, -NH-C (O) -
NH-T484, -NH-C(O)-NT485T486, -NT487-C(O)-O- T488, -NT489-C(O)-NH-T490, -NT491-C(O)- NT492T493, -NHS(O2)-T494, -NT495S(O2)-T496, -S- T497, -S(O)-T498, -S(O2)-T499, -S(O2)NH-T500, - S(O2)NT501T502, -S(O2)O-T503, - P(O)(OT504)(OT505), -Si(T506)(T507)(T508)"; wobei T457, T458, T459, T460, T461, T462, T463, T464, T465, T466, T467, T468, T469, T470, T471, T472, T473, T474, T475, T476, T477, T478, T479, T480, T481, T482,NH-T484, -NH-C (O) -NT485T486, -NT487-C (O) -O-T488, -NT489-C (O) -NH-T490, -NT491-C (O) -NT492T493, -NHS (O 2 ) -T494, -NT495S (O 2 ) -T496, -S- T 497, -S (O) -T 498, -S (O 2 ) -T 499, -S (O 2 ) NH-T500, S (O 2) NT501T502, -S (O 2) O-T503, - P (O) (OT504) (OT505), -Si (T506) (T507), (T508) "; wherein T457, T458, T459, T460 , T461, T462, T463, T464, T465, T466, T467, T468, T469, T470, T471, T472, T473, T474, T475, T476, T477, T478, T479, T480, T481, T482,
T483, T484, T485, T486, T487, T488, T489, T490, T491, T492, T493, T494, T495, T496, T497, T498, T499, T500, T501 , T502, T503, T504, T505, T506, T507, T508 unabhängig voneinander ausgewählt sind aus der Gruppe be- stehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylal- kyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroa- ryl, heteroarylalkyl" und wobei alternativ T463, T464 und/oder T472, T473 und/oder T485, T486 und/oder T492, T493 und/oder T501 , T502 jeweils zusammen auch „heterocyclyl" bilden können;T483, T484, T485, T486, T487, T488, T489, T490, T491, T492, T493, T494, T495, T496, T497, T498, T499, T500, T501, T502, T503, T504, T505, T506, T507, T508 are independently selected from the group con- sisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylal- kyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaromatics ryl, heteroarylalkyl" and wherein alternatively T463, T464 and / or T472, T473 and / or T485, T486 and / or T492, T493 and / or T501, T502 may together also form "heterocyclyl";
oder mit der Maßgabe, dass mindestens einer der Reste Z28, Z29 und mindestens einer der Reste Z30, Z31 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus: (II) „(Cg-C3o)alkyl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, -C(O)-(C9-C30)alkyl, -C(O)-cycloalkyl, -C(O)-cycloalkylalkyl, -C(O)-arylalkyl, -C(O)-heteroarylalkyl, -C(O)-heterocyclyl, -C(O)- heterocyclylalkyl, -S(O2)-alkyl, -S(02)-(C9-C3o)alkyl, -S(O2)- cycloalkyl, -S(O2)-cycloalkylalkyl, -S(O2)-aryl, -S(O2)-arylalkyl, - S(O2)-heteroaryl, -S(O2)-heteroarylalkyl, -S(O2)-heterocyclyl, -or with the proviso that at least one of Z28, Z29 and at least one of Z30, is Z31 independently selected from the group consisting of: (II) "(Cg-C 3 o) alkyl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, -C (O) - (C 9 -C 30 ) alkyl, -C (O) -cycloalkyl, -C (O) -cycloalkylalkyl, -C (O) -arylalkyl, -C (O) -heteroarylalkyl, - C (O) -heterocyclyl, -C (O) - heterocyclylalkyl, -S (O 2) alkyl, -S (0 2) - (C 9 -C 3 O) alkyl, -S (O 2) - cycloalkyl, (2 O) -S cycloalkylalkyl, -S (O 2) aryl, -S (O 2) arylalkyl, - (O 2) heteroaryl S (O 2) heteroarylalkyl -S, -S (O 2 ) heterocyclyl, -
S(O2)-heterocyclylalkyl"; wobei optional obige Substituenten der Substitutionsgruppe (II) unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:S (O 2 ) -heterocyclylalkyl "wherein optionally substituted substituents of the substitution group (II) may be independently further substituted with at least one substituent, same or different, selected from the group consisting of:
(i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT509, -NT510T511 , -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-T512, -C(O)O-T513, - C(O)NH-T514, -C(O)NT515T516, -O-T517, -0(-T518-O)3-H (a = 1 , 2, 3, 4, 5), -O(-T519-O)a-T520 (a = 1 , 2, 3, 4, 5), - 5 OC(O)-T521 , -OC(O)-O-T522, -OC(O)-N HT523, -0-C(O)-(i) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT509, -NT510T511, -NO 2 , -OH, - OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T512, -C (O) O-T513, -C (O) NH-T514, -C (O) NT515T516, -O-T517, -O (-T518-O) 3 - H (a = 1, 2, 3, 4, 5), -O (-T519-O) a -T520 (a = 1, 2, 3, 4, 5), - 5 OC (O) -T521, - OC (O) -O-T522, -OC (O) -N HT523, -O-C (O) -
NT524T525, -OP(O)(OT526)(OT527), -OSi(T528)(T529)(T530), -OS(O2)-T531 , -NHC(O)-T532, -NT533C(O)-T534, -NH- C(O)-O-T535, -N H-C(O)-N H-T536, -NH-C(O)-NT537T538, - NT539-C(O)-O-T540, -NT541 -C(O)-N H-T542, -NT543-NT524T525, -OP (O) (OT526) (OT527), -OSi (T528) (T529), (T530), -OS (O 2) -T531, -NHC (O) -T532, -NT533C (O) -T534 , -NH-C (O) -O-T535, -NHC (O) -NH-T536, -NH-C (O) -NT537T538, - NT539-C (O) -O-T540, -NT541 - C (O) -NH-T542, -NT543-
10 C(O)-NT544T545, -NHS(O2)-T546, -NT547S(O2)-T548, -S-10 C (O) -NT544T545, -NHS (O 2 ) -T546, -NT547S (O 2 ) -T548, -S-
T549, -S(O)-T550, -S(O2)-T551 , -S(O2)NH-T552, - S(O2)NT553T554, -S(O2)O-T555, -P(O)(OT556)(OT557), - Si(T558)(T559)(T560)"; wobei T509, T510, T51 1 , T512, T513, T514, T515, T516, T517,T549, -S (O) -T550, -S (O 2) -T551, -S (O 2) NH-T552, - S (O 2) NT553T554, -S (O 2) O-T555, -P ( O) (OT556) (OT557), -Si (T558) (T559) (T560) "; wherein T509, T510, T51 1, T512, T513, T514, T515, T516, T517,
15 T518, T519, T520, T521 , T522, T523, T524, T525, T526, T527,15 T518, T519, T520, T521, T522, T523, T524, T525, T526, T527,
T528, T529, T530, T531 , T532, T533, T534, T535, T536, T537, T538, T539, T540, T541 , T542, T543, T544, T545, T546, T547, T548, T549, T550, T551 , T552, T553, T554, T555, T556, T557, T558, T559, T560 unabhängig voneinander ausgewählt sind ausT528, T529, T530, T531, T532, T533, T534, T535, T536, T537, T538, T539, T540, T541, T542, T543, T544, T545, T546, T547, T548, T549, T550, T551, T552, T553, T554, T555, T556, T557, T558, T559, T560 are independently selected
20 der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cyc- loalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, hetero- aryl, heteroarylalkyl" und wobei alternativ T515, T516 und/oder T524, T525 und/oder T537, T538 und/oder T544, T545 und/oder T553, T554 jeweils zusammen auch „heterocyclyl" bilden kön- 25 nen; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:20 of the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively T515, T516 and / or T524, T525 and / or T537, T538 and / or T544, T545 and / or T553, T554 may together also form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
30 (ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT561 , -NT562T563, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-T564, -C(O)O-T565, -C(O)NH-T566, -C(O)NT567T568, -O-T569, -O(-T570- O)b-H (b = 1 , 2, 3, 4, 5), -O(-T571-O)b-T572 (b = 1 , 2, 3, 4, 5), -OC(O)-T573, -OC(O)-O-T574, -OC(O)-N HT575, -O- C(O)-NT576T577, -OP(O)(OT578)(OT579), -30 (ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT561, -NT562T563, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T564, -C (O) O-T565, -C (O) NH-T566, -C (O) NT567T568, -O-T569, -O (-T570-O) b -H (b = 1, 2, 3, 4, 5), -O (-) T571-O) b -T572 (b = 1, 2, 3, 4, 5), -OC (O) -T573, -OC (O) -O-T574, -OC (O) -N HT575, -O - C (O) -NT576T577, -OP (O) (OT578) (OT579),
5 OSi(T580)(T581 )(T582), -OS(O2)-T583, -NHC(O)-T584, -5 OSi (T580) (T581), (T582), -OS (O 2) -T583, -NHC (O) -T584 -
NT585C(O)-T586, -NH-C(O)-O-T587, -N H-C(O)-N H- T588, -NH-C(O)-NT589T590, -NT591-C(O)-O-T592, - NT593-C(O)-NH-T594, -NT595-C(O)-NT596T597, - NHS(O2)-T598, -NT599S(O2)-T600, -S-T601 , -S(O)-T602,NT585C (O) -T586, -NH-C (O) -O-T587, -NHC (O) -NH-T588, -NH-C (O) -NT589T590, -NT591-C (O) -O -T592 - NT593-C (O) -NH-T594, -NT595-C (O) -NT596T597, - NHS (O 2) -T598, -NT599S (O 2) -T600, -S-T601, -S (O) -T602,
10 -S(O2)-T603, -S(O2)NH-T604, -S(O2)NT605T606, -10 -S (O 2 ) -T 603, -S (O 2 ) NH-T 604, -S (O 2 ) NT 605T 606, -
S(O2)O-T607, -P(O)(OT608)(OT609), - Si(T610)(T611 )(T612)"; wobei T561, T562, T563, T564, T565, T566, T567, T568, T569, T570, T571 , T572, T573, T574, T575, T576, T577,S (O 2 ) O-T 607, -P (O) (OT608) (OT609), -Si (T610) (T611) (T612) "; wherein T561, T562, T563, T564, T565, T566, T567, T568 , T569, T570, T571, T572, T573, T574, T575, T576, T577,
15 T578, T579, T580, T581 , T582, T583, T584, T585, T586,15 T578, T579, T580, T581, T582, T583, T584, T585, T586,
T587, T588, T589, T590, T591 , T592, T593, T594, T595, T596, T597, T598, T599, T600, T601, T602, T603, T604, T605, T606, T607, T608, T609, T610, T611, T612 unabhängig voneinander ausgewählt sind aus der Gruppe bestehendT587, T588, T589, T590, T591, T592, T593, T594, T595, T596, T597, T598, T599, T600, T601, T602, T603, T604, T605, T606, T607, T608, T609, T610, T611, T612 are independently selected from the group consisting
20 aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" und wobei alternativ T567, T568 und/oder T576, T577 und/oder T589, T590 und/oder T596, T597 und/oder T605, T606 jeweils zusammen auch „heterocyclyl" bilden können;20 of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" and wherein alternatively T567, T568 and / or T576, T577, and / or T589, T590 and / or T596, T597 and / or T605, T606 may each together also form "heterocyclyl";
25 wobei optional obige Substituenten der Substituentengruppe25 wherein optionally substituents of the substituent group above
(ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(ii) may in turn be independently substituted with at least one substituent, the same or different, selected from the group consisting of:
(iii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc-(iii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl
30 IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT613, - NT614T615, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, - P(O)(OH)2, -C(O)-T616, -C(O)O-T617, -C(O)NH-T618, -C(O)NT619T620, -O-T621 , -O(-T622-O)c-H (c = 1 , 2, 3, 4, 5), -O(-T623-O)c-T624 (c = 1 , 2, 3, 4, 5), -OC(O)- T625, -OC(O)-O-T626, -OC(O)-NHT627, -0-C(O)- NT628T629, -OP(O)(OT630)(OT631 ), - OSi(T632)(T633)(T634), -OS(O2)-T635, -NHC(O)-T636,30 iyi, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHT613, - NT614T615, -NO 2, -OH, -OCF 3 , -SH, -O-SO 3 H, - OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, - P (O) (OH) 2 , -C (O) -T616, -C (O) O-T617, -C (O) NH-T618, -C (O) NT619T620, -O-T621, -O (-T622-O) c -H (c = 1, 2, 3, 4, 5), -O (-T623-O) c -T624 (c = 1, 2, 3, 4, 5), -OC (O) -T625, -OC (O) -O-T626, -OC (O) -NHT627, -O-C (O) - NT628T629, -OP (O) (OT630) (OT631), - OSi (T632) (T633), (T634), -OS (O 2) -T635, -NHC (O) -T636,
-NT637C(O)-T638, -NH-C(O)-O-T639, -NH-C(O)- NH-T640, -NH-C(O)-NT641T642, -NT643-C(O)-O- T644, -NT645-C(O)-NH-T646, -NT647-C(O)- NT648T649, -NHS(O2)-T650, -NT651 S(O2)-T652, -S- T653, -S(O)-T654, -S(O2)-T655, -S(O2)NH-T656, --NT637C (O) -T638, -NH-C (O) -O-T639, -NH-C (O) -NH-T640, -NH-C (O) -NT641T642, -NT643-C (O) - O- T644, -NT645-C (O) -NH-T646, -NT647-C (O) - NT648T649, -NHS (O 2) -T650, -NT651 S (O 2) -T652, -S- T653, -S (O) -T654, -S (O 2) -T655, -S (O 2) NH-T656, -
S(O2)NT657T658, -S(O2)O-T659, - P(O)(OT660)(OT661), -Si(T662)(T663)(T664)"; wobei T613, T614, T615, T616, T617, T618, T619, T620, T621 , T622, T623, T624, T625, T626, T627, T628, T629, T630, T631 , T632, T633, T634, T635, T636, T637, T638,S (O 2 ) NT657T658, -S (O 2 ) O-T 659, -P (O) (OT660) (OT661), -Si (T662) (T663) (T664) "; wherein T613, T614, T615, T616 , T617, T618, T619, T620, T621, T622, T623, T624, T625, T626, T627, T628, T629, T630, T631, T632, T633, T634, T635, T636, T637, T638,
T639, T640, T641 , T642, T643, T644, T645, T646, T647, T648, T649, T650, T651 , T652, T653, T654, T655, T656, T657, T658, T659, T660, T661 , T662, T663, T664 unabhängig voneinander ausgewählt sind aus der Gruppe be- stehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylal- kyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroa- ryl, heteroarylalkyl" und wobei alternativ T619, T620 und/oder T628, T629 und/oder T641 , T642 und/oder T648, T649 und/oder T657, T658 jeweils zusammen auch „heterocyclyl" bilden können;T639, T640, T641, T642, T643, T644, T645, T646, T647, T648, T649, T650, T651, T652, T653, T654, T655, T656, T657, T658, T659, T660, T661, T662, T663, T664 are independently selected from the group con- sisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylal- kyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaromatics ryl, heteroarylalkyl" and wherein alternatively T619 , T620 and / or T628, T629 and / or T641, T642 and / or T648, T649 and / or T657, T658 may each together also form "heterocyclyl";
und einer der Reste Z28, Z29 oder keiner der Reste Z28, Z29 und einer der Reste Z30, Z31 oder keiner der Reste Z30, Z31 und Rest Z32 unabhängig ausgewählt ist aus der Gruppe bestehend aus: (III) „Wasserstoff, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O)- alkyl, -C(O)-aryl, -C(O)-heteroaryl"; wobei optional obige Substituenten der Substituentengruppe (IM) unabhängig voneinander wiederum substituiert sein können mit min- destens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:and one of Z28, Z29 or none of Z28, Z29 and Z30, Z31 or none of Z30, Z31 and Z32 is independently selected from the group consisting of: (III) "hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C (O) -alkyl, -C (O) -aryl, -C (O) -heteroaryl ", where optionally above substituents of the substituent group (IM) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT665, -NT666T667, -NO2, -OH, -(i) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHT665, -NT666T667, -NO 2 , -OH, -
OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-T668, -C(O)O-T669, - C(O)NH-T670, -C(O)NT671T672, -O-T673, -O(-T674-O)d-H (d = 1 , 2, 3, 4, 5), -O(-T675-O)d-T676 (d = 1 , 2, 3, 4, 5), - OC(O)-T677, -OC(O)-O-T678, -OC(O)-N HT679, -0-C(O)-OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T668, -C (O) O-T669, -C (O) NH-T670, -C (O) NT671T672, -O-T673, -O (-T674-O) d - H (d = 1, 2, 3, 4, 5), -O (-T675-O) d -T676 (d = 1, 2, 3, 4, 5), - OC (O) -T677, -OC (O) -O-T678, -OC (O) -NHT679, -O-C (O) -
NT680T681 , -OP(O)(OT682)(OT683), -OSi(T684)(T685)(T686), -OS(O2)-T687, -NHC(O)-T688, -NT689C(O)-T690, -NH- C(O)-O-T691 , -N H-C(O)-N H-T692, -NH-C(O)-NT693T694, - NT695-C(O)-O-T696, -NT697-C(O)-NH-T698, -NT699- C(O)-NT700T701 , -NHS(O2)-T702, -NT703S(O2)-T704, -S-NT680T681, -OP (O) (OT682) (OT683), -OSi (T684) (T685), (T686), -OS (O 2) -T687, -NHC (O) -T688, -NT689C (O) -T690 , -NH-C (O) -O-T691, -NHC (O) -NH-T692, -NH-C (O) -NT693T694, -NT695-C (O) -O-T696, -NT697- C (O) -NH-T698, -NT699- C (O) -NT700T701, -NHS (O 2) -T702, -NT703S (O 2) -T704, -S-
T705, -S(O)-T706, -S(O2)-T707, -S(O2)NH-T708, - S(O2)NT709T710, -S(O2)O-T711 , -P(O)(OT712)(OT713), - Si(T714)(T715)(T716)"; wobei T665, T666, T667, T668, T669, T670, T671 , T672, T673, T674, T675, T676, T677, T678, T679, T680, T681 , T682, T683,T705, -S (O) -T706, -S (O 2) -T707, -S (O 2) NH-T708, - S (O 2) NT709T710, -S (O 2) O-T711, -P ( O) (OT712) (OT713), -Si (T714) (T715) (T716) "; wherein T665, T666, T667, T668, T669, T670, T671, T672, T673, T674, T675, T676, T677, T678 , T679, T680, T681, T682, T683,
T684, T685, T686, T687, T688, T689, T690, T691 , T692, T693, T694, T695, T696, T697, T698, T699, T700, T701 , T702, T703, T704, T705, T706, T707, T708, T709, T710, T71 1 , T712, T713, T714, T715, T716 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T671 , T672 und/oder T680, T681 und/oder T693, T694 und/oder T700, T701 und/oder T709, T710 jeweils zusammen auch „heterocyclyl" bilden kön- nen; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT717, -NT718T719, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH,T684, T685, T686, T687, T688, T689, T690, T691, T692, T693, T694, T695, T696, T697, T698, T699, T700, T701, T702, T703, T704, T705, T706, T707, T708, T709, T710, T71 1, T712, T713, T714, T715, T716 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively T671, T672 and / or T680, T681 and / or T693, T694 and / or T700, T701 and / or T709, T710 may together also also form" heterocyclyl "; optionally optionally substituents of the substituent group (i) may also be further substituted with at least one substituent, identical or different, selected from the group consisting of: (ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT717, -NT718T719, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH,
5 -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-T720, -C(O)O-T721 ,5 -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T 720, -C (O) O-T 721,
-C(O)NH-T722, -C(O)NT723T724, -O-T725, -O(-T726- O)e-H (e = 1 , 2, 3, 4, 5), -O(-T727-O)e-T728 (e = 1 , 2, 3, 4, 5), -OC(O)-T729, -OC(O)-O-T730, -OC(O)-N HT731 , -O- C(O)-NT732T733, -OP(O)(OT734)(OT735), --C (O) NH-T722, -C (O) NT723T724, -O-T725, -O (-T726-O) e -H (e = 1, 2, 3, 4, 5), -O (-) T727-O) e -T728 (e = 1, 2, 3, 4, 5), -OC (O) -T729, -OC (O) -O-T730, -OC (O) -N HT731, -O - C (O) -NT732T733, -OP (O) (OT734) (OT735),
10 OSi(T736)(T737)(T738), -OS(O2)-T739, -NHC(O)-T740, -10 OSi (T736) (T737), (T738), -OS (O 2) -T739, -NHC (O) -T740 -
NT741 C(O)-T742, -NH-C(O)-O-T743, -NH-C(O)-NH- T744, -NH-C(O)-NT745T746, -NT747-C(O)-O-T748, - NT749-C(O)-NH-T750, -NT751-C(O)-NT752T753, - NHS(O2)-T754, -NT755S(O2)-T756, -S-T757, -S(O)-T758,NT741 C (O) -T742, -NH-C (O) -O-T743, -NH-C (O) -NH-T744, -NH-C (O) -NT745T746, -NT747-C (O) - O-T748, - NT749-C (O) -NH-T750, -NT751-C (O) -NT752T753, - NHS (O 2) -T754, -NT755S (O 2) -T756, -S-T757, - S (O) -T758,
15 -S(O2)-T759, -S(O2)NH-T760, -S(O2)NT761T762, -15 -S (O 2 ) -T759, -S (O 2 ) NH-T 760, -S (O 2 ) NT 761T762,
S(O2)O-T763, -P(O)(OT764)(OT765), - Si(T766)(T767)(T768)"; wobei T717, T718, T719, T720, T721 , T722, T723, T724, T725, T726, T727, T728, T729, T730, T731 , T732, T733,S (O 2) O-T763, -P (O) (OT764) (OT765), - Si (T766) (T767), (T768) "; wherein T717, T718, T719, T720, T721, T722, T723, T724 , T725, T726, T727, T728, T729, T730, T731, T732, T733,
20 T734, T735, T736, T737, T738, T739, T740, T741 , T742,20 T734, T735, T736, T737, T738, T739, T740, T741, T742,
T743, T744, T745, T746, T747, T748, T749, T750, T751 , T752, T753, T754, T755, T756, T757, T758, T759, T760, T761 , T762, T763, T764, T765, T766, T767, T768 unabhängig voneinander ausgewählt sind aus der Gruppe bestehendT743, T744, T745, T746, T747, T748, T749, T750, T751, T752, T753, T754, T755, T756, T757, T758, T759, T760, T761, T762, T763, T764, T765, T766, T767, T768 are independently selected from the group consisting
25 aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T723, T724 und/oder T732, T733 und/oder T745, T746 und/oder T752, T753 und/oder T761 , T762 jeweils zusammen auch „heterocyclyl" bilden können;25 of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively T723, T724 and / or T732, T733 and / or T745, T746 and or T752, T753 and / or T761, T762 may together also form "heterocyclyl";
30 wobei optional obige Substituenten der SubstituentengruppeWherein optionally substituents of the substituent group above
(ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (iii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT769, - NT770T771 , -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -(ii) may in turn be independently substituted with at least one substituent, the same or different, selected from the group consisting of: (iii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, as heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl, F, Cl, Br, I, CN, CF 3, N 3 , NH 2 , -NHT769, - NT770T771, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, - OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -
P(O)(OH)2, -C(O)-T772, -C(O)O-T773, -C(O)NH-T774, -C(O)NT775T776, -O-T777, -O(-T778-O)^H (f = 1 , 2, 3, 4, 5), -O(-T779-O)H"780 (f = 1 , 2, 3, 4, 5), -OC(O)- T781 , -OC(O)-O-T782, -OC(O)-NHT783, -0-C(O)- NT784T785, -OP(O)(OT786)(OT787), -P (O) (OH) 2 , -C (O) -T772, -C (O) O-T773, -C (O) NH-T774, -C (O) NT775T776, -O-T777, -O ( -T778-O) ^ H (f = 1, 2, 3, 4, 5), -O (-T779-O) H " 780 (f = 1, 2, 3, 4, 5), -OC (O ) - T781, -OC (O) -O-T782, -OC (O) -NHT783, -O-C (O) -NT784T785, -OP (O) (OT786) (OT787),
OSi(T788)(T789)(T790), -OS(O2)-T791 , -NHC(O)-T792, -NT793C(O)-T794, -NH-C(O)-O-T795, -NH-C(O)- NH-T796, -NH-C(O)-NT797T798, -NT799-C(O)-O- T800, -NT801 -C(O)-N H-T802, -NT803-C(O)- NT804T805, -NHS(O2)-T806, -NT807S(O2)-T808, -S-OSi (T788) (T789), (T790), -OS (O 2) -T791, -NHC (O) -T792, -NT793C (O) -T794, -NH-C (O) -O-T795, -NH -C (O) -NH-T796, -NH-C (O) -NT797T798, -NT799-C (O) -O-T800, -NT801 -C (O) -NH-T802, -NT803-C ( O) - NT804T805, -NHS (O 2) -T806, -NT807S (O 2) -T808, -S-
T809, -S(O)-T810, -S(O2)-T81 1 , -S(O2)NH-T812, - S(O2)NT813T814, -S(O2)O-T815, - P(O)(OT816)(OT817), -Si(T818)(T819)(T820)"; wobei T769, T770, T771 , T772, T773, T774, T775, T776, T777, T778, T779, T780, T781 , T782, T783, T784, T785,T809, -S (O) -T810, -S (O 2) -T81 1, -S (O 2) NH-T812, - S (O 2) NT813T814, -S (O 2) O-T815, - P (O) (OT816) (OT817), -Si (T818) (T819) (T820) "; wherein T769, T770, T771, T772, T773, T774, T775, T776, T777, T778, T779, T780, T781, T782, T783, T784, T785,
T786, T787, T788, T789, T790, T791 , T792, T793, T794, T795, T796, T797, T798, T799, T800, T801 , T802, T803, T804, T805, T806, T807, T808, T809, T810, T81 1 , T812, T813, T814, T815, T816, T817, T818, T819, T820 unab- hängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T775, T776 und/oder T784, T785 und/oder T797, T798 und/oder T804, T805 und/oder T813, T814 jeweils zusammen auch „heterocyclyl" bilden können;T786, T787, T788, T789, T790, T791, T792, T793, T794, T795, T796, T797, T798, T799, T800, T801, T802, T803, T804, T805, T806, T807, T808, T809, T810, T81 1, T812, T813, T814, T815, T816, T817, T818, T819, T820 independently of one another are selected from the group consisting of: "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively T775, T776 and / or T784, T785 and / or T797, T798 and / or T804, T805 and / or T813, T814 may each together also form" heterocyclyl ";
(2) ,,-C(Y5)NZ33-Y6-Z34"; wobei Y5, Y6 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus „O, S, =NH, =NZ35"; wobei Z33, Z34, Z35 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: (I) „Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, - C(O)-alkyl, -C(0)-(C9-C3o)alkyl, -C(O)-cycloalkyl, -C(O)- cycloalkylalkyl, -C(O)-aryl, -C(O)-arylalkyl, -C(O)-heteroaryl, - C(O)-heteroarylalkyl, -C(O)-heterocyclyl, -C(O)-heterocyclylalkyl, -S(O2)-alkyl, -S(02)-(C9-C3o)alkyl, -S(O2)-cycloalkyl, -S(O2)- cycloalkylalkyl, -S(O2)-aryl, -S(O2)-arylalkyl, -S(O2)-heteroaryl, - S(O2)-heteroarylalkyl, -S(O2)-heterocyclyl, -S(O2)- heterocyclylalkyl"; wobei optional obige Substituenten der Substituentengruppe (I) un- abhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(2) ,, - C (Y5) NZ33-Y6-Z34 "; wherein Y5, Y6 are independently selected from the group consisting of "O, S, = NH, = NZ35"; wherein Z33, Z34, Z35 are independently selected from the group consisting of: (I) "hydrogen, alkyl, ( Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, - C (O) alkyl, -C (0) - (C 9 -C 3 o) alkyl, -C (O) -cycloalkyl, -C (O) -cycloalkylalkyl, -C (O) -aryl, -C (O) -arylalkyl, -C (O) -heteroaryl, -C (O) -heteroarylalkyl, -C (O) -heterocyclyl, -C (O) -heterocyclylalkyl, -S (O 2) alkyl, -S (0 2) - (C 9 -C 3 O) alkyl, -S (O 2) cycloalkyl, - S (O 2) - cycloalkylalkyl, (2 O) -aryl -S, -S (O 2) -arylalkyl, -S (O 2) heteroaryl, - (O 2) heteroarylalkyl S, -S (O 2) heterocyclyl, -S (O 2 ) heterocyclylalkyl "; wherein optionally substituents of the substituent group (I) above may in turn be independently substituted with at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT821 , -NT822T823, -NO2, -OH, -(i) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT821, -NT822T823, -NO 2 , -OH, -
OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-T824, -C(O)O-T825, - C(O)NH-T826, -C(O)NT827T828, -O-T829, -O(-T830-O)g-H (g = 1 , 2, 3, 4, 5), -O(-T831-O)g-T832 (g = 1 , 2, 3, 4, 5), - OC(O)-T833, -OC(O)-O-T834, -OC(O)-N HT835, -0-C(O)-OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T824, -C (O) O-T825, -C (O) NH-T826, -C (O) NT827T828, -O-T829, -O (-T830-O) g - H (g = 1,2,3,4,5), -O (-T831-O) g -T832 (g = 1,2,3,4,5), - OC (O) -T833, -OC (O) -O-T834, -OC (O) -NHT835, -O-C (O) -
NT836T837, -OP(O)(OT838)(OT839), -OSi(T840)(T814)(T842), -OS(O2)-T843, -NHC(O)-T844, -NT845C(O)-T846, -NH- C(O)-O-T847, -N H-C(O)-N H-T848, -NH-C(O)-NT849T850, - NT851-C(O)-O-T852, -NT853-C(O)-NH-T854, -NT855- C(O)-NT856T857, -NHS(O2)-T858, -NT859S(O2)-T860, -S-NT836T837, -OP (O) (OT838) (OT839), -OSi (T840) (T814), (T842), -OS (O 2) -T843, -NHC (O) -T844, -NT845C (O) -T846 , -NH-C (O) -O-T847, -NHC (O) -NH-T848, -NH-C (O) -NT849T850, -NT851-C (O) -O-T852, -NT853- C (O) -NH-T854, -NT855- C (O) -NT856T857, -NHS (O 2) -T858, -NT859S (O 2) -T860, -S-
T861 , -S(O)-T862, -S(O2)-T863, -S(O2)NH-T864, - S(O2)NT865T866, -S(O2)O-T867, -P(O)(OT868)(OT869), - Si(T870)(T871 )(T872)"; wobei T821 , T822, T823, T824, T825, T826, T827, T828, T829, T830, T831 , T832, T833, T834, T835, T836, T837, T838, T839, T840, T841 , T842, T843, T844, T845, T846, T847, T848, T849, T850, T851 , T852, T853, T854, T855, T856, T857, T858, T859,T861, -S (O) -T862, -S (O 2) -T863, -S (O 2) NH-T864, - S (O 2) NT865T866, -S (O 2) O-T867, -P ( O) (OT868) (OT869), -Si (T870) (T871) (T872) "; wherein T821, T822, T823, T824, T825, T826, T827, T828, T829, T830, T831, T832, T833, T834, T835, T836, T837, T838, T839, T840, T841, T842, T843, T844, T845 , T846, T847, T848, T849, T850, T851, T852, T853, T854, T855, T856, T857, T858, T859,
5 T860, T861 , T862, T863, T864, T865, T866, T867, T868, T869,5 T860, T861, T862, T863, T864, T865, T866, T867, T868, T869,
T870, T871 , T872 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cyc- loalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, hetero- aryl, heteroarylalkyl" und wobei alternativ T827, T828 und/oderT870, T871, T872 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, Cyc loalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, hetero- aryl, heteroarylalkyl" and wherein alternatively T827, T828 and / or
10 T836, T837 und/oder T849, T850 und/oder T856, T857 und/oder10 T836, T837 and / or T849, T850 and / or T856, T857 and / or
T865, T866 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander auch weiter substituiert seinT865, T866 may together also form "heterocyclyl", wherein optionally substituents of the substituent group (i) above may also be further substituted independently of one another
15 können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:15 may be substituted by at least one substituent, the same or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT873, -NT874T875, -NO2, -(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT873, -NT874T875, -NO 2 , -
20 OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH,20 OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH,
-C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-T876, -C(O)O-T877, -C(O)NH-T878, -C(O)NT879T880, -O-T881 , -O(-T882- O)h-H (h = 1 , 2, 3, 4, 5), -O(-T883-O)h-T884 (h = 1 , 2, 3, 4, 5), -OC(O)-T885, -OC(O)-O-T886, -OC(O)-NHT887, -O--C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T876, -C (O) O-T 877, -C (O) NH-T 878, - C (O) NT879T880, -O-T881, -O (-T882-O) h -H (h = 1, 2, 3, 4, 5), -O (-T883-O) h -T884 (h = 1, 2, 3, 4, 5), -OC (O) -T885, -OC (O) -O-T886, -OC (O) -NHT887, -O-
25 C(O)-NT888T889, -OP(O)(OT890)(OT891 ), -25 C (O) -NT888T889, -OP (O) (OT890) (OT891),
OSi(T892)(T893)(T894), -OS(O2)-T895, -NHC(O)-T896, - NT897C(O)-T898, -NH-C(O)-O-T899, -NH-C(O)-NH- T900, -NH-C(O)-NT901T902, -NT903-C(O)-O-T904, - NT905-C(O)-NH-T906, -NT907-C(O)-NT908T909, -OSi (T892) (T893), (T894), -OS (O 2) -T895, -NHC (O) -T896 - NT897C (O) -T898, -NH-C (O) -O-T899, -NH -C (O) -NH-T900, -NH-C (O) -NT901T902, -NT903-C (O) -O-T904, - NT905-C (O) -NH-T906, -NT907-C (O ) -NT908T909, -
30 NHS(O2)-T910, -NT91 1S(O2)-T912, -S-T913, -S(O)-T914,30 NHS (O 2) -T910, -NT91 1S (O 2) -T912, -S-T913, -S (O) -T914,
-S(O2)-T915, -S(O2)NH-T916, -S(O2)NT917T918, - S(O2)O-T919, -P(O)(OT920)(OT921 ), - Si(T922)(T923)(T924)"; wobei T873, T874, T875, T876, T877, T878, T879, T880, T881 , T882, T883, T884, T885, T886, T887, T888, T889, T890, T891 , T892, T893, T894, T895, T896, T897, T898, T899, T900, T901 , T902, T903, T904, T905, T906, T907, 5 T908, T909, T910, T911 , T912, T913, T914, T915, T916,-S (O 2) -T915, -S (O 2) NH-T916, -S (O 2) NT917T918, - S (O 2) O-T919, -P (O) (OT920) (OT921) - Si (T922) (T923), (T924) "; wherein T873, T874, T875, T876, T877, T878, T879, T880, T881, T882, T883, T884, T885, T886, T887, T888, T889, T890, T891, T892, T893, T894, T895, T896, T897 , T898, T899, T900, T901, T902, T903, T904, T905, T906, T907, 5 T908, T909, T910, T911, T912, T913, T914, T915, T916,
T917, T918, T919, T920, T921 , T922, T923, T924 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary-T917, T918, T919, T920, T921, T922, T923, T924 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl
10 lalkyl" und wobei alternativ T879, T880 und/oder T888, T889 und/oder T901 , T902 und/oder T908, T909 und/oder T917, T918 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein kön-Alternatively, T879, T880 and / or T888, T889 and / or T901, T902 and / or T908, T909 and / or T917, T918 may together also form "heterocyclyl"; optionally substituents of the substituent group (ii) above may be substituted independently of one another
15 nen mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:15 NEN having at least one substituent, the same or different, selected from the group consisting of:
(iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT925, -(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT925, -
20 NT926T927, -NO2, -OH, -OCF3, -SH, -0-SO3H, -20 NT926T927, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -
OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, - P(O)(OH)2, -C(O)-T928, -C(O)O-T929, -C(O)NH-T930, -C(O)NT931T932, -O-T933, -O(-T934-O),-H (i = 1 , 2, 3, 4, 5), -O(-T935-O),-T936 (i = 1 , 2, 3, 4, 5), -OC(O)-OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T 928, -C (O ) O-T929, -C (O) NH-T930, -C (O) NT931T932, -O-T933, -O (-T934-O), - H (i = 1, 2, 3, 4, 5) , -O (-T935-O), - T936 (i = 1, 2, 3, 4, 5), -OC (O) -
25 T937, -OC(O)-O-T938, -OC(O)-NHT939, -0-C(O)-25 T937, -OC (O) -O-T938, -OC (O) -NHT939, -O-C (O) -
NT940T941 , -OP(O)(OT942)(OT943), - OSi(T944)(T945)(T946), -OS(O2)-T947, -NHC(O)-T948, -NT949C(O)-T950, -NH-C(O)-O-T951 , -NH-C(O)- NH-T952, -NH-C(O)-NT953T954, -NT955-C(O)-O-NT940T941, -OP (O) (OT942) (OT943), - OSi (T944) (T945), (T946), -OS (O 2) -T947, -NHC (O) -T948, -NT949C (O) -T950 , -NH-C (O) -O-T951, -NH-C (O) -NH-T952, -NH-C (O) -NT953T954, -NT955-C (O) -O-
30 T956, -NT957-C(O)-NH-T958, -NT959-C(O)-30 T956, -NT957-C (O) -NH-T958, -NT959-C (O) -
NT960T961 , -NHS(O2)-T962, -NT963S(O2)-T964, -S- T965, -S(O)-T966, -S(O2)-T967, -S(O2)NH-T968, - S(O2)NT969T970, -S(O2)O-T971 , - P(O)(OT972)(OT973), -Si(T974)(T975)(T976)"; wobei T925, T926, T927, T928, T929, T930, T931 , T932, T933, T934, T935, T936, T937, T938, T939, T940, T941 , T942, T943, T944, T945, T946, T947, T948, T949, T950, T951 , T952, T953, T954, T955, T956, T957, T958, T959, T960, T961 , T962, T963, T964, T965, T966, T967, T968,NT960T961, -NHS (O 2) -T962, -NT963S (O 2) -T964, -S- T965, -S (O) -T966, -S (O 2) -T967, -S (O 2) NH- T968, -S (O 2 ) NT969T970, -S (O 2 ) O-T971, -P (O) (OT972) (OT973), -Si (T974) (T975) (T976) "; wherein T925, T926, T927, T928, T929, T930, T931, T932, T933, T934, T935, T936, T937, T938, T939, T940, T941, T942, T943, T944, T945, T946, T947, T948, T949 , T950, T951, T952, T953, T954, T955, T956, T957, T958, T959, T960, T961, T962, T963, T964, T965, T966, T967, T968,
T969, T970, T971 , T972, T973, T974, T975, T976 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylal- kyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroa- ryl, heteroarylalkyl" und wobei alternativ T931 , T932 und/oder T940, T941 und/oder T953, T954 und/oder T960, T961 und/oder T969, T970 jeweils zusammen auch „heterocyclyl" bilden können;T969, T970, T971, T972, T973, T974, T975 are, T976 independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylal- kyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively T931, T932 and / or T940, T941 and / or T953, T954 and / or T960, T961 and / or T969, T970 can each also together form" heterocyclyl ";
und einer der Reste Z26, Z27 oder keiner der Reste Z26, Z27 unabhängig voneinander auch ausgewählt ist aus der Gruppe bestehend aus:and one of the radicals Z26, Z27 or none of the radicals Z26, Z27 independently of one another is also selected from the group consisting of:
(3) „Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C(O)-alkyl, -C(0)-(C9-C3o)alkyl, -C(O)-cycloalkyl, -C(O)-cycloalkylalkyl, -C(O)- aryl, -C(O)-arylalkyl, -C(O)-heteroaryl, -C(O)-heteroarylalkyl, -C(O)- heterocyclyl, -C(O)-heterocyclylalkyl, -C(Y7)NZ36Z37, -C(=NZ38)- Z39, -S(O2)-alkyl, -S(02)-(C9-C3o)alkyl, -S(O2)-cycloalkyl, -S(O2)- cycloalkylalkyl, -S(O2)-aryl, -S(O2)-arylalkyl, -S(O2)-heteroaryl, - S(O2)-heteroarylalkyl, -S(O2)-heterocyclyl, -S(O2)-heterocyclylalkyl"; wobei Y7 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus „O, S, =NH, =NZ40"; wobei die Reste Z36, Z37, Z38, Z39, Z40 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:(3) "hydrogen, alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C (O) -alkyl, -C (O) - (C 9 -C 3 o) alkyl, -C (O) -cycloalkyl, -C (O) -cycloalkylalkyl, -C (O) -aryl, -C (O) -arylalkyl, -C (O) -heteroaryl, -C ( O) heteroarylalkyl, -C (O) - heterocyclyl, -C (O) -heterocyclylalkyl, -C (Y7) NZ36Z37, -C (= NZ38) - Z39, -S (O 2) alkyl, -S (0 2) - (C 9 -C 3 O) alkyl, -S (O 2) cycloalkyl, -S (O2) - cycloalkylalkyl, -S (O 2) aryl, -S (O 2) arylalkyl, - S (O 2 ) -heteroaryl, -S (O 2 ) -heteroarylalkyl, -S (O 2 ) -heterocyclyl, -S (O 2 ) -heterocyclylalkyl ", wherein Y 7 is independently selected from the group consisting of" O, S, = NH, = NZ40 "; wherein the radicals Z36, Z37, Z38, Z39, Z40 are independently selected from the group consisting of:
(I) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- cyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C(O)-alkyl, -(I) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- cyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C (O) -alkyl, -
C(0)-(C9-C3o)alkyl, -C(O)-cycloalkyl, -C(O)-cycloalkylalkyl, -C(O)- aryl, -C(O)-arylalkyl, -C(O)-heteroaryl, -C(O)-heteroarylalkyl, - C(O)-heterocyclyl, -C(O)-heterocyclylalkyl, -S(O2)-alkyl, -S(O2)- (C9-C3o)alkyl, -S(O2)-cycloalkyl, -S(O2)-cycloalkylalkyl, -S(O2)-aryl, -S(O2)-arylalkyl, -S(O2)-heteroaryl, -S(O2)-heteroarylalkyl, - S(O2)-heterocyclyl, -S(O2)-heterocyclylalkyl"; wobei optional obige Substituenten der Substituentengruppe (3) und/oder Substituentengruppe (I) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich o- der verschieden, ausgewählt aus der Gruppe bestehend aus:C (0) - (C 9 -C 3 O) alkyl, -C (O) cycloalkyl, -C (O) cycloalkylalkyl, -C (O) - aryl, -C (O) -arylalkyl, -C ( O) -heteroaryl, -C (O) -heteroarylalkyl, - C (O) -heterocyclyl, -C (O) -heterocyclylalkyl, -S (O 2 ) -alkyl, -S (O 2 ) - (C 9 -C 3 O) alkyl, -S (O 2) cycloalkyl, -S (O 2) cycloalkylalkyl, aryl, -S (O 2), (2 O) -arylalkyl, -S (O -S 2 ) -heteroaryl, -S (O 2 ) -heteroarylalkyl, - S (O 2 ) -heterocyclyl, -S (O 2 ) -heterocyclylalkyl ", wherein optionally above substituents of the substituent group (3) and / or substituent group (I) independently may in turn be substituted with at least one substituent, same or different, selected from the group consisting of:
(i) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- cyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT977, -NT978T979, -NO2, -OH, -OCF3, -SH, -(i) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- cyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHT 977, -NT 978 T 979, -NO 2 , -OH, -OCF 3 , -SH, -
0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, - P(O)(OH)2, -C(O)-T980, -C(O)O-T981 , -C(O)NH-T982, - C(O)NT983T984, -O-T985, -O(-T986-O)-H (j = 1, 2, 3, 4, 5), -0(- T987-O)-T988 (j = 1 , 2, 3, 4, 5), -OC(O)-T989, -OC(O)-O-T990, - OC(O)-NHT991 , -O-C(O)-NT992T993, -OP(O)(OT994)(OT995), -0-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, - P (O) (OH) 2 , -C (O) -T980, -C (O) O-T981, -C (O) NH-T982, -C (O) NT983T984, -O-T985, -O (-T986-O) -H (j = 1, 2, 3, 4, 5), -O (- T987-O) -T988 (j = 1, 2, 3, 4, 5), -OC (O) -T989, -OC (O) -O-T990, - OC (O) -NHT991, -OC (O) -NT992T993, -OP (O) (OT994) (OT995),
OSi(T996)(T997)(T998), -OS(O2)-T999, -NHC(O)-TIOOO, - NT1001C(O)-TI002, -NH-C(O)-O-TI003, -NH-C(O)-NH-TI004, -NH-C(O)-NTI005T1006, -NT1007-C(O)-O-TI008, -NT1009- C(O)-NH-TIOIO1-NTIOII-C(O)-NTIO^TIOIS1-NHS(O2)- T1014, -NT1015S(O2)-T1016, -S-T1017, -S(O)-TI018, -S(O2)-OSi (T996) (T997), (T998), -OS (O 2) -T999, -NHC (O) -TIOOO, - NT1001C (O) -TI002, -NH-C (O) -O-TI003, -NH -C (O) -NH-TI004, -NH-C (O) -NTI005T1006, -NT1007-C (O) -O-TI008, -NT1009-C (O) -NH-TIOIO 1 -NTIOII-C (O ) -NTIO ^ TIOIS 1 -NHS (O 2 ) - T 1014, -NT 10 15 S (O 2 ) -T 10 16, -S-T 10 17, -S (O) -TiO 18, -S (O 2 ) -
T1019, -S(O2)NH-TI020, -S(O2)NTI021T1022, -S(O2)O-TI023, - P(O)(OTI024)(OT1025), -Si(TI026)(T1027)(T1028)"; wobei T977, T978, T979, T980, T981, T982, T983, T984, T985, T986, T987, T988, T989, T990, T991, T992, T993, T994, T995, T996, T997, T998, T999, T1000, T1001, T1002, T1003, T1004,T1019, -S (O 2) NH-TI020, -S (O 2) NTI021T1022, -S (O 2) O-TI023, - P (O) (OTI024) (OT1025), -Si (TI026) (T1027) (T1028) "; wherein T977, T978, T979, T980, T981, T982, T983, T984, T985, T986, T987, T988, T989, T990, T991, T992, T993, T994, T995, T996, T997, T998, T999, T1000, T1001, T1002, T1003, T1004,
T1005, T1006, T1007, T1008, T1009, T1010, T1011, T1012, T1013, T1014, T1015, T1016, T1017, T1018, T1019, T1020, T1021, T1022, T1023, T1024, T1025, T1026, T1027, T1028 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T983, T984 und/oder T992, T993 und/oder T1005, T1006 und/oder T1012, T1013 und/oder T1021 , T1022 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1029, -NT1030T1031 , -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-TI 032, -C(O)O-T1033, - C(O)NH-TI034, -C(O)NTI035T1036, -O-T1037, -O(-T1038-T1005, T1006, T1007, T1008, T1009, T1010, T1011, T1012, T1013, T1014, T1015, T1016, T1017, T1018, T1019, T1020, T1021, T1022, T1023, T1024, T1025, T1026, T1027, T1028 are independently selected are selected from the group consisting of: "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively T983, T984 and / or T992, T993 and / or T1005, T1006 and / or T1012, T1013 and / or T1021, T1022 may together also form "heterocyclyl"; in which optional substituents of substituent group (i) may in turn also be further substituted with at least one substituent, identical or different, selected from the group consisting of: (ii) alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHT1029, -NT1030T1031, -NO 2, -OH, - OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Ti 032, -C (O) O-T1033, -C (O) NH-TI034, -C (O) NTI035T1036, -O-T1037, -O (-T1038-
O)k-H (k = 1, 2, 3, 4, 5), -O(-T1039-O)k-T1040 (k = 1, 2, 3, 4, 5), -OC(O)-TI041, -OC(O)-O-TI042, -OC(O)-NHTI043, -O- C(O)-NTI044T1045, -OP(O)(OTI046)(OT1047), - OSi(TI048)(T1049)(T1050), -0S(02)-T1051, -NHC(O)-TI052, -NT1053C(O)-TI054, -NH-C(O)-O-TI055, -NH-C(O)-NH-O) k -H (k = 1, 2, 3, 4, 5), -O (-T1039-O) k -T1040 (k = 1, 2, 3, 4, 5), -OC (O) - TI041, -OC (O) -O-TI042, -OC (O) -NHTI043, -O-C (O) -NTI044T1045, -OP (O) (OTI046) (OT1047), -OSi (TI048) (T1049) (T1050), -0S (0 2) -T1051, -NHC (O) -TI052, -NT1053C (O) -TI054, -NH-C (O) -O-TI055, -NH-C (O) -NH -
T1056, -NH-C(O)-NTI057T1058, -NT1059-C(O)-O-TI060, - NT1061-C(O)-NH-TI062, -NT1063-C(O)-NTI064T1065, - NHS(O2)-T1066, -NT1067S(O2)-T1068, -S-T1069, -S(O)- T1070, -S(O2)-T1071, -S(O2)NH-TI072, -S(O2)NTI073T1074, -S(O2)O-TI075, -P(O)(OTI076)(OT1077), -T1056, -NH-C (O) -NTI057T1058, -NT1059-C (O) -O-TI060, -NT1061-C (O) -NH-TI062, -NT1063-C (O) -NTI064T1065, -NHS (O 2) -T1066, -NT1067S (O 2) -T1068, -S-T1069, -S (O) - T1070, -S (O 2) -T1071, -S (O 2) NH-TI072, -S (O 2 ) NTI073T1074, -S (O 2 ) O-TI075, -P (O) (OTI076) (OT1077),
Si(TI078)(T1079)(T1080)"; wobei T1029, T1030, T1031, T1032, T1033, T1034, T1035, T1036, T1037, T1038, T1039, T1040, T1041, T1042, T1043, T1044, T1045, T1046, T1047, T1048, T1049, T1050, T1051, T1052, T1053, T1054, T1055, T1056, T1057, T1058, T1059,Si (TI078) (T1079) (T1080) "; wherein T1029, T1030, T1031, T1032, T1033, T1034, T1035, T1036, T1037, T1038, T1039, T1040, T1041, T1042, T1043, T1044, T1045, T1046, T1047 , T1048, T1049, T1050, T1051, T1052, T1053, T1054, T1055, T1056, T1057, T1058, T1059,
T1060, T1061, T1062, T1063, T1064, T1065, T1066, T1067, T1068, T1069, T1070, T1071, T1072, T1073, T1074, T1075, T1076, T1077, T1078, T1079, T1080 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylal- kyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T1035, T1036 und/oder T1044, T1045 und/oder T1057, T1058 und/oder T1064, T1065 und/oder T1073, T1074 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:T1060, T1061, T1062, T1063, T1064, T1065, T1066, T1067, T1068, T1069, T1070, T1071, T1072, T1073, T1074, T1075, T1076, T1077, T1078, T1079, T1080 are independently selected from the group consisting of "Alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclicalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively T 1035, T 1036 and / or T 1044, T 1045 and / or T 1057, T 1058 and or T1064, T1065 and / or T1073, T1074 may together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
5 (iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1081 , -NT1082T1083, - NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, - COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-TI 084, -5 (iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT1081, -NT1082T1083, - NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Ti 084, -
10 C(O)O-TI 085, -C(O)NH-TI 086, -C(O)NTI 087T1088, -O-10 C (O) O-TI 085, -C (O) NH-TI 086, -C (O) NTI 087T1088, -O-
T1089, -0(-T1090-O)1-H (I = 1 , 2, 3, 4, 5), -O(-T1091-O),- T1092 (I = 1 , 2, 3, 4, 5), -OC(O)-TI 093, -OC(O)-O-TI 094, -OC(O)-NHTI 095, -0-C(O)-NTI 096T1097, - OP(O)(OTI 098)(OT1099), -OSi(T1100)(T1101 )(T1 102), -T1089, -O (-T1090-O) 1 -H (I = 1,2,3,4,5), -O (-T1091-O), -T1092 (I = 1,2,3,4,5 ), -OC (O) -Ti 093, -OC (O) -O-TI 094, -OC (O) -NHTI 095, -O-C (O) -NTI 096T1097, - OP (O) (OTI 098 ) (OT1099), -OSi (T1100) (T1101) (T1 102), -
15 0S(02)-T1 103, -NHC(O)-T1 104, -NT1 105C(O)-T1106, -15 0S (0 2 ) -T1 103, -NHC (O) -T1 104, -NT1 105C (O) -T1106, -
NH-C(O)-O-T1107, -NH-C(O)-NH-T1108, -NH-C(O)- NT1109T1 110, -NT1 11 1-C(O)-O-T11 12, -NT11 13-C(O)- NH-T1 114, -NT11 15-C(O)-NT1 116T1 117, -NHS(O2)- T1 118, -NT1 119S(O2)-T1120, -S-T1121 , -S(O)-T1122, -NH-C (O) -O-T1107, -NH-C (O) -NH-T1108, -NH-C (O) -NT1109T1 110, -NT1 11 1-C (O) -O-T11 12, - NT11 13-C (O) - NH-T1 114, -NT11 15-C (O) -NT1 116T1 117, -NHS (O 2 ) - T1 118, -NT1 119S (O 2 ) -T1120, -S-T1121 , -S (O) -T1122, -
20 S(02)-T1123, -S(O2)NH-T1 124, -S(O2)NTI 125T1 126, -20S (0 2 ) -T1123, -S (O 2 ) NH-T1 124, -S (O 2 ) NTI 125T1 126, -
S(O2)O-T1 127, -P(O)(OT1128)(OT1129), - Si(T1130)(T1131 )(T1 132)"; wobei T1081 , T1082, T1083, T1084, T1085, T1086, T1087, T1088, T1089, T1090, T1091 , T1092, T1093, T1094, T1095,S (O 2) O-T1 127, -P (O) (OT1128) (OT1129), - Si (T1130) (T1131) (T1 132) "; wherein T1081, T1082, T1083, T1084, T1085, T1086, T1087 , T1088, T1089, T1090, T1091, T1092, T1093, T1094, T1095,
25 T1096, T1097, T1098, T1099, T1100, T1 101 , T1102, T1 103,25 T1096, T1097, T1098, T1099, T1100, T1101, T1102, T1103,
T1104, T1105, T1 106, T1107, T1108, T1 109, T11 10, T1 11 1 , T1112, T11 13, T1 114, T11 15, T11 16, T1 117, T11 18, T1 119, T1120, T1121 , T1 122, T1123, T1124, T1 125, T1126, T1 127, T1128, T1129, T1 130, T1131 , T1132 unabhängig voneinan-T1104, T1105, T1106, T1107, T1108, T1109, T1110, T1111, T1112, T1113, T1114, T1115, T1116, T1117, T1118, T1119, T1120, T1121, T1122 , T1123, T1124, T1125, T1126, T1127, T1128, T1129, T1301, T1131, T1132 independently of each other.
30 der ausgewählt sind aus der Gruppe bestehend aus: „alkyl,30 are selected from the group consisting of: "alkyl,
(Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T1087, T1088 und/oder T1096, T1097 und/oder T1 109, T11 10 und/oder T1 116, T11 17 und/oder T1 125,(Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively T1087, T1088 and / or T1096, T1097 and / or T1 109, T11 10 and / or T1 116th , T11 17 and / or T1 125,
35 T1 126 jeweils zusammen auch „heterocyclyl" bilden können; und einer der Reste Z1 , Z2 oder keiner der Reste Z1 , Z2 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus:35 T1 126 may together also form "heterocyclyl"; and one of the radicals Z1, Z2 or none of the radicals Z1, Z2 is independently selected from the group consisting of:
(c) Wasserstoff, alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,(c) hydrogen, alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,
CN, CF3, N3, NH2, -NHT1133, -NT1134T1135, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, - P(O)(OH)2, -C(O)-TH 36, -C(O)O-TH 37, -C(O)NH-TH 38, - C(O)NTI 139T1 140, -0-T1 141 , -0(-T1 142-O)m-H (m = 1 , 2, 3, 4, 5), - 0(-T1 143-O)m-T1 144 (m = 1 , 2, 3, 4, 5), -OC(O)-T1145, -OC(O)-O-CN, CF 3, N 3, NH 2, -NHT1133, -NT1134T1135, -NO 2, -OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2, -CHO , -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -TH 36, -C (O) O-TH 37, -C (O ) NH-TH 38, -C (O) NTI 139T1 140, -O-T1 141, -O (-T1 142-O) m -H (m = 1, 2, 3, 4, 5), - 0 ( -T1 143-O) m -T1 144 (m = 1, 2, 3, 4, 5), -OC (O) -T1145, -OC (O) -O-
T1146, -OC(O)-NHT1 147, -0-C(O)-NTI 148T1 149, - OP(O)(OT1 150)(OT1 151 ), -OSi(T1 152)(T1 153)(T1154), -0S(02)-T1155, -NHC(O)-T1156, -NT1 157C(O)-T1 158, -NH-C(O)-O-T1 159, -NH- C(O)-NH-T1160, -NH-C(O)-NT1161 T1162, -NT1163-C(O)-O-T1164, -NT1165-C(O)-NH-T1 166, -NT1 167-C(O)-NTI 168T1 169, -NHS(O2)-T1146, -OC (O) -NHT1 147, -O-C (O) -NTI 148T1 149, - OP (O) (OT1 150) (OT1 151), -OSi (T1 152) (T1 153) (T1154) , -0S (0 2) -T1155, -NHC (O) -T1156, -NT1 157C (O) -T1 158, -NH-C (O) -O-T1 159, -NH- C (O) -NH -T1160, -NH-C (O) -NT1161 T1162, -NT1163-C (O) -O-T1164, -NT1165-C (O) -NH-T1 166, -NT1 167-C (O) -NTI 168T1 169, -NHS (O 2 ) -
T1170, -NT1171 S(02)-T1 172, -S-T1 173, -S(O)-T1 174, -S(02)-T1175, -S(O2)NH-T1 176, -S(O2)NTI 177T1 178, -S(O2)O-T1 179, - P(O)(OT1180)(OT1181 ), -Si(T1182)(T1 183)(T1184)"; wobei T1 133, T1134, T1 135, T1136, T1137, T1 138, T1139, T1 140, T1141 , T1 142, T1143, T1 144, T1 145, T1146, T1 147, T1148, T1149,T1170, -NT1171 S (0 2) -T 1 -R 172, -S-T1 173, -S (O) -T 1 -R 174, -S (0 2) -T1175, -S (O 2) NH-T1 176, -S (O 2 ) NTI 177T1 178, -S (O 2 ) O-T1 179, -P (O) (OT1180) (OT1181), -Si (T1182) (T1 183) (T1184) "; wherein T1 133, T1134 , T1 135, T1136, T1137, T1 138, T1139, T1140, T1141, T1142, T1143, T1144, T1145, T1146, T1147, T1148, T1149,
T1150, T1 151 , T1152, T1 153, T1 154, T1155, T1 156, T1157, T1158, T1159, T1 160, T1161 , T1 162, T1 163, T1164, T1 165, T1166, T1167, T1168, T1 169, T1170, T1 171. T1 172, T1173, T1 174, T1175, T1176, T1177, T1 178, T1179, T1 180, T1181 , T1 182, T1 183, T1184 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-T1150, T1 151, T1152, T1 153, T1 154, T1155, T1 156, T1157, T1158, T1159, T1 160, T1161, T1 162, T1 163, T1164, T1 165, T1166, T1167, T1168, T1 169, T1170 , T1 171. T1 172, T1173, T1 174, T1175, T1176, T1177, T1 178, T1179, T1 180, T1181, T1 182, T1 183, T1184 are independently selected from the group consisting of: "alkyl, (Cg -
C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T1 139, T1140 und/oder T1148, T1 149 und/oder T1 161 , T1162 und/oder T1168, T1 169 und/oder T1177, T1 178 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (c) wiederum unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1 185, -NT1 186T1187, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-T1188, -C(O)O-T1189, -C(O)N H-T1190, -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively T1 139, T1140 and / or T1148, T1 149 and / or T1 161, T1162 and / or T1168, T1 169 and T1177, T1 178 may together also form "heterocyclyl"; optionally optionally substituents of the substituent group (c) may be further independently substituted with at least one substituent, same or different, selected from the group consisting of: "Alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , - NHT1 185, -NT1 186T1187, -NO 2, -OH, -OCF3, -SH, -O- SO3H, -OP (O) (OH) 2, -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T1188, -C (O) O-T 1189, -C (O) N H-T 1190, -
C(O)NTI 191T1192, -0-T1193, -0(-T1194-O)n-H (n = 1 , 2, 3, 4, 5), -0(-T1195-O)n-T1196 (n = 1 , 2, 3, 4, 5), -OC(O)-T1197, -OC(O)- 0-T1198, -OC(O)-NHT1199, -0-C(O)-NTI200T1201,- OP(O)(OTI202)(OT1203), -OSi(TI204)(T1205)(T1206), -OS(O2)- T1207, -NHC(O)-TI208, -NT1209C(O)-T1210, -NH-C(O)-O-C (O) NTI 191T1192, -0-T1193, -0 (-T1194-O) n -H (n = 1, 2, 3, 4, 5), -O (-T1195-O) n -T1196 (n = 1, 2, 3, 4, 5), -OC (O) -T1197, -OC (O) -O-T1198, -OC (O) -NHT1199, -O-C (O) -NTI200T1201, -OP (O) (OTI202) (OT1203), -OSi (TI204) (-T1205) (T1206), -OS (O 2) - T1207, -NHC (O) -TI208, -NT1209C (O) -T1210, -NH- C (O) -O-
T1211 , -N H-C(O)-N H-T1212, -N H-C(O)-NTI 213T1214, -NT1215- C(O)-O-T1216, -NT1217-C(O)-NH-T1218, -NT1219-C(O)- NT1220T1221 , -NHS(O2)-T1222, -NT1223S(O2)-T1224, -S-T1225, -S(O)-T1226, -S(O2)-T1227, -S(O2)NH-T1228, - S(O2)NTI 229T1230, -S(O2)O-TI 231 , -P(O)(OTI 232)(OT1233), -T1211, -NHC (O) -NH-T1212, -NHC (O) -NTI 213T1214, -NT1215-C (O) -O-T1216, -NT1217-C (O) -NH-T1218, -NT1219 -C (O) - NT1220T1221, -NHS (O 2) -T1222, -NT1223S (O 2) -T1224, -S-T1225, -S (O) -T1226, -S (O 2) -T1227, -S (O 2 ) NH-T1228, -S (O 2 ) NTI 229T1230, -S (O 2 ) O-TI 231, -P (O) (OTI 232) (OT1233),
Si(T1234)(T1235)(T1236)"; wobei T1 185, T1186, T1 187, T1188, T1189, T1 190, T1191 , T1 192, T1193, T1 194, T1195, T1 196, T1197, T1198, T1 199, T1200, T1201 , T1202, T1203, T1204, T1205, T1206, T1207, T1208, T1209, T1210, T1211 , T1212, T1213, T1214, T1215, T1216, T1217, T1218, T1219,Si (T1234) (T1235) (T1236) "where T1 185, T1186, T1 187, T1188, T1189, T1190, T1191, T1192, T1193, T1194, T1195, T1196, T1197, T1198, T1199, T1200, T1201, T1202, T1203, T1204, T1205, T1206, T1207, T1208, T1209, T1210, T1211, T1212, T1213, T1214, T1215, T1216, T1217, T1218, T1219,
T1220, T1221 , T1222, T1223, T1224, T1225, T1226, T1227, T1228, T1229, T1230, T1231 , T1232, T1233, T1234, T1235, T1236 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativT1220, T1221, T1222, T1223, T1224, T1225, T1226, T1227, T1228, T1229, T1230, T1231, T1232, T1233, T1234, T1235, T1236 are independently selected from the group consisting of: "alkyl, (C 9 - C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively
T1191 , T1 192 und/oder T1200, T1201 und/oder T1213, T1214 und/oder T1220, T1221 und/oder T1229, T1230 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wie- derum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:T1191, T1 192 and / or T1200, T1201 and / or T1213, T1214 and / or T1220, T1221 and / or T1229, T1230 may together also form "heterocyclyl", where optionally substituents of the substituent group (i) above are also independent may be substituted with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1237, -NT1238T1239, -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-T1240, -C(O)O-T1241 , -C(O)NH- T1242, -C(O)NTI 243T1244, -O-T1245, -0(-T1246-O)0-H (o = 1 , 2, 3, 4, 5), -O(-T1247-O)o-T1248 (o = 1 , 2, 3, 4, 5), -OC(O)-(ii) "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHT1237, -NT1238T1239, -NO 2, -OH, - OCF 3, -SH, -0-SO3H, -OP (O) (OH) 2, -CHO , -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T 1240, -C (O) O-T 1241, -C (O) NH - T1242, -C (O) NTI 243T1244, -O-T1245, -0 (-T1246-O) 0-H (o = 1, 2, 3, 4, 5), -O (-T1247-O) o -T1248 (o = 1, 2, 3, 4, 5), -OC (O) -
T1249, -OC(O)-O-TI250, -OC(O)-NHT^SI1-O-C(O)- NT1252T1253, -OP(O)(OTI254)(OT1255), - OSi(T1256)(T1257)(T1258), -OS(O2)-T1259, -NHC(O)-T1260, - NT1261C(O)-T1262, -NH-C(O)-O-TI263, -NH-C(O)-NH- T1264, -NH-C(O)-NTI265T1266, -NT1267-C(O)-O-TI268, -T1249, -OC (O) -O-TI250, -OC (O) -NHT ^ SI 1 -OC (O) -NT1252T1253, -OP (O) (OTI254) (OT1255), -OSi (T1256) (T1257) (T1258), -OS (O 2) -T1259, -NHC (O) -T1260, - NT1261C (O) -T1262, -NH-C (O) -O-TI263, -NH-C (O) -NH T1264, -NH-C (O) -NTI265T1266, -NT1267-C (O) -O-TI268, -
NT1269-C(O)-NH-T1270, -NT1271-C(O)-NT1272T1273, - NHS(O2)-T1274, -NT1275S(O2)-T1276, -S-T1277, -S(O)- T1278, -S(O2)-T1279, -S(O2)NH-T1280, -S(O2)NT1281T1282, - S(O2)O-TI283, -P(O)(OTI284)(OT1285), - Si(T1286)(T1287)(T1288)"; wobei T1237, T1238, T1239, T1240, T1241 , T1242, T1243, T1244, T1245, T1246, T1247, T1248, T1249, T1250, T1251 , T1252, T1253, T1254, T1255, T1256, T1257, T1258, T1259, T1260, T1261 , T1262, T1263, T1264, T1265, T1266, T1267, T1268, T1269, T1270, T1271 , T1272, T1273, T1274, T1275,NT1269-C (O) -NH-T1270, -NT1271-C (O) -NT1272T1273, - NHS (O 2) -T1274, -NT1275S (O 2) -T1276, -S-T1277, -S (O) - T1278, -S (O 2) -T1279, -S (O 2) NH-T1280, -S (O 2) NT1281T1282, - S (O 2) O-TI283, -P (O) (OTI284) (OT1285) , Si (T1286) (T1287) (T1288) "; wherein T1237, T1238, T1239, T1240, T1241, T1242, T1243, T1244, T1245, T1246, T1247, T1248, T1249, T1250, T1251, T1252, T1253, T1254 , T1255, T1256, T1257, T1258, T1259, T1260, T1261, T1262, T1263, T1264, T1265, T1266, T1267, T1268, T1269, T1270, T1271, T1272, T1273, T1274, T1275,
T1276, T1277, T1278, T1279, T1280, T1281 , T1282, T1283, T1284, T1285, T1286, T1287, T1288 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativAre T1276, T1277, T1278, T1279, T1280, T1281, T1282, T1283, T1284, T1285, T1286, T1287, T1288 independently selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively
T1243, T1244 und/oder T1252, T1253 und/oder T1265, T1266 und/oder T1272, T1273 und/oder T1281 , T1282 jeweils zusammen auch „heterocyclyl" bilden können;T1243, T1244 and / or T1252, T1253 and / or T1265, T1266 and / or T1272, T1273 and / or T1281, T1282 may together also form "heterocyclyl";
(d) -NZ41Z42, wobei die Reste Z41 , Z42 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:(d) -NZ41Z42, wherein the radicals Z41, Z42 are independently selected from the group consisting of:
(1 ) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C(O)-alkyl, -C(O)- (C9-C30)alkyl, -C(O)-cycloalkyl, -C(O)-cycloalkylalkyl, -C(O)-aryl, - C(O)-arylalkyl, -C(O)-heteroaryl, -C(O)-heteroarylalkyl, -C(O)- heterocyclyl, -C(O)-heterocyclylalkyl"; wobei optional obige Substituenten der Substituentengruppe (1 ) unabhängig voneinander weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der(1) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C (O) -alkyl, -C (O) - (C 9 -C 30 ) alkyl, -C (O) -cycloalkyl, -C (O) -cycloalkylalkyl, -C (O) -aryl, - C (O) -arylalkyl, -C (O) -heteroaryl, -C (O) -heteroarylalkyl, -C (O) -heterocyclyl, -C (O) -heterocyclylalkyl "; optionally wherein the above substituents of the substituent group (1) are independently each further substituted with at least one substituent, the same or different, selected from
Gruppe bestehend aus:Group consisting of:
(i) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1289, -NT1290T1291 , -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2,(i) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHT1289, -NT1290T1291, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 ,
-SO3H, -P(O)(OH)2, -C(O)-T1292, -C(O)O-T1293, -C(O)NH- T1294, -C(O)NTI295T1296, -O-T1297, -O(-T1298-O)rr-H (rr = 1, 2, 3, 4, 5), -O(-T1299-O)rr-T1300 (rr = 1, 2, 3, 4, 5), -OC(O)- T1301, -OC(O)-O-TI302, -OC(O)-NHTI303, -0-C(O)- NT1304T1305, -OP(O)(OTI306)(OT1307), --SO 3 H, -P (O) (OH) 2, -C (O) -T1292, -C (O) O-T1293, -C (O) NH- T1294, -C (O) NTI295T1296, -O -T1297, -O (-T1298-O) rr -H (rr = 1, 2, 3, 4, 5), -O (-T1299-O) rr -T1300 (rr = 1, 2, 3, 4, 5), -OC (O) -T1301, -OC (O) -O-TI302, -OC (O) -NHTI303, -O-C (O) -NT1304T1305, -OP (O) (OTI306) (OT1307) , -
OSi(T1308)(T1309)(T1310),-OS(O2)-T1311,-NHC(O)-T1312,- NT1313C(O)-TI314, -NH-C(O)-O-TI315, -NH-C(O)-NH- T1316, -NH-C(O)-NTI317T1318, -NT1319-C(O)-O-TI320, - NT1321-C(O)-NH-T1322, -NT1323-C(O)-NTI324T1325, - NHS(O2)-T1326, -NT1327S(O2)-T1328, -S-T1329, -S(O)-OSi (T1308) (T1309) (T1310), - OS (O 2) -T1311, -NHC (O) -T1312, - NT1313C (O) -TI314, -NH-C (O) -O-TI315, -NH -C (O) -NH-T1316, -NH-C (O) -NTI317T1318, -NT1319-C (O) -O-TI320, -NT1321-C (O) -NH-T1322, -NT1323-C (O ) -NTI324T1325, - NHS (O 2 ) -T 1326, -NT 1327S (O 2 ) -T 1328, -S-T 1329, -S (O) -
T1330, -S(02)-T1331 , -S(O2)NH-TI 332, -S(O2)NTI 333T1334, - S(O2)O-TI 335, -P(O)(OTI 336)(OT1337), - Si(TI 338)(T1339)(T1340)"; wobei T1289, T1290, T1291 , T1292, T1293, T1294, T1295, T1296, T1297, T1298, T1299, T1300, T1301 , T1302, T1303,T1330, -S (O 2 ) -T 1331, -S (O 2 ) NH-TI 332, -S (O 2 ) NTI 333T1334, -S (O 2 ) O-TI 335, -P (O) (OTI 336 Si (TI 338) (T1339) (T1340) "; wherein T1289, T1290, T1291, T1292, T1293, T1294, T1295, T1296, T1297, T1298, T1299, T1300, T1301, T1302, T1303,
T1304, T1305, T1306, T1307, T1308, T1309, T1310, T1311 , T1312, T1313, T1314, T1315, T1316, T1317, T1318, T1319, T1320, T1321 , T1322, T1323, T1324, T1325, T1326, T1327, T1328, T1329, T1330, T1331 , T1332, T1333, T1334, T1335, T1336, T1337, T1338, T1339, T1340 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T1295, T1296 und/oder T1304, T1305 und/oder T1317, T1318 und/oder T1324, T1325 und/oder T1333, T1334 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander auch weiter substituiert sein 5 können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:T1304, T1305, T1306, T1307, T1308, T1309, T1310, T1311, T1312, T1313, T1314, T1315, T1316, T1317, T1318, T1319, T1320, T1321, T1322, T1323, T1324, T1325, T1326, T1327, T1328, are T1329, T1330, T1331, T1332, T1333, T1334, T1335, T1336, T1337, T1338, T1339, T1340 independently selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively T1295, T1296 and / or T1304, T1305 and / or T1317, T1318 and / or T1324, T1325 and / or T1333, T1334 may in each case also form "heterocyclyl", where optionally substituents of the substituent group (i) which may optionally be further substituted independently of one another may also be further substituted with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1341 , -NT1342T1343, -NO2, -(ii) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHT1341, -NT1342T1343, -NO 2 , -
10 OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -10 OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -
C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-TI344, -C(O)O-TI345, -C(O)NH-TI346, -C(O)NTI347T1348, -O-T1349, -0(- T1350-O)rs-H (rs = 1, 2, 3, 4, 5), -O(-T1351-O)rs-T1352 (rs = 1, 2, 3, 4, 5), -OC(O)-TI353, -OC(O)-O-TI354, -OC(O)-C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -TI344, -C (O) O-TI345, -C (O) NH-TI346, -C (O) NTI347T1348, -O-T1349, -0 (- T1350-O) rs -H (rs = 1, 2, 3, 4, 5), -O (-T1351-O) rs -T1352 (rs = 1 , 2, 3, 4, 5), -OC (O) -TI353, -OC (O) -O-TI354, -OC (O) -
15 NHT1355, -0-C(O)-NTI356T1357,-15 NHT1355, -O-C (O) -NTI356T1357, -
OP(O)(OTI358)(OT1359), -OSi(TI360)(T1361)(T1362), - OS(O2)-T1363, -NHC(O)-TI364, -NT1365C(O)-TI366, - NH-C(O)-O-TI367, -NH-C(O)-NH-TI368, -NH-C(O)- NT1369T1370, -NT1371-C(O)-O-TI372, -NT1373-C(O)-OP (O) (OTI358) (OT1359), -OSi (TI360) (T1361) (T1362), - OS (O 2) -T1363, -NHC (O) -TI364, -NT1365C (O) -TI366, - NH -C (O) -O-TI367, -NH-C (O) -NH-TI368, -NH-C (O) -NT1369T1370, -NT1371-C (O) -O-TI372, -NT1373-C (O ) -
20 NH-T1374, -NT1375-C(O)-NTI376T1377, -NHS(O2)-T1378,20 NH-T1374, -NT1375-C (O) -NTI376T1377, -NHS (O 2) -T1378,
-NT1379S(O2)-T1380, -S-T1381 , -S(O)-TI 382, -S(O2)- T1383, -S(O2)NH-TI 384, -S(O2)NTI 385T1386, -S(O2)O- T1387, -P(O)(OTI 388)(OT1389), -Si(TI 390)(T1391 )(T1392)"; wobei T1341 , T1342, T1343, T1344, T1345, T1346, T1347,-NT1379S (O 2) -T1380, -S-T1381, -S (O) -TI 382, -S (O 2) - T1383, -S (O 2) NH-TI 384, -S (O 2) NTI 385T1386, -S (O 2 ) O-T 1387, -P (O) (OTI 388) (OT1389), -Si (TI 390) (T1391) (T1392) ", where T1341, T1342, T1343, T1344, T1345, T1346, T1347,
25 T1348, T1349, T1350, T1351 , T1352, T1353, T1354, T1355,25 T1348, T1349, T1350, T1351, T1352, T1353, T1354, T1355,
T1356, T1357, T1358, T1359, T1360, T1361 , T1362, T1363, T1364, T1365, T1366, T1367, T1368, T1369, T1370, T1371 , T1372, T1373, T1374, T1375, T1376, T1377, T1378, T1379, T1380, T1381 , T1382, T1383, T1384, T1385, T1386, T1387,T1356, T1357, T1358, T1359, T1360, T1361, T1362, T1363, T1364, T1365, T1366, T1367, T1368, T1369, T1370, T1371, T1372, T1373, T1374, T1375, T1376, T1377, T1378, T1379, T1380, T1381, T1382, T1383, T1384, T1385, T1386, T1387,
30 T1388, T1389, T1390, T1391 , T1392 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T1347, T1348 und/oder T1356, T1357 und/oder T1369, T1370 und/oder T1376, T1377 und/oder T1385, T1386 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können"Alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl: 30 T1388, T1389, T1390, T1391, T1392 independently selected from the group consisting of and alternatively T1347, T1348 and / or T1356, T1357 and / or T1369, T1370 and / or T1376, T1377 and / or T1385, T1386 may in each case also form "heterocyclyl", where optionally substituents of the substituent group (ii) above may be substituted independently of one another
5 mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:5 having at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1393, -NT1394T1395,(iii) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, - NHT1393, -NT1394T1395,
10 -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO,10 -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO,
-COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-TI 396, - C(O)O-TI 397, -C(O)NH-TI 398, -C(O)NTI 399T1400, - O-T1401 , -O(-T1402-O)rt-H (rt = 1 , 2, 3, 4, 5), -0(- T1403-O)rt-T1404 (rt = 1 , 2, 3, 4, 5), -OC(O)-TI 405, --COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -TI 396, -C (O) O-TI 397, -C (O) NH-TI 398, -C (O) NTI 399T1400, -O-T1401, -O (-T1402-O) rt -H (rt = 1, 2, 3, 4, 5), -O (- T1403-O ) rt -T1404 (rt = 1, 2, 3, 4, 5), -OC (O) -Ti 405, -
15 OC(O)-O-TI 406, -OC(O)-NHT1407, -0-C(O)-15 OC (O) -O-TI 406, -OC (O) -NHT1407, -O-C (O) -
NT1408T1409, -OP(O)(OTI410)(OTI411), - OSi(T1412)(T1413)(T1414), -OS(O2)-T1415, -NHC(O)- T1416, -NT1417C(O)-T1418, -NH-C(O)-O-TI419, -NH- C(O)-NH-TI420, -NH-C(O)-NT1421T1422, -NT1423-NT1408T1409, -OP (O) (OTI410) (OTI411), - OSi (T1412) (T1413) (T1414), -OS (O 2) -T1415, -NHC (O) - T1416, -NT1417C (O) -T1418 , -NH-C (O) -O-TI419, -NH-C (O) -NH-TI420, -NH-C (O) -NT1421T1422, -NT1423-
20 C(O)-O-T1424, -NT1425-C(O)-NH-T1426, -NT1427-20 C (O) -O-T1424, -NT1425-C (O) -NH-T1426, -NT1427-
C(O)-NTI428T1429, -NHS(O2)-T1430, -NT1431S(O2)- T1432, -S-T1433, -S(O)-TI434, -S(O2)-T1435, - S(O2)NH-T1436, -S(O2)NT1437T1438, -S(O2)O-TI439, - P(O)(OTI440)(OT1441), -Si(TI442)(T1443)(T1444)";C (O) -NTI428T1429, -NHS (O 2) -T1430, -NT1431S (O 2) - T1432, T1433 -S-, -S (O) -TI434, -S (O 2) -T1435, - S ( O 2) NH-T1436, -S (O 2) NT1437T1438, -S (O 2) O-TI439, - P (O) (OTI440) (OT1441), -Si (TI442) (T1443) (T1444) ";
25 wobei T1393, T1394, T1395, T1396, T1397, T1398, T1399,25 wherein T1393, T1394, T1395, T1396, T1397, T1398, T1399,
T1400, T1401, T1402, T1403, T1404, T1405, T1406, T1407, T1408, T1409, T1410, T1411, T1412, T1413, T1414, T1415, T1416, T1417, T1418, T1419, T1420, T1421, T1422, T1423, T1424, T1425, T1426, T1427,T1400, T1401, T1402, T1403, T1404, T1405, T1406, T1407, T1408, T1409, T1410, T1411, T1412, T1413, T1414, T1415, T1416, T1417, T1418, T1419, T1420, T1421, T1422, T1423, T1424, T1425, T1426, T1427,
30 T1428, T1429, T1430, T1431, T1432, T1433, T1434,30 T1428, T1429, T1430, T1431, T1432, T1433, T1434,
T1435, T1436, T1437, T1438, T1439, T1440, T1441, T1442, T1443, T1444 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T1399, T1400 und/oder T1408, T1409 und/oder T1421 , T1422 und/oder T1428, T1429 und/oder T1437, T1438 jeweils zusammen auch „heterocyclyl" bilden kön- nen;T1435, T1436, T1437, T1438, T1439, T1440, T1441, T1442, T1443, T1444 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively T1399, T1400 and / or T1408, T1409 and / or T1421, T1422 and / or T1428, T1429 and / or T1437, T1438 can in each case also form" heterocyclyl ";
(2) ,,-C(O)-C(O)-TI 445, -S(O2)-NT1446T1447"; wobei T1445, T1446, T1447 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: (I) „Wasserstoff, alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1448, -NT1449T1450, - NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, - COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-TI 451 , -C(O)O- T1452, -C(O)NH-T1453, -C(O)NTI454T1455, -O-T1456, -0(-(2) ,, - C (O) -C (O) -TI 445, -S (O 2 ) -NT1446T1447 "; wherein T1445, T1446, T1447 are independently selected from the group consisting of: (I)" hydrogen , alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHT1448 , -NT1449T1450, - NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , - SO 3 H, -P (O) (OH) 2, -C (O) -TI 451, -C (O) O- T1452, -C (O) NH-T1453, -C (O) NTI454T1455, -O -T1456, -0 (-
T1457-O)ru-H (ru = 1, 2, 3, 4, 5), -O(-T1458-O)ru-T1459 (ru = 1, 2, 3, 4, 5), -OC(O)-T1460, -OC(O)-O-TI461, -OC(O)-NHTI462, -0-C(O)-NTI463T1464, -OP(O)(OTI465)(OT1466), - OSi(T1467)(T1468)(T1469), -OS(O2)-T1470, -NHC(O)-T1471, - NT1472C(O)-TI473, -NH-C(O)-O-TI474, -NH-C(O)-NH-T1457-O) ru -H (ru = 1, 2, 3, 4, 5), -O (-T1458-O) ru -T1459 (ru = 1, 2, 3, 4, 5), -OC (O ) -T1460, -OC (O) -O-TI461, -OC (O) -NHTI462, -O-C (O) -NTI463T1464, -OP (O) (OTI465) (OT1466), -OSi (T1467) ( T1468) (T1469), -OS (O 2) -T1470, -NHC (O) -T1471, - NT1472C (O) -TI473, -NH-C (O) -O-TI474, -NH-C (O) -NH-
T1475, -NH-C(O)-NTI476T1477, -NT1478-C(O)-O-TI479, - NT1480-C(O)-NH-T1481, -NT1482-C(O)-NTI483T1484, - NHS(O2)-T1485, -NT1486S(O2)-T1487, -S-T1488, -S(O)- T1489, -S(O2)-T1490, -S(O2)NH-T1491, -S(O2)NT1492T1493, - S(O2)O-TI494, -P(O)(OTI495)(OT1496), -T1475, -NH-C (O) -NTI476T1477, -NT1478-C (O) -O-TI479, - NT1480-C (O) -NH-T1481, -NT1482-C (O) -NTI483T1484, - NHS (O 2) -T1485, -NT1486S (O 2) -T1487, -S-T1488, -S (O) - T1489, -S (O 2) -T1490, -S (O 2) NH-T1491, -S (O 2 ) NT1492T1493, -S (O 2 ) O-TI494, -P (O) (OTI495) (OT1496),
Si(T1497)(T1498)(T1499)"; wobei T1448, T1449, T1450, T1451, T1452, T1453, T1454, T1455, T1456, T1457, T1458, T1459, T1460, T1461, T1462, T1463, T1464, T1465, T1466, T1467, T1468, T1469, T1470, T1471 , T1472, T1473, T1474, T1475, T1476, T1477, T1478,Si (T1497) (T1498) (T1499) "; wherein T1448, T1449, T1450, T1451, T1452, T1453, T1454, T1455, T1456, T1457, T1458, T1459, T1460, T1461, T1462, T1463, T1464, T1465, T1466 , T1467, T1468, T1469, T1470, T1471, T1472, T1473, T1474, T1475, T1476, T1477, T1478,
T1479, T1480, T1481, T1482, T1483, T1484, T1485, T1486, T1487, T1488, T1489, T1490, T1491, T1492, T1493, T1494, T1495, T1496, T1497, T1498, T1499 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T1454, T1455 und/oder T1463, T1464 und/oder T1476, T1477 und/oder T1483, T1484 und/oder T1492, T1493 jeweils zusammen 5 auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substitutionsgruppe (I) unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:T1479, T1480, T1481, T1482, T1483, T1484, T1485, T1486, T1487, T1488, T1489, T1490, T1491, T1492, T1493, T1494, T1495, T1496, T1497, T1498, T1499 are independently selected from the group consisting of : "Alkyl, (Cg- C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively T1454, T1455 and / or T1463, T1464 and / or T1476, T1477 and / or T1483, T1484 and / or T1492 , T1493 together can also form 5 "heterocyclyl"; wherein optionally substituted substituents of the substitution group (I) may be independently further substituted with at least one substituent, same or different, selected from the group consisting of:
10 (i) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1500, -NT1501T1502, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-TI 503, -C(O)O-TI 504,10 (i) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHT1500, -NT1501T1502, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -TI 503, -C (O) O-TI 504,
15 -C(O)NH-TI 505, -C(O)NTI 506T1507, -O-T1508, -0(-15 -C (O) NH-TI 505, -C (O) NTI 506T1507, -O-T1508, -0 (-
T1509-O)rv-H (rv = 1 , 2, 3, 4, 5), -O(-T1510-O)rv-T1511 (rv = 1 , 2, 3, 4, 5), -OC(O)-TI 512, -OC(O)-O-TI 513, -OC(O)- NHT1514, -0-C(O)-NTI 515T1516, - OP(O)(OTI 517)(0T1518), -OSi(TI 519)(T1520)(T1521 ), -T1509-O) rv -H (rv = 1, 2, 3, 4, 5), -O (-T1510-O) rv -T1511 (rv = 1, 2, 3, 4, 5), -OC (O ) -TI 512, -OC (O) -O-TI 513, -OC (O) - NHT1514, -O-C (O) -NTI 515T1516, - OP (O) (OTI 517) (0T1518), -OSi (TI 519) (T1520) (T1521),
20 OS(O2)-T1522, -NHC(O)-TI 523, -NT1524C(O)-TI 525, -20 OS (O 2 ) -T1522, -NHC (O) -TI 523, -NT1524C (O) -Ti 525, -
NH-C(O)-O-TI526, -NH-C(O)-NH-TI527, -NH-C(O)- NT1528T1529, -NT1530-C(O)-O-TI531, -NT1532-C(O)- NH-T1533, -NT1534-C(O)-NTI535T1536, -NHS(O2)-T1537, -NT1538S(O2)-T1539, -S-T1540, -S(O)-TI541, -S(O2)-NH-C (O) -O-TI526, -NH-C (O) -NH-TI527, -NH-C (O) -NT1528T1529, -NT1530-C (O) -O-TI531, -NT1532-C ( O) - NH-T1533, -NT1534-C (O) -NTI535T1536, -NHS (O 2) -T1537, -NT1538S (O 2) -T1539, -S-T1540, -S (O) -TI541, -S (O 2 ) -
25 T1542, -S(O2)NH-TI543, -S(O2)NTI544T1545, -S(O2)O-25 T1542, -S (O 2) NH-TI543, -S (O 2) NTI544T1545, -S (O 2) O-
T1546, -P(O)(OTI547)(OT1548), -Si(TI549)(T1550)(T1551)"; wobei T1500, T1501 , T1502, T1503, T1504, T1505, T1506, T1507, T1508, T1509, T1510, T1511, T1512, T1513, T1514, T1515, T1516, T1517, T1518, T1519, T1520, T1521, T1522,T1546, -P (O) (OTI547) (OT1548), -Si (TI549) (T1550) (T1551) "; where T1500, T1501, T1502, T1503, T1504, T1505, T1506, T1507, T1508, T1509, T1510, T1511, T1512, T1513, T1514, T1515, T1516, T1517, T1518, T1519, T1520, T1521, T1522,
30 T1523, T1524, T1525, T1526, T1527, T1528, T1529, T1530,30 T1523, T1524, T1525, T1526, T1527, T1528, T1529, T1530,
T1531, T1532, T1533, T1534, T1535, T1536, T1537, T1538, T1539, T1540, T1541, T1542, T1543, T1544, T1545, T1546, T1547, T1548, T1549, T1550, T1551 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T1506, T1507 und/oder T1515, T1516 und/oder T1528, T1529 und/oder T1535, T1536 und/oder T1544, T1545 5 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:T1531, T1532, T1533, T1534, T1535, T1536, T1537, T1538, T1539, T1540, T1541, T1542, T1543, T1544, T1545, T1546, T1547, T1548, T1549, T1550, T1551 are independently selected from the group consisting of : "Alkyl, (Cg- C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and, alternatively, T1506, T1507 and / or T1515, T1516 and / or T1528, T1529 and / or T1535, T1536 and / or T1544, T1545 each may together also form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
10 (ii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1552, -NT1553T1554, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-TI 555, -10 (ii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHT1552, -NT1553T1554, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -TI 555, -
15 C(O)O-TI 556, -C(O)NH-TI 557, -C(O)NTI 558T1559, -15 C (O) O-TI 556, -C (O) NH-TI 557, -C (O) NTI 558T1559, -
O-T1560, -O(-T1561-O)rw-H (rw = 1 , 2, 3, 4, 5), -0(- T1562-O)rw-T1563 (rw = 1 , 2, 3, 4, 5), -OC(O)-TI 564, - OC(O)-O-TI 565, -OC(O)-NHTI 566, -0-C(O)- NT1567T1568, -OP(O)(OTI 569)(OT1570), -O-T1560, -O (-T1561-O) rw-H (rw = 1, 2, 3, 4, 5), -0 (- T1562-O) rw-T1563 (rw = 1, 2, 3, 4 , 5), -OC (O) -TI 564, - OC (O) -O-TI 565, -OC (O) -NHTI 566, -O-C (O) -NT1567T1568, -OP (O) (OTI 569) (OT1570), -
20 OSi(TI 571 )(T1572)(T1573), -OS(O2)-T1574, -NHC(O)-20 OSi (TI 571) (T1572) (T1573), -OS (O 2 ) -T1574, -NHC (O) -
T1575, -NT1576C(O)-TI577, -NH-C(O)-O-TI578, -NH- C(O)-NH-TI579, -NH-C(O)-NTI580T1581, -NT1582- C(O)-O-TI583, -NT1584-C(O)-NH-TI585, -NT1586- C(O)-NTI587T1588, -NHS(O2)-T1589, -NT1590S(O2)-T1575, -NT1576C (O) -TI577, -NH-C (O) -O-TI578, -NH-C (O) -NH-TI579, -NH-C (O) -NTI580T1581, -NT1582-C (O ) -O-TI583, -NT1584-C (O) -NH-TI585, -NT1586- C (O) -NTI587T1588, -NHS (O 2) -T1589, -NT1590S (O 2) -
25 T1591 , -S-T1592, -S(O)-TI593, -S(02)-T1594, -25 T1591, -S-T1592, -S (O) -TI593, -S (0 2 ) -T1594, -
S(O2)NH-TI595, -S(O2)NTI596T1597, -S(O2)O-TI598, - P(O)(OTI599)(OT1600), -Si(TI601)(T1602)(T1603)"; wobei T1552, T1553, T1554, T1555, T1556, T1557, T1558, T1559, T1560, T1561, T1562, T1563, T1564, T1565,S (O 2) NH-TI595, -S (O 2) NTI596T1597, -S (O 2) O-TI598, - P (O) (OTI599) (OT1600), -Si (TI601) (T1602) (T1603) where T1552, T1553, T1554, T1555, T1556, T1557, T1558, T1559, T1560, T1561, T1562, T1563, T1564, T1565,
30 T1566, T1567, T1568, T1569, T1570, T1571, T1572,30 T1566, T1567, T1568, T1569, T1570, T1571, T1572,
T1573, T1574, T1575, T1576, T1577, T1578, T1579, T1580, T1581, T1582, T1583, T1584, T1585, T1586, T1587, T1588, T1589, T1590, T1591, T1592, T1593, T1594, T1595, T1596, T1597, T1598, T1599, T1600, T1601 , T1602, T1603 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alter-T1573, T1574, T1575, T1576, T1577, T1578, T1579, T1580, T1581, T1582, T1583, T1584, T1585, T1586, T1587, T1588, T1589, T1590, T1591, T1592, T1593, T1594, T1595, T1596, T1597, T1598, T1599, T1600, T1601, T1602, T1603 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alter-
5 nativ T1558, T1559 und/oder T1567, T1568 und/oder5 natively T1558, T1559 and / or T1567, T1568 and / or
T1580, T1581 und/oder T1587, T1588 und/oder T1596, T1597 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengrup-T1580, T1581 and / or T1587, T1588 and / or T1596, T1597 may together also form "heterocyclyl", wherein optionally substituents of the substituent groups above
10 pe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:10 pe (ii) may in turn be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, hete-(iii) "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl
15 roarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1604, -Roarylalkyl 15, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHT1604, -
NT1605T1606, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, - P(O)(OH)2, -C(O)-TI 607, -C(O)O-TI 608, -C(O)NH- T1609, -C(O)NTI 610T161 1 , -0-T1612, -0(-T1613-NT1605T1606, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -TI 607, -C (O) O-TI 608, -C (O) NH-T1609, -C (O) NTI 610T161 1, - 0-T1612, -0 (-T1613-
20 O)rx-H (rx = 1 , 2, 3, 4, 5), -O(-T1614-O)rx-T1615 (rx =20 O) rx -H (rx = 1, 2, 3, 4, 5), -O (-T1614-O) rx -T1615 (rx =
1 , 2, 3, 4, 5), -OC(O)-TI 616, -OC(O)-O-TI 617, - OC(O)-NHTI 618, -0-C(O)-NTI 619T1620, - OP(O)(OTI 621 )(0T1622), - OSi(TI 623)(T1624)(T1625), -OS(O2)-T1626, -1, 2, 3, 4, 5), -OC (O) -TI 616, -OC (O) -O-TI 617, - OC (O) -NHTI 618, -O-C (O) -NTI 619T1620 , - OP (O) (OTI 621) (0T1622), - OSi (TI 623) (T1624) (T1625), -OS (O 2 ) -T1626, -
25 NHC(O)-TI 627, -NT1628C(O)-TI 629, -NH-C(O)-O-25 NHC (O) -TI 627, -NT1628C (O) -TI 629, -NH-C (O) -O-
T1630, -NH-C(O)-NH-TI631, -NH-C(O)- NT1632T1633, -NT1634-C(O)-O-TI635, -NT1636- C(O)-NH-TI637, -NT1638-C(O)-NTI639T1640, - NHS(O2)-T1641, -NT1642S(O2)-T1643, -S-T1644, -T1630, -NH-C (O) -NH-TI631, -NH-C (O) -NT1632T1633, -NT1634-C (O) -O-TI635, -NT1636-C (O) -NH-TI637, -NT1638 -C (O) -NTI639T1640, - NHS (O 2) -T1641, -NT1642S (O 2) -T1643, -S-T1644, -
30 S(O)-TI645, -S(02)-T1646, -S(O2)NH-TI647, -30 S (O) -TI645, -S (0 2) -T1646, -S (O 2) NH-TI647 -
S(O2)NTI648T1649, -S(O2)O-TI650, - P(O)(OTI651)(0T1652), -Si(TI653)(T1654)(T1655)"; wobei T1604, T1605, T1606, T1607, T1608, T1609, T1610, T1611, T1612, T1613, T1614, T1615, T1616, T1617, T1618, T1619, T1620, T1621 , T1622, T1623, T1624, T1625, T1626, T1627, T1628, T1629, T1630, T1631 , T1632, T1633, T1634, T1635, T1636, T1637, T1638, T1639, T1640, T1641 , T1642, T1643, T1644, T1645, T1646, T1647, T1648, T1649, T1650, T1651 ,S (O 2) NTI648T1649, -S (O 2) O-TI650, - P (O) (OTI651) (0T1652), -Si (TI653) (T1654) (T1655) "; wherein T1604, T1605, T1606, T1607 , T1608, T1609, T1610, T1611, T1612, T1613, T1614, T1615, T1616, T1617, T1618, T1619, T1620, T1621, T1622, T1623, T1624, T1625, T1626, T1627, T1628, T1629, T1630, T1631, T1632, T1633, T1634, T1635, T1636, T1637, T1638, T1639, T1640, T1641, T1642, T1643, T1644, T1645, T1646, T1647, T1648, T1649, T1650, T1651,
T1652, T1653, T1654, T1655 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" und wobei alternativ T1610, T161 1 und/oderT1652, T1653, T1654 is, T1655 independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" and wherein alternatively T1610, T161 1 and / or
T1619, T1620 und/oder T1632, T1633 und/oder T1639, T1640 und/oder T1648, T1649 jeweils zusammen auch „heterocyclyl" bilden können; wobei alternativ T1446, T1447 zusammen auch „heterocyclyl" bilden können;T1619, T1620 and / or T1632, T1633 and / or T1639, T1640 and / or T1648, T1649 may each also together form "heterocyclyl", alternatively T1446, T1447 may together also form "heterocyclyl";
(3) ,,-C(Y8)NZ43Z44, -C(=NZ45)-Z46, -C(Y9)NZ47-Y10-Z48"; wobei Y8, Y9, Y10 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus „O, S, =NH, =NZ49" wobei die Reste Z43, Z44, Z45, Z46, Z47, Z48, Z49 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:(3) ,, -C (Y8) NZ43Z44, -C (= NZ45) -Z46, -C (Y9) NZ47-Y10-Z48 "; wherein Y8, Y9, Y10 are independently selected from the group consisting of" O , S, = NH, = NZ49 "where the radicals Z43, Z44, Z45, Z46, Z47, Z48, Z49 are independently selected from the group consisting of:
(I) „Wasserstoff, alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl, -C(O)-alkyl, -C(0)-(C9-C3o)alkyl, -C(O)-cycloalkyl, -C(O)- cycloalkylalkyl, -C(O)-aryl, -C(O)-arylalkyl, -C(O)-heteroaryl, -(I) "is hydrogen, alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- alkyl, -C (O) alkyl, -C (0) - (C 9 -C 3 O) alkyl, -C (O) cycloalkyl, -C (O) - cycloalkylalkyl, -C (O) -aryl, -C (O) -arylalkyl, -C (O) -heteroaryl, -
C(O)-heteroarylalkyl, -C(O)-heterocyclyl, -C(O)- heterocyclylalkyl, -S(O2)-alkyl, -S(02)-(C9-C3o)alkyl, -S(O2)- cycloalkyl, -S(O2)-cycloalkylalkyl, -S(O2)-aryl, -S(O2)-arylalkyl, - S(O2)-heteroaryl, -S(O2)-heteroarylalkyl, -S(O2)-heterocyclyl, - S(O2)-heterocyclylalkyl"; wobei optional obige Substituenten der Substituentengruppe (I) unabhängig voneinander auch substituiert sein können mit min- destens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:C (O) heteroarylalkyl, -C (O) -heterocyclyl, -C (O) - heterocyclylalkyl, -S (O 2) alkyl, -S (0 2) - (C 9 -C 3 o) alkyl, - S (O 2) - cycloalkyl, (2 O) -S cycloalkylalkyl, -S (O 2) aryl, -S (O 2) arylalkyl, - (2 O) -heteroaryl S, -S (O 2) heteroarylalkyl, -S (O 2) heterocyclyl, - S (O 2) -heterocyclylalkyl "; wherein optionally above substituents of substituent group (I) may also be substituted independently with min- at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,(i) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
5 Br, I, CN, CF3, N3, NH2, -NHT1656, -NT1657T1658, -NO2, -5 Br, I, CN, CF 3 , N 3 , NH 2 , -NHT1656, -NT1657T1658, -NO 2 , -
OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-TI 659, -C(O)O-TI 660, -C(O)NH-TI 661 , -C(O)NTI 662T1663, -O-T1664, -0(- T1665-O)ry-H (ry = 1 , 2, 3, 4, 5), -O(-T1666-O)ry-T1667 (ry =OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Ti 659, -C (O) O-TI 660, -C (O) NH-TI 661, -C (O) NTI 662T1663, -O-T1664, -O ( - T1665-O) ry -H (ry = 1, 2, 3, 4, 5), -O (-T1666-O) ry -T1667 (ry =
10 1 , 2, 3, 4, 5), -OC(O)-TI 668, -OC(O)-O-TI 669, -OC(O)-10 1, 2, 3, 4, 5), -OC (O) -TI 668, -OC (O) -O-TI 669, -OC (O) -
NHT1670, -0-C(O)-NTI 671 T1672, - OP(O)(OTI 673)(OT1674), -OSi(TI 675)(T1676)(T1677), - OS(O2)-T1678, -NHC(O)-TI 679, -NT1680C(O)-TI 681 , - NH-C(O)-O-TI 682, -NH-C(O)-NH-TI 683, -NH-C(O)-NHT1670, -O-C (O) -NTI 671 T1672, - OP (O) (OTI 673) (OT1674), -OSi (TI 675) (T1676) (T1677), - OS (O 2 ) -T1678, NHC (O) -TI 679, -NT1680C (O) -TI 681, -NH-C (O) -O-TI 682, -NH-C (O) -NH-TI 683, -NH-C (O) -
15 NT1684T1685, -NT1686-C(O)-O-TI 687, -NT1688-C(O)-15NT1684T1685, -NT1686-C (O) -O-TI 687, -NT1688-C (O) -
NH-T1689, -NT1690-C(O)-NTI 691 T1692, -NHS(O2)-T1693, -NT1694S(O2)-T1695, -S-T1696, -S(O)-TI 697, -S(O2)- T1698, -S(O2)NH-TI 699, -S(O2)NTI 700T1701 , -S(O2)O- T1702, -P(O)(OTI 703)(OT1704), -Si(TI 705)(T1706)(T1707)";NH-T1689, -NT1690-C (O) -NTI 691 T1692, -NHS (O 2 ) -T 1693, -NT 1694S (O 2 ) -T 1695, -S-T 1696, -S (O) -TI 697, -S (O 2 ) - T1698, -S (O 2 ) NH-TI 699, -S (O 2 ) NTI 700T1701, -S (O 2 ) O-T 1702, -P (O) (OTI 703) (OT1704), -Si (TI 705) (T1706) (T1707) ";
20 wobei T1656, T1657, T1658, T1659, T1660, T1661 , T1662,20 wherein T1656, T1657, T1658, T1659, T1660, T1661, T1662,
T1663, T1664, T1665, T1666, T1667, T1668, T1669, T1670, T1671 , T1672, T1673, T1674, T1675, T1676, T1677, T1678, T1679, T1680, T1681 , T1682, T1683, T1684, T1685, T1686, T1687, T1688, T1689, T1690, T1691 , T1692, T1693, T1694,T1663, T1664, T1665, T1666, T1667, T1668, T1669, T1670, T1671, T1672, T1673, T1674, T1675, T1676, T1677, T1678, T1679, T1680, T1681, T1682, T1683, T1684, T1685, T1686, T1687, T1688, T1689, T1690, T1691, T1692, T1693, T1694,
25 T1695, T1696, T1697, T1698, T1699, T1700, T1701 , T1702,25 T1695, T1696, T1697, T1698, T1699, T1700, T1701, T1702,
T1703, T1704, T1705, T1706, T1707 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei al-T1703, T1704, T1705, T1706, T1707 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and whereby
30 ternativ T1662, T1663 und/oder T1671 , T1672 und/oder30 ternatively T1662, T1663 and / or T1671, T1672 and / or
T1684, T1685 und/oder T1691 , T1692 und/oder T1700, T1701 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:T1684, T1685 and / or T1691, T1692 and / or T1700, T1701 in each case together can also form "heterocyclyl", where optionally substituents of the substituent group (i) optionally substituted further independently of one another may be at least one substituent, the same or different, selected from the group consisting of:
(ii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,(ii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,
5 F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1708, -NT1709T1710,5 F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHT1708, -NT1709T1710,
-NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-TI 711 , - C(O)O-TI 712, -C(O)NH-TI 713, -C(O)NTI 714T1715, - O-T1716, -O(-T1717-O)rz-H (rz = 1 , 2, 3, 4, 5), -0(--NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Ti 711, -C (O) O-TI 712, -C (O) NH-TI 713, -C (O) NTI 714T1715, -O- T1716, -O (-T1717-O) rz -H (rz = 1, 2, 3, 4, 5), -0 (-
10 T1718-O)rz-T1719 (rz = 1 , 2, 3, 4, 5), -OC(O)-TI 720, -10 T1718-O) rz -T1719 (rz = 1, 2, 3, 4, 5), -OC (O) -Ti 720, -
OC(O)-O-TI 721 , -OC(O)-NHTI 722, -0-C(O)- NT1723T1724, -OP(O)(OTI 725)(OT1726), - OSi(TI 727)(T1728)(T1729), -OS(O2)-T1730, -NHC(O)- T1731 , -NT1732C(O)-TI 733, -NH-C(O)-O-TI 734, -NH-OC (O) -O-TI 721, -OC (O) -NHTI 722, -O-C (O) -NT 1723T1724, -OP (O) (OTI 725) (OT1726), -OSi (TI 727) (T1728 ) (T1729), -OS (O 2 ) -T1730, -NHC (O) -T1731, -NT 1732C (O) -TI 733, -NH-C (O) -O-TI 734, -NH-
15 C(O)-NH-TI 735, -NH-C(O)-NTI 736T1737, -NT1738-15 C (O) -NH-TI 735, -NH-C (O) -NTI 736T1737, -NT1738-
C(O)-O-TI 739, -NT1740-C(O)-NH-TI 741 , -NT1742- C(O)-NTI 743T1744, -NHS(O2)-T1745, -NT1746S(O2)- T1747, -S-T1748, -S(O)-TI 749, -S(O2)-T1750, - S(O2)NH-TI 751 , -S(O2)NTI 752T1753, -S(O2)O-TI 754, -C (O) -O-TI 739, -NT1740-C (O) -NH-TI 741, -NT1742-C (O) -NTI 743T1744, -NHS (O 2 ) -T 1745, -NT 1746S (O 2 ) - T1747, T1748 -S-, -S (O) -TI 749, -S (O 2) -T1750, - S (O 2) NH-TI 751, -S (O 2) NTI 752T1753, -S (O 2 ) O-TI 754, -
20 P(O)(OTI 755)(OT1756), -Si(TI 757)(T1758)(T1759)"; wobei T1708, T1709, T1710, T1711, T1712, T1713, T1714, T1715, T1716, T1717, T1718, T1719, T1720, T1721, T1722, T1723, T1724, T1725, T1726, T1727, T1728, T1729, T1730, T1731, T1732, T1733, T1734, T1735,20 P (O) (OTI 755) (OT1756), -Si (TI 757) (T1758) (T1759) "where T1708, T1709, T1710, T1711, T1712, T1713, T1714, T1715, T1716, T1717, T1718, T1719, T1720, T1721, T1722, T1723, T1724, T1725, T1726, T1727, T1728, T1729, T1730, T1731, T1732, T1733, T1734, T1735,
25 T1736, T1737, T1738, T1739, T1740, T1741, T1742,25 T1736, T1737, T1738, T1739, T1740, T1741, T1742,
T1743, T1744, T1745, T1746, T1747, T1748, T1749, T1750, T1751, T1752, T1753, T1754, T1755, T1756, T1757, T1758, T1759 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl,T1743, T1744, T1745, T1746, T1747, T1748, T1749, T1750, T1751, T1752, T1753, T1754, T1755, T1756, T1757, T1758, T1759 are independently selected from the group consisting of: "alkyl, (C 9 - 30) C alkyl,
30 cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T1714, T1715 und/oder T1723, T1724 und/oder T1736, T1737 und/oder T1743, T1744 und/oder T1752, T1753 jeweils zusammen auch „heterocyclyl" bilden kön-30 cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively T1714, T1715 and / or T1723, T1724 and / or T1736, T1737 and / or T1743, T1744 and / or T1752, T1753 also together in each case Form "heterocyclyl"
35 nen; wobei optional obige Substituenten der Substituentengrup- pe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:35 NEN; wherein optionally substituents of substituent group (ii) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
5 (iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, hete- roarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1760, - NT1761T1762, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -5 (iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT1760, -NT1761T1762, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -
10 P(O)(OH)2, -C(O)-TI 763, -C(O)O-TI 764, -C(O)NH-10 P (O) (OH) 2 , -C (O) -Ti 763, -C (O) O-TI 764, -C (O) NH-
T1765, -C(O)NTI 766T1767, -O-T1768, -O(-T1769- O)ra-H (ra = 1 , 2, 3, 4, 5), -O(-T1770-O)ra-T1771 (ra = 1 , 2, 3, 4, 5), -OC(O)-TI 772, -OC(O)-O-TI 773, - OC(O)-NHTI 774, -0-C(O)-NTI 775T1776, -T1765, -C (O) NTI 766T1767, -O-T1768, -O (-T1769-O) ra -H (ra = 1, 2, 3, 4, 5), -O (-T1770-O) ra - T1771 (ra = 1, 2, 3, 4, 5), -OC (O) -TI 772, -OC (O) -O-TI 773, - OC (O) -NHTI 774, -O-C (O ) -NTI 775T1776, -
15 OP(O)(OTI 777)(OT1778), -15 OP (O) (OTI 777) (OT1778), -
OSi(TI779)(T1780)(T1781), -OS(O2)-T1782, - NHC(O)-TI783, -NT1784C(O)-TI785, -NH-C(O)-O- T1786, -NH-C(O)-NH-TI787, -NH-C(O)- NT1788T1789, -NT1790-C(O)-O-TI791, -NT1792-OSi (TI779) (T1780) (T1781), -OS (O 2) -T1782, - NHC (O) -TI783, -NT1784C (O) -TI785, -NH-C (O) -O- T1786, -NH -C (O) -NH-TI787, -NH-C (O) -NT1788T1789, -NT1790-C (O) -O-TI791, -NT1792-
20 C(O)-NH-TI793, -NT1794-C(O)-NTI795T1796, -20 C (O) -NH-TI793, -NT1794-C (O) -NTI795T1796, -
NHS(O2)-T1797, -NT1798S(O2)-T1799, -S-T1800, - S(O)-TI801, -S(02)-T1802, -S(O2)NH-TI803, - S(O2)NTI804T1805, -S(O2)O-TI806, - P(O)(OTI807)(OT1808), -Si(TI809)(T1810)(TI811)";NHS (O 2 ) -T1797, -NT 1798S (O 2 ) -T 1799, -S-T 1800, - S (O) -TI801, -S (O 2 ) -T1802, -S (O 2 ) NH-TI 803, - S (O 2 ) NTI804T1805, -S (O 2 ) O-TI806, -P (O) (OTI807) (OT1808), -Si (TI809) (T1810) (TI811) ";
25 wobei T1760, T1761, T1762, T1763, T1764, T1765,25 where T1760, T1761, T1762, T1763, T1764, T1765,
T1766, T1767, T1768, T1769, T1770, T1771, T1772, T1773, T1774, T1775, T1776, T1777, T1778, T1779, T1780, T1781, T1782, T1783, T1784, T1785, T1786, T1787, T1788, T1789, T1790, T1791, T1792, T1793,T1766 T1767 T1768 T1769 T1770 T1771 T1772 T1773 T1774 T1775 T1776 T1777 T1778 T1779 T1780 T1781 T1782 T1783 T1784 T1785 T1786 T1787 T1788 T1789 T1790 T1791, T1792, T1793,
30 T1794, T1795, T1796, T1797, T1798, T1799, T1800,30 T1794, T1795, T1796, T1797, T1798, T1799, T1800,
T1801, T1802, T1803, T1804, T1805, T1806, T1807, T1808, T1809, T1810, T1811 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl,T1801, T1802, T1803, T1804, T1805, T1806, T1807, T1808, T1809, T1810, T1811 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl,
35 heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" und wobei alternativ T1766, T1767 und/oder T1775, T1776 und/oder T1788, T1789 und/oder T1795, T1796 und/oder T1804, T1805 jeweils zusammen auch „heterocyclyl" bilden können;35 heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl and wherein alternatively T1766, T1767 and / or T1775, T1776 and / or T1788, T1789 and / or T1795, T1796 and / or T1804, T1805 may each together also form "heterocyclyl";
undand
Reste Z3, Z4 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: (e) Wasserstoff;Radicals Z3, Z4 are independently selected from the group consisting of: (e) hydrogen;
(f) Halogen, F, Cl, Br, I;(f) halogen, F, Cl, Br, I;
(g) unsubstituiertes oder substituiertes Alkyl oder (C9-C30)Alkyl, wobei optional der Alkyl- oder (Cg-C3o)Alkylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Grup- pe bestehend aus:(g) unsubstituted or substituted alkyl or (C 9 -C 30 ) alkyl, wherein optionally the alkyl or (Cg-C 3 o) alkyl radical may be substituted by at least one substituent, identical or different, selected from the group consisting out:
(i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHB457, -NB458B459, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B460, -C(O)O-B461 , -C(O)NH-B462, -C(O)NB463B464, -(i) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHB457, -NB458B459, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) -B460, -C (O) O-B461, -C (O) NH-B462, -C (O) NB463B464 , -
O-B465, -O(-B466-O)x-H (x = 1 , 2, 3, 4, 5), -O(-B467-O)x-B468 (x = 1 , 2, 3, 4, 5), -OC(O)-B469, -OC(O)-O-B470, -OC(O)-NHB471 , - O-C(O)-NB472B473, -OP(O)(OB474)(OB475), - OSi(B476)(B477)(B478), -OS(O2)-B479, -NHC(O)-B480, - NB481C(O)-B482, -NH-C(O)-O-B483, -N H-C(O)-N H-B484, -NH-O-B465, -O (-B466-O) x -H (x = 1, 2, 3, 4, 5), -O (-B467-O) x -B468 (x = 1, 2, 3, 4 , 5), -OC (O) -B469, -OC (O) -O-B470, -OC (O) -NHB471, -OC (O) -NB472B473, -OP (O) (OB474) (OB475), - OSi (B476) (B477) (B478), -OS (O2) -B479, -NHC (O) -B480, - NB481C (O) -B482, -NH-C (O) -O-B483, - N HC (O) -NH-B484, -NH-
C(O)-NB485B486, -NB487-C(O)-O-B488, -NB489-C(O)-NH- B490, -NB491-C(O)-NB492B493, -NHS(O2)-B494, -NB495S(O2)- B496, -S-B497, -S(O)-B498, -S(O2)-B499, -S(O2)N H-B500, - S(O2)NB501 B502, -S(O2)O-B503, -P(O)(OB504)(OB505), - Si(B506)(B507)(B508)"; wobei B457, B458, B459, B460, B461, B462, B463, B464, B465, B466, B467, B468, B469, B470, B471, B472, B473, B474, B475, B476, B477, B478, B479, B480, B481 , B482, B483, B484, B485, B486, B487, B488, B489, B490, B491 , B492, B493, B494, B495, B496, B497, B498, B499, B500, B501 , B502, B503, B504, B505, B506, B507, B508 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ B463, B464 und/oder B472, B473 und/oder B485, B486 und/oder B492, B493 und/oder B501 , B502 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:C (O) -NB485B486, -NB487-C (O) -O-B488, -NB489-C (O) -NH- B490, -NB491-C (O) -NB492B493, -NHS (O2) -B494, -NB495S (O2) - B496, -S-B497, -S (O) -B498, -S (O2) -B499, -S (O2) N H-B500, - S (O 2) NB501 B502 , -S (O 2) O-B503, -P (O) (OB504) (OB505), - Si (B506) (B507) (B508) "; wherein B457, B458, B459, B460, B461, B462, B463 , B464, B465, B466, B467, B468, B469, B470, B471, B472, B473, B474, B475, B476, B477, B478, B479, B480, B481, B482, B483, B484, B485, B486, B487, B488, B489, B490, B491, B492, B493, B494, B495, B496, B497, B498, B499, B500, are B501, B502, B503, B504, B505, B506, B507, B508 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl "heteroarylalkyl" and in which case alternatively B463, B464 and / or B472, B473 and / or B485, B486 and / or B492, B493 and / or B501, B502 may in each case also form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,
CN, CF3, N3, NH2, -NHB509, -NB510B511 , -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B512, -C(O)O-B513, -C(O)NH-B514, - C(O)NB515B516, -O-B517, -O(-B518-O)y-H (y = 1 , 2, 3, 4, 5), - 0(-B519-O)y-B520 (y = 1 , 2, 3, 4, 5), -OC(O)-B521 , -OC(O)-O-CN, CF 3, N 3, NH 2, -NHB509, -NB510B511, -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP (O) (OH) 2, -CHO , -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -B512, -C (O) O-B513, -C (O) NH -B514, -C (O) NB515B516, -O-B517, -O (-B518-O) y -H (y = 1, 2, 3, 4, 5), - 0 (-B519-O) y - B520 (y = 1, 2, 3, 4, 5), -OC (O) -B521, -OC (O) -O-
B522, -OC(O)-NHB523, -0-C(O)-N B524B525, - OP(O)(OB526)(OB527), -OSi(B528)(B529)(B530), -OS(O2)- B531 , -NHC(O)-B532, -NB533C(O)-B534, -NH-C(O)-O-B535, -N H-C(O)-N H-B536, -NH-C(O)-NB537B538, -NB539-C(O)-O- B540, -NB541-C(O)-NH-B542, -NB543-C(O)-NB544B545, -B522, -OC (O) -NHB523, -O-C (O) -N B524B525, - OP (O) (OB526) (OB527), -OSi (B528) (B529) (B530), -OS (O 2 ) -B531, -NHC (O) -B532, -NB533C (O) -B534, -NH-C (O) -O-B535, -NHC (O) -NH-B536, -NH-C (O ) -NB537B538, -NB539-C (O) -O-B540, -NB541-C (O) -NH-B542, -NB543-C (O) -NB544B545, -
NHS(O2)-B546, -NB547S(O2)-B548, -S-B549, -S(O)-B550, - S(O2)-B551 , -S(O2)NH-B552, -S(O2)NB553B554, -S(O2)O- B555, -P(O)(OB556)(OB557), -Si(B558)(B559)(B560)"; wobei B509, B510, B51 1 , B512, B513, B514, B515, B516, B517, B518, B519, B520, B521 , B522, B523, B524, B525, B526, B527,NHS (O 2) -B546, -NB547S (O2) -B548, -S-B549, -S (O) -B550, - S (O 2) -B551, -S (O2) NH-B552, - S (O 2) NB553B554, -S (O 2) O- B555, -P (O) (OB556) (OB557), -Si (B558) (B559) (B560) "; wherein B509, B510, B51 1, B512, B513, B514, B515, B516, B517, B518, B519, B520, B521, B522, B523, B524, B525, B526, B527,
B528, B529, B530, B531 , B532, B533, B534, B535, B536, B537, B538, B539, B540, B541 , B542, B543, B544, B545, B546, B547, B548, B549, B550, B551 , B552, B553, B554, B555, B556, B557, B558, B559, B560 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B515, B516 und/oder B524, B525 und/oder B537, B538 und/oder B544, B545 und/oder B553, 5 B554 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:B528, B529, B530, B531, B532, B533, B534, B535, B536, B537, B538, B539, B540, B541, B542, B543, B544, B545, B546, B547, B548, B549, B550, B551, B552, B553, B554, B555, B556, B557, B558, B559, B560 are selected independently from each other the group consisting of: "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively B515, B516 and / or B524, B525 and / or B537, B538 and / or B544, B545 and / or B553, 5 B554 may together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
10 (iii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHB561 , -NB562B563, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B564, -C(O)O-B565, -10 (iii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHB561, -NB562B563, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -B564, -C (O) O-B565,
15 C(O)NH-B566, -C(O)NB567B568, -O-B569, -O(-B570-O)z-15 C (O) NH-B566, -C (O) NB567B568, -O-B569, -O (-B570-O) z -
H (z = 1 , 2, 3, 4, 5), -O(-B571-O)z-B572 (z = 1 , 2, 3, 4, 5), - OC(O)-B573, -OC(O)-O-B574, -OC(O)-NHB575, -0-C(O)- NB576B577, -OP(O)(OB578)(OB579), - OSi(B580)(B581 )(B582), -OS(O2)-B583, -NHC(O)-B584, -H (z = 1, 2, 3, 4, 5), -O (-B571-O) z -B572 (z = 1, 2, 3, 4, 5), - OC (O) -B573, -OC (O) -O-B574, -OC (O) -NHB575, -O-C (O) -NB576B577, -OP (O) (OB578) (OB579), -OSi (B580) (B581) (B582), -OS (O 2 ) -B 583, -NHC (O) -B 584, -
20 NB585C(O)-B586, -NH-C(O)-O-B587, -NH-C(O)-NH-20 NB585C (O) -B586, -NH-C (O) -O-B587, -NH-C (O) -NH-
B588, -NH-C(O)-NB589B590, -NB591-C(O)-O-B592, - NB593-C(O)-NH-B594, -NB595-C(O)-NB596B597, - NHS(O2)-B598, -NB599S(O2)-B600, -S-B601 , -S(O)-B602, -S(O2)-B603, -S(O2)NH-B604, -S(O2)NB605B606, -S(O2)O-B588, -NH-C (O) -NB589B590, -NB591-C (O) -O-B592, -NB593-C (O) -NH-B594, -NB595-C (O) -NB596B597, -NHS (O 2) -B598, -NB599S (O2) -B600, -S-B601, -S (O) -B602, -S (O2) -B603, -S (O2) NH-B604, -S (O 2 ) NB605B606, -S (O 2 ) O-
25 6607, -P(O)(OBeOS)(OBeOg)1 -Si(BeI O)(BeI I )(Be^)"; wobei B561 , B562, B563, B564, B565, B566, B567, B568, B569, B570, B571 , B572, B573, B574, B575, B576, B577, B578, B579, B580, B581 , B582, B583, B584, B585, B586, B587, B588, B589, B590, B591 , B592, B593, B594, B595, 30 B596, B597, B598, B599, B600, B601 , B602, B603, B604,25 6607, -P (O) (OBeOS) (OBeOg) 1 -Si (BeI O) (BeI) (Be ^) "; wherein B561, B562, B563, B564, B565, B566, B567, B568, B569, B570, B571, B572, B573, B574, B575, B576, B577, B578, B579, B580, B581, B582, B583, B584, B585, B586, B587, B588, B589, B590, B591, B592, B593, B594, B595, 30 B596, B597, B598, B599, B600, B601, B602, B603, B604,
B605, B606, B607, B608, B609, B610, B611 , B612 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B567, B568 und/oder B576, B577 und/oder B589, B590 und/oder B596, B597 und/oder B605, B606 jeweils zusammen auch „heterocyclyl" bilden können;B605, B606, B607, B608, B609, B610, B611, B612 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl "heteroarylalkyl" and alternatively B567, B568 and / or B576, B577 and / or B589, B590 and / or B596, B597 and / or B605, B606 may each together also form "heterocyclyl";
(h) unsubstituiertes oder substituiertes Aryl, wobei optional der Arylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(h) unsubstituted or substituted aryl wherein optionally the aryl radical may be substituted with at least one substituent, same or different, selected from the group consisting of:
(i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHB613, -NB614B615, -NO2, -OH, -OCF3, -SH, -O-(i) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHB613, -NB614B615, -NO 2 , -OH, -OCF 3 , -SH, -O-
SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B616, -C(O)O-B617, -C(O)NH-B618, -C(O)NB619B620, - O-B621 , -O(-B622-O)a-H (a = 1 , 2, 3, 4, 5), -O(-B623-O)a-B624 (a = 1 , 2, 3, 4, 5), -OC(O)-B625, -OC(O)-O-B626, -OC(O)-NHB627, - O-C(O)-NB628B629, -OP(O)(OB630)(OB631 ), -SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -B616 , -C (O) O-B617, -C (O) NH-B618, -C (O) NB619B620, -O-B621, -O (-B622-O) a -H (a = 1, 2, 3 , 4, 5), -O (-B623-O) a -B624 (a = 1, 2, 3, 4, 5), -OC (O) -B625, -OC (O) -O-B626, - OC (O) -NHB627, -OC (O) -NB628B629, -OP (O) (OB630) (OB631),
OSi(B632)(B633)(B634), -OS(O2)-B635, -NHC(O)-B636, - NB637C(O)-B638, -NH-C(O)-O-B639, -N H-C(O)-N H-B640, -NH- C(O)-NB641 B642, -NB643-C(O)-O-B644, -NB645-C(O)-NH- B646, -NB647-C(O)-NB648B649, -NHS(O2)-B650, -NB651 S(O2)- B652, -S-B653, -S(O)-B654, -S(O2)-B655, -S(O2)N H-B656, -OSi (B632) (B633) (B634), -OS (O2) -B635, -NHC (O) -B636, - NB637C (O) -B638, -NH-C (O) -O-B639, -N HC (O) -NH-B640, -NH-C (O) -NB641 B642, -NB643-C (O) -O-B644, -NB645-C (O) -NH-B646, -NB647-C ( O) -NB648B649, -NHS (O2) -B650, -NB651 S (O 2) - B652, -S-B653, -S (O) -B654, -S (O2) -B655, -S (O 2 ) N H-B656, -
S(O2)NB657B658, -S(O2)O-B659, -P(O)(OB660)(OB661 ), - Si(B662)(B663)(B664)"; wobei B613, B614, B615, B616, B617, B618, B619, B620, B621 , B622, B623, B624, B625, B626, B627, B628, B629, B630, B631 , B632, B633, B634, B635, B636, B637, B638, B639, B640, B641 ,S (O 2) NB657B658, -S (O2) O-B659, -P (O) (OB660) (OB661), - Si (B662) (B663) (B664) "; wherein B613, B614, B615, B616 , B617, B618, B619, B620, B621, B622, B623, B624, B625, B626, B627, B628, B629, B630, B631, B632, B633, B634, B635, B636, B637, B638, B639, B640, B641 .
B642, B643, B644, B645, B646, B647, B648, B649, B650, B651 , B652, B653, B654, B655, B656, B657, B658, B659, B660, B661 , B662, B663, B664 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B619, B620 und/oder B628, B629 und/oder B641 , B642 und/oder B648, B649 und/oder B657, B658 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHB665, -NB666B667, -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B668, -C(O)O-B669, -C(O)NH-B670, - C(O)NB671 B672, -O-B673, -O(-B674-O)b-H (b = 1 , 2, 3, 4, 5), -B642, B643, B644, B645, B646, B647, B648, B649, B650, B651, B652, B653, B654, B655, B656, B657, B658, B659, B660, B661, B662, B663, B664 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively B 619, B620 and / or B628, B629 and / or B641, B642 and / or B648, B649 and / or B657, B658 may together also form "heterocyclyl"; in which optionally substituents of substituent group (i) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of: (ii) alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHB665, -NB666B667, -NO2, -OH, -OCF 3, -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , - C (O) -B668, -C (O) O-B669, -C (O) NH-B670, -C (O) NB671 B672, -O-B673, -O (-B674-O) b -H ( b = 1, 2, 3, 4, 5), -
O(-B675-O)b-B676 (b = 1 , 2, 3, 4, 5), -OC(O)-B677, -OC(O)-O- B678, -OC(O)-NHB679, -O-C(O)-NB680B681 , - OP(O)(OB682)(OB683), -OSi(B684)(B685)(B686), -OS(O2)- B687, -NHC(O)-B688, -NB689C(O)-B690, -NH-C(O)-O-B691 , -N H-C(O)-N H-B692, -NH-C(O)-NB693B694, -NB695-C(O)-O-O (-B675-O) b -B676 (b = 1, 2, 3, 4, 5), -OC (O) -B677, -OC (O) -O-B678, -OC (O) -NHB679, -OC (O) -NB680B681, - OP (O) (OB682) (OB683), -OSi (B684) (B685) (B686), -OS (O2) - B687, -NHC (O) -B688, - NB689C (O) -B690, -NH-C (O) -O-B691, -NHC (O) -NH-B692, -NH-C (O) -NB693B694, -NB695-C (O) -O -
B696, -NB697-C(O)-NH-B698, -NB699-C(O)-NB700B701 , - NHS(O2)-B702, -NB703S(O2)-B704, -S-B705, -S(O)-B706, - S(O2)-B707, -S(O2)NH-B708, -S(O2)NB709B710, -S(O2)O- B71 1 , -P(O)(OB712)(OB713), -Si(B714)(B715)(B716)"; wobei B665, B666, B667, B668, B669, B670, B671 , B672, B673,B696, -NB697-C (O) -NH-B698, -NB699-C (O) -NB700B701, - NHS (O2) -B702, -NB703S (O2) -B704, -S-B705, -S ( O) -B706, - S (O 2) -B707, -S (O2) NH-B708, -S (O2) NB709B710, -S (O 2) O- B71 1, -P (O) (OB712 ) (B715) (B716) ", wherein B665, B666, B667, B668, B669, B670, B671, B672, B673,
B674, B675, B676, B677, B678, B679, B680, B681 , B682, B683, B684, B685, B686, B687, B688, B689, B690, B691 , B692, B693, B694, B695, B696, B697, B698, B699, B700, B701 , B702, B703, B704, B705, B706, B707, B708, B709, B710, B71 1 , B712, B713, B714, B715, B716 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B671 , B672 und/oder B680, B681 und/oder B693, B694 und/oder B700, B701 und/oder B709, B710 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHB717, -NB718B719, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B720, -C(O)O-B721 , -B674, B675, B676, B677, B678, B679, B680, B681, B682, B683, B684, B685, B686, B687, B688, B689, B690, B691, B692, B693, B694, B695, B696, B697, B698, B699, B700, B701, B702, B703, B704, B705, B706, B707, B708, B709, B710, B71 1, B712, B713, B714, B715, B716 are independently selected from the group consisting of: "alkyl, ( Cg-C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively B671, B672 and / or B680, B681 and / or B693, B694 and / or B700, B701 and / or B709, B710 may together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of: (iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHB717, -NB718B719, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -B 720, -C (O) O-B 721,
C(O)NH-B722, -C(O)NB723B724, -O-B725, -O(-B726-O)c- H (c = 1 , 2, 3, 4, 5), -O(-B727-O)c-B728 (c = 1, 2, 3, 4, 5), - OC(O)-B729, -OC(O)-O-B730, -OC(O)-NHB731, -0-C(O)- NB732B733, -OP(O)(OB734)(OB735), - OSi(B736)(B737)(B738), -OS(O2)-B739, -NHC(O)-B740, -C (O) NH-B722, -C (O) NB723B724, -O-B725, -O (-B726-O) c -H (c = 1, 2, 3, 4, 5), -O (-B727 -O) c -B728 (c = 1, 2, 3, 4, 5), - OC (O) -B729, -OC (O) -O-B730, -OC (O) -NHB731, -O-C (O) - NB732B733, -OP (O) (OB734) (OB735), - OSi (B736) (B737) (B738), -OS (O2) -B739, -NHC (O) -B740, -
NB741C(O)-B742, -NH-C(O)-O-B743, -NH-C(O)-NH- B744, -NH-C(O)-NB745B746, -NB747-C(O)-O-B748, - NB749-C(O)-NH-B750, -NB751-C(O)-NB752B753, - NHS(O2)-B754, -NB755S(O2)-B756, -S-B757, -S(O)-B758, -S(O2)-B759, -S(O2)NH-B760, -S(O2)NB761B762, -S(O2)O-NB741C (O) -B742, -NH-C (O) -O-B743, -NH-C (O) -NH-B744, -NH-C (O) -NB745B746, -NB747-C (O) -O -B748, - NB749-C (O) -NH-B750, -NB751-C (O) -NB752B753, - NHS (O2) -B754, -NB755S (O2) -B756, -S-B757, -S (O) -B758, -S (O2) -B759, -S (O2) NH-B760, -S (O2) NB761B762, -S (O 2) O-
B763, -P(O)(OB764)(OB765), -Si(B766)(B767)(B768)"; wobei B717, B718, B719, B720, B721, B722, B723, B724, B725, B726, B727, B728, B729, B730, B731, B732, B733, B734, B735, B736, B737, B738, B739, B740, B741, B742, B743, B744, B745, B746, B747, B748, B749, B750, B751 ,B763, -P (O) (OB764) (OB765), -Si (B766) (B767) (B768) "; wherein B717, B718, B719, B720, B721, B722, B723, B724, B725, B726, B727, B728, B729, B730, B731, B732, B733, B734, B735, B736, B737, B738, B739, B740, B741, B742, B743, B744, B745, B746, B747, B748, B749, B750, B751,
B752, B753, B754, B755, B756, B757, B758, B759, B760, B761, B762, B763, B764, B765, B766, B767, B768 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B723, B724 und/oder B732, B733 und/oder B745, B746 und/oder B752, B753 und/oder B761 , B762 jeweils zusammen auch „heterocyclyl" bilden können;B752, B753, B754, B755, B756, B757, B758, B759, B760, B761, B762, B763, B764, B765, B766, B767, B768 are independently selected from the group consisting of: "alkyl, (C 9 - C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyc IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively B723, B724 and / or B732, B733 and / or B745, B746 and / or B752, B753 and / or B761, B762 may together also form "heterocyclyl";
(j) unsubstituiertes oder substituiertes Heteroaryl, wobei optional der Hetero- arylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(j) unsubstituted or substituted heteroaryl, where optionally the heteroaryl radical may be substituted by at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHB769, -NB770B771 , -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B772, -C(O)O-B773, -C(O)NH-B774, -C(O)NB775B776, - O-B777, -O(-B778-O)d-H (d = 1 , 2, 3, 4, 5), -O(-B779-O)d-B780 (d = 1 , 2, 3, 4, 5), -OC(O)-B781 , -OC(O)-O-B782, -OC(O)-NHB783, -(i) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3, NH 2, -NHB769, -NB770B771, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP (O) (OH) 2, -CHO, -COOH, - C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -B772, -C (O) O -B773, -C (O) NH-B774, -C (O) NB775B776, -O-B777, -O (-B778-O) d -H (d = 1, 2, 3, 4, 5), -O (-B779-O) d -B780 (d = 1 , 2, 3, 4, 5), -OC (O) -B781, -OC (O) -O-B782, -OC (O) -NHB783, -
O-C(O)-NB784B785, -OP(O)(OB786)(OB787), - OSi(B788)(B789)(B790), -OS(O2)-B791 , -NHC(O)-B792, - NB793C(O)-B794, -NH-C(O)-O-B795, -N H-C(O)-N H-B796, -NH- C(O)-NB797B798, -NB799-C(O)-O-B800, -NB801-C(O)-NH- B802, -NB803-C(O)-NB804B805, -NHS(O2)-B806, -NB807S(O2)-OC (O) -NB784B785, -OP (O) (OB786) (OB787), - OSi (B788) (B789) (B790), -OS (O2) -B791, -NHC (O) -B792, - NB793C (O) -B794, -NH-C (O) -O-B795, -NHC (O) -NH-B796, -NH-C (O) -NB797B798, -NB799-C (O) -O- B800, -NB801-C (O) -NH- B802, -NB803-C (O) -NB804B805, -NHS (O2) -B806, -NB807S (O 2) -
B808, -S-B809, -S(O)-B810, -S(O2)-B811 , -S(O2)N H-B812, - S(O2)NB813B814, -S(O2)O-B815, -P(O)(OB816)(OB817), - Si(B818)(B819)(B820)"; wobei B769, B770, B771 , B772, B773, B774, B775, B776, B777, B778, B779, B780, B781 , B782, B783, B784, B785, B786, B787,B808, -S-B809, -S (O) -B810, -S (O2) -B811, -S (O2) N H-B812, - S (O 2) NB813B814, -S (O 2) O -B815, -P (O) (OB816) (OB817), -Si (B818) (B819) (B820) "; wherein B769, B770, B771, B772, B773, B774, B775, B776, B777, B778, B779 , B780, B781, B782, B783, B784, B785, B786, B787,
B788, B789, B790, B791 , B792, B793, B794, B795, B796, B797, B798, B799, B800, B801 , B802, B803, B804, B805, B806, B807, B808, B809, B810, B81 1 , B812, B813, B814, B815, B816, B817, B818, B819, B820 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ B775, B776 und/oder B784, B785 und/oder B797, B798 und/oder B804, B805 und/oder B813, B814 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:B788, B789, B790, B791, B792, B793, B794, B795, B796, B797, B798, B799, B800, B801, B802, B803, B804, B805, B806, B807, B808, B809, B810, B81 1, B812 , B813, B814, B815, B816, B817, B818, B819, B820 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and in which case alternatively B775, B776 and / or B784, B785 and / or B797, B798 and / or B804, B805 and / or B813, B814 can in each case also form" heterocyclyl "; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,(ii) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,
CN, CF3, N3, NH2, -NHB821 , -NB822B823, -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B824, -C(O)O-B825, -C(O)NH-B826, - C(O)NB827B828, -O-B829, -O(-B830-O)e-H (e = 1 , 2, 3, 4, 5), - O(-B831-O)e-B832 (e = 1 , 2, 3, 4, 5), -OC(O)-B833, -OC(O)-O- B834, -OC(O)-NHB835, -O-C(O)-NB836B837, - OP(O)(OB838)(OB839), -OSi(B840)(B841 )(B842), -OS(O2)- B843, -NHC(O)-B844, -NB845C(O)-B846, -NH-C(O)-O-B847,CN, CF 3, N 3, NH 2, -NHB821, -NB822B823, -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP (O) (OH) 2, -CHO , -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -B824, -C (O) O-B 825, -C (O) NH -B826, -C (O) NB827B828, -O-B829, -O (-B830-O) e -H (e = 1, 2, 3, 4, 5), O (-B831-O) e -B832 (e = 1, 2, 3, 4, 5), -OC (O) -B833, -OC (O) -O-B834, -OC (O) -NHB835, -OC (O) -NB836B837, - OP (O) (OB838) (OB839), -OSi (B840) (B841) (B842), -OS (O2) - B843, -NHC (O) -B844, - NB845C (O) -B846, -NH-C (O) -O-B847,
5 -N H-C(O)-N H-B848, -NH-C(O)-NB849B850, -NB851 -C(O)-O-5 -NH-C (O) -NH-B848, -NH-C (O) -NB849B850, -NB851 -C (O) -O-
B852, -NB853-C(O)-NH-B854, -NB855-C(O)-NB856B857, - NHS(O2)-B858, -NB859S(O2)-B860, -S-B861 , -S(O)-B862, - S(O2)-B863, -S(O2)NH-B864, -S(O2)NB865B866, -S(O2)O- B867, -P(O)(OB868)(OB869), -Si(B870)(B871 )(B872)";B852, -NB853-C (O) -NH-B854, -NB855-C (O) -NB856B857, - NHS (O2) -B858, -NB859S (O2) -B860, -S-B861, -S ( O) -B862, - S (O 2) -B863, -S (O2) NH-B864, -S (O2) NB865B866, -S (O 2) O- B867, -P (O) (OB868) (OB869), -Si (B870) (B871) (B872) ";
10 wobei B821 , B822, B823, B824, B825, B826, B827, B828, B829,10 wherein B821, B822, B823, B824, B825, B826, B827, B828, B829,
B830, B831 , B832, B833, B834, B835, B836, B837, B838, B839, B840, B841 , B842, B843, B844, B845, B846, B847, B848, B849, B850, B851 , B852, B853, B854, B855, B856, B857, B858, B859, B860, B861 , B862, B863, B864, B865, B866, B867, B868, B869,B830, B831, B832, B833, B834, B835, B836, B837, B838, B839, B840, B841, B842, B843, B844, B845, B846, B847, B848, B849, B850, B851, B852, B853, B854, B855, B856, B857, B858, B859, B860, B861, B862, B863, B864, B865, B866, B867, B868, B869,
15 B870, B871 , B872 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B827, B828 und/oder B836, B837 und/oder B849, B850 und/oder B856, B857 und/oder B865,15 B870, B871, B872 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively B827, B828 and / or B836, B837 and / or B849, B850 and / or B856, B857 and / or B865,
20 B866 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:20 B866 may in each case also form "heterocyclyl", where optionally substituted substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
25 (iii) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHB873, -NB874B875, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B876, -C(O)O-B877, -25 (iii) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHB873, -NB874B875, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -B876, -C (O) O-B 877, -
30 C(O)NH-B878, -C(O)NB879B880, -O-B881 , -O(-B882-O)r-30 C (O) NH-B878, -C (O) NB879B880, -O-B881, -O (-B882-O) r-
H (f = 1 , 2, 3, 4, 5), -O(-B883-O)f-B884 (f = 1 , 2, 3, 4, 5), - OC(O)-B885, -OC(O)-O-B886, -OC(O)-NHB887, -0-C(O)- NB888B889, -OP(O)(OB890)(OB891 ), - OSi(B892)(B893)(B894), -OS(O2)-B895, -NHC(O)-B896, - NB897C(O)-B898, -NH-C(O)-O-B899, -NH-C(O)-NH- B900, -NH-C(O)-NB901 B902, -NB903-C(O)-O-B904, - NB905-C(O)-NH-B906, -NB907-C(O)-NB908B909, - NHS(O2)-B910, -NB911S(O2)-B912, -S-B913, -S(O)-B914, -S(O2)-B915, -S(O2)NH-B916, -S(O2)NB917B918, -S(O2)O-H (f = 1, 2, 3, 4, 5), -O (-B883-O) f -B884 (f = 1, 2, 3, 4, 5), - OC (O) -B885, -OC (O) -O-B886, -OC (O) -NHB887, -O-C (O) -NB888B889, -OP (O) (OB890) (OB891), -OSi (B892) (B893) (B894), -OS (O 2 ) -B895, -NHC (O) -B 896, - NB897C (O) -B898, -NH-C (O) -O-B899, -NH-C (O) -NH-B900, -NH-C (O) -NB901 B902, -NB903-C (O) - O-B904, - NB905-C (O) -NH-B906, -NB907-C (O) -NB908B909, - NHS (O2) -B910, -NB911S (O2) -B912, -S-B913, - S (O) -B914, -S (O2) -B915, -S (O2) NH-B916, -S (O2) NB917B918, -S (O 2) O-
B919, -P(O)(OB920)(OB921 ), -Si(B922)(B923)(B924)"; wobei B873, B874, B875, B876, B877, B878, B879, B880, B881, B882, B883, B884, B885, B886, B887, B888, B889, B890, B891, B892, B893, B894, B895, B896, B897, B898, B899, B900, B901 , B902, B903, B904, B905, B906, B907,B919, -P (O) (OB920) (OB921), -Si (B922) (B923) (B924) "; wherein B873, B874, B875, B876, B877, B878, B879, B880, B881, B882, B883, B884, B885, B886, B887, B888, B889, B890, B891, B892, B893, B894, B895, B896, B897, B898, B899, B900, B901, B902, B903, B904, B905, B906, B907,
B908, B909, B910, B911, B912, B913, B914, B915, B916, B917, B918, B919, B920, B921, B922, B923, B924 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B879, B880 und/oder B888, B889 und/oder B901 , B902 und/oder B908, B909 und/oder B917, B918 jeweils zusammen auch „heterocyclyl" bilden können;B908, B909, B910, B911, B912, B913, B914, B915, B916, B917, B918, B919, B920, B921, B922, B923, B924 are independently selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively B 879, B 880 and / or B888, B889 and / or B901, B902 and / or B908, B909 and / or B917, B918 may together also form "heterocyclyl";
(k) OZ6, wobei Z6 unabhängig ausgewählt ist aus der Gruppe bestehend aus:(k) OZ6, wherein Z6 is independently selected from the group consisting of:
(i) „Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei optional obige Substituenten der Substituentengruppe (i) wie- derum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(i) "hydrogen, alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl", wherein optionally above substituents of the substituent group (i) in turn are independently substituted may be substituted by at least one substituent, the same or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHB925, -NB926B927, -NO2, -OH, -OCF3, -(ii) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, - NHB925, -NB926B927, -NO 2 , -OH, -OCF 3 , -
SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B928, -C(O)O-B929, -C(O)NH-B930, - C(O)NB931 B932, -O-B933, -O(-B934-O)g-H (g = 1 , 2, 3, 4, 5), - O(-B935-O)g-B936 (g = 1 , 2, 3, 4, 5), -OC(O)-B937, -OC(O)-O- B938, -OC(O)-NHB939, -O-C(O)-NB940B941 , - OP(O)(OB942)(OB943), -OSi(B944)(B945)(B946), -OS(O2)- B947, -NHC(O)-B948, -NB949C(O)-B950, -NH-C(O)-O-B951 ,SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -B928, -C (O) O-B929, -C (O) NH-B930, -C (O) NB931 B932, -O-B933, -O (-B934-O) g -H (g = 1, 2, 3, 4, 5), - O (-B935-O) g -B936 (g = 1, 2, 3, 4, 5), -OC (O) -B937, -OC (O) -O-B938, -OC (O) -NHB939, -OC (O) -NB940B941, - OP (O) (OB942) (OB943), -OSi (B944) (B945) (B946), -OS (O2) - B947, -NHC (O) -B948, - NB949C (O) -B950, -NH-C (O) -O-B951,
5 -N H-C(O)-N H-B952, -NH-C(O)-NB953B954, -NB955-C(O)-O-5 -NH-C (O) -NH-B952, -NH-C (O) -NB953B954, -NB955-C (O) -O-
B956, -NB957-C(O)-NH-B958, -NB959-C(O)-NB960B961 , - NHS(O2)-B962, -NB963S(O2)-B964, -S-B965, -S(O)-B966, - S(O2)-B967, -S(O2)NH-B968, -S(O2)NB969B970, -S(O2)O- B971 , -P(O)(OB972)(OB973), -Si(B974)(B975)(B976)";B956, -NB957-C (O) -NH-B958, -NB959-C (O) -NB960B961, - NHS (O2) -B962, -NB963S (O2) -B964, -S-B965, -S ( O) -B966, - S (O 2) -B967, -S (O2) NH-B968, -S (O2) NB969B970, -S (O 2) O- B971, -P (O) (OB972) (OB973), -Si (B974) (B975) (B976) ";
10 wobei B925, B926, B927, B928, B929, B930, B931 , B932, B933,10 wherein B925, B926, B927, B928, B929, B930, B931, B932, B933,
B934, B935, B936, B937, B938, B939, B940, B941 , B942, B943, B944, B945, B946, B947, B948, B949, B950, B951 , B952, B953, B954, B955, B956, B957, B958, B959, B960, B961 , B962, B963, B964, B965, B966, B967, B968, B969, B970, B971 , B972, B973,B934, B935, B936, B937, B938, B939, B940, B941, B942, B943, B944, B945, B946, B947, B948, B949, B950, B951, B952, B953, B954, B955, B956, B957, B958, B959, B960, B961, B962, B963, B964, B965, B966, B967, B968, B969, B970, B971, B972, B973,
15 B974, B975, B976 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B931 , B932 und/oder B940, B941 und/oder B953, B954 und/oder B960, B961 und/oder B969,15 B974, B975, B976 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively B931, B932 and / or B940, B941 and / or B953, B954 and / or B960, B961 and / or B969,
20 B970 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:20 B970 may in each case also form "heterocyclyl", where optionally above substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
25 (iii) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHB977, -NB978B979, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B980, -C(O)O-B981 , -25 (iii) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHB977, -NB978B979, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -B980, -C (O) O-B981,
30 C(O)NH-B982, -C(O)NB983B984, -O-B985, -O(-B986-O)h-30 C (O) NH-B982, -C (O) NB983B984, -O-B985, -O (-B986-O) h -
H (h = 1 , 2, 3, 4, 5), -O(-B987-O)h-B988 (h = 1 , 2, 3, 4, 5), - OC(O)-B989, -OC(O)-O-B990, -OC(O)-N H B991 , -0-C(O)- NB992B993, -OP(O)(OB994)(OB995), - OSi(B996)(B997)(B998), -OS(O2)-B999, -NHC(O)-BI OOO, - NB1001C(O)-BI002, -NH-C(O)-O-BI003, -NH-C(O)-NH- B1004, -NH-C(O)-NBI005B1006, -NB1007-C(O)-O-BI008, -NBIOOg-C(O)-NH-BIOIO1-NBIOII-C(O)-NBIO^BIOIS,- NHS(O2)-B1014, -NB1015S(O2)-B1016, -S-B1017, -S(O)- B1018, -S(O2)-B1019, -S(O2)NH-BI020, -H (h = 1, 2, 3, 4, 5), -O (-B987-O) h -B988 (h = 1, 2, 3, 4, 5), - OC (O) -B989, -OC (O) -O-B990, -OC (O) -NH B991, -O-C (O) -NB992B993, -OP (O) (OB994) (OB995), -OSi (B996) (B997) (B998) , -OS (O 2 ) -B999, -NHC (O) -BI OOO, - NB1001C (O) -BI002, -NH-C (O) -O-BI003, -NH-C (O) -NH-B1004, -NH-C (O) -NB1 O5 B1006, -NB1007-C (O) -O -BI008, -NBIOOg-C (O) -NH-BIOIO 1 -NBIOII-C (O) -NBIO ^ BIOIS, - NHS (O 2 ) -B1014, -NB1015S (O 2 ) -B 1016, -S-B1017, -S (O) - B1018, -S (O 2) -B1019, -S (O 2) NH-BI020, -
S(O2)NBI021B1022, -S(O2)O-BI023, - P(O)(OBI024)(OB1025), -Si(BI026)(B1027)(B1028)"; wobei B977, B978, B979, B980, B981 , B982, B983, B984, B985, B986, B987, B988, B989, B990, B991 , B992, B993, B994, B995, B996, B997, B998, B999, B1000, B1001 , B1002,S (O 2 ) NBI021B1022, -S (O 2 ) O-BI023, -P (O) (OBI024) (OB1025), -Si (BIO26) (B1027) (B1028) "; wherein B977, B978, B979, B980 , B981, B982, B983, B984, B985, B986, B987, B988, B989, B990, B991, B992, B993, B994, B995, B996, B997, B998, B999, B1000, B1001, B1002,
B1003, B1004, B1005, B1006, B1007, B1008, B1009, B1010, B101 1 , B1012, B1013, B1014, B1015, B1016, B1017, B1018, B1019, B1020, B1021 , B1022, B1023, B1024, B1025, B1026, B1027, B1028 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B983, B984 und/oder B992, B993 und/oder B1005, B1006 und/oder B1012, B1013 und/oder B1021 , B1022 jeweils zusammen auch „hete- rocyclyl" bilden können;B1003, B1004, B1005, B1006, B1007, B1008, B1009, B1010, B101 1, B1012, B1013, B1014, B1015, B1016, B1017, B1018, B1019, B1020, B1021, B1022, B1023, B1024, B1025, B1026, B1027 are, B1028 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively B983, B984 and / or B992 , B993 and / or B1005, B1006 and / or B1012, B1013 and / or B1021, B1022 in each case together can also form "heterocyclyl";
, wobei Z7 unabhängig ausgewählt ist aus der Gruppe bestehend aus: „Wasserstoff, alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:wherein Z7 is independently selected from the group consisting of: "hydrogen, alkyl, (C" 9 " -C" 30 " ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; optionally wherein the above substituents of the substituent group ( i) may again be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,(ii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,
CN, CF3, N3, NH2, -NHB1029, -NB1030B1031 , -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-BI 032, -C(O)O-BI 033, -C(O)NH- B1034, -C(O)NBI 035B1036, -O-B1037, -O(-B 1038-O)1-H (i = 1 , 2, 3, 4, 5), -O(-B1039-O)1-BI 040 (i = 1 , 2, 3, 4, 5), -OC(O)- B1041 , -OC(O)-O-BI 042, -OC(O)-NHBI 043, -0-C(O)- NB1044B1045, -OP(O)(OBI 046)(OB1047), -CN, CF 3, N 3, NH 2, -NHB1029, -NB1030B1031, -NO 2, -OH, - OCF 3, -SH, -0-SO3H, -OP (O) (OH) 2, -CHO , -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -BI 032, -C (O) O-BI 033, -C (O ) NH- B1034, -C (O) NBI 035B1036, -O-B1037, -O (-B 1038 -O) 1 -H (i = 1, 2, 3, 4, 5), -O (-B1039-O) 1 -BI 040 (i = 1, 2, 3, 4, 5), -OC (O) -B1041, -OC (O) -O-BI 042, -OC (O) -NHBI 043, -0-C ( O) - NB1044B1045, -OP (O) (OBI 046) (OB1047), -
5 OSi(BI 048)(B1049)(B1050), -OS(O2J-B 1051 , -NHC(O)-BI 052, -5 OSi (BI 048) (B1049) (B1050), -OS (O 2 JB 1051, -NHC (O) -BI 052, -
NB1053C(O)-BI054, -NH-C(O)-O-BI055, -NH-C(O)-NH- B1056, -NH-C(O)-NBI057B1058, -NB1059-C(O)-O-BI060, - NB1061-C(O)-NH-BI062, -NB1063-C(O)-NBI064B1065, - NHS(O2)-B1066, -NB1067S(O2)-B1068, -S-B1069, -S(O)-NB1053C (O) -BI054, -NH-C (O) -O-BI055, -NH-C (O) -NH-B1056, -NH-C (O) -NBI057B1058, -NB1059-C (O) -O -BI060, - NB1061-C (O) -NH-BI062, -NB1063-C (O) -NBI064B1065, - NHS (O 2) -B1066, -NB1067S (O 2) -B1068, -S-B1069, -S (O)-
10 B1070, -S(02)-B1071, -S(O2)NH-BI072, -S(O2)NBI073B1074, -10 B1070, -S (0 2) -B1071, -S (O 2) NH-BI072, -S (O 2) NBI073B1074, -
S(O2)O-BI075, -P(O)(OBI076)(OB1077), - Si(B1078)(B1079)(B1080)"; wobei B1029, B1030, B1031 , B1032, B1033, B1034, B1035, B1036, B1037, B1038, B1039, B1040, B1041 , B1042, B1043,S (O 2 ) O-BI075, -P (O) (OBI076) (OB1077), -Si (B1078) (B1079) (B1080) "; wherein B1029, B1030, B1031, B1032, B1033, B1034, B1035, B1036 , B1037, B1038, B1039, B1040, B1041, B1042, B1043,
15 B1044, B1045, B1046, B1047, B1048, B1049, B1050, B1051 ,15 B1044, B1045, B1046, B1047, B1048, B1049, B1050, B1051,
B1052, B1053, B1054, B1055, B1056, B1057, B1058, B1059, B1060, B1061 , B1062, B1063, B1064, B1065, B1066, B1067, B1068, B1069, B1070, B1071 , B1072, B1073, B1074, B1075, B1076, B1077, B1078, B1079, B1080 unabhängig voneinanderB1052, B1053, B1054, B1055, B1056, B1057, B1058, B1059, B1060, B1061, B1062, B1063, B1064, B1065, B1066, B1067, B1068, B1069, B1070, B1071, B1072, B1073, B1074, B1075, B1076, B1077, B1078, B1079, B1080 independent from each other
20 ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-20 are selected from the group consisting of: "alkyl, (C 9 -
C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B1035, B1036 und/oder B1044, B1045 und/oder B1057, B1058 und/oder B1064, B1065 und/oder B1073, B1074 jeweils zusam-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively B1035, B1036 and / or B1044, B1045 and / or B1057, B1058 and / or B1064, B1065 and / or B1073 , B1074 in each case
25 men auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:In which optional substituents of the substituent group (ii) above may be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
30 (iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHB1081 , -NB1082B1083, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-BI 084, -C(O)O-BI 085, -C(O)NH-BI 086, -C(O)NBI 087B1088, -O-B1089, -O(- B1090-O)-H C = 1 , 2, 3, 4, 5), -O(-B1091-O)-B1092 (j = 1 , 2, 3, 4, 5), -OC(O)-BI 093, -OC(O)-O-BI 094, -OC(O)- NHB1095, -0-C(O)-NBI 096B1097, - OP(O)(OBI 098)(OB1099), -OSi(BI 100)(B1101 )(B1102), -30 (iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHB1081, -NB1082B1083, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -BI 084, -C (O) O-BI 085, -C (O) NH-BI 086, -C (O) NBI 087B1088, -O-B1089, -O (-B-1090-O) -HC = 1, 2, 3, 4, 5), -O (-B1091 -O) -B1092 (j = 1, 2, 3, 4, 5), -OC (O) -BI 093, -OC (O) -O-BI 094, -OC (O) - NHB1095, -O- C (O) -NBi 096B1097, - OP (O) (OBI 098) (OB1099), -OSi (BI 100) (B1101) (B1102),
0S(02)-B1103, -NHC(O)-B1 104, -NB1105C(O)-B1 106, - NH-C(O)-O-B1107, -NH-C(O)-NH-B1 108, -NH-C(O)- NB1109B11 10, -NB111 1-C(O)-O-B1112, -NB11 13-C(O)- NH-B1 114, -NB11 15-C(O)-NB1 116B11 17, -NHS(O2)- B11 18, -NB1 119S(O2)-B1 120, -S-B1121 , -S(O)-B1 122, -0S (0 2 ) -B1103, -NHC (O) -B1 104, -NB1105C (O) -B1 106, -NH-C (O) -O-B1107, -NH-C (O) -NH-B1 108 , -NH-C (O) -NB1109B11 10, -NB111 1-C (O) -O-B1112, -NB11 13-C (O) -NH-B1 114, -NB11 15-C (O) -NB1 116B11 17, -NHS (O 2 ) -B11 18, -NB 1 119S (O 2 ) -B1 120, -S-B1121, -S (O) -B 1 122, -
S(02)-B1123, -S(O2)NH-B1124, -S(O2)NBI 125B1 126, - S(O2)O-B1127, -P(O)(OBI 128)(OB1 129), - Si(B1130)(B1131 )(B1132)"; wobei B1081 , B1082, B1083, B1084, B1085, B1086, B1087, B1088, B1089, B1090, B1091 , B1092, B1093, B1094, B1095,S (0 2) -B1123, -S (O 2) NH-B1124, -S (O 2) NBI 125B1 126, - S (O 2) O-B1127, -P (O) (OBI 128) (OB1 129 Si (B1130) (B1131) (B1132) "; wherein B1081, B1082, B1083, B1084, B1085, B1086, B1087, B1088, B1089, B1090, B1091, B1092, B1093, B1094, B1095,
B1096, B1097, B1098, B1099, B1 100, B1 101 , B1 102, B1 103, B1104, B1105, B1 106, B1 107, B1 108, B1 109, B1 110, B1 11 1 , B1112, B1113, B1 114, B1 115, B1 116, B1 117, B1 118, B1 119, B1120, B1121 , B1 122, B1 123, B1 124, B1 125, B1 126, B1 127, B1128, B1129, B1130, B1 131 , B1 132 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B1087, B1088 und/oder B1096, B1097 und/oder B1109, B1110 und/oder B1 116, B1 117 und/oder B1 125,B1096, B1097, B1098, B1099, B1100, B1101, B1102, B1103, B1104, B1105, B1106, B1107, B1108, B1109, B1101, B111 1, B1112, B1113, B1 114, B1 115, B1 116, B1 117, B1 118, B1 119, B1120, B1121, B1122, B1123, B1124, B1125, B1126, B1127, B1128, B1129, B1130, B1 131, B1 132 independently of one another are selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively B1087, B1088 and / or B1096, B1097 and / or B1109, B1110 and / or B1 116, B1 117 and / or B1 125,
B1126 jeweils zusammen auch „heterocyclyl" bilden können;B1126 may together also form "heterocyclyl";
(m) NZ8Z9, wobei Z8, Z9 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: (i) „Wasserstoff, alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C(O)- B1133, -C(O)O-B1 134, -C(O)-NBI 135B1 136, -S(02)-B1 137, - S(O2)O-B1138"; wobei B1133, B1134, B1135, B1136, B1137, B1138 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei al- ternativ B1135, B1 136 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHB1 139, -NB1140B1 141 , -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B1 142, -C(O)O-B1 143, -C(O)NH- B1144, -C(O)NBI 145B1146, -0-B1 147, -O(-B1148-O)k-H (k =(m) NZ8Z9, wherein Z8, Z9 are independently selected from the group consisting of: (i) "hydrogen, alkyl, (C" 9 " -C" 30 " ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C (O) -B1133, -C (O) O-B1 134, -C (O) -NBl 135B1 136, -S (0 2 ) -B1 137, -S (O 2 ) O-B 1138 "; wherein B1133, B1134, B1135, B1136, B1137, B1138 are independently selected from the group consisting of: hydrogen, alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl "heteroarylalkyl" and in which case alternatively B1135, B1 136 may together also form "heterocyclyl"; wherein optionally above substituents of substituent group (i) in turn may be independently substituted with at least one substituent, identical or different, selected from the group consisting of: (ii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl , heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHB1 139, -NB1140B1 141, -NO 2, -OH, - OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -B1 142, -C (O) O-B1 143, -C (O) NH-B1144, -C (O) NBI 145B1146, -O-B1 147, -O (-B1148- O) k -H (k =
1 , 2, 3, 4, 5), -O(-B1 149-O)k-B1150 (k = 1 , 2, 3, 4, 5), -OC(O)- B1151 , -OC(O)-O-B1 152, -OC(O)-NHB1 153, -0-C(O)- NB1154B1155, -OP(O)(OB1156)(OB1 157), - OSi(BI 158)(B1 159)(B1160), -0S(02)-B1161 , -NHC(O)-B1 162, - NB1163C(O)-B1164, -NH-C(O)-O-B1165, -NH-C(O)-NH-1, 2, 3, 4, 5), -O (-B1 149-O) k -B1150 (k = 1, 2, 3, 4, 5), -OC (O) - B1151, -OC (O) -O-B1 152, -OC (O) -NHB1 153, -O-C (O) -NB1154B1155, -OP (O) (OB1156) (OB1 157), -OSi (BI 158) (B1 159) (B1160 ) -0S (0 2) -B1161, -NHC (O) -B1 162 - NB1163C (O) -B1164, -NH-C (O) -O-B1165, -NH-C (O) -NH-
B1166, -NH-C(O)-NBI 167B1168, -NB1 169-C(O)-O-B1 170, - NB1171-C(O)-NH-B1 172, -NB1173-C(O)-NBI 174B1175, - NHS(O2)-B1 176, -NB1177S(O2)-B1178, -S-B1 179, -S(O)- B1180, -S(02)-B1 181 , -S(O2)NH-B1 182, -S(O2)NBI 183B1184, - S(O2)O-B1185, -P(O)(OB1186)(OB1 187), -B1166, -NH-C (O) -NBl 167B1168, -NB1 169-C (O) -O-B1 170, -NB1171-C (O) -NH-B1 172, -NB1173-C (O) -NBl 174B1175 , - NHS (O 2) -B1 176, -NB1177S (O 2) -B1178, -S-B1 179, -S (O) - B1180, -S (0 2) -B1 181, -S (O 2) NH-B1 182, -S (O 2) NBI 183B1184, - S (O 2) O-B1185, -P (O) (OB1186) (OB1 187), -
Si(B1188)(B1189)(B1190)"; wobei B1139, B1140, B1141, B1142, B1143, B1144, B1145, B1146, B1147, B1148, B1149, B1150, B1151, B1152, B1153, B1154, B1155, B1156, B1157, B1158, B1159, B1160, B1161, B1162, B1163, B1164, B1165, B1166, B1167, B1168, B1169,Si (B1188) (B1189) (B1190) "; wherein B1139, B1140, B1141, B1142, B1143, B1144, B1145, B1146, B1147, B1148, B1149, B1150, B1151, B1152, B1153, B1154, B1155, B1156, B1157 , B1158, B1159, B1160, B1161, B1162, B1163, B1164, B1165, B1166, B1167, B1168, B1169,
B1170, B1171, B1172, B1173, B1174, B1175, B1176, B1177, B1178, B1179, B1180, B1181, B1182, B1183, B1184, B1185, B1186, B1187, B1188, B1189, B1190 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B1145, B1146 und/oder B1 154, B1 155 und/oder B1 167, B1 168 und/oder B1 174, B1 175 und/oder B1 183, B1184 jeweils zusam- 5 men auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:B1170, B1171, B1172, B1173, B1174, B1175, B1176, B1177, B1178, B1179, B1180, B1181, B1182, B1183, B1184, B1185, B1186, B1187, B1188, B1189, B1190 are independently selected from the group consisting of : "Alkyl, (Cg- C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively B1145, B1146 and / or B1 154, B1 155 and / or B1 167, B1 168 and / or B1 174, B1 175 and / or B1 183, B1184 in each case together can also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
10 (iii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I1 CN1 CF3, N3, NH2, -NHB1191 , -NB1 192B1193, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B1 194, -C(O)O-B1 195,10 (iii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I 1 1 CN CF 3, N 3, NH 2 , -NHB1191, -NB1 192B1193, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O ) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -B 1 194, -C (O) O-B1 195,
15 -C(O)NH-B1196, -C(O)NB1197B1198, -0-B1199, -0(-15 -C (O) NH-B1196, -C (O) NB1197B1198, -O-B1199, -0 (-
B1200-O)1-H (I = 1 , 2, 3, 4, 5), -0(-B 1201-O)1-B 1202 (1 = 1 , 2, 3, 4, 5), -OC(O)-BI 203, -OC(O)-O-BI 204, -OC(O)- NHB1205, -O-C(O)-NB1206B1207, - OP(O)(OB1208)(OB1209), -OSi(B1210)(B1211 )(B1212), -B1200-O) 1 -H (I = 1, 2, 3, 4, 5), -O (-B 1201 -O) 1 -B 1202 (1 = 1, 2, 3, 4, 5), -OC (O) -BI 203, -OC (O) -O-BI 204, -OC (O) -NHB1205, -OC (O) -NB1206B1207, -OP (O) (OB1208) (OB1209), -OSi (B1210 ) (B1211) (B1212),
20 OS(O2)-B1213, -NHC(O)-B1214, -NB1215C(O)-B1216, -20 OS (O 2) -B1213, -NHC (O) -B1214, -NB1215C (O) -B1216, -
NH-C(O)-O-BI 217, -NH-C(O)-NH-BI 218, -NH-C(O)- NB1219B1220, -NB1221-C(O)-O-B1222, -NB1223-C(O)- NH-B1224, -NB1225-C(O)-NB1226B1227, -NHS(O2)- B1228, -NB1229S(O2)-B1230, -S-B1231 , -S(O)-B1232, -NH-C (O) -O-BI 217, -NH-C (O) -NH-BI 218, -NH-C (O) -NB 1219 B 1220, -NB 1221-C (O) -O-B 1222, -NB 1223- C (O) - NH-B1224, -NB1225-C (O) -NB1226B1227, -NHS (O 2) - B1228, -NB1229S (O 2) -B1230, -S-B1231, -S (O) -B1232, -
25 S(O2)-B1233, -S(O2)NH-B1234, -S(O2)NBI 235B1236, -25 S (O 2) -B1233, -S (O 2) NH-B1234, -S (O 2) NBI 235B1236, -
S(O2)O-B1237, -P(O)(OB1238)(OB1239), - Si(B1240)(B1241 )(B1242)"; wobei B1191, B1192, B1193, B1194, B1195, B1196, B1197, B1198, B1199, B1200, B1201, B1202, B1203, B1204, B1205,S (O 2) O-B1237, -P (O) (OB1238) (OB1239), - Si (B1240) (B1241) (B1242) "; wherein B1191, B1192, B1193, B1194, B1195, B1196, B1197, B1198 , B1199, B1200, B1201, B1202, B1203, B1204, B1205,
30 B1206, B1207, B1208, B1209, B1210, B1211, B1212, B1213,30 B1206, B1207, B1208, B1209, B1210, B1211, B1212, B1213,
B1214, B1215, B1216, B1217, B1218, B1219, B1220, B1221, B1222, B1223, B1224, B1225, B1226, B1227, B1228, B1229, B1230, B1231, B1232, B1233, B1234, B1235, B1236, B1237, B1238, B1239, B1240, B1241, B1242 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B1197, B1198 und/oder B1206, B1207 und/oder B1219, B1220 und/oder B1226, B1227 und/oder B1235,B1214, B1215, B1216, B1217, B1218, B1219, B1220, B1221, B1222, B1223, B1224, B1225, B1226, B1227, B1228, B1229, B1230, B1231, B1232, B1233, B1234, B1235, B1236, B1237, B1238, B1239, B1240, B1241, B1242 independent from each other are selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively B1197, B1198 and / or B1206, B1207 and / or B1219, B1220 and / or B1226, B1227 and / or B1235,
B1236 jeweils zusammen auch „heterocyclyl" bilden können;B1236 may together also form "heterocyclyl";
undand
Rest Z5 unabhängig ausgewählt ist aus der Gruppe bestehend aus:Rest Z5 is independently selected from the group consisting of:
(i) „Wasserstoff, alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHD1 , -ND2D3, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-D4, - C(O)O-D5, -C(O)NH-D6, -C(O)ND7D8, -0-D9, -O(-D10-O)r-H (r = 1 , 2, 3,(i) "hydrogen, alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3 , NH 2 , -NHD 1, -ND 2 D 3 , -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -D 4 , -C (O) O-D 5, -C (O) NH-D 6, -C ( O) ND7D8, -O-D9, -O (-D10-O) r -H (r = 1, 2, 3,
4, 5), -0(-D1 1-0)r-D12 (r = 1 , 2, 3, 4, 5), -OC(O)-DI 3, -OC(O)-O-D14, - OC(O)-NHDI 5, -0-C(O)-NDI 6D17, -OP(O)(ODI 8)(0D19), - OSi(D20)(D21 )(D22), -OS(O2)-D23, -NHC(O)-D24, -ND25C(O)-D26, -NH- C(O)-O-D27, -NH-C(O)-NH-D28, -NH-C(O)-ND29D30, -ND31-C(O)-O- D32, -ND33-C(O)-NH-D34, -ND35-C(O)-ND36D37, -NHS(O2)-D38, -4, 5), -0 (-D1 1-0) r -D12 (r = 1, 2, 3, 4, 5), -OC (O) -DI 3, -OC (O) -O-D14, OC (O) -NHDI 5, -O-C (O) -NDI 6D17, -OP (O) (ODI 8) (0D19), -OSi (D20) (D21) (D22), -OS (O 2 ) -D23, -NHC (O) -D24, -ND25C (O) -D26, -NH-C (O) -O-D27, -NH-C (O) -NH-D28, -NH-C (O ) -ND29D30, -ND31-C (O) -O- D32, -ND33-C (O) -NH-D34, -ND35-C (O) -ND36D37, -NHS (O 2) -D38, -
ND39S(O2)-D40, -S-D41 , -S(O)-D42, -S(O2)-D43, -S(O2)NH-D44, - S(O2)ND45D46, -S(O2)O-D47, -P(O)(OD48)(OD49), -Si(D50)(D51 )(D52)"; wobei D1 , D2, D3, D4, D5, D6, D7, D8, D9, D10, D1 1 , D12, D13, D14, D15, D16, D17, D18, D19, D20, D21 , D22, D23, D24, D25, D26, D27, D28, D29, D30, D31 , D32, D33, D34, D35, D36, D37, D38, D39, D40, D41 , D42, D43,ND39S (O 2) -D40, -S-D41, -S (O) -D42, -S (O 2) -D43, -S (O 2) NH-D44, - S (O 2) ND45D46, -S (O 2 ) O-D47, -P (O) (OD48) (OD49), -Si (D50) (D51) (D52) ", wherein D1, D2, D3, D4, D5, D6, D7, D8, D9, D10, D1, D12, D13, D14, D15, D16, D17, D18, D19, D20, D21, D22, D23, D24, D25, D26, D27, D28, D29, D30, D31, D32, D33 , D34, D35, D36, D37, D38, D39, D40, D41, D42, D43,
D44, D45, D46, D47, D48, D49, D50, D51 , D52 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ D7, D8 und/oder D16, D17 und/oder D29, D30 und/oder D36, D37 und/oder D45, D46 jeweils zusammen auchD44, D45, D46, D47, D48, D49, D50, D51, D52 are independently selected from the group consisting of: alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl , heteroaryl, heteroarylalkyl "and wherein alternatively D7, D8 and / or D16, D17 and / or D29, D30 and / or D36, D37 and / or D45, D46 also together in each case
„heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Can form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3,(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 ,
NH2, -NHD53, -ND54D55, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- D56, -C(O)O-D57, -C(O)NH-D58, -C(O)ND59D60, -0-D61 , -O(-D62- O)5-H (s = 1 , 2, 3, 4, 5), -O(-D63-O)t-D64 (t = 1 , 2, 3, 4, 5), -OC(O)- D65, -OC(O)-O-D66, -OC(O)-NHD67, -O-C(O)-ND68D69, -NH 2 , -NHD53, -ND54D55, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O ) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -D56, -C (O) O-D57, -C (O) NH-D58, -C (O) ND59D60, -O-D61, -O (-D62- O) 5 -H (s = 1, 2, 3, 4, 5), -O (-D63-O) t -D64 (t = 1, 2, 3, 4, 5), -OC (O) -D65, -OC (O) -O-D66, -OC (O) -NHD67, -OC (O) -ND68D69,
OP(O)(OD70)(OD71 ), -OSi(D72)(D73)(D74), -OS(O2)-D75, -NHC(O)- D76, -ND77C(O)-D78, -NH-C(O)-O-D79, -N H-C(O)-N H-D80, -NH- C(O)-ND81 D82, -ND83-C(O)-O-D84, -ND85-C(O)-NH-D86, -ND87- C(O)-ND88D89, -NHS(O2)-D90, -ND91S(O2)-D92, -S-D93, -S(O)- D94, -S(O2)-D95, -S(O2)NH-D96, -S(O2)ND97D98, -S(O2)O-D99, -OP (O) (OD70) (OD71), -OSi (D72) (D73) (D74), -OS (O 2) -D75, -NHC (O) - D76, -ND77C (O) -D78, -NH -C (O) -O-D79, -NHC (O) -NH-D80, -NH-C (O) -ND81 D82, -ND83-C (O) -O-D84, -ND85-C ( O) -NH-D86, -ND87- C (O) -ND88D89, -NHS (O 2) -D90, -ND91S (O 2) -D92, -S-D93, -S (O) - D94, -S (O 2 ) -D95, -S (O 2 ) NH-D96, -S (O 2 ) ND97D98, -S (O 2 ) O-D99, -
P(O)(OD100)(OD101 ), -Si(DI 02)(D103)(D104)"; wobei D53, D54, D55, D56, D57, D58, D59, D60, D61 , D62, D63, D64, D65, D66, D67, D68, D69, D70, D71 , D72, D73, D74, D75, D76, D77, D78, D79, D80, D81 , D82, D83, D84, D85, D86, D87, D88, D89, D90, D91 , D92, D93, D94, D95, D96, D97, D98, D99, D100, D101 , D102,P (O) (OD100) (OD101), -Si (DIO2) (D103) (D104) "; wherein D53, D54, D55, D56, D57, D58, D59, D60, D61, D62, D63, D64, D65, D66, D67, D68, D69, D70, D71, D72, D73, D74, D75, D76, D77, D78, D79, D80, D81, D82, D83, D84, D85, D86, D87, D88, D89, D90, D91, D92, D93, D94, D95, D96, D97, D98, D99, D100, D101, D102,
D103, D104 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ D59, D60 und/oder D68, D69 und/oder D81 , D82 und/oder D88, D89 und/oder D97, D98 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe be- stehend aus:Are D103, D104 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively D59, D60 and / or D68, D69 and / or D81, D82 and / or D88, D89 and / or D97, D98 may together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) can in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHD105, -ND106D107, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-DI 08, -C(O)O-DI 09, -C(O)NH-D1 10, -C(O)ND11 1 D112, - O-D1 13, -O(-D1 14-O)1-H (t = 1 , 2, 3, 4, 5), -O(-D1 15-O)t-D1 16 (t = 1 , 2, 3, 4, 5), -OC(O)-D117, -OC(O)-O-D118, -OC(O)-NHD119, - O-C(O)-ND120D121 , -OP(O)(OD122)(OD123), - OSi(D124)(D125)(D126), -OS(O2)-D127, -NHC(O)-D128, -(iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHD105, -ND106D107, -NO 2, -OH, -OCF3, -SH, -O- SO3H, -OP (O) (OH) 2, -CHO, -COOH, C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -DI 08, -C (O) O -DI 09, -C (O) NH-D1 10, -C (O) ND11 1 D112, -O-D1 13, -O (-D1 14 -O) 1 -H (t = 1, 2, 3, 4, 5), -O (-D1 15-O) t -D1 16 (t = 1, 2, 3, 4, 5), -OC ( O) -D117, -OC (O) -O-D118, -OC (O) -NHD119, -OC (O) -ND120D121, -OP (O) (OD122) (OD123), -OSi (D124) (D125 ) (D126), -OS (O 2 ) -D127, -NHC (O) -D128, -
ND129C(O)-DI 30, -NH-C(O)-O-DI 31 , -N H-C(O)-NH-DI 32, -NH- C(O)-NDI 33D134, -ND135-C(O)-O-DI 36, -N D 137-C(O)-N H- D138, -ND139-C(O)-ND140D141 , -NHS(O2)-D142, -ND143S(O2)- D144, -S-D145, -S(O)-D146, -S(O2)-D147, -S(O2)NH-D148, - S(O2)ND149D150, -S(O2)O-DI 51 , -P(O)(ODI 52)(OD153), -ND129C (O) -DI 30, -NH-C (O) -O-DI 31, -N HC (O) -NH-DI 32, -NH-C (O) -NDI 33D134, -ND135-C (O ) -O-DI 36, 137 ND-C (O) -N H- D138, -ND139-C (O) -ND140D141, -NHS (O 2) -D142, -ND143S (O 2) - D144, - S-D145, -S (O) -D146, -S (O 2) -D147, -S (O 2) NH-D148, - S (O 2) ND149D150, -S (O 2) O-DI 51 -P (O) (ODI 52) (OD153), -
Si(D154)(D155)(D156)"; wobei D105, D106, D107, D108, D109, D1 10, D1 11 , D1 12, D1 13, D1 14, D115, D116, D117, D118, D119, D120, D121 , D122, D123, D124, D125, D126, D127, D128, D129, D130, D131 , D132, D133, D134, D135, D136, D137, D138, D139, D140, D141 , D142, D143,Si (D154) (D155) (D156) "; where D105, D106, D107, D108, D109, D110, D111, D112, D113, D114, D115, D116, D117, D118, D119, D120, D121, D122, D123, D124, D125, D126, D127, D128, D129, D130, D131, D132, D133, D134, D135, D136, D137, D138, D139, D140, D141, D142, D143,
D144, D145, D146, D147, D148, D149, D150, D151 , D152, D153, D154, D155, D156 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ D1 11 , D1 12 und/oder D120, D121 und/oderD144, D145, D146, D147, D148, D149, D150, D151, D152, D153, D154, D155, D156 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl , heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, and wherein alternatively D1 11, D1 12 and / or D120, D121 and / or
D133, D134 und/oder D140, D141 und/oder D149, D150 jeweils zusammen auch „heterocyclyl" bilden können.D133, D134 and / or D140, D141 and / or D149, D150 may together also form "heterocyclyl".
Um Unklarheiten zu vermeiden, sind die oben dargestellten Fälle (A) bis (E) für die allgemeine Formel (I) im Folgenden erläutert:In order to avoid ambiguity, the cases (A) to (E) for the general formula (I) described above are explained below:
Gemäß Fall (A) können die neuen Pyrido[2,3-b]pyrazin-Derivate in mindestens einem ihrer Z3, Z4 Reste mit „substituierten Aryl" substituiert sein, wobei die Neuheit entweder durch Unterfall (a) oder durch Unterfall (c) gegeben ist. Falls nur ein Rest Z3, Z4 neues „substituiertes Aryl" ist, kann der jeweils andere Rest Z3, Z4 beliebig im ma- ximalen dargestellten Umfang substituiert sein [(„und"-Verknüpfung nach Unterfall (d)]. Optional können beide Reste Z3, Z4 zusätzlich auch noch weiter substituiert sein [Unterfall (b) bzw. (d)]. Reste Z1 , Z2 und Z5 sind beliebig im maximalen dargestellten Umfang substituiert [(„und"-Verknüpfung nach den Fällen (A) bis (D)]. Gemäß Fall (B) können die neuen Pyrido[2,3-b]pyrazin-Derivate in mindestens einem ihrer Z3, Z4 Reste mit „substituierten Heteroaryl" substituiert sein, wobei die Neuheit entweder durch Unterfall (a) oder durch Unterfall (c) gegeben ist. Falls nur ein Rest Z3, Z4 neues „substituiertes Heteroaryl" ist, kann der jeweils andere Rest Z3, Z4 belie- big im maximalen dargestellten Umfang substituiert sein [(„und"-Verknüpfung nach Unterfall (d)]. Optional können beide Reste Z3, Z4 zusätzlich auch noch weiter substituiert sein [Unterfall (b) bzw. (d)]. Reste Z1 , Z2 und Z5 sind beliebig im maximalen dargestellten Umfang substituiert [(„und"-Verknüpfung nach den Fällen (A) bis (D)].According to case (A), the new pyrido [2,3-b] pyrazine derivatives in at least one of their Z3, Z4 radicals can be substituted by "substituted aryl", the novelty being substituted either by subunit (a) or by subunit (c) If only one radical Z3, Z4 is new "substituted aryl", the other radical Z3, Z4 can be arbitrarily substituted to the maximum extent described [("" and "linkage according to sub-clause (d)] both radicals Z3, Z4 additionally also be further substituted [sub (b) or (d)]. radicals Z1, Z2 and Z5 are arbitrarily substituted to the maximum extent described [("and" linkage according to cases (A) to (D)]. According to case (B), the novel pyrido [2,3-b] pyrazine derivatives in at least one of their Z3, Z4 radicals may be substituted by "substituted heteroaryl", the novelty being substituted either by subunit (a) or by subunit (c) If only one radical Z3, Z4 is a new "substituted heteroaryl", the other radical Z3, Z4 can be optionally substituted to the maximum extent shown [("and" linkage according to sub-clause (d)] both radicals Z3, Z4 additionally also be further substituted [sub (b) or (d)]. radicals Z1, Z2 and Z5 are arbitrarily substituted to the maximum extent described [("and" linkage according to cases (A) to (D)].
Gemäß Fall (C) können die neuen Pyrido[2,3-b]pyrazin-Derivate in mindestens ei- nem ihrer Z3, Z4 Reste mit „substituierten Alkyl" oder „(Cg-C30)alkyr neu substituiert sein. Falls nur ein Rest Z3, Z4 neues „substituiertes Alkyl" oder „(C9-C3o)alkyr ist, kann der jeweils andere Rest Z3, Z4 beliebig im maximalen dargestellten Umfang substituiert sein [(„und"-Verknüpfung nach Unterfall „(Cg-C3o)alkyl"]. Reste Z1 , Z2 und Z5 sind beliebig im maximalen dargestellten Umfang substituiert [(„und"-Verknüpfung nach den Fällen (A) bis (D)].According to case (C) of the new pyrido can [2,3-b] pyrazine derivatives in at least egg nem their Z3, "substituted alkyl" radicals having Z4 or "(Cg-C 30) alkyr new substituted one in. If only radical Z3, Z4 new "substituted alkyl" or "(C 9 -C 3 o) alkyr is, the respective other radical Z3 may be substituted in any Z4 maximum extent shown [(" aND "operation to lower case" (Cg C 3 o) alkyl "]. Z1, Z 2 and Z 5 radicals are optionally substituted to the maximum extent shown [(""and" - linkage according to cases (A) to (D)].
Gemäß Fall (D) können die neuen Pyrido[2,3-b]pyrazin-Derivate in mindestens einem ihrer Z3, Z4 Reste mit „-NZ10Z1 1 , -OZ12, -SZ13" substituiert sein, wobei die Neuheit entweder durch Unterfall (a) oder durch Unterfall (b) gegeben ist. Falls nur ein Rest Z3, Z4 neues „-NZ10Z11 , -OZ12, -SZ13" ist, kann der jeweils andere Rest Z3, Z4 beliebig im maximalen dargestellten Umfang substituiert sein [(„und"-Verknüpfung nach Unterfall (b)]. Reste Z1 , Z2 und Z5 sind beliebig im maximalen dargestellten Umfang substituiert [(„und"-Verknüpfung nach den Fällen (A) bis (D)].According to case (D), the novel pyrido [2,3-b] pyrazine derivatives in at least one of their Z3, Z4 radicals may be substituted by "-NZ10Z1 1, -OZ12, -SZ13", the novelty being either subunit (a If only one remainder Z3, Z4 is new "-NZ10Z11, -OZ12, -SZ13", the other remainder Z3, Z4 can be arbitrarily substituted to the maximum extent shown [("and"). Linkage by sub (b)] radicals Z1, Z2 and Z5 are arbitrarily substituted to the maximum extent shown [("and" linkage according to cases (A) to (D)].
Gemäß Fall (E) können die neuen Pyrido[2,3-b]pyrazin-Derivate in mindestens einem ihrer Z1 , Z2 Reste mit „-NZ24Z25, -NZ26Z27" substituiert sein, wobei die Neuheit entweder durch Unterfall (a)(1 ), Unterfall (b)(1 )(l), Unterfall (b)(1 )(ll) oder Unterfall (b)(2) gegeben ist. Falls nur ein Rest Z1 , Z2 neues „-NZ24Z25, -NZ26Z27" ist, kann der jeweils andere Rest Z1 , Z2 beliebig im maximalen dargestellten Umfang [Unterfälle (c), (d)] substituiert sein [(„und"-Verknüpfung nach dem Unterfall (b)(2)]. Reste Z3, Z4 und Z5 sind beliebig im maximalen dargestellten Umfang substituiert [(„und"- Verknüpfung nach dem Unterfall (d)].According to case (E), the new pyrido [2,3-b] pyrazine derivatives in at least one of their Z1, Z2 radicals may be substituted by "-NZ24Z25, -NZ26Z27", the novelty being substituted either by sub (a) (1) , Sub-case (b) (1) (1), sub-case (b) (1) (II) or sub-case (b) (2) If only one of Z1, Z2 is new "-NZ24Z25, -NZ26Z27", the other radical Z1, Z2 can be arbitrarily substituted to the maximum extent shown [subunits (c), (d)] [("and" linkage to subunit (b) (2)]. radicals Z3, Z4 and Z5 arbitrarily substituted to the maximum extent represented [("and" - linkage to the subordinate (d)].
In einer bevorzugten Ausführungsform werden neue Pyrido[2,3-b]pyrazin-Derivate gemäß der allgemeinen Formel (I) bereitgestellt, wobei gemäß (A) der Rest Z1 unabhängig „NZ14Z15" ist; wobei Z14 Wasserstoff oder „aryl" ist und Z15 ,,-C(O)N H-alkyl" ist; wobei ,,-C(O)NH-alkyl" zusätzlich optional substituiert sein kann mit ,,-OH"; der Rest Z2 unabhängig Wasserstoff ist; der Rest Z3 unabhängig „substituiertes Aryl" ist, wobei „substituiertes Aryl" substituiert ist mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:In a preferred embodiment, novel pyrido [2,3-b] pyrazine derivatives according to the general formula (I) are provided, wherein according to (A) Z1 is independently "NZ14Z15" wherein Z14 is hydrogen or "aryl" and Z15 is --C (O) NH -alkyl ", wherein" --C (O) NH-alkyl "may additionally be optionally substituted with "--OH"; the radical Z2 is independently hydrogen; the radical Z3 is independently "substituted aryl", wherein "substituted aryl" is substituted with at least one substituent, the same or different, selected from the group consisting of:
(a) „alkyl, -OC(O)-alkyl, -O-alkyl, -NHC(O)-alkyl"; mit der Maßgabe, dass obige Substituenten der Substituentengruppe (a) unab- hängig voneinander weiter substituiert sind mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(a) "alkyl, -OC (O) -alkyl, -O-alkyl, -NHC (O) -alkyl"; provided that the above substituents of the substituent group (a) are further independently substituted with at least one Substituents, the same or different, selected from the group consisting of:
(i) „aryl, heterocyclyl, -O-alkyl-0-alkyl, -O-arylalkyl"; oder der Rest Z3 unabhängig „substituiertes Aryl" ist, wobei „substituiertes Aryl" substituiert ist mit mindestens einem Substituenten, gleich oder verschieden, aus- gewählt aus der Gruppe bestehend aus:(i) "aryl, heterocyclyl, -O-alkyl-O-alkyl, -O-arylalkyl" or the radical Z3 is independently "substituted aryl", where "substituted aryl" is substituted by at least one substituent, identical or different, selected from the group consisting of:
(c) ,,-OC(O)-O-alkyl,-OC(O)-O-aryl, -OC(O)-N(alkyl)2, -OC(O)-NH-alkyl, - OC(O)-(C9-C30)alkyl, -NHC(O)-O-alkyl, -N HC(O)-N H-alkyl, -NHC(O)- N(alkyl)2, -Si(alkyl)3"; wobei optional obige Substituenten der Substituentengruppe (c) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(c), - OC (O) -O-alkyl, -OC (O) -O-aryl, -OC (O) -N (alkyl) 2 , -OC (O) -NH-alkyl, - OC ( O) - (C 9 -C 30 ) alkyl, -NHC (O) -O-alkyl, -NHC (O) -NH-alkyl, -NHC (O) - N (alkyl) 2 , -Si (alkyl 3 ), optionally optionally substituted substituents of the substituent group (c) being in turn independently substituted with at least one substituent, identical or different, selected from the group consisting of:
(i) ,,-O-alkyl, -O-arylalkyl"; wobei optional der Rest Z3 unabhängig auch weiter substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(i) ,, - O-alkyl, -O-arylalkyl "; optionally wherein the radical Z3 can be further independently substituted with at least one substituent, identical or different, selected from the group consisting of:
(d) „halogen, F, Cl, Br, I, -O-alkyl"; der Rest Z4 unabhängig Wasserstoff ist; der Rest Z5 unabhängig Wasserstoff ist. In einer weiteren bevorzugten Ausführungsform werden neue Pyrido[2,3-b]pyrazin- Derivate gemäß der allgemeinen Formel (I) bereitgestellt, wobei gemäß (A) der Rest Z1 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus ,,-NHC(O)NH-ethyl, -N HC(O)N H-butyl-OH"; der Rest Z2 unabhängig Wasserstoff ist; der Rest Z3 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus „Kohlensäure-4-phenyl-ester-methyl-ester, Kohlensäure-3-phenyl-ester-2- methoxy-ethyl-ester, Kohlensäure-4-phenyl-ester-2-methoxy-ethyl-ester, Kohlen- säure-4-phenyl-ester-phenyl-ester, N-Diethyl-Carbaminsäure-4-phenyl-ester, 3- phenyl-acrylsäure-4-phenyl-ester, Nonadekansäure-4-phenyl-ester, Kohlensäure-4- phenyl-ester-isobutyl-ester, Kohlensäure-4-phenyl-ester-but-2-inyl-ester, N- Dimethyl-Carbaminsäure-4-phenyl-ester, N-Ethyl-Carbaminsäure-4-phenyl-ester, N-(4-Phenyl)-Carbaminsäure-tert-butyl-ester, N-(4-Phenyl)-Carbaminsäure-2- methoxy-ethyl-ester, 4-(3-ethyl-harnstoff)phenyl, 4-(3,3-methyl-harnstoff)phenyl, 4- morpholin-4-ylmethyl-phenyl, 4-[2-(2-methoxy-ethoxy)-ethoxy]-phenyl, N-(4-(d) "halo, F, Cl, Br, I, -O-alkyl"; the radical Z4 is independently hydrogen; the radical Z5 is independently hydrogen. In a further preferred embodiment, novel pyrido [2,3-b] pyrazine derivatives according to the general formula (I) are provided, wherein according to (A) the radical Z1 is independently selected from the group consisting of - NHC (O ) NH-ethyl, -NHC (O) NH -butyl-OH ", the radical Z2 is independently hydrogen, the radical Z3 is independently selected from the group consisting of" carbonic acid 4-phenyl-ester-methyl-ester , 3-phenyl-2-methoxyethyl carbonate, 4-phenyl-2-methoxy-4-carbon acid, 4-phenyl-4-phenylcarboxylate, N-diethyl 4-phenylcarbamate, 3-phenyl-4-phenylphenyl ester, 4-nonadaptanoic acid, 4-phenylacetate-isobutylic ester, 4-phenyl-4-carboxylic acid butyrate 2-ynyl ester, N-dimethyl-carbamic acid 4-phenyl-ester, N-ethyl-carbamic acid 4-phenyl-ester, N- (4-phenyl) -carbamic acid tert-butyl-ester, N- ( 4-phenyl) -carbamic acid-2-methoxy-ethyl-ester, 4- (3-ethyl-urea) p henyl, 4- (3,3-methylurea) phenyl, 4-morpholin-4-ylmethylphenyl, 4- [2- (2-methoxy-ethoxy) -ethoxy] -phenyl, N- (4-
Phenyl)-2-(2-methoxy-ethoxy)-acetamid, Kohlensäure-4-(2-methoxy)phenyl-ester- 2-methoxy-ethyl-ester, Kohlensäure-4-phenyl-ester-2-benzyloxy-ethyl-ester, Koh- lensäure-4-(2-methoxy)phenyl-ester-2-benzyloxy-ethyl-ester, N-(4-phenyl)-2- benzyloxy-acetamid, 3-trimethylsilanyl-phenyl, N-Diethyl-Carbaminsäure-4-(2- methoxy)phenyl-ester, N-Diethyl-Carbaminsäure-4-(2-chloro-6-methoxy)-phenyl es- ter, Kohlensäure 4-(2-methoxy)-phenyl-ester-2-[2-(2-methoxy-ethoxy)-ethoxy]-ethyl ester"; der Rest Z4 unabhängig Wasserstoff ist; der Rest Z5 unabhängig Wasserstoff ist.Phenyl) -2- (2-methoxy-ethoxy) -acetamide, 4- (2-methoxy) -phenyl-2-methoxyacetate, carbonic acid 4-phenyl-ester-2-benzyloxy-ethyl- esters, 2,4- (2-methoxy) phenyl chloroethyl 2-benzyloxyethyl ester, N- (4-phenyl) -2-benzyloxy-acetamide, 3-trimethylsilanyl-phenyl, N-diethyl-carbamic acid -4- (2-methoxy) phenyl ester, N-diethyl-carbamic acid 4- (2-chloro-6-methoxy) -phenyl ether, carbonic acid 4- (2-methoxy) -phenyl-ester-2- [2- (2-methoxy-ethoxy) -ethoxy] -ethyl ester "; the radical Z4 is independently hydrogen; the radical Z5 is independently hydrogen.
In einer weiteren bevorzugten Ausführungsform werden neue Pyrido[2,3-b]pyrazin- Derivate gemäß der allgemeinen Formel (I) bereitgestellt, wobei gemäß (B) der Rest Z1 unabhängig „NZ14Z15" ist; wobei Z14 Wasserstoff ist und Z15 „- C(O)NH-alkyl" ist; der Rest Z2 unabhängig Wasserstoff ist; der Rest Z3 unabhängig „substituiertes Heteroaryl" ist, wobei „substituiertes Hete- roaryl" substituiert ist mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:In a further preferred embodiment, novel pyrido [2,3-b] pyrazine derivatives according to the general formula (I) are provided, wherein according to (B) the radical Z1 is independently "NZ14Z15", where Z14 is hydrogen and Z15 "- C (O) NH-alkyl "; the radical Z 2 is independently hydrogen; the radical Z3 is independently "substituted heteroaryl", where "substituted heteroaryl" is substituted by at least one substituent, identical or different, selected from the group consisting of:
(a) ,,-NHC(O)-NH-alkyl"; der Rest Z4 unabhängig Wasserstoff ist; der Rest Z5 unabhängig Wasserstoff ist.(a) "- NHC (O) -NH-alkyl"; the radical Z4 is independently hydrogen; the radical Z5 is independently hydrogen.
In einer weiteren bevorzugten Ausführungsform werden neue Pyrido[2,3-b]pyrazin- Derivate gemäß der allgemeinen Formel (I) bereitgestellt, wobei gemäß (B) der Rest Z1 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus ,,-NHC(O)NH-ethyl"; der Rest Z2 unabhängig Wasserstoff ist; der Rest Z3 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus „6-(3-ethyl-harnstoff)-pyridin-3-yl"; der Rest Z4 unabhängig Wasserstoff ist; der Rest Z5 unabhängig Wasserstoff ist.In a further preferred embodiment, novel pyrido [2,3-b] pyrazine derivatives according to the general formula (I) are provided, wherein according to (B) the radical Z1 is independently selected from the group consisting of - NHC (O ) NH-ethyl "; the radical Z2 is independently hydrogen; the radical Z3 is independently selected from the group consisting of" 6- (3-ethyl-urea) -pyridin-3-yl "; the radical Z4 is independently hydrogen; the rest Z5 is independently hydrogen.
In einer weiteren bevorzugten Ausführungsform werden neue Pyrido[2,3-b]pyrazin- Derivate gemäß der allgemeinen Formel (I) bereitgestellt, wobei gemäß (C) der Rest Z1 unabhängig „NZ14Z15" ist; wobei Z14 Wasserstoff ist und Z15 „-In a further preferred embodiment, novel pyrido [2,3-b] pyrazine derivatives according to the general formula (I) are provided, wherein according to (C) the radical Z1 is independently "NZ14Z15", where Z14 is hydrogen and Z15 "
C(O)NH-alkyl" ist; der Rest Z2 unabhängig Wasserstoff ist; der Rest Z3 unabhängig „substituiertes Alkyl" ist, wobei „substituiertes Alkyl" substituiert ist mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:C (O) NH-alkyl "; Z2 is independently hydrogen; Z3 is independently" substituted alkyl "wherein" substituted alkyl "is substituted with at least one substituent, the same or different, selected from the group consisting of:
(a) „aryl, heteroaryl, cycloalkyl, -N(alkyl)2, -O-alkyl"; wobei optional obige Substituenten der Substituentengruppe (a) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (i) „halogen, F, Cl, Br, I"; der Rest Z4 unabhängig Wasserstoff ist; der Rest Z5 unabhängig Wasserstoff ist.(a) "aryl, heteroaryl, cycloalkyl, -N (alkyl) 2 , -O-alkyl"; wherein optional substituents of substituent group (a) may be independently substituted with at least one substituent, same or different, selected from among A group consisting of: (i) "halogen, F, Cl, Br, I"; the radical Z4 is independently hydrogen; the rest Z5 is independently hydrogen.
In einer weiteren bevorzugten Ausführungsform werden neue Pyrido[2,3-b]pyrazin- Derivate gemäß der allgemeinen Formel (I) bereitgestellt, wobei gemäß (C) der Rest Z1 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus ,,-NHC(O)NH-ethyl"; der Rest Z2 unabhängig Wasserstoff ist; der Rest Z3 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus „phenyl-ethinyl, thiophen-3-yl-ethinyl, cyclopropyl-ethinyl, N-Dimethyl-amino- prop-1-inyl, 2-Cyclohexyl-vinyl, 3-methoxy-propenyl, benzyl, 2-(4-fluoro-phenyl)- ethyl, 2-(4-fluoro-phenyl)-vinyl"; der Rest Z4 unabhängig Wasserstoff ist; der Rest Z5 unabhängig Wasserstoff ist.In a further preferred embodiment, novel pyrido [2,3-b] pyrazine derivatives according to the general formula (I) are provided, wherein according to (C) the radical Z1 is independently selected from the group consisting of - NHC (O ) NH-ethyl ", the radical Z 2 is independently hydrogen, the radical Z 3 is independently selected from the group consisting of" phenyl-ethynyl, thiophen-3-yl-ethynyl, cyclopropyl-ethynyl, N-dimethyl-amino-propyl 1-ynyl, 2-cyclohexyl-vinyl, 3-methoxy-propenyl, benzyl, 2- (4-fluoro-phenyl) -ethyl, 2- (4-fluoro-phenyl) -vinyl "; the radical Z4 is independently hydrogen; the rest Z5 is independently hydrogen.
In einer weiteren bevorzugten Ausführungsform werden neue Pyrido[2,3-b]pyrazin- Derivate gemäß der allgemeinen Formel (I) bereitgestellt, wobei gemäß (D) der Rest Z1 unabhängig „NZ14Z15" ist; wobei Z14 Wasserstoff ist und Z15 „- C(O)NH-alkyl" ist; der Rest Z2 unabhängig Wasserstoff ist; der Rest Z3 unabhängig ausgewählt aus der Gruppe bestehend aus: (1 ) „-NZ10Z1 1"; wobei die Reste Z10, Z11 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: (a) „Wasserstoff, aryl"; mit der Maßgabe, dass obige Substituenten der Substituentengruppe (a), wenn nicht Wasserstoff, unabhängig voneinander weiter substituiert sind mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (i) „cycloalkyl, heteroaryl, heterocyclylalkyl, -S(O)2-alkyl, -NH-S(O)2-alkyl, -C(O)NH-alkyl, -NH-C(O)-alkyl, -C(O)O-alkyl";In a further preferred embodiment, novel pyrido [2,3-b] pyrazine derivatives according to the general formula (I) are provided, wherein according to (D) the radical Z1 is independently "NZ14Z15", wherein Z14 is hydrogen and Z15 "- C (O) NH-alkyl "; the radical Z 2 is independently hydrogen; Z3 is independently selected from the group consisting of: (1) "-NZ10Z1 1"; wherein Z10, Z11 are independently selected from the group consisting of: (a) "hydrogen, aryl"; with the proviso that the above substituents of the substituent group (a), if not hydrogen, are further independently substituted with at least one substituent, same or different, selected from the group consisting of: (i) "cycloalkyl, heteroaryl, heterocyclylalkyl, -S (O) 2 -alkyl, -NH-S (O) 2 -alkyl, -C (O) NH-alkyl, -NH-C (O) -alkyl, - C (O) O-alkyl ";
(b) ,,-C(O)-aryl"; wobei optional obige Substituenten der Substituentengruppe (a) und/oder Substituentengruppe (b) unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(b) ,, - C (O) -aryl "wherein optional substituents of the substituent group (a) and / or substituent group (b) may be independently substituted with at least one substituent, same or different, selected from the group consisting of :
(i) „alkyl"; der Rest Z4 unabhängig Wasserstoff ist; der Rest Z5 unabhängig Wasserstoff ist.(i) "alkyl"; the radical Z4 is independently hydrogen; the radical Z5 is independently hydrogen.
In einer weiteren bevorzugten Ausführungsform werden neue Pyrido[2,3-b]pyrazin- Derivate gemäß der allgemeinen Formel (I) bereitgestellt, wobei gemäß (D) der Rest Z1 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus ,,-NHC(O)NH-ethyl"; der Rest Z2 unabhängig Wasserstoff ist; der Rest Z3 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus „4-methyl-benzamid, 4-cyclohexyl-phenyl-amino, 4-methansulfonyl-phenyl- amino, 3-(N-methansulfonamid)-4-methyl-phenyl-amino, 3-N-methyl-benzamid- amino, 4-piperidin-1-ylmethyl-phenyl-amino, 4-thiophen-3-ylphenyl-amino, 4-N- acetamido-phenyl-amino, 3-Benzoesäure-ethyl-ester-amino"; der Rest Z4 unabhängig Wasserstoff ist; der Rest Z5 unabhängig Wasserstoff ist.In a further preferred embodiment, novel pyrido [2,3-b] pyrazine derivatives according to the general formula (I) are provided, wherein according to (D) the radical Z1 is independently selected from the group consisting of --NHC (O ) NH-ethyl "; the radical Z 2 is independently hydrogen; the radical Z 3 is independently selected from the group consisting of" 4-methylbenzamide, 4-cyclohexyl-phenyl-amino, 4-methanesulfonyl-phenyl-amino, 3 (N-methanesulfonamide) -4-methyl-phenyl-amino, 3-N-methyl-benzamido-amino, 4-piperidin-1-ylmethyl-phenyl-amino, 4-thiophen-3-yl-phenyl-amino, 4-N- acetamido-phenyl-amino, 3-benzoic acid ethyl ester-amino "; the radical Z4 is independently hydrogen; the rest Z5 is independently hydrogen.
In einer weiteren bevorzugten Ausführungsform werden neue Pyrido[2,3-b]pyrazin-In a further preferred embodiment, new pyrido [2,3-b] pyrazine
Derivate gemäß der allgemeinen Formel (I) bereitgestellt, wobei gemäß (E) der Rest Z1 unabhängig ausgewählt ist aus der Gruppe bestehend aus:Derivatives according to the general formula (I) provided, wherein according to (E) the radical Z1 is independently selected from the group consisting of:
(a) „NZ24Z25"; wobei Z24 Wasserstoff ist und Z25 ,,-C(O)-C(O)-O-alkyl" oder „- C(O)-C(O)-N H-alkyl" oder ,,-C(O)-N H-O-alkyl" ist; wobei optional obige Substituenten der Substituentengruppe (a) unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(a) "NZ24Z25"; wherein Z24 is hydrogen and Z25 is --C (O) -C (O) -O-alkyl "or" -C (O) -C (O) -NH-alkyl "or, , -C (O) -NH-O-H-alkyl "; wherein optionally above substituents of the substituent group (a) may be independently substituted with at least one substituent, same or different, selected from the group consisting of:
(i) ,,-OSi(alkyl)3, -OC(O)-N H-alkyl, -OC(O)-O-alkyl, -P(O)(O-alkyl)2, - P(O)(OH)2, -O-alkyl"; wobei optional obige Substituenten der Substituentengruppe (i) unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „heterocyclyl, OH, -N(alkyl)2, -OC(O)-alkyl"; wobei optional obige Substituenten der Substituentengruppe (ii) unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (iii) „alkyl";(i), - OSi (alkyl) 3 , -OC (O) -NH-alkyl, -OC (O) -O-alkyl, -P (O) (O-alkyl) 2 , - P (O) (OH) 2 , -O-alkyl "; wherein optional substituents of the substituent group (i) may be further independently substituted with at least one substituent, same or different, selected from the group consisting of: (ii)" heterocyclyl, OH , -N (alkyl) 2 , -OC (O) -alkyl "; wherein optionally above substituents of the substituent group (ii) may be independently further substituted with at least one substituent, same or different, selected from the group consisting of: (iii) "alkyl";
(b) „NZ26Z27"; wobei Z26 Wasserstoff ist und Z27 ,,-C(O)-N H-alkyl" ist; mit der Maßgabe, dass obige Substituenten der Substituentengruppe (b) unabhängig voneinander weiter substituiert sind mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (i) ,,-OSi(alkyl)3, -OC(O)-N H-alkyl, -OC(O)-O-alkyl, -P(O)(O-alkyl)2, -(b) "NZ26Z27"; wherein Z26 is hydrogen and Z27 is - C (O) -NH-alkyl "; with the proviso that the above substituents of the substituent group (b) are independently further substituted with at least one substituent, same or different, selected from the group consisting of: (i), - OSi (alkyl) 3 , -OC (O) -NH-alkyl, -OC (O) -O-alkyl, -P (O) (O-alkyl) 2 , -
P(O)(OH)2, -O-alkyl"; wobei optional obige Substituenten der Substituentengruppe (i) unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe beste- hend aus:P (O) (OH) 2 , -O-alkyl "; optionally substituted substituents of the substituent group (i) may be further independently substituted with at least one substituent, same or different, selected from the group consisting of:
(ii) „heterocyclyl, OH, -N(alkyl)2, -OC(O)-alkyl"; wobei optional obige Substituenten der Substituentengruppe (ii) unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(ii) "heterocyclyl, OH, -N (alkyl) 2 , -OC (O) -alkyl" wherein optional substituents of the substituent group (ii) may be independently further substituted with at least one substituent, the same or different from the group consisting of:
(iü) „alkyl"; der Rest Z2 unabhängig Wasserstoff ist; der Rest Z3 unabhängig ausgewählt aus der Gruppe bestehend aus:(iü) "alkyl"; the radical Z 2 is independently hydrogen; the radical Z3 is independently selected from the group consisting of:
(a) „aryl"; wobei optional obige Substituenten der Substituentengruppe (a) unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(a) "aryl"; wherein optionally substituted substituents of the substituent group (a) may be independently substituted with at least one substituent, same or different, selected from the group consisting of:
(i) ,,-O-alkyl, OH"; der Rest Z4 unabhängig Wasserstoff ist; der Rest Z5 unabhängig Wasserstoff ist.(i) ,, - O-alkyl, OH "; the radical Z4 is independently hydrogen; the radical Z5 is independently hydrogen.
In einer weiteren bevorzugten Ausführungsform werden neue Pyrido[2,3-b]pyrazin- Derivate gemäß der allgemeinen Formel (I) bereitgestellt, wobei gemäß (E) der Rest Z1 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus „3-methoxy-1-yl-Harnstoff, 3-(prop-1-in-3-yl)-1-yl-Harnstoff, 3-[4-(tert-Butyl- dimethyl-silanyloxy)-butyl]-1 -yl-Harnstoff, 4-(Carbaminsäure-N-ethyl-ester)-butyl-1 - yl-Harnstoff, 4-(Kohlensäure-methyl-ester)-butyl-1 -yl-Harnstoff, 4-(Kohlensäure-2,3- dihydroxy-propyl-ester)-butyl-1 -yl-Harnstoff, 4-(Kohlensäure-2,2-dimethyl- [1 ,3]dioxolan-4ylmethyl-ester)-butyl-1 -yl-Harnstoff, 4-(Phosphorsäure-diethyl-ester)- butyl-1 -yl-Harnstoff, 4-Phosphorsäure-butyl-1 -yl-Harnstoff, N-Oxalsäure-monoamid- ethyl-ester, N-Ethyl-N'-Oxalsäure-amid, 2-(Phosphorsäure-diethyl-ester)-ethyl-1 -yl-In a further preferred embodiment, novel pyrido [2,3-b] pyrazine derivatives according to the general formula (I) are provided, wherein according to (E) the radical Z1 is independently selected from the group consisting of "3-methoxy-1 -yl-urea, 3- (prop-1-yn-3-yl) -1-yl urea, 3- [4- (tert-butyl-dimethyl-silanyloxy) -butyl] -1-yl-urea, 4 (Carbamic acid N-ethyl-ester) -butyl-1-yl-urea, 4- (carbonic acid-methyl-ester) -butyl-1-yl-urea, 4- (carbonic acid-2,3-dihydroxy-propyl) ester) -butyl-1-yl-urea, 4- (carbonic acid-2,2-dimethyl- [1,3] dioxolan-4-ylmethyl-ester) -butyl-1-yl-urea, 4- (phosphoric acid-diethyl-ester ) - butyl-1-yl-urea, 4-phosphoric-butyl-1-yl-urea, N-oxalic acid-monoamide-ethyl-ester, N-ethyl-N'-oxalic acid-amide, 2- (phosphoric acid-diethyl) ester) -ethyl-1-yl
Harnstoff, 2-Phosphorsäure-ethyl-1 -yl-Harnstoff, 3-(2-diethylamino-ethoxy)-propyl- 1 -yl-Harnstoff, 4-[2,2-Dimethyl-Propansäure-(2,2-Dimethyl-Propionyloxy-methoxy)- phospinoyloxymethyl-ester]-butyl-1 -yl-Harnstoff, 4-[Essigsäure-1-(1-acetoxy- ethoxy)-ethoxy-phospinoyloxy]-butyl-1 -yl-Harnstoff"; der Rest Z2 unabhängig Wasserstoff ist; der Rest Z3 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus „phenyl, 4-hydroxy-3-methoxy-phenyl"; der Rest Z4 unabhängig Wasserstoff ist; der Rest Z5 unabhängig Wasserstoff ist. Ein weiterer Aspekt der vorliegenden Anmeldung beschreibt neue Verbindungen aus der Reihe der Pyrido[2,3-b]pyrazine gemäß der allgemeinen Formel (II),Urea, 2-phosphoric acid ethyl-1-yl-urea, 3- (2-diethylamino-ethoxy) -propyl-1-yl-urea, 4- [2,2-dimethyl-propanoic acid (2,2-dimethyl) Propionyloxy-methoxy) -phosphino-oxymethyl-ester] -butyl-1-yl-urea, 4- [acetic acid-1- (1-acetoxy-ethoxy) -ethoxy-phosphino-oxy] -butyl-1-yl-urea ", the remainder Z2 is independently hydrogen; the radical Z3 is independently selected from the group consisting of "phenyl, 4-hydroxy-3-methoxy-phenyl"; the radical Z4 is independently hydrogen; the rest Z5 is independently hydrogen. Another aspect of the present application describes novel compounds from the series of pyrido [2,3-b] pyrazines according to the general formula (II),
worin die Substituenten R1-R4 folgende Bedeutung haben:in which the substituents R 1 -R 4 have the following meanings:
R1 und R2 können unabhängig voneinander Wasserstoff oder NR5R6 bedeuten, unter der Voraussetzung, dass, wenn R1 = NR5R6 ist, R2 = H ist, und wenn R2 = NR5R6 ist, R1 = H ist, wobei R5 Wasserstoff, Alkyl, R38, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl- Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl- Heteroaryl sein kann und die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl- und Heteroaryl-, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroarylsubstituenten ihrerseits wiederum mit F, Cl, Br, I, CN, CF3, NH2, NH-Alkyl, NH-Aryl, N(Alkyl)2, NO2, SH, S-Alkyl, OH, OCF3, O(-Alkyl-O)p- Alkyl, O-Aryl, OSO3H, OP(O)(OH)2, OP(O)(OAIkyl)2, OP(O)(OAryl)2 ,CHO, C(O)OH, C(O)OR12, C(O)NH2, C(0)NHR12, C(O)NR12R13, SO3H, SO2Alkyl, SO2Aryl, P(O)(OH)2, P(O)(OAIkyl)2, P(O)(OAryl)2, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl ein- oder mehrfach, gleich oder verschieden substituiert sein können, p den Wert O, 1 , 2, 3, 4 oder 5 annehmen kann und die Reste R12 und R13 unabhängig voneinander Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein können oder R12 und R13 zusammen einen Hete- rocyclyl-Ring bilden könnenR1 and R2 may be independently hydrogen or NR5R6, provided that when R1 = NR5R6, R2 = H, and when R2 = NR5R6, R1 = H, where R5 is hydrogen, alkyl, R38, cycloalkyl, Heterocyclic, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl and the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl- Aryl or alkyl heteroaryl substituents in turn with F, Cl, Br, I, CN, CF 3 , NH 2 , NH-alkyl, NH-aryl, N (alkyl) 2 , NO 2 , SH, S-alkyl, OH, OCF 3 , O (-alkyl-O) p -alkyl, O-aryl, OSO 3 H, OP (O) (OH) 2 , OP (O) (O-alkyl) 2 , OP (O) (O-aryl) 2 , CHO, C (O) OH, C (O) OR 12, C (O) NH 2 , C (O) NHR 12, C (O) NR 12 R 13, SO 3 H, SO 2 alkyl, SO 2 aryl, P (O) (OH) 2 , P (O) (OAlkyl) 2 , P (O) (OAryl) 2 , alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl may be mono- or polysubstituted by identical or different substituents, p is the value O, 1, 2, 3, 4 or 5 can u The radicals R 12 and R 13 can independently of one another be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl or R 12 and R 13 can together form a heterocyclyl ring
und R6:and R6:
-C(Y)NR7R8 bedeuten kann, wobei Y unabhängig voneinander O oder S sein kann und R7 und R8 unabhängig voneinander Wasserstoff,-C (Y) NR7R8, where Y can independently of one another be O or S and R7 and R8 independently of one another Hydrogen,
unsubstituiertes oder substituiertes Alkyl, wobei der Alkylrest mit F, Cl, Br, I, CF3, CN, NH2, NH-Alkyl, NH-Cycloalkyl, NH-Heterocyclyl, NH-Aryl, NH-Heteroaryl, NH-Alkyl- Cycloalkyl, NH-Alkyl-Heterocyclyl, NH-Alkyl-Aryl, NH-Alkyl-Heteroaryl, N(Alkyl)2, NHC(O)-Alkyl, NHC(O)-Cycloalkyl, NHC(O)-Heterocyclyl, NHC(O)-Aryl, NHC(O)- Heteroaryl, NHC(O)-Alkyl-Aryl, NHC(O)-Alkyl-Heteroaryl, NHSO2-Alkyl, NHSO2- Cycloalkyl, NHSO2-Heterocyclyl, NHSO2-Aryl, NHSO2-Heteroaryl, NHSO2-Alkyl-Aryl, NHSO2-Alkyl-Heteroaryl, NO2, SH, S-Alkyl, S-Cycloalkyl, S-Heterocyclyl, S-Aryl, S- Heteroaryl, OH, OCF3, O(-Alkyl-O)p-Alkyl, O-Cycloalkyl, O-Heterocyclyl, O-Aryl, O- Heteroaryl, O-Alkyl-Cycloalkyl, O-Alkyl-Heterocyclyl, O-Alkyl-Aryl, O-Alkyl-Heteroaryl, OC(O)-Alkyl, OC(O)-Cycloalkyl, OC(O)-Heterocyclyl, OC(O)-Aryl, OC(O)-Heteroaryl, OC(O)-Alkyl-Aryl, OC(O)-Alkyl-Heteroaryl, OSO3H, OSO2-Alkyl, OSO2-Cycloalkyl, O- SO2-Heterocyclyl, OSO2-Aryl, OSO2-Heteroaryl, OSO2-AI kyl-Ary I, OSO2-Alkyl- Heteroaryl, OP(O)(OH)2, C(O)-Alkyl, C(O)-Aryl, C(O)-Heteroaryl, CO2H, CO2-Alkyl, CO2-Cycloalkyl, CO2-Heterocyclyl, CO2-Aryl, CO2-H eteroaryl, CO2-Alkyl-Cycloalkyl, CO2-Alkyl-Heterocyclyl, CO2-AI kyl-Aryl, CO2-Alkyl-Heteroaryl, C(O)-NH2, C(O)NH-Alkyl, C(O)NH-Cycloalkyl, C(O)NH-Heterocyclyl, C(O)NH-Aryl, C(O)NH-Heteroaryl, C(O)NH- Alkyl-Cycloalkyl, C(O)N H-Alkyl-Heterocyclyl, C(O)N H-Alkyl-Aryl, C(O)NH-Alkyl- Heteroaryl, C(O)N(Alkyl)2, C(O)N(Cycloalkyl)2, C(O)N(Aryl)2, C(O)N(Heteroaryl)2, SO- Alkyl, SO-Aryl, SO2-Alkyl, SO2-Aryl, SO2NH2, SO2NH-Alkyl, SO2NH-Aryl, SO2NH- Heteroaryl, SO2NH-Alkyl-Aryl, SO3H, SO2O-Alkyl, SO2O-Aryl, SO2O-Alkyl-Aryl, Cycloalkyl, Heterocyclyl, Aryl oder Heteroaryl, ein- oder mehrfach, gleich oder verschieden substituiert sein kann, wobei p den Wert O, 1 , 2, 3, 4 oder 5 annehmen kann,unsubstituted or substituted alkyl, wherein the alkyl group with F, Cl, Br, I, CF 3 , CN, NH 2 , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl , NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl, N (alkyl) 2 , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -Aryl, NHC (O) -heteroaryl, NHC (O) -alkyl-aryl, NHC (O) -alkyl-heteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 Heteroaryl, NHSO 2 alkyl aryl, NHSO 2 alkyl heteroaryl, NO 2 , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S-aryl, S-heteroaryl, OH, OCF 3 , O (- Alkyl-O) p -alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, OC ( O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -Heteroaryl, OC (O) -alkyl-aryl, OC (O) -alkyl-heteroaryl , OSO 3 H, OSO 2 -alkyl, OSO 2 -cycloalkyl, O-SO 2 -heterocyclyl, OSO 2 -aryl, OSO 2 -heteroaryl, OSO 2 -alkyl-A ry I, OSO 2 alkyl heteroaryl, OP (O) (OH) 2 , C (O) alkyl, C (O) aryl, C (O) heteroaryl, CO 2 H, CO 2 alkyl, CO 2 cycloalkyl, CO 2 heterocyclyl, CO 2 aryl, CO 2 heteroaryl, CO 2 alkyl cycloalkyl, CO 2 alkyl heterocyclyl, CO 2 alkyl-aryl, CO 2 alkyl heteroaryl, C (O) -NH 2 , C (O) NH-alkyl, C (O) NH -cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O ) NH-alkyl-cycloalkyl, C (O) N H -alkyl-heterocyclyl, C (O) N H -alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , SO-alkyl, SO-aryl, SO 2 -alkyl, SO 2 -aryl, SO 2 NH 2 , SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkyl-aryl, SO 3 H, SO 2 O-alkyl, SO 2 O-aryl, SO 2 O-alkyl- Aryl, cycloalkyl, heterocyclyl, aryl or heteroaryl, mono- or polysubstituted by identical or different substituents, where p can assume the value O, 1, 2, 3, 4 or 5,
unsubstituiertes oder substituiertes Cycloalkyl, wobei der Cycloalkylrest mit F, Cl, Br, I, NH2, NH-Alkyl, NH-Cycloalkyl, NH-Heterocyclyl, NH-Aryl, NH-Heteroaryl, NH- Alkyl-Aryl, NH-Alkyl-Heteroaryl, N(Alkyl)2, NHC(O)-Alkyl, NHC(O)-Cycloalkyl, NHC(O)- Heterocyclyl, NHC(O)-Aryl, NHC(O)-Heteroaryl, NHC(O)-Alkyl-Aryl, NHC(O)-Alkyl- Heteroaryl, NHSO2-Alkyl, NHSO2-Cycloalkyl, NHSO2-Heterocyclyl, NHSO2-Aryl,unsubstituted or substituted cycloalkyl, where the cycloalkyl radical is substituted by F, Cl, Br, I, NH 2 , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl- Heteroaryl, N (alkyl) 2 , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -Heteroaryl, NHC (O) -alkyl- Aryl, NHC (O) -alkyl-heteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl,
NHSO2-Heteroaryl, NHSO2-Alkyl-Aryl, NHSO2-Alkyl-Heteroaryl, OH, O(-Alkyl-O)p-Alkyl, O-Cycloalkyl, O-Heterocyclyl, O-Aryl, O-Heteroaryl, O-Alkyl-Aryl, O-Alkyl-Heteroaryl, OC(O)-Alkyl, OC(O)-Cycloalkyl, OC(O)-Heterocyclyl, OC(O)-Aryl, OC(O)-Heteroaryl, OC(O)-Alkyl-Aryl, OC(O)-Alkyl-Heteroaryl, OSO3H, OSO2-Alkyl, OSO2-Cycloalkyl, O- SO2-Heterocyclyl, OSO2-Aryl, OSO2-Heteroaryl, OSO2-AI kyl-Ary I, OSO2-Alkyl- Heteroaryl, OP(O)(OH)2, CO2H, CO2-Alkyl, CO2-Cycloalkyl, CO2-Heterocyclyl, CO2- Aryl, CO2-Heteroaryl, CO2-AI kyl-Cycloa I kyl, CO2-Alkyl-Heterocyclyl, CO2-AI kyl-Ary I, CO2-Alkyl-Heteroaryl, C(O)-NH2, C(O)NH-Alkyl, C(O)NH-Cycloalkyl, C(O)NH- Heterocyclyl, C(O)NH-Aryl, C(O)NH-Heteroaryl, C(O)N H-Alkyl-Cycloalkyl, C(O)NH- Alkyl-Heterocyclyl, C(O)N H-Alkyl-Aryl, C(O)NH-Alkyl-Heteroaryl, C(O)N(Alkyl)2, C(O)N(Cycloalkyl)2, C(O)N(Aryl)2, C(O)N (Heteroaryl)2, Alkyl, oder Aryl ein- oder mehrfach, gleich oder verschieden substituiert sein kann, wobei p den Wert O, 1 , 2, 3, 4 oder 5 annehmen kann,NHSO 2 heteroaryl, NHSO 2 alkyl aryl, NHSO 2 alkyl heteroaryl, OH, O (alkyl-O) p alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O- Alkyl-aryl, O-alkyl-heteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) - Alkyl-aryl, OC (O) -alkyl-heteroaryl, OSO 3 H, OSO 2 -alkyl, OSO 2 -cycloalkyl, O- SO 2 -heterocyclyl, OSO 2 -aryl, OSO 2 -heteroaryl, OSO 2 -alkyl-aryl, OSO 2 -alkyl-heteroaryl, OP (O) (OH) 2 , CO 2 H, CO 2 -alkyl, CO 2 -cycloalkyl, CO 2 -heterocyclyl, CO 2 - aryl, CO 2 -heteroaryl, CO 2 -AI alkyl-Cycloa I kyl, CO 2 -alkyl-heterocyclyl, CO 2 -AI kyl-ary I, CO 2 alkyl Heteroaryl, C (O) -NH 2 , C (O) NH-alkyl, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) N H -alkyl-cycloalkyl, C (O) N-H-alkyl-heterocyclyl, C (O) N H -alkyl-aryl, C (O) -NH-alkyl-heteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , alkyl, or aryl mono- or polysubstituted by identical or different substituents, where p can assume the value 0, 1, 2, 3, 4 or 5,
unsubstituiertes oder substituiertes Heterocyclyl, wobei der Heterocyclylrest mit OH, O-Alkyl, O-Aryl, NH2, NH-Alkyl, NH-Aryl, Alkyl, Alkyl-Aryl oder Aryl ein- oder mehrfach, gleich oder verschieden substituiert sein kann,unsubstituted or substituted heterocyclyl, where the heterocyclyl radical may be mono- or polysubstituted by identical or different substituents with OH, O-alkyl, O-aryl, NH 2 , NH-alkyl, NH-aryl, alkyl, alkyl-aryl or aryl,
unsubstituiertes oder substituiertes Aryl, wobei der Arylrest mit F, Cl, Br, I, CF3, CN,unsubstituted or substituted aryl, where the aryl radical is substituted by F, Cl, Br, I, CF 3 , CN,
NH2, NH-Alkyl, NH-R38, NH-Cycloalkyl, NH-Heterocyclyl, NH-Aryl, NH-Heteroaryl, NH- Alkyl-Cycloalkyl, NH-Alkyl-Heterocyclyl, NH-Alkyl-Aryl, NH-Alkyl-Heteroaryl, NH-Alkyl- NH2, NH-Alkyl-OH, N(Alkyl)2, NHC(O)-Alkyl, NHC(O)-R38, NHC(O)-Cycloalkyl, NHC(O)-Heterocyclyl, NHC(O)-Aryl, NHC(O)-Heteroaryl, NHC(O)-Alkyl-Aryl, NHC(O)- Alkyl-Heteroaryl, NHSO2-Alkyl, NHSO2-Cycloalkyl, NHSO2-Heterocyclyl, NHSO2-Aryl, NHSO2-Heteroaryl, NHSO2-Alkyl-Aryl, NHSO2-Alkyl-Heteroaryl, NO2, SH, S-Alkyl, S- Cycloalkyl, S-Heterocyclyl, S-Aryl, S-Heteroaryl, OH, OCF3, O(-Alkyl-O)p-Alkyl, O-R38, O-Cycloalkyl, O-Heterocyclyl, O-Aryl, O-Heteroaryl, O-Alkyl-Cycloalkyl, O-Alkyl- Heterocyclyl, O-Alkyl-Aryl, O-Alkyl-Heteroaryl, O-Alkyl-OH, O-(CH2)n-O, OC(O)-Alkyl, OC(O)-R38, OC(O)-Cycloalkyl, OC(O)-Heterocyclyl, OC(O)-Aryl, OC(O)-Heteroaryl, OC(O)-Alkyl-Aryl, OC(O)-Alkyl-Heteroaryl, OSO3H, OSO2-Alkyl, OSO2-Cycloalkyl, O- SO2-Heterocyclyl, OSO2-Aryl, OSO2-Heteroaryl, OSO2-AI kyl-Ary I, OSO2-Alkyl- Heteroaryl, OP(O)(OH)2, C(O)-Alkyl, C(O)-Aryl, C(O)-Heteroaryl, CO2H, CO2-Alkyl, CO2-R38, CO2-Cycloalkyl, CO2-Heterocyclyl, CO2-Aryl, CO2-Heteroaryl, CO2-Alkyl- Cycloalkyl, CO2-Alkyl-Heterocyclyl, CO2-AI kyl-Ary I, CO2-Alkyl-Heteroaryl, C(O)-NH2, C(O)NH-Alkyl, C(O)NH-R38, C(O)N H-Cycloalkyl, C(O)NH-Heterocyclyl, C(O)NH-Aryl, C(O)N H-Heteroaryl, C(O)NH-Alkyl-Cycloalkyl, C(O)NH-Alkyl-Heterocyclyl, C(O)NH- Alkyl-Aryl, C(O)NH-Alkyl-Heteroaryl, C(O)N(Alkyl)2, C(O)N(Cycloalkyl)2, C(O)N(Aryl)2, C(O)N(Heteroaryl)2, SO-Alkyl, SO-Aryl, SO2-Alkyl, SO2-Aryl, SO2NH2, SO2NH-Alkyl, SO2NH-Aryl, SO2NH-Heteroaryl, SO2NH-Alkyl-Aryl, S03H, SO2O-Alkyl, SO2O-Aryl, SO2O-Alkyl-Aryl, Alkyl, Cycloalkyl, Heterocyclyl, Aryl oder Heteroaryl, ein- oder mehrfach, gleich oder verschieden substituiert sein kann, wobei p den Wert 0, 1 , 2, 3, 4 oder 5 und n den Wert 1 , 2 oder 3 annehmen kann,NH 2 , NH-alkyl, NH-R38, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl , NH-alkyl-NH 2 , NH-alkyl-OH, N (alkyl) 2 , NHC (O) -alkyl, NHC (O) -R38, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC ( O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl-aryl, NHC (O) -alkyl-heteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 heteroaryl, NHSO 2 alkyl aryl, NHSO 2 alkyl heteroaryl, NO 2 , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S-aryl, S-heteroaryl, OH, OCF 3 , O (-Alkyl-O) p -alkyl, O-R38, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O- Alkyl heteroaryl, O-alkyl-OH, O- (CH 2 ) n -O, OC (O) -alkyl, OC (O) -R38, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC ( O) aryl, OC (O) heteroaryl, OC (O) alkyl aryl, OC (O) alkyl heteroaryl, OSO 3 H, OSO 2 alkyl, OSO 2 cycloalkyl, O-SO 2 heterocyclyl , OSO 2 -aryl, OSO 2 -heteroaryl, OSO 2 -alkyl -Ary I, OSO 2 -alkyl- heteroaryl, OP (O) (OH) 2 , C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO 2 H, CO 2 -alkyl, CO 2 -R38, CO 2 -cycloalkyl, CO 2 -heterocyclyl, CO 2 -aryl, CO 2 -heteroaryl, CO 2 -alkyl-, cycloalkyl, CO 2 -alkyl-heterocyclyl, CO 2 -AI kyl-Ary I, CO 2 Alkyl heteroaryl, C (O) -NH 2 , C (O) NH-alkyl, C (O) NH-R38, C (O) N H -cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl-cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) -NH-alkyl-aryl, C (O) -NH-alkyl Heteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , SO-alkyl, SO-aryl , SO 2 alkyl, SO 2 -aryl, SO 2 NH 2 , SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkyl-aryl, SO 3 H, SO 2 O-alkyl, SO 2 O-aryl, SO 2 O-alkyl-aryl, alkyl, cycloalkyl, heterocyclyl, aryl or Heteroaryl, mono- or polysubstituted by identical or different substituents, p being 0, 1, 2, 3, 4 or 5 and n being 1, 2 or 3,
unsubstituiertes oder substituiertes Heteroaryl, wobei der Heteroarylrest F, Cl, Br, I, CF3, CN, NH2, NH-Alkyl, NH-R38, NH-Cycloalkyl, NH-Heterocyclyl, NH-Aryl, NH- Heteroaryl, NH-Alkyl-Cycloalkyl, NH-Alkyl-Heterocyclyl, NH-Alkyl-Aryl, NH-Alkyl- Heteroaryl, NH-Alkyl-NH2, NH-Alkyl-OH, N(Alkyl)2, NHC(O)-Alkyl, NHC(O)-R38, NHC(O)-Cycloalkyl, NHC(O)-Heterocyclyl, NHC(O)-Aryl, NHC(O)-Heteroaryl, NHC(O)- Alkyl-Aryl, NHC(O)-Alkyl-Heteroaryl, NHSO2-Alkyl, NHSO2-Cycloalkyl, NHSO2- Heterocyclyl, NHSO2-Aryl, N H SO2- Heteroaryl, NHSO2-Alkyl-Aryl, NHSO2-Alkyl- Heteroaryl, NO2, SH, S-Alkyl, S-Aryl, S-Heteroaryl, OH, OCF3, O(-Alkyl-O)p-Alkyl, O- R38, O-Cycloalkyl, O- Heterocyclyl, O-Aryl, O-Heteroaryl, O-Alkyl-Cycloalkyl, O-Alkyl- Heterocyclyl, O-Alkyl-Aryl, O-Alky I- Heteroaryl, OC(O)-Alkyl, OC(O)-R38, OC(O)- Cycloalkyl, OC(O)-Heterocyclyl, OC(O)-Aryl, OC(O)-Heteroaryl, OC(O)-Alkyl-Aryl, OC(O)-Alkyl-Heteroaryl, OSO3H, OSO2-Alkyl, OSO2-Cycloalkyl, OSO2-Heterocyclyl, OSO2-Aryl, OSO2-Heteroaryl, OSO2-Alkyl-Aryl, OSO2-AI ky I- Heteroaryl, OP(O)(OH)2, C(O)-Alkyl, C(O)-Aryl, C(O)-Heteroaryl, CO2H, CO2-Alkyl, CO2-R38, CO2-Cycloalkyl, CO2-H eterocyclyl, CO2-Aryl, CO2-Heteroaryl, CO2-Alkyl-Cycloalkyl, CO2-Alkyl-unsubstituted or substituted heteroaryl, wherein the heteroaryl group F, Cl, Br, I, CF 3, CN, NH 2, NH-alkyl, NH-R38, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH- heteroaryl, NH Alkylcycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl, NH-alkyl-NH 2 , NH-alkyl-OH, N (alkyl) 2 , NHC (O) -alkyl, NHC ( O) -R38, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl-aryl, NHC (O) -alkyl-heteroaryl , NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NH SO 2 -heteroaryl, NHSO 2 -alkyl-aryl, NHSO 2 -alkyl-heteroaryl, NO 2 , SH, S-alkyl, S-aryl, S-heteroaryl, OH, OCF 3 , O (-alkyl-O) p -alkyl, O-R 38, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O) -alkyl, OC (O) -R38, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O ) -Aryl, OC (O) -heteroaryl, OC (O) -alkyl-aryl, OC (O) -alkyl-heteroaryl, OSO 3 H, OSO 2 -alkyl, OSO 2 -cycloalkyl, OSO 2 -heterocyclyl , OSO 2 -aryl, OSO 2 -heteroaryl, OSO 2 -alkyl-aryl, OSO 2 -alkyl-heteroaryl, OP (O) (OH) 2 , C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO 2 H, CO 2 -alkyl, CO 2 -R38, CO 2 -cycloalkyl, CO 2 -H-heterocyclyl, CO 2 -aryl, CO 2 -Heteroaryl, CO 2 -alkyl-cycloalkyl, CO 2- alkyl
Heterocyclyl, CO2-AI kyl-Ary I, CO2-Alkyl-Heteroaryl, C(O)-NH2, C(O)NH-Alkyl, C(O)NH- R38, C(O)NH-Cycloalkyl, C(O)NH-Heterocyclyl, C(O)NH-Aryl, C(O)N H-Heteroaryl, C(O)NH-Alkyl-Cycloalkyl, C(O)NH-Alkyl-Heterocyclyl, C(O)NH-Alkyl-Aryl, C(O)NH- Alkyl-Heteroaryl, C(O)N(Alkyl)2, C(O)N(Cycloalkyl)2, C(O)N(Aryl)2, C(O)N(Heteroaryl)2, SO2NH2, SO2NH-Alkyl, SO2NH-Aryl, SO2NH-Heteroaryl, SO2NH-Alkyl-Aryl, SO3H,Heterocyclyl, CO 2 -alkyl-aryl, CO 2 -alkyl-heteroaryl, C (O) -NH 2 , C (O) -NH-alkyl, C (O) -NH-R 38, C (O) -NH-cycloalkyl, C (O) NH heterocyclyl, C (O) NH aryl, C (O) N H heteroaryl, C (O) NH alkyl cycloalkyl, C (O) NH alkyl heterocyclyl, C (O) NH -Alkyl-aryl, C (O) -NH-alkyl-heteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (Heteroaryl) 2 , SO 2 NH 2 , SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkyl-aryl, SO 3 H,
SO2O-Alkyl, SO2O-Aryl, SO2O-AI kyl-Aryl, Alkyl, Cycloalkyl, Heterocyclyl, Aryl oder Heteroaryl, ein- oder mehrfach, gleich oder verschieden substituiert sein kann, wobei p den Wert 0, 1 , 2, 3, 4 oder 5 annehmen kann,SO 2 O-alkyl, SO 2 O-aryl, SO 2 O-Al kyl-aryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, mono- or polysubstituted by identical or different substituents, where p is the value 0, 1 , 2, 3, 4 or 5,
-C(O)-R39, wobei R39 Alkyl, Aryl oder Heteroaryl sein kann, und die Alkyl-, Aryl- und Heteroarylsubstituenten ihrerseits wiederum substituiert sein können,-C (O) -R39, where R39 can be alkyl, aryl or heteroaryl, and the alkyl, aryl and heteroaryl substituents in turn can be substituted,
sein können, oder R7 und R8 zusammen einen Heterocyclyl-Ring bilden können, R3 und R4 können unabhängig voneinander:or R7 and R8 can together form a heterocyclyl ring, R3 and R4 can be independent of each other:
Wasserstoff, wobei R3 und R4 nicht gleichzeitig Wasserstoff sind,Hydrogen, wherein R3 and R4 are not simultaneously hydrogen,
substituiertes Alkyl, wobei der Alkylrest mit F, Cl, Br, I, CN, CF3, NH2, NH-Alkyl, NH- Aryl, N(Alkyl)2, SH, S-Alkyl, OH, OCF3, O(-Alkyl-O)p-Alkyl, O-Aryl, OSO3H, OP(O)(OH)2, OP(O)(OAIkyl)2, OP(O)(OAryl)2, C(O)OH, C(0)0R14, C(O)NH2, C(0)NHR14, C(O)NR14R15, SO3H, SO2Alkyl, SO2Aryl, P(O)(OH)2, P(O)(OAIkyl)2, P(O)(OAryl)2, Cycloalkyl, Heterocyclyl, Aryl oder Heteroaryl ein- oder mehrfach, gleich oder verschieden substituiert ist, wobei p den Wert 0, 1 , 2, 3, 4 oder 5 annehmen kann und die Reste R14 und R15 unabhängig voneinander Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl- Heteroaryl sein können oder R14 und R15 zusammen einen Heterocyclyl-Ring bilden können,substituted alkyl, wherein the alkyl radical with F, Cl, Br, I, CN, CF 3 , NH 2 , NH-alkyl, NH-aryl, N (alkyl) 2 , SH, S-alkyl, OH, OCF 3 , O ( -Alkyl-O) p -alkyl, O-aryl, OSO 3 H, OP (O) (OH) 2 , OP (O) (OAalkyl) 2 , OP (O) (O-aryl) 2 , C (O) OH, C (0) 0R14, C (O) NH 2, C (0) NHR14, C (O) NR14R15, SO 3 H, SO 2 alkyl, SO 2 aryl, P (O) (OH) 2, P (O) (OAlkyl) 2 , P (O) (OAryl) 2 , cycloalkyl, heterocyclyl, aryl or heteroaryl mono- or polysubstituted by identical or different substituents, where p can take the value 0, 1, 2, 3, 4 or 5 and R14 and R15 independently of one another may be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, or R14 and R15 may together form a heterocyclyl ring,
substituiertes Aryl, wobei der Arylrest ein- oder mehrfach, gleich oder verschieden substituiert ist mit Substituenten ausgewählt aus der Gruppe NH-Alkyl, NH-Cycloalkyl, NH-Heterocyclyl, NH-Aryl, NH-Heteroaryl, NH-Alkyl-Cycloalkyl, NH-Alkyl-Heterocyclyl, NH-Alkyl-Aryl, NH-Alkyl-Heteroaryl, N(Alkyl)2, N(Aryl)2, NHC(O)-Alkyl, NHC(O)- Cycloalkyl, NHC(O)-Heterocyclyl, NHC(O)-Aryl, NHC(O)-Heteroaryl, NHC(O)-Alkyl- Aryl, NHC(O)-Alkyl-Heteroaryl, NHSO2-Alkyl, NHSO2-Cycloalkyl, NHSO2-Heterocyclyl, NHSO2-Aryl, N H SO2- Heteroaryl, NHSO2-Alkyl-Aryl, NHSO2-Alkyl-Heteroaryl, S-Alkyl, S-Aryl, S-Heteroaryl, O-Alkyl, O-Cycloalkyl, O-Heterocyclyl, O-Aryl, O-Heteroaryl, O- Alkyl-Cycloalkyl, O-Alkyl-Heterocyclyl, O-Alkyl-Aryl, O-Alkyl-Heteroaryl, OC(O)-Alkyl, OC(O)-Cycloalkyl, OC(O)-Heterocyclyl, OC(O)-Aryl, OC(O)-Heteroaryl, OC(O)-Alkyl- Aryl, OC(O)-Alkyl-Heteroaryl, OSO2-Alkyl, OSO2-Cycloalkyl, OSO2-Heterocyclyl, OSO2- Aryl, OSO2-Heteroaryl, OSO2-AI kyl-Ary I, OSO2-Alkyl-Heteroaryl, C(O)-Alkyl, C(O)-Aryl, C(O)-Heteroaryl, CO2-Alkyl, CO2-CyCl oa I kyl, CO2-Heterocyclyl, CO2-Aryl, CO2- Heteroaryl, CO2-Alkyl-Cycloalkyl, CO2-Alkyl-Heterocyclyl, CO2-Alkyl-Aryl, CO2-Alkyl- Heteroaryl, C(O)NH-Alkyl, C(O)NH-Cycloalkyl, C(O)NH-Heterocyclyl, C(O)NH-Aryl, C(O)N H-Heteroaryl, C(O)NH-Alkyl-Cycloalkyl, C(O)NH-Alkyl-Heterocyclyl, C(O)NH- Alkyl-Aryl, C(O)NH-Alkyl-Heteroaryl, C(O)N(Alkyl)2, C(O)N(Cycloalkyl)2, C(O)N(Aryl)2, C(O)N(Heteroaryl)2, SO-Alkyl, SO-Aryl, SO2-Alkyl, SO2-Aryl, SO2NH-Alkyl, SO2NH-Aryl, SO2NH-Heteroaryl, SO2NH-Alkyl-Aryl, SO2O-Alkyl, SO2O-Aryl, SO2O-AI kyl-Ary I, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl und die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl- , Heteroaryl-, Alkyl-Cycloalkyl-, Alkyl-Heterocyclyl-, Alkyl-Aryl- und Alkyl- Heteroarylsubstituenten ihrerseits wiederum mit O(-Alkyl-O)p-Alkyl, OP(O)(OAIkyl)2, OP(O)(OAryl)2, C(O)OR16, C(O)NH2, C(O)NHR16, C(O)NR16R17, SO2Alkyl, SO2Aryl, P(O)(OH)2, P(O)(OAIkyl)2, P(O)(OAryl)2, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl oder Alkylaryl substituiert sind, wobei p den Wert 1 , 2, 3, 4 oder 5 annehmen kann und die Reste R16 und R17 unabhängig voneinander Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein kön- nen oder R16 und R17 zusammen einen Heterocyclyl-Ring bilden können, unter der Voraussetzung, dass, wenn R3 oder R4 Alkyl-Heterocyclyl-substituiertes Aryl bedeutet, entsprechend R4 bzw. R3 ≠ Aryl ist,substituted aryl, where the aryl radical is mono- or polysubstituted by identical or different substituents selected from the group consisting of NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl, NH-- Alkyl heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl, N (alkyl) 2 , N (aryl) 2 , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl-aryl, NHC (O) -alkyl-heteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl , NH SO 2 - heteroaryl, NHSO 2 alkyl aryl, NHSO 2 alkyl heteroaryl, S-alkyl, S-aryl, S-heteroaryl, O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O Heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC ( O) -aryl, OC (O) -heteroaryl, OC (O) -alkyl-aryl, OC (O) -alkyl-heteroaryl, OSO 2 -alkyl, OSO 2 -cycloalkyl, OSO 2 -heterocyclyl, OSO 2 -aryl, OSO 2 heteroaryl, OSO 2 -alkyl-aryl I, OSO 2 -alkyne l-heteroaryl, C (O) -alkyl, C (O) -aryl, C (O) -Heteroaryl, CO 2 -alkyl, CO 2 -cycloalkyl, CO 2 -heterocyclyl, CO 2 -aryl, CO 2 - heteroaryl, CO 2 alkyl cycloalkyl, CO 2 alkyl heterocyclyl, CO 2 alkyl aryl, CO 2 alkyl heteroaryl, C (O) NH alkyl, C (O) NH cycloalkyl, C (O ) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl-cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-alkyl- Aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , SO-alkyl, SO-aryl, SO 2 -alkyl, SO 2 -aryl, SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkyl-aryl, SO 2 O-alkyl, SO 2 O-aryl, SO 2 O-Al kyl-Ary I, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and the alkyl, Cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl and alkyl-heteroaryl substituents in turn with O (-alkyl-O) p- alkyl, OP (O) (OAlkyl ) 2 , OP (O) (O-aryl) 2 , C (O) OR 16, C (O) NH 2 , C (O) NHR 16, C (O) NR 16 R 17, SO 2 alkyl, SO 2 aryl, P (O) ( OH) 2 , P (O) (OAlkyl) 2 , P (O) (OAryl) 2 , cycloalkyl, heterocyclyl, aryl, heteroaryl or alkylaryl, where p can be 1, 2, 3, 4 or 5 and R16 and R17 may be independently alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, or R16 and R17 may together form a heterocyclyl ring, under which Provided that when R 3 or R 4 is alkyl-heterocyclyl-substituted aryl, R 4 or R 3 is ≠ aryl,
und wobei der Arylrest ein- oder mehrfach, gleich oder verschieden substituiert ist mit Substituenten ausgewählt aus der Gruppe NR20-Alkyl, NH-R38, NHC(O)-R38, NR19C(O)-Alkyl, NR19C(O)-Cycloalkyl, NR19C(O)-Heterocyclyl, NR19C(O)-Aryl, NR19C(O)-Heteroaryl, NR18C(O)-Alkyl-Cycloalkyl, NR18C(O)-Alkyl-Heterocyclyl, NR19C(0)-Alkyl-Aryl, NR19C(O)-Alkyl-Heteroaryl, NR18C(O)O-RI 9, NR18C(O)NR18R18, O-R38, OC(O)-R38, OC(O)-Alkyl-Cycloalkyl, OC(O)-Alkyl- Heterocyclyl, OC(O)O-RI 9, OC(O)NRI 8R18, OP(O)(OAIkyl)2, OP(O)(OAryl)2, C(O)O- R38, C(O)NH-R38, C(O)N R20-Alkyl, C(O)NRI 9-Alkyl-R21 , C(O)NRI 80-R18, C(O)NRI 8NR18R18 und die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl-, Heteroaryl-, Alkyl- Cycloalkyl-, Alkyl-Heterocyclyl-, Alkyl-Aryl- und Alkyl-Heteroarylsubstituenten ihrerseits wiederum mit F, Cl, Br, I, CN, CF3, NH2, NH-Alkyl, NH-Aryl, N(Alkyl)2, NO2, SH, S-Alkyl, OH, OCF3, O(-Alkyl-O)p-Alkyl, O-Aryl, OSO3H, OP(O)(OH)2, OP(O)(OAIkyl)2,and wherein the aryl radical is mono- or polysubstituted by identical or different substituents selected from the group consisting of NR20-alkyl, NH-R38, NHC (O) -R38, NR19C (O) -alkyl, NR19C (O) -cycloalkyl, NR19C (O) -heterocyclyl, NR19C (O) -aryl, NR19C (O) -heteroaryl, NR18C (O) -alkyl-cycloalkyl, NR18C (O) -alkyl-heterocyclyl, NR19C (O) -alkyl-aryl, NR19C (O ) -Alkyl-heteroaryl, NR18C (O) O-RI9, NR18C (O) NR18R18, O-R38, OC (O) -R38, OC (O) -alkyl-cycloalkyl, OC (O) -alkyl-heterocyclyl, OC (O) O-RI 9, OC (O) NRI 8R18, OP (O) (OAlkyl) 2 , OP (O) (O-Aryl) 2 , C (O) O-R38, C (O) NH-R38, C (O) N R 20 alkyl, C (O) NR I 9 alkyl R 21, C (O) NRI 80 R 18, C (O) NR I 8 N R 18 R 18 and the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl -, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl and alkyl heteroaryl substituents in turn with F, Cl, Br, I, CN, CF 3 , NH 2 , NH-alkyl, NH-aryl, N (alkyl ) 2 , NO 2 , SH, S-alkyl, OH, OCF 3 , O (-alkyl-O) p -alkyl, O-aryl, OSO 3 H, OP (O) (OH) 2 , OP (O) ( OAlkyl) 2 ,
OP(O)(OAryl)2, CHO, C(O)OH, C(O)OR22, C(O)NH2, C(O)NHR22, C(O)NR22R23, SO3H, SO2Alkyl, SO2Aryl, P(O)(OH)2, P(O)(OAIkyl)2, P(O)(OAryl)2, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl oder Alkylaryl substituiert sein können, wobei p den Wert O, 1 , 2, 3, 4 oder 5 annehmen kann und die Reste R22 und R23 unabhängig voneinan- der Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein können oder R22 und R23 zusammen einen Heterocyclyl-Ring bilden können, substituiertes Heteroaryl, wobei der Heteroarylrest ein- oder mehrfach, gleich oder verschieden substituiert ist mit Substituenten ausgewählt aus der Gruppe NH-Alkyl, NH-Cycloalkyl, NH-Heterocyclyl, NH-Aryl, NH-Heteroaryl, NH-Alkyl-Cycloalkyl, NH- Alkyl-Heterocyclyl, NH-Alkyl-Aryl, NH-Alkyl-Heteroaryl, N(Alkyl)2, N(Aryl)2, NHC(O)- Alkyl, NHC(O)-Cycloalkyl, NHC(O)-Heterocyclyl, NHC(O)-Aryl, NHC(O)-Heteroaryl, NHC(O)-Alkyl-Aryl, NHC(O)-Alkyl-Heteroaryl, NHSO2-Alkyl, NHSO2-Cycloalkyl, NHSO2-Heterocyclyl, NHSO2-Aryl, N H SO2- Heteroaryl, NHSO2-Alkyl-Aryl, NHSO2-Alkyl- Heteroaryl, S-Alkyl, S-Aryl, S-Heteroaryl, O-Alkyl, O-Cycloalkyl, O-Aryl, O-Heteroaryl, O-Alkyl-Cycloalkyl, O-Alkyl-Heterocyclyl, O-Alkyl-Aryl, O-Alkyl-Heteroaryl, OC(O)-Alkyl, OC(O)-Cycloalkyl, OC(O)-Heterocyclyl, OC(O)-Aryl, OC(O)-Heteroaryl, OC(O)-Alkyl- Aryl, OC(O)-Alkyl-Heteroaryl, OSO2-Alkyl, OSO2-Cycloalkyl, OSO2-Heterocyclyl, OSO2- Aryl, OSO2-Heteroaryl, OSO2-AI kyl-Ary I, OSO2-Alkyl-Heteroaryl, C(O)-Alkyl, C(O)-Aryl, C(O)-Heteroaryl, CO2-Alkyl, CO2-CyCl oa I kyl, CO2-Heterocyclyl, CO2-Aryl, CO2- Heteroaryl, CO2-Alkyl-Cycloalkyl, COMlkyl-Heterocyclyl, CO2-Alkyl-Aryl, CO2-Alkyl- Heteroaryl, C(O)NH-Alkyl, C(O)NH-Cycloalkyl, C(O)NH-Heterocyclyl, C(O)NH-Aryl, C(O)N H-Heteroaryl, C(O)NH-Alkyl-Cycloalkyl, C(O)NH-Alkyl-Heterocyclyl, C(O)NH- Alkyl-Aryl, C(O)NH-Alkyl-Heteroaryl, C(O)N(Alkyl)2, C(O)N(Cycloalkyl)2, C(O)N(Aryl)2, C(O)N(Heteroaryl)2, SO2NH-Alkyl, SO2NH-Aryl, SO2NH-Heteroaryl, SO2NH-Alkyl-Aryl, SO2O-Alkyl, SO2O-Aryl, SO2O-Alkyl-Aryl, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroa- ryl und die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl-, Heteroaryl-, Alkyl-Cycloalkyl-, Alkyl- Heterocyclyl-, Alkyl-Aryl- und Alkyl-Heteroarylsubstituenten ihrerseits wiederum mit 0(- Alkyl-O)p-Alkyl, OP(O)(OAIkyl)2, OP(O)(OAryl)2, C(O)OR16, C(O)NH2, C(O)NHR16, C(O)NRI 6R17, SO2Alkyl, SO2Aryl, P(O)(OH)2, P(O)(OAIkyl)2, P(O)(OAryl)2, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl oder Alkylaryl substituiert sind, wobei p den Wert 1 , 2, 3, 4 oder 5 annehmen kann und die Reste R16 und R17 unabhängig voneinander Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein können oder R16 und R17 zusammen einen Heterocyclyl- Ring bilden können,OP (O) (O-aryl) 2, CHO, C (O) OH, C (O) OR22, C (O) NH 2, C (O) NHR 22, C (O) NR22R23, SO 3 H, SO 2 alkyl, SO 2 aryl, P (O) (OH) 2 , P (O) (OAlkyl) 2 , P (O) (O-aryl) 2 , alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or alkylaryl may be substituted, wherein p is the value O, 1, 2, 3, 4 or 5 and the radicals R22 and R23 independently of one another alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl can be or R 22 and R 23 may together form a heterocyclyl ring, substituted heteroaryl, where the heteroaryl radical is mono- or polysubstituted by identical or different substituents selected from the group consisting of NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl, NH-- Alkyl heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl, N (alkyl) 2 , N (aryl) 2 , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl-aryl, NHC (O) -alkyl-heteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl , NH SO 2 - heteroaryl, NHSO 2 alkyl aryl, NHSO 2 alkyl heteroaryl, S-alkyl, S-aryl, S-heteroaryl, O-alkyl, O-cycloalkyl, O-aryl, O-heteroaryl, O -Alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl , OC (O) heteroaryl, OC (O) alkyl aryl, OC (O) alkyl heteroaryl, OSO 2 alkyl, OSO 2 cycloalkyl, OSO 2 heterocyclyl, OSO 2 aryl, OSO 2 heteroaryl , OSO 2 -Alkyl-Ary I, OSO 2 -alkyl-He teroaryl, C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO 2 -alkyl, CO 2 -cycloalkyl, CO 2 -heterocyclyl, CO 2 -aryl, CO 2 -heteroaryl , C 2 -C 4 -alkyl-cycloalkyl, C 1 -C 4 -alkyl-heterocyclyl, C 2 -alkyl-aryl, C 2 -alkyl-heteroaryl, C (O) -NH-alkyl, C (O) -NH-cycloalkyl, C (O) -H-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl-cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) -NH-alkyl-aryl, C (O ) NH-alkyl-heteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , SO 2 NH Alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkyl-aryl, SO 2 O-alkyl, SO 2 O-aryl, SO 2 O-alkyl-aryl, alkyl, cycloalkyl, heterocyclyl, aryl , Heteroaryl and the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl and alkyl heteroaryl substituents themselves in turn with 0 (-alkyl-O) p Alkyl, OP (O) (OAlkyl) 2 , OP (O) (OAryl) 2 , C (O) OR 16, C (O) NH 2 , C (O) NHR 16, C (O) NRI 6 R 17, SO 2 alkyl , SO 2 aryl, P (O) (OH) 2 , P (O) (Oalkyl) 2 , P (O) (O-aryl) 2 , Cycloalkyl, heterocyclyl, aryl, heteroaryl or alkylaryl are substituted, where p can assume the value 1, 2, 3, 4 or 5 and the radicals R16 and R17 are independently alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl Heterocyclyl, alkyl-aryl or alkyl-heteroaryl or R 16 and R 17 may together form a heterocyclyl ring,
und wobei der Heteroarylrest ein- oder mehrfach, gleich oder verschieden substituiert ist mit Substituenten ausgewählt aus der Gruppe NR20-Alkyl, NH-R38, NHC(O)- R38, NR19C(0)-Alkyl, NR19C(O)-Cycloalkyl, NR19C(O)-Heterocyclyl, NR19C(0)-Aryl, NR19C(O)-Heteroaryl, NR18C(O)-Alkyl-Cycloalkyl, NR18C(O)-Alkyl-Heterocyclyl, NR19C(0)-Alkyl-Aryl, NR19C(O)-Alkyl-Heteroaryl, NR18C(O)O-RI 9, NR18C(O)NR18R18, NHSO2-Alkyl-Heterocyclyl, O-R38, O- Heterocyclyl, OC(O)-R38, OC(O)-Alkyl-Cycloalkyl, OC(O)-Alkyl-Heterocyclyl, OC(O)O-RI 9, OC(O)NRI 8R18, OP(O)(OAIkyl)2, OP(O)(OAryl)2, C(O)O-R38, C(O)NH-R38, C(O)NR20-Alkyl, C(O)NRI 9-Alkyl-R21 , C(O)NRI 8O-R18, C(O)NRI 8NR18R18 und die Alkyl-, Cycloal- kyl-, Heterocyclyl-, Aryl-, Heteroaryl-, Alkyl-Cycloalkyl-, Alkyl-Heterocyclyl-, Alkyl-Aryl- und Alkyl-Heteroarylsubstituenten ihrerseits wiederum mit F, Cl, Br, I, CN, CF3, NH2, NH-Alkyl, NH-Aryl, N(Alkyl)2, NO2, SH, S-Alkyl, OH, OCF3, O(-Alkyl-O)p-Alkyl, O-Aryl, OSO3H, OP(O)(OH)2, OP(O)(OAIkyl)2, OP(O)(OAryl)2, CHO, C(O)OH, C(O)OR22, C(O)NH2, C(O)NHR22, C(O)NR22R23, SO3H, SO2Alkyl, SO2Aryl, P(O)(OH)2, P(O)(OAIkyl)2, P(O)(OAryl)2, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl oder Alky- laryl substituiert sein können, wobei p den Wert 0, 1 , 2, 3, 4 oder 5 annehmen kann und die Reste R22 und R23 unabhängig voneinander Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl- Heteroaryl sein können oder R22 und R23 zusammen einen Heterocyclyl-Ring bilden können,and wherein the heteroaryl radical is substituted one or more times, identically or differently, with substituents selected from the group consisting of NR20-alkyl, NH-R38, NHC (O) -R38, NR19C (O) -alkyl, NR19C (O) -cycloalkyl, NR19C (O) -heterocyclyl, NR19C (O) -aryl, NR19C (O) -heteroaryl, NR18C (O) -alkyl-cycloalkyl, NR18C (O) -alkyl-heterocyclyl, NR19C (O) -alkyl-aryl, NR19C (O ) alkyl-heteroaryl, NR18C (O) O-RI 9, NR18C (O) NR18R18, NHSO 2 -alkyl-heterocyclyl, O-R38, O-heterocyclyl, OC (O) -R38, OC (O) -alkyl-cycloalkyl, OC (O) -alkyl-heterocyclyl, OC (O) O-RI 9, OC (O) NRI 8R18, OP (O) (OAlkyl) 2 , OP (O) (O-aryl) 2 , C (O) O-R38, C (O) NH-R38, C (O) NR20-alkyl, C (O) NRl9-alkyl-R21, C (O) NRl8 O-R18, C (O) NRI 8NR18R18 and the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl and alkyl heteroaryl substituents themselves in turn with F, Cl, Br, I, CN, CF 3 , NH 2 , NH-alkyl, NH-aryl, N (alkyl) 2 , NO 2 , SH, S-alkyl, OH, OCF 3 , O (-alkyl-O) p- alkyl, O-aryl , OSO 3 H, OP (O) (OH) 2 , OP (O) (OAlkyl) 2 , OP (O) (OAryl) 2 , CHO, C (O) OH, C (O) OR 22, C (O) NH 2 , C (O) NHR22, C (O) NR 22 R 23, SO 3 H, SO 2 alkyl, SO 2 aryl, P (O) (OH) 2 , P (O) (Oalkyl) 2 , P (O) ( O-aryl) 2 , alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or alkylaryl, where p can assume the value 0, 1, 2, 3, 4 or 5 and the radicals R22 and R23 independently of one another alkyl, cycloalkyl, Heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl o may be the alkyl heteroaryl or R22 and R23 may together form a heterocyclyl ring,
NR24R25, wobei R24 -C(O)-R26, -SO2R26, -C(O)OR26 oder -C(O)-NR27R28 sein kann und wobei R25 Wasserstoff, Alkyl, Cycloalkyl, Aryl oder Heteroaryl sein kann und wobei R26 Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl- Heterocyclyl, Alkyl-Aryl, Alkyl-Heteroaryl sein kann, und R27 und R28 unabhängig voneinander Wasserstoff, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl- Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl, Alkyl-Heteroaryl sein können, oder R27 und R28 zusammen einen Heterocyclyl-Ring bilden können und die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl- und Heteroaryl-, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroarylsubstituenten ihrerseits wiederum substituiert sein können,NR24R25, wherein R24 is -C (O) -R26, -SO2 R26, -C (O) OR26 or -C (O) -NR27R28 wherein R25 and may be hydrogen, alkyl, cycloalkyl, aryl or heteroaryl may be, and wherein R26 Alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl, alkyl-heteroaryl, and R 27 and R 28 independently of one another are hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, Alkyl heterocyclyl, alkyl aryl, alkyl heteroaryl, or R27 and R28 may together form a heterocyclyl ring and the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, alkyl cycloalkyl, alkyl heterocyclyl, Alkyl-aryl or alkyl-heteroaryl substituents in turn may be substituted,
und R18 Wasserstoff, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-and R 18 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl
Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein kann,May be cycloalkyl, alkyl heterocyclyl, alkyl aryl or alkyl heteroaryl,
und R19 Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl- Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein kann,and R 19 may be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl,
und R20 Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl- Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein kann, und R21 Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl sein kann,and R 20 can be cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl, and R 21 can be cycloalkyl, heterocyclyl, aryl, heteroaryl,
und R38 Alkyl sein kann, wobei der Alkylrest gesättigt oder ungesättigt, geradkettig oder verzweigt sein kann, mit 9 bis 30 C-Atomen, d.h. C9-30-Alkanyle, C9-30-Alkenyle und Cg-30-Alkinyle. Dabei weisen Alkenyle mindestens eine C-C-Doppelbindung und Alkinyle mindestens eine C-C-Dreifachbindung auf, wobei die Alkenyle sowohl in (E)- als auch in (Z)-Konformation vorliegen können. Es ist bevorzugt, dass der Alkylrest ausgewählt ist aus der Gruppe, die nonyl, decyl, dodecyl, hexadecyl, octadecyl, eico- syl, henicosyl, docosyl, tetracosyl, nonacosyl, octadecenyl, docosenyl, tetracosenyl und octadecinyl enthält,and R 38 may be alkyl, wherein the alkyl radical may be saturated or unsaturated, straight-chain or branched, having 9 to 30 carbon atoms, ie C 9 - 30 alkynyls, C 9 - 30 alkenyls and Cg-30-alkynyls. In this case, alkenyls have at least one CC double bond and alkynyls at least one C-C triple bond, wherein the alkenyls can be present both in (E) - and in (Z) - conformation. It is preferred that the alkyl radical is selected from the group comprising nonyl, decyl, dodecyl, hexadecyl, octadecyl, eicosyl, henicosyl, docosyl, tetracosyl, nonacosyl, octadecenyl, docosenyl, tetracosenyl and octadecinyl,
bedeuten.mean.
Gemäß einem weiteren Aspekt werden in der vorliegenden Anmeldung neue Verbindungen aus der Reihe der Pyrido[2,3-b]pyrazine gemäß der allgemeinen Formel (II) beschrieben,In a further aspect, the present application describes novel compounds from the series of pyrido [2,3-b] pyrazines according to the general formula (II),
worin die Substituenten R1-R4 folgende Bedeutung haben:in which the substituents R 1 -R 4 have the following meanings:
R1 und R2 können unabhängig voneinander Wasserstoff oder NR5R6 bedeuten, unter der Voraussetzung, dass, wenn R1 = NR5R6 ist, R2 = H ist, und wenn R2 = NR5R6 ist, R1 = H ist, wobei R5 Wasserstoff, Alkyl, R38, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl- Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl- Heteroaryl sein kann und die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl- und Heteroaryl-, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroarylsubstituenten ihrerseits wiederum mit F, Cl, Br, I, CN, CF3, NH2, NH-Alkyl, NH-Aryl, N(Alkyl)2, NO2, SH, S-Alkyl, OH, OCF3, O(-Alkyl-O)p- Alkyl, O-Aryl, OSO3H, OP(O)(OH)2, OP(O)(OAIkyl)2, OP(O)(OAryl)2, CHO, C(O)OH, C(O)NH2, C(0)0R12, C(0)NHR12, C(O)NR12R13, SO3H, SO2Alkyl, SO2Aryl, P(O)(OH)2, P(O)(OAIkyl)2, P(O)(OAryl)2, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl ein- oder mehrfach, gleich oder verschieden substituiert sein können, p den Wert O, 1 , 2, 3, 4 oder 5 annehmen kann und die Reste R12 und R13 unabhängig voneinander Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein können oder R12 und R13 zusammen einen Hete- rocyclyl-Ring bilden könnenR1 and R2 may be independently hydrogen or NR5R6, provided that when R1 = NR5R6, R2 = H, and when R2 = NR5R6, R1 = H, where R5 is hydrogen, alkyl, R38, cycloalkyl, Heterocyclic, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl and the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl- Aryl or alkyl heteroaryl substituents in turn with F, Cl, Br, I, CN, CF 3 , NH 2 , NH-alkyl, NH-aryl, N (alkyl) 2 , NO 2 , SH, S-alkyl, OH, OCF 3 , O (-alkyl-O) p -alkyl, O-aryl, OSO 3 H, OP (O) (OH) 2 , OP (O) (OAlkyl) 2 , OP (O) (OAryl) 2 , CHO, C (O) OH, C (O) NH 2 , C (O) OR12 , C (0) NHR12, C (O) NR12R13, SO 3 H, SO 2 alkyl, SO 2 aryl, P (O) (OH) 2, P (O) (OAIkyl) 2, P (O) (OAryl) 2 , alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl mono- or polysubstituted by identical or different substituents, p can assume the value O, 1, 2, 3, 4 or 5 and the radicals R12 and R13 independently of one another alkyl, cycloalkyl , Heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl or R12 and R13 may together form a heterocyclyl ring
und R6:and R6:
-C(O)NR9-Y-R10 bedeuten kann, wobei Y unabhängig voneinander O oder NR1 1 sein kann-C (O) NR 9 -Y-R 10, where Y can independently of one another be O or NR 1
und R9 Wasserstoff, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl- Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl, Alkyl-Heteroaryl sein kann und die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl- und Heteroaryl-, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroarylsubstituenten ihrerseits substituiert sein können,and R9 may be hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl and the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, alkyl Cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl substituents in turn may be substituted,
und R10 und R1 1 unabhängig voneinanderand R10 and R1 1 are independent of each other
Wasserstoff,Hydrogen,
unsubstituiertes oder substituiertes Alkyl,unsubstituted or substituted alkyl,
unsubstituiertes oder substituiertes Cycloalkyl, unsubstituiertes oder substituiertes Heterocyclyl, wobei der Heterocyclylrest mit OH, O-Alkyl, O-Aryl, NH2, NH-Alkyl, NH-Aryl, Alkyl, Alkyl-Aryl oder Aryl ein- oder mehrfach, gleich oder verschieden substituiert sein kann,unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, where the heterocyclyl radical may be mono- or polysubstituted by identical or different substituents with OH, O-alkyl, O-aryl, NH 2 , NH-alkyl, NH-aryl, alkyl, alkyl-aryl or aryl,
unsubstituiertes oder substituiertes Aryl, wobei der Arylrest mit F, Cl, Br, I, CF3, CN,unsubstituted or substituted aryl, where the aryl radical is substituted by F, Cl, Br, I, CF 3 , CN,
NH2, NH-Alkyl, NH-R38, NH-Cycloalkyl, NH-Heterocyclyl, NH-Aryl, NH-Heteroaryl, NH- Alkyl-Cycloalkyl, NH-Alkyl-Heterocyclyl, NH-Alkyl-Aryl, NH-Alkyl-Heteroaryl, NH-Alkyl- NH2, NH-Alkyl-OH, N(Alkyl)2, NHC(O)-Alkyl, NHC(O)-R38, NHC(O)-Cycloalkyl, NHC(O)-Heterocyclyl, NHC(O)-Aryl, NHC(O)-Heteroaryl, NHC(O)-Alkyl-Aryl, NHC(O)- Alkyl-Heteroaryl, NHSO2-Alkyl, NHSO2-Cycloalkyl, NHSO2-Heterocyclyl, NHSO2-Aryl, NHSO2-Heteroaryl, NHSO2-Alkyl-Aryl, NHSO2-Alkyl-Heteroaryl, NO2, SH, S-Alkyl, S- Cycloalkyl, S-Heterocyclyl, S-Aryl, S-Heteroaryl, OH, OCF3, O(-Alkyl-O)p-Alkyl, O-R38, O-Cycloalkyl, O-Heterocyclyl, O-Aryl, O-Heteroaryl, O-Alkyl-Cycloalkyl, O-Alkyl- Heterocyclyl, O-Alkyl-Aryl, O-Alkyl-Heteroaryl, O-Alkyl-OH, O-(CH2)n-O, OC(O)-Alkyl, OC(O)-R38, OC(O)-Cycloalkyl, OC(O)-Heterocyclyl, OC(O)-Aryl, OC(O)-Heteroaryl, OC(O)-Alkyl-Aryl, OC(O)-Alkyl-Heteroaryl, OSO3H, OSO2-Alkyl, OSO2-Cycloalkyl, OSO2-Heterocyclyl, OSO2-Aryl, OSO2-Heteroaryl, OSO2-AI kyl-Ary I, OSO2-Alkyl- Heteroaryl, OP(O)(OH)2, C(O)-Alkyl, C(O)-Aryl, C(O)-Heteroaryl, CO2H, CO2-Alkyl, CO2-R38, CO2-Cycloalkyl, CO2-Heterocyclyl, CO2-Aryl, CO2-Heteroaryl, CO2-Alkyl- Cycloalkyl, CO2-Alkyl-Heterocyclyl, CO2-AI kyl-Ary I, CO2-Alkyl-Heteroaryl, C(O)-NH2, C(O)NH-Alkyl, C(O)NH-R38, C(O)N H-Cycloalkyl, C(O)NH-Heterocyclyl, C(O)NH-Aryl, C(O)N H-Heteroaryl, C(O)NH-Alkyl-Cycloalkyl, C(O)NH-Alkyl-Heterocyclyl, C(O)NH- Alkyl-Aryl, C(O)NH-Alkyl-Heteroaryl, C(O)N(Alkyl)2, C(O)N(Cycloalkyl)2, C(O)N(Aryl)2, C(O)N(Heteroaryl)2, SO-Alkyl, SO-Aryl, SO2-Alkyl, SO2-Aryl, SO2NH2, SO2NH-Alkyl, SO2NH-Aryl, SO2NH-Heteroaryl, SO2NH-Alkyl-Aryl, S03H, SO2O-Alkyl, SO2O-Aryl, SO2O-Alkyl-Aryl, Alkyl, Cycloalkyl, Heterocyclyl, Aryl oder Heteroaryl, ein- oder mehrfach, gleich oder verschieden substituiert sein kann, wobei p den Wert O, 1 , 2, 3, 4 oder 5 und n den Wert 1 , 2 oder 3 annehmen kann,NH 2 , NH-alkyl, NH-R38, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl , NH-alkyl-NH 2 , NH-alkyl-OH, N (alkyl) 2 , NHC (O) -alkyl, NHC (O) -R38, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC ( O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl-aryl, NHC (O) -alkyl-heteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 heteroaryl, NHSO 2 alkyl aryl, NHSO 2 alkyl heteroaryl, NO 2 , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S-aryl, S-heteroaryl, OH, OCF 3 , O (-Alkyl-O) p -alkyl, O-R38, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O- Alkyl heteroaryl, O-alkyl-OH, O- (CH 2 ) n -O, OC (O) -alkyl, OC (O) -R38, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC ( O) aryl, OC (O) heteroaryl, OC (O) alkyl aryl, OC (O) alkyl heteroaryl, OSO 3 H, OSO 2 alkyl, OSO 2 cycloalkyl, OSO 2 heterocyclyl, OSO 2 -aryl, OSO 2 -Heteroaryl, OSO 2 -AI kyl-A ry I, OSO 2 alkyl heteroaryl, OP (O) (OH) 2 , C (O) alkyl, C (O) aryl, C (O) heteroaryl, CO 2 H, CO 2 alkyl, CO 2 -R38, CO 2 -cycloalkyl, CO 2 -heterocyclyl, CO 2 -aryl, CO 2 -heteroaryl, CO 2 -alkyl-, cycloalkyl, CO 2 -alkyl-heterocyclyl, CO 2 -alkyl-aryl I, CO 2 - Alkyl heteroaryl, C (O) -NH 2 , C (O) NH-alkyl, C (O) NH-R 38, C (O) N H -cycloalkyl, C (O) NH-heterocyclyl, C (O) NH -Aryl, C (O) NH-heteroaryl, C (O) NH-alkyl-cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) -NH-alkyl-aryl, C (O) -NH-alkyl- Heteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , SO-alkyl, SO-aryl, SO 2 alkyl, SO 2 -aryl, SO 2 NH 2 , SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkyl-aryl, SO 3 H, SO 2 O-alkyl, SO 2 O-aryl, SO 2 O-alkyl-aryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, mono- or polysubstituted by identical or different substituents, where p is the value O, 1, 2, 3, 4 or 5 and n can take the value 1, 2 or 3,
unsubstituiertes oder substituiertes Heteroaryl, wobei der Heteroarylrest F, Cl, Br, I,unsubstituted or substituted heteroaryl, where the heteroaryl radical F, Cl, Br, I,
CF3, CN, NH2, NH-Alkyl, NH-R38, NH-Cycloalkyl, NH-Heterocyclyl, NH-Aryl, NH- Heteroaryl, NH-Alkyl-Cycloalkyl, NH-Alkyl-Heterocyclyl, NH-Alkyl-Aryl, NH-Alkyl- Heteroaryl, NH-Alkyl-NH2, NH-Alkyl-OH, N(Alkyl)2, NHC(O)-Alkyl, NHC(O)-R38, NHC(O)-Cycloalkyl, NHC(O)-Heterocyclyl, NHC(O)-Aryl, NHC(O)-Heteroaryl, NHC(O)- Alkyl-Aryl, NHC(O)-Alkyl-Heteroaryl, NHSO2-Alkyl, NHSO2-Cycloalkyl, NHSO2- Heterocyclyl, NHSO2-Aryl, NHSO2-Heteroaryl, NHSO2-Alkyl-Aryl, NHSO2-Alkyl- Heteroaryl, NO2, SH, S-Alkyl, S-Aryl, S-Heteroaryl, OH, OCF3, O(-Alkyl-O)p-Alkyl, O- R38, O-Cycloalkyl, O-Heterocyclyl, O-Aryl, O-Heteroaryl, O-Alkyl-Cycloalkyl, O-Alkyl- Heterocyclyl, O-Alkyl-Aryl, O-Alkyl-Heteroaryl, OC(O)-Alkyl, OC(O)-R38, OC(O)- Cycloalkyl, OC(O)-Heterocyclyl, OC(O)-Aryl, OC(O)-Heteroaryl, OC(O)-Alkyl-Aryl, OC(O)-Alkyl-Heteroaryl, OSO3H, OSO2-Alkyl, OSO2-Cycloalkyl, OSO2-Heterocyclyl, OSO2-Aryl, OSO2-Heteroaryl, OSO2-Alkyl-Aryl, OSO2-Alkyl-Heteroaryl, OP(O)(OH)2, C(O)-Alkyl, C(O)-Aryl, C(O)-Heteroaryl, CO2H, CO2-Alkyl, CO2-R38, CO2-Cycloalkyl, CO2-H eterocyclyl, CO2-Aryl, CO2-Heteroaryl, CO2-Alkyl-Cycloalkyl, CO2-Alkyl-CF 3 , CN, NH 2 , NH-alkyl, NH-R38, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl, NH-alkyl-NH 2 , NH-alkyl-OH, N (alkyl) 2 , NHC (O) -alkyl, NHC (O) -R38, NHC (O) -cycloalkyl, NHC (O) Heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) - Alkyl-aryl, NHC (O) -alkyl-heteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 -heteroaryl, NHSO 2 -alkyl-aryl, NHSO 2 -alkyl- Heteroaryl, NO 2 , SH, S-alkyl, S-aryl, S-heteroaryl, OH, OCF 3 , O (-alkyl-O) p -alkyl, O-R 38, O-cycloalkyl, O-heterocyclyl, O-aryl , O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O) -alkyl, OC (O) -R38, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkyl-aryl, OC (O) -alkyl-heteroaryl, OSO 3 H, OSO 2 -alkyl, OSO 2 Cycloalkyl, OSO 2 -heterocyclyl, OSO 2 -aryl, OSO 2 -heteroaryl, OSO 2 -alkyl-aryl, OSO 2 -alkyl-heteroaryl, OP (O) (OH) 2 , C (O) -alkyl, C ( O) -aryl, C (O) -heteroaryl, CO 2 H, CO 2 -alkyl, CO 2 -R38, CO 2 -cycloalkyl, CO 2 -H-heterocyclyl, CO 2 -aryl, CO 2 -heteroaryl, CO 2 - Alkyl-cycloalkyl, CO 2 -alkyl-
Heterocyclyl, CO2-AI kyl-Ary I, CO2-Alkyl-Heteroaryl, C(O)-NH2, C(O)NH-Alkyl, C(O)NH- R38, C(O)NH-Cycloalkyl, C(O)NH-Heterocyclyl, C(O)NH-Aryl, C(O)N H-Heteroaryl, C(O)NH-Alkyl-Cycloalkyl, C(O)NH-Alkyl-Heterocyclyl, C(O)NH-Alkyl-Aryl, C(O)NH- Alkyl-Heteroaryl, C(O)N(Alkyl)2, C(O)N(Cycloalkyl)2, C(O)N(Aryl)2, C(O)N(Heteroaryl)2, SO2NH2, SO2NH-Alkyl, SO2NH-Aryl, SO2NH-Heteroaryl, SO2NH-Alkyl-Aryl, SO3H,Heterocyclyl, CO 2 -alkyl-aryl, CO 2 -alkyl-heteroaryl, C (O) -NH 2 , C (O) -NH-alkyl, C (O) -NH-R 38, C (O) -NH-cycloalkyl, C (O) NH heterocyclyl, C (O) NH aryl, C (O) N H heteroaryl, C (O) NH alkyl cycloalkyl, C (O) NH alkyl heterocyclyl, C (O) NH -Alkyl-aryl, C (O) -NH-alkyl-heteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (Heteroaryl) 2 , SO 2 NH 2 , SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkyl-aryl, SO 3 H,
SO2O-Alkyl, SO2O-Aryl, SO2O-AI kyl-Aryl, Alkyl, Cycloalkyl, Heterocyclyl, Aryl oder He- teroaryl, ein- oder mehrfach, gleich oder verschieden substituiert sein kann, wobei p den Wert 0, 1 , 2, 3, 4 oder 5 annehmen kann,SO 2 O-alkyl, SO 2 O-aryl, SO 2 O-Al kyl-aryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, may be mono- or polysubstituted by identical or different substituents, where p is the value 0 , 1, 2, 3, 4 or 5,
sein können, oder R10 und R11 zusammen einen Heterocyclyl-Ring bilden können,or R10 and R11 can together form a heterocyclyl ring,
R3 und R4 können unabhängig voneinander:R3 and R4 can be independent of each other:
Wasserstoffhydrogen
Hydroxylhydroxyl
Halogen, wie Fluor, Chlor, Brom, lodHalogen, such as fluorine, chlorine, bromine, iodine
unsubstituiertes oder substituiertes Alkyl, wobei der Alkylrest mit F, Cl, Br, I, CN,unsubstituted or substituted alkyl, wherein the alkyl radical with F, Cl, Br, I, CN,
CF3, NH2, NH-Alkyl, NH-Aryl, N(Alkyl)2, SH, S-Alkyl, OH, OCF3, O(-Alkyl-O)p-Alkyl, O- Aryl, OSO3H, OP(O)(OH)2, OP(O)(OAIkyl)2, OP(O)(OAryl)2, C(O)OH, C(O)ORI 4, C(O)NH2, C(0)NHR14, C(O)NR14R15, SO3H, SO2Alkyl, SO2Aryl, P(O)(OH)2, P(O)(OAIkyl)2, P(O)(OAryl)2, Cycloalkyl, Heterocyclyl, Aryl oder Heteroaryl ein- oder mehrfach, gleich oder verschieden substituiert sein kann, wobei p den Wert 0, 1 , 2, 3, 4 oder 5 annehmen kann und die Reste R14 und R15 unabhängig voneinander Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein können oder R14 und R15 zusammen einen Heterocyclyl- Ring bilden können,CF 3 , NH 2 , NH-alkyl, NH-aryl, N (alkyl) 2 , SH, S-alkyl, OH, OCF 3 , O (-alkyl-O) p -alkyl, O- Aryl, OSO 3 H, OP (O) (OH) 2 , OP (O) (OAlkyl) 2 , OP (O) (O-aryl) 2 , C (O) OH, C (O) ORI 4, C (O) NH 2 , C (O) NHR 14, C (O) NR 14 R 15, SO 3 H, SO 2 alkyl, SO 2 aryl, P (O) (OH) 2 , P (O) (Oalkyl) 2 , P (O) ( OAryl) 2 , cycloalkyl, heterocyclyl, aryl or heteroaryl may be monosubstituted or polysubstituted by identical or different substituents, where p may assume the value 0, 1, 2, 3, 4 or 5 and the radicals R14 and R15 independently of one another alkyl, Cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl, or R 14 and R 15 may together form a heterocyclyl ring,
unsubstituiertes oder substituiertes Aryl, wobei der Arylrest mit F, Cl, Br, I, CF3, CN,unsubstituted or substituted aryl, where the aryl radical is substituted by F, Cl, Br, I, CF 3 , CN,
NH2, NH-Alkyl, NH-R38, NH-Cycloalkyl, NH-Heterocyclyl, NH-Aryl, NH-Heteroaryl, NH- Alkyl-Cycloalkyl, NH-Alkyl-Heterocyclyl, NH-Alkyl-Aryl, NH-Alkyl-Heteroaryl, N(Alkyl)2, N(Aryl)2, NR20-Alkyl, NHC(O)-Alkyl, NHC(O)-R38, NR19(0)-Alkyl, NHC(O)-Cycloalkyl, NR19C(O)-Cycloalkyl, NHC(O)-Heterocyclyl, NR19C(O)-Heterocyclyl, NHC(O)-Aryl, NR19C(0)-Aryl, NHC(O)-Heteroaryl, NR19C(O)-Heteroaryl, NR18C(0)-Alkyl-NH 2 , NH-alkyl, NH-R38, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl , N (alkyl) 2 , N (aryl) 2 , NR20-alkyl, NHC (O) -alkyl, NHC (O) -R38, NR19 (0) -alkyl, NHC (O) -cycloalkyl, NR19C (O) - Cycloalkyl, NHC (O) -heterocyclyl, NR19C (O) -heterocyclyl, NHC (O) -aryl, NR19C (O) -aryl, NHC (O) -Heteroaryl, NR19C (O) -Heteroaryl, NR18C (O) -alkyl -
Cycloalkyl, NR18C(O)-Alkyl-Heterocyclyl, NHC(O)-Alkyl-Aryl, NR19C(0)-Alkyl-Aryl, NHC(O)-Alkyl-Heteroaryl, NR19C(O)-Alkyl-Heteroaryl, NR18C(O)O-RI 9, NR18C(O)NR18R18, NHSO2-Alkyl, NHSO2-Cycloalkyl, NHSO2-Heterocyclyl, NHSO2- Aryl, NHSO2-Heteroaryl, NHSO2-Alkyl-Heterocyclyl, NHSO2-Alkyl-Aryl, NHSO2-Alkyl- Heteroaryl, NO2, SH, S-Alkyl, S-Aryl, S-Heteroaryl, OH, OCF3, O-Alkyl, O-R38, O- Cycloalkyl, O-Heterocyclyl, O-Aryl, O-Heteroaryl, O-Alkyl-Cycloalkyl, O-Alkyl- Heterocyclyl, O-Alkyl-Aryl, O-Alkyl- Heteroaryl, O-(CH2)n-O, OC(O)-Alkyl, OC(O)-R38, OC(O)-Cycloalkyl, OC(O)-Heterocyclyl, OC(O)-Aryl, OC(O)-Heteroaryl, OC(O)-Alkyl- Cycloalkyl, OC(O)-Alkyl-Heterocyclyl OC(O)-Alkyl-Aryl, OC(O)-Alkyl-Heteroaryl, 0C(0)0-R19, OC(O)NR18R18, OSO3H, OSO2-Alkyl, OSO2-Cycloalkyl, OSO2-Cycloalkyl, NR18C (O) alkyl heterocyclyl, NHC (O) alkyl aryl, NR19C (O) alkyl aryl, NHC (O) alkyl heteroaryl, NR19C (O) alkyl heteroaryl, NR18C (O ) O-RI 9, NR 18 C (O) NR 18 R 18, NHSO 2 alkyl, NHSO 2 cycloalkyl, NHSO 2 heterocyclyl, NHSO 2 aryl, NHSO 2 heteroaryl, NHSO 2 alkyl heterocyclyl, NHSO 2 alkyl aryl , NHSO 2 alkyl heteroaryl, NO 2 , SH, S-alkyl, S-aryl, S-heteroaryl, OH, OCF 3 , O-alkyl, O-R 38, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, O- (CH 2 ) n -O, OC (O) -alkyl, OC (O) - R38, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkyl-cycloalkyl, OC (O) -alkyl-heterocyclyl OC (O ) -Alkyl-aryl, OC (O) -alkyl-heteroaryl, 0C (O) O-R 19, OC (O) NR 18 R 18, OSO 3 H, OSO 2 -alkyl, OSO 2 -cycloalkyl, OSO 2 -
Heterocyclyl, OSO2-Aryl, OSO2-Heteroaryl, OSO2-Alkyl-Aryl, OSO2-AI ky I- Heteroaryl, OP(O)(OH)2, OP(O)(OAIkyl)2, OP(O)(OAryl)2, C(O)-Alkyl, C(O)-Aryl, C(O)-Heteroaryl, CO2H, CO2-Alkyl, CO2-R38, CO2-Cycloalkyl, CO2-Heterocyclyl, CO2-Aryl, CO2- Heteroaryl, CO2-Alkyl-Cycloalkyl, CO2-Alkyl-Heterocyclyl, CO2-Alkyl-Aryl, CO2-Alkyl- Heteroaryl, C(O)-NH2, C(O)NH-Alkyl, C(O)NH-R38, C(O)N H-Cycloalkyl, C(O)NH- Heterocyclyl, C(O)NH-Aryl, C(O)NH-Heteroaryl, C(O)N H-Alkyl-Cycloalkyl, C(O)NH- Alkyl-Heterocyclyl, C(O)N H-Alkyl-Aryl, C(O)NH-Alkyl-Heteroaryl, C(O)N(Alkyl)2, C(O)N(Cycloalkyl)2, C(O)N(Aryl)2, C(O)N(Heteroaryl)2, C(O)N R20-Alkyl, C(O)NRI 9- Alkyl-R21 , -C(O)NRI 80-R18, -C(O)NR18NR18R18, SO-Alkyl, SO-Aryl, SO2-Alkyl, SO2-Aryl, SO2NH2, SO2NH-Alkyl, SO2NH-Aryl, SO2NH-Heteroaryl, SO2NH-Alkyl-Aryl, SO3H, SO2O-Alkyl, SO2O-Aryl, SO2O-AI kyl-Ary I, Alkyl, Alkyl-Cycloalkyl, Alkyl- Heterocyclyl, Alkyl-Aryl, Alkyl-Heteroaryl, Cycloalkyl, Heterocyclyl, Aryl oder Heteroaryl, ein- oder mehrfach, gleich oder verschieden substituiert sein kann, n den Wert 1 ,2 oder 3 annehmen kann, und die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl-, Heteroaryl-, Alkyl- Cycloalkyl-, Alkyl-Heterocyclyl-, Alkyl-Aryl- und Alkyl-Heteroarylsubstituenten ihrerseits wiederum substituiert sein können,Heterocyclyl, OSO 2 -aryl, OSO 2 -heteroaryl, OSO 2 -alkyl-aryl, OSO 2 -alkyl-heteroaryl, OP (O) (OH) 2 , OP (O) (OAlkyl) 2 , OP (O) (O-aryl) 2 , C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO 2 H, CO 2 -alkyl, CO 2 -R38, CO 2 -cycloalkyl, CO 2 -heterocyclyl, CO 2 -aryl, CO 2 - heteroaryl, CO 2 -alkyl-cycloalkyl, CO 2 -alkyl-heterocyclyl, CO 2 -alkyl-aryl, CO 2 -alkyl heteroaryl C (O) -NH 2, C (O) NH-alkyl, C (O) NH-R38, C (O) NH -cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) N H-alkylcycloalkyl, C (O) NH-alkylheterocyclyl, C (O) NH -alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) 2 , C (O ) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , C (O) N R 20 alkyl, C (O) NRI 9 alkyl R21, -C ( O) NRI 80-R18, -C (O) NR 18 NR 18 R 18, SO-alkyl, SO-aryl, SO 2 -alkyl, SO 2 -aryl, SO 2 NH 2 , SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkyl-aryl, SO 3 H, SO 2 O-alkyl, SO 2 O-aryl, SO 2 O-Al kyl-Ary I, alkyl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl, alkyl-heteroaryl, cycloalkyl, heterocyclyl, aryl or Heteroaryl, mono- or polysubstituted by identical or different substituents, n can assume the value 1, 2 or 3, and the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl cycloalkyl, alkyl heterocyclyl -, alkyl-aryl and alkyl-heteroaryl substituents in turn may be substituted,
unsubstituiertes oder substituiertes Heteroaryl, wobei der Heteroarylrest mit F, Cl, Br, I, CF3, CN, NH2, NH-Alkyl, NH-R38, NH-Cycloalkyl, NH-Heterocyclyl, NH-Aryl, NH- Heteroaryl, NH-Alkyl-Cycloalkyl, NH-Alkyl-Heterocyclyl, NH-Alkyl-Aryl, NH-Alkyl- Heteroaryl, N(Alkyl)2, N(Aryl)2, NR20-Alkyl, NHC(O)-Alkyl, NHC(O)-R38, NR19C(O)- Alkyl, NHC(O)-Cycloalkyl, NR19C(O)-Cycloalkyl, NHC(O)-Heterocyclyl, NR19C(O)- Heterocyclyl, NHC(O)-Aryl, NR19C(O)-Aryl, NHC(O)-Heteroaryl, NR19C(O)-Heteroaryl, NR18C(O)-Alkyl-Cycloalkyl, NR18C(O)-Alkyl-Heterocyclyl, NHC(O)-Alkyl-Aryl, NR19C(O)-Alkyl-Aryl, NHC(O)-Alkyl-Heteroaryl, NR19C(O)-Alkyl-Heteroaryl,unsubstituted or substituted heteroaryl, wherein the heteroaryl radical with F, Cl, Br, I, CF 3 , CN, NH 2 , NH-alkyl, NH-R38, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH Alkyl-cycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl, N (alkyl) 2 , N (aryl) 2 , NR20-alkyl, NHC (O) -alkyl, NHC (O) -R38, NR19C (O) -alkyl, NHC (O) -cycloalkyl, NR19C (O) -cycloalkyl, NHC (O) -heterocyclyl, NR19C (O) -heterocyclyl, NHC (O) -aryl, NR19C (O) - Aryl, NHC (O) heteroaryl, NR19C (O) heteroaryl, NR18C (O) alkyl cycloalkyl, NR18C (O) alkyl heterocyclyl, NHC (O) alkyl aryl, NR19C (O) alkyl Aryl, NHC (O) -alkyl-heteroaryl, NR19C (O) -alkyl-heteroaryl,
NR18C(O)O-R19, NR18C(O)NR18R18, NHSO2-Alkyl, NHSO2-Cycloalkyl, NHSO2- Heterocyclyl, NHSO2-Aryl, N H SO2- Heteroaryl, NHSO2-Alkyl-Heterocyclyl, NHSO2-Alkyl- Aryl, NHSO2-Alkyl-Heteroaryl, NO2, SH, S-Alkyl, S-Aryl, S-Heteroaryl, OH, OCF3, O- Alkyl, O-R38, O-Cycloalkyl, O-Heterocyclyl, O-Aryl, O-Heteroaryl, O-Alkyl-Cycloalkyl, O-Alkyl-Heterocyclyl, O-Alkyl-Aryl, O-Alkyl-Heteroaryl, OC(O)-Alkyl, OC(O)-R38,NR18C (O) O-R19, NR18C (O) NR18R18, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 - heterocyclyl, NHSO 2 -aryl, SO 2 NH - heteroaryl, NHSO 2 -alkyl-heterocyclyl, NHSO2 - Alkyl-aryl, NHSO 2 -alkyl-heteroaryl, NO 2 , SH, S-alkyl, S-aryl, S-heteroaryl, OH, OCF 3 , O-alkyl, O-R 38, O-cycloalkyl, O-heterocyclyl, O -Aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O) -alkyl, OC (O) -R38,
OC(O)-Cycloalkyl, OC(O)-Heterocyclyl, OC(O)-Aryl, OC(O)-Heteroaryl, OC(O)-Alkyl- Cycloalkyl, OC(O)-Alkyl-Heterocyclyl OC(O)-Alkyl-Aryl, OC(O)-Alkyl-Heteroaryl, OC(O)O-R19, OC(O)NR18R18, OSO3H, OSO2-Alkyl, OSO2-Cycloalkyl, OSO2- Heterocyclyl, OSO2-Aryl, OSO2-Heteroaryl, OSO2-Alkyl-Aryl, OSO2-AI ky I- Heteroaryl, OP(O)(OH)2, OP(O)(OAIkyl)2, OP(O)(OAryl)2, C(O)-Alkyl, C(O)-Aryl, C(O)-Heteroaryl, CO2H, CO2-Alkyl, CO2-R38, CO2-Cycloalkyl, CO2-Heterocyclyl, CO2-Aryl, CO2- Heteroaryl, CO2-Alkyl-Cycloalkyl, CO2-Alkyl-Heterocyclyl, CO2-Alkyl-Aryl, CO2-Alkyl- Heteroaryl, C(O)-NH2, C(O)NH-Alkyl, C(O)NH-R38, C(O)N H-Cycloalkyl, C(O)NH- Heterocyclyl, C(O)NH-Aryl, C(O)NH-Heteroaryl, C(O)N H-Alkyl-Cycloalkyl, C(O)NH- Alkyl-Heterocyclyl, C(O)N H-Alkyl-Aryl, C(O)NH-Alkyl-Heteroaryl, C(O)N(Alkyl)2,OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkyl-cycloalkyl, OC (O) -alkyl-heterocyclyl OC (O) - alkyl-aryl, OC (O) -alkyl-heteroaryl, OC (O) O-R19, OC (O) NR18R18, OSO 3 H, OSO 2 -alkyl, OSO 2 -cycloalkyl, OSO 2 - heterocyclyl, OSO 2 -aryl , OSO 2 heteroaryl, OSO 2 alkyl aryl, OSO 2 alkyl ky I heteroaryl, OP (O) (OH) 2 , OP (O) (OAlkyl) 2 , OP (O) (OAryl) 2 , C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO 2 H, CO 2 -alkyl, CO 2 -R38, CO 2 -cycloalkyl, CO 2 -heterocyclyl, CO 2 -aryl, CO 2 - heteroaryl, CO 2 -alkyl-cycloalkyl, CO 2 -alkyl-heterocyclyl, CO 2 -alkyl-aryl, CO 2 -alkyl-heteroaryl, C (O) -NH 2 , C (O) -NH-alkyl, C ( O) NH-R38, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl-cycloalkyl, C (O) NH-alkyl heterocyclyl, C (O) N H -alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) 2 ,
C(O)N(Cycloalkyl)2, C(O)N(Aryl)2, C(O)N(Heteroaryl)2, C(O)N R20-Alkyl, C(O)NRI 9- Alkyl-R21 , -C(O)NRI 80-R18, -C(O)NRI 8NR18R18, SO2NH2, SO2NH-Alkyl, SO2NH- Aryl, SO2NH-Heteroaryl, SO2NH-Alkyl-Aryl, S03H, SO2O-Alkyl, SO2O-Aryl, SO2O- Alkyl-Aryl, Alkyl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl, Alkyl-Heteroaryl, Cyc- loalkyl, Heterocyclyl, Aryl oder Heteroaryl ein- oder mehrfach, gleich oder verschieden substituiert sein kann, und die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl-, Heteroaryl-, Al- kyl-Cycloalkyl-, Alkyl-Heterocyclyl-, Alkyl-Aryl- und Alkyl-Heteroarylsubstituenten ihrerseits wiederum substituiert sein können,C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , C (O) N R 20 alkyl, C (O) NRI 9 alkyl R21, -C (O) NRI 80-R18, -C (O) NRI 8NR 18 R 18, SO 2 NH 2 , SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkyl-aryl, SO 3 H , SO 2 O-alkyl, SO 2 O-aryl, SO 2 O-alkyl-aryl, alkyl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl, alkyl-heteroaryl, cycloalkyl, heterocyclyl, aryl or heteroaryl or several times, the same or different may be substituted, and the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl and alkyl heteroaryl substituents in turn may be substituted,
OR29, wobei R29 Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl,OR29, where R29 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl,
Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein kann, und die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl-, Heteroaryl-, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroarylsubstituenten ihrerseits wiederum substituiert sein können,Alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl, and the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl substituents in turn may be substituted can,
SR30, wobei R30 Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl,SR30, where R30 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl,
Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein kann, und die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl- und Heteroaryl-, Alkyl-Cycloalkyl-, Alkyl-Heterocyclyl-, Alkyl- Aryl- oder Alkyl-Heteroarylsubstituenten ihrerseits wiederum substituiert sein können,Alkyl heterocyclyl, alkyl aryl or alkyl heteroaryl, and the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, alkyl cycloalkyl, alkyl heterocyclyl, alkyl aryl or alkyl heteroaryl substituents in turn may be substituted again,
NR31 R32, wobei R31 und R32 unabhängig voneinander Wasserstoff, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl, Alkyl-Heteroaryl, -C(O)-R33, -SO2R33, -C(O)OR33 und -C(O)-NR34R35 sein können, wobei R33 Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl- Heterocyclyl, Alkyl-Aryl, Alkyl-Heteroaryl sein kann, und R34 und R35 unabhängig voneinander Wasserstoff, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl- Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl, Alkyl-Heteroaryl sein können oder R34 und R35 zusammen einen Heterocyclyl-Ring bilden können, oder R31 und R32 zusammen einen Heterocyclyl-Ring bilden können, und die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl- und Heteroaryl-, Alkyl-Cycloalkyl, Al- kyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroarylsubstituenten ihrerseits wiederum substituiert sein können,NR31 R32, wherein R31 and R32 are independently hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl, alkyl-heteroaryl, -C (O) -R33, -SO2 R33, -C (O) OR33 and -C (O) -NR34R35, where R33 can be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl, and R34 and R35 independently of one another may be hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl, or R34 and R35 may together form a heterocyclyl ring, or together R31 and R32 Can form heterocyclyl ring, and the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl substituents in turn can be substituted,
und R18 Wasserstoff, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl- Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein kann, und R19 Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl- Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein kann,and R18 can be hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, and R 19 may be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl,
und R20 Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl- Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein kann,and R 20 can be cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl,
und R21 Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl sein kann,and R 21 can be cycloalkyl, heterocyclyl, aryl, heteroaryl,
und R38 Alkyl sein kann, wobei der Alkylrest gesättigt oder ungesättigt, geradkettig oder verzweigt sein kann, mit 9 bis 30 C-Atomen, d.h. C9-3o-Alkanyle, C9-3o-Alkenyle und Cg-30-Alkinyle. Dabei weisen Alkenyle mindestens eine C-C-Doppelbindung und Alkinyle mindestens eine C-C-Dreifachbindung auf, wobei die Alkenyle sowohl in (E)- als auch in (Z)-Konformation vorliegen können. Es ist bevorzugt, dass der Alkylrest ausgewählt ist aus der Gruppe, die nonyl, decyl, dodecyl, hexadecyl, octadecyl, eico- syl, henicosyl, docosyl, tetracosyl, nonacosyl, octadecenyl, docosenyl, tetracosenyl und octadecinyl enthält,and R38 may be alkyl, where the alkyl radical is saturated or unsaturated, may be straight or branched, having from 9 to 30 carbon atoms, ie C 9-3 o-alkanyls, C 9-3 o-alkenyls and alkynyls Cg 30. In this case, alkenyls have at least one CC double bond and alkynyls at least one C-C triple bond, wherein the alkenyls can be present both in (E) - and in (Z) - conformation. It is preferred that the alkyl radical is selected from the group comprising nonyl, decyl, dodecyl, hexadecyl, octadecyl, eicosyl, henicosyl, docosyl, tetracosyl, nonacosyl, octadecenyl, docosenyl, tetracosenyl and octadecinyl,
bedeuten.mean.
Besonders bevorzugt sind Pyrido[2,3-b]pyrazin-Derivate der allgemeinen FormelParticularly preferred are pyrido [2,3-b] pyrazine derivatives of the general formula
(II), wobei R2 = H ist.(II) where R2 = H.
Weiterhin besonders bevorzugt sind Pyrido[2,3-b]pyrazin-Derivate der allgemeinen Formel (II), wobei R2 und R4 = H sind.Particular preference is furthermore given to pyrido [2,3-b] pyrazine derivatives of the general formula (II) where R 2 and R 4 are H.
Besonders bevorzugt sind dabei die folgenden Pyrido[2,3-b]pyrazin-Derivate der allgemeinen Formeln (I) und (II), die in Form ihrer freien Base oder auch als pharmazeutisch annehmbare Salze physiologisch verträglicher Säuren vorliegen können: Verbindung 1 1-Ethyl-3-(3-phenylethinyl-pyrido[2,3-b]pyrazin-6-yl)-HarnstoffParticular preference is given to the following pyrido [2,3-b] pyrazine derivatives of the general formulas (I) and (II) which may be present in the form of their free base or else as pharmaceutically acceptable salts of physiologically compatible acids: Compound 1 1-Ethyl-3- (3-phenylethynylpyrido [2,3-b] pyrazine-6-yl) urea
Verbindung 2 1-Ethyl-3-(3-thiophen-3-ylethinyl-pyrido[2,3-b]pyrazin-6-yl)-HarnstoffCompound 2 1-Ethyl-3- (3-thiophen-3-ylethynylpyrido [2,3-b] pyrazine-6-yl) urea
Verbindung 3 1-(3-Cyclopropylethinyl-pyrido[2,3-b]pyrazin-6-yl)-3-ethyl-HarnstoffCompound 3 1- (3-Cyclopropylethynylpyrido [2,3-b] pyrazine-6-yl) -3-ethyl-urea
Verbindung 4 1-[3-(3-Dimethylamino-prop-1-inyl)-pyrido[2,3-b]pyrazin-6-yl]-3-ethyl- HarnstoffCompound 4 1- [3- (3-Dimethylamino-prop-1-ynyl) -pyrido [2,3-b] pyrazine-6-yl] -3-ethyl-urea
Verbindung 5 1-[3-((E)-2-Cyclohexyl-vinyl)-pyrido[2,3-b]pyrazin-6-yl]-3-ethyl- HarnstoffCompound 5 1- [3 - ((E) -2-Cyclohexyl-vinyl) -pyrido [2,3-b] pyrazine-6-yl] -3-ethyl-urea
Verbindung 6 1-Ethyl-3-[3-((E)-3-methoxy-propenyl)-pyrido[2,3-b]pyrazin-6-yl]- Harnstoff Compound 6 1-Ethyl-3- [3 - ((E) -3-methoxy-propenyl) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 7Connection 7
Verbindung 8Connection 8
Verbindung 9 Kohlensäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl ester methyl esterCompound 9 Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester methyl ester
Verbindung 10 Kohlensäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl ester 2-methoxy-ethyl esterCompound 10 Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester 2-methoxy-ethyl ester
Verbindung 1 1 Kohlensäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl ester phenyl ester Compound 1 1 Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester phenyl ester
Verbindung 12 Diethyl-carbaminsäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin- 3-yl]-phenyl esterCompound 12 Diethylcarbamic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester
Verbindung 13 (E)-3-Phenyl-acrylsäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin- 3-yl]-phenyl esterCompound 13 (E) -3-phenyl-acrylic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester
Verbindung 14 Nonadekansäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]- phenyl esterCompound 14 Nonadocanoic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester
Verbindung 15 1-(3-Benzyl-pyrido[2,3-b]pyrazin-6-yl)-3-ethyl-HarnstoffCompound 15 1- (3-Benzyl-pyrido [2,3-b] pyrazine-6-yl) -3-ethyl-urea
Verbindung 16 Kohlensäure 3-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl ester 2-methoxy-ethyl ester Compound 16 Carbonic acid 3- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester 2-methoxy-ethyl ester
Verbindung 17 Kohlensäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl ester isobutyl esterCompound 17 Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester isobutyl ester
Verbindung 18 Kohlensäure but-2-inyl ester 4-[6-(3-ethyl-harnstoff)-pyrido[2,3- b]pyrazin-3-yl]-phenyl esterCompound 18 Carbonic acid but-2-ynyl ester 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester
Verbindung 19 Dimethyl-carbaminsäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3- b]pyrazin-3-yl]-phenyl esterCompound 19 Dimethylcarbamic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester
Verbindung 20 Ethyl-carbaminsäure 4-[6-(3-ethyl-1-phenyl-harnstoff)-pyrido[2,3- b]pyrazin-3-yl]-phenyl esterCompound 20 Ethyl carbamic acid 4- [6- (3-ethyl-1-phenyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester
Verbindung 21 {4-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl}- carbaminsäure tert-butyl ester Compound 21 {4- [6- (3-Ethyl-urea) -pyrido [2,3-b] pyrazine-3-yl] -phenyl} -carbamic acid tert-butyl ester
Verbindung 22 {4-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl}- carbaminsäure 2-methoxy-ethyl esterCompound 22 {4- [6- (3-Ethyl-urea) -pyrido [2,3-b] pyrazine-3-yl] -phenyl} -carbamic acid 2-methoxy-ethyl ester
Verbindung 23 1-Ethyl-3-{3-[4-(3-ethyl-harnstoff)-phenyl]-pyrido[2,3-b]pyrazin-6-yl}- HarnstoffCompound 23 1-Ethyl-3- {3- [4- (3-ethyl-urea) -phenyl] -pyrido [2,3-b] pyrazine-6-yl} -urea
Verbindung 24 1-{3-[4-(3,3-Dimethyl-harnstoff)-phenyl]-pyrido[2,3-b]pyrazin-6-yl}-3- ethyl-HarnstoffCompound 24 1- {3- [4- (3,3-Dimethyl-urea) -phenyl] -pyrido [2,3-b] pyrazine-6-yl} -3-ethyl-urea
Verbindung 25 1-Ethyl-3-{3-[6-(3-ethyl-harnstoff)-pyridin-3-yl]-pyrido[2,3-b]pyrazin-6- yl}-Harnstoff Compound 25 1-Ethyl-3- {3- [6- (3-ethyl-urea) -pyridin-3-yl] -pyrido [2,3-b] pyrazine-6-yl} -urea
Verbindung 26 1-Ethyl-3-{3-[2-(4-fluoro-phenyl)-ethyl]-pyrido[2,3-b]pyrazin-6-yl}- HarnstoffCompound 26 1-Ethyl-3- {3- [2- (4-fluoro-phenyl) -ethyl] -pyrido [2,3-b] pyrazine-6-yl} -urea
Verbindung 27 1-Ethyl-3-{3-[(E)-2-(4-fluoro-phenyl)-vinyl]-pyrido[2,3-b]pyrazin-6-yl}- HarnstoffCompound 27 1-Ethyl-3- {3 - [(E) -2- (4-fluoro-phenyl) -vinyl] -pyrido [2,3-b] pyrazine-6-yl} -urea
Verbindung 28 1-Ethyl-3-[3-(4-morpholin-4-ylmethyl-phenyl)-pyrido[2,3-b]pyrazin-6- yl]-HarnstoffCompound 28 1-Ethyl-3- [3- (4-morpholin-4-ylmethyl-phenyl) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 29 1-Ethyl-3-(3-{4-[2-(2-methoxy-ethoxy)-ethoxy]-phenyl}-pyrido[2,3- b]pyrazin-6-yl)-HarnstoffCompound 29 1-Ethyl-3- (3- {4- [2- (2-methoxy-ethoxy) -ethoxy] -phenyl} -pyrido [2,3-b] pyrazine-6-yl) -urea
Verbindung 30 N-{4-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl}-2-(2- methoxy-ethoxy)-acetamide Compound 30 N- {4- [6- (3-Ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl} -2- (2-methoxy-ethoxy) -acetamide
Verbindung 31 N-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-4-methyl- benzamideCompound 31 N- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -4-methyl-benzamide
Verbindung 32 Kohlensäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-2- methoxy-phenyl ester 2-methoxy-ethyl esterCompound 32 Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazino-3-yl] -2-methoxy-phenyl ester 2-methoxy-ethyl ester
Verbindung 33 Kohlensäure 2-benzyloxy-ethyl ester 4-[6-(3-ethyl-harnstoff)- pyrido[2,3-b]pyrazin-3-yl]-phenyl esterCompound 33 2-benzyloxyethyl carbonate 2- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester
Verbindung 34 Kohlensäure 2-benzyloxy-ethyl ester 4-[6-(3-ethyl-harnstoff)- pyrido[2,3-b]pyrazin-3-yl]-2-methoxy-phenyl esterCompound 34 2-benzyloxyethyl carbonate 2- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -2-methoxyphenyl ester
Verbindung 35 2-Benzyloxy-N-{4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]- phenyl}-acetamide Compound 35 2-Benzyloxy-N- {4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl} -acetamide
Verbindung 36 1-[4-(tert-Butyl-dimethyl-silanyloxy)-butyl]-3-(3-phenyl-pyrido[2,3- b]pyrazin-6-yl)-HarnstoffCompound 36 1- [4- (tert -butyl-dimethyl-silanyloxy) -butyl] -3- (3-phenyl-pyrido [2,3-b] pyrazine-6-yl) -urea
Verbindung 37 1-[4-(tert-Butyl-dimethyl-silanyloxy)-butyl]-3-[3-(4-hydroxy-3- methoxy-phenyl)-pyrido[2,3-b]pyrazin-6-yl]-HarnstoffCompound 37 1- [4- (tert -butyl-dimethyl-silanyloxy) -butyl] -3- [3- (4-hydroxy-3-methoxyphenyl) -pyrido [2,3-b] pyrazine-6-yl ]-Urea
Verbindung 38 Ethyl-carbaminsäure 4-[3-(3-phenyl-pyrido[2,3-b]pyrazin-6-yl)- harnstoff]-butyl esterCompound 38 Ethyl carbamic acid 4- [3- (3-phenylpyrido [2,3-b] pyrazine-6-yl) -urea] -butyl ester
Verbindung 39 Kohlensäure methyl ester 4-[3-(3-phenyl-pyrido[2, 3-b]pyrazin-6-yl)- harnstoff]-butyl esterCompound 39 Carbonic acid methyl ester 4- [3- (3-phenylpyrido [2,3-b] pyrazine-6-yl) -urea] -butyl ester
Verbindung 40 Kohlensäure 2,2-dimethyl-[1 ,3]dioxolan-4-ylmethyl ester 4-[3-(3- phenyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff]-butyl ester Compound 40 Carbonic acid 2,2-dimethyl- [1,3] dioxolan-4-ylmethyl ester 4- [3- (3-phenyl-pyrido [2,3-b] pyrazine-6-yl) -urea] -butyl ester
Verbindung 41 Kohlensäure 2, 3-dihydroxy-propylester 4-[3-(3-phenyl-pyrido[2, 3- b]pyrazin-6-yl)-harnstoff]-butyl esterCompound 41 Carbonic acid 2, 3-dihydroxy-propyl ester 4- [3- (3-phenylpyrido [2,3-b] pyrazine-6-yl) -urea] -butyl ester
Verbindung 42 {4-[3-(3-Phenyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff]-butyl}- phosphorsäure diethyl esterCompound 42 diethyl {4- [3- (3-phenyl-pyrido [2,3-b] pyrazine-6-yl) -urea] -butyl} -phosphoric acid
Verbindung 43 {4-[3-(3-Phenyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff]-butyl}- phosphorsäureCompound 43 {4- [3- (3-phenyl-pyrido [2,3-b] pyrazine-6-yl) -urea] -butyl} -phosphoric acid
Verbindung 44 (4-{3-[3-(4-Hydroxy-3-methoxy-phenyl)-pyrido[2,3-b]pyrazin-6-yl]- harnstoff}-butyl)-phosphorsäure diethyl esterCompound 44 (4- {3- [3- (4-Hydroxy-3-methoxy-phenyl) -pyrido [2,3-b] pyrazine-6-yl] -urea} -butyl) -phosphoric acid diethyl ester
Verbindung 45 (4-{3-[3-(4-Hydroxy-3-methoxy-phenyl)-pyrido[2,3-b]pyrazin-6-yl]- harnstoff}-butyl)-phosphorsäure Compound 45 (4- {3- [3- (4-Hydroxy-3-methoxy-phenyl) -pyrido [2,3-b] pyrazine-6-yl] -urea} -butyl) -phosphoric acid
Verbindung 46 1-Ethyl-3-[3-(3-trimethylsilanyl-phenyl)-pyrido[2,3-b]pyrazin-6-yl]- HarnstoffCompound 46 1-Ethyl-3- [3- (3-trimethylsilanylphenyl) pyrido [2,3-b] pyrazine-6-yl] urea
Verbindung 47 1-[3-(4-Cyclohexyl-phenylamino)-pyrido[2,3-b]pyrazin-6-yl]-3-ethyl- HarnstoffCompound 47 1- [3- (4-Cyclohexyl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -3-ethyl-urea
Verbindung 48 1-Ethyl-3-[3-(4-methanesulfonyl-phenylamino)-pyrido[2,3-b]pyrazin- 6-yl]-HarnstoffCompound 48 1-Ethyl-3- [3- (4-methanesulfonyl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 49 N-{5-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-ylamino]-2-methyl- phenyl}-methanesulfonamideCompound 49 N- {5- [6- (3-Ethyl-urea) -pyrido [2,3-b] pyrazine-3-ylamino] -2-methyl-phenyl} -methanesulfonamide
Verbindung 50 3-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-ylamino]-N-methyl- benzamide Compound 50 3- [6- (3-Ethyl-urea) -pyrido [2,3-b] pyrazine-3-ylamino] -N-methyl-benzamide
Verbindung 51 1-Ethyl-3-[3-(4-piperidin-1-ylmethyl-phenylamino)-pyrido[2,3- b]pyrazin-6-yl]-HarnstoffCompound 51 1-Ethyl-3- [3- (4-piperidin-1-ylmethyl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 52 1-Ethyl-3-[3-(4-thiophen-3-yl-phenylamino)-pyrido[2,3-b]pyrazin-6- yl]-HarnstoffCompound 52 1-Ethyl-3- [3- (4-thiophen-3-yl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 53 N-{4-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-ylamino]-phenyl}- acetamideCompound 53 N- {4- [6- (3-Ethyl-urea) -pyrido [2,3-b] pyrazine-3-ylamino] -phenyl} -acetamide
Verbindung 54 3-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-ylamino]-benzoesäure ethyl esterCompound 54 3- [6- (3-Ethyl-urea) -pyrido [2,3-b] pyrazine-3-ylamino] -benzoic acid ethyl ester
Verbindung 55 Kohlensäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl ester 2-methoxy-ethyl ester hydrochloride Compound 55 Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazine-3-yl] -phenyl ester 2-methoxy-ethyl ester hydrochloride
Verbindung 56 Kohlensäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl ester 2-methoxy-ethyl ester p-toluolsulfonatCompound 56 Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester 2-methoxy-ethyl ester p-toluenesulfonate
Verbindung 57 Kohlensäure 4-{6-[3-(4-hydroxy-butyl)-harnstoff]-pyrido[2,3- b]pyrazin-3-yl}-phenyl ester 2-methoxy-ethyl esterCompound 57 Carbonic acid 4- {6- [3- (4-hydroxy-butyl) -urea] -pyrido [2,3-b] pyrazin-3-yl} -phenyl ester 2-methoxy-ethyl ester
Verbindung 58 Kohlensäure 4-{6-[3-(4-hydroxy-butyl)-harnstoff]-pyrido[2, 3- b]pyrazin-3-yl}-phenyl ester 2-methoxy-ethyl ester hydrochlorideCompound 58 Carbonic acid 4- {6- [3- (4-hydroxy-butyl) -urea] -pyrido [2,3-b] pyrazine-3-yl} -phenyl ester 2-methoxy-ethyl ester hydrochloride
Verbindung 59 N-(3-Phenyl-pyrido[2,3-b]pyrazin-6-yl)-oxalsäure monoamid ethyl ester Compound 59 N- (3-Phenyl-pyrido [2,3-b] pyrazine-6-yl) -oxamide monoamide ethyl ester
Verbindung 60 N-Ethyl-N'-(3-phenyl-pyrido[2,3-b]pyrazin-6-yl)-oxalamidCompound 60 N-ethyl-N '- (3-phenylpyrido [2,3-b] pyrazine-6-yl) -oxalamide
Verbindung 61Connection 61
Verbindung 62 {2-[3-(3-Phenyl-pyrido[2,3-b]pyrazn-6-yl)-harnstoff]-ethyl}- phosphorsäure diethyl esterCompound 62 Diethyl {2- [3- (3-phenyl-pyrido [2,3-b] -pyrazn-6-yl) -urea] -ethyl} -phosphoric acid
Verbindung 63 {2-[3-(3-Phenyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff]-ethyl}- phosphorsäureCompound 63 {2- [3- (3-phenyl-pyrido [2,3-b] pyrazine-6-yl) -urea] -ethyl} -phosphoric acid
Verbindung 64 1-[3-(2-Diethylamino-ethoxy)-propyl]-3-[3-(4-hydroxy-3-methoxy- phenyl)-pyrido[2,3-b]pyrazin-6-yl]-Harnstoff Compound 64 1- [3- (2-diethylamino-ethoxy) -propyl] -3- [3- (4-hydroxy-3-methoxyphenyl) -pyrido [2,3-b] pyrazine-6-yl] - urea
Verbindung 65 2,2-Dimethyl-propansäure (2,2-dimethyl-propionyloxymethoxy)-(4-{3- [3-(4-hydroxy-3-methoxy-phenyl)-pyrido[2,3-b]pyrazin-6-yl]-harnstoff}-butyl)- phosphinoyloxymethyl esterCompound 65 2,2-Dimethyl-propanoic acid (2,2-dimethyl-propionyloxymethoxy) - (4- {3- [3- (4-hydroxy-3-methoxyphenyl) -pyrido [2,3-b] pyrazine] 6-yl] -urea} -butyl) - phosphinoyloxymethyl ester
Verbindung 66 Essigsäure 1-[(1-acetoxy-ethoxy)-(4-{3-[3-(4-hydroxy-3-methoxy- phenyl)-pyrido[2,3-b]pyrazin-6-yl]-harnstoff}-butyl)-phosphinoyloxy]-ethyl esterCompound 66 acetic acid 1 - [(1-acetoxy-ethoxy) - (4- {3- [3- (4-hydroxy-3-methoxyphenyl) -pyrido [2,3-b] pyrazine-6-yl] - urea} -butyl) -phosphinoyloxy] -ethyl ester
Verbindung 67 Diethyl-carbaminsäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin- 3-yl]2-methoxy-phenyl esterCompound 67 Diethylcarbamic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] 2-methoxyphenyl ester
Verbindung 68 Diethyl-carbaminsäure 2-chloro-4-[6-(3-ethyl-harnstoff)-pyrido[2,3- b]pyrazin-3-yl]-6-methoxy-phenyl ester Compound 68 diethylcarbamic acid 2-chloro-4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -6-methoxy-phenyl ester
Verbindung 69 Kohlensäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-2- methoxy-phenyl ester 2-[2-(2-methoxy-ethoxy)-ethoxy]-ethyl esterCompound 69 Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -2-methoxyphenyl ester 2- [2- (2-methoxyethoxy) - ethoxy] -ethyl ester
Verbindung 70 1-Ethyl-3-{3-[4-(morpholine-4-sulfonyl)-phenylamino]-pyrido[2,3- b]pyrazin-6-yl}-harnstoffCompound 70 1-Ethyl-3- {3- [4- (morpholine-4-sulfonyl) -phenylamino] -pyrido [2,3-b] pyrazine-6-yl} -urea
Verbindung 71 5-[6-(3-Ethyl-ureido)-pyrido[2,3-b]pyrazin-3-ylamino]-2-hydroxy- benzoesäureethylesterCompound 71 Ethyl 5- [6- (3-ethyl-ureido) -pyrido [2,3-b] pyrazine-3-ylamino] -2-hydroxybenzoate
Verbindung 72 1-[3-(3-Diethylaminomethyl-4-hydroxy-phenylamino)-pyrido[2,3- b]pyrazin-6-yl]-3-ethyl-harnstoffCompound 72 1- [3- (3-diethylaminomethyl-4-hydroxy-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -3-ethyl-urea
Verbindung 73 1-Ethyl-3-[3-(6-morpholin-4-yl-pyridin-3-ylamino)-pyrido[2,3- b]pyrazin-6-yl]-harnstoff Compound 73 1-Ethyl-3- [3- (6-morpholin-4-yl-pyridin-3-ylamino) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 74 1-Ethyl-3-{3-[3-(1 H-tetrazol-5-yl)-phenylamino]-pyrido[2,3-b]pyrazin- 6-yl}-harnstoffCompound 74 1-Ethyl-3- {3- [3- (1H-tetrazol-5-yl) -phenylamino] -pyrido [2,3-b] pyrazine-6-yl} -urea
Verbindung 75 1-Ethyl-3-[3-(3-morpholin-4-yl-phenylamino)-pyrido[2,3-b]pyrazin-6- yl]-harnstoffCompound 75 1-Ethyl-3- [3- (3-morpholin-4-yl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 76 1-Ethyl-3-[3-(4-imidazol-1-yl-phenylamino)-pyrido[2,3-b]pyrazin-6-yl]- harn stoffCompound 76 1-Ethyl-3- [3- (4-imidazol-1-yl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 77 1-Ethyl-3-[3-(4-pyrrolidin-1-yl-phenylamino)-pyrido[2,3-b]pyrazin-6- yl]-harnstoffCompound 77 1-Ethyl-3- [3- (4-pyrrolidin-1-yl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 78 1-Ethyl-3-{3-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrido[2,3- b]pyrazin-6-yl}-harnstoff Compound 78 1-Ethyl-3- {3- [4- (4-methyl-piperazin-1-yl) -phenylamino] -pyrido [2,3-b] pyrazine-6-yl} -urea
Verbindung 79 1-Ethyl-3-[3-(3-piperidin-1-ylmethyl-phenylamino)-pyrido[2,3- b]pyrazin-6-yl]-harnstoffCompound 79 1-Ethyl-3- [3- (3-piperidin-1-ylmethyl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 80 1-Ethyl-3-[3-(4-morpholin-4-ylmethyl-phenylamino)-pyrido[2,3- b]pyrazin-6-yl]-harnstoffCompound 80 1-Ethyl-3- [3- (4-morpholin-4-ylmethyl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 81 1-{3-[3-(2-Cyclohexyl-ethoxy)-phenylamino]-pyrido[2,3-b]pyrazin-6- yl}-3-ethyl-harnstoffCompound 81 1- {3- [3- (2-Cyclohexylethoxy) -phenylamino] -pyrido [2,3-b] pyrazine-6-yl} -3-ethyl-urea
Verbindung 82 1-Ethyl-3-[3-(3-[1 ,2,4]triazol-1-ylmethyl-phenylamino)-pyrido[2,3- b]pyrazin-6-yl]-harnstoffCompound 82 1-Ethyl-3- [3- (3- [1,2,4] triazol-1-ylmethyl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 83 Carbonic acid 2,2-dimethyl-[1 ,3]dioxolan-4-ylmethyl ester 4-{3-[3-(4- hydroxy-3-methoxy-phenyl)-pyrido[2,3-b]pyrazin-6-yl]-ureido}-butyl ester Compound 83 Carbonic acid 2,2-dimethyl- [1,3] dioxolan-4-ylmethyl ester 4- {3- [3- (4-hydroxy-3-methoxyphenyl) -pyrido [2,3-b] pyrazine -6-yl] -ureido} -butyl ester
Verbindung 84 Carbonic acid 2,3-dihydroxy-propylester 4-{3-[3-(4-hydroxy-3- methoxy-phenyl)-pyrido[2,3-b]pyrazin-6-yl]-ureido}-butyl esterCompound 84 Carbonic acid 2,3-dihydroxy-propyl ester 4- {3- [3- (4-hydroxy-3-methoxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -ureido} -butyl ester
Verbindung 85 1-[3-(2-Diethylamino-ethoxy)-propyl]-3-[3-(4-hydroxy-3-methoxy- phenyl)-pyrido[2,3-b]pyrazin-6-yl]-ureaCompound 85 1- [3- (2-diethylamino-ethoxy) -propyl] -3- [3- (4-hydroxy-3-methoxyphenyl) -pyrido [2,3-b] pyrazine-6-yl] - urea
Um Unklarheiten zu vermeiden: wenn chemische Struktur und chemischer Name der oben dargestellten expliziten Verbindungen fehlerhafterweise nicht miteinander übereinstimmen, so soll die chemische Struktur die jeweilige explizite Verbindung eindeutig definieren.In order to avoid ambiguity: if the chemical structure and chemical name of the explicit compounds shown above incorrectly do not agree with each other, then the chemical structure should unambiguously define the respective explicit connection.
Die oben dargestellten generischen Verbindungen der allgemeinen Formeln (I) und (II), die bevorzugten Ausführungsformen sowie die explizit genannten Pyridopyrazin- Verbindungen 1 bis 85 werden im folgenden gemeinsam als "erfindungsgemäße Verbindungen" bezeichnet.The above-illustrated generic compounds of the general formulas (I) and (II), the preferred embodiments and the explicitly mentioned pyridopyrazine compounds 1 to 85 are referred to collectively below as "compounds according to the invention".
Die zur Erläuterung der erfindungsgemäßen Verbindungen angegebenen Ausdrücke und Begriffe haben grundsätzlich, sofern in der Beschreibung oder in den Ansprüchen nichts anderes angegeben ist, folgende Bedeutungen: Der Ausdruck „Alkyl" umfasst im Sinne dieser Erfindung acyclische gesättigte oder ungesättigte Kohlenwasserstoffreste, die verzweigt oder geradkettig sein können, mit 1 bis 8 C-Atomen, d.h. d-β-Alkanyle, C2-β-Alkenyle und C2-β-Alkinyle. Dabei weisen Al- kenyle mindestens eine C-C-Doppelbindung und Alkinyle mindestens eine C-C- Dreifachbindung auf. Alkinyle können aber zusätzlich auch mindestens eine C-C- Doppelbindung aufweisen. Bevorzugte Alkyl-Reste sind Methyl, Ethyl, n-Propyl, 2- Propyl, n-Butyl, sec.-Butyl, te/t-Butyl, n-Pentyl, /so-Pentyl, neo-Pentyl, n-Hexyl, 2- Hexyl, n-Heptyl, n-Octyl, , n-Nonyl, n-Decyl, n-Undecyl, n-Dodecyl, Ethylenyl (Vinyl), Ethinyl, Propenyl (-CH2CH=CH2; -CH=CH-CH3, -C(=CH2)-CH3), Propinyl (-CH2-C≡CH, - C≡C-CH3), Butenyl, Butinyl, Pentenyl, Pentinyl, Hexenyl, Hexinyl, Heptenyl, Heptinyl, Octenyl, Octadienyl und Octinyl.The expressions and terms given for the explanation of the compounds according to the invention basically have the following meanings, unless stated otherwise in the description or in the claims: The term "alkyl" in the context of this invention comprises acyclic saturated or unsaturated hydrocarbon radicals which may be branched or straight-chain, having 1 to 8 carbon atoms, ie d-β-alkanylyl, C 2 -β-alkenyls and C 2 -β- Alkenyls have at least one CC double bond and alkynyls at least one C-C triple bond, but alkynyls may additionally also have at least one C-C double bond Preferred alkyl radicals are methyl, ethyl, n-propyl, 2-propyl, n-butyl, sec-butyl, te / t-butyl, n-pentyl, / so-pentyl, neo-pentyl, n-hexyl, 2-hexyl, n-heptyl, n-octyl,, n-nonyl, n Decyl, n-undecyl, n-dodecyl, ethylenyl (vinyl), ethynyl, propenyl (-CH 2 CH = CH 2 ; -CH = CH-CH 3 , -C (= CH 2 ) -CH 3 ), propynyl ( -CH 2 -C≡CH, -C≡C-CH 3 ), butenyl, butynyl, pentenyl, pentynyl, hexenyl, hexynyl, heptenyl, heptynyl, octenyl, octadienyl and octynyl.
Der Ausdruck "(C9-C30)alkyl" beschreibt im Sinne dieser Erfindung acyclische gesättigte oder ungesättigte Kohlenwasserstoff reste, die verzweigt oder geradkettig sein können, mit 9 bis 30 C-Atomen, d.h. C9-30-Alkanyle, C9-30-Alkenyle und C9-30-Alkinyle. Dabei weisen C9-3o-Alkenyle mindestens eine C-C-Doppelbindung und C9-3o-Alkinyle mindestens eine C-C-Dreifachbindung auf. C9-30-Alkinyle können aber zusätzlich auch mindestens eine C-C-Doppelbindung aufweisen. Bevorzugte (C9-C3o)alkyl-Reste sind Tetradecyl, Hexadecyl, Octadecyl, Eicosanyl, cis-13-Docosenyl (Erucyl), trans-13- Docosenyl (Brassidyl), cis-15-Tetracosenyl (Nervonyl) und trans-15-Tetracosenyl.The term "(C 9 -C 30 ) alkyl" for the purposes of this invention describes acyclic saturated or unsaturated hydrocarbon radicals which may be branched or straight-chain, having 9 to 30 C atoms, ie C 9 - 30 alkanyylene, C 9 - 30 alkenyls and C 9 - 30 alkynyls. In this case, C 9 - 3 o-alkenyls have at least one CC double bond and C 9 - 3 o-alkynyls at least one C-C triple bond. C 9-30 Alkynyl can but additionally also have at least one CC double bond. Preferred (C 9 -C 3 o) alkyl radicals are tetradecyl, hexadecyl, octadecyl, eicosanyl, cis-13-docosenyl (erucyl), trans-13-docosenyl (brassidyl), cis-15-tetracosenyl (nervonyl) and trans 15-tetracosenyl.
Der Ausdruck „Cycloalkyl" bedeutet für die Zwecke dieser Erfindung cyclische, nicht-aromatische Kohlenwasserstoffe mit 1 bis 3 Ringen mit 3 bis 20, bevorzugt 3 bis 12 Kohlenstoffen, die gesättigt oder ungesättigt sein können, besonders bevorzugt (C3- CβJ-cycloalkyl. Der Cycloalkyl-Rest kann auch Teil eines bi- oder polycyclischen Systems sein, wo bspw. der Cycloalkyl-Rest mit einem Aryl-, Heteroaryl- oder Heterocyc- lyl-Rest wie hierin definiert durch jede(s) mögliche und gewünschte Ringmitglied(er) kondensiert ist. Die Bindung an die Verbindungen der allgemeinen Formeln (I), (II) kann über jedes beliebige und mögliche Ringglied des Cycloalkyl-Restes erfolgen. Be- vorzugte Cycloalkyl-Reste sind Cyclopropyl, Cyclobutyl, Cyclopentyl, Cyclohexyl, Cyc- loheptyl, Cyclooctyl, Cyclodecyl, Cyclohexenyl, Cyclopentenyl und Cyclooctadienyl. Der Ausdruck „Heterocyclyl" steht für einen 3- bis 14-gliedrigen, bevorzugt 3-, 4-, 5- , 6-, 7- oder 8-gliedrigen cyclischen organischen Rest, der mindestens 1 , ggf. 2, 3, 4 oder 5 Heteroatome enthält, insbesondere Stickstoff, Sauerstoff und/oder Schwefel, wobei die Heteroatome gleich oder verschieden sind und der cyclische Rest gesättigt oder ungesättigt, aber nicht aromatisch ist. Der Heterocyclyl-Rest kann auch Teil eines bi- oder polycyclischen Systems sein, wo bspw. der Heterocyclyl-Rest mit einem Aryl-, Heteroaryl- oder Cycloalkyl-Rest wie hierin definiert durch jede(s) mögliche und gewünschte Ringmitglied(er) kondensiert ist. Die Bindung an die Verbindungen der allgemeinen Formeln (I), (II) kann über jedes beliebige und mögliche Ringglied des Hete- rocyclyl-Restes erfolgen. Bevorzugte Heterocyclyl-Reste sind Tetrahydrofuryl, Pyrroli- dinyl, Imidazolidinyl, Thiazolidinyl, Tetrahydropyranyl, Piperidinyl, Piperazinyl, Morpho- linyl, Thiapyrrolidinyl, Oxapiperazinyl, Oxapiperidinyl und Oxadiazolyl.The term "cycloalkyl" for the purposes of this invention means cyclic, non-aromatic hydrocarbons having from 1 to 3 rings having from 3 to 20, preferably 3 to 12 carbons, which may be saturated or unsaturated, most preferably (C 3 -C 6) cycloalkyl. The cycloalkyl radical may also be part of a bicyclic or polycyclic system, where, for example, the cycloalkyl radical having an aryl, heteroaryl or heterocyclyl radical as defined herein by any possible and desired ring member (s) The binding to the compounds of the general formulas (I), (II) can be effected via any and possible ring member of the cycloalkyl radical Preferred cycloalkyl radicals are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, Cyclooctyl, cyclodecyl, cyclohexenyl, cyclopentenyl and cyclooctadienyl. The term "heterocyclyl" represents a 3- to 14-membered, preferably 3-, 4-, 5-, 6-, 7- or 8-membered cyclic organic radical containing at least 1, optionally 2, 3, 4 or Contains heteroatoms, in particular nitrogen, oxygen and / or sulfur, where the heteroatoms are the same or different and the cyclic radical is saturated or unsaturated, but not aromatic The heterocyclyl radical can also be part of a bi- or polycyclic system, where, for example the heterocyclyl radical is fused with an aryl, heteroaryl or cycloalkyl radical as defined herein by any possible and desired ring member (s) .The attachment to the compounds of general formulas (I), (II) may The preferred heterocyclyl radicals are tetrahydrofuryl, pyrrolidinyl, imidazolidinyl, thiazolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, thiapyrrolidinyl, oxapiperazinyl, oxap iperidinyl and oxadiazolyl.
Der Ausdruck „Aryl" bedeutet im Sinne dieser Erfindung aromatische Kohlenwas- serstoffe mit 3 bis 14 C-Atomen, bevorzugt 5 bis 14 C-Atomen, besonders bevorzugt 6 bis 14 C-Atomen. Der Aryl-Rest kann auch Teil eines bi- oder polycyclischen Systems sein, wo bspw. der Aryl-Rest mit einem Heterocyclyl-, Heteroaryl- oder Cycloalkyl-Rest wie hierin definiert durch jede(s) mögliche und gewünschte Ringmitglied(er) kondensiert ist, bspw. mit Tetrahydrofuran, Tetrahydrothiophen, Pyrrolidin, Imidazolidin, Thia- zolidin, Tetrahydropyran, Dihydropyran, Piperidin, Furan, Thiophen, Imidazol, Thiazol, Oxazol, Isoxazol. Die Bindung an die Verbindungen der allgemeinen Formeln (I), (II) kann über jedes beliebige und mögliche Ringglied des Aryl-Restes erfolgen. Bevorzugte Aryl-Reste sind Phenyl, Biphenyl, Naphthyl und Anthracenyl, aber ebenso Indanyl, Indenyl oder 1 ,2,3,4-Tetrahydronaphthyl.The term "aryl" in the context of this invention means aromatic hydrocarbons having 3 to 14 C atoms, preferably 5 to 14 C atoms, particularly preferably 6 to 14 C atoms polycyclic system, where, for example, the aryl radical is fused with a heterocyclyl, heteroaryl or cycloalkyl radical as defined herein by any possible and desired ring member (s), for example with tetrahydrofuran, tetrahydrothiophene, pyrrolidine, imidazolidine , Thiazolidine, tetrahydropyran, dihydropyran, piperidine, furan, thiophene, imidazole, thiazole, oxazole, isoxazole The bonding to the compounds of the general formulas (I), (II) can be effected via any and possible ring member of the aryl radical Preferred aryl radicals are phenyl, biphenyl, naphthyl and anthracenyl, but also indanyl, indenyl or 1,2,3,4-tetrahydronaphthyl.
Der Ausdruck „Heteroaryl" steht für einen 5-, 6- oder 7-gliedrigen cyclischen aromatischen Rest, der mindestens 1 , ggf. auch 2, 3, 4 oder 5 Heteroatome enthält, insbesondere Stickstoff, Sauerstoff und/oder Schwefel, wobei die Heteroatome gleich oder verschieden sind. Die Anzahl der Stickstoffatome ist bevorzugt 0 bis 3, die der Sauer- stoff und Schwefelatome bevorzugt 0 oder 1. Der Heteroaryl-Rest kann auch Teil eines bi- oder polycyclischen Systems sein, wo bspw. der Heteroaryl-Rest mit einem Heterocyclyl-, Aryl- oder Cycloalkyl-Rest wie hierin definiert durch jede(s) mögliche und gewünschte Ringmitglied(er) kondensiert ist. Die Bindung an die Verbindungen der allgemeinen Formeln (I), (II) kann über jedes beliebige und mögliche Ringglied des Hete- roaryl-Restes erfolgen. Bevorzugte Heteroaryl-Reste sind Pyrrolyl, Furyl, Thienyl, Thia- zolyl, Isothiazolyl, Oxazolyl, Oxadiazolyl, Isoxazolyl, Pyrazolyl, Imidazolyl, Triazol, Tetrazol, Pyridinyl, Pyrimidinyl, Pyridazinyl, Pyrazinyl, Triazin, Phthalazinyl, Indolyl, Indazolyl, Indolizinyl, Chinolinyl, Isochinolinyl, Chinoxalinyl, Chinazolinyl, Pteridinyl, Carbazolyl, Phenazinyl, Phenoxazinyl, Phenothiazinyl, und Acridinyl.The term "heteroaryl" represents a 5-, 6- or 7-membered cyclic aromatic radical containing at least 1, optionally also 2, 3, 4 or 5 heteroatoms, in particular nitrogen, oxygen and / or sulfur, where the heteroatoms The number of nitrogen atoms is preferably 0 to 3, that of the oxygen and sulfur atoms is preferably 0 or 1. The heteroaryl radical may also be part of a bi- or polycyclic system, where, for example, the heteroaryl radical with a heterocyclyl, aryl or cycloalkyl radical as defined herein by any possible and desired ring member (s), The linkage to the compounds of general formulas (I), (II) may be via any and possible ring member of the roaryl residue done. Preferred heteroaryl radicals are pyrrolyl, furyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyrazolyl, imidazolyl, triazole, tetrazole, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazine, phthalazinyl, indolyl, indazolyl, indolizinyl, quinolinyl , Isoquinolinyl, quinoxalinyl, quinazolinyl, pteridinyl, carbazolyl, phenazinyl, phenoxazinyl, phenothiazinyl, and acridinyl.
Die Ausdrücke „Alkyl-Cycloalkyl", „Cycloalkylalkyl", „Alkyl-Heterocyclyl", „Heterocyc- lylalkyl", „Alkyl-Aryl", „Arylalkyl", „Alkyl-Heteroaryl" und „Heteroarylalkyl" bedeuten für die Zwecke der vorliegenden Erfindung, daß Alkyl, Cycloalkyl, Heterocyclyl, Aryl und Heteroaryl die oben definierten Bedeutungen haben und der Cycloalkyl-, Heterocyclyl-, Aryl- und Heteroaryl-Rest über einen Alkyl-Rest, bevorzugt C-rC8-Alkyl-Rest, besonders bevorzugt d-C4-Alkyl-Rest, an die Verbindungen der allgemeinen Formeln (I), (II) gebunden ist.The terms "alkylcycloalkyl", "cycloalkylalkyl", "alkylheterocyclyl", "heterocyclylalkyl", "alkylaryl", "arylalkyl", "alkylheteroaryl" and "heteroarylalkyl" mean for the purposes of the present invention in that alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl have the meanings defined above, and the cycloalkyl, heterocyclyl, aryl and heteroaryl radical has an alkyl radical, preferably C 1 -C 8 -alkyl radical, more preferably dC 4 -Alkyl radical to which compounds of the general formulas (I), (II) is bonded.
Im Zusammenhang mit „Alkyl", „Cycloalkyl", „Heterocyclyl", „Aryl", „Heteroaryl", „Alkyl-Cycloalkyl", „Alkyl-Heterocyclyl", „Alkyl-Aryl" und „Alkyl-Heteroaryl" versteht man unter dem Begriff substituiert im Sinne dieser Erfindung, insofern oben in der Beschreibung oder den Ansprüchen nicht explicit definiert, die Substitution eines oder mehrerer Wasserstoffreste durch F, Cl, Br, I, CN, CF3, NH2, NH-Alkyl, NH-Aryl, N(Alkyl)2, NO2, SH, S-Alkyl, OH, OCF3, O(-Alkyl-O)p-Alkyl, O-Aryl, OSO3H, OP(O)(OH)2, OP(O)(OAIkyl)2, OP(O)(OAryl)2, CHO, C(O)OH, C(O)OR36, C(O)NH2, C(O)NHR36, C(O)NR36R37, SO3H, SO2Alkyl, SO2Aryl, P(O)(OH)2, P(O)(OAIkyl)2, P(O)(OAryl)2, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl oder Alkylaryl, wobei p den Wert O, 1 , 2, 3, 4 oder 5 annehmen kann, und wobei die Reste R36 und R37 unabhängig voneinan- der Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein können und R36 und R37 zusammen einen Hete- rocyclyl-Ring bilden können. Die Substituenten können gleich oder verschieden sein und die Substitution kann in jeder beliebigen und möglichen Position des Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl- und Heteroarylrestes vorkommen.In the context of "alkyl", "cycloalkyl", "heterocyclyl", "aryl", "heteroaryl", "alkyl-cycloalkyl", "alkyl-heterocyclyl", "alkyl-aryl" and "alkyl-heteroaryl" is meant by the Term substituted in the sense of this invention, insofar as not explicitly defined in the description or the claims, the substitution of one or more hydrogen radicals by F, Cl, Br, I, CN, CF 3 , NH 2 , NH-alkyl, NH-aryl, N (alkyl) 2 , NO 2 , SH, S-alkyl, OH, OCF 3 , O (-alkyl-O) p -alkyl, O-aryl, OSO 3 H, OP (O) (OH) 2 , OP ( O) (OAIkyl) 2, OP (O) (O-aryl) 2, CHO, C (O) OH, C (O) OR36, C (O) NH 2, C (O) NHR36, C (O) NR36R37, SO 3 H, SO 2 alkyl, SO 2 aryl, P (O) (OH) 2 , P (O) (OAlkyl) 2 , P (O) (O-aryl) 2 , alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or alkylaryl, where p can assume the value 0, 1, 2, 3, 4 or 5, and wherein the radicals R36 and R37 independently of one another alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-het may be eroaryl and R36 and R37 together form a heterocyclyl ring. The substituents may be the same or different and the substitution may occur in any and possible position of the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups.
Der Ausdruck „Halogen" umfasst im Sinne dieser Erfindung die Halogenatome Fluor, Chlor, Brom und lod. Unter mehrfach substituierten Resten sind solche zu verstehen, die entweder an verschiedenen oder an gleichen Atomen mehrfach, z. B. zwei- oder dreifach substituiert sind, beispielsweise dreifach am gleichen C-Atom wie im Falle von CF3, -CH2CF3 oder an verschiedenen Stellen wie im Falle von -CH(OH)-CH=CH-CHCI2. Die Mehr- fachsubstitution kann mit dem gleichen oder verschiedenen Substituenten erfolgen.The term "halogen" for the purposes of this invention, the halogen atoms fluorine, chlorine, bromine and iodine. Under multiply substituted radicals are those to be understood that on several or on the same atoms multiply, z. B. are substituted two or three times, for example, three times on the same carbon atom as in the case of CF 3 , -CH 2 CF 3 or at different locations as in the case of -CH (OH) -CH = CH-CHCl 2 . The multiple substitution can be made with the same or different substituent.
Sofern die erfindungsgemäßen Verbindungen mindestens ein Asymmetriezentrum aufweisen, können sie in Form ihrer Racemate, in Form der reinen Enantiomeren und/oder Diastereomeren oder in Form von Mischungen dieser Enantiomeren und/oder Diastereomeren vorliegen und zwar sowohl in Substanz als auch als pharmazeutisch annehmbare Salze dieser Verbindungen. Die Mischungen können in jedem beliebigen Mischungsverhältnis der Stereoisomeren vorliegen.If the compounds according to the invention have at least one asymmetric center, they may be present in the form of their racemates, in the form of pure enantiomers and / or diastereomers or in the form of mixtures of these enantiomers and / or diastereomers both in substance and as pharmaceutically acceptable salts of these compounds , The mixtures can be present in any mixing ratio of the stereoisomers.
So lassen sich beispielsweise die erfindungsgemäßen Verbindungen, welche ein oder mehrere Chiralitätszentren aufweisen und die als Racemate auftreten, nach an sich bekannten Methoden in ihre optischen Isomeren, also Enantiomere oder Diastere- omere auftrennen. Die Trennung kann durch Säulentrennung an chiralen Phasen oder durch Umkristallisation aus einem optisch aktiven Lösungsmittel oder unter Verwendung einer optisch aktiven Säure oder Base oder durch Derivatisierung mit einem optisch aktiven Reagenz, wie beispielsweise einem optisch aktiven Alkohol, und an- schließender Abspaltung des Restes erfolgen.Thus, for example, the compounds according to the invention which have one or more centers of chirality and which occur as racemates can be separated into their optical isomers, ie enantiomers or diastereomers, by methods known per se. The separation can be carried out by column separation on chiral phases or by recrystallization from an optically active solvent or by using an optically active acid or base or by derivatization with an optically active reagent, such as an optically active alcohol, followed by cleavage of the residue.
Die erfindungsgemäßen Verbindungen können in Form ihrer Doppelbindungsisomere als „reine" E- oder Z-Isomere oder in Form von Mischungen dieser Doppelbindungsisomere vorliegen.The compounds according to the invention can be present in the form of their double bond isomers as "pure" E or Z isomers or in the form of mixtures of these double bond isomers.
Sofern möglich, können die erfindungsgemäßen Verbindungen in Form der Tautomeren vorliegen.If possible, the compounds of the invention may be in the form of tautomers.
Die erfindungsgemäßen Verbindungen können, falls sie eine ausreichend basische Gruppe, wie zum Beispiel ein primäres, sekundäres oder tertiäres Amin besitzen, mit anorganischen und organischen Säuren in ihre physiologisch verträglichen Salze überführt werden. Vorzugsweise werden die pharmazeutisch annehmbaren Salze der erfin- dungsgemäßen Verbindungen mit Salzsäure, Bromwasserstoffsäure, Schwefelsäure, Phosphorsäure, Methansulfonsäure, p-Toluolsulfonsäure, Kohlensäure, Ameisensäure, Essigsäure, Trifluoressigsäure, Sulfoessigsäure, Oxalsäure, Malonsäure, Maleinsäure, Bernsteinsäure, Weinsäure, Traubensäure, Äpfelsäure, Embonsäure, Mandelsäure, Fumarsäure, Milchsäure, Citronensäure, Glutaminsäure oder Asparaginsäure gebildet. Bei den gebildeten Salzen handelt es sich u.a. um Hydrochloride, Hydrobromide, Sulfate, Hydrogensulfate, Phosphate, Methansulfonate, Tosylate, Carbonate, Hydrogencar- bonate, Formiate, Acetate, Triflate, Sulfoacetate, Oxalate, Malonate, Maleate, Succina- te, Tartrate, Malate, Embonate, Mandelate, Fumarate, Lactate, Citrate, Glutaminate und Aspartate. Die Stöchiometrie der gebildeten Salze der erfindungsgemäßen Verbindungen kann dabei ganzzahlige oder nicht ganzzahlige Vielfache von eins betragen.The compounds of the invention, if they have a sufficiently basic group, such as a primary, secondary or tertiary amine, can be converted into their physiologically acceptable salts with inorganic and organic acids. Preferably, the pharmaceutically acceptable salts of the invention are Compounds of the invention with hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, p-toluenesulfonic, carbonic, formic, acetic, trifluoroacetic, sulfoacetic, oxalic, malonic, maleic, succinic, tartaric, malic, embonic, mandelic, fumaric, lactic, citric , Glutamic acid or aspartic acid. The salts formed are, inter alia, hydrochlorides, hydrobromides, sulfates, hydrogen sulfates, phosphates, methanesulfonates, tosylates, carbonates, hydrogencarbonates, formates, acetates, triflates, sulfoacetates, oxalates, malonates, maleates, succinates, tartrates, malates , Embonates, Mandelates, Fumarates, Lactates, Citrates, Glutaminates and Aspartates. The stoichiometry of the formed salts of the compounds according to the invention can be integer or non-integer multiples of one.
Die erfindungsgemäßen Verbindungen können, falls sie eine ausreichend saure Gruppe, wie zum Beispiel die Carboxygruppe oder die Phosphorsäuregruppe enthal- ten, mit anorganischen und organischen Basen in ihre physiologisch verträglichen Salze überführt werden. Als anorganische Basen kommen beispielsweise Natriumhydroxid, Kaliumhydroxid, Calciumhydroxid, als organische Basen Ethanolamin, Diethano- lamin, Triethanolamin, Cyclohexylamin, Dibenzylethylendiamin und Lysin in Betracht. Die Stöchiometrie der gebildeten Salze der erfindungsgemäßen Verbindungen kann dabei ganzzahlige oder nicht ganzzahlige Vielfache von eins betragen.The compounds according to the invention, if they contain a sufficiently acidic group, such as, for example, the carboxy group or the phosphoric acid group, can be converted into their physiologically tolerated salts with inorganic and organic bases. Suitable inorganic bases are, for example, sodium hydroxide, potassium hydroxide, calcium hydroxide, as organic bases ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dibenzylethylenediamine and lysine. The stoichiometry of the formed salts of the compounds according to the invention can be integer or non-integer multiples of one.
Ebenfalls bevorzugt sind Solvate und insbesondere Hydrate der erfindungsgemäßen Verbindungen, die z. B. durch Kristallisation aus einem Lösungsmittel oder aus wässriger Lösung erhalten werden können. Es können sich dabei ein, zwei, drei oder beliebig viele Solvat- oder Wasser-Moleküle mit den erfindungsgemäßen Verbindungen zu Solvaten und Hydraten verbinden.Also preferred are solvates and in particular hydrates of the compounds of the invention, the z. B. can be obtained by crystallization from a solvent or aqueous solution. One, two, three or any number of solvate or water molecules can combine with the compounds according to the invention to give solvates and hydrates.
Es ist bekannt, dass chemische Substanzen Festkörper ausbilden, die in verschiedenen Ordnungszuständen vorliegen, die man als polymorphe Formen oder Modifikati- onen bezeichnet. Die verschiedenen Modifikationen einer polymorphen Substanz können sich in ihren physikalischen Eigenschaften stark unterscheiden. Die erfindungsgemäßen Verbindungen können in verschiedenen polymorphen Formen vorliegen, dabei können bestimmte Modifikationen metastabil sein. Ebenfalls können die erfindungsgemäßen Verbindungen in Form beliebiger Prodrugs wie beispielsweise Ester, Carbonate, Carbamate, Harnstoffe, Amide oder Phosphate vorkommen, bei denen die tatsächlich biologisch aktive Form erst durch Verstoffwechselung freigesetzt wird.It is known that chemical substances form solids which exist in various states of order, which are called polymorphic forms or modifications. The various modifications of a polymorphic substance may differ greatly in their physical properties. The compounds of the invention may exist in various polymorphic forms, while certain modifications may be metastable. Likewise, the compounds according to the invention may be present in the form of any prodrugs such as, for example, esters, carbonates, carbamates, ureas, amides or phosphates, in which the actually biologically active form is released only by metabolism.
Es ist bekannt, dass chemische Substanzen im Körper zu Metaboliten umgewandelt werden die gegebenenfalls ebenfalls die erwünschte biologische Wirkung - unter Umständen sogar in stärker ausgeprägter Form - hervorrufen können.It is known that chemical substances in the body are converted to metabolites which may also produce the desired biological effect - possibly even in a more pronounced form.
Entsprechende Prodrugs und Metabolite der erfindungsgemäßen Verbindungen sind als zur Erfindung gehörig anzusehen.Corresponding prodrugs and metabolites of the compounds according to the invention are to be regarded as belonging to the invention.
Es wurde nun überraschend und vorteilhaft festgestellt, dass die erfindungsgemäßen Verbindungen auch gleichzeitig auf zwei oder mehrere Signaltransduktionswege bzw. Enzyme solcher Wege einwirken bzw. modulierend oder hemmend wirken kön- nen. Dabei hat sich herausgestellt, dass die erfindungsgemäßen Verbindungen mit hoher Selektivität einwirken bzw. modulierend oder hemmend wirken.It has now been found, surprisingly and advantageously, that the compounds according to the invention can also act simultaneously on two or more signal transduction pathways or enzymes of such pathways or can act modulating or inhibiting. It has been found that the compounds according to the invention act with high selectivity or have a modulating or inhibiting effect.
Eine solche gleichzeitige, bspw. duale, Modulation oder Inhibition von zwei oder mehreren Signaltransduktionswegen, z.B. ras-Raf-Mek-Erk-Signaltweg, PI3K-Akt- Signalweg und/oder SAPK-Signalweg, spezieller Erk1/Erk2 undoder PI3K und/oder Jnk und/oder p38, ist von Vorteil gegenüber der nur einfachen Modulation oder Inhibition eines Signaltransduktionsweges, da synergistische therapeutische Effekte bewirkt werden können, wie bspw. eine verstärkerte Apoptose und schnellere und effizientere Tumorregression.Such simultaneous, e.g. dual, modulation or inhibition of two or more signal transduction pathways, e.g. ras-Raf-Mek-Erk signaling pathway, PI3K-Akt signaling pathway and / or SAPK signaling pathway, specifically Erk1 / Erk2 and / or PI3K and / or Jnk and / or p38, is advantageous over simply modulating or inhibiting a signal transduction pathway, as synergistic therapeutic effects can be effected, such as an increased apoptosis and faster and more efficient tumor regression.
Die überraschenden vorteilhaften Wirkungen der erfindungsgemäßen Verbindun- gen ermöglichen die Verfolgung multipler Therapieansätze in den physiologischen und/oder pathophysiologischen Zuständen oder Krankheitsbildern, die sensitiv sind für die Behandlung oder Modulation von bzw. vermittelt werden durch zwei oder mehrereThe surprisingly advantageous effects of the compounds according to the invention make it possible to pursue multiple therapeutic approaches in the physiological and / or pathophysiological states or clinical pictures which are sensitive to the treatment or modulation of or mediated by two or more
Signaltransduktionswege.Signal transduction pathways.
Ferner wurde überraschend und vorteilhaft festgestellt, dass die erfindungsgemäßen Verbindungen auch mit hoher Selektivität einwirken bzw. modulierend oder hemmend wirken können auf den ras-Raf-Mek-Erk-Signaltransduktionsweg bzw. Enzyme dessen und dass die oben dargestellten multiplen Wirkmechanismen und Therapieansätze auch mit diesem Signalweg bzw. Enzymen Anwendung finden können.Furthermore, it has surprisingly and advantageously been found that the compounds according to the invention can also act with high selectivity or have a modulating or inhibiting effect on the ras-Raf-Mek-Erk signal transduction pathway or enzymes and that the above-described multiple mechanisms of action and therapeutic approaches can also be used with this signal pathway or enzymes.
Ferner wurde überraschend und vorteilhaft festgestellt, dass die erfindungsgemä- ßen Verbindungen auch mit hoher Selektivität einwirken bzw. modulierend oder hemmend wirken können auf den PI3K-Akt-Signaltransduktionsweg bzw. Enzyme dessen und dass die oben dargestellten multiplen Wirkmechanismen und Therapieansätze auch mit diesem Signalweg bzw. Enzymen Anwendung finden können.Furthermore, it has surprisingly and advantageously been found that the compounds according to the invention can also act with high selectivity or have a modulating or inhibiting effect on the PI3K-Akt signal transduction pathway or enzymes thereof and that the multiple modes of action and therapeutic approaches described above can also be achieved with this signal pathway Enzyme can be used.
Weiterhin wurde überraschend und vorteilhaft festgestellt, dass die erfindungsgemäßen Verbindungen auch mit hoher Selektivität einwirken bzw. modulierend oder hemmend wirken können auf den SAPK-Signaltransduktionsweg bzw. Enzyme dessen und dass die oben dargestellten multiplen Wirkmechanismen und Therapieansätze auch mit diesem Signalwegn bzw. Enzymen Anwendung finden können.Furthermore, it has surprisingly and advantageously been found that the compounds according to the invention can also act with high selectivity or have a modulating or inhibiting effect on the SAPK signal transduction pathway or enzymes and that the above-described multiple mechanisms of action and therapeutic approaches also find application with this signal pathway or enzymes can.
Desweiteren wurde überraschend und vorteilhaft festgestellt, dass die erfindungsgemäßen Verbindungen auch mit hoher Selektivität einwirken bzw. modulierend oder hemmend wirken können auf Enzyme, wie ATM, ATR, mTOR, DNA-PK und/oder hSMG-1 , und dass die oben dargestellten multiplen Wirkmechanismen und Therapie- ansätze auch mit diesen Enzymen Anwendung finden können.Furthermore, it has surprisingly and advantageously been found that the compounds according to the invention can also act with high selectivity or have a modulating or inhibiting effect on enzymes such as ATM, ATR, mTOR, DNA-PK and / or hSMG-1, and that the multiple modes of action described above and therapy approaches can also be used with these enzymes.
Unter dem Begriff "Modulation" wird erfindungsgemäß folgendes verstanden: "Aktivierung, partielle Aktivierung, Inhibierung, partielle Inhibierung". Hierbei liegt es im Fachwissen des durchschnittlichen Fachmanns, eine solche Aktivierung, partielle Akti- vierung, Inhibierung oder partielle Inhibierung mittels der üblichen Mess- und Bestimmungsverfahren zu messen und zu bestimmen. So kann eine partielle Aktivierung bspw. in Relation zu einer vollständigen Aktivierung gemessen und bestimmt werden; ebenso eine partielle Inhibierung in Relation zu einer vollständigen Inhibierung.The term "modulation" is understood according to the invention as follows: "activation, partial activation, inhibition, partial inhibition". It is within the expertise of the average person skilled in the art to measure and determine such activation, partial activation, inhibition or partial inhibition by means of the customary measuring and determination methods. Thus, a partial activation can be measured and determined, for example, in relation to a complete activation; as well as a partial inhibition in relation to a complete inhibition.
Unter den Begriffen "Inhibierung, Inhibition und/oder Hemmung" wird erfindungsgemäß folgendes verstanden: "partielle oder vollständige Inhibierung, Inhibition und/oder Hemmung". Hierbei liegt es im Fachwissen des durchschnittlichen Fach- manns, eine solche partielle oder vollständige Inhibierung, Inhibition und/oder Hemmung mittels der üblichen Mess- und Bestimmungsverfahren zu messen und zu bestimmen. So kann eine partielle Inhibierung, Inhibition und/oder Hemmung bspw. in Relation zu einer vollständigen Inhibierung, Inhibition und/oder Hemmung gemessen und bestimmt werden.The terms "inhibition, inhibition and / or inhibition" are understood according to the invention as "partial or complete inhibition, inhibition and / or inhibition". Here, it is the expertise of the average specialist man to measure and determine such partial or complete inhibition, inhibition and / or inhibition by means of the usual measuring and determination methods. Thus, a partial inhibition, inhibition and / or inhibition can be measured and determined, for example, in relation to a complete inhibition, inhibition and / or inhibition.
Die Begriffe "Modulation" und "Inhibierung, Inhibition und/oder Hemmung" beziehen sich im Zusammenhang mit "Enzymen" und/oder "Kinasen" im Rahmen dieser Erfindung sowohl auf die inaktive Form (enzymatisch inaktiv) und/oder aktive Form (enzy- matisch aktiv) des jeweiligen Enzyms und/oder Kinase. Dies bedeutet im Rahmen die- ser Erfindung, dass eine erfindungsgemäße Verbindung ihre modulierende Wirkung an der inaktiven Form, aktiven Form oder beiden Formen des Enzyms und/oder Kinase entfalten kann.The terms "modulation" and "inhibition, inhibition and / or inhibition" in connection with "enzymes" and / or "kinases" in the context of this invention refer both to the inactive form (enzymatically inactive) and / or active form (enzymatic). active) of the respective enzyme and / or kinase. In the context of this invention, this means that a compound according to the invention can display its modulating effect on the inactive form, active form or both forms of the enzyme and / or kinase.
Die erfinderische Aufgabe wurde in einem weiteren Aspekt überraschender Weise dadurch gelöst, dass ein Arzneimittel bereitgestellt wird, enthaltend mindestens eine erfindungsgemäßen Verbindung.The inventive task has surprisingly been achieved in a further aspect by providing a pharmaceutical composition comprising at least one compound according to the invention.
Die erfinderische Aufgabe wurde in einem weiteren Aspekt überraschender Weise dadurch gelöst, dass ein Arzneimittel bereitgestellt wird, enthaltend mindestens eine erfindungsgemäßen Verbindung in Kombination mit mindestens einem weiteren pharmazeutischen Wirkstoff und/oder pharmazeutisch akzeptablen Träger- und/oder Hilfs- stoffen.The inventive task has surprisingly been achieved in a further aspect by providing a medicament comprising at least one compound according to the invention in combination with at least one further pharmaceutical active ingredient and / or pharmaceutically acceptable excipients and / or auxiliaries.
Die erfinderische Aufgabe wurde in einem weiteren Aspekt überraschender Weise dadurch gelöst, dass ein Verfahren zur Herstellung eines Arzneimittels bereitsgestellt wird, dadurch gekennzeichnet, daß ein oder mehrere erfindungsgemäßen Verbindungen mit pharmazeutisch akzeptablen Träger- und/oder Hilfsstoffen zu pharmazeutischen Zubereitungen verarbeitet, beziehungsweise in eine therapeutisch anwendbare Form gebracht werden.The inventive task has surprisingly been achieved in a further aspect by providing a process for the preparation of a medicament, characterized in that one or more compounds according to the invention with pharmaceutically acceptable carriers and / or excipients are processed into pharmaceutical preparations or into a therapeutic one applicable form.
Die erfinderische Aufgabe wurde in einem weiteren Aspekt überraschender Weise dadurch gelöst, dass die erfindungsgemäßen Verbindungen bereitgestellt werden, die als Wirkstoffe in Arzneimitteln zur Modulation von fehlgeleiteten zellulären Signaltrans- duktionsprozessen, insbesondere zur Beeinflussung der Funktion von aktiven und inaktiven Rezeptor-Tyrosinkinasen, sowie cytoplasmatischen Tyrosin-, Serin/Threonin- und Lipidkinasen, wie c-Raf, B-Raf, Mek, MAPKs, PDGFRbeta, Flt-3, IGF1 R, PI3K, PKB/Akt1 , c-Kit, c-Abl, FGFR1 und KDR, verwendet werden können.The inventive task has surprisingly been solved in a further aspect by providing the compounds according to the invention which as active ingredients in medicaments for modulating misdirected cellular signal transduction processes, in particular for influencing the function of active and inactive receptor tyrosine kinases, as well as cytoplasmic tyrosine, serine / threonine and lipid kinases, such as c-Raf, B-Raf, Mek, MAPKs , PDGFRbeta, Flt-3, IGF1R, PI3K, PKB / Akt1, c-Kit, c-Abl, FGFR1 and KDR.
Die erfinderische Aufgabe wurde in einem weiteren Aspekt überraschender Weise dadurch gelöst, dass die erfindungsgemäßen Verbindungen bereitgestellt werden, die zur Herstellung eines Arzneimittels zur Behandlung oder Prophylaxe von physiologi- sehen und/oder pathophysiologischen Zuständen in Säugetieren verwendet werden können, wobei die Behandlung oder Prophylaxe durch Modulation des oder der Signaltransduktionswege ausgewählt aus der Gruppe bestehend aus: „ras-Raf-Mek- Erk-Signaltransduktionsweg, PI3K-Akt-Signaltransduktionsweg und/oder SAPK- Signaltransduktionsweg" bewirkt wird.The inventive task has surprisingly been achieved in a further aspect by providing the compounds according to the invention which can be used for the preparation of a medicament for the treatment or prophylaxis of physiological and / or pathophysiological conditions in mammals, the treatment or prophylaxis Modulation of the signal transduction pathways selected from the group consisting of: "ras-Raf-Mek- Erk signal transduction pathway, PI3K-Akt signal transduction pathway and / or SAPK signal transduction pathway" is effected.
In einem weiteren Aspekt wurde die erfinderische Aufgabe überraschender Weise dadurch gelöst, dass die erfindungsgemäßen Verbindungen bereitgestellt werden, die zur Herstellung eines Arzneimittels zur Behandlung oder Prophylaxe von durch Enzyme ausgewählt aus der Gruppe bestehend aus: „ATM, ATR, mTOR, DNA-PK, hSMG- 1 " vermittelte physiologischen und/oder pathophysiologischen Zuständen in Säugetieren verwendet werden können.In a further aspect, the inventive task has surprisingly been achieved by providing the compounds according to the invention which are used for the preparation of a medicament for the treatment or prophylaxis of enzymes selected from the group consisting of: "ATM, ATR, mTOR, DNA-PK, hSMG-1 "mediated physiological and / or pathophysiological conditions in mammals can be used.
In einem weiteren Aspekt wurde die erfinderische Aufgabe überraschender Weise dadurch gelöst, dass die erfindungsgemäßen Verbindungen bereitgestellt werden, die die zur Herstellung eines Arzneimittels zur Behandlung oder Prophylaxe von physiologischen und/oder pathophysiologischen Zuständen in Säugetieren verwendet werden können, wobei die Behandlung oder Prophylaxe durch Modulation eines oder mehrerer Enzyme ausgewählt aus der Gruppe bestehend aus: „ATM, ATR, mTOR, DNA-PK, hSMG-1" bewirkt wird.In a further aspect, the inventive task has surprisingly been achieved by providing the compounds of the invention which can be used for the preparation of a medicament for the treatment or prophylaxis of physiological and / or pathophysiological conditions in mammals, wherein the treatment or prophylaxis by modulation one or more enzymes selected from the group consisting of: "ATM, ATR, mTOR, DNA-PK, hSMG-1" is effected.
In einer bevorzugten Ausführungsform werden die erfindungsgemäßen Verbindungen bereitgestellt zur Verwendung zur Herstellung eines Arzneimittels zur Behandlung und/oder Prophylaxe von durch den ras-Raf-Mek-Erk-Signaltransduktionsweg und den PI3K-Akt-Signaltransduktionsweg vermittelten physiologischen und/oder pathophysio- logischen Zuständen in Säugetieren und/oder zur Herstellung eines Arzneimittels zur Behandlung oder Prophylaxe von physiologischen und/oder pathophysiologischen Zuständen in Säugetieren, wobei die Behandlung oder Prophylaxe durch Modulation des ras-Raf-Mek-Erk-Signaltransduktionswegs und des PI3K-Akt-Signaltransduktionswegs bewirkt wird.In a preferred embodiment, the compounds of the invention are provided for use in the manufacture of a medicament for the treatment and / or prophylaxis of by the Ras-Raf-Mek-Erk signal transduction pathway and the PI3K-Akt signal transduction pathway mediated physiological and / or pathophysiological conditions in mammals and / or for the manufacture of a medicament for the treatment or prophylaxis of physiological and / or pathophysiological conditions in mammals, wherein the treatment or prophylaxis by modulation of the ras Raf Mek -Erk signal transduction pathway and the PI3K-Akt signal transduction pathway.
In einem weiteren Aspekt wurde die erfinderische Aufgabe überraschender Weise dadurch gelöst, dass die erfindungsgemäßen Verbindungen bereitgestellt werden, die zur Herstellung eines Arzneimittels zur Behandlung oder Prophylaxe von durch den ras-Raf-Mek-Erk-Signaltransduktionsweg vermittelte physiologischen und/oder pathophysiologischen Zuständen in Säugetieren verwendet werden können.In a further aspect, the inventive task has been surprisingly achieved by providing the compounds of the invention for the manufacture of a medicament for the treatment or prophylaxis of physiological and / or pathophysiological conditions in mammals mediated by the ras-Raf-Mek-Erk signal transduction pathway can be used.
In einem weiteren Aspekt wurde die erfinderische Aufgabe überraschender Weise dadurch gelöst, dass die erfindungsgemäßen Verbindungen bereitgestellt werden, die zur Herstellung eines Arzneimittels zur Behandlung oder Prophylaxe von durch den PI3K-Akt-Signaltransduktionsweg vermittelte physiologischen und/oder pathophysiologischen Zuständen in Säugetieren verwendet werden können.In a further aspect, the inventive task has surprisingly been achieved by providing the compounds of the invention which can be used for the preparation of a medicament for the treatment or prophylaxis of physiological and / or pathophysiological conditions mediated by the PI3K-Akt signal transduction pathway in mammals.
In einem weiteren Aspekt wurde die erfinderische Aufgabe überraschender Weise dadurch gelöst, dass die erfindungsgemäßen Verbindungen bereitgestellt werden, die die zur Herstellung eines Arzneimittels zur Behandlung oder Prophylaxe von physiologischen und/oder pathophysiologischen Zuständen in Säugetieren verwendet werden können, wobei die Behandlung oder Prophylaxe durch Modulation des PI3K-Akt- Signaltransduktionswegs bewirkt wird.In a further aspect, the inventive task has surprisingly been achieved by providing the compounds of the invention which can be used for the preparation of a medicament for the treatment or prophylaxis of physiological and / or pathophysiological conditions in mammals, wherein the treatment or prophylaxis by modulation of the PI3K-Akt signal transduction path is effected.
In einer bevorzugten Ausführungsform werden die erfindungsgemäßen Verbindungen bereitgestellt zur Verwendung zur Herstellung eines Arzneimittels zur Behandlung und/oder Prophylaxe von durch den SAPK-Signaltransduktionsweg und den PI3K-Akt- Signaltransduktionsweg vermittelten physiologischen und/oder pathophysiologischen Zuständen in Säugetieren und/oder zur Herstellung eines Arzneimittels zur Behandlung oder Prophylaxe von physiologischen und/oder pathophysiologischen Zuständen in Säugetieren, wobei die Behandlung oder Prophylaxe durch Modulation des SAPK- Signaltransduktionswegs und des PI3K-Akt-Signaltransduktionswegs bewirkt wird.In a preferred embodiment, the compounds of the invention are provided for use in the manufacture of a medicament for the treatment and / or prophylaxis of physiological and / or pathophysiological conditions mediated by the SAPK signal transduction pathway and the PI3K-Akt signal transduction pathway in mammals and / or for the manufacture of a medicament for the treatment or prophylaxis of physiological and / or pathophysiological conditions in Mammals, wherein the treatment or prophylaxis is effected by modulation of the SAPK signal transduction pathway and the PI3K-Akt signal transduction pathway.
In einem weiteren Aspekt wurde die erfinderische Aufgabe überraschender Weise dadurch gelöst, dass die erfindungsgemäßen Verbindungen bereitgestellt werden, die zur Herstellung eines Arzneimittels zur Behandlung oder Prophylaxe von durch denIn a further aspect, the inventive task has been surprisingly achieved in that the compounds of the invention are provided for the manufacture of a medicament for the treatment or prophylaxis of by the
SAPK-Signaltransduktionsweg vermittelte physiologischen und/oder pathophysiologi- schen Zuständen in Säugetieren verwendet werden können.SAPK signal transduction pathway mediated physiological and / or pathophysiological conditions in mammals can be used.
In einem weiteren Aspekt wurde die erfinderische Aufgabe überraschender Weise dadurch gelöst, dass die erfindungsgemäßen Verbindungen bereitgestellt werden, die die zur Herstellung eines Arzneimittels zur Behandlung oder Prophylaxe von physiologischen und/oder pathophysiologischen Zuständen in Säugetieren verwendet werden können, wobei die Behandlung oder Prophylaxe durch Modulation des SAPK- Signaltransduktionswegs bewirkt wird.In a further aspect, the inventive task has surprisingly been achieved by providing the compounds of the invention which can be used for the preparation of a medicament for the treatment or prophylaxis of physiological and / or pathophysiological conditions in mammals, wherein the treatment or prophylaxis by modulation the SAPK signal transduction path is effected.
In einer bevorzugten Ausführungsform werden die erfindungsgemäßen Verbindungen bereitgestellt zu den oben dargestellten Verwendungen, wobei die Modulation des ras-Raf-Mek-Erk-Signaltransduktionsweges bewirkt wird durch Modulation eines oder mehrerer Enzyme ausgewählt aus der Gruppe bestehend aus: „Tyrosinkinase, Se- rin/Threoninkinase, Rezeptor-Tyrosinkinase, cytoplasmatische Tyrosinkinase, cy- toplasmatische Serin/Threoninkinase" und bevorzugt ausgewählt aus der Gruppe bestehend aus: „Erk, Erk1 , Erk2".In a preferred embodiment, the compounds of the present invention are provided for the uses set forth above, wherein the modulation of the ras Raf-Mek-Erk signal transduction pathway is effected by modulation of one or more enzymes selected from the group consisting of: "tyrosine kinase, serine / Threonine kinase, receptor tyrosine kinase, cytoplasmic tyrosine kinase, cytoplasmic serine / threonine kinase "and preferably selected from the group consisting of:" Erk, Erk1, Erk2 ".
In einer weiteren bevorzugten Ausführungsform werden die erfindungsgemäßenIn a further preferred embodiment, the inventive
Verbindungen bereitgestellt zu den oben dargestellten Verwendungen, wobei die Modulation des PI3K-Akt-Signaltransduktionsweges bewirkt wird durch Modulation eines oder mehrerer Enzyme ausgewählt aus der Gruppe bestehend aus: „Lipidkinasen" und bevorzugt ausgewählt aus der Gruppe bestehend aus: „PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34p". In einer weiteren bevorzugten Ausführungsform werden die erfindungsgemäßen Verbindungen bereitgestellt zu den oben dargestellten Verwendungen, wobei die Modulation des SAPK-Signaltransduktionsweges bewirkt wird durch Modulation eines oder mehrerer Enzyme ausgewählt aus der Gruppe bestehend aus: „Tyrosinkinase, Serin/Threoninkinase, Rezeptor-Tyrosinkinase, cytoplasmatische Tyrosinkinase, cy- toplasmatische Serin/Threoninkinase"und bevorzugt ausgewählt aus der Gruppe bestehend aus: „Jnk, Jnk1 , Jnk2, Jnk3, p38, p38alpha, p38beta, p38gamma, p38delta".Compounds provided for the uses set forth above, wherein the modulation of the PI3K-Akt signal transduction pathway is effected by modulating one or more enzymes selected from the group consisting of: "lipid kinases" and preferably selected from the group consisting of: "PI3K, PI3Kalpha, PI3Kbeta , PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34p ". In another preferred embodiment, the compounds of the present invention are provided for the uses set forth above, wherein the modulation of the SAPK signal transduction pathway is effected by modulating one or more enzymes selected from the group consisting of: "tyrosine kinase, serine / threonine kinase, receptor tyrosine kinase, cytoplasmic Tyrosine kinase, cytoplasmic serine / threonine kinase "and preferably selected from the group consisting of:" Jnk, Jnk1, Jnk2, Jnk3, p38, p38alpha, p38beta, p38gamma, p38delta ".
In einem weiteren Aspekt wurde die erfinderische Aufgabe überraschender Weise dadurch gelöst, dass die erfindungsgemäßen Verbindungen gemäß der oben dargestellten Aspekte, bevorzugten Ausführungsformen und Verwendungen bereitgestellt werden, die zur Herstellung eines Arzneimittels zur Behandlung oder Prophylaxe von physiologischen und/oder pathophysiologischen Zuständen in Säugetieren verwendet werden können, wobei die Behandlung oder Prophylaxe durch Modulation von zwei oder mehrerer Enzyme bewirkt wird.In a further aspect, the inventive task has surprisingly been accomplished by providing the compounds of the present invention in accordance with the aspects, preferred embodiments, and uses described above used in the preparation of a medicament for the treatment or prophylaxis of physiological and / or pathophysiological conditions in mammals wherein the treatment or prophylaxis is effected by modulation of two or more enzymes.
In einer weiter bevorzugten Ausführungsform werden die erfindungsgemäßen Verbindungen bereitgestellt zu den oben dargestellten Verwendungen, wobei bei der durch Modulation von zwei oder mehrerer Enzyme bewirkten Behandlung oder Prophy- laxe mindestens ein Enzym ausgewählt ist aus der Gruppe bestehend aus: "Erk, Erk1 , Erk2" und mindestens ein Enzym ausgewählt ist aus der Gruppe bestehend aus: „PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34p".In a further preferred embodiment, the compounds according to the invention are provided for the uses described above, wherein in the treatment or prophylaxis brought about by modulation of two or more enzymes, at least one enzyme is selected from the group consisting of: "Erk, Erk1, Erk2" and at least one enzyme is selected from the group consisting of: "PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34p".
In einer weiter bevorzugten Ausführungsform werden die erfindungsgemäßen Verbindungen bereitgestellt zu den oben dargestellten Verwendungen, wobei bei der durch Modulation von zwei oder mehrerer Enzyme bewirkten Behandlung oder Prophylaxe mindestens ein Enzym ausgewählt ist aus der Gruppe bestehend aus: "Jnk, Jnk1 , Jnk2, Jnk3, p38, p38alpha, p38beta, p38gamma, p38delta" und mindestens ein Enzym ausgewählt ist aus der Gruppe bestehend aus: „PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34p". In einer weiter bevorzugten Ausführungsform werden die erfindungsgemäßen Verbindungen bereitgestellt zu den oben dargestellten Verwendungen, wobei bei der durch Modulation von zwei oder mehrerer Enzyme bewirkten Behandlung oder Prophylaxe mindestens ein Enzym ausgewählt ist aus der Gruppe bestehend aus: "Erk, Erk1 , Erk2" und mindestens ein Enzym ausgewählt ist aus der Gruppe bestehend aus: „ATM, ATR, mTOR, DNA-PK, hSMG-1 ".In a further preferred embodiment, the compounds according to the invention are provided for the uses described above, wherein in the treatment or prophylaxis brought about by modulation of two or more enzymes at least one enzyme is selected from the group consisting of: "Jnk, Jnk1, Jnk2, Jnk3, p38, p38alpha, p38beta, p38gamma, p38delta "and at least one enzyme selected from the group consisting of:" PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34p ". In a further preferred embodiment, the compounds according to the invention are provided for the uses described above, wherein in the treatment or prophylaxis brought about by modulation of two or more enzymes, at least one enzyme is selected from the group consisting of: "Erk, Erk1, Erk2" and at least an enzyme is selected from the group consisting of: "ATM, ATR, mTOR, DNA-PK, hSMG-1".
In einer weiter bevorzugten Ausführungsform werden die erfindungsgemäßen Verbindungen bereitgestellt zu den oben dargestellten Verwendungen, wobei bei der durch Modulation von zwei oder mehrerer Enzyme bewirkten Behandlung oder Prophylaxe mindestens ein Enzym ausgewählt ist aus der Gruppe bestehend aus: "Jnk, Jnk1 , Jnk2, Jnk3, p38, p38alpha, p38beta, p38gamma, p38delta" und mindestens ein Enzym ausgewählt ist aus der Gruppe bestehend aus: „ATM, ATR, mTOR, DNA-PK, hSMG- 1 ".In a further preferred embodiment, the compounds according to the invention are provided for the uses described above, wherein in the treatment or prophylaxis brought about by modulation of two or more enzymes at least one enzyme is selected from the group consisting of: "Jnk, Jnk1, Jnk2, Jnk3, and at least one enzyme is selected from the group consisting of: "ATM, ATR, mTOR, DNA-PK, hSMG-1".
In einer weiter bevorzugten Ausführungsform werden die erfindungsgemäßen Verbindungen bereitgestellt zu den oben dargestellten Verwendungen, wobei bei der durch Modulation von zwei oder mehrerer Enzyme bewirkten Behandlung oder Prophylaxe mindestens ein Enzym ausgewählt ist aus der Gruppe bestehend aus: „PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K- Vps34p" und mindestens ein Enzym ausgewählt ist aus der Gruppe bestehend aus: „ATM, ATR, mTOR, DNA-PK, hSMG-1 ".In a further preferred embodiment, the compounds according to the invention are provided for the uses described above, wherein in the treatment or prophylaxis brought about by modulation of two or more enzymes at least one enzyme is selected from the group consisting of: "PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34p "and at least one enzyme is selected from the group consisting of:" ATM, ATR, mTOR, DNA-PK, hSMG-1 ".
In einer ferner bevorzugten Ausführungsform werden die erfindungsgemäßen Ver- bindungen bereitgestellt zu den oben dargestellten Verwendungen, wobei die Modulation eine Inhibition ist.In a further preferred embodiment, the compounds according to the invention are provided for the uses described above, wherein the modulation is an inhibition.
Die erfindungsgemäßen Verbindungen können im Rahmen dieser Erfindung allen bekannten Säugetieren, insbesondere dem Menschen, zur Behandlung und/oder Pro- phylaxe verabreicht werden.In the context of this invention, the compounds according to the invention can be administered to all known mammals, in particular humans, for the treatment and / or prophylaxis.
In einer anderen bevorzugten Ausführungsform werden die erfindungsgemäßen Verbindungen bereitgestellt zu den oben dargestellten Verwendungen, wobei das Sau- getier ausgewählt ist aus der Gruppe bestehend aus: „Mensch, Nutztier, Vieh, Haustier, Rind, Kuh, Schaf, Schwein, Ziege, Pferd, Pony, Esel, Maulesel, Maultier, Hase, Kaninchen, Katze, Hund, Meerschweinchen, Hamster, Ratte, Maus" und bevorzugt ein Mensch ist.In another preferred embodiment, the compounds according to the invention are provided for the uses described above, wherein the acid animal selected from the group consisting of: "human, farm animal, livestock, domestic animal, cattle, cow, sheep, pig, goat, horse, pony, donkey, mule, mule, rabbit, rabbit, cat, dog, guinea pig, hamster, Rat, mouse "and prefers a human.
Die erfindungsgemäßen Verbindungen können im Rahmen dieser Erfindung zur Behandlung und/oder Prophylaxe aller bekannten physiologischen und/oder pathophy- siologischen Zustände verwendet warden.The compounds according to the invention can be used in the context of this invention for the treatment and / or prophylaxis of all known physiological and / or pathophysiological states.
In einer bevorzugten Ausführungsform werden die erfindungsgemäßen Verbindun- gen bereitgestellt zu den oben dargestellten Verwendungen, wobei die physiologischen und/oder pathophysiologischen Zustände ausgewählt sind aus der Gruppe bestehend aus: „maligne Tumore, benigne Tumore, entzündliche Erkrankungen, Entzündungen, Schmerzen, rheumatische Erkrankungen, arthritische Erkrankungen, HIV Infektionen, neurologische oder neurodegenerative Erkrankungen, Rheuma, Arthritis, AIDS, ARC (AIDS related complex), Kaposi-Sarkom, Tumore ausgehend vom Hirn und/oder Nervensystem und/oder Hirnhäuten, Demenz, Alzheimer, hyperproliferative Erkrankungen, Psoriasis, Endometriose, Narbenbildung, benigne Prostatahyperplasie (BPH), Erkrankungen des Immunsystems, Autoimmunerkrankungen, Immundefizienzerkrankungen, Kolontumor, Magentumor, Darmtumor, Lungentumor, Pankreastumor, Ovarialtumor, Prosta- tatumor, Leukämie, Melanom, Lebertumor, Nierentumor, Kopftumor, Halstumor, Gliom, Brust-Tumor, Gebärmutterkrebs, Endometriumkrebs, Gebärmutterhalskrebs, Hirntumor, Adenokanthom, Blasenkrebs, Magentumor, Kolorectalrumor, Speiseröhrenkrebs, gynoko- logischer Tumor, Ovartumor, Schilddrüsenkrebs, Lymphom, chronische Leukämie, akute Leukämie, Restenose, Diabetis, diabetische Nephropathie, fibrotische Erkrankungen, cystische Fibrose, maligne Nephrosklerose, thrombotische Microangiopathie Syndrom, Organtransplantat-Abstoßung, Glomerulpathien, Erkrankungen des Stoffwechsels, solide/feste Tumore, rheumatische Arthritis, diabetische Retinopathie, Asthma, Allergien, allergische Erkrankungen, chronische obstruktive pulmonare Erkrankungen, inflammatorische Bowel-Erkrankung, Fibrose, Atheriosklerose, Herzerkrankungen, cardiovaskuläre Erkrankungen, Erkrankungen des Herzmuskels, vaskuläre Erkrankungen, angiogeneti- sche Erkrankungen, Nierenerkrankungen, Rhinitis, Grave Erkrankung, fokale Ischemie, Herzversagen, Ischemie, kardische Hypertrophie, Nierenversagen, kardische Myozyten Fehlfunktion, Bluthochdruck, Vasoconstriktion, Schlaganfall, anaphylaktischer Schock, Blutplättchen-Verklumpung, Skelettmuskelatrophie, Fettleibigkeit, Übergewicht, Glukose Homeostase, kongestive Herzinsuffizienz, Angina, Herzanfall, Herzinfarkt, Hyperglykä- mie, Hypoglykämie, Hypertension".In a preferred embodiment, the compounds according to the invention are provided for the uses described above, the physiological and / or pathophysiological states being selected from the group comprising: "malignant tumors, benign tumors, inflammatory diseases, inflammations, pain, rheumatic diseases, arthritic diseases, HIV infections, neurological or neurodegenerative diseases, rheumatism, arthritis, AIDS, ARC (AIDS related complex), Kaposi's sarcoma, tumors from the brain and / or nervous system and / or meninges, dementia, Alzheimer's disease, hyperproliferative disorders, psoriasis, Endometriosis, scarring, benign prostatic hyperplasia (BPH), immune system disorders, autoimmune diseases, immunodeficiency diseases, colon tumor, gastric tumor, colon tumor, lung tumor, pancreatic tumor, ovarian tumor, prostate tumor, leukemia, melanoma, liver tumor, kidney tumor, head tumor, cervical tumor, glioma, breast cancer Tumor, uterine cancer, endometrial cancer, cervical cancer, brain tumor, adenocanthoma, bladder cancer, gastric tumor, colorectal rumenor, esophageal cancer, gyno-logical tumor, ovarian tumor, thyroid cancer, lymphoma, chronic leukemia, acute leukemia, restenosis, diabetes, diabetic nephropathy, fibrotic diseases, cystic fibrosis, malignant nephrosclerosis , thrombotic microangiopathy syndrome, organ transplant rejection, glomerulopathies, metabolic disorders, solid / solid tumors, rheumatoid arthritis, diabetic retinopathy, asthma, allergies, allergic diseases, chronic obstructive pulmonary diseases, inflammatory bowel disease, fibrosis, atherosclerosis, heart disease, cardiovascular Diseases, diseases of the heart muscle, vascular diseases, angiogenic diseases, renal diseases, rhinitis, Grave disease, focal ischemia, heart failure, ischaemia, cardiac hypertrophy, renal failure, cardiac myocytes malfunction, B hypertension, vasoconstriction, stroke, anaphylactic shock, platelet clumping, skeletal muscle atrophy, obesity, obesity, glucose Homeostasis, congestive heart failure, angina, heart attack, myocardial infarction, hyperglycemia, hypoglycaemia, hypertension ".
In einem weiteren Aspekt der vorliegenden Erfindung wurde die erfinderische Auf- gäbe überraschender weise dadurch gelöst, dass die erfindungsgemäßen Verbindungen gemäß der oben dargestellten Aspekte, bevorzugten Ausführungsformen und Verwendungen bereitgestellt werden, zur Verwendung zur Herstellung eines Arzneimittels zur Behandlung oder Prophylaxe von physiologischen und/oder pathophysiologi- schen Zuständen in Säugetieren, wobei das Arzneimittel mindestens eine weitere pharmakologisch aktive Substanz umfasst.In a further aspect of the present invention, the inventive task was surprisingly achieved by providing the compounds according to the invention in accordance with the aspects, preferred embodiments and uses described above, for use in the manufacture of a medicament for the treatment or prophylaxis of physiological and / or pathophysiological conditions in mammals, wherein the medicament comprises at least one further pharmacologically active substance.
In einem weiteren Aspekt der vorliegenden Erfindung wurde die erfinderische Aufgabe überraschender weise dadurch gelöst, dass die erfindungsgemäßen Verbindungen gemäß der oben dargestellten Aspekte, bevorzugten Ausführungsformen und Verwendungen bereitgestellt werden, zur Verwendung zur Herstellung eines Arzneimittels zur Behandlung oder Prophylaxe von physiologischen und/oder pathophysiologi- schen Zuständen in Säugetieren, wobei das Arzneimittel vor und/oder während und/oder nach der Behandlung mit mindestens einer weiteren pharmakologisch aktiven Substanz verabreicht wird.In a further aspect of the present invention, the inventive task was surprisingly achieved by providing the compounds according to the invention in accordance with the aspects, preferred embodiments and uses described above, for use in the preparation of a medicament for the treatment or prophylaxis of physiological and / or pathophysiological In mammals, the drug is administered before and / or during and / or after treatment with at least one other pharmacologically active substance.
In einem weiteren Aspekt der vorliegenden Erfindung wurde die erfinderische Aufgabe überraschender weise dadurch gelöst, dass die erfindungsgemäßen Verbindungen gemäß der oben dargestellten Aspekte, bevorzugten Ausführungsformen und Verwendungen bereitgestellt werden, zur Verwendung zur Herstellung eines Arzneimit- tels zur Behandlung oder Prophylaxe von physiologischen und/oder pathophysiologi- schen Zuständen in Säugetieren, wobei das Arzneimittel vor und/oder während und/oder nach der Behandlung mit Strahlentherapie und/oder Chirurgie verabreicht wird.In a further aspect of the present invention, the inventive task has surprisingly been achieved by providing the compounds according to the invention in accordance with the aspects, preferred embodiments and uses described above, for use in the manufacture of a medicament for the treatment or prophylaxis of physiological and / or pathophysiological conditions in mammals, wherein the drug is administered before and / or during and / or after treatment with radiotherapy and / or surgery.
Die erfindungsgemäßen Verbindungen können dabei Rahmen dieser Erfindung mit allen bekannten pharmakologisch aktiven Substanzen in einer Kombinationstherapie wie dargestellt verabreicht werden. In einer bevorzugten Ausführungsform werden die erfindungsgemäßen Verbindungen bereitgestellt zu den oben dargestellten Verwendungen, wobei die weitere pharmakologisch aktive Substanz ausgewählt ist aus der Gruppe bestehend aus: "DNA Topoisomerase I und/oder Il Inhibitoren, DNA Interkalatoren, alkylierende Agentien, Microtubuli Destabilisatoren, Hormon- und/oder Wachstumsfaktor-Rezeptor-Agonisten und/oder -Antagonisten, Antikörper gegen Wachstumsfaktoren und deren Rezeptoren, Kinase Inhibitoren, Antimetabolite".The compounds according to the invention can be administered within the scope of this invention with all known pharmacologically active substances in a combination therapy as shown. In a preferred embodiment, the compounds according to the invention are provided for the uses described above, wherein the further pharmacologically active substance is selected from the group consisting of: "DNA topoisomerase I and / or II inhibitors, DNA intercalators, alkylating agents, microtubule destabilizers, hormone and / or growth factor receptor agonists and / or antagonists, antibodies to growth factors and their receptors, kinase inhibitors, antimetabolites ".
In einer bevorzugten Ausführungsform werden die erfindungsgemäßen Verbindungen bereitgestellt zu den oben dargestellten Verwendungen, wobei die weitere phar- makologisch aktive Substanz ausgewählt ist aus der Gruppe bestehend aus: "Aspara- ginase, Bleomycin, Carboplatin, Carmustin, Chlorambucil, Cisplatin, Colaspase, Cyc- lophosphamid, Cytarabin, Dacarbazin, Dactinomycin, Daunorubicin, Doxorubi- cin(Adriamycin), Epirubicin, Etoposide, 5-Fluorouracil, Hexamethylmelamin, Hydrox- harnstoff, Ifosfamid, Irinotecan, Leucovorin, Lomustin, Mechlorethamin,6- Mercaptopurin, Mesna, Methotrexat, Mitomycin C, Mitoxantrone, Prednisolon, Prednison, Procarbazin, Raloxifen, Streptozocin, Tamoxifen, Thioguanin, Topotecan, Vinblastin, Vincristin, Vindesin, Aminoglutethimid, L-Asparaginase, Azathioprin, 5- Azacytidin cladribin, Busulfan, Diethylstilbestrol, 2', 2'-Difluorodeoxycytidin, Docetaxel, Erythrohydroxynonyladenin, Ethinylestradiol, 5-Fluorodeoxyuridin, 5- Fluorodeoxyuridin Monophosphat, Fludarabin Phosphate, Fluoxymesteron, Flutamid, Hydroxyprogesteron Caproat, Idarubicin, Interferon, Medroxyprogesteron Acetat, Megestrol Acetat, Melpha- lan, Mitotan, Paclitaxel, Oxaliplatin, Pentostatin, N-Phosphonoacetyl-L-aspartat (PA- LA), Plicamycin, Semustin, Teniposide, Testosteron Propionat, Thiotepa, Trimethylme- lamin, Uridine, Vinorelbin, Epothilon, Gemcitabin, Taxotere, BCNU, CCNU, DTIC, 5- Fluorouarcil, Herceptin, Avastin, Erbitux, Sorafenib, Gleevec, Iressa, Tarceva, Rapa- mycin, Actinomycin D".In a preferred embodiment, the compounds according to the invention are provided for the uses described above, wherein the further pharmacologically active substance is selected from the group consisting of: "asparaginase, bleomycin, carboplatin, carmustine, chlorambucil, cisplatin, colaspase, cyclobin lophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, doxorubicin (adriamycin), epirubicin, etoposide, 5-fluorouracil, hexamethylmelamine, hydroxurea, ifosfamide, irinotecan, leucovorin, lomustine, mechlorethamine, 6-mercaptopurine, mesna, methotrexate, mitomycin C, mitoxantrone, prednisolone, prednisone, procarbazine, raloxifene, streptozocin, tamoxifen, thioguanine, topotecan, vinblastine, vincristine, vindesine, aminoglutethimide, L-asparaginase, azathioprine, 5-azacytidine cladribine, busulfan, diethylstilbestrol, 2 ', 2'-difluorodeoxycytidine , Docetaxel, erythrohydroxynonyladenine, ethinylestradiol, 5-fluorodeoxyuridine, 5-fluorodeoxyuridine monophosphate, Fluda rabin phosphates, fluoxymesterone, flutamide, hydroxyprogesterone caproate, idarubicin, interferon, medroxyprogesterone acetate, megestrol acetate, melphalan, mitotane, paclitaxel, oxaliplatin, pentostatin, N-phosphonoacetyl-L-aspartate (PA-LA), plicamycin, semustin, teniposide , Testosterone propionate, thiotepa, trimethylmelamine, uridines, vinorelbine, epothilone, gemcitabine, taxotere, BCNU, CCNU, DTIC, 5-fluorouracil, Herceptin, Avastin, Erbitux, sorafenib, Gleevec, Iressa, Tarceva, rapamycin, actinomycin D ".
Die orale Verabreichung kann beispielsweise in fester Form als Tablette, Kapsel, Gelkapsel, Dragee, Granulat oder Pulver, jedoch auch in Form einer trinkbaren Lösung erfolgen. Zur oralen Verabreichung können die neuen, erfindungsgemäßenThe oral administration can be carried out, for example, in solid form as a tablet, capsule, gel capsule, dragee, granules or powder, but also in the form of a drinkable solution. For oral administration, the novel, inventive
Verbindungen, wie vorstehend definiert, mit bekannten und gewöhnlich verwendeten, physiologisch verträglichen Hilfs- und Trägerstoffen kombiniert werden, wie z.B. Gummiarabikum, Talkum, Stärke, Zucker wie z.B. Mannit, Methylcellulose, Lactose, Gelatine, oberflächenaktive Mittel, Magnesiumstearat, Cyclodextrine, wässrige oder nicht- wässrige Trägerstoffe, Verdünnungsmittel, Dispergiermittel, Emulgatoren, Schmiermittel, Konservierungsstoffe und Geschmacksstoffe (z.B. etherische Öle). Die erfindungsgemäßen Verbindungen können auch in einer mikropartikulären, z.B. nanopartikulären Zusammensetzung dispergiert sein.Compounds, as defined above, are combined with known and commonly used, physiologically acceptable excipients and carriers, such as gum arabic, talc, starch, sugars such as mannitol, methyl cellulose, lactose, gelatin, surfactants, magnesium stearate, cyclodextrins, aqueous or otherwise - aqueous carriers, diluents, dispersants, emulsifiers, lubricants, preservatives and flavorings (eg essential oils). The compounds of the invention may also be dispersed in a microparticulate, eg nanoparticulate composition.
Die nicht orale Verabreichung kann beispielsweise durch intravenöse, subkutane oder intramuskuläre Injektion steriler wässriger oder öliger Lösungen, Suspensionen oder Emulsionen, mittels Implantaten oder durch Salben, Cremes oder Suppositorien erfolgen. Gegebenenfalls kann auch eine Verabreichung als Retardform erfolgen. Implantate können inerte Materialen enthalten, z.B. biologisch abbaubare Polymere oder synthetische Silicone wie z.B. Silicongummi. Eine intravaginale Verabreichung kann z.B. mittels Vaginalringen erfolgen. Eine intrauterine Verabreichung kann z.B. mittels Diaphragmen oder anderer geeigneter intrauteriner Vorrichtungen erfolgen. Darüber hinaus ist auch eine transdermale Verabreichung, insbesondere mittels einer dazu geeigneten Formulierung und/oder geeigneter Mittel wie z.B. Pflaster, vorgesehen.Non-oral administration can be accomplished, for example, by intravenous, subcutaneous or intramuscular injection of sterile aqueous or oily solutions, suspensions or emulsions, by implants or by ointments, creams or suppositories. Optionally, it can also be administered as a sustained-release form. Implants may contain inert materials, e.g. biodegradable polymers or synthetic silicones such as e.g. Silicone rubber. Intravaginal administration may e.g. done by vaginal rings. Intrauterine administration may e.g. by means of diaphragms or other suitable intrauterine devices. In addition, transdermal administration, in particular by means of a formulation suitable therefor and / or suitable means, e.g. Plaster, provided.
Die erfindungsgemäßen Arzneimittel können in einer geeigneten Darreichungsform auf die Haut, epicutan als Lösung, Suspension, Emulsion, Schaum, Salbe, Paste oder Pflaster; über die Mund- und Zungenschleimhaut, buccal, lingual oder sublingual als Tablette, Pastille, Dragees, Linctus oder Gurgelwasser; über die Magen- und Darmschleimhaut, enteral als Tablette, Dragees, Kapsel, Lösung, Suspension oder Emulsion; über die Rectumschleimhaut, rectal als Suppositorium, Rectalkapsel oder Salbe; über die Nasenschleimhaut, nasal als Tropfen, Salben oder Spray; über das Bronchial- und Alveolarepithel, pulmonal oder per inhalationem als Aerosol oder Inhalat; über die Conjunctiva, conjunctival als Augentropfen, Augensalbe, Augentabletten, Lamellae oder Augenwasser; über die Schleimhäute der Genitalorgane, intravaginal als Vaginalkugeln, Salben und Spülung, intrauterin als Uterus-Pessare; über die ableitenden Harnwege, intraurethral als Spülung, Salbe oder Arzneistäbchen; in eine Arterie, intraarteriell als Injektion; in eine Vene, intravenös als Injektion oder Infusion; in die Haut, intracutan als Injektion oder Implantat; unter die Haut, subcutan als Injektion oder Implantat; in den Muskel, intramusculär als Injektion oder Implantat; in die Bauchhöhle, intraperitoneal als Injektion oder Infusion verabreicht werden. Die erfindungsgemäßen Verbindungen können in Hinblick auf praktische therapeutische Erfordernisse mittels geeigneter Maßnahmen in ihrer Arzneistoffwirkung verlängert werden. Dieses Ziel kann auf chemischem und/oder galenischem Wege erreicht werden. Beispiele für die Erzielung einer Wirkungsverlängerung sind der Einsatz von Implantaten und Liposomen, die Bildung von schwerlöslichen Salzen und Komplexen oder der Einsatz von Kristall-Suspensionen.The medicaments according to the invention may be applied to the skin in a suitable dosage form, epicutaneously as a solution, suspension, emulsion, foam, ointment, paste or patch; via the mouth and tongue mucosa, buccally, lingually or sublingually as a tablet, troche, dragee, linctus or gargle; via the gastric and intestinal mucosa, enterally as a tablet, dragees, capsule, solution, suspension or emulsion; via the rectal mucosa, rectal as suppository, rectal capsule or ointment; via the nasal mucosa, nasally as drops, ointments or spray; via the bronchial and alveolar epithelium, pulmonary or by inhalation as aerosol or inhalant; via the conjunctiva, conjunctival as eye drops, eye ointment, eye tablets, lamellas or eye water; via the mucous membranes of the genital organs, intra vaginally as vaginal balls, ointments and rinses, intrauterine as uterine pessaries; via the draining urinary tract, intraurethrally as a conditioner, ointment or medicament sticks; in an artery, intraarterially as an injection; into a vein, intravenously as an injection or infusion; into the skin, intracutaneously as an injection or implant; under the skin, subcutaneously as an injection or implant; in the muscle, intramuscularly as an injection or implant; into the abdominal cavity, administered intraperitoneally as an injection or infusion. The compounds of the invention can be extended in terms of practical therapeutic requirements by means of suitable measures in their drug effect. This goal can be achieved by chemical and / or galenic means. Examples of achieving an effect extension are the use of implants and liposomes, the formation of poorly soluble salts and complexes or the use of crystal suspensions.
Wie bereits vorstehend erläutert, können die neuen, erfindungsgemäßen Verbindungen auch mit weiteren pharmazeutisch aktiven Wirkstoffen kombiniert werden. Im Rahmen einer Kombinationstherapie können die einzelnen wirksamen Bestandteile gleichzeitig oder getrennt verabreicht werden, und zwar entweder auf demselben Wege (z.B. oral) oder auf getrennten Wegen (z.B. oral und als Injektion). Sie können in gleichen oder unterschiedlichen Mengen in einer Einheitsdosis vorliegen bzw. verabreicht werden. Es kann auch ein bestimmtes Dosierungsregime angewendet werden, sofern dies zweckmäßig erscheint. Auf diese Weise können auch mehrere der neuen, erfindungsgemäßen Verbindungen miteinander kombiniert werden.As already explained above, the novel compounds according to the invention can also be combined with other pharmaceutically active substances. In combination therapy, the individual active ingredients may be administered simultaneously or separately, either by the same route (e.g., orally) or by separate routes (e.g., orally and by injection). They may be administered in equal or different amounts in a unit dose. It is also possible to use a specific dosage regimen, if appropriate. In this way, several of the novel compounds of the invention can be combined.
Die Dosierung kann je nach Art der Indikation, der Schwere der Erkrankung, der Art der Verabreichung, dem Alter, Geschlecht, Körpergewicht und der Sensitivität des zu behandelnden Subjekts in einem breiten Rahmen variieren. Es entspricht den Fähigkeiten eines Fachmanns, eine „pharmakologisch wirksame Menge" der kombinierten pharmazeutischen Zusammensetzung zu bestimmen. Die Verabreichung kann in einer einzigen Dosis oder mehreren getrennten Dosierungen erfolgen.The dosage may vary widely depending on the nature of the indication, the severity of the disease, the mode of administration, the age, sex, body weight and the sensitivity of the subject to be treated. It is within the ability of one skilled in the art to determine a "pharmacologically effective amount" of the combined pharmaceutical composition, and may be administered in a single dose or multiple separate dosages.
Eine geeignete Einheitsdosis ist z.B. 0,001 mg bis 100 mg des Wirkstoffs, d.h. mindestens einer erfindungsgemäßen Verbindung und gegebenenfalls eines weiteren pharmazeutisch aktiven Wirkstoffs, pro kg Körpergewicht eines Patienten.A suitable unit dose is e.g. From 0.001 mg to 100 mg of the active ingredient, i. at least one compound according to the invention and optionally one further pharmaceutically active ingredient per kg of body weight of a patient.
In einem weiteren Aspekt der vorliegenden Erfindung sind demnach auch pharmazeutische Zusammensetzungen umfassend eine pharmakologisch aktive Menge min- destens einer erfindungsgemäßen Verbindung, bevorzugt Verbindung 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 , 52, 53, 54, 55, 56, 57, 58, 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 , 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 , 82, 83, 84 und/oder Verbindung 85, sowie gegebenenfalls pharmazeutisch verträgliche Träger- und/oder Hilfsstoffe, von der vorliegenden Erfindung er- fasst.Accordingly, in a further aspect of the present invention are also pharmaceutical compositions comprising a pharmacologically active amount of at least one compound according to the invention, preferably compound 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 14, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37 , 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62 , 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84 and / or compound 85, and optionally pharmaceutically acceptable excipients and / or adjuvants, of the present invention.
Bevorzugte und besonders bevorzugte pharmazeutische Zusammensetzungen sind jene, die mindestens eine der vorstehend genannten bevorzugten erfindungsgemäßen Verbindungen umfassen, In pharmazeutischen Zusammensetzungen gemäß der vorliegenden Erfindung können neben mindestens einer erfindungsgemäßen Verbindung, wie vorstehend definiert, auch noch mindestens ein weiterer pharmazeutisch aktiver Wirkstoffe vorliegen, wie vorstehend bereits näher aufgeführt.Preferred and particularly preferred pharmaceutical compositions are those which comprise at least one of the abovementioned preferred compounds according to the invention. In addition to at least one compound of the invention as defined above, in pharmaceutical compositions according to the present invention at least one further pharmaceutically active ingredient may also be present as above already listed in detail.
In den erfindungsgemäßen pharmazeutischen Zusammensetzungen liegt mindestens eine der neuen, erfindungsgemäßen Verbindungen, wie vorstehend definiert, in einer pharmakologischen aktiven Menge, vorzugsweise in einer Einheitsdosis, z.B. der vorstehend genannten Einheitsdosis, vor, und zwar vorzugsweise in einer Verabreichungsform, die eine orale Verabreichung ermöglicht.In the pharmaceutical compositions of the present invention, at least one of the novel compounds of the present invention, as defined above, is present in a pharmacologically active amount, preferably in a unit dose, e.g. the above-mentioned unit dose, preferably in an administration form which allows oral administration.
Bezüglich der erfindungsgemäße Verbindungen umfassende pharmazeutische Zusammensetzungen sowie bezüglich der Verwendung der erfindungsgemäßen Verbindungen als Arzneimittel sei hinsichtlich Verwendungs- undAs regards the pharmaceutical compositions comprising the compounds according to the invention and with regard to the use of the compounds according to the invention as medicaments, reference should be made as regards use and use
Verabreichungsmöglichkeiten auf das bereits im Zusammenhang mit der Verwendung der neuen, erfindungsgemäßen Verbindungen selbst, Gesagte verwiesen.Administration options refer to the already in connection with the use of the novel compounds according to the invention, what has been said.
In einem weiteren Aspekt der vorliegenden Erfindung wurde die erfinderische Aufgabe überraschender Weise gelöst durch die Bereitstellung eines Kits umfassend eine pharmakologisch aktive Menge mindestens einer bevorzugten erfindungsgemäßen Verbindung, wie oben dargestellt, und eine pharmakologisch aktive Menge mindestens eines weiteren pharmakologisch aktiven Wirkstoffs wie vorstehend definiert. Allqemeine Svnthesevorschriften für die erfindunqsqemäßen VerbindungenIn a further aspect of the present invention, the inventive object has surprisingly been achieved by providing a kit comprising a pharmacologically active amount of at least one preferred compound of the invention as set forth above and a pharmacologically active amount of at least one further pharmacologically active ingredient as defined above. General Synthesis Rules for the Compounds of the Invention
Die Verfahren zur Herstellung erfindungsgemäßer substituierter Pyrido[2,3- b]pyrazine werden nachstehend erläutert.The processes for preparing substituted pyrido [2,3-b] pyrazines according to the invention are explained below.
Die erfindungsgemäßen Verbindungen sind gemäß der folgenden Schemata (Schema 1 - 9) bzw. entsprechenden, dem Fachmann bekannten Verfahren erhältlich:The compounds according to the invention are obtainable according to the following schemes (Schemes 1 to 9) or corresponding processes known to the person skilled in the art:
Die in den folgenden Schemata aufgeführten Reste R1 bis R36 entsprechen in ihrer Bedeutung den weiter oben in Zusammenhang mit den allgemeinen Formeln (I) und (II) definierten Substituenten, bspw. Z-Resten, R-Resten, X-Resten, T-Resten usw. Die jeweilige Zuordnung ist für den Fachmann aufgrund seines durchschnittlichen Fach- Wissens einfach zu bewerkstelligen. The radicals R1 to R36 listed in the following schemes correspond in their meaning to the substituents defined above in connection with the general formulas (I) and (II), for example Z radicals, R radicals, X radicals, T radicals etc. The respective assignment is easy for the skilled person to accomplish due to his average technical knowledge.
Schema 1Scheme 1
I .Stufe ReduktionI. Stage reduction
1 21 2
2.Stufe2nd stage
2.Stufe2nd stage
Vorstufen für ausgewählte Beispiele der erfindungsgemäßen Pyrido[2,3-b]pyrazine, bei denen die Substituenten R2 und R4 mit Wasserstoff substituiert sein sollen, sind beispielsweise nach dem Verfahren in Schema 2 bzw. einem entsprechenden, dem Fachmann bekannten Verfahren erhältlich. Schema 2Precursors for selected examples of the pyrido [2,3-b] pyrazines according to the invention, in which the substituents R 2 and R 4 are to be substituted by hydrogen, are obtainable, for example, by the process in Scheme 2 or a corresponding process known to the person skilled in the art. Scheme 2
88th
Vorstufen für ausgewählte Beispiele der erfindungsgemäßen Pyrido[2,3-b]pyrazine, bei denen die Substituenten R3 und/oder R4 die Reste OR31 , SR32, NR33R34 sein sollen, sind beispielsweise nach dem Verfahren in Schema 3 bzw. einem entsprechenden, dem Fachmann bekannten Verfahren erhältlich. Precursors for selected examples of the pyrido [2,3-b] pyrazines according to the invention, in which the substituents R3 and / or R4 are the radicals OR31, SR32, NR33R34, are, for example, according to the process in Scheme 3 or a corresponding one skilled in the art available.
Schema 3Scheme 3
HSR32 HSR32
11 12 HNR33R3411 12 HNR33R34
Für die oben dargestellte Vorstufe 1 1 können das Zwischenprodukt 22 aus Schema 6 oder auch die Zwischenprodukte 20, 21 , 21 a und 21 b aus Schema 5 verwendet wer- den.For the precursor 11 described above, the intermediate 22 from Scheme 6 or also the intermediates 20, 21, 21 a and 21 b from Scheme 5 can be used.
Vorstufen für ausgewählte Beispiele der erfindungsgemäßen Pyrido[2,3-b]pyrazine, bei denen der Substituent R9 ≠ H sein soll, sind beispielsweise nach dem Verfahren in Schema 4 bzw. einem entsprechenden, dem Fachmann bekannten Verfahren erhältlich. Schema 4Precursors for selected examples of the pyrido [2,3-b] pyrazines according to the invention, in which the substituent R9 is to be H, can be obtained, for example, by the process in Scheme 4 or a corresponding process known to the person skilled in the art. Scheme 4
R5— OTosR5- OTos
4 / 7 154/7 15
Die Umsetzung der Vorstufen 4, 7, 9 und 15 aus den Schemata 1-4 zu den erfindungsgemäßen substituierten Pyrido[2,3-b]pyrazinen kann beispielsweise nach den Verfahren in Schema 5 bzw. einem entsprechenden, dem Fachmann bekannten Verfahren erfolgen. The reaction of the precursors 4, 7, 9 and 15 from Schemes 1-4 to the substituted pyrido [2,3-b] pyrazines according to the invention can be carried out, for example, by the processes in Scheme 5 or a corresponding process known to the person skilled in the art.
Schema 5Scheme 5
I.StufeI.Stufe
4/7/9/15 164/7/9/15 16
odod
1717
18 18
Schema 5 Scheme 5
1. Stufe1st stage
Ausgewählte Beispiele der erfindungsgemäßen Pyrido[2,3-b]pyrazine, bei denen die Substituenten R3 und/oder R4 ausgewählte substituierte Aryl- Heteroaryl-, Alkyl-, Alke- nyl- oder Alkinyl-Reste sein können, sind beispielsweise nach dem Verfahren in Schema 6 oder entsprechenden, dem Fachmann bekannten Verfahren erhältlich. Selected examples of the inventive pyrido [2,3-b] pyrazines in which the substituents R3 and / or R4 can be selected substituted aryl-heteroaryl, alkyl, alkenyl or alkynyl radicals are, for example, according to the process in Scheme 6 or corresponding methods known to those skilled in the art.
Schema 6Scheme 6
I .StufeI .step
22 23 22 23
23a23a
X = -B(OR)2, -SnR3 X = -B (OR) 2, -SnR 3
2525
Ausgewählte Beispiele der erfindungsgemäßen Pyrido[2,3-b]pyrazine, bei denen die Substituenten R3 und/oder R4 -N-C(O)-, -N-SO2-, -N-C(O)-O- und -N-C(O)-N- sein können, sind beispielsweise nach dem Verfahren in Schema 7 oder entsprechenden, dem Fachmann bekannten Verfahren erhältlich. Schema 7Selected examples of the pyrido [2,3-b] pyrazines according to the invention, in which the substituents R3 and / or R4 -N-C (O) -, -N-SO 2 -, -NC (O) -O-, and -NC (O ) -N- can be obtained, for example, by the method in Scheme 7 or the corresponding methods known to those skilled in the art. Scheme 7
I.StufeI.Stufe
22 2622 26
2. Stufe2nd stage
2727
2626
2828
2929
Ausgewählte Beispiele der erfindungsgemäßen Pyrido[2,3-b]pyrazine, bei denen die Substituenten R3 und/oder R4 ausgewählte Harnstoff-, Carbamat- oder Carbonat- substituierte Reste sein können, sind beispielsweise nach dem Verfahren in Schema 8 oder entsprechenden, dem Fachmann bekannten Verfahren erhältlich. Selected examples of the pyrido [2,3-b] pyrazines according to the invention, in which the substituents R3 and / or R4 can be selected urea-, carbamate- or carbonate-substituted radicals, are, for example, according to the process in Scheme 8 or equivalent, those skilled in the art available.
Schema 8 1 StufeScheme 8 1 step
35 35
3434
Ausgewählte Beispiele der erfindungsgemäßen Pyrido[2,3-b]pyrazine, bei denen die Substituenten R3 und/oder R4 ausgewählte O-, S-, N-substituierte Reste sein können, sind beispielsweise nach dem Verfahren in Schema 9 oder entsprechenden, dem Fachmann bekannten Verfahren erhältlich. Schema 9Selected examples of the pyrido [2,3-b] pyrazines according to the invention in which the substituents R3 and / or R4 can be selected O, S, N-substituted radicals are, for example, according to the process in Scheme 9 or equivalent, the person skilled in the art available. Scheme 9
1 Stufe1st stage
3838
X = OH, SH , NHR36 X = O, S, NR36X = OH, SH, NHR36 X = O, S, NR36
Die Ausgangsverbindungen und Zwischenstufen sind entweder im Handel erhältlich oder können nach an sich oder dem Fachmann bekannten Verfahrensweisen hergestellt werden. Die Edukte 4, 7, 9-15, 22, 26, 31 , 34 und 37 stellen wertvolle Zwischen- Verbindungen für die Herstellung der erfindungsgemäßen Pyridopyrazine dar.The starting compounds and intermediates are either commercially available or can be prepared by methods known per se or to those skilled in the art. The educts 4, 7, 9-15, 22, 26, 31, 34 and 37 are valuable intermediates for the preparation of Pyridopyrazine invention.
Für die Herstellung der Ausgangs-, Zwischenverbindungen und der erfindungsgemäßen Pyridopyrazine sei unter anderem auf die Patentschriften WO 2004/104002 und WO 2004/104003, sowie beispielsweise auf folgende Primärliteratur verwiesen, deren Inhalt hiermit Bestandteil der Offenbarung der vorliegenden Anmeldung werden soll:Reference may be made, inter alia, to patents WO 2004/104002 and WO 2004/104003, as well as, for example, to the following primary literature for the preparation of the starting compounds, intermediates and the pyridopyrazines according to the invention, the content of which should become part of the disclosure of the present application:
1 ) Houben-Weyl, Methoden der Organischen Chemie, Band 4/1 a, S. 343-3501) Houben-Weyl, Methods of Organic Chemistry, Volume 4/1 a, pp 343-350
2) Houben-Weyl, Methoden der Organischen Chemie, 4.Aufl., Band E 7b (Teil 2), S. 579; Degussa GB 1184848 (1970); S. Seko, et al. EP 735025 (1996)2) Houben-Weyl, Methods of Organic Chemistry, 4th Ed., Vol. E 7b (Part 2), p. 579; Degussa GB 1184848 (1970); S. Seko, et al. EP 735025 (1996)
3) D. Catarzi, et al.; J. Med. Chem. 1996, 1330-1336; J. K. Seydel, et al.; J. Med. Chem. 1994, 3016-30223) D. Catarzi, et al .; J. Med. Chem. 1996, 1330-1336; J.K. Seydel, et al .; J. Med. Chem. 1994, 3016-3022
4) Houben-Weyl, Methods of Organic Chemistry, Volume E 9c, S.231-2354) Houben-Weyl, Methods of Organic Chemistry, Volume E 9c, p.231-235
5) Houben-Weyl/Science of Synthesis, Volume 16, S. 12695) Houben-Weyl / Science of Synthesis, Volume 16, p. 1269
6) C. L. Leese, H. N. Rydon J. Chem. Soc. 1955, 303-309; T. S. Osdene, G. M. Tim- mis J. Chem. Soc. 1955, 2033-2035 7) W. He, et al. Bioorg. Med. Chem. Lett. 2003, 13, 3097-31006) C.L. Leese, H.N. Rydon J. Chem. Soc. 1955, 303-309; T. S. Osdene, G.M. Timmis J. Chem. Soc. 1955, 2033-2035 7) W. He, et al. Bioorg. Med. Chem. Lett. 2003, 13, 3097-3100
8) M. S. A. El-Gaby, et al. Indian J. Chem. Sect. B 2001 , 40, 195- 200; M. R. Myers, et al. Bioorg. Med. Chem. Lett. 2003, 13, 3091-3096 ; A. R. Renslo, et al. J. Amer. Chem. Soc. 1999, 121, 7459-7460 ; C. O. Okafor, et al. J. Heterocyclic Chem. 1983, 20, 199-203; C. R. Hopkins, et al. Tel Lett. 2004, 45, 8631-8633 9) J. Yin, et al. Org. Lett. 2002, 4, 3481-3484 ; O. A. El-Sayed, et al. Arch. Pharm. 2002, 335, 403-410 ; C. Temple, et al. J. Med. Chem. 1992, 35, 988-993 10) A. M. Thompson, et al. J. Med. Chem. 2000, 43, 4200-421 1 ; N. A. Dales, et al. Org. Lett. 2001 , 2313-2316; G. Dannhardt, et al. Arch. Pharm. 2000, 267-274; G. S. Poindexter, et al. Bioorg. Med. Chem. 2004, 12, 507-521 ; J.-M. Receveur, et al. Bioorg. Med. Chem. Lett. 2004, 14, 5075-5080 1 1 ) G. Heinisch, et al. Arch. Pharm. 1997, 207-210; K. Matsuno, et al. J. Med. Chem. 2002, 45, 4513-4523; A. M. Papini, et al. J. Med. Chem. 2004, 47, 5224-52298) MSA El-Gaby, et al. Indian J. Chem. Sect. B 2001, 40, 195-200; MR Myers, et al. Bioorg. Med. Chem. Lett. 2003, 13, 3091-3096; AR Renslo, et al. J. Amer. Chem. Soc. 1999, 121, 7459-7460; CO Okafor, et al. J. Heterocyclic Chem. 1983, 20, 199-203; CR Hopkins, et al. Tel Lett. 2004, 45, 8631-8633 9) J. Yin, et al. Org. Lett. 2002, 4, 3481-3484; OA El-Sayed, et al. Arch. Pharm. 2002, 335, 403-410; C. Temple, et al. J. Med. Chem. 1992, 35, 988-993 10) AM Thompson, et al. J. Med. Chem. 2000, 43, 4200-421 1; NA Dales, et al. Org. Lett. 2001, 2313-2316; G. Dannhardt, et al. Arch. Pharm. 2000, 267-274; GS Poindexter, et al. Bioorg. Med. Chem. 2004, 12, 507-521; J.-M. Recever, et al. Bioorg. Med. Chem. Lett. 2004, 14, 5075-5080 1 1) G. Heinisch, et al. Arch. Pharm. 1997, 207-210; K. Matsuno, et al. J. Med. Chem. 2002, 45, 4513-4523; AM Papini, et al. J. Med. Chem. 2004, 47, 5224-5229
12) J. Mindl, et al. Collect. Czech. Chem. Commun. 1983, 48, 900-905 ; S. Sasaki, et al. J. Med. Chem. 2003, 46, 113-124 ; B.-B. Zeng, et al. Bioorg. Med. Chem. Lett.12) J. Mindl, et al. Collect. Czech. Chem. Commun. 1983, 48, 900-905; S. Sasaki, et al. J. Med. Chem. 2003, 46, 113-124; B.-B. Zeng, et al. Bioorg. Med. Chem. Lett.
2004, 14, 5565-5568 13) Q. Wang, et al. Synthetic Commun. 2004, 34, 255-264 ; W. Mederski, et al. Bioorg. Med. Chem. Lett. 2003, 13, 13715-3718 ; R. J. Brown, et al. Tetrahedron 2004, 60, 4361-43752004, 14, 5565-5568 13) Q. Wang, et al. Synthetic Commun. 2004, 34, 255-264; W. Mederski, et al. Bioorg. Med. Chem. Lett. 2003, 13, 13715-3718; R.J. Brown, et al. Tetrahedron 2004, 60, 4361-4375
14) L. Mao, et al. Synthesis 2004, 15, 2535-2539; M. Darabantu, et al. Tetrahedron14) L. Mao, et al. Synthesis 2004, 15, 2535-2539; M. Darabantu, et al. Tetrahedron
2005, 61, 2897-2905; E. Ford, et al. Tel Lett. 2000, 41, 3197-3198; T. Shiota, et al. J. Org. Chem. 1999, 64, 453-457; E. C. Taylor, et al. Synthetic Commun. 1987,2005, 61, 2897-2905; E. Ford, et al. Tel Lett. 2000, 41, 3197-3198; T. Shiota, et al. J. Org. Chem. 1999, 64, 453-457; E.C. Taylor, et al. Synthetic Commun. 1987
17, 1865-1868 ; G. A. Molander, et al. J. Org. Chem. 2002, 67, 8424-8429; G. Hughes, et al. Org. & Biomolecular Chem. 2004, 2, 3363-336717, 1865-1868; G.A. Molander, et al. J. Org. Chem. 2002, 67, 8424-8429; G. Hughes, et al. Org. & Biomolecular Chem. 2004, 2, 3363-3367
15) R. P. Tangallapally, et al. J. Med. Chem. 2004, 47, 5276-5283; R. H. Bradburry, et al. J. Med. Chem. 1997, 40, 996-1004 16) X. He, et al. Bioorg. Med. Chem. 2004, 12, 4003-4008; A. Gopalsamy, et al. Bioorg. Med. Chem. Lett. 2005, 15, 1591-1594 ; J.-F. Cheng, et al. Bioorg. Med. Chem. Lett. 2004, 14, 2411-2416; E. R. Parmee, et al. Bioorg. Med. Chem. Lett. 2004, 14, 43-4615) R.P. Tangallapally, et al. J. Med. Chem. 2004, 47, 5276-5283; R. H. Bradbury, et al. J. Med. Chem. 1997, 40, 996-1004 16) X. He, et al. Bioorg. Med. Chem. 2004, 12, 4003-4008; A. Gopalsamy, et al. Bioorg. Med. Chem. Lett. 2005, 15, 1591-1594; J.-F. Cheng, et al. Bioorg. Med. Chem. Lett. 2004, 14, 2411-2416; E.R. Parmee, et al. Bioorg. Med. Chem. Lett. 2004, 14, 43-46
17) G. Yang, et al. Synthetic Commun. 2006, 36, 561 1-5619; H. B. Woo, et al. Bioorg. Med. Chem. Lett. 2005, 15, 3782-3786.17) G. Yang, et al. Synthetic Commun. 2006, 36, 561 1-5619; H.B. Woo, et al. Bioorg. Med. Chem. Lett. 2005, 15, 3782-3786.
18) J. F. Miravet, et al. Org. Lett. 2005, 7, 4791-4794; A. L. Castelhano, et al. Bioorg. Med. Chem. Lett. 2005, 15, 1501-1504.18) J.F. Miravet, et al. Org. Lett. 2005, 7, 4791-4794; A.L. Castelhano, et al. Bioorg. Med. Chem. Lett. 2005, 15, 1501-1504.
19) Y. Lu, et al. Bioorg. Med. Chem. Lett. 2006, 16, 915-919; J. W. Szewczyk, et al. Bioorg. Med. Chem. Lett. 2006, 16, 3055-3060. Allgemeine Vorschriften zur Darstellung der erfindungsgemäßen Verbindungen :19) Y. Lu, et al. Bioorg. Med. Chem. Lett. 2006, 16, 915-919; JW Szewczyk, et al. Bioorg. Med. Chem. Lett. 2006, 16, 3055-3060. General instructions for the preparation of the compounds according to the invention:
Schema 1 : 1. StufeScheme 1: 1st stage
2,6-Diamino-3-nitropyridin oder 2-Amino-3,5-dinitro-pyridin werden in einem geeigneten, inerten Lösungsmittel, wie beispielsweise Methanol, Ethanol, Dimethylformamid oder Dioxan, gelöst. Nach Zugabe eines Katalysators, beispielsweise Raney-Nickel, Palladium auf Kohle oder Platin(IV)dioxid, setzt man das Reaktionsgemisch unter eine Wasserstoff-Atmosphäre, wobei ein Druck zwischen 1 und 5 bar eingestellt wird. Man läßt das Reaktionsgemisch mehrere Stunden, beispielsweise 1-16 Stunden, in einem Temperaturbereich zwischen 20 °C und 60 °C reagieren. Nach beendeter Umsetzung filtriert man die unlöslichen Rückstände ab, wobei das Filtermedium beispielsweise aus Kieselgel, Celite oder handelsüblichen Glasfaserfiltern bestehen kann, und wäscht mit dem entsprechenden Lösungsmittel nach. Das Rohprodukt wird, in Lösung vorliegend, ohne weitere Aufreinigung für die nächste Umsetzung verwendet.2,6-diamino-3-nitropyridine or 2-amino-3,5-dinitro-pyridine are dissolved in a suitable inert solvent such as methanol, ethanol, dimethylformamide or dioxane. After addition of a catalyst, for example Raney nickel, palladium on carbon or platinum (IV) dioxide, the reaction mixture is placed under a hydrogen atmosphere, wherein a pressure between 1 and 5 bar is set. The reaction mixture is allowed to react for several hours, for example 1-16 hours, in a temperature range between 20 ° C and 60 ° C. After completion of the reaction, the insoluble residues are filtered off, it being possible for the filter medium to consist, for example, of silica gel, celite or commercially available glass fiber filters, and the residue is washed with the appropriate solvent. The crude product is used in solution without further purification for the next reaction.
2. Stufe2nd stage
Das 1 ,2-Dion-Derivat wird in einem geeigneten, inerten Lösungsmittel, beispielsweise Methanol, Ethanol, Dioxan, Toluol oder Dimethylformamid, vorgelegt. 2,3,6- Triaminopyridin oder 2,3,5-Triaminopyridin werden direkt nach der Reduktion als Lösung der Rohprodukte in einem der oben genannten Lösungsmittel zum vorgelegten 1 ,2-Dion gegeben, gegebenenfalls unter Zugabe einer Säure, wie z. B. Essigsäure oder einer Base, beispielsweise Kaliumhydroxid. Das Reaktionsgemisch läßt man in einem Temperaturbereich von 20 °C bis 80 °C einige Zeit, beispielsweise 20 Minuten bis 40 Stunden, reagieren. Nach beendeter Umsetzung wird ein eventuell ausgefallener Niederschlag abfiltriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewa- sehen und der zurückbleibende Feststoff im Vakuum getrocknet, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Bei Verwendung von Dimethylformamid wird das Reaktionsgemisch in eine große Menge Wasser eingerührt und der ausgefallene Niederschlag abfiltriert bzw. die wässrige Phase mit einem geeigneten organischen Lösungsmittel, wie z. B. Dichlormethan oder Ethylacetat, extrahiert und die organischen Phasen im Vakuum eingeengt. Die Reinigung des zurückbleibenden Rohproduktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielsweise Dioxan, oder durch Säulen- bzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan.The 1, 2-dione derivative is presented in a suitable inert solvent, for example methanol, ethanol, dioxane, toluene or dimethylformamide. 2,3,6-triaminopyridine or 2,3,5-triaminopyridine are added directly after the reduction as a solution of the crude products in one of the abovementioned solvents for the presented 1, 2-dione, optionally with the addition of an acid such. As acetic acid or a base, for example potassium hydroxide. The reaction mixture is allowed to react in a temperature range of 20 ° C to 80 ° C for some time, for example, 20 minutes to 40 hours. After completion of the reaction, any precipitated precipitate is filtered off, the filter medium may consist for example of commercially available filter paper nachgewa- see with the appropriate solvent and the remaining solid dried in vacuo, or the reaction mixture is freed from the solvent in vacuo. When dimethylformamide is used, the reaction mixture is stirred into a large amount of water and the precipitate which has precipitated out is filtered off or the aqueous phase is filtered off with a suitable solvent organic solvents, such as. For example, dichloromethane or ethyl acetate, and the organic phases are concentrated in vacuo. The purification of the remaining crude product is carried out by recrystallization from a suitable solvent, for example dioxane, or by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.
Schema 2: 1. StufeScheme 2: 1st stage
Das Pyridopyrazin-on-Derivat 8 wird in einem geeigneten, inerten Lösungsmittel, beispielsweise Dimethylformamid, Dioxan oder Toluol, oder ohne Lösungsmittel vorgelegt. Ein Chlorierungsmittel, z. B. Phosphorylchlorid oder Thionylchlorid, wird bei Raumtemperatur zugegeben und das Reaktionsgemisch lässt man in einem Temperaturbereich von 20 °C bis 100 °C einige Zeit, beispielsweise 1 Stunde bis 24 Stunden, reagieren. Nach beendeter Umsetzung wird das Reaktionsgemisch auf Wasser gegossen und mit einer geeigneten wässrigen Base, beispielsweise Natronlauge, neutralisiert. Ein eventuell ausgefallener Niederschlag wird abfiltriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, oder die wässrige Phase wird mit einem geeigneten organischen Lösungsmittel, wie z. B. Dichlormethan oder Ethylacetat, extrahiert, und die organischen Phasen im Vakuum eingeengt. Die Reinigung des zurückbleibenden Rohproduktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielsweise Dioxan oder Toluol, oder durch Säulen- bzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan.The pyridopyrazine-on derivative 8 is initially charged in a suitable inert solvent, for example dimethylformamide, dioxane or toluene, or without solvent. A chlorinating agent, e.g. As phosphoryl chloride or thionyl chloride is added at room temperature and the reaction mixture is allowed to react in a temperature range of 20 ° C to 100 ° C for some time, for example, 1 hour to 24 hours. After completion of the reaction, the reaction mixture is poured into water and neutralized with a suitable aqueous base, for example sodium hydroxide solution. Any precipitated precipitate is filtered off, the filter medium may consist for example of commercial filter paper, washed with the appropriate solvent and the remaining solid dried in vacuo, or the aqueous phase is washed with a suitable organic solvent such. For example, dichloromethane or ethyl acetate, and the organic phases are concentrated in vacuo. The purification of the remaining crude product is carried out by recrystallization from a suitable solvent, for example dioxane or toluene, or by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.
Schema 3: 1. StufeScheme 3: 1st stage
2,3,6-Triaminopyridin oder 2,3,5-Triaminopyridin werden direkt nach der Reduktion als Lösung der Rohprodukte in einem der oben genannten Lösungsmittel vorgelegt. Nach Zugabe eines Oxalsäure-Derivates, wie z. B. Oxalsäurediethylester oder Oxa- lylchlorid, läßt man das Reaktionsgemisch, gegebenenfalls unter Zugabe einer Säure, wie z. B. Salzsäure, Schwefelsäure oder Eisessig, in einem Temperaturbereich von 20 °C bis 150 °C einige Zeit, beispielsweise 10 Minuten bis 24 Stunden, reagieren. Nach beendeter Umsetzung wird ein eventuell ausgefallener Niederschlag abfiltriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Alternativ kann das Reaktionsgemisch in eine große Menge Wasser eingerührt und der ausgefallene Niederschlag abfiltriert bzw. die wässrige Phase, nach Neutralisation mit einer geeigneten wässrigen Base, wie z. B. Natronlauge, mit einem geeigneten organischen Lösungsmittel, wie z. B. Dichlormethan oder Ethylace- tat, extrahiert und die organische Phase im Vakuum eingeengt werden. Die Reinigung des zurückbleibenden Rohproduktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielsweise Dioxan oder Toluol, oder durch Säulen- bzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient bei- spielsweise ein Gemisch aus Methanol und Dichlormethan.2,3,6-triaminopyridine or 2,3,5-triaminopyridine are introduced directly after the reduction as a solution of the crude products in one of the abovementioned solvents. After addition of an oxalic acid derivative, such as. For example, diethyl oxalate or oxalyl chloride, the reaction mixture, optionally with the addition of an acid, such as As hydrochloric acid, sulfuric acid or glacial acetic acid, in a temperature range of 20 ° C to 150 ° C for some time, for example, 10 minutes to 24 hours, react. After completion of the reaction, any precipitated precipitate is filtered off, the filter medium may consist for example of commercial filter paper, washed with the appropriate solvent and dried the remaining solid in vacuo, or the reaction mixture is freed from the solvent in vacuo. Alternatively, the reaction mixture may be stirred into a large amount of water and the precipitate filtered off or the aqueous phase, after neutralization with a suitable aqueous base, such as. For example, sodium hydroxide, with a suitable organic solvent such. As dichloromethane or ethyl acetate, extracted and the organic phase are concentrated in vacuo. The purification of the remaining crude product is carried out by recrystallization from a suitable solvent, for example dioxane or toluene, or by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.
2.Stufe2nd stage
Das Dion-Derivat 10 wird in einem geeigneten, inerten Lösungsmittel, beispielswei- se Dimethylformamid, Dioxan oder Toluol, oder ohne Lösungsmittel vorgelegt. EinThe dione derivative 10 is initially charged in a suitable inert solvent, for example dimethylformamide, dioxane or toluene, or without solvent. One
Chlorierungsmittel, z. B. Phosphorylchlorid oder Thionylchlorid, wird bei Raumtemperatur zugegeben und das Reaktionsgemisch lässt man in einem Temperaturbereich von 20 °C bis 100 °C einige Zeit, beispielsweise 1 Stunde bis 24 Stunden, reagieren. Nach beendeter Umsetzung wird das Reaktionsgemisch auf Wasser gegossen und mit einer geeigneten wässrigen Base, beispielsweise Natronlauge, neutralisiert. Ein eventuell ausgefallener Niederschlag wird abfiltriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, oder die wässrige Phase wird mit einem geeigneten organischen Lösungsmittel, wie z. B. Dich- lormethan oder Ethylacetat, extrahiert, und die organischen Phasen im Vakuum eingeengt. Die Reinigung des zurückbleibenden Rohproduktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielsweise Dioxan oder Toluol, oder durch Säulen- bzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan. 3. StufeChlorinating agent, eg. As phosphoryl chloride or thionyl chloride is added at room temperature and the reaction mixture is allowed to react in a temperature range of 20 ° C to 100 ° C for some time, for example, 1 hour to 24 hours. After completion of the reaction, the reaction mixture is poured into water and neutralized with a suitable aqueous base, for example sodium hydroxide solution. Any precipitated precipitate is filtered off, the filter medium may consist for example of commercial filter paper, washed with the appropriate solvent and the remaining solid dried in vacuo, or the aqueous phase is washed with a suitable organic solvent such. For example, dichloromethane or ethyl acetate, and the organic phases are concentrated in vacuo. The purification of the remaining crude product is carried out by recrystallization from a suitable solvent, for example dioxane or toluene, or by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane. 3rd stage
Die Zwischenstufe 1 1 kann mit einem entsprechenden Alkohol, Thiol oder Amin und gegebenenfalls mit einer geeigneten Base, vorzugsweise Natriumhydrid, Pyridin, Triethylamin, Kaliumcarbonat oder Natriummethanolat in Methanol, in einem geeigneten, inerten Lösungsmittel, wie beispielsweise Dimethylformamid, Dimethylsulfoxid, Methanol, Toluol, oder in einer Base als Lösungsmittel, wie z. B. Pyridin oder Triethylamin, oder ohne Lösungsmittel, umgesetzt werden. Das Reaktionsgemisch lässt man einige Zeit, beispielsweise 30 Minuten bis 2 Tage, in einem Temperaturbereich zwischen 20 °C und 140 °C reagieren. Alternativ kann die Zwischenstufe 1 1 mit einem entsprechenden Amin und einem geeigneten Katalysator, wie z. B. Tris(dibenzylidenaceton)dipalladium(0) oder Tetrakis(triphenylphosphin)-palladium(0), und einem geeigneten Liganden, wie z. B. 2-(Dicyclohexylphosphanyl)biphenyl, und einer geeigneten Base, beispielsweise Natrium-tert.butanolat, in einem geeignetem Lösungsmittel, wie beispielsweise Toluol oder Dimethylformamid, umgesetzt werden. Das Reaktionsgemisch lässt man einige Zeit, beispielsweise 2 Stunden bis 30 Stunden, in einem Temperaturbereich zwischen 60 °C und 120 °C reagieren. Nach beendeter Umsetzung wird ein eventuell ausgefallener Niederschlag abfiltriert, wobei das FiI- termedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Alternativ kann das Reaktionsgemisch in eine große Menge Wasser eingerührt und der ausgefallene Niederschlag abfiltriert bzw. die wässrige Phase, nach Neutrali- sation mit einer geeigneten wässrigen Säure, wie z. B. Salzsäure, mit einem geeigneten organischen Lösungsmittel, wie z. B. Dichlormethan oder Ethylacetat, extrahiert und die organische Phase im Vakuum eingeengt werden. Die Reinigung des zurückbleibenden Rohproduktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielsweise Dioxan, Ethylacetat oder Toluol, oder durch Säulen- bzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan. Schema 4: 1. StufeIntermediate 1 can be treated with a corresponding alcohol, thiol or amine and optionally with a suitable base, preferably sodium hydride, pyridine, triethylamine, potassium carbonate or sodium methoxide in methanol, in a suitable inert solvent such as dimethylformamide, dimethyl sulfoxide, methanol, toluene, or in a base as a solvent, such as. As pyridine or triethylamine, or without solvents. The reaction mixture is allowed to react for some time, for example 30 minutes to 2 days, in a temperature range between 20 ° C and 140 ° C. Alternatively, the intermediate 1 1 with a corresponding amine and a suitable catalyst, such as. B. tris (dibenzylideneacetone) dipalladium (0) or tetrakis (triphenylphosphine) palladium (0), and a suitable ligand, such as. B. 2- (Dicyclohexylphosphanyl) biphenyl, and a suitable base, for example, sodium tert.butanolat, in a suitable solvent, such as toluene or dimethylformamide, are reacted. The reaction mixture is allowed to react for some time, for example 2 hours to 30 hours, in a temperature range between 60 ° C and 120 ° C. After completion of the reaction, any precipitated precipitate is filtered off, whereby the filter medium can consist for example of commercially available filter paper, washed with the appropriate solvent and the residual solid dried in vacuo, or the reaction mixture is freed from the solvent in vacuo. Alternatively, the reaction mixture may be stirred into a large amount of water and the precipitate filtered off or the aqueous phase, after neutralization with a suitable aqueous acid, such as. Hydrochloric acid, with a suitable organic solvent, such as. For example, dichloromethane or ethyl acetate, and the organic phase are concentrated in vacuo. The purification of the remaining crude product is carried out by recrystallization from a suitable solvent, for example dioxane, ethyl acetate or toluene, or by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane. Scheme 4: 1st stage
Die Zwischenstufen 4 und 7 können mit einem entsprechenden, geeigneten Chlorid, Bromid oder Tosylat und gegebenenfalls mit einer geeigneten Base, vorzugsweise Natriumhydrid, Pyridin, Triethylamin, Kaliumcarbonat oder Natriummethanolat in Methanol, in einem geeigneten, inerten Lösungsmittel, wie beispielsweise Dimethylfor- mamid, Dimethylsulfoxid, Methanol oder in einer Base als Lösungsmittel, wie z. B. Pyridin oder Triethylamin, oder ohne Lösungsmittel, umgesetzt werden. Das Reaktionsgemisch lässt man einige Zeit, beispielsweise 1 Stunde bis 24 Stunden, in einem Tem- peraturbereich zwischen 20 °C und 150 °C reagieren. Alternativ können die Zwischenstufen 4 und 7 mit einem entsprechenden Aryl-Bromid oder -lodid und einem geeigneten Katalysator, wie z. B. Palladiumacetat oder Pd2(dba)3, und einem geeigneten Liganden, wie z. B. BINAP, und einer geeigneten Base, beispielsweise, Kaliumcarbonat oder Natrium-tert.butanolat, in einem geeignetem Lösungsmittel, wie beispielsweise Toluol oder Dioxan, umgesetzt werden. Das Reaktionsgemisch lässt man einige Zeit, beispielsweise 10 Stunden bis 30 Stunden, in einem Temperaturbereich zwischen 60 °C und 120 °C reagieren. Nach beendeter Umsetzung wird ein eventuell ausgefallener Niederschlag abfiltriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, bzw. werden evtl. vorhandene Katalysatorreste abfiltriert mit dem entsprechenden Lösungsmittel nachgewaschen und das Lösungsmittel im Vakuum entfernt, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Alternativ kann das Reaktionsgemisch in eine große Menge Wasser eingerührt und der ausgefallene Niederschlag abfiltriert bzw. die wäss- rige Phase, nach Neutralisation mit einer geeigneten wässrigen Säure, wie z. B. Salzsäure, mit einem geeigneten organischen Lösungsmittel, wie z. B. Dichlormethan oder Ethylacetat, extrahiert und die organische Phase im Vakuum eingeengt werden. Die Reinigung des zurückbleibenden Rohproduktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielsweise Ethanol oder Toluol, oder durch Säulen- bzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan. Schema δ: 1. StufeIntermediates 4 and 7 may be treated with an appropriate, suitable chloride, bromide or tosylate and optionally with a suitable base, preferably sodium hydride, pyridine, triethylamine, potassium carbonate or sodium methoxide in methanol, in a suitable inert solvent such as dimethylformamide, dimethyl sulfoxide , Methanol or in a base as a solvent, such as. As pyridine or triethylamine, or without solvents. The reaction mixture is allowed to react for some time, for example 1 hour to 24 hours, in a temperature range between 20 ° C and 150 ° C. Alternatively, intermediates 4 and 7 may be reacted with a corresponding aryl bromide or iodide and a suitable catalyst, such as e.g. B. palladium acetate or Pd 2 (dba) 3 , and a suitable ligand, such as. B. BINAP, and a suitable base, for example, potassium carbonate or sodium tert.butanolat, are reacted in a suitable solvent such as toluene or dioxane. The reaction mixture is allowed to react for some time, for example 10 hours to 30 hours, in a temperature range between 60 ° C and 120 ° C. After completion of the reaction, any precipitated precipitate is filtered off, the filter medium may consist for example of commercial filter paper, washed with the appropriate solvent and the remaining solid dried in vacuo, or any existing catalyst residues are filtered off with the appropriate solvent and washed the solvent in the Vacuum removed, or the reaction mixture is freed from the solvent in vacuo. Alternatively, the reaction mixture can be stirred into a large amount of water and the precipitate filtered off or the aqueous phase, after neutralization with a suitable aqueous acid, such as. Hydrochloric acid, with a suitable organic solvent, such as. For example, dichloromethane or ethyl acetate, and the organic phase are concentrated in vacuo. The purification of the residual crude product is carried out by recrystallization from a suitable solvent, for example ethanol or toluene, or by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane. Scheme δ: 1st stage
Im Anschluß an die Grundverfahren können in Folgereaktionen die nach dem Grundverfahren entstandenen Produkte in einer dem Fachmann bekannten Vorge- hensweise zu erfindungsgemässen Folgeprodukten umgesetzt werden.Subsequent to the basic processes, the products formed by the basic process can be reacted in subsequent reactions in a procedure known to the person skilled in the art to yield secondary products according to the invention.
So kann, wenn das Produkt ein Derivat der Verbindung 16 gemäß Schema 5 sein soll, das Reaktionsprodukt 4, 7, 9 oder 15 mit einem entsprechenden Isocyanat und gegebenenfalls einer geeigneten Base, vorzugsweise Natriumhydrid, Kaliumhexa- methyldisilazid, Pyridin, Triethylamin oder Kaliumcarbonat, in einem geeigneten, inerten Lösungsmittel, wie beispielsweise Dimethylformamid, Dimethylsulfoxid, Acetonitril, Dichlormethan, 1 ,2-Dichlorethan oder Dioxan, oder in einer Base als Lösungsmittel, wie z. B. Pyridin oder Triethylamin, oder ohne Lösungsmittel, umgesetzt werden. Das Reaktionsgemisch läßt man mehrere Stunden, beispielsweise 1 - 24 Stunden, in ei- nem Temperaturbereich zwischen 0 und 80 °C reagieren. Nach beendeter Umsetzung wird ein eventuell ausgefallener Niederschlag abfiltriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Alternativ kann das Reaktionsgemisch in eine große Menge Wasser eingerührt und der ausgefallene Niederschlag abfiltriert bzw. die wässrige Phase, nach Neutralisation mit einer geeigneten wässrigen Säure, wie z. B. Salzsäure, mit einem geeigneten organischen Lösungsmittel, wie z. B. Dichlormethan oder Ethylacetat, extrahiert und die organische Phase im Vakuum eingeengt werden. Die Reinigung des zurückbleibenden Rohpro- duktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielsweise Ethanol oder Ethylacetat, oder durch Säulen- bzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan.Thus, if the product is to be a derivative of compound 16 according to Scheme 5, the reaction product 4, 7, 9 or 15 with an appropriate isocyanate and optionally a suitable base, preferably sodium hydride, potassium hexamethyldisilazide, pyridine, triethylamine or potassium carbonate, in a suitable, inert solvent such as dimethylformamide, dimethyl sulfoxide, acetonitrile, dichloromethane, 1, 2-dichloroethane or dioxane, or in a base as a solvent such. As pyridine or triethylamine, or without solvents. The reaction mixture is allowed to react for several hours, for example 1 to 24 hours, in a temperature range between 0 and 80 ° C. After completion of the reaction, any precipitated precipitate is filtered off, the filter medium may consist for example of commercial filter paper, washed with the appropriate solvent and dried the remaining solid in vacuo, or the reaction mixture is freed from the solvent in vacuo. Alternatively, the reaction mixture can be stirred into a large amount of water and the precipitate filtered off or the aqueous phase, after neutralization with a suitable aqueous acid, such as. Hydrochloric acid, with a suitable organic solvent, such as. For example, dichloromethane or ethyl acetate, and the organic phase are concentrated in vacuo. The remaining crude product is purified by recrystallization from a suitable solvent, for example ethanol or ethyl acetate, or by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.
Oder es kann alternativ, wenn das Produkt ein Derivat der Verbindung 17 gemäßOr it may alternatively, if the product is a derivative of compound 17 according to
Schema 5 sein soll, das Reaktionsprodukt 4, 7, 9 oder 15 mit Phosgen oder Carbonyl- diimidazol und einem entsprechenden Amin in einem geeigneten, inerten Lösungsmittel, wie beispielsweise Dimethylformamid, Tetrahydrofuran, Toluol, Dichlormethan oder Acetonitril umgesetzt werden. Gegebenenfalls wird eine geeignete Base, vorzugsweise Pyridin, Natriumhydrogencarbonat, Triethylamin, N-Methyl-morpholin oder Natriumace- tat verwendet. Das Reaktionsgemisch läßt man einige Zeit, beispielsweise 15 Minuten bis 24 Stunden, in einem Temperaturbereich zwischen 0 und 60 °C reagieren. Alterna- tiv kann das Reaktionsprodukt 4, 7, 9 oder 15 mit einem entsprechenden Amin-Phenyl- Carbamat-Reagenz und gegebenenfalls mit einer geeigneten Base, vorzugsweise Pyridin, Natriumcarbonat, Triethylamin oder Natriumhydrid, in einem geeigneten, inerten Lösungsmittel, wie beispielsweise Tetrahydrofuran, Dioxan, Dichlormethan, Dimethyl- formamid oder Acetonitril, oder in einer Base als Lösungsmittel, wie z. B. Pyridin oder Triethylamin, oder ohne Lösungsmittel, umgesetzt werden. Das Reaktionsgemisch läßt man einige Zeit, beispielsweise 1 Stunde bis 18 Stunden, in einem Temperaturbereich zwischen 0 °C und 120 °C reagieren. Nach beendeter Umsetzung wird ein eventuell ausgefallener Niederschlag abfiltriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Alternativ kann das Reaktionsgemisch in eine große Menge Wasser eingerührt und der ausgefallene Niederschlag abfiltriert bzw. die wässrige Phase, nach Neutralisation mit einer geeigneten wässrigen Säure, wie z. B. Salzsäure, mit einem geeigneten organischen Lösungsmit- tel, wie z. B. Dichlormethan oder Ethylacetat, extrahiert und die organische Phase im Vakuum eingeengt werden. Die Reinigung des zurückbleibenden Rohproduktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielweise Ethanol oder Ethylacetat, oder durch Säulen- bzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan.Scheme 5, the reaction product 4, 7, 9 or 15 with phosgene or carbonyl diimidazole and a corresponding amine in a suitable inert solvent such as dimethylformamide, tetrahydrofuran, toluene, dichloromethane or Acetonitrile are reacted. If appropriate, a suitable base, preferably pyridine, sodium bicarbonate, triethylamine, N-methylmorpholine or sodium acetate, is used. The reaction mixture is allowed to react for some time, for example 15 minutes to 24 hours, in a temperature range between 0 and 60 ° C. Alternatively, reaction product 4, 7, 9 or 15 may be reacted with a corresponding amine-phenyl-carbamate reagent and optionally with a suitable base, preferably pyridine, sodium carbonate, triethylamine or sodium hydride, in a suitable inert solvent such as tetrahydrofuran. Dioxane, dichloromethane, dimethylformamide or acetonitrile, or in a base as a solvent such. As pyridine or triethylamine, or without solvents. The reaction mixture is allowed to react for some time, for example 1 hour to 18 hours, in a temperature range between 0 ° C and 120 ° C. After completion of the reaction, any precipitated precipitate is filtered off, the filter medium may consist for example of commercial filter paper, washed with the appropriate solvent and dried the remaining solid in vacuo, or the reaction mixture is freed from the solvent in vacuo. Alternatively, the reaction mixture can be stirred into a large amount of water and the precipitate filtered off or the aqueous phase, after neutralization with a suitable aqueous acid, such as. For example, hydrochloric acid, with a suitable organic solvent such. For example, dichloromethane or ethyl acetate, and the organic phase are concentrated in vacuo. The remaining crude product is purified by recrystallization from a suitable solvent, for example ethanol or ethyl acetate, or by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.
So kann, wenn das Produkt ein Derivat der Verbindung 18 gemäß Schema 5 sein soll, das Reaktionsprodukt 4, 7, 9 oder 15 mit einem entsprechenden Isothiocyanat und gegebenenfalls einer geeigneten Base, vorzugsweise Natriumhydrid, Triethylamin, Kaliumcarbonat oder Pyridin, in einem geeigneten, inerten Lösungsmittel, wie beispielsweise Dimethylformamid, Tetrahydrofuran, Aceton oder Toluol, oder in einer Base als Lösungsmittel, wie z. B. Pyridin oder Triethylamin, oder ohne Lösungsmittel, umgesetzt werden. Das Reaktionsgemisch läßt man einige Zeit, beispielsweise 30 Minuten bis 90 Stunden, in einem Temperaturbereich zwischen 0 und 115 °C reagieren. Nach beendeter Umsetzung wird ein eventuell ausgefallener Niederschlag abfiltriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Alternativ kann das Reaktionsgemisch in eine große Menge Wasser eingerührt und der ausgefallene Niederschlag abfiltriert bzw. die wässrige Phase, nach Neutralisation mit einer geeigneten wässrigen Säure, wie z. B. Salzsäure, mit einem geeigneten organischen Lösungsmittel, wie z. B. Dichlormethan oder Ethyl- acetat, extrahiert und die organische Phase im Vakuum eingeengt werden. Die Reinigung des zurückbleibenden Rohproduktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielsweise Ethanol oder Ethylacetat, oder durch Säulenbzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan.Thus, if the product is to be a derivative of Compound 18 according to Scheme 5, the reaction product 4, 7, 9 or 15 with an appropriate isothiocyanate and optionally a suitable base, preferably sodium hydride, triethylamine, potassium carbonate or pyridine, in a suitable inert Solvent such as dimethylformamide, tetrahydrofuran, acetone or toluene, or in a base as a solvent such. As pyridine or triethylamine, or without solvents. The reaction mixture is allowed to react for some time, for example 30 minutes to 90 hours, in a temperature range between 0 and 115 ° C. After completion of the reaction, any precipitated precipitate is filtered off, wherein the filter medium may consist for example of commercially available filter paper, washed with the appropriate solvent and the residual solid dried in vacuo, or the reaction mixture is freed from the solvent in vacuo. Alternatively, the reaction mixture can be stirred into a large amount of water and the precipitate filtered off or the aqueous phase, after neutralization with a suitable aqueous acid, such as. Hydrochloric acid, with a suitable organic solvent, such as. For example, dichloromethane or ethyl acetate, and the organic phase are concentrated in vacuo. The purification of the residual crude product is carried out by recrystallization from a suitable solvent, for example, ethanol or ethyl acetate, or by Säulenbzw. Flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.
Oder es kann alternativ, wenn das Produkt ein Derivat der Verbindung 19 gemäß Schema 5 sein soll, das Reaktionsprodukt 4, 7, 9 oder 15 mit Thiophosgen oder Thio- carbonyldiimidazol und einem entsprechenden Amin in einem geeigneten, inerten Lösungsmittel, wie beispielsweise Dimethylformamid, Tetrahydrofuran, Toluol, Dichlormethan, Ethanol oder Acetonitril umgesetzt werden. Gegebenenfalls wird eine geeignete Base, vorzugsweise Pyridin, Natriumhydrogencarbonat, Kaliumcarbonat, Triethy- lamin oder Imidazol verwendet. Das Reaktionsgemisch läßt man mehrere Stunden, beispielsweise 1 bis 24 Stunden, in einem Temperaturbereich zwischen -10 und 80 °C reagieren. Nach beendeter Umsetzung wird ein eventuell ausgefallener Niederschlag abfiltriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zu- rückbleibende Feststoff im Vakuum getrocknet, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Alternativ kann das Reaktionsgemisch in eine große Menge Wasser eingerührt und der ausgefallene Niederschlag abfiltriert bzw. die wässrige Phase, nach Neutralisation mit einer geeigneten wässrigen Säure, wie z. B. Salzsäure, mit einem geeigneten organischen Lösungsmittel, wie z. B. Dichlormethan oder Ethylacetat, extrahiert und die organische Phase im Vakuum eingeengt werden. Die Reinigung des zurückbleibenden Rohproduktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielweise Ethanol oder Ethylacetat, oder durch Säulen- bzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan. So kann, wenn das Produkt ein Derivat der Verbindung 20 gemäß Schema 5 sein soll, das Reaktionsprodukt 4, 7, 9 oder 15 mit Phosgen oder Carbonyldiimidazol und einem entsprechenden Hydroxyl-Amin in einem geeigneten, inerten Lösungsmittel, wie beispielsweise Dimethylformamid, Tetrahydrofuran, Dioxan, Dichlormethan oder Toluol umgesetzt werden. Gegebenenfalls wird eine geeignete Base, vorzugsweise Pyridin, Natriumcarbonat, Triethylamin oder Natriumacetat verwendet. Das Reaktionsgemisch läßt man einige Zeit, beispielsweise 1 Stunde bis 24 Stunden, in einem Temperaturbereich zwischen 0 und 100 °C reagieren. Alternativ kann das Reaktionsprodukt 4, 7, 9 oder 15 mit einem entsprechenden Hydroxylamin-Phenyl-Carbamat-Reagenz und gegebenenfalls mit einer geeigneten Base, vorzugsweise Pyridin, Natriumcarbonat, Triethylamin oder Natriumacetat, in einem geeigneten, inerten Lösungsmittel, wie beispielsweise Tetrahydrofuran, Dioxan, Dichlormethan, Dimethylformamid oder Toluol, oder in einer Base als Lösungsmittel, wie z. B. Pyridin oder Triethylamin, oder ohne Lösungsmittel, umgesetzt werden. Das Reaktionsgemisch läßt man einige Zeit, beispielsweise 1 Stunde bis 18 Stunden, in einem Temperaturbereich zwischen Raumtemperatur und 100 °C reagieren. Nach beendeter Umsetzung wird ein eventuell ausgefallener Niederschlag abfiltriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Alternativ kann das Reaktionsgemisch in eine große Menge Wasser eingerührt und der ausgefallene Niederschlag abfiltriert bzw. die wässrige Phase, nach Neutralisation mit einer geeigneten wässrigen Säure, wie z. B. Salzsäure, mit einem geeigneten organischen Lösungsmit- tel, wie z. B. Dichlormethan oder Ethylacetat, extrahiert und die organische Phase im Vakuum eingeengt werden. Die Reinigung des zurückbleibenden Rohproduktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielweise Ethanol oder Ethylacetat, oder durch Säulen- bzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan.Or, alternatively, if the product is to be a derivative of Compound 19 according to Scheme 5, the reaction product 4, 7, 9 or 15 with thiophosgene or thiocarbonyldiimidazole and a corresponding amine in a suitable inert solvent such as dimethylformamide, tetrahydrofuran , Toluene, dichloromethane, ethanol or acetonitrile. Optionally, a suitable base, preferably pyridine, sodium bicarbonate, potassium carbonate, triethylamine or imidazole is used. The reaction mixture is allowed to react for several hours, for example 1 to 24 hours, in a temperature range between -10 and 80 ° C. After completion of the reaction, a precipitate which may have precipitated out is filtered off, the filter medium being able to consist, for example, of commercially available filter paper, washed with the appropriate solvent and the remaining solid dried in vacuo, or the reaction mixture is freed from the solvent in vacuo. Alternatively, the reaction mixture can be stirred into a large amount of water and the precipitate filtered off or the aqueous phase, after neutralization with a suitable aqueous acid, such as. Hydrochloric acid, with a suitable organic solvent, such as. For example, dichloromethane or ethyl acetate, and the organic phase are concentrated in vacuo. The remaining crude product is purified by recrystallization from a suitable solvent, for example ethanol or ethyl acetate, or by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane. Thus, if the product is to be a derivative of Compound 20 according to Scheme 5, the reaction product 4, 7, 9 or 15 with phosgene or carbonyldiimidazole and a corresponding hydroxylamine in a suitable inert solvent such as dimethylformamide, tetrahydrofuran, dioxane , Dichloromethane or toluene. Optionally, a suitable base, preferably pyridine, sodium carbonate, triethylamine or sodium acetate is used. The reaction mixture is allowed to react for some time, for example 1 hour to 24 hours, in a temperature range between 0 and 100 ° C. Alternatively, reaction product 4, 7, 9 or 15 may be reacted with a corresponding hydroxylamine-phenyl carbamate reagent and optionally with a suitable base, preferably pyridine, sodium carbonate, triethylamine or sodium acetate in a suitable inert solvent such as tetrahydrofuran, dioxane, Dichloromethane, dimethylformamide or toluene, or in a base as a solvent such. As pyridine or triethylamine, or without solvents. The reaction mixture is allowed to react for some time, for example 1 hour to 18 hours, in a temperature range between room temperature and 100 ° C. After completion of the reaction, any precipitated precipitate is filtered off, the filter medium may consist for example of commercial filter paper, washed with the appropriate solvent and dried the remaining solid in vacuo, or the reaction mixture is freed from the solvent in vacuo. Alternatively, the reaction mixture can be stirred into a large amount of water and the precipitate filtered off or the aqueous phase, after neutralization with a suitable aqueous acid, such as. For example, hydrochloric acid, with a suitable organic solvent such. For example, dichloromethane or ethyl acetate, and the organic phase are concentrated in vacuo. The remaining crude product is purified by recrystallization from a suitable solvent, for example ethanol or ethyl acetate, or by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.
So kann, wenn das Produkt ein Derivat der Verbindung 21 gemäß Schema 5 sein soll, das Reaktionsprodukt 4, 7, 9 oder 15 mit Phosgen oder Carbonyldiimidazol und einem entsprechenden Hydrazin in einem geeigneten, inerten Lösungsmittel, wie bei- spielsweise Dioxan, Chloroform, Toluol oder Ethanol umgesetzt werden. Gegebenenfalls wird eine geeignete Base, vorzugsweise Pyridin, Natriumcarbonat, Diisopropy- lethylamin oder Natriumacetat verwendet. Das Reaktionsgemisch läßt man einige Zeit, beispielsweise 1 Stunde bis 24 Stunden, in einem Temperaturbereich zwischen 0 und 100 °C reagieren. Alternativ kann das Reaktionsprodukt 4, 7, 9 oder 15 mit einem entsprechenden Hydrazin-Phenyl-Carbamat-Reagenz und gegebenenfalls mit einer geeigneten Base, vorzugsweise Pyridin, Natriumcarbonat, Triethylamin oder Natriumacetat, in einem geeigneten, inerten Lösungsmittel, wie beispielsweise Tetrahydrofuran, Dioxan, Dichlormethan, Dimethylformamid oder Toluol, oder in einer Base als Lö- sungsmittel, wie z. B. Pyridin oder Triethylamin, oder ohne Lösungsmittel, umgesetzt werden. Das Reaktionsgemisch läßt man einige Zeit, beispielsweise 1 Stunde bis 15 Stunden, in einem Temperaturbereich zwischen 0 °C und 100 °C reagieren. Nach beendeter Umsetzung wird ein eventuell ausgefallener Niederschlag abfiltriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Alternativ kann das Reaktionsgemisch in eine große Menge Wasser eingerührt und der ausgefallene Niederschlag abfiltriert bzw. die wässrige Phase, nach Neutralisation mit einer geeigneten wässrigen Säure, wie z. B. Salzsäure, mit einem geeigne- ten organischen Lösungsmittel, wie z. B. Dichlormethan oder Ethylacetat, extrahiert und die organische Phase im Vakuum eingeengt werden. Die Reinigung des zurückbleibenden Rohproduktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielweise Ethanol oder Ethylacetat, oder durch Säulen- bzw. Flash- Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan.Thus, if the product is to be a derivative of compound 21 according to Scheme 5, the reaction product 4, 7, 9 or 15 with phosgene or carbonyldiimidazole and a corresponding hydrazine in a suitable inert solvent, such as at For example, dioxane, chloroform, toluene or ethanol are reacted. Optionally, a suitable base, preferably pyridine, sodium carbonate, diisopropylethylamine or sodium acetate is used. The reaction mixture is allowed to react for some time, for example 1 hour to 24 hours, in a temperature range between 0 and 100 ° C. Alternatively, reaction product 4, 7, 9 or 15 may be reacted with a corresponding hydrazine phenyl carbamate reagent and optionally with a suitable base, preferably pyridine, sodium carbonate, triethylamine or sodium acetate in a suitable inert solvent such as tetrahydrofuran, dioxane, Dichloromethane, dimethylformamide or toluene, or in a base as a solvent, such as. As pyridine or triethylamine, or without solvents. The reaction mixture is allowed to react for a period of time, for example 1 hour to 15 hours, in a temperature range between 0 ° C and 100 ° C. After completion of the reaction, any precipitated precipitate is filtered off, the filter medium may consist for example of commercial filter paper, washed with the appropriate solvent and dried the remaining solid in vacuo, or the reaction mixture is freed from the solvent in vacuo. Alternatively, the reaction mixture can be stirred into a large amount of water and the precipitate filtered off or the aqueous phase, after neutralization with a suitable aqueous acid, such as. Hydrochloric acid, with a suitable organic solvent such. For example, dichloromethane or ethyl acetate, and the organic phase are concentrated in vacuo. The purification of the remaining crude product is carried out by recrystallization from a suitable solvent, for example ethanol or ethyl acetate, or by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.
Oder es kann alternativ, wenn das Produkt ein Derivat der Verbindung 21 a gemäß Schema 5 sein soll, das Reaktionsprodukt 4, 7, 9 oder 15 mit Oxalylchlorid und einem entsprechenden Alkohol, gegebenenfalls mit einer geeigneten Base, vorzugsweise Pyridin, Natriumhydroxid, Triethylamin, in einem geeigneten, inerten Lösungsmittel, wie beispielsweise Tetrahydrofuran, Toluol, Dichlormethan, Ethanol oder in einer Base als Lösungsmittel, wie z. B. Pyridin oder Triethylamin, umgesetzt werden. Das Reaktionsgemisch läßt man einige Zeit, beispielsweise 15 Minuten bis 24 Stunden, in einem Temperaturbereich zwischen - 10 und 60 °C reagieren. Nach beendeter Umsetzung wird ein eventuell ausgefallener Niederschlag abfiltriert, wobei das Filtermedium bei- spielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Alternativ kann das Reaktionsgemisch in eine große Menge Wasser eingerührt und der ausgefal- lene Niederschlag abfiltriert bzw. die wässrige Phase, nach Neutralisation mit einer geeigneten wässrigen Säure, wie z. B. Salzsäure, mit einem geeigneten organischen Lösungsmittel, wie z. B. Dichlormethan oder Ethylacetat, extrahiert und die organische Phase im Vakuum eingeengt werden. Die Reinigung des zurückbleibenden Rohproduktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispiel- weise Ethanol oder Ethylacetat, oder durch Säulen- bzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan.Or alternatively, if the product is to be a derivative of compound 21a according to Scheme 5, the reaction product 4, 7, 9 or 15 with oxalyl chloride and a corresponding alcohol, optionally with a suitable base, preferably pyridine, sodium hydroxide, triethylamine, in a suitable inert solvent such as tetrahydrofuran, toluene, dichloromethane, ethanol or in a base as a solvent such. As pyridine or triethylamine are reacted. The reaction mixture is allowed to react for a period of time, for example 15 minutes to 24 hours, in a temperature range between -10 and 60 ° C. After completion of the reaction, any precipitate which has precipitated out is filtered off, the filter medium being added at the same time. For example, may consist of commercial filter paper, washed with the appropriate solvent and the residual solid dried in vacuo, or the reaction mixture is freed from the solvent in vacuo. Alternatively, the reaction mixture may be stirred into a large amount of water and the precipitate precipitated out or the aqueous phase, after neutralization with a suitable aqueous acid, such as. Hydrochloric acid, with a suitable organic solvent, such as. For example, dichloromethane or ethyl acetate, and the organic phase are concentrated in vacuo. The remaining crude product is purified by recrystallization from a suitable solvent, for example ethanol or ethyl acetate, or by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.
Oder es kann alternativ, wenn das Produkt ein Derivat der Verbindung 21 b gemäß Schema 5 sein soll, das Reaktionsprodukt 4, 7, 9 oder 15 mit Oxalylchlorid oder Ethy- loxalylchlorid und einem entsprechenden Amin, gegebenenfalls mit einer geeigneten Base, vorzugsweise Pyridin, Natriumhydroxid, Triethylamin, in einem geeigneten, inerten Lösungsmittel, wie beispielsweise Tetrahydrofuran, Toluol, Dichlormethan, Ethanol oder in einer Base als Lösungsmittel, wie z. B. Pyridin oder Triethylamin, umgesetzt werden. Das Reaktionsgemisch läßt man einige Zeit, beispielsweise 15 Minuten bis 24 Stunden, in einem Temperaturbereich zwischen - 10 und 60 °C reagieren. Alternativ kann die Zwischenstufe 21 a mit einem entsprechenden Amin, gegebenenfalls mit einer geeigneten Base, vorzugsweise Pyridin, Natriumhydrid oder Triethylamin, in einem geeigneten, inerten Lösungsmittel, wie beispielsweise Tetrahydrofuran, Toluol, Dich- lormethan, Ethanol oder in einer Base als Lösungsmittel, wie z. B. Pyridin oder Triethylamin, umgesetzt werden. Das Reaktionsgemisch läßt man einige Zeit, beispielsweise 1 Stunde bis 50 Stunden, in einem Temperaturbereich zwischen 10 und 120 °C reagieren. Nach beendeter Umsetzung wird ein eventuell ausgefallener Niederschlag abfiltriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier beste- hen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Alternativ kann das Reaktionsgemisch in eine große Menge Wasser eingerührt und der ausgefallene Niederschlag abfiltriert bzw. die wässrige Phase, nach Neutralisation mit einer geeigneten wässrigen Säure, wie z. B. Salzsäure, mit einem geeigneten organischen Lösungsmittel, wie z. B. Dichlormethan oder Ethyl- acetat, extrahiert und die organische Phase im Vakuum eingeengt werden. Die Reinigung des zurückbleibenden Rohproduktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielweise Ethanol oder Ethylacetat, oder durch Säulenbzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan.Or alternatively, if the product is to be a derivative of compound 21b according to Scheme 5, the reaction product 4, 7, 9 or 15 with oxalyl chloride or ethyl loxalyl chloride and a corresponding amine, optionally with a suitable base, preferably pyridine, sodium hydroxide , Triethylamine, in a suitable inert solvent such as tetrahydrofuran, toluene, dichloromethane, ethanol or in a base as a solvent such. As pyridine or triethylamine are reacted. The reaction mixture is allowed to react for a period of time, for example 15 minutes to 24 hours, in a temperature range between -10 and 60 ° C. Alternatively, the intermediate 21 a with a corresponding amine, optionally with a suitable base, preferably pyridine, sodium hydride or triethylamine, in a suitable inert solvent such as tetrahydrofuran, toluene, dichloromethane, ethanol or in a base as a solvent, such as z. As pyridine or triethylamine are reacted. The reaction mixture is allowed to react for some time, for example 1 hour to 50 hours, in a temperature range between 10 and 120 ° C. After completion of the reaction, any precipitate which has precipitated out is filtered off, it being possible for the filter medium to consist, for example, of commercially available filter paper, washed with the appropriate solvent and the residual solid dried in vacuo, or the reaction mixture is freed from the solvent in vacuo. Alternatively, the reaction mixture can be stirred into a large amount of water and the precipitate filtered off or the aqueous phase, after neutralization with a suitable aqueous acid, such as. Hydrochloric acid, with a suitable organic solvent, such as. As dichloromethane or ethyl acetate, extracted and the organic phase are concentrated in vacuo. The purification of the residual crude product is carried out by recrystallization from a suitable solvent, for example ethanol or ethyl acetate, or by Säulenbzw. Flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.
Schema 6: 1. StufeScheme 6: 1st stage
Im Anschluß an die Grundverfahren können in Folgereaktionen die nach dem Grundverfahren entstandenen Produkte in einer dem Fachmann bekannten Vorgehensweise zu erfindungsgemässen Folgeprodukten umgesetzt werden.Subsequent to the basic processes, the products produced by the basic process can be reacted in subsequent reactions in a procedure known to the person skilled in the art to yield secondary products according to the invention.
So kann, wenn das Produkt ein Derivat der Verbindung 23 gemäß Schema 6 sein soll, das Reaktionsprodukt 22 mit entsprechenden Aryl/Heteroaryl-Boronsäure- Derivaten oder Aryl/Heteroaryl-Organozinn-Verbindungen und einem geeigneten Katalysator, wie z. B. Pd(PPh3)4, [1 ,1 '-Bis(diphenylphosphino)ferrocen]-dichlor-palladium(ll) oder Pd2(dba)3, und einer geeigneten Base, beispielsweise, Natriumcarbonat, Cäsium- carbonat oder Triethylamin, in einem geeignetem Lösungsmittel, wie beispielsweise Dimethylformamid, Dimethylformamid/Wasser, Toluol, Acetonitril, Dimethoxyethan oder Dioxan, umgesetzt werden. Das Reaktionsgemisch lässt man einige Zeit, beispielsweise 6 Stunden bis mehrere Tage, in einem Temperaturbereich zwischen 60 °C und 120 °C reagieren. Nach beendeter Umsetzung wird ein eventuell ausgefallener Niederschlag abfiltriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, bzw. werden evtl. vorhandene Katalysatorreste abfiltriert mit dem entsprechenden Lösungsmittel nachgewaschen und das Lösungsmittel im Vakuum entfernt, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Alternativ kann das Reaktionsgemisch in eine große Menge Wasser eingerührt und der ausgefallene Niederschlag abfiltriert bzw. die wässrige Phase, nach Neutralisation mit einer geeigneten wässrigen Säure, wie z. B. Salzsäure, mit einem geeigneten organischen Lösungsmittel, wie z. B. Dichlormethan oder Ethylacetat, extrahiert und die organische Phase im Vakuum eingeengt werden. Die Reinigung des zurückbleibenden Rohproduktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielsweise Ethanol oder Ethylacetat, oder durch Säulenbzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan.Thus, if the product is to be a derivative of compound 23 according to Scheme 6, the reaction product 22 can be reacted with corresponding aryl / heteroaryl boronic acid derivatives or aryl / heteroaryl organotin compounds and a suitable catalyst, such as e.g. B. Pd (PPh 3 ) 4 , [1, 1 ' bis (diphenylphosphino) ferrocene] -dichloro-palladium (II) or Pd 2 (dba) 3 , and a suitable base, for example, sodium carbonate, cesium carbonate or triethylamine , in a suitable solvent such as dimethylformamide, dimethylformamide / water, toluene, acetonitrile, dimethoxyethane or dioxane. The reaction mixture is allowed to react for some time, for example 6 hours to several days, in a temperature range between 60 ° C and 120 ° C. After completion of the reaction, any precipitated precipitate is filtered off, the filter medium may consist for example of commercial filter paper, washed with the appropriate solvent and the remaining solid dried in vacuo, or any existing catalyst residues are filtered off with the appropriate solvent and washed the solvent in the Vacuum removed, or the reaction mixture is freed from the solvent in vacuo. Alternatively, the reaction mixture can be stirred into a large amount of water and the precipitate filtered off or the aqueous phase, after neutralization with a suitable aqueous acid, such as. Hydrochloric acid, with a suitable organic solvent, such as. For example, dichloromethane or ethyl acetate, and the organic phase are concentrated in vacuo. The purification of the residual crude product is carried out by recrystallization from a suitable solvents, for example ethanol or ethyl acetate, or by Säulenbzw. Flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.
So kann, wenn das Produkt ein Derivat der Verbindung 23a gemäß Schema 6 sein soll, das Reaktionsprodukt 22 mit entsprechenden Alkyl-Zink-Halogeniden und einem geeigneten Katalysator, wie z. B. Pd(PPh3)4, [1 ,1 '-Bis(diphenylphosphino)ferrocen]- dichlor-palladium(ll) oder PdCI2(PPh3)2 in einem geeignetem Lösungsmittel, wie beispielsweise Dimethylformamid, Tetra hydrofu ran, Toluol, Dimethoxyethan oder Dioxan, umgesetzt werden. Das Reaktionsgemisch lässt man einige Zeit, beispielsweise 30 Minuten bis 48 Stunden, in einem Temperaturbereich zwischen Raumtemperatur und 120 °C reagieren. Nach beendeter Umsetzung wird ein eventuell ausgefallener Niederschlag abfiltriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, bzw. werden evtl. vorhandene Katalysatorreste abfiltriert mit dem entsprechenden Lösungsmittel nachgewaschen und das Lösungsmittel im Vakuum entfernt, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Alternativ kann das Reaktionsgemisch in eine große Menge Wasser eingerührt und der ausgefallene Niederschlag abfiltriert bzw. die wässrige Phase mit einem geeigneten organischen Lösungsmittel, wie z. B. Dichlormethan oder Ethylacetat, extrahiert und die organische Phase im Vakuum eingeengt werden. Die Reinigung des zurückbleibenden Rohproduktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielsweise Ethanol oder Ethylacetat, oder durch Säulen- bzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan.Thus, if the product is to be a derivative of compound 23a according to Scheme 6, the reaction product 22 can be reacted with appropriate alkyl-zinc halides and a suitable catalyst, such as e.g. B. Pd (PPh 3 ) 4 , [1, 1 ' -Bis (diphenylphosphino) ferrocene] - dichloro-palladium (II) or PdCl 2 (PPh 3 ) 2 in a suitable solvent, such as dimethylformamide, tetrahydrofuran, toluene , Dimethoxyethane or dioxane. The reaction mixture is allowed to react for some time, for example 30 minutes to 48 hours, in a temperature range between room temperature and 120 ° C. After completion of the reaction, any precipitated precipitate is filtered off, the filter medium may consist for example of commercial filter paper, washed with the appropriate solvent and the remaining solid dried in vacuo, or any existing catalyst residues are filtered off with the appropriate solvent and washed the solvent in the Vacuum removed, or the reaction mixture is freed from the solvent in vacuo. Alternatively, the reaction mixture is stirred into a large amount of water and the precipitate filtered off or the aqueous phase with a suitable organic solvent such. For example, dichloromethane or ethyl acetate, and the organic phase are concentrated in vacuo. The purification of the remaining crude product is carried out by recrystallization from a suitable solvent, for example ethanol or ethyl acetate, or by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.
So kann, wenn das Produkt ein Derivat der Verbindung 24 gemäß Schema 6 sein soll, das Reaktionsprodukt 22 mit entsprechenden Vinyl-Boronsäure-Derivaten, Vinyl- Organozinn-Verbindungen oder Alken-Derivaten und einem geeigneten Katalysator, wie z. B. Pd(PPh3)4, [1 ,1 '-Bis(diphenylphosphino)ferrocen]-dichlor-palladium(ll) oder Pd(OAc)2, und einem geeigneten Liganden, wie z. B. Triphenylphosphin oder Tri-o- tolylphosphin, und einer geeigneten Base, beispielsweise Kaliumcarbonat, Natriumcar- bonat, Triethylamin oder Natriumacetat, in einem geeignetem Lösungsmittel, wie beispielsweise Toluol, Dimethylformamid, Dimethylformamid/Wasser, Acetonitril, Di- methoxyethan oder Dimethylacetamid, umgesetzt werden. Das Reaktionsgemisch lässt man einige Zeit, beispielsweise 3 Stunden bis 24 Stunden, in einem Temperaturbereich zwischen 60 °C und 140 °C reagieren. Nach beendeter Umsetzung wird ein e- ventuell ausgefallener Niederschlag abfiltriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, bzw. werden evtl. vorhandene Katalysatorreste abfiltriert mit dem entsprechenden Lösungsmittel nachgewaschen und das Lösungsmittel im Vakuum entfernt, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Alternativ kann das Reakti- onsgemisch in eine große Menge Wasser eingerührt und der ausgefallene Niederschlag abfiltriert bzw. die wässrige Phase, nach Neutralisation mit einer geeigneten wässrigen Säure, wie z. B. Salzsäure, mit einem geeigneten organischen Lösungsmittel, wie z. B. Dichlormethan oder Ethylacetat, extrahiert und die organische Phase im Vakuum eingeengt werden. Die Reinigung des zurückbleibenden Rohproduktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielsweise Ethanol oder Toluol, oder durch Säulen- bzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan.Thus, if the product is to be a derivative of compound 24 according to Scheme 6, the reaction product 22 can be reacted with corresponding vinyl boronic acid derivatives, vinyl organotin compounds or alkene derivatives and a suitable catalyst, such as e.g. B. Pd (PPh 3 ) 4 , [1, 1 ' -Bis (diphenylphosphino) ferrocene] -dichloro-palladium (II) or Pd (OAc) 2 , and a suitable ligand, such as. B. triphenylphosphine or tri-o-tolylphosphin, and a suitable base, for example potassium carbonate, sodium carbonate, triethylamine or sodium acetate, in a suitable solvent such as toluene, dimethylformamide, dimethylformamide / water, acetonitrile, di- methoxyethane or dimethylacetamide. The reaction mixture is allowed to react for some time, for example 3 hours to 24 hours, in a temperature range between 60 ° C and 140 ° C. After completion of the reaction, an e-vented precipitate is filtered off, the filter medium may consist for example of commercial filter paper, washed with the appropriate solvent and the remaining solid dried in vacuo, or any existing catalyst residues are filtered off with the appropriate solvent and washed the Solvent removed in vacuo, or the reaction mixture is freed from the solvent in vacuo. Alternatively, the reaction mixture can be stirred into a large amount of water and the precipitate filtered off or the aqueous phase, after neutralization with a suitable aqueous acid, such as. Hydrochloric acid, with a suitable organic solvent, such as. For example, dichloromethane or ethyl acetate, and the organic phase are concentrated in vacuo. The purification of the residual crude product is carried out by recrystallization from a suitable solvent, for example ethanol or toluene, or by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.
So kann, wenn das Produkt ein Derivat der Verbindung 25 gemäß Schema 6 sein soll, das Reaktionsprodukt 22 mit entsprechenden Alkin-Derivaten und einem geeigneten Katalysator, wie z. B. Pd(PPh3)4, PdCl2(PPhs)2 oder Pd2(dba)3, und einem geeigneten Zusatzstoff, wie beispielsweise Kupfer(i)iodid, und einer geeigneten Base, beispielsweise Kaliumcarbonat, Triethylamin oder Kaliumacetat, in einem geeignetem Lösungsmittel, wie beispielsweise Dimethylformamid, Tetrahydrofuran, Tetrahydrofu- ran/Wasser, Toluol oder Dimethylacetamid, umgesetzt werden. Das Reaktionsgemisch lässt man einige Zeit, beispielsweise 1 Stunde bis mehrere Tage, in einem Temperaturbereich zwischen Raumtemperatur und 120 °C reagieren. Nach beendeter Umsetzung wird ein eventuell ausgefallener Niederschlag abfiltriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, bzw. werden evtl. vorhandene Katalysatorreste abfiltriert mit dem entsprechenden Lösungsmittel nachgewaschen und das Lösungsmittel im Vakuum entfernt, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Alternativ kann das Reaktionsgemisch in eine große Menge Wasser eingerührt und der ausgefallene Niederschlag abfiltriert bzw. die wässrige Phase, nach Neutralisation mit einer geeigneten wässrigen Säure, wie z. B. Salzsäure, mit einem geeigneten organischen Lösungsmittel, wie z. B. Dichlormethan oder Ethylacetat, extrahiert und die organische Phase im Vakuum eingeengt werden. Die Reinigung des zurückbleibenden Rohpro- duktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielsweise Ethanol oder Toluol, oder durch Säulen- bzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan.Thus, if the product is to be a derivative of compound 25 according to Scheme 6, the reaction product 22 can be reacted with appropriate alkyne derivatives and a suitable catalyst, such as e.g. Pd (PPh 3 ) 4 , PdCl 2 (PPhs) 2 or Pd 2 (dba) 3, and a suitable additive, such as copper (i) iodide, and a suitable base, for example potassium carbonate, triethylamine or potassium acetate, in one suitable solvent such as dimethylformamide, tetrahydrofuran, tetrahydrofuran / water, toluene or dimethylacetamide. The reaction mixture is allowed to react for some time, for example 1 hour to several days, in a temperature range between room temperature and 120 ° C. After completion of the reaction, any precipitated precipitate is filtered off, the filter medium may consist for example of commercial filter paper, washed with the appropriate solvent and the remaining solid dried in vacuo, or any existing catalyst residues are filtered off with the appropriate solvent and washed the solvent in the Vacuum removed, or the reaction mixture is freed from the solvent in vacuo. Alternatively, the reaction mixture may be stirred into a large amount of water and the precipitated The precipitate is filtered off or the aqueous phase, after neutralization with a suitable aqueous acid, such as. Hydrochloric acid, with a suitable organic solvent, such as. For example, dichloromethane or ethyl acetate, and the organic phase are concentrated in vacuo. The remaining crude product is purified by recrystallization from a suitable solvent, for example ethanol or toluene, or by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.
Schema 7: 1. StufeScheme 7: 1st stage
Im Anschluß an die Grundverfahren können in Folgereaktionen die nach dem Grundverfahren entstandenen Produkte in einer dem Fachmann bekannten Vorgehensweise zu erfindungsgemässen Folgeprodukten umgesetzt werden.Subsequent to the basic processes, the products produced by the basic process can be reacted in subsequent reactions in a procedure known to the person skilled in the art to yield secondary products according to the invention.
Die Zwischenstufe 22 kann mit einem entsprechenden Amin und gegebenenfalls mit einer geeigneten Base, vorzugsweise Natriumhydrid, Pyridin, Triethylamin, Kalium- carbonat oder Natriummethanolat in Methanol, in einem geeigneten, inerten Lösungsmittel, wie beispielsweise Dimethylformamid, Dimethylsulfoxid, Methanol, Toluol, oder in einer Base als Lösungsmittel, wie z. B. Pyridin oder Triethylamin, oder ohne Lösungsmittel, umgesetzt werden. Das Reaktionsgemisch lässt man einige Zeit, beispielsweise 1 Stunde bis mehrere Tage, in einem Temperaturbereich zwischen 20 °C und 140 °C reagieren. Alternativ kann die Zwischenstufe 22 mit einem entsprechenden Amin und einem geeigneten Katalysator, wie z. B. Palladiumacetat oder Pd2(dba)3, und einem geeigneten Liganden, wie z. B. BINAP, und einer geeigneten Base, beispielsweise, Kaliumcarbonat oder Natrium-tert.butanolat, in einem geeignetem Lösungsmittel, wie beispielsweise Toluol oder Dioxan, umgesetzt werden. Das Reaktionsgemisch lässt man einige Zeit, beispielsweise 10 Stunden bis 30 Stunden, in einem Temperaturbereich zwischen 60 °C und 120 °C reagieren. Nach beendeter Umsetzung wird ein eventuell ausgefallener Niederschlag abfiltriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, bzw. werden evtl. vorhandene Katalysatorreste abfiltriert mit dem entsprechenden Lö- sungsmittel nachgewaschen und das Lösungsmittel im Vakuum entfernt, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Alternativ kann das Reaktionsgemisch in eine große Menge Wasser eingerührt und der ausgefallene Niederschlag abfiltriert bzw. die wässrige Phase, nach Neutralisation mit einer geeigneten wässrigen Säure, wie z. B. Salzsäure, mit einem geeigneten organischen Lösungsmittel, wie z. B. Dichlormethan oder Ethylacetat, extrahiert und die organische Phase im Vakuum eingeengt werden. Die Reinigung des zurückbleibenden Rohproduktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielsweise Dioxan, Ethylacetat oder Toluol, oder durch Säulen- bzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan.Intermediate 22 may be treated with a corresponding amine and optionally with a suitable base, preferably sodium hydride, pyridine, triethylamine, potassium carbonate or sodium methoxide in methanol, in a suitable inert solvent such as dimethylformamide, dimethylsulfoxide, methanol, toluene, or in a Base as a solvent, such as. As pyridine or triethylamine, or without solvents. The reaction mixture is allowed to react for some time, for example 1 hour to several days, in a temperature range between 20 ° C and 140 ° C. Alternatively, the intermediate 22 may be treated with a suitable amine and a suitable catalyst, e.g. B. palladium acetate or Pd 2 (dba) 3 , and a suitable ligand, such as. B. BINAP, and a suitable base, for example, potassium carbonate or sodium tert.butanolat, are reacted in a suitable solvent such as toluene or dioxane. The reaction mixture is allowed to react for some time, for example 10 hours to 30 hours, in a temperature range between 60 ° C and 120 ° C. After completion of the reaction, any precipitated precipitate is filtered off, the filter medium may consist for example of commercially available filter paper, washed with the appropriate solvent and the residual solid dried in vacuo, or any existing catalyst residues are filtered off with the appropriate Lö- After washing solvent and the solvent removed in vacuo, or the reaction mixture is freed from the solvent in vacuo. Alternatively, the reaction mixture can be stirred into a large amount of water and the precipitate filtered off or the aqueous phase, after neutralization with a suitable aqueous acid, such as. Hydrochloric acid, with a suitable organic solvent, such as. For example, dichloromethane or ethyl acetate, and the organic phase are concentrated in vacuo. The purification of the remaining crude product is carried out by recrystallization from a suitable solvent, for example dioxane, ethyl acetate or toluene, or by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.
2. Stufe2nd stage
So kann, wenn das Produkt ein Derivat der Verbindung 27 gemäß Schema 7 sein soll, das Reaktionsprodukt 26 mit einem entsprechenden Carbonsäurechlorid und gegebenenfalls einer geeigneten Base, vorzugsweise Natriumhydrid, Kaliumhydroxid, Pyridin, Triethylamin oder Kaliumcarbonat, und gegebenenfalls einem Katalysator, wie z. B. Dimethylaminopyridin, in einem geeigneten, inerten Lösungsmittel, wie beispiels- weise Tetrahydrofuran, Toluol, Acetonitril, Dichlormethan, Aceton oder Dioxan, oder in einer Base als Lösungsmittel, wie z. B. Pyridin oder Triethylamin, oder ohne Lösungsmittel, umgesetzt werden. Das Reaktionsgemisch läßt man einige Zeit, beispielsweise 30 Minuten bis 24 Stunden, in einem Temperaturbereich zwischen 0 und 1 10 °C reagieren. Nach beendeter Umsetzung wird ein eventuell ausgefallener Niederschlag ab- filtriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Alternativ kann das Reaktionsgemisch in eine große Menge Wasser eingerührt und der ausgefallene Niederschlag abfiltriert bzw. die wäss- rige Phase, nach Neutralisation mit einer geeigneten wässrigen Säure, wie z. B. Salzsäure, mit einem geeigneten organischen Lösungsmittel, wie z. B. Dichlormethan oder Ethylacetat, extrahiert und die organische Phase im Vakuum eingeengt werden. Die Reinigung des zurückbleibenden Rohproduktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielsweise Ethanol oder Ethylacetat, oder durch Säulen- bzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan.Thus, if the product is to be a derivative of Compound 27 according to Scheme 7, the reaction product 26 may be treated with a corresponding carboxylic acid chloride and optionally a suitable base, preferably sodium hydride, potassium hydroxide, pyridine, triethylamine or potassium carbonate, and optionally a catalyst such. As dimethylaminopyridine, in a suitable inert solvent such as tetrahydrofuran, toluene, acetonitrile, dichloromethane, acetone or dioxane, or in a base as a solvent such. As pyridine or triethylamine, or without solvents. The reaction mixture is allowed to react for some time, for example 30 minutes to 24 hours, in a temperature range between 0 and 1 10 ° C. After completion of the reaction, any precipitate which has precipitated out is filtered off, it being possible for the filter medium to consist, for example, of commercially available filter paper, washed with the appropriate solvent and the residual solid dried in vacuo, or the reaction mixture is freed from the solvent in vacuo. Alternatively, the reaction mixture can be stirred into a large amount of water and the precipitate filtered off or the aqueous phase, after neutralization with a suitable aqueous acid, such as. Hydrochloric acid, with a suitable organic solvent, such as. For example, dichloromethane or ethyl acetate, and the organic phase are concentrated in vacuo. The purification of the residual crude product is carried out by recrystallization from a suitable solvent, for example, ethanol or ethyl acetate, or by Column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.
So kann, wenn das Produkt ein Derivat der Verbindung 28 gemäß Schema 7 sein soll, das Reaktionsprodukt 26 mit einem entsprechenden Sulfonsäurechlorid und gegebenenfalls einer geeigneten Base, vorzugsweise Natriumhydrid, Kaliumhydroxid, Pyridin, Triethylamin oder Kaliumcarbonat, und gegebenenfalls einem Katalysator, wie z. B. Dimethylaminopyridin, in einem geeigneten, inerten Lösungsmittel, wie beispielsweise Tetrahydrofuran, Toluol, Acetonitril, Dichlormethan, Aceton, Dimethylformamid oder Dioxan, oder in einer Base als Lösungsmittel, wie z. B. Pyridin oder Triethylamin, oder ohne Lösungsmittel, umgesetzt werden. Das Reaktionsgemisch läßt man einige Zeit, beispielsweise 30 Minuten bis 16 Stunden, in einem Temperaturbereich zwischen 0 und 120 °C reagieren. Nach beendeter Umsetzung wird ein eventuell ausgefallener Niederschlag abfiltriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Alternativ kann das Reaktionsgemisch in eine große Menge Wasser eingerührt und der ausgefallene Niederschlag abfiltriert bzw. die wässrige Phase, nach Neutralisation mit einer geeigneten wässrigen Säure, wie z. B. Salzsäure, mit einem geeigneten organischen Lösungsmittel, wie z. B. Dichlormethan oder Ethylacetat, extrahiert und die organische Phase im Vakuum eingeengt werden. Die Reinigung des zurückbleibenden Rohproduktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielsweise Ethanol oder Ethylacetat, oder durch Säulen- bzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan.Thus, if the product is to be a derivative of Compound 28 according to Scheme 7, the reaction product 26 may be treated with a corresponding sulfonic acid chloride and optionally a suitable base, preferably sodium hydride, potassium hydroxide, pyridine, triethylamine or potassium carbonate, and optionally a catalyst, e.g. For example, dimethylaminopyridine, in a suitable inert solvent such as tetrahydrofuran, toluene, acetonitrile, dichloromethane, acetone, dimethylformamide or dioxane, or in a base as a solvent such. As pyridine or triethylamine, or without solvents. The reaction mixture is allowed to react for some time, for example 30 minutes to 16 hours, in a temperature range between 0 and 120 ° C. After completion of the reaction, any precipitated precipitate is filtered off, the filter medium may consist for example of commercial filter paper, washed with the appropriate solvent and dried the remaining solid in vacuo, or the reaction mixture is freed from the solvent in vacuo. Alternatively, the reaction mixture can be stirred into a large amount of water and the precipitate filtered off or the aqueous phase, after neutralization with a suitable aqueous acid, such as. Hydrochloric acid, with a suitable organic solvent, such as. For example, dichloromethane or ethyl acetate, and the organic phase are concentrated in vacuo. The purification of the remaining crude product is carried out by recrystallization from a suitable solvent, for example ethanol or ethyl acetate, or by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.
So kann, wenn das Produkt ein Derivat der Verbindung 29 gemäß Schema 7 sein soll, das Reaktionsprodukt 26 mit einem entsprechenden Chlorkohlensäureester und gegebenenfalls einer geeigneten Base, vorzugsweise Natriumhydrid, Natriumhydroxid, Pyridin, Triethylamin oder Kaliumcarbonat, und gegebenenfalls einem Katalysator, wie z. B. Dimethylaminopyridin, in einem geeigneten, inerten Lösungsmittel, wie beispielsweise Dioxan, Tetrahydrofuran, Dichlormethan, Aceton, Dimethylformamid oder Dichlo- rethan, oder in einer Base als Lösungsmittel, wie z. B. Pyridin oder Triethylamin, oder ohne Lösungsmittel, umgesetzt werden. Das Reaktionsgemisch läßt man einige Zeit, beispielsweise 1 Stunde bis 24 Stunden, in einem Temperaturbereich zwischen -10 °C und 100 °C reagieren. Nach beendeter Umsetzung wird ein eventuell ausgefallener Niederschlag abfiltriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Alternativ kann das Reaktionsgemisch in eine große Menge Wasser eingerührt und der ausgefallene Niederschlag abfiltriert bzw. die wässrige Phase, nach Neutralisation mit einer geeigneten wässrigen Säure, wie z. B. Salzsäure, mit einem geeigneten organischen Lösungsmittel, wie z. B. Dich- lormethan oder Ethylacetat, extrahiert und die organische Phase im Vakuum eingeengt werden. Die Reinigung des zurückbleibenden Rohproduktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielsweise Ethanol oder Ethylacetat, oder durch Säulen- bzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan.Thus, if the product is to be a derivative of compound 29 according to Scheme 7, the reaction product 26 may be treated with a corresponding chloroformate and optionally a suitable base, preferably sodium hydride, sodium hydroxide, pyridine, triethylamine or potassium carbonate, and optionally a catalyst such as e.g. For example, dimethylaminopyridine, in a suitable inert solvent such as dioxane, tetrahydrofuran, dichloromethane, acetone, dimethylformamide or dichloroethane, or in a base as a solvent such. As pyridine or triethylamine, or without solvents. The reaction mixture is left for some time, for example, 1 hour to 24 hours, in a temperature range between -10 ° C and 100 ° C react. After completion of the reaction, any precipitated precipitate is filtered off, the filter medium may consist for example of commercial filter paper, washed with the appropriate solvent and dried the remaining solid in vacuo, or the reaction mixture is freed from the solvent in vacuo. Alternatively, the reaction mixture can be stirred into a large amount of water and the precipitate filtered off or the aqueous phase, after neutralization with a suitable aqueous acid, such as. Hydrochloric acid, with a suitable organic solvent, such as. For example, dichloromethane or ethyl acetate, and the organic phase are concentrated in vacuo. The purification of the remaining crude product is carried out by recrystallization from a suitable solvent, for example ethanol or ethyl acetate, or by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.
So kann, wenn das Produkt ein Derivat der Verbindung 30 gemäß Schema 7 sein soll, das Reaktionsprodukt 26 mit einem entsprechenden Isocyanat oder Carbaminsäu- rechlorid und gegebenenfalls einer geeigneten Base, vorzugsweise Natriumhydrid, Pyridin, Triethylamin, Piperidin oder Kaliumcarbonat, und gegebenenfalls einem Kata- lysator, wie z. B. Dimethylaminopyridin, in einem geeigneten, inerten Lösungsmittel, wie beispielsweise Dioxan, Tetrahydrofuran, Dimethylformamid, Toluol oder Acetonitril, oder in einer Base als Lösungsmittel, wie z. B. Pyridin oder Triethylamin, oder ohne Lösungsmittel, umgesetzt werden. Das Reaktionsgemisch läßt man einige Zeit, beispielsweise 2 Stunde bis 40 Stunden, in einem Temperaturbereich zwischen Raum- temperatur und 100 °C reagieren. Nach beendeter Umsetzung wird ein eventuell ausgefallener Niederschlag abfiltriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Alternativ kann das Re- aktionsgemisch in eine große Menge Wasser eingerührt und der ausgefallene Niederschlag abfiltriert bzw. die wässrige Phase, nach Neutralisation mit einer geeigneten wässrigen Säure, wie z. B. Salzsäure, mit einem geeigneten organischen Lösungsmittel, wie z. B. Dichlormethan oder Ethylacetat, extrahiert und die organische Phase im Vakuum eingeengt werden. Die Reinigung des zurückbleibenden Rohproduktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielsweise Ethanol oder Ethylacetat, oder durch Säulen- bzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan.Thus, if the product is to be a derivative of compound 30 according to Scheme 7, the reaction product 26 may be treated with an appropriate isocyanate or carbamic acid chloride and optionally a suitable base, preferably sodium hydride, pyridine, triethylamine, piperidine or potassium carbonate, and optionally a catalyst. lysator, such as. For example, dimethylaminopyridine, in a suitable inert solvent such as dioxane, tetrahydrofuran, dimethylformamide, toluene or acetonitrile, or in a base as a solvent such. As pyridine or triethylamine, or without solvents. The reaction mixture is allowed to react for some time, for example 2 hours to 40 hours, in a temperature range between room temperature and 100 ° C. After completion of the reaction, any precipitated precipitate is filtered off, the filter medium may consist for example of commercial filter paper, washed with the appropriate solvent and dried the remaining solid in vacuo, or the reaction mixture is freed from the solvent in vacuo. Alternatively, the reaction mixture stirred into a large amount of water and the precipitate filtered off or the aqueous phase, after neutralization with a suitable aqueous acid, such as. Hydrochloric acid, with a suitable organic solvent, such as. For example, dichloromethane or ethyl acetate, and the organic phase are concentrated in vacuo. The purification of the remaining crude product is carried out by recrystallization from a suitable solvent, for example ethanol or ethyl acetate, or by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.
Schema 8: 1. StufeScheme 8: 1st stage
Im Anschluß an die Grundverfahren können in Folgereaktionen die nach dem Grundverfahren entstandenen Produkte in einer dem Fachmann bekannten Vorgehensweise zu erfindungsgemässen Folgeprodukten umgesetzt werden.Subsequent to the basic processes, the products produced by the basic process can be reacted in subsequent reactions in a procedure known to the person skilled in the art to yield secondary products according to the invention.
So kann, wenn das Produkt ein Derivat der Verbindung 32 oder 35 gemäß Schema 8 sein soll, das Reaktionsprodukt 31 oder 34 mit einem entsprechenden Chlorkohlensäureester und gegebenenfalls einer geeigneten Base, vorzugsweise Natriumhydrid, Natriumhydroxid, Pyridin, Triethylamin oder Kaliumcarbonat, und gegebenenfalls ei- nem Katalysator, wie z. B. Dimethylaminopyridin, in einem geeigneten, inerten Lösungsmittel, wie beispielsweise Dioxan, Tetrahydrofuran, Dichlormethan, Aceton, Di- methylformamid oder Dichlorethan, oder in einer Base als Lösungsmittel, wie z. B. Pyridin oder Triethylamin, oder ohne Lösungsmittel, umgesetzt werden. Das Reaktionsgemisch läßt man einige Zeit, beispielsweise 1 Stunde bis 24 Stunden, in einem Tem- peraturbereich zwischen -10 °C und 100 °C reagieren. Nach beendeter Umsetzung wird ein eventuell ausgefallener Niederschlag abfiltriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Alternativ kann das Reaktionsgemisch in eine große Menge Wasser eingerührt und der ausgefallene Niederschlag abfiltriert bzw. die wässrige Phase, nach Neutralisation mit einer geeigneten wässrigen Säure, wie z. B. Salzsäure, mit einem geeigneten organischen Lösungsmittel, wie z. B. Dichlormethan oder Ethylacetat, extrahiert und die organische Phase im Vakuum eingeengt werden. Die Reinigung des zurückbleibenden Rohpro- duktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielsweise Ethanol oder Ethylacetat, oder durch Säulen- bzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan. So kann, wenn das Produkt ein Derivat der Verbindung 33 oder 36 gemäß Schema 8 sein soll, das Reaktionsprodukt 31 oder 34 mit einem entsprechenden Isocyanat oder Carbaminsäurechlorid und gegebenenfalls einer geeigneten Base, vorzugsweise Natriumhydrid, Pyridin, Triethylamin, Piperidin oder Kaliumcarbonat, und gegebenenfalls einem Katalysator, wie z. B. Dimethylaminopyridin, in einem geeigneten, inerten Lösungsmittel, wie beispielsweise Dioxan, Tetrahydrofuran, Dimethylformamid, Toluol oder Acetonitril, oder in einer Base als Lösungsmittel, wie z. B. Pyridin oder Triethylamin, oder ohne Lösungsmittel, umgesetzt werden. Das Reaktionsgemisch läßt man einige Zeit, beispielsweise 2 Stunde bis 40 Stunden, in einem Temperaturbereich zwischen Raumtemperatur und 100 °C reagieren. Nach beendeter Umsetzung wird ein eventuell ausgefallener Niederschlag abfiltriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Alternativ kann das Reaktionsgemisch in eine große Menge Wasser eingerührt und der ausgefallene Niederschlag abfiltriert bzw. die wässrige Phase, nach Neutralisation mit einer geeigneten wässrigen Säure, wie z. B. Salzsäure, mit einem geeigneten organischen Lösungsmittel, wie z. B. Dichlormethan oder Ethylacetat, extrahiert und die organische Phase im Vakuum eingeengt werden. Die Reinigung des zurückbleibenden Rohproduktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielsweise Ethanol oder Ethylacetat, oder durch Säulen- bzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan.Thus, if the product is to be a derivative of Compound 32 or 35 according to Scheme 8, reaction product 31 or 34 may be treated with a corresponding chloroformate and optionally a suitable base, preferably sodium hydride, sodium hydroxide, pyridine, triethylamine or potassium carbonate, and optionally one Catalyst, such as. For example, dimethylaminopyridine, in a suitable inert solvent such as dioxane, tetrahydrofuran, dichloromethane, acetone, dimethylformamide or dichloroethane, or in a base as a solvent such. As pyridine or triethylamine, or without solvents. The reaction mixture is allowed to react for some time, for example 1 hour to 24 hours, in a temperature range between -10 ° C and 100 ° C. After completion of the reaction, any precipitated precipitate is filtered off, the filter medium may consist for example of commercial filter paper, washed with the appropriate solvent and dried the remaining solid in vacuo, or the reaction mixture is freed from the solvent in vacuo. Alternatively, the reaction mixture can be stirred into a large amount of water and the precipitate filtered off or the aqueous phase, after neutralization with a suitable aqueous acid, such as. Hydrochloric acid, with a suitable organic solvent, such as. For example, dichloromethane or ethyl acetate, and the organic phase are concentrated in vacuo. The remaining crude product is purified by recrystallization from a suitable solvent, for example ethanol or ethyl acetate, or by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane. Thus, if the product is to be a derivative of compound 33 or 36 of Scheme 8, reaction product 31 or 34 may be treated with a corresponding isocyanate or carbamic acid chloride and optionally a suitable base, preferably sodium hydride, pyridine, triethylamine, piperidine or potassium carbonate, and optionally one Catalyst, such as. For example, dimethylaminopyridine, in a suitable inert solvent such as dioxane, tetrahydrofuran, dimethylformamide, toluene or acetonitrile, or in a base as a solvent such. As pyridine or triethylamine, or without solvents. The reaction mixture is allowed to react for some time, for example 2 hours to 40 hours, in a temperature range between room temperature and 100 ° C. After completion of the reaction, any precipitated precipitate is filtered off, the filter medium may consist for example of commercial filter paper, washed with the appropriate solvent and dried the remaining solid in vacuo, or the reaction mixture is freed from the solvent in vacuo. Alternatively, the reaction mixture can be stirred into a large amount of water and the precipitate filtered off or the aqueous phase, after neutralization with a suitable aqueous acid, such as. Hydrochloric acid, with a suitable organic solvent, such as. For example, dichloromethane or ethyl acetate, and the organic phase are concentrated in vacuo. The purification of the remaining crude product is carried out by recrystallization from a suitable solvent, for example ethanol or ethyl acetate, or by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.
Schema 9: 1. StufeScheme 9: 1st stage
Im Anschluß an die Grundverfahren können in Folgereaktionen die nach dem Grundverfahren entstandenen Produkte in einer dem Fachmann bekannten Vorge- hensweise zu erfindungsgemässen Folgeprodukten umgesetzt werden.Subsequent to the basic processes, the products formed by the basic process can be reacted in subsequent reactions in a procedure known to the person skilled in the art to yield secondary products according to the invention.
So kann, wenn das Produkt ein Derivat der Verbindung 38 gemäß Schema 9 sein soll, das Reaktionsprodukt 37 z. B. mit einem entsprechenden Chlorid, Bromid oder lodid und gegebenenfalls mit einer geeigneten Base, vorzugsweise Natriumhydrid, Pyridin, Triethylamin, Kaliumcarbonat oder Natriummethanolat in Methanol, in einem geeigneten, inerten Lösungsmittel, wie beispielsweise Dimethylformamid, Dimethylsul- foxid, Methanol, Dioxan, Tetrahydrofuran, Toluol, oder in einer Base als Lösungsmittel, wie z. B. Pyridin oder Triethylamin, oder ohne Lösungsmittel, umgesetzt werden. Das Reaktionsgemisch lässt man einige Zeit, beispielsweise 30 Minuten bis 2 Tage, in einem Temperaturbereich zwischen 0 °C und 140 °C reagieren. Alternativ kann eine A- mino-substituierte Zwischenstufe 37 z. B. mit einem entsprechenden Chlorid, Bromid oder lodid und einem geeigneten Katalysator, wie z. B. Tris(dibenzylidenaceton)dipalladium(0) oder Tetrakis(triphenylphosphin)-palladium(0), und einem geeigneten Liganden, wie z. B. 2-(Dicyclohexylphosphanyl)biphenyl, und einer geeigneten Base, beispielsweise Natrium-tert.butanolat, in einem geeignetem Lösungsmittel, wie beispielsweise Toluol oder Dimethylformamid, umgesetzt werden. Das Reaktionsgemisch lässt man einige Zeit, beispielsweise 2 Stunden bis 30 Stun- den, in einem Temperaturbereich zwischen 60 °C und 120 °C reagieren. Nach beendeter Umsetzung wird ein eventuell ausgefallener Niederschlag abfiltriert, wobei das Filtermedium beispielsweise aus handelsüblichem Filterpapier bestehen kann, mit dem entsprechenden Lösungsmittel nachgewaschen und der zurückbleibende Feststoff im Vakuum getrocknet, bzw. wird das Reaktionsgemisch im Vakuum vom Lösungsmittel befreit. Alternativ kann das Reaktionsgemisch in eine große Menge Wasser eingerührt und der ausgefallene Niederschlag abfiltriert bzw. die wässrige Phase, nach Neutralisation mit einer geeigneten wässrigen Säure, wie z. B. Salzsäure, mit einem geeigneten organischen Lösungsmittel, wie z. B. Dichlormethan oder Ethylacetat, extrahiert und die organische Phase im Vakuum eingeengt werden. Die Reinigung des zurück- bleibenden Rohproduktes erfolgt durch Umkristallisieren aus einem geeigneten Lösungsmittel, beispielsweise Dioxan, Ethylacetat oder Toluol, oder durch Säulen- bzw. Flash-Chromatographie an Kieselgel oder Aluminiumoxid. Als Laufmittel dient beispielsweise ein Gemisch aus Methanol und Dichlormethan.Thus, if the product is to be a derivative of compound 38 according to Scheme 9, the reaction product may be, for. B. with an appropriate chloride, bromide or iodide and optionally with a suitable base, preferably sodium hydride, pyridine, triethylamine, potassium carbonate or sodium methoxide in methanol, in a suitable inert solvent such as dimethylformamide, dimethylsulfoxide, methanol, dioxane, tetrahydrofuran, toluene or in a base as solvent , such as As pyridine or triethylamine, or without solvents. The reaction mixture is allowed to react for some time, for example 30 minutes to 2 days, in a temperature range between 0 ° C and 140 ° C. Alternatively, an amino-substituted intermediate 37, for. B. with an appropriate chloride, bromide or iodide and a suitable catalyst, such as. B. tris (dibenzylideneacetone) dipalladium (0) or tetrakis (triphenylphosphine) palladium (0), and a suitable ligand, such as. B. 2- (Dicyclohexylphosphanyl) biphenyl, and a suitable base, for example, sodium tert.butanolat, in a suitable solvent, such as toluene or dimethylformamide, are reacted. The reaction mixture is allowed to react for some time, for example 2 hours to 30 hours, in a temperature range between 60 ° C and 120 ° C. After completion of the reaction, any precipitated precipitate is filtered off, the filter medium may consist for example of commercial filter paper, washed with the appropriate solvent and dried the remaining solid in vacuo, or the reaction mixture is freed from the solvent in vacuo. Alternatively, the reaction mixture can be stirred into a large amount of water and the precipitate filtered off or the aqueous phase, after neutralization with a suitable aqueous acid, such as. Hydrochloric acid, with a suitable organic solvent, such as. For example, dichloromethane or ethyl acetate, and the organic phase are concentrated in vacuo. The residual crude product is purified by recrystallization from a suitable solvent, for example dioxane, ethyl acetate or toluene, or by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.
Unter einigen der genannten Reaktionsbedingungen können OH-, SH- und NH2-Under some of the reaction conditions mentioned, OH, SH and NH 2 -
Gruppen möglicherweise unerwünschte Nebenreaktionen eingehen. Es ist daher bevorzugt, diese mit Schutzgruppen zu versehen oder im Falle von NH2 durch NO2 zu ersetzen und nachfolgend die Schutzgruppe abzuspalten oder die NO2-Gruppe zu reduzieren. So kann in Abwandlung der oben beschriebenen Verfahren in den Aus- gangsverbindungen mindestens eine OH-Gruppe beispielsweise durch eine Benzylo- xygruppe und/oder mindestens eine SH-Gruppe beispielsweise durch eine S- Benzylgruppe und/oder mindestens eine NH2-Gruppe durch eine NH-Benzylgruppe oder durch eine NO2-Gruppe ersetzt werden. Nachfolgend kann mindestens eine - vorzugsweise alle - Benzyloxygruppe/n oder NH-Benzylgruppe/n beispielsweise mit Wasserstoff und Palladium auf Kohle und/oder mindestens eine - vorzugsweise alle - S-Benzylgruppe/n beispielsweise mit Natrium in Ammoniak abgespalten und/oder mindestens eine - vorzugsweise alle - NO2-Gruppe/n beispielsweise mit Wasserstoff und Raney-Nickel zu NH2 reduziert werden.Groups may undergo undesirable side reactions. It is therefore preferred to provide these with protective groups or replace in the case of NH 2 by NO 2 and subsequently to split off the protecting group or to reduce the NO 2 group. Thus, in a modification of the above-described processes in the starting compounds, at least one OH group can be replaced, for example, by a benzyloxy group. xygruppe and / or at least one SH group are replaced for example by an S-benzyl group and / or at least one NH 2 group by an NH-benzyl group or by a NO 2 group. In the following, at least one - preferably all - benzyloxy group (s) or NH-benzyl group (s) can be cleaved with, for example, sodium and ammonia in at least one, and / or at least one, preferably all, S-benzyl group (s). preferably all - NO 2 group (s ) are reduced to NH 2 , for example with hydrogen and Raney nickel.
Unter einigen der genannten Reaktionsbedingungen können OH-, NH2- undUnder some of the above reaction conditions OH, NH 2 - and
COOH-Gruppen möglicherweise unerwünschte Nebenreaktionen eingehen. Es ist daher bevorzugt, Ausgangsverbindungen und Zwischenstufen, welche mindestens eine OH- und/oder mindestens eine NH2- und/oder mindestens eine COOH-Gruppe enthalten, in entsprechende Carbonsäureester- und Carbonsäureamid-Derivate zu überfüh- ren. In Abwandlung der oben beschriebenen Verfahren können Ausgangsverbindungen und Zwischenstufen, welche mindestens eine OH-Gruppe besitzen, und/oder welche mindestens eine NH2-Gruppe besitzen, durch Umsetzung mit einer aktivierten Carbonsäuregruppe, beispielsweise einer Carbonsäurechloridgruppe, in Carbonsäureester- bzw. Carbonsäureamid-Derivate überführt werden. In Abwandlung der oben beschriebenen Verfahren können Ausgangsverbindungen und Zwischenstufen, welche mindestens eine COOH-Gruppe besitzen, durch Umsetzung mit einem Aktivierungsmittel, wie beispielsweise Thionylchlorid oder Carbonyldiimidazol, und nachfolgender Umsetzung mit einem geeigneten Alkohol oder Amin in Carbonsäureester- bzw. Carbonsäureamid-Derivate überführt werden. Nachfolgend kann mindestens eine - vorzugs- weise alle - Carbonsäureester- bzw. Carbonsäureamidgruppe/n in den Ausgangsverbindungen und Zwischenstufen beispielsweise mit verdünnten wässrigen Säuren bzw. Basen gespalten werden, um mindestens eine - vorzugsweise alle - OH-Gruppe/n und/oder NH2-Gruppe/n und/oder COOH-Gruppe/n in Freiheit zu setzen.COOH groups may possibly undergo undesirable side reactions. It is therefore preferred to convert starting compounds and intermediates which contain at least one OH and / or at least one NH 2 and / or at least one COOH group into corresponding carboxylic acid ester and carboxylic acid amide derivatives. In a modification of those described above Processes can be converted into carboxylic acid ester or carboxylic acid amide derivatives by reaction with an activated carboxylic acid group, for example a carboxylic acid chloride group, starting compounds and intermediates which have at least one OH group and / or which have at least one NH 2 group. In a modification of the processes described above, starting compounds and intermediates having at least one COOH group can be converted to carboxylic acid ester or carboxylic acid amide derivatives by reaction with an activating agent such as thionyl chloride or carbonyldiimidazole, followed by reaction with a suitable alcohol or amine , Subsequently, at least one - preferably all - carboxylic ester or carboxamide group / s in the starting compounds and intermediates, for example, with dilute aqueous acids or bases are cleaved, at least one - preferably all - OH group / s and / or NH 2 Group / s and / or COOH group (s) to freedom.
Die Benennung der erfindungsgemäßen Verbindungen und insbesondere der Verbindungen 1 bis 85, erfolgte mit der AutoNom 2000 - Software (ISIS ™/ Draw 2.5; MDL).The naming of the compounds according to the invention and in particular of the compounds 1 to 85 was carried out with the AutoNom 2000 software (ISIS ™ / Draw 2.5, MDL).
Die Erfindung soll anhand der nachfolgenden Beispiele näher erläutert werden, ohne jedoch auf diese Beispiele beschränkt zu sein. BeispieleThe invention will be explained in more detail with reference to the following examples, but without being limited to these examples. Examples
I) Herstellung von erfindungsgemäßen VerbindungenI) Preparation of compounds of the invention
Gemäß den allgemeinen Synthesevorschriften, denen die Syntheseschemata 1 - 9 zugrundeliegen, wurden die folgende erfindungsgemäße Verbindungen synthetisiert. Ferner sind ihre NMR-spektroskopischen Daten und massenspektrometrischen Daten bzw. Schmelzpunkte beigefügt.In accordance with the general synthetic instructions on which synthesis schemes 1-9 are based, the following compounds according to the invention were synthesized. Furthermore, their NMR spectroscopic data and mass spectrometric data or melting points are attached.
Die eingesetzten Vorstufen für die Herstellung der erfindungsgemäßen Verbindungen können - soweit nicht anderweitig beschreiben - nach dem Fachmann bekannten Verfahren synthetisiert werden.The precursors used for the preparation of the compounds of the invention can - unless otherwise described - be synthesized by methods known in the art.
Die eingesetzten Chemikalien und Lösungsmittel wurden kommerziell bei den herkömmlichen Anbietern erworben (Acros, Aldrich, Fluka, Lancaster, Maybridge, Merck, Sigma, TCI, etc.) oder synthetisiert.The chemicals and solvents used were purchased commercially from conventional suppliers (Acros, Aldrich, Fluka, Lancaster, Maybridge, Merck, Sigma, TCI, etc.) or synthesized.
Beispiel 1 :Example 1 :
1-Ethyl-3-(3-phenylethinyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff (Verbindung 1 )1-Ethyl-3- (3-phenylethynylpyrido [2,3-b] pyrazine-6-yl) urea (Compound 1)
Herstellung von 1-(3-Chlor-pyrido[2,3-b]pyrazin-6-yl)-3-ethyl-harnstoff (Umsetzung gemäß Schema 5) 100 mg 3-Chlor-pyrido[2,3-b]pyrazin-6-yl-amin (0.55 mmol) wurden in 5 ml Pyridin vorgelegt und 44 μl_ Ethylisocyanat (0.55 mmol) bei Raumtemperatur zugegeben. Man ließ das Gemisch 3h bei 75 °C rühren und fügte dann nochmal insgesamt 132 μl_ Ethylisocyanat (1.65 mmol) über 18 h in kleinen Portionen zum Reaktionsgemisch hinzu. Dann wurde das Lösungsmittel im Vakuum entfernt. Der resultierende Feststoff wurde über Säulenchromatographie an Kieselgel (Laufmittel Dichlormethan/Methanol) gereinigt. Man erhielt einen hellgelben Feststoff.Preparation of 1- (3-chloropyrido [2,3-b] pyrazin-6-yl) -3-ethylurea (reaction according to Scheme 5) 100 mg of 3-chloropyrido [2,3-b] pyrazine 6-yl-amine (0.55 mmol) was initially charged in 5 ml pyridine and 44 μl ethyl isocyanate (0.55 mmol) added at room temperature. The mixture was allowed to stir for 3 h at 75 ° C and then added again a total of 132 .mu.l ethyl isocyanate (1.65 mmol) over 18 h in small portions to the reaction mixture. Then the solvent was removed in vacuo. The resulting solid was purified by column chromatography on silica gel (eluent dichloromethane / methanol). A pale yellow solid was obtained.
Herstellung von 1-Ethyl-3-(3-phenylethinyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff (Umsetzung gemäß Schema 6) 98.1 mg 1-(3-Chlor-pyrido[2,3-b]pyrazin-6-yl)-3-ethyl-harnstoff (0.39 mmol), 10.1 mg Kupfer(l)iodid (0.05 mmol) und 193 μl Triethylamin (1.38 mmol) wurden in 2 ml wasser- freiem Dimethylformamid unter Stickstoff als Schutzgas vorgelegt. Anschließend wurden nacheinander 29.1 mg Dichlor-bis(triphenylphosphin)-palladium(ll) (0.04 mmol) und 54 μl_ Phenylacetylen (0.49 mmol) zugegeben und das Gemisch wird 16h bei Raumtemperatur gerührt. Zur Aufarbeitung wurde das Gemisch mit Dichlormethan ver- dünnt und in verdünnte Salzsäure gegeben. Der ausgefallene Feststoff wurde abgesaugt und die organische Phase mit verdünnter Salzsäure und destilliertem Wasser gewaschen. Nach Phasentrennung wurde das organische Lösungsmittel im Vakuum entfernt. Die weitere Aufreinigung erfolgte durch Säulenchromatographie an Kieselgel (Laufmittelgemisch Dichlormethan/Methanol). Man erhielt einen gelben Feststoff. Schmelzpunkt: 236-238 °C (Zers.)Preparation of 1-ethyl-3- (3-phenylethynylpyrido [2,3-b] pyrazine-6-yl) urea (reaction according to Scheme 6) 98.1 mg of 1- (3-chloropyrido [2,3- b] pyrazine-6-yl) -3-ethyl-urea (0.39 mmol), 10.1 mg copper (I) iodide (0.05 mmol) and 193 μl triethylamine (1.38 mmol) were dissolved in 2 ml water. submitted to free dimethylformamide under nitrogen as inert gas. Subsequently, 29.1 mg of dichloro-bis (triphenylphosphine) palladium (II) (0.04 mmol) and 54 μl of phenylacetylene (0.49 mmol) were successively added and the mixture was stirred at room temperature for 16 h. For workup, the mixture was diluted with dichloromethane and added to dilute hydrochloric acid. The precipitated solid was filtered off with suction and the organic phase was washed with dilute hydrochloric acid and distilled water. After phase separation, the organic solvent was removed in vacuo. Further purification was carried out by column chromatography on silica gel (eluent mixture dichloromethane / methanol). A yellow solid was obtained. Melting point: 236-238 ° C (decomp.)
ESI-MS: gef. m/z = 318.0 (M + H+); ber. 317 amuESI-MS: gef. m / z = 318.0 (M + H + ); ber. 317 amu
1H-NMR (d6-DMSO): δ = 1.20 (t, 3H), 3.35 - 3.45 (m, 2H), 7.51 - 7.59 (m, 3H), 7.68 (d, 1 H), 7.75 (d, 2H), 8.37 (d, 1 H), 9.01 (s, 1 H), 9.14 (s, 1 H), 10.23 (s, 1 H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.35-3.45 (m, 2H), 7.51-7.59 (m, 3H), 7.68 (d, 1 H), 7.75 (d, 2H), 8.37 (d, 1H), 9.01 (s, 1H), 9.14 (s, 1H), 10.23 (s, 1H) ppm.
Folgende Beispiele wurden gemäß Beispiel 1 und den allgemeinen Synthesevorschriften synthetisiert:The following examples were synthesized according to Example 1 and the general synthesis instructions:
Beispiel 2:Example 2:
1-Ethyl-3-(3-thiophen-3-ylethinyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff (Verbindung 2)1-Ethyl-3- (3-thiophen-3-yl-ethynylpyrido [2,3-b] pyrazine-6-yl) -urea (Compound 2)
Smp.: 239-242 °C (Zers.)Mp .: 239-242 ° C (Zers.)
ESI-MS: gef. m/z = 324.2 (M + H+); ber. 323 amuESI-MS: gef. m / z = 324.2 (M + H + ); ber. 323 amu
1H-NMR (d6-DMSO): δ = 1.20 (t, 3H), 3.25 - 3.35 (m, 2H), 7.43 (d, 1 H), 7.66 (d, 1 H), 7.76 (dd, 1 H), 8.21 (d, 1 H), 8.36 (d, 1 H), 8.97 (s, 1 H), 9.14 (s, 1 H), 10.23 (s, 1 H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.25-3.35 (m, 2H), 7.43 (d, 1 H), 7.66 (d, 1 H), 7.76 (dd, 1 H), 8.21 (d, 1H), 8.36 (d, 1H), 8.97 (s, 1H), 9.14 (s, 1H), 10.23 (s, 1H) ppm.
Beispiel 3:Example 3:
1-(3-Cyclopropylethinyl-pyrido[2,3-b]pyrazin-6-yl)-3-ethyl-harnstoff (Verbindung 3)1- (3-Cyclopropylethynyl-pyrido [2,3-b] pyrazine-6-yl) -3-ethyl-urea (Compound 3)
Smp.: 227-228 °C (Zers.) ESI-MS: gef. m/z = 282.3 (M + H+); ber. 281 amuMp .: 227-228 ° C (Zers.) ESI-MS: gef. m / z = 282.3 (M + H + ); ber. 281 amu
1H-NMR (d6-DMSO): δ = 1.00 - 1.10 (m, 2H), 1.19 (t, 3H), 1.69 - 1.79 (m, 1 H), 3.25 - 3.35 (m, 2H), 7.63 (d, 1 H), 8.32 (d, 1 H), 8.77 (s, 1 H), 9.11 (s, 1 H), 10.18 (s, 1 H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.00-1.10 (m, 2H), 1.19 (t, 3H), 1.69-1.79 (m, 1H), 3.25-3.35 (m, 2H), 7.63 ( d, 1H), 8.32 (d, 1H), 8.77 (s, 1H), 9.11 (s, 1H), 10.18 (s, 1H) ppm.
Beispiel 4:Example 4:
1-[3-(3-Dimethylamino-prop-1-inyl)-pyrido[2,3-b]pyrazin-6-yl]-3-ethyl-harnstoff (Verbindung 4)1- [3- (3-Dimethylamino-prop-1-ynyl) -pyrido [2,3-b] pyrazine-6-yl] -3-ethyl-urea (Compound 4)
ESI-MS: gef. m/z = 299.2 (M + H+); ber. 298 amu 1H-NMR (de-DMSO): δ = 1.19 (t, 3H), 2.33 (s, 6H), 3.27 - 3.35 (m, 2H), 3.67 (s, 2H), 7.67 (d, 1 H), 8.34 (d, 1 H), 8.85 (s, 1 H), 9.05 (s, 1 H), 10.19 (s, 1 H) ppm.ESI-MS: gef. m / z = 299.2 (M + H + ); 298 amu 1 H NMR (de-DMSO): δ = 1.19 (t, 3H), 2.33 (s, 6H), 3.27-3.35 (m, 2H), 3.67 (s, 2H), 7.67 (d, 1H), 8.34 (d, 1H), 8.85 (s, 1H), 9.05 (s, 1H), 10.19 (s, 1H) ppm.
Beispiel 5:Example 5:
1-[3-((E)-2-Cyclohexyl-vinyl)-pyrido[2,3-b]pyrazin-6-yl]-3-ethyl-harnstoff (Verbin- düng 5)1- [3 - ((E) -2-Cyclohexyl-vinyl) -pyrido [2,3-b] pyrazine-6-yl] -3-ethyl-urea (compound 5)
Herstellung von 1 -[3-((E)-2-Cyclohexyl-vinyl)-pyrido[2,3-b]pyrazin-6-yl]-3-ethyl-harnstoff (Umsetzung gemäß Schema 6)Preparation of 1 - [3 - ((E) -2-cyclohexyl-vinyl) -pyrido [2,3-b] pyrazine-6-yl] -3-ethyl-urea (Reaction According to Scheme 6)
99.6 mg 1-(3-Chlor-pyrido[2,3-b]pyrazin-6-yl)-3-ethyl-harnstoff (0.40 mmol), 73.6 mg Cyclohexylvinylboronsäure (0.48 mmol), 84.4 mg Natriumcarbonat (0.80 mmol) und 33.4 mg [1 ,1 '-Bis(diphenylphosphino)ferrocen]dichlorpalladium(ll) (0.04 mmol) wurden in 6 ml Dimethylformamid/Wasser (1 :1 ) unter Stickstoff vorgelegt. Dann wurde die Mischung 6.5h auf 90 °C erhitzt. Zum Reaktionsgemisch wurde dann destilliertes Wasser hinzugefügt und der entstandene Niederschlag abgesaugt. Die weitere Aufreinigung erfolgte durch Säulenchromatographie an Kieselgel (Laufmittelgemisch Ethylace- tat/Heptan). Man erhielt einen hellbraunen Feststoff.99.6 mg of 1- (3-chloro-pyrido [2,3-b] pyrazin-6-yl) -3-ethyl-urea (0.40 mmol), 73.6 mg of cyclohexylvinylboronic acid (0.48 mmol), 84.4 mg of sodium carbonate (0.80 mmol) and 33.4 mg of [1, 1 '-bis (diphenylphosphino) ferrocene] dichloropalladium (II) (0.04 mmol) were dissolved in 6 ml of dimethylformamide / water under nitrogen (1: 1). The mixture was then heated to 90 ° C for 6.5h. Distilled water was then added to the reaction mixture and the resulting precipitate was filtered off with suction. Further purification was carried out by column chromatography on silica gel (eluent mixture ethyl acetate / heptane). A light brown solid was obtained.
Smp.: 202-204 °C (Zers.)Mp .: 202-204 ° C (decomp.)
ESI-MS: gef. m/z = 326.0 (M + H+); ber. 325 amu 1H-NMR (de-DMSO): δ = 1.10 - 1.40 (m, 8H), 1.65 - 1.90 (m, 5H), 2.28 - 2.38 (m, 1H), 3.25- 3.35 (m, 2H), 6.69 (d, 1H), 7.15 (dd, 1H), 7.58 (d, 1H), 8.28 (d, 1H), 8.98 (s, 1H), 9.15(s, 1H), 10.05 (s, 1H)ppm.ESI-MS: gef. m / z = 326.0 (M + H + ); About 325 amu 1 H-NMR (de-DMSO): δ = 1.10-1.40 (m, 8H), 1.65-1.90 (m, 5H), 2.28-2.38 (m, 1H), 3.25-3.35 (m, 2H), 6.69 ( d, 1H), 7.15 (dd, 1H), 7.58 (d, 1H), 8.28 (d, 1H), 8.98 (s, 1H), 9.15 (s, 1H), 10.05 (s, 1H) ppm.
Folgende Beispiele wurde gemäß Beispiel 5 und der allgemeinen Synthesevorschriften synthetisiert:The following examples were synthesized according to Example 5 and the general synthesis instructions:
Beispiel 6:Example 6:
1-Ethyl-3-[3-((E)-3-methoxy-propenyl)-pyrido[2,3-b]pyrazin-6-yl]-harnstoff (Verbin- düng 6)1-Ethyl-3- [3 - ((E) -3-methoxy-propenyl) -pyrido [2,3-b] pyrazine-6-yl] -urea (Compound 6)
ESI-MS: gef. m/z = 288.3 (M + H+); ber.287 amuESI-MS: gef. m / z = 288.3 (M + H + ); over .287 amu
1H-NMR (de-DMSO): δ = 1.20 (t, 3H), 3.25 - 3.35 (m, 2H), 3.39 (s, 3H), 4.25 (d, 2H), 6.92 (d, 1H), 7.15-7.25 (m, 1H), 7.62 (d, 1H), 8.30 (d, 1H), 9.02 (s, 1H), 9.15 (s, 1H), 10.10 (s, 1H) ppm. 1 H-NMR (de-DMSO): δ = 1.20 (t, 3H), 3.25-3.35 (m, 2H), 3.39 (s, 3H), 4.25 (d, 2H), 6.92 (d, 1H), 7.15 -7.25 (m, 1H), 7.62 (d, 1H), 8.30 (d, 1H), 9.02 (s, 1H), 9.15 (s, 1H), 10.10 (s, 1H) ppm.
Beispiel 7:Example 7:
1-Ethyl-3-{3-[(E)-2-(4-fluor-phenyl)-vinyl]-pyrido[2,3-b]pyrazin-6-yl}-harnstoff (Verbindung 27)1-Ethyl-3- {3 - [(E) -2- (4-fluoro-phenyl) -vinyl] -pyrido [2,3-b] pyrazine-6-yl} -urea (Compound 27)
Smp.: 217-219 °CMp: 217-219 ° C
ESI-MS: gef. m/z = 338.2 (M + H+); ber.337 amuESI-MS: gef. m / z = 338.2 (M + H + ); about .377 amu
1H-NMR (d6-DMSO): δ = 1.20 (t, 3H), 3.25 - 3.38 (m, 2H), 7.10 (t, 2H), 7.32 (dd, 2H), 7.54 (d, 1H), 7.61 (d, 1H), 7.87 (t, 2H), 8.02 (d, 1H), 8.31 (d, 1H), 9.09 (s, 1H), 9.17 (bs, 1H), 10.09(s, 1H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.25-3.338 (m, 2H), 7.10 (t, 2H), 7.32 (dd, 2H), 7.54 (d, 1H), 7.61 (d, 1H), 7.87 (t, 2H), 8.02 (d, 1H), 8.31 (d, 1H), 9.09 (s, 1H), 9.17 (bs, 1H), 10.09 (s, 1H) ppm.
Beispiel 8Example 8
Kohlensäure-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl-methyl-ester (Verbindung 9) Herstellung von 1 -Ethyl-3-[3-(4-hydroxy-phenyl)-pyrido[2,3-b]pyrazin-6-yl]-harnstoff (Umsetzung gemäß Schema 5)Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl-methyl-ester (compound 9) Preparation of 1-ethyl-3- [3- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazine-6-yl] -urea (Reaction according to Scheme 5)
0.50 g 4-(6-Amino-pyrido[2,3-b]pyrazin-3-yl)-phenol (2.10 mmol) wuden in 5.0 ml Pyri- din vorgelegt. 183 μl_ Ethylisocyanat (2.31 mmol) wuden bei Raumtemperatur zugetropft und das Gemisch wird für 2h auf 70 - 80 °C erhitzt. Danach wuden nochmals 183 μl_ Ethylisocyanat zugegeben und das Gemisch weitere 2h auf 70 -80 °C erhitzt. Nach beendeter Umsetzung wurde das Reaktionsgemisch auf Eiswasser gegeben und mit 1 N Salzsäure neutralisiert. Das ausgefallene Produkt wurde abgesaugt und ge- trocknet. Das abgesaugt Produkt wurde in Ethanol angelöst und mit 52 mg Kaliumhydroxid (0.93 mmol), in Wasser gelöst, versetzt. Das Gemisch erwärmte man ca.1 h auf 40 °C. Danach wurde die Reaktionslösung mit 1 N Salzsäure neutral gestellt und das Lösungsmittel im Vakuum entfernt. Der resultierende Feststoff wurde säulenchro- matographisch an Kieselgel gereinigt (Laufmittel Dichlormethan/Methanol). Man erhielt einen gelben Feststoff.0.50 g of 4- (6-amino-pyrido [2,3-b] pyrazin-3-yl) -phenol (2.10 mmol) were initially charged in 5.0 ml of pyridine. 183 μl of ethyl isocyanate (2.31 mmol) were added dropwise at room temperature and the mixture was heated to 70-80 ° C. for 2 h. Thereafter, another 183 μl of ethyl isocyanate were added and the mixture was heated at 70 ° -80 ° C. for a further 2 hours. After completion of the reaction, the reaction mixture was added to ice water and neutralized with 1 N hydrochloric acid. The precipitated product was filtered off with suction and dried. The filtered off product was dissolved in ethanol and treated with 52 mg of potassium hydroxide (0.93 mmol), dissolved in water. The mixture was heated for 1 h to 40 ° C. Thereafter, the reaction solution was made neutral with 1 N hydrochloric acid and the solvent was removed in vacuo. The resulting solid was purified by column chromatography on silica gel (mobile phase dichloromethane / methanol). A yellow solid was obtained.
Herstellung von Kohlensäure-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl- methyl-ester (Umsetzung gemäß Schema 8)Preparation of carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl-methyl-ester (reaction according to Scheme 8)
100 mg 1-Ethyl-3-[3-(4-hydroxy-phenyl)-pyrido[2,3-b]pyrazin-6-yl]-harnstoff (0.32 mmol), 30 μL Chlorameisensäuremethylester (0.39 mmol) und 45 μL Triethylamin (0.32 mmol) wurden in 10 ml wasserfreiem Dioxan vorgelegt und 1 h auf 100 °C erhitzt. Nach dem Abkühlen wurde der ausgefallene Feststoff abgesaugt und getrocknet. Nach Umkristallisieren aus Ethanol erhielt man einen schwach gelben Feststoff.100 mg of 1-ethyl-3- [3- (4-hydroxyphenyl) -pyrido [2,3-b] pyrazin-6-yl] urea (0.32 mmol), 30 μL of methyl chloroformate (0.39 mmol) and 45 μL Triethylamine (0.32 mmol) was placed in 10 ml of anhydrous dioxane and heated to 100 ° C for 1 h. After cooling, the precipitated solid was filtered off with suction and dried. Recrystallization from ethanol gave a pale yellow solid.
Smp.: 243-245 °C ESI-MS: gef. m/z = 368.2 (M + H+); ber. 367 amuMp: 243-245 ° C ESI-MS: gef. m / z = 368.2 (M + H + ); ber. 367 amu
1H-NMR (d6-DMSO): δ = 1.20 (t, 3H), 3.30 - 3.39 (m, 2H), 3.90 (s, 3H), 7.49 (d, 2H), 7.70 (d, 1 H), 8.38 (d, 1 H), 8.42 (d, 2H), 9.03 (s, 1 H), 9.47 (s, 1 H), 10.09 (s, 1 H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.30-3.39 (m, 2H), 3.90 (s, 3H), 7.49 (d, 2H), 7.70 (d, 1H) , 8.38 (d, 1H), 8.42 (d, 2H), 9.03 (s, 1H), 9.47 (s, 1H), 10.09 (s, 1H) ppm.
Folgende Beispiele wurden gemäß Beispiel 8 und der allgemeinen Synthesevorschrif- ten synthetisiert: Beispiel 9:The following examples were synthesized according to Example 8 and the general synthesis instructions: Example 9:
Kohlensäure-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl-(2-methoxy- ethyl)-ester (Verbindung 10)Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl- (2-methoxy-ethyl) -ester (Compound 10)
Smp.: 230-232 °CMp .: 230-232 ° C
ESI-MS: gef. m/z = 412.2 (M + H+); ber. 41 1 amuESI-MS: gef. m / z = 412.2 (M + H + ); ber. 41 1 amu
1H-NMR (de-DMSO): δ = 1.20 (t, 3H), 3.30 - 3.39 (m, 5H), 3.68 (t, 2H), 4.40 (t, 2H), 7.50 (d, 2H), 7.70 (d, 1 H), 8.38 (d, 1 H), 8.41 (d, 2H), 9.10 (s, 1 H), 9.50 (s, 1 H), 10.15 (s, 1 H) ppm. 1 H NMR (de-DMSO): δ = 1.20 (t, 3H), 3.30-3.39 (m, 5H), 3.68 (t, 2H), 4.40 (t, 2H), 7.50 (d, 2H), 7.70 (d, 1H), 8.38 (d, 1H), 8.41 (d, 2H), 9.10 (s, 1H), 9.50 (s, 1H), 10.15 (s, 1H) ppm.
Beispiel 10:Example 10:
Kohlensäure-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl-phenyl-ester (Verbindung 1 1 )Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl-phenyl-ester (Compound 1 1)
ESI-MS: gef. m/z = 430.2 (M + H+); ber. 429 amuESI-MS: gef. m / z = 430.2 (M + H + ); ber. 429 amu
1H-NMR (de-DMSO): δ = 1.21 (t, 3H), 3.30 - 3.33 (m, 2H), 7.33 - 7.38 (m, 1 H), 7.43 (d, 2H), 7.51 (t, 2H), 7.65 (d, 2H), 8.39 (d, 1 H), 8.45 (d, 2H), 9.1 1 (s, 1 H), 9.50 (s, 1 H), 10.19 (s, 1 H) ppm. 1 H-NMR (de-DMSO): δ = 1.21 (t, 3H), 3.30-3.33 (m, 2H), 7.33-7.38 (m, 1H), 7.43 (d, 2H), 7.51 (t, 2H ), 7.65 (d, 2H), 8.39 (d, 1H), 8.45 (d, 2H), 9.1 l (s, 1H), 9.50 (s, 1H), 10.19 (s, 1H) ppm.
Beispiel 1 1 :Example 1 1:
Diethyl-carbaminsäure-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl-ester (Verbindung 12)Diethylcarbamic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl-ester (Compound 12)
ESI-MS: gef. m/z = 409.4 (M + H+); ber. 408 amu 1H-NMR (d6-DMSO): δ = 1.15 (t, 3H), 1.20 (t, 3H), 1.24 (t, 3H), 3.30 - 3.39 (m, 4H), 3.45 (q, 2H), 7.37 (d, 2H), 7.69 (d, 1 H), 8.34 - 8.39 (m, 3H), 9.1 1 (s, 1 H), 9.48 (s, 1 H), 10.15 (s, 1 H) ppm. Beispiel 12:ESI-MS: gef. m / z = 409.4 (M + H + ); 408 amu 1 H NMR (d 6 -DMSO): δ = 1.15 (t, 3H), 1.20 (t, 3H), 1.24 (t, 3H), 3.30- 3.39 (m, 4H), 3.45 (q , 2H), 7.37 (d, 2H), 7.69 (d, 1H), 8.34 - 8.39 (m, 3H), 9.1 1 (s, 1H), 9.48 (s, 1H), 10.15 (s, 1 H) ppm. Example 12:
Kohlensäure-3-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl-ester-2-methoxy- ethyl-ester (Verbindung 16)Carbonic acid 3- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl-ester-2-methoxy-ethyl-ester (Compound 16)
ESI-MS: gef. m/z = 412.2 (M + H+); ber. 41 1 amuESI-MS: gef. m / z = 412.2 (M + H + ); ber. 41 1 amu
1H-NMR (Cl6-DMSO): δ = 1.20 (t, 3H), 3.33 - 3.38 (m, 5H), 3.63-3.66 (m, 2H), 4.37-4.39 (m, 2H), 7.48 (d, 2H), 7.68 (t, 1 H), 7.72 (d, 1 H), 8.22 (s, 1 H), 8.29 (d, 1 H), 8.39 (d, 1 H), 9.06 (s, 1 H), 9.48 (s, 1 H), 10.14 (s, 1 H) ppm. 1 H-NMR (Cl 6 -DMSO): δ = 1.20 (t, 3H), 3.33- 3.38 (m, 5H), 3.63-3.66 (m, 2H), 4.37-4.39 (m, 2H), 7.48 (i.e. , 2H), 7.68 (t, 1H), 7.72 (d, 1H), 8.22 (s, 1H), 8.29 (d, 1H), 8.39 (d, 1H), 9.06 (s, 1H ), 9.48 (s, 1H), 10.14 (s, 1H) ppm.
Beispiel 13:Example 13:
Kohlensäure-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl-ester-isobutyl- ester (Verbindung 17)Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester isobutyl ester (compound 17)
ESI-MS: gef. m/z = 410.3 (M + H+); ber. 409 amu 1H-NMR (de-DMSO): δ = 0.97 (d, 6H), 1.20 (t, 3H), 2.02 (sep, 1 H), 3.25 - 3.38 (m, 2H), 4.06 (d, 2H), 7.50 (d, 2H), 7.70 (d, 1 H), 8.38 (d, 1 H), 8.41 (d, 2H), 9.10 (s, 1 H), 9.47 (s, 1 H), 10.14 (s, 1 H) ppm.ESI-MS: gef. m / z = 410.3 (M + H + ); Calc. 409 amu 1 H NMR (de-DMSO): δ = 0.97 (d, 6H), 1.20 (t, 3H), 2.02 (sep, 1H), 3.25-3.338 (m, 2H), 4.06 (i.e. , 2H), 7.50 (d, 2H), 7.70 (d, 1H), 8.38 (d, 1H), 8.41 (d, 2H), 9.10 (s, 1H), 9.47 (s, 1H), 10.14 (s, 1H) ppm.
Beispiel 14: Kohlensäure-but-2-ynyl-ester-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl- ester (Verbindung 18)Example 14: Carbonic acid but-2-ynyl ester 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester (Compound 18)
ESI-MS: gef. m/z = 406.1 (M + H+); ber. 405 amuESI-MS: gef. m / z = 406.1 (M + H + ); About 405 amu
1H-NMR (d6-DMSO): δ = 1.20 (t, 3H), 1.89 (t, 3H), 3.25 - 3.38 (m, 2H), 4.90 (q, 2H), 7.50 (d, 2H), 7.70 (d, 1 H), 8.38 (d, 1 H), 8.41 (d, 2H), 9.09 (s, 1 H), 9.47 (s, 1 H), 10.14 (s, 1 H) ppm. Beispiel 15: 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 1.89 (t, 3H), 3.25-3.338 (m, 2H), 4.90 (q, 2H), 7.50 (d, 2H), 7.70 (d, 1H), 8.38 (d, 1H), 8.41 (d, 2H), 9.09 (s, 1H), 9.47 (s, 1H), 10.14 (s, 1H) ppm. Example 15:
Dimethyl-carbaminsäure-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl-ester (Verbindung 19)Dimethyl-carbamic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl-ester (Compound 19)
Beispiel 15 wurde unter Verwendung von Natriumhydrid als Base und Dimethylforma- mid als Lösungsmittel hergestellt.Example 15 was prepared using sodium hydride as base and dimethylformamide as solvent.
Smp.: > 230 °C (Zers.)Mp .:> 230 ° C (decomp.)
ESI-MS: gef. m/z = 381.2 (M + H+); ber. 380 amuESI-MS: gef. m / z = 381.2 (M + H + ); About 380 amu
1H-NMR (d6-DMSO): δ = 1.20 (t, 3H), 2.95 (s, 3H), 3.09 (s, 3H), 3.25 - 3.38 (m, 2H), 7.37 (d, 2H), 7.68 (d, 1 H), 8.35-8.38 (m, 3H), 9.1 1 (s, 1 H), 9.46 (s, 1 H), 10.12 (s, 1 H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 2.95 (s, 3H), 3.09 (s, 3H), 3.25-3.338 (m, 2H), 7.37 (d, 2H), 7.68 (d, 1H), 8.35-8.38 (m, 3H), 9.1 1 (s, 1H), 9.46 (s, 1H), 10.12 (s, 1H) ppm.
Beispiel 16:Example 16:
Kohlensäure-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-2-methoxy-phenyl-ester- 2-methoxy-ethyl-ester (Verbindung 32)Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazino-3-yl] -2-methoxy-phenyl-2-methoxy-ethyl ester (Compound 32)
ESI-MS: gef. m/z = 442.3 (M + H+); ber. 441 amuESI-MS: gef. m / z = 442.3 (M + H + ); ber. 441 amu
1H-NMR (d6-DMSO): δ = 1.20 (t, 3H), 3.25 - 3.38 (m, 5H), 3.62 (dd, 2H), 3.97 (s, 3H), 4.35 (dd, 2H), 7.45 (d, 1 H), 7.74 (d, 1 H), 7.97 (d, 1 H), 8.06 (s, 1 H), 8.39 (d, 1 H), 8.99 (bs, 1 H), 9.52 (s, 1 H), 10.15 (s, 1 H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.25-3.338 (m, 5H), 3.62 (dd, 2H), 3.97 (s, 3H), 4.35 (dd, 2H), 7.45 (d, 1H), 7.74 (d, 1H), 7.97 (d, 1H), 8.06 (s, 1H), 8.39 (d, 1H), 8.99 (bs, 1H), 9.52 ( s, 1H), 10.15 (s, 1H) ppm.
Beispiel 17:Example 17:
Kohlensäure-2-benzyloxy-ethyl-ester-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]- phenyl-ester (Verbindung 33)Carbonic acid 2-benzyloxyethyl ester 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl-ester (Compound 33)
ESI-MS: gef. m/z = 488.2 (M + H+); ber. 487 amuESI-MS: gef. m / z = 488.2 (M + H + ); ber. 487 amu
1H-NMR (de-DMSO): δ = 1.20 (t, 3H), 3.28 - 3.38 (m, 2H), 3.75 (t, 2H), 4.43 (t, 2H), 4.57 (s, 2H), 7.31 (t, 1 H), 7.36-7.40 (m, 4H), 7.48 (d, 2H), 7.70 (d, 1 H), 8.38 (d, 1 H), 8.41 (d, 2H), 9.09 (bs, 1 H), 9.47 (s, 1 H), 10.13 (s, 1 H) ppm. Beispiel 18: 1 H NMR (de-DMSO): δ = 1.20 (t, 3H), 3.28-3.338 (m, 2H), 3.75 (t, 2H), 4.43 (t, 2H), 4.57 (s, 2H), 7.31 (t, 1H), 7.36-7.40 (m, 4H), 7.48 (d, 2H), 7.70 (d, 1H), 8.38 (d, 1H), 8.41 (d, 2H), 9.09 (bs, 1H), 9.47 (s, 1H), 10.13 (s, 1H) ppm. Example 18:
Kohlensäure-2-benzyloxy-ethyl-ester-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]- 2-methoxy-phenyl-ester (Verbindung 34)Carbonic acid 2-benzyloxyethyl ester 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -2-methoxy-phenyl-ester (Compound 34)
Smp.: 172-174 °CMp: 172-174 ° C
ESI-MS: gef. m/z = 518.3 (M + H+); ber. 517 amuESI-MS: gef. m / z = 518.3 (M + H + ); ber. 517 amu
1H-NMR (de-DMSO): δ = 1.20 (t, 3H), 3.28 - 3.38 (m, 2H), 3.74 (dd, 2H), 3.96 (s, 3H), 4.41 (dd, 2H), 4.56 (s, 2H), 7.31 (t, 1 H), 7.35-7.40 (m, 3H), 7.44 (d, 2H), 7.74 (d, 1 H), 7.97 (d, 1 H), 8.06 (s, 1 H), 8.39 (d, 1 H), 8.99 (bs, 1 H), 9.51 (s, 1 H), 10.14 (s, 1 H) ppm. 1 H NMR (de-DMSO): δ = 1.20 (t, 3H), 3.28-3.338 (m, 2H), 3.74 (dd, 2H), 3.96 (s, 3H), 4.41 (dd, 2H), 4.56 (s, 2H), 7.31 (t, 1H), 7.35-7.40 (m, 3H), 7.44 (d, 2H), 7.74 (d, 1H), 7.97 (d, 1H), 8.06 (s, 1H), 8.39 (d, 1H), 8.99 (bs, 1H), 9.51 (s, 1H), 10.14 (s, 1H) ppm.
Beispiel 19:Example 19:
Diethyl-carbaminsäure-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-2-methoxy- phenyl-ester (Verbindung 67)Diethylcarbamic acid 4- [6- (3-ethylurea) -pyrido [2,3-b] pyrazin-3-yl] -2-methoxyphenyl ester (Compound 67)
Smp.: 220-222 °CMp .: 220-222 ° C
ESI-MS: gef. m/z = 439.3 (M + H+); ber. 438 amuESI-MS: gef. m / z = 439.3 (M + H + ); ber. 438 amu
1H-NMR (d6-DMSO): δ = 1.13 (t, 3H), 1.20 (t, 3H), 1.24 (t, 3H), 3.28 - 3.36 (m, 4H), 3.44 (q, 2H), 3.94 (s, 3H), 7.31 (d, 1 H), 7.73 (d, 1 H), 7.94 (d, 1 H), 8.01 (s, 1 H), 8.37 (d, 1 H), 8.97 (bs, 1 H), 9.50 (s, 1 H), 10.11 (s, 1 H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.13 (t, 3H), 1.20 (t, 3H), 1.24 (t, 3H), 3.28-3.36 (m, 4H), 3.44 (q, 2H), 3.94 (s, 3H), 7.31 (d, 1H), 7.73 (d, 1H), 7.94 (d, 1H), 8.01 (s, 1H), 8.37 (d, 1H), 8.97 (bs , 1H), 9.50 (s, 1H), 10.11 (s, 1H) ppm.
Beispiel 20:Example 20:
Diethyl-carbaminsäure-2-chlor-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-6- methoxy-phenyl-ester (Verbindung 68)Diethylcarbamic acid 2-chloro-4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -6-methoxy-phenyl-ester (Compound 68)
Smp.: 237-239 °CMp: 237-239 ° C
ESI-MS: gef. m/z = 473.4 (M + H+); ber. 472 amu 1H-NMR (de-DMSO): δ = 1.14 (t, 3H), 1.19 (t, 3H), 1.27 (t, 3H), 3.25-3.38 (m, 4H), 3.46 (q, 2H), 3.97 (s, 3H), 7.76 (d, 1 H), 8.00 (s, 1 H), 8.09 (s, 1 H), 8.39 (d, 1 H), 8.94 (bs, 1 H), 9.55 (s, 1 H), 10.13 (s, 1 H) ppm.ESI-MS: gef. m / z = 473.4 (M + H + ); ber. 472 amu 1 H-NMR (de-DMSO): δ = 1.14 (t, 3H), 1.19 (t, 3H), 1.27 (t, 3H), 3.25-3.38 (m, 4H), 3.46 (q, 2H), 3.97 (s, 3H), 7.76 (d, 1H), 8.00 (s, 1H), 8.09 (s, 1H), 8.39 (d, 1H), 8.94 (bs, 1H), 9.55 (s, 1H), 10.13 (s, 1H) ppm.
Beispiel 21 :Example 21:
Kohlensäure-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-2-methoxy-phenyl ester- 2-[2-(2-methoxy-ethoxy)-ethoxy]-ethyl-ester (Verbindung 69)Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -2-methoxyphenyl ester 2- [2- (2-methoxyethoxy) - ethoxy] ethyl ester (Compound 69)
Smp.: 166-167 °C ESI-MS: gef. m/z = 530.2 (M + H+); ber. 529 amuMp: 166-167 ° C ESI-MS: gef. m / z = 530.2 (M + H + ); ber. 529 amu
1H-NMR (d6-DMSO): δ = 1.20 (t, 3H), 3.25 (s, 3H), 3.28-3.35 (m, 2H), 3.45 (t, 2H), 3.53- 3.60 (m, 6H), 3.71 (t, 2H), 3.98 (s, 3H), 4.35 (t, 2H), 7.45 (d, 1 H), 7.74 (d, 1 H), 7.96 (d, 1 H), 8.06 (s, 1 H), 8.39 (d, 1 H), 8.96 (bs, 1 H), 9.51 (s, 1 H), 10.12 (s, 1 H) ppm. 1 H-NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.25 (s, 3H), 3.28-3.35 (m, 2H), 3.45 (t, 2H), 3.53- 3.60 (m, 6H ), 3.71 (t, 2H), 3.98 (s, 3H), 4.35 (t, 2H), 7.45 (d, 1H), 7.74 (d, 1H), 7.96 (d, 1H), 8.06 (s , 1H), 8.39 (d, 1H), 8.96 (bs, 1H), 9.51 (s, 1H), 10.12 (s, 1H) ppm.
Beispiel 22:Example 22:
(E)-3-Phenyl-acrylsäure-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl-ester (Verbindung 13)(E) -3-Phenyl-acrylic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl-ester (Compound 13)
Herstellung von (E)-3-Phenyl-acrylsäure-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3- yl]-phenyl-esterPreparation of (E) -3-phenyl-acrylic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazine-3-yl] -phenyl ester
38.9 mg 1-Ethyl-3-[3-(4-hydroxy-phenyl)-pyrido[2,3-b]pyrazin-6-yl]-harnstoff (0.13 mmol) wurden in 3.0 ml getrocknetem Pyridin vorgelegt. 17.5 mg Dimethylaminopyridin (0.14 mmol) und 22.9 mg frans-Zimtsäurechlorid (0.13 mmol) wurden bei Raumtemperatur zugegeben und das Reaktionsgemisch wurde bei Raumtemperatur gerührt. Nach 3h wurden nochmal 22.9 mg frans-Zimtsäurechlorid (0.13 mmol) zugegeben und das Gemisch weitere 3h bei Raumtemperatur gerührt. Zur Aufarbeitung goß man das Gemisch auf Eiswasser und neutralisierte mit 1 N Salzsäure. Der ausgefallene Niederschlag wurde abgesaugt und im Vakuum getrocknet. Ohne weitere Aufreinigung erhielt man als Produkt einen gelben Feststoff. Smp.: 236-238 °C ESI-MS: gef. m/z = 440.3 (M + H+); ber. 439 amu38.9 mg of 1-ethyl-3- [3- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazine-6-yl] -urea (0.13 mmol) were initially charged in 3.0 ml of dried pyridine. 17.5 mg of dimethylaminopyridine (0.14 mmol) and 22.9 mg of frans-cinnamic acid chloride (0.13 mmol) were added at room temperature and the reaction mixture was stirred at room temperature. After 3 h, again 22.9 mg of frans-cinnamic acid chloride (0.13 mmol) were added and the mixture was stirred for a further 3 h at room temperature. For workup, the mixture was poured into ice-water and neutralized with 1 N hydrochloric acid. The precipitate was filtered off with suction and dried in vacuo. Without further purification, the product was a yellow solid. Mp: 236-238 ° C ESI-MS: gef. m / z = 440.3 (M + H + ); ber. 439 amu
1H-NMR (de-DMSO): δ = 1.20 (t, 3H), 3.25 - 3.40 (m, 2H), 6.95 (d, 1 H), 7.46 - 7.51 (m, 5H), 7.70 (d, 1 H), 7.83 - 7.87 (m, 2H), 7.94 (d, 1 H), 8.38 (d, 1 H), 8.43 (d, 2H), 9.12 (s, 1 H), 9.49 (s, 1 H), 10.19 (s, 1 H) ppm. 1 H NMR (de-DMSO): δ = 1.20 (t, 3H), 3.25-3.40 (m, 2H), 6.95 (d, 1H), 7.46-7.51 (m, 5H), 7.70 (d, 1 H), 7.83-7.87 (m, 2H), 7.94 (d, 1H), 8.38 (d, 1H), 8.43 (d, 2H), 9.12 (s, 1H), 9.49 (s, 1H) , 10.19 (s, 1H) ppm.
Beispiel 23:Example 23:
Nonadecansäure-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl-ester (Verbindung 14)Nonadecanoic Acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl Ester (Compound 14)
Herstellung von Nonadecansäure-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]- phenyl-esterPreparation of nonadecanoic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl-ester
50.0 mg 1-Ethyl-3-[3-(4-hydroxy-phenyl)-pyrido[2,3-b]pyrazin-6-yl]-harnstoff (0.16 mmol) wurden in 5.0 ml getrocknetem Pyridin vorgelegt. 19.7 mg Dimethylaminopyridin (0.16 mmol) und 51.2 mg Nonadecanoylchlorid (0.16 mmol) wurden bei Raumtempe- ratur zugegeben und das Reaktionsgemisch wird 4 h bei Raumtemperatur gerührt. Zur Aufarbeitung gab man das Reaktionsgemisch in ca. 200 ml destilliertes Wasser. Der ausgefallene Niederschlag wurde abgesaugt und mit Wasser gewaschen. Nach säu- lenchromatographischer Reinigung des Rohproduktes an Kieselgel (Laufmittel Dich- lormethan/Methanol) erhielt man einen weißen Feststoff. Smp.: 147.2 °C50.0 mg of 1-ethyl-3- [3- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazine-6-yl] -urea (0.16 mmol) were initially charged in 5.0 ml of dried pyridine. 19.7 mg dimethylaminopyridine (0.16 mmol) and 51.2 mg nonadecanoyl chloride (0.16 mmol) were added at room temperature and the reaction mixture was stirred at room temperature for 4 h. For workup, the reaction mixture was added to about 200 ml of distilled water. The precipitate was filtered off with suction and washed with water. After purification by column chromatography on silica gel (eluent dichloromethane / methanol), a white solid was obtained. Mp .: 147.2 ° C
1H-NMR (d6-DMSO): δ = 0.90 (t, 3H), 1.20 - 1.50 (m, 33H), 1.75 - 1.85 (m, 2H), 2.60 - 2.68 (m, 2H), 3.50 - 3.60 (m, 2H), 7.26 - 7.36 (m, 3H), 8.25 - 8.31 (m, 3H), 8.71 (s, 1 H), 9.22 (s, 1 H), 9.75 (s, 1 H) ppm. 1 H NMR (d 6 -DMSO): δ = 0.90 (t, 3H), 1.20-1.50 (m, 33H), 1.75-1.85 (m, 2H), 2.60-2.68 (m, 2H), 3.50-3.60 (m, 2H), 7.26 - 7.36 (m, 3H), 8.25 - 8.31 (m, 3H), 8.71 (s, 1H), 9.22 (s, 1H), 9.75 (s, 1H) ppm.
Beispiel 24:Example 24:
1-(3-Benzyl-pyrido[2,3-b]pyrazin-6-yl]-3-ethyl-harnstoff (Verbindung 15)1- (3-Benzylpyrido [2,3-b] pyrazine-6-yl] -3-ethyl-urea (Compound 15)
Herstellung von 1-(3-Benzyl-pyrido[2,3-b]pyrazin-6-yl]-3-ethyl-harnstoff (Umsetzung gemäß Schema 6) 2.4 ml einer 0.5 M Lösung von Benzylzinkbromid (1.20 mmol) in THF und 24.7 mg Tetrakis(triphenylphosphin)-palladium(0) (0.02 mmol) wurden unter Stickstoff in 1 ml Dioxan vorgelegt. Anschließend wurden portionsweise 102.4 mg 1-(3-Chlor-pyrido[2,3- b]pyrazin-6-yl)-3-ethyl-harnstoff (0.41 mmol) und 1 ml Dioxan zugegeben. Danach wurde das Gemisch auf 100 °C erhitzt. Nach 7h ließ man das Reaktionsgemisch abkühlen und gab dann gesättigte Ammoniumchlorid-Lösung hinzu. Die wässrige Phase wurde mehrfach mit Dichlormethan extrahiert und die gesammelten organischen Phasen wurden mit gesättigter Kochsalz-Lösung gewaschen, über Natriumsulfat getrocknet und im Vakuum vom Lösungsmittel befreit. Nach säulenchromatographischer Auf- reinigung an Kieselgel (Laufmittel Dichlormethan/Methanol) erhielt man einen gelben Feststoff.Preparation of 1- (3-benzylpyrido [2,3-b] pyrazine-6-yl] -3-ethylurea (Reaction According to Scheme 6) 2.4 ml of a 0.5 M solution of benzylzinc bromide (1.20 mmol) in THF and 24.7 mg of tetrakis (triphenylphosphine) palladium (0) (0.02 mmol) were placed under nitrogen in 1 ml of dioxane. Then, portionwise, 102.4 mg of 1- (3-chloropyrido [2,3-b] pyrazine-6-yl) -3-ethyl-urea (0.41 mmol) and 1 ml of dioxane were added. Thereafter, the mixture was heated to 100 ° C. After 7 h, the reaction was allowed to cool and then saturated ammonium chloride solution was added. The aqueous phase was extracted several times with dichloromethane and the collected organic phases were washed with saturated sodium chloride solution, dried over sodium sulphate and freed from the solvent in vacuo. After purification by column chromatography on silica gel (eluent dichloromethane / methanol), a yellow solid was obtained.
ESI-MS: gef. m/z = 308.3 (M + H+); ber. 307 amuESI-MS: gef. m / z = 308.3 (M + H + ); About 307 amu
1H-NMR (d6-DMSO): δ = 1.19 (t, 3H), 3.25 - 3.35 (m, 2H), 4.35 (s, 2H), 7.25 (t, 1 H), 7.30 - 7.39 (m, 4H), 7.64 (d, 1 H), 8.32 (d, 1 H), 8.77 (s, 1 H), 9.05 (s, 1 H), 10.08 (s, 1 H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.19 (t, 3H), 3.25-3.35 (m, 2H), 4.35 (s, 2H), 7.25 (t, 1H), 7.30-7.39 (m, 4H), 7.64 (d, 1H), 8.32 (d, 1H), 8.77 (s, 1H), 9.05 (s, 1H), 10.08 (s, 1H) ppm.
Beispiel 25:Example 25:
1-Methoxy-3-(3-phenyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff (Verbindung 7)1-Methoxy-3- (3-phenyl-pyrido [2,3-b] pyrazine-6-yl) -urea (Compound 7)
Herstellung von 3-Phenyl-pyrido[2,3-b]pyrazin-6-yl-amin (Umsetzung gemäß Schema 6)Preparation of 3-phenyl-pyrido [2,3-b] pyrazine-6-yl-amine (reaction according to Scheme 6)
1.00 g 3-Chlor-pyrido[2,3-b]pyrazin-6-yl-amin (5.54 mmol), 743 mg Phenylboronsäure (6.09 mmol), 640 mg Tetrakis(triphenylphosphin)-palladium(0) (0.55 mmol) und 1.76 g Natriumcarbonat (16.6 mmol) wurden in 100 ml Dimethylformamid/Wasser (1 :1 ) unter Stickstoff als Schutzgas vorgelegt und 2h bei 80 °C gerührt. Nach beendeter Umsetzung wurde das Gemisch abgesaugt und das Filtrat auf 800 ml destilliertes Wasser gegossen. Die wässrige Phase wurde mehrmals mit Ethylacetat extrahiert. Die organische Phase wurde im Vakuum von Lösungsmitteln befreit. Der resultierende Feststoff wurde über Säulenchromatographie an Kieselgel aufgereinigt (Laufmittel Dichlor- methan/Methanol). Man erhielt einen gelben Feststoff. Herstellung von 1-Methoxy-3-(3-phenyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff (Umsetzung gemäß Schema 5)1.00 g of 3-chloro-pyrido [2,3-b] pyrazine-6-yl-amine (5.54 mmol), 743 mg of phenylboronic acid (6.09 mmol), 640 mg of tetrakis (triphenylphosphine) palladium (0) (0.55 mmol) and 1.76 g of sodium carbonate (16.6 mmol) were placed in 100 ml of dimethylformamide / water (1: 1) under nitrogen as a protective gas and stirred at 80 ° C for 2h. After completion of the reaction, the mixture was sucked off and the filtrate was poured into 800 ml of distilled water. The aqueous phase was extracted several times with ethyl acetate. The organic phase was freed of solvents in vacuo. The resulting solid was purified by column chromatography on silica gel (eluent dichloromethane / methanol). A yellow solid was obtained. Preparation of 1-methoxy-3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea (reaction according to Scheme 5)
100 mg 3-Phenyl-pyrido[2,3-b]pyrazin-6-yl-amin (0.45 mmol) wurden in Pyridin gelöst und mit 191 mg p-Nitrophenyl-N-methoxy-carbamat (0.90 mmol) versetzt. Das Ge- misch wurde 4h unter Rückfluß erhitzt. Zur Aufarbeitung wurde das Pyridin im Vakuum entfernt und der Rückstand in Ethylacetat und destilliertem Wasser verteilt. Die Phasen wurden getrennt und die wässrige Phase zweimal mit Ethylacetat extrahiert. Die vereinigten organischen Phasen wurden über MgSO4 getrocknet und das Lösungsmittel im Vakuum entfernt. Der Rückstand wurde säulenchromatographisch an Kieselgel aufge- reinigt (Laufmittel Dichlormethan/Methanol). Es wurde ein hellbeiger Feststoff isoliert.100 mg of 3-phenyl-pyrido [2,3-b] pyrazine-6-yl-amine (0.45 mmol) were dissolved in pyridine and treated with 191 mg of p-nitrophenyl-N-methoxy-carbamate (0.90 mmol). The mixture was heated at reflux for 4 h. For workup, the pyridine was removed in vacuo and the residue was partitioned in ethyl acetate and distilled water. The phases were separated and the aqueous phase extracted twice with ethyl acetate. The combined organic phases were dried over MgSO 4 and the solvent removed in vacuo. The residue was purified by column chromatography on silica gel (eluent dichloromethane / methanol). A light beige solid was isolated.
ESI-MS: gef. m/z = 296.2 (M + H+); ber. 295 amuESI-MS: gef. m / z = 296.2 (M + H + ); ber. 295 amu
1H-NMR (d6-DMSO): δ = 3.75 (s, 3H), 7.58 - 7.65 (m, 3H), 8.03 (s, 1 H), 8.36 (d, 2H), 8.45 (d, 1 H), 9.52 (s, 1 H), 10.16 (s, 1 H), 1 1.01 (s, 1 H) ppm. 1 H NMR (d 6 -DMSO): δ = 3.75 (s, 3H), 7.58-7.65 (m, 3H), 8.03 (s, 1H), 8.36 (d, 2H), 8.45 (d, 1H ), 9.52 (s, 1H), 10.16 (s, 1H), 1 1.01 (s, 1H) ppm.
Folgende Beispiele wurden gemäß Beispiel 25 und den allgemeinen Synthesevorschriften synthetisiert:The following examples were synthesized according to Example 25 and the general synthesis instructions:
Beispiel 26:Example 26:
1-Allyloxy-3-(3-phenyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff (Verbindung 8)1-Allyloxy-3- (3-phenyl-pyrido [2,3-b] pyrazine-6-yl) -urea (Compound 8)
ESI-MS: gef. m/z = 322.2 (M + H+); ber. 321 amuESI-MS: gef. m / z = 322.2 (M + H + ); ber. 321 amu
1H-NMR (d6-DMSO): δ = 4.44 (d, 2H), 5.33 (d, 1 H), 5.41 (d, 1 H), 6.02 - 6.10 (m, 1 H), 7.58 - 7.65 (m, 3H), 8.00 (s, 1 H), 8.36 (d, 2H), 8.45 (d, 1 H), 9.52 (s, 1 H), 10.13 (s, 1 H), 11.07 (s, 1 H) ppm. 1 H NMR (d 6 -DMSO): δ = 4.44 (d, 2H), 5.33 (d, 1H), 5.41 (d, 1H), 6.02-6.10 (m, 1H), 7.58-7.65 ( m, 3H), 8.00 (s, 1H), 8.36 (d, 2H), 8.45 (d, 1H), 9.52 (s, 1H), 10.13 (s, 1H), 11.07 (s, 1H ) ppm.
Beispiel 27:Example 27:
1-[4-(tert-Butyl-dimethyl-silanyloxy)-butyl]-3-(3-phenyl-pyrido[2,3-b]pyrazin-6-yl)- harnstoff (Verbindung 36)1- [4- (tert -butyl-dimethyl-silanyloxy) -butyl] -3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) -urea (Compound 36)
ESI-MS: gef. m/z = 452.6 (M + H+); ber. 451 amu 1H-NMR (DMSO-de) δ = 0.02 (s, 6H), 0.84 (s, 9H), 1.62-1.65 (m, 4H), 3.30-3.33 (m, 2H), 3.66-3.69 (m, 2H), 7.59-7.62 (m, 3H), 7.64 (d, 1 H), 8.35 (d, 2H), 8.38 (d, 1 H), 9.37 (s, 1 H), 9.47 (s, 1 H), 10.15 (s, 1 H) ppm.ESI-MS: gef. m / z = 452.6 (M + H + ); ber. 451 amu 1 H-NMR (DMSO-de) δ = 0.02 (s, 6H), 0.84 (s, 9H), 1.62-1.65 (m, 4H), 3.30-3.33 (m, 2H), 3.66-3.69 (m, 2H ), 7.59-7.62 (m, 3H), 7.64 (d, 1H), 8.35 (d, 2H), 8.38 (d, 1H), 9.37 (s, 1H), 9.47 (s, 1H), 10.15 (s, 1H) ppm.
Beispiel 28:Example 28:
1-[4-(tert-Butyl-dimethyl-silanyloxy)-butyl]-3-[3-(4-hydroxy-3-methoxy-phenyl)- pyrido[2,3-b]pyrazin-6-yl]-harnstoff (Verbindung 37)1- [4- (tert -butyl-dimethyl-silanyloxy) -butyl] -3- [3- (4-hydroxy-3-methoxy-phenyl) -pyrido [2,3-b] pyrazine-6-yl] - urea (compound 37)
ESI-MS: gef. m/z = 498.5 (M + H+); ber. 497 amu 1H-NMR (DMSO-d6) δ = 0.01 (s, 6H), 0.83 (s, 9H), 1.61-1.66 (m, 4H), 3.30-3.33 (m, 2H), 3.65-3.68 (m, 2H), 3.93 (s, 3H), 6.96 (d, 1 H), 7.59 (d, 1 H), 7.86 (dd, 1 H), 7.92 (d, 1 H), 8.32 (d, 1 H), 9.29 (s, 1 H), 9.42 (s, 1 H), 9.73 (s, 1 H), 10.08 (s, 1 H) ppm.ESI-MS: gef. m / z = 498.5 (M + H + ); calc. 497 amu 1 H-NMR (DMSO-d 6) δ = 0.01 (s, 6H), 0.83 (s, 9H), 1.61-1.66 (m, 4H), 3:30 to 3:33 (m, 2H), 3.65- 3.68 (m, 2H), 3.93 (s, 3H), 6.96 (d, 1H), 7.59 (d, 1H), 7.86 (dd, 1H), 7.92 (d, 1H), 8.32 (d, 1H), 9.29 (s, 1H), 9.42 (s, 1H), 9.73 (s, 1H), 10.08 (s, 1H) ppm.
Beispiel 29: {4-[3-(3-Phenyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff]-butyl}-phosphonsäure-diethyl-ester (Verbindung 42)Example 29: Diethyl {4- [3- (3-phenyl-pyrido [2,3-b] pyrazine-6-yl) -urea] -butyl} -phosphonic acid (Compound 42)
ESI-MS: gef. m/z = 458.2 (M + H+); ber. 457 amuESI-MS: gef. m / z = 458.2 (M + H + ); ber. 457 amu
1H-NMR (DMSO-d6) δ = 1.16 (t, 6H), 1.59-1.69 (m, 4H), 1.77-1.84 (m, 2H), 3.33-3.36 (m, 2H), 3.90-3.99 (m, 4H), 7.58-7.63 (m, 3H), 7.68 (d, 1 H), 8.36 (d, 2H), 8.38 (d, 1 H), 9.22 (s, 1 H), 9.47 (s, 1 H), 10.16 (s, 1 H) ppm. 1 H-NMR (DMSO-d 6 ) δ = 1.16 (t, 6H), 1.59-1.69 (m, 4H), 1.77-1.84 (m, 2H), 3.33-3.36 (m, 2H), 3.90-3.99 ( m, 4H), 7.58-7.63 (m, 3H), 7.68 (d, 1H), 8.36 (d, 2H), 8.38 (d, 1H), 9.22 (s, 1H), 9.47 (s, 1 H), 10.16 (s, 1H) ppm.
Beispiel 30:Example 30:
(4-{3-[3-(4-Hydroxy-3-methoxy-phenyl)-pyrido[2,3-b]pyrazin-6-yl]-harnstoff}-butyl)- phosphonsäure-diethyl-ester (Verbindung 44)(4- {3- [3- (4-Hydroxy-3-methoxy-phenyl) -pyrido [2,3-b] pyrazine-6-yl] -urea} -butyl) -phosphonic acid diethyl ester (Compound 44 )
ESI-MS: gef. m/z = 504.5 (M + H+); ber. 503 amu 1H-NMR (DMSO-de) δ = 1.15 (t, 6 H), 1.58-1.69 (m, 4H), 1.76-1.82 (m, 2H), 3.30-3.33 (m, 2H), 3.89-3.97 (m, 7H), 6.97 (d, 1 H), 7.63 (d, 1 H), 7.86 (dd, 1 H), 7.91 (d, 1 H), 8.32 (d, 1 H), 9.13 (s, 1 H), 9.41 (s, 1 H), 9.71 (s, 1 H), 10.07 (s, 1 H) ppm.ESI-MS: gef. m / z = 504.5 (M + H + ); ber. 503 amu 1 H-NMR (DMSO-de) δ = 1.15 (t, 6H), 1.58-1.69 (m, 4H), 1.76-1.82 (m, 2H), 3.30-3.33 (m, 2H), 3.89-3.97 ( m, 7H), 6.97 (d, 1H), 7.63 (d, 1H), 7.86 (dd, 1H), 7.91 (d, 1H), 8.32 (d, 1H), 9.13 (s, 1 H), 9.41 (s, 1H), 9.71 (s, 1H), 10.07 (s, 1H) ppm.
Beispiel 31 :Example 31:
1-Methoxy-3-[3-(4-hydroxy-3-methoxy-phenyl)-pyrido[2,3-b]pyrazin-6-yl]-harnstoff (Verbindung 61 )1-Methoxy-3- [3- (4-hydroxy-3-methoxy-phenyl) -pyrido [2,3-b] pyrazine-6-yl] -urea (Compound 61)
ESI-MS: gef. m/z = 342.3 (M + H+); ber. 341 amu 1H-NMR (d6-DMSO): δ = 3.74 (s, 3H), 3.93 (s, 3H), 6.98 (d, 1 H), 7.87 (dd, 1 H), 7.91 (d, 1 H), 8.02 (d, 1 H), 8.39 (d, 1 H), 9.46 (s, 1 H), 9.74 (s, 1 H), 10.03 (s, 1 H), 10.84 (s, 1 H) ppm.ESI-MS: gef. m / z = 342.3 (M + H + ); 341 amu 1 H NMR (d 6 -DMSO): δ = 3.74 (s, 3H), 3.93 (s, 3H), 6.98 (d, 1H), 7.87 (dd, 1H), 7.91 (i.e. , 1H), 8.02 (d, 1H), 8.39 (d, 1H), 9.46 (s, 1H), 9.74 (s, 1H), 10.03 (s, 1H), 10.84 (s, 1 H) ppm.
Beispiel 32: {2-[3-(3-Phenyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff]-ethyl}-phosphonsäure-diethyl-ester (Verbindung 62)Example 32: Diethyl {2- [3- (3-phenyl-pyrido [2,3-b] pyrazine-6-yl) -urea] -ethyl} -phosphonic acid (Compound 62)
ESI-MS: gef. m/z = 430.1 (M + H+); ber. 429 amuESI-MS: gef. m / z = 430.1 (M + H + ); ber. 429 amu
1H-NMR (d6-DMSO): δ = 1.21 (t, 6 H), 2.08-2.14 (m, 2 H), 3.48-3.55 (m, 2H), 3.98-4.08 (m, 4H), 7.58-7.63 (m, 3H), 7.72 (d, 1 H), 8.35 (d, 2H), 8.39 (d, 1 H), 9.14 (s, 1 H), 9.47 (s, 1 H), 10.22 (s, 1 H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.21 (t, 6H), 2.08-2.14 (m, 2H), 3.48-3.55 (m, 2H), 3.98-4.08 (m, 4H), 7.58 -7.63 (m, 3H), 7.72 (d, 1H), 8.35 (d, 2H), 8.39 (d, 1H), 9.14 (s, 1H), 9.47 (s, 1H), 10.22 (s , 1 H) ppm.
Beispiel 33:Example 33:
Ethyl-carbaminsäure-4-[3-(3-phenyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff]-butyl-ester (Verbindung 38)Ethyl carbamic acid 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl ester (Compound 38)
Herstellung von 1 -(4-Hydroxy-butyl)-3-(3-phenyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoffPreparation of 1- (4-hydroxybutyl) -3- (3-phenylpyrido [2,3-b] pyrazine-6-yl) urea
360 mg (0.22 mmol) 1-[4-(tert-Butyl-dimethyl-silanyloxy)-butyl]-3-(3-phenyl-pyrido[2,3- b]pyrazin-6-yl)-harnstoff wurden in 20 ml Dichlormethan gelöst und mit 5 ml einer 2 molaren isopropanolischen HCI-Lösung versetzt. Nach 12 h Rühren bei Raumtemperatur wurde der Reaktionsansatz mit Wasser gewaschen und getrocknet (Na2SO4). Nach Entfernen des Lösungsmittels im Vakuum erhielt man einen hellgelben Feststoff.360 mg (0.22 mmol) of 1- [4- (tert-butyl-dimethyl-silanyloxy) -butyl] -3- (3-phenylpyrido [2,3-b] pyrazine-6-yl) -urea were used in 20 Dissolved dichloromethane and with 5 ml of a 2 molar isopropanolic HCI solution. After 12 h of stirring at room temperature, the reaction mixture was washed with water and dried (Na 2 SO 4 ). Removal of the solvent in vacuo gave a light yellow solid.
ESI-MS: gef. m/z = 338.3 (M + H+); ber. 337 amu 1H-NMR (DMSO-d6) δ = 1.58-1.64 (m, 4H), 3.30-3.34 (m, 2H), 3.48-3.53 (m, 2H), 4.48 (t, 1 H), 7.57-7.63 (m, 3H), 7.66 (d, 1 H), 8.35-8.38 (m, 2H), 9.30 (s, 1 H), 9.46 (s, 1 H), 10.13 (s, 1 H) ppm.ESI-MS: gef. m / z = 338.3 (M + H + ); calc. 337 amu 1 H-NMR (DMSO-d 6) δ = 1.58-1.64 (m, 4H), 3:30 to 3:34 (m, 2H), 3:48 to 3:53 (m, 2H), 4:48 (t, 1 H) , 7.57-7.63 (m, 3H), 7.66 (d, 1H), 8.35-8.38 (m, 2H), 9.30 (s, 1H), 9.46 (s, 1H), 10.13 (s, 1H) ppm.
Herstellung von Ethyl-carbaminsäure-4-[3-(3-phenyl-pyrido[2,3-b]pyrazin-6-yl)- harnstoff]-butyl-esterPreparation of ethyl carbamic acid 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl ester
30 mg (0.08 mmol) 1-(4-Hydroxy-butyl)-3-(3-phenyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff wurden in 5 ml Pyridin gelöst, mit 7.6 μl (0.10 mmol) Ethylisocyanat versetzt und für der 6 h bei 100 °C gerührt. Das Reaktionsgemisch wurde auf 200 ml Wasser gegossen und für 15 min gerührt. Der ausgefallene Niederschlag wurde abfiltriert und getrocknet. Man erhielt einen weißen Feststoff.30 mg (0.08 mmol) of 1- (4-hydroxybutyl) -3- (3-phenyl-pyrido [2,3-b] pyrazine-6-yl) -urea were dissolved in 5 ml of pyridine, washed with 7.6 μl ( 0.10 mmol) of ethyl isocyanate and stirred at 100 ° C for 6 h. The reaction mixture was poured onto 200 ml of water and stirred for 15 min. The precipitate was filtered off and dried. A white solid was obtained.
ESI-MS: gef. m/z = 409.4 (M + H+); ber. 408 amuESI-MS: gef. m / z = 409.4 (M + H + ); ber. 408 amu
1H-NMR (DMSO-d6) δ = 0.97 (t, 3H), 1.60-1.77 (m, 4H), 2.96-3.00 (m, 2H), 3.33-3.35 (m, 2H), 4.01-4.04 (m, 2H), 7.07 (t, 1 H), 7.58-7.64 (m, 3H), 7.66 (d, 1 H), 8.35 (d, 2H), 8.38 (d, 1 H), 9.32 (s, 1 H), 9.47 (s, 1 H), 10.17 (s, 1 H) ppm. 1 H-NMR (DMSO-d 6) δ = 0.97 (t, 3H), 1.60-1.77 (m, 4H), 2.96-3.00 (m, 2H), 3:33 to 3:35 (m, 2H), 4:01 to 4:04 ( m, 2H), 7.07 (t, 1H), 7.58-7.64 (m, 3H), 7.66 (d, 1H), 8.35 (d, 2H), 8.38 (d, 1H), 9.32 (s, 1 H), 9.47 (s, 1H), 10.17 (s, 1H) ppm.
Bespiel 34:Example 34:
Kohlensäure-methyl-ester-4-[3-(3-phenyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff]-butyl- ester (Verbindung 39)Carbonic acid methyl ester 4- [3- (3-phenyl-pyrido [2,3-b] pyrazine-6-yl) -urea] -butyl ester (compound 39)
Herstellung von Kohlensäure-methyl-ester-4-[3-(3-phenyl-pyrido[2,3-b]pyrazin-6-yl)- harnstoff]-butyl-esterPreparation of carbonic acid methyl ester 4- [3- (3-phenyl-pyrido [2,3-b] pyrazine-6-yl) -urea] -butyl ester
30 mg (0.08 mmol) 1-(4-Hydroxy-butyl)-3-(3-phenyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff wurden in 2 ml Dichlormethan suspendiert und mit 9.3 μl (0.12 mmol) Chlorameisensäuremethylester, 23 μl (0.16 mmol) Triethylamin und 1 mg (0.01 mmol) Dimethylami- nopyridin versetzt. Die Lösung wurde für 4 h bei Raumtemperatur gerührt. Der Reaktionsansatz wurde mit 50 ml Dichlormethan verdünnt, mit Wasser gewaschen und ge- trocknet (Na2SO4). Das Lösungsmittel wurde im Vakuum entfernt und der Rückstand säulenchromatographisch an Kieselgel aufgereinigt (Laufmittel Dichlor- methan/Methanol). Es wurde ein weißer Feststoff isoliert.30 mg (0.08 mmol) of 1- (4-hydroxybutyl) -3- (3-phenyl-pyrido [2,3-b] pyrazine-6-yl) -urea were suspended in 2 ml of dichloromethane and treated with 9.3 μl ( 0.12 mmol) of methyl chloroformate, 23 .mu.l (0.16 mmol) of triethylamine and 1 mg (0.01 mmol) of dimethylaminopyridine were added. The solution was stirred for 4 h at room temperature. The reaction mixture was diluted with 50 ml of dichloromethane, washed with water and dried. dried (Na 2 SO 4 ). The solvent was removed in vacuo and the residue was purified by column chromatography on silica gel (eluent dichloromethane / methanol). A white solid was isolated.
ESI-MS: gef. m/z = 396.3 (M + H+); ber. 395 amu 1H-NMR (DMSO-d6) δ = 1.61-1.66 (m, 2H), 1.76-1.78 (m, 2H), 3.34-3.36 (m, 2H), 3.67 (s, 1 H), 4.17-4.19 (m, 2H), 7.59-7.63 (m, 3H), 7.66 (d, 1 H), 8.35 (d, 2H), 8.38 (d, 1 H), 9.34 (s, 1 H), 9.47 (s, 1 H), 10.17 (s, 1 H) ppm.ESI-MS: gef. m / z = 396.3 (M + H + ); calc. 395 amu 1 H-NMR (DMSO-d 6) δ = 1.61-1.66 (m, 2H), 1.76-1.78 (m, 2H), 3:34 to 3:36 (m, 2H), 3.67 (s, 1 H) , 4.17-4.19 (m, 2H), 7.59-7.63 (m, 3H), 7.66 (d, 1H), 8.35 (d, 2H), 8.38 (d, 1H), 9.34 (s, 1H), 9.47 (s, 1H), 10.17 (s, 1H) ppm.
Folgendes Beispiel wurde gemäß Beispiel 34 und den allgemeinen Synthesevorschrif- ten synthetisiert:The following example was synthesized according to Example 34 and the general synthesis instructions:
Beispiel 35:Example 35:
Kohlensäure-2,2-dimethyl-[1 ,3]dioxolan-4-ylmethyl-ester-4-[3-(3-phenyl-pyrido[2,3- b]pyrazin-6-yl)-harnstoff]-butyl-ester (Verbindung 40)Carbonic acid 2,2-dimethyl- [1,3] dioxolan-4-ylmethyl ester 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] -butyl ester (compound 40)
ESI-MS: gef. m/z = 496.0 (M + H+); ber. 495 amuESI-MS: gef. m / z = 496.0 (M + H + ); ber. 495 amu
1H-NMR (DMSO-d6) δ = 1.24 (s, 3H), 1.29 (s, 3H), 1.61-1.67 (m, 2H), 1.77-1.82 (m, 2H), 3.34-3.37 (m, 2H), 3.65 (dd, 1 H), 3.98 (dd, 1 H), 4.03 (dd, 1 H), 4.15 (dd, 1 H), 4.17- 4.28 (m, 3H), 7.58-7.63 (m, 3H), 7.67 (d, 1 H), 8.36 (d, 2H), 8.38 (d, 1 H), 9.34 (s, 1 H), 9.47 (s, 1 H), 10.17 (s, 1 H) ppm. 1 H-NMR (DMSO-d 6 ) δ = 1.24 (s, 3H), 1.29 (s, 3H), 1.61-1.67 (m, 2H), 1.77-1.82 (m, 2H), 3.34-3.37 (m, 2H), 3.65 (dd, 1H), 3.98 (dd, 1H), 4.03 (dd, 1H), 4.15 (dd, 1H), 4.17-4.28 (m, 3H), 7.58-7.63 (m, 3H), 7.67 (d, 1H), 8.36 (d, 2H), 8.38 (d, 1H), 9.34 (s, 1H), 9.47 (s, 1H), 10.17 (s, 1H) ppm ,
Beispiel 36:Example 36:
Kohlensäure-2,3-dihydroxy-propyl-ester-4-[3-(3-phenyl-pyrido[2,3-b]pyrazin-6-yl)- harnstoff]-butyl-ester (Verbindung 41 )Carbonic acid 2,3-dihydroxy-propyl ester 4- [3- (3-phenyl-pyrido [2,3-b] pyrazin-6-yl) -urea] -butyl ester (Compound 41)
Herstellung von Kohlensäure-2,3-dihydroxy-propyl-ester-4-[3-(3-phenyl-pyrido[2,3- b]pyrazin-6-yl)-harnstoff]-butyl-esterPreparation of carbonic acid 2,3-dihydroxypropyl ester 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl ester
50 mg (0.10 mmol) Kohlensäure-2,2-dimethyl-[1 ,3]dioxolan-4-ylmethyl-ester-4-[3-(3- phenyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff]-butyl-ester wurden in 20 ml Dichlormethan gelöst, mit 17 μl (0.13 mmol) Bortrifluorid-ethyletherat versetzt und für 4 h bei Raum- temperatur gerührt. Das Lösungsmittel wurde im Vakuum entfernt und der Rückstand säulenchromatographisch an Kieselgel aufgereinigt (Laufmittel Dichlor- methan/Methanol). Es wurde ein weißer Feststoff isoliert.Carbonic acid 2,2-dimethyl- [1,3-dioxolan-4-ylmethyl-ester-4- [3- (3-phenyl-pyrido [2,3-b] pyrazine-6-yl] 50 mg (0.10 mmol) ) urea] -butyl ester were dissolved in 20 ml of dichloromethane, treated with 17 .mu.l (0.13 mmol) boron trifluoride ethyl etherate and for 4 h at Raum- temperature stirred. The solvent was removed in vacuo and the residue was purified by column chromatography on silica gel (eluent dichloromethane / methanol). A white solid was isolated.
ESI-MS: gef. m/z = 456.4 (M + H+); ber. 455 amu 1H-NMR (DMSO-d6) δ = 1.62-1.67 (m, 2H), 1.76-1.82 (m, 2H), 3.28-3.52 (m, 4H), 3.62- 3.66 (m, 1 H), 3.96 (dd, 1 H), 4.1 1 (dd, 1 H), 4.16-4.20 (m, 2H), 4.66 (t, 1 H), 4.96 (d, 1 H), 7.58-7.65 (m, 3H), 7.67 (d, 1 H), 8.35 (d, 2H), 8.38 (d, 1 H), 9.31 (s, 1 H), 9.47 (s, 1 H), 10.17 (s, 1 H) ppm.ESI-MS: gef. m / z = 456.4 (M + H + ); calc. 455 amu 1 H-NMR (DMSO-d 6) δ = 1.62-1.67 (m, 2H), 1.76-1.82 (m, 2H), 3:28 to 3:52 (m, 4H), 3.62- 3.66 (m, 1 H), 3.96 (dd, 1H), 4.1 1 (dd, 1H), 4.16-4.20 (m, 2H), 4.66 (t, 1H), 4.96 (d, 1H), 7.58-7.65 (m , 3H), 7.67 (d, 1H), 8.35 (d, 2H), 8.38 (d, 1H), 9.31 (s, 1H), 9.47 (s, 1H), 10.17 (s, 1H) ppm.
Beispiel 37:Example 37:
{4-[3-(3-Phenyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff]-butyl}-phosphonsäure (Verbindung 43){4- [3- (3-phenyl-pyrido [2,3-b] pyrazine-6-yl) -urea] -butyl} -phosphonic acid (Compound 43)
Herstellung {4-[3-(3-Phenyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff]-butyl}-phosphonsäure 60 mg (0.13 mmol) {4-[3-(3-Phenyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff]-butyl}- phosphonsäure-diethyl-ester wurde in jeweils 5 ml Dichlormethan und Hexamethyldisi- lazan gelöst und mit 100 mg (0.66 mmol) Bromtrimethylsilan versetzt. Nach 6 h Rühren bei Raumtemperatur wurde der Reaktionsansatz im Vakuum eingeengt und der Rückstand 2 h mit Wasser ausgerührt. Man erhielt einen gelben Feststoff. ESI-MS: gef. m/z = 402.3 (M + H+); ber. 401 amuPreparation of {4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl} phosphonic Acid 60 mg (0.13 mmol) of {4- [3- (3-phenyl -pyrido [2,3-b] pyrazine-6-yl) -urea] -butyl} - phosphonic acid diethyl ester was dissolved in 5 ml of dichloromethane and hexamethyldisilazane and treated with 100 mg (0.66 mmol) of bromotrimethylsilane. After stirring for 6 h at room temperature, the reaction mixture was concentrated in vacuo and the residue was stirred with water for 2 h. A yellow solid was obtained. ESI-MS: gef. m / z = 402.3 (M + H + ); ber. 401 amu
1H-NMR (DMSO-d6) δ = 1.51-1.68 (m, 6H), 3.33-3.36 (m, 2H), 7.58-7.63 (m, 3H), 7.73 (d, 1 H), 8.33-8.37 (m, 3H), 9.06 (s, 1 H), 9.44 (s, 1 H), 10.12 (s, 1 H) ppm. 1 H-NMR (DMSO-d 6) δ = 1.51-1.68 (m, 6H), 3:33 to 3:36 (m, 2H), 7.58-7.63 (m, 3H), 7.73 (d, 1 H), 8:33 to 8:37 (m, 3H), 9.06 (s, 1H), 9.44 (s, 1H), 10.12 (s, 1H) ppm.
Folgende Beispiele wurde gemäß Beispiel 37 und den allgemeinen Synthesevorschrif- ten synthetisiert:The following examples were synthesized according to Example 37 and the general synthesis instructions:
Beispiel 38:Example 38:
(4-{3-[3-(4-Hydroxy-3-methoxy-phenyl)-pyrido[2,3-b]pyrazin-6-yl]-harnstoff}-butyl)- phosphonic acid (Verbindung 45) ESI-MS: gef. m/z = 448.3 (M + H+); ber. 447 amu(4- {3- [3- (4-Hydroxy-3-methoxyphenyl) -pyrido [2,3-b] pyrazine-6-yl] -urea} -butyl) - phosphonic acid (Compound 45) ESI-MS: gef. m / z = 448.3 (M + H + ); ber. 447 amu
1H-NMR (DMSO-de) δ = 1.48-1.67 (m, 6H), 3.24-3.28 (m, 2H), 3.92 (s, 3H), 6.98 (d, 1 H), 7.70 (d, 1 H), 7.85 (dd, 1 H), 7.89 (d, 1 H), 8.28 (d, 1 H), 8.95 (s, 1 H), 9.38 (s, 1 H), 10.02 (s, 1 H) ppm. 1 H-NMR (DMSO-de) δ = 1.48-1.67 (m, 6H), 3.24-3.28 (m, 2H), 3.92 (s, 3H), 6.98 (d, 1H), 7.70 (d, 1H ), 7.85 (dd, 1H), 7.89 (d, 1H), 8.28 (d, 1H), 8.95 (s, 1H), 9.38 (s, 1H), 10.02 (s, 1H) ppm ,
Beispiel 39:Example 39:
{2-[3-(3-Phenyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff]-ethyl}-phosphonsäure (Verbindung 63){2- [3- (3-Phenyl-pyrido [2,3-b] pyrazine-6-yl) -urea] -ethyl} -phosphonic acid (Compound 63)
ESI-MS: gef. m/z = 374.2 (M + H+); ber. 373 amuESI-MS: gef. m / z = 374.2 (M + H + ); About 373 amu
1H-NMR (de-DMSO): δ = 1.86-1.93 (m, 2 H), 3.45-3.52 (m, 2H), 7.57-7.63 (m, 3H), 7.76 (d, 1 H), 8.35 (d, 2H), 8.37 (d, 1 H), 8.96 (s, 1 H), 9.45 (s, 1 H), 10.17 (s, 1 H) ppm. 1 H-NMR (de-DMSO): δ = 1.86-1.93 (m, 2H), 3.45-3.52 (m, 2H), 7.57-7.63 (m, 3H), 7.76 (d, 1H), 8.35 ( d, 2H), 8.37 (d, 1H), 8.96 (s, 1H), 9.45 (s, 1H), 10.17 (s, 1H) ppm.
Beispiel 40: N-(3-Phenyl-pyrido[2,3-b]pyrazin-6-yl)-oxalamidsäure-ethyl-ester (Verbindung 59)Example 40: N- (3-Phenyl-pyrido [2,3-b] pyrazine-6-yl) -oxaleamic acid ethyl ester (Compound 59)
Herstellung von N-(3-Phenyl-pyrido[2,3-b]pyrazin-6-yl)-oxalamidsäure-ethyl-ester (Umsetzung gemäß Schema 5)Preparation of N- (3-phenyl-pyrido [2,3-b] pyrazine-6-yl) -oxalamic acid ethyl ester (reaction according to Scheme 5)
200 mg (0.90 mmol) 3-Phenyl-pyrido[2,3-b]pyrazin-6-ylamin wurden in 20 ml Pyridin gelöst und mit 0.11 ml (0.99 mmol) Ethyloxalylchlorid versetzt. Nach 2 h Rühren bei Raumtemperatur wurde die Lösung auf Eiswasser gegossen. Der ausgefallene Feststoff wurde abfiltriert und gründlich mit Wasser nachgewaschen. Man erhielt einen hellgelben Feststoff.200 mg (0.90 mmol) of 3-phenyl-pyrido [2,3-b] pyrazine-6-ylamine were dissolved in 20 ml of pyridine and admixed with 0.11 ml (0.99 mmol) of ethyl oxalyl chloride. After stirring for 2 h at room temperature, the solution was poured onto ice-water. The precipitated solid was filtered off and washed thoroughly with water. A pale yellow solid was obtained.
ESI-MS: gef. m/z = 323.2 (M + H+); ber. 322 amu 1H-NMR (DMSO-de) δ = 1.37 (t, 3H), 4.35-4.41 (m, 2H), 7.60-7.66 (m, 3H), 8.38 (d, 2H), 8.43 (bs, 1 H), 8.61 (d, 1 H), 9.63 (s, 1 H), 11.67 (s, 1 H) ppm.ESI-MS: gef. m / z = 323.2 (M + H + ); 322 amu 1 H-NMR (DMSO-de) δ = 1.37 (t, 3H), 4.35-4.41 (m, 2H), 7.60-7.66 (m, 3H), 8.38 (d, 2H), 8.43 (bs , 1H), 8.61 (d, 1H), 9.63 (s, 1H), 11.67 (s, 1H) ppm.
Beispiel 41 :Example 41:
N-Ethyl-N'-(3-phenyl-pyrido[2,3-b]pyrazin-6-yl)-oxalamide (Verbindung 60) Herstellung von N-Ethyl-N'-(3-phenyl-pyrido[2,3-b]pyrazin-6-yl)-oxalsäureamid (Umsetzung gemäß Schema 5)N-ethyl-N '- (3-phenyl-pyrido [2,3-b] pyrazine-6-yl) -oxalamide (Compound 60) Preparation of N-ethyl-N '- (3-phenylpyrido [2,3-b] pyrazine-6-yl) oxalic acid amide (reaction according to Scheme 5)
23 mg (0.07 mmol) N-(3-Phenyl-pyrido[2,3-b]pyrazin-6-yl)-oxalamidsäure-ethyl-ester wurden in 5 ml trockenen THF gelöst und mit 0.15 ml (0.38 mmol) einer 2.0 M Ethyla- minlösung in THF versetzt. Nach 48 h Rühren bei Raumtemperatur wurde der Reaktionsansatz neutralisiert. Der aufgefallene Feststoff wurde abfiltiert und das Filtrat im Vakuum zur Trockene eingeengt. Der resultierende Feststoff wurde durch Säulenchromatographie an Kieselgel (Laufmittel Dichlormethan/Methanol) gereinigt. Man erhielt einen hellgelben Feststoff.23 mg (0.07 mmol) of N- (3-phenyl-pyrido [2,3-b] pyrazine-6-yl) -oxalamic acid ethyl ester were dissolved in 5 ml of dry THF and mixed with 0.15 ml (0.38 mmol) of 2.0 M ethylamine solution in THF. After stirring for 48 h at room temperature, the reaction mixture was neutralized. The precipitated solid was filtered off and the filtrate was concentrated to dryness in vacuo. The resulting solid was purified by column chromatography on silica gel (eluent dichloromethane / methanol). A pale yellow solid was obtained.
ESI-MS: gef. m/z = 322.3 (M + H+); ber. 321 amuESI-MS: gef. m / z = 322.3 (M + H + ); ber. 321 amu
1H-NMR (DMSO-de) δ = 1.13 (t, 3H), 3.27 (q, 2H), 7.60-7.66 (m, 3H), 8.39 (d, 2H), 8.54 (d, 1 H), 8.65 (d, 1 H), 9.24 (t, 1 H), 9.64 (s, 1 H), 10.31 (s, 1 H) ppm. 1 H-NMR (DMSO-de) δ = 1.13 (t, 3H), 3.27 (q, 2H), 7.60-7.66 (m, 3H), 8.39 (d, 2H), 8.54 (d, 1H), 8.65 (d, 1H), 9.24 (t, 1H), 9.64 (s, 1H), 10.31 (s, 1H) ppm.
Beispiel 42:Example 42:
Ethyl-carbaminsäure-4-[6-(3-ethyl-1-phenyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl- ester (Verbindung 20)Ethyl carbamic acid 4- [6- (3-ethyl-1-phenyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester (Compound 20)
Herstellung von Ethyl-carbaminsäure-4-[6-(3-ethyl-1 -phenyl-harnstoff)-pyrido[2,3- b]pyrazin-3-yl]-phenyl-ester (Umsetzung gemäß Schema 5)Preparation of ethyl carbamic acid 4- [6- (3-ethyl-1-phenylurea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester (reaction according to Scheme 5)
100 mg 4-(6-Phenylamino-pyrido[2,3-b]pyrazin-3-yl)-phenol Hydrochlorid (0.28 mmol) wurden in 3 ml Pyridin vorgelegt und 65.3 mg Ethylisocyanat (0.90 mmol) bei Raumtemperatur zugegeben. Man ließ das Gemisch 5h bei 80 °C rühren, fügte dann nochmal 32.0 mg Ethylisocyanat (0.45 mmol) hinzu und ließ das Gemisch weitere 4h bei 80 °C rühren. Dann wurde das Lösungsmittel im Vakuum entfernt. Der resultierende Feststoff wurde über zweifache Säulenchromatographie an Kieselgel (Laufmittel Dichlormethan/Methanol und n-Heptan/Aceton) gereinigt. Man erhielt einen hellgelben Feststoff.100 mg of 4- (6-phenylamino-pyrido [2,3-b] pyrazin-3-yl) -phenol hydrochloride (0.28 mmol) were initially charged in 3 ml of pyridine and 65.3 mg of ethyl isocyanate (0.90 mmol) were added at room temperature. The mixture was allowed to stir for 5 h at 80 ° C, then added again 32.0 mg of ethyl isocyanate (0.45 mmol) and the mixture was stirred at 80 ° C for a further 4h. Then the solvent was removed in vacuo. The resulting solid was purified by double column chromatography on silica gel (eluent dichloromethane / methanol and n-heptane / acetone). A pale yellow solid was obtained.
Smp.: 147-151 °C ESI-MS: gef. m/z = 457.3 (M + H+); ber. 456 amu 1H-NMR (CDCI3): δ = 1.28 (t, 3H), 1.40 (t, 3H), 3.39 (quint, 2H), 3.57 (quint, 2H), 5.09 (t, 1 H), 6.80 (d, 1 H), 7.37 (d, 2H), 7.40 (d, 2H), 7.50 (t, 1 H), 7.57 (t, 2H), 8.10 (d, 1 H), 8.30 (d, 2H), 9.25 (s, 1 H), 10.76 (t, 1 H) ppm.Mp: 147-151 ° C ESI-MS: gef. m / z = 457.3 (M + H + ); ber. 456 amu 1 H-NMR (CDCl3): δ = 1.28 (t, 3H), 1.40 (t, 3H), 3.39 (quint, 2H), 3.57 (quint, 2H), 5.09 (t, 1H), 6.80 (d, 1 H), 7.37 (d, 2H), 7.40 (d, 2H), 7.50 (t, 1H), 7.57 (t, 2H), 8.10 (d, 1H), 8.30 (d, 2H), 9.25 ( s, 1H), 10.76 (t, 1H) ppm.
Für die Herstellung von 4-(6-Phenylamino-pyrido[2,3-b]pyrazin-3-yl)-phenol Hydrochlo- rid sei hiermit auf WO 99/17759 verwiesen.Reference should be made to WO 99/17759 for the preparation of 4- (6-phenylamino-pyrido [2,3-b] pyrazin-3-yl) -phenol hydrochloride.
Beispiel 43:Example 43:
{4-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl}-carbaminsäure-tert-butyl- ester (Verbindung 21 ){4- [6- (3-Ethyl-urea) -pyrido [2,3-b] pyrazine-3-yl] -phenyl} -carbamic acid tert-butyl ester (Compound 21)
Herstellung von {4-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl}- carbaminsäure-tert-butyl-ester (Umsetzung gemäß Schema 6)Preparation of {4- [6- (3-ethyl-urea) -pyrido [2,3-b] -pyrazino-3-yl] -phenyl} -carbamic acid tert-butyl-ester (reaction according to Scheme 6)
83 mg 1-(3-Chlor-pyrido[2,3-b]pyrazin-6-yl)-3-ethyl-harnstoff (0.33 mmol), 120 mg [4- (4,4,5,5-Tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-phenyl]-carbaminsäure-tert-butyl-ester (0.36 mmol), 106 mg Natriumcarbonat (1.00 mmol) und 19 mg Tetrakis- (triphenylphosphin)palladium (0.02 mmol) wurden in 7 ml entgastem Dimethylforma- mid/Wasser-Gemisch vorgelegt. Man erhitzte das Gemisch für 4h auf 100 °C. Das abgekühlte Gemisch wurde mit Wasser versetzt. Der ausgefallene Niederschlag wurde abfiltriert und mit Wasser und Dichlormethan nachgewaschen. Man erhielt einen beigefarbenen Feststoff.83 mg of 1- (3-chloropyrido [2,3-b] pyrazin-6-yl) -3-ethylurea (0.33 mmol), 120 mg of [4- (4,4,5,5-tetramethyl) [1,2,2] dioxaborolan-2-yl) -phenyl] -carbamic acid tert -butyl ester (0.36 mmol), 106 mg of sodium carbonate (1.00 mmol) and 19 mg of tetrakis (triphenylphosphine) palladium (0.02 mmol) presented in 7 ml of degassed dimethylformamide / water mixture. The mixture was heated for 4 h at 100 ° C. The cooled mixture was mixed with water. The precipitate was filtered off and washed with water and dichloromethane. A beige solid was obtained.
Smp.: 281-283 °CMp: 281-283 ° C
ESI-MS: gef. m/z = 409.4 (M + H+); ber. 408 amuESI-MS: gef. m / z = 409.4 (M + H + ); ber. 408 amu
1H-NMR (d6-DMSO): δ = 1.20 (t, 3H), 1.52 (s, 9H), 3.25 - 3.38 (m, 2H), 7.65 (d, 1 H), 7.69 (d, 2H), 8.29 (d, 2H), 8.33 (d, 1 H), 9.09 (bs, 1 H), 9.41 (s, 1 H), 9.72 (s, 1 H), 10.09 (s, 1 H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 1.52 (s, 9H), 3.25-3.338 (m, 2H), 7.65 (d, 1H), 7.69 (d, 2H) , 8.29 (d, 2H), 8.33 (d, 1H), 9.09 (bs, 1H), 9.41 (s, 1H), 9.72 (s, 1H), 10.09 (s, 1H) ppm.
Folgende Beispiele wurden gemäß Beispiel 43 und der allgemeinen Synthesevorschriften synthetisiert: Beispiel 44:The following examples were synthesized according to Example 43 and the general synthesis instructions: Example 44:
{4-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyraziri-3-yl]-phenyl}-carbaminsäure-2-methoxy- ethyl-ester (Verbindung 22){4- [6- (3-Ethyl-urea) -pyrido [2,3-b] pyraziri-3-yl] -phenyl} -carbamic acid 2-methoxy-ethyl-ester (Compound 22)
Smp.: 249-251 °CMp .: 249-251 ° C
ESI-MS: gef. m/z = 411.3 (M + H+); ber. 410 amuESI-MS: gef. m / z = 411.3 (M + H + ); ber. 410 amu
1H-NMR (de-DMSO): δ = 1.20 (t, 3H), 3.31 (s, 3H), 3.45 - 3.38 (m, 2H), 3.58 - 3.64 (m, 2H), 4.24 - 4.27 (m, 2H), 7.65 (d, 1 H), 7.70 (d, 2H), 8.31 (d, 2H), 8.37 (d, 1 H), 9.08 (bs, 1 H), 9.41 (s, 1 H), 10.09 (s, 1 H), 10.11 (s, 1 H) ppm. 1 H-NMR (de-DMSO): δ = 1.20 (t, 3H), 3.31 (s, 3H), 3.45 - 3.38 (m, 2H), 3.58 - 3.64 (m, 2H), 4.24 - 4.27 (m, 2H), 7.65 (d, 1H), 7.70 (d, 2H), 8.31 (d, 2H), 8.37 (d, 1H), 9.08 (bs, 1H), 9.41 (s, 1H), 10.09 (s, 1H), 10.11 (s, 1H) ppm.
Beispiel 45:Example 45:
1-Ethyl-3-{3-[4-(3-ethyl-harnstoff)-phenyl]-pyrido[2,3-b]pyrazin-6-yl}-harnstoff (Verbindung 23)1-Ethyl-3- {3- [4- (3-ethyl-urea) -phenyl] -pyrido [2,3-b] pyrazine-6-yl} -urea (Compound 23)
Smp.: > 350 °C (Zers.)Mp .:> 350 ° C (decomp.)
ESI-MS: gef. m/z = 380.2 (M + H+); ber. 379 amuESI-MS: gef. m / z = 380.2 (M + H + ); About 379 amu
1H-NMR (de-DMSO): δ = 1.08 (t, 3H), 1.20 (t, 3H), 3.14 (quint, 2H), 3.32 - 3.38 (m, 2H), 6.33 (t, 1 H), 7.60-7.64 (m, 3H), 8.25 (d, 2H), 8.32 (d, 1 H), 8.88 (s, 1 H), 9.12 (bs, 1 H), 9.39 (s, 1 H), 10.06 (s, 1 H) ppm. 1 H-NMR (de-DMSO): δ = 1:08 (t, 3H), 1.20 (t, 3H), 3.14 (quint, 2H), 3:32 to 3:38 (m, 2H), 6:33 (t, 1 H), 7.60-7.64 (m, 3H), 8.25 (d, 2H), 8.32 (d, 1H), 8.88 (s, 1H), 9.12 (bs, 1H), 9.39 (s, 1H), 10.06 ( s, 1 H) ppm.
Beispiel 46:Example 46:
1-{3-[4-(3,3-Dimethyl-harnstoff)-phenyl]-pyrido[2,3-b]pyrazin-6-yl}-3-ethyl-harnstoff (Verbindung 24)1- {3- [4- (3,3-Dimethyl-urea) -phenyl] -pyrido [2,3-b] pyrazine-6-yl} -3-ethyl-urea (Compound 24)
Smp.: > 350 °CMp .:> 350 ° C
ESI-MS: gef. m/z = 380.3 (M + H+); ber. 379 amuESI-MS: gef. m / z = 380.3 (M + H + ); About 379 amu
1H-NMR (d6-DMSO): δ = 1.20 (t, 3H), 2.98 (s, 6H), 3.25 - 3.38 (m, 2H), 7.63 (d, 1 H), 7.74 (d, 2H), 8.26 (d, 2H), 8.33 (d, 1 H), 8.63 (s, 1 H), 9.12 (bs, 1 H), 9.41 (s, 1 H), 10.07 (s, 1 H) ppm. Beispiel 47: 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 2.98 (s, 6H), 3.25-3.338 (m, 2H), 7.63 (d, 1 H), 7.74 (d, 2H) , 8.26 (d, 2H), 8.33 (d, 1H), 8.63 (s, 1H), 9.12 (bs, 1H), 9.41 (s, 1H), 10.07 (s, 1H) ppm. Example 47:
1-Ethyl-3-{3-[6-(3-ethyl-harnstoff)-pyridin-3-yl]-pyrido[2,3-b]pyrazin-6-yl}-harnstoff (Verbindung 25)1-Ethyl-3- {3- [6- (3-ethyl-urea) -pyridin-3-yl] -pyrido [2,3-b] pyrazine-6-yl} -urea (Compound 25)
ESI-MS: gef. m/z = 381.2 (M + H+); ber. 380 amuESI-MS: gef. m / z = 381.2 (M + H + ); About 380 amu
1H-NMR (de-DMSO): δ = 1.13 (t, 3H), 1.20 (t, 3H), 3.23 (quint, 2H), 3.25 - 3.38 (m, 2H), 7.63 (d, 1 H), 7.67 (d, 1 H), 8.25 (d, 1 H), 8.00 (bs, 1 H), 8.35 (d, 1 H), 8.61 (d, 1 H), 9.08 (bs, 1 H), 9.17 (s, 1 H), 9.44 (s, 1 H), 9.55 (s, 1 H), 10.12 (s, 1 H) ppm. 1 H-NMR (de-DMSO): δ = 1.13 (t, 3H), 1.20 (t, 3H), 3.23 (quint, 2H), 3.25-3.338 (m, 2H), 7.63 (d, 1 H), 7.67 (d, 1H), 8.25 (d, 1H), 8.00 (bs, 1H), 8.35 (d, 1H), 8.61 (d, 1H), 9.08 (bs, 1H), 9.17 ( s, 1H), 9.44 (s, 1H), 9.55 (s, 1H), 10.12 (s, 1H) ppm.
Beispiel 48:Example 48:
1-Ethyl-3-[3-(4-morpholin-4-ylmethyl-phenyl)-pyrido[2,3-b]pyrazin-6-yl]-harnstoff (Verbindung 28)1-Ethyl-3- [3- (4-morpholin-4-ylmethyl-phenyl) -pyrido [2,3-b] pyrazine-6-yl] -urea (Compound 28)
ESI-MS: gef. m/z = 393.4 (M + H+); ber. 392 amuESI-MS: gef. m / z = 393.4 (M + H + ); ber. 392 amu
1H-NMR (de-DMSO): δ = 1.20 (t, 3H), 2.41 (bs, 4H), 3.33 - 3.38 (m, 2H), 3.58 (s, 2H), 3.61 (t, 4H), 7.55 (d, 2H), 7.69 (t, 1 H), 8.30 (d, 2H), 8.37 (d, 1 H), 9.10 (bs, 1 H), 9.44 (s, 1 H), 10.13 (s, 1 H) ppm. 1 H NMR (de-DMSO): δ = 1.20 (t, 3H), 2.41 (bs, 4H), 3.33-3.338 (m, 2H), 3.58 (s, 2H), 3.61 (t, 4H), 7.55 (d, 2H), 7.69 (t, 1H), 8.30 (d, 2H), 8.37 (d, 1H), 9.10 (bs, 1H), 9.44 (s, 1H), 10.13 (s, 1 H) ppm.
Beispiel 49:Example 49:
N-{4-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl}-2-(2-methoxy-ethoxy)- acetamid (Verbindung 30)N- {4- [6- (3-Ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl} -2- (2-methoxyethoxy) -acetamide (Compound 30)
Smp.: 212-215 °C ESI-MS: gef. m/z = 425.2 (M + H+); ber. 424 amuMp: 212-215 ° C ESI-MS: gef. m / z = 425.2 (M + H + ); ber. 424 amu
1H-NMR (d6-DMSO): δ = 1.20 (t, 3H), 3.32 (s, 3H), 3.34 - 3.38 (m, 2H), 3.56 (dd, 2H), 3.71 (dd, 2H), 4.15 (s, 2H), 7.66 (d, 1 H), 7.89 (d, 2H), 8.33-8.36 (m, 3H), 9.11 (bs, 1 H), 9.43 (s, 1 H), 9.97 (s, 1 H), 10.1 1 (s, 1 H) ppm. Beispiel 50: 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.32 (s, 3H), 3.34-3.338 (m, 2H), 3.56 (dd, 2H), 3.71 (dd, 2H), 4.15 (s, 2H), 7.66 (d, 1H), 7.89 (d, 2H), 8.33-8.36 (m, 3H), 9.11 (bs, 1H), 9.43 (s, 1H), 9.97 (s , 1H), 10.1 1 (s, 1H) ppm. Example 50:
2-Benzyloxy-N-{4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl}-acetamid (Verbindung 35)2-Benzyloxy-N- {4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl} -acetamide (Compound 35)
Smp.: 254-256 °CMp: 254-256 ° C
ESI-MS: gef. m/z = 457.3 (M + H+); ber. 456 amuESI-MS: gef. m / z = 457.3 (M + H + ); ber. 456 amu
1H-NMR (de-DMSO): δ = 1.20 (t, 3H), 3.28 - 3.38 (m, 2H), 4.16 (s, 2H), 4.66 (s, 2H), 7.31 (t, 1 H), 7.33 (t, 1 H), 7.40 (t, 2H), 7.44 (d, 1 H), 7.66 (d, 1 H), 7.91 (d, 2H), 8.33-8.36 (m, 3H), 9.1 1 (bs, 1 H), 9.44 (s, 1 H), 10.10 (s, 1 H), 10.14 (s, 1 H) ppm. 1 H-NMR (de-DMSO): δ = 1.20 (t, 3H), 3.28-3.338 (m, 2H), 4.16 (s, 2H), 4.66 (s, 2H), 7.31 (t, 1H), 7.33 (t, 1H), 7.40 (t, 2H), 7.44 (d, 1H), 7.66 (d, 1H), 7.91 (d, 2H), 8.33-8.36 (m, 3H), 9.1 1 ( bs, 1H), 9.44 (s, 1H), 10.10 (s, 1H), 10.14 (s, 1H) ppm.
Beispiel 51 :Example 51:
1-Ethyl-3-[3-(3-trimethylsilanyl-phenyl)-pyrido[2,3-b]pyrazin-6-yl]-harnstoff (Verbindung 46)1-Ethyl-3- [3- (3-trimethylsilanyl-phenyl) -pyrido [2,3-b] pyrazine-6-yl] -urea (Compound 46)
Smp.: 224-228 °CMp .: 224-228 ° C
ESI-MS: gef. m/z = 366.4 (M + H+); ber. 365 amuESI-MS: gef. m / z = 366.4 (M + H + ); About. 365 amu
1H-NMR (de-DMSO): δ = 0.35 (s, 9H), 1.21 (t, 3H), 3.28 - 3.38 (m, 2H), 7.60 (t, 1 H), 7.73 (t, 2H), 8.32 (d, 1 H), 8.37 (d, 1 H), 8.46 (s, 1 H), 9.04 (bs, 1 H), 9.48 (s, 1 H), 10.12 (s, 1 H) ppm. 1 H-NMR (de-DMSO): δ = 0.35 (s, 9H), 1.21 (t, 3H), 3.28-3.338 (m, 2H), 7.60 (t, 1H), 7.73 (t, 2H), 8.32 (d, 1H), 8.37 (d, 1H), 8.46 (s, 1H), 9.04 (bs, 1H), 9.48 (s, 1H), 10.12 (s, 1H) ppm.
Bei Beispiel 51 wurde Dioxan/Wasser anstelle von Dimethylformamid/Wasser als Lösungsmittel verwendet.In Example 51, dioxane / water was used instead of dimethylformamide / water as a solvent.
Nicht käufliche Boronsäure-Derivate wurden nach folgender Vorschrift oder dem Fachmann bekannten Verfahren hergestellt:Non-commercial boronic acid derivatives were prepared according to the following procedure or methods known to the person skilled in the art:
Herstellung von [4-(4,4,5,5-Tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-phenyl]- carbaminsäure-2-methoxy-ethyl-ester 107 mg 4-(4,4,5,5-Tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-phenylamin (0.48 mmol) wurden in Tetrahydrofuran gelöst. 96 mg 2-Methoxyethylchlorformiat (0.68 mmol) und 79 mg N-Methylmorpholin (0.78 mmol) wurden bei Raumtemperatur zugegeben. Man ließ das Reaktionsgemisch für 1 Tag bei Raumtemperatur rühren, filtrierte ausgefallenen Niederschlag ab und entfernte das Lösungsmittel im Vakuum. Man erhielt ein gelbliches Öl, das ohne weitere Reinigung in die nächste Reaktion eingesetzt wurde.Preparation of [4- (4,4,5,5-tetramethyl- [1,2,2] dioxaborolan-2-yl) -phenyl] -carbamic acid 2-methoxy-ethyl-ester 107 mg of 4- (4,4,5,5-tetramethyl- [1,2,2] dioxaborolan-2-yl) -phenylamine (0.48 mmol) were dissolved in tetrahydrofuran. 96 mg of 2-methoxyethyl chloroformate (0.68 mmol) and 79 mg of N-methylmorpholine (0.78 mmol) were added at room temperature. The reaction mixture was allowed to stir for 1 day at room temperature, filtered precipitated precipitate and the solvent removed in vacuo. A yellowish oil was obtained which was used without further purification in the next reaction.
Folgende Boronsäure-Derivate wurden gemäß der obigen Vorschrift oder dem Fachmann bekannten Verfahren hergestellt: 1 -Ethyl-3-[4-(4 ,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-phenyl]-harnstoffThe following boronic acid derivatives were prepared according to the above procedure or methods known to those skilled in the art: 1-Ethyl-3- [4- (4,5,5-tetramethyl- [1,2,2] dioxaborolan-2-yl) - phenyl] -urea
1 ,1-Dimethyl-3-[4-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-phenyl]-harnstoff 1-Ethyl-3-[5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pyridin-2-yl]-harnstoff1, 1-Dimethyl-3- [4- (4,4,5,5-tetramethyl- [1,2,2] dioxaborolan-2-yl) -phenyl] -urea 1-ethyl-3- [5- (1 4,4,5,5-tetramethyl- [1,2,2] dioxaborolan-2-yl) -pyridin-2-yl] -urea
2-(2-Methoxy-ethoxy)-N-[4-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-phenyl]- acetamid 2-Benzyloxy-N-[4-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-phenyl]-acetamid2- (2-methoxy-ethoxy) -N- [4- (4,4,5,5-tetramethyl- [1,2,2] dioxaborolan-2-yl) -phenyl] -acetamide 2-benzyloxy-N- [4- (4,4,5,5-tetramethyl- [1,2,2] dioxaborolan-2-yl) -phenyl] -acetamide
Beispiel 52:Example 52:
1-Ethyl-3-{3-[2-(4-fluor-phenyl)-ethyl]-pyrido[2,3-b]pyrazin-6-yl}-harnstoff (Verbindung 26)1-Ethyl-3- {3- [2- (4-fluoro-phenyl) -ethyl] -pyrido [2,3-b] pyrazine-6-yl} -urea (Compound 26)
Herstellung von 1 -Ethyl-3-{3-[2-(4-fluor-phenyl)-ethyl]-pyrido[2,3-b]pyrazin-6-yl}- harn stoffPreparation of 1-ethyl-3- {3- [2- (4-fluoro-phenyl) -ethyl] -pyrido [2,3-b] pyrazine-6-yl} -urea
108 mg 1-Ethyl-3-{3-[2-(4-fluor-phenyl)-vinyl]-pyrido[2,3-b]pyrazin-6-yl}-harnstoff (0.32 mmol) (Beispiel 27) wurden in heißem Ethanol gelöst. Es wurden 112 mg Ammonium- formiat (1.78 mmol) und 110 mg Palladium auf Kohle (10 %ig) zugegeben und das Reaktionsgemisch für 7.5 h unter Rückfluß erhitzt. Vom abgekühlten Reaktionsgemisch wurde der Katalysator abfiltriert und die Mutterlauge vom Lösungsmittel befreit. Das Rohprodukt wurde durch Säulenchromatographie an Kieselgel (Laufmittel Dich- lormethan/Methanol) gereinigt. Man erhielt einen gelben Feststoff. Smp.: 207-209 °C ESI-MS: gef. m/z = 340.2 (M + H+); ber. 339 amu108 mg of 1-ethyl-3- {3- [2- (4-fluoro-phenyl) -vinyl] -pyrido [2,3-b] pyrazine-6-yl} -urea (0.32 mmol) (Example 27) dissolved in hot ethanol. 112 mg of ammonium formate (1.78 mmol) and 110 mg of palladium on carbon (10% strength) were added and the reaction mixture was refluxed for 7.5 h. From the cooled reaction mixture, the catalyst was filtered off and the mother liquor was freed from the solvent. The crude product was purified by column chromatography on silica gel (dichloromethane / methanol eluent). A yellow solid was obtained. Mp: 207-209 ° C ESI-MS: gef. m / z = 340.2 (M + H + ); About 339 amu
1H-NMR (de-DMSO): δ = 1.20 (t, 3H), 3.12 (t, 2H), 3.25 - 3.38 (m, 4H), 7.10 (t, 2H), 7.32 (dd, 2H), 7.63 (d, 1 H), 8.31 (d, 1 H), 8.71 (s, 1 H), 9.09 (bs, 1 H), 10.06 (s, 1 H) ppm. 1 H NMR (de-DMSO): δ = 1.20 (t, 3H), 3.12 (t, 2H), 3.25-3.338 (m, 4H), 7.10 (t, 2H), 7.32 (dd, 2H), 7.63 (d, 1H), 8.31 (d, 1H), 8.71 (s, 1H), 9.09 (bs, 1H), 10.06 (s, 1H) ppm.
Beispiel 53:Example 53:
1-Ethyl-3-(3-{4-[2-(2-methoxy-ethoxy)-ethoxy]-phenyl}-pyrido[2,3-b]pyrazin-6-yl)- harnstoff (Verbindung 29)1-Ethyl-3- (3- {4- [2- (2-methoxy-ethoxy) -ethoxy] -phenyl} -pyrido [2,3-b] pyrazine-6-yl) -urea (Compound 29)
Herstellung von 1 -Ethyl-3-(3-{4-[2-(2-methoxy-ethoxy)-ethoxy]-phenyl}-pyrido[2,3- b]pyrazin-6-yl)-harnstoff (Umsetzung gemäß Schema 9)Preparation of 1-ethyl-3- (3- {4- [2- (2-methoxy-ethoxy) -ethoxy] -phenyl} -pyrido [2,3-b] pyrazin-6-yl) -urea (reaction according to Scheme 9)
29 mg Natriumhydrid (0.71 mmol) (60 %ige Suspension in Mineralöl) wurden in 4 ml getrocknetem Dimethylformamid vorgelegt. Bei 0 °C wurden 70 mg 1-Ethyl-3-[3-(4- hydroxy-phenyl)-pyrido[2,3-b]pyrazin-6-yl]-harnstoff (0.23 mmol) in 2.5 ml Dimethylformamid gelöst zugegeben. Das Gemisch wurde bei Raumtemperatur 1 h gerührt. An- schließend wurden 68 mg 1-Brom-2-(2-ethoxymethoxy)ethan (0.34 mmol) bei 0 °C zugegeben und das Reaktionsgemisch 17 h bei Raumtemperatur gerührt. Danach wurden nochmals 22 mg 1-Brom-2-(2-ethoxymethoxy)ethan (0.12 mmol) zugegeben und das Reaktionsgemisch bei 80 °C für 2h gerührt. Zum abgekühlten Reaktionsgemisch wurde Wasser gegeben und die wässrige Phase mit Dichlormethan extrahiert. Nach Trocknung der organischen Phase über Natriumsulfat wurde das Lösungsmittel entfernt und das Rohprodukt durch Säulenchromatographie an Kieselgel (Laufmittel Dichlormethan/Methanol) gereinigt. Man erhielt einen gelben Feststoff.29 mg of sodium hydride (0.71 mmol) (60% suspension in mineral oil) were initially charged in 4 ml of dried dimethylformamide. At 0 ° C., 70 mg of 1-ethyl-3- [3- (4-hydroxy-phenyl) -pyrido [2,3-b] pyrazine-6-yl] -urea (0.23 mmol) dissolved in 2.5 ml of dimethylformamide were added in solution , The mixture was stirred at room temperature for 1 h. Subsequently, 68 mg of 1-bromo-2- (2-ethoxymethoxy) ethane (0.34 mmol) were added at 0 ° C. and the reaction mixture was stirred at room temperature for 17 h. Then another 22 mg of 1-bromo-2- (2-ethoxymethoxy) ethane (0.12 mmol) were added and the reaction mixture was stirred at 80 ° C. for 2 h. Water was added to the cooled reaction mixture, and the aqueous phase was extracted with dichloromethane. After drying the organic phase over sodium sulfate, the solvent was removed and the crude product was purified by column chromatography on silica gel (mobile phase dichloromethane / methanol). A yellow solid was obtained.
ESI-MS: gef. m/z = 412.3 (M + H+); ber. 41 1 amuESI-MS: gef. m / z = 412.3 (M + H + ); ber. 41 1 amu
1H-NMR (d6-DMSO): δ = 1.20 (t, 3H), 3.26 (s, 3H), 3.29 - 3.38 (m, 2H), 3.48 (dd, 2H), 3.62 (dd, 2H), 3.80 (dd, 2H), 4.22 (dd, 2H), 7.17 (d, 2H), 7.64 (t, 1 H), 8.31-8.35 (m, 3H), 9.14 (bs, 1 H), 9.42 (s, 1 H), 10.09 (s, 1 H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.26 (s, 3H), 3.29-3.338 (m, 2H), 3.48 (dd, 2H), 3.62 (dd, 2H), 3.80 (dd, 2H), 4.22 (dd, 2H), 7.17 (d, 2H), 7.64 (t, 1H), 8.31-8.35 (m, 3H), 9.14 (bs, 1H), 9.42 (s, 1H), 10.09 (s, 1H) ppm.
Beispiel 54:Example 54:
N-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-4-methyl-benzamid (Verbindung 31 ) Herstellung von N-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-4-methyl-benzamid (Umsetzung gemäß Schema 7)N- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -4-methyl-benzamide (Compound 31) Preparation of N- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -4-methylbenzamide (Reaction According to Scheme 7)
100 mg 1-(3-Amino-pyrido[2,3-b]pyrazin-6-yl)-3-ethyl-harnstoff (0.43 mmol) wurden in 5 ml getrocknetem Pyridin vorgelegt und 57 μl p-Tolylchlorid (0.43 mmol) zugetropft. Das Reaktionsgemisch wurde 2h bei 60 °C gerührt. Danach wurden nochmal 29 μl p- Tolylchlorid (0.22 mmol) zugetropft und das Reaktionsgemisch weitere 2h bei 60 °C gerührt. Das abgekühlte Reaktionsgemisch wurde auf Eiswasser gegeben, mit 1 N HCl neutral gestellt und der Feststoff abgesaugt. Das Rohprodukt wurde durch Säulenchromatographie an Kieselgel (Laufmittel Dichlormethan/Methanol) gereinigt. Man erhielt einen gelblichen Feststoff.100 mg of 1- (3-amino-pyrido [2,3-b] pyrazine-6-yl) -3-ethyl-urea (0.43 mmol) were initially charged in 5 ml of dried pyridine and 57 μl of p-tolyl chloride (0.43 mmol). dropwise. The reaction mixture was stirred at 60 ° C for 2 h. Thereafter, again 29 .mu.l of p-tolyl chloride (0.22 mmol) were added dropwise and the reaction mixture stirred for a further 2 h at 60 ° C. The cooled reaction mixture was added to ice-water, neutralized with 1 N HCl and the solid was filtered off with suction. The crude product was purified by column chromatography on silica gel (eluent dichloromethane / methanol). A yellowish solid was obtained.
ESI-MS: gef. m/z = 351.1 (M + H+); ber. 350 amuESI-MS: gef. m / z = 351.1 (M + H + ); About 350 amu
1H-NMR (d6-DMSO): δ = 1.18 (t, 3H), 2.42 (s, 3H), 3.31 (quint, 2H), 7.37 (d, 2H), 7.55 (d, 1 H), 8.04 (d, 2H), 8.31 (d, 1 H), 9.10 (bs, 1 H), 9.56 (s, 1 H), 9.96 (s, 1 H), 1 1.39 (bs, 1 H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.18 (t, 3H), 2.42 (s, 3H), 3.31 (quint, 2H), 7.37 (d, 2H), 7.55 (d, 1H), 8.04 (d, 2H), 8.31 (d, 1H), 9.10 (bs, 1H), 9.56 (s, 1H), 9.96 (s, 1H), 1.39 (bs, 1H) ppm.
Beispiel 55:Example 55:
1-[3-(4-Cyclohexyl-phenylamino)-pyrido[2,3-b]pyrazin-6-yl]-3-ethyl-harnstoff (Verbindung 47)1- [3- (4-Cyclohexyl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -3-ethyl-urea (Compound 47)
Herstellung von 1-[3-(4-Cyclohexyl-phenylamino)-pyrido[2,3-b]pyrazin-6-yl]-3-ethyl- harnstoff (Umsetzung gemäß Schema 3)Preparation of 1- [3- (4-cyclohexylphenylamino) -pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea (Reaction According to Scheme 3)
83 mg 1-(3-Chlor-pyrido[2,3-b]pyrazin-6-yl)-3-ethyl-harnstoff (0.33 mmol), 99 mg 4- Cyclohexylanilin (0.55 mmol), 30 mg Natrium-tert.-butylat (0.30 mmol), 29 mg Tris(dibenzylidenaceton)dipalladium(0) (0.03 mmol) und 68 mg 2- (Dicyclohexylphosphanyl)biphenyl (0.19 mmol) wurden in 1.5 ml getrocknetem Toluol vorgelegt. Das Reaktionsgemisch wurde unter Stickstoff in der Mikrowelle für 30 Minuten auf 100 °C erhitzt (100 Watt). Das Lösungsmittel wurde im Vakuum entfernt und das Rohprodukt durch Säulenchromatographie an Kieselgel (Laufmittel Dichlormethan/Methanol) gereinigt. Man erhielt einen gelben Feststoff. Smp.: 246-248 °C83 mg of 1- (3-chloro-pyrido [2,3-b] pyrazin-6-yl) -3-ethyl-urea (0.33 mmol), 99 mg of 4-cyclohexylaniline (0.55 mmol), 30 mg of sodium tert. -butylate (0.30 mmol), 29 mg of tris (dibenzylideneacetone) dipalladium (0) (0.03 mmol) and 68 mg of 2- (dicyclohexylphosphanyl) biphenyl (0.19 mmol) were initially charged in 1.5 ml of dried toluene. The reaction mixture was heated under nitrogen in the microwave for 30 minutes at 100 ° C (100 watts). The solvent was removed in vacuo and the crude product was purified by column chromatography on silica gel (mobile phase dichloromethane / methanol). A yellow solid was obtained. Mp .: 246-248 ° C
ESI-MS: gef. m/z = 391.3 (M + H+); ber. 390 amu 1H-NMR (de-DMSO): δ = 1.18 (t, 3H), 1.22-1.26 (m, 1 H), 1.33-1.44 (m, 4H), 1.71 (d, 1 H), 1.80 (d, 4H), 2.45-2.51 (m, 1 H), 3.25 - 3.30 (m, 2H), 7.22 (d, 2H), 7.40 (d, 1 H), 7.89 (d, 2H), 8.08 (d, 1 H), 8.37 (s, 1 H), 8.73 (bs, 1 H), 9.87 (s, 1 H), 10.06 (s, 1 H) ppm.ESI-MS: gef. m / z = 391.3 (M + H + ); About 390 amu 1 H-NMR (de-DMSO): δ = 1.18 (t, 3H), 1.22-1.26 (m, 1H), 1.33-1.44 (m, 4H), 1.71 (d, 1H), 1.80 (d, 4H), 2.45-2.51 (m, 1H), 3.25-3.30 (m, 2H), 7.22 (d, 2H), 7.40 (d, 1H), 7.89 (d, 2H), 8.08 (d, 1H ), 8.37 (s, 1H), 8.73 (bs, 1H), 9.87 (s, 1H), 10.06 (s, 1H) ppm.
Folgende Beispiele wurden gemäß Beispiel 55 und der allgemeinen Synthesevorschriften synthetisiert:The following examples were synthesized according to Example 55 and the general synthesis instructions:
Beispiel 56:Example 56:
1-Ethyl-3-[3-(4-methansulfonyl-phenylamino)-pyrido[2,3-b]pyrazin-6-yl]-harnstoff (Ver- bindung 48)1-Ethyl-3- [3- (4-methanesulfonyl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -urea (Compound 48)
Smp.: 275-280 °CMp: 275-280 ° C
ESI-MS: gef. m/z = 387.3 (M + H+); ber. 386 amuESI-MS: gef. m / z = 387.3 (M + H + ); About 386 amu
1H-NMR (de-DMSO): δ = 1.20 (t, 3H), 3.19 (s, 3H), 3.25 - 3.38 (m, 2H), 7.54 (d, 1 H), 7.92 (d, 2H), 8.16 (d, 1 H), 8.24 (d, 2H), 8.49 (s, 1 H), 8.62 (bs, 1 H), 9.93 (s, 1 H), 10.56 (s, 1 H) ppm. 1 H NMR (de-DMSO): δ = 1.20 (t, 3H), 3.19 (s, 3H), 3.25-3.338 (m, 2H), 7.54 (d, 1H), 7.92 (d, 2H), 8.16 (d, 1H), 8.24 (d, 2H), 8.49 (s, 1H), 8.62 (bs, 1H), 9.93 (s, 1H), 10.56 (s, 1H) ppm.
Beispiel 57:Example 57:
N-{5-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-ylamino]-2-methyl-phenyl}- methansulfonamid (Verbindung 49)N- {5- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazine-3-ylamino] -2-methyl-phenyl} -methanesulfonamide (Compound 49)
Smp.: 247-250 °CMp .: 247-250 ° C
ESI-MS: gef. m/z = 416.2 (M + H+); ber. 415 amuESI-MS: gef. m / z = 416.2 (M + H + ); ber. 415 amu
1H-NMR (d6-DMSO): δ = 1.17(t, 3H), 2.28 (s, 3H), 3.03 (s, 3H), 3.25 - 3.38 (m, 2H), 7.23 (d, 1 H), 7.33 (d, 1 H), 7.75 (d, 1 H), 8.06-8.09 (m, 2H), 8.37 (s, 1 H), 8.92 (bs, 1 H), 9.09 (s, 1 H), 9.77 (s, 1 H), 10.09 (s, 1 H) ppm. Beispiel 58: 1 H NMR (d 6 -DMSO): δ = 1.17 (t, 3H), 2.28 (s, 3H), 3.03 (s, 3H), 3.25-3.338 (m, 2H), 7.23 (d, 1H) , 7.33 (d, 1H), 7.75 (d, 1H), 8.06-8.09 (m, 2H), 8.37 (s, 1H), 8.92 (bs, 1H), 9.09 (s, 1H), 9.77 (s, 1H), 10.09 (s, 1H) ppm. Example 58:
3-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-ylamino]-N-methyl-benzamid (Verbindung 50)3- [6- (3-Ethyl-urea) -pyrido [2,3-b] pyrazine-3-ylamino] -N-methyl-benzamide (Compound 50)
Smp.: 228-234 °CMp: 228-234 ° C
ESI-MS: gef. m/z = 366.4 (M + H+); ber. 365 amuESI-MS: gef. m / z = 366.4 (M + H + ); About. 365 amu
1H-NMR (de-DMSO): δ = 1.19 (t, 3H), 2.80 (d, 3H), 3.25 - 3.38 (m, 2H), 7.39-7.48 (m, 3H), 8.09 - 8.11 (m, 2H), 8.41 (s, 2H), 8.46 (s, 1 H), 8.83 (bs, 1 H), 9.86 (s, 1 H), 10.22 (s, 1 H) ppm. 1 H-NMR (de-DMSO): δ = 1.19 (t, 3H), 2.80 (d, 3H), 3.25-3.338 (m, 2H), 7.39-7.48 (m, 3H), 8.09-8.11 (m, 2H), 8.41 (s, 2H), 8.46 (s, 1H), 8.83 (bs, 1H), 9.86 (s, 1H), 10.22 (s, 1H) ppm.
Beispiel 59:Example 59:
1-Ethyl-3-[3-(4-piperidin-1-ylmethyl-phenylamino)-pyrido[2,3-b]pyrazin-6-yl]-harnstoff (Verbindung 51 )1-Ethyl-3- [3- (4-piperidin-1-ylmethyl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -urea (Compound 51)
Smp.: 221-224 °CMp: 221-224 ° C
ESI-MS: gef. m/z = 406.4 (M + H+); ber. 405 amuESI-MS: gef. m / z = 406.4 (M + H + ); About 405 amu
1H-NMR (de-DMSO): δ = 1.19 (t, 3H), 1.39 (bs, 2H), 1.49 (quint, 4H), 2.32 (bs, 4H), 3.25 - 3.35 (m, 2H), 3.39 (s, 2H), 7.27 (d, 2H), 7.39 (d, 1 H), 7.92 (d, 2H), 8.08 (d, 1 H), 8.38 (s, 1 H), 8.78 (bs, 1 H), 9.82 (s, 1 H), 10.05 (s, 1 H) ppm. 1 H-NMR (de-DMSO): δ = 1.19 (t, 3H), 1.39 (bs, 2H), 1.49 (quint, 4H), 2.32 (bs, 4H), 3.25-3.35 (m, 2H), 3.39 (s, 2H), 7.27 (d, 2H), 7.39 (d, 1H), 7.92 (d, 2H), 8.08 (d, 1H), 8.38 (s, 1H), 8.78 (bs, 1H ), 9.82 (s, 1H), 10.05 (s, 1H) ppm.
Beispiel 60:Example 60:
1-Ethyl-3-[3-(4-thiophen-3-yl-phenylamino)-pyrido[2,3-b]pyrazin-6-yl]-harnstoff (Verbindung 52)1-Ethyl-3- [3- (4-thiophen-3-yl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -urea (Compound 52)
Smp.: 264-267 °CMp: 264-267 ° C
ESI-MS: gef. m/z = 391.4 (M + H+); ber. 390 amuESI-MS: gef. m / z = 391.4 (M + H + ); About 390 amu
1H-NMR (d6-DMSO): δ = 1.21 (t, 3H), 3.25 - 3.35 (m, 2H), 7.47 (d, 1 H), 7.58 (d, 1 H), 7.65 (dd, 1 H), 7.74 (d, 2H), 7.82 (d, 1 H), 8.05 (d, 2H), 8.11 (d, 1 H), 8.42 (s, 1 H), 8.62 (bs, 1 H), 9.86 (s, 1 H), 10.18 (s, 1 H) ppm. Beispiel 61 : 1 H NMR (d 6 -DMSO): δ = 1.21 (t, 3H), 3.25-3.35 (m, 2H), 7.47 (d, 1 H), 7.58 (d, 1 H), 7.65 (dd, 1 H), 7.74 (d, 2H), 7.82 (d, 1H), 8.05 (d, 2H), 8.11 (d, 1H), 8.42 (s, 1H), 8.62 (bs, 1H), 9.86 (s, 1H), 10.18 (s, 1H) ppm. Example 61:
N-{4-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-ylamino]-phenyl}-acetamid (Verbindung 53)N- {4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazine-3-ylamino] -phenyl} -acetamide (Compound 53)
ESI-MS: gef. m/z = 366.2 (M + H+); ber. 365 amuESI-MS: gef. m / z = 366.2 (M + H + ); About. 365 amu
1H-NMR (de-DMSO): δ = 1.20 (t, 3H), 2.03 (s, 3H), 3.25 - 3.35 (m, 2H), 7.27 (d, 1 H), 7.34 (d, 2H), 7.57 (d, 2H), 7.90 (d, 1 H), 8.07 (d, 1 H), 8.94 (bs, 1 H), 9.79 (s, 1 H), 9.89 (s, 1 H), 10.03 (s, 1 H) ppm. 1 H-NMR (de-DMSO): δ = 1.20 (t, 3H), 2:03 (s, 3H), 3:25 to 3:35 (m, 2H), 7.27 (d, 1 H), 7:34 (d, 2H), 7.57 (d, 2H), 7.90 (d, 1H), 8.07 (d, 1H), 8.94 (bs, 1H), 9.79 (s, 1H), 9.89 (s, 1H), 10.03 (s , 1 H) ppm.
Beispiel 62:Example 62:
3-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-ylamino]-benzoesäure-ethyl-ester (Verbindung 54)3- [6- (3-Ethyl-urea) -pyrido [2,3-b] pyrazine-3-ylamino] -benzoic acid ethyl ester (Compound 54)
Smp.: 252-255 °CMp: 252-255 ° C
ESI-MS: gef. m/z = 381.3 (M + H+); ber. 380 amuESI-MS: gef. m / z = 381.3 (M + H + ); About 380 amu
1H-NMR (de-DMSO): δ = 1.19 (t, 3H), 1.35 (t, 3H), 3.25 - 3.35 (m, 2H), 4.35 (q, 2H), 7.40 (d, 1 H), 7.52 (t, 1 H), 7.64 (d, 1 H), 8.12 (d, 1 H), 8.29 (d, 1 H), 8.41 (s, 1 H), 8.62 (s, 1 H), 8.90 (bs, 1 H), 9.86 (s, 1 H), 10.31 (s, 1 H) ppm. 1 H-NMR (de-DMSO): δ = 1.19 (t, 3H), 1.35 (t, 3H), 3.25-3.35 (m, 2H), 4.35 (q, 2H), 7.40 (d, 1 H), 7.52 (t, 1H), 7.64 (d, 1H), 8.12 (d, 1H), 8.29 (d, 1H), 8.41 (s, 1H), 8.62 (s, 1H), 8.90 ( bs, 1H), 9.86 (s, 1H), 10.31 (s, 1H) ppm.
Beispiel 63:Example 63:
Kohlensäure-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl-ester-2-methoxy- ethyl-ester Hydrochlorid (Verbindung 55)Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl-ester-2-methoxy-ethyl-ester hydrochloride (Compound 55)
Herstellung von Kohlensäure-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl- ester-2-methoxy-ethyl-ester HydrochloridPreparation of carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl-ester 2-methoxy-ethyl-ester hydrochloride
21 mg Kohlensäure-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl-ester-2- methoxy-ethyl-ester (0.05 mmol) (Beispiel 10) wurden in 2.5 ml Dichlor- methan/Methanol (2:1 ) gelöst. Es wurden 0.02 ml 5-6N HCI-Lösung in 2-Propanol zu- gegeben und das Gemisch bei Raumtemperatur 1 Tag gerührt. Danach wurde das Lösungsmittel entfernt. Man erhielt einen gelben Feststoff.21 mg carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl-ester-2-methoxy-ethyl-ester (0.05 mmol) (Example 10 ) were dissolved in 2.5 ml of dichloromethane / methanol (2: 1). 0.02 ml of 5-6N HCl solution in 2-propanol were added. and the mixture stirred at room temperature for 1 day. Thereafter, the solvent was removed. A yellow solid was obtained.
Smp.: 190-193 °CMp .: 190-193 ° C
1H-NMR (d6-DMSO): δ = 1.20 (t, 3H), 3.31 - 3.35 (m, 5H), 3.63-3.66 (m, 2H), 4.37 (dd, 2H), 7.50 (d, 2H), 7.70 (d, 1 H), 8.38 (d, 1 H), 8.41 (d, 2H), 9.09 (bs, 1 H), 9.47 (s, 1 H), 10.14 (s, 1 H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 3.31-3.35 (m, 5H), 3.63-3.66 (m, 2H), 4.37 (dd, 2H), 7.50 (d, 2H ), 7.70 (d, 1H), 8.38 (d, 1H), 8.41 (d, 2H), 9.09 (bs, 1H), 9.47 (s, 1H), 10.14 (s, 1H) ppm.
Beispiel 64:Example 64:
Kohlensäure-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl-ester-2-methoxy- ethyl-ester p-Toluolsulfonat (Verbindung 56)Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl-ester-2-methoxy-ethyl-ester p-toluenesulfonate (Compound 56)
Herstellung von Kohlensäure-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl- ester-2-methoxy-ethyl-ester p-ToluolsulfonatPreparation of carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl-ester 2-methoxy-ethyl-ester p-toluenesulfonate
48 mg Kohlensäure-4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl-ester-2- methoxy-ethyl-ester (0.12 mmol) wurden in 4 ml Dichlormethan und 0.7 ml Methanol vorgelegt. 23 mg p-Toluolsulfonsäure Monohydrat (0.12 mmol) wurden in 2 ml Dichlormethan und 0.5 ml Methanol gelöst bei Raumtemperatur zugegeben. Das Reaktionsgemisch wurde 1 h bei 0 °C und 1 Tag bei Raumtemperatur gerührt. Das Lösungsmittel wurde entfernt und der Rückstand aus Dichlormethan/n-Heptan umkristallisiert. Das ausgefallene Produkt wurde abgesaugt und mit n-Heptan gewaschen. Man erhielt einen gelben Feststoff.48 mg of carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl-ester-2-methoxy-ethyl-ester (0.12 mmol) were dissolved in 4 ml of dichloromethane and 0.7 ml of methanol. 23 mg of p-toluenesulfonic acid monohydrate (0.12 mmol) were added in 2 ml of dichloromethane and 0.5 ml of methanol dissolved at room temperature. The reaction mixture was stirred at 0 ° C for 1 h and at room temperature for 1 day. The solvent was removed and the residue recrystallized from dichloromethane / n-heptane. The precipitated product was filtered off with suction and washed with n-heptane. A yellow solid was obtained.
Smp.: 145-147 °CMp .: 145-147 ° C
1H-NMR (d6-DMSO): δ = 1.20 (t, 3H), 2.29 (s, 3H), 3.30 - 3.36 (m, 5H), 3.64 (dd, 2H), 4.38 (dd, 2H), 7.11 (d, 2H), 7.47 (d, 2H), 7.50 (d, 2H), 7.70 (d, 1 H), 8.38 (d, 1 H), 8.41 (d, 2H), 9.09 (bs, 1 H), 9.47 (s, 1 H), 10.14 (s, 1 H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.20 (t, 3H), 2.29 (s, 3H), 3.30-3.36 (m, 5H), 3.64 (dd, 2H), 4.38 (dd, 2H), 7.11 (d, 2H), 7.47 (d, 2H), 7.50 (d, 2H), 7.70 (d, 1H), 8.38 (d, 1H), 8.41 (d, 2H), 9.09 (bs, 1H ), 9.47 (s, 1H), 10.14 (s, 1H) ppm.
Beispiel 65:Example 65:
Kohlensäure-4-{6-[3-(4-hydroxy-butyl)-harnstoff]-pyrido[2,3-b]pyrazin-3-yl}-phenyl- ester-2-methoxy-ethyl-ester Hydrochlorid (Verbindung 58) Herstellung von Kohlensäure-4-{6-[3-(4-hydroxy-butyl)-harnstoff]-pyrido[2,3-b]pyrazin- 3-yl}-phenyl-ester-2-methoxy-ethyl-ester HydrochloridCarbonic acid 4- {6- [3- (4-hydroxy-butyl) -urea] -pyrido [2,3-b] pyrazine-3-yl} -phenyl-ester 2-methoxy-ethyl-ester hydrochloride (Compound 58) Preparation of carbonic acid 4- {6- [3- (4-hydroxy-butyl) urea] -pyrido [2,3-b] pyrazine-3-yl} -phenyl-ester-2-methoxy-ethyl-ester hydrochloride
1 17 mg Kohlensäure-4-{6-[3-(4-(tert.-butyl-dimethyl-silanyloxy)-butyl)-harnstoff]- pyrido[2,3-b]pyrazin-3-yl}-phenyl-ester-2-methoxy-ethyl-ester (0.21 mmol) wurden in 40 ml vorgetrocknetem Dichlormethan gelöst. Es wurden 0.5 ml 5-6N HCI-Lösung in 2- Propanol zugegeben und das Reaktionsgemisch 15 Minuten bei Raumtemperatur gerührt. Die organische Phase wurde mit Wasser gewaschen, über Natriumsulfat getrocknet und eingeengt. Man erhielt einen gelben Feststoff.1 17 mg carbonic acid 4- {6- [3- (4- (tert-butyl-dimethyl-silanyloxy) -butyl) -urea] - pyrido [2,3-b] pyrazin-3-yl} -phenyl- Ester-2-methoxy-ethyl ester (0.21 mmol) was dissolved in 40 ml of predried dichloromethane. 0.5 ml of 5-6N HCl solution in 2-propanol were added and the reaction mixture was stirred for 15 minutes at room temperature. The organic phase was washed with water, dried over sodium sulfate and concentrated. A yellow solid was obtained.
Smp.: 165-168 °C ESI-MS: gef. m/z = 456.2 (M + H+); ber. 455 amuMp: 165-168 ° C ESI-MS: gef. m / z = 456.2 (M + H + ); ber. 455 amu
1H-NMR (d6-DMSO): δ = 1.61 (quint, 4H), 2.29 (s, 3H), 3.30 - 3.36 (m, 2H), 3.49 (t, 2H), 3.64 (dd, 2H), 4.38 (dd, 2H), 7.49 (d, 2H), 7.66 (d, 1 H), 8.38 (d, 1 H), 8.43 (d, 2H), 9.33 (bs, 1 H), 9.48 (s, 1 H), 10.17 (s, 1 H) ppm. 1 H NMR (d 6 -DMSO): δ = 1.61 (quint, 4H), 2.29 (s, 3H), 3.30-3.36 (m, 2H), 3.49 (t, 2H), 3.64 (dd, 2H), 4.38 (dd, 2H), 7.49 (d, 2H), 7.66 (d, 1H), 8.38 (d, 1H), 8.43 (d, 2H), 9.33 (bs, 1H), 9.48 (s, 1 H), 10.17 (s, 1H) ppm.
Für die Herstellung von Kohlensäure-4-{6-[3-(4-(tert.-butyl-dimethyl-silanyloxy)-butyl)- harnstoff]-pyrido[2,3-b]pyrazin-3-yl}-phenyl-ester-2-methoxy-ethyl-ester sei hiermit auf die Schemata 5, 6 und 8, die allgemeinen Synthesevorschriften und die dem Fachmann bekannten Verfahren verwiesen.For the preparation of carbonic acid 4- {6- [3- (4- (tert-butyl-dimethyl-silanyloxy) -butyl) -urea] -pyrido [2,3-b] pyrazin-3-yl} -phenyl ester 2-methoxy-ethyl ester is hereby referred to Schemes 5, 6 and 8, the general synthesis instructions and the methods known to those skilled in the art.
Beispiel 66:Example 66:
2,2-Dimethyl-propionsäure-(2,2-dimethyl-propionyloxymethoxy)-(4-{3-[3-(4-hydroxy-3- methoxy-phenyl)-pyrido[2,3-b]pyrazin-6-yl]-harnstoff}-butyl)-phosphinoyloxymethyl- ester (Verbindung 65)2,2-Dimethyl-propionic acid- (2,2-dimethyl-propionyloxymethoxy) - (4- {3- [3- (4-hydroxy-3-methoxyphenyl) -pyrido [2,3-b] pyrazine-6 -yl] -urea} -butyl) -phosphinoyloxymethyl ester (Compound 65)
Herstellung von 2,2-Dimethyl-propionsäure-(2,2-dimethyl-propionyloxymethoxy)-(4-{3- [3-(4-hydroxy-3-methoxy-phenyl)-pyrido[2,3-b]pyrazin-6-yl]-harnstoff}-butyl)- phosphinoyloxymethyl-esterPreparation of 2,2-dimethyl-propionic acid- (2,2-dimethyl-propionyloxymethoxy) - (4- {3- [3- (4-hydroxy-3-methoxyphenyl) -pyrido [2,3-b] pyrazine -6-yl] -urea} -butyl) - phosphinoyloxymethyl-ester
94 mg 4-{3-[3-(4-Hydroxy-3-methoxy-phenyl)-pyrido[2,3-b]pyrazin-6-yl]-harnstoff}- butyl)-phosphonsäure (0.20 mmol) wurden in 15 ml DMF gelöst, mit 360 μl_ Pivalinsäu- rechlor-methylester (2.40 mmol) und 30 μl_ Triethylamin (0.21 mmol) versetzt und für 10 h bei 60 °C gerührt. Der Reaktionsansatz wurde auf 50 ml_ Wasser gegossen und dreimal mit Ethylacetat extrahiert. Die vereinigten organischen Phasen wurden über MgSO4 getrocknet und das Lösungsmittel im Vakuum entfernt. Der Rückstand wurde anschließend durch Säulenchromatographie aufgereinigt (Laufmittel Dichlor- methan/Methanol). Es wurde ein beiger Feststoff isoliert.94 mg of 4- {3- [3- (4-hydroxy-3-methoxy-phenyl) -pyrido [2,3-b] pyrazine-6-yl] -urea} -butyl) -phosphonic acid (0.20 mmol) were added in Dissolve 15 ml of DMF, add 360 μl of pivalic acid methyl ester (2.40 mmol) and 30 μl of triethylamine (0.21 mmol) and dissolve Stirred at 60 ° C for 10 h. The reaction was poured into 50 ml of water and extracted three times with ethyl acetate. The combined organic phases were dried over MgSO 4 and the solvent removed in vacuo. The residue was then purified by column chromatography (eluent dichloromethane / methanol). A beige solid was isolated.
ESI-MS: gef. m/z = 676.4 (M + H+); ber. 675 amuESI-MS: gef. m / z = 676.4 (M + H + ); ber. 675 amu
1H-NMR (de-DMSO): δ = 1.12 (s, 18H), 1.57-1.68 (m, 4 H), 1.90-1.97 (m, 2 H), 3.28- 3.31 (m, 3.93 (s, 3 H), 5.54-5.59 (m, 4H), 6.97 (d, 1 H), 7.64 (d, 1 H), 7.86 (dd, 1 H), 7.91 (d, 1 H), 8.32 (d, 1 H), 9.08 (s, 1 H), 9.41 (s, 1 H), 9.70 (s, 1 H), 10.06 (s, 1 H) ppm. 1 H NMR (de-DMSO): δ = 1.12 (s, 18H), 1.57-1.68 (m, 4H), 1.90-1.97 (m, 2H), 3.28-3.31 (m, 3.93 (s, 3 H), 5.54-5.59 (m, 4H), 6.97 (d, 1H), 7.64 (d, 1H), 7.86 (dd, 1H), 7.91 (d, 1H), 8.32 (d, 1H ), 9.08 (s, 1H), 9.41 (s, 1H), 9.70 (s, 1H), 10.06 (s, 1H) ppm.
II) Biologische Wirkungen der erfindungsgemäßen VerbindungenII) Biological effects of the compounds of the invention
11.1 ) Zellfreie Kinaseassays (mittels ALPHA-Technologie)11.1) Cell-free kinase assays (using ALPHA technology)
Die inhibitorische Wirkung der erfindungsgemäßen Verbindungen wurde an diversen humanen Serin/Threonin-, Tyrosin- und Lipidkinasen in enzymatischen Assays getestet. Dabei wurden rekombinante humane Kinasen wie z.B. Erk2, PI3Kalpha, -beta, - gamma, -delta, p38alpha, p38gamma, Jnk1 , Jnk2 und andere eingesetzt, teils als VoII- längenkinasen, teils als verkürzte Fragmente - mindestens aber bestehend aus der funktionellen Kinasedomäne. Die käuflichen Kinaseproteine (Proqinase, Upstate) wurden als rekombinante Fusionsproteine mit GST-(Glutathion-S-Transferase) oder His- Tag eingesetzt. Je nach Substrattyp wurden die verschiedenen Kinasereaktionen mittels geeigneter ALPHA™-beads (PerkinElmer) quantifiziert.The inhibitory activity of the compounds according to the invention was tested on various human serine / threonine, tyrosine and lipid kinases in enzymatic assays. Recombinant human kinases, e.g. Erk2, PI3Kalpha, -beta, - gamma, -delta, p38alpha, p38gamma, Jnk1, Jnk2 and others, partly as full-length kinases, partly as truncated fragments - but at least consisting of the functional kinase domain. The commercially available kinase proteins (Proqinase, Upstate) were used as recombinant fusion proteins with GST (glutathione-S-transferase) or His-tag. Depending on the type of substrate, the different kinase reactions were quantified by means of suitable ALPHA ™ beads (PerkinElmer).
TestunqTestunq
Nachfolgend wird die Substanztestung am Erk-Assay genauer beschrieben. Ausgewählte Testergebnisse der Erk2-, PI3Kalpha-Assays sind unten aufgeführt. Zur Bestimmung des I C50-Wert.es wurden die potenziellen Inhibitorsubstanzen bei 10 halblo- garitmisch abgestuften Konzentration von 3.16nM-100μM untersucht.The substance testing on the Erk assay is described in more detail below. Selected test results of the Erk2, PI3Kalpha assays are listed below. To determine the IC 50 value, the potential inhibitor substances were examined at a hemogarithmically graded concentration of 3.16 nM-100 μM.
a) Erk2-ALPHA: Die Testsubstanz, 0.625ng Erk2 (#14-173, Upstate), 10μM ATP und 15nM biotinyliertem MBP (myelin basic protein )-Substrat wurden auf einer 384er Optiplate (PerkinElmer) in einem Volumen von 15μl für 1 h in 25mM Tris, 1OmM MgCI2, 0.1 % Tween-20, 100μM NaVO4, 2mM DTT bei pH 7.5 inkubiert. Anschlie- ßend wurde die Kinasereaktion durch Zugabe von 10μl des mit anti-phospho MBP-a) Erk2-ALPHA: The test substance, 0.625ng Erk2 (# 14-173, Upstate), 10μM ATP and 15nM biotinylated MBP (myelin basic protein) substrate were spiked on a 384 Optiplate (PerkinElmer) in a volume of 15μl for 1 h in 25mM Tris, 10mM MgCl 2 , 0.1% Tween-20, 100μM NaVO 4 , 2mM DTT at pH 7.5. The kinase reaction was then terminated by addition of 10 μl of the anti-phospho MBP
Antikörpers (32OpM, #05-429/ Upstate) präinkubierten ALPHA-Beadmixes (10μg/ml, #6760617/ PerkinElmer) in 25mM Tris, 20OmM NaCI, 10OmM EDTA und 0.3% BSA abgestoppt und über Nacht stehen gelassen. b) PI3K-ALPHAs (z.B. PI3Kalpha): Die Testsubstanz, 1 ng PI3Kalpha (#14-602, Upstate), 100μM ATP und 20μM PIP2-Substrat (#P4508, Echelon) auf einer 384erAntibody (32OpM, # 05-429 / Upstate) pre-incubated ALPHA bead mix (10 μg / ml, # 6760617 / PerkinElmer) in 25 mM Tris, 20 mM NaCl, 10 mM EDTA and 0.3% BSA and allowed to stand overnight. b) PI3K-ALPHAs (eg PI3Kalpha): The test substance, 1 ng PI3Kalpha (# 14-602, Upstate), 100μM ATP and 20μM PIP 2 substrate (# P4508, Echelon) on a 384er
Optiplate (PerkinElmer) für 1 h in 5OmM Hepes, 5OmM NaCI, 5mM MgCI2, 0.05% Chaps, 5mM DTT bei pH 7.4 inkubiert. Anschließend wurde die Kinasereaktion durch Zugabe des mit 1 nM GST:Grp1-Fusionsprotein (Upstate) und 15nM biotiny- liertem PIP3 (#C-39B6/ Echelon) präinkubierten ALPHA-Beadmixes (10μg/ml, #6760603/ PerkinElmer) in 5OmM Hepes, 5OmM NaCI, 5OmM EDTA und 0.1 % BSA abgestoppt und über Nacht stehen gelassen.Optiplate (PerkinElmer) for 1 h in 50 mM Hepes, 50 mM NaCl, 5 mM MgCl 2 , 0.05% chaps, 5 mM DTT at pH 7.4. Subsequently, the kinase reaction by adding the ALPHA bead mix (10 μg / ml, # 6760603 / PerkinElmer) preincubated with 1 mM GST: Grp1 fusion protein (UPSTATE) and 15 mM biotinylated PIP3 (# C-39B6 / Echelon) in 50 mM Hepes, 50 mM NaCl, 50 mM EDTA and 0.1% BSA stopped and allowed to stand overnight.
Die Fluoreszenzdetektion erfolgte am nächsten Morgen in einem Fusion™alpha-Gerät (PerkinElmer).Fluorescence detection was performed the next morning in a Fusion ™ alpha device (PerkinElmer).
Auswertung Die Berechnung der %-lnhibitionswerte je Substanz-Konzentration geschah mittels folgender Formel aus den im Fusion™alpha ermittelten Rohdaten:Evaluation The calculation of the% inhibition values per substance concentration was carried out using the following formula from the raw data determined in the Fusion ™ alpha:
Mittelwerte . , - Mittelwert m„ „ , „ , % Kinase Inhibition^, „ , = 100 - 100* ff ' (0%κO n tto i k) (Prob.) , Mittelwert(100% Kontio]k) - Mittelwert (0%KoπtIolk) Mean values. , - mean m "", ",% kinase inhibition ^ ,", = 100 - 100 * ff ' (0% κ O n tto i k) (Prob . ) , Mean (100% Kontio] k) - mean (0% KoπtIolk)
Die Kontrollen wurden jeweils δfach, die Substanzproben jeweils 2fach bestimmt. Die 0%-Kontrolle enthielt entweder kein ATP oder kein Substrat, die 100%-Kontrolle enthielt keine Testsubstanz. Die IC50-Werte wurden mit GraphPadPrism ermittelt.The controls were each δfach, the substance samples each determined 2 times. The 0% control contained either no ATP or no substrate, the 100% control contained no test substance. The IC 50 values were determined with GraphPadPrism.
Die erfindungsgemäßen Verbindungen zeigten eine effektive Inhibition von Erk, PI3K, p38alpha und Jnk1 + Jnk2 mit IC50-Werten bis zu 88nM (siehe Tabelle 1 ). The compounds according to the invention showed an effective inhibition of Erk, PI3K, p38alpha and Jnk1 + Jnk2 with IC 50 values up to 88 nM (see Table 1).
Tabelle 1 : MAPK und PI3Kalpha Kinaseassay Versuchsergebnisse (IC50 [μM] bei 10μM bzw. 100μM* ATP)Table 1: MAPK and PI3Kalpha kinase assay results (IC50 [μM] at 10μM and 100μM * ATP, respectively)
11.2) Zellulärer Assay: Testung auf anti-proliferative Wirkung (XTT-Assay) 11.2) Cellular Assay: Testing for Anti-proliferative Effect (XTT Assay)
Das Prinzip dieses Testes beruht auf der intrazellulären Reduktion des Tetrazolium- Farbstoffes XTT (Natrium 3'-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy- 6-nitro)benzensulfonsäure, Sigma) zu einem Formazan-Farbstoff durch mitochondriale Dehydrogenasen. Der Farbstoff wird nur von stoffwechselaktiven Zellen gebildet, seine photometrisch messbare Intensität ist ein quantitativer Indikator für das Vorhandensein lebender Zellen. Die Reduzierung der Farbstoffbildung durch Inkubation der Zellen mit Substanzen dient als Parameter für die anti-proliferative Wirkung.The principle of this assay is based on the intracellular reduction of the tetrazolium dye XTT (sodium 3 '- [1- (phenylaminocarbonyl) -3,4-tetrazolium] bis (4-methoxy-6-nitro) benzenesulfonic acid, Sigma) to a formazan Dye by mitochondrial dehydrogenases. The dye is only produced by metabolically active cells, its photometrically measurable intensity is a quantitative indicator of the presence of living cells. The reduction of dye formation by incubation of the cells with substances serves as a parameter for the anti-proliferative effect.
TestunqTestunq
Die Tumorzelllinien (ATCC) wurden in 96er Mikrotiterplatten in definierter Zellzahl (5000 Zellen/ Well für BxPC3 und Hct1 16; 10000 Zellen/ Well für MDA MB468) einge- säat und anschließend über Nacht im Brutschrank bei 37°C, 5% CO2 und 95% Luft- feuchtigkeit inkubiert. Die Testsubstanzen wurden als Stammlösungen (10 mM) in DMSO angesetzt. Zur Bestimmung der EC50-Werte wurden die potenziellen Inhibitorsubstanzen in viertellogarithmisch abgestuften Verdünnungen zu den Zellen gegeben, sodass finale Konzentrationen von 0.28μM-50μM resulierten. Die Zellplatten wurden dann für 45h im Brutschrank bei 37°C, 5% CO2 und 95% Luftfeuchtigkeit inkubiert. Für die Detektionssreaktion wurde das Substrat XTT mit PMS (N-Methyl Dibenzopyra- zine Methylsulfat, Sigma) versetzt und zu den Zellen gegeben, sodass eine finale Konzentration von 325μg XTT/ml und 2.5μg PMS/ml resultierte. Es wurde dann für 3h bei 37°C, 95% Luftfeuchte inkubiert. Anschließend konnte das durch zelluläre Dehydrogenasen gebildete Formazan Salz bei einer Adsorption bei 490nm quantifiziert werden.The tumor cell lines (ATCC) were in 96-well microtiter plates in a defined cell count (5000 cells / well for BxPC3 and Hct1 16, 10000 cells / well for MDA MB468) and then incubated overnight in the incubator at 37 ° C, 5% CO 2 and 95% humidity was incubated. The test substances were prepared as stock solutions (10 mM) in DMSO. To determine the EC 50 values, the potential inhibitor substances were added to the cells in quarter logarithmic graduated dilutions, resulting in final concentrations of 0.28 μM-50 μM. The cell plates were then incubated for 45 h in the incubator at 37 ° C, 5% CO 2 and 95% humidity. For the detection reaction, the substrate XTT was mixed with PMS (N-methyldibenzo-pyrazine methylsulfate, Sigma) and added to the cells, resulting in a final concentration of 325 μg XTT / ml and 2.5 μg PMS / ml. It was then incubated for 3h at 37 ° C, 95% humidity. Subsequently, the formazan salt formed by cellular dehydrogenases could be quantified by adsorption at 490nm.
Auswertungevaluation
Die Auswertung der %-lnhibitions-Werte geschah mittels folgender Formel aus den Werten für die jeweils gemessenen optischen Dichten bei 490nm:The evaluation of the% inhibition values was carried out by means of the following formula from the values for the respectively measured optical densities at 490 nm:
Mittelwe ^rt 1 C „PrO .bC ,) - Mittelwer itι (,0% Kontrolle) % Inhibition Zeilproliferation ffrob , = 100 - 100 x-Mittelwe ^ rt 1 C 'per .bc,) - MEAN i t ι (0% control)% inhibition cell proliferation ffrob = 100-100 x
Mittelwert 0% κ - Mittelwert (0% Kontrolle) Die Kontrollen wurden jeweils δfach, die Substanzproben jeweils 2fach bestimmt. Die 0%-Kontrolle enthielt keine Zellen, die 100%-Kontrolle enthielt keine Testsubstanz. Die EC50-Werte wurden mit GraphPadPrism ermittelt.Mean 0% κ - mean (0% control) The controls were each δfach, the substance samples each determined 2 times. The 0% control contained no cells, the 100% control contained no test substance. The EC 50 values were determined with GraphPadPrism.
Die erfindungsgemäßen Verbindungen zeigten eine teils effektive Inhibition der Zellpro- liferation mit EC50-Werten bis zu 2,2 μM (siehe Tabelle 2).The compounds of the invention showed a partially effective inhibition of cell proliferation with EC 50 values up to 2.2 μM (see Table 2).
Tabelle 2: XTT-Assay Versuchsergebnisse (EC50 [μM])Table 2: XTT assay test results (EC50 [μM])
11.3) Zellulärer Assay: Testung auf Substrat-Inhibtion (Western Blotting)11.3) Cellular Assay: Testing for Substrate Inhibtion (Western Blotting)
Diese Methode ermöglicht eine Aussage darüber, ob der untersuchte Kinasemodulator auch in einem zellulären Kontext die gewünschte Wirkung erzielt, d.h. hierbei wird ein der Targetkinase nachgeschaltetes Substrat- Protein auf seinen Phosphorylierungs- Status untersucht. Dazu werden die mit Substanz inkubierten Zellen lysiert und das Gesamtprotein auf einem reduzierenden Polyacrylamidgel aufgetrennt. Anschließend werden die Proteine mittels Western Blotting auf eine PVDF-Membran transferiert und die gesuchten Substratbanden mit spezifischen Antikörpern und einer geeigneten De- tektionsmethode sichtbar gemacht. Die den Targetkinasen nachgeschalteten Substratproteine werden mit einem jeweils speziellen anti-Phospho-Antikörper und gleichzeitig einem total-Antikörper, welcher das Substrat-Totalprotein erkennt, gleichzeitig detek- tiert. Die Duplex-Technologie des ODYSSEY-Imagers (LiCOR) ermöglicht diese simultane Messung. Die Intensität der Totalsubstrat-Banden wird zur Normalisierung bzw. Quantifizierung der Phosphorylierungs-Inhibition oder Aktivierung heran gezogen.This method provides information as to whether the kinase modulator under investigation also achieves the desired effect in a cellular context, i. In this case, a substrate protein downstream of the target kinase is examined for its phosphorylation status. For this purpose, the cells incubated with substance are lysed and the total protein is separated on a reducing polyacrylamide gel. Subsequently, the proteins are transferred to a PVDF membrane by Western blotting and the desired substrate bands are visualized with specific antibodies and a suitable detection method. The substrate proteins downstream of the target kinases are simultaneously detected with a particular anti-phospho antibody and simultaneously with a total antibody which recognizes the substrate total protein. The duplex technology of the ODYSSEY imager (LiCOR) enables this simultaneous measurement. The intensity of the total substrate bands is used to normalize or quantify phosphorylation inhibition or activation.
TestunqTestunq
Geeignete Tumorzelllinien (z.B. BxPC3, Hct1 16 oder MDA MB468) wurden in 6-WeII Mikrotiterplatten in definierter Zellzahl (z.B. 350 000 Zellen/ Well für BxPC3 und Hct1 16) in den jeweiligen Standard-Vollmedien eingesäat und anschließend überSuitable tumor cell lines (e.g., BxPC3, Hct1 16, or MDA MB468) were seeded into 6-well microtiter plates in defined cell counts (e.g., 350,000 cells / well for BxPC3 and Hct1 16) in the respective standard bulk media and then plated
Nacht im Brutschrank bei 37°C, 5% CO2 und 95% Luftfeuchtigkeit inkubiert. Die Zellen wurden anschließend für weitere 24h unter Serum-reduzierten Bedingungen, d.h. im jeweiligen Medium, jedoch bei nur 0.25% Serum, weiter inkubiert. Die Testsubstanzen wurden als Stammlösungen (10 mM) in DMSO angesetzt und bei finalen Konzentratio- nen von 5, 15.8 und 50μM für 5h mit den Zellen inkubiert. Daraufhin erfolgte die ZeIIIy- se in 25mM Tris, 15OmM NaCI, 1 OmM Na-Pyrophosphat, 2mM EGTA, 25mM beta- Glycerophosphat, 25mM NaF, 10% Glycerin, 0.75% NP-40, 100μM NaVO4-Puffer. Nach Proteinquantifizierung mittels BCA-(Bicinchonic acid protein assay kit, Sig- ma)Assay wurden Proteinmengen von etwa 20μg pro Laufspur auf einem Lämmli- Polyacrylamidgel aufgetrennt und danach mittels Semi-Dry Western-Blotting bei 0.8mA/cm2 für 1 h auf eine PVDF-Membran (Millipore) transferiert. Es folgte eine 1 stündige Prähyridisierung der Membran in I-Block Reagenz (Applied Biosystems) und die Über-Nacht-Inkubation mit den spezifischen Antikörpern. Zur Bestimmung der Erk- und PI3K-lnhibition wurden die jeweils abwärts folgenden Substrate Rsk1 mit dem To- tal-Antikörper (Rsk #sc-231g C-21 , Santa Cruz) und dem Phospho-Antikörper (Phospho-p90RSK (S380) #9341 , NEB Cell Signalling) und Akt mit dem Total- Antikörper (Akt1 #sc-1618 C-20, Santa Cruz) und dem Phospho-Antikörper (Phospho- Akt (Ser 473) #9271 , NEB Cell Signaling) detektiert. Nach Waschen der Membran erfolgte die Sekundärantikörperinkubation mit anti-Kaninchen IR Dye 800 (#611-732-127, Rockland) für die Phospho-Antikörper und anti-Ziege Alexa Fluor 680 (#A-21081 , Mo- lecular Probes) für die Totalprotein-Antikörper. Nach Inkubation für 30min bei Raumtemperatur im Dunkeln wurde die Hybridisierung des Detektionsantikörpers an die Membran durch Scannen im ODYSSEY-Imager (LiCOR) detektiert.Incubated overnight in the incubator at 37 ° C, 5% CO 2 and 95% humidity. The cells were then further incubated for a further 24 h under serum-reduced conditions, ie in the respective medium but with only 0.25% serum. The test substances were prepared as stock solutions (10 mM) in DMSO and incubated with the cells for 5 h at final concentrations of 5, 15.8 and 50 μM. The cells were then replaced with 25 mM Tris, 15 mM NaCl, 1 OmM Na pyrophosphate, 2 mM EGTA, 25 mM beta-glycerophosphate, 25 mM NaF, 10% glycerol, 0.75% NP-40, 100 mM NaVO 4 buffer. After protein quantification by BCA (Bicinchonic Acid Protein Assay Kit, Sigma) assay, protein amounts of about 20 μg per lane were separated on a Lämmli polyacrylamide gel and then by semi-dry Western blotting at 0.8 mA / cm 2 for 1 h PVDF membrane (Millipore) transferred. This was followed by prehyridation of the membrane in I-block reagent (Applied Biosystems) for 1 hour and overnight incubation with the specific antibodies. To determine the Erk and PI3K inhibition, the respective downstream substrates Rsk1 were tal-antibody (Rsk # sc-231g C-21, Santa Cruz) and the phospho-antibody (Phospho-p90RSK (S380) # 9341, NEB cell signaling) and Akt with the total antibody (Akt1 # sc-1618C). 20, Santa Cruz) and the phospho-antibody (phospho-Akt (Ser 473) # 9271, NEB cell signaling). After washing the membrane, the secondary antibody incubation was carried out with anti-rabbit IR Dye 800 (# 611-732-127, Rockland) for the phospho-antibodies and anti-goat Alexa Fluor 680 (# A-21081, Molecular Probes) for the total protein -Antibody. After incubation for 30 min at room temperature in the dark, hybridization of the detection antibody to the membrane was detected by scanning in the ODYSSEY imager (LiCOR).
Auswertungevaluation
Bei Konzentrationen von 5-50μM zeigten die erfindungsgemäßen Verbindungen eine duale Inhibition der Erk (MAPK1/2) und der PI3K (siehe Tabelle 3), welche durch Hemmung der Bandenintensität beider korrespondierender phospho-Substratproteine Rsk1 und Akt angezeigt wird.At concentrations of 5-50 μM, the compounds of the invention showed a dual inhibition of Erk (MAPK1 / 2) and PI3K (see Table 3), which is indicated by inhibition of the band intensity of both corresponding phospho-substrate proteins Rsk1 and Akt.
Tabelle 3 Inhibition der zellulären Substratphosphorylierung (bei 50μM)Table 3 Inhibition of cellular substrate phosphorylation (at 50μM)
AbkürzunqenAbkürzunqen
Akt von: murine Aktδ retrovirus oder protein kinase B (PKB)Act of: murine Aktδ retrovirus or protein kinase B (PKB)
Ask1 apoptosis signal-regulating kinase ATR ataxia-telangiectasia and Rad3-relatedAsk1 apoptosis signal-regulating kinase atr ataxia-telangiectasia and rad3-related
ATM Ataxia-telangiectasia mutatedATM Ataxia-telangiectasia mutated
Bag1 Bcl-2 associated athanogene-1Bag1 Bcl-2 associated athanogene-1
Bcl-2 B-cell leukemia/lymhoma-2 geneBcl-2 B-cell leukemia / lymhoma-2 gene
DNA-PK DNA-dependent protein kinase Erk extracellular signal-regulated kinaseDNA-PK DNA-dependent protein kinase Erk extracellular signal-regulated kinase
Flt-3 fms like tyrosine kinase 3Flt-3 fms like tyrosine kinase 3
GSK-3 Glycogen synthase kinase-3 hSMG-1 human ortholog of product of seven nematode gene-1GSK-3 glycogen synthase kinase-3 hSMG-1 human orthologue of product of seven nematodes gene-1
JAK-3 Janus kinase 3 JNK c-jun N-terminal kinaseJAK-3 Janus kinase 3 JNK c-jun N-terminal kinase
MAPK mitogen activated protein kinaseMAPK mitogen activated protein kinase
Mek MAP or Erk kinase mTOR mammalian target of rapamycinMek MAP or Erk kinase mTOR mammalian target of rapamycin
PDGFR platelet derived growth factor receptor PI3K phosphoinositol 3-KinasePDGFR platelets derived PI3K phosphoroinositol 3-kinase growth factor receptor
PIKK phosphoinositol 3-Kinase related kinasePIKK phosphoinositol 3-kinase related kinase
PIP2 phosphatidylinositol-biphosphatPIP 2 phosphatidylinositol biphosphate
PIP3 phosphatidylinositol-triphosphatPIP 3 phosphatidylinositol triphosphate
Ptdlns phosphatidylinositol Raf rapid accelerated fibrosarcomaPtdlns phosphatidylinositol Raf rapidly accelerated fibrosarcoma
Ras rat sarcomaRas rat sarcoma
RTK receptor tyrosine kinaseRTK receptor tyrosine kinase
SAPK stress-activated protein kinaseSAPK stress-activated protein kinase
Ser Serin Syk spieen tyrosine kinaseSer serine Syk spy tyrosine kinase
Thr ThreoninThr threonine
Tyr TyrosinTyr tyrosine
VEGFR vascular endothelial growth factor receptor VEGFR vascular endothelial growth factor receptor

Claims

Patentansprüche claims
1. Neue Pyrido[2,3-b]pyrazin-Derivate gemäß der allgemeinen Formel (I)1. New pyrido [2,3-b] pyrazine derivatives according to the general formula (I)
worin:wherein:
(A) einer der Reste Z3, Z4 oder beide Reste Z3, Z4 unabhängig voneinander „substituiertes Aryl" sind, wobei „substituiertes Aryl" substituiert ist mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(A) one of the radicals Z3, Z4 or both radicals Z3, Z4 is independently "substituted aryl", where "substituted aryl" is substituted by at least one substituent, identical or different, selected from the group consisting of:
(a) „alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NH-X1 , -N(alkyl)2, - NHC(O)-alkyl, -NHC(O)-cycloalkyl, -NHC(O)-heterocyclyl, -NHC(O)- aryl, -NHC(O)-heteroaryl, -NHC(O)-arylalkyl, -NHC(O)-heteroarylalkyl, -NHS(O2)-alkyl, -NHS(O2)-cycloalkyl, -NHS(O2)-heterocyclyl, -(a) "alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NH-X1, -N (alkyl) 2 , -NHC (O) -alkyl, -NHC (O) -cycloalkyl, -NHC (O) -heterocyclyl, -NHC (O) -aryl, -NHC (O) -heteroaryl, -NHC (O) -arylalkyl, -NHC (O) -heteroarylalkyl, -NHS (O 2 ) -alkyl, -NHS (O 2 ) -cycloalkyl, -NHS (O 2 ) -heterocyclyl, -
NHS(O2)-aryl, -NHS(O2)-heteroaryl, -NHS(O2)-arylalkyl, -NHS(O2)- heteroarylalkyl, -S-alkyl, -S-aryl, -S-heteroaryl, -O-X2, -OC(O)-alkyl, - OC(O)-cycloalkyl, -OC(O)-heterocyclyl, -OC(O)-aryl, -OC(O)- heteroaryl, -OC(O)-arylalkyl, -OC(O)-heteroarylalkyl, -OS(O2)-alkyl, - OS(O2)-cycloalkyl, -OS(O2)-heterocyclyl, -OS(O2)-aryl, -OS(O2)- heteroaryl, -OS(O2)-arylalkyl, -OS(O2)-heteroarylalkyl, -C(O)-alkyl, - C(O)-aryl, -C(O)-heteroaryl, -C(O)O-X3, -C(O)NH-X4, -C(O)N(alkyl)2, -C(O)N(cycloalkyl)2, -C(O)N(aryl)2, -C(O)N(heteroraryl)2, -S(O)-alkyl, - S(O)-aryl, -S(O2)-alkyl, -S(O2)-aryl, -S(O2)NH-alkyl, -S(O2)NH-aryl, - S(O2)NH-heteroaryl, -S(O2)NH-arylalkyl, S(O2)O-alkyl, -S(O2)O-aryl, -NHS (O 2 ) -aryl, -NHS (O 2 ) -heteroaryl, -NHS (O 2 ) -arylalkyl, -NHS (O 2 ) -heteroarylalkyl, -S-alkyl, -S-aryl, -S-heteroaryl, -O-X 2, -OC (O) -alkyl, - OC (O) -cycloalkyl, -OC (O) -heterocyclyl, -OC (O) -aryl, -OC (O) -heteroaryl, -OC (O) -arylalkyl, -OC (O) -heteroarylalkyl, -OS (O 2 ) -alkyl, -OS (O 2 ) -cycloalkyl, -OS (O 2 ) -heterocyclyl, -OS (O 2 ) -aryl, -OS ( O 2 ) - heteroaryl, -OS (O 2 ) -arylalkyl, -OS (O 2 ) -heteroarylalkyl, -C (O) -alkyl, - C (O) -aryl, -C (O) -heteroaryl, -C (O) O-X3, -C (O) NH-X4, -C (O) N (alkyl) 2 , -C (O) N (cycloalkyl) 2 , -C (O) N (aryl) 2 , - C (O) N (heteroaryl) 2 , -S (O) -alkyl, -S (O) -aryl, -S (O 2 ) -alkyl, -S (O 2 ) -aryl, -S (O 2 ) NH-alkyl, -S (O 2 ) NH -aryl, -S (O 2 ) NH-heteroaryl, -S (O 2 ) -NH-arylalkyl, S (O 2 ) O-alkyl, -S (O 2 ) O -aryl, -
S(O2)O-arylalkyl"; wobei X1 , X2, X3, X4 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; mit der Maßgabe, dass obige Substituenten der Substituentengruppe (a) unabhängig voneinander weiter substituiert sind mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (i) „(C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylal- kyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, N3, -NH-cycloalkyl, - NH-cycloalkylalkyl, -NH-heteroaryl, -NH-heteroarylalkyl, -NH- arylalkyl, -NH-heterocyclyl, -NH-heterocyclylalkyl, -NX5X6, -S- cycloalkyl, -S-cycloalkylalkyl, -S-aryl, —S— arylalkyl, -S-heteroaryl, - S-heteroarylalkyl, -S-heterocyclyl, -S-heterocyclylalkyl, -O- cycloalkyl, -O-cycloalkylalkyl, -O-arylalkyl, -O-heteroaryl, -O- heteroarylalkyl, -O-heterocyclyl, -O-heterocyclylalkyl,-O(-X7-O)p- X8 (p = 1 , 2, 3, 4, 5), -OP(O)(OX9)(OX10), -C(O)O-XH 1 -C(O)NH2, -C(O)NH-XI 2, -C(O)NXI 3X14, -S(O2)-X15, -P(O)(OH)2, - P(O)(OXI 6)(0X17), -Si(XI 8)(X19)(X20), -O-Si(X21 )(X22)(X23), -O-S (O 2 ) O -arylalkyl "; wherein X 1, X 2, X 3, X 4 are independently selected from the group consisting of:" alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "; with the proviso that the above substituent of the substituent group (a) are independently further substituted, or different with at least one substituent the same, selected from the group consisting of: (i) "(C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl , heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, N 3 , -NH-cycloalkyl, --NH-cycloalkylalkyl, -NH-heteroaryl, -NH-heteroarylalkyl, -NH-arylalkyl, -NH-heterocyclyl, -NH -heterocyclylalkyl, -NX5X6, -S- cycloalkyl, -S-cycloalkylalkyl, -S-aryl, -S-arylalkyl, -S-heteroaryl, - S-heteroarylalkyl, -S-heterocyclyl, -S-heterocyclylalkyl, -O-cycloalkyl , -O-cycloalkylalkyl, -O-arylalkyl, -O-heteroaryl, -O-heteroarylalkyl, -O-heterocyclyl, -O-heterocyclylalkyl, -O (-X7-O) p -X8 (p = 1, 2, 3 , 4, 5), -OP (O) (OX9) (OX10), -C (O) O-XH 1 -C (O) NH 2 , -C (O) NH-XI 2, -C (O) NXI 3X14, -S (O 2 ) -X 15, -P (O) (OH) 2 , -P (O) (OXI 6) (0X17), -Si (XI 8) (X 19) (X20), -O -Si (X21) (X22) (X23), -O-
C(O)-O-X24, -0-C(O)-N H-X25, -O-C(O)-NX26X27, -NH-C(O)- O-X28, -N H-C(O)-N H-X29, -NH-C(O)-NX30X31 , -NX32-C(O)-O- X33, -NX34-C(O)-NH-X35, -NX36-C(O)-NX37X38, -O-S(O2)-X39, -NH-C(O)-X40, -NX41-C(O)-X42, -C(O)-X43, -OC(O)-X44, - S(O)-X45, -S(O2)-NHX46, -S(O2)-NX47X48, -S(O2)-OX49, -0(-C (O) -O-X24, -O-C (O) -NH-X25, -OC (O) -NX26X27, -NH-C (O) -O-X28, -NHC (O) -N H-X29, -NH-C (O) -NX30X31, -NX32-C (O) -O-X33, -NX34-C (O) -NH-X35, -NX36-C (O) -NX37X38, -OS (O 2 ) -X39, -NH-C (O) -X40, -NX41-C (O) -X42, -C (O) -X43, -OC (O) -X44, -S (O) -X45 , -S (O 2 ) -NHX46, -S (O 2 ) -NX 47 X 48, -S (O 2 ) -OX 49, -O (-)
X50-O)p-H (p = 1 , 2, 3, 4, 5)"; mit der weiteren Maßgabe, dass ,,-N(alkyl)2" weiter substituiert ist mit mindestens einem Substituenten ausgewählt aus der untigen Substituentengruppe (b); wobei X5, X6, X7, X8, X9, X10, X1 1 , X12, X13, X14, X15, X16, X17,X 50 -O) p -H (p = 1, 2, 3, 4, 5) ", with the further proviso that" --N (alkyl) 2 "is further substituted by at least one substituent selected from the sub-substituent group ( b); where X5, X6, X7, X8, X9, X10, X1 1, X12, X13, X14, X15, X16, X17,
X18, X19, X20, X21 , X22, X23, X24, X25, X26, X27, X28, X29, X30, X31 , X32, X33, X34, X35, X36, X37, X38, X39, X40, X41 , X42, X43, X44, X45, X46, X47, X48, X49, X50 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cyclo- alkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X13, X14 und/oder X26, X27 und/oder X30, X31 und/oder X37, X38 und/oder X47, X48 zusammen auch „heterocyclyl" bilden können; und mit der weiteren Maßgabe, dass wenn einer der Reste Z3 oder Z4 „substituiertes Aryl" substiuiert mit „heterocyclylalkyl" ist, der jeweils andere Rest Z3 oder Z4 nicht „substituiertes oder unsubstituiertes Aryl" ist; wobei optional zusätzlich einer der Reste Z3, Z4 oder zusätzlich beide Reste Z3, Z4 unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:X18, X19, X20, X21, X22, X23, X24, X25, X26, X27, X28, X29, X30, X31, X32, X33, X34, X35, X36, X37, X38, X39, X40, X41, X42, are X43, X44, X45, X46, X47, X48, X49, X50 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cyclo- alkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl heteroaryl, heteroarylalkyl "and wherein alternatively X13, X14 and / or X26, X27 and / or X30, X31 and / or X37, X38 and / or X47, X48 may together also form" heterocyclyl "; and with the further proviso that when one of Z3 or Z4 is "substituted aryl" substituted with "heterocyclylalkyl", the other each of Z3 or Z4 is not "substituted or unsubstituted aryl"; optionally additionally, one of Z3, Z4 or additionally both radicals Z3, Z4 can also be further independently substituted with at least one substituent, identical or different, selected from the group consisting of:
(b) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX51 , -NX52X53, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -(b) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHX51, -NX52X53, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -
CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X54, -C(O)O-X55, -C(O)NH-X56, -C(O)NX57X58, -O-X59, -O(-X60-O)r-H (r = 1 , 2, 3, 4, 5), -O(-X61-O)r-X62 (r = 1 , 2, 3, 4, 5), -OC(O)-X63, -OC(O)-O-X64, - OC(O)-N HX65, -O-C(O)-NX66X67, -OP(O)(OX68)(OX69), - OSi(X70)(X71 )(X72), -OS(O2)-X73, -NHC(O)-X74, -NX75C(O)-X76, -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X54, -C (O) O-X55, -C (O) NH-X56, -C (O) NX57X58, -O-X59, -O (-X60-O) r -H (r = 1, 2, 3, 4, 5), -O (-X61-O) r -X62 (r = 1, 2, 3, 4, 5), -OC (O) -X63, -OC (O) -O-X64, -OC (O) -N HX65, -OC (O) -NX66X67 , -OP (O) (OX68) (OX69), - OSi (X70) (X71) (X72), -OS (O 2) -X73, -NHC (O) -X74, -NX75C (O) -X76, -
NH-C(O)-O-X77, -N H-C(O)-N H-X78, -NH-C(O)-NX79X80, -NX81- C(O)-O-X82, -NX83-C(O)-NH-X84, -NX85-C(O)-NX86X87, -NHS(O2)- X88, -NX89S(O2)-X90, -S-X91 , -S(O)-X92, -S(O2)-X93, -S(O2)NH-X94, -S(O2)NX95X96, -S(O2)O-X97, -P(O)(OX98)(OX99), - Si(XI 00)(X101 )(X102)"; wobei X51 , X52, X53, X54, X55, X56, X57, X58, X59, X60, X61 , X62, X63, X64, X65, X66, X67, X68, X69, X70, X71 , X72, X73, X74, X75, X76, X77, X78, X79, X80, X81 , X82, X83, X84, X85, X86, X87, X88, X89, X90, X91 , X92, X93, X94, X95, X96, X97, X98, X99, X100, X101 , X102 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-NH-C (O) -O-X77, -NHC (O) -NH-X78, -NH-C (O) -NX79X80, -NX81-C (O) -O-X82, -NX83-C ( O) -NH-X84, -NX85-C (O) -NX86X87, -NHS (O 2) - X88, -NX89S (O 2) -X90, -S-X91, -S (O) -X92, -S (O 2) -X93, -S (O2) NH-X94, -S (O 2) NX95X96, -S (O2) O-X97, -P (O) (OX98) (OX99), - Si ( XI 00) (X101) (X102) "; wherein X51, X52, X53, X54, X55, X56, X57, X58, X59, X60, X61, X62, X63, X64, X65, X66, X67, X68, X69, X70, X71, X72, X73, X74, X75, X76, X77, X78, X79, X80, X81, X82, X83, X84, X85, X86, X87, X88, X89, X90, X91, X92, X93, X94, X95, X96, X97, X98, X99, X100, X101, X102 are independently selected from the group consisting of: "alkyl, (Cg-
C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X57, X58 und/oder X66, X67 und/oder X79, X80 und/oder X86, X87 und/oder X95, X96 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (b) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX103, -NX104X105, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- X106, -C(O)O-XI 07, -C(O)NH-XI 08, -C(O)NXI 09X1 10, -0-X1 11 , -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X57, X58 and / or X66, X67 and / or X79, X80 and / or X86, X87 and / or X95, X96 together can also form "heterocyclyl"; optionally optionally substituted substituents of the substituent group (b) may in turn be substituted with at least one substituent, identical or different, selected from the group consisting of: (ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2, -NHX103, -NX104X105, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP (O) (OH) 2, -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X106, -C (O) O-XI 07, -C (O) NH-XI 08, -C (O ) NXI 09X1 10, -0-X1 11, -
0(-X1 12-O)5-H (s = 1 , 2, 3, 4, 5), -0(-X113-0)s-X1 14 (s = 1 , 2, 3, 4, 5), -OC(O)-X115, -OC(O)-O-X1 16, -OC(O)-NHX117, -0-C(O)- NX118X119, -OP(O)(OXI 20)(OX121 ), -OSi(XI 22)(X123)(X124), - OS(O2)-X125, -NHC(O)-X126, -NX127C(O)-XI 28, -NH-C(O)-O- X129, -NH-C(O)-NH-XI 30, -N H-C(O)-NXI 31X132, -NX133-C(O)-0 (-X1 12-O) 5 -H (s = 1, 2, 3, 4, 5), -0 (-X113-0) s -X1 14 (s = 1, 2, 3, 4, 5) , -OC (O) -X115, -OC (O) -O-X1 16, -OC (O) -NHX117, -O-C (O) -NX118X119, -OP (O) (OXI 20) (OX121) , -OSi (XI 22) (X123) (X124), - OS (O 2 ) -X125, -NHC (O) -X126, -NX 127C (O) -XI 28, -NH-C (O) -O- X129, -NH-C (O) -NH-XI 30, -NHC (O) -NXI 31X132, -NX133-C (O) -
O-X134, -NX135-C(O)-NH-XI 36, -NX137-C(O)-NXI 38X139, - NHS(O2)-X140, -NX141S(O2)-X142, -S-X143, -S(O)-X144, -S(O2)- X145, -S(O2)NH-XI 46, -S(O2)NXI 47X148, -S(O2)O-XI 49, - P(O)(OXI 50)(OX151 ), -Si(XI 52)(X153)(X154)"; wobei X103, X104, X105, X106, X107, X108, X109, X1 10, X1 1 1 , X1 12,O-X134, -NX135-C (O) -NH-XI 36, -NX137-C (O) -NXI 38X139, - NHS (O 2) -X140, -NX141S (O 2) -X142, -S-X143 , -S (O) -X144, -S (O2) - X145, -S (O2) NH-XI 46, -S (O 2) NXI 47X148, -S (O 2) O-XI 49, - P (O) (OXI 50) (OX151), -Si (XI 52) (X153) (X154) "; wherein X103, X104, X105, X106, X107, X108, X109, X1 10, X1 1 1, X1 12 .
X1 13, X1 14, X1 15, X1 16, X1 17, X1 18, X1 19, X120, X121 , X122, X123, X124, X125, X126, X127, X128, X129, X130, X131 , X132, X133, X134, X135, X136, X137, X138, X139, X140, X141 , X142, X143, X144, X145, X146, X147, X148, X149, X150, X151 , X152, X153, X154 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl,X1 13, X1 14, X1 15, X1 16, X1 17, X1 18, X1 19, X120, X121, X122, X123, X124, X125, X126, X127, X128, X129, X130, X131, X132, X133, X134 , X135, X136, X137, X138, X139, X140, X141, X142, X143, X144, X145, X146, X147, X148, X149, X150, X151, X152, X153, X154 are independently selected from the group consisting of: "alkyl,
(Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X109, X110 und/oder X1 18, X119 und/oder X131 , X132 und/oder X138, X139 und/oder X147, X148 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) und/oder(Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X109, X110 and / or X1 18, X119 and / or X131, X132 and / or X138, X139 and / or X147, X148 may together also form "heterocyclyl"; wherein optionally substituents above the substituent group (i) and / or
Substituentengruppe (ii) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Substituent group (ii) may be independently substituted with at least one substituent, same or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3,(iii) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3,
NH2, -NHX155, -NX156X157, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- X158, -C(O)O-XI 59, -C(O)NH-XI 60, -C(O)NXI 61X162, -O-X163, - O(-X164-O)t-H (t = 1 , 2, 3, 4, 5), -0(-X165-O)t-X166 (t = 1 , 2, 3, 4, 5), -OC(O)-XI67, -OC(O)-O-XI68, -OC(O)-NHXI69, -0-C(O)- NX170X171 , -OP(O)(OXI72)(OX173), -OSi(XI74)(X175)(X176), - OS(O2)-X177, -NHC(O)-XI78, -NX179C(O)-XI80, -NH-C(O)-O- X181, -NH-C(O)-NH-XI82, -NH-C(O)-NXI83X184, -NX185-C(O)- O-X186, -NX187-C(O)-NH-XI88, -NX189-C(O)-NXI90X191, -NH 2 , -NHX155, -NX156X157, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O ) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X158, -C (O) O -Xl 59, -C (O) NH-XI 60, -C ( O) NXI 61X162, -O-X163, -O (-X164-O) t -H (t = 1, 2, 3, 4, 5), -O (-X165-O) t -X166 (t = 1 , 2, 3, 4, 5), -OC (O) -XI67, -OC (O) -O-XI68, -OC (O) -NHXI69, -O-C (O) -NX170X171, -OP (O) (OXI72) (OX173), -OSi (XI74) (X175) (x176), - OS (O 2) -X177, -NHC (O) -XI78, -NX179C (O) -XI80, -NH-C (O) -O- X181, -NH- C (O) -NH-XI82, -NH-C (O) -NXI83X184, -NX185-C (O) -O-X186, -NX187-C (O) -NH-XI88, -NX189-C (O) -NXI90X191, -
NHS(O2)-X192, -NX193S(O2)-X194, -S-X195, -S(O)-XI96, -S(O2)- X197, -S(O2)NH-XI98, -S(O2)NXI99X200, -S(O2)O-X201, - P(O)(OX202)(OX203), -Si(X204)(X205)(X206)"; wobei X155, X156, X157, X158, X159, X160, X161 , X162, X163, X164, X165, X166, X167, X168, X169, X170, X171 , X172, X173, X174, X175,NHS (O 2) -X192, -NX193S (O 2) -X194, -S-x195, -S (O) -XI96, -S (O 2) - x197, -S (O 2) NH-XI98, - S (O 2) NXI99X200, -S (O 2) O-X201, - P (O) (OX202) (OX203), -Si (X204) (X205) (X206) "; wherein X155, X156, X157, x158 , X159, X160, X161, X162, X163, X164, X165, X166, X167, X168, X169, X170, X171, X172, X173, X174, X175,
X176, X177, X178, X179, X180, X181 , X182, X183, X184, X185, X186, X187, X188, X189, X190, X191 , X192, X193, X194, X195, X196, X197, X198, X199, X200, X201 , X202, X203, X204, X205, X206 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X161 , X162 und/oder X170, X171 und/oder X183, X184 und/oder X190, X191 und/oder X199, X200 zusammen auch „heterocyclyl" bilden können;X176, X177, X178, X179, X180, X181, X182, X183, X184, X185, X186, X187, X188, X189, X190, X191, X192, X193, X194, X195, X196, X197, X198, X199, X200, X201, X202, X203, X204, X205, are X206 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively, X161, X162 and / or X170, X171 and / or X183, X184 and / or X190, X191 and / or X199, X200 may together also form "heterocyclyl";
oder einer der Reste Z3, Z4 oder beide Reste Z3, Z4 unabhängig voneinanderor one of the radicals Z3, Z4 or both radicals Z3, Z4 independently of one another
„substituiertes Aryl" sind, wobei „substituiertes Aryl" substituiert ist mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:"Substituted aryl", wherein "substituted aryl" is substituted with at least one substituent, same or different, selected from the group consisting of:
(C) „(C9-C3o)alkyl, -NX207X208, -NH-(C9-C30)alkyl, -NHC(O)-cycloalkylalkyl, - NHC(O)-heterocyclylalkyl, -NHC(O)-(C9-C30)alkyl, -NX209C(O)-X210, -(C) "(C 9 -C 3 o) alkyl, -NX207X208, -NH- (C 9 -C 30) alkyl, -NHC (O) cycloalkylalkyl, - NHC (O) -heterocyclylalkyl, -NHC (O) - (C 9 -C 30 ) alkyl, -NX 2 O 9 C (O) -X 2 O, -
NX21 1C(0)-(C9-C3o)alkyl, -NHC(O)-OX212, -NX213C(O)-OX214, - N HC(O)-N HX215, -NHC(O)-NX216X217, -NX218C(O)-NHX219, - NX220C(O)-NX221X222, -NHS(O2)-cycloalkylalkyl, -NHS(O2)- heterocyclylalkyl, -NX223S(O2)-X224, -O-(C9-C30)alkyl, -S-cycloalkyl, -S- heterocyclyl, —S— arylalkyl, -S-heteroarylalkyl, -S-cycloalkylalkyl, -S- heterocyclylalkyl, -S-(C9-C30)alkyl, -OC(O)-cycloalkylalkyl, -OC(O)- heterocyclylalkyl, -OC(O)-(C9-C30)alkyl, -OS(O2)-cycloalkylalkyl, -OS(O2)- heterocyclylalkyl, -OS(O2)-(C9-C30)alkyl, -OC(O)-OX225, -OC(O)- NHX226, -OC(O)-NX227X228, -OP(O)(OX229)(OX230), -C(O)-cycloalkyl, -C(O)-heterocyclyl, -C(O)-arylalkyl, -C(O)-heteroarylalkyl, -C(O)- cycloalkylalkyl, -C(O)-heterocyclylalkyl, -C(0)-(C9-C3o)alkyl, -C(O)O-(C9- C30)alkyl, -C(0)NH-(C9-C3o)alkyl, -C(0)NX231X232, -C(O)NH-OX233, - C(O)NX234-OX235, -C(O)N H-NX236X237, -C(O)NX238-NX239X240, - S(O)-cycloalkyl, -S(O)-heterocyclyl, -S(O)-heteroaryl, -S(O)-arylalkyl, -Nx21 1C (0) - (C 9 -C 3 o) alkyl, -NHC (O) -OX212, -NX213C (O) -OX214, - N HC (O) -N HX215, -NHC (O) -NX216X217, -NX218C (O) -NHX219, - NX220C (O) -NX221X222, -NHS (O 2) cycloalkylalkyl, -NHS (O 2) - heterocyclylalkyl, -NX223S (O 2) -X224, -O- (C 9 - C 30 ) alkyl, -S-cycloalkyl, -S-heterocyclyl, -S-arylalkyl, -S-heteroarylalkyl, -S-cycloalkylalkyl, -S-heterocyclylalkyl, -S- (C 9 -C 30 ) -alkyl, -OC ( O) -cycloalkylalkyl, -OC (O) -heterocyclylalkyl, -OC (O) - (C 9 -C 30 ) -alkyl, -OS (O 2 ) -cycloalkylalkyl, -OS (O 2 ) -heterocyclylalkyl, -OS (O alkyl (C 9 -C 30), -OC (O) -OX225, -OC (O) - - 2) NHX226, -OC (O) -NX227X228, -OP (O) (OX229) (OX230), -C (O) -cycloalkyl, -C (O) -heterocyclyl, -C (O) -arylalkyl, -C (O) -heteroarylalkyl, -C (O) -cycloalkylalkyl, -C (O) -heterocyclylalkyl, -C (O) - (C 9 - C 3 o) alkyl, -C (O) O- (C 9 - C 30) alkyl, -C (0) NH- (C 9 -C 3 O) alkyl, -C (0) NX231X232, -C (O ) NH-OX233, - C (O) NX234-OX235, -C (O) N H -NX236X237, -C (O) NX238-NX239X240, - S (O) -cycloalkyl, -S (O) -heterocyclyl, - S (O) -heteroaryl, -S (O) -arylalkyl, -
S(O)-heteroarylalkyl, -S(O)-cycloalkylalkyl, -S(O)-heterocyclylalkyl, - S(O)-(C9-C30)alkyl, -S(O2)-cycloalkyl, -S(O2)-heterocyclyl, -S(O2)- heteroaryl, -S(O2)-arylalkyl, -S(O2)-heteroarylalkyl, -S(O2)-cycloalkylalkyl, -S(O2)-heterocyclylalkyl, -S(O2)-(C9-C30)alkyl, -S(O2)NH-cycloalkyl, - S(O2)N H-heterocyclyl, -S(O2)NH-heteroarylalkyl, -S(O2)NH- cycloalkylalkyl, -S(O2)NH-heterocyclylalkyl, -S(O2)NH-(C9-C30)alkyl, - S(O2)O-cycloalkyl, -S(O2)O-heterocyclyl, -S(O2)O-heteroaryl, -S(O2)O- heteroarylalkyl, -S(O2)O-cycloalkylalkyl, -S(O2)O-heterocyclylalkyl, - S(O2)O-(C9-C30)alkyl, -P(O)(OH)2, -P(O)(OX241 )(OX242), - Si(X243)(X244)(X245), -O-Si(X246)(X247)(X248)"; wobei X207, X208, X209, X210, X21 1 , X212, X213, X214, X215, X216, X217, X218, X219, X220, X221 , X222, X223, X224, X225, X226, X227, X228, X229, X230, X231 , X232, X233, X234, X235, X236, X237, X238, X239, X240, X241 , X242, X243, X244, X245, X246, X247, X248 unabhän- gig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl,S (O) -heteroarylalkyl, -S (O) -cycloalkylalkyl, -S (O) -heterocyclylalkyl, -S (O) - (C 9 -C 30 ) -alkyl, -S (O 2 ) -cycloalkyl, -S ( O 2 ) heterocyclyl, -S (O 2 ) heteroaryl, -S (O 2 ) arylalkyl, -S (O 2 ) heteroarylalkyl, -S (O 2 ) cycloalkylalkyl, -S (O 2 ) heterocyclylalkyl , -S (O 2 ) - (C 9 -C 30 ) alkyl, -S (O 2 ) NH -cycloalkyl, - S (O 2 ) N H -heterocyclyl, -S (O 2 ) NH-heteroarylalkyl, -S (O 2) NH- cycloalkylalkyl, -S (O 2) NH-heterocyclylalkyl, -S (O 2) NH- (C 9 -C 30) alkyl, - S (O 2) O-cycloalkyl, -S (O 2 ) O-heterocyclyl, -S (O 2 ) O-heteroaryl, -S (O 2 ) O-heteroarylalkyl, -S (O 2 ) O -cycloalkylalkyl, -S (O 2 ) O-heterocyclylalkyl, - S (O 2 ) O- (C 9 -C 30) alkyl, -P (O) (OH) 2, -P (O) (OX241) (OX242), - Si (x243) (X244) (X245), -O-Si (X246) (X247) (X248) "; wherein X207, X208, X209, X210, X21 1, X212, X213, X214, X215, X216, X217, X218, X219, X220, X221, X222, X223, X224, X225 , X226, X227, X228, X229, X230, X231, X232, X233, X234, X235, X236, X237, X238, X239, X240, X241, X242, X243, X244, X245, X246, X247, X248 independently g are selected from the group consisting of: "alkyl,
(C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X216, X217 und/oder X221 , X222 und/oder X227, X228 und/oder X231 , X232 und/oder X236, X237 und/oder X239, X240 jeweils zusammen auch „heterocyclyl" bilden können; mit der Maßgabe, dass die Substituenten ,,-N(alkyl)2", ,,-C(O)N(alkyl)2", „- C(O)N(cycloalkyl)2", ,,-C(O)N(aryl)2", ,,-C(O)N(heteroraryl)2" weiter substituiert sind mit mindestens einem Substituenten ausgewählt aus der untigen Substituentengruppe (i); mit der weiteren Maßgabe, dass wenn einer der Reste Z3 oder Z4 „substituiertes Aryl" substituiert mit „heterocyclylalkyl" ist, der jeweils andere Rest Z3 oder Z4 nicht „unsubstituiertes oder substituiertes Aryl" ist; wobei optional obige Substituenten der Substituentengruppe (c) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Sub- stituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X216, X217 and / or X221, X222 and / or X227, x228 and / or X231, x232 and / or X236, X237 and / or X239, X240 may each together also form "heterocyclyl"; with the proviso that the substituents "- N (alkyl) 2 ", "- C (O) N (alkyl) 2 ", "- C (O) N (cycloalkyl) 2 ", "- C (O ) N (aryl) 2 ", - C (O) N (heteroaryl) 2 " are further substituted with at least one substituent selected from the lower substituent group (i), with the further proviso that when one of Z3 or Z4 "Substituted aryl" substituted with "heterocyclylalkyl", each other of Z3 or Z4 is not "unsubstituted or substituted aryl"; optionally optionally substituted substituents of the substituent group (c) may be substituted in turn with at least one sub- substituents, same or different, selected from the group consisting of:
(i) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX249, -NX250X251 , -NO2, -OH, -OCF3, -SH, -0-SO3H, -(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHX249, -NX250X251, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -
OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- X252, -C(O)O-X253, -C(O)NH-X254, -C(O)NX255X256, -O-X257, - O(-X258-O)u-H (u = 1 , 2, 3, 4, 5), -O(-X259-O)u-X260 (u = 1 , 2, 3, 4, 5), -OC(O)-X261 , -OC(O)-O-X262, -OC(O)-N HX263, -0-C(O)- NX264X265, -OP(O)(OX266)(OX267), -OSi(X268)(X269)(X270), -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X 252, -C (O ) O-X253, -C (O) NH-X254, -C (O) NX255X256, -O-X257, -O (-X258-O) u -H (u = 1, 2, 3, 4, 5) , -O (-X259-O) u -X260 (u = 1, 2, 3, 4, 5), -OC (O) -X261, -OC (O) -O-X262, -OC (O) - N HX263, -O-C (O) - NX264X265, -OP (O) (OX266) (OX267), -OSi (X268) (X269) (X270), -
OS(O2)-X271 , -NHC(O)-X272, -NX273C(O)-X274, -NH-C(O)-O- X275, -N H-C(O)-N H-X276, -NH-C(O)-NX277X278, -NX279-C(O)- O-X280, -NX281 -C(O)-N H-X282, -NX283-C(O)-NX284X285, - NHS(O2)-X286, -NX287S(O2)-X288, -S-X289, -S(O)-X290, -S(O2)- X291 , -S(O2)N H-X292, -S(O2)NX293X294, -S(O2)O-X295, -OS (O 2) -X271, -NHC (O) -X272, -NX273C (O) -X274, -NH-C (O) -O- X275, -N HC (O) -N H-X276, -NH -C (O) -NX277X278, -NX279-C (O) -O-X280, -NX281 -C (O) -NH-X282, -NX283-C (O) -NX284X285, -NHS (O 2 ) - X286, -NX287S (O 2) -X288, -S-X289, -S (O) -X290, -S (O2) - X291, -S (O2) N H-X292, -S (O 2) NX293X294, -S (O2) O-X295, -
P(O)(OX296)(OX297), -Si(X298)(X299)(X300)"; wobei X249, X250, X251 , X252, X253, X254, X255, X256, X257, X258, X259, X260, X261 , X262, X263, X264, X265, X266, X267, X268, X269, X270, X271 , X272, X273, X274, X275, X276, X277, X278, X279, X280, X281 , X282, X283, X284, X285, X286, X287, X288, X289, X290, X291 ,P (O) (OX296) (OX297), -Si (X298) (X299) (X300) "; wherein X249, X250, X251, X252, X253, X254, X255, X256, X257, X258, X259, X260, X261 , X262, X263, X264, X265, X266, X267, X268, X269, X270, X271, X272, X273, X274, X275, X276, X277, X278, X279, X280, X281, X282, X283, X284, X285, X286 , X287, X288, X289, X290, X291,
X292, X293, X294, X295, X296, X297, X298, X299, X300 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X255, X256 und/oder X264, X265 und/oder X277, X278 und/oder X284, X285 und/oder X293, X294 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional zusätzlich einer der Reste Z3, Z4 oder zusätzlich beide Reste Z3, Z4 unabhängig voneinander auch weiter substituiert sein können mit min- destens einem Substituenten, gleich oder verschieden, ausgewählt aus derX292, X293, X294, X295, X296, X297, X298, are X299, X300 are independently selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X255, X256 and / or X264, X265 and / or X277, X278 and / or X284, X285 and / or X293, X294 may each together also form" heterocyclyl "; wherein optionally additionally one of the radicals Z3, Z4 or additionally both radicals Z3, Z4 can also be further substituted with at least one substituent, identical or different, selected from among
Gruppe bestehend aus:Group consisting of:
(d) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX301 , -NX302X303, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- X304, -C(O)O-X305, -C(O)NH-X306, -C(O)NX307X308, -O-X309, -0(- X310-O)uu-H (uu = 1 , 2, 3, 4, 5), -O(-X311-O)uu-X312 (uu = 1 , 2, 3, 4, 5), -OC(O)-X313, -OC(O)-O-X314, -OC(O)-N HX315, -0-C(O)- NX316X317, -OP(O)(OX318)(OX319), -OSi(X320)(X321 )(X322), -OS(O2)-(d) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHX301, -NX302X303, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, - OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X304, -C (O ) O-X305, -C (O) NH-X306, -C (O) NX307X308, -O-X309, -O (- X310-O) uu -H (uu = 1, 2, 3, 4, 5) , -O (-X311-O) uu -X312 (uu = 1, 2, 3, 4, 5), -OC (O) -X313, -OC (O) -O-X314, -OC (O) - N HX315, -0-C (O) - NX316X317, -OP (O) (OX318) (OX319), -OSi (X320) (X321) (X322), -OS (O 2) -
X323, -NHC(O)-X324, -NX325C(O)-X326, -NH-C(O)-O-X327, -NH- C(O)-NH-X328, -NH-C(O)-NX329X330, -NX331-C(O)-O-X332, - NX333-C(O)-NH-X334, -NX335-C(O)-NX336X337, -NHS(O2)-X338, - NX339S(O2)-X340, -S-X341 , -S(O)-X342, -S(O2)-X343, -S(O2)NH- X344, -S(O2)NX345X346, -S(O2)O-X347, -P(O)(OX348)(OX349), -X323, -NHC (O) -X324, -NX325C (O) -X326, -NH-C (O) -O-X327, -NH-C (O) -NH-X328, -NH-C (O) - NX329X330, -NX331-C (O) -O-X332, - NX333-C (O) -NH-X334, -NX335-C (O) -NX336X337, -NHS (O 2) -X338, - NX339S (O 2 ) -X340, -S-X341, -S (O) -X342, -S (O 2) -X343, -S (O2) NH- X344, -S (O 2) NX345X346, -S (O 2) O-X347, -P (O) (OX348) (OX349),
Si(X350)(X351 )(X352)"; wobei X301 , X302, X303, X304, X305, X306, X307, X308, X309, X310, X311 , X312, X313, X314, X315, X316, X317, X318, X319, X320, X321 , X322, X323, X324, X325, X326, X327, X328, X329, X330, X331 , X332, X333, X334, X335, X336, X337, X338, X339, X340, X341 , X342, X343,Si (X350) (X351) (X352) "; wherein X301, X302, X303, X304, X305, X306, X307, X308, X309, X310, X311, X312, X313, X314, X315, X316, X317, X318, X319 , X320, X321, X322, X323, X324, X325, X326, X327, X328, X329, X330, X331, X332, X333, X334, X335, X336, X337, X338, X339, X340, X341, X342, X343,
X344, X345, X346, X347, X348, X349, X350, X351 , X352 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, ary- lalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X307, X308 und/oder X316, X317 und/oder X329, X330 und/oder X336, X337 und/oder X345,X344, X345, X346, X347, X348, X349, X350, X351, X352 are independently selected from the group consisting of: "alkyl, (C 9 -C 30) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aryl- lalkyl, heteroaryl, heteroarylalkyl "and alternatively X307, X308 and / or X316, X317 and / or X329, X330 and / or X336, X337 and / or X345,
X346 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (d) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe beste- hend aus:X346 in each case together can also form "heterocyclyl", where optionally above substituents of the substituent group (d) may in turn be substituted by at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX353, -NX354X355, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- X356, -C(O)O-X357, -C(O)NH-X358, -C(O)NX359X360, -O-X361 , -(ii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHX353, -NX354X355, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X356, -C (O) O-X 357, -C (O) NH-X 358, -C (O) NX 359 X 360, -O-X361, -
O(-X362-O)v-H (v = 1 , 2, 3, 4, 5), -O(-X363-O)v-X364 (v = 1 , 2, 3, 4, 5), -OC(O)-X365, -OC(O)-O-X366, -OC(O)-N HX367, -0-C(O)- NX368X369, -OP(O)(OX370)(OX371 ), -OSi(X372)(X373)(X374), - OS(O2)-X375, -NHC(O)-X376, -NX377C(O)-X378, -NH-C(O)-O- X379, -NH-C(O)-NH-X380, -NH-C(O)-NX381X382, -NX383-C(O)- O-X384, -NX385-C(O)-NH-X386, -NX387-C(O)-NX388X389, - NHS(O2)-X390, -NX391S(O2)-X392, -S-X393, -S(O)-X394, -S(O2)- X395, -S(O2)N H-X396, -S(O2)NX397X398, -S(O2)O-X399, - P(O)(OX400)(OX401 ), -Si(X402)(X403)(X404)"; wobei X353, X354, X355, X356, X357, X358, X359, X360, X361 , X362, X363, X364, X365, X366, X367, X368, X369, X370, X371 , X372, X373, X374, X375, X376, X377, X378, X379, X380, X381 , X382, X383, X384, X385, X386, X387, X388, X389, X390, X391 , X392, X393, X394, X395, X396, X397, X398, X399, X400, X401 , X402, X403, X404 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X359, X360 und/oder X368, X369 und/oder X381 , X382 und/oder X388, X389 und/oder X397, X398 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) und/oder Substituentengruppe (ii) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:O (-X362-O) v -H (v = 1, 2, 3, 4, 5), -O (-X363-O) v -X364 (v = 1, 2, 3, 4, 5), OC (O) -X365, -OC (O) -O-X366, -OC (O) -N HX367, -O-C (O) -NX368X369, -OP (O) (OX370) (OX371), -OSi (X372) (X373) (X374), - OS (O 2) -X375, -NHC (O) -X376, -NX377C (O) -X378, -NH-C (O) -O- X379, -NH-C (O) -NH-X380, -NH-C (O) -NX381X382, -NX383-C (O) -O-X384, -NX385-C (O) -NH-X386, -NX387 -C (O) -NX388X389, - NHS (O 2) -X390, -NX391S (O 2) -X392, -S-X393, -S (O) -X394, -S (O2) - X395, -S (O 2) N H-X396, -S (O 2) NX397X398, -S (O2) O-X399, - P (O) (OX400) (OX401), -Si (X402) (X403) (X404) where X353, X354, X355, X356, X357, X358, X359, X360, X361, X362, X363, X364, X365, X366, X367, X368, X369, X370, X371, X372, X373, X374, X375, X376 , X377, X378, X379, X380, X381, X382, X383, X384, X385, X386, X387, X388, X389, X390, X391, X392, X393, X394, X395, X396, X397, X398, X399, X400, X401 , X402, X403 are, X404 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively X359, X360 and / or X368, X369 and / or X381, X382 and / or X388, X389 and / or X397, X398 may each also together form "heterocyclyl", optionally with obi ge substituents of the substituent group (i) and / or substituent group (ii) may be independently substituted with at least one substituent, same or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX405, -NX406X407, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- X408, -C(O)O-X409, -C(O)NH-X410, -C(O)NX411X412, -O-X413, -(iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHX405, -NX406X407, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP (O) (OH) 2, -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X408, -C (O) O -X409, -C (O) NH-X410, -C (O) NX 4 11 X 412, O-X413, -
O(-X414-O)w-H (w = 1 , 2, 3, 4, 5), -O(-X415-O)w-X416 (w = 1 , 2, 3, 4, 5), -OC(O)-X417, -OC(O)-O-X418, -OC(O)-NHX419, -0-C(O)- NX420X421 , -OP(O)(OX422)(OX423), -OSi(X424)(X425)(X426), - OS(O2)-X427, -NHC(O)-X428, -NX429C(O)-X430, -NH-C(O)-O- X431 , -N H-C(O)-N H-X432, -NH-C(O)-NX433X434, -NX435-C(O)-O (-X414-O) w -H (w = 1, 2, 3, 4, 5), -O (-X415-O) w -X416 (w = 1, 2, 3, 4, 5), OC (O) -X417, -OC (O) -O-X418, -OC (O) -NHX419, -O-C (O) -NX420X421, -OP (O) (OX422) (OX423), -OSi ( X424) (X425) (X426), - OS (O 2) -X427, -NHC (O) -X428, -NX429C (O) -X430, -NH-C (O) -O- X431, -N HC ( O) -NH-X432, -NH-C (O) -NX433X434, -NX435-C (O) -
O-X436, -NX437-C(O)-NH-X438, -NX439-C(O)-NX440X441 , - NHS(O2)-X442, -NX443S(O2)-X444, -S-X445, -S(O)-X446, -S(O2)- X447, -S(O2)N H-X448, -S(O2)NX449X450, -S(O2)O-X451 , - P(O)(OX452)(OX453), -Si(X454)(X455)(X456)"; wobei X405, X406, X407, X408, X409, X410, X411 , X412, X413, X414, X415, X416, X417, X418, X419, X420, X421 , X422, X423, X424, X425, X426, X427, X428, X429, X430, X431 , X432, X433, X434, X435, X436, X437, X438, X439, X440, X441 , X442, X443, X444, X445, X446, X447, X448, X449, X450, X451 , X452, X453, X454, X455, X456 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X411 , X412 und/oder X420, X421 und/oder X433, X434 und/oder X440, X441 und/oder X449, X450 jeweils zusammen auch „heterocyclyl" bilden können;O X436, -NX437-C (O) -NH-X438, -NX439-C (O) -NX440X441, - NHS (O 2) -X442, -NX443S (O 2) -X444, -S-X445, - S (O) -X446, -S (O2) - X447, -S (O2) N H-X448, -S (O 2) NX449X450, -S (O2) O-X451, - P (O) (OX452) (OX453), -Si (X454) (X455) (X456) "; wherein X405, X406, X407, X408, X409, X410, X411, X412, X413, X414, X415, X416, X417, X418, X419, X420, X421, X422, X423, X424, X425, X426, X427, X428, X429 , X430, X431, X432, X433, X434, X435, X436, X437, X438, X439, X440, X441, X442, X443, X444, X445, X446, X447, X448, X449, X450, X451, X452, X453, X454 are X455, X456 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively X411, X412 and / or X420, X421 and / or X433, X434 and / or X440, X441 and / or X449, X450 may each also together form "heterocyclyl";
und einer der Reste Z3, Z4 oder keiner der Reste Z3, Z4 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus: (e) Wasserstoff;and one of Z3, Z4 or none of Z3, Z4 is independently selected from the group consisting of: (e) hydrogen;
(f) Halogen, F, Cl, Br, I;(f) halogen, F, Cl, Br, I;
(g) unsubstituiertes oder substituiertes Alkyl oder (Cg-C3o)Alkyl, wobei optional der Alkyl- oder (C9-C30 )Alkylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Grup- pe bestehend aus:(g) unsubstituted or substituted alkyl or (Cg-C3o) alkyl, may be optionally substituted with (C 9 -C 30 C) alkyl moiety of the alkyl or at least one substituent, identical or different, selected from the group-consisting of pe:
(i) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX457, -NX458X459, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X460, -C(O)O-X461 , -C(O)NH-X462, -C(O)NX463X464, -(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHX457, -NX458X459, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X460, -C (O) O-X 461, -C (O) NH-X 462, -C (O) NX463X464,
O-X465, -O(-X466-O)x-H (x = 1 , 2, 3, 4, 5), -O(-X467-O)x-X468 (x = 1 , 2, 3, 4, 5), -OC(O)-X469, -OC(O)-O-X470, -OC(O)-N HX471 , - O-C(O)-NX472X473, -OP(O)(OX474)(OX475), - OSi(X476)(X477)(X478), -OS(O2)-X479, -NHC(O)-X480, - NX481 C(O)-X482, -NH-C(O)-O-X483, -N H-C(O)-N H-X484, -NH-O-X465, -O (-X466-O) x -H (x = 1, 2, 3, 4, 5), -O (-X467-O) x -X468 (x = 1, 2, 3, 4 , 5), -OC (O) -X469, -OC (O) -O-X470, -OC (O) -N HX471, -OC (O) -NX472X473, -OP (O) (OX474) (OX475) , - OSi (X476) (X477) (X478), -OS (O 2) -X479, -NHC (O) -X480, - NX481 -C (O) -X482, -NH-C (O) -O-X483 , -NHC (O) -NH-X484, -NH-
C(O)-NX485X486, -NX487-C(O)-O-X488, -NX489-C(O)-NH- X490, -NX491-C(O)-NX492X493, -NHS(O2)-X494, -NX495S(O2)- X496, -S-X497, -S(O)-X498, -S(O2)-X499, -S(O2)NH-X500, - S(O2)NX501X502, -S(O2)O-X503, -P(O)(OX504)(OX505), - Si(X506)(X507)(X508)"; wobei X457, X458, X459, X460, X461 , X462, X463, X464, X465, X466, X467, X468, X469, X470, X471 , X472, X473, X474, X475, X476, X477, X478, X479, X480, X481 , X482, X483, X484, X485,C (O) -NX485X486, -NX487-C (O) -O-X488, -NX489-C (O) -NH- X490, -NX491-C (O) -NX492X493, -NHS (O 2) -X494, -NX495S (O 2 ) - X496, -S-X497, -S (O) -X498, -S (O 2 ) -X499, -S (O 2 ) NH-X500, - S (O 2) NX501X502, -S (O2) O-X503, -P (O) (OX504) (OX505), - Si (X506) (X507) (X508) "; wherein X457, X458, X459, X460 , X461, X462, X463, X464, X465, X466, X467, X468, X469, X470, X471, X472, X473, X474, X475, X476, X477, X478, X479, X480, X481, X482, X483, X484, X485 .
X486, X487, X488, X489, X490, X491 , X492, X493, X494, X495, X496, X497, X498, X499, X500, X501 , X502, X503, X504, X505, X506, X507, X508 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ X463, X464 und/oder X472, X473 und/oder X485, X486 und/oder X492, X493 und/oder X501 , X502 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wie- derum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:X486, X487, X488, X489, X490, X491, X492, X493, X494, X495, X496, X497, X498, X499, X500, X501, X502, X503, X504, X505, X506, X507, X508 are independently selected consisting of the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- alkyl" and wherein alternatively X463, X464 and / or X472, X473 and / or X485, X486 and / or X492, X493 and / or X501, X502 may each together also form "heterocyclyl"; in which optionally above substituents of the substituent group (i) can in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX509, -NX510X511, -NO2, -OH, -OCF3, -(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHX509, -NX510X511, -NO 2 , -OH, -OCF 3 , -
SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X512, -C(O)O-X513, -C(O)NH-X514, - C(O)NX515X516, -O-X517, -O(-X518-O)y-H (y = 1, 2, 3, 4, 5), - O(-X519-O)y-X520 (y = 1, 2, 3, 4, 5), -OC(O)-X521, -OC(O)-O- X522, -OC(O)-NHX523, -O-C(O)-NX524X525, -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X512, -C (O) O -X513, -C (O) NH-X514, -C (O) NX515X516, -O-X517, -O (-X518-O) y -H (y = 1, 2, 3, 4, 5), - O (-X519-O) y -X520 (y = 1, 2, 3, 4, 5), -OC (O) -X521, -OC (O) - O-X522, -OC (O) -NHX523, -OC (O) -NX524X525, -
OP(O)(OX526)(OX527), -OSi(X528)(X529)(X530), -OS(O2)- X531, -NHC(O)-X532, -NX533C(O)-X534, -NH-C(O)-O-X535, -NH-C(O)-NH-X536, -NH-C(O)-NX537X538, -NX539-C(O)-O- X540, -NX541-C(O)-NH-X542, -NX543-C(O)-NX544X545, - NHS(O2)-X546, -NX547S(O2)-X548, -S-X549, -S(O)-X550, -OP (O) (OX526) (OX527), -OSi (X528) (X529) (X530), -OS (O2) - X531, -NHC (O) -X532, -NX533C (O) -X534, -NH -C (O) -O-X535, -NH-C (O) -NH-X536, -NH-C (O) -NX537X538, -NX539-C (O) -O-X540, -NX541-C (O ) -NH-X542, -NX543-C (O) -NX544X545, - NHS (O 2) -X546, -NX547S (O 2) -X548, -S-X549, -S (O) -X550, -
S(O2)-X551, -S(O2)NH-X552, -S(O2)NX553X554, -S(O2)O- X555, -P(O)(OX556)(OX557), -Si(X558)(X559)(X560)"; wobei X509, X510, X51 1 , X512, X513, X514, X515, X516, X517, X518, X519, X520, X521 , X522, X523, X524, X525, X526, X527, X528, X529, X530, X531 , X532, X533, X534, X535, X536, X537, X538, X539, X540, X541 , X542, X543, X544, X545, X546, X547, X548, X549, X550, X551 , X552, X553, X554, X555, X556, X557, X558, X559, X560 unabhängig voneinander ausgewählt sind ausS (O 2) -X551, -S (O2) NH-X552, -S (O 2) NX553X554, -S (O2) O- X555, -P (O) (OX556) (OX557), -Si (X558) (X559) (X560) "; wherein X509, X510, X51 1, X512, X513, X514, X515, X516, X517, X518, X519, X520, X521, X522, X523, X524, X525, X526, X527 . X528, X529, X530, X531, X532, X533, X534, X535, X536, X537, X538, X539, X540, X541, X542, X543, X544, X545, X546, X547, X548, X549, X550, X551, X552, X553, X554, X555, X556, X557, X558, X559, X560 are selected independently from each other
5 der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X515, X516 und/oder X524, X525 und/oder X537, X538 und/oder X544, X545 und/oder X553, X554 jeweils zusammen auch „heterocyclyl" bilden können;5 the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively X515, X516 and / or X524, X525 and / or X537, X538 and / or X544, X545 and / or X553, X554 may each together also form "heterocyclyl";
10 wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:In which optionally substituents of the substituent group (ii) above may be substituted independently with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he-(iii) "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE
15 terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,15 terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
Br, I, CN, CF3, N3, NH2, -NHX561 , -NX562X563, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X564, -C(O)O-X565, - C(O)NH-X566, -C(O)NX567X568, -O-X569, -O(-X570-O)z-Br, I, CN, CF 3, N 3, NH 2, -NHX561, -NX562X563, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2 , -CHO, -COOH, - C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X564, -C (O) O-X 565, - C ( O) NH-X566, -C (O) NX567X568, -O-X569, -O (-X570-O) z -
20 H (z = 1 , 2, 3, 4, 5), -O(-X571-O)z-X572 (z = 1 , 2, 3, 4, 5), -20 H (z = 1, 2, 3, 4, 5), -O (-X571-O) z -X572 (z = 1, 2, 3, 4, 5),
OC(O)-X573, -OC(O)-O-X574, -OC(O)-N HX575, -0-C(O)- NX576X577, -OP(O)(OX578)(OX579), - OSi(X580)(X581 )(X582), -OS(O2)-X583, -NHC(O)-X584, - NX585C(O)-X586, -NH-C(O)-O-X587, -NH-C(O)-NH-OC (O) -X573, -OC (O) -O-X574, -OC (O) -N HX575, -O-C (O) -NX576X577, -OP (O) (OX578) (OX579), -OSi (X580) (X581) (x582), -OS (O 2) -X583, -NHC (O) -X584, - NX585C (O) -X586, -NH-C (O) -O-X587, -NH- C (O) -NH-
25 X588, -NH-C(O)-NX589X590, -NX591-C(O)-O-X592, -25 X588, -NH-C (O) -NX589X590, -NX591-C (O) -O-X592, -
NX593-C(O)-NH-X594, -NX595-C(O)-NX596X597, - NHS(O2)-X598, -NX599S(O2)-X600, -S-X601 , -S(O)-X602, -S(O2)-X603, -S(O2)N H-X604, -S(O2)NX605X606, -S(O2)O- X607, -P(O)(OX608)(OX609), -Si(X610)(X61 1 )(X612)";NX593-C (O) -NH-X594, -NX595-C (O) -NX596X597, - NHS (O 2) -X598, -NX599S (O 2) -X600, -S-X601, -S (O) - X602, -S (O 2) -X603, -S (O2) N H-X604, -S (O 2) NX605X606, -S (O2) O- X607, -P (O) (OX608) (OX609 ), -Si (X610) (X61 1) (X612) ";
30 wobei X561, X562, X563, X564, X565, X566, X567, X568,30 where X561, X562, X563, X564, X565, X566, X567, X568,
X569, X570, X571 , X572, X573, X574, X575, X576, X577, X578, X579, X580, X581, X582, X583, X584, X585, X586, X587, X588, X589, X590, X591, X592, X593, X594, X595, X596, X597, X598, X599, X600, X601, X602, X603, X604, X605, X606, X607, X608, X609, X610, X61 1 , X612 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X567, X568 und/oder X576, X577 und/oder X589, X590 und/oder X596, X597 und/oder X605, X606 jeweils zusammen auch „heterocyclyl" bilden können;X569, X570, X571, X572, X573, X574, X575, X576, X577, X578, X579, X580, X581, X582, X583, X584, X585, X586, X587, X588, X589, X590, X591, X592, X593, X594, X595, X596, X597, X598, X599, X600, X601, X602, X603, X604, X605, X606, X607, X608, X609, X610, X61 1, X612 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, as heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X567, X568 and / or X576, X577 and / or X589, X590 and / or X596, X597 and / or X605, X606 may each together also form" heterocyclyl ";
(h) unsubstituiertes oder substituiertes Aryl, wobei optional der Arylrest sub- stituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(h) unsubstituted or substituted aryl, wherein optionally the aryl radical can be substituted by at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX613, -NX614X615, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2,(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHX613, -NX614X615, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 ,
-C(O)-X616, -C(O)O-X617, -C(O)NH-X618, -C(0)NX619X620, - O-X621 , -O(-X622-O)a-H (a = 1 , 2, 3, 4, 5), -O(-X623-O)a-X624 (a = 1 , 2, 3, 4, 5), -OC(O)-X625, -OC(O)-O-X626, -OC(O)-N HX627, - O-C(O)-NX628X629, -OP(O)(OX630)(OX631 ), - OSi(X632)(X633)(X634), -OS(O2)-X635, -NHC(O)-X636, --C (O) -X616, -C (O) O -X617, -C (O) NH-X618, -C (O) NX619X620, -O-X621, -O (-X622-O) a -H ( a = 1, 2, 3, 4, 5), -O (-X623-O) a -X624 (a = 1, 2, 3, 4, 5), -OC (O) -X625, -OC (O ) -O-X626, -OC (O) -N HX627, -OC (O) -NX628X629, -OP (O) (OX630) (OX631), -OSi (X632) (X633) (X634), -OS ( O 2 ) -X635, -NHC (O) -X636, -
NX637C(O)-X638, -NH-C(O)-O-X639, -N H-C(O)-N H-X640, -NH- C(O)-NX641X642, -NX643-C(O)-O-X644, -NX645-C(O)-NH- X646, -NX647-C(O)-NX648X649, -NHS(O2)-X650, -NX651 S(O2)- X652, -S-X653, -S(O)-X654, -S(O2)-X655, -S(O2)N H-X656, - S(O2)NX657X658, -S(O2)O-X659, -P(O)(OX660)(OX661 ), -NX637C (O) -X638, -NH-C (O) -O-X639, -NHC (O) -NH-X640, -NH-C (O) -NX641X642, -NX643-C (O) -O -X644, -NX645-C (O) -NH- X646, -NX647-C (O) -NX648X649, -NHS (O 2) -X650, -NX651 S (O 2) - X652, -S-X653, - S (O) -X654, -S (O 2) -X655, -S (O2) N H-X656, - S (O 2) NX657X658, -S (O2) O-X659, -P (O) (OX660) (OX661), -
Si(X662)(X663)(X664)"; wobei X613, X614, X615, X616, X617, X618, X619, X620, X621 , X622, X623, X624, X625, X626, X627, X628, X629, X630, X631 , X632, X633, X634, X635, X636, X637, X638, X639, X640, X641 , X642, X643, X644, X645, X646, X647, X648, X649, X650, X651 ,Si (X662) (X663) (X664) "; wherein X613, X614, X615, X616, X617, X618, X619, X620, X621, X622, X623, X624, X625, X626, X627, X628, X629, X630, X631 , X632, X633, X634, X635, X636, X637, X638, X639, X640, X641, X642, X643, X644, X645, X646, X647, X648, X649, X650, X651,
X652, X653, X654, X655, X656, X657, X658, X659, X660, X661 , X662, X663, X664 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ X619, X620 und/oder X628, X629 und/oder X641 , X642 und/oder X648, X649 und/oder X657, X658 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wie- derum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:X652, X653, X654, X655, X656, X657, X658, X659, X660, X661, X662, X663, X664 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl , heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-allyl kyl "and wherein alternatively X619, X620 and / or X628, X629 and / or X641, X642 and / or X648, X649 and / or X657, X658 may each together also form" heterocyclyl "; in which optionally above substituents of the substituent group (i) can in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX665, -NX666X667, -NO2, -OH, -OCF3, -(ii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHX665, -NX666X667, -NO 2 , -OH, -OCF 3 , -
SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X668, -C(O)O-X669, -C(O)NH-X670, - C(O)NX671X672, -O-X673, -O(-X674-O)b-H (b = 1 , 2, 3, 4, 5), - O(-X675-O)b-X676 (b = 1 , 2, 3, 4, 5), -OC(O)-X677, -OC(O)-O- X678, -OC(O)-NHX679, -O-C(O)-NX680X681 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X668, -C (O) O -X669, -C (O) NH-X670, -C (O) NX671X672, -O-X673, -O (-X674-O) b -H (b = 1, 2, 3, 4, 5), - O (-X675-O) b -X676 (b = 1, 2, 3, 4, 5), -OC (O) -X677, -OC (O) - O-X678, -OC (O) -NHX679, -OC (O) -NX680X681, -
OP(O)(OX682)(OX683), -OSi(X684)(X685)(X686), -OS(O2)- X687, -NHC(O)-X688, -NX689C(O)-X690, -NH-C(O)-O-X691, -NH-C(O)-NH-X692, -NH-C(O)-NX693X694, -NX695-C(O)-O- X696, -NX697-C(O)-NH-X698, -NX699-C(O)-NX700X701, - NHS(O2)-X702, -NX703S(O2)-X704, -S-X705, -S(O)-X706, -OP (O) (OX682) (OX683), -OSi (X684) (X685) (X686), -OS (O2) - X687, -NHC (O) -X688, -NX689C (O) -X690, -NH -C (O) -O-X691, -NH-C (O) -NH-X692, -NH-C (O) -NX693X694, -NX695-C (O) -O-X696, -NX697-C (O ) -NH-X698, -NX699-C (O) -NX700X701, - NHS (O 2 ) -X702, -NX703S (O 2 ) -X704, -S-X705, -S (O) -X706, -
S(O2)-X707, -S(O2)NH-X708, -S(O2)NX709X710, -S(O2)O- X711,-P(O)(OX712)(OX713), -Si(X714)(X715)(X716)"; wobei X665, X666, X667, X668, X669, X670, X671, X672, X673, X674, X675, X676, X677, X678, X679, X680, X681 , X682, X683, X684, X685, X686, X687, X688, X689, X690, X691 , X692, X693,S (O 2) -X707, -S (O2) NH-X708, -S (O 2) NX709X710, -S (O2) O- X711, -P (O) (OX712) (OX713), -Si (X714) (X715) (X716) "; wherein X665, X666, X667, X668, X669, X670, X671, X672, X673, X674, X675, X676, X677, X678, X679, X680, X681, X682, X683, X684, X685, X686, X687, X688, X689, X690, X691, X692, X693,
X694, X695, X696, X697, X698, X699, X700, X701, X702, X703, X704, X705, X706, X707, X708, X709, X710, X711, X712, X713, X714, X715, X716 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C30)alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X671 , X672 und/oder X680, X681 und/oder X693, X694 und/oder X700, X701 und/oder X709, X710 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:X694, X695, X696, X697, X698, X699, X700, X701, X702, X703, X704, X705, X706, X707, X708, X709, X710, X711, X712, X713, X714, X715, X716 are independently selected consisting of the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively X671, X672 and / or X680, X681 and / or X693 , X694 and / or X700, X701 and / or X709, X710 may together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
5 (iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX717, -NX718X719, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X720, -C(O)O-X721 , -5 (iii) "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHX717, -NX718X719, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O ) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X 720, -C (O) O-X 721, -
10 C(O)NH-X722, -C(O)NX723X724, -O-X725, -O(-X726-O)c-10 C (O) NH-X722, -C (O) NX723X724, -O-X725, -O (-X726-O) c -
H (c = 1 , 2, 3, 4, 5), -O(-X727-O)c-X728 (c = 1 , 2, 3, 4, 5), - OC(O)-X729, -OC(O)-O-X730, -OC(O)-N HX731 , -0-C(O)- NX732X733, -OP(O)(OX734)(OX735), - OSi(X736)(X737)(X738), -OS(O2)-X739, -NHC(O)-X740, -H (c = 1, 2, 3, 4, 5), -O (-X727-O) c -X728 (c = 1, 2, 3, 4, 5), - OC (O) -X729, -OC (O) -O-X730, -OC (O) -N HX731, -O-C (O) -NX732X733, -OP (O) (OX734) (OX735), -OSi (X736) (X737) (X738) , -OS (O 2 ) -X739, -NHC (O) -X740, -
15 NX741 C(O)-X742, -NH-C(O)-O-X743, -NH-C(O)-NH-15 NX741 C (O) -X742, -NH-C (O) -O-X743, -NH-C (O) -NH-
X744, -NH-C(O)-NX745X746, -NX747-C(O)-O-X748, - NX749-C(O)-NH-X750, -NX751-C(O)-NX752X753, - NHS(O2)-X754, -NX755S(O2)-X756, -S-X757, -S(O)-X758, -S(O2)-X759, -S(O2)N H-X760, -S(O2)NX761X762, -S(O2)O-X744, -NH-C (O) -NX745X746, -NX747-C (O) -O-X748, -NX749-C (O) -NH-X750, -NX751-C (O) -NX752X753, -NHS (O 2) -X754, -NX755S (O 2) -X756, -S-X757, -S (O) -X758, -S (O 2) -X759, -S (O2) N H-X760, -S ( O 2 ) NX761X762, -S (O 2 ) O-
20 X763, -P(O)(OX764)(OX765), -Si(X766)(X767)(X768)"; wobei X717, X718, X719, X720, X721 , X722, X723, X724, X725, X726, X727, X728, X729, X730, X731 , X732, X733, X734, X735, X736, X737, X738, X739, X740, X741 , X742, X743, X744, X745, X746, X747, X748, X749, X750, X751 ,20 X763, -P (O) (OX764) (OX765), -Si (X766) (X767) (X768) "; wherein X717, X718, X719, X720, X721, X722, X723, X724, X725, X726, X727 , X728, X729, X733, X731, X732, X733, X734, X735, X736, X737, X738, X739, X740, X741, X742, X743, X744, X745, X746, X747, X748, X749, X750, X751,
25 X752, X753, X754, X755, X756, X757, X758, X759, X760,25 X752, X753, X754, X755, X756, X757, X758, X759, X760,
X761 , X762, X763, X764, X765, X766, X767, X768 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"X761, X762, X763, X764, X765, X766, are X767, X768 are independently selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "
30 und wobei alternativ X723, X724 und/oder X732, X733 und/oder X745, X746 und/oder X752, X753 und/oder X761 , X762 jeweils zusammen auch „heterocyclyl" bilden können; (j) unsubstituiertes oder substituiertes Heteroaryl, wobei optional der Hetero- arylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:And wherein alternatively X723, X724 and / or X732, X733 and / or X745, X746 and / or X752, X753 and / or X761, X762 may each also together form "heterocyclyl"; (j) unsubstituted or substituted heteroaryl, where optionally the heteroaryl radical may be substituted by at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3,(i) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 ,
N3, NH2, -NHX769, -NX770X771 , -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X772, -C(O)O-X773, -C(O)NH-X774, -C(O)NX775X776, - O-X777, -O(-X778-O)d-H (d = 1 , 2, 3, 4, 5), -O(-X779-O)d-X780 (d = 1 , 2, 3, 4, 5), -OC(O)-X781 , -OC(O)-O-X782, -OC(O)-N HX783, -N 3, NH 2, -NHX769, -NX770X771, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP (O) (OH) 2, -CHO, -COOH, - C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X772, -C (O) O -X773, -C (O) NH-X774, -C (O) NX775X776, -O-X777, -O (-X778-O) d -H (d = 1, 2, 3, 4, 5), -O (-X779-O) d -X780 (d = 1 , 2, 3, 4, 5), -OC (O) -X781, -OC (O) -O-X782, -OC (O) -N HX783, -
O-C(O)-NX784X785, -OP(O)(OX786)(OX787), - OSi(X788)(X789)(X790), -OS(O2)-X791 , -NHC(O)-X792, - NX793C(O)-X794, -NH-C(O)-O-X795, -N H-C(O)-N H-X796, -NH- C(O)-NX797X798, -NX799-C(O)-O-X800, -NX801-C(O)-NH- X802, -NX803-C(O)-NX804X805, -NHS(O2)-X806, -NX807S(O2)-OC (O) -NX784X785, -OP (O) (OX786) (OX787), - OSi (X788) (X789) (X790), -OS (O 2) -X791, -NHC (O) -X792, - NX793C (O) -X794, -NH-C (O) -O-X795, -NHC (O) -NH-X796, -NH-C (O) -NX797X798, -NX799-C (O) -O- X800, -NX801-C (O) -NH- X802, -NX803-C (O) -NX804X805, -NHS (O 2) -X806, -NX807S (O 2) -
X808, -S-X809, -S(O)-X810, -S(O2)-X811 , -S(O2)N H-X812, - S(O2)NX813X814, -S(O2)O-X815, -P(O)(OX816)(OX817), - Si(X818)(X819)(X820)"; wobei X769, X770, X771 , X772, X773, X774, X775, X776, X777, X778, X779, X780, X781 , X782, X783, X784, X785, X786, X787,X808, -S-X809, -S (O) -X810, -S (O 2) -X811, -S (O2) N H-X812, - S (O 2) NX813X814, -S (O 2) O -X815, -P (O) (OX816) (OX817), -Si (X818) (X819) (X820) "; wherein X769, X770, X771, X772, X773, X774, X775, X776, X777, X778, X779 , X780, X781, X782, X783, X784, X785, X786, X787,
X788, X789, X790, X791 , X792, X793, X794, X795, X796, X797, X798, X799, X800, X801 , X802, X803, X804, X805, X806, X807, X808, X809, X810, X81 1 , X812, X813, X814, X815, X816, X817, X818, X819, X820 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X775, X776 und/oder X784, X785 und/oder X797, X798 und/oder X804, X805 und/oder X813, X814 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX821 , -NX822X823, -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X824, -C(O)O-X825, -C(O)NH-X826, -X788, X789, X790, X791, X792, X793, X794, X795, X796, X797, X798, X799, X800, X801, X802, X803, X804, X805, X806, X807, X808, X809, X810, X81 1, X812 , X813, X814, X815, X816, X817, X818, X819, X820 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X775, X776 and / or X784, X785 and / or X797, X798 and / or X804, X805 and / or X813, X814 can each also together form" heterocyclyl "; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of: (ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHX821, -NX822X823, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X824, -C (O) O-X 825, -C (O) NH-X 826, -
C(O)NX827X828, -O-X829, -O(-X830-O)e-H (e = 1 , 2, 3, 4, 5), - O(-X831-O)e-X832 (e = 1 , 2, 3, 4, 5), -OC(O)-X833, -OC(O)-O- X834, -OC(O)-N HX835, -O-C(O)-NX836X837, - OP(O)(OX838)(OX839), -OSi(X840)(X841 )(X842), -OS(O2)- X843, -NHC(O)-X844, -NX845C(O)-X846, -NH-C(O)-O-X847,C (O) NX827X828, -O-X829, -O (-X830-O) e -H (e = 1, 2, 3, 4, 5), - O (-X831-O) e -X832 (e = 1, 2, 3, 4, 5), -OC (O) -X833, -OC (O) -O-X834, -OC (O) -N HX835, -OC (O) -NX836X837, -OP (O ) (OX838) (OX839), -OSi (X840) (X841) (X842), -OS (O2) - X843, -NHC (O) -X844, -NX845C (O) -X846, -NH-C ( O) -O-X847,
-N H-C(O)-N H-X848, -NH-C(O)-NX849X850, -NX851 -C(O)-O- X852, -NX853-C(O)-NH-X854, -NX855-C(O)-NX856X857, - NHS(O2)-X858, -NX859S(O2)-X860, -S-X861 , -S(O)-X862, - S(O2)-X863, -S(O2)NH-X864, -S(O2)NX865X866, -S(O2)O- X867, -P(O)(OX868)(OX869), -Si(X870)(X871 )(X872)"; wobei X821 , X822, X823, X824, X825, X826, X827, X828, X829, X830, X831 , X832, X833, X834, X835, X836, X837, X838, X839, X840, X841 , X842, X843, X844, X845, X846, X847, X848, X849, X850, X851 , X852, X853, X854, X855, X856, X857, X858, X859, X860, X861 , X862, X863, X864, X865, X866, X867, X868, X869,-NHC (O) -NH-X848, -NH-C (O) -NX849X850, -NX851 -C (O) -O-X852, -NX853-C (O) -NH-X854, -NX855-C (O) -NX856X857, - NHS (O 2) -X858, -NX859S (O 2) -X860, -S-X861, -S (O) -X862, - S (O 2) -X863, -S (O 2) NH-X864, -S (O 2) NX865X866, -S (O2) O- X867, -P (O) (OX868) (OX869), -Si (X870) (X871) (X872) "; wherein X821, X822, X823, X824, X825, X826, X827, X828, X829, X830, X831, X832, X833, X834, X835, X836, X837, X838, X839, X840, X841, X842, X843, X844, X845, X846, X847, X848, X849, X850, X851, X852, X853, X854, X855, X856, X857, X858, X859, X860, X861, X862, X863, X864, X865, X866, X867, X868, X869,
X870, X871 , X872 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X827, X828 und/oder X836, X837 und/oder X849, X850 und/oder X856, X857 und/oder X865,X870, X871, X872 are independently selected from the group consisting of: "alkyl, (C" 9 " -C" 30 " ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively X827, X828 and / or X836, X837 and / or X849, X850 and / or X856, X857 and / or X865,
X866 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausge- wählt aus der Gruppe bestehend aus:X866 in each case together can also form "heterocyclyl", where optionally above substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX873, -NX874X875, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X876, -C(O)O-X877, - C(O)NH-X878, -C(O)NX879X880, -O-X881 , -O(-X882-O)r- H (f = 1 , 2, 3, 4, 5), -O(-X883-O)f-X884 (f = 1 , 2, 3, 4, 5), - OC(O)-X885, -OC(O)-O-X886, -OC(O)-N HX887, -0-C(O)- NX888X889, -OP(O)(OX890)(OX891 ), -(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHX873, -NX874X875, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, - C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X876, -C (O) O -X877, -C (O) NH-X878, -C (O) NX879X880, -O-X881, -O (-X882-O) r -H (f = 1, 2, 3, 4, 5), -O (-X883-O) f -X884 (f = 1 , 2, 3, 4, 5), - OC (O) -X885, -OC (O) -O-X886, -OC (O) -N HX887, -O-C (O) -NX888X889, -OP ( O) (OX890) (OX891), -
OSi(X892)(X893)(X894), -OS(O2)-X895, -NHC(O)-X896, - NX897C(O)-X898, -NH-C(O)-O-X899, -NH-C(O)-NH- X900, -NH-C(O)-NX901X902, -NX903-C(O)-O-X904, - NX905-C(O)-NH-X906, -NX907-C(O)-NX908X909, - NHS(O2)-X910, -NX91 1 S(O2)-X912, -S-X913, -S(O)-X914,OSi (X892) (X893) (X894), -OS (O 2) -X895, -NHC (O) -X896, - NX897C (O) -X898, -NH-C (O) -O-X899, -NH -C (O) -NH-X900, -NH-C (O) -NX901X902, -NX903-C (O) -O-X904, - NX905-C (O) -NH-X906, -NX907-C (O ) -NX908X909, - NHS (O 2) -X910, -NX91 1 S (O 2) -X912, -S-X913, -S (O) -X914,
-S(O2)-X915, -S(O2)NH-X916, -S(O2)NX917X918, -S(O2)O- X919, -P(O)(OX920)(OX921 ), -Si(X922)(X923)(X924)"; wobei X873, X874, X875, X876, X877, X878, X879, X880, X881 , X882, X883, X884, X885, X886, X887, X888, X889, X890, X891, X892, X893, X894, X895, X896, X897, X898,-S (O 2) -X915, -S (O2) NH-X916, -S (O 2) NX917X918, -S (O2) O- X919, -P (O) (OX920) (OX921), - Si (X922) (X923) (X924) "; wherein X873, X874, X875, X876, X877, X878, X879, X880, X881, X882, X883, X884, X885, X886, X887, X888, X889, X890, X891 , X892, X893, X894, X895, X896, X897, X898,
X899, X900, X901 , X902, X903, X904, X905, X906, X907, X908, X909, X910, X911, X912, X913, X914, X915, X916, X917, X918, X919, X920, X921, X922, X923, X924 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc-X999, X900, X901, X902, X903, X904, X905, X906, X907, X908, X909, X910, X911, X912, X913, X914, X915, X916, X917, X918, X919, X920, X921, X922, X923, (C 9 -C 3 o) "alkyl, alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl: X924 are independently selected from the group consisting of
IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X879, X880 und/oder X888, X889 und/oder X901 , X902 und/oder X908, X909 und/oder X917, X918 jeweils zusammen auch „heterocyclyl" bilden können;IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X879, X880 and / or X888, X889 and / or X901, X902 and / or X908, X909 and / or X917, X918 may together also form" heterocyclyl " ;
(k) 0Z6, wobei Z6 unabhängig ausgewählt ist aus der Gruppe bestehend aus:(k) 0Z6, where Z6 is independently selected from the group consisting of:
(i) „Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX925, -NX926X927, -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X928, -C(O)O-X929, -C(O)NH-X930, -(i) "hydrogen, alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wherein optionally substituents of the substituent group (i) above may be independently substituted with at least one substituent, identical or different, selected from the group consisting of: (ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHX925, -NX926X927, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X 928, -C (O) O-X 929, -C (O) NH-X 930, -
C(O)NX931X932, -O-X933, -O(-X934-O)g-H (g = 1 , 2, 3, 4, 5), - O(-X935-O)g-X936 (g = 1 , 2, 3, 4, 5), -OC(O)-X937, -OC(O)-O- X938, -OC(O)-NHX939, -O-C(O)-NX940X941 , - OP(O)(OX942)(OX943), -OSi(X944)(X945)(X946), -OS(O2)- X947, -NHC(O)-X948, -NX949C(O)-X950, -NH-C(O)-O-X951 ,C (O) NX931X932, -O-X933, -O (-X934-O) g -H (g = 1, 2, 3, 4, 5), - O (-X935-O) g -X936 (g = 1, 2, 3, 4, 5), -OC (O) -X937, -OC (O) -O-X 938, -OC (O) -NHX 939, -OC (O) -NX 940 X 941, - OP (O) (OX942) (OX943), -OSi (X944) (X945) (X946), -OS (O2) - X947, -NHC (O) -X948, -NX949C (O) -X950, -NH-C (O ) -O-X951,
-N H-C(O)-N H-X952, -NH-C(O)-NX953X954, -NX955-C(O)-O- X956, -NX957-C(O)-NH-X958, -NX959-C(O)-NX960X961 , - NHS(O2)-X962, -NX963S(O2)-X964, -S-X965, -S(O)-X966, - S(O2)-X967, -S(O2)NH-X968, -S(O2)NX969X970, -S(O2)O- X971 , -P(O)(OX972)(OX973), -Si(X974)(X975)(X976)"; wobei X925, X926, X927, X928, X929, X930, X931 , X932, X933, X934, X935, X936, X937, X938, X939, X940, X941 , X942, X943, X944, X945, X946, X947, X948, X949, X950, X951 , X952, X953, X954, X955, X956, X957, X958, X959, X960, X961 , X962, X963, X964, X965, X966, X967, X968, X969, X970, X971 , X972, X973,-NHC (O) -NH-X952, -NH-C (O) -NX953X954, -NX955-C (O) -O-X956, -NX957-C (O) -NH-X958, -NX959-C (O) -NX 960 X 961, - NHS (O 2 ) -X 962, -NX 963S (O 2 ) -X 964, -S-X 965, -S (O) -X 966, -S (O 2 ) -X 967, -S (O 2) NH-X968, -S (O 2) NX969X970, -S (O2) O- X971, -P (O) (OX972) (OX973), -Si (X974) (X975) (X976) "; wherein X925, X926, X927, X928, X929, X930, X931, X932, X933, X934, X935, X936, X937, X938, X939, X940, X941, X942, X943, X944, X945, X946, X947, X948, X949, X950, X951, X952, X953, X954, X955, X956, X957, X958, X959, X960, X961, X962, X963, X964, X965, X966, X967, X968, X969, X970, X971, X972, X973,
X974, X975, X976 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X931 , X932 und/oder X940, X941 und/oder X953, X954 und/oder X960, X961 und/oder X969,X974, X975, X976 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively X 931, X 932 and / or X940, X941 and / or X953, X954 and / or X960, X961 and / or X969,
X970 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausge- wählt aus der Gruppe bestehend aus:X970 in each case together can also form "heterocyclyl", where optionally above substituents of the substituent group (ii) may again be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX977, -NX978X979, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X980, -C(O)O-X981 , - C(O)NH-X982, -C(O)NX983X984, -O-X985, -O(-X986-O)h- H (h = 1 , 2, 3, 4, 5), -O(-X987-O)h-X988 (h = 1 , 2, 3, 4, 5), - OC(O)-X989, -OC(O)-O-X990, -OC(O)-N HX991 , -0-C(O)- NX992X993, -OP(O)(OX994)(OX995), -(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHX977, -NX978X979, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, - C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X980, -C (O) O -X981, -C (O) NH-X982, -C (O) NX983X984, -O-X985, -O (-X986-O) h -H (h = 1, 2, 3, 4, 5), -O (-X987-O) h -X988 (h = 1 , 2, 3, 4, 5), - OC (O) -X989, -OC (O) -O-X990, -OC (O) -N HX991, -O-C (O) -NX992X993, -OP ( O) (OX994) (OX995),
OSi(X996)(X997)(X998), -OS(O2)-X999, -NHC(O)-XI OOO, - NX1001 C(O)-XI 002, -NH-C(O)-O-XI 003, -NH-C(O)-NH- X1004, -NH-C(O)-NXI 005X1006, -NX1007-C(O)-O-XI 008, -NXIOOg-C(O)-NH-XI OIO1 -NXIOI I-C(O)-NXIO^XI OI S, - NHS(O2)-X1014, -NX1015S(O2)-X1016, -S-X1017, -S(O)-OSi (X996) (X997) (X998), -OS (O 2) -X999, -NHC (O) -XI OOO, - NX1001 C (O) -XI 002, -NH-C (O) -O-XI 003, -NH-C (O) -NH-X1004, -NH-C (O) -NXI 005X1006, -NX1007-C (O) -O-XI 008, -NXIOOg-C (O) -NH-XI OIO 1 -NXIOI IC (O) -NXIO ^ XI OI S, - NHS (O 2 ) -X1014, -NX1015S (O 2 ) -X1016, -S-X1017, -S (O) -
X1018, -S(O2)-X1019, -S(O2)NH-XI 020, - S(O2)NX1021X1022, -S(O2)O-XI 023, - P(O)(OXI 024)(OX1025), -Si(XI 026)(X1027)(X1028)"; wobei X977, X978, X979, X980, X981 , X982, X983, X984, X985, X986, X987, X988, X989, X990, X991 , X992, X993,X1018, -S (O 2) -X1019, -S (O2) NH-XI 020, - S (O 2) NX1021X1022, -S (O2) OXI 023, - P (O) (OXI 024) (OX1025), -Si (XI 026) (X1027) (X1028) "; wherein X977, X978, X979, X980, X981, X982, X983, X984, X985, X986, X987, X988, X989, X990, X991, X992 , X993,
X994, X995, X996, X997, X998, X999, X1000, X1001 , X1002, X1003, X1004, X1005, X1006, X1007, X1008, X1009, X1010, X101 1 , X1012, X1013, X1014, X1015, X1016, X1017, X1018, X1019, X1020, X1021 , X1022, X1023, X1024, X1025, X1026, X1027, X1028 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X983, X984 und/oder X992, X993 und/oder X1005, X1006 und/oder X1012, X1013 und/oder X1021 , X1022 jeweils zusammen auch „heterocyclyl" bilden können;X994, X995, X996, X997, X998, X999, X1000, X1001, X1002, X1003, X1004, X1005, X1006, X1007, X1008, X1009, X1010, X101 1, X1012, X1013, X1014, X1015, X1016, X1017, X1018 , x1019, X1020, X1021, X1022, X1023, X1024, X1025, X1026, are X1027, X1028 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X983, X984 and / or X992, X993 and / or X1005, X1006 and / or X1012, X1013 and / or X1021, X1022 may each also together form" heterocyclyl ";
, wobei Z7 unabhängig ausgewählt ist aus der Gruppe bestehend aus: „Wasserstoff, alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX1029, -NX1030X1031 , -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-XI 032, -C(O)O-XI 033, -C(O)NH-wherein Z7 is independently selected from the group consisting of: "hydrogen, alkyl, (C" 9 " -C" 3 " ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl;""wherein optional substituents above the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of: (ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHX1029, -NX1030X1031, -NO 2 , -OH, - OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -XI 032, -C (O) O-XI 033, -C (O) NH-
X1034, -C(O)NXI 035X1036, -O-X1037, -0(-X1038-O)-H (i = 1 , 2, 3, 4, 5), -0(-X1039-O)1-XI 040 (i = 1 , 2, 3, 4, 5), -OC(O)- X1041 , -OC(O)-O-XI 042, -OC(O)-NHXI 043, -0-C(O)- NX1044X1045, -OP(O)(OXI 046)(OX1047), - OSi(XI 048)(X1049)(X1050), -OS(O2)-X1051 , -N HC(O)-XI 052, -X1034, -C (O) NXI 035X1036, -O-X1037, -0 (-X1038-O) -H (i = 1, 2, 3, 4, 5), -O (-X1039-O) 1 -XI 040 (i = 1, 2, 3, 4, 5), -OC (O) -X1041, -OC (O) -O-XI 042, -OC (O) -NHXI 043, -O-C (O) - NX1044X1045, -OP (O) (OXI 046) (OX1047), - OSi (XI 048) (X1049) (X1050), -OS (O 2 ) -X1051, -N HC (O) -XI 052, -
NX1053C(O)-XI054, -NH-C(O)-O-XI055, -NH-C(O)-NH- X1056, -NH-C(O)-NXI057X1058, -NX1059-C(O)-O-XI060, - NX1061-C(O)-NH-X1062, -NX1063-C(O)-NXI064X1065, - NHS(O2)-X1066, -NX1067S(O2)-X1068, -S-X1069, -S(O)- X1070, -S(O2)-X1071, -S(O2)NH-XI072, -S(O2)NXI073X1074, -NX1053C (O) -XI054, -NH-C (O) -O-XI055, -NH-C (O) -NH-X1056, -NH-C (O) -NXI057X1058, -NX1059-C (O) -O -XI060, - NX1061-C (O) -NH-X1062, -NX1063-C (O) -NXI064X1065, - NHS (O 2) -X1066, -NX1067S (O 2) -X1068, -S-X1069, -S (O) - X1070, -S (O 2) -X1071, -S (O2) NH-XI072, -S (O 2) NXI073X1074, -
S(O2)O-XI075, -P(O)(OXI076)(OX1077), - Si(XI078)(X1079)(X1080)"; wobei X1029, X1030, X1031 , X1032, X1033, X1034, X1035, X1036, X1037, X1038, X1039, X1040, X1041 , X1042, X1043, X1044, X1045, X1046, X1047, X1048, X1049, X1050, X1051 ,S (O 2) O-XI075, -P (O) (OXI076) (OX1077), - Si (XI078) (X1079) (x1080) "; wherein X1029, X1030, X1031, X1032, X1033, X1034, X1035, X1036 , X1037, X1038, X1039, X1040, X1041, X1042, X1043, X1044, X1045, X1046, X1047, X1048, X1049, X1050, X1051,
X1052, X1053, X1054, X1055, X1056, X1057, X1058, X1059, X1060, X1061 , X1062, X1063, X1064, X1065, X1066, X1067, X1068, X1069, X1070, X1071 , X1072, X1073, X1074, X1075, X1076, X1077, X1078, X1079, X1080 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-X1052, X1053, X1054, X1055, X1056, X1057, X1058, X1059, X1060, X1061, X1062, X1063, X1064, X1065, X1066, X1067, X1068, X1069, X1070, X1071, X1072, X1073, X1074, X1075, X1076, X1077, X1078, X1079, X1080 are independently selected from the group consisting of: "alkyl, (Cg-
C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X1035, X1036 und/oder X1044, X1045 und/oder X1057, X1058 und/oder X1064, X1065 und/oder X1073, X1074 jeweils zusam- men auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHX1081 , -NX1082X1083, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-XI 084, -C(O)O-XI 085,C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and, alternatively, X1035, X1036 and / or X1044, X1045 and / or X1057, X1058 and / or X1064, X1065 and / or X1073, X1074 can together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of: (iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHX1081, -NX1082X1083, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -XI 084, -C (O) O-XI 085,
-C(O)NH-XI 086, -C(O)NXI 087X1088, -O-X1089, -0(- X1090-O)-H C = 1 , 2, 3, 4, 5), -O(-X1091-O)-X1092 (j = 1 , 2, 3, 4, 5), -OC(O)-XI 093, -OC(O)-O-XI 094, -OC(O)- NHX1095, -0-C(O)-NXI 096X1097, - OP(O)(OXI 098)(OX1099), -OSi(X1100)(X1101 )(X1102), --C (O) NH-XI 086, -C (O) NXI 087X1088, -O-X1089, -O (- X1090-O) -HC = 1, 2, 3, 4, 5), -O (-X1091 -O) -X1092 (j = 1, 2, 3, 4, 5), -OC (O) -XI 093, -OC (O) -O-XI 094, -OC (O) - NHX1095, -0- C (O) -NXI 096X1097, - OP (O) (OXI 098) (OX1099), -OSi (X1100) (X1101) (X1102),
OS(O2)-X1103, -NHC(O)-X1104, -NX1105C(O)-X1106, - NH-C(O)-O-X1107, -NH-C(O)-NH-X1108, -NH-C(O)- NX1 109X11 10, -NX1 11 1-C(O)-O-X1 112, -NX11 13-C(O)- NH-X1 114, -NX11 15-C(O)-NX1 116X11 17, -NHS(O2)- X1 118, -NX11 19S(O2)-X1120, -S-X1 121 , -S(O)-X1 122, -OS (O 2) -X1103, -NHC (O) -X1104, -NX1105C (O) -X1106, - NH-C (O) -O-X1107, -NH-C (O) -NH-X1108, -NH -C (O) -NX1 109X11 10, -NX1 11 1-C (O) -O-X1 112, -NX11 13-C (O) -NH-X1 114, -NX11 15-C (O) -NX1 116X11 17, -NHS (O 2 ) - X 1 118, -NX 11 19S (O 2 ) -X 11 20, -S-X 1 121, -S (O) -X 1 122, -
S(O2)-X1123, -S(O2)NH-X1124, -S(O2)NX1 125X1126, - S(O2)O-X1127, -P(O)(OX1128)(OX1 129), - Si(XI 130)(X1 131 )(X1 132)"; wobei X1081 , X1082, X1083, X1084, X1085, X1086, X1087, X1088, X1089, X1090, X1091 , X1092, X1093, X1094, X1095,S (O 2) -X1123, -S (O 2) NH-X1124, -S (O 2) NX1 125X1126, - S (O 2) O-X1127, -P (O) (OX1128) (OX1 129) Si (XI 130) (X1 131) (X1 132) ", wherein X1081, X1082, X1083, X1084, X1085, X1086, X1087, X1088, X1089, X1090, X1091, X1092, X1093, X1094, X1095,
X1096, X1097, X1098, X1099, X1100, X1101 , X1102, X1103, X1 104, X1 105, X1 106, X1 107, X1108, X1109, X11 10, X11 11 , X1 112, X1 113, X1 114, X1 115, X11 16, X11 17, X11 18, X11 19, X1 120, X1 121 , X1 122, X1 123, X1124, X1125, X1126, X1127, X1 128, X1 129, X1 130, X1 131 , X1132 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X1087, X1088 und/oder X1096, X1097 und/oder X1 109, X1 110 und/oder X11 16, X11 17 und/oder X1125,X1096, X1097, X1098, X1099, X1100, X1101, X1102, X1103, X1 104, X1 105, X1 106, X1 107, X1108, X1109, X11 10, X11 11, X1 112, X1 113, X1 114, X1 115, X11 16, X11 17, X11 18, X11 19, X1 120, X1 121, X1 122, X1 123, X1124, X1125, X1126, X1127, X1 128, X1 129, X1 130, X1 131, X1132 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively X 1087, X 1088 and / or X 1096, X 1097 and / or X1 109, X1 110 and / or X11 16, X11 17 and / or X1125,
X1 126 jeweils zusammen auch „heterocyclyl" bilden können;X1 126 together can also form "heterocyclyl";
(m) NZ8Z9, wobei Z8, Z9 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C(O)- X1 133, -C(O)O-X1134, -C(O)-NX1135X1136, -S(O2)-X1 137, - S(O2)O-X1138"; wobei X1133, X1134, X1135, X1136, X1 137, X1138 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: Wasserstoff, alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X1 135, X1 136 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(m) NZ8Z9, wherein Z8, Z9 are independently selected from the group consisting of: "Hydrogen, alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclic, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C (O) -X 1 133, -C (O) O-X 1134, -C (O) -NX1135X1136, -S (O 2) -X1 137, - S (O 2) O-X1138 "; wherein X1133, X1134, X1135, X1136, X1 137, X1138 are independently selected from the group consisting from: hydrogen, alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X1 135, X1 136 together also" heterocyclyl "may form, optionally wherein the above substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,(ii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,
CN, CF3, N3, NH2, -NHX1 139, -NX1 140X1141 , -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X1 142, -C(O)O-X1 143, -C(O)NH- X1 144, -C(O)NX1145X1 146, -0-X1147, -0(-X1 148-O)k-H (k = 1 , 2, 3, 4, 5), -0(-X1 149-O)k-X1 150 (k = 1 , 2, 3, 4, 5), -OC(O)-CN, CF 3 , N 3 , NH 2 , -NHX 1 139, -NX 1 140X 1141, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X 1 142, -C (O) O-X 1 143, -C (O) NH-X 1 144, -C (O) NX 1145 X 1 146, -O-X 1147, -O (-X 1 148-O) k -H (k = 1, 2, 3, 4, 5), -O ( -X1 149-O) k -X1 150 (k = 1, 2, 3, 4, 5), -OC (O) -
X1 151 , -OC(O)-O-X1 152, -OC(O)-NHX1 153, -0-C(O)- NX1 154X1155, -OP(O)(OX1156)(OX1 157), - OSi(X1 158)(X1159)(X1160), -0S(02)-X1161 , -NHC(O)-X1 162, - NX1 163C(O)-X1 164, -NH-C(O)-O-X1165, -N H-C(O)-N H- X1 166, -NH-C(O)-NX1 167X1168, -NX1 169-C(O)-O-X1170, -X1 151, -OC (O) -O-X1 152, -OC (O) -NHX1 153, -O-C (O) -NX1 154X1155, -OP (O) (OX1156) (OX1 157), -OSi ( X1 158) (X1159) (X1160), -0S (0 2) -X1161, -NHC (O) -X1 162 - 163C NX1 (O) -X1 164, -NH-C (O) -O-X1165, -NHC (O) -NH-X1 166, -NH-C (O) -NX1 167X1168, -NX1 169-C (O) -O-X1170, -
NX1 171-C(O)-NH-X1172, -NX1 173-C(O)-NXI 174X1175, - NHS(02)-X1 176, -NX1 177S(O2)-X1178, -S-X1 179, -S(O)- X1 180, -S(02)-X1 181 , -S(O2)NH-X1 182, -S(O2)NXI 183X1 184, - S(O2)O-X1185, -P(O)(OX1186)(OX1 187), - Si(XI 188)(X1 189)(X1 190)"; wobei X1139, X1140, X1141, X1142, X1143, X1144, X1145, X1146, X1147, X1148, X1149, X1150, X1151, X1152, X1153, X1154, X1155, X1156, X1157, X1158, X1159, X1160, X1161, X1162, X1163, X1164, X1165, X1166, X1167, X1168, X1169, X1170, X1171, X1172, X1173, X1174, X1175, X1176, X1177, X1178, X1179, X1180, X1181 , X1182, X1183, X1184, X1185, X1186, X1187, X1188, X1189, X1190 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-171 NX1-C (O) -NH-X1172, -NX1 173-C (O) -NXI 174X1175, - NHS (0 2) -X1 176, -NX1 177S (O 2) -X1178, -S-X1 179, -S (O) - X 1 180, -S (O 2 ) -X 1 181, -S (O 2 ) NH-X 1 182, -S (O 2 ) NXI 183X 1 184, -S (O 2 ) O-X 11 85, -P (O) (OX1186) (OX1 187), -Si (XI188) (X1189) (X1 190) "; wherein X1139, X1140, X1141, X1142, X1143, X1144, X1145, X1146, X1147, X1148, X1149, X1150, X1151, X1152, X1153, X1154, X1155, X1156, X1157, X1158, X1159, X1160, X1161, X1162, X1163, X1164, X1165, X1166, X1167, X1168, X1169, X1170, X1171, X1172, X1173, X1174, X1175, X1176, X1177, X1178, X1179, X1180, X1181, X1182, X1183, X1184, X1185, X1186, X1187, X1188, X1189, X1190 are independently selected from the group consisting of : "Alkyl, (C 9 -
5 C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X1 145, X1 146 und/oder X1 154, X1155 und/oder X1167, X1168 und/oder X1 174, X1175 und/oder X1183, X1184 jeweils zusammen auch „heterocyclyl" bilden können;5 C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X1 145, X1 146 and / or X1 154, X1155 and / or X1167, X1168 and / or X1 174, X1175 and / or X1183, X1184 may together also form "heterocyclyl";
10 wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:In which optionally substituents of the substituent group (ii) above may be substituted independently with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he-(iii) "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE
15 terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,15 terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
Br, I1 CN1 CF3, N3, NH2, -NHX1 191 , -NX1 192X1193, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X1 194, -C(O)O-X1 195, -C(O)NH-X1 196, -C(O)NX1197X1198, -0-X1199, -0(-Br, I 1 CN 1 CF 3 , N 3 , NH 2 , -NHX 1 191, -NX 1 192X1193, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) ( OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -X 1 194, -C (O) O-X1 195, -C (O) NH-X1 196, -C (O) NX1197X1198, -0-X1199, -0 (-
20 X1200-O)1-H (I = 1 , 2, 3, 4, 5), -O(-X1201-O),-X1202 (1 = 1 ,20 X1200-O) 1 -H (I = 1, 2, 3, 4, 5), -O (-X1201-O), - X1202 (1 = 1,
2, 3, 4, 5), -OC(O)-XI 203, -OC(O)-O-XI 204, -OC(O)- NHX1205, -0-C(O)-NXI 206X1207, - OP(O)(OX1208)(OX1209), -OSi(X1210)(X1211 )(X1212), - OS(O2)-X1213, -NHC(O)-X1214, -NX1215C(O)-X1216, -2, 3, 4, 5), -OC (O) -XI 203, -OC (O) -O-XI 204, -OC (O) -NHX1205, -O-C (O) -NXI 206X1207, -OP (O) (OX1208) (OX1209), -OSi (X1210) (X1211) (X1212), - OS (O 2) -X1213, -NHC (O) -X1214, -NX1215C (O) -X1216, -
25 NH-C(O)-O-X1217, -NH-C(O)-NH-X1218, -NH-C(O)-25 NH-C (O) -O-X1217, -NH-C (O) -NH-X1218, -NH-C (O) -
NX1219X1220, -NX1221-C(O)-O-XI 222, -NX1223-C(O)- NH-X1224, -NX1225-C(O)-NXI 226X1227, -NHS(O2)- X1228, -NX1229S(O2)-X1230, -S-X1231 , -S(O)-XI 232, - S(O2)-X1233, -S(O2)NH-X1234, -S(O2)NXI 235X1236, -NX1219X1220, -NX1221-C (O) -O-XI 222, -NX1223-C (O) -NH-X1224, -NX1225-C (O) -NXI 226X1227, -NHS (O 2 ) -X1228, -NX1229S ( O 2 ) -X1230, -S-X 1231, -S (O) -XI 232, -S (O 2 ) -X 1233, -S (O 2 ) NH-X 1234, -S (O 2 ) NXI 235X 1236, -
30 S(O2)O-XI 237, -P(O)(OXI 238)(OX1239), -30S (O 2 ) O-XI 237, -P (O) (OXI 238) (OX 1239),
Si(XI 240)(X1241 )(X1242)"; wobei X1191.X1192, X1193, X1194, X1195, X1196, X1197, X1198, X1199, X1200, X1201 , X1202, X1203, X1204, X1205, X1206, X1207, X1208, X1209, X1210, X1211, X1212, X1213, X1214, X1215, X1216, X1217, X1218, X1219, X1220, X1221 , X1222, X1223, X1224, X1225, X1226, X1227, X1228, X1229, X1230, X1231 , X1232, X1233, X1234, X1235, X1236, X1237, X1238, X1239, X1240, X1241 , X1242 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-Si (XI 240) (X1241) (X1242) "; wherein X1191.X1192, X1193, X1194, X1195, X1196, X1197, X1198, X1199, X1200, X1201, X1202, X1203, X1204, X1205, X1206, X1207, X1208, X1209, X1210, X1211, X1212, X1213, X1214, X1215, X1216, X1217, X1218, X1219, X1220, X1221, X1222, X1223, X1224, X1225, X1226, X1227, X1228, X1229, X1230, X1231, X1232, X1233, X1234, X1235, X1236, X1237, X1238, X1239, X1240, X1241, X1242 are independently selected from the group consisting of: "alkyl, (Cg-
C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ X1 197, X1 198 und/oder X1206, X1207 und/oder X1219, X1220 und/oder X1226, X1227 und/oder X1235, X1236 jeweils zusammen auch „heterocyclyl" bilden können;C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively X1 197, X1 198 and / or X1206, X1207 and / or X1219, X1220 and / or X1226, X1227 and or X1235, X1236 may together also form "heterocyclyl";
oderor
(B) einer der Reste Z3, Z4 oder beide Reste Z3, Z4 unabhängig voneinander „sub- stituiertes Heteroaryl" sind, wobei „substituiertes Heteroaryl" substituiert ist mit mindestens einem Substituenten ausgewählt aus der Gruppe bestehend aus:(B) one of the radicals Z3, Z4 or both radicals Z3, Z4 is independently "substituted heteroaryl", where "substituted heteroaryl" is substituted by at least one substituent selected from the group consisting of:
(a) „alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NH-V1 , -N(alkyl)2, -(a) "alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NH-V1, -N (alkyl) 2 , -
NHC(O)-alkyl, -NHC(O)-cycloalkyl, -NHC(O)-heterocyclyl, -NHC(O)-aryl, -NHC(O)-heteroaryl, -NHC(O)-arylalkyl, -NHC(O)-heteroarylalkyl, - NHS(O2)-alkyl, -NHS(O2)-cycloalkyl, -NHS(O2)-heterocyclyl, -NHS(O2)- aryl, -NHS(O2)-heteroaryl, -NHS(O2)-arylalkyl, -NHS(O2)-heteroarylalkyl, -S-alkyl, -S-aryl, -S-heteroaryl, -O-alkyl, -O-cycloalkyl, -O- cycloalkylalkyl, -O-aryl, -O-arylalkyl, -O-heteroaryl, -O-heteroarylalkyl, - O-heterocyclylalkyl, -OC(O)-alkyl, -OC(O)-cycloalkyl, -OC(O)- heterocyclyl, -OC(O)-aryl, -OC(O)-heteroaryl, -OC(O)-arylalkyl, -OC(O)- heteroarylalkyl, -OS(O2)-alkyl, -OS(O2)-cycloalkyl, -OS(O2)-heterocyclyl, -OS(O2)-aryl, -OS(O2)-heteroaryl, -OS(O2)-arylalkyl, -OS(O2)- heteroarylalkyl, -C(O)-alkyl, -C(O)-aryl, -C(O)-heteroaryl, -C(O)O-V2, - C(O)NH-V3, -C(O)N(alkyl)2, -C(O)N(cycloalkyl)2, -C(O)N(aryl)2, - C(O)N(heteroraryl)2, -S(O2)N H-alkyl, -S(O2)N H-aryl, -S(O2)NH- heteroaryl, -S(O2)NH-arylalkyl, -S(O2)O-alkyl, -S(O2)O-aryl, -S(O2)O- arylalkyl"; wobei V1 , V2, V3 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; mit der Maßgabe, dass obige Substituenten der Substituentengruppe (a) unabhängig voneinander weiter substituiert sind mit mindestens einemNHC (O) -alkyl, -NHC (O) -cycloalkyl, -NHC (O) -heterocyclyl, -NHC (O) -aryl, -NHC (O) -heteroaryl, -NHC (O) -arylalkyl, -NHC ( O) -heteroarylalkyl, - NHS (O 2 ) -alkyl, -NHS (O 2 ) -cycloalkyl, -NHS (O 2 ) -heterocyclyl, -NHS (O 2 ) -aryl, -NHS (O 2 ) -heteroaryl, -NHS (O 2 ) -arylalkyl, -NHS (O 2 ) -heteroarylalkyl, -S-alkyl, -S-aryl, -S-heteroaryl, -O-alkyl, -O-cycloalkyl, -O-cycloalkylalkyl, -O -aryl, -O-arylalkyl, -O-heteroaryl, -O-heteroarylalkyl, - O-heterocyclylalkyl, -OC (O) -alkyl, -OC (O) -cycloalkyl, -OC (O) -heterocyclyl, -OC ( O) -aryl, -OC (O) -heteroaryl, -OC (O) -arylalkyl, -OC (O) -heteroarylalkyl, -OS (O 2 ) -alkyl, -OS (O 2 ) -cycloalkyl, -OS ( O 2 ) -heterocyclyl, -OS (O 2 ) -aryl, -OS (O 2 ) -heteroaryl, -OS (O 2 ) -arylalkyl, -OS (O 2 ) -heteroarylalkyl, -C (O) -alkyl, -C (O) -aryl, -C (O) -heteroaryl, -C (O) O-V2, -C (O) NH-V3, -C (O) N (alkyl) 2 , -C (O) N (cycloalkyl) 2 , -C (O) N (aryl) 2 , - C (O) N (heteroaryl) 2 , -S (O 2 ) N H -alkyl, -S (O 2 ) N H -aryl, -S (O 2) NH- heteroaryl, -S (O 2) NH-arylalkyl, -S (O 2) O-alkyl, -S (O 2) O-aryl, - S (O 2 ) O -arylalkyl "; wherein V1, V2, V3 are independently selected from the group consisting of: "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; with the proviso that the above substituents of the substituent group (a) independently further substituted with at least one
Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Substituents, the same or different, selected from the group consisting of:
(i) „(C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, N3, -NH-cycloalkyl, -NH- cycloalkylalkyl, -NH-heteroaryl, -NH-heteroarylalkyl, -NH-arylalkyl, -(i) "(C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, N 3, -NH-cycloalkyl, cycloalkylalkyl -NH-, -NH-heteroaryl, -NH -heteroarylalkyl, -NH-arylalkyl, -
NH-heterocyclyl, -NH-heterocyclylalkyl, -NV4V5, -S-cycloalkyl, -S- cycloalkylalkyl, -S-aryl, —S— arylalkyl, -S-heteroaryl, -S-heteroarylalkyl, -S-heterocyclyl, -S-heterocyclylalkyl, -O-cycloalkyl, -O- cycloalkylalkyl, —O— arylalkyl, -O-heteroaryl, -O-heteroarylalkyl, -O- heterocyclyl, -O-heterocyclylalkyl, -O(-V6-O)p-H (p = 1 , 2, 3, 4, 5), -NH-heterocyclyl, -NH-heterocyclylalkyl, -NV4V5, -S-cycloalkyl, -S-cycloalkylalkyl, -S-aryl, -S-arylalkyl, -S-heteroaryl, -S-heteroarylalkyl, -S-heterocyclyl, -S- heterocyclylalkyl, -O-cycloalkyl, -O-cycloalkylalkyl, -O-arylalkyl, -O-heteroaryl, -O-heteroarylalkyl, -O-heterocyclyl, -O-heterocyclylalkyl, -O (-V6-O) p -H (p = 1, 2, 3, 4, 5), -
O(-V7-O)p-V8 (p = 1 , 2, 3, 4, 5), -OP(O)(OV9)(OV10), -C(O)O-V1 1 , - C(O)NH2, -C(O)NH-V12, -C(O)NV13V14, -S(O2)-V15, -P(O)(OH)2, - P(O)(OVI 6)(0V17), -Si(VI 8)(V19)(V20), -O-Si(V21 )(V22)(V23), -O- C(O)-O-V24, -0-C(O)-N H-V25, -0-C(O)-N V26V27, -NH-C(O)-O- V28, -N H-C(O)-N H-V29, -N H-C(O)-N V30V31 , -NV32-C(O)-O-V33,O (-V7-O) p -V8 (p = 1, 2, 3, 4, 5), -OP (O) (OV9) (OV10), -C (O) O-V1 1, -C (O ) NH 2, -C (O) NH-V12, -C (O) NV13V14, -S (O 2) -V15, -P (O) (OH) 2, - P (O) (OVI 6) (0V17 ), -Si (VI8) (V19) (V20), -O-Si (V21) (V22) (V23), -O-C (O) -O-V24, -O-C (O) -N H-V25, -O-C (O) -N V26V27, -NH-C (O) -O-V28, -NHC (O) -NH-V29, -NHC (O) -N V30V31, - NV32-C (O) -O-V33,
-NV34-C(O)-NH-V35, -NV36-C(O)-NV37V38, -NV39-S(O2)-V40, - NH-S(O2)-V41 , -O-S(O2)-V42, -NH-C(O)-V43, -NV44-C(O)-V45, - C(O)-V46, -OC(O)-V47, -S(O)-V48, -S(O2)-NHV49, -S(O2)- NV50V51 , -S(O2)-OV52"; mit der weiteren Maßgabe, dass ,,-N(alkyl)2" weiter substituiert ist mit mindestens einem Substituenten ausgewählt aus der untigen Substituentengruppe (b); wobei V4, V5, V6, V7, V8, V9, V10, V11 , V12, V13, V14, V15, V16, V17, V18, V19, V20, V21 , V22, V23, V24, V25, V26, V27, V28, V29, V30, V31 , V32, V33, V34, V35, V36, V37, V38, V39, V40, V41 , V42, V43,-NV34-C (O) -NH-V35, -NV36-C (O) -NV37V38, -NV39-S (O 2) -V40, - NH-S (O 2) -V41, -OS (O 2) -V42, -NH-C (O) -V43, -NV44-C (O) -V45, -C (O) -V46, -OC (O) -V47, -S (O) -V48, -S ( O 2 ) -NHV49, -S (O 2 ) - NV 50 V 51, -S (O 2 ) -OV52 ", with the further proviso that" --N (alkyl) 2 "is further substituted by at least one substituent selected from the lower substituent group (b); wherein V4, V5, V6, V7, V8, V9, V10, V11, V12, V13, V14, V15, V16, V17, V18, V19, V20, V21, V22, V23, V24, V25, V26, V27, V28 , V29, V30, V31, V32, V33, V34, V35, V36, V37, V38, V39, V40, V41, V42, V43,
V44, V45, V46, V47, V48, V49, V50, V51 , V52 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V13, V14 und/oder V26, V27 und/oder V30, V31 und/oder V37, V38 und/oder V50, V51 zusammen auch „heterocyclyl" bilden können; wobei optional zusätzlich einer der Reste Z3, Z4 oder zusätzlich beide Reste Z3, Z4 unabhängig voneinander auch weiter substituiert sein können mit min- destens einem Substituenten, gleich oder verschieden, ausgewählt aus derV44, V45, V46, V47, V48, V49, V50, V51, V52 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively V13, V14 and / or V26, V27 and / or V30, V31 and / or V37, V38 and / or V50, V51 can also together form "heterocyclyl", where optionally additionally one of the radicals Z3, Z4 or additionally both radicals Z3, Z4 can also be further substituted independently of one another with at least one substituent, the same or different, selected from
Gruppe bestehend aus:Group consisting of:
(b) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylal- kyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV53, -NV54V55, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, - CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V56, -C(O)O-V57,(b) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclicalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2, -NHV53, -NV54V55, -NO 2, -OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2, - CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -V56, -C (O) O-V57,
-C(O)NH-V58, -C(O)NV59V60, -0-V61 , -O(-V62-O) -H (r = 1 , 2, 3, 4, 5), -O(-V63-O)r-V64 (r = 1 , 2, 3, 4, 5), -OC(O)-V65, -OC(O)-O-V66, - OC(O)-NHV67, -O-C(O)-NV68V69, -OP(O)(OV70)(OV71 ), - OSi(V72)(V73)(V74), -OS(O2)-V75, -NHC(O)-V76, -NV77C(O)-V78, - NH-C(O)-O-V79, -N H-C(O)-N H-V80, -N H-C(O)-N V81V82, -NV83--C (O) NH-V58, -C (O) NV59V60, -O-V61, -O (-V62-O) -H (r = 1, 2, 3, 4, 5), -O (-V63 -O) r -V64 (r = 1, 2, 3, 4, 5), -OC (O) -V65, -OC (O) -O-V66, -OC (O) -NHV67, -OC (O ) -NV68V69, -OP (O) (OV70) (OV71), - OSi (V72) (V73) (V74), -OS (O 2) -V75, -NHC (O) -V76, -NV77C (O) -V78, - NH-C (O) -O-V79, -NHC (O) -NH-V80, -NHC (O) -N V81V82, -NV83-
C(O)-O-V84, -NV85-C(O)-NH-V86, -NV87-C(O)-NV88V89, -NHS(O2)- V90, -NV91 S(O2)-V92, -S-V93, -S(O)-V94, -S(O2)-V95, -S(O2)NH-V96, -S(O2)NV97V98, -S(O2)O-V99, -P(O)(OVI 00)(OV101 ), - Si(VI 02)(V103)(V104)"; wobei V53, V54, V55, V56, V57, V58, V59, V60, V61 , V62, V63, V64, V65,C (O) -O-V84, -NV85-C (O) -NH-V86, -NV87-C (O) -NV88V89, -NHS (O 2) - V90, -NV91 S (O 2) -V92, -S-V93, -S (O) -V94, -S (O 2) -V95, -S (O 2) NH-V96, -S (O 2) NV97V98, -S (O 2) O-V99, -P (O) (OVI 00) (OV101), -Si (VIO2) (V103) (V104) ", wherein V53, V54, V55, V56, V57, V58, V59, V60, V61, V62, V63, V64, V65,
V66, V67, V68, V69, V70, V71 , V72, V73, V74, V75, V76, V77, V78, V79, V80, V81 , V82, V83, V84, V85, V86, V87, V88, V89, V90, V91 , V92, V93, V94, V95, V96, V97, V98, V99, V100, V101 , V102, V103, V104 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V59, V60 und/oder V68, V69 und/oder V81 , V82 und/oder V88, V89 und/oder V97, V98 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (b) unabhän- gig voneinander wiederum substituiert sein können mit mindestens einemV66, V67, V68, V69, V70, V71, V72, V73, V74, V75, V76, V77, V78, V79, V80, V81, V82, V83, V84, V85, V86, V87, V88, V89, V90, (- C 30 C 9) alkyl, cycloalkyl "alkyl,: V91, V92, V93, V94, V95, V96, V97, V98, V99, V100, V101, V102, V103, V104 are each independently selected from the group consisting of , cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively V59, V60 and / or V68, V69 and / or V81, V82 and / or V88, V89 and / or V97, V98 together also" heterocyclyl " can form; wherein optionally substituents above the substituent group (b) independently of one another in turn may be substituted with at least one
Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Substituents, the same or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV105, -NV106V107, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- V108, -C(O)O-VI09, -C(O)NH-V110, -C(O)NV111V112, -O-V113, - O(-V114-O)8-H (s = 1, 2, 3, 4, 5), -O(-V115-O)s-V116 (s = 1, 2, 3, 4, 5), -OC(O)-V117, -OC(O)-O-V118, -OC(O)-NHV119, -0-C(O)-(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV105, -NV106V107, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O ) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) - V108, -C (O) O-VI09, -C (O) NH-V110, -C (O) NV111V112, -O-V113, - O (-V114-O) 8 -H (s = 1, 2, 3, 4, 5), -O (-V115-O) s -V116 (s = 1, 2, 3, 4, 5), -OC (O) -V117, -OC (O) -O-V118, -OC (O) -NHV119, -O-C (O) -
NV120V121, -OP(O)(OVI22)(OV123), -OSi(VI24)(V125)(V126), - OS(O2)-V127, -NHC(O)-V128, -NV129C(O)-VI30, -NH-C(O)-O- V131, -NH-C(O)-NH-VI32, -NH-C(O)-NVI33V134, -NV135-C(O)- O-V136, -NV137-C(O)-NH-VI38, -NV139-C(O)-NVI40V141, - NHS(O2)-V142, -NV143S(O2)-V144, -S-V145, -S(O)-V146, -S(O2)-NV120V121, -OP (O) (OVI22) (OV123), -OSi (VI24) (V125) (V126), - OS (O 2) -V127, -NHC (O) -V128, -NV129C (O) -VI30 , -NH-C (O) -O-V131, -NH-C (O) -NH-VI32, -NH-C (O) -NVI33V134, -NV135-C (O) -O-V136, -NV137- C (O) -NH-VI38, -NV139-C (O) -NVI40V141, - NHS (O 2) -V142, -NV143S (O 2) -V144, -S-V145, -S (O) -V146, -S (O 2 ) -
V147, -S(O2)NH-VI48, -S(O2)NVI49V150, -S(O2)O-VI51, - P(O)(OVI52)(OV153), -Si(VI54)(V155)(V156)"; wobei V105, V106, V107, V108, V109, V110, V111 , V112, V113, V114, V115, V116, V117, V118, V119, V120, V121, V122, V123, V124, V125, V126, V127, V128, V129, V130, V131 , V132, V133, V134, V135, V136,V147, -S (O 2) NH-VI48, -S (O 2) NVI49V150, -S (O 2) O-VI51, - P (O) (OVI52) (OV153), -Si (VI54) (V155) (V156) ", wherein V105, V106, V107, V108, V109, V110, V111, V112, V113, V114, V115, V116, V117, V118, V119, V120, V121, V122, V123, V124, V125, V126, V127, V128, V129, V130, V131, V132, V133, V134, V135, V136,
V137, V138, V139, V140, V141 , V142, V143, V144, V145, V146, V147, V148, V149, V150, V151 , V152, V153, V154, V155, V156 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V1 11 ,V137, V138, V139, V140, V141, V142, V143, V144, V145, V146, V147, V148, V149, V150, V151, V152, V153, V154, V155, V156 are independently selected from the group consisting of: " alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively V1 11,
V1 12 und/oder V120, V121 und/oder V133, V134 und/oder V140, V141 und/oder V149, V150 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) und/oder Substituentengruppe (ii) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:V1 12 and / or V120, V121 and / or V133, V134 and / or V140, V141 and / or V149, V150 can together also form "heterocyclyl", where optionally substituents of the substituent group (i) and / or substituent group (ii) above independently of one another may in turn be substituted by at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV157, -NV158V159, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-(iii) "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, - NHV157, -NV158V159, -NO 2, -OH, -OCF3, -SH, -0-SO3H, - OP (O) (OH) 2, -CHO, -COOH, -C (O) NH 2, -SO 3 H, -P (O) (OH) 2 , -C (O) -
V160, -C(O)O-VI 61 , -C(O)NH-VI 62, -C(O)NVI 63V164, -O-V165, - O(-V166-O)t-H (t = 1 , 2, 3, 4, 5), -0(-V167-O)t-V168 (t = 1 , 2, 3, 4, 5), -OC(O)-VI 69, -OC(O)-O-VI 70, -OC(O)-N HV171 , -0-C(O)- NV172V173, -OP(O)(OVI 74)(OV175), -OSi(VI 76)(V177)(V178), - OS(O2)-V179, -NHC(O)-VI80, -NV181C(O)-VI82, -NH-C(O)-O- V183, -NH-C(O)-NH-VI84, -NH-C(O)-NVI85V186, -NV187-C(O)- O-V188, -NV189-C(O)-NH-VI90, -NV191-C(O)-NVI92V193, - NHS(O2)-V194, -NV195S(O2)-V196, -S-V197, -S(O)-VI98, -S(O2)- V199, -S(O2)NH-V200, -S(O2)NV201V202, -S(O2)O-V203, -V160, -C (O) O-VI 61, -C (O) NH-VI 62, -C (O) NVI 63V164, -O-V165, -O (-V166-O) t -H (t = 1 , 2, 3, 4, 5), -0 (-V167-O) t -V168 (t = 1, 2, 3, 4, 5), -OC (O) -VI 69, -OC (O) - O-VI 70, -OC (O) -N HV 171, -O-C (O) - NV 172 V 173, -OP (O) (OVI 74) (OV 175), -OSi (VI 76) (V 177) (V 178), - OS (O 2) -V179, -NHC (O) -VI80, -NV181C (O) -VI82, -NH-C (O) -O- V183, -NH-C (O) -NH-VI84, -NH -C (O) -NVI85V186, -NV187-C (O) - O-V188, -NV189-C (O) -NH-VI90, -NV191-C (O) -NVI92V193, - NHS (O 2) -V194 , -NV195S (O 2) -V196, -S-V197, -S (O) -VI98, -S (O 2) - V199, -S (O 2) NH-V200, -S (O 2) NV201V202, -S (O 2 ) O-V 2 O 3, -
P(O)(OV204)(OV205), -Si(V206)(V207)(V208)"; wobei V157, V158, V159, V160, V161, V162, V163, V164, V165, V166, V167, V168, V169, V170, V171, V172, V173, V174, V175, V176, V177, V178, V179, V180, V181, V182, V183, V184, V185, V186, V187, V188, V189, V190, V191 , V192, V193, V194, V195, V196, V197, V198, V199,P (O) (OV204) (OV205), -Si (V206) (V207) (V208) "; wherein V157, V158, V159, V160, V161, V162, V163, V164, V165, V166, V167, V168, V169 , V170, V171, V172, V173, V174, V175, V176, V177, V178, V179, V180, V181, V182, V183, V184, V185, V186, V187, V188, V189, V190, V191, V192, V193, V194 , V195, V196, V197, V198, V199,
V200, V201 , V202, V203, V204, V205, V206, V207, V208 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V163, V164 und/oder V172, V173 und/oder V185, V186 und/oder V192, V193 und/oder V201 , V202 zusammen auch „heterocyclyl" bilden können;V200, V201, V202, V203, V204, V205, V206, V207, V208 are independently selected from the group consisting of: "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl heteroaryl, heteroarylalkyl "and wherein alternatively V163, V164 and / or V172, V173 and / or V185, V186 and / or V192, V193 and / or V201, V202 may together also form" heterocyclyl ";
oder einer der Reste Z3, Z4 oder beide Reste Z3, Z4 unabhängig voneinander voneinander „substituiertes Heteroaryl" sind, wobei voneinander „substituiertes Heteroaryl" substituiert ist mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:or one of the radicals Z3, Z4 or both radicals Z3, Z4 independently of one another are "substituted heteroaryl", where "substituted heteroaryl" is substituted by at least one substituent, identical or different, selected from the group consisting of:
(C) „(C9-C3o)alkyl, -NV209V210, -NH-(C9-C30)alkyl, -NHC(O)-cycloalkylalkyl, - NHC(O)-heterocyclylalkyl, -NHC(O)-(C9-C30)alkyl, -NV21 1C(O)-V212, - NV213C(0)-(C9-C3o)alkyl, -NHC(O)-OV214, -NV215C(O)-OV216, - N HC(O)-N HV217, -NHC(O)-NV218V219, -NV220C(O)-NHV221 , -(C) "(C 9 -C 3 o) alkyl, -NV209V210, -NH- (C 9 -C 30) alkyl, -NHC (O) cycloalkylalkyl, - NHC (O) -heterocyclylalkyl, -NHC (O) - (C 9 -C 30) alkyl, -NV21 1C (O) -V212, - NV213C (0) - (C 9 -C 3 o) alkyl, -NHC (O) -OV214, -NV215C (O) -OV216 , - N HC (O) -N HV217, -NHC (O) -NV218V219, -NV220C (O) -NHV221, -
NV222C(O)-NV223V224, -NHS(O2)-cycloalkylalkyl, -NHS(O2)- heterocyclylalkyl, -NV225S(O2)-V226, -O-heterocyclyl, -O-(C9-C30)alkyl, - S-cycloalkyl, -S-heterocyclyl, —S— arylalkyl, -S-heteroarylalkyl, -S- cycloalkylalkyl, -S-heterocyclylalkyl, -S-(C9-C30)alkyl, -OC(O)- cycloalkylalkyl, -OC(O)-heterocyclylalkyl, -OC(O)-(C9-C30)alkyl, -OC(O)-NV222C (O) -NV223V224, -NHS (O 2) cycloalkylalkyl, -NHS (O 2) - heterocyclylalkyl, -NV225S (O 2) -V226, -O-heterocyclyl, -O- (C 9 -C 30) alkyl , - S-cycloalkyl, -S-heterocyclyl, -S-arylalkyl, -S-heteroarylalkyl, -S- cycloalkylalkyl, -S-heterocyclylalkyl, -S- (C 9 -C 30 ) alkyl, -OC (O) - cycloalkylalkyl , -OC (O) -heterocyclylalkyl, -OC (O) - (C 9 -C 30 ) -alkyl, -OC (O) -
OV227, -OC(O)-N H V228, -OC(O)-NV229V230, -OP(O)(OV231 )(OV232), -OS(O2)-cycloalkylalkyl, -OS(O2)-heterocyclylalkyl, -OS(O2)-(C9-C30)alkyl, -C(O)-cycloalkyl, -C(O)-heterocyclyl, -C(O)-arylalkyl, -C(O)- heteroarylalkyl, -C(O)-cycloalkylalkyl, -C(O)-heterocyclylalkyl, -C(O)-(C9- C30)alkyl, -C(0)0-(C9-C3o)alkyl, -C(0)NH-(C9-C3o)alkyl, -C(O)NV233V234, -C(O)N H-OV235, -C(O)N V236-OV237, -C(O)NH-NV238V239, - C(O)NV240-NV241V242, -S(O)-V243, -S(O2)-V244, -S(O2)NH- cycloalkyl, -S(O2)NH-heterocyclyl, -S(O2)NH-heteroarylalkyl, -S(O2)NH- cycloalkylalkyl, -S(O2)NH-heterocyclylalkyl, -S(02)NH-(C9-C3o)alkyl, -OV227, -OC (O) -NH V228, -OC (O) -NV229V230, -OP (O) (OV231) (OV232), -OS (O 2) cycloalkylalkyl, -OS (O 2) -heterocyclylalkyl, - OS (O 2 ) - (C 9 -C 30 ) alkyl, -C (O) -cycloalkyl, -C (O) -heterocyclyl, -C (O) -arylalkyl, -C (O) -heteroarylalkyl, -C ( O) -cycloalkylalkyl, -C (O) -heterocyclylalkyl, -C (O) - (C 9 - C 30) alkyl, -C (0) 0- (C 9 -C 3 O) alkyl, -C (0) NH- (C 9 -C 3 O) alkyl, -C (O) NV233V234, -C (O ) N H-OV235, -C (O) N V236-OV237, -C (O) NH-NV238V239, - C (O) NV240-NV241V242, -S (O) -V243, -S (O 2) -V244 , -S (O 2 ) NH-cycloalkyl, -S (O 2 ) NH-heterocyclyl, -S (O 2 ) NH-heteroarylalkyl, -S (O 2 ) NH-cycloalkylalkyl, -S (O 2 ) NH-heterocyclylalkyl , -S (0 2) NH- (C 3 -C 9 o) alkyl, -
S(O2)O-cycloalkyl, -S(O2)O-heterocyclyl, -S(O2)O-heteroaryl, -S(O2)O- heteroarylalkyl, -S(O2)O-cycloalkylalkyl, -S(O2)O-heterocyclylalkyl, - S(O2)O-(C9-C30)alkyl, -P(O)(OH)2, -P(O)(OV245)(OV246), - Si(V247)(V248)(V249), -O-Si(V250)(V251 )(V252)"; wobei V209, V210, V211 , V212, V213, V214, V215, V216, V217, V218,S (O 2 ) O -cycloalkyl, -S (O 2 ) O-heterocyclyl, -S (O 2 ) O-heteroaryl, -S (O 2 ) O-heteroarylalkyl, -S (O 2 ) O -cycloalkylalkyl, - S (O 2 ) O-heterocyclylalkyl, -S (O 2 ) O- (C 9 -C 30 ) alkyl, -P (O) (OH) 2 , -P (O) (OV245) (OV246), -Si (V247) (V248) (V249), -O-Si (V250) (V251) (V252) ", wherein V209, V210, V211, V212, V213, V214, V215, V216, V217, V218,
V219, V220, V221 , V222, V223, V224, V225, V226, V227, V228, V229, V230, V231 , V232, V233, V234, V235, V236, V237, V238, V239, V240, V241 , V242, V243, V244, V245, V246, V247, V248, V249, V250, V251 , V252 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V218, V219 und/oder V223, V224 und/oder V229, V230 und/oder V233, V234 und/oder V238, V239 und/oder V241 , V242 zusammen auch „heterocyclyl" bilden können; mit der Maßgabe, dass die Substituenten ,,-N(alkyl)2", ,,-C(O)N(alkyl)2", „-V219, V220, V221, V222, V223, V224, V225, V226, V227, V228, V229, V230, V231, V232, V233, V234, V235, V236, V237, V238, V239, V240, V241, V242, V243, V244, V245, V246, V247, V248, V249, V250, V251, V252 are each independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively V218, V219 and / or V223, V224 and / or V229, V230 and / or V233, V234 and / or V238, V239 and / or V241, V242 together also form" heterocyclyl "can; with the proviso that the substituents "- N (alkyl) 2 ", "- C (O) N (alkyl) 2 ", "-
C(O)N(cycloalkyl)2", ,,-C(O)N(aryl)2", ,,-C(O)N(heteroraryl)2" weiter substituiert sind mit mindestens einem Substituenten ausgewählt aus untiger Sub- stituentengruppe (i); wobei optional obige Substituenten der Substituentengruppe (c) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:C (O) N (cycloalkyl) 2 ", - C (O) N (aryl) 2 ", - C (O) N (heteroaryl) 2 "are further substituted by at least one substituent selected from among optionally substituted substituents of the substituent group (c) may in turn be substituted with at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV253, -NV254V255, -NO2, -OH, -OCF3, -SH, -0-SO3H, -(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV253, -NV254V255, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -
OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- V256, -C(O)O-V257, -C(O)NH-V258, -C(O)NV259V260, -O-V261 , - O(-V262-O)u-H (u = 1 , 2, 3, 4, 5), -O(-V263-O)u-V264 (u = 1 , 2, 3, 4, 5), -OC(O)-V265, -OC(O)-O-V266, -OC(O)-N HV267, -0-C(O)- NV268V269, -OP(O)(OV270)(OV271 ), -OSi(V272)(V273)(V274), - OS(O2)-V275, -NHC(O)-V276, -NV277C(O)-V278, -NH-C(O)-O- V279, -N H-C(O)-N H-V280, -N H-C(O)-N V281V282, -NV283-C(O)- O-V284, -NV285-C(O)-NH-V286, -NV287-C(O)-NV288V289, - NHS(O2)-V290, -NV291S(O2)-V292, -S-V293, -S(O)-V294, -S(O2)-OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -V 256, -C (O ) O-V257, -C (O) NH-V258, -C (O) NV259V260, -O-V261, -O (-V262-O) u -H (u = 1, 2, 3, 4, 5) , -O (-V263-O) u -V264 (u = 1, 2, 3, 4, 5), -OC (O) -V265, -OC (O) -O-V266, -OC (O) - N HV267, -0-C (O) - NV268V269, -OP (O) (OV270) (OV271), -OSi (V272) (V273) (V274), - OS (O 2) -V275, -NHC (O) -V276, -NV277C (O) -V278 , -NH-C (O) -O-V279, -NHC (O) -NH-V280, -NHC (O) -N V281V282, -NV283-C (O) -O-V284, -NV285- C (O) -NH-V286, -NV287-C (O) -NV288V289, - NHS (O 2) -V290, -NV291S (O 2) -V292, -S-V293, -S (O) -V294, -S (O 2 ) -
V295, -S(O2)N H-V296, -S(O2)NV297V298, -S(O2)O-V299, - P(O)(OV300)(OV301 ), -Si(V302)(V303)(V304)"; wobei V253, V254, V255, V256, V257, V258, V259, V260, V261 , V262, V263, V264, V265, V266, V267, V268, V269, V270, V271, V272, V273, V274, V275, V276, V277, V278, V279, V280, V281 , V282, V283, V284,V295, -S (O 2) N H-V296, -S (O 2) NV297V298, -S (O 2) O-V299, - P (O) (OV300) (OV301), -Si (V302) (V303 ) (V304) "; wherein V253, V254, V255, V256, V257, V258, V259, V260, V261, V262, V263, V264, V265, V266, V267, V268, V269, V270, V271, V272, V273, V274 , V275, V276, V277, V278, V279, V280, V281, V282, V283, V284,
V285, V286, V287, V288, V289, V290, V291 , V292, V293, V294, V295, V296, V297, V298, V299, V300, V301 , V302, V303, V304 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V259,V285, V286, V287, V288, V289, V290, V291, V292, V293, V294, V295, V296, V297, V298, V299, V300, V301, V302, V303, V304 are independently selected from the group consisting of: " alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively V259,
V260 und/oder V268, V269 und/oder V281 , V282 und/oder V288, V289 und/oder V297, V298 zusammen auch „heterocyclyl" bilden können; wobei optional zusätzlich einer der Reste Z3, Z4 oder zusätzlich beide Reste Z3, Z4 unabhängig voneinander auch weiter substituiert sein können mit min- destens einem Substituenten, gleich oder verschieden, ausgewählt aus derV260 and / or V268, V269 and / or V281, V282 and / or V288, V289 and / or V297, V298 may together also form "heterocyclyl", optionally additionally one of the radicals Z3, Z4 or additionally both radicals Z3, Z4 independently from each other can also be further substituted with at least one substituent, identical or different, selected from
Gruppe bestehend aus:Group consisting of:
(d) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV305, -NV306V307, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-(d) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHV305, -NV306V307, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -
V308, -C(O)O-V309, -C(O)NH-V310, -C(O)NV311V312, -O-V313, -0(- V314-O)v-H (v = 1, 2, 3, 4, 5), -O(-V315-O)v-V316 (v = 1, 2, 3, 4, 5), - OC(O)-V317, -OC(O)-O-V318, -OC(O)-NHV319, -0-C(O)-NV320V321, -OP(O)(OV322)(OV323), -OSi(V324)(V325)(V326), -OS(O2)-V327, - NHC(O)-V328, -NV329C(O)-V330, -NH-C(O)-O-V331 , -NH-C(O)-NH- V332, -NH-C(O)-NV333V334, -NV335-C(O)-O-V336, -NV337-C(O)- NH-V338, -NV339-C(O)-NV340V341, -NHS(O2)-V342, -NV343S(O2)- V344, -S-V345, -S(O)-V346, -S(O2)-V347, -S(O2)NH-V348, - S(O2)NV349V350, -S(O2)O-V351 , -P(O)(OV352)(OV353), - Si(V354)(V355)(V356)"; wobei V305, V306, V307, V308, V309, V310, V311 , V312, V313, V314, V315, V316, V317, V318, V319, V320, V321 , V322, V323, V324, V325, V326, V327, V328, V329, V330, V331 , V332, V333, V334, V335, V336,V308, -C (O) O-V309, -C (O) NH-V310, -C (O) NV311V312, -O-V313, -O (- V314-O) v -H (v = 1, 2, 3, 4, 5), -O (-V315-O) v -V316 (v = 1, 2, 3, 4, 5), - OC (O) -V317, -OC (O) -O-V318, -OC (O) -NHV319, -0-C (O) -NV320V321, -OP (O) (OV322) (OV323), -OSi (V324) (V325) (V326), -OS (O 2) -V327 , - NHC (O) -V328, -NV329C (O) -V330, -NH-C (O) -O-V331, -NH-C (O) -NH-V332, -NH-C (O) -NV333V334 , -NV335-C (O) -O-V336, -NV337-C (O) - NH-V338, -NV339-C (O) -NV340V341, -NHS (O 2) -V342, -NV343S (O 2) - V344, V345 -S-, -S (O) -V346, -S (O 2) -V347, -S (O 2) NH-V348, - S (O 2) NV349V350, -S (O 2) O-V351, -P (O) (OV352) (OV353), - Si (V354) (V355) (V356) "; wherein V305, V306, V307, V308 , V309, V310, V311, V312, V313, V314, V315, V316, V317, V318, V319, V320, V321, V322, V323, V324, V325, V326, V327, V328, V329, V330, V331, V332, V333 , V334, V335, V336,
V337, V338, V339, V340, V341 , V342, V343, V344, V345, V346, V347, V348, V349, V350, V351 , V352, V353, V354, V355, V356 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, ary- lalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V311 , V312 und/oderV337, V338, V339, V340, V341, V342, V343, V344, V345, V346, V347, V348, V349, V350, V351, V352, V353, V354, V355, V356 are independently selected from the group consisting of: " alkyl, alkyl (Cg-C 30) cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, ary lalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively V311, V312, and / or
V320, V321 und/oder V333, V334 und/oder V340, V341 und/oder V349, V350 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (d) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:V320, V321 and / or V333, V334 and / or V340, V341 and / or V349, V350 may together also form "heterocyclyl" wherein optional substituents of the substituent group (d) may be independently substituted with at least one substituent, the same or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV357, -NV358V359, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV357, -NV358V359, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -
V360, -C(O)O-V361 , -C(O)NH-V362, -C(O)NV363V364, -O-V365, - O(-V366-O)w-H (w = 1 , 2, 3, 4, 5), -O(-V367-O)w-V368 (w = 1 , 2, 3, 4, 5), -OC(O)-V369, -OC(O)-O-V370, -OC(O)-NHV371, -0-C(O)- NV372V373, -OP(O)(OV374)(OV375), -OSi(V376)(V377)(V378), - OS(O2)-V379, -NHC(O)-V380, -NV381C(O)-V382, -NH-C(O)-O-V360, -C (O) O-V361, -C (O) NH-V362, -C (O) NV363V364, -O-V365, -O (-V366-O) w -H (w = 1, 2, 3, 4, 5), -O (-V367-O) w -V368 (w = 1, 2, 3, 4, 5), -OC (O) -V369, -OC (O) -O-V370, -OC (O) -NHV371, -0-C (O) - NV372V373, -OP (O) (OV374) (OV375), -OSi (V376) (V377) (V378), - OS (O 2) -V379 , -NHC (O) -V380, -NV381C (O) -V382, -NH-C (O) -O-
V383, -NH-C(O)-NH-V384, -NH-C(O)-NV385V386, -NV387-C(O)- O-V388, -NV389-C(O)-NH-V390, -NV391-C(O)-NV392V393, - NHS(O2)-V394, -NV395S(O2)-V396, -S-V397, -S(O)-V398, -S(O2)- V399, -S(O2)NH-V400, -S(O2)NV401V402, -S(O2)O-V403, - P(O)(OV404)(OV405), -Si(V406)(V407)(V408)"; wobei V357, V358, V359, V360, V361 , V362, V363, V364, V365, V366, V367, V368, V369, V370, V371, V372, V373, V374, V375, V376, V377, V378, V379, V380, V381 , V382, V383, V384, V385, V386, V387, V388, V389, V390, V391, V392, V393, V394, V395, V396, V397, V398, V399, V400, V401 , V402, V403, V404, V405, V406, V407, V408 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V363, V364 und/oder V372, V373 und/oder V385, V386 und/oder V392, V393 und/oder V401 , V402 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) und/oder Substituentengruppe (ii) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:V383, -NH-C (O) -NH-V384, -NH-C (O) -NV385V386, -NV387-C (O) -O-V388, -NV389-C (O) -NH-V390, -NV391 -C (O) -NV392V393, - NHS (O 2) -V394, -NV395S (O 2) -V396, -S-V397, -S (O) -V398, -S (O 2) - V399, -S (O 2) NH-V400, -S (O 2) NV401V402, -S (O 2) O-V403, - P (O) (OV404) (OV405), -Si (V406) (V407) (V408) " wherein V357, V358, V359, V360, V361, V362, V363, V364, V365, V366, V367, V368, V369, V370, V371, V372, V373, V374, V375, V376, V377, V378, V379, V380, V381, V382, V383, V384, V385, V386, V387, V388, V389, V390, V391, V392, V393, V394, V395, V396, V397, V398, V399, V400, V401, V402, V403, V404, V405, V406, V407, V408 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl heteroaryl, heteroarylalkyl "and wherein alternatively V363, V364 and / or V372, V373 and / or V385, V386 and / or V392, V393 and / or V401, V402 may together also form" heterocyclyl "; wherein optionally above substituents of the substituent group (i) and / or substituent group (ii) may be independently substituted with at least one substituent, same or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV409, -NV410V41 1 , -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- V412, -C(O)O-V413, -C(O)NH-V414, -C(O)NV415V416, -O-V417, -(iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV409, -NV410V41 1, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) - V412, -C (O) O-V413, -C (O) NH-V414, -C (O) NV415V416, -O-V417, -
0(-V418-O)x-H (x = 1 , 2, 3, 4, 5), -O(-V419-O)x-V420 (x = 1 , 2, 3, 4, 5), -OC(O)-V421 , -OC(O)-O-V422, -OC(O)-N HV423, -0-C(O)- NV424V425, -OP(O)(OV426)(OV427), -OSi(V428)(V429)(V430), - OS(O2)-V431 , -NHC(O)-V432, -NV433C(O)-V434, -NH-C(O)-O- V435, -N H-C(O)-N H-V436, -N H-C(O)-N V437V438, -NV439-C(O)-0 (-V418-O) x -H (x = 1, 2, 3, 4, 5), -O (-V419-O) x -V420 (x = 1, 2, 3, 4, 5), - OC (O) -V421, -OC (O) -O-V422, -OC (O) -N HV423, -O-C (O) - NV424V425, -OP (O) (OV426) (OV427), -OSi (V428) (V429) (V430) - OS (O 2) -V431, -NHC (O) -V432, -NV433C (O) -V434, -NH-C (O) -O- V435, -N HC (O) -NH-V436, -NHC (O) -N V437V438, -NV439-C (O) -
O-V440, -NV441-C(O)-NH-V442, -NV443-C(O)-NV444V445, - NHS(O2)-V446, -NV447S(O2)-V448, -S-V449, -S(O)-V450, -S(O2)- V451 , -S(O2)N H-V452, -S(O2)NV453V454, -S(O2)O-V455, - P(O)(OV456a)(OV456b), -Si(V456c)(V456d)(V456e)"; wobei V409, V410, V411 , V412, V413, V414, V415, V416, V417, V418,O-V440, -NV441-C (O) -NH-V442, -NV443-C (O) -NV444V445, - NHS (O 2) -V446, -NV447S (O 2) -V448, -S-V449, - S (O) -V450, -S (O 2) - V451, -S (O 2) N H-V452, -S (O 2) NV453V454, -S (O 2) O-V455, - P (O) (OV456a) (OV456b), -Si (V456c) (V456d) (V456e) "; wherein V409, V410, V411, V412, V413, V414, V415, V416, V417, V418,
V419, V420, V421 , V422, V423, V424, V425, V426, V427, V428, V429, V430, V431 , V432, V433, V434, V435, V436, V437, V438, V439, V440, V441 , V442, V443, V444, V445, V446, V447, V448, V449, V450, V451 , V452, V453, V454, V455, V456a, V456b, V456c, V456d, V456e unab- hängig voneinander ausgewählt sind aus der Gruppe bestehend aus:V419, V420, V421, V422, V423, V424, V425, V426, V427, V428, V429, V430, V431, V432, V433, V434, V435, V436, V437, V438, V439, V440, V441, V442, V443, V444, V445, V446, V447, V448, V449, V450, V451, V452, V453, V454, V455, V456a, V456b, V456c, V456d, V456e are independently selected from the group consisting of:
„alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V415, V416 und/oder V424, V425 und/oder V437, V438 und/oder V444, V445 und/oder V453, V454 zusammen auch „heterocyclyl" bilden können;"Alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V415, V416 and / or V424, V425 and / or V437, V438 and / or V444 . V445 and / or V453, V454 may together also form "heterocyclyl";
und einer der Reste Z3, Z4 oder keiner der Reste Z3, Z4 unabhängig vonein- ander ausgewählt ist aus der Gruppe bestehend aus:and one of Z3, Z4 or none of Z3, Z4 is independently selected from the group consisting of:
(e) Wasserstoff;(e) hydrogen;
(f) Halogen, F, Cl, Br, I;(f) halogen, F, Cl, Br, I;
(g) unsubstituiertes oder substituiertes Alkyl oder (Cg-C3o)Alkyl, wobei optional der Alkyl- oder (C9-C3o)Alkylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(g) unsubstituted or substituted alkyl or (Cg-C 3 o) alkyl, optionally wherein said alkyl or (C 9 -C 3 o) alkyl group may be substituted may be different with at least one substituent, identical or different, selected from the group consisting of :
(i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV457, -NV458V459, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2,(i) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV457, -NV458V459, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 ,
-C(O)-V460, -C(O)O-V461 , -C(O)NH-V462, -C(O)NV463V464, - O-V465, -O(-V466-O)y-H (y = 1 , 2, 3, 4, 5), -O(-V467-O)y-V468 (y = 1 , 2, 3, 4, 5), -OC(O)-V469, -OC(O)-O-V470, -OC(O)-N H V471 , - 0-C(O)-N V472V473, -OP(O)(OV474)(OV475), - OSi(V476)(V477)(V478), -OS(O2)-V479, -NHC(O)-V480, --C (O) -V460, -C (O) O -V461, -C (O) NH -V462, -C (O) NV463V464, -O-V465, -O (-V466-O) y -H ( y = 1,2,3,4,5), -O (-V467-O) y -V468 (y = 1,2,3,4,5), -OC (O) -V469, -OC (O ) -O-V470, -OC (O) -NH V471, -O-C (O) -N V472V473, -OP (O) (OV474) (OV475), -OSi (V476) (V477) (V478), -OS (O 2 ) -V 479, -NHC (O) -V 4 80, -
NV481C(O)-V482, -NH-C(O)-O-V483, -NH-C(O)-NH-V484, -NH- C(O)-NV485V486, -NV487-C(O)-O-V488, -NV489-C(O)-NH- V490, -NV491-C(O)-NV492V493, -NHS(O2)-V494, -NV495S(O2)- V496, -S-V497, -S(O)-V498, -S(O2)-V499, -S(O2)NH-V500, - S(O2)NV501V502, -S(O2)O-V503, -P(O)(OV504)(OV505), -NV481C (O) -V482, -NH-C (O) -O-V483, -NH-C (O) -NH-V484, -NH-C (O) -NV485V486, -NV487-C (O) -O -V488, -NV489-C (O) -NH- V490, -NV491-C (O) -NV492V493, -NHS (O 2) -V494, -NV495S (O 2) - V496, V497 -S-, -S (O) -V498, -S (O 2) -V499, -S (O 2) NH-V500, - S (O 2) NV501V502, -S (O 2) O-V503, -P (O) (OV504 ) (OV505), -
Si(V506)(V507)(V508)"; wobei V457, V458, V459, V460, V461, V462, V463, V464, V465, V466, V467, V468, V469, V470, V471, V472, V473, V474, V475, V476, V477, V478, V479, V480, V481, V482, V483, V484, V485, V486, V487, V488, V489, V490, V491, V492, V493, V494, V495,Si (V506) (V507) (V508) "; wherein V457, V458, V459, V460, V461, V462, V463, V464, V465, V466, V467, V468, V469, V470, V471, V472, V473, V474, V475 , V476, V477, V478, V479, V480, V481, V482, V483, V484, V485, V486, V487, V488, V489, V490, V491, V492, V493, V494, V495,
V496, V497, V498, V499, V500, V501, V502, V503, V504, V505, V506, V507, V508 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ V463, V464 und/oder V472, V473 und/oder V485, V486 und/oder V492, V493 und/oder V501 , V502 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:V496, V497, V498, V499, V500, V501, V502, V503, V504, V505, V506, V507, V508 are independently selected from the group consisting of: alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl . heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where as an alternative V463, V464 and / or V472, V473 and / or V485, V486 and / or V492, V493 and / or V501, V502 in each case together also" heterocyclyl " can form; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,
CN, CF3, N3, NH2, -NHV509, -NV510V511 , -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V512, -C(O)O-V513, -C(O)NH-V514, - C(O)NV515V516, -O-V517, -O(-V518-O)z-H (z = 1 , 2, 3, 4, 5), - 0(-V519-O)z-V520 (z = 1 , 2, 3, 4, 5), -OC(O)-V521 , -OC(O)-O-CN, CF 3, N 3, NH 2, -NHV509, -NV510V511, -NO 2, -OH, -OCF3, - SH, -0-SO3H, -OP (O) (OH) 2, -CHO , -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -V 5 12, -C (O) O-V 513, -C (O) NH -V514, - C (O) NV515V516, -O-V517, -O (-V518-O) z -H (z = 1, 2, 3, 4, 5), - 0 (-V519-O) z - V520 (z = 1, 2, 3, 4, 5), -OC (O) -V521, -OC (O) -O-
V522, -OC(O)-N HV523, -O-C(O)-NV524V525, - OP(O)(OV526)(OV527), -OSi(V528)(V529)(V530), -OS(O2)- V531 , -NHC(O)-V532, -NV533C(O)-V534, -NH-C(O)-O-V535, -N H-C(O)-N H-V536, -N H-C(O)-N V537V538, -NV539-C(O)-O- V540, -NV541 -C(O)-N H-V542, -NV543-C(O)-NV544V545, -V522, -OC (O) -N HV523, -OC (O) -NV524V525, - OP (O) (OV526) (OV527), -OSi (V528) (V529) (V530), -OS (O 2 ) - V531, -NHC (O) -V532, -NV533C (O) -V534, -NH-C (O) -O-V535, -NHC (O) -NH-V536, -NHC (O) -N V537V538, -NV539-C (O) -O-V540, -NV541 -C (O) -NH-V542, -NV543-C (O) -NV544V545, -
NHS(O2)-V546, -NV547S(O2)-V548, -S-V549, -S(O)-V550, - S(O2)-V551 , -S(O2)NH-V552, -S(O2)NV553V554, -S(O2)O- V555, -P(O)(OV556)(OV557), -Si(V558)(V559)(V560)"; wobei V509, V510, V51 1 , V512, V513, V514, V515, V516, V517, V518, V519, V520, V521 , V522, V523, V524, V525, V526, V527,NHS (O 2) -V546, -NV547S (O 2) -V548, -S-V549, -S (O) -V550, - S (O 2) -V551, -S (O 2) NH-V552, - S (O 2 ) NV553V554, -S (O 2 ) O-V555, -P (O) (OV556) (OV557), -Si (V558) (V559) (V560) "; wherein V509, V510, V51 1, V512, V513, V514, V515, V516, V517, V518, V519, V520, V521, V522, V523, V524, V525, V526, V527,
V528, V529, V530, V531 , V532, V533, V534, V535, V536, V537, V538, V539, V540, V541 , V542, V543, V544, V545, V546, V547, V548, V549, V550, V551 , V552, V553, V554, V555, V556, V557, V558, V559, V560 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V515, V516 und/oder V524, V525 und/oder V537, V538 und/oder V544, V545 und/oder V553, V554 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:V528, V529, V530, V531, V532, V533, V534, V535, V536, V537, V538, V539, V540, V541, V542, V543, V544, V545, V546, V547, V548, V549, V550, V551, V552, are V553, V554, V555, V556, V557, V558, V559, V560 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl "heteroarylalkyl" and wherein alternatively V515, V516 and / or V524, V525 and / or V537, V538 and / or V544, V545 and / or V553, V554 may each together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
5 (iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV561 , -NV562V563, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V564, -C(O)O-V565, -5 (iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV561, -NV562V563, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -V564, -C (O) O-V 565, -
10 C(O)N H-V566, -C(O)NV567V568, -O-V569, -O(-V570-O)a-10 C (O) N H -V566, -C (O) NV567V568, -O-V569, -O (-V570-O) a -
H (a = 1 , 2, 3, 4, 5), -O(-V571-O)a-V572 (a = 1 , 2, 3, 4, 5), - OC(O)-V573, -OC(O)-O-V574, -OC(O)-N H V575, -0-C(O)- NV576V577, -OP(O)(OV578)(OV579), - OSi(V580)(V581 )(V582), -OS(O2)-V583, -NHC(O)-V584, -H (a = 1, 2, 3, 4, 5), -O (-V571-O) a -V572 (a = 1, 2, 3, 4, 5), - OC (O) -V573, -OC (O) -O-V574, -OC (O) -NH V575, -O-C (O) - NV576V577, -OP (O) (OV578) (OV579), - OSi (V580) (V581) (V582) , -OS (O 2 ) -V583, -NHC (O) -V584, -
15 NV585C(O)-V586, -NH-C(O)-O-V587, -NH-C(O)-NH-15 NV585C (O) -V586, -NH-C (O) -O-V587, -NH-C (O) -NH-
V588, -N H-C(O)-N V589V590, -NV591-C(O)-O-V592, - NV593-C(O)-NH-V594, -NV595-C(O)-NV596V597, - NHS(O2)-V598, -NV599S(O2)-V600, -S-V601 , -S(O)-V602, -S(O2)-V603, -S(O2)N H-V604, -S(O2)NV605V606, -S(O2)O-V588, -NHC (O) -N V589V590, -NV591-C (O) -O-V592, - NV593-C (O) -NH-V594, -NV595-C (O) -NV596V597, - NHS (O 2) -V598, -NV599S (O 2) -V600, -S-V601, -S (O) -V602, -S (O 2) -V603, -S (O 2) N H-V604, -S ( O 2 ) NV605V606, -S (O 2 ) O-
20 V607, -P(O)(OV608)(OV609), -Si(V610)(V611 )(V612)"; wobei V561 , V562, V563, V564, V565, V566, V567, V568, V569, V570, V571 , V572, V573, V574, V575, V576, V577, V578, V579, V580, V581 , V582, V583, V584, V585, V586, V587, V588, V589, V590, V591 , V592, V593, V594, V595,20 V607, -P (O) (OV608) (OV609), -Si (V610) (V611) (V612) "; wherein V561, V562, V563, V564, V565, V566, V567, V568, V569, V570, V571 , V572, V573, V574, V575, V576, V577, V578, V579, V580, V581, V582, V583, V584, V585, V586, V587, V588, V589, V590, V591, V592, V593, V594, V595,
25 V596, V597, V598, V599, V600, V601 , V602, V603, V604,25 V596, V597, V598, V599, V600, V601, V602, V603, V604,
V605, V606, V607, V608, V609, V610, V611 , V612 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"V605, V606, V607, V608, V609, V610, V611, V612 are independently selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "
30 und wobei alternativ V567, V568 und/oder V576, V577 und/oder V589, V590 und/oder V596, V597 und/oder V605, V606 jeweils zusammen auch „heterocyclyl" bilden können; (h) unsubstituiertes oder substituiertes Aryl, wobei optional der Arylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:And wherein alternatively V567, V568 and / or V576, V577 and / or V589, V590 and / or V596, V597 and / or V605, V606 may each also together form "heterocyclyl"; (h) unsubstituted or substituted aryl wherein optionally the aryl radical may be substituted with at least one substituent, same or different, selected from the group consisting of:
(i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3,(i) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 ,
N3, NH2, -NHV613, -NV614V615, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V616, -C(O)O-V617, -C(O)NH-V618, -C(O)NV619V620, - O-V621 , -O(-V622-O)b-H (b = 1 , 2, 3, 4, 5), -O(-V623-O)b-V624 (b = 1 , 2, 3, 4, 5), -OC(O)-V625, -OC(O)-O-V626, -OC(O)-N HV627, -N 3, NH 2, -NHV613, -NV614V615, -NO 2, -OH, -OCF3, -SH, -O- SO3H, -OP (O) (OH) 2, -CHO, -COOH, - C (O) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) -V616, -C (O) O-V617, -C (O) NH-V618, -C (O) NV619V620, -O-V621, -O (-V622-O) b -H (b = 1, 2, 3, 4, 5), -O (-V623-O) b -V624 (b = 1 , 2, 3, 4, 5), -OC (O) -V625, -OC (O) -O-V626, -OC (O) -N HV627, -
0-C(O)-N V628V629, -OP(O)(OV630)(OV631 ), - OSi(V632)(V633)(V634), -OS(O2)-V635, -NHC(O)-V636, - NV637C(O)-V638, -NH-C(O)-O-V639, -N H-C(O)-N H-V640, -NH- C(O)-NV641V642, -NV643-C(O)-O-V644, -NV645-C(O)-NH- V646, -NV647-C(O)-NV648V649, -NHS(O2)-V650, -NV651 S(O2)-0-C (O) -N V628V629, -OP (O) (OV630) (OV631), - OSi (V632) (V633) (V634), -OS (O 2) -V635, -NHC (O) -V636 , - NV637C (O) -V638, -NH-C (O) -O-V639, -NHC (O) -NH-V640, -NH-C (O) -NV641V642, -NV643-C (O) -O-V644, -NV645-C (O) -NH- V646, -NV647-C (O) -NV648V649, -NHS (O 2) -V650, -NV651 S (O 2) -
V652, -S-V653, -S(O)-V654, -S(O2)-V655, -S(O2)N H-V656, - S(O2)NV657V658, -S(O2)O-V659, -P(O)(OV660)(OV661 ), - Si(V662)(V663)(V664)"; wobei V613, V614, V615, V616, V617, V618, V619, V620, V621 , V622, V623, V624, V625, V626, V627, V628, V629, V630, V631 ,V652, V653 -S-, -S (O) -V654, -S (O 2) -V655, -S (O 2) N H-V656, - S (O 2) NV657V658, -S (O 2) O -V659, -P (O) (OV660) (OV661), -Si (V662) (V663) (V664) "; wherein V613, V614, V615, V616, V617, V618, V619, V620, V621, V622, V623 , V624, V625, V626, V627, V628, V629, V630, V631,
V632, V633, V634, V635, V636, V637, V638, V639, V640, V641 , V642, V643, V644, V645, V646, V647, V648, V649, V650, V651 , V652, V653, V654, V655, V656, V657, V658, V659, V660, V661 , V662, V663, V664 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V619, V620 und/oder V628, V629 und/oder V641 , V642 und/oder V648, V649 und/oder V657, V658 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV665, -NV666V667, -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V668, -C(O)O-V669, -C(O)NH-V670, -V632, V633, V634, V635, V636, V637, V638, V639, V640, V641, V642, V643, V644, V645, V646, V647, V648, V649, V650, V651, V652, V653, V654, V655, V656, V657, V658, V659, V660, V661, V662, V663, V664 are independently selected from the group consisting of: alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl "heteroarylalkyl" and wherein alternatively V619, V620 and / or V628, V629 and / or V641, V642 and / or V648, V649 and / or V657, V658 may each together also form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of: (ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV665, -NV666V667, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -V668, -C (O) O-V669, -C (O) NH-V670, -
C(O)NV671V672, -O-V673, -O(-V674-O)c-H (c = 1 , 2, 3, 4, 5), - O(-V675-O)c-V676 (c = 1 , 2, 3, 4, 5), -OC(O)-V677, -OC(O)-O- V678, -OC(O)-N HV679, -0-C(O)-N V680V681 , - OP(O)(OV682)(OV683), -OSi(V684)(V685)(V686), -OS(O2)- V687, -NHC(O)-V688, -NV689C(O)-V690, -NH-C(O)-O-V691 ,C (O) NV671V672, -O-V673, -O (-V674-O) c -H (c = 1, 2, 3, 4, 5), - O (-V675-O) c -V676 (c = 1, 2, 3, 4, 5), -OC (O) -V677, -OC (O) -O-V678, -OC (O) -N HV679, -O-C (O) -N V680V681, - OP (O) (OV682) (OV683), -OSi (V684) (V685) (V686), -OS (O 2) - V687, -NHC (O) -V688, -NV689C (O) -V690, -NH -C (O) -O-V691,
-N H-C(O)-N H-V692, -NH-C(O)-NV693V694, -NV695-C(O)-O- V696, -NV697-C(O)-NH-V698, -NV699-C(O)-NV700V701 , - NHS(O2)-V702, -NV703S(O2)-V704, -S-V705, -S(O)-V706, - S(O2)-V707, -S(O2)NH-V708, -S(O2)NV709V710, -S(O2)O- V71 1 , -P(O)(OV712)(OV713), -Si(V714)(V715)(V716)"; wobei V665, V666, V667, V668, V669, V670, V671, V672, V673, V674, V675, V676, V677, V678, V679, V680, V681, V682, V683, V684, V685, V686, V687, V688, V689, V690, V691, V692, V693, V694, V695, V696, V697, V698, V699, V700, V701, V702, V703, V704, V705, V706, V707, V708, V709, V710, V711, V712, V713,-NHC (O) -NH-V692, -NH-C (O) -NV693V694, -NV695-C (O) -O-V696, -NV697-C (O) -NH-V698, -NV699-C (O) -NV700V701, - NHS (O 2) -V702, -NV703S (O 2) -V704, -S-V705, -S (O) -V706, - S (O 2) -V707, -S (O 2 ) NH-V708, -S (O 2 ) NV709V710, -S (O 2 ) O-V71 1, -P (O) (OV712) (OV713), -Si (V714) (V715) (V716) "; wherein V665, V666, V667, V668, V669, V670, V671, V672, V673, V674, V675, V676, V677, V678, V679, V680, V681, V682, V683, V684, V685, V686, V687, V688, V689 , V690, V691, V692, V693, V694, V695, V696, V697, V698, V699, V700, V701, V702, V703, V704, V705, V706, V707, V708, V709, V710, V711, V712, V713,
V714, V715, V716 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V671 , V672 und/oder V680, V681 und/oder V693, V694 und/oder V700, V701 und/oder V709,V714, V715, V716 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V671, V672 and / or V680, V681 and / or V693, V694 and / or V700, V701 and / or V709,
V710 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausge- wählt aus der Gruppe bestehend aus:In each case together, they may also form "heterocyclyl", where optionally substituted substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV717, -NV718V719, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V720, -C(O)O-V721 , - C(O)N H-V722, -C(O)NV723V724, -O-V725, -O(-V726-O)d- H (d = 1 , 2, 3, 4, 5), -O(-V727-O)d-V728 (d = 1 , 2, 3, 4, 5), - OC(O)-V729, -OC(O)-O-V730, -OC(O)-N H V731 , -0-C(O)- NV732V733, -OP(O)(OV734)(OV735), -(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV717, -NV718V719, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, - C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -V 720, -C (O) O-V 721, -C (O) N H -V 722, - C (O) NV723V724, -O-V725, -O (-V726-O) d -H (d = 1, 2, 3, 4, 5), -O (-V727-O) d -V728 (d = 1, 2, 3, 4, 5), - OC (O) -V729, -OC (O) -O-V730, -OC (O) -NH V731, -O-C (O) - NV732V733, -OP (O) (OV734) (OV735), -
OSi(V736)(V737)(V738), -OS(O2)-V739, -NHC(O)-V740, - NV741C(O)-V742, -NH-C(O)-O-V743, -NH-C(O)-NH- V744, -N H-C(O)-N V745V746, -NV747-C(O)-O-V748, - NV749-C(O)-NH-V750, -NV751-C(O)-NV752V753, - NHS(O2)-V754, -NV755S(O2)-V756, -S-V757, -S(O)-V758,OSi (V736) (V737) (V738), -OS (O 2) -V739, -NHC (O) -V740, - NV741C (O) -V742, -NH-C (O) -O-V743, -NH -C (O) -NH-V744, -NHC (O) -N V745V746, -NV747-C (O) -O-V748, - NV749-C (O) -NH-V750, -NV751-C (O ) -NV752V753, - NHS (O 2 ) -V754, -NV755S (O 2 ) -V756, -S-V757, -S (O) -V758,
-S(O2)-V759, -S(O2)N H-V760, -S(O2)NV761V762, -S(O2)O- V763, -P(O)(OV764)(OV765), -Si(V766)(V767)(V768)"; wobei V717, V718, V719, V720, V721, V722, V723, V724, V725, V726, V727, V728, V729, V730, V731 , V732, V733, V734, V735, V736, V737, V738, V739, V740, V741, V742,-S (O 2 ) -V 759, -S (O 2 ) N H -V 760, -S (O 2 ) NV 761 V 762, -S (O 2 ) O-V 763, -P (O) (OV 764) (OV765), -Si (V766) (V767) (V768) "; wherein V717, V718, V719, V720, V721, V722, V723, V724, V725, V726, V727, V728, V729, V730, V731, V732, V733, V734, V735, V736, V737, V738, V739, V740, V741, V742,
V743, V744, V745, V746, V747, V748, V749, V750, V751 , V752, V753, V754, V755, V756, V757, V758, V759, V760, V761 , V762, V763, V764, V765, V766, V767, V768 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc-V743, V744, V745, V746, V747, V748, V749, V750, V751, V752, V753, V754, V755, V756, V757, V758, V759, V760, V761, V762, V763, V764, V765, V766, V767, (C 9 -C 3 o) "alkyl, alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl: V768 are each independently selected from the group consisting of
IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V723, V724 und/oder V732, V733 und/oder V745, V746 und/oder V752, V753 und/oder V761 , V762 jeweils zusammen auch „heterocyclyl" bilden können;IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively V723, V724 and / or V732, V733 and / or V745, V746 and / or V752, V753 and / or V761, V762 can each also together form" heterocyclyl " ;
(j) unsubstituiertes oder substituiertes Heteroaryl, wobei optional der Hetero- arylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(j) unsubstituted or substituted heteroaryl, where optionally the heteroaryl radical may be substituted by at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3,(i) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3,
N3, NH2, -NHV769, -NV770V771 , -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V772, -C(O)O-V773, -C(O)NH-V774, -C(O)NV775V776, - O-V777, -O(-V778-O)e-H (e = 1 , 2, 3, 4, 5), -O(-V779-O)e-V780 (e = 1 , 2, 3, 4, 5), -OC(O)-V781 , -OC(O)-O-V782, -OC(O)-N HV783, - O-C(O)-NV784V785, -OP(O)(OV786)(OV787), - OSi(V788)(V789)(V790), -OS(O2)-V791 , -NHC(O)-V792, - NV793C(O)-V794, -NH-C(O)-O-V795, -N H-C(O)-N H-V796, -NH- C(O)-NV797V798, -NV799-C(O)-O-V800, -NV801 -C(O)-N H-N 3 , NH 2 , -NHV769, -NV770V771, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, - C (O) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) -V772, -C (O) O-V773, -C (O) NH-V774, -C (O) NV775V776, -O-V777, -O (-V778-O) e -H (e = 1, 2, 3, 4, 5), -O (-V779-O) e -V780 (e = 1, 2, 3, 4, 5), -OC (O) -V781, -OC (O) -O-V782, -OC (O) -N HV783, -OC (O) -NV784V785, -OP ( O) (OV786) (OV787), - OSi (V788) (V789) (V790), -OS (O 2) -V791, -NHC (O) -V792, - NV793C (O) -V794, -NH-C (O) -O-V795, -NHC (O) -NH-V796, -NH-C (O) -NV797V798, -NV799-C (O) -O-V800, -NV801 -C (O) - N H
V802, -NV803-C(O)-NV804V805, -NHS(O2)-V806, -NV807S(O2)- V808, -S-V809, -S(O)-V810, -S(O2)-V811 , -S(O2)N H-V812, - S(O2)NV813V814, -S(O2)O-V815, -P(O)(OV816)(OV817), - Si(V818)(V819)(V820)"; wobei V769, V770, V771 , V772, V773, V774, V775, V776, V777,V802, -NV803-C (O) -NV804V805, -NHS (O 2) -V806, -NV807S (O 2) - V808, V809 -S-, -S (O) -V810, -S (O 2) - V811, -S (O 2) N H-V812, - S (O 2) NV813V814, -S (O 2) O-V815, -P (O) (OV816) (OV817), - Si (V818) (V819 ) (V820) "; wherein V769, V770, V771, V772, V773, V774, V775, V776, V777,
V778, V779, V780, V781 , V782, V783, V784, V785, V786, V787, V788, V789, V790, V791 , V792, V793, V794, V795, V796, V797, V798, V799, V800, V801 , V802, V803, V804, V805, V806, V807, V808, V809, V810, V81 1 , V812, V813, V814, V815, V816, V817, V818, V819, V820 unabhängig voneinander ausgewählt sind aus derV778, V779, V780, V781, V782, V783, V784, V785, V786, V787, V788, V789, V790, V791, V792, V793, V794, V795, V796, V797, V798, V799, V800, V801, V802, V803, V804, V805, V806, V807, V808, V809, V810, V81 1, V812, V813, V814, V815, V816, V817, V818, V819, V820 are independently selected from the
Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ V775, V776 und/oder V784, V785 und/oder V797, V798 und/oder V804, V805 und/oder V813, V814 jeweils zu- sammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV821 , -NV822V823, -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V824, -C(O)O-V825, -C(O)NH-V826, - C(O)NV827V828, -O-V829, -O(-V830-O)^H (f = 1 , 2, 3, 4, 5), -A group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V775, V776 and / or V784, V785 and / or V797 , V798 and / or V804, V805 and / or V813, V814 together can also form "heterocyclyl"; wherein optionally above substituents of substituent group (i) in turn may be independently substituted with at least one substituent, identical or different, selected from the group consisting of: (ii) "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHV821, -NV822V823, -NO 2, -OH, -OCF3, - SH , -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C ( O) -V824, -C (O) O-V825, -C (O) NH-V826, -C (O) NV827V828, -O-V829, -O (-V830-O) ^ H (f = 1, 2, 3, 4, 5), -
O(-V831-O)^V832 (f = 1 , 2, 3, 4, 5), -OC(O)-V833, -OC(O)-O- V834, -OC(O)-N HV835, -0-C(O)-N V836V837, - OP(O)(OV838)(OV839), -OSi(V840)(V841 )(V842), -OS(O2)- V843, -NHC(O)-V844, -NV845C(O)-V846, -NH-C(O)-O-V847, -NH-C(O)-NH-V848, -NH-C(O)-NV849V850, -NV851-C(O)-O- V852, -NV853-C(O)-NH-V854, -NV855-C(O)-NV856V857, - NHS(O2)-V858, -NV859S(O2)-V860, -S-V861, -S(O)-V862, - S(O2)-V863, -S(O2)NH-V864, -S(O2)NV865V866, -S(O2)O- 5 V867, -P(O)(OV868)(OV869), -Si(V870)(V871)(V872)"; wobei V821, V822, V823, V824, V825, V826, V827, V828, V829, V830, V831, V832, V833, V834, V835, V836, V837, V838, V839, V840, V841, V842, V843, V844, V845, V846, V847, V848, V849, V850, V851, V852, V853, V854, V855, V856, V857, V858, V859,O (-V831-O) VV832 (f = 1, 2, 3, 4, 5), -OC (O) -V833, -OC (O) -O-V834, -OC (O) -N HV835, -0-C (O) -N V836V837, - OP (O) (OV838) (OV839), -OSi (V840) (V841) (V842), -OS (O 2) - V843, -NHC (O) - V844, -NV845C (O) -V846, -NH-C (O) -O-V847, -NH-C (O) -NH-V848, -NH-C (O) -NV849V850, -NV851-C (O) -O-V852, -NV853-C (O) -NH-V854, -NV855-C (O) -NV856V857, - NHS (O 2) -V858, -NV859S (O 2) -V860, -S-V861, -S (O) -V862, - S (O 2) -V863, -S (O 2) NH-V864, -S (O 2) NV865V866, -S (O 2) O- 5 V867, -P (O) (OV868) (OV869), -Si (V870) (V871) (V872) "; where V821, V822, V823, V824, V825, V826, V827, V828, V829, V830, V831, V832, V833, V834, V835, V836, V837, V838, V839, V840, V841, V842, V843, V844, V845 , V846, V847, V848, V849, V850, V851, V852, V853, V854, V855, V856, V857, V858, V859,
10 V860, V861, V862, V863, V864, V865, V866, V867, V868, V869,10 V860, V861, V862, V863, V864, V865, V866, V867, V868, V869,
V870, V871 , V872 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V827, V828 und/oder V836,V870, V871 are, V872 independently selected from the group consisting of: "alkyl, (C 9 -C 30) alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V827 V828 and / or V836,
15 V837 und/oder V849, V850 und/oder V856, V857 und/oder V865,15 V837 and / or V849, V850 and / or V856, V857 and / or V865,
V866 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausge- 20 wählt aus der Gruppe bestehend aus:In each case together, they may also form "heterocyclyl", where optionally substituted substituents of the substituent group (ii) may in turn be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV873, -NV874V875, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -(iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV873, -NV874V875, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -
25 C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V876, -C(O)O-V877, -25 C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -V 876, -C (O) O-V 877, -
C(O)NH-V878, -C(O)NV879V880, -O-V881 , -O(-V882-O)g- H (g = 1 , 2, 3, 4, 5), -O(-V883-O)g-V884 (g = 1 , 2, 3, 4, 5), - OC(O)-V885, -OC(O)-O-V886, -OC(O)-N HV887, -0-C(O)- NV888V889, -OP(O)(OV890)(OV891 ), -C (O) NH-V878, -C (O) NV879V880, -O-V881, -O (-V882-O) g -H (g = 1, 2, 3, 4, 5), -O (-V883 -O) g -V884 (g = 1, 2, 3, 4, 5), - OC (O) -V885, -OC (O) -O-V886, -OC (O) -N HV887, -O- C (O) - NV888V889, -OP (O) (OV890) (OV891),
30 OSi(V892)(V893)(V894), -OS(O2)-V895, -NHC(O)-V896, -30 OSi (V892) (V893) (V894), -OS (O 2) -V895, -NHC (O) -V896, -
NV897C(O)-V898, -NH-C(O)-O-V899, -NH-C(O)-NH- V900, -N H-C(O)-N V901V902, -NV903-C(O)-O-V904, - NV905-C(O)-NH-V906, -NV907-C(O)-NV908V909, - NHS(O2)-V910, -NV911S(O2)-V912, -S-V913, -S(O)-V914, -S(O2)-V915, -S(O2)NH-V916, -S(O2)NV917V918, -S(O2)O- V919, -P(O)(OV920)(OV921 ), -Si(V922)(V923)(V924)"; wobei V873, V874, V875, V876, V877, V878, V879, V880, V881 , V882, V883, V884, V885, V886, V887, V888, V889, V890, V891, V892, V893, V894, V895, V896, V897, V898,NV897C (O) -V898, -NH-C (O) -O-V899, -NH-C (O) -NH-V900, -NHC (O) -N V901V902, -NV903-C (O) -O -V904, - NV905-C (O) -NH-V906, -NV907-C (O) -NV908V909, - NHS (O 2) -V910, -NV911S (O 2) -V912, -S-V913, -S (O) -V914, -S (O 2) -V915, -S (O 2) NH-V916, -S (O 2) NV917V918, -S (O 2) O- V919, -P (O) (OV920) (OV921) - Si (V922) (V923) (V924) "; wherein V873, V874, V875, V876, V877, V878, V879, V880, V881, V882, V883, V884, V885, V886, V887, V888, V889, V890, V891 , V892, V893, V894, V895, V896, V897, V898,
V899, V900, V901 , V902, V903, V904, V905, V906, V907, V908, V909, V910, V911, V912, V913, V914, V915, V916, V917, V918, V919, V920, V921 , V922, V923, V924 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc-V899, V900, V901, V902, V903, V904, V905, V906, V907, V908, V909, V910, V911, V912, V913, V914, V915, V916, V917, V918, V919, V920, V921, V922, V923, V924 are each independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl
IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V879, V880 und/oder V888, V889 und/oder V901 , V902 und/oder V908, V909 und/oder V917, V918 jeweils zusammen auch „heterocyclyl" bilden können;IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively V879, V880 and / or V888, V889 and / or V901, V902 and / or V908, V909 and / or V917, V918 may each together also form" heterocyclyl " ;
(k) OZ6, wobei Z6 unabhängig ausgewählt ist aus der Gruppe bestehend aus:(k) OZ6, wherein Z6 is independently selected from the group consisting of:
(i) „Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(i) "hydrogen, alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wherein optionally substituents of the substituent group (i) above may be independently substituted with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,
CN, CF3, N3, NH2, -NHV925, -NV926V927, -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V928, -C(O)O-V929, -C(O)NH-V930, - C(O)NV931 V932, -O-V933, -O(-V934-O)h-H (h = 1 , 2, 3, 4, 5), - O(-V935-O)h-V936 (h = 1 , 2, 3, 4, 5), -OC(O)-V937, -OC(O)-O-CN, CF 3, N 3, NH 2, -NHV925, -NV926V927, -NO 2, -OH, -OCF3, - SH, -0-SO3H, -OP (O) (OH) 2, -CHO , -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -V 928, -C (O) O-V 929, -C (O) NH -V930, -C (O) NV931 V932, -O-V933, -O (-V934-O) h -H (h = 1, 2, 3, 4, 5), - O (-V935-O) h -V936 (h = 1, 2, 3, 4, 5), -OC (O) -V937, -OC (O) -O-
V938, -OC(O)-N HV939, -0-C(O)-N V940V941 , - OP(O)(OV942)(OV943), -OSi(V944)(V945)(V946), -OS(O2)- V947, -NHC(O)-V948, -NV949C(O)-V950, -NH-C(O)-O-V951 , -NH-C(O)-NH-V952, -NH-C(O)-NV953V954, -NV955-C(O)-O- V956, -NV957-C(O)-NH-V958, -NV959-C(O)-NV960V961, - NHS(O2)-V962, -NV963S(O2)-V964, -S-V965, -S(O)-V966, - S(O2)-V967, -S(O2)NH-V968, -S(O2)NV969V970, -S(O2)O- 5 V971, -P(O)(OV972)(OV973), -Si(V974)(V975)(V976)"; wobei V925, V926, V927, V928, V929, V930, V931, V932, V933, V934, V935, V936, V937, V938, V939, V940, V941, V942, V943, V944, V945, V946, V947, V948, V949, V950, V951, V952, V953, V954, V955, V956, V957, V958, V959, V960, V961, V962, V963,V938, -OC (O) -N HV939, -O-C (O) -N V940V941, - OP (O) (OV942) (OV943), -OSi (V944) (V945) (V946), -OS (O 2 ) - V947, -NHC (O) -V948, -NV949C (O) -V950, -NH-C (O) -O-V951, -NH-C (O) -NH-V952, -NH-C (O) -NV953V954, -NV955-C (O) -O-V956, -NV957-C (O) -NH-V958, -NV959-C (O) -NV960V961, - NHS (O 2) -V962, -NV963S (O 2) -V964, -S-V965, -S (O) -V966, - S (O 2) -V967, -S (O 2) NH-V968, -S (O 2) NV969V970, -S (O 2) O- 5 V971, -P (O) (OV972) (OV973), -Si (V974) (V975) (V976) "; wherein V925, V926, V927, V928, V929, V930, V931, V932, V933, V934, V935, V936, V937, V938, V939, V940, V941, V942, V943, V944, V945, V946, V947, V948, V949 , V950, V951, V952, V953, V954, V955, V956, V957, V958, V959, V960, V961, V962, V963,
10 V964, V965, V966, V967, V968, V969, V970, V971, V972, V973,10 V964, V965, V966, V967, V968, V969, V970, V971, V972, V973,
V974, V975, V976 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V931 , V932 und/oder V940,V974, V975, V976 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V931, V932 and / or V940,
15 V941 und/oder V953, V954 und/oder V960, V961 und/oder V969,15 V941 and / or V953, V954 and / or V960, V961 and / or V969,
V970 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausge- 20 wählt aus der Gruppe bestehend aus:In each case together they can also form "heterocyclyl", where optionally substituted substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV977, -NV978V979, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -(iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHV977, -NV978V979, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -
25 C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V980, -C(O)O-V981 , -25 C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -V 980, -C (O) O-V981,
C(O)N H-V982, -C(O)NV983V984, -O-V985, -O(-V986-O),- H (i = 1 , 2, 3, 4, 5), -O(-V987-O),-V988 (i = 1 , 2, 3, 4, 5), - OC(O)-V989, -OC(O)-O-V990, -OC(O)-N H V991 , -0-C(O)- NV992V993, -OP(O)(OV994)(OV995), -C (O) N H -V982, -C (O) NV983V984, -O-V985, -O (-V986-O), - H (i = 1, 2, 3, 4, 5), -O (- V987-O), - V988 (i = 1, 2, 3, 4, 5), - OC (O) -V989, -OC (O) -O-V990, -OC (O) -NH V991, -0 -C (O) - NV992V993, -OP (O) (OV994) (OV995), -
30 OSi(V996)(V997)(V998), -OS(O2)-V999, -NHC(O)-VI 000, -30 OSi (V996) (V997) (V998), -OS (O 2) -V999, -NHC (O) -VI 000, -
NV1001 C(O)-VI 002, -NH-C(O)-O-VI 003, -NH-C(O)-NH- V1004, -NH-C(O)-NVI 005V1006, -NV1007-C(O)-O-VI 008, -NVI OOg-C(O)-NH-VI OIO1 -NVI OI I-C(O)-NVIO^VI OI S, - NHS(O2)-V1014, -NV1015S(O2)-V1016, -S-V1017, -S(O)- V1018, -S(O2)-V1019, -S(O2)NH-VI 020, -NV1001 C (O) -VI 002, -NH-C (O) -O-VI 003, -NH-C (O) -NH-V1004, -NH-C (O) -NVI 005V1006, -NV1007-C ( O) -O-VI 008, -NVI OOg-C (O) -NH-VI OIO 1 -NVI OI IC (O) -NVIO ^ VI OI S, - NHS (O 2 ) -V1014, -NV1015S (O 2 ) -V1016, -S-V1017, -S (O) - V1018, -S (O 2) -V1019, -S (O 2) NH-VI 020 -
S(O2)NVI 021 V1022, -S(O2)O-VI 023, -S (O 2 ) NVI 021 V1022, -S (O 2 ) O-VI 023, -
P(O)(OVI 024)(OV1025), -Si(VI 026)(V1027)(V1028)"; wobei V977, V978, V979, V980, V981 , V982, V983, V984, V985, V986, V987, V988, V989, V990, V991 , V992, V993,P (O) (OVI 024) (OV1025), -Si (VI 026) (V1027) (V1028) "; wherein V977, V978, V979, V980, V981, V982, V983, V984, V985, V986, V987, V988 , V989, V990, V991, V992, V993,
V994, V995, V996, V997, V998, V999, V1000, V1001 , V1002, V1003, V1004, V1005, V1006, V1007, V1008, V1009, V1010, V101 1 , V1012, V1013, V1014, V1015, V1016, V1017, V1018, V1019, V1020, V1021 , V1022, V1023, V1024, V1025, V1026, V1027, V1028 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V983, V984 und/oder V992, V993 und/oder V1005, V1006 und/oder V1012, V1013 und/oder V1021 , V1022 jeweils zusammen auch „heterocyclyl" bilden können;V994, V995, V996, V997, V998, V999, V1000, V1001, V1002, V1003, V1004, V1005, V1006, V1007, V1008, V1009, V1010, V101 1, V1012, V1013, V1014, V1015, V1016, V1017, V1018 , V1019, V1020, V1021, V1022, V1023, V1024 are, V1025, V1026, V1027, V1028 independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl , aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively V983, V984 and / or V992, V993 and / or V1005, V1006 and / or V1012, V1013 and / or V1021, V1022 may each together also form" heterocyclyl ";
, wobei Z7 unabhängig ausgewählt ist aus der Gruppe bestehend aus: „Wasserstoff, alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV1029, -NV1030V1031 , -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-VI 032, -C(O)O-VI 033, -C(O)NH- V1034, -C(O)NVI 035V1036, -0-V1037, -O(-V1038-O)-H (j = 1 ,wherein Z7 is independently selected from the group consisting of: "hydrogen, alkyl, (C" 9 " -C" 3 " ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl;""wherein optional substituents above substituent (i) in turn may be independently substituted with at least one substituent, identical or different, selected from the group consisting of: (ii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl , aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHV1029, -NV1030V1031, -NO 2, -OH, - OCF 3, -SH, -0 -SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) - VI 032, -C (O) O-VI 033, -C (O) NH-V1034, -C (O) NVI 035V1036, -O-V1037, -O (-V1038-O) -H (j = 1,
2, 3, 4, 5), -O(-V1039-O)-V1040 C = 1 , 2, 3, 4, 5), -OC(O)- V1041 , -OC(O)-O-VI 042, -OC(O)-NHVI 043, -0-C(O)- NV1044V1045, -OP(O)(OVI 046)(OV1047), - OSi(VI 048)(V1049)(V1050), -0S(02)-V1051 , -N HC(O)-VI 052, - NV1053C(O)-VI 054, -NH-C(O)-O-VI 055, -NH-C(O)-NH- V1056, -NH-C(O)-NVI 057V1058, -NV1059-C(O)-O-VI 060, - NV1061-C(O)-NH-VI 062, -NV1063-C(O)-NVI 064V1065, - 5 NHS(O2)-V1066, -NV1067S(O2)-V1068, -S-V1069, -S(O)-2, 3, 4, 5), -O (-V1039-O) -V1040 C = 1, 2, 3, 4, 5), -OC (O) -V1041, -OC (O) -O-VI 042 , -OC (O) -NHVI 043, -O-C (O) - NV1044V1045, -OP (O) (OVI 046) (OV1047), OSi (VI 048) (V1049) (V1050), -0S (0 2 ) -V1051, -N HC (O) -VI 052, - NV1053C (O) -VI 054, -NH-C (O) -O- VI 055, -NH-C (O) -NH-V1056, -NH-C (O) -NVI 057V1058, -NV1059-C (O) -O-VI 060, - NV1061-C (O) -NH-VI 062, -NV1063-C (O) -NVI 064V1065, - 5 NHS (O 2 ) -V 1066, -NV 1067S (O 2 ) -V 1068, -S-V 1069, -S (O) -
V1070, -S(02)-V1071 , -S(O2)NH-VI 072, -S(O2)NVI 073V1074, - S(O2)O-VI 075, -P(O)(OVI 076)(OV1077), - Si(VI 078)(V1079)(V1080)"; wobei V1029, V1030, V1031 , V1032, V1033, V1034, V1035,V1070, -S (O 2 ) -V 1071, -S (O 2 ) NH-VI 072, -S (O 2 ) NVI 073V1074, -S (O 2 ) O-VI 075, -P (O) (OVI 076 (OV1077), -Si (VI078) (V1079) (V1080) "; where V1029, V1030, V1031, V1032, V1033, V1034, V1035,
10 V1036, V1037, V1038, V1039, V1040, V1041 , V1042, V1043,10 V1036, V1037, V1038, V1039, V1040, V1041, V1042, V1043,
V1044, V1045, V1046, V1047, V1048, V1049, V1050, V1051 , V1052, V1053, V1054, V1055, V1056, V1057, V1058, V1059, V1060, V1061 , V1062, V1063, V1064, V1065, V1066, V1067, V1068, V1069, V1070, V1071 , V1072, V1073, V1074, V1075,V1044, V1045, V1046, V1047, V1048, V1049, V1050, V1051, V1052, V1053, V1054, V1055, V1056, V1057, V1058, V1059, V1060, V1061, V1062, V1063, V1064, V1065, V1066, V1067, V1068, V1069, V1070, V1071, V1072, V1073, V1074, V1075,
15 V1076, V1077, V1078, V1079, V1080 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V1035, V1036 und/oder V1044, V1045 und/oder V1057, V105815 V1076, V1077, are V1078, V1079, V1080 independently selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively, V1035, V1036 and / or V1044, V1045 and / or V1057, V1058
20 und/oder V1064, V1065 und/oder V1073, V1074 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausge- 25 wählt aus der Gruppe bestehend aus:20 and / or V1064, V1065 and / or V1073, V1074 may together also form "heterocyclyl" wherein optionally substituents of substituent group (ii) above may be substituted independently with at least one substituent, the same or different, selected from the group consisting of:
(iii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV1081 , -NV1082V1083, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -(iii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHV1081, -NV1082V1083, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -
30 C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-VI 084, -C(O)O-VI 085,30 C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -VI 084, -C (O) O-VI 085,
-C(O)NH-VI 086, -C(O)NVI 087V1088, -O-V1089, -O(- V1090-O)k-H (k = 1 , 2, 3, 4, 5), -O(-V1091-O)k-V1092 (k = 1 , 2, 3, 4, 5), -OC(O)-VI 093, -OC(O)-O-VI 094, -OC(O)- NHV1095, -O-C(O)-NV1096V1097, - OP(O)(OVI 098)(OV1099), -OSi(V1 100)(V1101 )(V1102), - 0S(02)-V1103, -NHC(O)-V1 104, -NV1105C(O)-V1 106, - NH-C(O)-O-V1107, -NH-C(O)-NH-V1 108, -NH-C(O)- NV1109V11 10, -NV111 1-C(O)-O-V1112, -NV11 13-C(O)- NH-V1 114, -NV11 15-C(O)-NV1 116V11 17, -NHS(O2)--C (O) NH-VI 086, -C (O) NVI 087V1088, -O-V1089, -O (- V1090-O) k -H (k = 1, 2, 3, 4, 5), -O (-V1091-O) k -V1092 (k = 1, 2, 3, 4, 5), -OC (O) -VI 093, -OC (O) -O-VI 094, -OC (O) -NHV1095 , -OC (O) -NV1096V1097, - OP (O) (OVI 098) (OV1099), -OSi (V1 100) (V1101) (V1102), -0S (0 2 ) -V1103, -NHC (O) -V1 104, -NV1105C (O) -V1 106, - NH-C (O) -O-V1107, -NH-C (O) -NH-V1 108, -NH-C (O) - NV1109V11 10, -NV111 1-C (O) -O-V1112 , -NV11 13-C (O) - NH-V1 114, -NV11 15-C (O) -NV1 116V11 17, -NHS (O 2 ) -
V11 18, -NV1 119S(O2)-V1 120, -S-V1121 , -S(O)-V1 122, - S(O2)-V1123, -S(O2)NH-V1124, -S(O2)NVI 125V1 126, - S(O2)O-V1127, -P(O)(OV1128)(OV1 129), - Si(VI 130)(V1131 )(V1132)"; wobei V1081 , V1082, V1083, V1084, V1085, V1086, V1087,V11 18 -NV1 119S (O 2) -V1 120, -S-V1121, -S (O) -V1 122, - S (O 2) -V1123, -S (O 2) NH-V1124, -S ( O 2 ) NVI 125V1 126, -S (O 2 ) O-V1127, -P (O) (OV1128) (OV1 129), -Si (VI 130) (V1131) (V1132) "; wherein V1081, V1082, V1083 , V1084, V1085, V1086, V1087,
V1088, V1089, V1090, V1091 , V1092, V1093, V1094, V1095, V1096, V1097, V1098, V1099, V1 100, V1 101 , V1 102, V1 103, V1104, V1105, V1 106, V1 107, V1 108, V1 109, V1 110, V1 11 1 , V1112, V1113, V1 114, V1 115, V1 116, V1 117, V1 118, V1 119, V1120, V1121 , V1 122, V1 123, V1 124, V1 125, V1 126, V1 127,V1088, V1089, V1090, V1091, V1092, V1093, V1094, V1095, V1096, V1097, V1098, V1099, V1100, V1101, V1102, V1103, V1104, V1105, V1106, V1107, V1108, V1 109, V1 110, V1 11 1, V1112, V1113, V1 114, V1 115, V1 116, V1 117, V1 118, V1 119, V1120, V1121, V1 122, V1 123, V1 124, V1 125, V1 126, V1 127,
V1128, V1129, V1130, V1 131 , V1 132 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei al- ternativ V1087, V1088 und/oder V1096, V1097 und/oderV1128, V1129, V1130, V1 131 V1 132 are independently selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V1087, V1088 and / or V1096, V1097 and / or
V1109, V1110 und/oder V1 116, V1 117 und/oder V1 125, V1126 jeweils zusammen auch „heterocyclyl" bilden können;V1109, V1110 and / or V1 116, V1 117 and / or V1 125, V1126 may together also form "heterocyclyl";
(m) NZ8Z9, wobei Z8, Z9 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:(m) NZ8Z9, wherein Z8, Z9 are independently selected from the group consisting of:
(i) „Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C(O)- V1133, -C(O)O-V1 134, -C(O)-NV1135V1 136, -S(O2)-V1 137, - S(O2)O-V1138"; wobei V1133, V1134, V1135, V1136, V1137, V1138 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V1135, V1 136 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHV1 139, -NV1140V1 141 , -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V1 142, -C(O)O-V1 143, -C(O)NH- V1144, -C(O)NVI 145V1146, -0-V1147, -0(-V1148-O)1-H (1 = 1,(i) "hydrogen, alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C (O) -V1133, -C (O) O-V1 134 , -C (O) -NV1135V1 136, -S (O 2) -V1 137, - S (O 2) O-V1138 "; wherein V1133, V1134, V1135, V1136 are, V1137, V1138 independently selected from the group consisting of: hydrogen, alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively V1135, V1 136 together also" heterocyclyl may form "; in which optionally substituents of substituent group (i) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of: (ii) alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHV1 139, -NV1140V1 141, -NO 2, -OH, - OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -V1 142, -C (O) O-V1 143, -C (O) NH-V1144, -C (O) NVI 145V1146, -O-V1147, -O (-V1148-O) 1 -H (1 = 1,
2, 3, 4, 5), -0(-V1149-O)1-V1150 (I = 1, 2, 3, 4, 5), -OC(O)- V1151, -OC(O)-O-V1152, -OC(O)-NHV1153, -0-C(O)- NV1154V1155, -OP(O)(OV1156)(OV1157), - OSi(V1158)(V1159)(V1160), -0S(02)-V1161, -NHC(O)-V1162, - NV1163C(O)-V1164, -NH-C(O)-O-V1165, -NH-C(O)-NH-2, 3, 4, 5), -O (-V1149-O) 1 -V1150 (I = 1, 2, 3, 4, 5), -OC (O) -V1151, -OC (O) -O- V1152, -OC (O) -NHV1153, -O-C (O) - NV1154V1155, -OP (O) (OV1156) (OV1157), - OSi (V1158) (V1159) (V1160), -0S (0 2 ) -V1161, -NHC (O) -V1162, - NV1163C (O) -V1164, -NH-C (O) -O-V1165, -NH-C (O) -NH-
V1166, -NH-C(O)-NV1 167V1168, -NV1 169-C(O)-O-V1 170, - NV1171-C(O)-N H-V1 172, -NV1173-C(O)-NVI 174V1175, - NHS(02)-V1 176, -NV1177S(O2)-V1178, -S-V1 179, -S(O)- V1180, -S(02)-V1 181 , -S(O2)NH-V1 182, -S(O2)NVI 183V1184, - S(O2)O-V1185, -P(O)(OV1186)(OV1 187), -V1166, -NH-C (O) -NV1 167V1168, -NV1 169-C (O) -O-V1 170, - NV1171-C (O) -N H-V1 172, -NV1173-C (O) -NVI 174V1175, - NHS (0 2) -V1 176, -NV1177S (O 2) -V1178, -S-V1 179, -S (O) - V1180, -S (0 2) -V1 181, -S (O 2 ) NH-V1 182, -S (O 2) NVI 183V1184, - S (O 2) O-V1185, -P (O) (OV1186) (OV1 187), -
Si(VI 188)(V1189)(V1190)"; wobei V1139, V1140, V1141, V1142, V1143, V1144, V1145, V1146, V1147, V1148, V1149, V1150, V1151, V1152, V1153, V1154, V1155, V1156, V1157, V1158, V1159, V1160, V1161, V1162, V1163, V1164, V1165, V1166, V1167, V1168, V1169,Si (VI 188) (V1189) (V1190) "; wherein V1139, V1140, V1141, V1142, V1143, V1144, V1145, V1146, V1147, V1148, V1149, V1150, V1151, V1152, V1153, V1154, V1155, V1156, V1157, V1158, V1159, V1160, V1161, V1162, V1163, V1164, V1165, V1166, V1167, V1168, V1169,
V1170, V1171, V1172, V1173, V1174, V1175, V1176, V1177, V1178, V1179, V1180, V1181, V1182, V1183, V1184, V1185, V1186, V1187, V1188, V1189, V1190 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V1145, V1146 und/oder V1 154, V1 155 und/oder V1 167, V1 168 und/oder V1 174, V1 175 und/oder V1 183, V1184 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:V1170, V1171, V1172, V1173, V1174, V1175, V1176, V1177, V1178, V1179, V1180, V1181, V1182, V1183, V1184, V1185, V1186, V1187, V1188, V1189, V1190 are independently selected from the group consisting of "Alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively V1145, V1146 and / or V1 154, V1 155 and / or V1 167, V1 168 and / or V1 174, V1 175 and / or V1 183, V1184 in each case can together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
5 (iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I1 CN1 CF3, N3, NH2, -NHV1191 , -NV1 192V1193, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-V1 194, -C(O)O-V1 195,5 (iii) alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I 1 CN 1 CF 3 , N 3 , NH 2, -NHV1191, -NV1 192V1193, -NO 2, - OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2, -CHO, -COOH, - C ( O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -V 1 194, -C (O) O-V1 195,
10 -C(O)NH-V1196, -C(O)NV1197V1198, -0-V1199, -0(-10 -C (O) NH-V1196, -C (O) NV1197V1198, -0-V1199, -0 (-
V1200-O)m-H (m = 1 , 2, 3, 4, 5), -O(-V1201-O)m-V1202 (m = 1 , 2, 3, 4, 5), -OC(O)-VI 203, -OC(O)-O-VI 204, -OC(O)- NHV1205, -0-C(O)-NVI 206V1207, - OP(O)(OVI 208)(OV1209), -OSi(V1210)(V1211 )(V1212), -V1200-O) m -H (m = 1, 2, 3, 4, 5), -O (-V1201-O) m -V1202 (m = 1, 2, 3, 4, 5), -OC (O ) -VI 203, -OC (O) -O-VI 204, -OC (O) -NHV1205, -O-C (O) -NVI 206V1207, - OP (O) (OVI 208) (OV1209), -OSi (V1210) (V1211) (V1212),
15 OS(O2)-V1213, -NHC(O)-VI 214, -NV1215C(O)-V1216, -15 OS (O 2 ) -V 12 13, -NHC (O) -VI 214, -NV 1215C (O) -V 1216, -
NH-C(O)-O-V1217, -NH-C(O)-NH-VI218, -NH-C(O)- NV1219V1220, -NV1221-C(O)-O-VI222, -NV1223-C(O)- NH-V1224, -NV1225-C(O)-NVI226V1227, -NHS(O2)- V1228, -NV1229S(O2)-V1230, -S-V1231, -S(O)-VI232, -NH-C (O) -O-V1217, -NH-C (O) -NH-VI218, -NH-C (O) -NV1219V1220, -NV1221-C (O) -O-VI222, -NV1223-C ( O) - NH-V1224, -NV1225-C (O) -NVI226V1227, -NHS (O 2) - V1228, -NV1229S (O 2) -V1230, -S-V1231, -S (O) -VI232, -
20 S(O2)-V1233, -S(O2)NH-V1234, -S(O2)NVI235V1236, -20 S (O 2) -V1233, -S (O 2) NH-V1234, -S (O 2) NVI235V1236, -
S(O2)O-VI237, -P(O)(OVI238)(OV1239), - Si(V1240)(V1241)(V1242)"; wobei V1191 , V1192, V1193, V1194, V1195, V1196, V1197, V1198, V1199, V1200, V1201 , V1202, V1203, V1204, V1205,S (O 2 ) O -VI237, -P (O) (OVI238) (OV1239), -Si (V1240) (V1241) (V1242) "; wherein V1191, V1192, V1193, V1194, V1195, V1196, V1197, V1198 , V1199, V1200, V1201, V1202, V1203, V1204, V1205,
25 V1206, V1207, V1208, V1209, V1210, V121 1 , V1212, V1213,25 V1206, V1207, V1208, V1209, V1210, V121 1, V1212, V1213,
V1214, V1215, V1216, V1217, V1218, V1219, V1220, V1221 , V1222, V1223, V1224, V1225, V1226, V1227, V1228, V1229, V1230, V1231 , V1232, V1233, V1234, V1235, V1236, V1237, V1238, V1239, V1240, V1241 , V1242 unabhängig voneinanderV1214, V1215, V1216, V1217, V1218, V1219, V1220, V1221, V1222, V1223, V1224, V1225, V1226, V1227, V1228, V1229, V1230, V1231, V1232, V1233, V1234, V1235, V1236, V1237, V1238, V1239, V1240, V1241, V1242 independent from each other
30 ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-30 are selected from the group consisting of: "alkyl, (C 9 -
C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ V1197, V1198 und/oder V1206, V1207 und/oder V1219, V1220 und/oder V1226, V1227 und/oder V1235,C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and where alternatively V1197, V1198 and / or V1206, V1207 and / or V1219, V1220 and / or V1226, V1227 and / or V1235,
35 V1236 jeweils zusammen auch „heterocyclyl" bilden können; oder35 V1236 may together also form "heterocyclyl"; or
(C) einer der Reste Z3, Z4 oder beide Reste Z3, Z4 unabhängig voneinander „sub- stituiertes Alkyl" sind, wobei „substituiertes Alkyl" substituiert ist mit mindestens einem Substituenten ausgewählt aus der Gruppe bestehend aus:(C) one of the radicals Z3, Z4 or both radicals Z3, Z4 are each independently "substituted alkyl", where "substituted alkyl" is substituted by at least one substituent selected from the group consisting of:
(a) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW1 , -NW2W3, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(0)-W4,(a) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2, -NHW1, -NW2W3, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP (O) (OH) 2, -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W 4,
-C(0)0-W5, -C(0)NH-W6, -C(O)NW7W8, -0-W9, -0(-WI O-O) -H (r = 1 , 2, 3, 4, 5), -0(-W1 1-0)r-W12 (r = 1 , 2, 3, 4, 5), -OC(O)-WI 3, - 0C(0)-0-W14, -0C(0)-NHW15, -0-C(0)-NW16W17, - OP(O)(OWI 8)(0W19), -OSi(W20)(W21 )(W22), -OS(O2)-W23, - NHC(O)-W24, -NW25C(O)-W26, -NH-C(O)-O-W27, -NH-C(O)-NH--C (O) O-W5, -C (O) NH-W6, -C (O) NW7W8, -O-W9, -O (-WIOO) -H (r = 1, 2, 3, 4, 5), -0 (-W1 1-0) r -W12 (r = 1, 2, 3, 4, 5), -OC (O) -WI3, -0C (0) -0-W14, -0C (0) -NHW15, -0-C (0) -NW16W17, - OP (O) (OWI 8) (0W19), -OSi (W20) (W21) (W22), -OS (O2) -W23, NHC (O) -W24, -NW25C (O) -W26, -NH-C (O) -O-W27, -NH-C (O) -NH-
W28, -N H-C(O)-N W29W30, -NW31-C(O)-O-W32, -NW33-C(O)-NH- W34, -NW35-C(O)-NW36W37, -NHS(O2)-W38, -NW39S(O2)-W40, - S-W41 , -S(O)-W42, -S(O2)-W43, -S(O2)NH-W44, -S(O2)NW45W46, - S(O2)O-W47, -P(O)(OW48)(OW49), -Si(W50)(W51 )(W52)"; wobei W1 , W2, W3, W4, W5, W6, W7, W8, W9, W10, W1 1 , W12, W13,W28, -NHC (O) -N W29W30, -NW31-C (O) -O-W32, -NW33-C (O) -NH-W34, -NW35-C (O) -NW36W37, -NHS (O 2) -W38, -NW39S (O2) -W40, - S-W41, -S (O) -W42, -S (O2) -W43, -S (O2) NH-W44, -S (O 2) NW45W46, - S (O 2) O-W47, -P (O) (OW48) (OW49), -Si (W50) (W51) (W52) "; wherein W1, W2, W3, W4, W5, W6, W7, W8, W9, W10, W1 1, W12, W13,
W14, W15, W16, W17, W18, W19, W20, W21 , W22, W23, W24, W25, W26, W27, W28, W29, W30, W31 , W32, W33, W34, W35, W36, W37, W38, W39, W40, W41 , W42, W43, W44, W45, W46, W47, W48, W49, W50, W51 , W52 unabhängig voneinander ausgewählt sind aus der Grup- pe bestehend aus: „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W7, W8 und/oder W16, W17 und/oder W29, W30 und/oder W36, W37 und/oder W45, W46 jeweils zusammen auch „heterocyclyl" bilden können; mit der Maßgabe, dass ,,-C(O)N H-aryl", ,,-C(O)N H-heteroaryl", „-W, W, W, W, W, W, W, W, W, W, W, W, W, W, W, W, W, W, W, W, W, W39, W40, W41, W42, W43, W44, W45, W46, W47, W48, W49, W50, W51, W52 are independently selected from the group-pe consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively W7, W8 and / or W16, W17 and / or W29, W30 and / or W36, W37 and / or W45, W46 also together" heterocyclyl "can form; with the proviso that "--C (O) NH-aryl", "- C (O) NH-heteroaryl", "-
C(O)NH-cycloalkyl", ,,-C(O)N H-heterocyclyl" weiter substituiert sind mit mindestens einem Substituenten ausgewählt aus untiger Substitutionsgruppe (i); wobei optional obige Substituenten der Substituentengruppe (a) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (i) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW53, -NW54W55, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, - C(O)-W56, -C(O)O-W57, -C(O)NH-W58, -C(O)NW59W60, -O- W61 , -O(-W62-O)s-H (s = 1 , 2, 3, 4, 5), -O(-W63-O)t-W64 (t = 1 , 2,C (O) -NH-cycloalkyl "," - C (O) N H-heterocyclyl "are further substituted by at least one substituent selected from the following substituent group (i); in which optional substituents of the substituent group (a) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of: (i) alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHW53, -NW54W55, -NO 2, -OH, -OCF 3, -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , - C (O) -W56, -C (O) O-W57, -C (O) NH-W58, -C (O) NW59W60, -O-W61, -O (-W62-O) s -H (s = 1, 2, 3, 4, 5), -O (-W63-O) t -W64 (t = 1, 2,
3, 4, 5), -OC(O)-W65, -OC(O)-O-W66, -OC(O)-NHW67, -0-C(O)- NW68W69, -OP(O)(OW70)(OW71 ), -OSi(W72)(W73)(W74), - OS(O2)-W75, -NHC(O)-W76, -NW77C(O)-W78, -NH-C(O)-O- W79, -N H-C(O)-N H-W80, -NH-C(O)-NW81W82, -NW83-C(O)-O- W84, -NW85-C(O)-NH-W86, -NW87-C(O)-NW88W89, -NHS(O2)-3, 4, 5), -OC (O) -W65, -OC (O) -O-W66, -OC (O) -NHW67, -O-C (O) -NW68W69, -OP (O) (OW70 ) (OW71), -OSi (W72) (W73) (W74), - OS (O2) -W75, -NHC (O) -W76, -NW77C (O) -W78, -NH- C (O) - O-W79, -NHC (O) -NH-W80, -NH-C (O) -NW81W82, -NW83-C (O) -O-W84, -NW85-C (O) -NH-W86, -NW87-C (O) -NW88W89, -NHS (O 2 ) -
W90, -NW91S(O2)-W92, -S-W93, -S(O)-W94, -S(O2)-W95, - S(O2)NH-W96, -S(O2)NW97W98, -S(O2)O-W99, - P(O)(OWI 00)(OW101 ), -Si(WI 02)(W103)(W104)"; wobei W53, W54, W55, W56, W57, W58, W59, W60, W61 , W62, W63, W64, W65, W66, W67, W68, W69, W70, W71 , W72, W73, W74,W90, -NW91S (O2) -W92, -S-W93, -S (O) -W94, -S (O2) -W95, - S (O 2) NH-W96, -S (O2) NW97W98 , -S (O 2 ) O-W99, -P (O) (OWI 00) (OW101), -Si (WI 02) (W103) (W104) "; wherein W53, W54, W55, W56, W57, W58 , W59, W60, W61, W62, W63, W64, W65, W66, W67, W68, W69, W70, W71, W72, W73, W74,
W75, W76, W77, W78, W79, W80, W81 , W82, W83, W84, W85, W86, W87, W88, W89, W90, W91 , W92, W93, W94, W95, W96, W97, W98, W99, W100, W101 , W102, W103, W104 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W59, W60 und/oder W68, W69 und/oder W81 , W82 und/oder W88, W89 und/oder W97, W98 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW105, -NW106W107, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-WI 08, -C(O)O-WI 09,W75, W76, W77, W78, W79, W80, W81, W82, W83, W84, W85, W86, W87, W88, W89, W90, W91, W92, W93, W94, W95, W96, W97, W98, W99, W100, W101, W102, W103, are W104 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively W59, W60 and / or W68, W69 and / or W81, W82 and / or W88, W89 and / or W97, W98 may together also form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of: (ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2, -NHW105, -NW106W107, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2, -CHO, -COOH, - C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Wi 08, -C (O) O-WI 09,
-C(O)N H-W110, -C(O)NW11 1 W1 12, -0-W113, -0(-W114- O)1-H (t = 1 , 2, 3, 4, 5), -0(-W1 15-0)t-W1 16 (t = 1 , 2, 3, 4, 5), -OC(O)-W1 17, -OC(O)-O-W1 18, -OC(O)-NHW1 19, -O- C(O)-NW120W121 , -OP(O)(OWI 22)(OW123), - OSi(W124)(W125)(W126), -OS(O2)-W127, -NHC(O)-W128,-C (O) N H-W110, -C (O) NW11 1 W1 12, -0-W113, -0 (-W114-O) 1 -H (t = 1, 2, 3, 4, 5), -0 (-W1 15-0) t -W1 16 (t = 1, 2, 3, 4, 5), -OC (O) -W1 17, -OC (O) -O-W1 18, -OC ( O) -NHW1 19, -O- C (O) -NW120W121, -OP (O) (OWI 22) (OW123), - OSi (W124) (W125) (W126), -OS (O2) -W127, -NHC (O) -W128,
-NW129C(O)-WI 30, -N H-C(0)-0-W131 , -NH-C(O)-NH- W132, -NH-C(O)-NWI 33W134, -NW135-C(O)-O-WI 36, - NW137-C(O)-NH-WI 38, -NW139-C(O)-NWI 40W141 , - NHS(O2)-W142, -NW143S(O2)-W144, -S-W145, -S(O)- W146, -S(O2)-W147, -S(O2)NH-W148, -S(O2)NWI 49W150,-NW129C (O) -WI 30, -NHC (0) -O-W131, -NH-C (O) -NH-W132, -NH-C (O) -NWI 33W134, -NW135-C (O) -O-WI 36, -NW137-C (O) -NH-WI 38, -NW139-C (O) -NWI 40W141, -NHS (O 2 ) -W 14 2 , -NW 143S (O 2 ) -W 144, -S -W145, -S (O) - W146, -S (O2) -W147, -S (O2) NH-W148, -S (O 2) NWI 49W150,
-S(O2)O-WI 51 , -P(0)(0W152)(OW153), - Si(WI 54)(W155)(W156)"; wobei W105, W106, W107, W108, W109, W110, W11 1 , W1 12, W1 13, W1 14, W115, W116, W1 17, W1 18, W119, W120, W121 , W122, W123, W124, W125, W126, W127, W128,-S (O 2 ) O-WI 51, -P (0) (0W152) (OW153), -Si (WI 54) (W155) (W156) ", where W105, W106, W107, W108, W109, W110, W11 1, W1 12, W1 13, W1 14, W115, W116, W1 17, W1 18, W119, W120, W121, W122, W123, W124, W125, W126, W127, W128,
W129, W130, W131 , W132, W133, W134, W135, W136, W137, W138, W139, W140, W141 , W142, W143, W144, W145, W146, W147, W148, W149, W150, W151 , W152, W153, W154, W155, W156 unabhängig voneinander ausge- wählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W1 11 , W1 12 und/oder W120, W121 und/oder W133, W134 und/oder W140, W141 und/oder W149, W150 jeweils zusam- men auch „heterocyclyl" bilden können;W129, W130, W131, W132, W133, W134, W135, W136, W137, W138, W139, W140, W141, W142, W143, W144, W145, W146, W147, W148, W149, W150, W151, W152, W153, W154, W155, W156 are independently selected exported from the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively W1 11 W1 12 and / or W120, W121 and / or W133, W134 and / or W140, W141 and / or W149, W150 can each also together form "heterocyclyl";
oder einer der Reste Z3, Z4 oder beide Reste Z3, Z4 unabhängig voneinander voneinander „(C9-C3o)alkyl" sind; wobei „(Cg-C3o)alkyl" optional unabhängig voneinander substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:or one of Z3, Z4 or both radicals Z3, Z4 independently of one another, "(C 9 -C 3 o) alkyl"are; wherein "(Cg-C 3 o) alkyl" may optionally be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylal- kyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2,(i) "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylal- kyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 ,
-NHW157, -NW158W159, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- W160, -C(O)O-WI 61 , -C(O)NH-WI 62, -C(O)NWI 63W164, -O-W165, - O(-W166-O)u-H (u = 1 , 2, 3, 4, 5), -0(-W167-O)u-W168 (u = 1 , 2, 3, 4, 5), -OC(O)-WI 69, -OC(O)-O-WI 70, -OC(O)-NHW^I 1 -O-C(O)--NHW157, -NW158W159, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W160, -C (O) O-WI 61, -C (O) NH-WI 62, -C (O) NWI 63W164, -O-W165, - O (-W166-O) u -H (u = 1, 2, 3, 4, 5), -O (-W167-O) u -W168 (u = 1, 2, 3, 4, 5), -OC (O) -WI 69, -OC (O) -O-WI 70, -OC (O) -NHW ^ I 1 -OC (O) -
NW172W173, -OP(O)(OWI 74)(OW175), -OSi(WI 76)(W177)(W178), - OS(O2)-W179, -NHC(O)-WI 80, -NW181 C(O)-WI 82, -NH-C(O)-O- W183, -NH-C(O)-NH-WI 84, -NH-C(O)-NWI 85W186, -NW187-C(O)- O-W188, -NW189-C(O)-NH-WI 90, -NW191-C(0)-NW192W193, - NHS(02)-W194, -NW195S(O2)-W196, -S-W197, -S(O)-WI 98, -S(O2)-NW172W173, -OP (O) (OWI 74) (OW175), -OSi (WI 76) (W177) (W178), - OS (O2) -W179, -NHC (O) -WI 80, -NW181 C ( O) -WI 82, -NH-C (O) -O-W183, -NH-C (O) -NH-WI 84, -NH-C (O) -NWI 85W186, -NW187-C (O) - O-W188, -NW189-C (O) -NH-WI 90, -NW191-C (0) -NW192W193, - NHS (0 2) -W194, -NW195S (O2) -W196, -S-W197, -S (O) -WI 98, -S (O 2 ) -
W199, -S(O2)N H-W200, -S(O2)NW201W202, -S(O2)O-W203, - P(O)(OW204)(OW205), -Si(W206)(W207)(W208)"; wobei W157, W158, W159, W160, W161 , W162, W163, W164, W165, W166, W167, W168, W169, W170, W171 , W172, W173, W174, W175, W176, W177, W178, W179, W180, W181 , W182, W183, W184, W185,W199 -S (O 2) N H-W200, -S (O2) NW201W202, is -S (O 2) O-W203, - P (O) (OW204) (OW205), -Si (W206) (W207 ) (W208) "where W157, W158, W159, W160, W161, W162, W163, W164, W165, W166, W167, W168, W169, W170, W171, W172, W173, W174, W175, W176, W177, W178 , W179, W180, W181, W182, W183, W184, W185,
W186, W187, W188, W189, W190, W191 , W192, W193, W194, W195, W196, W197, W198, W199, W200, W201 , W202, W203, W204, W205, W206, W207, W208 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, hete- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W163, W164 und/oder W172, W173 und/oder W185, W186 und/oder W192, W193 und/oder W201 , W202 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einemW186, W187, W188, W189, W190, W191, W192, W193, W194, W195, W196, W197, W198, W199, W200, W201, W202, W203, W204, W205, W206, W207, W208 are independently selected consisting of the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively W163, W164 and / or W172, W173 and / or W185, W186 and / or W192, W193 and / or W201, W202 may together also form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be independently substituted with at least one
Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Substituents, the same or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW209, -NW210W21 1 , -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- W212, -C(O)O-W213, -C(O)N H-W214, -C(O)NW215W216, -O- W217, -O(-W218-O)v-H (v = 1 , 2, 3, 4, 5), -O(-W219-O)v-W220 (v = 1 , 2, 3, 4, 5), -OC(O)-W221 , -OC(O)-O-W222, -OC(O)-N H W223, -(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2, -NHW209, -NW210W21 1, -NO 2, -OH, -OCF3, -SH, -0-SO3H, - OP (O) (OH) 2, -CHO, -COOH, -C ( O) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) - W212, -C (O) O-W213, -C (O) N H-W214, -C ( O) NW215W216, -O-W217, -O (-W218-O) v -H (v = 1, 2, 3, 4, 5), -O (-W219-O) v -W220 (v = 1, 2, 3, 4, 5), -OC (O) -W221, -OC (O) -O-W222, -OC (O) -NH W223, -
O-C(O)-NW224W225, -OP(O)(OW226)(OW227), - OSi(W228)(W229)(W230), -OS(O2)-W231 , -NHC(O)-W232, - NW233C(O)-W234, -NH-C(O)-O-W235, -N H-C(O)-N H-W236, -NH- C(O)-NW237W238, -NW239-C(O)-O-W240, -NW241 -C(O)-N H- W242, -NW243-C(O)-NW244W245, -NHS(O2)-W246, -NW247S(O2)-OC (O) -NW224W225, -OP (O) (OW226) (OW227), - OSi (W228) (W229) (W230), -OS (O2) -W231, -NHC (O) -W232, - NW233C (O) -W234, -NH-C (O) -O-W235, -NHC (O) -NH-W236, -NH-C (O) -NW237W238, -NW239-C (O) -O- W240, -NW241 -C (O) -N H-W242, -NW243-C (O) -NW244W245, -NHS (O2) -W246, -NW247S (O 2) -
W248, -S-W249, -S(O)-W250, -S(O2)-W251 , -S(O2)N H-W252, - S(O2)NW253W254, -S(O2)O-W255, -P(O)(OW256)(OW257), - Si(W258)(W259)(W260)"; wobei W209, W210, W21 1 , W212, W213, W214, W215, W216, W217, W218, W219, W220, W221 , W222, W223, W224, W225, W226, W227,W248, -S-W249, -S (O) -W250, -S (O2) -W251, -S (O2) N H-W252, - S (O 2) NW253W254, -S (O 2) O -W255, -P (O) (OW256) (OW257), -Si (W258) (W259) (W260) ", where W209, W210, W21 1, W212, W213, W214, W215, W216, W217, W218, W219, W220, W221, W222, W223, W224, W225, W226, W227,
W228, W229, W230, W231 , W232, W233, W234, W235, W236, W237, W238, W239, W240, W241 , W242, W243, W244, W245, W246, W247, W248, W249, W250, W251 , W252, W253, W254, W255, W256, W257, W258, W259, W260 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W215, W216 und/oder W224, W225 und/oder W237, W238 und/oder W244, W245 und/oder W253, W254 jeweils zusammen auch „heterocyclyl" bilden können;W228, W229, W230, W231, W232, W233, W234, W235, W236, W237, W238, W239, W240, W241, W242, W243, W244, W245, W246, W247, W248, W249, W250, W251, W252, W253, W254, W255, W256, W257, W258, W259, W260 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl "heteroarylalkyl" and alternatively W215, W216 and / or W224, W225 and / or W237, W238 and / or W244, W245 and / or W253, W254 may together also form "heterocyclyl";
und einer der Reste Z3, Z4 oder keiner der Reste Z3, Z4 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus:and one of Z3, Z4 or none of Z3, Z4 is independently selected from the group consisting of:
(b) Wasserstoff;(b) hydrogen;
(c) Halogen, F, Cl, Br, I; (d) unsubstituiertes oder substituiertes Alkyl oder (C9-C30)Alkyl, wobei optional der Alkyl- oder (Cg-C3O )Alkylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW457, -NW458W459, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-W460, -C(O)O-W461 , -C(O)N H-W462, -C(O)NW463W464,(c) halogen, F, Cl, Br, I; (d) unsubstituted or substituted alkyl or (C 9 -C 30 ) alkyl, wherein optionally the alkyl or (Cg-C 3O ) alkyl radical may be substituted by at least one substituent, identical or different, selected from the group consisting of: "Alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , - NHW457, -NW458W459, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2, -C (O) -W460, -C (O) O-W461, -C (O) N H-W462, -C (O) NW463W464,
-O-W465, -O(-W466-O)x-H (x = 1 , 2, 3, 4, 5), -O(-W467-O)x- W468 (x = 1 , 2, 3, 4, 5), -OC(O)-W469, -OC(O)-O-W470, -OC(O)- NHW471 , -O-C(O)-NW472W473, -OP(O)(OW474)(OW475), - OSi(W476)(W477)(W478), -OS(O2)-W479, -NHC(O)-W480, - NW481 C(O)-W482, -NH-C(O)-O-W483, -N H-C(O)-N H-W484, --O-W465, -O (-W466-O) x -H (x = 1, 2, 3, 4, 5), -O (-W467-O) x - W468 (x = 1, 2, 3, 4, 5), -OC (O) -W469, -OC (O) -O-W470, -OC (O) -NHW471, -OC (O) -NW472W473, -OP (O) (OW474) (OW475) , - OSi (W476) (W477) (W478), -OS (O2) -W479, -NHC (O) -W480, - NW481 C (O) -W482, -NH-C (O) -O-W483 , -NHC (O) -NH-W484, -
NH-C(O)-NW485W486, -NW487-C(O)-O-W488, -NW489-C(O)- NH-W490, -NW491 -C(O)-N W492W493, -NHS(O2)-W494, - NW495S(O2)-W496, -S-W497, -S(O)-W498, -S(O2)-W499, - S(O2)N H-W500, -S(O2)NW501W502, -S(O2)O-W503, - P(O)(OW504)(OW505), -Si(W506)(W507)(W508)"; wobei W457, W458, W459, W460, W461 , W462, W463, W464, W465, W466, W467, W468, W469, W470, W471 , W472, W473, W474, W475, W476, W477, W478, W479, W480, W481 , W482, W483, W484, W485, W486, W487, W488, W489, W490, W491 , W492, W493, W494, W495, W496, W497, W498, W499, W500, W501 ,NH-C (O) -NW485W486, -NW487-C (O) -O-W488, -NW489-C (O) -NH-W490, -NW491 -C (O) -N W492W493, -NHS (O 2 ) -W494, - NW495S (O2) -W496, -S-W497, -S (O) -W498, -S (O2) -W499, - S (O 2) N H-W500, -S (O 2 ) NW501W502, -S (O2) O-W503, - P (O) (OW504) (OW505), -Si (W506) (W507) (W508) "; wherein W457, W458, W459, W460, W461, W462 , W463, W464, W465, W466, W467, W468, W469, W470, W471, W472, W473, W474, W475, W476, W477, W478, W479, W480, W481, W482, W483, W484, W485, W486, W487 , W488, W489, W490, W491, W492, W493, W494, W495, W496, W497, W498, W499, W500, W501,
W502, W503, W504, W505, W506, W507, W508 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, a- ryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W463, W464 und/oder W472, W473 und/oder W485, W486 und/oder W492,W502, W503, W504, W505, W506, W507, W508 are independently selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, a- ryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively W463, W464 and / or W472, W473 and / or W485, W486 and / or W492,
W493 und/oder W501 , W502 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindes- tens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:W493 and / or W501, W502 may each together also form "heterocyclyl", where optionally substituents of the substituent group (i) above may be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW509, -NW510W511 , -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, - SO3H, -P(O)(OH)2, -C(O)-W512, -C(O)O-W513, -C(O)NH- W514, -C(O)NW515W516, -O-W517, -O(-W518-O)y-H (y = 1 , 2, 3, 4, 5), -O(-W519-O)y-W520 (y = 1 , 2, 3, 4, 5), -OC(O)- 5 W521 , -OC(O)-O-W522, -OC(O)-N H W523, -0-C(O)-(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW509, -NW510W511, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , - C (O) -W512, -C (O) O-W513, -C (O) NH-W514, -C (O) NW515W516, -O-W517, -O (-W518-O) y -H (y = 1, 2, 3, 4, 5), -O (-W519-O) y -W520 (y = 1, 2, 3, 4, 5), -OC (O) -5 W521, -OC (O ) -O-W522, -OC (O) -NH W523, -O-C (O) -
NW524W525, -OP(O)(OW526)(OW527), - OSi(W528)(W529)(W530), -OS(O2)-W531 , -NHC(O)-W532, - NW533C(O)-W534, -NH-C(O)-O-W535, -N H-C(O)-N H-W536, -N H-C(O)-N W537W538, -NW539-C(O)-O-W540, -NW541-NW524W525, -OP (O) (OW526) (OW527), - OSi (W528) (W529) (W530), -OS (O2) -W531, -NHC (O) -W532, - NW533C (O) -W534 , -NH-C (O) -O-W535, -NHC (O) -NH-W536, -NHC (O) -N W537W538, -NW539-C (O) -O-W540, -NW541-
10 C(O)-NH-W542, -NW543-C(O)-NW544W545, -NHS(O2)-W546,10 C (O) -NH-W542, -NW543-C (O) -NW544W545, -NHS (O 2 ) -W546,
-NW547S(O2)-W548, -S-W549, -S(O)-W550, -S(O2)-W551 , - S(O2)N H-W552, -S(O2)NW553W554, -S(O2)O-W555, - P(O)(OW556)(OW557), -Si(W558)(W559)(W560)"; wobei W509, W510, W511 , W512, W513, W514, W515, W516,-NW547S (O2) -W548, -S-W549, -S (O) -W550, -S (O2) -W551, - S (O 2) N H-W552, -S (O2) NW553W554, -S (O 2 ) O-W555, -P (O) (OW556) (OW557), -Si (W558) (W559) (W560) "; wherein W509, W510, W511, W512, W513, W514, W515, W516,
15 W517, W518, W519, W520, W521 , W522, W523, W524, W525,15 W517, W518, W519, W520, W521, W522, W523, W524, W525,
W526, W527, W528, W529, W530, W531 , W532, W533, W534, W535, W536, W537, W538, W539, W540, W541 , W542, W543, W544, W545, W546, W547, W548, W549, W550, W551 , W552, W553, W554, W555, W556, W557, W558, W559, W560 unabhän-W526, W527, W528, W529, W530, W531, W532, W533, W534, W535, W536, W537, W538, W539, W540, W541, W542, W543, W544, W545, W546, W547, W548, W549, W550, W551, W552, W553, W554, W555, W556, W557, W558, W559, W560 independently
20 gig voneinander ausgewählt sind aus der Gruppe bestehend aus:20 gig selected from the group consisting of:
„alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W515, W516 und/oder W524, W525 und/oder W537, W538 und/oder W544, W545 und/oder W553, W554 jeweils zu- 25 sammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:"Alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively W515, W516 and / or W524, W525 and / or W537, W538 and / or W544, W545 and / or W553, W554 in each case together can also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
30 (iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW561 , -NW562W563, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-W564, -C(O)O-W565, -C(O)NH-W566, -C(O)N W567W568, -O-W569, -O(-W570- O)z-H (z = 1 , 2, 3, 4, 5), -O(-W571-O)z-W572 (z = 1 , 2, 3, 4, 5), -OC(O)-W573, -OC(O)-O-W574, -OC(O)-N H W575, -O- C(O)-NW576W577, -OP(O)(OW578)(OW579), - OSi(W580)(W581 )(W582), -OS(O2)-W583, -NHC(O)-W584,30 (iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW561, -NW562W563, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) -W564, -C (O) O-W565, -C (O) NH-W566, -C (O) N W567W568, -O-W569, -O (-W570-O) z -H (z = 1, 2, 3, 4, 5), -O ( -W571-O) z -W572 (z = 1, 2, 3, 4, 5), -OC (O) -W573, -OC (O) -O-W574, -OC (O) -NH W575, - O- C (O) -NW576W577, -OP (O) (OW578) (OW579), - OSi (W580) (W581) (W582), -OS (O2) -W583, -NHC (O) -W584,
-NW585C(O)-W586, -NH-C(O)-O-W587, -NH-C(O)-NH- W588, -NH-C(O)-NW589W590, -NW591-C(O)-O-W592, - NW593-C(O)-NH-W594, -NW595-C(O)-NW596W597, - NHS(O2)-W598, -NW599S(O2)-W600, -S-W601 , -S(O)- W602, -S(O2)-W603, -S(O2)N H-W604, -S(O2)NW605W606,-NW585C (O) -W586, -NH-C (O) -O-W587, -NH-C (O) -NH-W588, -NH-C (O) -NW589W590, -NW591-C (O) - O-W592, - NW593-C (O) -NH-W594, -NW595-C (O) -NW596W597, - NHS (O2) -W598, -NW599S (O2) -W600, -S-W601, - S (O) - W602, -S (O2) -W603, -S (O2) N H-W604, -S (O2) NW605W606,
-S(O2)O-W607, -P(O)(OW608)(OW609), - Si(W610)(W611 )(W612)"; wobei W561 , W562, W563, W564, W565, W566, W567, W568, W569, W570, W571 , W572, W573, W574, W575, W576, W577, W578, W579, W580, W581 , W582, W583, W584,-S (O 2 ) O-W 607, -P (O) (OW608) (OW609), -Si (W610) (W611) (W612) "; wherein W561, W562, W563, W564, W565, W566, W567, W568, W569, W570, W571, W572, W573, W574, W575, W576, W577, W578, W579, W580, W581, W582, W583, W584,
W585, W586, W587, W588, W589, W590, W591 , W592, W593, W594, W595, W596, W597, W598, W599, W600, W601 , W602, W603, W604, W605, W606, W607, W608, W609, W610, W61 1 , W612 unabhängig voneinander ausge- wählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W567, W568 und/oder W576, W577 und/oder W589, W590 und/oder W596, W597 und/oder W605, W606 jeweils zusam- men auch „heterocyclyl" bilden können;W585, W586, W587, W588, W589, W590, W591, W592, W593, W594, W595, W596, W597, W598, W599, W600, W601, W602, W603, W604, W605, W606, W607, W608, W609, W610, W61 1, W612 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively W567 , W568 and / or W576, W577 and / or W589, W590 and / or W596, W597 and / or W605, W606 in each case together can also form "heterocyclyl";
(e) unsubstituiertes oder substituiertes Aryl, wobei optional der Arylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (i) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW613, -NW614W615, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-W616, -C(O)O-W617, -C(O)NH-W618, -C(O)NW619W620, -O-W621 , -O(-W622-O)a-H (a = 1 , 2, 3, 4, 5), -O(-W623-O)a- W624 (a = 1 , 2, 3, 4, 5), -OC(O)-W625, -OC(O)-O-W626, -OC(O)- NHW627, -O-C(O)-NW628W629, -OP(O)(OW630)(OW631 ), - OSi(W632)(W633)(W634), -OS(O2)-W635, -NHC(O)-W636, - NW637C(O)-W638, -NH-C(O)-O-W639, -N H-C(O)-N H-W640, -(e) unsubstituted or substituted aryl, wherein the aryl moiety optionally may be substituted with at least one substituent, identical or different, selected from the group consisting of: (i) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl , heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHW613, -NW614W615, -NO2, -OH, -OCF3, - SH, -O- SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W616, -C (O) O-W617, -C (O) NH-W618, -C (O) NW619W620, -O-W621, -O (-W622-O) a -H (a = 1, 2, 3, 4, 5), -O (-W623-O) a - W624 (a = 1, 2, 3, 4, 5), -OC (O) -W625, -OC (O) -O-W626, -OC (O) -NHW627, -OC (O) -NW628W629, -OP (O) (OW630) (OW631) , - OSi (W632) (W633) (W634), -OS (O2) -W635, -NHC (O) -W636, - NW637C (O) -W638, -NH-C (O) -O-W639, -N HC (O) -N H-W640, -
N H-C(O)-N W641W642, -NW643-C(O)-O-W644, -NW645-C(O)- NH-W646, -NW647-C(O)-NW648W649, -NHS(O2)-W650, - NW651 S(O2)-W652, -S-W653, -S(O)-W654, -S(O2)-W655, - S(O2)NH-W656, -S(O2)NW657W658, -S(O2)O-W659, - P(O)(OW660)(OW661 ), -Si(W662)(W663)(W664)"; wobei W613, W614, W615, W616, W617, W618, W619, W620, W621 , W622, W623, W624, W625, W626, W627, W628, W629, W630, W631 , W632, W633, W634, W635, W636, W637, W638, W639, W640, W641 , W642, W643, W644, W645, W646, W647, W648, W649, W650, W651 , W652, W653, W654, W655, W656, W657,N HC (O) -N W641W642, -NW643-C (O) -O-W644, -NW645-C (O) -NH-W646, -NW647-C (O) -NW648W649, -NHS (O 2 ) - W650, - NW651 S (O 2) -W652, -S-W653, -S (O) -W654, -S (O2) -W655, - S (O 2) NH-W656, -S (O 2) NW657W658, -S (O2) O-W659, - P (O) (OW660) (OW661), -Si (W662) (W663) (W664) "; wherein W613, W614, W615, W616, W617, W618, W619, W620, W621, W622, W623, W624, W625, W626, W627, W628, W629, W630, W631, W632, W633, W634, W635, W636, W637, W638, W639, W640, W641, W642, W643, W644, W645, W646, W647, W648, W649, W650, W651, W652, W653, W654, W655, W656, W657,
W658, W659, W660, W661 , W662, W663, W664 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, a- ryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W619, W620 und/oder W628, W629 und/oder W641 , W642 und/oder W648,W658, W659, W660, W661, W662, W663, W664 are independently selected from the group consisting of: "alkyl, alkyl (Cg-C 30) cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, a- ryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively W619, W620 and / or W628, W629 and / or W641, W642 and / or W648,
W649 und/oder W657, W658 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindes- tens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:W649 and / or W657, W658 may together also form "heterocyclyl", where optionally substituents of the substituent group (i) above may be substituted independently with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW665, -NW666W667, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW665, -NW666W667, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -
SO3H, -P(O)(OH)2, -C(O)-W668, -C(O)O-W669, -C(O)NH- W670, -C(O)NW671W672, -O-W673, -O(-W674-O)b-H (b = 1 , 2, 3, 4, 5), -O(-W675-O)b-W676 (b = 1 , 2, 3, 4, 5), -OC(O)- W677, -OC(O)-O-W678, -OC(O)-N H W679, -0-C(O)- NW680W681 , -OP(O)(OW682)(OW683), - OSi(W684)(W685)(W686), -OS(O2)-W687, -NHC(O)-W688, - NW689C(O)-W690, -NH-C(O)-O-W691 , -N H-C(O)-N H-W692, -N H-C(O)-N W693W694, -NW695-C(O)-O-W696, -NW697-SO 3 H, -P (O) (OH) 2 , -C (O) -W668, -C (O) O-W669, -C (O) NH-W670, -C (O) NW671W672, -O- W673, -O (-W674-O) b -H (b = 1, 2, 3, 4, 5), -O (-W675-O) b -W676 (b = 1, 2, 3, 4, 5 ), -OC (O) -W677, -OC (O) -O-W678, -OC (O) -NH W679, -O-C (O) - NW680W681, -OP (O) (OW682) (OW683), - OSi (W684) (W685) (W686), -OS (O2) -W687, -NHC (O) -W688, - NW689C (O) -W690 , -NH-C (O) -O-W691, -NHC (O) -NH-W692, -NHC (O) -N W693W694, -NW695-C (O) -O-W696, -NW697-
5 C(O)-NH-W698, -NW699-C(O)-NW700W701 , -NHS(O2)-W702,5 C (O) -NH-W698, -NW699-C (O) -NW700W701, -NHS (O 2 ) -W702,
-NW703S(O2)-W704, -S-W705, -S(O)-W706, -S(O2)-W707, - S(O2)N H-W708, -S(O2)NW709W710, -S(O2)O-W711 , - P(0)(0W712)(OW713), -Si(W714)(W715)(W716)"; wobei W665, W666, W667, W668, W669, W670, W671 , W672,-NW703S (O2) -W704, -S-W705, -S (O) -W706, -S (O2) -W707, - S (O 2) N H-W708, -S (O2) NW709W710, -S (O 2 ) O-W 711, -P (0) (0W712) (OW713), -Si (W714) (W715) (W716) "; wherein W665, W666, W667, W668, W669, W670, W671, W672,
10 W673, W674, W675, W676, W677, W678, W679, W680, W681 ,10 W673, W674, W675, W676, W677, W678, W679, W680, W681,
W682, W683, W684, W685, W686, W687, W688, W689, W690, W691 , W692, W693, W694, W695, W696, W697, W698, W699, W700, W701 , W702, W703, W704, W705, W706, W707, W708, W709, W710, W71 1 , W712, W713, W714, W715, W716 unabhän- 15 gig voneinander ausgewählt sind aus der Gruppe bestehend aus:W682, W683, W684, W685, W686, W687, W688, W689, W690, W691, W692, W693, W694, W695, W696, W697, W698, W699, W700, W701, W702, W703, W704, W705, W706, W707, W708, W709, W710, W71 1, W712, W713, W714, W715, W716 are independently selected from the group consisting of:
„alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W671 , W672 und/oder W680, W681 und/oder W693, W694 und/oder W700, W701 und/oder W709, W710 jeweils zu- 20 sammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:"Alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively, W671, W672 and / or W680, W681 and / or W693, W694 and / or W700, W701 and / or W709, W710 may in each case also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
25 (iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW717, -NW718W719, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-W720, -C(O)O-W721 ,25 (iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW 717, -NW 718 W 719, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O ) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W 720, -C (O) O-W 721,
30 -C(O)N H-W722, -C(O)N W723W724, -O-W725, -O(-W726-30 -C (O) N H-W722, -C (O) N W723W724, -O-W725, -O (-W726-
O)c-H (c = 1 , 2, 3, 4, 5), -O(-W727-O)c-W728 (c = 1 , 2, 3, 4, 5), -OC(O)-W729, -OC(O)-O-W730, -OC(O)-N H W731 , -O- C(O)-NW732W733, -OP(O)(OW734)(OW735), - OSi(W736)(W737)(W738), -OS(O2)-W739, -NHC(O)-W740, -NW741C(O)-W742, -NH-C(O)-O-W743, -NH-C(O)-NH- W744, -NH-C(O)-NW745W746, -NW747-C(O)-O-W748, - NW749-C(O)-NH-W750, -NW751-C(O)-NW752W753, - NHS(O2)-W754, -NW755S(O2)-W756, -S-W757, -S(O)- W758, -S(O2)-W759, -S(O2)N H-W760, -S(O2)NW761W762,O) c -H (c = 1, 2, 3, 4, 5), -O (-W727-O) c-W728 (c = 1, 2, 3, 4, 5), -OC (O) - W729, -OC (O) -O-W730, -OC (O) -NH W731, -O-C (O) -NW732W733, -OP (O) (OW734) (OW735), -OSi (W736) (W737 ) (W738), -OS (O2) -W739, -NHC (O) -W740, -NW741C (O) -W742, -NH-C (O) -O-W743, -NH-C (O) -NH-W744, -NH-C (O) -NW745W746, -NW747-C (O) - O-W748, - NW749-C (O) -NH-W750, -NW751-C (O) -NW752W753, - NHS (O2) -W754, -NW755S (O2) -W756, -S-W757, - S (O) - W758, -S (O2) -W759, -S (O2) N H-W760, -S (O2) NW761W762,
-S(O2)O-W763, -P(O)(OW764)(OW765), - Si(W766)(W767)(W768)"; wobei W717, W718, W719, W720, W721 , W722, W723, W724, W725, W726, W727, W728, W729, W730, W731 , W732, W733, W734, W735, W736, W737, W738, W739, W740,-S (O2) O-W763, -P (O) (OW764) (OW765), - Si (W766) (W767) (W768) "; wherein W717, W718, W719, W720, W721, W722, W723, W724, W725, W726, W727, W728, W729, W730, W731, W732, W733, W734, W735, W736, W737, W738, W739, W740,
W741 , W742, W743, W744, W745, W746, W747, W748, W749, W750, W751 , W752, W753, W754, W755, W756, W757, W758, W759, W760, W761 , W762, W763, W764, W765, W766, W767, W768 unabhängig voneinander ausge- wählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W723, W724 und/oder W732, W733 und/oder W745, W746 und/oder W752, W753 und/oder W761 , W762 jeweils zusam- men auch „heterocyclyl" bilden können;W741, W742, W743, W744, W745, W746, W747, W748, W749, W750, W751, W752, W753, W754, W755, W756, W757, W758, W759, W760, W761, W762, W763, W764, W765, W766, W767, W768 are independently selected exported from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively W723, W724 and / or W732, W733 and / or W745, W746 and / or W752, W753 and / or W761, W762 can each also together form "heterocyclyl";
(f) unsubstituiertes oder substituiertes Heteroaryl, wobei optional der Hetero- arylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (i) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW769, -NW770W771 , -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-W772, -C(O)O-W773, -C(O)N H-W774, -C(O)NW775W776, -O-W777, -O(-W778-O)d-H (d = 1 , 2, 3, 4, 5), -O(-W779-O)d-(f) unsubstituted or substituted heteroaryl, wherein optionally the hetero aryl group may be substituted with at least one substituent, identical or different, selected from the group consisting of: (i) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl , cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHW769, -NW770W771, -NO2, -OH, -OCF3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W772, -C (O) O-W773, -C (O) NH-W774, -C (O) NW775W776, -O-W777, -O (-W778-O) d -H (d = 1, 2, 3, 4, 5), -O (-W779-O) d -
W780 (d = 1 , 2, 3, 4, 5), -OC(O)-W781 , -OC(O)-O-W782, -OC(O)- NHW783, -O-C(O)-NW784W785, -OP(O)(OW786)(OW787), - OSi(W788)(W789)(W790), -OS(O2)-W791 , -NHC(O)-W792, - NW793C(O)-W794, -NH-C(O)-O-W795, -N H-C(O)-N H-W796, - NH-C(O)-NW797W798, -NW799-C(O)-O-W800, -NW801-C(O)- NH-W802, -NW803-C(O)-NW804W805, -NHS(O2)-W806, - NW807S(O2)-W808, -S-W809, -S(O)-W810, -S(O2)-W81 1 , - S(O2)NH-W812, -S(O2)NW813W814, -S(O2)O-W815, - P(O)(OW816)(OW817), -Si(W818)(W819)(W820)"; wobei W769, W770, W771 , W772, W773, W774, W775, W776, W777, W778, W779, W780, W781 , W782, W783, W784, W785, W786, W787, W788, W789, W790, W791 , W792, W793, W794, W795, W796, W797, W798, W799, W800, W801 , W802, W803, W804, W805, W806, W807, W808, W809, W810, W81 1 , W812, W813,W780 (d = 1, 2, 3, 4, 5), -OC (O) -W781, -OC (O) -O-W782, -OC (O) -NHW783, -OC (O) -NW784W785, - OP (O) (OW786) (OW787), - OSi (W788) (W789) (W790), -OS (O2) -W791, -NHC (O) -W792, - NW793C (O) -W794, -NH -C (O) -O-W795, -NHC (O) -NH-W796, - NH-C (O) -NW797W798, -NW799-C (O) -O-W800, -NW801-C (O) -NH-W802, -NW803-C (O) -NW804W805, -NHS (O 2 ) - W806, - NW807S (O2) -W808, -S-W809, -S (O) -W810, -S (O2) -W81 1, - S (O 2) NH-W812, -S (O 2) NW813W814, -S (O2) O-W815, - P (O) (OW816) (OW817), -Si (W818) (W819) (W820) "; wherein W769, W770, W771, W772, W773, W774, W775, W776, W777, W778, W779, W780, W781, W782, W783, W784, W785, W786, W787, W788, W789, W790, W791, W792, W793, W794, W795, W796, W797, W798, W799, W800, W801, W802, W803, W804, W805, W806, W807, W808, W809, W810, W81 1, W812, W813,
W814, W815, W816, W817, W818, W819, W820 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C3o)alkyl, cycloalkyl, cycloal kyl alkyl , heterocyclyl, heterocyclylalkyl, a- ryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W775, W776 und/oder W784, W785 und/oder W797, W798 und/oder W804,W814, W815, W816, W817, W818, W819 are, W820 are independently selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylene kyl alkyl, heterocyclyl, heterocyclylalkyl, a- ryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively W775, W776 and / or W784, W785 and / or W797, W798 and / or W804,
W805 und/oder W813, W814 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindes- tens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:W805 and / or W813, W814 may in each case also form "heterocyclyl", wherein optionally substituted substituents of the substituent group (i) may in turn be independently substituted with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, ( C9-C30 )a I kyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW821 , -NW822W823, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW821, -NW822W823, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -
SO3H, -P(O)(OH)2, -C(O)-W824, -C(O)O-W825, -C(O)NH- W826, -C(O)NW827W828, -O-W829, -O(-W830-O)e-H (e = 1 , 2, 3, 4, 5), -O(-W831-O)e-W832 (e = 1 , 2, 3, 4, 5), -OC(O)- W833, -OC(O)-O-W834, -OC(O)-N H W835, -0-C(O)- NW836W837, -OP(O)(OW838)(OW839), -SO 3 H, -P (O) (OH) 2, -C (O) -W824, -C (O) O-W825, -C (O) NH- W826, -C (O) NW827W828, -O- W829, -O (-W830-O) e -H (e = 1, 2, 3, 4, 5), -O (-W831-O) e -W832 (e = 1, 2, 3, 4, 5 ), -OC (O) -W833, -OC (O) -O-W834, -OC (O) -NH W835, -O-C (O) -NW836W837, -OP (O) (OW838) (OW839) , -
OSi(W840)(W841 )(W842), -OS(O2)-W843, -NHC(O)-W844, - NW845C(O)-W846, -NH-C(O)-O-W847, -N H-C(O)-N H-W848, -N H-C(O)-N W849W850, -NW851-C(O)-O-W852, -NW853- C(O)-N H-W854, -NW855-C(O)-NW856W857, -NHS(O2)-W858, -NW859S(O2)-W860, -S-W861 , -S(O)-W862, -S(O2)-W863, - S(O2)NH-W864, -S(O2)NW865W866, -S(O2)O-W867, - P(O)(OW868)(OW869), -Si(W870)(W871 )(W872)"; wobei W821 , W822, W823, W824, W825, W826, W827, W828,OSi (W840) (W841) (W842), -OS (O2) -W843, -NHC (O) -W844, - NW845C (O) -W846, -NH-C (O) -O-W847, -N HC (O) -NH-W848, -NHC (O) -N W849W850, -NW851-C (O) -O-W852, -NW853-C (O) -NH-W854, -NW855-C ( O) -NW856W857, -NHS (O 2 ) -W858, -NW859S (O2) -W860, -S-W861, -S (O) -W862, -S (O2) -W863, - S (O 2) NH-W864, -S (O2) NW865W866, - S (O 2 ) O-W867, -P (O) (OW868) (OW869), -Si (W870) (W871) (W872) "; wherein W821, W822, W823, W824, W825, W826, W827, W828 .
5 W829, W830, W831 , W832, W833, W834, W835, W836, W837,5 W829, W830, W831, W832, W833, W834, W835, W836, W837,
W838, W839, W840, W841 , W842, W843, W844, W845, W846, W847, W848, W849, W850, W851 , W852, W853, W854, W855, W856, W857, W858, W859, W860, W861 , W862, W863, W864, W865, W866, W867, W868, W869, W870, W871 , W872 unabhän-W838, W839, W840, W841, W842, W843, W844, W845, W846, W847, W848, W849, W850, W851, W852, W853, W854, W855, W856, W857, W858, W859, W860, W861, W862, W863, W864, W865, W866, W867, W868, W869, W870, W871, W872
10 gig voneinander ausgewählt sind aus der Gruppe bestehend aus:10 gig are selected from the group consisting of:
„alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W827, W828 und/oder W836, W837 und/oder W849, W850 und/oder W856, W857 und/oder W865, W866 jeweils zu-"Alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively W827, W828 and / or W836, W837 and / or W849, W850 and / or W856, W857 and / or W865, W866 in each case
15 sammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:15 optionally together can also form "heterocyclyl", where optionally substituted substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
20 (iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW873, -NW874W875, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-W876, -C(O)O-W877,20 (iii) "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW 873, -NW 874 W 875, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O ) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W 876, -C (O) O-W 877,
25 -C(O)N H-W878, -C(O)N W879W880, -O-W881 , -O(-W882-25 -C (O) N H-W878, -C (O) N W879W880, -O-W881, -O (-W882-
O)^H (f = 1 , 2, 3, 4, 5), -O(-W883-O)^W884 (f = 1 , 2, 3, 4, 5), -OC(O)-W885, -OC(O)-O-W886, -OC(O)-N H W887, -O- C(O)-NW888W889, -OP(O)(OW890)(OW891 ), - OSi(W892)(W893)(W894), -OS(O2)-W895, -NHC(O)-W896,O) ^ H (f = 1, 2, 3, 4, 5), -O (-W883-O) ^ W884 (f = 1, 2, 3, 4, 5), -OC (O) -W885, -OC (O) -O-W886, -OC (O) -NH W887, -O-C (O) -NW888W889, -OP (O) (OW890) (OW891), -OSi (W892) (W893) ( W894), -OS (O 2 ) -W895, -NHC (O) -W896,
30 -NW897C(O)-W898, -NH-C(O)-O-W899, -NH-C(O)-NH-30 -NW897C (O) -W898, -NH-C (O) -O-W899, -NH-C (O) -NH-
W900, -N H-C(O)-N W901W902, -NW903-C(O)-O-W904, - NW905-C(O)-NH-W906, -NW907-C(O)-NW908W909, - NHS(O2)-W910, -NW91 1S(O2)-W912, -S-W913, -S(O)- W914, -S(O2)-W915, -S(O2)NH-W916, -S(O2)NW917W918, -S(O2)O-W919, -P(O)(OW920)(OW921 ), - Si(W922)(W923)(W924)"; wobei W873, W874, W875, W876, W877, W878, W879, W880, W881 , W882, W883, W884, W885, W886, W887, W888, W889, W890, W891 , W892, W893, W894, W895, W896,W900, -NHC (O) -N W901W902, -NW903-C (O) -O-W904, -NW905-C (O) -NH-W906, -NW907-C (O) -NW908W909, -NHS (O 2) -W910, -NW91 1S (O 2) -W912, -S-W913, -S (O) - W914, -S (O2) -W915, -S (O2) NH-W916, -S ( O 2 ) NW917W918, -S (O2) O-W919, --P (O) (OW920) (OW921), - Si (W922) (W923) (W924) "; wherein W873, W874, W875, W876, W877, W878, W879, W880, W881, W882, W883, W884, W885, W886, W887, W888, W889, W890, W891, W892, W893, W894, W895, W896,
W897, W898, W899, W900, W901 , W902, W903, W904, W905, W906, W907, W908, W909, W910, W91 1 , W912, W913, W914, W915, W916, W917, W918, W919, W920, W921 , W922, W923, W924 unabhängig voneinander ausge- wählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W879, W880 und/oder W888, W889 und/oder W901 , W902 und/oder W908, W909 und/oder W917, W918 jeweils zusam- men auch „heterocyclyl" bilden können;W897, W898, W899, W900, W901, W902, W903, W904, W905, W906, W907, W908, W909, W910, W911, W912, W913, W914, W915, W916, W917, W918, W919, W920, W921 , W922, W923 are, W924 are independently selected exported from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively W879 , W880 and / or W888, W889 and / or W901, W902 and / or W908, W909 and / or W917, W918 in each case together can also form "heterocyclyl";
(g) OZ6, wobei Z6 unabhängig ausgewählt ist aus der Gruppe bestehend aus:(g) OZ6, wherein Z6 is independently selected from the group consisting of:
(i) „Wasserstoff, alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW925, -NW926W927, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, - SO3H, -P(O)(OH)2, -C(O)-W928, -C(O)O-W929, -C(O)NH- W930, -C(O)NW931 W932, -O-W933, -O(-W934-O)g-H (g = 1 ,(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyc IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; optionally substituting the above substituents of the substituent group (i) independently can with at least one substituent, identical or different, selected from the group consisting of: (ii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F , Cl, Br, I, CN, CF 3, N 3, NH 2, -NHW925, -NW926W927, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W 928, -C (O) O-W929 , -C (O) NH-W930, -C (O) NW931 W932, -O-W933, -O (-W934-O) g -H (g = 1,
2, 3, 4, 5), -O(-W935-O)g-W936 (g = 1 , 2, 3, 4, 5), -OC(O)- W937, -OC(O)-O-W938, -OC(O)-N H W939, -0-C(O)- NW940W941 , -OP(O)(OW942)(OW943), - OSi(W944)(W945)(W946), -OS(O2)-W947, -NHC(O)-W948, - NW949C(O)-W950, -NH-C(O)-O-W951 , -N H-C(O)-N H-W952, -N H-C(O)-N W953W954, -NW955-C(O)-O-W956, -NW957- C(O)-NH-W958, -NW959-C(O)-NW960W961 , -NHS(O2)-W962,2, 3, 4, 5), -O (-W935-O) g -W936 (g = 1, 2, 3, 4, 5), -OC (O) - W937, -OC (O) -O- W938, -OC (O) -NH W939, -O-C (O) - NW940W941, -OP (O) (OW942) (OW943), OSi (W944) (W945) (W946), -OS (O2) -W947, -NHC (O) -W948, - NW949C (O) -W950, -NH-C (O) -O-W951, -N HC (O) -NH-W952, -NHC (O) -N W953W954, -NW955-C (O) -O-W956, -NW957-C (O) -NH-W958, -NW959-C (O -NW960W961, -NHS (O 2 ) -W962,
5 -NW963S(O2)-W964, -S-W965, -S(O)-W966, -S(O2)-W967, -5 -NW963S (O2) -W964, -S-W965, -S (O) -W966, -S (O2) -W967, -
S(O2)NH-W968, -S(O2)NW969W970, -S(O2)O-W971 , - P(O)(OW972)(OW973), -Si(W974)(W975)(W976)"; wobei W925, W926, W927, W928, W929, W930, W931, W932, W933, W934, W935, W936, W937, W938, W939, W940, W941 ,S (O 2) NH-W968, -S (O2) NW969W970, -S (O2) O-W971, - P (O) (OW972) (OW973), -Si (W974) (W975) (W976) W925, W926, W927, W928, W929, W930, W931, W932, W933, W934, W935, W936, W937, W938, W939, W940, W941,
10 W942, W943, W944, W945, W946, W947, W948, W949, W950,10 W942, W943, W944, W945, W946, W947, W948, W949, W950,
W951 , W952, W953, W954, W955, W956, W957, W958, W959, W960, W961 , W962, W963, W964, W965, W966, W967, W968, W969, W970, W971, W972, W973, W974, W975, W976 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:W951, W952, W953, W954, W955, W956, W957, W958, W959, W960, W961, W962, W963, W964, W965, W966, W967, W968, W969, W970, W971, W972, W973, W974, W975, W976 are independently selected from the group consisting of:
15 „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W931 , W932 und/oder W940, W941 und/oder W953, W954 und/oder W960, W961 und/oder W969, W970 jeweils zusammen auch „heterocyclyl" bilden können;15 "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively W931, W932 and / or W940, W941 and / or W953, W954 and or W960, W961 and / or W969, W970 may together also form "heterocyclyl";
20 wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:In which optionally substituents of the substituent group (ii) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he-(iii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE
25 terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,25 terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
Br, I, CN, CF3, N3, NH2, -NHW977, -NW978W979, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-W980, -C(O)O-W981 , -C(O)N H-W982, -C(O)N W983W984, -O-W985, -O(-W986-Br, I, CN, CF 3, N 3, NH 2, -NHW977, -NW978W979, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W980, -C (O) O-W981, -C (O) N H-W982, -C (O) N W983W984, -O-W985, -O (-W986-
30 O)h-H (h = 1 , 2, 3, 4, 5), -O(-W987-O)h-W988 (h = 1 , 2, 3, 4,30 O) h -H (h = 1, 2, 3, 4, 5), -O (-W987-O) h -W988 (h = 1, 2, 3, 4,
5), -OC(O)-W989, -OC(O)-O-W990, -OC(O)-N H W991 , -O- C(O)-NW992W993, -OP(O)(OW994)(OW995), - OSi(W996)(W997)(W998), -OS(O2)-W999, -NHC(O)-WIOOO, -NW1001 C(O)-WI 002, -NH-C(O)-O-WI 003, -NH-C(O)- NH-W1004, -NH-C(O)-NWI 005W1006, -NW1007-C(O)-O- W1008, -NWI OOg-C(O)-NH-WI OI O, -NW1011-C(O)- NW1012W1013, -NHS(O2)-W1014, -NW1015S(O2)-W1016, -S-W1017, -S(O)-WI 018, -S(O2)-W1019, -S(O2)NH- W1020, -S(O2)NW1021W1022, -S(O2)O-WI 023, -5), -OC (O) -W989, -OC (O) -O-W990, -OC (O) -NH W991, -O-C (O) -NW992W993, -OP (O) (OW994) (OW995 ), - OSi (W996) (W997) (W998), -OS (O2) -W999, -NHC (O) -WIOOO, -NW1001 C (O) -WI 002, -NH-C (O) -O -WI 003, -NH-C (O) - NH-W1004, -NH-C (O) -NWI 005W1006, -NW1007-C (O) -O-W1008, -NWI OOg-C (O) -NH-WI OI O, -NW1011-C (O) - NW1012W1013, -NHS (O 2) -W1014, -NW1015S (O 2) -W1016, -S-W1017, -S (O) -WI 018, -S (O 2) -W1019, -S (O 2) NH - W1020, -S (O 2 ) NW1021W1022, -S (O 2 ) O-WI 023, -
P(O)(OWI 024)(OW1025), -Si(WI 026)(W1027)(W1028)"; wobei W977, W978, W979, W980, W981 , W982, W983, W984, W985, W986, W987, W988, W989, W990, W991 , W992, W993, W994, W995, W996, W997, W998, W999, W1000, W1001 , W1002, W1003, W1004, W1005, W1006, W1007,P (O) (OWI 024) (OW1025), -Si (WI 026) (W1027) (W1028) "; wherein W977, W978, W979, W980, W981, W982, W983, W984, W985, W986, W987, W988 , W989, W990, W991, W992, W993, W994, W995, W996, W997, W998, W999, W1000, W1001, W1002, W1003, W1004, W1005, W1006, W1007,
W1008, W1009, W1010, W101 1 , W1012, W1013, W1014, W1015, W1016, W1017, W1018, W1019, W1020, W1021 , W1022, W1023, W1024, W1025, W1026, W1027, W1028 unabhängig voneinander ausgewählt sind aus der Gruppe beste- hend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, hete- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" und wobei alternativ W983, W984 und/oder W992, W993 und/oder W1005, W1006 und/oder W1012, W1013 und/oder W1021 , W1022 jeweils zusammen auch „heterocyc- IyI" bilden können;W1008, W1009, W1010, W101 1, W1012, W1013, W1014, W1015, W1016, W1017, W1018, W1019, W1020, W1021, W1022, W1023, W1024, W1025, W1026, W1027, W1028 are independently selected from the group best - starting from: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" and wherein alternatively W983, W984 and / or W992, W993 and / or W1005, W1006 and / or W1012, W1013 and / or W1021, W1022 may together also form "heterocyclyl";
(h) SZ7, wobei Z7 unabhängig ausgewählt ist aus der Gruppe bestehend aus:(h) SZ7, wherein Z7 is independently selected from the group consisting of:
(i) „Wasserstoff, alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(i) "hydrogen, alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, as heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wherein optionally above substituents of substituent group (i) in turn independently substituted may be at least one substituent, the same or different, selected from the group consisting of:
(ii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,(ii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,
CN, CF3, N3, NH2, -NHW1029, -NW1030W1031 , -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-WI 032, -C(O)O-WI 033, -C(O)NH- W1034, -C(O)NWI 035W1036, -O-W1037, -O(-W1038-O),-H (i = 1 , 2, 3, 4, 5), -O(-W1039-O)1-WI 040 (i = 1 , 2, 3, 4, 5), -OC(O)- W1041 , -OC(O)-O-WI 042, -OC(O)-NHWI 043, -0-C(O)- NW1044W1045, -OP(O)(OWI 046)(OW1047), -CN, CF 3, N 3, NH 2, -NHW1029, -NW1030W1031, -NO 2, -OH, - OCF 3, -SH, -0-SO3H, -OP (O) (OH) 2, -CHO , -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -WI 032, -C (O) O-WI 033, -C (O ) NH- W1034, -C (O) NWI 035W1036, -O-W1037, -O (-W1038-O), - H (i = 1, 2, 3, 4, 5), -O (-W1039-O) 1 - WI 040 (i = 1, 2, 3, 4, 5), -OC (O) -W1041, -OC (O) -O-WI 042, -OC (O) -NHWI 043, -O-C (O ) - NW1044W1045, -OP (O) (OWI 046) (OW1047), -
5 OSi(WI 048)(W1049)(W1050), -OS(O2)-W1051 , -NHC(O)-5 OSi (WI 048) (W1049) (W1050), -OS (O 2 ) -W1051, -NHC (O) -
W1052, -NW1053C(O)-WI 054, -NH-C(O)-O-WI 055, -NH- C(O)-NH-WI 056, -NH-C(O)-NWI 057W1058, -NW1059-C(O)- O-W1060, -NW1061-C(O)-NH-WI 062, -NW1063-C(O)- NW1064W1065, -NHS(O2)-W1066, -NW1067S(O2)-W1068, -S- 10 W1069, -S(O)-WI 070, -S(02)-W1071 , -S(O2)NH-WI 072, -W1052, -NW1053C (O) -WI 054, -NH-C (O) -O-WI 055, -NH-C (O) -NH-WI 056, -NH-C (O) -NWI 057W1058, -NW1059 -C (O) - O-W1060, -NW1061-C (O) -NH-WI 062, -NW1063-C (O) - NW1064W1065, -NHS (O 2) -W1066, -NW1067S (O 2) -W1068 , -S- 10 W1069, -S (O) -WI 070, -S (0 2 ) -W1071, -S (O 2 ) NH-WI 072, -
S(O2)NWI 073W1074, -S(O2)O-WI 075, - P(O)(OWI 076)(OW1077), -Si(WI 078)(W1079)(W1080)"; wobei W1029, W1030, W1031 , W1032, W1033, W1034, W1035, W1036, W1037, W1038, W1039, W1040, W1041 , W1042, W1043,S (O 2 ) NWI 073W1074, -S (O 2 ) O-WI 075, -P (O) (OWI 076) (OW1077), -Si (WI 078) (W1079) (W1080) "where W1029, W1030 , W1031, W1032, W1033, W1034, W1035, W1036, W1037, W1038, W1039, W1040, W1041, W1042, W1043,
15 W1044, W1045, W1046, W1047, W1048, W1049, W1050, W1051 ,15 W1044, W1045, W1046, W1047, W1048, W1049, W1050, W1051,
W1052, W1053, W1054, W1055, W1056, W1057, W1058, W1059, W1060, W1061 , W1062, W1063, W1064, W1065, W1066, W1067, W1068, W1069, W1070, W1071 , W1072, W1073, W1074, W1075, W1076, W1077, W1078, W1079, W1080 unabhängig voneinanderW1052, W1053, W1054, W1055, W1056, W1057, W1058, W1059, W1060, W1061, W1062, W1063, W1064, W1065, W1066, W1067, W1068, W1069, W1070, W1071, W1072, W1073, W1074, W1075, W1076, W1077, W1078, W1079, W1080 independent from each other
20 ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-20 are selected from the group consisting of: "alkyl, (C 9 -
C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W1035, W1036 und/oder W1044, W1045 und/oder W1057, W1058 und/oder W1064, W1065 und/oder W1073, W1074 jeweilsC 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively W1035, W1036 and / or W1044, W1045 and / or W1057, W1058 and / or W1064, W1065 and / or W1073 , W1074 respectively
25 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:25 together may also form "heterocyclyl", where optionally substituted substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
30 (iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW1081 , -NW1082W1083, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-W1084, -C(O)O- W1085, -C(O)NH-WI 086, -C(O)NWI 087W1088, -O-W1089, -O(-W1090-O)-H C = 1 , 2, 3, 4, 5), -O(-W1091 -O)-WI 092 C = 1 , 2, 3, 4, 5), -OC(O)-WI 093, -OC(O)-O-WI 094, - OC(O)-NHWI 095, -0-C(O)-NWI 096W1097, - OP(O)(OWI 098)(OW1099), -OSi(W1 100)(W1101 )(W1 102), -30 (iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW1081, -NW1082W1083, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W 1084, -C (O) O- W1085, -C (O) NH-WI 086, -C (O) NWI 087W1088, -O-W1089, -O (-W1090-O) -HC = 1, 2, 3, 4, 5), -O ( -W1091 -O) -WI 092 C = 1, 2, 3, 4, 5), -OC (O) -WI 093, -OC (O) -O-WI 094, - OC (O) -NHWI 095, -O-C (O) -NWI 096W1097, - OP (O) (OWI 098) (OW1099), -OSi (W1 100) (W1101) (W1 102),
0S(02)-W1 103, -NHC(O)-W1 104, -NW1 105C(O)-W1 106, - NH-C(O)-O-W1107, -NH-C(O)-NH-W1108, -NH-C(O)- NW1 109W1 110, -NW11 11-C(O)-O-W1 112, -NW1 113- C(O)-NH-W11 14, -NW11 15-C(O)-NW1 116W1 117, - NHS(02)-W11 18, -NW1 119S(O2)-W1120, -S-W1 121 , -0S (0 2 ) -W1 103, -NHC (O) -W1 104, -NW1 105C (O) -W1 106, -NH-C (O) -O-W1107, -NH-C (O) -NH- W1108, -NH-C (O) - NW1 109W1 110, -NW11 11-C (O) -O-W1 112, -NW1 113-C (O) -NH-W11 14, -NW11 15-C (O) -NW1 116W1 117, - NHS (0 2 ) -W11 18, -NW1 119S (O 2 ) -W1120, -S-W1 121, -
S(O)-W1 122, -S(O2)-W1 123, -S(O2)NH-W1124, - S(O2)NW1 125W1 126, -S(O2)O-W1127, - P(O)(OW1128)(OW1 129), -Si(W1130)(W1131 )(W1 132)"; wobei W1081 , W1082, W1083, W1084, W1085, W1086, W1087, W1088, W1089, W1090, W1091 , W1092, W1093,S (O) -W1 122, -S (O 2) -W1 123, -S (O 2) NH-W1124, - S (O 2) NW1 125W1 126, -S (O 2) O-W1127, - P (O) (OW1128) (OW1 129), -Si (W1130) (W1131) (W1 132) ", wherein W1081, W1082, W1083, W1084, W1085, W1086, W1087, W1088, W1089, W1090, W1091, W1092, W1093,
W1094, W1095, W1096, W1097, W1098, W1099, W1100, W1 101 , W1102, W1103, W1 104, W1 105, W1106, W1107, W1 108, W1109, W11 10, W1 11 1 , W1 112, W11 13, W11 14, W1 115, W11 16, W11 17, W1 118, W1 119, W1120, W1121 , W1 122, W1123, W1124, W1 125, W1 126, W1127, W1128,W1094, W1095, W1096, W1097, W1098, W1099, W1100, W1101, W1102, W1103, W1104, W1105, W1106, W1107, W1108, W1109, W1110, W1111, W1121, W1113, W11 14, W1 115, W11 16, W11 17, W1 118, W1 119, W1120, W1121, W1 122, W1123, W1124, W1 125, W1 126, W1127, W1128,
W1 129, W1130, W1131 , W1 132 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei al- ternativ W1087, W1088 und/oder W1096, W1097 und/oderW1 129, W1130, W1131 are, W1 132 are independently selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively W1087, W1088 and / or W1096, W1097 and / or
W1 109, W11 10 und/oder W1 116, W11 17 und/oder W1 125, W1 126 jeweils zusammen auch „heterocyclyl" bilden können;W1 109, W11 10 and / or W1 116, W11 17 and / or W1 125, W1 126 may together also form "heterocyclyl";
(j) NZ8Z9, wobei Z8, Z9 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:(j) NZ8Z9, wherein Z8, Z9 are independently selected from the group consisting of:
(i) „Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C(O)- W1 133, -C(O)O-W1134, -C(O)-NW1135W1136, -S(02)-W1137, - S(O2)O-W1 138"; wobei W1133, W1 134, W1 135, W1136, W1137, W1 138 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W1135, W1136 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(i) "hydrogen, alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C (O) - W1 133, -C (O) O-W1134 , -C (O) -NW1135W1136, -S (0 2) -W1137, - S (O 2) O-W1 138 "; wherein W1133, W1 134, W1 135, W1136, W1137, W1 138 are independently selected from the group consisting of: hydrogen, alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively W1135, W1136 may together also form" heterocyclyl "; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHW1139, -NW1 140W1 141 , -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-W1142, -C(0)0-W1143, -C(O)NH-(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHW1139, -NW1 140W1 141, -NO 2 , -OH, - OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W 1142, -C (O) O-W 1143, -C (O) NH-
W1 144, -C(O)NW1145W1146, -0-W1 147, -0(-W1148-O)k-H (k = 1 , 2, 3, 4, 5), -O(-W1 149-O)k-W1 150 (k = 1 , 2, 3, 4, 5), - OC(O)-W1151 , -OC(O)-O-W1 152, -OC(O)-NHW1153, -O- C(O)-NW1154W1 155, -OP(O)(OW1 156)(OW1157), - OSi(W1158)(W1159)(W1 160), -0S(02)-W1161 , -NHC(O)-W1 144, -C (O) NW1145W1146, -0-W1 147, -0 (-W1148-O) k -H (k = 1, 2, 3, 4, 5), -O (-W1 149-O) k -W1 150 (k = 1, 2, 3, 4, 5), - OC (O) -W1151, -OC (O) -O-W1 152, -OC (O) -NHW1153, -O-C ( O) -NW1154W1 155, -OP (O) (OW1 156) (OW1157), -OSi (W1158) (W1159) (W1 160), -0S (0 2 ) -W1161, -NHC (O) -
W1 162, -N W1 163C(O)-W1 164, -NH-C(O)-O-W1165, -NH- C(O)-NH-W1166, -NH-C(O)-NW1167W1168, -NW1169-C(O)- O-W1 170, -NW1 171-C(O)-NH-W1172, -N W1173-C(O)- NW1 174W1175, -NHS(02)-W1 176, -NW1 177S(O2)-W1178, -S- W1 179, -S(O)-W1 180, -S(02)-W1 181 , -S(O2)NH-W1182, -W1 162, -N W1 163C (O) -W1 164, -NH-C (O) -O-W1165, -NH-C (O) -NH-W1166, -NH-C (O) -NW1167W1168, -NW1169 -C (O) - O-W1 170, 171 -NW1-C (O) -NH-W1172, W1173 -N-C (O) - NW1 174W1175, -NHS (0 2) -W1 176, -NW1 177S ( O 2 ) -W1178, -S-W1 179, -S (O) -W1 180, -S (O 2 ) -W1 181, -S (O 2 ) NH-W1182,
S(O2)NW1 183W1 184, -S(O2)O-W1185, - P(0)(0W1186)(OW1 187), -Si(W1188)(W1189)(W1 190)"; wobei W1139, W1 140, W1 141 , W1142, W1 143, W1 144, W1145, W1 146, W1147, W1148, W1 149, W1 150, W1151 , W1152, W1 153, W1 154, W1155, W1156, W1 157, W1 158, W1159, W1160, W1 161 ,S (O 2) NW1 183W1 184, -S (O 2) O-W1185, - P (0) (0W1186) (OW1 187), -Si (W1188) (W1189) (W1 190) "; wherein W1139, W1 140, W1 141, W1142, W1 143, W1 144, W1145, W1 146, W1147, W1148, W1 149, W1 150, W1151, W1152, W1 153, W1 154, W1155, W1156, W1 157, W1 158, W1159, W1160, W1 161,
W1 162, W1163, W1164, W1 165, W1 166, W1167, W1168, W1 169, W1 170, W1171 , W1172, W1 173, W1 174, W1175, W1176, W1 177, W1 178, W1179, W1180, W1 181 , W1 182, W1183, W1184, W1 185, W1 186, W1187, W1188, W1 189, W1190 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W1 145, W1146 und/oder W1 154, W1155 und/oder W1 167,W1 162, W1163, W1164, W1 165, W1 166, W1167, W1168, W1 169, W1 170, W1171, W1172, W1 173, W1 174, W1175, W1176, W1 177, W1 178, W1179, W1180, W1 181, W1 182, W1183, W1184, W1 185, W1 186, W1187, W1188, W1 189, W1190 independently of each other are selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively W1 145, W1146 and / or W1 154, W1155, and / or W1 167,
5 W1 168 und/oder W1174, W1 175 und/oder W1 183, W1184 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausge- 10 wählt aus der Gruppe bestehend aus:5 W1 168 and / or W1174, W1 175 and / or W1 183, W1184 may in each case also form "heterocyclyl", where optionally substituents of the substituent group (ii) above may be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I1 CN1 CF3, N3, NH2, -NHW1 191 , -NW1192W1193, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH,(iii) "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I 1 CN 1 CF 3, N 3, NH 2, -NHW1 191, -NW1192W1193, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH,
15 -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-W1194, -C(O)O-15 -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -W 1194, -C (O) O-
W1 195, -C(O)NH-W1 196, -C(O)NW1197W1198, -0-W1199, -0(-W1200-O)1-H (I = 1 , 2, 3, 4, 5), -0(-W1201 -O)1-WI 202 (I = 1 , 2, 3, 4, 5), -OC(O)-WI 203, -OC(O)-O-WI 204, - OC(O)-NHW1205, -0-C(0)-NW1206W1207, -W1 195, -C (O) NH-W1 196, -C (O) NW1197W1198, -0-W1199, -O (-W1200-O) 1 -H (I = 1, 2, 3, 4, 5), -0 (-W1201 -O) 1 -WI 202 (I = 1, 2, 3, 4, 5), -OC (O) -WI 203, -OC (O) -O-WI 204, - OC (O ) -NHW1205, -0-C (0) -NW1206W1207, -
20 OP(O)(OW1208)(OW1209), -OSi(W1210)(W1211 )(W1212), -20 OP (O) (OW1208) (OW1209), -OSi (W1210) (W1211) (W1212), -
OS(O2)-W1213, -NHC(O)-WI 214, -NW1215C(O)-WI 216, - N H-C(O)-O-WI 217, -NH-C(O)-NH-W1218, -NH-C(O)- NW1219W1220, -NW1221-C(O)-O-W1222, -NW1223- C(O)-NH-W1224, -NW1225-C(O)-NWI 226W1227, -OS (O 2 ) -W 1213, -NHC (O) -WI 214, -NW 1215C (O) -WI 216, -N HC (O) -O-WI 217, -NH-C (O) -NH-W 1218, -NH-C (O) - NW1219W1220, -NW1221-C (O) -O-W1222, -NW1223-C (O) -NH-W1224, -NW1225-C (O) -NWI 226W1227, -
25 NHS(O2)-W1228, -NW1229S(O2)-W1230, -S-W1231 , -25 NHS (O 2 ) -W 1228, -NW 1229S (O 2 ) -W 1230, -S-W 1231, -
S(O)-W1232, -S(O2)-W1233, -S(O2)NH-W1234, - S(O2)NWI 235W1236, -S(O2)O-WI 237, - P(0)(0W1238)(OW1239), -Si(WI 240)(W1241 )(W1242)"; wobei W1191 , W1192, W1193, W1194, W1195, W1196,S (O) -W1232, -S (O 2) -W1233, -S (O 2) NH-W1234, - S (O 2) NWI 235W1236, -S (O 2) O-WI 237, - P (0 (0W1238) (OW1239), -Si (WI 240) (W1241) (W1242) "; wherein W1191, W1192, W1193, W1194, W1195, W1196,
30 W1197, W1198, W1199, W1200, W1201, W1202, W1203,30 W1197, W1198, W1199, W1200, W1201, W1202, W1203,
W1204, W1205, W1206, W1207, W1208, W1209, W1210, W1211, W1212, W1213, W1214, W1215, W1216, W1217, W1218, W1219, W1220, W1221, W1222, W1223, W1224, W1225, W1226, W1227, W1228, W1229, W1230, W1231, W1232, W1233, W1234, W1235, W1236, W1237, W1238, W1239, W1240, W1241 , W1242 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ W1 197, W1 198 und/oder W1206, W1207 und/oder W1219, W1220 und/oder W1226, W1227 und/oder W1235, W1236 jeweils zusammen auch „heterocyclyl" bilden können;W1204, W1205, W1206, W1207, W1208, W1209, W1210, W1211, W1212, W1213, W1214, W1215, W1216, W1217, W1218, W1219, W1220, W1221, W1222, W1223, W1224, W1225, W1226, W1227, W1228, W1229, W1230, W1231, W1232, W1233, W1234, W1235, W1236, W1237, W1238, W1239, W1240, W1241 are, W1242 independently selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively W1 197, W1 198 and / or W1206, W1207 and / or W1219, W1220 and / or W1226, W1227 and / or W1235, W1236 may together also also form" heterocyclyl ";
oderor
(D) einer der Reste Z3, Z4 oder beide Reste Z3, Z4 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:(D) one of the radicals Z3, Z4 or both radicals Z3, Z4 are independently selected from the group consisting of:
(1 ) ,,-NZ10Z1 1 , -OZ12, -SZ13"; wobei einer der Reste Z10, Z11 oder beide Reste Z10, Z1 1 und Reste Z12, Z13 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:(1) ,, - NZ10Z1 1, -OZ12, -SZ13 ", one of the radicals Z10, Z11 or both radicals Z10, Z1 1 and radicals Z12, Z13 being selected independently of one another from the group consisting of:
(a) „Wasserstoff, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl"; mit der Maßgabe, dass nicht beide Reste Z10, Z11 gleichzeitig Wasser- stoff sind; mit der weiteren Maßgabe, dass Rest Z12 nicht Wasserstoff ist; mit der weiteren Maßgabe, dass obige Substituenten der Substituen- tengruppe (a), wenn nicht Wasserstoff, unabhängig voneinander weiter substituiert sind mit mindestens einem Substituenten, gleich oder ver- schieden, ausgewählt aus der Gruppe bestehend aus:(a) "hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl" with the proviso that not both radicals Z10, Z11 are simultaneously hydrogen, with the further proviso that radical Z12 is not hydrogen, with the further proviso that the above substituents of the substituent group (a), if not hydrogen, are further independently substituted with at least one substituent, the same or different, selected from the group consisting of:
(i) „(C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, N3, -NH-cycloalkyl, - NH-cycloalkylalkyl, -NH-heteroaryl, -NH-heteroarylalkyl, -NH- arylalkyl, -NH-heterocyclyl, -NH-heterocyclylalkyl, -NQ1Q2, -S- cycloalkyl, -S-cycloalkylalkyl, -S-aryl, —S— arylalkyl, -S-heteroaryl, -(i) "(C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, N 3, -NH-cycloalkyl, - NH-cycloalkylalkyl, -NH-heteroaryl, -NH -heteroarylalkyl, -NH-arylalkyl, -NH-heterocyclyl, -NH-heterocyclylalkyl, -NQ1Q2, -S-cycloalkyl, -S-cycloalkylalkyl, -S-aryl, -S-arylalkyl, -S-heteroaryl, -
S-heteroarylalkyl, -S-heterocyclyl, -S-heterocyclylalkyl, -O- cycloalkyl, -O-cycloalkylalkyl, -O-arylalkyl, -O-heteroaryl, -O- heteroarylalkyl, -O-heterocyclyl, -O-heterocyclylalkyl, -O(-Q3-O)p- H (p = 1 , 2, 3, 4, 5), -O(-Q4-O)p-Q5 (p = 1 , 2, 3, 4, 5), - OP(O)(OQ6)(OQ7), -C(O)O-Q8, -C(O)NH2, -C(O)NH-Q9, - C(O)NQ10Q11 , -S(O2)-Q12, -P(O)(OH)2, -P(O)(OQI 3)(OQ14), - Si(QI 5)(Q16)(Q17), -O-Si(Q18)(Q19)(Q20), -O-C(O)-O-Q21 , -O-S-heteroarylalkyl, -S-heterocyclyl, -S-heterocyclylalkyl, -O-cycloalkyl, -O-cycloalkylalkyl, -O-arylalkyl, -O-heteroaryl, -O- heteroarylalkyl, -O-heterocyclyl, -O-heterocyclylalkyl, -O (-Q3-O) p -H (p = 1, 2, 3, 4, 5), -O (-Q4-O) p -Q5 (p = 1, 2, 3, 4, 5), - OP (O) (OQ6) (OQ7), -C (O) O-Q8, -C (O) NH 2, -C (O) NH-Q9, - C (O) NQ10Q11, -S (O 2) -Q12, -P (O) (OH) 2, -P (O) (OQI 3) (OQ14), - Si (QI 5) (Q16) (Q17 ), -O-Si (Q18) (Q19) (Q20), -OC (O) -O-Q21, -O-
C(O)-NH-Q22, -0-C(O)-N Q23Q24, -NH-C(O)-O-Q25, -NH-C(O)- NH-Q26, -NH-C(O)-NQ27Q28, -NQ29-C(O)-O-Q30, -NQ31- C(O)-NH-Q32, -NQ33-C(O)-NQ34Q35, -NQ36-S(O2)-Q37, -NH- S(O2)-Q38, -O-S(O2)-Q39, -NH-C(O)-Q40, -NQ41-C(O)-Q42, - C(O)-Q43, -OC(O)-Q44, -S(O)-Q45, -S(O2)-NHQ46, -S(O2)-C (O) -NH-Q22, -O-C (O) -N Q23Q24, -NH-C (O) -O-Q25, -NH-C (O) -NH-Q26, -NH-C (O ) -NQ27Q28, -NQ29-C (O) -O-Q30, -NQ31- C (O) -NH-Q32, -NQ33-C (O) -NQ34Q35, -NQ36-S (O 2) -Q37, - NH- S (O 2) -Q38, -OS (O 2) -Q39, -NH-C (O) -Q40, -NQ41-C (O) -Q42, - C (O) -Q43, -OC ( O) -Q44, -S (O) -Q45, -S (O 2) -NHQ46, -S (O 2) -
NQ47Q48, -S(O2)-OQ49"; mit der weiteren Maßgabe, dass ,,-N(alkyl)2" weiter substituiert ist mit mindestens einem Substituenten ausgewählt aus der untigen Substi- tuentengruppe (ii); wobei Q1 , Q2, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q10, Q11 , Q12, Q13,NQ47Q48, -S (O 2 ) -OQ49 "; with the further proviso that" --N (alkyl) 2 "is further substituted with at least one substituent selected from the lower substituent group (ii); where Q1, Q2, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q10, Q11, Q12, Q13,
Q14, Q15, Q16, Q17, Q18, Q19, Q20, Q21 , Q22, Q23, Q24, Q25, Q26, Q27, Q28, Q29, Q30, Q31 , Q32, Q33, Q34, Q35, Q36, Q37, Q38, Q39, Q40, Q41 , Q42, Q43, Q44, Q45, Q46, Q47, Q48, Q49 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q10, Q11 und/oder Q23, Q24 und/oder Q27, Q28 und/oder Q34, Q35 und/oder Q47, Q48 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (a) und/oder der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Q14, Q15, Q16, Q17, Q18, Q19, Q20, Q21, Q22, Q23, Q24, Q25, Q26, Q27, Q28, Q29, Q30, Q31, Q32, Q33, Q34, Q35, Q36, Q37, Q38, Q39, Q40, Q41, Q42, Q43, Q44, Q45, Q46, Q47, are Q48, Q49 is independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete - Rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively Q10, Q11 and / or Q23, Q24 and / or Q27, Q28 and / or Q34, Q35 and / or Q47, Q48 can each also together form" heterocyclyl "; in which optionally above substituents of the substituent group (a) and / or the substituent group (i) may in turn be independently substituted with at least one substituent, same or different, selected from the group consisting of:
(ii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,(ii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,
CN, CF3, N3, NH2, -NHQ50, -NQ51 Q52, -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q53, -C(O)O-Q54, -C(O)NH-Q55, - C(O)NQ56Q57, -O-Q58, -O(-Q59-O)r-H (r = 1 , 2, 3, 4, 5), -0(- Q60-O)^Q61 (r = 1 , 2, 3, 4, 5), -OC(O)-Q62, -OC(O)-O-Q63, - OC(O)-NHQ64, -O-C(O)-NQ65Q66, -OP(O)(OQ67)(OQ68), - OSi(Q69)(Q70)(Q71 ), -OS(O2)-Q72, -NHC(O)-Q73, - NQ74C(O)-Q75, -NH-C(O)-O-Q76, -N H-C(O)-N H-Q77, -NH-CN, CF 3, N 3, NH 2, -NHQ50, -NQ51 Q52, -NO 2, -OH, -OCF3, - SH, -0-SO3H, -OP (O) (OH) 2, - CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q 53, -C (O) O-Q 54, -C (O) NH-Q55, -C (O) NQ56Q57, -O-Q58, -O (-Q59-O) r -H (r = 1, 2, 3, 4, 5), -0 (- Q60-O) ^ Q61 (r = 1, 2, 3, 4, 5), -OC (O) -Q62, -OC (O) -O-Q63, -OC (O) -NHQ64, -OC (O ) -NQ65Q66, -OP (O) (OQ67) (OQ68), - OSi (Q69) (Q70) (Q71), -OS (O 2) -Q72, -NHC (O) -Q73, - NQ74C (O) -Q75, -NH-C (O) -O-Q76, -NHC (O) -NH-Q77, -NH-
5 C(O)-NQ78Q79, -NQ80-C(O)-O-Q81 , -NQ82-C(O)-NH-Q83, -5 C (O) -NQ78Q79, -NQ80-C (O) -O-Q81, -NQ82-C (O) -NH-Q83, -
NQ84-C(O)-NQ85Q86, -NHS(O2)-Q87, -NQ88S(O2)-Q89, -S- Q90, -S(0)-Q91 , -S(O2)-Q92, -S(O2)NH-Q93, -S(O2)NQ94Q95, -S(O2)O-Q96, -P(O)(OQ97)(OQ98), -Si(Q99)(Q100)(Q101 )"; wobei Q50, Q51 , Q52, Q53, Q54, Q55, Q56, Q57, Q58, Q59, Q60,NQ84-C (O) -NQ85Q86, -NHS (O 2) -Q87, -NQ88S (O 2) -Q89, Q90 is -S-, -S (0) -Q91, -S (O 2) -Q92, - S (O 2) NH-Q93, -S (O 2) NQ94Q95, -S (O 2) O-Q96, -P (O) (OQ97) (OQ98), -Si (Q99) (Q100) (Q101) Q50, Q51, Q52, Q53, Q54, Q55, Q56, Q57, Q58, Q59, Q60,
10 Q61 , Q62, Q63, Q64, Q65, Q66, Q67, Q68, Q69, Q70, Q71 , Q72,10 Q61, Q62, Q63, Q64, Q65, Q66, Q67, Q68, Q69, Q70, Q71, Q72,
Q73, Q74, Q75, Q76, Q77, Q78, Q79, Q80, Q81 , Q82, Q83, Q84, Q85, Q86, Q87, Q88, Q89, Q90, Q91 , Q92, Q93, Q94, Q95, Q96, Q97, Q98, Q99, Q100, Q101 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloal-Q73, Q74, Q75, Q76, Q77, Q78, Q79, Q80, Q81, Q82, Q83, Q84, Q85, Q86, Q87, Q88, Q89, Q90, Q91, Q92, Q93, Q94, Q95, Q96, Q97, Q98, Q99, Q100, Q101 are independently selected from the group consisting of: "alkyl, (C9-C30) alkyl, -cycloalkyl
15 kyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q56, Q57 und/oder Q65, Q66 und/oder Q78, Q79 und/oder Q85, Q86 und/oder Q94, Q95 jeweils zusammen auch „heterocyclyl" bilden können;15 kyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and, alternatively, Q56, Q57 and / or Q65, Q66 and / or Q78, Q79 and / or Q85, Q86 and / or Q94, Q95 also together Can form "heterocyclyl";
20 wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:In which optionally substituents of the substituent group (ii) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he-(iii) "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he-
25 terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,25 terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
Br, I, CN, CF3, N3, NH2, -NHQ102, -NQ103Q104, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-QI 05, -C(O)O-QI 06, - C(O)NH-QI 07, -C(O)NQI 08Q109, -0-Q110, -0(-Q1 11 -Br, I, CN, CF 3, N 3, NH 2, -NHQ102, -NQ103Q104, -NO 2, -OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -QI 05, -C (O) O-QI 06, - C (O) NH-QI 07, -C (O) NQI 08Q109, -0-Q110, -0 (-Q1 11 -
30 O)5-H (s = 1 , 2, 3, 4, 5), -0(-Q1 12-O)S-Q1 13 (s = 1 , 2, 3, 4,30 O) 5 -H (s = 1,2,3,4,5), -0 (-Q1 12-O) S -Q1 13 (s = 1,2,3,4,
5), -OC(O)-Q114, -OC(O)-O-Q1 15, -OC(O)-NHQ116, -O- C(O)-NQ1 17Q118, -OP(O)(OQ119)(0Q120), - OSi(Q121 )(Q122)(Q123), -OS(O2)-Q124, -NHC(O)-Q125, - NQ126C(O)-Q127, -NH-C(O)-O-Q128, -NH-C(O)-NH- Q129, -NH-C(O)-NQI 30Q131 , -NQ132-C(O)-O-QI 33, - NQ134-C(O)-NH-QI 35, -NQ136-C(O)-NQI 37Q138, - NHS(O2)-Q139, -NQ140S(O2)-Q141 , -S-Q142, -S(O)-Q143, -S(O2)-Q144, -S(O2)NH-QI 45, -S(O2)NQI 46Q147, - S(O2)O-QI 48, -P(O)(OQI 49)(OQ150), -5), -OC (O) -Q114, -OC (O) -O-Q1 15, -OC (O) -NHQ116, -O-C (O) -NQ1 17Q118, -OP (O) (OQ119) ( 0Q120), - OSi (Q121) (Q122) (Q123), -OS (O 2) -Q124, -NHC (O) -Q125, - NQ126C (O) -Q127, -NH-C (O) -O- Q128, -NH-C (O) -NH- Q129, -NH-C (O) -NQI 30Q131, -NQ132-C (O) -O-QI 33, -NQ134-C (O) -NH-QI 35, -NQ136-C (O) -NQI 37Q138, - NHS (O 2) -Q139, -NQ140S (O 2) -Q141, -S-Q142, -S (O) -Q143, -S (O 2) -Q144, -S (O 2) NH-QI 45 , -S (O 2) NQI 46Q147, - S (O 2) OQI 48, -P (O) (OQI 49) (OQ150) -
Si(QI 51 )(Q152)(Q153)"; wobei Q102, Q103, Q104, Q105, Q106, Q107, Q108, Q109, Q110, Q111 , Q112, Q113, Q114, Q115, Q116, Q117, Q118, Q119, Q120, Q121, Q122, Q123, Q124, Q125, Q126, Q127, Q128, Q129, Q130, Q131, Q132, Q133, Q134, Q135, Q136,Si (QI 51) (Q152) (Q153) "; wherein Q102, Q103, Q104, Q105, Q106, Q107, Q108, Q109, Q110, Q111, Q112, Q113, Q114, Q115, Q116, Q117, Q118, Q119, Q120, Q121, Q122, Q123, Q124, Q125, Q126, Q127, Q128, Q129, Q130, Q131, Q132, Q133, Q134, Q135, Q136,
Q137, Q138, Q139, Q140, Q141 , Q142, Q143, Q144, Q145, Q146, Q147, Q148, Q149, Q150, Q151 , Q152, Q153 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, hete- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" und wobei alternativ Q108, Q109 und/oder Q117, Q1 18 und/oder Q130, Q131 und/oder Q137, Q138 und/oder Q146, Q147 jeweils zusammen auch „heterocyclyl" bilden können;Q137, Q138, Q139, Q140, Q141, Q142, Q143, Q144, Q145, Q146, Q147, Q148, Q149, Q150, Q151, Q152, Q153 are independently selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and where alternatively Q108, Q109 and / or Q117, Q1 18 and / or Q130, Q131 and / or Q137, Q138 and / or Q146, Q147 may together also form "heterocyclyl";
(b) „(C9-C3o)alkyl, -C(O)-QI 54, -C(O)O-QI 55, -C(O)-NQI 56Q157, -S(O2)-(b) "(C 9 -C 3 O) alkyl, -C (O) -qi 54, -C (O) O-QI 55, -C (O) -NQI 56Q157, -S (O 2) -
Q158, -S(O2)O-QI 59"; wobei Q154, Q155, Q156, Q157, Q158, Q159 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „Wasserstoff, alkyl, (C9- C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q156, Q157 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (b) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe be- stehend aus:Q158, -S (O 2) O-QI 59 "; said Q154, Q155, Q156, Q157, Q158, Q159 are independently selected from the group consisting of" hydrogen, alkyl, (C 9 - C 3 o) alkyl , cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively Q156, Q157 may together also form" heterocyclyl "wherein optionally substituted substituents of substituent group (b) may in turn be independently substituted with at least one substituent , the same or different, selected from the group consisting of:
(i) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ160, -NQ161Q162, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-QI 63, -C(O)O-QI 64, -C(O)NH-QI 65, -C(O)NQI 66Q167, - O-Q168, -O(-Q169-O)t-H (t = 1 , 2, 3, 4, 5), -O(-Q170-O)t-Q171 (t = 1 , 2, 3, 4, 5), -OC(O)-QI 72, -OC(O)-O-QI 73, -OC(O)-NHQI 74, - 0-C(O)-NQI 75Q176, -OP(O)(OQI 77)(OQ178), -(i) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHQ160, -NQ161Q162, -NO 2 , -OH, -OCF 3 , -SH, -O- SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -QI 63, -C (O) O -QI 64, -C (O) NH-QI 65, -C (O) NQI 66Q167, -O-Q168, -O (-Q169-O) t -H (t = 1 , 2, 3, 4, 5), -O (-Q170-O) t -Q171 (t = 1, 2, 3, 4, 5), -OC (O) -QI 72, -OC (O) - O-QI 73, -OC (O) -NHQI 74, 0-C (O) -NQI 75Q176, -OP (O) (OQI 77) (OQ178),
OSi(QI 79)(Q180)(Q181 ), -OS(O2)-Q182, -NHC(O)-QI 83, - NQ184C(O)-QI 85, -NH-C(O)-O-QI 86, -NH-C(O)-NH-QI 87, - NH-C(O)-NQI 88Q189, -NQ190-C(O)-O-QI 91 , -NQ192-C(O)-NH- Q193, -NQ194-C(O)-NQI 95Q196, -NHS(O2)-Q197, -NQ198S(O2)- Q199, -S-Q200, -S(O)-Q201 , -S(O2)-Q202, -S(O2)NH-Q203, -OSi (QI 79) (Q180) (Q181), -OS (O 2) -Q182, -NHC (O) -qi 83 - NQ184C (O) -qi 85, -NH-C (O) -O-QI 86, -NH-C (O) -NH-QI 87, -NH-C (O) -NQI 88Q189, -NQ190-C (O) -O-QI 91, -NQ192-C (O) -NH-Q193 , -NQ194-C (O) -NQI 95Q196, -NHS (O 2) -Q197, -NQ198S (O 2) - Q199, Q200 -S-, -S (O) -Q201, -S (O 2) - Q 2 O 2 , -S (O 2 ) NH-Q 2 O 3, -
S(O2)NQ204Q205, -S(O2)O-Q206, -P(O)(OQ207)(OQ208), - Si(Q209)(Q210)(Q21 1 )"; wobei Q160, Q161 , Q162, Q163, Q164, Q165, Q166, Q167, Q168, Q169, Q170, Q171 , Q172, Q173, Q174, Q175, Q176, Q177, Q178, Q179, Q180, Q181 , Q182, Q183, Q184, Q185, Q186, Q187, Q188,S (O 2) NQ204Q205, -S (O 2) O-Q206, -P (O) (OQ207) (OQ208), - Si (Q209) (Q210) (Q21 1) "; wherein Q160, Q161, Q162, Q163, Q164, Q165, Q166, Q167, Q168, Q169, Q170, Q171, Q172, Q173, Q174, Q175, Q176, Q177, Q178, Q179, Q180, Q181, Q182, Q183, Q184, Q185, Q186, Q187, Q188,
Q189, Q190, Q191 , Q192, Q193, Q194, Q195, Q196, Q197, Q198, Q199, Q200, Q201 , Q202, Q203, Q204, Q205, Q206, Q207, Q208, Q209, Q210, Q21 1 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ Q166, Q167 und/oder Q175, Q176 und/oder Q188, Q189 und/oder Q195, Q196 und/oder Q204, Q205 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wie- derum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Q189, Q190, Q191, Q192, Q193, Q194, Q195, Q196, Q197, Q198, Q199, Q200, Q201, Q202, Q203, Q204, Q205, Q206, Q207, Q208, Q209, Q210, Q21 1 are independently selected from the group consisting of: "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and where alternatively Q166, Q167 and / or Q175, Q176 and / or Q188, Q189 and / or Q195, Q196 and / or Q204, Q205 may each together also form "heterocyclyl"; in which optionally above substituents of the substituent group (i) can in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ212, -NQ213Q214, -NO2, -OH, -OCF3,(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ212, -NQ213Q214, -NO 2 , -OH, -OCF 3 ,
-SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, - SO3H, -P(O)(OH)2, -C(O)-Q215, -C(O)O-Q216, -C(O)NH-Q217, -C(O)NQ218Q219, -O-Q220, -O(-Q221-O)u-H (u = 1 , 2, 3, 4, 5), -O(-Q222-O)u-Q223 (u = 1 , 2, 3, 4, 5), -OC(O)-Q224, - OC(O)-O-Q225, -OC(O)-NHQ226, -O-C(O)-NQ227Q228, - OP(O)(OQ229)(OQ230), -OSi(Q231 )(Q232)(Q233), -OS(O2)- Q234, -NHC(O)-Q235, -NQ236C(O)-Q237, -NH-C(O)-O-Q238, -NH-C(O)-NH-Q239, -NH-C(O)-NQ240Q241 , -NQ242-C(O)--SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , - C (O) -Q215, -C (O) O-Q216, -C (O) NH-Q217, -C (O) NQ218Q219, -O-Q220, -O (-Q221-O) u -H (u = 1, 2, 3, 4, 5), -O (-Q222-O) u -Q223 (u = 1, 2, 3, 4, 5), -OC (O) -Q224, - OC (O) -O-Q225, -OC (O) -NHQ226, -OC (O) -NQ227Q228, - OP (O) (OQ229) (OQ230), -OSi (Q231) (Q232) (Q233), OS (O 2) - Q234, -NHC (O) -Q235, -NQ236C (O) -Q237, -NH-C (O) -O-Q238, -NH-C (O) -NH-Q239, -NH -C (O) -NQ240Q241, -NQ242-C (O) -
5 O-Q243, -NQ244-C(O)-NH-Q245, -NQ246-C(O)-NQ247Q248,5 O-Q243, -NQ244-C (O) -NH-Q245, -NQ246-C (O) -NQ247Q248,
-NHS(O2)-Q249, -NQ250S(O2)-Q251 , -S-Q252, -S(O)-Q253, - S(O2)-Q254, -S(O2)N H-Q255, -S(O2)NQ256Q257, -S(O2)O- Q258, -P(O)(OQ259)(OQ260), -Si(Q261 )(Q262)(Q263)"; wobei Q212, Q213, Q214, Q215, Q216, Q217, Q218, Q219, Q220, 10 Q221 , Q222, Q223, Q224, Q225, Q226, Q227, Q228, Q229,-NHS (O 2) -Q249, -NQ250S (O 2) -Q251, -S-Q252, -S (O) -Q253, - S (O 2) -Q254, -S (O 2) N H-Q255 , -S (O 2) NQ256Q257, -S (O 2) O- Q258, -P (O) (OQ259) (OQ260), -Si (Q261) (Q262) (Q263) "; wherein Q212, Q213, Q214 , Q215, Q216, Q217, Q218, Q219, Q220, 10 Q221, Q222, Q223, Q224, Q225, Q226, Q227, Q228, Q229,
Q230, Q231 , Q232, Q233, Q234, Q235, Q236, Q237, Q238, Q239, Q240, Q241 , Q242, Q243, Q244, Q245, Q246, Q247, Q248, Q249, Q250, Q251 , Q252, Q253, Q254, Q255, Q256, Q257, Q258, Q259, Q260, Q261 , Q262, Q263 unabhängig von-Q230, Q231, Q232, Q233, Q234, Q235, Q236, Q237, Q238, Q239, Q240, Q241, Q242, Q243, Q244, Q245, Q246, Q247, Q248, Q249, Q250, Q251, Q252, Q253, Q254, Q255, Q256, Q257, Q258, Q259, Q260, Q261, Q262, Q263 independently of-
15 einander ausgewählt sind aus der Gruppe bestehend aus: „alkyl,15 are selected from the group consisting of: "alkyl,
(C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q218, Q219 und/oder Q227, Q228 und/oder Q240, Q241 und/oder Q247, Q248 und/oder Q256, Q257 jeweils zusammen 20 auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively Q218, Q219 and / or Q227, Q228 and / or Q240, Q241 and / or Q247 Q248 and / or Q256, Q257 may each together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
25 (iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ264, -NQ265Q266, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q267, -C(O)O-Q268, -25 (iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ 264, -NQ 2 65Q 266, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O ) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q267, -C (O) O-Q 268, -
30 C(O)N H-Q269, -C(O)NQ270Q271 , -O-Q272, -O(-Q273-30 C (O) N H-Q269, -C (O) NQ270Q271, -O-Q272, -O (-Q273-
O)v-H (v = 1 , 2, 3, 4, 5), -O(-Q274-O)v-Q275 (v = 1 , 2, 3, 4, 5), -OC(O)-Q276, -OC(O)-O-Q277, -OC(O)-NHQ278, -O- C(O)-NQ279Q280, -OP(O)(OQ281 )(OQ282), - OSi(Q283)(Q284)(Q285), -OS(O2)-Q286, -NHC(O)-Q287, - NQ288C(O)-Q289, -NH-C(O)-O-Q290, -NH-C(O)-NH- Q291 , -NH-C(O)-NQ292Q293, -NQ294-C(O)-O-Q295, - NQ296-C(O)-NH-Q297, -NQ298-C(O)-NQ299Q300, - NHS(O2)-Q301 , -NQ302S(O2)-Q303, -S-Q304, -S(O)-Q305, -S(O2)-Q306, -S(O2)NH-Q307, -S(O2)NQ308Q309, -O) v -H (v = 1, 2, 3, 4, 5), -O (-Q274-O) v -Q275 (v = 1, 2, 3, 4, 5), -OC (O) - Q276, -OC (O) -O-Q277, -OC (O) -NHQ278, -O- C (O) -NQ279Q280, -OP (O) (OQ281) (OQ282), -OSi (Q283) (Q284) (Q285), -OS (O 2) -Q286, -NHC (O) -Q287, - NQ288C (O) -Q289, -NH-C (O) -O-Q290, -NH-C (O) -NH-Q291, -NH-C (O) -NQ292Q293, -NQ294-C (O) -O -Q295, - NQ296-C (O) -NH-Q297, -NQ298-C (O) -NQ299Q300, - NHS (O 2) -Q301, -NQ302S (O 2) -Q303, -S-Q304, -S (O) -Q305, -S (O 2) -Q306, -S (O 2) NH-Q307, -S (O 2) NQ308Q309, -
S(O2)O-Q310, -P(O)(OQ311 )(OQ312), - Si(Q313)(Q314)(Q315)"; wobei Q264, Q265, Q266, Q267, Q268, Q269, Q270, Q271 , Q272, Q273, Q274, Q275, Q276, Q277, Q278, Q279, Q280, Q281 , Q282, Q283, Q284, Q285, Q286, Q287, Q288, Q289,S (O 2 ) O-Q310, -P (O) (OQ311) (OQ312), -Si (Q313) (Q314) (Q315) "; wherein Q264, Q265, Q266, Q267, Q268, Q269, Q270, Q271 , Q272, Q273, Q274, Q275, Q276, Q277, Q278, Q279, Q280, Q281, Q282, Q283, Q284, Q285, Q286, Q287, Q288, Q289,
Q290, Q291 , Q292, Q293, Q294, Q295, Q296, Q297, Q298, Q299, Q300, Q301 , Q302, Q303, Q304, Q305, Q306, Q307, Q308, Q309, Q310, Q31 1 , Q312, Q313, Q314, Q315 unabhängig voneinander ausgewählt sind aus der Gruppe beste- hend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, hete- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" und wobei alternativ Q270, Q271 und/oder Q279, Q280 und/oder Q292, Q293 und/oder Q299, Q300 und/oder Q308, Q309 jeweils zusammen auch „heterocyclyl" bilden können;Q290, Q291, Q292, Q293, Q294, Q295, Q296, Q297, Q298, Q299, Q300, Q301, Q302, Q303, Q304, Q305, Q306, Q307, Q308, Q309, Q310, Q31 1, Q312, Q313, Q314 are Q315 independently selected from the group consist- ing of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" and wherein alternatively Q270 , Q271 and / or Q279, Q280 and / or Q292, Q293 and / or Q299, Q300 and / or Q308, Q309 may together also form "heterocyclyl";
oder einer der Reste Z10, Z1 1 oder keiner der Reste Z10, Z11 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:or one of the radicals Z10, Z1 1 or none of the radicals Z10, Z11 are selected independently of one another from the group consisting of:
(c) „Wasserstoff, alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -C(O)-Q316, - C(O)O-Q317, -C(O)-NQ318Q319, -S(O2)-Q320, -S(O2)O-Q321"; wobei Q316, Q317, Q318, Q319, Q320, Q321 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „Wasserstoff, alkyl, (Cg- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q318, Q319 zu- sammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (c), wenn nicht Wasserstoff, wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(c) "hydrogen, alkyl, (C" 9 " -C" 30 " ) alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -C (O) -Q316, -C (O) O-Q317, -C (O) -NQ318Q319, -S (O 2) -Q320, -S (O 2) O-Q321 "; wherein Q316, Q317, Q318, Q319, Q320 are, Q321 independently selected from the group consisting of: "alkyl hydrogen, alkyl, (Cg-C 30) cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively Q318, Q319 together can also form "heterocyclyl"; wherein optionally above substituents of Substituent group (c), if not hydrogen, in turn be substituted independently of one another may be substituted by at least one substituent, the same or different, selected from the group consisting of:
(i) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ322, -NQ323Q324, -NO2, -OH, -OCF3, -SH, -O-(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ322, -NQ323Q324, -NO 2 , -OH, -OCF 3 , -SH, -O-
SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q325, -C(O)O-Q326, -C(O)NH-Q327, -C(O)NQ328Q329, - O-Q330, -O(-Q331-O)w-H (w = 1 , 2, 3, 4, 5), -O(-Q332-O)w-Q333 (w = 1 , 2, 3, 4, 5), -OC(O)-Q334, -OC(O)-O-Q335, -OC(O)- NHQ336, -O-C(O)-NQ337Q338, -OP(O)(OQ339)(OQ340), -SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q325 , -C (O) O-Q326, -C (O) NH-Q327, -C (O) NQ328Q329, -O-Q330, -O (-Q331-O) w -H (w = 1, 2, 3 , 4, 5), -O (-Q332-O) w -Q333 (w = 1, 2, 3, 4, 5), -OC (O) -Q334, -OC (O) -O-Q335, - OC (O) -NHQ336, -OC (O) -NQ337Q338, -OP (O) (OQ339) (OQ340),
OSi(Q341 )(Q342)(Q343), -OS(O2)-Q344, -NHC(O)-Q345, - NQ346C(O)-Q347, -NH-C(O)-O-Q348, -N H-C(O)-N H-Q349, - NH-C(O)-NQ350Q351 , -NQ352-C(O)-O-Q353, -NQ354-C(O)-NH- Q355, -NQ356-C(O)-NQ357Q358, -NHS(O2)-Q359, -NQ360S(O2)- Q361 , -S-Q362, -S(O)-Q363, -S(O2)-Q364, -S(O2)NH-Q365, -OSi (Q341) (Q342) (Q343), -OS (O 2) -Q344, -NHC (O) -Q345, - NQ346C (O) -Q347, -NH-C (O) -O-Q348, -N HC (O) -N H-Q349, -NH-C (O) -NQ350Q351, -NQ352-C (O) -O-Q353, -NQ354-C (O) -NH-Q355, -NQ356-C (O ) -NQ357Q358, -NHS (O 2) -Q359, -NQ360S (O 2) - Q361, Q362 -S-, -S (O) -Q363, -S (O 2) -Q364, -S (O 2) NH-Q365, -
S(O2)NQ366Q367, -S(O2)O-Q368, -P(O)(OQ369)(OQ370), - Si(Q371 )(Q372)(Q373)"; wobei Q322, Q323, Q324, Q325, Q326, Q327, Q328, Q329, Q330, Q331 , Q332, Q333, Q334, Q335, Q336, Q337, Q338, Q339, Q340, Q341 , Q342, Q343, Q344, Q345, Q346, Q347, Q348, Q349, Q350,S (O 2) NQ366Q367, -S (O 2) O-Q368, -P (O) (OQ369) (OQ370), - Si (Q371) (Q372) (Q373) "; wherein Q322, Q323, Q324, Q325 , Q326, Q327, Q328, Q329, Q330, Q331, Q332, Q333, Q334, Q335, Q336, Q337, Q338, Q339, Q340, Q341, Q342, Q343, Q344, Q345, Q346, Q347, Q348, Q349, Q350 .
Q351 , Q352, Q353, Q354, Q355, Q356, Q357, Q358, Q359, Q360, Q361 , Q362, Q363, Q364, Q365, Q366, Q367, Q368, Q369, Q370, Q371 , Q372, Q373 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q328, Q329 und/oder Q337, Q338 und/oder Q350, Q351 und/oder Q357, Q358 und/oder Q366, Q367 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wie- derum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Q351, Q352, Q353, Q354, Q355, Q356, Q357, Q358, Q359, Q360, Q361, Q362, Q363, Q364, Q365, Q366, Q367, Q368, Q369, Q370, Q371, Q372, Q373 are selected independently from each other the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively Q328, Q329 and / or Q337, Q338 and / or Q350, Q351 and / or Q357, Q358 and / or Q366, Q367 may together also form "heterocyclyl"; in which optionally above substituents of the substituent group (i) can in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ374, -NQ375Q376, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, - SO3H, -P(O)(OH)2, -C(O)-Q377, -C(O)O-Q378, -C(O)NH-Q379, -C(O)NQ380Q381 , -O-Q382, -0(-0383-O)x-H (x = 1 , 2, 3, 4, 5),(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHQ374, -NQ375Q376, -NO 2, -OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2, -CHO , -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q377, -C (O) O-Q 378, -C (O) NH -Q379, -C (O) NQ380Q381, -O-Q382, -O (-0383-O) x -H (x = 1, 2, 3, 4, 5),
5 -O(-Q384-O)x-Q385 (x = 1 , 2, 3, 4, 5), -OC(O)-Q386, -OC(O)-5 -O (-Q384-O) x -Q385 (x = 1, 2, 3, 4, 5), -OC (O) -Q386, -OC (O) -
O-Q387, -OC(O)-N HQ388, -O-C(O)-NQ389Q390, - OP(O)(OQ391 )(OQ392), -OSi(Q393)(Q394)(Q395), -OS(O2)- Q396, -NHC(O)-Q397, -NQ398C(O)-Q399, -NH-C(O)-O-Q400, -N H-C(O)-N H-Q401 , -NH-C(O)-NQ402Q403, -NQ404-C(O)-O-Q387, -OC (O) -N HQ388, -OC (O) -NQ389Q390, - OP (O) (OQ391) (OQ392), -OSi (Q393) (Q394) (Q395), -OS (O 2 ) - Q396, -NHC (O) -Q397, -NQ398C (O) -Q399, -NH-C (O) -O-Q400, -NHC (O) -NH-Q401, -NH-C (O ) -NQ402Q403, -NQ404-C (O) -
10 O-Q405, -NQ406-C(O)-NH-Q407, -NQ408-C(O)-NQ409Q410,10 O-Q405, -NQ406-C (O) -NH-Q407, -NQ408-C (O) -NQ409Q410,
-NHS(O2)-Q41 1 , -NQ412S(O2)-Q413, -S-Q414, -S(O)-Q415, - S(O2)-Q416, -S(O2)NH-Q417, -S(O2)NQ418Q419, -S(O2)O- Q420, -P(O)(OQ421 )(OQ422), -Si(Q423)(Q424)(Q425)"; wobei Q374, Q375, Q376, Q377, Q378, Q379, Q380, Q381 , Q382, 15 Q383, Q384, Q385, Q386, Q387, Q388, Q389, Q390, Q391 ,-NHS (O 2) -Q41 1, -NQ412S (O 2) -Q413, -S-Q414, -S (O) -Q415, - S (O 2) -Q416, -S (O 2) NH-Q417 , -S (O 2) NQ418Q419, -S (O 2) O- Q420, -P (O) (OQ421) (OQ422), -Si (Q423) (Q424) (Q425) "; wherein Q374, Q375, Q376 , Q377, Q378, Q379, Q380, Q381, Q382, Q383, Q384, Q385, Q386, Q387, Q388, Q389, Q390, Q391,
Q392, Q393, Q394, Q395, Q396, Q397, Q398, Q399, Q400, Q401 , Q402, Q403, Q404, Q405, Q406, Q407, Q408, Q409, Q410, Q411 , Q412, Q413, Q414, Q415, Q416, Q417, Q418, Q419, Q420, Q421 , Q422, Q423, Q424, Q425 unabhängig von-Q392, Q393, Q394, Q395, Q396, Q397, Q398, Q399, Q400, Q401, Q402, Q403, Q404, Q405, Q406, Q407, Q408, Q409, Q410, Q411, Q412, Q413, Q414, Q415, Q416, Q417, Q418, Q419, Q420, Q421, Q422, Q423, Q424, Q425 regardless of-
20 einander ausgewählt sind aus der Gruppe bestehend aus: „alkyl,20 are selected from the group consisting of: "alkyl,
(Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q380, Q381 und/oder Q389, Q390 und/oder Q402, Q403 und/oder Q409, Q410 und/oder Q418, Q419 jeweils zusammen 25 auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and, alternatively, Q380, Q381 and / or Q389, Q390 and / or Q402, Q403 and / or Q409, Q410 and / or Q418, Q419 may together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
30 (iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ426, -NQ427Q428, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q429, -C(O)O-Q430, - C(O)NH-Q431 , -C(O)NQ432Q433, -O-Q434, -O(-Q435- O)y-H (y = 1 , 2, 3, 4, 5), -O(-Q436-O)y-Q437 (y = 1 , 2, 3, 4, 5), -OC(O)-Q438, -OC(O)-O-Q439, -OC(O)-N HQ440, -O- C(O)-NQ441Q442, -OP(O)(OQ443)(OQ444), - OSi(Q445)(Q446)(Q447), -OS(O2)-Q448, -NHC(O)-Q449, -30 (iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2, -NHQ426, -NQ427Q428, -NO 2, -OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2, -CHO, -COOH, - C (O ) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q 4 29, -C (O) O-Q 430, C (O) NH-Q431, -C (O) NQ432Q433, -O-Q434, -O (-Q435-O) y -H (y = 1, 2, 3, 4, 5), -O (-Q436 -O) y -Q437 (y = 1, 2, 3, 4, 5), -OC (O) -Q438, -OC (O) -O-Q439, -OC (O) -N HQ440, -O- C (O) -NQ441Q442, -OP (O) (OQ443) (OQ444), - OSi (Q445) (Q446) (Q447), -OS (O 2) -Q448, -NHC (O) -Q449, -
NQ450C(O)-Q451 , -NH-C(O)-O-Q452, -NH-C(O)-NH- Q453, -NH-C(O)-NQ454Q455, -NQ456a-C(O)-O-Q456b, - NQ456c-C(O)-NH-Q456d, -NQ456e-C(O)-NQ456fQ456g, - NHS(O2)-Q456h, -NQ456iS(O2)-Q456j, -S-Q456k, -S(O)- Q456I, -S(O2)-Q456m, -S(O2)NH-Q456n, -NQ450C (O) -Q451, -NH-C (O) -O-Q452, -NH-C (O) -NH-Q453, -NH-C (O) -NQ454Q455, -NQ456a-C (O) -O -Q456b, - NQ456c-C (O) -NH-Q456d, -NQ456e-C (O) -NQ456fQ456g, - NHS (O 2) -Q456h, -NQ456iS (O 2) -Q456j, -S-Q456k, -S (O) - Q456I, is -S (O 2) -Q456m. -S (O 2) NH-Q456n -
S(O2)NQ456oQ456p, -S(O2)O-Q456q, - P(O)(OQ456r)(OQ456s), -Si(Q456t)(Q456u)(Q456v)"; wobei Q426, Q427, Q428, Q429, Q430, Q431 , Q432, Q433, Q434, Q435, Q436, Q437, Q438, Q439, Q440, Q441 , Q442, Q443, Q444, Q445, Q446, Q447, Q448, Q449, Q450, Q451 ,S (O 2) NQ456oQ456p, -S (O 2) O-Q456q, - P (O) (OQ456r) (OQ456s), -Si (Q456t) (Q456u) (Q456v) "; wherein Q426, Q427, Q428, Q429 , Q430, Q431, Q432, Q433, Q434, Q435, Q436, Q437, Q438, Q439, Q440, Q441, Q442, Q443, Q444, Q445, Q446, Q447, Q448, Q449, Q450, Q451,
Q452, Q453, Q454, Q455, Q456a, Q456b, Q456c, Q456d, Q456e, Q456f, Q456g, Q456h, Q456i, Q456J, Q456k, Q456I, Q456m, Q456n, Q456o, Q456p, Q456q, Q456r, Q456s, Q456t, Q456u, Q456v unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q432, Q433 und/oder Q441 , Q442 und/oder Q454, Q455 und/oder Q456f, Q456g und/oder Q456o, Q456p jeweils zusammen auch „hete- rocyclyl" bilden können;Q452, Q453, Q454, Q456, Q456a, Q456b, Q456c, Q456d, Q456e, Q456f, Q456g, Q456h, Q456i, Q456J, Q456k, Q456I, Q456m, Q456n, Q456o, Q456p, Q456q, Q456r, Q456s, Q456t, Q456u, Q456v are independently selected from the group consisting of: "alkyl, (C 9 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively Q432, Q433 and / or Q441, Q442 and / or Q454, Q455 and / or Q456f, Q456g and / or Q456o, Q456p may each together also form "heterocyclyl";
und einer der Reste Z3, Z4 oder keiner der Reste Z3, Z4 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus:and one of Z3, Z4 or none of Z3, Z4 is independently selected from the group consisting of:
(d) Wasserstoff; (e) Halogen, F, Cl, Br, I;(d) hydrogen; (e) halogen, F, Cl, Br, I;
(f) unsubstituiertes oder substituiertes Alkyl oder (Cg-C3o)Alkyl, wobei optional der Alkyl- oder (C9-C30 )Alkylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(f) unsubstituted or substituted alkyl or (Cg-C3o) alkyl, optionally wherein said alkyl or (C 9 -C 30) alkyl group may be substituted with at least a substituent, the same or different, selected from the group consisting of:
(i) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ457, -NQ458Q459, -NO2, -OH, -OCF3, -SH, -O-(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ457, -NQ458Q459, -NO 2 , -OH, -OCF 3 , -SH, -O-
SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q460, -C(O)O-Q461 , -C(O)NH-Q462, -C(O)NQ463Q464, - O-Q465, -O(-Q466-O)z-H (z = 1 , 2, 3, 4, 5), -O(-Q467-O)z-Q468 (z = 1 , 2, 3, 4, 5), -OC(O)-Q469, -OC(O)-O-Q470, -OC(O)-N HQ471 , - O-C(O)-NQ472Q473, -OP(O)(OQ474)(OQ475), -SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q460 , -C (O) O-Q461, -C (O) NH-Q462, -C (O) NQ463Q464, -O-Q465, -O (-Q466-O) z -H (z = 1, 2, 3 , 4, 5), -O (-Q467-O) z -Q468 (z = 1, 2, 3, 4, 5), -OC (O) -Q469, -OC (O) -O-Q470, - OC (O) -N HQ471, - OC (O) -NQ472Q473, -OP (O) (OQ474) (OQ475),
OSi(Q476)(Q477)(Q478), -OS(O2)-Q479, -NHC(O)-Q480, - NQ481C(O)-Q482, -NH-C(O)-O-Q483, -N H-C(O)-N H-Q484, - NH-C(O)-NQ485Q486, -NQ487-C(O)-O-Q488, -NQ489-C(O)-NH- Q490, -NQ491-C(O)-NQ492Q493, -NHS(O2)-Q494, -NQ495S(O2)- Q496, -S-Q497, -S(O)-Q498, -S(O2)-Q499, -S(O2)NH-Q500, -OSi (Q476) (Q477) (Q478), -OS (O 2) -Q479, -NHC (O) -Q480, - NQ481C (O) -Q482, -NH-C (O) -O-Q483, -N HC (O) -N H-Q484, -NH-C (O) -NQ485Q486, -NQ487-C (O) -O-Q488, -NQ489-C (O) -NH-Q490, -NQ491-C (O ) -NQ492Q493, -NHS (O 2) -Q494, -NQ495S (O 2) - Q496, Q497 -S-, -S (O) -Q498, -S (O 2) -Q499, -S (O 2) NH-Q500, -
S(O2)NQ501Q502, -S(O2)O-Q503, -P(O)(OQ504)(OQ505), - Si(Q506)(Q507)(Q508)"; wobei Q457, Q458, Q459, Q460, Q461 , Q462, Q463, Q464, Q465, Q466, Q467, Q468, Q469, Q470, Q471 , Q472, Q473, Q474, Q475, Q476, Q477, Q478, Q479, Q480, Q481 , Q482, Q483, Q484, Q485,S (O 2) NQ501Q502, -S (O 2) O-Q503, -P (O) (OQ504) (OQ505), - Si (Q506) (Q507) (Q508) "; wherein Q457, Q458, Q459, Q460 , Q461, Q462, Q463, Q464, Q465, Q466, Q467, Q468, Q469, Q470, Q471, Q472, Q473, Q474, Q475, Q476, Q477, Q478, Q479, Q480, Q481, Q482, Q483, Q484, Q485 .
Q486, Q487, Q488, Q489, Q490, Q491 , Q492, Q493, Q494, Q495, Q496, Q497, Q498, Q499, Q500, Q501 , Q502, Q503, Q504, Q505, Q506, Q507, Q508 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q463, Q464 und/oder Q472, Q473 und/oder Q485, Q486 und/oder Q492, Q493 und/oder Q501 , Q502 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wie- derum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Q486, Q487, Q488, Q489, Q490, Q491, Q492, Q493, Q494, Q495, Q496, Q497, Q498, Q499, Q500, Q501, Q502, Q503, Q504, Q505, Q506, Q507, Q508 are independently selected the group consisting of: "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively Q463, Q464 and / or Q472, Q473 and / or Q485, Q486 and / or Q492, Q493 and / or Q501, Q502 may together also form "heterocyclyl"; in which optionally above substituents of the substituent group (i) can in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ509, -NQ510Q511 , -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, - SO3H, -P(O)(OH)2, -C(O)-Q512, -C(O)O-Q513, -C(O)NH-Q514, -C(O)NQ515Q516, -O-Q517, -O (-0518-O)3-H (a = 1 , 2, 3, 4, 5 5), -0(-Q519-O)a-Q520 (a = 1 , 2, 3, 4, 5), -OC(O)-Q521 , -(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHQ509, -NQ510Q511, -NO 2, -OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2, -CHO , -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q 5 12, -C (O) O-Q 513, -C (O) NH -Q514, -C (O) NQ515Q516, -O-Q517, -O (-0518-O) 3 -H (a = 1, 2, 3, 4, 5, 5), -O (-Q519-O) a -Q520 (a = 1, 2, 3, 4, 5), -OC (O) -Q521, -
OC(O)-O-Q522, -OC(O)-NHQ523, -O-C(O)-NQ524Q525, - OP(O)(OQ526)(OQ527), -OSi(Q528)(Q529)(Q530), -OS(O2)- Q531 , -NHC(O)-Q532, -NQ533C(O)-Q534, -NH-C(O)-O-Q535, -NH-C(O)-NH-Q536, -NH-C(O)-NQ537Q538, -NQ539-C(O)-OC (O) -O-Q522, -OC (O) -NHQ523, -OC (O) -NQ524Q525, - OP (O) (OQ526) (OQ527), -OSi (Q528) (Q529) (Q530), OS (O 2 ) -Q531, -NHC (O) -Q532, -NQ533C (O) -Q534, -NH-C (O) -O-Q535, -NH-C (O) -NH-Q536, -NH -C (O) -NQ537Q538, -NQ539-C (O) -
10 O-Q540, -NQ541 -C(O)-N H-Q542, -NQ543-C(O)-NQ544Q545,10 O-Q540, -NQ541 -C (O) -NH-Q542, -NQ543-C (O) -NQ544Q545,
-NHS(O2)-Q546, -NQ547S(O2)-Q548, -S-Q549, -S(O)-Q550, - S(O2)-Q551 , -S(O2)N H-Q552, -S(O2)NQ553Q554, -S(O2)O- Q555, -P(O)(OQ556)(OQ557), -Si(Q558)(Q559)(Q560)"; wobei Q509, Q510, Q511 , Q512, Q513, Q514, Q515, Q516, Q517, 15 Q518, Q519, Q520, Q521 , Q522, Q523, Q524, Q525, Q526,-NHS (O 2) -Q546, -NQ547S (O 2) -Q548, -S-Q549, -S (O) -Q550, - S (O 2) -Q551, -S (O 2) N H-Q552 , -S (O 2 ) NQ553Q554, -S (O 2 ) O -Q555, -P (O) (OQ556) (OQ557), -Si (Q558) (Q559) (Q560) "; wherein Q509, Q510, Q511 , Q512, Q513, Q514, Q515, Q516, Q517, 15 Q518, Q519, Q520, Q521, Q522, Q523, Q524, Q525, Q526,
Q527, Q528, Q529, Q530, Q531 , Q532, Q533, Q534, Q535, Q536, Q537, Q538, Q539, Q540, Q541 , Q542, Q543, Q544, Q545, Q546, Q547, Q548, Q549, Q550, Q551 , Q552, Q553, Q554, Q555, Q556, Q557, Q558, Q559, Q560 unabhängig von-Q527, Q528, Q529, Q530, Q531, Q532, Q533, Q534, Q535, Q536, Q537, Q538, Q539, Q540, Q541, Q542, Q543, Q544, Q545, Q546, Q547, Q548, Q549, Q550, Q551, Q552, Q553, Q554, Q555, Q556, Q557, Q558, Q559, Q560 independently of-
20 einander ausgewählt sind aus der Gruppe bestehend aus: „alkyl,20 are selected from the group consisting of: "alkyl,
(Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q515, Q516 und/oder Q524, Q525 und/oder Q537, Q538 und/oder Q544, Q545 und/oder Q553, Q554 jeweils zusammen 25 auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and, alternatively, Q515, Q516 and / or Q524, Q525 and / or Q537, Q538 and / or Q544, Q545 and / or Q553, Q554 may together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
30 (iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ561 , -NQ562Q563, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q564, -C(O)O-Q565, - C(O)N H-Q566, -C(O)NQ567Q568, -O-Q569, -O(-Q570- O)b-H (b = 1 , 2, 3, 4, 5), -O(-Q571-O)b-Q572 (b = 1 , 2, 3, 4, 5), -OC(O)-Q573, -OC(O)-O-Q574, -OC(O)-N HQ575, -O- C(O)-NQ576Q577, -OP(O)(OQ578)(OQ579), - OSi(Q580)(Q581 )(Q582), -OS(O2)-Q583, -NHC(O)-Q584, -30 (iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ561, -NQ562Q563, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q564, -C (O) O-Q565, C (O) N H -Q566, -C (O) NQ567Q568, -O-Q569, -O (-Q570-O) b -H (b = 1, 2, 3, 4, 5), -O (-) Q571-O) b -Q572 (b = 1, 2, 3, 4, 5), -OC (O) -Q573, -OC (O) -O-Q574, -OC (O) -N HQ575, -O - C (O) -NQ576Q577, -OP (O) (OQ578) (OQ579), - OSi (Q580) (Q581) (Q582), -OS (O 2) -Q583, -NHC (O) -Q584, -
NQ585C(O)-Q586, -NH-C(O)-O-Q587, -NH-C(O)-NH- Q588, -NH-C(O)-NQ589Q590, -NQ591-C(O)-O-Q592, - NQ593-C(O)-NH-Q594, -NQ595-C(O)-NQ596Q597, - NHS(O2)-Q598, -NQ599S(O2)-Q600, -S-Q601 , -S(O)-Q602, -S(O2)-Q603, -S(O2)NH-Q604, -S(O2)NQ605Q606, -NQ585C (O) -Q586, -NH-C (O) -O-Q587, -NH-C (O) -NH-Q588, -NH-C (O) -NQ589Q590, -NQ591-C (O) -O -Q592, - NQ593-C (O) -NH-Q594, -NQ595-C (O) -NQ596Q597, - NHS (O 2) -Q598, -NQ599S (O 2) -Q600, -S-Q601, -S (O) -Q602, -S (O 2) -Q603, -S (O 2) NH-Q604, -S (O 2) NQ605Q606, -
S(O2)O-Q607, -P(O)(OQ608)(OQ609), - Si(Q610)(Q611 )(Q612)"; wobei Q561 , Q562, Q563, Q564, Q565, Q566, Q567, Q568, Q569, Q570, Q571 , Q572, Q573, Q574, Q575, Q576, Q577, Q578, Q579, Q580, Q581 , Q582, Q583, Q584, Q585, Q586,S (O 2 ) O-Q607, -P (O) (OQ608) (OQ609), -Si (Q610) (Q611) (Q612) "; where Q561, Q562, Q563, Q564, Q565, Q566, Q567, Q568 , Q569, Q570, Q571, Q572, Q573, Q574, Q575, Q576, Q577, Q578, Q579, Q580, Q581, Q582, Q583, Q584, Q585, Q586,
Q587, Q588, Q589, Q590, Q591 , Q592, Q593, Q594, Q595, Q596, Q597, Q598, Q599, Q600, Q601 , Q602, Q603, Q604, Q605, Q606, Q607, Q608, Q609, Q610, Q611 , Q612 unabhängig voneinander ausgewählt sind aus der Gruppe beste- hend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, hete- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" und wobei alternativ Q567, Q568 und/oder Q576, Q577 und/oder Q589, Q590 und/oder Q596, Q597 und/oder Q605, Q606 jeweils zusammen auch „heterocyclyl" bilden können;Q587, Q588, Q589, Q590, Q591, Q592, Q593, Q594, Q595, Q596, Q597, Q598, Q599, Q600, Q601, Q602, Q603, Q604, Q605, Q606, Q607, Q608, Q609, Q610, Q611, Q612 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively Q567, Q568 and / or Q576, Q577 and / or Q589, Q590 and / or Q596, Q597 and / or Q605, Q606 may each together also form "heterocyclyl";
(g) unsubstituiertes oder substituiertes Aryl, wobei optional der Arylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(g) unsubstituted or substituted aryl wherein optionally the aryl radical may be substituted with at least one substituent, same or different, selected from the group consisting of:
(i) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3,(i) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3,
N3, NH2, -NHQ613, -NQ614Q615, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q616, -C(O)O-Q617, -C(O)NH-Q618, -C(O)NQ619Q620, - O-Q621 , -O(-Q622-O)c-H (c = 1 , 2, 3, 4, 5), -O(-Q623-O)c-Q624 (c = 1 , 2, 3, 4, 5), -OC(O)-Q625, -OC(O)-O-Q626, -OC(O)-NHQ627, - O-C(O)-NQ628Q629, -OP(O)(OQ630)(OQ631 ), - OSi(Q632)(Q633)(Q634), -OS(O2)-Q635, -NHC(O)-Q636, - NQ637C(O)-Q638, -NH-C(O)-O-Q639, -N H-C(O)-N H-Q640, - NH-C(O)-NQ641 Q642, -NQ643-C(O)-O-Q644, -NQ645-C(O)-NH-N 3, NH 2, -NHQ613, -NQ614Q615, -NO 2, -OH, -OCF3, -SH, -O- SO3H, -OP (O) (OH) 2, -CHO, -COOH, - C (O) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) -Q616, -C (O) O-Q617, -C (O) NH-Q618, -C (O) NQ619Q620, -O-Q621, -O (-Q622-O) c -H (c = 1, 2, 3, 4, 5), -O (-Q623-O) c -Q624 (c = 1, 2, 3, 4, 5), -OC (O) -Q625, -OC (O) -O-Q626, -OC (O) -NHQ627, -OC (O) -NQ628Q629, -OP (O ) (OQ630) (OQ631), - OSi (Q632) (Q633) (Q634), -OS (O 2) -Q635, -NHC (O) -Q636, - NQ637C (O) -Q638, -NH-C ( O) -O-Q639, -NHC (O) -NH-Q640, -NH-C (O) -NQ641Q642, -NQ643-C (O) -O-Q644, -NQ645-C (O) - NH-
Q646, -NQ647-C(O)-NQ648Q649, -NHS(O2)-Q650, -NQ651 S(O2)- Q652, -S-Q653, -S(O)-Q654, -S(O2)-Q655, -S(O2)NH-Q656, - S(O2)NQ657Q658, -S(O2)O-Q659, -P(O)(OQ660)(OQ661 ), - Si(Q662)(Q663)(Q664)"; wobei Q613, Q614, Q615, Q616, Q617, Q618, Q619, Q620, Q621 ,Q646, -NQ647-C (O) -NQ648Q649, -NHS (O 2) -Q650, -NQ651 S (O 2) - Q652, Q653 -S-, -S (O) -Q654, -S (O 2) -Q655, -S (O 2) NH-Q656, - S (O 2) NQ657Q658, -S (O 2) O-Q659, -P (O) (OQ660) (OQ661), - Si (Q662) (Q663 ) (Q664) "where Q613, Q614, Q615, Q616, Q617, Q618, Q619, Q620, Q621,
Q622, Q623, Q624, Q625, Q626, Q627, Q628, Q629, Q630, Q631 , Q632, Q633, Q634, Q635, Q636, Q637, Q638, Q639, Q640, Q641 , Q642, Q643, Q644, Q645, Q646, Q647, Q648, Q649, Q650, Q651 , Q652, Q653, Q654, Q655, Q656, Q657, Q658, Q659, Q660, Q661 , Q662, Q663, Q664 unabhängig voneinander ausgewählt sind aus derQ622, Q623, Q624, Q625, Q626, Q627, Q628, Q629, Q630, Q631, Q632, Q633, Q634, Q635, Q636, Q637, Q638, Q639, Q640, Q641, Q642, Q643, Q644, Q645, Q646, Q647, Q648, Q649, Q650, Q651, Q652, Q653, Q654, Q655, Q656, Q657, Q658, Q659, Q660, Q661, Q662, Q663, Q664 are independently selected from the
Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ Q619, Q620 und/oder Q628, Q629 und/oder Q641 , Q642 und/oder Q648, Q649 und/oder Q657, Q658 jeweils zu- sammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ665, -NQ666Q667, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, - SO3H, -P(O)(OH)2, -C(O)-Q668, -C(O)O-Q669, -C(O)NH-Q670, -C(O)NQ671 Q672, -O-Q673, -O(-Q674-O)d-H (d = 1 , 2, 3, 4,A group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively Q619, Q620 and / or Q628, Q629 and / or Q641 , Q642 and / or Q648, Q649 and / or Q657, Q658 together can also form "heterocyclyl"; wherein optionally above substituents of substituent group (i) in turn may be independently substituted with at least one substituent, identical or different, selected from the group consisting of: (ii) "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHQ665, -NQ666Q667, -NO 2, -OH, -OCF 3, -SH , -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C ( O) -Q668, -C (O) O-Q669, -C (O) NH-Q670, -C (O) NQ671 Q672, -O-Q673, -O (-Q674-O) d -H (d = 1, 2, 3, 4,
5), -O(-Q675-O)d-Q676 (d = 1 , 2, 3, 4, 5), -OC(O)-Q677, - OC(O)-O-Q678, -OC(O)-NHQ679, -O-C(O)-NQ680Q681 , - OP(O)(OQ682)(OQ683), -OSi(Q684)(Q685)(Q686), -OS(O2)- Q687, -NHC(O)-Q688, -NQ689C(O)-Q690, -NH-C(O)-O-Q691 , -NH-C(O)-NH-Q692, -NH-C(O)-NQ693Q694, -NQ695-C(O)- O-Q696, -NQ697-C(O)-NH-Q698, -NQ699-C(O)-NQ700Q701 , -NHS(O2)-Q702, -NQ703S(O2)-Q704, -S-Q705, -S(O)-Q706, - S(O2)-Q707, -S(O2)NH-Q708, -S(O2)NQ709Q710, -S(O2)O- 5 Q71 1 , -P(O)(OQ712)(OQ713), -Si(Q714)(Q715)(Q716)"; wobei Q665, Q666, Q667, Q668, Q669, Q670, Q671 , Q672, Q673, Q674, Q675, Q676, Q677, Q678, Q679, Q680, Q681 , Q682, Q683, Q684, Q685, Q686, Q687, Q688, Q689, Q690, Q691 , Q692, Q693, Q694, Q695, Q696, Q697, Q698, Q699, Q700,5), -O (-Q675-O) d -Q676 (d = 1, 2, 3, 4, 5), -OC (O) -Q677, -OC (O) -O-Q678, -OC (O ) -NHQ679, -OC (O) -NQ680Q681, - OP (O) (OQ682) (OQ683), -OSi (Q684) (Q685) (Q686), -OS (O 2) - Q687, -NHC (O) -Q688, -NQ689C (O) -Q690, -NH-C (O) -O-Q691, -NH-C (O) -NH-Q692, -NH-C (O) -NQ693Q694, -NQ695-C (O) -O-Q696, -NQ697-C (O) -NH-Q698, -NQ699-C (O) -NQ700Q701, -NHS (O 2) -Q702, -NQ703S (O 2) -Q704, -S-Q705, -S (O) -Q706, - S (O 2) -Q707, -S (O 2) NH-Q708, -S (O 2) NQ709Q710, -S (O 2) O- 5 Q71 1, -P (O) (OQ712) (OQ713), -Si (Q714) (Q715) (Q716) " Q665, Q666, Q667, Q668, Q669, Q670, Q671, Q672, Q673, Q674, Q675, Q676, Q677, Q678, Q679, Q680, Q681, Q682, Q683, Q684, Q685, Q686, Q687, Q688, Q689, Q690, Q691, Q692, Q693, Q694, Q695, Q696, Q697, Q698, Q699, Q700,
10 Q701 , Q702, Q703, Q704, Q705, Q706, Q707, Q708, Q709,10 Q701, Q702, Q703, Q704, Q705, Q706, Q707, Q708, Q709,
Q710, Q711 , Q712, Q713, Q714, Q715, Q716 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alterna-Q710, Q711, Q712, Q713, Q714, Q715, Q716 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl , heteroarylalkyl "and wherein
15 tiv Q671 , Q672 und/oder Q680, Q681 und/oder Q693, Q694 und/oder Q700, Q701 und/oder Q709, Q710 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit15 tiv Q671, Q672 and / or Q680, Q681 and / or Q693, Q694 and / or Q700, Q701 and / or Q709, Q710 may together also form "heterocyclyl" wherein optionally substituents of substituent group (ii) above independently may be substituted with
20 mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:At least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ717, -NQ718Q719, -NO2, -OH,(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ717, -NQ718Q719, -NO 2 , -OH,
25 -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -25 -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -
C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q720, -C(O)O-Q721 , - C(O)N H-Q722, -C(O)NQ723Q724, -O-Q725, -O(-Q726- O)6-H (e = 1 , 2, 3, 4, 5), -O(-Q727-O)e-Q728 (e = 1 , 2, 3, 4, 5), -OC(O)-Q729, -OC(O)-O-Q730, -OC(O)-N HQ731 , -O-C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q 720, -C (O) O-Q 721, -C (O) N H-Q 722, - C (O) NQ723Q724, -O-Q725, -O (-Q726-O) 6 -H (e = 1, 2, 3, 4, 5), -O (-Q727-O) e -Q728 (e = 1, 2, 3, 4, 5), -OC (O) -Q729, -OC (O) -O-Q730, -OC (O) -N HQ731, -O-
30 C(O)-NQ732Q733, -OP(O)(OQ734)(OQ735), -30 C (O) -NQ732Q733, -OP (O) (OQ734) (OQ735),
OSi(Q736)(Q737)(Q738), -OS(O2)-Q739, -NHC(O)-Q740, - NQ741C(O)-Q742, -NH-C(O)-O-Q743, -NH-C(O)-NH- Q744, -NH-C(O)-NQ745Q746, -NQ747-C(O)-O-Q748, - NQ749-C(O)-NH-Q750, -NQ751-C(O)-NQ752Q753, - NHS(O2)-Q754, -NQ755S(O2)-Q756, -S-Q757, -S(O)-Q758, -S(O2)-Q759, -S(O2)NH-Q760, -S(O2)NQ761 Q762, - S(O2)O-Q763, -P(O)(OQ764)(OQ765), - Si(Q766)(Q767)(Q768)"; wobei Q717, Q718, Q719, Q720, Q721 , Q722, Q723, Q724,OSi (Q736) (Q737) (Q738), -OS (O 2) -Q739, -NHC (O) -Q740, - NQ741C (O) -Q742, -NH-C (O) -O-Q743, -NH -C (O) -NH-Q744, -NH-C (O) -NQ745Q746, -NQ747-C (O) -O-Q748, -NQ749-C (O) -NH-Q750, -NQ751-C (O ) -NQ752Q753, - NHS (O 2) -Q754, -NQ755S (O 2) -Q756, -S-Q757, -S (O) -Q758, -S (O 2) -Q759, -S (O 2) NH-Q760, - S (O 2) NQ761 Q762, - S (O 2) O-Q763, -P (O) (OQ764) (OQ765), - Si (Q766) (Q767) (Q768) "; wherein Q717, Q718, Q719, Q720, Q721, Q722, Q723, Q724,
Q725, Q726, Q727, Q728, Q729, Q730, Q731 , Q732, Q733, Q734, Q735, Q736, Q737, Q738, Q739, Q740, Q741 , Q742, Q743, Q744, Q745, Q746, Q747, Q748, Q749, Q750, Q751 , Q752, Q753, Q754, Q755, Q756, Q757, Q758, Q759, Q760, Q761 , Q762, Q763, Q764, Q765, Q766, Q767, Q768 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, hete- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" und wobei alternativ Q723, Q724 und/oder Q732, Q733 und/oder Q745, Q746 und/oder Q752, Q753 und/oder Q761 ,Q725, Q726, Q727, Q728, Q729, Q730, Q731, Q732, Q733, Q734, Q735, Q736, Q737, Q738, Q739, Q740, Q741, Q742, Q743, Q744, Q745, Q746, Q747, Q748, Q749, Q750, Q751, Q752, Q753, Q754, Q755, Q756, Q757, Q758, Q759, Q760, Q761, Q762, Q763, Q764, Q765, Q766, Q767, Q768 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively Q723, Q724 and / or Q732, Q733 and / or Q745, Q746 and / or Q752, Q753 and / or Q761,
Q762 jeweils zusammen auch „heterocyclyl" bilden können;Q762 together can also form "heterocyclyl";
(h) unsubstituiertes oder substituiertes Heteroaryl, wobei optional der Hetero- arylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(h) unsubstituted or substituted heteroaryl, where optionally the heteroaryl radical may be substituted by at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ769, -NQ770Q771 , -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q772, -C(O)O-Q773, -C(O)NH-Q774, -C(O)NQ775Q776, -(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ769, -NQ770Q771, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q772, -C (O) O -Q773, -C (O) NH-Q774, -C (O) NQ 775Q776,
O-Q777, -O(-Q778-O)f-H (f = 1 , 2, 3, 4, 5), -O(-Q779-O)^Q780 (f = 1 , 2, 3, 4, 5), -OC(O)-Q781 , -OC(O)-O-Q782, -OC(O)-NHQ783, - O-C(O)-NQ784Q785, -OP(O)(OQ786)(OQ787), - OSi(Q788)(Q789)(Q790), -OS(O2)-Q791 , -NHC(O)-Q792, - NQ793C(O)-Q794, -NH-C(O)-O-Q795, -N H-C(O)-N H-Q796, -O-Q777, -O (-Q778-O) f -H (f = 1, 2, 3, 4, 5), -O (-Q779-O) Q780 (f = 1, 2, 3, 4, 5), -OC (O) -Q781, -OC (O) -O-Q782, -OC (O) -NHQ783, -OC (O) -NQ784Q785, -OP (O) (OQ786) (OQ787), OSi (Q788) (Q789) (Q790), -OS (O 2) -Q791, -NHC (O) -Q792, - NQ793C (O) -Q794, -NH-C (O) -O-Q795, -N HC (O) -N H-Q796, -
NH-C(O)-NQ797Q798, -NQ799-C(O)-O-Q800, -NQ801 -C(O)-N H- Q802, -NQ803-C(O)-NQ804Q805, -NHS(O2)-Q806, -NQ807S(O2)- Q808, -S-Q809, -S(O)-Q810, -S(O2)-Q811 , -S(O2)NH-Q812, - S(O2)NQ813Q814, -S(O2)O-Q815, -P(O)(OQ816)(OQ817), - Si(Q818)(Q819)(Q820)"; wobei Q769, Q770, Q771 , Q772, Q773, Q774, Q775, Q776, Q777, Q778, Q779, Q780, Q781 , Q782, Q783, Q784, Q785, Q786, Q787, Q788, Q789, Q790, Q791 , Q792, Q793, Q794, Q795, Q796, Q797,NH-C (O) -NQ797Q798, -NQ799-C (O) -O-Q800, -NQ801 -C (O) -N H- Q802, -NQ803-C (O) -NQ804Q805, -NHS (O 2) -Q806, -NQ807S (O 2) - Q808, Q809 -S-, -S (O) -Q810, -S (O 2) -Q811, -S (O 2) NH-Q812, - S (O 2) NQ813Q814, -S (O 2) O-Q815, -P (O) (OQ816) (OQ817), - Si (Q818) (Q819) (Q820) "; wherein Q769, Q770, Q771, Q772 , Q773, Q774, Q775, Q776, Q777, Q778, Q779, Q780, Q781, Q782, Q783, Q784, Q785, Q786, Q787, Q788, Q789, Q790, Q791, Q792, Q793, Q794, Q795, Q796, Q797 .
Q798, Q799, Q800, Q801 , Q802, Q803, Q804, Q805, Q806, Q807, Q808, Q809, Q810, Q81 1 , Q812, Q813, Q814, Q815, Q816, Q817, Q818, Q819, Q820 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ Q775, Q776 und/oder Q784, Q785 und/oder Q797, Q798 und/oder Q804, Q805 und/oder Q813, Q814 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wie- derum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Q798, Q799, Q800, Q801, Q802, Q803, Q804, Q805, Q806, Q807, Q808, Q809, Q810, Q81 1, Q812, Q813, Q814, Q815, Q816, Q817, Q818, Q819, Q820 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- alkyl" and wherein alternatively Q775, Q776 and / or Q784, Q785 and or Q797, Q798 and / or Q804, Q805 and / or Q813, Q814 may together also form "heterocyclyl"; in which optionally above substituents of the substituent group (i) can in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ821 , -NQ822Q823, -NO2, -OH, -OCF3,(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ821, -NQ822Q823, -NO 2 , -OH, -OCF 3 ,
-SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, - SO3H, -P(O)(OH)2, -C(O)-Q824, -C(O)O-Q825, -C(O)NH-Q826, -C(O)NQ827Q828, -O-Q829, -O(-Q830-O)g-H (g = 1 , 2, 3, 4, 5), -O(-Q831-O)g-Q832 (g = 1 , 2, 3, 4, 5), -OC(O)-Q833, - OC(O)-O-Q834, -OC(O)-NHQ835, -O-C(O)-NQ836Q837, --SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , - C (O) -Q824, -C (O) O-Q825, -C (O) NH-Q826, -C (O) NQ827Q828, -O-Q829, -O (-Q830-O) g -H (g = 1, 2, 3, 4, 5), -O (-Q831-O) g -Q832 (g = 1, 2, 3, 4, 5), -OC (O) -Q833, - OC (O) -O-Q834, -OC (O) -NHQ835, -OC (O) -NQ836Q837, -
OP(O)(OQ838)(OQ839), -OSi(Q840)(Q841 )(Q842), -OS(O2)- Q843, -NHC(O)-Q844, -NQ845C(O)-Q846, -NH-C(O)-O-Q847, -NH-C(O)-NH-Q848, -NH-C(O)-NQ849Q850, -NQ851-C(O)- O-Q852, -NQ853-C(O)-NH-Q854, -NQ855-C(O)-NQ856Q857, -NHS(O2)-Q858, -NQ859S(O2)-Q860, -S-Q861 , -S(O)-Q862, -OP (O) (OQ838) (OQ839), -OSi (Q840) (Q841) (Q842), -OS (O 2) - Q843, -NHC (O) -Q844, -NQ845C (O) -Q846, -NH -C (O) -O-Q847, -NH-C (O) -NH-Q848, -NH-C (O) -NQ849Q850, -NQ851-C (O) -O-Q852, -NQ853-C (O ) -NH-Q854, -NQ855-C (O) -NQ856Q857, -NHS (O 2) -Q858, -NQ859S (O 2) -Q860, -S-Q861, -S (O) -Q862, -
S(O2)-Q863, -S(O2)N H-Q864, -S(O2)NQ865Q866, -S(O2)O- Q867, -P(O)(OQ868)(OQ869), -Si(Q870)(Q871 )(Q872)"; wobei Q821 , Q822, Q823, Q824, Q825, Q826, Q827, Q828, Q829, Q830, Q831 , Q832, Q833, Q834, Q835, Q836, Q837, Q838, Q839, Q840, Q841 , Q842, Q843, Q844, Q845, Q846, Q847, Q848, Q849, Q850, Q851 , Q852, Q853, Q854, Q855, Q856, Q857, Q858, Q859, Q860, Q861 , Q862, Q863, Q864, Q865, Q866, Q867, Q868, Q869, Q870, Q871 , Q872 unabhängig von-S (O 2) -Q863, -S (O 2) N H-Q864, -S (O 2) NQ865Q866, -S (O 2) O- Q867, -P (O) (OQ868) (OQ869) - Si (Q870) (Q871) (Q872) "; where Q821, Q822, Q823, Q824, Q825, Q826, Q827, Q828, Q829, Q830, Q831, Q832, Q833, Q834, Q835, Q836, Q837, Q838, Q839, Q840, Q841, Q842, Q843, Q844, Q845, Q846, Q847, Q848, Q849, Q850, Q851, Q852, Q853, Q854, Q855, Q856, Q857, Q858, Q859, Q860, Q861, Q862, Q863, Q864, Q865, Q866, Q867, Q868, Q869, Q870, Q871, Q872 independently of-
5 einander ausgewählt sind aus der Gruppe bestehend aus: „alkyl,5 are selected from the group consisting of: "alkyl,
(C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q827, Q828 und/oder Q836, Q837 und/oder Q849, Q850 und/oder Q856, Q857 und/oder Q865, Q866 jeweils zusammen 10 auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively Q827, Q828 and / or Q836, Q837 and / or Q849, Q850 and / or Q856 , Q857 and / or Q865, Q866 together may also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
15 (iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ873, -NQ874Q875, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q876, -C(O)O-Q877, -15 (iii) "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ 873, -NQ 874 Q 875, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O ) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q876, -C (O) O-Q 877, -
20 C(O)N H-Q878, -C(O)NQ879Q880, -O-Q881 , -O(-Q882-20 C (O) N H-Q878, -C (O) NQ879Q880, -O-Q881, -O (-Q882-
O)h-H (h = 1 , 2, 3, 4, 5), -O(-Q883-O)h-Q884 (h = 1 , 2, 3, 4, 5), -OC(O)-Q885, -OC(O)-O-Q886, -OC(O)-NHQ887, -O- C(O)-NQ888Q889, -OP(O)(OQ890)(OQ891 ), - OSi(Q892)(Q893)(Q894), -OS(O2)-Q895, -NHC(O)-Q896, -O) h -H (h = 1, 2, 3, 4, 5), -O (-Q883-O) h -Q884 (h = 1, 2, 3, 4, 5), -OC (O) - Q885, -OC (O) -O-Q886, -OC (O) -NHQ887, -O-C (O) -NQ888Q889, -OP (O) (OQ890) (OQ891), -OSi (Q892) (Q893) (Q894), -OS (O 2) -Q895, -NHC (O) -Q896, -
25 NQ897C(O)-Q898, -NH-C(O)-O-Q899, -NH-C(O)-NH-25 NQ897C (O) -Q898, -NH-C (O) -O-Q899, -NH-C (O) -NH-
Q900, -NH-C(O)-NQ901 Q902, -NQ903-C(O)-O-Q904, - NQ905-C(O)-NH-Q906, -NQ907-C(O)-NQ908Q909, - NHS(O2)-Q910, -NQ911 S(O2)-Q912, -S-Q913, -S(O)-Q914, -S(O2)-Q915, -S(O2)NH-Q916, -S(O2)NQ917Q918, -Q900, -NH-C (O) -NQ901 Q902, -NQ903-C (O) -O-Q904, -NQ905-C (O) -NH-Q906, -NQ907-C (O) -NQ908Q909, -NHS ( O 2) -Q910, -NQ911 S (O 2) -Q912, -S-Q913, -S (O) -Q914, -S (O 2) -Q915, -S (O 2) NH-Q916, -S (O 2 ) NQ917Q918, -
30 S(O2)O-Q919, -P(O)(OQ920)(OQ921 ), -30 S (O 2) O-Q919, -P (O) (OQ920) (OQ921) -
Si(Q922)(Q923)(Q924)"; wobei Q873, Q874, Q875, Q876, Q877, Q878, Q879, Q880, Q881 , Q882, Q883, Q884, Q885, Q886, Q887, Q888, Q889, Q890, Q891 , Q892, Q893, Q894, Q895, Q896, Q897, Q898, Q899, Q900, Q901 , Q902, Q903, Q904, Q905, Q906, Q907, Q908, Q909, Q910, Q91 1 , Q912, Q913, Q914, Q915, Q916, Q917, Q918, Q919, Q920, Q921 , Q922, Q923, Q924 unabhängig voneinander ausgewählt sind aus der Gruppe beste- hend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, hete- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" und wobei alternativ Q879, Q880 und/oder Q888, Q889 und/oder Q901 , Q902 und/oder Q908, Q909 und/oder Q917, Q918 jeweils zusammen auch „heterocyclyl" bilden können;Si (Q922) (Q923) (Q924) "; where Q873, Q874, Q875, Q876, Q877, Q878, Q879, Q880, Q881, Q882, Q883, Q884, Q885, Q886, Q887, Q888, Q889, Q890, Q891 , Q892, Q893, Q894, Q895, Q896, Q897, Q898, Q999, Q900, Q901, Q902, Q903, Q904, Q905, Q906, Q907, Q908, Q909, Q910, Q91 1, Q912, Q913, Q914, Q915, Q916, Q917, Q918, Q919, Q920, Q921, Q922, Q923 are Q924 independently selected from the group consist- ing of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- rocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" and wherein alternatively Q879 , Q880 and / or Q888, Q889 and / or Q901, Q902 and / or Q908, Q909 and / or Q917, Q918 may together also form "heterocyclyl";
(j) OZ6, wobei Z6 unabhängig ausgewählt ist aus der Gruppe bestehend aus:(j) OZ6, wherein Z6 is independently selected from the group consisting of:
(i) „Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(i) "hydrogen, alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wherein optionally substituents of the substituent group (i) above may be independently substituted with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,
CN, CF3, N3, NH2, -NHQ925, -NQ926Q927, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, - SO3H, -P(O)(OH)2, -C(O)-Q928, -C(O)O-Q929, -C(O)NH-Q930, -C(O)NQ931 Q932, -O-Q933, -O(-Q934-O),-H (i = 1 , 2, 3, 4, 5), -O(-Q935-O),-Q936 (i = 1 , 2, 3, 4, 5), -OC(O)-Q937, -OC(O)-CN, CF 3, N 3, NH 2, -NHQ925, -NQ926Q927, -NO 2, -OH, -OCF 3, -SH, -0-SO 3 H, -OP (O) (OH) 2, -CHO , -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q 928, -C (O) O-Q 929, -C (O) NH -Q930, -C (O) NQ931 Q932, -O-Q933, -O (-Q934-O), - H (i = 1, 2, 3, 4, 5), -O (-Q935-O), -Q936 (i = 1, 2, 3, 4, 5), -OC (O) -Q937, -OC (O) -
O-Q938, -OC(O)-N HQ939, -0-C(O)-N Q940Q941 , - OP(O)(OQ942)(OQ943), -OSi(Q944)(Q945)(Q946), -OS(O2)- Q947, -NHC(O)-Q948, -NQ949C(O)-Q950, -NH-C(O)-O-Q951 , -N H-C(O)-N H-Q952, -NH-C(O)-NQ953Q954, -NQ955-C(O)- O-Q956, -NQ957-C(O)-NH-Q958, -NQ959-C(O)-NQ960Q961 ,O-Q938, -OC (O) -N HQ939, -O-C (O) -N Q940Q941, - OP (O) (OQ942) (OQ943), -OSi (Q944) (Q945) (Q946), -OS (O 2 ) -Q947, -NHC (O) -Q948, -NQ949C (O) -Q950, -NH-C (O) -O-Q951, -NHC (O) -N H-Q952, -NH- C (O) -NQ953Q954, -NQ955-C (O) -O-Q956, -NQ957-C (O) -NH-Q958, -NQ959-C (O) -NQ960Q961,
-NHS(O2)-Q962, -NQ963S(O2)-Q964, -S-Q965, -S(O)-Q966, - S(O2)-Q967, -S(O2)NH-Q968, -S(O2)NQ969Q970, -S(O2)O- Q971 , -P(O)(OQ972)(OQ973), -Si(Q974)(Q975)(Q976)"; wobei Q925, Q926, Q927, Q928, Q929, Q930, Q931 , Q932, Q933, Q934, Q935, Q936, Q937, Q938, Q939, Q940, Q941 , Q942, Q943, Q944, Q945, Q946, Q947, Q948, Q949, Q950, Q951 , Q952, Q953, Q954, Q955, Q956, Q957, Q958, Q959, Q960, 5 Q961 , Q962, Q963, Q964, Q965, Q966, Q967, Q968, Q969,-NHS (O 2) -Q962, -NQ963S (O 2) -Q964, -S-Q965, -S (O) -Q966, - S (O 2) -Q967, -S (O 2) NH-Q968, -S (O 2) NQ969Q970, -S (O 2) O- Q971, -P (O) (OQ972) (OQ973), -Si (Q974) (Q975) (Q976) "; where Q925, Q926, Q927, Q928, Q929, Q930, Q931, Q932, Q933, Q934, Q935, Q936, Q937, Q938, Q939, Q940, Q941, Q942, Q943, Q944, Q945, Q946, Q947, Q948, Q949 , Q950, Q951, Q952, Q953, Q954, Q955, Q956, Q957, Q958, Q959, Q960, Q961, Q962, Q963, Q964, Q965, Q966, Q967, Q968, Q969,
Q970, Q971 , Q972, Q973, Q974, Q975, Q976 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alterna- 10 tiv Q931 , Q932 und/oder Q940, Q941 und/oder Q953, Q954 und/oder Q960, Q961 und/oder Q969, Q970 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mitQ970, Q971, Q972, Q973, Q974, Q975 are, Q976 independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternately Q931, Q932 and / or Q940, Q941 and / or Q953, Q954 and / or Q960, Q961 and / or Q969, Q970 can each also together form" heterocyclyl "; optionally substituents of substituent group (ii) above may be substituted independently of one another with
15 mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:At least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ977, -NQ978Q979, -NO2, -OH,(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ977, -NQ978Q979, -NO 2 , -OH,
20 -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -20 -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -
C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q980, -C(O)O-Q981 , - C(O)N H-Q982, -C(O)NQ983Q984, -O-Q985, -O(-Q986-O)- H C = 1 , 2, 3, 4, 5), -O(-Q987-O)-Q988 (j = 1 , 2, 3, 4, 5), - OC(O)-Q989, -OC(O)-O-Q990, -OC(O)-N HQ991 , -0-C(O)-C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q980, -C (O) O -Q981, -C (O) N H -Q982, - C (O) NQ983Q984, -O-Q985, -O (-Q986-O) - HC = 1, 2, 3, 4, 5), -O (-Q987-O) -Q988 (j = 1, 2, 3, 4, 5), - OC (O) -Q989, -OC (O) -O-Q990, -OC (O) -N HQ991, -O-C (O) -
25 NQ992Q993, -OP(O)(OQ994)(OQ995), -25 NQ992Q993, -OP (O) (OQ994) (OQ995), -
OSi(Q996)(Q997)(Q998), -OS(O2)-Q999, -NHC(O)-QIOOO, - NQ1001 C(O)-QI 002, -NH-C(O)-O-QI 003, -NH-C(O)-NH- Q1004, -NH-C(O)-NQI 005Q1006, -NQ1007-C(O)-O- Q1008, -NQ1009-C(O)-NH-QI 010, -NQ1011-C(O)-OSi (Q996) (Q997) (Q998), -OS (O 2) -Q999, -NHC (O) -QIOOO, - NQ1001 C (O) -qi 002, -NH-C (O) -O-QI 003 , -NH-C (O) -NH-Q1004, -NH-C (O) -NQI 005Q1006, -NQ1007-C (O) -O-Q1008, -NQ1009-C (O) -NH-QI 010, - NQ1011-C (O) -
30 NQ1012Q1013, -NHS(O2)-Q1014, -NQ1015S(O2)-Q1016, -30 NQ1012Q1013, -NHS (O 2 ) -Q1014, -NQ1015S (O 2 ) -Q1016, -
S-Q1017, -S(O)-QI 018, -S(O2)-Q1019, -S(O2)NH-QI 020, - S(O2)NQI 021 Q1022, -S(O2)O-QI 023, - P(O)(OQI 024)(OQ1025), -Si(QI 026)(Q1027)(Q1028)"; wobei Q977, Q978, Q979, Q980, Q981 , Q982, Q983, Q984, Q985, Q986, Q987, Q988, Q989, Q990, Q991 , Q992, Q993, Q994, Q995, Q996, Q997, Q998, Q999, Q1000, Q1001 , Q1002, Q1003, Q1004, Q1005, Q1006, Q1007, Q1008, Q1009, Q1010, Q1011 , Q1012, Q1013, Q1014, Q1015,S-Q1017, -S (O) -qi 018, -S (O 2) -Q1019, -S (O 2) NH-QI 020, - S (O 2) NQI 021 Q1022, -S (O 2) O -QI 023, - P (O) (OQI 024) (OQ1025), -Si (QI 026) (Q1027) (Q1028) "; where Q977, Q978, Q979, Q980, Q981, Q982, Q983, Q984, Q985, Q986, Q987, Q988, Q989, Q990, Q991, Q992, Q993, Q994, Q995, Q996, Q997, Q998, Q999, Q1000, Q1001 , Q1002, Q1003, Q1004, Q1005, Q1006, Q1007, Q1008, Q1009, Q1010, Q1011, Q1012, Q1013, Q1014, Q1015,
Q1016, Q1017, Q1018, Q1019, Q1020, Q1021 , Q1022, Q1023, Q1024, Q1025, Q1026, Q1027, Q1028 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q983, Q984 und/oder Q992, Q993 und/oder Q1005, Q1006 und/oder Q1012, Q1013 und/oder Q1021 , Q1022 jeweils zusammen auch „heterocyclyl" bilden können;Are Q1016, Q1017, Q1018, Q1019, Q1020, Q1021, Q1022, Q1023, Q1024, Q1025, Q1026, Q1027, Q1028 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl , heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively, Q983, Q984 and / or Q992, Q993 and / or Q1005, Q1006 and / or Q1012, Q1013 and / or Q1021, Q1022 also together also" heterocyclyl "can form;
(k) SZ7, wobei Z7 unabhängig ausgewählt ist aus der Gruppe bestehend aus:(k) SZ7, wherein Z7 is independently selected from the group consisting of:
(i) „Wasserstoff, alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindes- tens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(i) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wherein optionally above substituents of the substituent group (i) may in turn be independently substituted with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ1029, -NQ1030Q1031 , -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2,(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHQ1029, -NQ1030Q1031, -NO 2 , -OH, - OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 .
-SO3H, -P(O)(OH)2, -C(O)-QI 032, -C(O)O-QI 033, -C(O)NH- Q1034, -C(O)NQI 035Q1036, -O-Q1037, -O(-Q1038-O)k-H (k = 1 , 2, 3, 4, 5), -O(-Q1039-O)k-Q1040 (k = 1 , 2, 3, 4, 5), -OC(O)- Q1041 , -OC(O)-O-QI 042, -OC(O)-NHQI 043, -0-C(O)- NQ1044Q1045, -OP(O)(OQI 046)(OQ1047), --SO 3 H, -P (O) (OH) 2 , -C (O) -QI 032, -C (O) O-QI 033, -C (O) NH-Q 1034, -C (O) NQI 035Q1036 , -O-Q1037, -O (-Q1038-O) k -H (k = 1, 2, 3, 4, 5), -O (-Q1039-O) k -Q1040 (k = 1, 2, 3 , 4, 5), -OC (O) -Q1041, -OC (O) -O-QI 042, -OC (O) -NHQI 043, -O-C (O) -NQ1044Q1045, -OP (O) ( OQI 046) (OQ1047), -
OSi(QI 048)(Q1049)(Q1050), -OS(O2)-Q1051 , -NHC(O)-QI 052, -NQ1053C(O)-QI 054, -NH-C(O)-O-QI 055, -NH-C(O)-NH- Q1056, -NH-C(O)-NQI 057Q1058, -NQ1059-C(O)-O-QI 060, - NQ1061-C(O)-NH-Q1062, -NQ1063-C(O)-NQI 064Q1065, - NHS(O2)-Q1066, -NQ1067S(O2)-Q1068, -S-Q1069, -S(O)- Q1070, -S(02)-Q1071 , -S(O2)NH-QI 072, -S(O2)NQI 073Q1074, -S(O2)O-QI 075, -P(O)(OQI 076)(OQ1077), - Si(QI 078)(Q1079)(Q1080)";OSi (QI 048) (Q1049) (Q1050), -OS (O 2) -Q1051, -NHC (O) -qi 052, -NQ1053C (O) -qi 054, -NH-C (O) -O-QI 055, -NH-C (O) -NH-Q1056, -NH-C (O) -NQI 057Q1058, -NQ1059-C (O) -O-QI 060, -NQ1061-C (O) -NH-Q1062, -NQ1063-C (O) -NQI 064Q1065, - NHS (O 2) -Q1066, -NQ1067S (O 2) -Q1068, -S-Q1069, -S (O) - Q1070, -S (0 2) -Q1071, -S (O 2) NH-QI 072, -S (O 2 ) NQI 073Q1074, -S (O 2 ) O-QI 075, -P (O) (OQI 076) (OQ1077), -Si (QI 078) (Q1079) (Q1080) ";
5 wobei Q1029, Q1030, Q1031 , Q1032, Q1033, Q1034, Q1035,5 wherein Q1029, Q1030, Q1031, Q1032, Q1033, Q1034, Q1035,
Q1036, Q1037, Q1038, Q1039, Q1040, Q1041 , Q1042, Q1043, Q1044, Q1045, Q1046, Q1047, Q1048, Q1049, Q1050, Q1051 , Q1052, Q1053, Q1054, Q1055, Q1056, Q1057, Q1058, Q1059, Q1060, Q1061 , Q1062, Q1063, Q1064, Q1065, Q1066, Q1067,Q1036, Q1037, Q1038, Q1039, Q1040, Q1041, Q1042, Q1043, Q1044, Q1045, Q1046, Q1047, Q1048, Q1049, Q1050, Q1051, Q1052, Q1053, Q1054, Q1055, Q1056, Q1057, Q1058, Q1059, Q1060, Q1061, Q1062, Q1063, Q1064, Q1065, Q1066, Q1067,
10 Q1068, Q1069, Q1070, Q1071 , Q1072, Q1073, Q1074, Q1075,10 Q1068, Q1069, Q1070, Q1071, Q1072, Q1073, Q1074, Q1075,
Q1076, Q1077, Q1078, Q1079, Q1080 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativQ1076, Q1077, Q1078, are Q1079, Q1080 independently selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternative
15 Q1035, Q1036 und/oder Q1044, Q1045 und/oder Q1057, Q1058 und/oder Q1064, Q1065 und/oder Q1073, Q1074 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit15 Q1035, Q1036 and / or Q1044, Q1045 and / or Q1057, Q1058 and / or Q1064, Q1065 and / or Q1073, Q1074 may together also form "heterocyclyl" wherein optionally substituents of substituent group (ii) above independently substituted can be with
20 mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:At least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I1 CN1 CF3, N3, NH2, -NHQ1081 , -NQ1082Q1083, -NO2, -(iii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I 1 1 CN CF 3, N 3, NH 2 , -NHQ1081, -NQ1082Q1083, -NO 2 , -
25 OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -25 OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -
C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-QI 084, -C(O)O- Q1085, -C(O)NH-QI 086, -C(O)NQI 087Q1088, -O-Q1089, - O(-Q1090-O)1-H (I = 1 , 2, 3, 4, 5), -O(-Q1091 -O)1-QI 092 (I = 1 , 2, 3, 4, 5), -OC(O)-QI 093, -OC(O)-O-QI 094, -OC(O)-C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -QI 084, -C (O) O-Q 1085, -C (O) NH-QI 086, -C (O) NQI 087Q1088, -O-Q1089, - O (-Q1090-O) 1 -H (I = 1, 2, 3, 4, 5), -O (-Q1091 -O) 1 -QI 092 (I = 1, 2, 3, 4, 5), -OC (O) -QI 093, -OC (O) -O-QI 094, -OC (O) -
30 NHQ1095, -O-C(O)-NQ1096Q1097, -30 NHQ1095, -O-C (O) -NQ1096Q1097, -
OP(O)(OQI 098)(OQ1099), -OSi(Q1 100)(Q1 101 )(Q1102), - OS(O2)-Q1103, -NHC(O)-Q1 104, -NQ1105C(O)-Q1106, - NH-C(O)-O-Q1107, -NH-C(O)-NH-Q1108, -NH-C(O)- NQ1109Q1 110, -NQ11 1 1-C(O)-O-Q1 112, -NQ11 13-C(O)- NH-Q1 114, -NQ11 15-C(O)-NQ11 16Q1 117, -NHS(O2)- Q11 18, -NQ1 119S(O2)-Q1 120, -S-Q1121 , -S(O)-Q1 122, - S(02)-Q1123, -S(O2)NH-Q1124, -S(O2)NQ1 125Q1126, - S(O2)O-Q1127, -P(O)(OQ1128)(OQ1129), - Si(QI 130)(Q1131 )(Q1132)"; wobei Q1081 , Q1082, Q1083, Q1084, Q1085, Q1086, Q1087, Q1088, Q1089, Q1090, Q1091 , Q1092, Q1093, Q1094, Q1095, Q1096, Q1097, Q1098, Q1099, Q1100, Q1101 , Q1102, Q1103, Q1104, Q1105, Q1106, Q1107, Q1108, Q1109, Q11 10, Q11 11 , Q11 12, Q11 13, Q11 14, Q11 15,OP (O) (OQI 098) (OQ1099), -OSi (Q1 100) (Q1 101) (Q1102), - OS (O 2) -Q1103, -NHC (O) -Q1 104 -NQ1105C (O) - Q1106, - NH-C (O) -O-Q1107, -NH-C (O) -NH-Q1108, -NH-C (O) - NQ1109Q1 110, -NQ11 1 1-C (O) -O-Q1 112, -NQ11 13-C (O) - NH-Q1 114, -NQ11 15-C (O) -NQ11 16Q1 117, -NHS (O 2 ) -Q11 18, -NQ1 119S (O 2 ) -Q1 120, -S-Q1121, -S (O) - Q1 122, - S (0 2) -Q1123, -S (O 2) NH-Q1124, -S (O 2) NQ1 125Q1126, - S (O 2) O-Q1127, -P (O) (OQ1128) ( OQ1129), - Si (QI 130) (Q1131) (Q1132) ", wherein Q1081, Q1082, Q1083, Q1084, Q1085, Q1086, Q1087, Q1088, Q1089, Q1090, Q1091, Q1092, Q1093, Q1094, Q1095, Q1096, Q1097, Q1098, Q1099, Q1100, Q1101, Q1102, Q1103, Q1104, Q1105, Q1106, Q1107, Q1108, Q1109, Q11 10, Q11 11, Q11 12, Q11 13, Q11 14, Q11 15,
Q11 16, Q11 17, Q11 18, Q11 19, Q1120, Q1121. Q1122, Q1123, Q1124, Q1125, Q1126, Q1127, Q1128, Q1129, Q1130, Q1131 , Q1132 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cyc- loalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, ary- lalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q1087, Q1088 und/oder Q1096, Q1097 und/oder Q1 109, Q1 110 und/oder Q1 116, Q1 117 und/oder Q1 125, Q1 126 jeweils zusammen auch „heterocyclyl" bilden können;Q11 16, Q11 17, Q11 18, Q11 19, Q1120, Q1121. Q1122, Q1123, Q1124, Q1125, Q1126, Q1127, Q1128, Q1129, Q1130, Q1131, Q1132 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, Cyc loalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively Q1087, Q1088 and / or Q1096, Q1097 and / or Q1 109, Q1 110 and / or Q1 116, Q1 117 and / or Q1 125, Q1 126 together can also form "heterocyclyl";
NZ8Z9, wobei Z8, Z9 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:NZ8Z9, wherein Z8, Z9 are independently selected from the group consisting of:
(i) „Wasserstoff, alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C(O)- Q1133, -C(O)O-Q1134, -C(O)-NQ1 135Q1136, -S(O2)-Q1137, -(i) "hydrogen, alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C (O) - Q1133, -C (O) O-Q1134 , -C (O) -NQ1 135Q1136, -S (O 2) -Q1137, -
S(O2)O-Q1138"; wobei Q1 133, Q1 134, Q1 135, Q1 136, Q1 137, Q1 138 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q1 135, Q1 136 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHQ1 139, -NQ1140Q1 141 , -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q1 142, -C(O)O-Q1 143, -C(O)NH- Q1144, -C(O)NQ1 145Q1146, -0-Q1147, -0(-Q1148-O)m-H (mS (O 2) O-Q1138 "; wherein Q1 133, Q1 134, Q1 135, Q1 136, Q1 137, Q1 138 are independently selected from the group consisting of: hydrogen, alkyl, (Cg-C 3 o) alkyl , cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively Q1 135, Q1 136 may together also form" heterocyclyl "; in which optionally substituents of substituent group (i) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of: (ii) alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHQ1 139, -NQ1140Q1 141, -NO 2, -OH, - OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q1 142, -C (O) O-Q1 143, -C (O) NH-Q1144, -C (O) NQ1 145Q1146, -O-Q1147, -O (-Q1148-O) m -H (m
= 1 , 2, 3, 4, 5), -0(-Q1149-O)m-Q1150 (m = 1 , 2, 3, 4, 5), - OC(O)-Q1151 , -OC(O)-O-Q1152, -OC(O)-NHQ1153, -O- C(O)-NQ1 154Q1155, -OP(O)(OQ1 156)(OQ1 157), - OSi(QI 158)(Q1 159)(Q1 160), -0S(02)-Q1 161 , -NHC(O)-Q1162, -NQ1 163C(O)-Q1 164, -NH-C(O)-O-Q1 165, -NH-C(O)-NH-= 1, 2, 3, 4, 5), -0 (-Q1149-O) m -Q1150 (m = 1, 2, 3, 4, 5), - OC (O) -Q1151, -OC (O) -O-Q1152, -OC (O) -NHQ1153, -O- C (O) -NQ1 154Q1155, -OP (O) (OQ1 156) (OQ1 157), - OSi (QI 158) (Q1 159) (Q1 160), -0S (0 2 ) -Q1 161, -NHC (O) -Q1162, -NQ1 163C (O) -Q1 164, -NH-C (O) -O-Q1 165, -NH-C (O ) -NH-
Q1166, -NH-C(O)-NQ1 167Q1 168, -NQ1169-C(O)-O-Q1 170, - NQ1171 -C(O)-NH-Q1 172, -NQ1173-C(O)-NQ1174Q1 175, - NHS(02)-Q1 176, -NQ1177S(O2)-Q1178, -S-Q1179, -S(O)- Q1180, -S(02)-Q1181 , -S(O2)NH-Q1 182, -S(O2)NQ1183Q1 184, -S(O2)O-Q1 185, -P(O)(OQ1 186)(OQ1 187), -Q1166, -NH-C (O) -NQ1 167Q1 168, -NQ1169-C (O) -O-Q1 170, -NQ1171 -C (O) -NH-Q1 172, -NQ1173-C (O) -NQ1174Q1 175 , - NHS (0 2) -Q1 176, -NQ1177S (O 2) -Q1178, -S-Q1179, -S (O) - Q1180, -S (0 2) -Q1181, -S (O 2) NH- Q1 182, -S (O 2) NQ1183Q1 184, -S (O 2) OQ1 185, -P (O) (OQ1 186) (OQ1 187), -
Si(QI 188)(Q1189)(Q1190)"; wobei Q1 139, Q1 140, Q1 141 , Q1 142, Q1 143, Q1 144, Q1 145, Q1146, Q1147, Q1148, Q1149, Q1150, Q1151 , Q1152, Q1153, Q1154, Q1155, Q1156, Q1157, Q1158, Q1159, Q1160, Q1161 , Q1162, Q1163, Q1164, Q1165, Q1166, Q1167, Q1168, Q1169,Si (QI 188) (Q1189) (Q1190) "; where Q1 is 139, Q1 is 140, Q1 is 141, Q1 is 142, Q1 is 143, Q1 is 144, Q1 is 145, Q1146, Q1147, Q1148, Q1149, Q1150, Q1151, Q1152, Q1153 , Q1154, Q1155, Q1156, Q1157, Q1158, Q1159, Q1160, Q1161, Q1162, Q1163, Q1164, Q1165, Q1166, Q1167, Q1168, Q1169,
Q1170, Q1171 , Q1172, Q1173, Q1174, Q1175, Q1176, Q1177, Q1178, Q1179, Q1180, Q1181 , Q1182, Q1183, Q1184, Q1185, Q1186, Q1187, Q1188, Q1189, Q1190 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q1145, Q1146 und/oder Q1154, Q1155 und/oder Q1 167, Q1 168 und/oder Q1 174, Q1 175 und/oder Q1 183, Q1 184 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Q1170, Q1171, Q1172, Q1173, Q1174, Q1175, Q1176, Q1177, Q1178, Q1179, Q1180, Q1181, Q1182, Q1183, Q1184, Q1185, Q1186, Q1187, Q1188, Q1189, Q1190 are independently selected from the group consisting of "Alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively Q1145, Q1146 and / or Q1154, Q1155 and / or Q1 167, Q1 168 and / or Q1 174, Q1 175 and / or Q1 183, Q1 184 may together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
5 (iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I1 CN1 CF3, N3, NH2, -NHQ1191 , -NQ1 192Q1193, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-Q1194, -C(O)O-5 (iii) alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I 1 CN 1 CF 3 , N 3 , NH 2 , -NHQ1191, -NQ1 192Q1193, -NO 2 , - OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, - C ( O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Q 1194, -C (O) O-
10 Q1195, -C(O)NH-Q1 196, -C(O)NQ1 197Q1198, -0-Q1 199, -10 Q1195, -C (O) NH-Q1 196, -C (O) NQ1 197Q1198, -0-Q1 199, -
0(-Q1200-O)n-H (n = 1 , 2, 3, 4, 5), -0(-Q1201-O)n-QI 202 (n = 1 , 2, 3, 4, 5), -OC(O)-QI 203, -OC(O)-O-QI 204, - OC(O)-NHQI 205, -0-C(O)-NQI 206Q1207, - OP(O)(OQ1208)(OQ1209), -OSi(Q1210)(Q1211 )(Q1212), -0 (-Q1200-O) n -H (n = 1, 2, 3, 4, 5), -0 (-Q1201-O) n -QI 202 (n = 1, 2, 3, 4, 5), -OC (O) -QI 203, -OC (O) -O-QI 204, - OC (O) -NHQI 205, -O-C (O) -NQI 206Q1207, - OP (O) (OQ1208) (OQ1209 ), -OSi (Q1210) (Q1211) (Q1212), -
15 OS(O2)-Q1213, -NHC(O)-Q1214, -NQ1215C(O)-Q1216, -15 OS (O 2) -Q1213, -NHC (O) -Q1214, -NQ1215C (O) -Q1216, -
N H-C(O)-O-QI 217, -NH-C(O)-NH-Q1218, -NH-C(O)- NQ1219Q1220, -N Q 1221-C(O)-O-Q 1222, -NQ1223-C(O)- NH-Q1224, -NQ1225-C(O)-NQI 226Q1227, -NHS(O2)- Q1228, -NQ1229S(O2)-Q1230, -S-Q1231 , -S(O)-Q1232, -N HC (O) -O-QI 217, -NH-C (O) -NH-Q1218, -NH-C (O) - NQ1219Q1220, -NQ 1221-C (O) -OQ 1222, -NQ1223-C ( O) - NH-Q1224, -NQ1225-C (O) -NQI 226Q1227, -NHS (O 2) - Q1228, -NQ1229S (O 2) -Q1230, -S-Q1231, -S (O) -Q1232, -
20 S(O2)-Q1233, -S(O2)NH-Q1234, -S(O2)NQ1235Q1236, -20S (O 2 ) -Q 1233, -S (O 2 ) NH-Q 1234, -S (O 2 ) NQ 1235Q 1236, -
S(O2)O-Q1237, -P(O)(OQ1238)(OQ1239), - Si(Q1240)(Q1241 )(Q1242)"; wobei Q1191 , Q1192, Q1193, Q1194, Q1195, Q1196, Q1197, Q1198, Q1199, Q1200, Q1201, Q1202, Q1203, Q1204,S (O 2) O-Q1237, -P (O) (OQ1238) (OQ1239), - Si (Q1240) (Q1241) (Q1242) "; wherein Q1191, Q1192, Q1193, Q1194, Q1195, Q1196, Q1197, Q1198 , Q1199, Q1200, Q1201, Q1202, Q1203, Q1204,
25 Q1205, Q1206, Q1207, Q1208, Q1209, Q1210, Q1211,25 Q1205, Q1206, Q1207, Q1208, Q1209, Q1210, Q1211,
Q1212, Q1213, Q1214, Q1215, Q1216, Q1217, Q1218, Q1219, Q1220, Q1221, Q1222, Q1223, Q1224, Q1225, Q1226, Q1227, Q1228, Q1229, Q1230, Q1231, Q1232, Q1233, Q1234, Q1235, Q1236, Q1237, Q1238, Q1239,Q1212, Q1213, Q1214, Q1215, Q1216, Q1217, Q1218, Q1219, Q1220, Q1221, Q1222, Q1223, Q1224, Q1225, Q1226, Q1227, Q1228, Q1229, Q1230, Q1231, Q1232, Q1233, Q1234, Q1235, Q1236, Q1237, Q1238, Q1239,
30 Q1240, Q1241 , Q1242 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ Q1 197, Q1198 und/oder Q1206, Q1207 und/oder Q1219, Q1220 und/oder Q1226, Q1227 und/oder Q1235, Q1236 jeweils zusammen auch „heterocyclyl" bilden können;30 Q1240 are Q1241, Q1242 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively Q1 197, Q1198 and / or Q1206, Q1207 and / or Q1219, Q1220 and / or Q1226, Q1227 and / or Q1235, Q1236 may together also form "heterocyclyl";
undand
Reste Z1 , Z2 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „Wasserstoff, NZ14Z15"; mit der Maßgabe, dass wenn Z1 = H ist, Z2 = NZ14Z15 ist, und wenn Z1 = NZ14Z15 ist, Z2 = H ist; wobei Z14, Z15 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:Radicals Z1, Z2 are independently selected from the group consisting of: "hydrogen, NZ14Z15"; provided that when Z1 = H, Z2 = NZ14Z15, and when Z1 = NZ14Z15, Z2 = H, wherein Z14 , Z15 are independently selected from the group consisting of:
(a) „Wasserstoff, alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C(Y1 )NZ16Z17, - C(=NZ18)-Z19, -C(Y2)NZ20-Y3-Z21 "; mit der Maßgabe, dass Z14, Z15 nicht gleichzeitig Wasserstoff oder „alkyl, (C9-(a) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C (Y 1) NZ16Z17, -C (= NZ18) -Z 19 , -C (Y2) NZ20-Y3 -Z21 "; with the proviso that Z14, Z15 are not simultaneously hydrogen or" alkyl, (C 9 -
C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" sind; mit der weiteren Maßgabe, dass wenn einer der Reste Z14, Z15 Wasserstoff oder „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylal- kyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" ist, der jeweils andere Rest Z14,C 3 o) alkyl, cycloalkyl, "are, with the further proviso that when one of Z14, Z15 hydrogen or" cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl alkyl, (Cg-C 3 o) alkyl , cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", in each case the other radical Z14,
Z15 ,,-C(Y1 )NZ16Z17", ,,-C(=NZ18)-Z19" oder ,,-C(Y2)NZ20-Y3-Z21 " ist; wobei Y1 , Y2, Y3 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus „O, S, =NH, =NZ22"; wobei Z16, Z17, Z18, Z19, Z20, Z21 , Z22 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:Z15 ,, - C (Y1) NZ16Z17 "," - C (= NZ18) -Z19 "or" - C (Y2) NZ20-Y3-Z21 "; wherein Y1, Y2, Y3 are independently selected from Group consisting of "O, S, = NH, = NZ22"; wherein Z16, Z17, Z18, Z19, Z20, Z21, Z22 are independently selected from the group consisting of:
(1 ) Wasserstoff(1) hydrogen
(2) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl"; wobei obige Substituenten der Substitutionsgruppe (a) und/oder Substitutions- gruppe (2) unabhängig voneinander optional substituiert sein können mit min- destens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(2) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl"; wherein the above substituents of the substitution group (a) and / or substitution group (2) are independently may optionally be substituted from one another with at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHU1 , -NU2U3, -NO2, -OH, -OCF3, -SH, -0-SO3H, -(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2, -NHU1, -NU2U3, -NO 2, -OH, -OCF3, -SH, -0-SO 3 H, -
OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- U4, -C(0)0-U5, -C(0)NH-U6, -C(O)NU7U8, -0-U9, -0(-UI O-O) - H (r = 1 , 2, 3, 4, 5), -0(-U1 1-0) -U12 (r = 1 , 2, 3, 4, 5), -OC(O)-UI 3, -0C(0)-0-U14, -0C(0)-NHU15, -0-C(O)-N U 16U 17, - OP(O)(OU18)(OU19), -OSi(U20)(U21 )(U22), -OS(O2)-U23, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -U 4 , -C (O ) 0-U5, -C (O) NH-U6, -C (O) NU7U8, -O-U9, -O (-UI OO) - H (r = 1, 2, 3, 4, 5), 0 (-U1 1-0) -U12 (r = 1, 2, 3, 4, 5), -OC (O) -UI3, -0C (0) -0-U14, -0C (0) -NHU15 , -0-C (O) -NU 16U 17, - OP (O) (OU18) (OU19), -OSi (U20) (U21) (U22), -OS (O 2) -U23, -
NHC(O)-U24, -NU25C(O)-U26, -NH-C(O)-O-U27, -NH-C(O)-NH- U28, -NH-C(O)-NU29U30, -NU31-C(O)-O-U32, -NU33-C(O)-NH- U34, -NU35-C(O)-NU36U37, -NHS(O2)-U38, -NU39S(O2)-U40, - S-U41 , -S(O)-U42, -S(O2)-U43, -S(O2)NH-U44, -S(O2)NU45U46, - S(O2)O-U47, -P(O)(OU48)(OU49), -Si(U50)(U51 )(U52)"; wobei U1 , U2, U3, U4, U5, U6, U7, U8, U9, U10, U1 1 , U12, U13, U14, U15, U16, U17, U18, U19, U20, U21 , U22, U23, U24, U25, U26, U27, U28, U29, U30, U31 , U32, U33, U34, U35, U36, U37, U38, U39, U40, U41 , U42, U43, U44, U45, U46, U47, U48, U49, U50, U51 , U52 unab- hängig voneinander ausgewählt sind aus der Gruppe bestehend aus:NHC (O) -U24, -NU25C (O) -U26, -NH-C (O) -O-U27, -NH-C (O) -NH-U28, -NH-C (O) -NU29U30, - NU31-C (O) -O-U32, -NU33-C (O) -NH- U34, -NU35-C (O) -NU36U37, -NHS (O 2) -U38, -NU39S (O 2) -U40 , - S-U41, -S (O) -U42, -S (O 2) -U43, -S (O 2) NH-U44, -S (O 2) NU45U46, - S (O 2) O-U47 , -P (O) (OU48) (OU49), -Si (U50) (U51) (U52) ", where U1, U2, U3, U4, U5, U6, U7, U8, U9, U10, U1 1, U, U, U, U, U, U, U, U, U, U, U, U, U, U, U, U, U, U, U, U, U U37, U38, U39, U40, U41, U42, U43, U44, U45, U46, U47, U48, U49, U50, U51, U52 independently of one another are selected from the group consisting of:
„alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ U7, U8 und/oder U16, U17 und/oder U29, U30 und/oder U36, U37 und/oder U45, U46 jeweils zusammen auch „heterocyclyl" bilden kön- nen; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHU53, -NU54U55, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, - P(O)(OH)2, -C(O)-U56, -C(O)O-U57, -C(O)NH-U58, - C(O)NU59U60, -O-U61 , -O(-U62-O)r-H (r = 1 , 2, 3, 4, 5), -O(- U63-O)r-U64 (r = 1 , 2, 3, 4, 5), -OC(O)-U65, -OC(O)-O-U66, - OC(O)-NHU67, -O-C(O)-NU68U69, -OP(O)(OU70)(OU71 ), - OSi(U72)(U73)(U74), -OS(O2)-U75, -NHC(O)-U76, -NU77C(O)- 5 U78, -NH-C(O)-O-U79, -NH-C(O)-NH-U80, -NH-C(O)-"Alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and where alternatively U 7, U 8 and / or U 16, U 17 and / or U 29, U 30 and / or U36, U37 and / or U45, U46 may together also form "heterocyclyl"; in which optionally substituents of substituent group (i) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of: (ii) alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHU53, -NU54U55, -NO 2, -OH, -OCF 3, -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, - P (O) (OH) 2 , - C (O) -U56, -C (O) O -U57, -C (O) NH -U58, - C (O) NU59U60, -O-U61, -O (-U62-O) r -H (r = 1, 2, 3, 4, 5), -O (- U63-O) r -U64 (r = 1, 2, 3, 4, 5), -OC (O) -U65, -OC (O) -O-U66, -OC (O) -NHU67, -OC (O) -NU68U69, -OP (O) (OU70) (OU71), - OSi (U72) (U73) (U74), -OS (O 2) -U75, -NHC (O) -U76, -NU77C (O) - 5 U78, -NH-C ( O) -O-U79, -NH-C (O) -NH-U80, -NH-C (O) -
NU81 U82, -NU83-C(O)-O-U84, -NU85-C(O)-NH-U86, -NU87- C(O)-NU88U89, -NHS(O2)-U90, -NU91S(O2)-U92, -S-U93, - S(O)-U94, -S(O2)-U95, -S(O2)NH-U96, -S(O2)NU97U98, - S(O2)O-U99, -P(O)(OU I OO)(OU I OI ), -Si(UI 02)(U103)(U104)";NU81 U82, -NU83-C (O) -O-U84, -NU85-C (O) -NH-U86, -NU87- C (O) -NU88U89, -NHS (O 2) -U90, -NU91S (O 2) -U92, -S-U93, - S (O) -U94, -S (O 2) -U95, -S (O 2) NH-U96, -S (O 2) NU97U98, - S (O 2 ) O-U99, -P (O) (OUIOO) (OUIOI), -Si (UIO2) (U103) (U104) ";
10 wobei U53, U54, U55, U56, U57, U58, U59, U60, U61 , U62, U63,10 where U53, U54, U55, U56, U57, U58, U59, U60, U61, U62, U63,
U64, U65, U66, U67, U68, U69, U70, U71 , U72, U73, U74, U75, U76, U77, U78, U79, U80, U81 , U82, U83, U84, U85, U86, U87, U88, U89, U90, U91 , U92, U93, U94, U95, U96, U97, U98, U99, U100, U101 , U 102, U103, U104 unabhängig voneinander ausge-U64, U65, U66, U67, U68, U69, U70, U71, U72, U73, U74, U75, U76, U77, U78, U79, U80, U81, U82, U83, U84, U85, U86, U87, U88, U89, U90, U91, U92, U93, U94, U95, U96, U97, U98, U99, U100, U101, U102, U103, U104 are independent of each other.
15 wählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, ary- lalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ U59, U60 und/oder U68, U69 und/oder U81 , U82 und/oder U88, U89 und/oder U97, U98 jeweils zusammen auch „heterocyclyl" bilden15 selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and where alternatively U 59, U 60 and / or U 68, U69 and / or U81, U82 and / or U88, U89 and / or U97, U98 together also form "heterocyclyl"
20 können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:20 can; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
25 (iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHU105, -NU106U107, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-U108, -C(O)O-U109, -25 (iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHU105, -NU106U107, -NO 2, -OH, -OCF3, -SH, -0-SO3H, -OP (O) (OH) 2, -CHO, -COOH, - C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -U108, -C (O) O-U109, -
30 C(O)NH-U1 10, -C(O)NU11 1 U1 12, -0-U113, -0(-U114-O)5-30 C (O) NH-U1 10, -C (O) NU11 1 U1 12, -O-U113, -O (-U114-O) 5 -
H (s = 1 , 2, 3, 4, 5), -0(-111 15-O)8-U1 16 (S = 1 , 2, 3, 4, 5), - OC(O)-UI ^1 -OC(O)-O-UI IS1 -OC(O)-NHUI Ig1 -O-C(O)- NU120U121 , -OP(O)(OU122)(OU123), - OSi(U124)(U125)(U126), -OS(O2)-U127, -NHC(O)-U128, - NU^gC(O)-UI SO1 -NH-C(O)-O-UI SI 1 -NH-C(O)-NH- U132, -NH-C(O)-NU133U134, -N U 135-C(O)-O-U 136, - NU137-C(O)-NH-UI 38, -NU139-C(O)-NU140U141 , - NHS(O2)-U142, -NU143S(O2)-U144, -S-U145, -S(O)-U146, -S(O2)-U147, -S(O2)NH-U148, -S(O2)NU149U150, -S(O2)O-H (s = 1, 2, 3, 4, 5), -0 (-111 15-O) 8 -U1 16 (S = 1, 2, 3, 4, 5), - OC (O) -Ul ^ 1 -OC (O) -O-UI IS 1 -OC (O) -NHUI Ig 1 -OC (O) - NU120U121, -OP (O) (OU122) (OU123), - OSi (U124) (U125) ( U126), -OS (O 2 ) -U127, -NHC (O) -U128, - NU ^ gC (O) -UI SO 1 -NH-C (O) -O-UI SI 1 -NH-C (O) -NH-U132, -NH-C (O) -NU 13 3U134, -NU 135-C (O) ou 136 - NU137-C (O) -NH-UI 38, -NU139-C (O) -NU140U141, - NHS (O 2) -U142, -NU143S (O 2) -U144, -S -U145, -S (O) -U146, -S (O 2) -U147, -S (O 2) NH-U148, -S (O 2) NU149U150, -S (O 2) O-
U151 , -P(O)(OU152)(OU153), -Si(U154)(U155)(U156)"; wobei U105, U106, U107, U108, U109, U110, U111, U112, U113, U114, U115, U116, U117, U118, U119, U120, U121, U122, U123, U124, U125, U126, U127, U128, U129, U130, U131, U132, U133, U134, U135, U136, U137, U138, U139,U151, -P (O) (OU152) (OU153), -Si (U154) (U155) (U156) ", where U105, U106, U107, U108, U109, U110, U111, U112, U113, U114, U115, U116, U117, U118, U119, U120, U121, U122, U123, U124, U125, U126, U127, U128, U129, U130, U131, U132, U133, U134, U135, U136, U137, U138, U139,
U140, U141, U142, U143, U144, U145, U146, U147, U148, U149, U150, U151, U152, U153, U154, U155, U156 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ U1 11 , U1 12 und/oder U 120, U 121 und/oder U133, U134 und/oder U140, U141 und/oder U149, U150 jeweils zusammen auch „heterocyclyl" bilden können;U140, U141, U142, U143, U144, U145, U146, U147, U148, U149, U150, U151, U152, U153, U154, U155, U156 are independently selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyc IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively U1 11, U1 12 and / or U 120, U 121 and / or U133, U134 and / or U140 , U141 and / or U149, U150 may together also form "heterocyclyl";
(3) -C(O)-Z23, wobei Z23 unabhängig ausgewählt ist aus der Gruppe bestehend aus:(3) -C (O) -Z23, wherein Z23 is independently selected from the group consisting of:
(a) „Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei obige Substituenten der Substitutionsgruppe (a) unabhängig voneinander optional substituiert sein können mit mindestens einem(a) "hydrogen, alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wherein above substituents of the substitution group (a) may be independently optionally substituted with at least one
Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Substituents, the same or different, selected from the group consisting of:
(i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHU157, -NU158U159, -NO2, -OH, -OCF3, -(i) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHU157, -NU158U159, -NO 2 , -OH, -OCF 3 , -
SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-U 160, -C(O)O-U 161 , -C(O)NH-U 162, - C(O)NUI 63U164, -O-U165, -0(-U166-O)1-H (t = 1 , 2, 3, 4, 5), - O(-U167-O)t-U168 (t = 1 , 2, 3, 4, 5), -OC(O)-UI 69, -OC(O)-O- U170, -OC(O)-NHU 171 , -O-C(O)-NU172U173, - OP(O)(OU174)(OU175), -OSi(U176)(U177)(U178), -OS(O2)- U179, -NHC(O)-U180, -NU181C(O)-U182, -NH-C(O)-O-UI 83,SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -U 160, -C (O) OU 161, -C (O) NH -U 162, -C (O) NUI 63U164, -O-U165, -O (-U166-O) 1 -H ( t = 1, 2, 3, 4, 5), - O (-U167-O) t -U168 (t = 1, 2, 3, 4, 5), -OC (O) -UI 69, -OC (O) -O-U170, -OC (O) -NHU 171, -OC (O) -NU172U173, - OP (O) (OU174) (OU175), -OSi (U176) (U177), (U178), -OS (O 2) - U179, -NHC (O) -U180 , -NU181C (O) -U182, -NH-C (O) -O-UI 83,
5 -N H-C(O)-N H-U 184, -NH-C(O)-NU185U186, -NU187-C(O)-5 -NH-C (O) -NH-U184, -NH-C (O) -NU185U186, -NU187-C (O) -
O-U188, -N U 189-C(O)-N H-U 190, -NU191-C(O)-NU192U193, -NHS(O2)-U194, -NU195S(O2)-U196, -S-U197, -S(O)-U198, - S(O2)-U199, -S(O2)NH-U200, -S(O2)NU201 U202, -S(O2)O- U203, -P(O)(OU204)(OU205), -Si(U206)(U207)(U208)";O-U188, -NU 189-C (O) -N HU 190 -NU191-C (O) -NU192U193, -NHS (O 2) -U194, -NU195S (O 2) -U196, -S-U197, -S (O) -U198, - S (O 2) -U199, -S (O 2) NH-U200, -S (O 2) NU201 U202, -S (O 2) O- U203, -P (O ) (OU204) (OU205), -Si (U206) (U207) (U208) ";
10 wobei U157, U158, U159, U160, U161 , U162, U163, U164, U165,10 where U157, U158, U159, U160, U161, U162, U163, U164, U165,
U166, U167, U168, U169, U170, U171 , U172, U173, U174, U175, U176, U177, U178, U179, U180, U181 , U182, U183, U184, U185, U186, U187, U188, U189, U190, U191 , U192, U193, U194, U195, U196, U197, U198, U199, U200, U201 , U202, U203, U204, U205,U166, U167, U168, U169, U170, U171, U172, U173, U174, U175, U176, U177, U178, U179, U180, U181, U182, U183, U184, U185, U186, U187, U188, U189, U190, U191, U192, U193, U194, U195, U196, U197, U198, U199, U200, U201, U202, U203, U204, U205,
15 U206, U207, U208 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ U 163, U 164 und/oder U 172, U173 und/oder U185, U186 und/oder U192, U193 und/oder U201 ,15 U206, U207, U208 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively U 163, U 164 and / or U 172, U173 and / or U185, U186 and / or U192, U193 and / or U201,
20 U202 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:20 U202 may in each case also form "heterocyclyl", where optionally substituted substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
25 (ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHU209, -NU210U211 , -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-U212, -C(O)O-U213, -25 (ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHU209, -NU210U211, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) -U212, -C (O) O-U213, -
30 C(O)NH-U214, -C(O)NU215U216, -O-U217, -O(-U218-O)u-30 C (O) NH-U214, -C (O) NU215U216, -O-U217, -O (-U218-O) u -
H (u = 1 , 2, 3, 4, 5), -O(-U219-O)u-U220 (u = 1 , 2, 3, 4, 5), - OC(O)-U221 , -OC(O)-O-U222, -OC(O)-NHU223, -0-C(O)- NU224U225, -OP(O)(OU226)(OU227), - OSi(U228)(U229)(U230), -OS(O2)-U231 , -NHC(O)-U232, - NU233C(O)-U234, -NH-C(O)-O-U235, -NH-C(O)-NH- U236, -NH-C(O)-NU237U238, -NU239-C(O)-O-U240, - NU241-C(O)-NH-U242, -NU243-C(O)-NU244U245, - NHS(O2)-U246, -NU247S(O2)-U248, -S-U249, -S(O)-U250,H (u = 1, 2, 3, 4, 5), -O (-U219-O) u -U220 (u = 1, 2, 3, 4, 5), - OC (O) -U221, -OC (O) -O-U222, -OC (O) -NHU223, -O-C (O) -NU224U225, -OP (O) (OU226) (OU227), -OSi (U228) (U229) (U230), -OS (O 2) -U231, -NHC (O) -U232, - NU233C (O) -U234, -NH-C (O) -O-U235, -NH-C (O) -NH-U236, -NH-C (O) -NU237U238, -NU239-C (O) -O -U240, - NU241-C (O) -NH-U242, -NU243-C (O) -NU244U245, - NHS (O 2) -U246, -NU247S (O 2) -U248, -S-U249, -S (O) -U250,
5 -S(O2)-U251 , -S(O2)NH-U252, -S(O2)NU253U254, -S(O2)O-5 -S (O 2) -U251, -S (O 2) NH-U252, -S (O 2) NU253U254, -S (O 2) O-
U255, -P(O)(OU256)(OU257), -Si(U258)(U259)(U260)"; wobei U209, U210, U211 , U212, U213, U214, U215, U216, U217, U218, U219, U220, U221 , U222, U223, U224, U225, U226, U227, U228, U229, U230, U231 , U232, U233, U234,U255, -P (O) (OU256) (OU257), -Si (U258) (U259) (U260) "; where U209, U210, U211, U212, U213, U214, U215, U216, U217, U218, U219, U220, U221, U222, U223, U224, U225, U226, U227, U228, U229, U230, U231, U232, U233, U234,
10 U235, U236, U237, U238, U239, U240, U241 , U242, U243,10 U235, U236, U237, U238, U239, U240, U241, U242, U243,
U244, U245, U246, U247, U248, U249, U250, U251 , U252, U253, U254, U255, U256, U257, U258, U259, U260 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc-U244, U245, U246, U247, U248, U249, U250, U251, U252, U253, U254, U255, U256, U257, U258, U259, U260 are independently selected from the group consisting of: "alkyl, (C 9 - C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyc-
15 IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ U215, U216 und/oder U224, U225 und/oder U237, U238 und/oder U244, U245 und/oder U253, U254 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe15 IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively U215, U216 and / or U224, U225 and / or U237, U238 and / or U244, U245 and / or U253, U254 in each case also form" heterocyclyl " can; optionally with the above substituents of the substituent group
20 (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:20 (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,(iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,
25 F, Cl, Br, I, CN, CF3, N3, NH2, -NHU261 , -NU262U263, -25 F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHU261, -NU262U263, -
NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-U264, - C(O)O-U265, -C(O)NH-U266, -C(O)NU267U268, -O- U269, -O(-U270-O)v-H (v = 1 , 2, 3, 4, 5), -O(-U271-O)v-NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, - P (O) (OH) 2 , -C (O) -U264, -C (O) O-U265, -C (O) NH-U266, -C (O) NU267U268, -O-U269, -O ( -U270-O) v -H (v = 1, 2, 3, 4, 5), -O (-U271-O) v -
30 U272 (v = 1, 2, 3, 4, 5), -OC(O)-U273, -OC(O)-O-U274,30 U272 (v = 1, 2, 3, 4, 5), -OC (O) -U273, -OC (O) -O-U274,
-OC(O)-NHU275, -O-C(O)-NU276U277, - OP(O)(OU278)(OU279), -OSi(U280)(U281)(U282), - OS(O2)-U283, -NHC(O)-U284, -NU285C(O)-U286, -NH- C(O)-O-U287, -NH-C(O)-NH-U288, -NH-C(O)- NU289U290, -NU291-C(O)-O-U292, -N 11293-C(O)-NH- U294, -NU295-C(O)-NU296U297, -NHS(O2)-U298, - NU299S(O2)-U300, -S-U301 , -S(O)-U302, -S(O2)-U303, -S(O2)NH-U304, -S(O2)NU305U306, -S(O2)O-U307, - P(O)(OU308)(OU309), -Si(U310)(U311 )(U312)"; wobei U261 , U262, U263, U264, U265, U266, U267, U268, U269, U270, U271 , U272, U273, U274, U275, U276, U277, U278, U279, U280, U281 , U282, U283, U284, U285, U286, U287, U288, U289, U290, U291 , U292, U293, U294, U295, U296, U297, U298, U299, U300, U301 , U302, U303, U304,-OC (O) -NHU275, -OC (O) -NU276U277, - OP (O) (OU278) (OU279), -OSi (U280) (U281), (U282), - OS (O 2) -U283, - NHC (O) -U284, -NU285C (O) -U286, -NH-C (O) -O-U287, -NH-C (O) -NH-U288, -NH-C (O) - NU289U290, -NU291-C (O) -O-U292, -N 11293-C (O) -NH- U294, -NU295-C (O) -NU296U297, -NHS (O 2) -U298, - NU299S (O 2) -U300, U301 -S, -S (O) -U302, -S (O 2) -U303, -S (O 2) NH-U304, -S (O 2) NU305U306, -S (O 2 ) O-U307, -P (O) (OU308) (OU309), -Si (U310) (U311) (U312) "; wherein U261, U262, U263, U264, U265, U266, U267, U268, U269, U270 , U271, U272, U273, U274, U275, U276, U277, U278, U279, U280, U281, U282, U283, U284, U285, U286, U287, U288, U289, U290, U291, U292, U293, U294, U295 , U296, U297, U298, U299, U300, U301, U302, U303, U304,
U305, U306, U307, U308, U309, U310, U31 1 , U312 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ U267, U268 und/oderU305, U306, U307, U308, U309, U310, U31 1, U312 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively U267, U268 and / or
U276, U277 und/oder U289, U290 und/oder U296, U297 und/oder U305, U306 jeweils zusammen auch „heterocyclyl" bilden können;U276, U277 and / or U289, U290 and / or U296, U297 and / or U305, U306 may together also form "heterocyclyl";
(4) Z16, Z17 unabhängig optional zusammen auch „heterocyclyl" bilden können";(4) Z16, Z17 independently optionally together can also form "heterocyclyl" ";
(5) ,,-C(O)-C(O)-U313, -S(O2)-NU314U315"; wobei U313, U314, U315 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:(5) ,, - C (O) -C (O) -U313, -S (O 2) -NU314U315 "; wherein U313, U314, U315 independently selected from the group consisting of:
(I) „Wasserstoff, alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHU316, -NU317U318, -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, - SO3H, -P(O)(OH)2, -C(O)-U319, -C(O)O-U320, -C(O)NH-U321 , -(I) "is hydrogen, alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHU316, -NU317U318, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O ) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -U 3 19, -C (O) O -U320, -C (O) NH-U 321, -
C(O)NU322U323, -O-U324, -O(-U325-O)w-H (w = 1 , 2, 3, 4, 5), - O(-U326-O)w-U327 (w = 1 , 2, 3, 4, 5), -OC(O)-U328, -OC(O)-O- U329, -OC(O)-NHU330, -O-C(O)-NU331 U332, - OP(O)(OU333)(OU334), -OSi(U335)(U336)(U337), -OS(O2)-U338, -NHC(O)-U339, -NU340C(O)-U341 , -NH-C(O)-O-U342, -NH- C(O)-NH-U343, -NH-C(O)-NU344U345, -NU346-C(O)-O-U347, -NU348-C(O)-NH-U349, -NU350-C(O)-NU351 U352, -NHS(O2)- U353, -NU354S(O2)-U355, -S-U356, -S(O)-U357, -S(O2)-U358,C (O) NU322U323, -O-U324, -O (-U325-O) w -H (w = 1, 2, 3, 4, 5), - O (-U326-O) w -U327 (w = 1, 2, 3, 4, 5), -OC (O) -U328, -OC (O) -O-U329, -OC (O) -NHU330, -OC (O) -NU331 U332, - OP (O) (OU333) (OU334), -OSi (U335) (U336), (U337), -OS (O 2) -U338, -NHC (O) -U339, -NU340C (O) -U341, -NH -C (O) -O-U342, -NH-C (O) -NH-U343, -NH-C (O) -NU344U345, -Nu346-C (O) -O-U347, -NU348-C (O ) -NH-U349, -NU350-C (O) -NU351 U352, -NHS (O 2) - U353, -NU354S (O 2) -U355, U356 -S, -S (O) -U357, -S (O 2 ) -U358,
-S(O2)NH-U359, -S(O2)NU360U361 , -S(O2)O-U362, - P(O)(OU363)(OU364), -Si(U365)(U366)(U367)"; wobei U316, U317, U318, U319, U320, U321 , U322, U323, U324, U325, U326, U327, U328, U329, U330, U331 , U332, U333, U334, U335, U336, U337, U338, U339, U340, U341 , U342, U343, U344,-S (O 2) NH-U359, -S (O 2) NU360U361, -S (O 2) O-U362, - P (O) (OU363) (OU364), -Si (U365) (U366), (U367 U316, U317, U318, U319, U320, U321, U322, U323, U324, U325, U326, U327, U328, U329, U330, U331, U332, U333, U334, U335, U336, U337, U338, U339, U340, U341, U342, U343, U344,
U345, U346, U347, U348, U349, U350, U351 , U352, U353, U354, U355, U356, U357, U358, U359, U360, U361 , U362, U363, U364, U365, U366, U367 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloal- kylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, he- teroarylalkyl" und wobei alternativ U322, U323 und/oder U331 , U332 und/oder U344, U345 und/oder U351 , U352 und/oder U360, U361 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substitutionsgruppe (I) un- abhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:U345, U346, U347, U348, U349, U350, U351, U352, U353, U354, U355, U356, U357, U358, U359, U360, U361, U362, U363, U364, U365, U366, U367 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and where, alternatively, U322, U323 and / or U331, U332 and or U344, U345 and / or U351, U352 and / or U360, U361 may together also form "heterocyclyl"; optionally optionally substituents of the substitution group (I) can also be further substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHU368, -NU369U370, -NO2, -OH, -(i) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHU368, -NU369U370, -NO 2 , -OH, -
OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-U371 , -C(O)O-U372, - C(O)NH-U373, -C(O)NU374U375, -O-U376, -0(-11377-O)x-H (x = 1 , 2, 3, 4, 5), -O(-U378-O)x-U379 (x = 1 , 2, 3, 4, 5), - OC(O)-U380, -OC(O)-O-U381 , -OC(O)-NHU382, -0-C(O)-OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -U371, -C (O) O -U372, -C (O) NH-U373, -C (O) NU374U375, -O-U376, -O (-11377-O) x - H (x = 1, 2, 3, 4, 5), -O (-U378-O) x -U379 (x = 1, 2, 3, 4, 5), - OC (O) -U380, -OC (O) -O-U381, -OC (O) -NHU382, -O-C (O) -
NU383U384, -OP(O)(OU385)(OU386), - OSi(U387)(U388)(U389), -OS(O2)-U390, -NHC(O)-U391 , - NU392C(O)-U393, -NH-C(O)-O-U394, -NH-C(O)-NH-U395, -NH-C(O)-NU396U397, -NU398-C(O)-O-U399, -NU400- C(O)-NH-U401 , -NU402-C(O)-NU403U404, -NHS(O2)-U405, -NU406S(O2)-U407, -S-U408, -S(O)-U409, -S(O2)-U410, - S(O2)NH-U411 , -S(θ2)NU412U413, -S(O2)O-U414, - P(0)(0U415)(OU416), -Si(U417)(U418)(U419)";NU383U384, -OP (O) (OU385) (OU386), - OSi (U387) (U388), (U389), -OS (O 2) -U390, -NHC (O) -U391, - NU392C (O) -U393 , -NH-C (O) -O-U394, -NH-C (O) -NH-U395, -NH-C (O) -NU396U397, -NU398-C (O) -O-U399, -NU400 C (O) -NH-U401, -NU402-C (O) -NU403U404, -NHS (O 2) -U405, -NU406S (O 2) -U407, U408 -S, -S (O) -U409, -S (O 2) -U410, - S (O 2) NH-U411, -S (θ 2) NU412U413, -S (O 2) O-U414, - P (0) (0U415) (OU416) - Si (U417) (U418), (U419) ";
5 wobei U368, U369, U370, U371 , U372, U373, U374, U375,5 where U368, U369, U370, U371, U372, U373, U374, U375,
U376, U377, U378, U379, U380, U381 , U382, U383, U384, U385, U386, U387, U388, U389, U390, U391 , U392, U393, U394, U395, U396, U397, U398, U399, U400, U401 , U402, U403, U404, U405, U406, U407, U408, U409, U410, U411 ,U376, U377, U378, U379, U380, U381, U382, U383, U384, U385, U386, U387, U388, U389, U390, U391, U392, U393, U394, U395, U396, U397, U398, U399, U400, U401, U402, U403, U404, U405, U406, U407, U408, U409, U410, U411,
10 U412, U413, U414, U415, U416, U417, U418, U419 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ U374, U375 und/oder U383, U384 und/oder U396,Are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively U374, U375 and / or U383, U384 and / or U396,
15 U397 und/oder U403, U404 und/oder U412, U413 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, aus- 20 gewählt aus der Gruppe bestehend aus:U397 and / or U403, U404 and / or U412, U413 may in each case also form "heterocyclyl", where optionally substituted substituents of the substituent group (i) may in turn be substituted independently with at least one substituent, identical or different, aus 20 selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHU420, -NU421 U422, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHU420, -NU421 U422, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -
25 COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-U423, -25 COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -U423, -
C(O)O-U424, -C(O)NH-U425, -C(O)NU426U427, -O- U428, -O(-U429-O)y-H (y = 1 , 2, 3, 4, 5), -O(-U430-O)y- U431 (y = 1 , 2, 3, 4, 5), -OC(O)-U432, -OC(O)-O-U433, - OC(O)-NHU434, -O-C(O)-NU435U436, -C (O) O-U424, -C (O) NH-U425, -C (O) NU426U427, -O-U428, -O (-U429-O) y -H (y = 1, 2, 3, 4 , 5), -O (-U430-O) y -U431 (y = 1, 2, 3, 4, 5), -OC (O) -U432, -OC (O) -O-U433, -OC ( O) -NHU434, -OC (O) -NU435U436, -
30 OP(O)(OU437)(OU438), -OSi(U439)(U440)(U441 ), -30 OP (O) (OU437) (OU438), -OSi (U439) (U440) (U441), -
OS(O2)-U442, -NHC(O)-U443, -NU444C(O)-U445, -NH- C(O)-O-U446, -NH-C(O)-NH-U447, -NH-C(O)- NU448U449, -NU450-C(O)-O-U451 , -NU452-C(O)-NH- U453, -NU454-C(O)-NU455U456, -NHS(O2)-U457, - NU458S(O2)-U459, -S-U460, -S(O)-U461 , -S(O2)-U462, - S(O2)NH-U463, -S(O2)NU464U465, -S(O2)O-U466, - P(O)(OU467)(OU468), -Si(U469)(U470)(U471 )"; wobei U420, U421 , U422, U423, U424, U425, U426, U427,OS (O 2) -U442, -NHC (O) -U443, -NU444C (O) -U445, -NH- C (O) -O-U446, -NH-C (O) -NH-U447, -NH -C (O) - NU448U449, -NU450-C (O) -O-U451, -NU452-C (O) -NH- U453, -NU454-C (O) -NU455U456, -NHS (O 2) -U457 , - NU458S (O 2) -U459, U460 -S, -S (O) -U461, -S (O 2) -U462, - S (O 2) NH-U463, -S (O 2) NU464U465, -S (O 2 ) O-U466, -P (O) (OU467) (OU468), -Si (U469) (U470) (U471) "; where U420, U421, U422, U423, U424, U425, U426, U427,
5 U428, U429, U430, U431 , U432, U433, U434, U435, U436,5 U428, U429, U430, U431, U432, U433, U434, U435, U436,
U437, U438, U439, U440, U441 , U442, U443, U444, U445, U446, U447, U448, U449, U450, U451 , U452, U453, U454, U455, U456, U457, U458, U459, U460, U461 , U462, U463, U464, U465, U466, U467, U468, U469, U470, U471 unab-U437, U438, U439, U440, U441, U442, U443, U444, U445, U446, U447, U448, U449, U450, U451, U452, U453, U454, U455, U456, U457, U458, U459, U460, U461, U462, U463, U464, U465, U466, U467, U468, U469, U470, U471
10 hängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, he- terocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, hete- roarylalkyl" und wobei alternativ U426, U427 und/oder U435, U436 und/oder U448, U449 und/oder U455, U456 und/oder"(C 9 -C 3 o) alkyl, alkyl, cycloalkyl, cycloalkylalkyl, HE terocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, het- roarylalkyl" and wherein alternatively U426, U427: 10 pending selected from the group consisting of and / or U435, U436 and / or U448, U449 and / or U455, U456 and / or
15 U464, U465 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder ver- 20 schieden, ausgewählt aus der Gruppe bestehend aus:U464, U465 and U465 may each together also form "heterocyclyl", where optionally substituted substituents of substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHU472, - NU473U474, -NO2, -OH, -OCF3, -SH, -0-SO3H, -(iii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHU 472, - NU 473U474, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -
25 OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -25 OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -
P(O)(OH)2, -C(O)-U475, -C(O)O-U476, -C(O)NH- U477, -C(O)NU478U479, -O-U480, -O(-U481-O)z-H (z = 1, 2, 3, 4, 5), -O(-U482-O)z-U483 (z = 1, 2, 3, 4, 5), - OC(O)-U484, -OC(O)-O-U485, -OC(O)-NHU486, -O-P (O) (OH) 2 , -C (O) -U475, -C (O) O-U476, -C (O) NH-U477, -C (O) NU478U479, -O-U480, -O ( -U481-O) z -H (z = 1, 2, 3, 4, 5), -O (-U482-O) z -U483 (z = 1, 2, 3, 4, 5), - OC ( O) -U484, -OC (O) -O-U485, -OC (O) -NHU486, -O-
30 C(O)-NU487U488, -OP(O)(OU489)(OU490), -30 C (O) -NU487U488, -OP (O) (OU489) (OU490),
OSi(U491)(U492)(U493), -OS(O2)-U494, -NHC(O)- U495, -NU496C(O)-U497, -NH-C(O)-O-U498, -NH- C(O)-NH-U499, -NH-C(O)-NU500U501, -NU502- C(O)-O-U503, -NU504-C(O)-NH-U505, -NU506- C(O)-NU507U508, -NHS(O2)-U509, -NU51 OS(O2)- U511 , -S-U512, -S(O)-U513, -S(O2)-U514, -S(O2)NH- U515, -S(O2)NU516U517, -S(O2)O-U518, - P(O)(OU519)(OU520), -Si(U521 )(U522)(U523)"; wobei U472, U473, U474, U475, U476, U477, U478,OSi (U491) (U492), (U493), -OS (O 2) -U494, -NHC (O) - U495, -NU496C (O) -U497, -NH-C (O) -O-U498, -NH C (O) -NH-U499, -NH-C (O) -NU500U501, -NU502-C (O) -O-U503, -NU504-C (O) -NH-U505, -NU506- C (O) -NU507U508, -NHS (O 2) -U509, -NU51 OS (O 2) - U511, U512 -S-, -S (O) -U513, -S (O 2) -U514, -S (O 2) NH- U515, -S (O 2) NU516U517, -S (O 2) O-U518, - P (O) (OU519) (OU520), -Si (U521) (U522), (U523) " U472, U473, U474, U475, U476, U477, U478,
U479, U480, U481 , U482, U483, U484, U485, U486, U487, U488, U489, U490, U491 , U492, U493, U494, U495, U496, U497, U498, U499, U500, U501 , U502, U503, U504, U505, U506, U507, U508, U509, U510, U511 , U512, U513, U514, U515, U516, U517, U518,U479, U480, U481, U482, U483, U484, U485, U486, U487, U488, U489, U490, U491, U492, U493, U494, U495, U496, U497, U498, U499, U500, U501, U502, U503, U504, U505, U506, U507, U508, U509, U510, U511, U512, U513, U514, U515, U516, U517, U518,
U519, U520, U521 , U522, U523 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ U478, U479 und/oder U487, U488 und/oder U500, U501 und/oder U507, U508 und/oder U516, U517 jeweils zusammen auch „heterocyclyl" bilden können; und wobei alternativ U314, U315 zusammen auch „heterocyclyl" bilden können;U519, U520, U521, U522, U523 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively, U478, U479 and / or U487, U488 and / or U500, U501 and / or U507, U508 and / or U516, U517 may together also form "heterocyclyl"; and alternatively, U314, U315 may together also form "heterocyclyl";
undand
Rest Z5 unabhängig ausgewählt ist aus der Gruppe bestehend aus: (i) „Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, het- erocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHA1 , -NA2A3, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(0)-A4, - C(0)0-A5, -C(O)NH-A6, -C(O)NA7A8, -0-A9, -0(-AIO-O) -H (r = 1 , 2, 3, 4, 5), -0(-A11-0)r-A12 (r = 1 , 2, 3, 4, 5), -OC(O)-AI 3, -OC(O)-O-AI 4, -Radical Z5 is independently selected from the group consisting of: (i) "hydrogen, alkyl, (Cg-C 3 o), alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, het- erocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHA1, -NA2A3, -NO 2, -OH, -OCF3, -SH, -0-SO3H, - OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -A 4, -C (O) 0-A5, -C (O) NH-A6, -C (O) NA7A8, -O-A9, -O (-AIO-O) -H (r = 1, 2, 3, 4, 5), -O (-A11-0 ) r -A12 (r = 1, 2, 3, 4, 5), -OC (O) -Al 3, -OC (O) -O-Al 4, -
OC(O)-NHAI 5, -0-C(O)-NAI 6A17, -OP(O)(OAI 8)(0A19), - OSi(A20)(A21 )(A22), -OS(O2)-A23, -NHC(O)-A24, -NA25C(O)-A26, -NH- C(O)-O-A27, -N H-C(O)-N H-A28, -N H-C(O)-N A29A30, -NA31 -C(O)-O- A32, -NA33-C(O)-NH-A34, -NA35-C(O)-NA36A37, -NHS(O2)-A38, - NA39S(O2)-A40, -S-A41 , -S(O)-A42, -S(O2)-A43, -S(O2)NH-A44, - S(O2)NA45A46, -S(O2)O-A47, -P(O)(OA48)(OA49), -Si(A50)(A51 )(A52)"; wobei A1 , A2, A3, A4, A5, A6, A7, A8, A9, A10, A1 1 , A12, A13, A14, A15, A16, A17, A18, A19, A20, A21 , A22, A23, A24, A25, A26, A27, A28, A29,OC (O) -NHAI 5, -O-C (O) -NAI 6A17, -OP (O) (OAl 8) (0A19), - OSi (A20) (A21) (A22), -OS (O 2 ) -A23, -NHC (O) -A24, -Na25C (O) -A26, -NH-C (O) -O-A27, -NHC (O) -NH-A28, -NHC (O) - N A29A30, -NA31 -C (O) -O- A32, -NA33-C (O) -NH-A34, -NA35-C (O) -NA36A37, -NHS (O 2) -A38, - NA39S (O2) -A40, -S-A41, -S ( O) -A42, -S (O2) -A43, -S (O2) NH-A44, - S (O 2) NA45A46, -S (O2) O-A47, -P (O) (OA48) (OA49), -Si (A50) (A51) (A52) "; wherein A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, A1, A12, A13, A14, A15, A16 , A17, A18, A19, A20, A21, A22, A23, A24, A25, A26, A27, A28, A29,
A30, A31 , A32, A33, A34, A35, A36, A37, A38, A39, A40, A41 , A42, A43, A44, A45, A46, A47, A48, A49, A50, A51 , A52 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, het- eroarylalkyl" und wobei alternativ A7, A8 und/oder A16, A17 und/oder A29,A30, A31, A32, A33, A34, A35, A36, A37, A38, A39, A40, A41, A42, A43, A44, A45, A46, A47, A48, A49, A50, A51, A52 are independently selected from consisting of the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, het- eroarylalkyl" and wherein alternatively A7, A8 and / or A16, A17 and / or A29,
A30 und/oder A36, A37 und/oder A45, A46 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substi- tuenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:A30 and / or A36, A37 and / or A45, A46 may together also form "heterocyclyl" where optionally substituents of the substituent group (i) above may be substituted independently with at least one substituent, the same or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHA53, -NA54A55, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- A56, -C(O)O-A57, -C(O)NH-A58, -C(O)NA59A60, -0-A61 , -O(-A62-(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHA53, -NA54A55, -NO 2, -OH, -OCF3, -SH, -0-SO3H, - OP (O) (OH) 2, -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -A56, -C (O) O-A57, -C (O) NH-A58, -C (O) NA59A60, 0-A61, -O (-A62-
O)5-H (s = 1 , 2, 3, 4, 5), -O(-A63-O)t-A64 (t = 1 , 2, 3, 4, 5), -OC(O)- A65, -OC(O)-O-A66, -OC(O)-NHA67, -0-C(O)-N A68A69, - OP(O)(OA70)(OA71 ), -OSi(A72)(A73)(A74), -OS(O2)-A75, -NHC(O)- A76, -NA77C(O)-A78, -NH-C(O)-O-A79, -N H-C(O)-N H-A80, -NH- C(O)-NA81A82, -NA83-C(O)-O-A84, -NA85-C(O)-NH-A86, -NA87-O) 5 -H (s = 1, 2, 3, 4, 5), -O (-A63-O) t -A64 (t = 1, 2, 3, 4, 5), -OC (O) - A65, -OC (O) -O-A66, -OC (O) -NHA67, -O-C (O) -N A68A69, - OP (O) (OA70) (OA71), -OSi (A72) (A73 ) (A74), -OS (O 2 ) -A75, -NHC (O) -A76, -NA77C (O) -A78, -NH-C (O) -O-A79, -NHC (O) -N H-A80, -NH-C (O) -NA81A82, -Na83-C (O) -O-A84, -NA85-C (O) -NH-A86, -NA87-
C(O)-NA88A89, -NHS(O2)-A90, -NA91 S(O2)-A92, -S-A93, -S(O)-A94, -S(O2)-A95, -S(O2)NH-A96, -S(O2)NA97A98, -S(O2)O-A99, - P(O)(OAI 00)(OA101 ), -Si(AI 02)(A103)(A104)"; wobei A53, A54, A55, A56, A57, A58, A59, A60, A61 , A62, A63, A64, A65, A66, A67, A68, A69, A70, A71 , A72, A73, A74, A75, A76, A77, A78,C (O) -NA88A89, -NHS (O 2) -A90, -NA91 S (O 2) -A92, -S-A93, -S (O) -A94, -S (O2) -A95, -S (O 2) NH-A96, -S (O2) NA97A98, -S (O2) O-A99, - P (O) (OAI 00) (OA101), -Si (AI 02) (A103) (A104 A53, A54, A55, A56, A57, A58, A59, A60, A61, A62, A63, A64, A65, A66, A67, A68, A69, A70, A71, A72, A73, A74, A75, A76, A77, A78,
A79, A80, A81 , A82, A83, A84, A85, A86, A87, A88, A89, A90, A91 , A92, A93, A94, A95, A96, A97, A98, A99, A100, A101 , A102, A103, A104 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ A59, A60 und/oder A68, A69 und/oder A81 , A82 und/oder A88, A89 und/oder A97, A98 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einemA79, A80, A81, A82, A83, A84, A85, A86, A87, A88, A89, A90, A91, A92, A93, A94, A95, A96, A97, A98, A99, A100, A101, A102, A103, A104 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclic- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively A59, A60 and / or A68, A69 and / or A81, A82 and / or A88, A89 and / or A97, A98 may together also form" heterocyclyl "; optionally substituents of the substituent group (ii) above may be substituted independently with at least one
Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Substituents, the same or different, selected from the group consisting of:
(iii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocy- clylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHA105, -NA106A107, -NO2, -OH, -OCF3, -SH, -O-(iii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- clylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHA105, -NA106A107, -NO 2 , -OH, -OCF 3 , -SH, -O-
SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-AI 08, -C(O)O-AI 09, -C(O)NH-AH O, -C(O)NA1 11 A1 12, - 0-A113, -O(-A114-O)t-H (t = 1 , 2, 3, 4, 5), -O(-A115-O)t-A116 (t = 1 , 2, 3, 4, 5), -OC(O)-A1 17, -OC(O)-O-A118, -OC(O)-NHA1 19, - 0-C(O)-NAI 20A121 , -OP(O)(OAI 22)(OA123), -SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Al 08, -C (O) O-Al 09, -C (O) NH-AH O, -C (O) NA 11 Al 12, 0-A113, -O (-A114-O) t -H (t = 1, 2, 3, 4, 5), -O (-A115-O) t -A116 (t = 1, 2, 3, 4, 5), -OC (O) -Al 17, -OC (O ) -O-A118, -OC (O) -NHA1 19, -O-C (O) -NAI 20A121, -OP (O) (OAI 22) (OA123),
OSi(AI 24)(A125)(A126), -OS(O2)-A127, -NHC(O)-A128, - NA129C(O)-AI 30, -N H-C(O)-O-AI 31 , -N H-C(O)-NH-AI 32, -NH- C(O)-NAI 33A134, -NA135-C(O)-O-AI 36, -NA137-C(O)-N H- A138, -NA139-C(O)-NAI 40A141 , -NHS(O2)-A142, -NA143S(O2)- A144, -S-A145, -S(O)-AI 46, -S(O2)-A147, -S(O2)NH-AI 48, -OSi (AI 24) (A125) (A126), -OS (O2) -A127, -NHC (O) -A128, - NA129C (O) -AI 30, -N HC (O) -O-AI 31, -NHC (O) -NH-Al 32, -NH-C (O) -NAI 33A134, -NA 135-C (O) -O-Al 36, -NA 137-C (O) -N H-A138, - NA139-C (O) -nai 40A141, -NHS (O 2) -A142, -NA143S (O2) - A144, -S-A145, -S (O) -AI 46, -S (O 2) -A147 , -S (O 2 ) NH-AI 48, -
S(O2)NAI 49A150, -S(O2)O-AI 51 , -P(O)(OAI 52)(OA153), - Si(AI 54)(A155)(A156)"; wobei A105, A106, A107, A108, A109, A1 10, A11 1 , A1 12, A113, A114, A115, A1 16, A117, A1 18, A119, A120, A121 , A122, A123, A124, A125, A126, A127, A128, A129, A130, A131 , A132, A133,S (O 2 ) NAI 49A150, -S (O 2 ) O -Al 51, -P (O) (OAI 52) (OA153), -Si (Al 54) (A155) (A156) "; wherein A105, A106 , A107, A108, A109, A110, A111, A112, A113, A114, A115, A116, A117, A118, A119, A120, A121, A122, A123, A124, A125, A126, A127, A128, A129, A130, A131, A132, A133,
A134, A135, A136, A137, A138, A139, A140, A141 , A142, A143, A144, A145, A146, A147, A148, A149, A150, A151 , A152, A153, A154, A155, A156 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ A11 1 , A1 12 und/oder A120, A121 und/oder A133, A134 und/oder A140, A141 und/oder A149, A150 jeweils zusammen auch „heterocyclyl" bilden können; oderA134, A135, A136, A137, A138, A139, A140, A141, A142, A143, A144, A145, A146, A147, A148, A149, A150, A151, A152, A153, A154, A155, A156 are selected independently from each other consisting of the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively A11 1, A1 12 and / or A120, A121 and / or A133 , A134 and / or A140, A141 and / or A149, A150 may together also form "heterocyclyl"; or
(E) einer der Reste Z1 , Z2 oder beide Reste Z1 , Z2 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: (a) -NZ24Z25; mit der Maßgabe, dass einer der Reste Z24, Z25 oder beide Reste Z24, Z25 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:(E) one of the radicals Z1, Z2 or both radicals Z1, Z2 are independently selected from the group consisting of: (a) -NZ24Z25; with the proviso that one of the radicals Z24, Z25 or both radicals Z24, Z25 are selected independently of one another from the group consisting of:
(1 ) ,,-C(O)-C(O)-TI , -S(O2)-NT2T3"; wobei T1 , T2, T3 unabhängig voneinander ausgewählt sind aus der(1) ,, - C (O) -C (O) -Ti, -S (O 2 ) -NT2T3 ", wherein T1, T2, T3 are independently selected from
Gruppe bestehend aus:Group consisting of:
(I) „Wasserstoff, alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT4, -NT5T6, -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -(I) "is hydrogen, alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3 , NH 2 , -NHT 4, -NT 5 T 6, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -
P(O)(OH)2, -C(0)-T7, -C(0)0-T8, -C(0)NH-T9, -C(O)NTI 0T11 , - 0-T12, -O(-T13-O)p-H (p = 1 , 2, 3, 4, 5), -O(-T14-O)p-T15 (p = 1 , 2, 3, 4, 5), -OC(O)-TI 6, -OC(O)-O-TI 7, -OC(O)-NHTI 8, -O- C(O)-NTI 9T20, -OP(O)(OT21 )(OT22), -OSi(T23)(T24)(T25), - OS(O2)-T26, -NHC(O)-T27, -NT28C(O)-T29, -NH-C(O)-O-T30,P (O) (OH) 2 , -C (O) -T7, -C (O) 0-T8, -C (O) NH-T9, -C (O) NTI 0T11, -O-T12, -O (-T13-O) p -H (p = 1, 2, 3, 4, 5), -O (-T14-O) p -T15 (p = 1, 2, 3, 4, 5), -OC (O) -Ti 6, -OC (O) -O-TI 7, -OC (O) -NHTI 8, -O-C (O) -NTI 9T20, -OP (O) (OT21) (OT22), -OSi (T23) (T24) (T25), - OS (O 2) -T26, -NHC (O) -T27, -NT28C (O) -T29, -NH-C (O) -O-T30,
-N H-C(O)-N H-T31 , -NH-C(O)-NT32T33, -NT34-C(O)-O-T35, - NT36-C(O)-NH-T37, -NT38-C(O)-NT39T40, -NHS(O2)-T41 , - NT42S(O2)-T43, -S-T44, -S(O)-T45, -S(O2)-T46, -S(O2)NH-T47, -S(O2)NT48T49, -S(O2)O-T50, -P(O)(OT51 )(OT52), - Si(T53)(T54)(T55)"; wobei T4, T5, T6, T7, T8, T9, T10, T11 , T12, T13, T14, T15, T16, T17, T18, T19, T20, T21 , T22, T23, T24, T25, T26, T27, T28, T29, T30, T31 , T32, T33, T34, T35, T36, T37, T38, T39, T40, T41 , T42, T43, T44, T45, T46, T47, T48, T49, T50, T51 , T52, T53, T54, T55 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T10, T1 1 und/oder T19, T20 und/oder T32, T33 und/oder T39, T40 und/oder T48, T49 jeweils zusammen auch „he- terocyclyl" bilden können; wobei optional obige Substituenten der Substitutionsgruppe (I) unabhängig voneinander auch weiter substituiert sein können mit min- destens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:-NHC (O) -NH-T31, -NH-C (O) -NT32T33, -NT34-C (O) -O-T35, -NT36-C (O) -NH-T37, -NT38-C (O) -NT39T40, -NHS (O 2) -T41, - NT42S (O 2) -T43, -S-T44, -S (O) -T45, -S (O 2) -T46, -S (O 2) NH-T47, -S (O 2) NT48T49, -S (O 2) O-T50, -P (O) (OT51) (OT52), - Si (T53) (T54) (T55) "; wherein T4, T5, T6, T7, T8, T9, T10, T11, T12, T13, T14, T15, T16, T17, T18, T19, T20, T21, T22, T23, T24, T25, T26, T27, T28, T29, T30, T31, T32, T33, T34, T35, T36, T37, T38, T39, T40, T41, T42, T43, T44, T45, T46, T47, T48, T49, T50, T51, T52, T53, are T54, T55 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, as heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively T10, T1 1 and / or T19, T20 and / or T32, T33 and / or T39, T40 and / or T48, T49 may together also also form "heterocyclyl", where optionally substituted substituents of the substitution group (I) may also be further substituted with at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT56, -NT57T58, -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -(i) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT56, -NT57T58, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -
SO3H, -P(O)(OH)2, -C(O)-T59, -C(O)O-T60, -C(0)NH-T61 , - C(O)NT62T63, -O-T64, -O(-T65-O)^H (r = 1 , 2, 3, 4, 5), -0(- T66-O)r-T67 (r = 1 , 2, 3, 4, 5), -OC(O)-T68, -OC(O)-O-T69, - OC(O)-NHT70, -O-C(O)-NT71T72, -OP(O)(OT73)(OT74), - OSi(T75)(T76)(T77), -OS(O2)-T78, -NHC(O)-T79, -NT80C(O)-SO 3 H, -P (O) (OH) 2, -C (O) -T59, -C (O) O-T60, -C (0) NH-T61, - C (O) NT62T63, -O- T64, -O (-T65-O) ^ H (r = 1, 2, 3, 4, 5), -0 (- T66-O) r -T67 (r = 1, 2, 3, 4, 5) , -OC (O) -T68, -OC (O) -O-T69, - OC (O) -NHT70, -OC (O) -NT71T72, -OP (O) (OT73) (OT74), - OSi ( T75) (T76) (T77), -OS (O 2) -T78, -NHC (O) -T79, -NT80C (O) -
T81 , -NH-C(O)-O-T82, -N H-C(O)-N H-T83, -NH-C(O)- NT84T85, -NT86-C(O)-O-T87, -NT88-C(O)-NH-T89, -NT90- C(O)-NT91T92, -NHS(O2)-T93, -NT94S(O2)-T95, -S-T96, - S(O)-T97, -S(O2)-T98, -S(O2)NH-T99, -S(O2)NTI 00T101 , - S(O2)O-TI 02, -P(O)(OTI 03)(OT104), -Si(TI 05)(T106)(T107)"; wobei T56, T57, T58, T59, T60, T61 , T62, T63, T64, T65, T66, T67, T68, T69, T70, T71 , T72, T73, T74, T75, T76, T77, T78, T79, T80, T81 , T82, T83, T84, T85, T86, T87, T88, T89, T90, T91 , T92, T93, T94, T95, T96, T97, T98, T99, T100, T101 , T102, T103, T104, T105, T106, T107 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T62, T63 und/oder T71 , T72 und/oder T84, T85 und/oder T91 , T92 und/oder T100, T101 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:T81, -NH-C (O) -O-T82, -NHC (O) -NH-T83, -NH-C (O) -NT84T85, -NT86-C (O) -O-T87, -NT88 -C (O) -NH-T89, -NT90- C (O) -NT91T92, -NHS (O 2) -T93, -NT94S (O 2) -T95, -S-T96, - S (O) -T97 , -S (O 2 ) -T 98, -S (O 2 ) NH-T99, -S (O 2 ) NTI 00T101, -S (O 2 ) O-TI 02, -P (O) (OTI 03) OT104), -Si (TI 05) (T106) (T107) "; wherein T56, T57, T58, T59, T60, T61, T62, T63, T64, T65, T66, T67, T68, T69, T70, T71, T72, T73, T74, T75, T76, T77, T78, T79, T80, T81, T82, T83, T84, T85, T86, T87, T88, T89, T90, T91, T92, T93, T94, T95, T96, T97, T98, T99, T100, T101, T102, T103, T104, T105, T106, T107 are independently selected from the group consisting of: alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl where aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively T62, T63 and / or T71, T72 and / or T84, T85 and / or T91, T92 and / or T100, T101 may each together also form" heterocyclyl "; above substituents of the substituent group (i) as which may be substituted independently of one another at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F,(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F,
5 CI1 Br, I1 CN1 CF31 N3, NH2, -NHT108, -NT109T110, -NO2, -5 CI 1 Br, I 1 CN 1 CF 31 N 3 , NH 2 , -NHT108, -NT109T110, -NO 2 , -
OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-TH 1 , -C(O)O-T112, -C(O)NH-T1 13, -C(O)NT114T1 15, -0-T116, -0(-T1 17- O)5-H (s = 1 , 2, 3, 4, 5), -0(-T1 18-0)s-T1 19 (s = 1 , 2, 3, 4,OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -TH1, -C (O) O-T112, -C (O) NH-T1 13, -C (O) NT114T1 15, -O-T116, -0 (- T1 17- O) 5 -H (s = 1, 2, 3, 4, 5), -0 (-T1 18-0) s -T1 19 (s = 1, 2, 3, 4,
10 5), -OC(O)-T120, -OC(O)-O-TI 21 , -OC(O)-NHTI 22, -O-10 5), -OC (O) -T120, -OC (O) -O-TI 21, -OC (O) -NHTI 22, -O-
C(O)-NTI 23T124, -OP(O)(OTI 25)(OT126), - OSi(TI 27)(T128)(T129), -OS(O2)-T130, -NHC(O)-TI 31 , - NT132C(O)-TI 33, -NH-C(O)-O-TI 34, -NH-C(O)-NH- T135, -NH-C(O)-NTI 36T137, -NT138-C(O)-O-TI 39, -C (O) -NTI 23T124, -OP (O) (OTI 25) (OT126), - OSi (TI 27) (T128) (T129), -OS (O 2 ) -T130, -NHC (O) -TI 31, - NT132C (O) -TI 33, -NH-C (O) -O-TI 34, -NH-C (O) -NH-T135, -NH-C (O) -NTI 36T137, -NT138- C (O) -O-TI 39, -
15 NT140-C(O)-NH-TI 41 , -NT142-C(O)-NTI 43T144, -15 NT140-C (O) -NH-TI 41, -NT142-C (O) -NTI 43T144, -
NHS(O2)-T145, -NT146S(O2)-T147, -S-T148, -S(O)-T149, -S(O2)-T150, -S(O2)NH-TI 51 , -S(O2)NTI 52T153, - S(O2)O-TI 54, -P(O)(OTI 55)(OT156), - Si(TI 57)(T158)(T159)";NHS (O 2) -T145, -NT146S (O 2) -T147, -S-T148, -S (O) -T149, -S (O 2) -T150, -S (O 2) NH-TI 51, -S (O 2) NTI 52T153, - S (O 2) OTI 54, -P (O) (OTI 55) (OT156), - Si (TI 57) (T158), (T159) ";
20 wobei T108, T109, T110, T11 1 , T112, T113, T1 14, T1 15,20 where T108, T109, T110, T11 1, T112, T113, T1 14, T1 15,
T116, T1 17, T1 18, T1 19, T120, T121 , T122, T123, T124, T125, T126, T127, T128, T129, T130, T131 , T132, T133, T134, T135, T136, T137, T138, T139, T140, T141 , T142, T143, T144, T145, T146, T147, T148, T149, T150, T151 ,T116, T117, T118, T119, T120, T121, T122, T123, T124, T125, T126, T127, T128, T129, T130, T131, T132, T133, T134, T135, T136, T137, T138, T139 , T140, T141, T142, T143, T144, T145, T146, T147, T148, T149, T150, T151,
25 T152, T153, T154, T155, T156, T157, T158, T159 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T114, T115 und/oder T123, T12425 T152, T153, T154, T155, T156, T157, T158, T159 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively T114, T115 and / or T123, T124
30 und/oder T136, T137 und/oder T143, T144 und/oder T152,30 and / or T136, T137 and / or T143, T144 and / or T152,
T153 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein kön- nen mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:T153 may in each case also form "heterocyclyl", where optionally substituents of the substituent group (ii) above may be substituted independently of one another NEN having at least one substituent, the same or different, selected from the group consisting of:
(iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT160, -(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT160, -
NT161T162, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, - P(O)(OH)2, -C(O)-TI 63, -C(O)O-TI 64, -C(O)NH-TI 65, -C(O)NTI 66T167, -O-T168, -0(-T169-O)1-H (t = 1 , 2, 3, 4, 5), -O(-T170-O)t-T171 (t = 1 , 2, 3, 4, 5), -OC(O)-NT161T162, -NO 2, -OH, -OCF3, -SH, -0-SO3H, - OP (O) (OH) 2, -CHO, -COOH, -C (O) NH 2, -SO 3 H, -P (O) (OH) 2 , -C (O) -TI 63, -C (O) O-TI 64, -C (O) NH-TI 65, -C (O) NTI 66T167, O-T168, -O (-T169-O) 1 -H (t = 1, 2, 3, 4, 5), -O (-T170-O) t -T171 (t = 1, 2, 3, 4 , 5), -OC (O) -
T172, -OC(O)-O-TI 73, -OC(O)-NHTI 74, -0-C(O)- NT175T176, -OP(O)(OTI 77)(OT178), - OSi(TI 79)(T180)(T181 ), -OS(O2)-T182, -NHC(O)-TI 83, -NT184C(O)-TI 85, -NH-C(O)-O-TI 86, -NH-C(O)- NH-T187, -N H-C(O)-NTI 88T189, -NT190-C(O)-O-T172, -OC (O) -O-TI 73, -OC (O) -NHTI 74, -O-C (O) -NT175T176, -OP (O) (OTI 77) (OT178), -OSi (TI 79 ) (T180), (T181), -OS (O 2) -T182, -NHC (O) -TI 83, -NT184C (O) -TI 85, -NH-C (O) -O-TI 86, -NH -C (O) -NH-T187, -NHC (O) -NTI 88T189, -NT190-C (O) -O-
T191 , -NT192-C(O)-NH-TI 93, -NT194-C(O)- NT195T196, -NHS(O2)-T197, -NT198S(O2)-T199, -S- T200, -S(O)-T201 , -S(O2)-T202, -S(O2)NH-T203, - S(O2)NT204T205, -S(O2)O-T206, - P(O)(OT207)(OT208), -Si(T209)(T210)(T211 )"; wobei T160, T161 , T162, T163, T164, T165, T166, T167, T168, T169, T170, T171 , T172, T173, T174, T175, T176, T177, T178, T179, T180, T181 , T182, T183, T184, T185, T186, T187, T188, T189, T190, T191 , T192, T193, T194, T195, T196, T197, T198, T199, T200, T201 , T202, T203,T191, -NT192-C (O) -NH-TI 93, -NT194-C (O) - NT195T196, -NHS (O 2) -T197, -NT198S (O 2) -T199, -S- T200, -S (O) -T201, -S (O 2) -T202, -S (O 2) NH-T203, - S (O 2) NT204T205, -S (O 2) O-T206, - P (O) (OT207 ) (T209), -Si (T209) (T210) (T211) "; wherein T160, T161, T162, T163, T164, T165, T166, T167, T168, T169, T170, T171, T172, T173, T174, T175 , T176, T177, T178, T179, T180, T181, T182, T183, T184, T185, T186, T187, T188, T189, T190, T191, T192, T193, T194, T195, T196, T197, T198, T199, T200 , T201, T202, T203,
T204, T205, T206, T207, T208, T209, T210, T21 1 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroa- ryl, heteroarylalkyl" und wobei alternativ T166, T167 und/oder T175, T176 und/oder T188, T189 und/oder T195, T196 und/oder T204, T205 jeweils zusammen auch „heterocyclyl" bilden können; wobei alternativ T2, T3 zusammen auch „heterocyclyl" bilden können; und einer der Reste Z24, Z25 oder keiner der Reste Z24, Z25 unabhängig voneinander auch ausgewählt ist aus der Gruppe bestehend aus:T204, T205, T206, T207, T208, T209, T210, T21 1 are independently selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroa - Ryl, heteroarylalkyl "and wherein alternatively T166, T167 and / or T175, T176 and / or T188, T189 and / or T195, T196 and / or T204, T205 may each together also form" heterocyclyl "; alternatively T2, T3 may together also form "heterocyclyl"; and one of Z24, Z25 or none of Z24, Z25 is also independently selected from the group consisting of:
(2) „Wasserstoff, alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei optional obige Substituenten der Substitutionsgruppe (2) unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (i) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT212, -NT213T214, -NO2, -OH, -OCF3, -SH, - 0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, - P(O)(OH)2, -C(O)-T215, -C(O)O-T216, -C(O)NH-T217, - C(O)NT218T219, -O-T220, -O(-T221-O)u-H (u = 1 , 2, 3, 4, 5), -(2) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; optionally substituting the above substituents of the substitution group (2) independently of one another with at least one substituent, identical or different, selected from the group consisting of: (i) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHT212, -NT213T214, -NO 2, -OH, -OCF 3, -SH, - 0-SO 3 H, -OP (O) ( OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, - P (O) (OH) 2 , -C (O) -T 215, -C (O) O-T216, -C (O) NH-T217, -C (O) NT218T219, -O-T220, -O (-T221-O) u -H (u = 1, 2, 3, 4, 5),
O(-T222-O)u-T223 (u = 1 , 2, 3, 4, 5), -OC(O)-T224, -OC(O)-O- T225, -OC(O)-NHT226, -O-C(O)-NT227T228, - OP(O)(OT229)(OT230), -OSi(T231 )(T232)(T233), -OS(O2)-T234, - NHC(O)-T235, -NT236C(O)-T237, -NH-C(O)-O-T238, -NH- C(O)-NH-T239, -NH-C(O)-NT240T241 , -NT242-C(O)-O-T243, -O (-T222-O) u -T223 (u = 1, 2, 3, 4, 5), -OC (O) -T224, -OC (O) -O-T225, -OC (O) -NHT226, -OC (O) -NT227T228, - OP (O) (OT229) (OT230), -OSi (T231) (T232), (T233), -OS (O 2) -T234, - NHC (O) -T235 - NT236C (O) -T237, -NH-C (O) -O-T238, -NH-C (O) -NH-T239, -NH-C (O) -NT240T241, -NT242-C (O) -O -T243, -
NT244-C(O)-NH-T245, -NT246-C(O)-NT247T248, -NHS(O2)- T249, -NT250S(O2)-T251 , -S-T252, -S(O)-T253, -S(O2)-T254, - S(O2)N H-T255, -S(O2)NT256T257, -S(O2)O-T258, - P(O)(OT259)(OT260), -Si(T261 )(T262)(T263)"; wobei T212, T213, T214, T215, T216, T217, T218, T219, T220,NT244-C (O) -NH-T245, -NT246-C (O) -NT247T248, -NHS (O 2) - T249, -NT250S (O 2) -T251, -S-T252, -S (O) - T253, -S (O 2) -T254, - S (O 2) N H-T255, -S (O 2) NT256T257, -S (O 2) O-T258, - P (O) (OT259) (OT260 -Si (T261) (T262) (T263) "where T212, T213, T214, T215, T216, T217, T218, T219, T220,
T221 , T222, T223, T224, T225, T226, T227, T228, T229, T230, T231 , T232, T233, T234, T235, T236, T237, T238, T239, T240, T241 , T242, T234, T244, T245, T246, T247, T248, T249, T250, T251 , T252, T253, T254, T255, T256, T257, T258, T259, T260, T261 , T262, T263 unabhängig voneinander ausgewählt sind aus derT221, T222, T223, T224, T225, T226, T227, T228, T229, T230, T231, T232, T233, T234, T235, T236, T237, T238, T239, T240, T241, T242, T234, T244, T245, T246, T247, T248, T249, T250, T251, T252, T253, T254, T255, T256, T257, T258, T259, T260, T261, T262, T263 are independently selected from the
Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T218, T219 und/oder T227, T228 und/oder T240, T241 und/oder T247, T248 und/oder T256, T257 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindes- tens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:A group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively T218, T219 and / or T227, T228 and / or T240, T241 and / or T247, T248 and / or T256, T257 may together also form "heterocyclyl" wherein optionally substituted substituents of the substituent group (i) may in turn be independently substituted with at least one substituent, the same or different, selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT264, -NT265T266, -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT264, -NT265T266, -NO 2 , -OH, - OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -
C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-T267, -C(O)O-T268, - C(O)NH-T269, -C(O)NT270T271 , -O-T272, -O(-T273-O)v-H (v = 1 , 2, 3, 4, 5), -O(-T274-O)v-T275 (v = 1 , 2, 3, 4, 5), - OC(O)-T276, -OC(O)-O-T277, -OC(O)-N HT278, -0-C(O)- NT279T280, -OP(O)(OT281 )(OT282), -OSi(T283)(T284)(T285),C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T 267, -C (O) O-T 268, -C (O) NH-T 269, -C (O) NT270T271, -O-T272, -O (-T273-O) v -H (v = 1, 2, 3, 4, 5), -O (-T274-O) v -T275 (v = 1 , 2, 3, 4, 5), - OC (O) -T276, -OC (O) -O-T277, -OC (O) -NHT278, -O-C (O) -NT279T280, -OP ( O) (OT281) (OT282), -OSi (T283) (T284) (T285),
-OS(O2)-T286, -NHC(O)-T287, -NT288C(O)-T289, -NH- C(O)-O-T290, -N H-C(O)-N H-T291 , -N H-C(O)-NT292T293, - NT294-C(O)-O-T295, -NT296-C(O)-NH-T297, -NT298- C(O)-NT299T300, -NHS(O2)-T301 , -NT302S(O2)-T303, -S- T304, -S(O)-T305, -S(O2)-T306, -S(O2)NH-T307, --OS (O 2) -T286, -NHC (O) -T287, -NT288C (O) -T289, -NH- C (O) -O-T290, -N HC (O) -N H-T291, - N HC (O) -NT292T293, - NT294-C (O) -O-T295, -NT296-C (O) -NH-T297, -NT298- C (O) -NT299T300, -NHS (O 2) -T301 , -NT302S (O 2) -T303, -S- T304, -S (O) -T305, -S (O 2) -T306, -S (O 2) NH-T307, -
S(O2)NT308T309, -S(O2)O-T310, -P(O)(OT311 )(OT312), - Si(T313)(T314)(T315)"; wobei T264, T265, T266, T267, T268, T269, T270, T271 , T272, T273, T274, T275, T276, T277, T278, T279, T280, T281 , T282, T283, T284, T285, T286, T287, T288, T289, T290, T291 , T292,S (O 2) NT308T309, -S (O 2) O-T310, -P (O) (OT311) (OT312), - Si (T313) (T314), (T315) "; wherein T264, T265, T266, T267 , T268, T269, T270, T271, T272, T273, T274, T275, T276, T277, T278, T279, T280, T281, T282, T283, T284, T285, T286, T287, T288, T289, T290, T291, T292 .
T293, T294, T295, T296, T297, T298, T299, T300, T301 , T302, T303, T304, T305, T306, T307, T308, T309, T310, T31 1 , T312, T313, T314, T315 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cyc- loalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T270, T271 und/oder T279, T280 und/oder T292, T293 und/oder T299, T300 und/oder T308, T309 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:T293, T294, T295, T296, T297, T298, T299, T300, T301, T302, T303, T304, T305, T306, T307, T308, T309, T310, T311, T312, T313, T314, T315 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and in which case T270, T271 and / or T279, T280 and / or or T292, T293 and / or T299, T300 and / or T308, T309 may together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
5 (iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT316, -NT317T318, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-T319, -C(O)O-T320,5 (iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT316, -NT317T318, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) -T319, -C (O) O-T320,
10 -C(O)NH-T321 , -C(O)NT322T323, -O-T324, -O(-T325-10 -C (O) NH-T321, -C (O) NT322T323, -O-T324, -O (-T325-
O)w-H (w = 1 , 2, 3, 4, 5), -O(-T326-O)w-T327 (w = 1 , 2, 3, 4, 5), -OC(O)-T328, -OC(O)-O-T329, -OC(O)-NHT330, - O-C(O)-NT331T332, -OP(O)(OT333)(OT334), - OSi(T335)(T336)(T337), -OS(O2)-T338, -NHC(O)-T339, -O) w -H (w = 1, 2, 3, 4, 5), -O (-T326-O) w -T327 (w = 1, 2, 3, 4, 5), -OC (O) - T328, -OC (O) -O-T329, -OC (O) -NHT330, -OC (O) -NT331T332, -OP (O) (OT333) (OT334), -OSi (T335) (T336) (T337 ), -OS (O 2 ) -T338, -NHC (O) -T339, -
15 NT340C(O)-T341 , -NH-C(O)-O-T342, -N H-C(O)-N H-15 NT340C (O) -T341, -NH-C (O) -O-T342, -NH-C (O) -N H-
T343, -NH-C(O)-NT344T345, -NT346-C(O)-O-T347, - NT348-C(O)-NH-T349, -NT350-C(O)-NT351T352, - NHS(O2)-T353, -NT354S(O2)-T355, -S-T356, -S(O)-T357, -S(O2)-T358, -S(O2)NH-T359, -S(O2)NT360T361 , -T343, -NH-C (O) -NT344T345, -NT346-C (O) -O-T347, - NT348-C (O) -NH-T349, -NT350-C (O) -NT351T352, - NHS (O 2) -T353, -NT354S (O 2) -T355, -S-T356, -S (O) -T357, -S (O 2) -T358, -S (O 2) NH-T359, -S (O 2 ) NT360T361, -
20 S(O2)O-T362, -P(O)(OT363)(OT364), -20S (O 2 ) O-T 362, -P (O) (OT363) (OT364),
Si(T365)(T366)(T367)"; wobei T316, T317, T318, T319, T320, T321 , T322, T323, T324, T325, T326, T327, T328, T329, T330, T331 , T332, T333, T334, T335, T336, T337, T338, T339, T340, T341 ,Si (T365) (T366) (T367) "; wherein T316, T317, T318, T319, T320, T321, T322, T323, T324, T325, T326, T327, T328, T329, T330, T331, T332, T333, T334 , T335, T336, T337, T338, T339, T340, T341,
25 T342, T343, T344, T345, T346, T347, T348, T349, T350,25 T342, T343, T344, T345, T346, T347, T348, T349, T350,
T351 , T352, T353, T354, T355, T356, T357, T358, T359, T360, T361 , T362, T363, T364, T365, T366, T367 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, hetero-T351, T352, T353, T354, T355, T356, T357, T358, T359, T360, T361, T362, T363, T364, T365, T366, T367 are independently selected from the group consisting of: "alkyl, (C 9 - C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heteroaromatic
30 cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T322, T323 und/oder T331 , T332 und/oder T344, T345 und/oder T351 , T352 und/oder T360, T361 jeweils zusammen auch „heterocyclyl" bilden können; (b) -NZ26Z27, wobei einer der Reste Z26, Z27 oder beide Reste Z26, Z27 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:30 cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively T322, T323 and / or T331, T332 and / or T344, T345 and / or T351, T352 and / or T360, T361 in each case also form" heterocyclyl "can; (b) -NZ26Z27, wherein one of the radicals Z26, Z27 or both radicals Z26, Z27 are independently selected from the group consisting of:
(1 ) ,,-C(Y4)NZ28Z29, -C(=NZ30)-Z31 "; wobei Y4 unabhängig voneinander ausgewählt ist aus der Gruppe be- stehend aus „O, S, =NH, =NZ32"; mit der Maßgabe, dass mindestens einer der Reste Z28, Z29 und mindestens einer der Reste Z30, Z31 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus:(1) ,, -C (Y4) NZ28Z29, -C (= NZ30) -Z31 "; wherein Y4 is independently selected from the group consisting of" O, S, = NH, = NZ32 "; with the proviso that at least one of Z28, Z29 and at least one of Z30, Z31 is independently selected from the group consisting of:
(I) „alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O)-alkyl, -C(O)- aryl, -C(O)-heteroaryl"; mit der weiteren Maßgabe, dass obige Substituenten der Substituen- tengruppe (I) unabhängig voneinander weiter substituiert sind mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (i) „(C9-C3o)alkyl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroa- rylalkyl, N3, -NT368T369, -NHC(O)-cycloalkylalkyl, -NHC(O)- heterocyclylalkyl, -NT370C(O)-T371 , -NH-C(O)-O-T372, - N H-C(O)-N H-T373, -NH-C(O)-NT374T375, -NT376-C(O)- O-T377, -NT378-C(O)-NH-T379, -NT380-C(O)-NT381T382, -NHS(O2)-cycloalkylalkyl, -NHS(O2)-heterocyclylalkyl, -(I) "alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C (O) -alkyl, -C (O) -aryl, -C (O) -heteroaryl", with the further proviso that the above substituents of the substituents tengruppe (I) are independently further substituted with at least one substituent, identical or different, selected from the group consisting of: (i) "(C 9 -C 3 o) alkyl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroaromatics rylalkyl, N 3 , -NT368T369, -NHC (O) -cycloalkylalkyl, -NHC (O) -heterocyclylalkyl, -NT370C (O) -T371, -NH-C (O) -O-T372, -NHC (O) -NH -T373, -NH-C (O) -NT374T375, -NT376-C (O) -O-T377, -NT378-C (O) -NH-T379, -NT380-C (O) -NT381T382, -NHS ( O 2 ) -cycloalkylalkyl, -NHS (O 2 ) -heterocyclylalkyl, -
NT383S(O2)-T384, -O-T385, -O(-T386-O)x-T387 (x = 1 , 2, 3, 4, 5), -O(-T388-O)x-H (x = 1 , 2, 3, 4, 5), -OC(O)- cycloalkylalkyl, -OC(O)-heterocyclylalkyl, -OC(O)-O-T389, - OC(O)-NHT390, -O-C(O)-NT391T392, -OS(O2)- cycloalkylalkyl, -OS(O2)-heterocyclylalkyl, -NT383S (O 2) -T384, -O-T385, -O (-T386-O) x -T387 (x = 1, 2, 3, 4, 5), -O (O -T388-) x -H ( x = 1, 2, 3, 4, 5), -OC (O) -cycloalkylalkyl, -OC (O) -heterocyclylalkyl, -OC (O) -O-T389, -OC (O) -NHT390, -OC ( O) -NT391T392, -OS (O 2 ) - cycloalkylalkyl, -OS (O 2 ) -heterocyclylalkyl, -
OP(O)(OT393)(OT394), -OSi(T395)(T396)(T397), -CHO, - C(O)-cycloalkyl, -C(O)-heterocyclyl, -C(O)-cycloalkylalkyl, - C(O)-heterocyclylalkyl, -C(O)-arylalkyl, -C(O)-heteroarylalkyl, -S- cycloalkylalkyl, -S-heterocyclylalkyl, —S— arylalkyl, -S- heteroarylalkyl, -S(O)-cycloalkyl, -S(O)-heterocyclyl, -S(O)- heteroaryl, -S(O)-cycloalkylalkyl, -S(O)-heterocyclylalkyl, - S(O)-arylalkyl, -S(O)-heteroarylalkyl, -S(O2)-cycloalkyl, - S(O2)-heterocyclyl, -S(O2)-heteroaryl, -S(O2)-cycloalkylalkyl, - S(O2)-heterocyclylalkyl, -S(O2)-arylalkyl, -S(O2)- heteroarylalkyl, -S(O2)NH-cycloalkyl, -S(O2)NH-heterocyclyl, - S(O2)N H-cycloalkylalkyl, -S(O2)NH-heterocyclylalkyl, - S(O2)NH-heteroarylalkyl, -S(O2)NT398T399, -S(O2)O-OP (O) (OT393) (OT394), -OSi (T395) (T396) (T397), -CHO, - C (O) -cycloalkyl, -C (O) -heterocyclyl, -C (O) -cycloalkylalkyl, - C (O) -heterocyclylalkyl, -C (O) -arylalkyl, -C (O) -heteroarylalkyl, -S-cycloalkylalkyl, -S-heterocyclylalkyl, -S-arylalkyl, -S-heteroarylalkyl, -S (O) - cycloalkyl, -S (O) -heterocyclyl, -S (O) -heteroaryl, -S (O) -cycloalkylalkyl, -S (O) -heterocyclylalkyl, -S (O) -arylalkyl, -S (O) -heteroarylalkyl, -S (O 2 ) -cycloalkyl, - S (O 2 ) -heterocyclyl, -S (O 2 ) -heteroaryl, -S (O 2 ) -cycloalkylalkyl, - S (O 2) -heterocyclylalkyl, -S (O2) -arylalkyl, -S (O 2) - heteroarylalkyl, -S (O 2) NH-cycloalkyl, -S (O 2) NH-heterocyclyl, - S (O 2) N H-cycloalkylalkyl, -S (O 2) NH-heterocyclylalkyl, - S (O 2) NH-heteroaryl, -S (O 2) NT398T399, -S (O 2) O-
5 cycloalkyl, -S(O2)O-heterocyclyl, -S(O2)O-heteroaryl, -S(O2)O- cycloalkylalkyl, -S(O2)O-heterocyclylalkyl, -S(O2)O- heteroarylalkyl, -P(O)(OH)2, -P(O)(OT400)(OT401 ), - Si(T402)(T403)(T404)"; mit der weiteren Maßgabe, dass ,,-N(alkyl)2", ,,-C(O)N(alkyl)2", „-5 cycloalkyl, -S (O 2 ) O-heterocyclyl, -S (O 2 ) O-heteroaryl, -S (O 2 ) O -cycloalkylalkyl, -S (O 2 ) O-heterocyclylalkyl, -S (O 2 ) O heteroarylalkyl, -P (O) (OH) 2 , -P (O) (OT400) (OT401), -Si (T402) (T403) (T404) ", with the further proviso that" - N (alkyl ) 2 "," - C (O) N (alkyl) 2 "," -
10 C(O)N(cycloalkyl)2", ,,-C(O)N(Aryl)2", ,,-C(O)N(Heteroaryl)2" weiter substituiert sind mit mindestens einem Substituenten ausgewählt aus der untigen Substituentengruppe (ii); wobei T368, T369, T370, T371 , T372, T373, T374, T375, T376, T377, T378, T379, T380, T381 , T382, T383, T384, T385, T386,10 C (O) N (cycloalkyl) 2 ", - C (O) N (aryl) 2 ", - C (O) N (heteroaryl) 2 "are further substituted by at least one substituent selected from the below Substituent group (ii); wherein T368, T369, T370, T371, T372, T373, T374, T375, T376, T377, T378, T379, T380, T381, T382, T383, T384, T385, T386,
15 T387, T388, T389, T390, T391 , T392, T393, T394, T395, T396,15 T387, T388, T389, T390, T391, T392, T393, T394, T395, T396,
T397, T398, T399, T400, T401 , T402, T403, T404 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wo-T397, T398, T399, T400, T401, T402, T403 are, T404 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl , heteroaryl, heteroarylalkyl "and where
20 bei alternativ T374, T375 und/oder T381 , T382 und/oder T391 ,20 with alternatively T374, T375 and / or T381, T382 and / or T391,
T392 und/oder T398, T399 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander auch weiter substituiert seinT392 and / or T398, T399 in each case together can also form "heterocyclyl", where optionally substituents of the substituent group (i) above are also independently of one another further substituted
25 können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:25 may be substituted with at least one substituent, the same or different, selected from the group consisting of:
(ii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT405, -NT406T407, -NO2, -(ii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHT405, -NT406T407, -NO 2 , -
30 OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH,30 OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH,
-C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-T408, -C(O)O-T409, -C(O)NH-T410, -C(O)NT41 1T412, -O-T413, -O(-T414- O)y-H (y = 1 , 2, 3, 4, 5), -O(-T415-O)y-T416 (y = 1 , 2, 3, 4, 5), -OC(O)-T417, -OC(O)-O-T418, -OC(O)-N HT419, -O- C(O)-NT420T421 , -OP(O)(OT422)(OT423), - OSi(T424)(T425)(T426), -OS(O2)-T427, -NHC(O)-T428, - NT429C(O)-T430, -NH-C(O)-O-T431 , -N H-C(O)-N H- T432, -NH-C(O)-NT433T434, -NT435-C(O)-O-T436, - 5 NT437-C(O)-NH-T438, -NT439-C(O)-NT440T441 , --C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T408, -C (O) O-T 409, -C (O) NH-T 410, - C (O) NT41 1T412, -O-T413, -O (-T414-O) y -H (y = 1, 2, 3, 4, 5), -O (-T415-O) y -T416 (y = 1, 2, 3, 4, 5), -OC (O) -T417, -OC (O) -O-T418, -OC (O) -N HT419, -O- C (O) -NT420T421, -OP (O) (OT422) (OT423), - OSi (T424) (T425), (T426), -OS (O 2) -T427, -NHC (O) -T428 - NT429C (O) -T430, -NH-C (O) -O-T431, -NHC (O) -NH-T432, -NH-C (O) -NT433T434, -NT435-C (O) -O- T436, - 5 NT437-C (O) -NH-T438, -NT439-C (O) -NT440T441, -
NHS(O2)-T442, -NT443S(O2)-T444, -S-T445, -S(O)-T446, -S(O2)-T447, -S(O2)N H-T448, -S(O2)NT449T450, - S(O2)O-T451 , -P(O)(OT452)(OT453), - Si(T454)(T455)(T456)";NHS (O 2) -T442, -NT443S (O 2) -T444, -S-T445, -S (O) -T446, -S (O 2) -T447, -S (O 2) N H-T448, -S (O 2) NT449T450, - S (O 2) O-T451, -P (O) (OT452) (OT453), - Si (T454) (T455), (T456) ";
10 wobei T405, T406, T407, T408, T409, T410, T411, T412,10 wherein T405, T406, T407, T408, T409, T410, T411, T412,
T413, T414, T415, T416, T417, T418, T419, T420, T421, T422, T423, T424, T425, T426, T427, T428, T429, T430, T431 , T432, T433, T434, T435, T436, T437, T438, T439, T440, T441 , T442, T443, T444, T445, T446, T447, T448,T413, T414, T415, T416, T417, T418, T419, T420, T421, T422, T423, T424, T425, T426, T427, T428, T429, T430, T431, T432, T433, T434, T435, T436, T437, T438, T439, T440, T441, T442, T443, T444, T445, T446, T447, T448,
15 T449, T450, T451 , T452, T453, T454, T455, T456 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" und wobei alternativ T41 1 , T412 und/oder T420, T421"Alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl: 15 T449, T450, T451, T452, T453, T454, T455, T456 independently selected from the group consisting of , arylalkyl, heteroaryl, heteroarylalkyl "and alternatively T41 1, T412 and / or T420, T421
20 und/oder T433, T434 und/oder T440, T441 und/oder T449,20 and / or T433, T434 and / or T440, T441 and / or T449,
T450 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder ver- 25 schieden, ausgewählt aus der Gruppe bestehend aus:T450 in each case together can also form "heterocyclyl", where optionally substituted substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT457, - NT458T459, -NO2, -OH, -OCF3, -SH, -0-SO3H, - 30 OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -(iii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHT457, -NT458T459, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -30 OP (O) (OH) 2 , -CHO, -COOH, -C ( O) NH 2 , -SO 3 H, -
P(O)(OH)2, -C(O)-T460, -C(O)O-T461 , -C(O)N H-T462, -C(O)NT463T464, -O-T465, -O(-T466-O)z-H (z = 1 , 2, 3, 4, 5), -O(-T467-O)z-T468 (z = 1 , 2, 3, 4, 5), -OC(O)- T469, -OC(O)-O-T470, -OC(O)-NHT471 , -0-C(O)- NT472T473, -OP(O)(OT474)(OT475), - OSi(T476)(T477)(T478), -OS(O2)-T479, -NHC(O)-T480, -NT481C(O)-T482, -NH-C(O)-O-T483, -NH-C(O)- NH-T484, -NH-C(O)-NT485T486, -NT487-C(O)-O- T488, -NT489-C(O)-NH-T490, -NT491-C(O)-P (O) (OH) 2 , -C (O) -T460, -C (O) O-T461, -C (O) NH-T462, -C (O) NT463T464, -O-T465, -O (-T466-O) z -H (z = 1, 2, 3, 4, 5), -O (-T467-O) z -T468 (z = 1, 2, 3, 4, 5), -OC (O) - T469, -OC (O) -O-T470, -OC (O) -NHT471, -O-C (O) - NT472T473, -OP (O) (OT474) (OT475), - OSi (T476) (T477), (T478), -OS (O 2) -T479, -NHC (O) -T480, -NT481C (O) -T482 , -NH-C (O) -O-T483, -NH-C (O) -NH-T484, -NH-C (O) -NT485T486, -NT487-C (O) -O-T488, -NT489- C (O) -NH-T490, -NT491-C (O) -
NT492T493, -NHS(O2)-T494, -NT495S(O2)-T496, -S- T497, -S(O)-T498, -S(O2)-T499, -S(O2)NH-T500, - S(O2)NT501T502, -S(O2)O-T503, - P(O)(OT504)(OT505), -Si(T506)(T507)(T508)"; wobei T457, T458, T459, T460, T461, T462, T463, T464,NT492T493, -NHS (O 2) -T494, -NT495S (O 2) -T496, -S- T497, -S (O) -T498, -S (O 2) -T499, -S (O 2) NH- T500, - S (O 2) NT501T502, -S (O 2) O-T503, - P (O) (OT504) (OT505), -Si (T506) (T507), (T508) "; wherein T457, T458, T459, T460, T461, T462, T463, T464,
T465, T466, T467, T468, T469, T470, T471, T472, T473, T474, T475, T476, T477, T478, T479, T480, T481, T482, T483, T484, T485, T486, T487, T488, T489, T490, T491, T492, T493, T494, T495, T496, T497, T498, T499, T500, T501 , T502, T503, T504, T505, T506, T507, T508 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylal- kyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroa- ryl, heteroarylalkyl" und wobei alternativ T463, T464 und/oder T472, T473 und/oder T485, T486 und/oderT465, T466, T467, T468, T469, T470, T471, T472, T473, T474, T475, T476, T477, T478, T479, T480, T481, T482, T483, T484, T485, T486, T487, T488, T489, T490, T491, T492, T493, T494, T495, T496, T497, T498, T499, T500, T501, T502, T503, T504, T505, T506, T507, T508 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively T463, T464 and / or T472, T473 and / or T485, T486 and / or
T492, T493 und/oder T501 , T502 jeweils zusammen auch „heterocyclyl" bilden können;T492, T493 and / or T501, T502 may together also form "heterocyclyl";
oder mit der Maßgabe, dass mindestens einer der Reste Z28, Z29 und mindestens einer der Reste Z30, Z31 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus:or with the proviso that at least one of Z28, Z29 and at least one of Z30, Z31 is independently selected from the group consisting of:
(II) „(C9-C3o)alkyl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, -C(0)-(C9-C3o)alkyl, -C(O)-cycloalkyl, -C(O)-cycloalkylalkyl, -C(O)-arylalkyl, -C(O)-heteroarylalkyl, -C(O)-heterocyclyl, -C(O)- heterocyclylalkyl, -S(O2)-alkyl, -S(02)-(C9-C3o)alkyl, -S(O2)- cycloalkyl, -S(O2)-cycloalkylalkyl, -S(O2)-aryl, -S(O2)-arylalkyl, - S(O2)-heteroaryl, -S(O2)-heteroarylalkyl, -S(O2)-heterocyclyl, - S(O2)-heterocyclylalkyl"; wobei optional obige Substituenten der Substitutionsgruppe (II) unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (i) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT509, -NT510T511 , -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-T512, -C(O)O-T513, - C(O)NH-T514, -C(O)NT515T516, -O-T517, -0(-T518-O)3-H(II) "(C 9 -C 3 o) alkyl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, -C (0) - (C 9 -C 3 O) alkyl, -C (O) cycloalkyl, -C (O ) -cycloalkylalkyl, -C (O) -arylalkyl, -C (O) -heteroarylalkyl, -C (O) -heterocyclyl, -C (O) -heterocyclylalkyl, -S (O 2 ) -alkyl, -S (O 2 arylalkyl cycloalkyl, 2) cycloalkylalkyl, -S (O, -S (O 2) aryl, -S (O 2), - -) - (C 9 -C 3 O) alkyl, -S (O 2) S (O 2) heteroaryl, -S (O 2) heteroarylalkyl, -S (O 2) heterocyclyl, - S (O 2) -heterocyclylalkyl "; wherein optional substituents of substituent group (II) may be independently further substituted with at least one substituent, same or different, selected from the group consisting of: (i) alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl , heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHT509, -NT510T511, -NO 2, -OH, - OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T512, -C (O) O-T513, -C (O) NH-T514, -C (O) NT515T516, -O-T517, -O (-T518-O) 3 -H
(a = 1 , 2, 3, 4, 5), -O(-T519-O)a-T520 (a = 1 , 2, 3, 4, 5), - OC(O)-T521 , -OC(O)-O-T522, -OC(O)-N HT523, -0-C(O)- NT524T525, -OP(O)(OT526)(OT527), -OSi(T528)(T529)(T530), -OS(O2)-T531 , -NHC(O)-T532, -NT533C(O)-T534, -NH- C(O)-O-T535, -N H-C(O)-N H-T536, -NH-C(O)-NT537T538, -(a = 1, 2, 3, 4, 5), -O (-T519-O) a -T520 (a = 1, 2, 3, 4, 5), - OC (O) -T521, -OC ( O) -O-T522, -OC (O) -N HT523, -O-C (O) -NT524T525, -OP (O) (OT526) (OT527), -OSi (T528) (T529) (T530), -OS (O 2) -T531, -NHC (O) -T532, -NT533C (O) -T534, -NH- C (O) -O-T535, -N HC (O) -N H-T536, - NH-C (O) -NT537T538, -
NT539-C(O)-O-T540, -NT541 -C(O)-N H-T542, -NT543- C(O)-NT544T545, -NHS(O2)-T546, -NT547S(O2)-T548, -S- T549, -S(O)-T550, -S(O2)-T551 , -S(O2)NH-T552, - S(O2)NT553T554, -S(O2)O-T555, -P(O)(OT556)(OT557), - Si(T558)(T559)(T560)"; wobei T509, T510, T51 1 , T512, T513, T514, T515, T516, T517, T518, T519, T520, T521 , T522, T523, T524, T525, T526, T527, T528, T529, T530, T531 , T532, T533, T534, T535, T536, T537, T538, T539, T540, T541 , T542, T543, T544, T545, T546, T547, T548, T549, T550, T551 , T552, T553, T554, T555, T556, T557,NT539-C (O) -O-T540, -NT541 -C (O) -N H-T542, -NT543- C (O) -NT544T545, -NHS (O 2) -T546, -NT547S (O 2) - T548, T549 -S-, -S (O) -T550, -S (O 2) -T551, -S (O 2) NH-T552, - S (O 2) NT553T554, -S (O 2) O- T555, -P (O) (OT556) (OT557), -Si (T558) (T559) (T560) "; wherein T509, T510, T51 1, T512, T513, T514, T515, T516, T517, T518, T519 , T520, T521, T522, T523, T524, T525, T526, T527, T528, T529, T530, T531, T532, T533, T534, T535, T536, T537, T538, T539, T540, T541, T542, T543, T544 , T545, T546, T547, T548, T549, T550, T551, T552, T553, T554, T555, T556, T557,
T558, T559, T560 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T515, T516 und/oder T524, T525 und/oder T537, T538 und/oder T544, T545 und/oderT558, T559, T560 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively T515, T516 and / or T524, T525 and / or T537, T538 and / or T544, T545 and / or
T553, T554 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:T553, T554 may together also form "heterocyclyl", where optionally substituents of the substituent group (i) above may be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F,(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F,
5 Cl, Br, I, CN, CF3, N3, NH2, -NHT561 , -NT562T563, -NO2, -5 Cl, Br, I, CN, CF 3, N 3, NH 2, -NHT561, -NT562T563, -NO 2, -
OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-T564, -C(O)O-T565, -C(O)NH-T566, -C(O)NT567T568, -O-T569, -O(-T570- O)b-H (b = 1 , 2, 3, 4, 5), -O(-T571-O)b-T572 (b = 1 , 2, 3, 4,OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T564, -C (O) O-T565, -C (O) NH-T566, -C (O) NT567T568, -O-T569, -O (-T570-O ) b -H (b = 1, 2, 3, 4, 5), -O (-T571-O) b -T572 (b = 1, 2, 3, 4,
10 5), -OC(O)-T573, -OC(O)-O-T574, -OC(O)-N HT575, -O-10 5), -OC (O) -T573, -OC (O) -O-T574, -OC (O) -N HT575, -O-
C(O)-NT576T577, -OP(O)(OT578)(OT579), - OSi(T580)(T581 )(T582), -OS(O2)-T583, -NHC(O)-T584, - NT585C(O)-T586, -NH-C(O)-O-T587, -N H-C(O)-N H- T588, -NH-C(O)-NT589T590, -NT591-C(O)-O-T592, -C (O) -NT576T577, -OP (O) (OT578) (OT579), - OSi (T580) (T581), (T582), -OS (O 2) -T583, -NHC (O) -T584 - NT585C (O) -T586, -NH-C (O) -O-T587, -NHC (O) -NH-T588, -NH-C (O) -NT589T590, -NT591-C (O) -O- T592, -
15 NT593-C(O)-NH-T594, -NT595-C(O)-NT596T597, -15NT593-C (O) -NH-T594, -NT595-C (O) -NT596T597, -
NHS(O2)-T598, -NT599S(O2)-T600, -S-T601 , -S(O)-T602, -S(O2)-T603, -S(O2)NH-T604, -S(O2)NT605T606, - S(O2)O-T607, -P(O)(OT608)(OT609), - Si(T610)(T611 )(T612)";NHS (O 2 ) -T598, -NT599S (O 2 ) -T6O, -S-T 601, -S (O) -T 602, -S (O 2 ) -T 603, -S (O 2 ) NH-T 604, - S (O 2) NT605T606, - S (O 2) O-T607, -P (O) (OT608) (OT609), - Si (T610) (T611), (T612) ";
20 wobei T561, T562, T563, T564, T565, T566, T567, T568,20 wherein T561, T562, T563, T564, T565, T566, T567, T568,
T569, T570, T571 , T572, T573, T574, T575, T576, T577, T578, T579, T580, T581 , T582, T583, T584, T585, T586, T587, T588, T589, T590, T591 , T592, T593, T594, T595, T596, T597, T598, T599, T600, T601, T602, T603, T604,T569, T570, T571, T572, T573, T574, T575, T576, T577, T578, T579, T580, T581, T582, T583, T584, T585, T586, T587, T588, T589, T590, T591, T592, T593, T594, T595, T596, T597, T598, T599, T600, T601, T602, T603, T604,
25 T605, T606, T607, T608, T609, T610, T61 1 , T612 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T567, T568 und/oder T576, T57725 T605, T606, T607, T608, T609, T610, T61 1, T612 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl , heteroaryl, heteroarylalkyl "and alternatively T567, T568 and / or T576, T577
30 und/oder T589, T590 und/oder T596, T597 und/oder T605,30 and / or T589, T590 and / or T596, T597 and / or T605,
T606 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein kön- nen mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:T606 may in each case also form "heterocyclyl", in which case optionally substituents of the substituent group (ii) above may be substituted independently of one another NEN having at least one substituent, the same or different, selected from the group consisting of:
(iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- 5 lalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT613, -(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT613, -
NT614T615, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, - P(O)(OH)2, -C(O)-T616, -C(O)O-T617, -C(O)NH-T618, -C(O)NT619T620, -O-T621 , -O(-T622-O)c-H (c = 1 , 2,NT614T615, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T616, -C (O) O-T617, -C (O) NH-T618, -C (O) NT619T620, -O-T621, -O (-T622-O) c -H (c = 1, 2,
10 3,4, 5), -O(-T623-O)c-T624 (c = 1 , 2, 3, 4, 5), -OC(O)-10, 3,4, 5), -O (-T623-O) c -T624 (c = 1, 2, 3, 4, 5), -OC (O) -
T625, -OC(O)-O-T626, -OC(O)-NHT627, -0-C(O)- NT628T629, -OP(O)(OT630)(OT631), - OSi(T632)(T633)(T634), -OS(O2)-T635, -NHC(O)-T636, -NT637C(O)-T638, -NH-C(O)-O-T639, -NH-C(O)-T625, -OC (O) -O-T626, -OC (O) -NHT627, -O-C (O) -NT628T629, -OP (O) (OT630) (OT631), -OSi (T632) (T633) (T634), -OS (O 2) -T635, -NHC (O) -T636, -NT637C (O) -T638, -NH-C (O) -O-T639, -NH-C (O) -
15 NH-T640, -NH-C(O)-NT641T642, -NT643-C(O)-O-15 NH-T640, -NH-C (O) -NT641T642, -NT643-C (O) -O-
T644, -NT645-C(O)-NH-T646, -NT647-C(O)- NT648T649, -NHS(O2)-T650, -NT651 S(O2)-T652, -S- T653, -S(O)-T654, -S(O2)-T655, -S(O2)NH-T656, - S(O2)NT657T658, -S(O2)O-T659, -T644, -NT645-C (O) -NH-T646, -NT647-C (O) - NT648T649, -NHS (O 2) -T650, -NT651 S (O 2) -T652, -S- T653, -S (O) -T654, -S (O 2) -T655, -S (O 2) NH-T656, - S (O 2) NT657T658, -S (O 2) O-T659, -
20 P(O)(OT660)(OT661 ), -Si(T662)(T663)(T664)"; wobei T613, T614, T615, T616, T617, T618, T619, T620, T621 , T622, T623, T624, T625, T626, T627, T628, T629, T630, T631 , T632, T633, T634, T635, T636, T637, T638, T639, T640, T641 , T642, T643, T644, T645, T646, T647,20 P (O) (OT660) (OT661), -Si (T662) (T663) (T664) "; wherein T613, T614, T615, T616, T617, T618, T619, T620, T621, T622, T623, T624, T625, T626, T627, T628, T629, T630, T631, T632, T633, T634, T635, T636, T637, T638, T639, T640, T641, T642, T643, T644, T645, T646, T647,
25 T648, T649, T650, T651 , T652, T653, T654, T655, T656,25 T648, T649, T650, T651, T652, T653, T654, T655, T656,
T657, T658, T659, T660, T661 , T662, T663, T664 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroa-T657, T658, T659, T660, T661, T662, T663 are, T664 independently selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaromatics
30 ryl, heteroarylalkyl" und wobei alternativ T619, T620 und/oder T628, T629 und/oder T641 , T642 und/oder T648, T649 und/oder T657, T658 jeweils zusammen auch „heterocyclyl" bilden können; und einer der Reste Z28, Z29 oder keiner der Reste Z28, Z29 und einer der Reste Z30, Z31 oder keiner der Reste Z30, Z31 und Rest Z32 unabhängig ausgewählt ist aus der Gruppe bestehend aus:30 ryl, heteroarylalkyl "and wherein alternatively T619, T620 and / or T628, T629 and / or T641, T642 and / or T648, T649 and / or T657, T658 may each together also form" heterocyclyl "; and one of Z28, Z29 or none of Z28, Z29 and one of Z30, Z31 or none of Z30, Z31 and Z32 is independently selected from the group consisting of:
(III) „Wasserstoff, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O)- alkyl, -C(O)-aryl, -C(O)-heteroaryl"; wobei optional obige Substituenten der Substituentengruppe (IM) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT665, -NT666T667, -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-T668, -C(O)O-T669, - C(O)NH-T670, -C(O)NT671T672, -O-T673, -O(-T674-O)d-H(III) "hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C (O) -alkyl, -C (O) -aryl, -C (O) -heteroaryl", where optionally substituents of the substituent group (IM) above independently of one another may be substituted by at least one substituent, identical or different, selected from the group consisting of: (i) alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl , heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHT665, -NT666T667, -NO 2, -OH, - OCF 3, -SH, -0-SO 3 H , -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T668, -C (O) O-T669, -C (O) NH-T670, -C (O) NT671T672, -O-T673, -O (-T674-O) d -H
(d = 1 , 2, 3, 4, 5), -O(-T675-O)d-T676 (d = 1 , 2, 3, 4, 5), - OC(O)-T677, -OC(O)-O-T678, -OC(O)-N HT679, -0-C(O)- NT680T681 , -OP(O)(OT682)(OT683), -OSi(T684)(T685)(T686), -OS(O2)-T687, -NHC(O)-T688, -NT689C(O)-T690, -NH- C(O)-O-T691 , -N H-C(O)-N H-T692, -NH-C(O)-NT693T694, -(d = 1, 2, 3, 4, 5), -O (-T675-O) d -T676 (d = 1, 2, 3, 4, 5), - OC (O) -T677, -OC ( O) -O-T678, -OC (O) -N HT679, -O-C (O) -NT680T681, -OP (O) (OT682) (OT683), -OSi (T684) (T685) (T686), -OS (O 2 ) -T687, -NHC (O) -T688, -NT689C (O) -T690, -NH-C (O) -O-T691, -NHC (O) -NH-T692, - NH-C (O) -NT693T694, -
NT695-C(O)-O-T696, -NT697-C(O)-NH-T698, -NT699- C(O)-NT700T701 , -NHS(O2)-T702, -NT703S(O2)-T704, -S- T705, -S(O)-T706, -S(O2)-T707, -S(O2)NH-T708, - S(O2)NT709T710, -S(O2)O-T711 , -P(O)(OT712)(OT713), - Si(T714)(T715)(T716)"; wobei T665, T666, T667, T668, T669, T670, T671 , T672, T673, T674, T675, T676, T677, T678, T679, T680, T681 , T682, T683, T684, T685, T686, T687, T688, T689, T690, T691 , T692, T693, T694, T695, T696, T697, T698, T699, T700, T701 , T702, T703, T704, T705, T706, T707, T708, T709, T710, T71 1 , T712, T713,NT695-C (O) -O-T696, -NT697-C (O) -NH-T698, -NT699- C (O) -NT700T701, -NHS (O 2) -T702, -NT703S (O 2) -T704 , -S- T705, -S (O) -T706, -S (O 2) -T707, -S (O 2) NH-T708, - S (O 2) NT709T710, -S (O 2) O-T711 , -P (O) (OT712) (OT713), -Si (T714) (T715) (T716) "; wherein T665, T666, T667, T668, T669, T670, T671, T672, T673, T674, T675, T676 , T677, T678, T679, T680, T681, T682, T683, T684, T685, T686, T687, T688, T689, T690, T691, T692, T693, T694, T695, T696, T697, T698, T699, T700, T701 , T702, T703, T704, T705, T706, T707, T708, T709, T710, T71 1, T712, T713,
T714, T715, T716 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T671 , T672 und/oder T680, T681 und/oder T693, T694 und/oder T700, T701 und/oder T709, T710 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i)T714, T715, T716 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively T671, T672 and /or T680, T681 and / or T693, T694 and / or T700, T701 and / or T709, T710 may together also form "heterocyclyl" wherein optionally substituents of the substituent group (i) above
5 wiederum unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:5 again independently of one another may also be further substituted with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F,(ii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F,
10 Cl, Br, I, CN, CF3, N3, NH2, -NHT717, -NT718T719, -NO2, -10 Cl, Br, I, CN, CF 3, N 3, NH 2, -NHT717, -NT718T719, -NO 2, -
OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-T720, -C(O)O-T721 , -C(O)NH-T722, -C(O)NT723T724, -O-T725, -O(-T726- O)6-H (e = 1 , 2, 3, 4, 5), -O(-T727-O)e-T728 (e = 1 , 2, 3, 4,OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T720, -C (O) O-T721, -C (O) NH-T722, -C (O) NT723T724, -O-T725, -O (-T726-0 ) 6 -H (e = 1, 2, 3, 4, 5), -O (-T727-O) e -T728 (e = 1, 2, 3, 4,
15 5), -OC(O)-T729, -OC(O)-O-T730, -OC(O)-N HT731 , -O-15 5), -OC (O) -T729, -OC (O) -O-T730, -OC (O) -N HT731, -O-
C(O)-NT732T733, -OP(O)(OT734)(OT735), - OSi(T736)(T737)(T738), -OS(O2)-T739, -NHC(O)-T740, - NT741 C(O)-T742, -NH-C(O)-O-T743, -NH-C(O)-NH- T744, -NH-C(O)-NT745T746, -NT747-C(O)-O-T748, -C (O) -NT732T733, -OP (O) (OT734) (OT735), - OSi (T736) (T737), (T738), -OS (O 2) -T739, -NHC (O) -T740 - NT741 C (O) -T742, -NH-C (O) -O-T743, -NH-C (O) -NH-T744, -NH-C (O) -NT745T746, -NT747-C (O) -O -T748, -
20 NT749-C(O)-NH-T750, -NT751-C(O)-NT752T753, -20 NT749-C (O) -NH-T750, -NT751-C (O) -NT752T753, -
NHS(O2)-T754, -NT755S(O2)-T756, -S-T757, -S(O)-T758, -S(O2)-T759, -S(O2)NH-T760, -S(O2)NT761T762, - S(O2)O-T763, -P(O)(OT764)(OT765), - Si(T766)(T767)(T768)";NHS (O 2) -T754, -NT755S (O 2) -T756, -S-T757, -S (O) -T758, -S (O 2) -T759, -S (O 2) NH-T760, - S (O 2) NT761T762, - S (O 2) O-T763, -P (O) (OT764) (OT765), - Si (T766) (T767), (T768) ";
25 wobei T717, T718, T719, T720, T721, T722, T723, T724,25 where T717, T718, T719, T720, T721, T722, T723, T724,
T725, T726, T727, T728, T729, T730, T731, T732, T733, T734, T735, T736, T737, T738, T739, T740, T741, T742, T743, T744, T745, T746, T747, T748, T749, T750, T751, T752, T753, T754, T755, T756, T757, T758, T759, T760,T725, T726, T727, T728, T729, T730, T731, T732, T733, T734, T735, T736, T737, T738, T739, T740, T741, T742, T743, T744, T745, T746, T747, T748, T749, T750, T751, T752, T753, T754, T755, T756, T757, T758, T759, T760,
30 T761 , T762, T763, T764, T765, T766, T767, T768 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T723, T724 und/oder T732, T733 und/oder T745, T746 und/oder T752, T753 und/oder T761 , T762 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein kön-T761, T762, T763, T764, T765, T766, T767, T768 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively T723, T724 and / or T732, T733 and / or T745, T746 and / or T752, T753 and / or T761, T762 may in each case also form "heterocyclyl", where optionally substituted substituents of the substituent group (ii) may in turn be substituted independently of one another.
5 nen mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:5 nen with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT769, -(iii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHT769, -
10 NT770T771, -NO2, -OH, -OCF3, -SH, -0-SO3H, -10 NT770T771, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -
OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, - P(O)(OH)2, -C(O)-T772, -C(O)O-T773, -C(O)NH-T774, -C(O)NT775T776, -O-T777, -O(-T778-O)^H (f = 1, 2, 3, 4, 5), -O(-T779-OHT780 (f = 1 , 2, 3, 4, 5), -OC(O)-OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T 772, -C (O ) O-T773, -C (O) NH-T774, -C (O) NT775T776, -O-T777, -O (-T778-O) ^ H (f = 1, 2, 3, 4, 5), -O (-T779-OHT780 (f = 1, 2, 3, 4, 5), -OC (O) -
15 T781 , -OC(O)-O-T782, -OC(O)-NHT783, -0-C(O)-15 T781, -OC (O) -O-T782, -OC (O) -NHT783, -O-C (O) -
NT784T785, -OP(O)(OT786)(OT787), - OSi(T788)(T789)(T790), -OS(O2)-T791, -NHC(O)-T792, -NT793C(O)-T794, -NH-C(O)-O-T795, -NH-C(O)- NH-T796, -NH-C(O)-NT797T798, -NT799-C(O)-O-NT784T785, -OP (O) (OT786) (OT787), - OSi (T788) (T789), (T790), -OS (O 2) -T791, -NHC (O) -T792, -NT793C (O) -T794 , -NH-C (O) -O-T795, -NH-C (O) -NH-T796, -NH-C (O) -NT797T798, -NT799-C (O) -O-
20 T800, -NT801-C(O)-NH-T802, -NT803-C(O)-20 T800, -NT801-C (O) -NH-T802, -NT803-C (O) -
NT804T805, -NHS(O2)-T806, -NT807S(O2)-T808, -S- T809, -S(O)-T810, -S(O2)-T811, -S(O2)NH-T812, - S(O2)NT813T814, -S(O2)O-T815, - P(O)(OT816)(OT817), -Si(T818)(T819)(T820)";NT804T805, -NHS (O 2) -T806, -NT807S (O 2) -T808, -S- T809, -S (O) -T810, -S (O 2) -T811, -S (O 2) NH- T812, - S (O 2) NT813T814, -S (O 2) O-T815, - P (O) (OT816) (OT817), -Si (T818) (T819), (T820) ";
25 wobei T769, T770, T771, T772, T773, T774, T775, T776,25 where T769, T770, T771, T772, T773, T774, T775, T776,
T777, T778, T779, T780, T781 , T782, T783, T784, T785, T786, T787, T788, T789, T790, T791, T792, T793, T794, T795, T796, T797, T798, T799, T800, T801, T802, T803, T804, T805, T806, T807, T808, T809, T810, T811, T812,T777, T778, T779, T780, T781, T782, T783, T784, T785, T786, T787, T788, T789, T790, T791, T792, T793, T794, T795, T796, T797, T798, T799, T800, T801, T802, T803, T804, T805, T806, T807, T808, T809, T810, T811, T812,
30 T813, T814, T815, T816, T817, T818, T819, T820 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T775, T776 und/oder T784, T785 und/oder T797, T798 und/oder T804, T805 und/oder T813, T814 jeweils zusammen auch „heterocyclyl" bilden können;30 T813, T814, T815, T816, T817, T818, are T819, T820 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively T775, T776 and / or T784, T785 and / or T797, T798 and / or T804, T805 and / or T813, T814 may together also form "heterocyclyl";
(2) ,,-C(Y5)NZ33-Y6-Z34"; wobei Y5, Y6 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus „O, S, =NH, =NZ35"; wobei Z33, Z34, Z35 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: (I) „Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, - C(O)-alkyl, -C(0)-(C9-C3o)alkyl, -C(O)-cycloalkyl, -C(O)- cycloalkylalkyl, -C(O)-aryl, -C(O)-arylalkyl, -C(O)-heteroaryl, - C(O)-heteroarylalkyl, -C(O)-heterocyclyl, -C(O)-heterocyclylalkyl, -S(O2)-alkyl, -S(02)-(C9-C3o)alkyl, -S(O2)-cycloalkyl, -S(O2)- cycloalkylalkyl, -S(O2)-aryl, -S(O2)-arylalkyl, -S(O2)-heteroaryl, - S(O2)-heteroarylalkyl, -S(O2)-heterocyclyl, -S(O2)- heterocyclylalkyl"; wobei optional obige Substituenten der Substituentengruppe (I) un- abhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(2) ,, - C (Y5) NZ33-Y6-Z34 "; wherein Y5, Y6 are independently selected from the group consisting of" O, S, = NH, = NZ35 "; wherein Z33, Z34, are Z35 independently selected from the group consisting of: (i) "hydrogen, alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, - C (O) alkyl, -C (0) - (C 9 -C 3 O) alkyl, -C (O) cycloalkyl, -C (O) - cycloalkylalkyl, -C (O) -aryl, -C ( O) -arylalkyl, -C (O) -heteroaryl, - C (O) -heteroarylalkyl, -C (O) -heterocyclyl, -C (O) -heterocyclylalkyl, -S (O 2 ) -alkyl, -S (0 2) - (C 9 -C 3 O) alkyl, -S (O 2) cycloalkyl, -S (O2) - cycloalkylalkyl, -S (O 2) aryl, -S (O 2) arylalkyl, - S (O 2) heteroaryl, - (O 2) heteroarylalkyl S, -S (O 2) -heterocyclyl, -S (O 2) - heterocyclylalkyl "; wherein optionally above substituents of substituent group (I) independently of each other in turn may be substituted with at least one substituent, the same or different, selected from the group consisting of:
(i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT821 , -NT822T823, -NO2, -OH, -(i) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT821, -NT822T823, -NO 2 , -OH, -
OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-T824, -C(O)O-T825, - C(O)NH-T826, -C(O)NT827T828, -O-T829, -O(-T830-O)g-H (g = 1 , 2, 3, 4, 5), -O(-T831-O)g-T832 (g = 1 , 2, 3, 4, 5), - OC(O)-T833, -OC(O)-O-T834, -OC(O)-N HT835, -0-C(O)-OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T824, -C (O) O-T825, -C (O) NH-T826, -C (O) NT827T828, -O-T829, -O (-T830-O) g - H (g = 1,2,3,4,5), -O (-T831-O) g -T832 (g = 1,2,3,4,5), - OC (O) -T833, -OC (O) -O-T834, -OC (O) -NHT835, -O-C (O) -
NT836T837, -OP(O)(OT838)(OT839), -OSi(T840)(T814)(T842), -OS(O2)-T843, -NHC(O)-T844, -NT845C(O)-T846, -NH- C(O)-O-T847, -N H-C(O)-N H-T848, -NH-C(O)-NT849T850, - NT851-C(O)-O-T852, -NT853-C(O)-NH-T854, -NT855- C(O)-NT856T857, -NHS(O2)-T858, -NT859S(O2)-T860, -S- T861 , -S(O)-T862, -S(O2)-T863, -S(O2)NH-T864, - S(O2)NT865T866, -S(O2)O-T867, -P(O)(OT868)(OT869), - 5 Si(T870)(T871 )(T872)"; wobei T821 , T822, T823, T824, T825, T826, T827, T828, T829, T830, T831 , T832, T833, T834, T835, T836, T837, T838, T839, T840, T841 , T842, T843, T844, T845, T846, T847, T848, T849, T850, T851 , T852, T853, T854, T855, T856, T857, T858, T859,NT836T837, -OP (O) (OT838) (OT839), -OSi (T840) (T814), (T842), -OS (O 2) -T843, -NHC (O) -T844, -NT845C (O) -T846 , -NH-C (O) -O-T847, -NHC (O) -NH-T848, -NH-C (O) -NT849T850, - NT851-C (O) -O-T852, -NT853-C (O) -NH-T854, -NT855- C (O) -NT856T857, -NHS (O 2) -T858, -NT859S (O 2) -T860 , -S- T861, -S (O) -T862, -S (O 2) -T863, -S (O 2) NH-T864, - S (O 2) NT865T866, -S (O 2) O-T867 , -P (O) (OT868) (OT869), -Si (T870) (T871) (T872) "; where T821, T822, T823, T824, T825, T826, T827, T828, T829, T830, T831, T832, T833, T834, T835, T836, T837, T838, T839, T840, T841, T842, T843, T844, T845, T846, T847, T848, T849, T850, T851, T852, T853, T854, T855, T856, T857, T858, T859,
10 T860, T861 , T862, T863, T864, T865, T866, T867, T868, T869,10 T860, T861, T862, T863, T864, T865, T866, T867, T868, T869,
T870, T871 , T872 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cyc- loalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, hetero- aryl, heteroarylalkyl" und wobei alternativ T827, T828 und/oderT870, T871, T872 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively T827, T828 and / or
15 T836, T837 und/oder T849, T850 und/oder T856, T857 und/oder15 T836, T837 and / or T849, T850 and / or T856, T857 and / or
T865, T866 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander auch weiter substituiert seinT865, T866 may together also form "heterocyclyl", wherein optionally substituents of the substituent group (i) above may also be further substituted independently of one another
20 können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:20 may be substituted by at least one substituent, the same or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT873, -NT874T875, -NO2, -(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT873, -NT874T875, -NO 2 , -
25 OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH,25 OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH,
-C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-T876, -C(O)O-T877, -C(O)NH-T878, -C(O)NT879T880, -O-T881 , -O(-T882- O)h-H (h = 1 , 2, 3, 4, 5), -O(-T883-O)h-T884 (h = 1 , 2, 3, 4, 5), -OC(O)-T885, -OC(O)-O-T886, -OC(O)-NHT887, -O--C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T876, -C (O) O-T 877, -C (O) NH-T 878, - C (O) NT879T880, -O-T881, -O (-T882-O) h -H (h = 1, 2, 3, 4, 5), -O (-T883-O) h -T884 (h = 1, 2, 3, 4, 5), -OC (O) -T885, -OC (O) -O-T886, -OC (O) -NHT887, -O-
30 C(O)-NT888T889, -OP(O)(OT890)(OT891 ), -30 C (O) -NT888T889, -OP (O) (OT890) (OT891),
OSi(T892)(T893)(T894), -OS(O2)-T895, -NHC(O)-T896, - NT897C(O)-T898, -NH-C(O)-O-T899, -NH-C(O)-NH- T900, -NH-C(O)-NT901T902, -NT903-C(O)-O-T904, - NT905-C(O)-NH-T906, -NT907-C(O)-NT908T909, - NHS(O2)-T910, -NT91 1S(O2)-T912, -S-T913, -S(O)-T914, -S(O2)-T915, -S(O2)NH-T916, -S(O2)NT917T918, - S(O2)O-T919, -P(O)(OT920)(OT921 ), - Si(T922)(T923)(T924)";OSi (T892) (T893), (T894), -OS (O 2) -T895, -NHC (O) -T896 - NT897C (O) -T898, -NH-C (O) -O-T899, -NH -C (O) -NH-T900, -NH-C (O) -NT901T902, -NT903-C (O) -O-T904, - NT905-C (O) -NH-T906, -NT907-C (O ) -NT908T909, - NHS (O 2) -T910, -NT91 1S (O 2) -T912, -S-T913, -S (O) -T914, -S (O 2) -T915, -S (O 2) NH-T916, -S (O 2) NT917T918, - S (O 2) O-T919, -P (O) (OT920) (OT921), - Si (T922) (T923), (T924) ";
5 wobei T873, T874, T875, T876, T877, T878, T879, T880,5 wherein T873, T874, T875, T876, T877, T878, T879, T880,
T881 , T882, T883, T884, T885, T886, T887, T888, T889, T890, T891 , T892, T893, T894, T895, T896, T897, T898, T899, T900, T901 , T902, T903, T904, T905, T906, T907, T908, T909, T910, T911, T912, T913, T914, T915, T916,T881, T882, T883, T884, T885, T886, T887, T888, T889, T890, T891, T892, T893, T894, T895, T896, T897, T898, T899, T900, T901, T902, T903, T904, T905, T906, T907, T908, T909, T910, T911, T912, T913, T914, T915, T916,
10 T917, T918, T919, T920, T921 , T922, T923, T924 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, hetero- cyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" und wobei alternativ T879, T880 und/oder T888, T889T917, T918, T919, T920, T921, T922, T923, T924 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively T879, T880 and / or T888, T889
15 und/oder T901 , T902 und/oder T908, T909 und/oder T917,15 and / or T901, T902 and / or T908, T909 and / or T917,
T918 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder ver- 20 schieden, ausgewählt aus der Gruppe bestehend aus:T918 may in each case also form "heterocyclyl", where optionally substituted substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT925, - NT926T927, -NO2, -OH, -OCF3, -SH, -0-SO3H, -(iii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHT 925, - NT 926 T 927, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -
25 OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -25 OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -
P(O)(OH)2, -C(O)-T928, -C(O)O-T929, -C(O)NH-T930, -C(O)NT931T932, -O-T933, -O(-T934-O),-H (i = 1 , 2, 3, 4, 5), -O(-T935-O),-T936 (i = 1 , 2, 3, 4, 5), -OC(O)- T937, -OC(O)-O-T938, -OC(O)-NHT939, -0-C(O)-P (O) (OH) 2 , -C (O) -T928, -C (O) O-T929, -C (O) NH-T930, -C (O) NT931T932, -O-T933, -O ( -T934-O), - H (i = 1, 2, 3, 4, 5), -O (-T935-O), - T936 (i = 1, 2, 3, 4, 5), -OC ( O) - T937, -OC (O) -O-T938, -OC (O) -NHT939, -O-C (O) -
30 NT940T941 , -OP(O)(OT942)(OT943), -30 NT940T941, -OP (O) (OT942) (OT943),
OSi(T944)(T945)(T946), -OS(O2)-T947, -NHC(O)-T948, -NT949C(O)-T950, -NH-C(O)-O-T951 , -NH-C(O)- NH-T952, -NH-C(O)-NT953T954, -NT955-C(O)-O- T956, -NT957-C(O)-NH-T958, -NT959-C(O)- NT960T961 , -NHS(O2)-T962, -NT963S(O2)-T964, -S- T965, -S(O)-T966, -S(O2)-T967, -S(O2)NH-T968, - S(O2)NT969T970, -S(O2)O-T971 , - P(O)(OT972)(OT973), -Si(T974)(T975)(T976)"; wobei T925, T926, T927, T928, T929, T930, T931 , T932,OSi (T944) (T945), (T946), -OS (O 2) -T947, -NHC (O) -T948, -NT949C (O) -T950, -NH-C (O) -O-T951, -NH -C (O) -NH-T952, -NH-C (O) -NT953T954, -NT955-C (O) -O-T956, -NT957-C (O) -NH-T958, -NT959-C (O ) - NT960T961, -NHS (O 2) -T962, -NT963S (O 2) -T964, -S- T965, -S (O) -T966, -S (O 2) -T967, -S (O 2) NH- T968, - S (O 2) NT969T970, -S (O 2) O-T971, - P (O) (OT972) (OT973), -Si (T974) (T975), (T976) "; wherein T925, T926, T927, T928, T929, T930, T931, T932,
T933, T934, T935, T936, T937, T938, T939, T940, T941, T942, T943, T944, T945, T946, T947, T948, T949, T950, T951 , T952, T953, T954, T955, T956, T957, T958, T959, T960, T961 , T962, T963, T964, T965, T966, T967, T968, T969, T970, T971 , T972, T973, T974, T975, T976 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylal- kyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroa- ryl, heteroarylalkyl" und wobei alternativ T931 , T932 und/oder T940, T941 und/oder T953, T954 und/oderT933, T934, T935, T936, T937, T938, T939, T940, T941, T942, T943, T944, T945, T946, T947, T948, T949, T950, T951, T952, T953, T954, T955, T956, T957, T958, T959, T960, T961, T962, T963, T964, T965, T966, T967, T968, T969, T970, T971, T972, T973, T974, T975, T976 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively T931, T932 and / or T940, T941 and / or T953, T954 and / or
T960, T961 und/oder T969, T970 jeweils zusammen auch „heterocyclyl" bilden können;T960, T961 and / or T969, T970 may together also form "heterocyclyl";
und einer der Reste Z26, Z27 oder keiner der Reste Z26, Z27 unabhängig voneinander auch ausgewählt ist aus der Gruppe bestehend aus:and one of the radicals Z26, Z27 or none of the radicals Z26, Z27 independently of one another is also selected from the group consisting of:
(2) „Wasserstoff, alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C(O)-alkyl, -C(0)-(C9-C3o)alkyl, -C(O)-cycloalkyl, -C(O)-cycloalkylalkyl, -C(O)- aryl, -C(O)-arylalkyl, -C(O)-heteroaryl, -C(O)-heteroarylalkyl, -C(O)- heterocyclyl, -C(O)-heterocyclylalkyl, -C(Y7)NZ36Z37, -C(=NZ38)-(2) "hydrogen, alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C (O) -alkyl, -C (O) - (C 9 -C 3 o) alkyl, -C (O) -cycloalkyl, -C (O) -cycloalkylalkyl, -C (O) -aryl, -C (O) -arylalkyl, -C (O) -heteroaryl, -C ( O) -heteroarylalkyl, -C (O) -heterocyclyl, -C (O) -heterocyclylalkyl, -C (Y7) NZ36Z37, -C (= NZ38) -
Z39, -S(O2)-alkyl, -S(02)-(C9-C3o)alkyl, -S(O2)-cycloalkyl, -S(O2)- cycloalkylalkyl, -S(O2)-aryl, -S(O2)-arylalkyl, -S(O2)-heteroaryl, - S(O2)-heteroarylalkyl, -S(O2)-heterocyclyl, -S(O2)-heterocyclylalkyl"; wobei Y7 unabhängig voneinander ausgewählt ist aus der Gruppe be- stehend aus „O, S, =NH, =NZ40"; wobei die Reste Z36, Z37, Z38, Z39, Z40 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: (I) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- cyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C(O)-alkyl, - C(0)-(C9-C3o)alkyl, -C(O)-cycloalkyl, -C(O)-cycloalkylalkyl, -C(O)- aryl, -C(O)-arylalkyl, -C(O)-heteroaryl, -C(O)-heteroarylalkyl, - C(O)-heterocyclyl, -C(O)-heterocyclylalkyl, -S(O2)-alkyl, -S(O2)-Z39, -S (O 2) alkyl, -S (0 2) - (C 9 -C 3 O) alkyl, -S (O 2) cycloalkyl, -S (O2) - cycloalkylalkyl, -S (O 2 ) -aryl, -S (O 2 ) -arylalkyl, -S (O 2 ) -heteroaryl, - S (O 2 ) -heteroarylalkyl, -S (O 2 ) -heterocyclyl, -S (O 2 ) -heterocyclylalkyl " where Y7 is independently selected from the group consisting of "O, S, = NH, = NZ40"; wherein the radicals Z36, Z37, Z38, Z39, Z40 are independently selected from the group consisting of: (I) "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C (O) -alkyl, - C (O) - (C 9 -C 3 o) alkyl, -C (O) -cycloalkyl, -C (O) -cycloalkylalkyl, -C (O) -aryl, -C (O) -arylalkyl, -C (O) -heteroaryl, -C ( O) -heteroarylalkyl, - C (O) -heterocyclyl, -C (O) -heterocyclylalkyl, -S (O 2 ) -alkyl, -S (O 2 ) -
(C9-C3o)alkyl, -S(O2)-cycloalkyl, -S(O2)-cycloalkylalkyl, -S(O2)-aryl, -S(O2)-arylalkyl, -S(O2)-heteroaryl, -S(O2)-heteroarylalkyl, - S(O2)-heterocyclyl, -S(O2)-heterocyclylalkyl"; wobei optional obige Substituenten der Substituentengruppe (3) und/oder Substituentengruppe (I) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich o- der verschieden, ausgewählt aus der Gruppe bestehend aus:(C 9 -C 3 O) alkyl, -S (O 2) cycloalkyl, -S (O 2) cycloalkylalkyl, aryl, -S (O 2), (2 O) -arylalkyl, -S (O -S 2 ) -heteroaryl, -S (O 2 ) -heteroarylalkyl, - S (O 2 ) -heterocyclyl, -S (O 2 ) -heterocyclylalkyl ", wherein optionally above substituents of the substituent group (3) and / or substituent group (I) independently may in turn be substituted with at least one substituent, same or different, selected from the group consisting of:
(i) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- cyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT977, -NT978T979, -NO2, -OH, -OCF3, -SH, -(i) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- cyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHT 977, -NT 978 T 979, -NO 2 , -OH, -OCF 3 , -SH, -
0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, - P(O)(OH)2, -C(O)-T980, -C(O)O-T981 , -C(O)NH-T982, - C(O)NT983T984, -O-T985, -O(-T986-O)-H C = 1, 2, 3, 4, 5), -0(- T987-O)-T988 (j = 1 , 2, 3, 4, 5), -OC(O)-T989, -OC(O)-O-T990, - OC(O)-NHT991 , -O-C(O)-NT992T993, -OP(O)(OT994)(OT995), -0-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, - P (O) (OH) 2 , -C (O) -T980, -C (O) O-T981, -C (O) NH-T982, -C (O) NT983T984, -O-T985, -O (-T986-O) -HC = 1, 2, 3, 4, 5), -0 (- T987-O) -T988 (j = 1, 2, 3, 4, 5), -OC (O) -T989, -OC (O) -O-T990, - OC ( O) -NHT991, -OC (O) -NT992T993, -OP (O) (OT994) (OT995),
OSi(T996)(T997)(T998), -OS(O2)-T999, -NHC(O)-TIOOO, - NT1001C(O)-TI002, -NH-C(O)-O-TI003, -NH-C(O)-NH-TI004, -NH-C(O)-NTI005T1006, -NT1007-C(O)-O-TI008, -NT1009- C(O)-NH-TIOIO1-NTIOII-C(O)-NTIO^TIOIS1-NHS(O2)- T1014, -NT1015S(O2)-T1016, -S-T1017, -S(O)-TI018, -S(O2)-OSi (T996) (T997), (T998), -OS (O 2) -T999, -NHC (O) -TIOOO, - NT1001C (O) -TI002, -NH-C (O) -O-TI003, -NH -C (O) -NH-TI004, -NH-C (O) -NTI005T1006, -NT1007-C (O) -O-TI008, -NT1009-C (O) -NH-TIOIO 1 -NTIOII-C (O ) -NTIO ^ TIOIS 1 -NHS (O 2 ) - T 1014, -NT 10 15 S (O 2 ) -T 10 16, -S-T 10 17, -S (O) -TiO 18, -S (O 2 ) -
T1019, -S(O2)NH-TI020, -S(O2)NTI021T1022, -S(O2)O-TI023, - P(O)(OTI024)(OT1025), -Si(TI026)(T1027)(T1028)"; wobei T977, T978, T979, T980, T981, T982, T983, T984, T985,T1019, -S (O 2) NH-TI020, -S (O 2) NTI021T1022, -S (O 2) O-TI023, - P (O) (OTI024) (OT1025), -Si (TI026) (T1027) (T1028) "; wherein T977, T978, T979, T980, T981, T982, T983, T984, T985,
T986, T987, T988, T989, T990, T991, T992, T993, T994, T995, T996, T997, T998, T999, T1000, T1001, T1002, T1003, T1004,T986, T987, T988, T989, T990, T991, T992, T993, T994, T995, T996, T997, T998, T999, T1000, T1001, T1002, T1003, T1004,
T1005, T1006, T1007, T1008, T1009, T1010, T1011, T1012, T1013, T1014, T1015, T1016, T1017, T1018, T1019, T1020, T1021, T1022, T1023, T1024, T1025, T1026, T1027, T1028 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T983, T984 und/oder T992, T993 und/oder T1005, T1006 und/oder T1012, T1013 und/oder T1021 , T1022 jeweils zusammen auch „heterocyc- IyI" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1029, -NT1030T1031 , -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-TI 032, -C(O)O-T1033, - C(O)NH-TI034, -C(O)NTI035T1036, -O-T1037, -O(-T1038-T1005, T1006, T1007, T1008, T1009, T1010, T1011, T1012, T1013, T1014, T1015, T1016, T1017, T1018, T1019, T1020, T1021, T1022, T1023, T1024, T1025, T1026, T1027, T1028 are independently selected are selected from the group consisting of: "alkyl, (Cg- C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively T983, T984 and / or T992, T993 and / or T1005, T1006 and / or T1012, T1013 and / or T1021 , T1022 may together also form "heterocyclyl"; wherein optionally above substituents of substituent group (i), in turn, independently of one another can also be further substituted with at least one substituent, identical or different, selected from the group consisting of: (ii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl , cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHT1029, -NT1030T1031, -NO 2, -OH, - OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -TI 032, -C (O) O-T1033, -C (O) NH-TI034, -C (O) NTI035T1036, -O-T1037, -O (-T1038-
O)k-H (k = 1, 2, 3, 4, 5), -O(-T1039-O)k-T1040 (k = 1, 2, 3, 4, 5), -OC(O)-TI041, -OC(O)-O-TI042, -OC(O)-NHTI043, -O- C(O)-NTI044T1045, -OP(O)(OTI046)(OT1047), - OSi(TI048)(T1049)(T1050), -OS(O2)-T1051, -NHC(O)-TI052, -NT1053C(O)-TI054, -NH-C(O)-O-TI055, -NH-C(O)-NH-O) k -H (k = 1, 2, 3, 4, 5), -O (-T1039-O) k -T1040 (k = 1, 2, 3, 4, 5), -OC (O) - TI041, -OC (O) -O-TI042, -OC (O) -NHTI043, -O-C (O) -NTI044T1045, -OP (O) (OTI046) (OT1047), -OSi (TI048) (T1049) (T1050), -OS (O 2) -T1051, -NHC (O) -TI052, -NT1053C (O) -TI054, -NH-C (O) -O-TI055, -NH-C (O) -NH -
T1056, -NH-C(O)-NTI057T1058, -NT1059-C(O)-O-TI060, - NT1061-C(O)-NH-TI062, -NT1063-C(O)-NTI064T1065, - NHS(O2)-T1066, -NT1067S(O2)-T1068, -S-T1069, -S(O)- T1070, -S(O2)-T1071, -S(O2)NH-TI072, -S(O2)NTI073T1074, -S(O2)O-TI075, -P(O)(OTI076)(OT1077), -T1056, -NH-C (O) -NTI057T1058, -NT1059-C (O) -O-TI060, -NT1061-C (O) -NH-TI062, -NT1063-C (O) -NTI064T1065, -NHS (O 2) -T1066, -NT1067S (O 2) -T1068, -S-T1069, -S (O) - T1070, -S (O 2) -T1071, -S (O 2) NH-TI072, -S (O 2 ) NTI073T1074, -S (O 2 ) O-TI075, -P (O) (OTI076) (OT1077),
Si(TI078)(T1079)(T1080)"; wobei T1029, T1030, T1031, T1032, T1033, T1034, T1035, T1036, T1037, T1038, T1039, T1040, T1041, T1042, T1043, T1044, T1045, T1046, T1047, T1048, T1049, T1050, T1051, T1052, T1053, T1054, T1055, T1056, T1057, T1058, T1059,Si (TI078) (T1079) (T1080) "; wherein T1029, T1030, T1031, T1032, T1033, T1034, T1035, T1036, T1037, T1038, T1039, T1040, T1041, T1042, T1043, T1044, T1045, T1046, T1047 , T1048, T1049, T1050, T1051, T1052, T1053, T1054, T1055, T1056, T1057, T1058, T1059,
T1060, T1061, T1062, T1063, T1064, T1065, T1066, T1067, T1068, T1069, T1070, T1071, T1072, T1073, T1074, T1075, T1076, T1077, T1078, T1079, T1080 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylal- kyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T1035, T1036 und/oder T1044, T1045 und/oder T1057, T1058 und/oder T1064, T1065 und/oder T1073, T1074 jeweils 5 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:T1060, T1061, T1062, T1063, T1064, T1065, T1066, T1067, T1068, T1069, T1070, T1071, T1072, T1073, T1074, T1075, T1076, T1077, T1078, T1079, T1080 are independently selected from the group consisting of : "Alkyl, (Cg- C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and, alternatively, T1035, T1036 and / or T1044, T1045 and / or T1057, T1058 and / or T1064, T1065 and / or T1073, T1074 each 5 may together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
10 (iii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1081 , -NT1082T1083, - NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, - COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-TI 084, -10 (iii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHT1081, -NT1082T1083, - NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Ti 084, -
15 C(O)O-TI 085, -C(O)NH-TI 086, -C(O)NTI 087T1088, -O-15 C (O) O-TI 085, -C (O) NH-TI 086, -C (O) NTI 087T1088, -O-
T1089, -O(-T1090-O)1-H (I = 1, 2, 3, 4, 5), -O(-T1091-O),- T1092 (I = 1, 2, 3, 4, 5), -OC(O)-TI093, -OC(O)-O-TI094, -OC(O)-NHTI095, -0-C(O)-NTI096T1097, - OP(O)(OTI098)(OT1099), -OSi(T1100)(T1101)(T1102), -T1089, -O (-T1090-O) 1 -H (I = 1,2,3,4,5), -O (-T1091-O), -T1092 (I = 1,2,3,4,5 ), -OC (O) -TI093, -OC (O) -O-TI094, -OC (O) -NHTI095, -O-C (O) -NTI096T1097, - OP (O) (OTI098) (OT1099), OSi (T1100) (T1101) (T1102), -
20 OS(O2)-T1103, -NHC(O)-T1104, -NT1105C(O)-T1106, -20 OS (O 2 ) -T1103, -NHC (O) -T1104, -NT1105C (O) -T1106, -
NH-C(O)-O-T1107, -NH-C(O)-NH-T1108, -NH-C(O)- NT1109T1110, -NT1111-C(O)-O-T1112, -NT1113-C(O)- NH-T1114, -NT1115-C(O)-NT1116T1117, -NHS(O2)- T1118, -NT1119S(O2)-T1120, -S-T1121, -S(O)-T1122, -NH-C (O) -O-T1107, -NH-C (O) -NH-T1108, -NH-C (O) -NT1109T1110, -NT1111-C (O) -O-T1112, -NT1113-C ( O) - NH-T1114, -NT1115-C (O) -NT1116T1117, -NHS (O 2) - T1118, -NT1119S (O 2) -T1120, -S-T1121, -S (O) -T1122, -
25 S(O2)-T1123, -S(O2)NH-T1124, -S(O2)NTI 125T1126, -25S (O 2 ) -T1123, -S (O 2 ) NH-T1124, -S (O 2 ) NTI 125T1126, -
S(O2)O-T1127, -P(O)(OT1128)(OT1129), - Si(T1130)(T1131)(T1132)"; wobei T1081, T1082, T1083, T1084, T1085, T1086, T1087, T1088, T1089, T1090, T1091, T1092, T1093, T1094, T1095,S (O 2) O-T1127, -P (O) (OT1128) (OT1129), - Si (T1130) (T1131) (T1132) "; wherein T1081, T1082, T1083, T1084, T1085, T1086, T1087, T1088 , T1089, T1090, T1091, T1092, T1093, T1094, T1095,
30 T1096, T1097, T1098, T1099, T1100, T1101, T1102, T1103,30 T1096, T1097, T1098, T1099, T1100, T1101, T1102, T1103,
T1104, T1105, T1106, T1107, T1108, T1109, T1110, T1111, T1112, T1113, T1114, T1115, T1116, T1117, T1118, T1119, T1120, T1121 , T1122, T1123, T1124, T1125, T1126, T1127, T1128, T1129, T1130, T1131, T1132 unabhängig voneinan- der ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- cyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T1087, T1088 und/oder T1096, T1097 und/oder T1 109, T11 10 und/oder T1 116, T11 17 und/oder T1 125,T1104, T1105, T1106, T1107, T1108, T1109, T1110, T1111, T1112, T1113, T1114, T1115, T1116, T1117, T1118, T1119, T1120, T1121, T1122, T1123, T1124, T1125, T1126, T1127, T1128, T1129, T1130, T1131, T1132 independently of each other of are selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- cyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively T1087, T1088 and / or T1096, T1097 and / or T1 109, T11 10 and / or T1 116, T11 17 and / or T1 125,
T1 126 jeweils zusammen auch „heterocyclyl" bilden können;T1 126 may together also form "heterocyclyl";
und einer der Reste Z1 , Z2 oder keiner der Reste Z1 , Z2 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus: (c) Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1133, -NT1134T1135, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, - P(O)(OH)2, -C(O)-T1136, -C(O)O-T1 137, -C(O)NH-T1138, - C(O)NTI 139T1 140, -0-T1 141 , -0(-T1 142-O)m-H (m = 1 , 2, 3, 4, 5), -and one of the radicals Z1, Z2, or none of the groups Z1, Z2 are independently selected from from the group consisting of: (c) hydrogen, alkyl, (Cg-C 3 o), alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHT1133, -NT1134T1135, -NO 2, -OH, -OCF3, -SH, -0-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, - P (O) (OH) 2 , -C (O) -T 1136, C (O) O-T1 137, -C (O) NH-T1138, -C (O) NTI 139T1 140, -O-T1 141, -O (-T1 142-O) m -H (m = 1, 2, 3, 4, 5), -
O(-T1 143-O)m-T1 144 (m = 1 , 2, 3, 4, 5), -OC(O)-T1145, -OC(O)-O- T1146, -OC(O)-NHT1 147, -0-C(O)-NTI 148T1 149, - OP(O)(OT1 150)(OT1 151 ), -OSi(T1 152)(T1 153)(T1154), -0S(02)-T1155, -NHC(O)-T1156, -NT1 157C(O)-T1 158, -NH-C(O)-O-T1 159, -NH- C(O)-NH-T1160, -NH-C(O)-NT1161 T1162, -NT1163-C(O)-O-T1164,O (-T1 143-O) m -T1 144 (m = 1, 2, 3, 4, 5), -OC (O) -T1145, -OC (O) -O-T1146, -OC (O) - NHT1 147, -O-C (O) -NTI 148T1 149, - OP (O) (OT1 150) (OT1 151), -OSi (T1 152) (T1 153) (T1154), -0S (0 2 ) - T1155, -NHC (O) -T1156, -NT1 157C (O) -T1 158, -NH-C (O) -O-T1 159, -NH-C (O) -NH-T1160, -NH-C ( O) -NT1161 T1162, -NT1163-C (O) -O-T1164,
-NT1165-C(O)-NH-T1 166, -NT1 167-C(O)-NTI 168T1 169, -NHS(O2)- T1170, -NT1171 S(02)-T1 172, -S-T1 173, -S(O)-T1 174, -S(02)-T1175, -S(O2)NH-T1 176, -S(O2)NTI 177T1 178, -S(O2)O-T1 179, - P(O)(OT1180)(OT1181 ), -Si(T1182)(T1 183)(T1184)"; wobei T1 133, T1134, T1 135, T1136, T1137, T1 138, T1139, T1 140,-NT1165-C (O) -NH-T1 166, 167 -NT1-C (O) -NTI 168T1 169, -NHS (O 2) - T1170, -NT1171 S (0 2) -T 1 -R 172, -S-T1 173, -S (O) -T 1 -R 174, -S (0 2) -T1175, -S (O 2) NH-T1 176, -S (O 2) NTI 177T1 178, -S (O 2) O-T1 179, - P (O) (OT1180) (OT1181), -Si (T1182) (T1 183) (T1184) ", where T1 133, T1134, T1 135, T1136, T1137, T1 138, T1139, T1 140,
T1141 , T1 142, T1143, T1 144, T1 145, T1146, T1 147, T1148, T1149, T1150, T1 151 , T1152, T1 153, T1 154, T1155, T1 156, T1157, T1158, T1159, T1 160, T1161 , T1 162, T1 163, T1164, T1 165, T1166, T1167, T1168, T1 169, T1170, T1 171. T1 172, T1173, T1 174, T1175, T1176, T1177, T1 178, T1179, T1 180, T1181 , T1 182, T1 183, T1184 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T1 139, T1140 und/oder T1148, T1 149 und/oder T1 161 , T1162 und/oder T1168, T1 169 und/oder T1177, T1 178 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (c) wiederum unabhängig voneinander auch weiter substituiert sein können mit mindes- tens einem Substituenten, gleich oder verschieden, ausgewählt aus derT1141, T1142, T1143, T1144, T1145, T1146, T1147, T1148, T1149, T1150, T1151, T1152, T1153, T1154, T1155, T1156, T1157, T1158, T1159, T1160, T1161 , T1 162, T1 163, T1164, T1 165, T1166, T1167, T1168, T1 169, T1170, T1 171. T1 172, T1173, T1 174, T1175, T1176, T1177, T1 178, T1179, T1 180, T1181, T1 182, T1 183, T1184 are independently selected from the group consisting of: "alkyl, alkyl (Cg-C 30) cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively T1 139, T1140 and / or T1148, T1 149 and / or T1 161, T1162 and / or T1168, T1 169 and / or T1177, T1 178 may in each case also form "heterocyclyl"; optionally substituted substituents of substituent group (c) may in turn also be further substituted with at least one substituent, identical or different, selected from among
Gruppe bestehend aus:Group consisting of:
(i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1 185, -NT1 186T1187, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2,(i) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT1 185, -NT1 186T1187, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C ( O) NH 2 , -SO 3 H, -P (O) (OH) 2 ,
-C(O)-T1188, -C(O)O-T1189, -C(O)NH-T1190, - C(O)NTI 191T1192, -0-T1193, -0(-T1194-O)n-H (n = 1 , 2, 3, 4, 5), -0(-T1195-O)n-T1196 (n = 1 , 2, 3, 4, 5), -OC(O)-T1197, -OC(O)- 0-T1198, -OC(O)-NHT1199, -0-C(O)-NTI200T1201,- OP(O)(OTI202)(OT1203), -OSi(TI204)(T1205)(T1206), -OS(O2)--C (O) -T1188, -C (O) O-T1189, -C (O) NH-T1190, -C (O) NTI 191T1192, -O-T1193, -O (-T1194-O) n -H (n = 1, 2, 3, 4, 5), -O (-T1195-O) n -T1196 (n = 1, 2, 3, 4, 5), -OC (O) -T1197, -OC ( O) - 0-T1198, -OC (O) -NHT1199, -O-C (O) -NTI200T1201, - OP (O) (OTI202) (OT1203), -OSi (TI204) (T1205) (T1206), OS (O 2 ) -
T1207, -NHC(O)-TI208, -NT1209C(O)-T1210, -NH-C(O)-O- T1211, -NH-C(O)-NH-T1212, -NH-C(O)-NTI213T1214, -NT1215- C(O)-O-T1216, -NT1217-C(O)-NH-T1218, -NT1219-C(O)- NT1220T1221, -NHS(O2)-T1222, -NT1223S(O2)-T1224, -S-T1225, -S(O)-T1226, -S(O2)-T1227, -S(O2)NH-T1228, -T1207, -NHC (O) -TI208, -NT1209C (O) -T1210, -NH-C (O) -O-T1211, -NH-C (O) -NH-T1212, -NH-C (O) - NTI213T1214, -NT1215- C (O) -O-T1216, -NT1217-C (O) -NH-T1218, -NT1219-C (O) - NT1220T1221, -NHS (O 2) -T1222, -NT1223S (O 2 ) -T1224, -S-T1225, -S (O) -T1226, -S (O 2) -T1227, -S (O 2) NH-T1228, -
S(O2)NTI229T1230, -S(O2)O-TI231 , -P(O)(OTI232)(OT1233), - Si(T1234)(T1235)(T1236)"; wobei T1 185, T1186, T1 187, T1188, T1189, T1 190, T1191 , T1 192, T1193, T1 194, T1195, T1 196, T1197, T1198, T1 199, T1200, T1201 , T1202, T1203, T1204, T1205, T1206, T1207, T1208, T1209, T1210,S (O 2) NTI229T1230, -S (O 2) O-TI231, -P (O) (OTI232) (OT1233), - Si (T1234) (T1235) (T1236) "; wherein T1 185, T1186, 187 T1 , T1188, T1189, T1190, T1191, T1192, T1193, T1194, T1195, T1199, T1197, T1198, T1199, T1200, T1201, T1202, T1203, T1204, T1205, T1206, T1207, T1208, T1209, T1210,
T1211 , T1212, T1213, T1214, T1215, T1216, T1217, T1218, T1219, T1220, T1221 , T1222, T1223, T1224, T1225, T1226, T1227, T1228, T1229, T1230, T1231 , T1232, T1233, T1234, T1235, T1236 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T1191 , T1 192 und/oder T1200, T1201 und/oder T1213, T1214 und/oder T1220, T1221 und/oder T1229, T1230 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1237, -NT1238T1239, -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-T1240, -C(O)O-T1241 , -C(O)NH- T1242, -C(O)NTI243T1244, -O-T1245, -0(-T1246-O)0-H (o =T1211, T1212, T1213, T1214, T1215, T1216, T1217, T1218, T1219, T1220, T1221, T1222, T1223, T1224, T1225, T1226, T1227, T1228, T1229, T1230, T1231, T1232, T1233, T1234, T1235, T1236 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively T1191, 192 T1 and / or T1200, T1201 and / or T1213, T1214 and / or T1220, T1221 and / or T1229, T1230 may together also form "heterocyclyl"; in which optionally substituents of substituent group (i) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of: (ii) alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHT1237, -NT1238T1239, -NO 2, -OH, - OCF 3, -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , - C (O) -T1240, -C (O) O-T1241, -C (O) NH-T1242, -C (O) NTI243T1244, -O-T1245, -O (-T1246-O) 0 -H (o =
1, 2, 3, 4, 5), -0(-T1247-O)0-TI248 (o = 1, 2, 3, 4, 5), -OC(O)- T1249, -OC(O)-O-TI250, -OC(O)-NHT^SI1-O-C(O)- NT1252T1253, -OP(O)(OTI254)(OT1255), - OSi(T1256)(T1257)(T1258), -OS(O2)-T1259, -NHC(O)-T1260, - NT1261C(O)-T1262, -NH-C(O)-O-TI263, -NH-C(O)-NH-1, 2, 3, 4, 5), -O (-T1247-O) 0 -TI248 (o = 1, 2, 3, 4, 5), -OC (O) - T1249, -OC (O) - O-TI 250, -OC (O) -NHT ^ SI 1 -OC (O) -NT 1252T1253, -OP (O) (OTI 254) (OT1255), -OSi (T1256) (T1257) (T1258), -OS (O 2 ) -T1259, -NHC (O) -T1260, - NT1261C (O) -T1262, -NH-C (O) -O-TI263, -NH-C (O) -NH-
T1264, -NH-C(O)-NTI265T1266, -NT1267-C(O)-O-TI268, - NT1269-C(O)-NH-T1270, -NT1271-C(O)-NT1272T1273, - NHS(O2)-T1274, -NT1275S(O2)-T1276, -S-T1277, -S(O)- T1278, -S(O2)-T1279, -S(O2)NH-T1280, -S(O2)NT1281T1282, - S(O2)O-TI283, -P(O)(OTI284)(OT1285), -T1264, -NH-C (O) -NTI265T1266, -NT1267-C (O) -O-TI268, - NT1269-C (O) -NH-T1270, -NT1271-C (O) -NT1272T1273, - NHS (O 2) -T1274, -NT1275S (O 2) -T1276, -S-T1277, -S (O) - T1278, -S (O 2) -T1279, -S (O 2) NH-T1280, -S (O 2 ) NT1281T1282, -S (O 2 ) O-TI 283, -P (O) (OTI 284) (OT1285),
Si(T1286)(T1287)(T1288)"; wobei T1237, T1238, T1239, T1240, T1241, T1242, T1243, T1244, T1245, T1246, T1247, T1248, T1249, T1250, T1251, T1252, T1253, T1254, T1255, T1256, T1257, T1258, T1259, T1260, T1261, T1262, T1263, T1264, T1265, T1266, T1267,Si (T1286) (T1287) (T1288) "; wherein T1237, T1238, T1239, T1240, T1241, T1242, T1243, T1244, T1245, T1246, T1247, T1248, T1249, T1250, T1251, T1252, T1253, T1254, T1255 , T1256, T1257, T1258, T1259, T1260, T1261, T1262, T1263, T1264, T1265, T1266, T1267,
T1268, T1269, T1270, T1271, T1272, T1273, T1274, T1275, T1276, T1277, T1278, T1279, T1280, T1281, T1282, T1283, T1284, T1285, T1286, T1287, T1288 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T1243, T1244 und/oder T1252, T1253 und/oder T1265, T1266 und/oder T1272, T1273 und/oder T1281 , T1282 jeweils zusammen auch „heterocyclyl" bilden können; (d) -NZ41Z42, wobei die Reste Z41 , Z42 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:T1268, T1269, T1270, T1271, T1272, T1273, T1274, T1275, T1276, T1277, T1278, T1279, T1280, T1281, T1282, T1283, T1284, T1285, T1286, T1287, T1288 are independently selected from the group consisting of "alkyl, - alkyl (C 9 30 C), cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively T1243, T1244 and / or T1252, T1253 and / or T1265, T1266 and / or T1272, T1273 and / or T1281, T1282 may together also form "heterocyclyl"; (d) -NZ41Z42, wherein the radicals Z41, Z42 are independently selected from the group consisting of:
(1 ) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C(O)-alkyl, -C(O)-(1) "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C (O) -alkyl, -C (O) -
(C9-C3o)alkyl, -C(O)-cycloalkyl, -C(O)-cycloalkylalkyl, -C(O)-aryl, - C(O)-arylalkyl, -C(O)-heteroaryl, -C(O)-heteroarylalkyl, -C(O)- heterocyclyl, -C(O)-heterocyclylalkyl"; wobei optional obige Substituenten der Substituentengruppe (1 ) un- abhängig voneinander weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(C 9 -C 3 O) alkyl, -C (O) cycloalkyl, -C (O) cycloalkylalkyl, -C (O) -aryl, - C (O) -arylalkyl, -C (O) -heteroaryl, -C (O) -heteroarylalkyl, -C (O) -heterocyclyl, -C (O) -heterocyclylalkyl "; optionally optionally substituted substituents of the substituent group (1) may be further substituted independently with at least one substituent, identical or different selected from the group consisting of:
(i) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1289, -NT1290T1291 , -NO2, -OH, -(i) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHT1289, -NT1290T1291, -NO 2 , -OH, -
OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-T1292, -C(O)O-T1293, -C(O)NH- T1294, -C(O)NTI 295T1296, -O-T1297, -O(-T1298-O)rr-H (rr = 1 , 2, 3, 4, 5), -O(-T1299-O)rr-T1300 (rr = 1 , 2, 3, 4, 5), -OC(O)- T1301 , -OC(O)-O-TI 302, -OC(O)-NHTI 303, -0-C(O)-OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T1292, -C (O) O-T1293, -C (O) NH-T1294, -C (O) NTI 295T1296, -O-T1297, -O (-T1298-O) rr -H (rr = 1, 2, 3, 4, 5), -O (-T1299-O) rr -T1300 (rr = 1, 2, 3, 4, 5), -OC (O) - T1301, - OC (O) -O-TI 302, -OC (O) -NHTI 303, -O-C (O) -
NT1304T1305, -OP(O)(OTI 306)(OT1307), - OSi(T1308)(T1309)(T1310), -OS(O2)-T1311 , -NHC(O)-T1312, - NT1313C(O)-TI 314, -NH-C(O)-O-TI 315, -NH-C(O)-NH- T1316, -NH-C(O)-NTI 317T1318, -NT1319-C(O)-O-TI 320, - NT1321-C(O)-NH-T1322, -NT1323-C(O)-NTI 324T1325, -NT1304T1305, -OP (O) (OTI 306) (OT1307), - OSi (T1308) (T1309) (T1310), -OS (O 2) -T1311, -NHC (O) -T1312, - NT1313C (O) - TI 314, -NH-C (O) -O-TI 315, -NH-C (O) -NH-T1316, -NH-C (O) -NTI 317T1318, -NT1319-C (O) -O-TI 320, - NT1321-C (O) -NH-T1322, -NT1323-C (O) -NTI 324T1325, -
NHS(O2)-T1326, -NT1327S(O2)-T1328, -S-T1329, -S(O)- T1330, -S(02)-T1331, -S(O2)NH-TI332, -S(O2)NTI333T1334, - S(O2)O-TI335, -P(O)(OTI336)(OT1337), - Si(TI338)(T1339)(T1340)"; wobei T1289, T1290, T1291, T1292, T1293, T1294, T1295,NHS (O 2) -T1326, -NT1327S (O 2) -T1328, -S-T1329, -S (O) - T1330, -S (0 2) -T1331, -S (O 2) NH-TI332 - S (O 2 ) NTI333T1334, -S (O 2 ) O-TI335, -P (O) (OTI336) (OT1337), -Si (TI338) (T1339) (T1340) ", wherein T1289, T1290, T1291, T1292 , T1293, T1294, T1295,
T1296, T1297, T1298, T1299, T1300, T1301, T1302, T1303, T1304, T1305, T1306, T1307, T1308, T1309, T1310, T1311, T1312, T1313, T1314, T1315, T1316, T1317, T1318, T1319, T1320, T1321, T1322, T1323, T1324, T1325, T1326, T1327, T1328, T1329, T1330, T1331 , T1332, T1333, T1334, T1335, T1336, T1337, T1338, T1339, T1340 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, 5 aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativT1296, T1297, T1298, T1299, T1300, T1301, T1302, T1303, T1304, T1305, T1306, T1307, T1308, T1309, T1310, T1311, T1312, T1313, T1314, T1315, T1316, T1317, T1318, T1319, T1320, T1321, T1322, T1323, T1324, T1325, T1326, T1327, T1328, T1329, T1330, T1331, T1332, T1333, T1334, T1335, T1336, T1337, T1338, T1339 is, T1340 independently selected from the group consisting of: "alkyl, alkyl, cycloalkyl, cycloalkylalkyl (Cg-C 30), heterocyclyl, heterocyclylalkyl, 5-aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively
T1295, T1296 und/oder T1304, T1305 und/oder T1317, T1318 und/oder T1324, T1325 und/oder T1333, T1334 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i)T1295, T1296 and / or T1304, T1305 and / or T1317, T1318 and / or T1324, T1325 and / or T1333, T1334 may in each case also form "heterocyclyl", where optionally substituents of the substituent group (i) above
10 wiederum unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:10 may in turn independently of one another be further substituted with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
15 Br, I, CN, CF3, N3, NH2, -NHT1341 , -NT1342T1343, -NO2, -15 Br, I, CN, CF 3 , N 3 , NH 2 , -NHT1341, -NT1342T1343, -NO 2 , -
OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-TI 344, -C(O)O-TI 345, -C(O)NH-TI 346, -C(O)NTI 347T1348, -O-T1349, -0(- T1350-O)rs-H (rs = 1 , 2, 3, 4, 5), -O(-T1351-O)rs-T1352 (rs =OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Ti 344, -C (O) O-TI 345, -C (O) NH-TI 346, -C (O) NTI 347T1348, -O-T1349, -O ( - T1350-O) rs -H (rs = 1, 2, 3, 4, 5), -O (-T1351-O) rs -T1352 (rs =
20 1 , 2, 3, 4, 5), -OC(O)-TI 353, -OC(O)-O-TI 354, -OC(O)-20 1, 2, 3, 4, 5), -OC (O) -TI 353, -OC (O) -O-TI 354, -OC (O) -
NHT1355, -0-C(O)-NTI356T1357, - OP(O)(OTI358)(OT1359), -OSi(TI360)(T1361)(T1362), - OS(O2)-T1363, -NHC(O)-TI364, -NT1365C(O)-TI366, - NH-C(O)-O-TI367, -NH-C(O)-NH-TI368, -NH-C(O)-NHT1355, -0-C (O) -NTI356T1357, - OP (O) (OTI358) (OT1359), -OSi (TI360) (T1361) (T1362), - OS (O 2) -T1363, -NHC (O) -TI364, -NT1365C (O) -TI366, - NH-C (O) -O-TI367, -NH-C (O) -NH-TI368, -NH-C (O) -
25 NT1369T1370, -NT1371-C(O)-O-TI372, -NT1373-C(O)-25 NT1369T1370, -NT1371-C (O) -O-TI372, -NT1373-C (O) -
NH-T1374, -NT1375-C(O)-NTI376T1377, -NHS(O2)-T1378, -NT1379S(O2)-T1380, -S-T1381, -S(O)-TI382, -S(O2)- T1383, -S(O2)NH-TI384, -S(O2)NTI385T1386, -S(O2)O- T1387, -P(O)(OTI388)(OT1389), -Si(TI390)(T1391)(T1392)";NH-T1374, -NT1375-C (O) -NTI376T1377, -NHS (O 2) -T1378, -NT1379S (O 2) -T1380, -S-T1381, -S (O) -TI382, -S (O 2 ) - T1383, -S (O 2) NH-TI384, -S (O 2) NTI385T1386, -S (O 2) O- T1387, -P (O) (OTI388) (OT1389), -Si (TI390) ( T1391) (T1392) ";
30 wobei T1341, T1342, T1343, T1344, T1345, T1346, T1347,30 wherein T1341, T1342, T1343, T1344, T1345, T1346, T1347,
T1348, T1349, T1350, T1351, T1352, T1353, T1354, T1355, T1356, T1357, T1358, T1359, T1360, T1361, T1362, T1363, T1364, T1365, T1366, T1367, T1368, T1369, T1370, T1371, T1372, T1373, T1374, T1375, T1376, T1377, T1378, T1379, T1380, T1381 , T1382, T1383, T1384, T1385, T1386, T1387, T1388, T1389, T1390, T1391 , T1392 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly-T1348, T1349, T1350, T1351, T1352, T1353, T1354, T1355, T1356, T1357, T1358, T1359, T1360, T1361, T1362, T1363, T1364, T1365, T1366, T1367, T1368, T1369, T1370, T1371, T1372, T1373, T1374, T1375, T1376, T1377, T1378, T1379, Are T1380, T1381, T1382, T1383, T1384, T1385, T1386, T1387, T1388, T1389, T1390, T1391, T1392 independently selected from the group consisting of: "alkyl, alkyl, cycloalkyl, cycloalkylalkyl (Cg-C 30), heterocyclyl, heterocyclyl
5 lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T1347, T1348 und/oder T1356, T1357 und/oder T1369, T1370 und/oder T1376, T1377 und/oder T1385, T1386 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe5 lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively T1347, T1348 and / or T1356, T1357 and / or T1369, T1370 and / or T1376, T1377 and / or T1385, T1386 can each also together form" heterocyclyl "; optionally with the above substituents of the substituent group
10 (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:10 (ii) may in turn be independently substituted with at least one substituent, the same or different, selected from the group consisting of:
(iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,(iii) "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,
15 F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1393, -NT1394T1395,15 F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHT1393, -NT1394T1395,
-NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-TI 396, - C(O)O-TI 397, -C(O)NH-TI 398, -C(O)NTI 399T1400, - O-T1401 , -O(-T1402-O)rt-H (rt = 1 , 2, 3, 4, 5), -0(--NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -TI 396, -C (O) O-TI 397, -C (O) NH-TI 398, -C (O) NTI 399T1400, -O- T1401, -O (-T1402-O) rt -H (rt = 1, 2, 3, 4, 5), -0 (-
20 T1403-O)rt-T1404 (rt = 1 , 2, 3, 4, 5), -OC(O)-TI 405, -20 T1403-O) rt -T1404 (rt = 1, 2, 3, 4, 5), -OC (O) -Ti 405, -
OC(O)-O-TI406, -OC(O)-NHT1407, -0-C(O)- NT1408T1409, -OP(O)(OTI410)(OTI411), - OSi(T1412)(T1413)(T1414), -OS(O2)-T1415, -NHC(O)- T1416, -NT1417C(O)-T1418, -NH-C(O)-O-TI419, -NH-OC (O) -O-TI406, -OC (O) -NHT1407, -O-C (O) -NT1408T1409, -OP (O) (OTI410) (OTI411), -OSi (T1412) (T1413) (T1414) , -OS (O 2 ) -T 1415, -NHC (O) -T1416, -NT 1417C (O) -T 1418, -NH-C (O) -O-TI 419, -NH-
25 C(O)-NH-TI420, -NH-C(O)-NT1421T1422, -NT1423-25 C (O) -NH-TI420, -NH-C (O) -NT1421T1422, -NT1423-
C(O)-O-T1424, -NT1425-C(O)-NH-T1426, -NT1427- C(O)-NTI428T1429, -NHS(O2)-T1430, -NT1431S(O2)- T1432, -S-T1433, -S(O)-TI434, -S(O2)-T1435, - S(O2)NH-T1436, -S(O2)NT1437T1438, -S(O2)O-TI439, -C (O) -O-T1424, -NT1425-C (O) -NH-T1426, -NT1427- C (O) -NTI428T1429, -NHS (O 2) -T1430, -NT1431S (O 2) - T1432, - S-T1433, -S (O) -TI434, -S (O 2) -T1435, - S (O 2) NH-T1436, -S (O 2) NT1437T1438, -S (O 2) O-TI439 -
30 P(O)(OT1440)(OT1441), -Si(TI442)(T1443)(T1444)"; wobei T1393, T1394, T1395, T1396, T1397, T1398, T1399, T1400, T1401, T1402, T1403, T1404, T1405, T1406, T1407, T1408, T1409, T1410, T1411, T1412, T1413, T1414, T1415, T1416, T1417, T1418, T1419, T1420, T1421 , T1422, T1423, T1424, T1425, T1426, T1427, T1428, T1429, T1430, T1431 , T1432, T1433, T1434, T1435, T1436, T1437, T1438, T1439, T1440, T1441 , T1442, T1443, T1444 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T1399, T1400 und/oder T1408, T1409 und/oder T1421 , T1422 und/oder T1428, T1429 und/oder T1437, T1438 jeweils zusammen auch „heterocyclyl" bilden können;30 P (O) (OT1440) (OT1441), -Si (TI442) (T1443) (T1444) "where T1393, T1394, T1395, T1396, T1397, T1398, T1399, T1400, T1401, T1402, T1403, T1404, T1405, T1406, T1407, T1408, T1409, T1410, T1411, T1412, T1413, T1414, T1415, T1416, T1417, T1418, T1419, T1420, T1421, T1422, T1423, T1424, T1425, T1426, T1427, T1428, T1429, T1430, T1431, T1432, T1433, T1434, T1435, T1436, T1437, T1438, T1439, T1440, T1441, T1442, T1443, T1444 independently selected are selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively T1399, T1400 and / or T1408, T1409 and / or T1421, T1422 and / or T1428, T1429 and / or T1437, T1438 may together also form "heterocyclyl";
(2) ,,-C(O)-C(O)-TI 445, -S(O2)-NT1446T1447"; wobei T1445, T1446, T1447 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:(2) ,, - C (O) -C (O) -TI 445, -S (O 2 ) -NT1446T1447 "; wherein T1445, T1446, T1447 are independently selected from the group consisting of:
(I) „Wasserstoff, alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1448, -NT1449T1450, - NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, - COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-T1451 , -C(O)O-(I) "is hydrogen, alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHT1448, -NT1449T1450, - NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O ) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -T 1451, -C (O) O-
T1452, -C(O)NH-T1453, -C(O)NTI 454T1455, -O-T1456, -0(- T1457-O)ru-H (ru = 1 , 2, 3, 4, 5), -O(-T1458-O)ru-T1459 (ru = 1 , 2, 3, 4, 5), -OC(O)-T1460, -OC(O)-O-TI 461 , -OC(O)-NHTI 462, -0-C(O)-NTI 463T1464, -OP(O)(OTI 465)(OT1466), - OSi(T1467)(T1468)(T1469), -OS(O2)-T1470, -NHC(O)-T1471 , -T1452, -C (O) NH-T1453, -C (O) NTI 454T1455, -O-T1456, -O (- T1457-O) ru -H (ru = 1, 2, 3, 4, 5), O (-T1458-O) ru -T1459 (ru = 1, 2, 3, 4, 5), -OC (O) -T1460, -OC (O) -O-TI 461, -OC (O) -NHTI 462, -0-C (O) -NTI 463T1464, -OP (O) (OTI 465) (OT1466), - OSi (T1467) (T1468) (T1469), -OS (O 2) -T1470, -NHC ( O) -T1471, -
NT1472C(O)-TI473, -NH-C(O)-O-TI474, -NH-C(O)-NH- T1475, -NH-C(O)-NTI476T1477, -NT1478-C(O)-O-TI479, - NT1480-C(O)-NH-T1481, -NT1482-C(O)-NTI483T1484, - NHS(O2)-T1485, -NT1486S(O2)-T1487, -S-T1488, -S(O)- T1489, -S(O2)-T1490, -S(O2)NH-T1491, -S(O2)NT1492T1493, -NT1472C (O) -TI473, -NH-C (O) -O-TI474, -NH-C (O) -NH-T1475, -NH-C (O) -NTI476T1477, -NT1478-C (O) -O -TI479, - NT1480-C (O) -NH-T1481, -NT1482-C (O) -NTI483T1484, - NHS (O 2) -T1485, -NT1486S (O 2) -T1487, -S-T1488, -S (O) - T1489, -S (O 2) -T1490, -S (O 2) NH-T1491, -S (O 2) NT1492T1493, -
S(O2)O-TI494, -P(O)(OTI495)(OT1496), - Si(T1497)(T1498)(T1499)"; wobei T1448, T1449, T1450, T1451, T1452, T1453, T1454, T1455, T1456, T1457, T1458, T1459, T1460, T1461, T1462, T1463, T1464, T1465, T1466, T1467, T1468, T1469, T1470, T1471 , T1472, T1473, T1474, T1475, T1476, T1477, T1478, T1479, T1480, T1481 , T1482, T1483, T1484, T1485, T1486, T1487, T1488, T1489, T1490, T1491 , T1492, T1493, T1494,S (O 2 ) O-TI494, -P (O) (OTI495) (OT1496), -Si (T1497) (T1498) (T1499) "; wherein T1448, T1449, T1450, T1451, T1452, T1453, T1454, T1455 , T1456, T1457, T1458, T1459, T1460, T1461, T1462, T1463, T1464, T1465, T1466, T1467, T1468, T1469, T1470, T1471, T1472, T1473, T1474, T1475, T1476, T1477, T1478, T1479, T1480, T1481, T1482, T1483, T1484, T1485, T1486, T1487, T1488, T1489, T1490, T1491, T1492, T1493, T1494,
5 T1495, T1496, T1497, T1498, T1499 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T1454, T1455 und/oder T1463, T1464 und/oder T1476, T14775 T1495, T1496, T1497, T1498, T1499 are independently selected from the group consisting of: "alkyl, (C 9 - C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively T1454, T1455 and / or T1463, T1464 and / or T1476, T1477
10 und/oder T1483, T1484 und/oder T1492, T1493 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substitutionsgruppe (I) unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausge- 15 wählt aus der Gruppe bestehend aus:10 and / or T1483, T1484 and / or T1492, T1493 may together also form "heterocyclyl", where optionally substituents of the substitution group (I) above may be further substituted independently with at least one substituent, identical or different, selected from 15 selects from the group consisting of:
(i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1500, -NT1501T1502, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -(i) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT1500, -NT1501T1502, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -
20 C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-TI 503, -C(O)O-TI 504,20 C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -TI 503, -C (O) O-TI 504,
-C(O)NH-TI505, -C(O)NTI506T1507, -O-T1508, -0(- T1509-O)rv-H (rv = 1, 2, 3, 4, 5), -O(-T1510-O)rv-T1511 (rv = 1, 2, 3, 4, 5), -OC(O)-TI512, -OC(O)-O-TI513, -OC(O)- NHT1514, -0-C(O)-NTI515T1516, --C (O) NH-TI505, -C (O) NTI506T1507, -O-T1508, -O (- T1509-O) rv -H (rv = 1, 2, 3, 4, 5), -O (- T1510-O) rv -T1511 (rv = 1, 2, 3, 4, 5), -OC (O) -TI512, -OC (O) -O-TI513, -OC (O) -NHT1514, -0- C (O) -NTI515T1516, -
25 OP(O)(OTI517)(0T1518), -OSi(TI519)(T1520)(T1521),-25 OP (O) (OTI517) (0T1518), -OSi (TI519) (T1520) (T1521),
OS(O2)-T1522, -NHC(O)-TI523, -NT1524C(O)-TI525, - NH-C(O)-O-TI526, -NH-C(O)-NH-TI527, -NH-C(O)- NT1528T1529, -NT1530-C(O)-O-TI531, -NT1532-C(O)- NH-T1533, -NT1534-C(O)-NTI535T1536, -NHS(O2)-T1537,OS (O 2 ) -T1522, -NHC (O) -TI523, -NT1524C (O) -TI525, -NH-C (O) -O-TI526, -NH-C (O) -NH-TI527, -NH -C (O) - NT1528T1529, -NT1530-C (O) -O-TI531, -NT1532-C (O) - NH-T1533, -NT1534-C (O) -NTI535T1536, -NHS (O 2) -T1537 .
30 -NT1538S(O2)-T1539, -S-T1540, -S(O)-TI541 , -S(O2)-30 -NT1538S (O 2) -T1539, -S-T1540, -S (O) -TI541, -S (O 2) -
T1542, -S(O2)NH-TI543, -S(O2)NTI544T1545, -S(O2)O- T1546, -P(O)(OTI547)(OT1548), -Si(TI549)(T1550)(T1551)"; wobei T1500, T1501 , T1502, T1503, T1504, T1505, T1506, T1507, T1508, T1509, T1510, T1511, T1512, T1513, T1514, T1515, T1516, T1517, T1518, T1519, T1520, T1521 , T1522, T1523, T1524, T1525, T1526, T1527, T1528, T1529, T1530, T1531 , T1532, T1533, T1534, T1535, T1536, T1537, T1538, T1539, T1540, T1541 , T1542, T1543, T1544, T1545, T1546,T1542, -S (O 2) NH-TI543, -S (O 2) NTI544T1545, -S (O 2) O- T1546, -P (O) (OTI547) (OT1548), -Si (TI549) (T1550) (T1551) "; where T1500, T1501, T1502, T1503, T1504, T1505, T1506, T1507, T1508, T1509, T1510, T1511, T1512, T1513, T1514, T1515, T1516, T1517, T1518, T1519, T1520, T1521, T1522, T1523, T1524, T1525, T1526, T1527, T1528, T1529, T1530, T1531, T1532, T1533, T1534, T1535, T1536, T1537, T1538, T1539, T1540, T1541, T1542, T1543, T1544, T1545, T1546,
5 T1547, T1548, T1549, T1550, T1551 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T1506, T1507 und/oder T1515, T1516 und/oder5 are T1547, T1548, T1549, T1550, T1551 independently selected from the group consisting of: "alkyl, - alkyl (C 9 -C 30), cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively T1506, T1507 and / or T1515, T1516 and / or
10 T1528, T1529 und/oder T1535, T1536 und/oder T1544, T1545 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, 15 ausgewählt aus der Gruppe bestehend aus:T1528, T1529 and / or T1535, T1536 and / or T1544, T1545 may together also form "heterocyclyl" wherein optionally substituents of the substituent group (i) above may be substituted independently with at least one substituent, same or different, 15 selected from the group consisting of:
(ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1552, -NT1553T1554, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO,(ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHT1552, -NT1553T1554, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO,
20 -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-TI 555, -20 -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -TI 555, -
C(O)O-TI556, -C(O)NH-TI557, -C(O)NTI558T1559, - O-T1560, -O(-T1561-O)m-H (rw = 1, 2, 3, 4, 5), -0(- T1562-O)m-T1563 (rw = 1, 2, 3, 4, 5), -OC(O)-TI564, - OC(O)-O-TI565, -OC(O)-NHTI566, -0-C(O)-C (O) O-Tl556, -C (O) NH-TI557, -C (O) NTI558T1559, -O-T1560, -O (-T1561-O) m -H (rw = 1, 2, 3, 4 , 5), -0 (- T1562-O) m -T1563 (rw = 1, 2, 3, 4, 5), -OC (O) -TI564, - OC (O) -O-TI565, -OC ( O) -NHTI566, -O-C (O) -
25 NT1567T1568, -OP(O)(OTI569)(OT1570), -25 NT1567T1568, -OP (O) (OTI569) (OT1570),
OSi(TI 571 )(T1572)(T1573), -OS(O2)-T1574, -NHC(O)- T1575, -NT1576C(O)-TI 577, -NH-C(O)-O-TI 578, -NH- C(O)-NH-TI 579, -NH-C(O)-NTI 580T1581 , -NT1582- C(O)-O-TI 583, -NT1584-C(O)-NH-TI 585, -NT1586-OSi (TI 571) (T1572) (T1573), -OS (O 2 ) -T1574, -NHC (O) -T1575, -NT1576C (O) -TI 577, -NH-C (O) -O-TI 578 , -NH-C (O) -NH-TI 579, -NH-C (O) -NTI 580T1581, -NT1582-C (O) -O-TI 583, -NT1584-C (O) -NH-TI 585 , -NT1586-
30 C(O)-NTI 587T1588, -NHS(O2)-T1589, -NT1590S(O2)-30 C (O) -NTI 587T1588, -NHS (O 2 ) -T1589, -NT1590S (O 2 ) -
T1591 , -S-T1592, -S(O)-TI 593, -S(O2)-T1594, - S(O2)NH-TI 595, -S(O2)NTI 596T1597, -S(O2)O-TI 598, - P(O)(OTI 599)(OT1600), -Si(TI 601 )(T1602)(T1603)"; wobei T1552, T1553, T1554, T1555, T1556, T1557, T1558, T1559, T1560, T1561, T1562, T1563, T1564, T1565, T1566, T1567, T1568, T1569, T1570, T1571, T1572, T1573, T1574, T1575, T1576, T1577, T1578, T1579,T1591, T1592 -S-, -S (O) -TI 593, -S (O 2) -T1594, - S (O 2) NH-TI 595, -S (O 2) NTI 596T1597, -S (O 2 ) O-TI 598, -P (O) (OTI 599) (OT1600), -Si (TI 601) (T1602) (T1603) "; wherein T1552, T1553, T1554, T1555, T1556, T1557, T1558, T1559, T1560, T1561, T1562, T1563, T1564, T1565, T1566, T1567, T1568, T1569, T1570, T1571, T1572, T1573, T1574, T1575, T1576 , T1577, T1578, T1579,
5 T1580, T1581, T1582, T1583, T1584, T1585, T1586,5 T1580, T1581, T1582, T1583, T1584, T1585, T1586,
T1587, T1588, T1589, T1590, T1591, T1592, T1593, T1594, T1595, T1596, T1597, T1598, T1599, T1600, T1601, T1602, T1603 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl,T1587, T1588, T1589, T1590, T1591, T1592, T1593, T1594, T1595, T1596, T1597, T1598, T1599, T1600, T1601, T1602, T1603 are independently selected from the group consisting of: "alkyl, (C 9 - C 3 o) alkyl,
10 cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T1558, T1559 und/oder T1567, T1568 und/oder T1580, T1581 und/oder T1587, T1588 und/oder T1596, T1597 jeweils zusammen auch „heterocyclyl" bilden kön-10 cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively T1558, T1559 and / or T1567, T1568 and / or T1580, T1581 and / or T1587, T1588 and / or T1596, T1597 also together Form "heterocyclyl"
15 nen; wobei optional obige Substituenten der Substituentengrup- pe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:15 years; wherein optionally substituents of substituent group (ii) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
20 (iii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1604, - NT1605T1606, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -20 (iii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHT1604, - NT1605T1606, -NO 2, -OH, -OCF3, -SH, -0-SO3H, - OP (O) (OH) 2, -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -
25 P(O)(OH)2, -C(O)-TI 607, -C(O)O-TI 608, -C(O)NH-25 P (O) (OH) 2 , -C (O) -TI 607, -C (O) O-TI 608, -C (O) NH-
T1609, -C(O)NTI610T1611, -0-T1612, -0(-T1613- O)rx-H (rx = 1, 2, 3, 4, 5), -O(-T1614-O)rx-T1615 (rx = 1, 2, 3, 4, 5), -OC(O)-TI616, -OC(O)-O-TI617, - OC(O)-NHTI618, -0-C(O)-NTI619T1620, -T1609, -C (O) NTI610T1611, -0-T1612, -0 (-T1613-O) rx -H (rx = 1, 2, 3, 4, 5), -O (-T1614-O) rx -T1615 (rx = 1, 2, 3, 4, 5), -OC (O) -TI616, -OC (O) -O-TI617, - OC (O) -NHTI618, -O-C (O) -NTI619T1620, -
30 OP(O)(OTI621)(0T1622), -30 OP (O) (OTI621) (0T1622), -
OSi(TI 623)(T1624)(T1625), -OS(O2)-T1626, - NHC(O)-TI 627, -NT1628C(O)-TI 629, -NH-C(O)-O- T1630, -NH-C(O)-NH-TI 631 , -NH-C(O)- NT1632T1633, -NT1634-C(O)-O-TI 635, -NT1636-OSi (TI 623) (T1624) (T1625), -OS (O 2) -T1626, - NHC (O) -TI 627, -NT1628C (O) -TI 629, -NH-C (O) -O- T1630 , -NH-C (O) -NH-TI 631, -NH-C (O) -NT1632T1633, -NT1634-C (O) -O-TI 635, -NT1636-
35 C(O)-NH-TI 637, -NT1638-C(O)-NTI 639T1640, - NHS(O2)-T1641 , -NT1642S(O2)-T1643, -S-T1644, - S(O)-TI 645, -S(O2)-T1646, -S(O2)NH-TI 647, - S(O2)NTI 648T1649, -S(O2)O-TI 650, - P(O)(OTI 651 )(OT1652), -Si(TI 653)(T1654)(T1655)"; wobei T1604, T1605, T1606, T1607, T1608, T1609,35 C (O) -NH-TI 637, -NT1638-C (O) -NTI 639T1640, - NHS (O 2 ) -T 1641, -NT 1642S (O 2 ) -T 1643, -S-T 1644, -S (O) -TI 645, -S (O 2 ) -T 1646, -S (O 2 ) NH-TI 647 , - S (O 2 ) NTI 648T1649, -S (O 2 ) O-TI 650, -P (O) (OTI 651) (OT1652), -Si (TI 653) (T1654) (T1655) ", wherein T1604 , T1605, T1606, T1607, T1608, T1609,
T1610, T1611, T1612, T1613, T1614, T1615, T1616, T1617, T1618, T1619, T1620, T1621, T1622, T1623, T1624, T1625, T1626, T1627, T1628, T1629, T1630, T1631, T1632, T1633, T1634, T1635, T1636, T1637, T1638, T1639, T1640, T1641, T1642, T1643, T1644,T1610, T1611, T1612, T1613, T1614, T1615, T1616, T1617, T1618, T1619, T1620, T1621, T1622, T1623, T1624, T1625, T1626, T1627, T1628, T1629, T1630, T1631, T1632, T1633, T1634, T1635, T1636, T1637, T1638, T1639, T1640, T1641, T1642, T1643, T1644,
T1645, T1646, T1647, T1648, T1649, T1650, T1651, T1652, T1653, T1654, T1655 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" und wobei alternativ T1610, T161 1 und/oder T1619, T1620 und/oder T1632, T1633 und/oder T1639, T1640 und/oder T1648, T1649 jeweils zusammen auch „heterocyclyl" bilden können; wobei alternativ T1446, T1447 zusammen auch „heterocyclyl" bilden können;T1645, T1646, T1647, T1648, T1649, T1650, T1651, T1652, T1653, T1654, T1655 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively T1610, T161 1 and / or T1619, T1620 and / or T1632, T1633 and / or T1639, T1640 and / or T1648, T1649 in each case together also form" heterocyclyl "can; alternatively, T1446, T1447 may together also form "heterocyclyl";
(3) ,,-C(Y8)NZ43Z44, -C(=NZ45)-Z46, -C(Y9)NZ47-Y10-Z48"; wobei Y8, Y9, Y10 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus „O, S, =NH, =NZ49" wobei die Reste Z43, Z44, Z45, Z46, Z47, Z48, Z49 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:(3) ,, -C (Y8) NZ43Z44, -C (= NZ45) -Z46, -C (Y9) NZ47-Y10-Z48 "; wherein Y8, Y9, Y10 are independently selected from the group consisting of" O , S, = NH, = NZ49 "where the radicals Z43, Z44, Z45, Z46, Z47, Z48, Z49 are independently selected from the group consisting of:
(I) „Wasserstoff, alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl, -C(O)-alkyl, -C(0)-(C9-C3o)alkyl, -C(O)-cycloalkyl, -C(O)- cycloalkylalkyl, -C(O)-aryl, -C(O)-arylalkyl, -C(O)-heteroaryl, - C(O)-heteroarylalkyl, -C(O)-heterocyclyl, -C(O)- heterocyclylalkyl, -S(O2)-alkyl, -S(02)-(C9-C3o)alkyl, -S(O2)- cycloalkyl, -S(O2)-cycloalkylalkyl, -S(O2)-aryl, -S(O2)-arylalkyl, - S(O2)-heteroaryl, -S(O2)-heteroarylalkyl, -S(O2)-heterocyclyl, - S(O2)-heterocyclylalkyl"; wobei optional obige Substituenten der Substituentengruppe (I)(I) "is hydrogen, alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- alkyl, -C (O) alkyl, -C (0) - (C 9 -C 3 O) alkyl, -C (O) cycloalkyl, -C (O) - cycloalkylalkyl, -C (O) -aryl, -C (O) -arylalkyl, -C (O) -heteroaryl, - C (O) heteroarylalkyl, -C (O) -heterocyclyl, -C (O) - heterocyclylalkyl, -S (O 2) -alkyl, -S (0 2) - (C 9 -C 3 o) alkyl, -S (O 2 ) - cycloalkyl, -S (O 2) cycloalkylalkyl, -S (O 2) aryl, -S (O 2) arylalkyl, - (O 2) heteroaryl S (O 2) heteroarylalkyl -S, -S ( O 2 ) -heterocyclyl, - S (O 2 ) -heterocyclylalkyl ", wherein optionally substituents of the substituent group (I) above
5 unabhängig voneinander auch substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:5 independently of one another may also be substituted by at least one substituent, identical or different, selected from the group consisting of:
(i) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,(i) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
10 Br, I, CN, CF3, N3, NH2, -NHT1656, -NT1657T1658, -NO2, -10 Br, I, CN, CF 3 , N 3 , NH 2 , -NHT1656, -NT1657T1658, -NO 2 , -
OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-TI 659, -C(O)O-TI 660, -C(O)NH-TI 661 , -C(O)NTI 662T1663, -O-T1664, -0(- T1665-O)ry-H (ry = 1 , 2, 3, 4, 5), -O(-T1666-O)ry-T1667 (ry =OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Ti 659, -C (O) O-TI 660, -C (O) NH-TI 661, -C (O) NTI 662T1663, -O-T1664, -O ( - T1665-O) ry -H (ry = 1, 2, 3, 4, 5), -O (-T1666-O) ry -T1667 (ry =
15 1 , 2, 3, 4, 5), -OC(O)-TI 668, -OC(O)-O-TI 669, -OC(O)-15 1, 2, 3, 4, 5), -OC (O) -TI 668, -OC (O) -O-TI 669, -OC (O) -
NHT1670, -0-C(O)-NTI 671 T1672, - OP(O)(OTI 673)(OT1674), -OSi(TI 675)(T1676)(T1677), - OS(O2)-T1678, -NHC(O)-TI 679, -NT1680C(O)-TI 681 , - NH-C(O)-O-TI 682, -NH-C(O)-NH-TI 683, -NH-C(O)-NHT1670, -O-C (O) -NTI 671 T1672, - OP (O) (OTI 673) (OT1674), -OSi (TI 675) (T1676) (T1677), - OS (O 2 ) -T1678, NHC (O) -TI 679, -NT1680C (O) -TI 681, -NH-C (O) -O-TI 682, -NH-C (O) -NH-TI 683, -NH-C (O) -
20 NT1684T1685, -NT1686-C(O)-O-TI 687, -NT1688-C(O)-20 NT1684T1685, -NT1686-C (O) -O-TI 687, -NT1688-C (O) -
NH-T1689, -NT1690-C(O)-NTI691T1692, -NHS(O2)-T1693, -NT1694S(O2)-T1695, -S-T1696, -S(O)-TI697, -S(O2)- T1698, -S(O2)NH-TI699, -S(O2)NTI700T1701, -S(O2)O- T1702, -P(O)(OTI703)(OT1704), -Si(TI705)(T1706)(T1707)";NH-T1689, -NT1690-C (O) -NTI691T1692, -NHS (O 2) -T1693, -NT1694S (O 2) -T1695, -S-T1696, -S (O) -TI697, -S (O 2 ) - T1698, -S (O 2) NH-TI699, -S (O 2) NTI700T1701, -S (O 2) O- T1702, -P (O) (OTI703) (OT1704), -Si (TI705) ( T1706) (T1707) ";
25 wobei T1656, T1657, T1658, T1659, T1660, T1661, T1662,25 wherein T1656, T1657, T1658, T1659, T1660, T1661, T1662,
T1663, T1664, T1665, T1666, T1667, T1668, T1669, T1670, T1671, T1672, T1673, T1674, T1675, T1676, T1677, T1678, T1679, T1680, T1681, T1682, T1683, T1684, T1685, T1686, T1687, T1688, T1689, T1690, T1691, T1692, T1693, T1694,T1663, T1664, T1665, T1666, T1667, T1668, T1669, T1670, T1671, T1672, T1673, T1674, T1675, T1676, T1677, T1678, T1679, T1680, T1681, T1682, T1683, T1684, T1685, T1686, T1687, T1688, T1689, T1690, T1691, T1692, T1693, T1694,
30 T1695, T1696, T1697, T1698, T1699, T1700, T1701, T1702,30 T1695, T1696, T1697, T1698, T1699, T1700, T1701, T1702,
T1703, T1704, T1705, T1706, T1707 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei al- ternativ T1662, T1663 und/oder T1671 , T1672 und/oder T1684, T1685 und/oder T1691 , T1692 und/oder T1700, T1701 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) 5 wiederum unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:T1703, T1704, T1705, T1706, T1707 are independently selected from the group consisting of: "alkyl, (Cg-C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein al- T1662, T1663 and / or T1671, T1672 and / or T1684, T1685 and / or T1691, T1692 and / or T1700, T1701 may together also form "heterocyclyl", wherein optionally substituents of substituent group (i) 5 above are independently of one another may also be further substituted with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,(ii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,
10 F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1708, -NT1709T1710,10 F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHT1708, -NT1709T1710,
-NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-TI 711 , - C(O)O-TI 712, -C(O)NH-TI 713, -C(O)NTI 714T1715, - O-T1716, -O(-T1717-O)rz-H (rz = 1 , 2, 3, 4, 5), -0(--NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -Ti 711, -C (O) O-TI 712, -C (O) NH-TI 713, -C (O) NTI 714T1715, -O- T1716, -O (-T1717-O) rz -H (rz = 1, 2, 3, 4, 5), -0 (-
15 T1718-O)rz-T1719 (rz = 1 , 2, 3, 4, 5), -OC(O)-TI 720, -15 T1718-O) rz -T1719 (rz = 1, 2, 3, 4, 5), -OC (O) -Ti 720, -
OC(O)-O-TI 721 , -OC(O)-NHTI 722, -0-C(O)- NT1723T1724, -OP(O)(OTI 725)(OT1726), - OSi(TI 727)(T1728)(T1729), -OS(O2)-T1730, -NHC(O)- T1731 , -NT1732C(O)-TI 733, -NH-C(O)-O-TI 734, -NH-OC (O) -O-TI 721, -OC (O) -NHTI 722, -O-C (O) -NT 1723T1724, -OP (O) (OTI 725) (OT1726), -OSi (TI 727) (T1728 ) (T1729), -OS (O 2 ) -T1730, -NHC (O) -T1731, -NT 1732C (O) -TI 733, -NH-C (O) -O-TI 734, -NH-
20 C(O)-NH-TI 735, -NH-C(O)-NTI 736T1737, -NT1738-20 C (O) -NH-TI 735, -NH-C (O) -NTI 736T1737, -NT1738-
C(O)-O-TI 739, -NT1740-C(O)-NH-TI 741 , -NT1742- C(O)-NTI 743T1744, -NHS(O2)-T1745, -NT1746S(O2)- T1747, -S-T1748, -S(O)-TI 749, -S(O2)-T1750, - S(O2)NH-TI 751 , -S(O2)NTI 752T1753, -S(O2)O-TI 754, -C (O) -O-TI 739, -NT1740-C (O) -NH-TI 741, -NT1742-C (O) -NTI 743T1744, -NHS (O 2 ) -T 1745, -NT 1746S (O 2 ) - T1747, T1748 -S-, -S (O) -TI 749, -S (O 2) -T1750, - S (O 2) NH-TI 751, -S (O 2) NTI 752T1753, -S (O 2 ) O-TI 754, -
25 P(O)(OTI 755)(OT1756), -Si(TI 757)(T1758)(T1759)"; wobei T1708, T1709, T1710, T1711, T1712, T1713, T1714, T1715, T1716, T1717, T1718, T1719, T1720, T1721, T1722, T1723, T1724, T1725, T1726, T1727, T1728, T1729, T1730, T1731, T1732, T1733, T1734, T1735,25P (O) (OTI 755) (OT1756), -Si (TI 757) (T1758) (T1759) "; where T1708, T1709, T1710, T1711, T1712, T1713, T1714, T1715, T1716, T1717, T1718, T1719, T1720, T1721, T1722, T1723, T1724, T1725, T1726, T1727, T1728, T1729, T1730, T1731, T1732, T1733, T1734, T1735,
30 T1736, T1737, T1738, T1739, T1740, T1741, T1742,30 T1736, T1737, T1738, T1739, T1740, T1741, T1742,
T1743, T1744, T1745, T1746, T1747, T1748, T1749, T1750, T1751, T1752, T1753, T1754, T1755, T1756, T1757, T1758, T1759 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ T1714, T1715 und/oder T1723, T1724 und/oder T1736, T1737 und/oder T1743, T1744 und/oder T1752,T1743, T1744, T1745, T1746, T1747, T1748, T1749, T1750, T1751, T1752, T1753, T1754, T1755, T1756, T1757, T1758, T1759 are independently selected from the group consisting of: "alkyl, (C 9 - 30) C alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively T1714, T1715 and / or T1723, T1724 and / or T1736, T1737 and / or T1743, T1744 and / or T1752,
5 T1753 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengrup- pe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder 10 verschieden, ausgewählt aus der Gruppe bestehend aus:T1753 in each case together can also form "heterocyclyl", where optionally above substituents of the substituent group (ii) can again be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHT1760, - NT1761T1762, -NO2, -OH, -OCF3, -SH, -0-SO3H, -(iii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2 , -NHT1760, - NT1761T1762, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -
15 OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -15 OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -
P(O)(OH)2, -C(O)-TI763, -C(O)O-TI764, -C(O)NH- T1765, -C(O)NTI766T1767, -O-T1768, -O(-T1769- O)ra-H (ra = 1, 2, 3, 4, 5), -O(-T1770-O)ra-T1771 (ra = 1, 2, 3, 4, 5), -OC(O)-TI772, -OC(O)-O-TI773, -P (O) (OH) 2 , -C (O) -TI763, -C (O) O-TI764, -C (O) NH-T1765, -C (O) NTI766T1767, -O-T1768, -O ( -T1769- O) ra -H (ra = 1, 2, 3, 4, 5), -O (-T1770-O) ra -T1771 (ra = 1, 2, 3, 4, 5), -OC ( O) -TI772, -OC (O) -O-TI773, -
20 OC(O)-NHTI774, -0-C(O)-NTI775T1776, -20 OC (O) -NHTI774, -O-C (O) -NTI775T1776, -
OP(O)(OTI777)(OT1778), - OSi(TI779)(T1780)(T1781), -OS(O2)-T1782, - NHC(O)-TI783, -NT1784C(O)-TI785, -NH-C(O)-O- T1786, -NH-C(O)-NH-TI787, -NH-C(O)-OP (O) (OTI777) (OT1778), - OSi (TI779) (T1780) (T1781), -OS (O 2) -T1782, - NHC (O) -TI783, -NT1784C (O) -TI785, -NH -C (O) -O-T1786, -NH-C (O) -NH-TI787, -NH-C (O) -
25 NT1788T1789, -NT1790-C(O)-O-TI791, -NT1792-25 NT1788T1789, -NT1790-C (O) -O-TI791, -NT1792-
C(O)-NH-TI793, -NT1794-C(O)-NTI795T1796, - NHS(O2)-T1797, -NT1798S(O2)-T1799, -S-T1800, - S(O)-TI801, -S(02)-T1802, -S(O2)NH-TI803, - S(O2)NTI804T1805, -S(O2)O-TI806, -C (O) -NH-TI793, -NT1794-C (O) -NTI795T1796, - NHS (O 2) -T1797, -NT1798S (O 2) -T1799, -S-T1800, - S (O) -TI801, -S (0 2) -T1802, -S (O 2) NH-TI803, - S (O 2) NTI804T1805, -S (O 2) O-TI806 -
30 P(O)(OTI807)(OT1808), -Si(TI809)(T1810)(TI811)"; wobei T1760, T1761, T1762, T1763, T1764, T1765, T1766, T1767, T1768, T1769, T1770, T1771, T1772, T1773, T1774, T1775, T1776, T1777, T1778, T1779, T1780, T1781, T1782, T1783, T1784, T1785, T1786, T1787, T1788, T1789, T1790, T1791 , T1792, T1793, T1794, T1795, T1796, T1797, T1798, T1799, T1800, T1801 , T1802, T1803, T1804, T1805, T1806, T1807, T1808, T1809, T1810, T181 1 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl,30 P (O) (OTI807) (OT1808), -Si (TI809) (T1810) (TI811) "; wherein T1760, T1761, T1762, T1763, T1764, T1765, T1766, T1767, T1768, T1769, T1770, T1771, T1772, T1773, T1774, T1775, T1776, T1777, T1778, T1779, T1780, T1781, T1782, T1783, T1784, T1785, T1786, T1787, T1788, T1789, T1790, T1791, T1792, T1793, T1794, T1795, T1796, T1797, T1798, T1799, T1800, T1801, T1802, T1803, T1804, T1805, T1806, T1807, T1808, T1809, T1810, T181 1 are independently selected from the group consisting of: "alkyl,
(C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl" und wobei alternativ T1766, T1767 und/oder T1775, T1776 und/oder T1788, T1789 und/oder T1795, T1796 und/oder T1804, T1805 jeweils zusammen auch(C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroary- lalkyl "and wherein alternatively T1766, T1767 and / or T1775, T1776 and / or T1788, T1789 and / or T1795 , T1796 and / or T1804, T1805 respectively together as well
„heterocyclyl" bilden können;Can form "heterocyclyl";
undand
Reste Z3, Z4 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:Radicals Z3, Z4 are independently selected from the group consisting of:
(e) Wasserstoff;(e) hydrogen;
(f) Halogen, F, Cl, Br, I;(f) halogen, F, Cl, Br, I;
(g) unsubstituiertes oder substituiertes Alkyl oder (Cg-C3o)Alkyl, wobei optio- nal der Alkyl- oder (C9-C3o)Alkylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(g) unsubstituted or substituted alkyl or (Cg-C3o) alkyl, wherein the op- nal alkyl or (C 9 -C 3 o) alkyl group may be substituted with at least one substituent, identical or different, selected from the group consisting of :
(i) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHB457, -NB458B459, -NO2, -OH, -OCF3, -SH, -O-(i) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHB457, -NB458B459, -NO 2 , -OH, -OCF 3 , -SH, -O-
SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B460, -C(O)O-B461 , -C(O)NH-B462, -C(O)NB463B464, - O-B465, -O(-B466-O)x-H (x = 1 , 2, 3, 4, 5), -O(-B467-O)x-B468 (x = 1 , 2, 3, 4, 5), -OC(O)-B469, -OC(O)-O-B470, -OC(O)-NHB471 , - O-C(O)-NB472B473, -OP(O)(OB474)(OB475), -SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -B460 , -C (O) O-B461, -C (O) NH-B462, -C (O) NB463B464, -O-B465, -O (-B466-O) x -H (x = 1, 2, 3 , 4, 5), -O (-B467-O) x -B468 (x = 1, 2, 3, 4, 5), -OC (O) -B469, -OC (O) -O-B470, - OC (O) -NHB471, -OC (O) -NB472B473, -OP (O) (OB474) (OB475),
OSi(B476)(B477)(B478), -OS(O2)-B479, -NHC(O)-B480, - NB481C(O)-B482, -NH-C(O)-O-B483, -N H-C(O)-N H-B484, -NH- C(O)-NB485B486, -NB487-C(O)-O-B488, -NB489-C(O)-NH- B490, -NB491-C(O)-NB492B493, -NHS(O2)-B494, -NB495S(O2)- B496, -S-B497, -S(O)-B498, -S(O2)-B499, -S(O2)NH-B500, - S(O2)NB501 B502, -S(O2)O-B503, -P(O)(OB504)(OB505), - Si(B506)(B507)(B508)"; wobei B457, B458, B459, B460, B461 , B462, B463, B464, B465,OSi (B476) (B477) (B478), -OS (O2) -B479, -NHC (O) -B480, - NB481C (O) -B482, -NH-C (O) -O-B483, -N HC (O) -NH-B484, -NH-C (O) -NB485B486, -NB487-C (O) -O-B488, -NB489-C (O) -NH- B490, -NB491-C (O) -NB492B493, -NHS (O2) -B494, -NB495S (O2) - B496, -S-B497, -S (O) -B498, -S (O 2) - B499, -S (O2) NH-B500, - S (O 2) NB501 B502, -S (O2) O-B503, -P (O) (OB504) (OB505), - Si (B506) (B507 ) (B508) "; wherein B457, B458, B459, B460, B461, B462, B463, B464, B465,
B466, B467, B468, B469, B470, B471 , B472, B473, B474, B475, B476, B477, B478, B479, B480, B481 , B482, B483, B484, B485, B486, B487, B488, B489, B490, B491 , B492, B493, B494, B495, B496, B497, B498, B499, B500, B501 , B502, B503, B504, B505, B506, B507, B508 unabhängig voneinander ausgewählt sind aus derB466, B467, B468, B479, B470, B471, B472, B473, B474, B475, B476, B477, B478, B479, B480, B481, B482, B483, B484, B485, B486, B487, B488, B489, B490, B491, B492, B493, B494, B495, B496, B497, B498, B499, B500, B501, B502, B503, B504, B505, B506, B507, B508 are independently selected from the
Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ B463, B464 und/oder B472, B473 und/oder B485, B486 und/oder B492, B493 und/oder B501 , B502 jeweils zu- sammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHB509, -NB510B511 , -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B512, -C(O)O-B513, -C(O)NH-B514, - C(O)NB515B516, -0-B517, -0(-B518-0)y-H (y = 1 , 2, 3, 4, 5), -Group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- alkyl" and wherein alternatively B463, B464 and / or B472, B473 and / or B485, B486 and / or B492, B493 and / or B501, B502 in each case together can also form "heterocyclyl"; in which optionally substituents of substituent group (i) above may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of: (ii) alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHB509, -NB510B511, -NO2, -OH, -OCF3, - SH , -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C ( O) -B512, -C (O) O-B513, -C (O) NH-B514, - C (O) NB515B516, -0-B517, -0 (-B518-0) y -H (y = 1 , 2, 3, 4, 5), -
O(-B519-O)y-B520 (y = 1 , 2, 3, 4, 5), -OC(O)-B521 , -OC(O)-O- B522, -OC(O)-NHB523, -0-C(O)-N B524B525, - OP(O)(OB526)(OB527), -OSi(B528)(B529)(B530), -OS(O2)- B531 , -NHC(O)-B532, -NB533C(O)-B534, -NH-C(O)-O-B535, -N H-C(O)-N H-B536, -NH-C(O)-NB537B538, -NB539-C(O)-O-O (-B519-O) y -B520 (y = 1, 2, 3, 4, 5), -OC (O) -B521, -OC (O) -O-B522, -OC (O) -NHB523, -0-C (O) -N B524B525, - OP (O) (OB526) (OB527), -OSi (B528) (B529) (B530), -OS (O2) - B531, -NHC (O) - B532, -NB533C (O) -B534, -NH-C (O) -O-B535, -NHC (O) -NH-B536, -NH-C (O) -NB537B538, -NB539-C (O )-O-
B540, -NB541-C(O)-NH-B542, -NB543-C(O)-NB544B545, - NHS(O2)-B546, -NB547S(O2)-B548, -S-B549, -S(O)-B550, - S(O2)-B551 , -S(O2)NH-B552, -S(O2)NB553B554, -S(O2)O- B555, -P(O)(OB556)(OB557), -Si(B558)(B559)(B560)"; wobei B509, B510, B51 1 , B512, B513, B514, B515, B516, B517, B518, B519, B520, B521 , B522, B523, B524, B525, B526, B527, B528, B529, B530, B531 , B532, B533, B534, B535, B536, B537, B538, B539, B540, B541 , B542, B543, B544, B545, B546, B547,B540, -NB541-C (O) -NH-B542, -NB543-C (O) -NB544B545, - NHS (O2) -B546, -NB547S (O2) -B548, -S-B549, -S ( O) -B550, - S (O 2) -B551, -S (O2) NH-B552, -S (O2) NB553B554, -S (O 2) O- B555, -P (O) (OB556) (OB557), -Si (B558) (B559) (B560) "; B509, B510, B51 1, B512, B513, B514, B515, B516, B517, B518, B519, B520, B521, B522, B523, B524, B525, B526, B527, B528, B529, B530, B531, B532, B533, B534, B535, B536, B537, B538, B539, B540, B541, B542, B543, B544, B545, B546, B547,
5 B548, B549, B550, B551 , B552, B553, B554, B555, B556, B557,5 B548, B549, B550, B551, B552, B553, B554, B555, B556, B557,
B558, B559, B560 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B515, B516 und/oder B524,B558, B559 are, B560 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cyclo- alkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively B515 B516 and / or B524,
10 B525 und/oder B537, B538 und/oder B544, B545 und/oder B553,10 B525 and / or B537, B538 and / or B544, B545 and / or B553,
B554 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausge- 15 wählt aus der Gruppe bestehend aus:B554 may in each case together also form "heterocyclyl", where optionally substituted substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHB561 , -NB562B563, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -(iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , - NHB561, -NB562B563, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -
20 C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B564, -C(O)O-B565, -20 C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -B564, -C (O) O-B565,
C(O)NH-B566, -C(O)NB567B568, -O-B569, -O(-B570-O)z- H (z = 1 , 2, 3, 4, 5), -O(-B571-O)z-B572 (z = 1, 2, 3, 4, 5), - OC(O)-B573, -OC(O)-O-B574, -OC(O)-NHB575, -0-C(O)- NB576B577, -OP(O)(OB578)(OB579), -C (O) NH-B566, -C (O) NB567B568, -O-B569, -O (-B570-O) z - H (z = 1, 2, 3, 4, 5), -O (-B571 -O) z -B572 (z = 1, 2, 3, 4, 5), - OC (O) -B573, -OC (O) -O-B574, -OC (O) -NHB575, -O-C (O) - NB576B577, -OP (0) (OB578) (OB579), -
25 OSi(B580)(B581)(B582), -OS(O2)-B583, -NHC(O)-B584, -25 OSi (B580) (B581) (B582), -OS (O2) -B583, -NHC (O) -B584, -
NB585C(O)-B586, -NH-C(O)-O-B587, -NH-C(O)-NH- B588, -NH-C(O)-NB589B590, -NB591-C(O)-O-B592, - NB593-C(O)-NH-B594, -NB595-C(O)-NB596B597, - NHS(O2)-B598, -NB599S(O2)-B600, -S-B601, -S(O)-B602,NB585C (O) -B586, -NH-C (O) -O-B587, -NH-C (O) -NH-B588, -NH-C (O) -NB589B590, -NB591-C (O) -O -B592, - NB593-C (O) -NH-B594, -NB595-C (O) -NB596B597, - NHS (O2) -B598, -NB599S (O2) -B600, -S-B601, -S (O) -B602,
30 -S(O2)-B603, -S(O2)NH-B604, -S(O2)NB605B606, -S(O2)O-30 -S (O 2 ) -B 603, -S (O 2 ) NH-B 604, -S (O 2 ) NB 605B 606, -S (O 2 ) O-
6607,-P(O)(OBeOS)(OBeOg)1-Si(BeIO)(BeIi)(Be^)"; wobei B561, B562, B563, B564, B565, B566, B567, B568, B569, B570, B571, B572, B573, B574, B575, B576, B577, B578, B579, B580, B581, B582, B583, B584, B585, B586, B587, B588, B589, B590, B591, B592, B593, B594, B595, B596, B597, B598, B599, B600, B601, B602, B603, B604, B605, B606, B607, B608, B609, B610, B611, B612 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc-6607, -P (O) (OBeOS) (OBeOg) 1 -Si (BeIO) (BeI) (Be ^) "; wherein B561, B562, B563, B564, B565, B566, B567, B568, B569, B570, B571 , B572, B573, B574, B575, B576, B577, B578, B579, B580, B581, B582, B583, B584, B585, B586, B587, B588, B589, B590, B591, B592, B593, B594, B595, B596, B597, B598, B599, B600, B601, B602, B603, B604, B605, B606, B607, B608, B609, B610, B611, B612 are independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl
IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B567, B568 und/oder B576, B577 und/oder B589, B590 und/oder B596, B597 und/oder B605, B606 jeweils zusammen auch „heterocyclyl" bilden können;IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively B567, B568 and / or B576, B577 and / or B589, B590 and / or B596, B597 and / or B605, B606 can each also together form" heterocyclyl " ;
(h) unsubstituiertes oder substituiertes Aryl, wobei optional der Arylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(h) unsubstituted or substituted aryl wherein optionally the aryl radical may be substituted with at least one substituent, same or different, selected from the group consisting of:
(i) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3,(i) "alkyl, (C 9 -C 30 ) -alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 ,
N3, NH2, -NHB613, -NB614B615, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B616, -C(O)O-B617, -C(O)NH-B618, -C(O)NB619B620, - O-B621 , -O(-B622-O)a-H (a = 1 , 2, 3, 4, 5), -O(-B623-O)a-B624 (a = 1 , 2, 3, 4, 5), -OC(O)-B625, -OC(O)-O-B626, -OC(O)-NHB627, -N 3, NH 2, -NHB613, -NB614B615, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP (O) (OH) 2, -CHO, -COOH, - C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -B616, -C (O) O-B617, -C (O) NH-B618, -C (O) NB619B620, -O-B621, -O (-B622-O) a -H (a = 1, 2, 3, 4, 5), -O (-B623-O) a -B624 (a = 1 , 2, 3, 4, 5), -OC (O) -B625, -OC (O) -O-B626, -OC (O) -NHB627, -
O-C(O)-NB628B629, -OP(O)(OB630)(OB631 ), - OSi(B632)(B633)(B634), -OS(O2)-B635, -NHC(O)-B636, - NB637C(O)-B638, -NH-C(O)-O-B639, -N H-C(O)-N H-B640, -NH- C(O)-NB641 B642, -NB643-C(O)-O-B644, -NB645-C(O)-NH- B646, -NB647-C(O)-NB648B649, -NHS(O2)-B650, -NB651S(O2)-OC (O) -NB628B629, -OP (O) (OB630) (OB631), - OSi (B632) (B633) (B634), -OS (O2) -B635, -NHC (O) -B636, - NB637C (O) -B638, -NH-C (O) -O-B639, -NHC (O) -NH-B640, -NH-C (O) -NB641 B642, -NB643-C (O) -O -B644, -NB645-C (O) -NH- B646, -NB647-C (O) -NB648B649, -NHS (O2) -B650, -NB651S (O 2) -
B652, -S-B653, -S(O)-B654, -S(O2)-B655, -S(O2)NH-B656, - S(O2)NB657B658, -S(O2)O-B659, -P(O)(OB660)(OB661), - Si(B662)(B663)(B664)"; wobei B613, B614, B615, B616, B617, B618, B619, B620, B621, B622, B623, B624, B625, B626, B627, B628, B629, B630, B631,B652, -S-B653, -S (O) -B654, -S (O2) -B655, -S (O2) NH-B656, - S (O 2) NB657B658, -S (O 2) O- B659, -P (O) (OB660) (OB661), -Si (B662) (B663) (B664) "; wherein B613, B614, B615, B616, B617, B618, B619, B620, B621, B622, B623, B624, B625, B626, B627, B628, B629, B630, B631,
B632, B633, B634, B635, B636, B637, B638, B639, B640, B641, B642, B643, B644, B645, B646, B647, B648, B649, B650, B651, B652, B653, B654, B655, B656, B657, B658, B659, B660, B661, B662, B663, B664 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ B619, B620 und/oder B628, B629 und/oder B641 , B642 und/oder B648, B649 und/oder B657, B658 jeweils zu- sammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHB665, -NB666B667, -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B668, -C(O)O-B669, -C(O)NH-B670, - C(O)NB671 B672, -O-B673, -O(-B674-O)b-H (b = 1 , 2, 3, 4, 5), -B632, B633, B634, B635, B636, B637, B638, B639, B640, B641, B642, B643, B644, B645, B646, B647, B648, B649, B650, B651, B652, B653, B654, B655, B656, B657, B658, B659, B660, B661, B662, B663, B664 are independently selected from the A group consisting of: "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively B619, B620 and / or B628, B629 and / or B641 , B642 and / or B648, B649 and / or B657, B658 in each case together can also form "heterocyclyl"; wherein optionally above substituents of substituent group (i) in turn may be independently substituted with at least one substituent, identical or different, selected from the group consisting of: (ii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl , heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHB665, -NB666B667, -NO2, -OH, -OCF3, - SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -B668, -C (O) O-B669, -C (O) NH-B670, -C (O) NB671 B672, -O-B673, -O (-B674-O) b -H (b = 1, 2, 3, 4, 5), -
O(-B675-O)b-B676 (b = 1 , 2, 3, 4, 5), -OC(O)-B677, -OC(O)-O- B678, -OC(O)-NHB679, -O-C(O)-NB680B681 , - OP(O)(OB682)(OB683), -OSi(B684)(B685)(B686), -OS(O2)- B687, -NHC(O)-B688, -NB689C(O)-B690, -NH-C(O)-O-B691 , -N H-C(O)-N H-B692, -NH-C(O)-NB693B694, -NB695-C(O)-O-O (-B675-O) b -B676 (b = 1, 2, 3, 4, 5), -OC (O) -B677, -OC (O) -O-B678, -OC (O) -NHB679, -OC (O) -NB680B681, - OP (O) (OB682) (OB683), -OSi (B684) (B685) (B686), -OS (O2) - B687, -NHC (O) -B688, - NB689C (O) -B690, -NH-C (O) -O-B691, -NHC (O) -NH-B692, -NH-C (O) -NB693B694, -NB695-C (O) -O -
B696, -NB697-C(O)-NH-B698, -NB699-C(O)-NB700B701 , - NHS(O2)-B702, -NB703S(O2)-B704, -S-B705, -S(O)-B706, - S(O2)-B707, -S(O2)NH-B708, -S(O2)NB709B710, -S(O2)O- B71 1 , -P(O)(OB712)(OB713), -Si(B714)(B715)(B716)"; wobei B665, B666, B667, B668, B669, B670, B671 , B672, B673,B696, -NB697-C (O) -NH-B698, -NB699-C (O) -NB700B701, - NHS (O2) -B702, -NB703S (O2) -B704, -S-B705, -S ( O) -B706, - S (O 2) -B707, -S (O2) NH-B708, -S (O2) NB709B710, -S (O 2) O- B71 1, -P (O) (OB712 ) (B715) (B716) ", wherein B665, B666, B667, B668, B669, B670, B671, B672, B673,
B674, B675, B676, B677, B678, B679, B680, B681 , B682, B683, B684, B685, B686, B687, B688, B689, B690, B691 , B692, B693, B694, B695, B696, B697, B698, B699, B700, B701 , B702, B703, B704, B705, B706, B707, B708, B709, B710, B71 1 , B712, B713, B714, B715, B716 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B671 , B672 und/oder B680, B681 und/oder B693, B694 und/oder B700, B701 und/oder B709, B710 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mitB674, B675, B676, B677, B678, B679, B680, B681, B682, B683, B684, B685, B686, B687, B688, B689, B690, B691, B692, B693, B694, B695, B696, B697, B698, B699, B700, B701, B702, B703, B704, B705, B706, B707, B708, B709, B710, B71 1, B712, B713, B714, B715, B716 are independently selected from the group consisting of: "alkyl, ( C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and where alternatively B671, B672 and / or B680, B681 and / or B693, B694 and / or B700, B701 and / or B709, B710 in each case together can also form "heterocyclyl", where optionally substituents of the substituent group (ii) above may be substituted independently of one another with
5 mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:5 at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHB717, -NB718B719, -NO2, -OH,(iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHB717, -NB718B719, -NO 2 , -OH,
10 -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -10 -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -
C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B720, -C(O)O-B721 , - C(O)NH-B722, -C(O)NB723B724, -O-B725, -O(-B726-O)c- H (c = 1 , 2, 3, 4, 5), -O(-B727-O)c-B728 (c = 1 , 2, 3, 4, 5), - OC(O)-B729, -OC(O)-O-B730, -OC(O)-N H B731 , -0-C(O)-C (O) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) -B720, -C (O) O-B721, - C (O) NH-B722, -C (O) NB723B724, -O-B725, -O (-B726-O) c -H (c = 1, 2, 3, 4, 5), -O (-B727-O) c -B728 (c = 1 , 2, 3, 4, 5), - OC (O) -B729, -OC (O) -O-B730, -OC (O) -NH B731, -O-C (O) -
15 NB732B733, -OP(O)(OB734)(OB735), -15 NB732B733, -OP (O) (OB734) (OB735), -
OSi(B736)(B737)(B738), -OS(O2)-B739, -NHC(O)-B740, - NB741C(O)-B742, -NH-C(O)-O-B743, -NH-C(O)-NH- B744, -NH-C(O)-NB745B746, -NB747-C(O)-O-B748, - NB749-C(O)-NH-B750, -NB751-C(O)-NB752B753, -OSi (B736) (B737) (B738), -OS (O2) -B739, -NHC (O) -B740, - NB741C (O) -B742, -NH-C (O) -O-B743, -NH -C (O) -NH-B744, -NH-C (O) -NB745B746, -NB747-C (O) -O-B748, -NB749-C (O) -NH-B750, -NB751-C (O ) -NB752B753, -
20 NHS(O2)-B754, -NB755S(O2)-B756, -S-B757, -S(O)-B758,20 NHS (O 2 ) -B754, -NB755S (O 2 ) -B756, -S-B757, -S (O) -B758,
-S(O2)-B759, -S(O2)NH-B760, -S(O2)NB761 B762, -S(O2)O- B763, -P(O)(OB764)(OB765), -Si(B766)(B767)(B768)"; wobei B717, B718, B719, B720, B721 , B722, B723, B724, B725, B726, B727, B728, B729, B730, B731 , B732, B733,-S (O 2) -B759, -S (O2) NH-B760, -S (O 2) NB761 B762, -S (O 2) O- B763, -P (O) (OB764) (OB765), -Si (B766) (B767) (B768) "; wherein B717, B718, B719, B720, B721, B722, B723, B724, B725, B726, B727, B728, B729, B730, B731, B732, B733,
25 B734, B735, B736, B737, B738, B739, B740, B741 , B742,25 B734, B735, B736, B737, B738, B739, B740, B741, B742,
B743, B744, B745, B746, B747, B748, B749, B750, B751 , B752, B753, B754, B755, B756, B757, B758, B759, B760, B761 , B762, B763, B764, B765, B766, B767, B768 unabhängig voneinander ausgewählt sind aus der Gruppe bestehendB743, B744, B745, B746, B747, B748, B749, B750, B751, B752, B753, B754, B755, B756, B757, B758, B759, B760, B761, B762, B763, B764, B765, B766, B767, B768 are independently selected from the group consisting
30 aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B723, B724 und/oder B732, B733 und/oder B745, B746 und/oder B752, B753 und/oder B761 , B762 jeweils zusammen auch „heterocyclyl" bilden können; (j) unsubstituiertes oder substituiertes Heteroaryl, wobei optional der Hetero- arylrest substituiert sein kann mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (i) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyc- lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHB769, -NB770B771 , -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B772, -C(O)O-B773, -C(O)NH-B774, -C(O)NB775B776, - O-B777, -O(-B778-O)d-H (d = 1 , 2, 3, 4, 5), -O(-B779-O)d-B780 (d30 of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively B723, B724 and / or B732, B733 and / or B745, B746 and or B752, B753 and / or B761, B762 may together also form "heterocyclyl"; (j) unsubstituted or substituted heteroaryl, wherein optionally the hetero aryl group may be substituted with at least one substituent, identical or different, selected from the group consisting of: (i) "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl lylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHB769, -NB770B771, -NO2, -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -B772, -C (O) O-B773, -C (O) NH-B774, -C (O) NB775B776, -O-B777, -O (-B778-O) d -H (d = 1, 2, 3, 4, 5), -O (-B779-O) d -B780 (i.e.
= 1 , 2, 3, 4, 5), -OC(O)-B781 , -OC(O)-O-B782, -OC(O)-NHB783, - O-C(O)-NB784B785, -OP(O)(OB786)(OB787), - OSi(B788)(B789)(B790), -OS(O2)-B791 , -NHC(O)-B792, - NB793C(O)-B794, -NH-C(O)-O-B795, -N H-C(O)-N H-B796, -NH- C(O)-NB797B798, -NB799-C(O)-O-B800, -NB801-C(O)-NH-= 1, 2, 3, 4, 5), -OC (O) -B781, -OC (O) -O-B782, -OC (O) -NHB783, - OC (O) -NB784B785, -OP (O ) (OB786) (OB787), - OSi (B788) (B789) (B790), -OS (O2) -B791, -NHC (O) -B792, - NB793C (O) -B794, -NH-C ( O) -O-B795, -NHC (O) -NH-B796, -NH-C (O) -NB797B798, -NB799-C (O) -O-B800, -NB801-C (O) -NH -
B802, -NB803-C(O)-NB804B805, -NHS(O2)-B806, -NB807S(O2)- B808, -S-B809, -S(O)-B810, -S(O2)-B811 , -S(O2)N H-B812, - S(O2)NB813B814, -S(O2)O-B815, -P(O)(OB816)(OB817), - Si(B818)(B819)(B820)"; wobei B769, B770, B771 , B772, B773, B774, B775, B776, B777,B802, -NB803-C (O) -NB804B805, -NHS (O2) -B806, -NB807S (O2) - B808, -S-B809, -S (O) -B810, -S (O 2) - B811, -S (O2) N H-B812, - S (O 2) NB813B814, -S (O2) O-B815, -P (O) (OB816) (OB817), - Si (B818) (B819 ) (B820) "; wherein B769, B770, B771, B772, B773, B774, B775, B776, B777,
B778, B779, B780, B781 , B782, B783, B784, B785, B786, B787, B788, B789, B790, B791 , B792, B793, B794, B795, B796, B797, B798, B799, B800, B801 , B802, B803, B804, B805, B806, B807, B808, B809, B810, B81 1 , B812, B813, B814, B815, B816, B817, B818, B819, B820 unabhängig voneinander ausgewählt sind aus derB778, B779, B780, B781, B782, B783, B784, B785, B786, B787, B788, B789, B790, B791, B792, B793, B794, B795, B796, B797, B798, B799, B800, B801, B802, B803, B804, B805, B806, B807, B808, B809, B810, B81 1, B812, B813, B814, B815, B816, B817, B818, B819, B820 are independently selected from the
Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B775, B776 und/oder B784, B785 und/oder B797, B798 und/oder B804, B805 und/oder B813, B814 jeweils zu- sammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHB821 , -NB822B823, -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B824, -C(O)O-B825, -C(O)NH-B826, -A group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively B775, B776 and / or B784, B785 and / or B797, B798 and / or B804, B805 and / or B813, B814 in each case together can also form "heterocyclyl"; in which optional substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of: (ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHB821, -NB822B823, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -B824, -C (O) O-B 825, -C (O) NH-B 826,
C(O)NB827B828, -O-B829, -O(-B830-O)e-H (e = 1 , 2, 3, 4, 5), - O(-B831-O)e-B832 (e = 1 , 2, 3, 4, 5), -OC(O)-B833, -OC(O)-O- B834, -OC(O)-NHB835, -O-C(O)-NB836B837, - OP(O)(OB838)(OB839), -OSi(B840)(B841 )(B842), -OS(O2)- B843, -NHC(O)-B844, -NB845C(O)-B846, -NH-C(O)-O-B847,C (O) NB827B828, -O-B829, -O (-B830-O) e -H (e = 1, 2, 3, 4, 5), - O (-B831-O) e -B832 (e = 1, 2, 3, 4, 5), -OC (O) -B833, -OC (O) -O-B834, -OC (O) -NHB835, -OC (O) -NB836B837, - OP (O) (OB838) (OB839), -OSi (B840) (B841) (B842), -OS (O2) - B843, -NHC (O) -B844, -NB845C (O) -B846, -NH-C (O ) -O-B847,
-N H-C(O)-N H-B848, -NH-C(O)-NB849B850, -NB851 -C(O)-O- B852, -NB853-C(O)-NH-B854, -NB855-C(O)-NB856B857, - NHS(O2)-B858, -NB859S(O2)-B860, -S-B861 , -S(O)-B862, - S(O2)-B863, -S(O2)NH-B864, -S(O2)NB865B866, -S(O2)O- B867, -P(O)(OB868)(OB869), -Si(B870)(B871 )(B872)"; wobei B821 , B822, B823, B824, B825, B826, B827, B828, B829, B830, B831 , B832, B833, B834, B835, B836, B837, B838, B839, B840, B841 , B842, B843, B844, B845, B846, B847, B848, B849, B850, B851 , B852, B853, B854, B855, B856, B857, B858, B859, B860, B861 , B862, B863, B864, B865, B866, B867, B868, B869,-NHC (O) -NH-B848, -NH-C (O) -NB849B850, -NB851 -C (O) -O-B852, -NB853-C (O) -NH-B854, -NB855-C (O) -NB856B857, - NHS (O2) -B858, -NB859S (O2) -B860, -S-B861, -S (O) -B862, - S (O 2) -B863, -S (O 2) NH-B864, -S (O2) NB865B866, -S (O 2) O- B867, -P (O) (OB868) (OB869), -Si (B870) (B871) (B872) "; wherein B821, B822, B823, B824, B825, B826, B827, B828, B829, B830, B831, B832, B833, B834, B835, B836, B837, B838, B839, B840, B841, B842, B843, B844, B845, B846, B847, B848, B849, B850, B851, B852, B853, B854, B855, B856, B857, B858, B859, B860, B861, B862, B863, B864, B865, B866, B867, B868, B869,
B870, B871 , B872 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B827, B828 und/oder B836, B837 und/oder B849, B850 und/oder B856, B857 und/oder B865,B870, B871, B872 are independently selected from the group consisting of: "alkyl, (C 9 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively B827, B828 and / or B836, B837 and / or B849, B850 and / or B856, B857 and / or B865,
B866 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausge- wählt aus der Gruppe bestehend aus:B866 may in each case also form "heterocyclyl", where optionally substituted substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHB873, -NB874B875, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B876, -C(O)O-B877, - C(O)NH-B878, -C(O)NB879B880, -O-B881, -O(-B882-O)r- H (f = 1 , 2, 3, 4, 5), -O(-B883-O)f-B884 (f = 1, 2, 3, 4, 5), - OC(O)-B885, -OC(O)-O-B886, -OC(O)-NHB887, -0-C(O)- NB888B889, -OP(O)(OB890)(OB891), -(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHB873, -NB874B875, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, - C (O) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) -B876, -C (O) O-B877, - C (O) NH-B878, -C (O) NB879B880, -O-B881, -O (-B882-O) r -H (f = 1, 2, 3, 4, 5), -O (-B883-O) f -B884 (f = 1 , 2, 3, 4, 5), - OC (O) -B885, -OC (O) -O-B886, -OC (O) -NHB887, -O-C (O) -NB888B889, -OP (O ) (OB890) (OB891), -
OSi(B892)(B893)(B894), -OS(O2)-B895, -NHC(O)-B896, - NB897C(O)-B898, -NH-C(O)-O-B899, -NH-C(O)-NH- B900, -NH-C(O)-NB901B902, -NB903-C(O)-O-B904, - NB905-C(O)-NH-B906, -NB907-C(O)-NB908B909, - NHS(O2)-B910, -NB911S(O2)-B912, -S-B913, -S(O)-B914,OSi (B892) (B893) (B894), -OS (O2) -B895, -NHC (O) -B896, - NB897C (O) -B898, -NH-C (O) -O-B899, -NH -C (O) -NH-B900, -NH-C (O) -NB901B902, -NB903-C (O) -O-B904, -NB905-C (O) -NH-B906, -NB907-C (O ) -NB908B909, - NHS (O2) -B910, -NB911S (O2) -B912, -S-B913, -S (O) -B914,
-S(O2)-B915, -S(O2)NH-B916, -S(O2)NB917B918, -S(O2)O- B919, -P(O)(OB920)(OB921), -Si(B922)(B923)(B924)"; wobei B873, B874, B875, B876, B877, B878, B879, B880, B881, B882, B883, B884, B885, B886, B887, B888, B889, B890, B891, B892, B893, B894, B895, B896, B897, B898,-S (O 2) -B915, -S (O2) NH-B916, -S (O2) NB917B918, -S (O 2) O- B919, -P (O) (OB920) (OB921), - Si (B922) (B923) (B924) "; wherein B873, B874, B875, B876, B877, B878, B879, B880, B881, B882, B883, B884, B885, B886, B887, B888, B889, B890, B891 , B892, B893, B894, B895, B896, B897, B898,
B899, B900, B901, B902, B903, B904, B905, B906, B907, B908, B909, B910, B911, B912, B913, B914, B915, B916, B917, B918, B919, B920, B921, B922, B923, B924 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc-B899, B900, B901, B902, B903, B904, B905, B906, B907, B908, B909, B910, B911, B912, B913, B914, B915, B916, B917, B918, B919, B920, B921, B922, B923, B924 are independently selected from the group consisting of: "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl
IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B879, B880 und/oder B888, B889 und/oder B901 , B902 und/oder B908, B909 und/oder B917, B918 jeweils zusammen auch „heterocyclyl" bilden können;IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively B879, B880 and / or B888, B889 and / or B901, B902 and / or B908, B909 and / or B917, B918 may together also form" heterocyclyl " ;
(k) 0Z6, wobei Z6 unabhängig ausgewählt ist aus der Gruppe bestehend aus:(k) 0Z6, where Z6 is independently selected from the group consisting of:
(i) „Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHB925, -NB926B927, -NO2, -OH, -OCF3, - SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B928, -C(O)O-B929, -C(O)NH-B930, -(i) "hydrogen, alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wherein optionally substituents of the substituent group (i) above may be independently substituted with at least one substituent, identical or different, selected from the group consisting of: (ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHB925, -NB926B927, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -B 928, -C (O) O-B 929, -C (O) NH-B 930,
C(O)NB931 B932, -O-B933, -O(-B934-O)g-H (g = 1 , 2, 3, 4, 5), - O(-B935-O)g-B936 (g = 1 , 2, 3, 4, 5), -OC(O)-B937, -OC(O)-O- B938, -OC(O)-NHB939, -O-C(O)-NB940B941 , - OP(O)(OB942)(OB943), -OSi(B944)(B945)(B946), -OS(O2)- B947, -NHC(O)-B948, -NB949C(O)-B950, -NH-C(O)-O-B951 ,C (O) NB931 B932, -O-B933, -O (-B934-O) g -H (g = 1, 2, 3, 4, 5), - O (-B935-O) g -B936 (g = 1, 2, 3, 4, 5), -OC (O) -B937, -OC (O) -O-B938, -OC (O) -NHB939, -OC (O) -NB940B941, -OP (O ) (OB942) (OB943), -OSi (B944) (B945) (B946), -OS (O2) - B947, -NHC (O) -B948, -NB949C (O) -B950, -NH-C ( O) -O-B951,
-N H-C(O)-N H-B952, -NH-C(O)-NB953B954, -NB955-C(O)-O- B956, -NB957-C(O)-NH-B958, -NB959-C(O)-NB960B961 , - NHS(O2)-B962, -NB963S(O2)-B964, -S-B965, -S(O)-B966, - S(O2)-B967, -S(O2)NH-B968, -S(O2)NB969B970, -S(O2)O- B971 , -P(O)(OB972)(OB973), -Si(B974)(B975)(B976)"; wobei B925, B926, B927, B928, B929, B930, B931 , B932, B933, B934, B935, B936, B937, B938, B939, B940, B941 , B942, B943, B944, B945, B946, B947, B948, B949, B950, B951 , B952, B953, B954, B955, B956, B957, B958, B959, B960, B961 , B962, B963, B964, B965, B966, B967, B968, B969, B970, B971 , B972, B973,-NHC (O) -NH-B952, -NH-C (O) -NB953B954, -NB955-C (O) -O-B956, -NB957-C (O) -NH-B958, -NB959-C (O) -NB960B961, - NHS (O2) -B962, -NB963S (O2) -B964, -S-B965, -S (O) -B966, - S (O 2) -B967, -S (O 2) NH-B968, -S (O2) NB969B970, -S (O 2) O- B971, -P (O) (OB972) (OB973), -Si (B974) (B975) (B976) "; wherein B925, B926, B927, B928, B929, B930, B931, B932, B933, B934, B935, B936, B937, B938, B939, B940, B941, B942, B943, B944, B945, B946, B947, B948, B949, B950, B951, B952, B953, B954, B955, B956, B957, B958, B959, B960, B961, B962, B963, B964, B965, B966, B967, B968, B969, B970, B971, B972, B973,
B974, B975, B976 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B931 , B932 und/oder B940, B941 und/oder B953, B954 und/oder B960, B961 und/oder B969,B974, B975, B976 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively B931, B932 and / or B940, B941 and / or B953, B954 and / or B960, B961 and / or B969,
B970 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausge- wählt aus der Gruppe bestehend aus:B970 may in each case also form "heterocyclyl", where optionally substituents of the substituent group (ii) above may be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHB977, -NB978B979, -NO2, -OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B980, -C(O)O-B981 , - C(O)NH-B982, -C(O)NB983B984, -O-B985, -O(-B986-O)h- H (h = 1 , 2, 3, 4, 5), -O(-B987-O)h-B988 (h = 1 , 2, 3, 4, 5), - OC(O)-B989, -OC(O)-O-B990, -OC(O)-N H B991 , -0-C(O)- NB992B993, -OP(O)(OB994)(OB995), -(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHB977, -NB978B979, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, - C (O) NH 2, -SO 3 H, -P (O) (OH) 2, -C (O) -B980, -C (O) O-B981, - C (O) NH-B982, -C (O) NB983B984, -O-B985, -O (-B986-O) h -H (h = 1, 2, 3, 4, 5), -O (-B987-O) h -B988 (h = 1 , 2, 3, 4, 5), - OC (O) -B989, -OC (O) -O-B990, -OC (O) -NH B991, -O-C (O) -NB992B993, -OP ( O) (OB994) (OB995), -
OSi(B996)(B997)(B998), -OS(O2)-B999, -NHC(O)-BI OOO, - NB1001 C(O)-BI 002, -NH-C(O)-O-BI 003, -NH-C(O)-NH- B1004, -NH-C(O)-NBI 005B1006, -NB1007-C(O)-O-BI 008, -NBI OOg-C(O)-NH-BI OIO1 -NBI OI I-C(O)-NBIO^BI OI S, - NHS(O2)-B1014, -NB1015S(O2)-B1016, -S-B1017, -S(O)-OSi (B996) (B997) (B998), -OS (O2) -B999, -NHC (O) -BI OOO, - NB1001 C (O) -BI 002, -NH-C (O) -O-BI 003, -NH-C (O) -NH-B1004, -NH-C (O) -NBi 005B1006, -NB1007-C (O) -O-BI 008, -NBI OOg-C (O) -NH-BI OIO 1 -NBI OI IC (O) -NBIO 2 BI OI S, - NHS (O 2 ) -B 10 14, -NB 10 15S (O 2 ) -B 10 16, -S-B 10 17, -S (O) -
B1018, -S(O2)-B1019, -S(O2)NH-BI 020, - S(O2)NBI 021 B1022, -S(O2)O-BI 023, - P(O)(OBI 024)(OB1025), -Si(BI 026)(B1027)(B1028)"; wobei B977, B978, B979, B980, B981 , B982, B983, B984, B985, B986, B987, B988, B989, B990, B991 , B992, B993,B1018, -S (O 2) -B1019, -S (O 2) NH-BI 020, - S (O 2) NBI 021 B1022, -S (O 2) OBI 023, - P (O) (OBI 024) (OB1025), -Si (BI 026) (B1027) (B1028) "; wherein B977, B978, B979, B980, B981, B982, B983, B984, B985, B986, B987, B988, B989, B990, B991 , B992, B993,
B994, B995, B996, B997, B998, B999, B1000, B1001 , B1002, B1003, B1004, B1005, B1006, B1007, B1008, B1009, B1010, B101 1 , B1012, B1013, B1014, B1015, B1016, B1017, B1018, B1019, B1020, B1021 , B1022, B1023, B1024, B1025, B1026, B1027, B1028 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B983, B984 und/oder B992, B993 und/oder B1005, B1006 und/oder B1012, B1013 und/oder B1021 , B1022 jeweils zusammen auch „heterocyclyl" bilden können;B994, B995, B996, B997, B998, B999, B1000, B1001, B1002, B1003, B1004, B1005, B1006, B1007, B1008, B1009, B1010, B101 1, B1012, B1013, B1014, B1015, B1016, B1017, B1018 , B1019, B1020, B1021, B1022, B1023, B1024, B1025, B1026, B1027, are B1028 independently selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively B983, B984 and / or B992, B993 and / or B1005, B1006 and / or B1012, B1013 and / or B1021, B1022 may together also form" heterocyclyl ";
, wobei Z7 unabhängig ausgewählt ist aus der Gruppe bestehend aus: „Wasserstoff, alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (ii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHB1029, -NB1030B1031 , -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-BI 032, -C(O)O-BI 033, -C(O)NH-wherein Z7 is independently selected from the group consisting of: "hydrogen, alkyl, (C" 9 " -C" 3 " ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl;""wherein optional substituents above the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of: (ii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHB1029, -NB1030B1031, -NO 2 , -OH, - OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -BI 032, -C (O) O-BI 033, -C (O) NH-
B1034, -C(O)NBI035B1036, -O-B1037, -0(-B1038-O)1-H (i = 1, 2, 3, 4, 5), -0(-B1039-O)1-BI040 (i = 1, 2, 3, 4, 5), -OC(O)- B1041, -OC(O)-O-BI042, -OC(O)-NHBI043, -0-C(O)- NB1044B1045, -OP(O)(OBI046)(OB1047), - OSi(BI048)(B1049)(B1050), -0S(02)-B1051 , -NHC(O)-BI052, -B1034, -C (O) NBI035B1036, -O-B1037, -0 (-B1038-O) 1 -H (i = 1, 2, 3, 4, 5), -O (-B1039-O) 1 -BI040 (i = 1, 2, 3, 4, 5), -OC (O) -B1041, -OC (O) -O-BI042, -OC (O) -NHBI043, -O-C (O) - NB1044B1045, -OP (O) (OBI046) (OB1047), - OSi (BI048) (B1049) (B1050), -0S (0 2 ) -B1051, -NHC (O) -BI052, -
NB1053C(O)-BI054, -NH-C(O)-O-BI055, -NH-C(O)-NH- B1056, -NH-C(O)-NBI057B1058, -NB1059-C(O)-O-BI060, - NB1061-C(O)-NH-BI062, -NB1063-C(O)-NBI064B1065, - NHS(O2)-B1066, -NB1067S(O2)-B1068, -S-B1069, -S(O)- B1070, -S(O2)-B1071, -S(O2)NH-BI072, -S(O2)NBI073B1074, -NB1053C (O) -BI054, -NH-C (O) -O-BI055, -NH-C (O) -NH-B1056, -NH-C (O) -NBI057B1058, -NB1059-C (O) -O -BI060, - NB1061-C (O) -NH-BI062, -NB1063-C (O) -NBI064B1065, - NHS (O 2) -B1066, -NB1067S (O 2) -B1068, -S-B1069, -S (O) - B1070, -S (O 2) -B1071, -S (O 2) NH-BI072, -S (O 2) NBI073B1074, -
S(O2)O-BI075, -P(O)(OBI076)(OB1077), - Si(B1078)(B1079)(B1080)"; wobei B1029, B1030, B1031 , B1032, B1033, B1034, B1035, B1036, B1037, B1038, B1039, B1040, B1041 , B1042, B1043, B1044, B1045, B1046, B1047, B1048, B1049, B1050, B1051 ,S (O 2 ) O-BI075, -P (O) (OBI076) (OB1077), -Si (B1078) (B1079) (B1080) "; wherein B1029, B1030, B1031, B1032, B1033, B1034, B1035, B1036 , B1037, B1038, B1039, B1040, B1041, B1042, B1043, B1044, B1045, B1046, B1047, B1048, B1049, B1050, B1051,
B1052, B1053, B1054, B1055, B1056, B1057, B1058, B1059, B1060, B1061 , B1062, B1063, B1064, B1065, B1066, B1067, B1068, B1069, B1070, B1071 , B1072, B1073, B1074, B1075, B1076, B1077, B1078, B1079, B1080 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-B1052, B1053, B1054, B1055, B1056, B1057, B1058, B1059, B1060, B1061, B1062, B1063, B1064, B1065, B1066, B1067, B1068, B1069, B1070, B1071, B1072, B1073, B1074, B1075, B1076, B1077, B1078, B1079, B1080 are independently selected from the group consisting of: "alkyl, (Cg-
C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B1035, B1036 und/oder B1044, B1045 und/oder B1057, B1058 und/oder B1064, B1065 und/oder B1073, B1074 jeweils zusam- men auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHB1081 , -NB1082B1083, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-BI 084, -C(O)O-BI 085,C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and alternatively B1035, B1036 and / or B1044, B1045 and / or B1057, B1058 and / or B1064, B1065 and / or B1073, B1074 can together also form "heterocyclyl"; in which optional substituents of the substituent group (ii) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of: (iii) "alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2 , -NHB1081, -NB1082B1083, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -BI 084, -C (O) O-BI 085,
-C(O)NH-BI086, -C(O)NBI087B1088, -O-B1089, -0(- B1090-O)-H C = 1, 2, 3, 4, 5), -0(-B1091-O)-B1092 C = 1, 2, 3, 4, 5), -OC(O)-BI093, -OC(O)-O-BI094, -OC(O)- NHB1095, -0-C(O)-NBI096B1097, - OP(O)(OBI098)(OB1099), -OSi(B1100)(B1101)(B1102), --C (O) NH-BI086, -C (O) NBI087B1088, -O-B1089, -0 (- B1090-O) -HC = 1, 2, 3, 4, 5), -0 (-B1091-O ) -B1092 C = 1, 2, 3, 4, 5), -OC (O) -BI093, -OC (O) -O-BI094, -OC (O) - NHB1095, -O-C (O) - NBI096B1097, - OP (0) (OBI098) (OB1099), -OSi (B1100) (B1101) (B1102),
0S(02)-B1103, -NHC(O)-B1 104, -NB1105C(O)-B1 106, - NH-C(O)-O-B1107, -NH-C(O)-NH-B1 108, -NH-C(O)- NB1109B11 10, -NB111 1-C(O)-O-B1112, -NB11 13-C(O)- NH-B1 114, -NB11 15-C(O)-NB1 116B11 17, -NHS(O2)- B11 18, -NB1 119S(O2)-B1 120, -S-B1121 , -S(O)-B1 122, -0S (0 2 ) -B1103, -NHC (O) -B1 104, -NB1105C (O) -B1 106, -NH-C (O) -O-B1107, -NH-C (O) -NH-B1 108 , -NH-C (O) -NB1109B11 10, -NB111 1-C (O) -O-B1112, -NB11 13-C (O) -NH-B1 114, -NB11 15-C (O) -NB1 116B11 17, -NHS (O 2 ) -B11 18, -NB 1 119S (O 2 ) -B1 120, -S-B1121, -S (O) -B 1 122, -
S(02)-B1123, -S(O2)NH-B1124, -S(O2)NBI 125B1 126, - S(O2)O-B1127, -P(O)(OBI 128)(OB1 129), - Si(B1130)(B1131 )(B1132)"; wobei B1081 , B1082, B1083, B1084, B1085, B1086, B1087, B1088, B1089, B1090, B1091 , B1092, B1093, B1094, B1095,S (0 2) -B1123, -S (O 2) NH-B1124, -S (O 2) NBI 125B1 126, - S (O 2) O-B1127, -P (O) (OBI 128) (OB1 129 Si (B1130) (B1131) (B1132) "; wherein B1081, B1082, B1083, B1084, B1085, B1086, B1087, B1088, B1089, B1090, B1091, B1092, B1093, B1094, B1095,
B1096, B1097, B1098, B1099, B1 100, B1 101 , B1 102, B1 103, B1104, B1105, B1 106, B1 107, B1 108, B1 109, B1 110, B1 11 1 , B1112, B1113, B1 114, B1 115, B1 116, B1 117, B1 118, B1 119, B1120, B1121 , B1 122, B1 123, B1 124, B1 125, B1 126, B1 127, B1128, B1129, B1130, B1 131 , B1 132 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9- C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B1087, B1088 und/oder B1096, B1097 und/oder B1109, B1110 und/oder B1 116, B1 117 und/oder B1 125,B1096, B1097, B1098, B1099, B1100, B1101, B1102, B1103, B1104, B1105, B1106, B1107, B1108, B1109, B1101, B111 1, B1112, B1113, B1 114, B1 115, B1 116, B1 117, B1 118, B1 119, B1120, B1121, B1122, B1123, B1124, B1125, B1126, B1127, B1128, B1129, B1130, B1 131, B1 132 independently of one another are selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and alternatively B1087, B1088 and / or B1096, B1097 and / or B1109, B1110 and / or B1 116, B1 117 and / or B1 125,
B1126 jeweils zusammen auch „heterocyclyl" bilden können;B1126 may together also form "heterocyclyl";
(m) NZ8Z9, wobei Z8, Z9 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C(O)- B1133, -C(O)O-B1 134, -C(O)-NBI 135B1 136, -S(O2J-B 1 137, - S(O2)O-B1138"; wobei B1133, B1134, B1135, B1136, B1137, B1138 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: Wasserstoff, alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B1135, B1 136 zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(m) NZ8Z9, wherein Z8, Z9 are independently selected from the group consisting of: "Hydrogen, alkyl, (C 3 -C 30) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C (O) -B1133, -C (O) O-B1 134, -C (O) -NBI 135b1 136, -S (O 2 JB 1 137, - S (O 2) O-B1138 "; said B1133, B1134, B1135, B1136, B1137, B1138 are independently selected from the group from: hydrogen, alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively B1135, B1 136 together also" heterocyclyl may form "; wherein optionally above Substituents of the substituent group (i) may in turn be substituted independently of one another with at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hete- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,(ii) "alkyl, (C 9 -C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero- rocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I,
CN, CF3, N3, NH2, -NHB1 139, -NB1140B1 141 , -NO2, -OH, - OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B1 142, -C(O)O-B1 143, -C(O)NH- B1144, -C(O)NBI 145B1146, -0-B1 147, -O(-B1148-O)k-H (k = 1 , 2, 3, 4, 5), -O(-B1 149-O)k-B1150 (k = 1 , 2, 3, 4, 5), -OC(O)-CN, CF 3 , N 3 , NH 2 , -NHB 1 139, -NB 1140B 1 141, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -B 1 142, -C (O) O-B1 143, -C (O) NH-B1144, -C (O) NBI 145B1146, -O-B1 147, -O (-B1148-O) k -H (k = 1, 2, 3, 4, 5), -O (- B1 149-O) k -B1150 (k = 1, 2, 3, 4, 5), -OC (O) -
B1151 , -OC(O)-O-B1 152, -OC(O)-NHB1 153, -0-C(O)- NB1154B1155, -OP(O)(OB1156)(OB1 157), - OSi(BI 158)(B1 159)(B1160), -0S(02)-B1161 , -NHC(O)-B1 162, - NB1163C(O)-B1164, -NH-C(O)-O-B1165, -N H-C(O)-N H- B1166, -NH-C(O)-NBI 167B1168, -NB1 169-C(O)-O-B1 170, -B1151, -OC (O) -O-B1 152, -OC (O) -NHB1 153, -O-C (O) -NB1154B1155, -OP (O) (OB1156) (OB1 157), -OSi (BI 158 ) (B1 159) (B1160), -0S (0 2) -B1161, -NHC (O) -B1 162 - NB1163C (O) -B1164, -NH-C (O) -O-B1165, -N HC (O) -NH-B1166, -NH-C (O) -NBl 167B1168, -NB1 169-C (O) -O-B1 170, -
NB1171-C(O)-NH-B1 172, -NB1173-C(O)-NBI 174B1175, - NHS(O2)-B1 176, -NB1177S(O2)-B1178, -S-B1 179, -S(O)- B1180, -S(02)-B1 181 , -S(O2)NH-B1 182, -S(O2)NBI 183B1184, - S(O2)O-B1185, -P(O)(OB1186)(OB1 187), - Si(B1188)(B1189)(B1190)"; wobei B1139, B1140, B1141, B1142, B1143, B1144, B1145, B1146, B1147, B1148, B1149, B1150, B1151, B1152, B1153, B1154, B1155, B1156, B1157, B1158, B1159, B1160, B1161, B1162, B1163, B1164, B1165, B1166, B1167, B1168, B1169, B1170, B1171, B1172, B1173, B1174, B1175, B1176, B1177, B1178, B1179, B1180, B1181, B1182, B1183, B1184, B1185, B1186, B1187, B1188, B1189, B1190 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-NB1171-C (O) -NH-B1 172, -NB1173-C (O) -NBl 174B1175, - NHS (O 2 ) -B1 176, -NB1177S (O 2 ) -B1178, -S-B1 179, -S (O) - B1180, -S (0 2) -B1 181, -S (O 2) NH-B1 182, -S (O 2) NBI 183B1184, - S (O 2) O-B1185, -P (O ) (OB1186) (OB1 187), -Si (B1188) (B1189) (B1190) "; wherein B1139, B1140, B1141, B1142, B1143, B1144, B1145, B1146, B1147, B1148, B1149, B1150, B1151, B1152 , B1153, B1154, B1155, B1156, B1157, B1158, B1159, B1160, B1161, B1162, B1163, B1164, B1165, B1166, B1167, B1168, B1169, B1170, B1171, B1172, B1173, B1174, B1175, B1176, B1177, B1178, B1179, B1180, B1181, B1182, B1183, B1184, B1185, B1186, B1187, B1188, B1189, B1190 are independently selected from the group consisting of : "Alkyl, (C 9 -
5 C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B1145, B1146 und/oder B1 154, B1 155 und/oder B1 167, B1 168 und/oder B1 174, B1 175 und/oder B1 183, B1184 jeweils zusammen auch „heterocyclyl" bilden können;5 C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively B1145, B1146 and / or B1 154, B1 155 and / or B1 167, B1 168 and / or B1 174 B1, B1 and / or B1 183, B1184 may together also form "heterocyclyl";
10 wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:In which optionally substituents of the substituent group (ii) above may be substituted independently with at least one substituent, identical or different, selected from the group consisting of:
(iii) „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he-(iii) "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE
15 terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,15 terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl,
Br, I1 CN1 CF3, N3, NH2, -NHB1191 , -NB1 192B1193, -NO2, - OH, -OCF3, -SH, -0-SO3H, -OP(O)(OH)2, -CHO, -COOH, - C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-B1 194, -C(O)O-B1 195, -C(O)NH-B1196, -C(O)NB1197B1198, -0-B1199, -0(-Br, I 1 CN 1 CF 3 , N 3 , NH 2 , -NHB1191, -NB1 192B1193, -NO 2 , -OH, -OCF 3 , -SH, -O-SO 3 H, -OP (O) (OH ) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -B 1 194, -C (O) O-B1 195 , -C (O) NH-B1196, -C (O) NB1197B1198, -O-B1199, -0 (-
20 B1200-O)1-H (I = 1 , 2, 3, 4, 5), -0(-B 1201-O)1-B 1202 (1 = 1 ,20 B1200-O) 1 -H (I = 1, 2, 3, 4, 5), -O (-B 1201-O) 1 -B 1202 (1 = 1,
2, 3, 4, 5), -OC(O)-BI 203, -OC(O)-O-BI 204, -OC(O)- NHB1205, -O-C(O)-NB1206B1207, - OP(O)(OB1208)(OB1209), -OSi(B1210)(B1211 )(B1212), - OS(O2)-B1213, -NHC(O)-B1214, -NB1215C(O)-B1216, -2, 3, 4, 5), -OC (O) -BI 203, -OC (O) -O-BI 204, -OC (O) -NHB1205, -OC (O) -NB1206B1207, -OP (O) (OB1208) (OB1209), -OSi (B1210) (B1211) (B1212), - OS (O 2) -B1213, -NHC (O) -B1214, -NB1215C (O) -B1216, -
25 NH-C(O)-O-BI 217, -NH-C(O)-NH-BI 218, -NH-C(O)-25 NH-C (O) -O-BI 217, -NH-C (O) -NH-BI 218, -NH-C (O) -
NB1219B1220, -NB1221-C(O)-O-B1222, -NB1223-C(O)- NH-B1224, -NB1225-C(O)-NB1226B1227, -NHS(O2)- B1228, -NB1229S(O2)-B1230, -S-B1231 , -S(O)-B1232, - S(O2)-B1233, -S(O2)NH-B1234, -S(O2)NBI 235B1236, -NB1219B1220, -NB1221-C (O) -O-B1222, -NB1223-C (O) - NH-B1224, -NB1225-C (O) -NB1226B1227, -NHS (O 2) - B1228, -NB1229S (O 2 ) -B1230, -S-B1231, -S (O) -B1232, - S (O 2) -B1233, -S (O 2) NH-B1234, -S (O 2) NBI 235B1236, -
30 S(O2)O-B1237, -P(O)(OB1238)(OB1239), -30 S (O 2 ) O-B 12 37, -P (O) (OB 1238) (OB 1239),
Si(B1240)(B1241 )(B1242)"; wobei B1191, B1192, B1193, B1194, B1195, B1196, B1197, B1198, B1199, B1200, B1201, B1202, B1203, B1204, B1205, B1206, B1207, B1208, B1209, B1210, B1211, B1212, B1213, B1214, B1215, B1216, B1217, B1218, B1219, B1220, B1221 , B1222, B1223, B1224, B1225, B1226, B1227, B1228, B1229, B1230, B1231 , B1232, B1233, B1234, B1235, B1236, B1237, B1238, B1239, B1240, B1241 , B1242 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-Si (B1240) (B1241) (B1242) "; wherein B1191, B1192, B1193, B1194, B1195, B1196, B1197, B1198, B1199, B1200, B1201, B1202, B1203, B1204, B1205, B1206, B1207, B1208, B1209 , B1210, B1211, B1212, B1213, B1214, B1215, B1216, B1217, B1218, B1219, B1220, B1221, B1222, B1223, B1224, B1225, B1226, B1227, B1228, B1229, B1230, B1231, B1232, B1233, B1234, B1235, B1236, B1237, B1238, B1239, B1240, B1241, B1242 are independently selected from the group consisting of: "alkyl, (Cg-
C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ B1197, B1198 und/oder B1206, B1207 und/oder B1219, B1220 und/oder B1226, B1227 und/oder B1235, B1236 jeweils zusammen auch „heterocyclyl" bilden können;C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl "and wherein alternatively B1197, B1198 and / or B1206, B1207 and / or B1219, B1220 and / or B1226, B1227 and / or B1235, B1236 may together also form "heterocyclyl";
undand
Rest Z5 unabhängig ausgewählt ist aus der Gruppe bestehend aus: (i) „Wasserstoff, alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, he- terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHD1 , -ND2D3, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-D4, - C(O)O-D5, -C(O)NH-D6, -C(O)ND7D8, -0-D9, -O(-D10-O)r-H (r = 1 , 2, 3, 4, 5), -0(-D1 1-0HD12 (r = 1 , 2, 3, 4, 5), -OC(O)-DI 3, -OC(O)-O-D14, -Radical Z5 is independently selected from the group consisting of: (i) "hydrogen, alkyl, (Cg-C 3 o), alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, HE terocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3, N 3, NH 2, -NHD1, -ND2D3, -NO 2, -OH, -OCF3, -SH, -0-SO3H, - OP (O) (OH) 2 , -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -D 4 , -C (O) O-D5, -C (O) NH-D6, -C (O) ND7D8, -O-D9, -O (-D10-O) r -H (r = 1, 2, 3, 4, 5), -O (-D1 1 -0HD12 (r = 1, 2, 3, 4, 5), -OC (O) -DI 3, -OC (O) -O-D14, -
OC(O)-NHDI 5, -0-C(O)-NDI 6D17, -OP(O)(ODI 8)(0D19), - OSi(D20)(D21 )(D22), -OS(O2)-D23, -NHC(O)-D24, -ND25C(O)-D26, -NH- C(O)-O-D27, -NH-C(O)-NH-D28, -NH-C(O)-ND29D30, -ND31-C(O)-O- D32, -ND33-C(O)-NH-D34, -ND35-C(O)-ND36D37, -NHS(O2)-D38, - ND39S(O2)-D40, -S-D41 , -S(O)-D42, -S(O2)-D43, -S(O2)NH-D44, -OC (O) -NHDI 5, -0-C (O) -NDI 6D17, -OP (O) (ODI 8) (0D19), - OSi (D20) (D21) (D22), -OS (O 2) -D23, -NHC (O) -D24, -ND25C (O) -D26, -NH-C (O) -O-D27, -NH-C (O) -NH-D28, -NH-C (O) -ND29D30, -ND31-C (O) -O- D32, -ND33-C (O) -NH-D34, -ND35-C (O) -ND36D37, -NHS (O 2) -D38, - ND39S (O 2) -D40, -S-D41, -S (O) -D42, -S (O 2) -D43, -S (O 2) NH-D44 -
S(O2)ND45D46, -S(O2)O-D47, -P(O)(OD48)(OD49), -Si(D50)(D51 )(D52)"; wobei D1 , D2, D3, D4, D5, D6, D7, D8, D9, D10, D1 1 , D12, D13, D14, D15, D16, D17, D18, D19, D20, D21 , D22, D23, D24, D25, D26, D27, D28, D29, D30, D31 , D32, D33, D34, D35, D36, D37, D38, D39, D40, D41 , D42, D43, D44, D45, D46, D47, D48, D49, D50, D51 , D52 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (Cg-C3o)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ D7, D8 und/oder D16, D17 und/oder D29, D30 und/oder D36, D37 und/oder D45, D46 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (i) wiederum unabhängig voneinander substituiert sein können mit mindestens einem Substi- tuenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:S (O 2) ND45D46, -S (O 2) O-D47, -P (O) (OD48) (OD49), -Si (D50) (D51) (D52) "; wherein D1, D2, D3, D4 , D5, D6, D7, D8, D9, D10, D1, D12, D13, D14, D15, D16, D17, D18, D19, D20, D21, D22, D23, D24, D25, D26, D27, D28, D29, D30, D31, D32, D33, D34, D35, D36, D37, D38, D39, D40, D41, D42, D43, D44, D45, D46, D47, D48, D49, D50, D51, D52 independently selected are selected from the group consisting of: "alkyl, (Cg-C 3 o) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively D7, D8 and / or D16, D17 and / or D29, D30 and / or D36, D37 and / or D45, D46 may in each case also form "heterocyclyl", where optionally substituted substituents of substituent group (i) may in turn be substituted independently of one another by at least one substituent, identical or different, selected from the group consisting of:
(ii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycly- lalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHD53, -ND54D55, -NO2, -OH, -OCF3, -SH, -0-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)- D56, -C(O)O-D57, -C(O)NH-D58, -C(O)ND59D60, -0-D61 , -O(-D62-(ii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3 , NH 2, -NHD53, -ND54D55, -NO 2, -OH, -OCF3, -SH, -0-SO3H, - OP (O) (OH) 2, -CHO, -COOH, -C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -D56, -C (O) O-D57, -C (O) NH-D58, -C (O) ND59D60 , -0-D61, -O (-D62-
O)5-H (s = 1 , 2, 3, 4, 5), -O(-D63-O)t-D64 (t = 1 , 2, 3, 4, 5), -OC(O)- D65, -OC(O)-O-D66, -OC(O)-NHD67, -O-C(O)-ND68D69, - OP(O)(OD70)(OD71 ), -OSi(D72)(D73)(D74), -OS(O2)-D75, -NHC(O)- D76, -ND77C(O)-D78, -NH-C(O)-O-D79, -N H-C(O)-N H-D80, -NH- C(0)-ND81 D82, -ND83-C(O)-O-D84, -ND85-C(O)-NH-D86, -ND87-O) 5 -H (s = 1, 2, 3, 4, 5), -O (-D63-O) t -D64 (t = 1, 2, 3, 4, 5), -OC (O) - D65, -OC (O) -O-D66, -OC (O) -NHD67, -OC (O) -ND68D69, -OP (O) (OD70) (OD71), -OSi (D72) (D73) (D74 ), -OS (O 2 ) -D75, -NHC (O) -D76, -ND77C (O) -D78, -NH-C (O) -O-D79, -NHC (O) -NH-D80 , -NH-C (O) -ND81 D82, -ND83-C (O) -O-D84, -ND85-C (O) -NH-D86, -ND87-
C(O)-ND88D89, -NHS(O2)-D90, -ND91S(O2)-D92, -S-D93, -S(O)- D94, -S(O2)-D95, -S(O2)NH-D96, -S(O2)ND97D98, -S(O2)O-D99, - P(O)(OD100)(OD101 ), -Si(DI 02)(D103)(D104)"; wobei D53, D54, D55, D56, D57, D58, D59, D60, D61 , D62, D63, D64, D65, D66, D67, D68, D69, D70, D71 , D72, D73, D74, D75, D76, D77,C (O) -ND88D89, -NHS (O 2) -D90, -ND91S (O 2) -D92, -S-D93, -S (O) - D94, -S (O 2) -D95, -S ( O 2) NH-D96, -S (O 2) ND97D98, -S (O 2) O-D99, - P (O) (OD100) (OD101), -Si (DI 02) (D103) (D104) " D53, D54, D55, D56, D57, D58, D59, D60, D61, D62, D63, D64, D65, D66, D67, D68, D69, D70, D71, D72, D73, D74, D75, D76, D77,
D78, D79, D80, D81 , D82, D83, D84, D85, D86, D87, D88, D89, D90, D91 , D92, D93, D94, D95, D96, D97, D98, D99, D100, D101 , D102, D103, D104 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyc- IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" und wobei alternativ D59, D60 und/oder D68, D69 und/oder D81 , D82 und/oder D88, D89 und/oder D97, D98 jeweils zusammen auch „heterocyclyl" bilden können; wobei optional obige Substituenten der Substituentengruppe (ii) wiederum unabhängig voneinander substituiert sein können mit mindestens einemD78, D79, D80, D81, D82, D83, D84, D85, D86, D87, D88, D89, D90, D91, D92, D93, D94, D95, D96, D97, D98, D99, D100, D101, D102, D103, D104 are independently selected from the group consisting of: "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyc IyI, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively D59, D60 and or D68, D69 and / or D81, D82 and / or D88, D89 and / or D97, D98 may together also form "heterocyclyl"; optionally substituents of the substituent group (ii) above may be substituted independently with at least one
Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:Substituents, the same or different, selected from the group consisting of:
(iii) „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF3, N3, NH2, -NHD105, -ND106D107, -NO2, -OH, -OCF3, -SH, -O- SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-DI 08, -C(O)O-DI 09, -C(O)NH-D1 10, -C(O)NDI 1 1 D112, - 0-D1 13, -0(-D1 14-O)1-H (t = 1 , 2, 3, 4, 5), -0(-D1 15-0)t-D1 16 (t = 1 , 2, 3, 4, 5), -OC(O)-D117, -OC(O)-O-D118, -OC(O)-NHD119, -(iii) "alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF 3 , N 3, NH 2, -NHD105, -ND106D107, -NO 2, -OH, -OCF3, -SH, -O- SO3H, -OP (O) (OH) 2, -CHO, -COOH, - C (O) NH 2 , -SO 3 H, -P (O) (OH) 2 , -C (O) -DI 08, -C (O) O-DI 09, -C (O) NH-D1 10 , -C (O) NDI 1 1 D112, -O-D1 13, -O (-D1 14-O) 1 -H (t = 1, 2, 3, 4, 5), -O (-D1 15- 0) t -D1 16 (t = 1, 2, 3, 4, 5), -OC (O) -D117, -OC (O) -O-D118, -OC (O) -NHD119, -
O-C(O)-ND120D121 , -OP(O)(OD122)(OD123), - OSi(D124)(D125)(D126), -OS(O2)-D127, -NHC(O)-D128, - ND129C(O)-DI 30, -NH-C(O)-O-DI 31 , -NH-C(O)-NH-DI 32, -NH- C(O)-NDI 33D134, -ND135-C(O)-O-DI 36, -N D 137-C(O)-N H- D138, -ND139-C(O)-ND140D141 , -NHS(O2)-D142, -ND143S(O2)-OC (O) -ND120D121, -OP (O) (OD122) (OD123), - OSi (D124) (D125) (D126), -OS (O 2) -D127, -NHC (O) -D128, - ND129C (O) -DI 30, -NH-C (O) -O-DI 31, -NH-C (O) -NH-DI 32, -NH-C (O) -NDI 33D134, -ND135-C (O ) -O-DI 36, 137 ND-C (O) -N H- D138, -ND139-C (O) -ND140D141, -NHS (O 2) -D142, -ND143S (O 2) -
D144, -S-D145, -S(O)-D146, -S(O2)-D147, -S(O2)NH-D148, - S(O2)ND149D150, -S(O2)O-DI 51 , -P(O)(ODI 52)(OD153), - Si(D154)(D155)(D156)"; wobei D105, D106, D107, D108, D109, D1 10, D1 11 , D1 12, D1 13, D1 14, D115, D116, D117, D118, D119, D120, D121 , D122, D123,D144, -S-D145, -S (O) -D146, -S (O 2) -D147, -S (O 2) NH-D148, - S (O 2) ND149D150, -S (O 2) O- DI 51, -P (O) (ODI 52) (OD153), -Si (D154) (D155) (D156) ", where D105, D106, D107, D108, D109, D1 10, D1 11, D1 12, D1 13, D1 14, D115, D116, D117, D118, D119, D120, D121, D122, D123,
D124, D125, D126, D127, D128, D129, D130, D131 , D132, D133, D134, D135, D136, D137, D138, D139, D140, D141 , D142, D143, D144, D145, D146, D147, D148, D149, D150, D151 , D152, D153, D154, D155, D156 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus: „alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylal- kyl" und wobei alternativ D1 11 , D1 12 und/oder D120, D121 und/oder D133, D134 und/oder D140, D141 und/oder D149, D150 jeweils zusammen auch „heterocyclyl" bilden können.D124, D125, D126, D127, D128, D129, D130, D131, D132, D133, D134, D135, D136, D137, D138, D139, D140, D141, D142, D143, D144, D145, D146, D147, D148, D149, D150, D151, D152, D153, D154, D155, D156 are independently selected from the group consisting of: alkyl, (C 9 -C 30 ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl "heteroarylalkyl" and in which case alternatively D1 11, D1 12 and / or D120, D121 and / or D133, D134 and / or D140, D141 and / or D149, D150 may together also form "heterocyclyl".
2. Neue Pyrido[2,3-b]pyrazin-Derivate gemäß der allgemeinen Formel (I) gemäß Anspruch 1 , wobei gemäß (A) der Rest Z1 unabhängig „NZ14Z15" ist; wobei Z14 Wasserstoff oder „aryl" ist und Z15 ,,-C(O)N H-alkyl" ist; wobei ,,-C(O)NH-alkyl" zusätzlich optional substituiert sein kann mit ,,-OH"; der Rest Z2 unabhängig Wasserstoff ist; der Rest Z3 unabhängig „substituiertes Aryl" ist, wobei „substituiertes Aryl" substituiert ist mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:2. Novel pyrido [2,3-b] pyrazine derivatives according to the general formula (I) according to claim 1, wherein according to (A) the radical Z1 is independently "NZ14Z15" wherein Z14 is hydrogen or "aryl" and Z15, "--C (O) NH-alkyl" wherein "--C (O) NH-alkyl" may additionally be optionally substituted with "--OH"; the radical Z2 is independently hydrogen; the radical Z3 is independently "substituted aryl", where "substituted aryl" is substituted by at least one substituent, identical or different, selected from the group consisting of:
(a) „alkyl, -OC(O)-alkyl, -O-alkyl, -NHC(O)-alkyl"; mit der Maßgabe, dass obige Substituenten der Substituentengruppe (a) unabhängig voneinander weiter substituiert sind mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(a) "alkyl, -OC (O) -alkyl, -O-alkyl, -NHC (O) -alkyl"; with the proviso that the above substituents of the substituent group (a) are independently further substituted with at least one substituent, the same or different, selected from the group consisting of:
(i) „aryl, heterocyclyl, -O-alkyl-O-alkyl, -O-arylalkyl"; oder der Rest Z3 unabhängig „substituiertes Aryl" ist, wobei „substituiertes Aryl" substituiert ist mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(i) "aryl, heterocyclyl, -O-alkyl-O-alkyl, -O-arylalkyl" or the radical Z3 is independently "substituted aryl", where "substituted aryl" is substituted by at least one substituent, identical or different, selected from the group consisting of:
(b) ,,-OC(O)-O-alkyl,-OC(O)-O-aryl, -OC(O)-N(alkyl)2, -OC(O)-NH-alkyl, - OC(O)-(C9-C30)alkyl, -NHC(O)-O-alkyl, -N HC(O)-N H-alkyl, -NHC(O)- N(alkyl)2, -Si(alkyl)3"; wobei optional obige Substituenten der Substituentengruppe (c) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(b), - OC (O) -O-alkyl, -OC (O) -O-aryl, -OC (O) -N (alkyl) 2 , -OC (O) -NH-alkyl, - OC ( O) - (C 9 -C 30 ) alkyl, -NHC (O) -O-alkyl, -NHC (O) -NH-alkyl, -NHC (O) - N (alkyl) 2 , -Si (alkyl 3 ), optionally optionally substituted substituents of the substituent group (c) being in turn independently substituted with at least one substituent, identical or different, selected from the group consisting of:
(i) ,,-O-alkyl, -O-arylalkyl"; wobei optional der Rest Z3 unabhängig auch weiter substituiert sein kann mit min- destens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(i) "-O-alkyl, -O-arylalkyl"; optionally wherein the radical Z3 can also be independently further substituted by at least one substituent, identical or different, selected from the group consisting of:
(i) „halogen, F, Cl, Br, I, -O-alkyl"; der Rest Z4 unabhängig Wasserstoff ist; der Rest Z5 unabhängig Wasserstoff ist.(i) "halo, F, Cl, Br, I, -O-alkyl"; the radical Z4 is independently hydrogen; the radical Z5 is independently hydrogen.
3. Neue Pyrido[2,3-b]pyrazin-Derivate gemäß der allgemeinen Formel (I) gemäß einem der Ansprüche 1 , 2, wobei gemäß (A) der Rest Z1 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus ,,-NHC(O)NH-ethyl, -NHC(O)NH-butyl-OH"; der Rest Z2 unabhängig Wasserstoff ist; der Rest Z3 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus „Kohlensäure-4-phenyl-ester-methyl-ester, Kohlensäure-3-phenyl-ester-2- methoxy-ethyl-ester, Kohlensäure-4-phenyl-ester-2-methoxy-ethyl-ester, Kohlen- säure-4-phenyl-ester-phenyl-ester, N-Diethyl-Carbaminsäure-4-phenyl-ester, 3- phenyl-acrylsäure-4-phenyl-ester, Nonadekansäure-4-phenyl-ester, Kohlensäure-4- phenyl-ester-isobutyl-ester, Kohlensäure-4-phenyl-ester-but-2-inyl-ester, N- Dimethyl-Carbaminsäure-4-phenyl-ester, N-Ethyl-Carbaminsäure-4-phenyl-ester, N-(4-Phenyl)-Carbaminsäure-tert-butyl-ester, N-(4-Phenyl)-Carbaminsäure-2- methoxy-ethyl-ester, 4-(3-ethyl-harnstoff)phenyl, 4-(3,3-methyl-harnstoff)phenyl, 4- morpholin-4-ylmethyl-phenyl, 4-[2-(2-methoxy-ethoxy)-ethoxy]-phenyl, N-(4-3. New pyrido [2,3-b] pyrazine derivatives according to the general formula (I) according to one of claims 1, 2, wherein according to (A) the radical Z1 is independently selected from the group consisting of - NHC (O) NH-ethyl, -NHC (O) NH-butyl-OH "; the radical Z2 is independently hydrogen; the radical Z3 is independently selected from the group consisting of "carbonic acid 4-phenyl-ester-methyl-ester, 3-phenyl-2-methoxy-carbonic acid, carbonic acid 4-phenyl-2-ester methoxyethyl ester, 4-phenyl-4-phenylcarboxylate, 4-phenyl N-diethylcarbamate, 4-phenylphenyl 3-phenylacetate, 4-nonadaptanic acid 4-phenyl ester-2-ynyl ester, N-dimethyl-4-carbamate carbamate, N-ethyl-carbamic acid-4-ester phenyl ester, N- (4-phenyl) carbamic acid tert-butyl ester, N- (4-phenyl) carbamic acid 2-methoxyethyl ester, 4- (3-ethylurea) phenyl, 4- (3,3-methyl-urea) -phenyl, 4-morpholin-4-ylmethyl-phenyl, 4- [2- (2-methoxy-ethoxy) -ethoxy] -phenyl, N- (4-
Phenyl)-2-(2-methoxy-ethoxy)-acetamid, Kohlensäure-4-(2-methoxy)phenyl-ester- 2-methoxy-ethyl-ester, Kohlensäure-4-phenyl-ester-2-benzyloxy-ethyl-ester, Koh- lensäure-4-(2-methoxy)phenyl-ester-2-benzyloxy-ethyl-ester, N-(4-phenyl)-2- benzyloxy-acetamid, 3-trimethylsilanyl-phenyl, N-Diethyl-Carbaminsäure-4-(2- methoxy)phenyl-ester, N-Diethyl-Carbaminsäure-4-(2-chloro-6-methoxy)-phenyl es- ter, Kohlensäure 4-(2-methoxy)-phenyl-ester-2-[2-(2-methoxy-ethoxy)-ethoxy]-ethyl ester"; der Rest Z4 unabhängig Wasserstoff ist; der Rest Z5 unabhängig Wasserstoff ist.Phenyl) -2- (2-methoxy-ethoxy) -acetamide, 4- (2-methoxy) -phenyl-2-methoxyacetate, carbonic acid 4-phenyl-ester-2-benzyloxy-ethyl- esters, 2,4- (2-methoxy) phenyl chloroethyl 2-benzyloxyethyl ester, N- (4-phenyl) -2-benzyloxy-acetamide, 3-trimethylsilanyl-phenyl, N-diethyl-carbamic acid -4- (2-methoxy) phenyl ester, N-diethyl-carbamic acid 4- (2-chloro-6-methoxy) -phenyl ether, carbonic acid 4- (2-methoxy) -phenyl-ester-2- [2- (2-methoxy-ethoxy) -ethoxy] -ethyl ester "; the radical Z4 is independently hydrogen; the radical Z5 is independently hydrogen.
4. Neue Pyrido[2,3-b]pyrazin-Derivate gemäß der allgemeinen Formel (I) gemäß Anspruch 1 , wobei gemäß (B) der Rest Z1 unabhängig „NZ14Z15" ist; wobei Z14 Wasserstoff ist und Z15 „- C(O)NH-alkyl" ist; der Rest Z2 unabhängig Wasserstoff ist; der Rest Z3 unabhängig „substituiertes Heteroaryl" ist, wobei „substituiertes Hete- roaryl" substituiert ist mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:4. Novel pyrido [2,3-b] pyrazine derivatives according to the general formula (I) according to claim 1, wherein according to (B) the radical Z1 is independently "NZ14Z15" wherein Z14 is hydrogen and Z15 "- C (O ) NH-alkyl "; the radical Z 2 is independently hydrogen; the radical Z3 is independently "substituted heteroaryl", where "substituted heteroaryl" is substituted by at least one substituent, identical or different, selected from the group consisting of:
(a) ,,-NHC(O)-NH-alkyl"; der Rest Z4 unabhängig Wasserstoff ist; der Rest Z5 unabhängig Wasserstoff ist. (a) "- NHC (O) -NH-alkyl"; the radical Z4 is independently hydrogen; the radical Z5 is independently hydrogen.
5. Neue Pyrido[2,3-b]pyrazin-Derivate gemäß der allgemeinen Formel (I) gemäß einem der Ansprüche 1 , 4, wobei gemäß (B) der Rest Z1 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus ,,-NHC(O)NH-ethyl"; der Rest Z2 unabhängig Wasserstoff ist; der Rest Z3 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus „6-(3-ethyl-harnstoff)-pyridin-3-yl"; der Rest Z4 unabhängig Wasserstoff ist; der Rest Z5 unabhängig Wasserstoff ist.5. New pyrido [2,3-b] pyrazine derivatives according to the general formula (I) according to one of claims 1, 4, wherein according to (B) the radical Z1 is independently selected from the group consisting of - NHC (O) NH-ethyl "; the radical Z 2 is independently hydrogen; the radical Z 3 is independently selected from the group consisting of" 6- (3-ethyl-urea) -pyridin-3-yl "; the radical Z4 is independently hydrogen; the rest Z5 is independently hydrogen.
6. Neue Pyrido[2,3-b]pyrazin-Derivate gemäß der allgemeinen Formel (I) gemäß Anspruch 1 , wobei gemäß (C) der Rest Z1 unabhängig „NZ14Z15" ist; wobei Z14 Wasserstoff ist und Z15 „- C(O)NH-alkyl" ist; der Rest Z2 unabhängig Wasserstoff ist; der Rest Z3 unabhängig „substituiertes Alkyl" ist, wobei „substituiertes Alkyl" substituiert ist mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:6. A novel pyrido [2,3-b] pyrazine derivative according to the general formula (I) according to claim 1, wherein according to (C) the radical Z1 is independently "NZ14Z15", wherein Z14 is hydrogen and Z15 "- C (O ) NH-alkyl "; the radical Z 2 is independently hydrogen; the radical Z3 is independently "substituted alkyl", where "substituted alkyl" is substituted by at least one substituent, identical or different, selected from the group consisting of:
(a) „aryl, heteroaryl, cycloalkyl, -N(alkyl)2, -O-alkyl"; wobei optional obige Substituenten der Substituentengruppe (a) unabhängig voneinander wiederum substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(a) "aryl, heteroaryl, cycloalkyl, -N (alkyl) 2 , -O-alkyl"; wherein optional substituents of substituent group (a) may be independently substituted with at least one substituent, same or different, selected from among Group consisting of:
(i) „halogen, F, Cl, Br, I"; der Rest Z4 unabhängig Wasserstoff ist; der Rest Z5 unabhängig Wasserstoff ist.(i) "halo, F, Cl, Br, I"; the radical Z4 is independently hydrogen; the radical Z5 is independently hydrogen.
7. Neue Pyrido[2,3-b]pyrazin-Derivate gemäß der allgemeinen Formel (I) gemäß einem der Ansprüche 1 , 6, wobei gemäß (C) der Rest Z1 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus ,,-NHC(O)NH-ethyl"; der Rest Z2 unabhängig Wasserstoff ist; der Rest Z3 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus „phenyl-ethinyl, thiophen-3-yl-ethinyl, cyclopropyl-ethinyl, N-Dimethyl-amino- prop-1-inyl, 2-Cyclohexyl-vinyl, 3-methoxy-propenyl, benzyl, 2-(4-fluoro-phenyl)- ethyl, 2-(4-fluoro-phenyl)-vinyl"; der Rest Z4 unabhängig Wasserstoff ist; der Rest Z5 unabhängig Wasserstoff ist.7. New pyrido [2,3-b] pyrazine derivatives according to the general formula (I) according to any one of claims 1, 6, wherein according to (C) the radical Z1 is independently selected from the group consisting of - NHC (O) NH-ethyl "; the radical Z 2 is independently hydrogen; the radical Z3 is independently selected from the group consisting of "phenyl-ethynyl, thiophen-3-yl-ethynyl, cyclopropyl-ethynyl, N-dimethyl-amino-prop-1-ynyl, 2-cyclohexyl-vinyl, 3-methoxy -propenyl, benzyl, 2- (4-fluoro-phenyl) -ethyl, 2- (4-fluoro-phenyl) -vinyl "; the radical Z4 is independently hydrogen; the radical Z5 is independently hydrogen.
8. Neue Pyrido[2,3-b]pyrazin-Derivate gemäß der allgemeinen Formel (I) gemäß An- spruch 1 , wobei gemäß (D) der Rest Z1 unabhängig „NZ14Z15" ist; wobei Z14 Wasserstoff ist und Z15 „- C(O)NH-alkyl" ist; der Rest Z2 unabhängig Wasserstoff ist; der Rest Z3 unabhängig ausgewählt aus der Gruppe bestehend aus: (1 ) „-NZ10Z1 1"; wobei die Reste Z10, Z11 unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus:8. Novel pyrido [2,3-b] pyrazine derivatives according to the general formula (I) according to claim 1, wherein according to (D) the radical Z1 is independently "NZ14Z15" wherein Z14 is hydrogen and Z15 "- C (O) NH-alkyl "; the radical Z 2 is independently hydrogen; the radical Z3 is independently selected from the group consisting of: (1) "-NZ10Z1 1", where the radicals Z10, Z11 are selected independently of one another from the group consisting of:
(a) „Wasserstoff, aryl"; mit der Maßgabe, dass obige Substituenten der Substituentengruppe (a), wenn nicht Wasserstoff, unabhängig voneinander weiter substituiert sind mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(a) "hydrogen, aryl"; with the proviso that the above substituents of substituent group (a), if not hydrogen, are independently further substituted with at least one substituent, same or different, selected from the group consisting of:
(i) „cycloalkyl, heteroaryl, heterocyclylalkyl, -S(O)2-alkyl, -NH-S(O)2-alkyl, -C(O)NH-alkyl, -NH-C(O)-alkyl, -C(O)O-alkyl"; (b) ,,-C(O)-aryl"; wobei optional obige Substituenten der Substituentengruppe (a) und/oder Substituentengruppe (b) unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (i) „alkyl"; der Rest Z4 unabhängig Wasserstoff ist; der Rest Z5 unabhängig Wasserstoff ist.(i) "cycloalkyl, heteroaryl, heterocyclylalkyl, -S (O) 2 -alkyl, -NH-S (O) 2 -alkyl, -C (O) NH-alkyl, -NH-C (O) -alkyl, - C (O) O-alkyl "; (b) ,, -C (O) -aryl"; wherein optionally above substituents of the substituent group (a) and / or substituent group (b) may be independently substituted with at least one substituent, same or different, selected from the group consisting of: (i) "alkyl"; the radical Z4 is independently hydrogen; the rest Z5 is independently hydrogen.
9. Neue Pyrido[2,3-b]pyrazin-Derivate gemäß der allgemeinen Formel (I) gemäß ei- nem der Ansprüche 1 , 8, wobei gemäß (D) der Rest Z1 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus ,,-NHC(O)NH-ethyl"; der Rest Z2 unabhängig Wasserstoff ist; der Rest Z3 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus „4-methyl-benzamid, 4-cyclohexyl-phenyl-amino, 4-methansulfonyl-phenyl- amino, 3-(N-methansulfonamid)-4-methyl-phenyl-amino, 3-N-methyl-benzamid- amino, 4-piperidin-1-ylmethyl-phenyl-amino, 4-thiophen-3-ylphenyl-amino, 4-N- acetamido-phenyl-amino, 3-Benzoesäure-ethyl-ester-amino"; der Rest Z4 unabhängig Wasserstoff ist; der Rest Z5 unabhängig Wasserstoff ist.9. Novel pyrido [2,3-b] pyrazine derivatives according to the general formula (I) according to one of claims 1, 8, wherein according to (D) the radical Z1 is independently selected from the group consisting of -NHC (O) NH-ethyl ", the radical Z 2 is independently hydrogen, the radical Z 3 is independently selected from the group consisting of" 4-methyl-benzamide, 4-cyclohexyl-phenyl-amino, 4-methanesulfonyl-phenyl- amino, 3- (N-methanesulfonamide) -4-methyl-phenyl-amino, 3-N-methyl-benzamido-amino, 4-piperidin-1-ylmethyl-phenyl-amino, 4-thiophen-3-yl-phenyl-amino, 4-N-acetamido-phenyl-amino, 3-benzoic acid ethyl ester-amino "; the radical Z4 is independently hydrogen; the rest Z5 is independently hydrogen.
10. Neue Pyrido[2,3-b]pyrazin-Derivate gemäß der allgemeinen Formel (I) gemäß Anspruch 1 , wobei gemäß (E) der Rest Z1 unabhängig ausgewählt ist aus der Gruppe bestehend aus: (a) „NZ24Z25"; wobei Z24 Wasserstoff ist und Z25 ,,-C(O)-C(O)-O-alkyl" oder „-10. Novel pyrido [2,3-b] pyrazine derivatives according to the general formula (I) according to claim 1, wherein according to (E) the radical Z1 is independently selected from the group consisting of: (a) "NZ24Z25"; Z24 is hydrogen and Z25 is --C (O) -C (O) -O-alkyl "or" -
C(O)-C(O)-N H-alkyl" oder ,,-C(O)-N H-O-alkyl" ist; wobei optional obige Substituenten der Substituentengruppe (a) unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus: (i) ,,-OSi(alkyl)3, -OC(O)-N H-alkyl, -OC(O)-O-alkyl, -P(O)(O-alkyl)2, -C is (O) -C (O) -NH-alkyl "or" -C (O) -NH-O-C ""; wherein optionally substituted substituents of the substituent group (a) may be independently substituted with at least one substituent, same or different, selected from the group consisting of: (i), - OSi (alkyl) 3 , -OC (O) -NH -alkyl, -OC (O) -O-alkyl, -P (O) (O-alkyl) 2 , -
P(O)(OH)2, -O-alkyl"; wobei optional obige Substituenten der Substituentengruppe (i) unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe beste- hend aus: (ii) „heterocyclyl, OH, -N(alkyl)2, -OC(O)-alkyl"; wobei optional obige Substituenten der Substituentengruppe (ii) unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:P (O) (OH) 2 , -O-alkyl "; optionally substituted substituents of the substituent group (i) may be further independently substituted with at least one substituent, same or different, selected from the group consisting of: (ii) "heterocyclyl, OH, -N (alkyl) 2 , -OC (O) -alkyl" wherein optional substituents of the substituent group (ii) may be independently further substituted with at least one substituent, the same or different from the group consisting of:
(iii) „alkyl"; (b) „NZ26Z27"; wobei Z26 Wasserstoff ist und Z27 ,,-C(O)-N H-alkyl" ist; mit der Maßgabe, dass obige Substituenten der Substituentengruppe (b) unabhängig voneinander weiter substituiert sind mit mindestens einem Substituen- ten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(iii) "alkyl"; (b) "NZ26Z27"; wherein Z26 is hydrogen and Z27 is --C (O) -NH-alkyl "; provided that the above substituents of the substituent group (b) are independently further substituted with at least one substituent, the same or different from the group consisting of:
(i) ,,-OSi(alkyl)3, -OC(O)-N H-alkyl, -OC(O)-O-alkyl, -P(O)(O-alkyl)2, - P(O)(OH)2, -O-alkyl"; wobei optional obige Substituenten der Substituentengruppe (i) unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(i), - OSi (alkyl) 3 , -OC (O) -NH-alkyl, -OC (O) -O-alkyl, -P (O) (O-alkyl) 2 , - P (O) (OH) 2 , -O-alkyl "; wherein optionally substituted substituents of the substituent group (i) may be independently further substituted with at least one substituent, same or different, selected from the group consisting of:
(ii) „heterocyclyl, OH, -N(alkyl)2, -OC(O)-alkyl"; wobei optional obige Substituenten der Substituentengruppe (ii) unabhängig voneinander auch weiter substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der(ii) "heterocyclyl, OH, -N (alkyl) 2 , -OC (O) -alkyl" wherein optional substituents of the substituent group (ii) may be independently further substituted with at least one substituent, the same or different from the
Gruppe bestehend aus:Group consisting of:
(iii) „alkyl"; der Rest Z2 unabhängig Wasserstoff ist; der Rest Z3 unabhängig ausgewählt aus der Gruppe bestehend aus: (a) „aryl"; wobei optional obige Substituenten der Substituentengruppe (a) unabhängig voneinander substituiert sein können mit mindestens einem Substituenten, gleich oder verschieden, ausgewählt aus der Gruppe bestehend aus:(iii) "alkyl"; the radical Z2 is independently hydrogen; the radical Z3 is independently selected from the group consisting of: (a) "aryl"; wherein optionally above substituents of the substituent group (a) may be independently substituted with at least one substituent, same or different, selected from the group consisting of:
(i) ,,-O-alkyl, OH"; der Rest Z4 unabhängig Wasserstoff ist; der Rest Z5 unabhängig Wasserstoff ist.(i) ,, - O-alkyl, OH "; the radical Z4 is independently hydrogen; the rest Z5 is independently hydrogen.
11. Neue Pyrido[2,3-b]pyrazin-Derivate gemäß der allgemeinen Formel (I) gemäß einem der Ansprüche 1 , 10, wobei gemäß (E) der Rest Z1 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus „3-methoxy-1-yl-Harnstoff, 3-(prop-1-in-3-yl)-1-yl-Harnstoff, 3-[4-(tert-Butyl- dimethyl-silanyloxy)-butyl]-1 -yl-Harnstoff, 4-(Carbaminsäure-N-ethyl-ester)-butyl-1 - yl-Harnstoff, 4-(Kohlensäure-methyl-ester)-butyl-1 -yl-Harnstoff, 4-(Kohlensäure-2,3- dihydroxy-propyl-ester)-butyl-1 -yl-Harnstoff, 4-(Kohlensäure-2,2-dimethyl- [1 ,3]dioxolan-4ylmethyl-ester)-butyl-1 -yl-Harnstoff, 4-(Phosphorsäure-diethyl-ester)- butyl-1 -yl-Harnstoff, 4-Phosphorsäure-butyl-1 -yl-Harnstoff, N-Oxalsäure-monoamid- ethyl-ester, N-Ethyl-N'-Oxalsäure-amid, 2-(Phosphorsäure-diethyl-ester)-ethyl-1 -yl- Harnstoff, 2-Phosphorsäure-ethyl-1 -yl-Harnstoff, 3-(2-diethylamino-ethoxy)-propyl- 1 -yl-Harnstoff, 4-[2,2-Dimethyl-Propansäure-(2,2-Dimethyl-Propionyloxy-methoxy)- phospinoyloxymethyl-ester]-butyl-1 -yl-Harnstoff, 4-[Essigsäure-1-(1-acetoxy- ethoxy)-ethoxy-phospinoyloxy]-butyl-1 -yl-Harnstoff"; der Rest Z2 unabhängig Wasserstoff ist; der Rest Z3 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus „phenyl, 4-hydroxy-3-methoxy-phenyl"; der Rest Z4 unabhängig Wasserstoff ist; der Rest Z5 unabhängig Wasserstoff ist.11. New pyrido [2,3-b] pyrazine derivatives according to the general formula (I) according to one of claims 1, 10, wherein according to (E) the radical Z1 is independently selected from the group consisting of "3-methoxy 1-yl urea, 3- (prop-1-yn-3-yl) -1-yl urea, 3- [4- (tert -butyl-dimethyl-silanyloxy) -butyl] -1-yl-urea , 4- (Carbamic acid-N-ethyl-ester) -butyl-1-yl-urea, 4- (carbonic acid-methyl-ester) -butyl-1-yl-urea, 4- (carbonic acid-2,3-dihydroxy-) propyl-ester) -butyl-1-yl-urea, 4- (carbonic acid-2,2-dimethyl- [1,3] dioxolan-4-ylmethyl-ester) -butyl-1-yl-urea, 4- (phosphoric acid-diethyl -ester) - butyl-1-yl-urea, 4-phosphoric-butyl-1-yl-urea, N-oxalic acid mono-amide-ethyl-ester, N-ethyl-N'-oxalic acid-amide, 2- (phosphoric acid) diethyl ester) -ethyl-1-yl-urea, 2-phosphoric acid-ethyl-1-yl-urea, 3- (2-diethylamino-ethoxy) -propyl-1-yl-urea, 4- [2.2- Dimethylpropanoic acid (2,2-dimethyl-propionyloxy-methoxy) -phosphinosinoxymethyl ester ] -butyl-1-yl-urea, 4- [acetic acid-1- (1-acetoxy-ethoxy) -ethoxy-phosphinoyloxy] -butyl-1-yl-urea "; the radical Z 2 is independently hydrogen; the radical Z3 is independently selected from the group consisting of "phenyl, 4-hydroxy-3-methoxy-phenyl"; the radical Z4 is independently hydrogen; the radical Z5 is independently hydrogen.
12. Neue Pyrido[2,3-b]pyrazin-Derivate gemäß der allgemeinen Formel (II)12. New pyrido [2,3-b] pyrazine derivatives according to the general formula (II)
worin die Substituenten R1-R4 folgende Bedeutung haben: R1 und R2 können unabhängig voneinander Wasserstoff oder NR5R6 bedeuten, unter der Voraussetzung, dass, wenn R1 = NR5R6 ist, R2 = H ist, und wenn R2 = NR5R6 ist, R1 = H ist, wobei R5 Wasserstoff, Alkyl, R38, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl- Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl- Heteroaryl sein kann und diein which the substituents R 1 -R 4 have the following meanings: R1 and R2 may be independently hydrogen or NR5R6, provided that when R1 = NR5R6, R2 = H, and when R2 = NR5R6, R1 = H, where R5 is hydrogen, alkyl, R38, cycloalkyl, Heterocyclyl, aryl, heteroaryl, alkyl cycloalkyl, alkyl heterocyclyl, alkyl aryl or alkyl heteroaryl may be and the
Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl- und Heteroaryl-, Alkyl-Cycloalkyl, Alkyl- Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroarylsubstituenten ihrerseits wiederum mit F, Cl, Br, I, CN, CF3, NH2, NH-Alkyl, NH-Aryl, N(Alkyl)2, NO2, SH, S-Alkyl, OH, OCF3, O(-Alkyl-O)p-Alkyl, O-Aryl, OSO3H, OP(O)(OH)2, OP(O)(OAIkyl)2, OP(O)(OAryl)2 ,CHO, C(O)OH, C(O)OR12, C(O)NH2, C(O)NHR12, C(O)NR12R13,Alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, alkyl cycloalkyl, alkyl heterocyclyl, alkyl aryl or alkyl heteroaryl substituents in turn with F, Cl, Br, I, CN, CF 3 , NH 2 , NH Alkyl, NH-aryl, N (alkyl) 2 , NO 2 , SH, S-alkyl, OH, OCF 3 , O (-alkyl-O) p- alkyl, O-aryl, OSO 3 H, OP (O) (OH) 2, OP (O) (OAIkyl) 2, OP (O) (O-aryl) 2, CHO, C (O) OH, C (O) OR12, C (O) NH 2, C (O) NHR12, C (O) NR12R13,
SO3H, SO2Alkyl, SO2Aryl, P(O)(OH)2, P(O)(OAIkyl)2, P(O)(OAryl)2, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl ein- oder mehrfach, gleich oder verschieden substituiert sein können, p den Wert O, 1 , 2, 3, 4 oder 5 annehmen kann und die Reste R12 und R13 unabhängig voneinander Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl- Heteroaryl sein können oder R12 und R13 zusammen einen Heterocyclyl-Ring bilden könnenSO 3 H, SO 2 alkyl, SO 2 aryl, P (O) (OH) 2 , P (O) (OAlkyl) 2 , P (O) (O-aryl) 2 , alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or polysubstituted by identical or different substituents, p can assume the value 0, 1, 2, 3, 4 or 5 and the radicals R 12 and R 13, independently of one another, are alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkyl- Heterocyclyl, alkyl-aryl or alkyl-heteroaryl or R12 and R13 may together form a heterocyclyl ring
und R6:and R6:
-C(Y)NR7R8 bedeuten kann, wobei Y unabhängig voneinander O oder S sein kann und R7 und R8 unabhängig voneinander-C (Y) NR7R8, where Y can independently of one another be O or S and R7 and R8 independently of one another
Wasserstoff,Hydrogen,
unsubstituiertes oder substituiertes Alkyl, wobei der Alkylrest mit F, Cl, Br, I, CF3,unsubstituted or substituted alkyl, wherein the alkyl radical with F, Cl, Br, I, CF 3 ,
CN, NH2, NH-Alkyl, NH-Cycloalkyl, NH-Heterocyclyl, NH-Aryl, NH-Heteroaryl, NH- Alkyl-Cycloalkyl, NH-Alkyl-Heterocyclyl, NH-Alkyl-Aryl, NH-Alkyl-Heteroaryl, N(Alkyl)2, NHC(O)-Alkyl, NHC(O)-Cycloalkyl, NHC(O)-Heterocyclyl, NHC(O)-Aryl, NHC(O)-Heteroaryl, NHC(O)-Alkyl-Aryl, NHC(O)-Alkyl-Heteroaryl, NHSO2-Alkyl, NHSO2-Cycloalkyl, NHSO2-Heterocyclyl, NHSO2-Aryl, NHSO2-Heteroaryl, NHSO2-CN, NH 2 , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl, N (Alkyl) 2 , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -Heteroaryl, NHC (O) -alkyl-aryl, NHC (O) -alkyl-heteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 -heteroaryl, NHSO 2 -
Alkyl-Aryl, N H SO2-AI ky I- Heteroaryl, NO2, SH, S-Alkyl, S-Cycloalkyl, S-Heterocyclyl, S-Aryl, S-Heteroaryl, OH, OCF3, O(-Alkyl-O)p-Alkyl, O-Cycloalkyl, O- Heterocyclyl, O-Aryl, O-Heteroaryl, O-Alkyl-Cycloalkyl, O-Alky I- Heterocyclyl, O-Alkyl-Aryl, O- Alkyl-Heteroaryl, OC(O)-Alkyl, OC(O)-Cycloalkyl, OC(O)-Heterocyclyl, OC(O)-Aryl, OC(O)-Heteroaryl, OC(O)-Alkyl-Aryl, OC(O)-Alkyl-Heteroaryl, OSO3H, OSO2-Alkyl, OSO2-Cycloalkyl, OSO2-Heterocyclyl, OSO2-Aryl, OSO2-Heteroaryl, OSO2-Alkyl- Aryl, OSO2-Alkyl-Heteroaryl, OP(O)(OH)2, C(O)-Alkyl, C(O)-Aryl, C(O)-Heteroaryl, CO2H, CO2-Alkyl, CO2-CyCl oa I ky I, CO2-Heterocyclyl, CO2-Aryl, CO2-Heteroaryl, CO2-Alkyl-Cycloalkyl, CO2-Alkyl-Heterocyclyl, CO2-Alkyl-Aryl, CO2-Alkyl-Heteroaryl,Alkyl-aryl, NH-SO 2 -alkyl-heteroaryl, NO 2 , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S-aryl, S-heteroaryl, OH, OCF 3 , O (-alkyl-O ) p -alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-Alky I-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O) Alkyl, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkyl-aryl, OC (O) -alkyl-heteroaryl, OSO 3 H, OSO 2 -alkyl, OSO 2 -cycloalkyl, OSO 2 -heterocyclyl, OSO 2 -aryl, OSO 2- heteroaryl, OSO 2 -alkyl-aryl, OSO 2 -alkyl-heteroaryl, OP (O) (OH) 2 , C (O) -alkyl, C (O) -aryl, C (O) -Heteroaryl, CO 2 H, CO 2 -alkyl, CO 2 -cyclo or I ky I, CO 2 -heterocyclyl, CO 2 -aryl, CO 2 -heteroaryl, CO 2 -alkyl-cycloalkyl, CO 2 -alkyl-heterocyclyl, CO 2 -alkyl- Aryl, CO 2 -alkyl-heteroaryl,
C(O)-NH2, C(O)NH-Alkyl, C(O)NH-Cycloalkyl, C(O)NH-Heterocyclyl, C(O)NH-Aryl, C(O)N H-Heteroaryl, C(O)NH-Alkyl-Cycloalkyl, C(O)NH-Alkyl-Heterocyclyl, C(O)NH- Alkyl-Aryl, C(O)NH-Alkyl-Heteroaryl, C(O)N(Alkyl)2, C(O)N(Cycloalkyl)2, C(O)N(Aryl)2, C(O)N(Heteroaryl)2, SO-Alkyl, SO-Aryl, SO2-Alkyl, SO2-Aryl, SO2NH2, SO2NH-Alkyl, SO2NH-Aryl, SO2NH-Heteroaryl, SO2NH-Alkyl-Aryl, SO3H, SO2O-C (O) -NH 2 , C (O) NH-alkyl, C (O) NH -cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) N H -heteroaryl, C (O) NH-alkyl-cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) -NH-alkyl-aryl, C (O) -NH-alkyl-heteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , SO-alkyl, SO-aryl, SO 2 -alkyl, SO 2 -aryl, SO 2 NH 2 , SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkyl-aryl, SO 3 H, SO 2 O-
Alkyl, SO2O-Aryl, SO2O-Alkyl-Aryl, Cycloalkyl, Heterocyclyl, Aryl oder Heteroaryl, ein- oder mehrfach, gleich oder verschieden substituiert sein kann, wobei p den Wert 0, 1 , 2, 3, 4 oder 5 annehmen kann,Alkyl, SO 2 O-aryl, SO 2 O-alkyl-aryl, cycloalkyl, heterocyclyl, aryl or heteroaryl, mono- or polysubstituted by identical or different substituents, where p is 0, 1, 2, 3, 4 or 5 can assume
unsubstituiertes oder substituiertes Cycloalkyl, wobei der Cycloalkyl rest mit F, Cl,unsubstituted or substituted cycloalkyl, where the cycloalkyl radical with F, Cl,
Br, I, NH2, NH-Alkyl, NH-Cycloalkyl, NH-Heterocyclyl, NH-Aryl, N H-Heteroaryl, NH- Alkyl-Aryl, NH-Alkyl-Heteroaryl, N(Alkyl)2, NHC(O)-Alkyl, NHC(O)-Cycloalkyl, NHC(O)-Heterocyclyl, NHC(O)-Aryl, NHC(O)-Heteroaryl, NHC(O)-Alkyl-Aryl, NHC(O)-Alkyl-Heteroaryl, NHSO2-Alkyl, NHSO2-Cycloalkyl, NHSO2-Heterocyclyl, NHSO2-Aryl, N H SO2- Heteroaryl, NHSO2-Alkyl-Aryl, NHSO2-Alkyl-Heteroaryl, OH,Br, I, NH 2 , NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl-heteroaryl, N (alkyl) 2 , NHC (O) Alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl-aryl, NHC (O) -alkyl-heteroaryl, NHSO 2 alkyl, NHSO 2 cycloalkyl, NHSO 2 heterocyclyl, NHSO 2 aryl, NH SO 2 heteroaryl, NHSO 2 alkyl aryl, NHSO 2 alkyl heteroaryl, OH,
O(-Alkyl-O)p-Alkyl, O-Cycloalkyl, O-Heterocyclyl, O-Aryl, O-Heteroaryl, O-Alkyl-Aryl, O-Alkyl-Heteroaryl, OC(O)-Alkyl, OC(O)-Cycloalkyl, OC(O)-Heterocyclyl, OC(O)- Aryl, OC(O)-Heteroaryl, OC(O)-Alkyl-Aryl, OC(O)-Alkyl-Heteroaryl, OSO3H, OSO2- Alkyl, OSO2-Cycloalkyl, OSO2-Heterocyclyl, OSO2-Aryl, OSO2-Heteroaryl, OSO2- Alkyl-Aryl, OSO2-Alkyl-Heteroaryl, OP(O)(OH)2, CO2H, CO2-Alkyl, CO2-CyCl oa I ky I,O (-alkyl-O) p -alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O) -alkyl, OC (O) Cycloalkyl, OC (O) heterocyclyl, OC (O) aryl, OC (O) heteroaryl, OC (O) alkyl aryl, OC (O) alkyl heteroaryl, OSO 3 H, OSO 2 alkyl , OSO 2 cycloalkyl, OSO 2 heterocyclyl, OSO 2 aryl, OSO 2 heteroaryl, OSO 2 alkyl aryl, OSO 2 alkyl heteroaryl, OP (O) (OH) 2 , CO 2 H, CO 2 Alkyl, CO 2 -CyCl or I ky I,
CO2-H eterocyclyl, CO2-Aryl, CO2-Heteroaryl, CO2-Alkyl-Cycloalkyl, CO2-Alkyl- Heterocyclyl, CO2-AI kyl-Ary I, CO2-Alkyl-Heteroaryl, C(O)-NH2, C(O)NH-Alkyl, C(O)NH-Cycloalkyl, C(O)NH-Heterocyclyl, C(O)NH-Aryl, C(O)N H-Heteroaryl, C(O)NH-Alkyl-Cycloalkyl, C(O)NH-Alkyl-Heterocyclyl, C(O)NH-Alkyl-Aryl, C(O)NH- Alkyl-Heteroaryl, C(O)N(Alkyl)2, C(O)N(Cycloalkyl)2, C(O)N(Aryl)2,CO 2 -H-heterocyclyl, CO 2 -aryl, CO 2 -heteroaryl, CO 2 -alkyl-cycloalkyl, CO 2 -alkyl-heterocyclyl, CO 2 -alkyl-aryl I, CO 2 -alkyl-heteroaryl, C (O) -NH 2 , C (O) NH-alkyl, C (O) NH -cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) N H -heteroaryl, C (O) NH Alkyl cycloalkyl, C (O) NH alkyl heterocyclyl, C (O) NH alkyl aryl, C (O) NH alkyl heteroaryl, C (O) N (alkyl) 2 , C (O) N (Cycloalkyl) 2 , C (O) N (aryl) 2 ,
C(O)N(Heteroaryl)2, Alkyl, oder Aryl ein- oder mehrfach, gleich oder verschieden substituiert sein kann, wobei p den Wert O, 1 , 2, 3, 4 oder 5 annehmen kann, unsubstituiertes oder substituiertes Heterocyclyl, wobei der Heterocyclylrest mit OH, O-Alkyl, O-Aryl, NH2, NH-Alkyl, NH-Aryl, Alkyl, Alkyl-Aryl oder Aryl ein- oder mehrfach, gleich oder verschieden substituiert sein kann,C (O) N (heteroaryl) 2 , alkyl, or aryl mono- or polysubstituted by identical or different substituents, where p can assume the value O, 1, 2, 3, 4 or 5, unsubstituted or substituted heterocyclyl, where the heterocyclyl radical may be mono- or polysubstituted by identical or different substituents with OH, O-alkyl, O-aryl, NH 2 , NH-alkyl, NH-aryl, alkyl, alkyl-aryl or aryl,
unsubstituiertes oder substituiertes Aryl, wobei der Arylrest mit F, Cl, Br, I, CF3, CN,unsubstituted or substituted aryl, where the aryl radical is substituted by F, Cl, Br, I, CF 3 , CN,
NH2, NH-Alkyl, NH-R38, NH-Cycloalkyl, NH-Heterocyclyl, NH-Aryl, NH-Heteroaryl, NH-Alkyl-Cycloalkyl, NH-Alkyl-Heterocyclyl, NH-Alkyl-Aryl, NH-Alkyl-Heteroaryl, NH-Alkyl-NH2, NH-Alkyl-OH, N(Alkyl)2, NHC(O)-Alkyl, NHC(O)-R38, NHC(O)- Cycloalkyl, NHC(O)-Heterocyclyl, NHC(O)-Aryl, NHC(O)-Heteroaryl, NHC(O)-Alkyl- Aryl, NHC(O)-Alkyl-Heteroaryl, NHSO2-Alkyl, NHSO2-Cycloalkyl, NHSO2-NH 2 , NH-alkyl, NH-R38, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl , NH-alkyl-NH 2 , NH-alkyl-OH, N (alkyl) 2 , NHC (O) -alkyl, NHC (O) -R38, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC ( O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl-aryl, NHC (O) -alkyl-heteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -
Heterocyclyl, NHSO2-Aryl, NHSO2-Heteroaryl, NHSO2-Alkyl-Aryl, NHSO2-Alkyl- Heteroaryl, NO2, SH, S-Alkyl, S-Cycloalkyl, S-Heterocyclyl, S-Aryl, S-Heteroaryl, OH, OCF3, O(-Alkyl-O)p-Alkyl, O-R38, O-Cycloalkyl, O-Heterocyclyl, O-Aryl, O- Heteroaryl, O-Alkyl-Cycloalkyl, O-Alkyl-Heterocyclyl, O-Alkyl-Aryl, O-Alkyl- Heteroaryl, O-Alkyl-OH, O-(CH2)n-O, OC(O)-Alkyl, OC(O)-R38, OC(O)-Cycloalkyl,Heterocyclyl, NHSO 2 -aryl, NHSO 2 -heteroaryl, NHSO 2 -alkyl-aryl, NHSO 2 -alkyl-heteroaryl, NO 2 , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S-aryl, S-heteroaryl , OH, OCF 3 , O (-alkyl-O) p -alkyl, O-R 38, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O -Alkyl-aryl, O-alkyl-heteroaryl, O-alkyl-OH, O- (CH 2 ) n -O, OC (O) -alkyl, OC (O) -R38, OC (O) -cycloalkyl,
OC(O)-Heterocyclyl, OC(O)-Aryl, OC(O)-Heteroaryl, OC(O)-Alkyl-Aryl, OC(O)-Alkyl- Heteroaryl, OSO3H, OSO2-Alkyl, OSO2-Cycloalkyl, OSO2-Heterocyclyl, OSO2-Aryl, OSO2-Heteroaryl, OSO2-Alkyl-Aryl, OSO2-Alkyl-Heteroaryl, OP(O)(OH)2, C(O)- Alkyl, C(O)-Aryl, C(O)-Heteroaryl, CO2H, CO2-Alkyl, CO2-R38, CO2-Cycloalkyl, CO2-H eterocyclyl, CO2-Aryl, CO2-Heteroaryl, CO2-Alkyl-Cycloalkyl, CO2-Alkyl-OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkyl-aryl, OC (O) -alkyl-heteroaryl, OSO 3 H, OSO 2 -alkyl, OSO 2 Cycloalkyl, OSO 2 heterocyclyl, OSO 2 aryl, OSO 2 heteroaryl, OSO 2 alkyl aryl, OSO 2 alkyl heteroaryl, OP (O) (OH) 2 , C (O) alkyl, C ( O) -aryl, C (O) -heteroaryl, CO 2 H, CO 2 -alkyl, CO 2 -R38, CO 2 -cycloalkyl, CO 2 -H-heterocyclyl, CO 2 -aryl, CO 2 -heteroaryl, CO 2 - Alkyl-cycloalkyl, CO 2 -alkyl-
Heterocyclyl, CO2-AI kyl-Ary I, CO2-Alkyl-Heteroaryl, C(O)-NH2, C(O)NH-Alkyl, C(O)NH-R38, C(O)NH-Cycloalkyl, C(O)NH-Heterocyclyl, C(O)NH-Aryl, C(O)NH- Heteroaryl, C(O)NH-Alkyl-Cycloalkyl, C(O)NH-Alkyl-Heterocyclyl, C(O)NH-Alkyl- Aryl, C(O)NH-Alkyl-Heteroaryl, C(O)N(Alkyl)2, C(O)N(Cycloalkyl)2, C(O)N(Aryl)2, C(O)N(Heteroaryl)2, SO-Alkyl, SO-Aryl, SO2-Alkyl, SO2-Aryl, SO2NH2, SO2NH-Alkyl,Heterocyclyl, CO 2 -alkyl-aryl, CO 2 -alkyl-heteroaryl, C (O) -NH 2 , C (O) -NH-alkyl, C (O) -NH-R 38, C (O) -NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl-cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH- Alkyl-aryl, C (O) -NH-alkyl-heteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N ( Heteroaryl) 2 , SO-alkyl, SO-aryl, SO 2 -alkyl, SO 2 -aryl, SO 2 NH 2 , SO 2 NH-alkyl,
SO2NH-Aryl, SO2NH-Heteroaryl, SO2NH-Alkyl-Aryl, S03H, SO2O-Alkyl, SO2O-Aryl, SO2O-Alkyl-Aryl, Alkyl, Cycloalkyl, Heterocyclyl, Aryl oder Heteroaryl, ein- oder mehrfach, gleich oder verschieden substituiert sein kann, wobei p den Wert 0, 1 , 2, 3, 4 oder 5 und n den Wert 1 , 2 oder 3 annehmen kann,SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkyl-aryl, SO 3 H, SO 2 O-alkyl, SO 2 O-aryl, SO 2 O-alkyl-aryl, alkyl, cycloalkyl, heterocyclyl, aryl or Heteroaryl, mono- or polysubstituted by identical or different substituents, p being 0, 1, 2, 3, 4 or 5 and n being 1, 2 or 3,
unsubstituiertes oder substituiertes Heteroaryl, wobei der Heteroarylrest F, Cl, Br, I, CF3, CN, NH2, NH-Alkyl, NH-R38, NH-Cycloalkyl, NH-Heterocyclyl, NH-Aryl, NH- Heteroaryl, NH-Alkyl-Cycloalkyl, NH-Alkyl-Heterocyclyl, NH-Alkyl-Aryl, NH-Alkyl- Heteroaryl, NH-Alkyl-NH2, NH-Alkyl-OH, N(Alkyl)2, NHC(O)-Alkyl, NHC(O)-R38, NHC(O)-Cycloalkyl, NHC(O)-Heterocyclyl, NHC(O)-Aryl, NHC(O)-Heteroaryl, NHC(O)-Alkyl-Aryl, NHC(O)-Alkyl-Heteroaryl, NHSO2-Alkyl, NHSO2-Cycloalkyl, NHSO2-Heterocyclyl, NHSO2-Aryl, NHSO2-Heteroaryl, NHSO2-Alkyl-Aryl, NHSO2- Alkyl-Heteroaryl, NO2, SH, S-Alkyl, S-Aryl, S-Heteroaryl, OH, OCF3, O(-Alkyl-O)p- Alkyl, O-R38, O-Cycloalkyl, O-Heterocyclyl, O-Aryl, O-Heteroaryl, O-Alkyl- Cycloalkyl, O-Alkyl-Heterocyclyl, O-Alkyl-Aryl, O-Alkyl-Heteroaryl, OC(O)-Alkyl,unsubstituted or substituted heteroaryl, wherein the heteroaryl group F, Cl, Br, I, CF 3, CN, NH 2, NH-alkyl, NH-R38, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH- heteroaryl, NH Alkylcycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl, NH-alkyl-NH 2 , NH-alkyl-OH, N (alkyl) 2 , NHC (O) -alkyl, NHC ( O) -R38, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) alkyl aryl, NHC (O) alkyl heteroaryl, NHSO 2 alkyl, NHSO 2 cycloalkyl, NHSO 2 heterocyclyl, NHSO 2 aryl, NHSO 2 heteroaryl, NHSO 2 alkyl aryl, NHSO 2 - alkyl heteroaryl, NO 2 , SH, S-alkyl, S-aryl, S-heteroaryl, OH, OCF 3 , O (-alkyl-O) p -alkyl, O-R 38, O-cycloalkyl, O- Heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O) -alkyl,
OC(O)-R38, OC(O)-Cycloalkyl, OC(O)-Heterocyclyl, OC(O)-Aryl, OC(O)-Heteroaryl, OC(O)-Alkyl-Aryl, OC(O)-Alkyl-Heteroaryl, OSO3H, OSO2-Alkyl, OSO2-Cycloalkyl, OSO2-Heterocyclyl, OSO2-Aryl, OSO2-Heteroaryl, OSO2-AI kyl-Ary I, OSO2-Alkyl- Heteroaryl, OP(O)(OH)2, C(O)-Alkyl, C(O)-Aryl, C(O)-Heteroaryl, CO2H, CO2-Alkyl, CO2-R38, CO2-Cycloalkyl, CO2-Heterocyclyl, CO2-Aryl, CO2-Heteroaryl, CO2-Alkyl-OC (O) -R38, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -Heteroaryl, OC (O) -alkyl-aryl, OC (O) -alkyl Heteroaryl, OSO 3 H, OSO 2 -alkyl, OSO 2 -cycloalkyl, OSO 2 -heterocyclyl, OSO 2 -aryl, OSO 2 -heteroaryl, OSO 2 -alkyl-aryl, OSO 2 -alkyl-heteroaryl, OP ( O) (OH) 2 , C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO 2 H, CO 2 -alkyl, CO 2 -R38, CO 2 -cycloalkyl, CO 2 - Heterocyclyl, CO 2 -aryl, CO 2 -heteroaryl, CO 2 -alkyl-
Cycloalkyl, CO2-Alkyl-Heterocyclyl, CO2-AI kyl-Ary I, CO2-Alkyl-Heteroaryl, C(O)-NH2, C(O)NH-Alkyl, C(O)NH-R38, C(O)NH-Cycloalkyl, C(O)N H-Heterocyclyl, C(O)NH- Aryl, C(O)NH-Heteroaryl, C(O)NH-Alkyl-Cycloalkyl, C(O)NH-Alkyl-Heterocyclyl, C(O)NH-Alkyl-Aryl, C(O)N H-Alkyl-Heteroaryl, C(O)N(Alkyl)2, C(O)N(Cycloalkyl)2, C(O)N(Aryl)2, C(O)N(Heteroaryl)2, SO2NH2, SO2NH-Alkyl, SO2NH-Aryl, SO2NH-Cycloalkyl, CO 2 -alkyl-heterocyclyl, CO 2 -AI alkyl-Ary I, CO 2 -alkyl-heteroaryl, C (O) -NH 2, C (O) NH-alkyl, C (O) NH-R38, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl-cycloalkyl, C (O) NH-alkyl- Heterocyclyl, C (O) NH-alkyl-aryl, C (O) N H -alkyl-heteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl ) 2 , C (O) N (heteroaryl) 2 , SO 2 NH 2 , SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-
Heteroaryl, SO2NH-Alkyl-Aryl, SO3H, SO2O-Alkyl, SO2O-Aryl, SO2O-Alkyl-Aryl, Al- kyl, Cycloalkyl, Heterocyclyl, Aryl oder Heteroaryl, ein- oder mehrfach, gleich oder verschieden substituiert sein kann, wobei p den Wert 0, 1 , 2, 3, 4 oder 5 annehmen kann,Heteroaryl, SO 2 NH-alkyl-aryl, SO 3 H, SO 2 O-alkyl, SO 2 O-aryl, SO 2 O-alkyl-aryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, one or more times , may be substituted, identically or differently, where p can assume the value 0, 1, 2, 3, 4 or 5,
-C(O)-R39, wobei R39 Alkyl, Aryl oder Heteroaryl sein kann, und die Alkyl-, Aryl- und Heteroarylsubstituenten ihrerseits wiederum substituiert sein können,-C (O) -R39, where R39 can be alkyl, aryl or heteroaryl, and the alkyl, aryl and heteroaryl substituents in turn can be substituted,
sein können, oder R7 und R8 zusammen einen Heterocyclyl-Ring bilden können,or R7 and R8 can together form a heterocyclyl ring,
R3 und R4 können unabhängig voneinander:R3 and R4 can be independent of each other:
Wasserstoff, wobei R3 und R4 nicht gleichzeitig Wasserstoff sind,Hydrogen, wherein R3 and R4 are not simultaneously hydrogen,
substituiertes Alkyl, wobei der Alkylrest mit F, Cl, Br, I, CN, CF3, NH2, NH-Alkyl, NH-substituted alkyl, wherein the alkyl radical with F, Cl, Br, I, CN, CF 3 , NH 2 , NH-alkyl, NH-
Aryl, N(Alkyl)2, SH, S-Alkyl, OH, OCF3, O(-Alkyl-O)p-Alkyl, O-Aryl, OSO3H, OP(O)(OH)2, OP(O)(OAIkyl)2, OP(O)(OAryl)2, C(O)OH, C(O)OR14, C(O)NH2, C(0)NHR14, C(O)NR14R15, SO3H, SO2Alkyl, SO2Aryl, P(O)(OH)2, P(O)(OAIkyl)2, P(O)(OAryl)2, Cycloalkyl, Heterocyclyl, Aryl oder Heteroaryl ein- oder mehrfach, gleich oder verschieden substituiert ist, wobei p den Wert 0, 1 , 2, 3, 4 oder 5 an- nehmen kann und die Reste R14 und R15 unabhängig voneinander Alkyl, Cycloal- kyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein können oder R14 und R15 zusammen einen Heterocyc- lyl-Ring bilden können,Aryl, N (alkyl) 2 , SH, S-alkyl, OH, OCF 3 , O (-alkyl-O) p -alkyl, O-aryl, OSO 3 H, OP (O) (OH) 2 , OP (O ) (OAlkyl) 2 , OP (O) (O-aryl) 2 , C (O) OH, C (O) OR 14, C (O) NH 2 , C (O) NHR 14, C (O) NR 14 R 15, SO 3 H, SO 2 alkyl, SO 2 aryl, P (O) (OH) 2 , P (O) (OAlkyl) 2 , P (O) (O-aryl) 2 , cycloalkyl, heterocyclyl, aryl or heteroaryl one or more times, same or different is substituted, where p is the value 0, 1, 2, 3, 4 or 5 R14 and R15 can independently of one another be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, or R14 and R15 together form a heterocyclyl ring can form
substituiertes Aryl, wobei der Arylrest ein- oder mehrfach, gleich oder verschieden substituiert ist mit Substituenten ausgewählt aus der Gruppe NH-Alkyl, NH- Cycloalkyl, NH-Heterocyclyl, NH-Aryl, NH-Heteroaryl, NH-Alkyl-Cycloalkyl, NH- Alkyl-Heterocyclyl, N H -Alkyl -Aryl, NH-Alkyl-Heteroaryl, N(Alkyl)2, N(Aryl)2, NHC(O)- Alkyl, NHC(O)-Cycloalkyl, NHC(O)-Heterocyclyl, NHC(O)-Aryl, NHC(O)-Heteroaryl,substituted aryl, where the aryl radical is mono- or polysubstituted by identical or different substituents selected from the group consisting of NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl, NH-- Alkyl heterocyclyl, NH alkyl -aryl, NH-alkyl-heteroaryl, N (alkyl) 2 , N (aryl) 2 , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl,
NHC(O)-Alkyl-Aryl, NHC(O)-Alkyl-Heteroaryl, NHSO2-Alkyl, NHSO2-Cycloalkyl, NHSO2-Heterocyclyl, NHSO2-Aryl, N H SO2- Heteroaryl, NHSO2-Alkyl-Aryl, NHSO2- Alkyl-Heteroaryl, S-Alkyl, S-Aryl, S-Heteroaryl, O-Alkyl, O-Cycloalkyl, O- Heterocyclyl, O-Aryl, O-Heteroaryl, O-Alkyl-Cycloalkyl, O-Alkyl-Heterocyclyl, O- Alkyl-Aryl, O-Alkyl-Heteroaryl, OC(O)-Alkyl, OC(O)-Cycloalkyl, OC(O)-H eterocyclyl,NHC (O) alkyl aryl, NHC (O) alkyl heteroaryl, NHSO 2 alkyl, NHSO 2 cycloalkyl, NHSO 2 heterocyclyl, NHSO 2 aryl, NH SO 2 heteroaryl, NHSO 2 alkyl aryl , NHSO 2 - alkyl heteroaryl, S-alkyl, S-aryl, S-heteroaryl, O-alkyl, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl Heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) -H-heterocyclyl,
OC(O)-Aryl, OC(O)-Heteroaryl, OC(O)-Alkyl-Aryl, OC(O)-Alkyl-Heteroaryl, OSO2- Alkyl, OSO2-Cycloalkyl, OSO2-Heterocyclyl, OSO2-Aryl, OSO2-Heteroaryl, OSO2- Alkyl-Aryl, OSO2-Alkyl-Heteroaryl, C(O)-Alkyl, C(O)-Aryl, C(O)-Heteroaryl, CO2- Alkyl, CO2-Cycloalkyl, CO2-Heterocyclyl, CO2-Aryl, CO2-Heteroaryl, CO2-Alkyl- Cycloalkyl, CO2-Alkyl-Heterocyclyl, CO2-AI kyl-Ary I, CO2-Alkyl-Heteroaryl, C(O)NH-OC (O) aryl, OC (O) heteroaryl, OC (O) alkyl aryl, OC (O) alkyl heteroaryl, OSO 2 alkyl, OSO 2 cycloalkyl, OSO 2 heterocyclyl, OSO 2 aryl, OSO 2 -heteroaryl, OSO 2 - alkyl-aryl, OSO 2 -alkyl-heteroaryl, C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO 2 - alkyl, CO 2 - Cycloalkyl, CO 2 heterocyclyl, CO 2 aryl, CO 2 heteroaryl, CO 2 alkyl cycloalkyl, CO 2 alkyl heterocyclyl, CO 2 -AI kyl-Ary I, CO 2 alkyl heteroaryl, C (O ) NH-
Alkyl, C(O)NH-Cycloalkyl, C(O)N H-Heterocyclyl, C(O)NH-Aryl, C(O)NH-Heteroaryl, C(O)NH-Alkyl-Cycloalkyl, C(O)NH-Alkyl-Heterocyclyl, C(O)NH-Alkyl-Aryl, C(O)NH- Alkyl-Heteroaryl, C(O)N(Alkyl)2, C(O)N(Cycloalkyl)2, C(O)N(Aryl)2, C(O)N(Heteroaryl)2, SO-Alkyl, SO-Aryl, SO2-Alkyl, SO2-Aryl, SO2NH-Alkyl, SO2NH- Aryl, SO2NH-Heteroaryl, SO2NH-Alkyl-Aryl, SO2O-Alkyl, SO2O-Aryl, SO2O-Alkyl-Alkyl, C (O) NH cycloalkyl, C (O) N H heterocyclyl, C (O) NH aryl, C (O) NH heteroaryl, C (O) NH alkyl cycloalkyl, C (O) NH Alkyl heterocyclyl, C (O) NH alkyl aryl, C (O) NH alkyl heteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (Aryl) 2 , C (O) N (heteroaryl) 2 , SO-alkyl, SO-aryl, SO 2 -alkyl, SO 2 -aryl, SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl , SO 2 NH-alkyl-aryl, SO 2 O-alkyl, SO 2 O-aryl, SO 2 O-alkyl-
Aryl, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl und die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl-, Heteroaryl-, Alkyl-Cycloalkyl-, Alkyl-Heterocyclyl-, Alkyl-Aryl- und Alkyl-Heteroarylsubstituenten ihrerseits wiederum mit O(-Alkyl-O)p-Alkyl, OP(O)(OAIkyl)2, OP(O)(OAryl)2, C(0)0R16, C(O)NH2, C(O)NHR16, C(O)NR16R17, SO2Alkyl, SO2Aryl, P(O)(OH)2, P(O)(OAIkyl)2, P(O)(OAryl)2, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl oder Alkylaryl substituiert sind, wobei p den Wert 1 , 2, 3, 4 oder 5 annehmen kann und die Reste R16 und R17 unabhängig voneinander Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein können oder R16 und R17 zusammen einen Heterocyc- lyl-Ring bilden können, unter der Voraussetzung, dass, wenn R3 oder R4 Alkyl-Heterocyclyl-substituiertes Aryl bedeutet, entsprechend R4 bzw. R3 ≠ Aryl ist,Aryl, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl and alkyl heteroaryl substituents in turn with O (alkyl-O) p alkyl, OP (O) (OAIkyl) 2, OP (O) (O-aryl) 2, C (0) 0R16, C (O) NH 2, C (O) NHR16, C (O ) NR16R17, SO 2 alkyl, SO 2 aryl, P (O) (OH) 2, P (O) (OAIkyl) 2, P (O) (O-aryl) 2, cycloalkyl, heterocyclyl, aryl, heteroaryl or alkyl substituted, where p can assume the value 1, 2, 3, 4 or 5 and the radicals R 16 and R 17 independently of one another can be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl or R 16 and R 17 together can form a heterocyclyl ring, with the proviso that when R 3 or R 4 is alkyl-heterocyclyl-substituted aryl, then R 4 or R 3 is ≠ aryl,
und wobei der Arylrest ein- oder mehrfach, gleich oder verschieden substituiert ist mit Substituenten ausgewählt aus der Gruppe NR20-Alkyl, NH-R38, NHC(O)-R38,and wherein the aryl radical is mono- or polysubstituted by identical or different substituents selected from the group consisting of NR20-alkyl, NH-R38, NHC (O) -R38,
NR19C(O)-Alkyl, NR19C(O)-Cycloalkyl, NR19C(O)-Heterocyclyl, NR19C(O)-Aryl, NR19C(O)-Heteroaryl, NR18C(O)-Alkyl-Cycloalkyl, NR18C(O)-Alkyl-Heterocyclyl, NR19C(O)-Alkyl-Aryl, NR19C(O)-Alkyl-Heteroaryl, NR18C(O)O-RI 9, NR18C(O)NR18R18, O-R38, OC(O)-R38, OC(O)-Alkyl-Cycloalkyl, OC(O)-Alkyl- Heterocyclyl, OC(O)O-RI 9, OC(O)NRI 8R18, OP(O)(OAIkyl)2, OP(O)(OAryl)2,NR19C (O) -alkyl, NR19C (O) -cycloalkyl, NR19C (O) -heterocyclyl, NR19C (O) -aryl, NR19C (O) -Heteroaryl, NR18C (O) -alkyl-cycloalkyl, NR18C (O) -alkyl Heterocyclyl, NR19C (O) -alkyl-aryl, NR19C (O) -alkyl-heteroaryl, NR18C (O) O-RI9, NR18C (O) NR18R18, O-R38, OC (O) -R38, OC (O ) -Alkyl-cycloalkyl, OC (O) -alkyl-heterocyclyl, OC (O) O-RI 9, OC (O) NRI 8R 18, OP (O) (O-alkyl) 2 , OP (O) (O-aryl) 2 ,
C(O)O-R38, C(O)NH-R38, C(O)NR20-Alkyl, C(O)NRI 9-Alkyl-R21 , C(O)NRI 80- R18, C(O)NRI 8NR18R18 und die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl-, Heteroa- ryl-, Alkyl-Cycloalkyl-, Alkyl-Heterocyclyl-, Alkyl-Aryl- und Alkyl- Heteroarylsubstituenten ihrerseits wiederum mit F, Cl, Br, I, CN, CF3, NH2, NH- Alkyl, NH-Aryl, N(Alkyl)2, NO2, SH, S-Alkyl, OH, OCF3, O(-Alkyl-O)p-Alkyl, O-Aryl,C (O) O-R38, C (O) NH-R38, C (O) NR20-alkyl, C (O) NRI 9-alkyl-R21, C (O) NRI 80-R18, C (O) NRI 8NR18 R18 and the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl and alkyl heteroaryl substituents themselves in turn with F, Cl, Br, I, CN, CF 3 , NH 2 , NH-alkyl, NH-aryl, N (alkyl) 2 , NO 2 , SH, S-alkyl, OH, OCF 3 , O (-alkyl-O) p- alkyl, O-aryl,
OSO3H, OP(O)(OH)2, OP(O)(OAIkyl)2, OP(O)(OAryl)2, CHO, C(O)OH, C(O)OR22, C(O)NH2, C(O)NHR22, C(O)NR22R23, SO3H, SO2Alkyl, SO2Aryl, P(O)(OH)2, P(O)(OAIkyl)2, P(O)(OAryl)2, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl oder Alkylaryl substituiert sein können, wobei p den Wert 0, 1 , 2, 3, 4 oder 5 annehmen kann und die Reste R22 und R23 unabhängig voneinander Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl- Heteroaryl sein können oder R22 und R23 zusammen einen Heterocyclyl-Ring bilden können,OSO 3 H, OP (O) (OH) 2 , OP (O) (OAlkyl) 2 , OP (O) (OAryl) 2 , CHO, C (O) OH, C (O) OR 22, C (O) NH 2, C (O) NHR 22, C (O) NR22R23, SO 3 H, SO 2 alkyl, SO 2 aryl, P (O) (OH) 2, P (O) (OAIkyl) 2, P (O) (OAryl ) 2 , alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or alkylaryl may be substituted, wherein p can take the value 0, 1, 2, 3, 4 or 5 and the radicals R22 and R23 independently alkyl, cycloalkyl, heterocyclyl, aryl , Heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl or R 22 and R 23 may together form a heterocyclyl-ring,
substituiertes Heteroaryl, wobei der Heteroarylrest ein- oder mehrfach, gleich oder verschieden substituiert ist mit Substituenten ausgewählt aus der Gruppe NH-Alkyl, NH-Cycloalkyl, NH-Heterocyclyl, NH-Aryl, NH-Heteroaryl, NH-Alkyl-Cycloalkyl, NH- Alkyl-Heterocyclyl, N H -Alkyl -Aryl, NH-Alkyl-Heteroaryl, N(Alkyl)2, N(Aryl)2, NHC(O)- Alkyl, NHC(O)-Cycloalkyl, NHC(O)-Heterocyclyl, NHC(O)-Aryl, NHC(O)-Heteroaryl, NHC(O)-Alkyl-Aryl, NHC(O)-Alkyl-Heteroaryl, NHSO2-Alkyl, NHSO2-Cycloalkyl,substituted heteroaryl, where the heteroaryl radical is mono- or polysubstituted by identical or different substituents selected from the group consisting of NH-alkyl, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl, NH-- Alkyl heterocyclyl, NH alkyl -aryl, NH-alkyl-heteroaryl, N (alkyl) 2 , N (aryl) 2 , NHC (O) -alkyl, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl-aryl, NHC (O) -alkyl-heteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl,
NHSO2-Heterocyclyl, NHSO2-Aryl, N H SO2- Heteroaryl, NHSO2-Alkyl-Aryl, NHSO2- Alkyl-Heteroaryl, S-Alkyl, S-Aryl, S-Heteroaryl, O-Alkyl, O-Cycloalkyl, O-Aryl, O- Heteroaryl, O-Alkyl-Cycloalkyl, O-Alkyl-Heterocyclyl, O-Alkyl-Aryl, O-Alkyl- Heteroaryl, OC(O)-Alkyl, OC(O)-Cycloalkyl, OC(O)-Heterocyclyl, OC(O)-Aryl, OC(O)-Heteroaryl, OC(O)-Alkyl-Aryl, OC(O)-Alkyl-Heteroaryl, OSO2-Alkyl, OSO2- Cycloalkyl, OSO2-Heterocyclyl, OSO2-Aryl, OSO2-Heteroaryl, OSO2-Alkyl-Aryl, OSO2-Alkyl-Heteroaryl, C(O)-Alkyl, C(O)-Aryl, C(O)-Heteroaryl, CO2-Alkyl, CO2- Cycloalkyl, CO2-Heterocyclyl, CO2-Aryl, CO2-Heteroaryl, CO2-Alkyl-Cycloalkyl, CO2- Alkyl-Heterocyclyl, CO2-AI kyl-Ary I, CO2-Alkyl-Heteroaryl, C(O)NH-Alkyl, C(O)NH- Cycloalkyl, C(O)NH-Heterocyclyl, C(O)NH-Aryl, C(O)N H-Heteroaryl, C(O)NH-Alkyl-NHSO 2 heterocyclyl, NHSO 2 -aryl, NH SO 2 -heteroaryl, NHSO 2 -alkyl-aryl, NHSO 2 -alkyl-heteroaryl, S-alkyl, S-aryl, S-heteroaryl, O-alkyl, O-cycloalkyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O) -alkyl, OC (O) -cycloalkyl, OC (O) Heterocyclyl, OC (O) aryl, OC (O) heteroaryl, OC (O) alkyl aryl, OC (O) alkyl heteroaryl, OSO 2 alkyl, OSO 2 - Cycloalkyl, OSO 2 heterocyclyl, OSO 2 aryl, OSO 2 heteroaryl, OSO 2 alkyl aryl, OSO 2 alkyl heteroaryl, C (O) alkyl, C (O) -aryl, C (O) - heteroaryl, CO 2 -alkyl, CO 2 - cycloalkyl, CO 2 -heterocyclyl, CO 2 -aryl, CO 2 -heteroaryl, CO 2 -alkyl-cycloalkyl, CO 2 - alkyl-heterocyclyl, CO 2 -AI alkyl-Ary I, CO 2 alkyl heteroaryl, C (O) NH alkyl, C (O) NH cycloalkyl, C (O) NH heterocyclyl, C (O) NH aryl, C (O) N H heteroaryl, C ( O) NH-alkyl
Cycloalkyl, C(O)NH-Alkyl-Heterocyclyl, C(O)NH-Alkyl-Aryl, C(O)NH-Alkyl- Heteroaryl, C(O)N(Alkyl)2, C(O)N(Cycloalkyl)2, C(O)N(Aryl)2, C(O)N(Heteroaryl)2, SO2NH-Alkyl, SO2NH-Aryl, SO2NH-Heteroaryl, SO2NH-Alkyl-Aryl, SO2O-Alkyl, SO2O-Aryl, SO2O-Alkyl-Aryl, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl und die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl-, Heteroaryl-, Alkyl-Cycloalkyl-, Alkyl-Cycloalkyl, C (O) NH-alkyl heterocyclyl, C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkyl-aryl, SO 2 O-alkyl, SO 2 O-aryl, SO 2 O-alkyl-aryl, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl -
Heterocyclyl-, Alkyl-Aryl- und Alkyl-Heteroarylsubstituenten ihrerseits wiederum mit O(-Alkyl-O)p-Alkyl, OP(O)(OAIkyl)2, OP(O)(OAryl)2, C(O)ORI 6, C(O)NH2, C(O)NHRI 6, C(O)NRI 6R17, SO2Alkyl, SO2Aryl, P(O)(OH)2, P(O)(OAIkyl)2, P(O)(OAryl)2, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl oder Alkylaryl substituiert sind, wobei p den Wert 1 , 2, 3, 4 oder 5 annehmen kann und die Reste R16 undHeterocyclyl, alkyl-aryl and alkyl heteroaryl substituents in turn with O (-alkyl-O) p- alkyl, OP (O) (OAlkyl) 2 , OP (O) (O-aryl) 2 , C (O) ORI 6, C (O) NH 2 , C (O) NHRI 6, C (O) NRI 6 R 17, SO 2 alkyl, SO 2 aryl, P (O) (OH) 2 , P (O) (OAlkyl) 2 , P (O ) (OAryl) 2 , cycloalkyl, heterocyclyl, aryl, heteroaryl or alkylaryl, where p can assume the value 1, 2, 3, 4 or 5 and the radicals R16 and
R17 unabhängig voneinander Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein können oder R16 und R17 zusammen einen Heterocyclyl-Ring bilden können,R 17 independently of one another may be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl or R 16 and R 17 may together form a heterocyclyl ring,
und wobei der Heteroarylrest ein- oder mehrfach, gleich oder verschieden substituiert ist mit Substituenten ausgewählt aus der Gruppe NR20-Alkyl, NH-R38, NHC(O)-R38, NR19C(0)-Alkyl, NR19C(O)-Cycloalkyl, NR19C(O)-Heterocyclyl, NR19C(0)-Aryl, NR19C(O)-Heteroaryl, NR18C(O)-Alkyl-Cycloalkyl, NR18C(O)- Alkyl-Heterocyclyl, NR19C(0)-Alkyl-Aryl, NR19C(O)-Alkyl-Heteroaryl, NR18C(O)O- R19, NR18C(O)NRI 8R18, NHSO2-Alkyl-Heterocyclyl, O-R38, O-Heterocyclyl,and wherein the heteroaryl radical is monosubstituted or polysubstituted by identical or different substituents selected from the group NR20-alkyl, NH-R38, NHC (O) -R38, NR19C (O) -alkyl, NR19C (O) -cycloalkyl, NR19C (O) -heterocyclyl, NR19C (O) -aryl, NR19C (O) -heteroaryl, NR18C (O) -alkyl-cycloalkyl, NR18C (O) -alkyl-heterocyclyl, NR19C (O) -alkyl-aryl, NR19C (O ) alkyl-heteroaryl, NR18C (O) O- R19, NR18C (O) NRI 8R18, NHSO 2 -alkyl-heterocyclyl, O-R38, O-heterocyclyl,
OC(O)-R38, OC(O)-Alkyl-Cycloalkyl, OC(O)-Alkyl-Heterocyclyl, OC(O)O-RI 9, OC(O)NRI 8R18, OP(O)(OAIkyl)2, OP(O)(OAryl)2, C(O)O-R38, C(O)NH-R38, C(O)NR20-Alkyl, C(O)NRI 9-Alkyl-R21 , C(O)NRI 80-R18, C(O)NRI 8NR18R18 und die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl-, Heteroaryl-, Alkyl-Cycloalkyl-, Alkyl- Heterocyclyl-, Alkyl-Aryl- und Alkyl-Heteroarylsubstituenten ihrerseits wiederum mitOC (O) -R38, OC (O) -alkyl-cycloalkyl, OC (O) -alkyl-heterocyclyl, OC (O) O-RI 9, OC (O) NRI 8R18, OP (O) (OAlkyl) 2 , OP (O) (O-aryl) 2 , C (O) O-R38, C (O) NH-R38, C (O) NR20-alkyl, C (O) NRI9-alkyl-R21, C (O) NRI80 -R18, C (O) NRI 8NR18R18 and the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl and alkyl heteroaryl substituents in turn with
F, Cl, Br, I, CN, CF3, NH2, NH-Alkyl, NH-Aryl, N(Alkyl)2, NO2, SH, S-Alkyl, OH, OCF3, O(-Alkyl-O)p-Alkyl, O-Aryl, OSO3H, OP(O)(OH)2, OP(O)(OAIkyl)2, OP(O)(OAryl)2, CHO, C(O)OH, C(O)OR22, C(O)NH2, C(O)NHR22, C(O)NR22R23, SO3H, SO2Alkyl, SO2Aryl, P(O)(OH)2, P(O)(OAIkyl)2, P(O)(OAryl)2, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl oder Alkylaryl substituiert sein können, wobei p den Wert 0, 1 , 2, 3, 4 oder 5 annehmen kann und die Reste R22 und R23 unabhängig voneinander Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl- Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein können oder R22 und R23 zusammen einen Heterocyclyl-Ring bilden können,F, Cl, Br, I, CN, CF 3, NH 2, NH-alkyl, NH-aryl, N (alkyl) 2, NO 2, SH, S-alkyl, OH, OCF 3, O (alkyl-O ) p -alkyl, O-aryl, OSO 3 H, OP (O) (OH) 2 , OP (O) (OAlkyl) 2 , OP (O) (O-aryl) 2 , CHO, C (O) OH, C ( O) OR 22, C (O) NH 2, C (O) NHR 22, C (O) NR22R23, SO 3 H, SO 2 alkyl, SO 2 aryl, P (O) (OH) 2, P (O) (OAIkyl ) 2 , P (O) (O-aryl) 2 , alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or alkylaryl may be substituted, wherein p is the Can assume 0, 1, 2, 3, 4 or 5 and the radicals R22 and R23 independently of one another can be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl or R22 and R23 together can form a heterocyclyl ring,
NR24R25, wobei R24 -C(O)-R26, -SO2R26, -C(O)OR26 oder -C(O)-N R27R28 sein kann und wobei R25 Wasserstoff, Alkyl, Cycloalkyl, Aryl oder Heteroaryl sein kann und wobei R26 Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl- Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl, Alkyl-Heteroaryl sein kann, und R27 und R28 unabhängig voneinander Wasserstoff, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl, Alkyl-Heteroaryl sein können, oder R27 und R28 zusammen einen Heterocyclyl-Ring bilden können und die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl- und Heteroaryl-, Alkyl-Cycloalkyl, Alkyl- Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroarylsubstituenten ihrerseits wiederum substituiert sein können,NR24R25, wherein R24 is -C (O) -R26, -SO2 R26, -C (O) OR26 or -C (O) -N R27R28 wherein R25 and may be hydrogen, alkyl, cycloalkyl, aryl or heteroaryl may be, and wherein R 26 can be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl, alkyl-heteroaryl, and R 27 and R 28 independently of one another are hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl , Alkyl-heterocyclyl, alkyl-aryl, alkyl-heteroaryl, or R27 and R28 may together form a heterocyclyl ring and the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl , Alkyl-aryl or alkyl-heteroaryl substituents in turn may be substituted,
und R18 Wasserstoff, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl- Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein kann,and R18 can be hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl,
und R19 Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl-and R 19 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkyl
Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein kann,Heterocyclyl, alkyl-aryl or alkyl-heteroaryl,
und R20 Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl- Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein kann,and R 20 can be cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl,
und R21 Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl sein kann,and R 21 can be cycloalkyl, heterocyclyl, aryl, heteroaryl,
und R38 Alkyl sein kann, wobei der Alkylrest gesättigt oder ungesättigt, geradkettig oder verzweigt sein kann, mit 9 bis 30 C-Atomen, und die C9-3o-Alkenyle mindes- tens eine C-C-Doppelbindung und C9-3o-Alkinyle mindestens eine C-C-and R38 may be alkyl, where the alkyl radical is saturated or unsaturated, may be straight or branched, having from 9 to 30 carbon atoms, and the C 9 - 3 o-alkenyls Any artwork least one CC double bond and C 9-3 o- Alkynyls have at least one CC
Dreifachbindung aufweisen, wobei die Alkenyle sowohl in (E)- als auch in (Z)- Konformation vorliegen können,Having triple bond, wherein the alkenyls may be in both (E) and (Z) conformation,
bedeuten; sowie physiologisch verträgliche Salze, Derivate oder Analoga der Verbindungen nach Formel I, sowie deren Solvate, Hydrate, polymorphe Formen und Prodrugs, wobei die Verbindungen der allgemeinen Formel I sowie deren Salze, Derivate o- der Analoga, deren Solvate, Hydrate, polymorphe Formen und Prodrugs in Form ihrer Racemate, in Form der reinen Enantiomeren und/oder Diastereomeren oder in Form von Mischungen dieser Enantiomeren und/oder Diasteromeren oder in Form der Tautomeren vorliegen können.mean; and physiologically acceptable salts, derivatives or analogs of the compounds of formula I, and their solvates, hydrates, polymorphs and prodrugs, wherein the compounds of general formula I and their salts, derivatives or analogs, their solvates, hydrates, polymorphic forms and Prodrugs in the form of their racemates, in the form of pure enantiomers and / or diastereomers or in the form of mixtures of these enantiomers and / or diastereomers or in the form of tautomers may be present.
13. Neue Pyrido[2,3-b]pyrazin-Derivate der allgemeinen Formel (II) gemäß Anspruch 12, worin die Substituenten R1-R4 folgende Bedeutung haben:13. Novel pyrido [2,3-b] pyrazine derivatives of the general formula (II) according to claim 12, in which the substituents R1-R4 have the following meanings:
R1 und R2 können unabhängig voneinander Wasserstoff oder NR5R6 bedeuten, unter der Voraussetzung, dass, wenn R1 = NR5R6 ist, R2 = H ist, und wenn R2 = NR5R6 ist, R1 = H ist, wobei R5 Wasserstoff, Alkyl, R38, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl- Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl- Heteroaryl sein kann und dieR1 and R2 may be independently hydrogen or NR5R6, provided that when R1 = NR5R6, R2 = H, and when R2 = NR5R6, R1 = H, where R5 is hydrogen, alkyl, R38, cycloalkyl, Heterocyclyl, aryl, heteroaryl, alkyl cycloalkyl, alkyl heterocyclyl, alkyl aryl or alkyl heteroaryl may be and the
Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl- und Heteroaryl-, Alkyl-Cycloalkyl, Alkyl- Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroarylsubstituenten ihrerseits wiederum mit F, Cl, Br, I, CN, CF3, NH2, NH-Alkyl, NH-Aryl, N(Alkyl)2, NO2, SH, S-Alkyl, OH, OCF3, O(-Alkyl-O)p-Alkyl, O-Aryl, OSO3H, OP(O)(OH)2, OP(O)(OAIkyl)2, OP(O)(OAryl)2, CHO, C(O)OH, C(O)NH2, C(O)OR12, C(0)NHR12, C(O)NR12R13,Alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, alkyl cycloalkyl, alkyl heterocyclyl, alkyl aryl or alkyl heteroaryl substituents in turn with F, Cl, Br, I, CN, CF 3 , NH 2 , NH Alkyl, NH-aryl, N (alkyl) 2 , NO 2 , SH, S-alkyl, OH, OCF 3 , O (-alkyl-O) p- alkyl, O-aryl, OSO 3 H, OP (O) (OH) 2 , OP (O) (OAlkyl) 2 , OP (O) (OAryl) 2 , CHO, C (O) OH, C (O) NH 2 , C (O) OR 12, C (O) NHR 12, C (O) NR12R13,
SO3H, SO2Alkyl, SO2Aryl, P(O)(OH)2, P(O)(OAIkyl)2, P(O)(OAryl)2, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl ein- oder mehrfach, gleich oder verschieden substituiert sein können, p den Wert O, 1 , 2, 3, 4 oder 5 annehmen kann und die Reste R12 und R13 unabhängig voneinander Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl- Heteroaryl sein können oder R12 und R13 zusammen einen Heterocyclyl-Ring bilden könnenSO 3 H, SO 2 alkyl, SO 2 aryl, P (O) (OH) 2 , P (O) (OAlkyl) 2 , P (O) (O-aryl) 2 , alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or polysubstituted by identical or different substituents, p can assume the value 0, 1, 2, 3, 4 or 5 and the radicals R 12 and R 13, independently of one another, are alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkyl- Heterocyclyl, alkyl-aryl or alkyl-heteroaryl or R12 and R13 may together form a heterocyclyl ring
und R6:and R6:
-C(O)NR9-Y-R10 bedeuten kann, wobei Y unabhängig voneinander O oder NR11 sein kann-C (O) NR 9 -Y-R 10, where Y can independently be O or NR 11
und R9 Wasserstoff, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl- Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl, Alkyl- Heteroaryl sein kann und die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl- und Heteroaryl-, Alkyl-Cycloalkyl, Alkyl- Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroarylsubstituenten ihrerseits substituiert sein können,and R9 may be hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl, and the alkyl, Cycloalkyl, heterocyclyl, aryl and heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl substituents in turn may be substituted,
und R10 und R11 unabhängig voneinanderand R10 and R11 are independent of each other
Wasserstoff,Hydrogen,
unsubstituiertes oder substituiertes Alkyl,unsubstituted or substituted alkyl,
unsubstituiertes oder substituiertes Cycloalkyl,unsubstituted or substituted cycloalkyl,
unsubstituiertes oder substituiertes Heterocyclyl, wobei der Heterocyclylrest mit OH, O-Alkyl, O-Aryl, NH2, NH-Alkyl, NH-Aryl, Alkyl, Alkyl-Aryl oder Aryl ein- oder mehrfach, gleich oder verschieden substituiert sein kann,unsubstituted or substituted heterocyclyl, where the heterocyclyl radical may be mono- or polysubstituted by identical or different substituents with OH, O-alkyl, O-aryl, NH 2 , NH-alkyl, NH-aryl, alkyl, alkyl-aryl or aryl,
unsubstituiertes oder substituiertes Aryl, wobei der Arylrest mit F, Cl, Br, I, CF3, CN, NH2, NH-Alkyl, NH-R38, NH-Cycloalkyl, NH-Heterocyclyl, NH-Aryl, NH-Heteroaryl, NH-Alkyl-Cycloalkyl, NH-Alkyl-Heterocyclyl, NH-Alkyl-Aryl, NH-Alkyl-Heteroaryl, NH-Alkyl-NH2, NH-Alkyl-OH, N(Alkyl)2, NHC(O)-Alkyl, NHC(O)-R38, NHC(O)-unsubstituted or substituted aryl, wherein the aryl radical with F, Cl, Br, I, CF 3 , CN, NH 2 , NH-alkyl, NH-R38, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl, NH Alkyl-cycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl, NH-alkyl-NH 2 , NH-alkyl-OH, N (alkyl) 2 , NHC (O) -alkyl, NHC (O) -R38, NHC (O) -
Cycloalkyl, NHC(O)-Heterocyclyl, NHC(O)-Aryl, NHC(O)-Heteroaryl, NHC(O)-Alkyl- Aryl, NHC(O)-Alkyl-Heteroaryl, NHSO2-Alkyl, NHSO2-Cycloalkyl, NHSO2- Heterocyclyl, NHSO2-Aryl, N H SO2- Heteroaryl, NHSO2-Alkyl-Aryl, NHSO2-Alkyl- Heteroaryl, NO2, SH, S-Alkyl, S-Cycloalkyl, S-Heterocyclyl, S-Aryl, S-Heteroaryl, OH, OCF3, O(-Alkyl-O)p-Alkyl, O-R38, O-Cycloalkyl, O-Heterocyclyl, O-Aryl, O-Cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl-aryl, NHC (O) -alkyl-heteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl , NHSO 2 - heterocyclyl, NHSO 2 -aryl, NH SO 2 -heteroaryl, NHSO 2 -alkyl-aryl, NHSO 2 -alkyl-heteroaryl, NO 2 , SH, S-alkyl, S-cycloalkyl, S-heterocyclyl, S- Aryl, S-heteroaryl, OH, OCF 3 , O (-alkyl-O) p -alkyl, O-R 38, O-cycloalkyl, O-heterocyclyl, O-aryl, O-
Heteroaryl, O-Alkyl-Cycloalkyl, O-Alkyl-Heterocyclyl, O-Alkyl-Aryl, O-Alkyl- Heteroaryl, O-Alkyl-OH, O-(CH2)n-O, OC(O)-Alkyl, OC(O)-R38, OC(O)-Cycloalkyl, OC(O)-Heterocyclyl, OC(O)-Aryl, OC(O)-Heteroaryl, OC(O)-Alkyl-Aryl, OC(O)-Alkyl- Heteroaryl, OSO3H, OSO2-Alkyl, OSO2-Cycloalkyl, OSO2-Heterocyclyl, OSO2-Aryl, OSO2-Heteroaryl, OSO2-Alkyl-Aryl, OSO2-Alkyl-Heteroaryl, OP(O)(OH)2, C(O)-Heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, O-alkyl-OH, O- (CH 2 ) n -O, OC (O) -alkyl, OC (O) -R38, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -Heteroaryl, OC (O) -alkyl-aryl, OC (O) -alkyl- Heteroaryl, OSO 3 H, OSO 2 alkyl, OSO 2 cycloalkyl, OSO 2 heterocyclyl, OSO 2 aryl, OSO 2 heteroaryl, OSO 2 alkyl aryl, OSO 2 alkyl heteroaryl, OP (O) ( OH) 2 , C (O) -
Alkyl, C(O)-Aryl, C(O)-Heteroaryl, CO2H, CO2-Alkyl, CO2-R38, CO2-Cycloalkyl, CO2-H eterocyclyl, CO2-Aryl, CO2-Heteroaryl, CO2-Alkyl-Cycloalkyl, CO2-Alkyl- Heterocyclyl, CO2-AI kyl-Ary I, CO2-Alkyl-Heteroaryl, C(O)-NH2, C(O)NH-Alkyl, C(O)NH-R38, C(O)NH-Cycloalkyl, C(O)NH-Heterocyclyl, C(O)NH-Aryl, C(O)NH- Heteroaryl, C(O)NH-Alkyl-Cycloalkyl, C(O)NH-Alkyl-Heterocyclyl, C(O)NH-Alkyl- Aryl, C(O)NH-Alkyl-Heteroaryl, C(O)N(Alkyl)2, C(O)N(Cycloalkyl)2, C(O)N(Aryl)2, C(O)N(Heteroaryl)2, SO-Alkyl, SO-Aryl, SO2-Alkyl, SO2-Aryl, SO2NH2, SO2NH-Alkyl, SO2NH-Aryl, SO2NH-Heteroaryl, SO2NH-Alkyl-Aryl, SO3H, SO2O-Alkyl, SO2O-Aryl, SO2O-Alkyl-Aryl, Alkyl, Cycloalkyl, Heterocyclyl, Aryl oder Heteroaryl, ein- oder mehrfach, gleich oder verschieden substituiert sein kann, wobei p den Wert 0, 1 , 2,Alkyl, C (O) -aryl, C (O) -heteroaryl, CO 2 H, CO 2 -alkyl, CO 2 -R38, CO 2 -cycloalkyl, CO 2 -H-heterocyclyl, CO 2 -aryl, CO 2 -heteroaryl , CO 2 -alkyl-cycloalkyl, CO 2 -alkyl heterocyclyl, CO 2 -AI alkyl-Ary I, CO 2 -alkyl-heteroaryl, C (O) -NH 2, C (O) NH-alkyl, C (O ) NH-R38, C (O) NH -cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl-cycloalkyl, C (O ) NH-alkyl heterocyclyl, C (O) NH-alkyl- Aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , SO-alkyl, SO-aryl, SO 2 -alkyl, SO 2 -aryl, SO 2 NH 2 , SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkyl-aryl , SO 3 H, SO 2 O-alkyl, SO 2 O-aryl, SO 2 O-alkyl-aryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, mono- or polysubstituted by identical or different substituents, where p is 0 , 1, 2,
3, 4 oder 5 und n den Wert 1 , 2 oder 3 annehmen kann,3, 4 or 5 and n can be 1, 2 or 3,
unsubstituiertes oder substituiertes Heteroaryl, wobei der Heteroarylrest F, Cl, Br, I, CF3, CN, NH2, NH-Alkyl, NH-R38, NH-Cycloalkyl, NH-Heterocyclyl, NH-Aryl, NH- Heteroaryl, NH-Alkyl-Cycloalkyl, NH-Alkyl-Heterocyclyl, NH-Alkyl-Aryl, NH-Alkyl-unsubstituted or substituted heteroaryl, wherein the heteroaryl group F, Cl, Br, I, CF 3, CN, NH 2, NH-alkyl, NH-R38, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH- heteroaryl, NH Alkyl-cycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-
Heteroaryl, NH-Alkyl-NH2, NH-Alkyl-OH, N(Alkyl)2, NHC(O)-Alkyl, NHC(O)-R38, NHC(O)-Cycloalkyl, NHC(O)-Heterocyclyl, NHC(O)-Aryl, NHC(O)-Heteroaryl, NHC(O)-Alkyl-Aryl, NHC(O)-Alkyl-Heteroaryl, NHSO2-Alkyl, NHSO2-Cycloalkyl, NHSO2-Heterocyclyl, NHSO2-Aryl, N H SO2- Heteroaryl, NHSO2-Alkyl-Aryl, NHSO2- Alkyl-Heteroaryl, NO2, SH, S-Alkyl, S-Aryl, S-Heteroaryl, OH, OCF3, O(-Alkyl-O)p-Heteroaryl, NH-alkyl-NH 2 , NH-alkyl-OH, N (alkyl) 2 , NHC (O) -alkyl, NHC (O) -R38, NHC (O) -cycloalkyl, NHC (O) -heterocyclyl, NHC (O) -aryl, NHC (O) -heteroaryl, NHC (O) -alkyl-aryl, NHC (O) -alkyl-heteroaryl, NHSO 2 -alkyl, NHSO 2 -cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl , NH SO 2 - heteroaryl, NHSO 2 -alkyl-aryl, NHSO 2 -alkyl-heteroaryl, NO 2 , SH, S-alkyl, S-aryl, S-heteroaryl, OH, OCF 3 , O (-alkyl-O) p -
Alkyl, O-R38, O-Cycloalkyl, O-Heterocyclyl, O-Aryl, O-Heteroaryl, O-Alkyl- Cycloalkyl, O-Alkyl-Heterocyclyl, O-Alkyl-Aryl, O-Alkyl-Heteroaryl, OC(O)-Alkyl, OC(O)-R38, OC(O)-Cycloalkyl, OC(O)-Heterocyclyl, OC(O)-Aryl, OC(O)-Heteroaryl, OC(O)-Alkyl-Aryl, OC(O)-Alkyl-Heteroaryl, OSO3H, OSO2-Alkyl, OSO2-Cycloalkyl, OSO2-Heterocyclyl, OSO2-Aryl, OSO2-Heteroaryl, OSO2-AI kyl-Ary I, OSO2-Alkyl-Alkyl, O-R38, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, OC (O) Alkyl, OC (O) -R38, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkyl-aryl, OC (O ) -Alkyl-heteroaryl, OSO 3 H, OSO 2 -alkyl, OSO 2 -cycloalkyl, OSO 2 -heterocyclyl, OSO 2 -aryl, OSO 2 -heteroaryl, OSO 2 -alkyl-aryl I, OSO 2 -alkyl-
Heteroaryl, OP(O)(OH)2, C(O)-Alkyl, C(O)-Aryl, C(O)-Heteroaryl, CO2H, CO2-Alkyl, CO2-R38, CO2-Cycloalkyl, CO2-Heterocyclyl, CO2-Aryl, CO2-Heteroaryl, CO2-Alkyl- Cycloalkyl, CO2-Alkyl-Heterocyclyl, CO2-AI kyl-Ary I, CO2-Alkyl-Heteroaryl, C(O)-NH2, C(O)NH-Alkyl, C(O)NH-R38, C(O)NH-Cycloalkyl, C(O)N H-Heterocyclyl, C(O)NH- Aryl, C(O)NH-Heteroaryl, C(O)NH-Alkyl-Cycloalkyl, C(O)NH-Alkyl-Heterocyclyl,Heteroaryl, OP (O) (OH) 2 , C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO 2 H, CO 2 -alkyl, CO 2 -R38, CO 2 -cycloalkyl , CO 2 heterocyclyl, CO 2 aryl, CO 2 heteroaryl, CO 2 alkyl cycloalkyl, CO 2 alkyl heterocyclyl, CO 2 alkyl-aryl I, CO 2 alkyl heteroaryl, C (O) -NH 2 , C (O) NH-alkyl, C (O) NH-R38, C (O) NH -cycloalkyl, C (O) N H -heterocyclyl, C (O) NH-aryl, C (O) NH Heteroaryl, C (O) NH-alkyl-cycloalkyl, C (O) NH-alkyl-heterocyclyl,
C(O)NH-Alkyl-Aryl, C(O)N H-Alkyl-Heteroaryl, C(O)N(Alkyl)2, C(O)N(Cycloalkyl)2, C(O)N(Aryl)2, C(O)N(Heteroaryl)2, SO2NH2, SO2NH-Alkyl, SO2NH-Aryl, SO2NH- Heteroaryl, SO2NH-Alkyl-Aryl, SO3H, SO2O-Alkyl, SO2O-Aryl, SO2O-Alkyl-Aryl, Alkyl, Cycloalkyl, Heterocyclyl, Aryl oder Heteroaryl, ein- oder mehrfach, gleich oder verschieden substituiert sein kann, wobei p den Wert 0, 1 , 2, 3, 4 oder 5 annehmen kann,C (O) NH-alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , SO 2 NH 2 , SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkyl-aryl, SO 3 H, SO 2 O- Alkyl, SO 2 O-aryl, SO 2 O-alkyl-aryl, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, mono- or polysubstituted by identical or different substituents, where p is the value 0, 1, 2, 3, 4 or 5,
sein können, oder R10 und R1 1 zusammen einen Heterocyclyl-Ring bilden können,or R10 and R1 1 together can form a heterocyclyl ring,
R3 und R4 können unabhängig voneinander: WasserstoffR3 and R4 can be independent of each other: hydrogen
Hydroxylhydroxyl
Halogen, wie Fluor, Chlor, Brom, lodHalogen, such as fluorine, chlorine, bromine, iodine
unsubstituiertes oder substituiertes Alkyl, wobei der Alkylrest mit F, Cl, Br, I, CN, CF3, NH2, NH-Alkyl, NH-Aryl, N(Alkyl)2, SH, S-Alkyl, OH, OCF3, O(-Alkyl-O)p-Alkyl, O-Aryl, OSO3H, OP(O)(OH)2, OP(O)(OAIkyl)2, OP(O)(OAryl)2, C(O)OH, C(O)ORI 4,unsubstituted or substituted alkyl, wherein the alkyl radical with F, Cl, Br, I, CN, CF 3 , NH 2 , NH-alkyl, NH-aryl, N (alkyl) 2 , SH, S-alkyl, OH, OCF 3 , O (-alkyl-O) p -alkyl, O-aryl, OSO 3 H, OP (O) (OH) 2 , OP (O) (OAlkyl) 2 , OP (O) (O-aryl) 2 , C (O) OH, C (O) ORI 4,
C(O)NH2, C(0)NHR14, C(O)NR14R15, SO3H, SO2Alkyl, SO2Aryl, P(O)(OH)2, P(O)(OAIkyl)2, P(O)(OAryl)2, Cycloalkyl, Heterocyclyl, Aryl oder Heteroaryl ein- oder mehrfach, gleich oder verschieden substituiert sein kann, wobei p den Wert 0, 1 , 2, 3, 4 oder 5 annehmen kann und die Reste R14 und R15 unabhängig voneinander Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl,C (O) NH 2 , C (O) NHR 14, C (O) NR 14 R 15, SO 3 H, SO 2 alkyl, SO 2 aryl, P (O) (OH) 2 , P (O) (OAlkyl) 2 , P (O) (OAryl) 2 , cycloalkyl, heterocyclyl, aryl or heteroaryl may be monosubstituted or polysubstituted by identical or different substituents, where p may assume the value 0, 1, 2, 3, 4 or 5 and the radicals R14 and R15 independently of one another alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl,
Alkyl-Aryl oder Alkyl-Heteroaryl sein können oder R14 und R15 zusammen einen Heterocyclyl-Ring bilden können,Alkyl-aryl or alkyl-heteroaryl or R14 and R15 can together form a heterocyclyl ring,
unsubstituiertes oder substituiertes Aryl, wobei der Arylrest mit F, Cl, Br, I, CF3, CN, NH2, NH-Alkyl, NH-R38, NH-Cycloalkyl, NH-Heterocyclyl, NH-Aryl, NH-Heteroaryl,unsubstituted or substituted aryl, where the aryl radical is substituted by F, Cl, Br, I, CF 3 , CN, NH 2 , NH-alkyl, NH-R 38, NH-cycloalkyl, NH-heterocyclyl, NH-aryl, NH-heteroaryl,
NH-Alkyl-Cycloalkyl, NH-Alkyl-Heterocyclyl, NH-Alkyl-Aryl, NH-Alkyl-Heteroaryl, N(Alkyl)2, N(Aryl)2, NR20-Alkyl, NHC(O)-Alkyl, NHC(O)-R38, NR19(0)-Alkyl, NHC(O)-Cycloalkyl, NR19C(O)-Cycloalkyl, NHC(O)-Heterocyclyl, NR19C(O)- Heterocyclyl, NHC(O)-Aryl, NR19C(0)-Aryl, NHC(O)-Heteroaryl, NR19C(O)- Heteroaryl, NR18C(O)-Alkyl-Cycloalkyl, NR18C(O)-Alkyl-Heterocyclyl, NHC(O)-NH-alkyl-cycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-alkyl-heteroaryl, N (alkyl) 2 , N (aryl) 2 , NR20-alkyl, NHC (O) -alkyl, NHC (O ) -R38, NR19 (O) -alkyl, NHC (O) -cycloalkyl, NR19C (O) -cycloalkyl, NHC (O) -heterocyclyl, NR19C (O) -heterocyclyl, NHC (O) -aryl, NR19C (0) -Aryl, NHC (O) -Heteroaryl, NR19C (O) - Heteroaryl, NR18C (O) -alkyl-cycloalkyl, NR18C (O) -alkyl-heterocyclyl, NHC (O) -
Alkyl-Aryl, NR19C(0)-Alkyl-Aryl, NHC(O)-Alkyl-Heteroaryl, NR19C(0)-Alkyl- Heteroaryl, NR18C(O)O-R19, NR18C(O)NR18R18, NHSO2-Alkyl, NHSO2- Cycloalkyl, NHSO2-Heterocyclyl, NHSO2-Aryl, NHSO2-Heteroaryl, NHSO2-Alkyl- Heterocyclyl, NHSO2-Alkyl-Aryl, NHSO2-Alkyl-Heteroaryl, NO2, SH, S-Alkyl, S-Aryl, S-Heteroaryl, OH, OCF3, O-Alkyl, O-R38, O-Cycloalkyl, O-Heterocyclyl, O-Aryl, O-Alkyl-aryl, NR19C (0) -alkyl-aryl, NHC (O) -alkyl-heteroaryl, NR19C (0) alkyl- heteroaryl, NR18C (O) O-R19, NR18C (O) NR18R18, NHSO 2 alkyl, NHSO 2 - cycloalkyl, NHSO 2 heterocyclyl, NHSO 2 aryl, NHSO 2 heteroaryl, NHSO 2 alkyl heterocyclyl, NHSO 2 alkyl aryl, NHSO 2 alkyl heteroaryl, NO 2 , SH, S-alkyl, S-aryl, S-heteroaryl, OH, OCF 3 , O-alkyl, O-R 38, O-cycloalkyl, O-heterocyclyl, O-aryl, O-
Heteroaryl, O-Alkyl-Cycloalkyl, O-Alkyl-Heterocyclyl, O-Alkyl-Aryl, O-Alkyl- Heteroaryl, O-(CH2)n-O, OC(O)-Alkyl, OC(O)-R38, OC(O)-Cycloalkyl, OC(O)- Heterocyclyl, OC(O)-Aryl, OC(O)-Heteroaryl, OC(O)-Alkyl-Cycloalkyl, OC(O)-Alkyl- Heterocyclyl OC(O)-Alkyl-Aryl, OC(O)-Alkyl-Heteroaryl, OC(O)O-RI 9, OC(O)NRI 8R18, OSO3H, OSO2-Alkyl, OSO2-Cycloalkyl, OSO2-Heterocyclyl, O- SO2-Aryl, OSO2-Heteroaryl, OSO2-Alkyl-Aryl, OSO2-Alkyl-Heteroaryl, OP(O)(OH)2, OP(O)(OAIkyl)2, OP(O)(OAryl)2, C(O)-Alkyl, C(O)-Aryl, C(O)-Heteroaryl, CO2H, CO2-Alkyl, CO2-R38, CO2-Cycloalkyl, CO2-Heterocyclyl, CO2-Aryl, CO2-Heteroaryl, CO2-Alkyl-Cycloalkyl, CO2-Alkyl-Heterocyclyl, CO2-Alkyl-Aryl, CO2-Alkyl-Heteroaryl, C(O)-NH2, C(O)NH-Alkyl, C(O)NH-R38, C(O)NH-Cycloalkyl, C(O)N H-Heterocyclyl,Heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-heteroaryl, O- (CH 2 ) n -O, OC (O) -alkyl, OC (O) -R38, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -heteroaryl, OC (O) -alkyl-cycloalkyl, OC (O) -alkyl-heterocyclyl OC (O) - Alkyl-aryl, OC (O) -alkyl-heteroaryl, OC (O) O-RI 9, OC (O) NRI 8R18, OSO 3 H, OSO 2 -alkyl, OSO 2 -cycloalkyl, OSO 2 -heterocyclyl, O- SO 2 -aryl, OSO 2 -heteroaryl, OSO 2 -alkyl-aryl, OSO 2 -alkyl-heteroaryl, OP (O) (OH) 2 , OP (O) (OAlkyl) 2 , OP (O) (O-aryl) 2 , C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO 2 H, CO 2 -alkyl, CO 2 -R38, CO 2 -cycloalkyl, CO 2 -heterocyclyl, CO 2 -aryl , CO 2 heteroaryl, CO 2 alkyl cycloalkyl, CO 2 alkyl heterocyclyl, CO 2 alkyl aryl, CO 2 alkyl heteroaryl, C (O) -NH 2 , C (O) NH alkyl, C (O) NH-R38, C (O) NH-cycloalkyl, C (O) NH-heterocyclyl,
C(O)NH-Aryl, C(O)NH-Heteroaryl, C(O)N H-Alkyl-Cycloalkyl, C(O)NH-Alkyl- Heterocyclyl, C(O)N H-Al kyl-Aryl, C(O)NH-Alkyl-Heteroaryl, C(O)N(Alkyl)2, C(O)N(Cycloalkyl)2, C(O)N(Aryl)2, C(O)N(Heteroaryl)2, C(O)N R20-Alkyl, C(O)NRI 9- Alkyl-R21 , -C(O)NRI 80-R18, -C(O)NR18NR18R18, SO-Alkyl, SO-Aryl, SO2-Alkyl, SO2-Aryl, SO2NH2, SO2NH-Alkyl, SO2NH-Aryl, SO2NH-Heteroaryl, SO2NH-Alkyl-C (O) NH-aryl, C (O) NH-heteroaryl, C (O) NH-alkyl-cycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) N H -alkyl-aryl, C (O) NH-alkyl heteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N (heteroaryl) 2 , C (O) N R 20 alkyl, C (O) NRl 9 alkyl R 21, -C (O) NRl 80 R 18, -C (O) NR 18 NR 18 R 18, SO-alkyl, SO-aryl, SO 2 alkyl, SO 2 -aryl, SO 2 NH 2 , SO 2 NH-alkyl, SO 2 NH-aryl, SO 2 NH-heteroaryl, SO 2 NH-alkyl-
Aryl, SO3H, SO2O-Alkyl, SO2O-Aryl, SO2O-Alkyl-Aryl, Alkyl, Alkyl-Cycloalkyl, Alkyl- Heterocyclyl, Alkyl-Aryl, Alkyl-Heteroaryl, Cycloalkyl, Heterocyclyl, Aryl oder Hete- roaryl, ein- oder mehrfach, gleich oder verschieden substituiert sein kann, n den Wert 1 ,2 oder 3 annehmen kann, und die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl-, Heteroaryl-, Alkyl-Cycloalkyl-, Alkyl-Heterocyclyl-, Alkyl-Aryl- und Alkyl-Aryl, SO 3 H, SO 2 O-alkyl, SO 2 O-aryl, SO 2 O-alkyl-aryl, alkyl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl, alkyl-heteroaryl, cycloalkyl, heterocyclyl, aryl or Heteroaryl, mono- or polysubstituted by identical or different substituents, n can assume the value 1, 2 or 3, and the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl Heterocyclyl, alkyl-aryl and alkyl
Heteroarylsubstituenten ihrerseits wiederum substituiert sein können,Heteroaryl substituents in turn may be substituted,
unsubstituiertes oder substituiertes Heteroaryl, wobei der Heteroarylrest mit F, Cl, Br, I, CF3, CN, NH2, NH-Alkyl, NH-R38, NH-Cycloalkyl, N H-Heterocyclyl, NH-Aryl, NH-Heteroaryl, NH-Alkyl-Cycloalkyl, NH-Alkyl-Heterocyclyl, NH-Alkyl-Aryl, NH-unsubstituted or substituted heteroaryl, where the heteroaryl radical with F, Cl, Br, I, CF 3, CN, NH 2, NH-alkyl, NH-R38, NH-cycloalkyl, N H-heterocyclyl, NH-aryl, NH-heteroaryl, NH-alkyl-cycloalkyl, NH-alkyl-heterocyclyl, NH-alkyl-aryl, NH-
Alkyl-Heteroaryl, N(Alkyl)2, N(Aryl)2, NR20-Alkyl, NHC(O)-Alkyl, NHC(O)-R38, NR19C(0)-Alkyl, NHC(O)-Cycloalkyl, NR19C(O)-Cycloalkyl, NHC(O)-Heterocyclyl, NR19C(O)-Heterocyclyl, NHC(O)-Aryl, NR19C(0)-Aryl, NHC(O)-Heteroaryl, NR19C(O)-Heteroaryl, NR18C(O)-Alkyl-Cycloalkyl, NR18C(O)-Alkyl-Heterocyclyl, NHC(O)-Alkyl-Aryl, NR19C(0)-Alkyl-Aryl, NHC(O)-Alkyl-Heteroaryl, NR19C(O)-Alkyl-heteroaryl, N (alkyl) 2 , N (aryl) 2 , NR20-alkyl, NHC (O) -alkyl, NHC (O) -R38, NR19C (O) -alkyl, NHC (O) -cycloalkyl, NR19C ( O) -cycloalkyl, NHC (O) -heterocyclyl, NR19C (O) -heterocyclyl, NHC (O) -aryl, NR19C (O) -aryl, NHC (O) -Heteroaryl, NR19C (O) -Heteroaryl, NR18C (O ) -Alkyl-cycloalkyl, NR18C (O) -alkyl-heterocyclyl, NHC (O) -alkyl-aryl, NR19C (O) -alkyl-aryl, NHC (O) -alkyl-heteroaryl, NR19C (O) -
Alkyl-Heteroaryl, NR18C(O)O-RI 9, NR18C(O)NRI 8R18, NHSO2-Alkyl, NHSO2- Cycloalkyl, NHSO2-Heterocyclyl, NHSO2-Aryl, NHSO2-Heteroaryl, NHSO2-Alkyl- Heterocyclyl, NHSO2-Alkyl-Aryl, NHSO2-Alkyl-Heteroaryl, NO2, SH, S-Alkyl, S-Aryl, S-Heteroaryl, OH, OCF3, O-Alkyl, O-R38, O-Cycloalkyl, O-Heterocyclyl, O-Aryl, O- Heteroaryl, O-Alkyl-Cycloalkyl, O-Alkyl-Heterocyclyl, O-Alkyl-Aryl, O-Alkyl-Alkyl-heteroaryl, NR18C (O) O-RI 9, NR18C (O) NRI 8R18, NHSO 2 alkyl, NHSO 2 - cycloalkyl, NHSO 2 -heterocyclyl, NHSO 2 -aryl, NHSO 2 -heteroaryl, NHSO 2 -alkyl Heterocyclyl, NHSO 2 -alkyl-aryl, NHSO 2 -alkyl-heteroaryl, NO 2 , SH, S-alkyl, S-aryl, S-heteroaryl, OH, OCF 3 , O-alkyl, O-R 38, O-cycloalkyl, O-heterocyclyl, O-aryl, O-heteroaryl, O-alkyl-cycloalkyl, O-alkyl-heterocyclyl, O-alkyl-aryl, O-alkyl-
Heteroaryl, OC(O)-Alkyl, OC(O)-R38, OC(O)-Cycloalkyl, OC(O)-Heterocyclyl, OC(O)-Aryl, OC(O)-Heteroaryl, OC(O)-Alkyl-Cycloalkyl, OC(O)-Alkyl-Heterocyclyl OC(O)-Alkyl-Aryl, OC(O)-Alkyl-Heteroaryl, OC(O)O-RI 9, OC(O)NRI 8R18, OSO3H, OSO2-Alkyl, OSO2-Cycloalkyl, OSO2-Heterocyclyl, OSO2-Aryl, OSO2-Heteroaryl, OSO2-Alkyl-Aryl, OSO2-Alkyl-Heteroaryl, OP(O)(OH)2, OP(O)(OAIkyl)2, OP(O)(OAryl)2, C(O)-Alkyl, C(O)-Aryl, C(O)-Heteroaryl, CO2H, CO2-Alkyl, CO2-R38, CO2-Cycloalkyl, CO2-Heterocyclyl, CO2-Aryl, CO2-H eteroaryl, CO2-Alkyl-Cycloalkyl, CO2-Alkyl-Heterocyclyl, CO2-AI kyl-Aryl, CO2-Alkyl-Heteroaryl, C(O)-NH2, C(O)NH- Alkyl, C(O)NH-R38, C(O)NH-Cycloalkyl, C(O)NH-Heterocyclyl, C(O)NH-Aryl, C(O)N H-Heteroaryl, C(O)NH-Alkyl-Cycloalkyl, C(O)NH-Alkyl-Heterocyclyl, C(O)NH-Heteroaryl, OC (O) -alkyl, OC (O) -R38, OC (O) -cycloalkyl, OC (O) -heterocyclyl, OC (O) -aryl, OC (O) -Heteroaryl, OC (O) -alkyl Cycloalkyl, OC (O) alkyl heterocyclyl, OC (O) alkyl aryl, OC (O) alkyl heteroaryl, OC (O) O-RI 9, OC (O) NRI 8R18, OSO 3 H, OSO 2 alkyl, OSO 2 cycloalkyl, OSO 2 heterocyclyl, OSO 2 aryl, OSO 2 heteroaryl, OSO 2 alkyl aryl, OSO 2 alkyl heteroaryl, OP (O) (OH) 2 , OP (O. ) (OAlkyl) 2 , OP (O) (O-aryl) 2 , C (O) -alkyl, C (O) -aryl, C (O) -heteroaryl, CO 2 H, CO 2 -alkyl, CO 2 -R38, CO 2 -cycloalkyl, CO 2 heterocyclyl, CO 2 aryl, CO 2 heteroaryl, CO 2 alkyl cycloalkyl, CO 2 alkyl heterocyclyl, CO 2 alkyl-aryl, CO 2 alkyl heteroaryl, C (O) -NH 2 , C (O) NH-alkyl, C (O) NH-R38, C (O) NH -cycloalkyl, C (O) NH-heterocyclyl, C (O) NH-aryl, C (O) N H -heteroaryl , C (O) NH-alkylcycloalkyl, C (O) NH-alkyl-heterocyclyl, C (O) NH-
Alkyl-Aryl, C(O)NH-Alkyl-Heteroaryl, C(O)N(Alkyl)2, C(O)N(Cycloalkyl)2, C(O)N(Aryl)2, C(O)N(Heteroaryl)2, C(O)N R20-Alkyl, C(O)NRI 9-Alkyl-R21 , - C(O)NR18O-R18, -C(O)NR18NR18R18, SO2NH2, SO2NH-Alkyl, SO2NH-Aryl, SO2N H-Heteroaryl, SO2NH-Alkyl-Aryl, S03H, SO2O-Alkyl, SO2O-Aryl, SO2O-Alkyl- Aryl, Alkyl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl, Alkyl-Heteroaryl, Cycloal- kyl, Heterocyclyl, Aryl oder Heteroaryl ein- oder mehrfach, gleich oder verschieden substituiert sein kann, und die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl-, Heteroaryl-, Alkyl-Cycloalkyl-, Alkyl-Heterocyclyl-, Alkyl-Aryl- und Alkyl-Heteroarylsubstituenten ihrerseits wiederum substituiert sein können,Alkyl-aryl, C (O) NH-alkyl-heteroaryl, C (O) N (alkyl) 2 , C (O) N (cycloalkyl) 2 , C (O) N (aryl) 2 , C (O) N ( Heteroaryl) 2 , C (O) N R 20 alkyl, C (O) NR I 9 alkyl R 21, C (O) NR 18 O-R 18, -C (O) NR 18 NR 18 R 18, SO 2 NH 2 , SO 2 NH-alkyl , SO 2 NH-aryl, SO 2 N H-heteroaryl, SO 2 NH-alkyl-aryl, SO 3 H, SO 2 O-alkyl, SO 2 O-aryl, SO 2 O-alkyl-aryl, alkyl, alkyl-cycloalkyl, Alkyl-heterocyclyl, alkyl-aryl, alkyl-heteroaryl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be mono- or polysubstituted by identical or different substituents, and the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, Alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl and alkyl-heteroaryl substituents in turn may be substituted,
OR29, wobei R29 Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein kann, und die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl-, Heteroaryl-, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl- Aryl oder Alkyl-Heteroarylsubstituenten ihrerseits wiederum substituiert sein kön- nen,OR29, wherein R29 may be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, and the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl -Cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl substituents in turn can be substituted,
SR30, wobei R30 Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein kann, und die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl- und Heteroaryl-, Alkyl-Cycloalkyl-, Alkyl-Heterocyclyl-, Al- kyl-Aryl- oder Alkyl-Heteroarylsubstituenten ihrerseits wiederum substituiert sein können,SR30, wherein R30 may be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, and the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, alkyl Cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl substituents in turn may be substituted,
NR31 R32, wobei R31 und R32 unabhängig voneinander Wasserstoff, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl, Alkyl-Heteroaryl, -C(O)-R33, -SO2R33, -C(O)OR33 und -C(O)-NR34R35 sein können, wobei R33 Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl- Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl, Alkyl-Heteroaryl sein kann, und R34 und R35 unabhängig voneinander Wasserstoff, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl, Alkyl-Heteroaryl sein kön- nen oder R34 und R35 zusammen einen Heterocyclyl-Ring bilden können, oder R31 und R32 zusammen einen Heterocyclyl-Ring bilden können, und die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl- und Heteroaryl-, Alkyl-Cycloalkyl, Al- kyl-Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroarylsubstituenten ihrerseits wiederum substituiert sein können,NR31 R32, wherein R31 and R32 are independently hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl, alkyl-heteroaryl, -C (O) -R33, -SO2 R33, -C (O) OR33 and -C (O) -NR34R35, wherein R33 can be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl, and R34 and R35 independently of one another can be hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl or R34 and R35 can together form a heterocyclyl ring, or R31 and R32 may together form a heterocyclyl ring, and the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl substituents in turn be substituted can,
und R18 Wasserstoff, Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl- Cycloalkyl, Alkyl-Heterocyclyl, Alkyl-Aryl oder Alkyl- Heteroaryl sein kann,and R18 can be hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl,
und R19 Alkyl, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl- Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein kann,and R 19 may be alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl,
und R20 Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Alkyl-Cycloalkyl, Alkyl- Heterocyclyl, Alkyl-Aryl oder Alkyl-Heteroaryl sein kann,and R 20 can be cycloalkyl, heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl-heteroaryl,
und R21 Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl sein kann,and R 21 can be cycloalkyl, heterocyclyl, aryl, heteroaryl,
und R38 Alkyl sein kann, wobei der Alkylrest gesättigt oder ungesättigt, geradkettig oder verzweigt sein kann, mit 9 bis 30 C-Atomen, und die Cg-3o-Alkenyle mindestens eine C-C-Doppelbindung und C9-3o-Alkinyle mindestens eine C-C- Dreifachbindung aufweisen, wobei die Alkenyle sowohl in (E)- als auch in (Z)-and R38 may be alkyl, wherein the alkyl radical may be saturated or unsaturated, straight-chain or branched, having 9 to 30 carbon atoms, and the Cg- 3 o-alkenyls at least one CC double bond and C 9 - 3 o-alkynyls at least one Have CC triple bond, the alkenyls in both (E) - and in (Z) -
Konformation vorliegen können,Conformation can exist
sowie physiologisch verträgliche Salze, Derivate oder Analoga der Verbindungen nach Formel I, sowie deren Solvate, Hydrate, polymorphe Formen und Prodrugs, wobei die Verbindungen der allgemeinen Formel I sowie deren Salze, Derivate o- der Analoga, deren Solvate, Hydrate, polymorphe Formen und Prodrugs in Form ihrer Racemate, in Form der reinen Enantiomeren und/oder Diastereomeren oder in Form von Mischungen dieser Enantiomeren und/oder Diasteromeren oder in Form der Tautomeren vorliegen können.and physiologically acceptable salts, derivatives or analogs of the compounds of formula I, and their solvates, hydrates, polymorphs and prodrugs, wherein the compounds of general formula I and their salts, derivatives or analogs, their solvates, hydrates, polymorphic forms and Prodrugs in the form of their racemates, in the form of pure enantiomers and / or diastereomers or in the form of mixtures of these enantiomers and / or diastereomers or in the form of tautomers may be present.
14. Pyrido[2,3-b]pyrazin-Derivate der allgemeinen Formel (II) gemäß einem der Ansprüche 12, 13, wobei R2 = H ist. 14. Pyrido [2,3-b] pyrazine derivatives of the general formula (II) according to one of claims 12, 13, wherein R 2 = H.
15. Pyrido[2,3-b]pyrazin-Derivate der allgemeinen Formel (II) gemäß einem der Ansprüche 12, 13, wobei R2 und R4 = H sind.15. Pyrido [2,3-b] pyrazine derivatives of the general formula (II) according to any one of claims 12, 13, wherein R 2 and R 4 = H.
16. Pyrido[2,3-b]pyrazin-Derivate der allgemeinen Formel (II) gemäß Anspruch 12, wobei R2 und R4 = H sind und R6 = -C(Y)NR7R8 bedeutet, wobei Y unabhängig voneinander O oder S sein kann und R7 und R8 die im Anspruch 12 genannnte Bedeutung haben.16. Pyrido [2,3-b] pyrazine derivatives of the general formula (II) according to claim 12, wherein R 2 and R 4 are H and R 6 = -C (Y) NR 7 R 8, where Y can independently of one another be O or S. and R7 and R8 have the meaning given in claim 12.
17. Pyrido[2,3-b]pyrazin-Derivate der allgemeinen Formel (II) gemäß einem der An- sprüche 12, 13, dadurch gekennzeichnet, dass der Alkylrest Methyl, Ethyl, n-17. Pyrido [2,3-b] pyrazine derivatives of the general formula (II) according to any one of claims 12, 13, characterized in that the alkyl radical methyl, ethyl, n-
Propyl, 2-Propyl, n-Butyl, sec.-Butyl, te/t-Butyl, n-Pentyl, /so-Pentyl, neo-Pentyl, n- Hexyl, 2-Hexyl, n-Octyl, Ethylenyl (Vinyl), Ethinyl, Propenyl (-CH2CH=CH2; - CH=CH-CH3, -C(=CH2)-CH3), Propinyl (-CH2-C≡CH, -C≡C-CH3), Butenyl, Butinyl, Pentenyl, Pentinyl, Hexenyl, Hexinyl, Heptenyl, Heptinyl, Octenyl und Octinyl sein kann.Propyl, 2-propyl, n-butyl, sec-butyl, te / t-butyl, n-pentyl, / so-pentyl, neo-pentyl, n-hexyl, 2-hexyl, n-octyl, ethylenyl (vinyl) , Ethynyl, propenyl (-CH 2 CH = CH 2 ; -CH = CH-CH 3 , -C (= CH 2 ) -CH 3 ), propynyl (-CH 2 -C≡CH, -C≡C-CH 3 ), Butenyl, butynyl, pentenyl, pentynyl, hexenyl, hexynyl, heptenyl, heptynyl, octenyl and octynyl.
18. Pyrido[2,3-b]pyrazin-Derivate der allgemeinen Formel (II) gemäß einem der Ansprüche 12, 13, dadurch gekennzeichnet, dass der Heterocyclyl-Rest Tetrahydro- furyl, Pyrrolidinyl, Imidazolidinyl, Thiazolidinyl, Tetrahydropyranyl, Piperidinyl, Pipe- razinyl und Morpholinyl sein kann.18. Pyrido [2,3-b] pyrazine derivatives of the general formula (II) according to any one of claims 12, 13, characterized in that the heterocyclyl radical tetrahydro furyl, pyrrolidinyl, imidazolidinyl, thiazolidinyl, tetrahydropyranyl, piperidinyl, Pipe - Razinyl and morpholinyl may be.
19. Pyrido[2,3-b]pyrazin-Derivate der allgemeinen Formel (II) gemäß einem der Ansprüche 12, 13, dadurch gekennzeichnet, dass der Heteroaryl-Rest Pyrrolyl, Furyl, Thienyl, Thiazolyl, Oxazolyl, Oxadiazolyl, Isoxazolyl, Pyrazolyl, Imidazolyl, Triazol, Tetrazol, Pyridinyl, Pyrimidinyl, Pyridazinyl, Pyrazinyl, Triazin, Phthalazinyl, Indolyl,19. Pyrido [2,3-b] pyrazine derivatives of the general formula (II) according to one of claims 12, 13, characterized in that the heteroaryl radical pyrrolyl, furyl, thienyl, thiazolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyrazolyl , Imidazolyl, triazole, tetrazole, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazine, phthalazinyl, indolyl,
Indazolyl, Indolizinyl, Chinolinyl, Isochinolinyl, Chinoxalinyl, Chinazolinyl, Pteridinyl, Carbazolyl, Phenazinyl, Phenoxazinyl, Phenothiazinyl, Acridinyl sein kann.Indazolyl, indolizinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, pteridinyl, carbazolyl, phenazinyl, phenoxazinyl, phenothiazinyl, acridinyl.
20. Pyrido[2,3-b]pyrazin-Derivate der allgemeinen Formeln (I), (II) gemäß einem der Ansprüche 1 bis 19 ausgewählt aus der Gruppe bestehend aus: Verbindung 1 1-Ethyl-3-(3-phenylethinyl-pyrido[2,3-b]pyrazin-6-yl)-Harnstoff20. Pyrido [2,3-b] pyrazine derivatives of the general formulas (I), (II) according to any one of claims 1 to 19 selected from the group consisting of: Compound 1 1-Ethyl-3- (3-phenylethynylpyrido [2,3-b] pyrazine-6-yl) urea
Verbindung 2 1-Ethyl-3-(3-thiophen-3-ylethinyl-pyrido[2,3-b]pyrazin-6-yl)-HarnstoffCompound 2 1-Ethyl-3- (3-thiophen-3-ylethynylpyrido [2,3-b] pyrazine-6-yl) urea
Verbindung 3 1-(3-Cyclopropylethinyl-pyrido[2,3-b]pyrazin-6-yl)-3-ethyl-HarnstoffCompound 3 1- (3-Cyclopropylethynylpyrido [2,3-b] pyrazine-6-yl) -3-ethyl-urea
Verbindung 4 1-[3-(3-Dimethylamino-prop-1-inyl)-pyrido[2,3-b]pyrazin-6-yl]-3-ethyl- HarnstoffCompound 4 1- [3- (3-Dimethylamino-prop-1-ynyl) -pyrido [2,3-b] pyrazine-6-yl] -3-ethyl-urea
Verbindung 5 1-[3-((E)-2-Cyclohexyl-vinyl)-pyrido[2,3-b]pyrazin-6-yl]-3-ethyl- HarnstoffCompound 5 1- [3 - ((E) -2-Cyclohexyl-vinyl) -pyrido [2,3-b] pyrazine-6-yl] -3-ethyl-urea
Verbindung 6 1-Ethyl-3-[3-((E)-3-methoxy-propenyl)-pyrido[2,3-b]pyrazin-6-yl]- Harnstoff Compound 6 1-Ethyl-3- [3 - ((E) -3-methoxy-propenyl) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 7Connection 7
Verbindung 8Connection 8
Verbindung 9 Kohlensäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl ester methyl esterCompound 9 Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester methyl ester
Verbindung 10 Kohlensäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl ester 2-methoxy-ethyl esterCompound 10 Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester 2-methoxy-ethyl ester
Verbindung 1 1 Kohlensäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl ester phenyl ester Compound 1 1 Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester phenyl ester
Verbindung 12 Diethyl-carbaminsäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin- 3-yl]-phenyl esterCompound 12 Diethylcarbamic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester
Verbindung 13 (E)-3-Phenyl-acrylsäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin- 3-yl]-phenyl esterCompound 13 (E) -3-phenyl-acrylic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester
Verbindung 14 Nonadekansäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]- phenyl esterCompound 14 Nonadocanoic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester
Verbindung 15 1-(3-Benzyl-pyrido[2,3-b]pyrazin-6-yl)-3-ethyl-HarnstoffCompound 15 1- (3-Benzyl-pyrido [2,3-b] pyrazine-6-yl) -3-ethyl-urea
Verbindung 16 Kohlensäure 3-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl ester 2-methoxy-ethyl ester Compound 16 Carbonic acid 3- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester 2-methoxy-ethyl ester
Verbindung 17 Kohlensäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl ester isobutyl esterCompound 17 Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester isobutyl ester
Verbindung 18 Kohlensäure but-2-inyl ester 4-[6-(3-ethyl-harnstoff)-pyrido[2,3- b]pyrazin-3-yl]-phenyl esterCompound 18 Carbonic acid but-2-ynyl ester 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester
Verbindung 19 Dimethyl-carbaminsäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3- b]pyrazin-3-yl]-phenyl esterCompound 19 Dimethylcarbamic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester
Verbindung 20 Ethyl-carbaminsäure 4-[6-(3-ethyl-1-phenyl-harnstoff)-pyrido[2,3- b]pyrazin-3-yl]-phenyl esterCompound 20 Ethyl carbamic acid 4- [6- (3-ethyl-1-phenyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester
Verbindung 21 {4-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl}- carbaminsäure tert-butyl ester Compound 21 {4- [6- (3-Ethyl-urea) -pyrido [2,3-b] pyrazine-3-yl] -phenyl} -carbamic acid tert-butyl ester
Verbindung 22 {4-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl}- carbaminsäure 2-methoxy-ethyl esterCompound 22 {4- [6- (3-Ethyl-urea) -pyrido [2,3-b] pyrazine-3-yl] -phenyl} -carbamic acid 2-methoxy-ethyl ester
Verbindung 23 1-Ethyl-3-{3-[4-(3-ethyl-harnstoff)-phenyl]-pyrido[2,3-b]pyrazin-6-yl}- HarnstoffCompound 23 1-Ethyl-3- {3- [4- (3-ethyl-urea) -phenyl] -pyrido [2,3-b] pyrazine-6-yl} -urea
Verbindung 24 1-{3-[4-(3,3-Dimethyl-harnstoff)-phenyl]-pyrido[2,3-b]pyrazin-6-yl}-3- ethyl-HarnstoffCompound 24 1- {3- [4- (3,3-Dimethyl-urea) -phenyl] -pyrido [2,3-b] pyrazine-6-yl} -3-ethyl-urea
Verbindung 25 1-Ethyl-3-{3-[6-(3-ethyl-harnstoff)-pyridin-3-yl]-pyrido[2,3-b]pyrazin-6- yl}-Harnstoff Compound 25 1-Ethyl-3- {3- [6- (3-ethyl-urea) -pyridin-3-yl] -pyrido [2,3-b] pyrazine-6-yl} -urea
Verbindung 26 1-Ethyl-3-{3-[2-(4-fluoro-phenyl)-ethyl]-pyrido[2,3-b]pyrazin-6-yl}- HarnstoffCompound 26 1-Ethyl-3- {3- [2- (4-fluoro-phenyl) -ethyl] -pyrido [2,3-b] pyrazine-6-yl} -urea
Verbindung 27 1-Ethyl-3-{3-[(E)-2-(4-fluoro-phenyl)-vinyl]-pyrido[2,3-b]pyrazin-6-yl}- HarnstoffCompound 27 1-Ethyl-3- {3 - [(E) -2- (4-fluoro-phenyl) -vinyl] -pyrido [2,3-b] pyrazine-6-yl} -urea
Verbindung 28 1-Ethyl-3-[3-(4-morpholin-4-ylmethyl-phenyl)-pyrido[2,3-b]pyrazin-6- yl]-HarnstoffCompound 28 1-Ethyl-3- [3- (4-morpholin-4-ylmethyl-phenyl) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 29 1-Ethyl-3-(3-{4-[2-(2-methoxy-ethoxy)-ethoxy]-phenyl}-pyrido[2,3- b]pyrazin-6-yl)-HarnstoffCompound 29 1-Ethyl-3- (3- {4- [2- (2-methoxy-ethoxy) -ethoxy] -phenyl} -pyrido [2,3-b] pyrazine-6-yl) -urea
Verbindung 30 N-{4-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl}-2-(2- methoxy-ethoxy)-acetamide Compound 30 N- {4- [6- (3-Ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl} -2- (2-methoxy-ethoxy) -acetamide
Verbindung 31 N-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-4-methyl- benzamideCompound 31 N- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -4-methyl-benzamide
Verbindung 32 Kohlensäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-2- methoxy-phenyl ester 2-methoxy-ethyl esterCompound 32 Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazino-3-yl] -2-methoxy-phenyl ester 2-methoxy-ethyl ester
Verbindung 33 Kohlensäure 2-benzyloxy-ethyl ester 4-[6-(3-ethyl-harnstoff)- pyrido[2,3-b]pyrazin-3-yl]-phenyl esterCompound 33 2-benzyloxyethyl carbonate 2- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester
Verbindung 34 Kohlensäure 2-benzyloxy-ethyl ester 4-[6-(3-ethyl-harnstoff)- pyrido[2,3-b]pyrazin-3-yl]-2-methoxy-phenyl esterCompound 34 2-benzyloxyethyl carbonate 2- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -2-methoxyphenyl ester
Verbindung 35 2-Benzyloxy-N-{4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]- phenyl}-acetamide Compound 35 2-Benzyloxy-N- {4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl} -acetamide
Verbindung 36 1-[4-(tert-Butyl-dimethyl-silanyloxy)-butyl]-3-(3-phenyl-pyrido[2,3- b]pyrazin-6-yl)-HarnstoffCompound 36 1- [4- (tert -butyl-dimethyl-silanyloxy) -butyl] -3- (3-phenyl-pyrido [2,3-b] pyrazine-6-yl) -urea
Verbindung 37 1-[4-(tert-Butyl-dimethyl-silanyloxy)-butyl]-3-[3-(4-hydroxy-3- methoxy-phenyl)-pyrido[2,3-b]pyrazin-6-yl]-HarnstoffCompound 37 1- [4- (tert -butyl-dimethyl-silanyloxy) -butyl] -3- [3- (4-hydroxy-3-methoxyphenyl) -pyrido [2,3-b] pyrazine-6-yl ]-Urea
Verbindung 38 Ethyl-carbaminsäure 4-[3-(3-phenyl-pyrido[2,3-b]pyrazin-6-yl)- harnstoff]-butyl esterCompound 38 Ethyl carbamic acid 4- [3- (3-phenylpyrido [2,3-b] pyrazine-6-yl) -urea] -butyl ester
Verbindung 39 Kohlensäure methyl ester 4-[3-(3-phenyl-pyrido[2, 3-b]pyrazin-6-yl)- harnstoff]-butyl esterCompound 39 Carbonic acid methyl ester 4- [3- (3-phenylpyrido [2,3-b] pyrazine-6-yl) -urea] -butyl ester
Verbindung 40 Kohlensäure 2,2-dimethyl-[1 ,3]dioxolan-4-ylmethyl ester 4-[3-(3- phenyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff]-butyl ester Compound 40 Carbonic acid 2,2-dimethyl- [1,3] dioxolan-4-ylmethyl ester 4- [3- (3-phenyl-pyrido [2,3-b] pyrazine-6-yl) -urea] -butyl ester
Verbindung 41 Kohlensäure 2, 3-dihydroxy-propylester 4-[3-(3-phenyl-pyrido[2, 3- b]pyrazin-6-yl)-harnstoff]-butyl esterCompound 41 Carbonic acid 2, 3-dihydroxy-propyl ester 4- [3- (3-phenylpyrido [2,3-b] pyrazine-6-yl) -urea] -butyl ester
Verbindung 42 {4-[3-(3-Phenyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff]-butyl}- phosphorsäure diethyl esterCompound 42 diethyl {4- [3- (3-phenyl-pyrido [2,3-b] pyrazine-6-yl) -urea] -butyl} -phosphoric acid
Verbindung 43 {4-[3-(3-Phenyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff]-butyl}- phosphorsäureCompound 43 {4- [3- (3-phenyl-pyrido [2,3-b] pyrazine-6-yl) -urea] -butyl} -phosphoric acid
Verbindung 44 (4-{3-[3-(4-Hydroxy-3-methoxy-phenyl)-pyrido[2,3-b]pyrazin-6-yl]- harnstoff}-butyl)-phosphorsäure diethyl esterCompound 44 (4- {3- [3- (4-Hydroxy-3-methoxy-phenyl) -pyrido [2,3-b] pyrazine-6-yl] -urea} -butyl) -phosphoric acid diethyl ester
Verbindung 45 (4-{3-[3-(4-Hydroxy-3-methoxy-phenyl)-pyrido[2,3-b]pyrazin-6-yl]- harnstoff}-butyl)-phosphorsäure Compound 45 (4- {3- [3- (4-Hydroxy-3-methoxy-phenyl) -pyrido [2,3-b] pyrazine-6-yl] -urea} -butyl) -phosphoric acid
Verbindung 46 1-Ethyl-3-[3-(3-tπmethylsilanyl-phenyl)-pyrido[2,3-b]pyrazin-6-yl]- HarnstoffCompound 46 1-Ethyl-3- [3- (3-t-methylsilanyl-phenyl) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 47 1-[3-(4-Cyclohexyl-phenylamino)-pyrido[2,3-b]pyrazin-6-yl]-3-ethyl- HarnstoffCompound 47 1- [3- (4-Cyclohexyl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -3-ethyl-urea
Verbindung 48 1-Ethyl-3-[3-(4-methanesulfonyl-phenylamino)-pyrido[2,3-b]pyrazin- 6-yl]-HarnstoffCompound 48 1-Ethyl-3- [3- (4-methanesulfonyl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 49 N-{5-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-ylamino]-2-methyl- phenyl}-methanesulfonamideCompound 49 N- {5- [6- (3-Ethyl-urea) -pyrido [2,3-b] pyrazine-3-ylamino] -2-methyl-phenyl} -methanesulfonamide
Verbindung 50 3-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-ylamino]-N-methyl- benzamide Compound 50 3- [6- (3-Ethyl-urea) -pyrido [2,3-b] pyrazine-3-ylamino] -N-methyl-benzamide
Verbindung 51 1-Ethyl-3-[3-(4-piperidin-1-ylmethyl-phenylamino)-pyrido[2,3- b]pyrazin-6-yl]-HarnstoffCompound 51 1-Ethyl-3- [3- (4-piperidin-1-ylmethyl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 52 1-Ethyl-3-[3-(4-thiophen-3-yl-phenylamino)-pyrido[2,3-b]pyrazin-6- yl]-HarnstoffCompound 52 1-Ethyl-3- [3- (4-thiophen-3-yl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 53 N-{4-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-ylamino]-phenyl}- acetamideCompound 53 N- {4- [6- (3-Ethyl-urea) -pyrido [2,3-b] pyrazine-3-ylamino] -phenyl} -acetamide
Verbindung 54 3-[6-(3-Ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-ylamino]-benzoesäure ethyl esterCompound 54 3- [6- (3-Ethyl-urea) -pyrido [2,3-b] pyrazine-3-ylamino] -benzoic acid ethyl ester
Verbindung 55 Kohlensäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl ester 2-methoxy-ethyl ester hydrochloride Compound 55 Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazine-3-yl] -phenyl ester 2-methoxy-ethyl ester hydrochloride
Verbindung 56 Kohlensäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-phenyl ester 2-methoxy-ethyl ester p-toluolsulfonatCompound 56 Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -phenyl ester 2-methoxy-ethyl ester p-toluenesulfonate
Verbindung 57 Kohlensäure 4-{6-[3-(4-hydroxy-butyl)-harnstoff]-pyrido[2,3- b]pyrazin-3-yl}-phenyl ester 2-methoxy-ethyl esterCompound 57 Carbonic acid 4- {6- [3- (4-hydroxy-butyl) -urea] -pyrido [2,3-b] pyrazin-3-yl} -phenyl ester 2-methoxy-ethyl ester
Verbindung 58 Kohlensäure 4-{6-[3-(4-hydroxy-butyl)-harnstoff]-pyrido[2, 3- b]pyrazin-3-yl}-phenyl ester 2-methoxy-ethyl ester hydrochlorideCompound 58 Carbonic acid 4- {6- [3- (4-hydroxy-butyl) -urea] -pyrido [2,3-b] pyrazine-3-yl} -phenyl ester 2-methoxy-ethyl ester hydrochloride
Verbindung 59 N-(3-Phenyl-pyrido[2,3-b]pyrazin-6-yl)-oxalsäure monoamid ethyl ester Compound 59 N- (3-Phenyl-pyrido [2,3-b] pyrazine-6-yl) -oxamide monoamide ethyl ester
Verbindung 60 N-Ethyl-N'-(3-phenyl-pyrido[2,3-b]pyrazin-6-yl)-oxalamidCompound 60 N-ethyl-N '- (3-phenylpyrido [2,3-b] pyrazine-6-yl) -oxalamide
Verbindung 61Connection 61
Verbindung 62 {2-[3-(3-Phenyl-pyrido[2,3-b]pyrazn-6-yl)-harnstoff]-ethyl}- phosphorsäure diethyl esterCompound 62 Diethyl {2- [3- (3-phenyl-pyrido [2,3-b] -pyrazn-6-yl) -urea] -ethyl} -phosphoric acid
Verbindung 63 {2-[3-(3-Phenyl-pyrido[2,3-b]pyrazin-6-yl)-harnstoff]-ethyl}- phosphorsäureCompound 63 {2- [3- (3-phenyl-pyrido [2,3-b] pyrazine-6-yl) -urea] -ethyl} -phosphoric acid
Verbindung 64 1-[3-(2-Diethylamino-ethoxy)-propyl]-3-[3-(4-hydroxy-3-methoxy- phenyl)-pyrido[2,3-b]pyrazin-6-yl]-Harnstoff Compound 64 1- [3- (2-diethylamino-ethoxy) -propyl] -3- [3- (4-hydroxy-3-methoxyphenyl) -pyrido [2,3-b] pyrazine-6-yl] - urea
Verbindung 65 2,2-Dimethyl-propansäure (2,2-dimethyl-propionyloxymethoxy)-(4-{3- [3-(4-hydroxy-3-methoxy-phenyl)-pyrido[2,3-b]pyrazin-6-yl]-harnstoff}-butyl)- phosphinoyloxymethyl esterCompound 65 2,2-Dimethyl-propanoic acid (2,2-dimethyl-propionyloxymethoxy) - (4- {3- [3- (4-hydroxy-3-methoxyphenyl) -pyrido [2,3-b] pyrazine] 6-yl] -urea} -butyl) - phosphinoyloxymethyl ester
Verbindung 66 Essigsäure 1-[(1-acetoxy-ethoxy)-(4-{3-[3-(4-hydroxy-3-methoxy- phenyl)-pyrido[2,3-b]pyrazin-6-yl]-harnstoff}-butyl)-phosphinoyloxy]-ethyl esterCompound 66 acetic acid 1 - [(1-acetoxy-ethoxy) - (4- {3- [3- (4-hydroxy-3-methoxyphenyl) -pyrido [2,3-b] pyrazine-6-yl] - urea} -butyl) -phosphinoyloxy] -ethyl ester
Verbindung 67 Diethyl-carbaminsäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin- 3-yl]2-methoxy-phenyl esterCompound 67 Diethylcarbamic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] 2-methoxyphenyl ester
Verbindung 68 Diethyl-carbaminsäure 2-chloro-4-[6-(3-ethyl-harnstoff)-pyrido[2,3- b]pyrazin-3-yl]-6-methoxy-phenyl ester Compound 68 diethylcarbamic acid 2-chloro-4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -6-methoxy-phenyl ester
Verbindung 69 Kohlensäure 4-[6-(3-ethyl-harnstoff)-pyrido[2,3-b]pyrazin-3-yl]-2- methoxy-phenyl ester 2-[2-(2-methoxy-ethoxy)-ethoxy]-ethyl esterCompound 69 Carbonic acid 4- [6- (3-ethyl-urea) -pyrido [2,3-b] pyrazin-3-yl] -2-methoxyphenyl ester 2- [2- (2-methoxyethoxy) - ethoxy] -ethyl ester
Verbindung 70 1-Ethyl-3-{3-[4-(morpholine-4-sulfonyl)-phenylamino]-pyrido[2,3- b]pyrazin-6-yl}-harnstoffCompound 70 1-Ethyl-3- {3- [4- (morpholine-4-sulfonyl) -phenylamino] -pyrido [2,3-b] pyrazine-6-yl} -urea
Verbindung 71 5-[6-(3-Ethyl-ureido)-pyrido[2,3-b]pyrazin-3-ylamino]-2-hydroxy- benzoesäureethylesterCompound 71 Ethyl 5- [6- (3-ethyl-ureido) -pyrido [2,3-b] pyrazine-3-ylamino] -2-hydroxybenzoate
Verbindung 72 1-[3-(3-Diethylaminomethyl-4-hydroxy-phenylamino)-pyrido[2,3- b]pyrazin-6-yl]-3-ethyl-harnstoffCompound 72 1- [3- (3-diethylaminomethyl-4-hydroxy-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -3-ethyl-urea
Verbindung 73 1-Ethyl-3-[3-(6-morpholin-4-yl-pyridin-3-ylamino)-pyrido[2,3- b]pyrazin-6-yl]-harnstoff Compound 73 1-Ethyl-3- [3- (6-morpholin-4-yl-pyridin-3-ylamino) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 74 1-Ethyl-3-{3-[3-(1 H-tetrazol-5-yl)-phenylamino]-pyrido[2,3-b]pyrazin- 6-yl}-harnstoffCompound 74 1-Ethyl-3- {3- [3- (1H-tetrazol-5-yl) -phenylamino] -pyrido [2,3-b] pyrazine-6-yl} -urea
Verbindung 75 1-Ethyl-3-[3-(3-morpholin-4-yl-phenylamino)-pyrido[2,3-b]pyrazin-6- yl]-harnstoffCompound 75 1-Ethyl-3- [3- (3-morpholin-4-yl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 76 1-Ethyl-3-[3-(4-imidazol-1-yl-phenylamino)-pyrido[2,3-b]pyrazin-6-yl]- harn stoffCompound 76 1-Ethyl-3- [3- (4-imidazol-1-yl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 77 1-Ethyl-3-[3-(4-pyrrolidin-1-yl-phenylamino)-pyrido[2,3-b]pyrazin-6- yl]-harnstoffCompound 77 1-Ethyl-3- [3- (4-pyrrolidin-1-yl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 78 1-Ethyl-3-{3-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrido[2,3- b]pyrazin-6-yl}-harnstoff Compound 78 1-Ethyl-3- {3- [4- (4-methyl-piperazin-1-yl) -phenylamino] -pyrido [2,3-b] pyrazine-6-yl} -urea
Verbindung 79 1-Ethyl-3-[3-(3-piperidin-1-ylmethyl-phenylamino)-pyrido[2,3- b]pyrazin-6-yl]-harnstoffCompound 79 1-Ethyl-3- [3- (3-piperidin-1-ylmethyl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 80 1-Ethyl-3-[3-(4-morpholin-4-ylmethyl-phenylamino)-pyrido[2,3- b]pyrazin-6-yl]-harnstoffCompound 80 1-Ethyl-3- [3- (4-morpholin-4-ylmethyl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 81 1-{3-[3-(2-Cyclohexyl-ethoxy)-phenylamino]-pyrido[2,3-b]pyrazin-6- yl}-3-ethyl-harnstoffCompound 81 1- {3- [3- (2-Cyclohexylethoxy) -phenylamino] -pyrido [2,3-b] pyrazine-6-yl} -3-ethyl-urea
Verbindung 82 1-Ethyl-3-[3-(3-[1 ,2,4]triazol-1-ylmethyl-phenylamino)-pyrido[2,3- b]pyrazin-6-yl]-harnstoffCompound 82 1-Ethyl-3- [3- (3- [1,2,4] triazol-1-ylmethyl-phenylamino) -pyrido [2,3-b] pyrazine-6-yl] -urea
Verbindung 83 Carbonic acid 2,2-dimethyl-[1 ,3]dioxolan-4-ylmethyl ester 4-{3-[3-(4- hydroxy-3-methoxy-phenyl)-pyrido[2,3-b]pyrazin-6-yl]-ureido}-butyl ester Compound 83 Carbonic acid 2,2-dimethyl- [1,3] dioxolan-4-ylmethyl ester 4- {3- [3- (4-hydroxy-3-methoxyphenyl) -pyrido [2,3-b] pyrazine -6-yl] -ureido} -butyl ester
Verbindung 84 Carbonic acid 2,3-dihydroxy-propylester 4-{3-[3-(4-hydroxy-3- methoxy-phenyl)-pyrido[2,3-b]pyrazin-6-yl]-ureido}-butyl esterCompound 84 Carbonic acid 2,3-dihydroxy-propyl ester 4- {3- [3- (4-hydroxy-3-methoxy-phenyl) -pyrido [2,3-b] pyrazin-6-yl] -ureido} -butyl ester
Verbindung 85 1-[3-(2-Diethylamino-ethoxy)-propyl]-3-[3-(4-hydroxy-3-methoxy- phenyl)-pyrido[2,3-b]pyrazin-6-yl]-ureaCompound 85 1- [3- (2-diethylamino-ethoxy) -propyl] -3- [3- (4-hydroxy-3-methoxyphenyl) -pyrido [2,3-b] pyrazine-6-yl] - urea
21. Arzneimittel, enthaltend mindestens ein Pyrido[2,3-b]pyrazin-Derivat gemäß einem der Ansprüche 1 bis 20.21. A pharmaceutical composition containing at least one pyrido [2,3-b] pyrazine derivative according to any one of claims 1 to 20.
22. Arzneimittel gemäß Anspruch 21 , enthaltend das Pyrido[2,3-b]pyrazin-Derivat in Kombination mit mindestens einem weiteren pharmazeutischen Wirkstoff und/oder pharmazeutisch akzeptablen Träger- und/oder Hilfsstoffen.22. Medicament according to claim 21, containing the pyrido [2,3-b] pyrazine derivative in combination with at least one further pharmaceutical active ingredient and / or pharmaceutically acceptable excipients and / or adjuvants.
23. Verfahren zur Herstellung eines Arzneimittels nach einem der Ansprüche 21 bis 22, dadurch gekennzeichnet, daß ein oder mehrere Pyrido[2,3-b]pyrazin-Derivate gemäß einem der Ansprüche 1 bis 20 mit pharmazeutisch akzeptablen Träger- und/oder Hilfsstoffen zu pharmazeutischen Zubereitungen verarbeitet, beziehungsweise in eine therapeutisch anwendbare Form gebracht werden. 23. A process for the preparation of a medicament according to any one of claims 21 to 22, characterized in that one or more pyrido [2,3-b] pyrazine derivatives according to any one of claims 1 to 20 with pharmaceutically acceptable carriers and / or excipients to processed pharmaceutical preparations, or be brought into a therapeutically applicable form.
24. Verbindung gemäß einem der Ansprüche 1 bis 20 zur Verwendung als pharmazeutisches Mittel.A compound according to any one of claims 1 to 20 for use as a pharmaceutical agent.
25. Verwendung einer Verbindung gemäß einem der Ansprüche 1 bis 20 zur Herstellung eines Arzneimittels zur Modulation von fehlgeleiteten zellulären Signaltrans- duktionsprozessen, insbesondere zur Beeinflussung der Funktion von aktiven und inaktiven Rezeptor-Tyrosin-kinasen, sowie cytoplasmatischen Tyrosin-, Se- rin/Threonin- und Lipidkinasen, wie c-Raf, B-Raf, Mek, MAPKs, PDGFRbeta, Flt-3, IGF1 R, PI3K, PKB/Akt1 , c-Kit, c-Abl, FGFR1 und KDR.25. Use of a compound according to one of claims 1 to 20 for the production of a medicament for modulating misdirected cellular signal transduction processes, in particular for influencing the function of active and inactive receptor tyrosine kinases, and cytoplasmic tyrosine, serine / threonine and lipid kinases such as c-Raf, B-Raf, Mek, MAPKs, PDGFRbeta, Flt-3, IGF1R, PI3K, PKB / Akt1, c-Kit, c-Abl, FGFR1 and KDR.
26. Verwendung einer Verbindung gemäß einem der Ansprüche 1 bis 20 zur Herstellung eines Arzneimittels zur Behandlung oder Prophylaxe von durch Signaltrans- duktionswege ausgewählt aus der Gruppe bestehend aus: „ras-Raf-Mek-Erk- Signaltransduktionsweg, PI3K-Akt-Signaltransduktionsweg und/oder SAPK-26. Use of a compound according to claim 1 for the preparation of a medicament for the treatment or prophylaxis of signal transduction pathways selected from the group consisting of: ras ras Mek-Erk signal transduction pathway, PI3K-Akt signal transduction pathway and / or or SAPK
Signaltransduktionsweg" vermittelten physiologischen und/oder pathophysiologi- schen Zuständen in Säugetieren.Signal transduction pathway "mediated physiological and / or pathophysiological conditions in mammals.
27. Verwendung einer Verbindung gemäß einem der Ansprüche 1 bis 20, 26, wobei die Behandlung oder Prophylaxe durch Modulation des oder der Signaltransdukti- onswege ausgewählt aus der Gruppe bestehend aus: „ras-Raf-Mek-Erk- Signaltransduktionsweg, PI3K-Akt-Signaltransduktionsweg und/oder SAPK- Signaltransduktionsweg" bewirkt wird.27. Use of a compound according to any one of claims 1 to 20, 26, wherein the treatment or prophylaxis by modulation of the signal transduction pathways selected from the group consisting of: "ras-Raf-Mek-Erk signal transduction pathway, PI3K Akt- Signal transduction pathway and / or SAPK signal transduction path "is effected.
28. Verwendung gemäß einem der Ansprüche 1 bis 20, 26, wobei die physiologischen und/oder pathophysiologischen Zustände durch Enzyme ausgewählt aus der Gruppe bestehend aus: „ATM, ATR, mTOR, DNA-PK, hSMG-1 " vermittelt werden.28. Use according to any one of claims 1 to 20, 26, wherein the physiological and / or pathophysiological conditions are mediated by enzymes selected from the group consisting of: "ATM, ATR, mTOR, DNA-PK, hSMG-1".
29. Verwendung gemäß einem der Ansprüche 1 bis 20, 26, 28, wobei die Behandlung oder Prophylaxe durch Modulation eines oder mehrerer Enzyme ausgewählt aus der Gruppe bestehend aus: „ATM, ATR, mTOR, DNA-PK, hSMG-1 " bewirkt wird. 29. Use according to any one of claims 1 to 20, 26, 28, wherein the treatment or prophylaxis is effected by modulation of one or more enzymes selected from the group consisting of: "ATM, ATR, mTOR, DNA-PK, hSMG-1" ,
30. Verwendung gemäß einem der Ansprüche 1 bis 20, 26, 27, wobei die vermittelnden und/oder modulierten Signaltransduktionswege der ras-Raf-Mek-Erk- Signaltransduktionsweg und der PI3K-Akt-Signaltransduktionsweg sind.Use according to any one of claims 1 to 20, 26, 27, wherein the mediating and / or modulated signal transduction pathways are the ras Raf-Mek-Erk signal transduction pathway and the PI3K-Akt signal transduction pathway.
31. Verwendung gemäß einem der Ansprüche 1 bis 20, 26, 27, wobei der vermittelnde und/oder modulierte Signaltransduktionsweg der ras-Raf-Mek-Erk- Signaltransduktionsweg ist.Use according to any one of claims 1 to 20, 26, 27, wherein the mediating and / or modulated signal transduction pathway is the ras Raf-Mek-Erk signal transduction pathway.
32. Verwendung gemäß einem der Ansprüche 1 bis 20, 26, 27, wobei der vermittelnde und/oder modulierte Signaltransduktionsweg der PI3K-Akt-Signaltransduktionsweg ist.Use according to any one of claims 1 to 20, 26, 27, wherein the mediating and / or modulated signal transduction pathway is the PI3K-Akt signal transduction pathway.
33. Verwendung gemäß einem der Ansprüche 1 bis 20, 26, 27, wobei die vermittelnden und/oder modulierten Signaltransduktionswege der SAPK- Signaltransduktionsweg und der PI3K-Akt-Signaltransduktionsweg sind.Use according to any one of claims 1 to 20, 26, 27, wherein the mediating and / or modulated signal transduction pathways are the SAPK signal transduction pathway and the PI3K-Akt signal transduction pathway.
34. Verwendung gemäß einem der Ansprüche 1 bis 20, 26, 27, wobei der vermittelnde und/oder modulierte Signaltransduktionsweg der SAPK-Signaltransduktionsweg ist.The use according to any one of claims 1 to 20, 26, 27, wherein the mediating and / or modulated signal transduction pathway is the SAPK signal transduction pathway.
35. Verwendung gemäß einem der Ansprüche 1 bis 20, 26, 27, 30, 31 , wobei die Modulation des ras-Raf-Mek-Erk-Signaltransduktionsweges bewirkt wird durch Modulation eines oder mehrerer Enzyme ausgewählt aus der Gruppe bestehend aus: „Tyrosinkinase, Serin/Threoninkinase, Rezeptor-Tyrosinkinase, cytoplasmatische Tyrosinkinase, cytoplasmatische Serin/Threoninkinase".35. Use according to any one of claims 1 to 20, 26, 27, 30, 31, wherein the modulation of the ras Raf-Mek-Erk signal transduction pathway is effected by modulation of one or more enzymes selected from the group consisting of: "tyrosine kinase, Serine / threonine kinase, receptor tyrosine kinase, cytoplasmic tyrosine kinase, cytoplasmic serine / threonine kinase ".
36. Verwendung gemäß Anspruch 35, wobei das Enzym ausgewählt ist aus der Gruppe bestehend aus: „Erk, Erk1 , Erk2".The use according to claim 35, wherein the enzyme is selected from the group consisting of: "Erk, Erk1, Erk2".
37. Verwendung gemäß einem der Ansprüche 1 bis 20, 26, 27, 30, 32, 33, wobei die Modulation des PI3K-Akt-Signaltransduktionsweges bewirkt wird durch Modulation eines oder mehrerer Enzyme ausgewählt aus der Gruppe bestehend aus: „PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K- Vps34p".37. Use according to any one of claims 1 to 20, 26, 27, 30, 32, 33, wherein the modulation of the PI3K-Akt signal transduction pathway is effected by modulation of one or more enzymes selected from the group consisting of: "PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3KVps34p ".
38. Verwendung gemäß einem der Ansprüche 1 bis 20, 26, 27, 33, 34, wobei die Mo- dulation des SAPK-Signaltransduktionsweges bewirkt wird durch Modulation eines oder mehrerer Enzyme ausgewählt aus der Gruppe bestehend aus: „Tyrosinkinase, Serin/Threoninkinase, Rezeptor-Tyrosinkinase, cytoplasmatische Tyrosinkinase, cytoplasmatische Serin/Threoninkinase"38. Use according to any one of claims 1 to 20, 26, 27, 33, 34, wherein the modulation of the SAPK signal transduction pathway is effected by modulation of one or more enzymes selected from the group consisting of: "tyrosine kinase, serine / threonine kinase, Receptor Tyrosine Kinase, Cytoplasmic Tyrosine Kinase, Cytoplasmic Serine / Threonine Kinase
39. Verwendung gemäß Anspruch 38, wobei das Enzym ausgewählt ist aus der Gruppe bestehend aus: „Jnk, Jnk1 , Jnk2, Jnk3, p38, p38alpha, p38beta, p38gamma, p38delta".39. Use according to claim 38, wherein the enzyme is selected from the group consisting of: "Jnk, Jnk1, Jnk2, Jnk3, p38, p38alpha, p38beta, p38gamma, p38delta".
40. Verwendung gemäß einem der Ansprüche 1 bis 20, 25 bis 39, wobei zwei oder mehrere Enzyme moduliert werden.40. Use according to any one of claims 1 to 20, 25 to 39, wherein two or more enzymes are modulated.
41. Verwendung gemäß Anspruch 40, wobei mindestens ein Enzym ausgewählt ist aus der Gruppe bestehend aus: "Erk, Erk1 , Erk2" und mindestens ein Enzym ausgewählt ist aus der Gruppe bestehend aus: „PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34p".41. Use according to claim 40, wherein at least one enzyme is selected from the group consisting of: "Erk, Erk1, Erk2" and at least one enzyme is selected from the group consisting of: "PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K -C2alpha, PI3K-C2beta, PI3K-Vps34p ".
42. Verwendung gemäß Anspruch 40, wobei mindestens ein Enzym ausgewählt ist aus der Gruppe bestehend aus: "Jnk, Jnk1 , Jnk2, Jnk3, p38, p38alpha, p38beta, p38gamma, p38delta" und mindestens ein Enzym ausgewählt ist aus der Gruppe bestehend aus: „PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-42. Use according to claim 40, wherein at least one enzyme is selected from the group consisting of: "Jnk, Jnk1, Jnk2, Jnk3, p38, p38alpha, p38beta, p38gamma, p38delta" and at least one enzyme is selected from the group consisting of: "PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-
C2alpha, PI3K-C2beta, PI3K-Vps34p".C2alpha, PI3K-C2beta, PI3K-Vps34p ".
43. Verwendung gemäß Anspruch 40, wobei mindestens ein Enzym ausgewählt ist aus der Gruppe bestehend aus: "Erk, Erk1 , Erk2" und mindestens ein Enzym aus- gewählt ist aus der Gruppe bestehend aus: „ATM, ATR, mTOR, DNA-PK, hSMG-43. Use according to claim 40, wherein at least one enzyme is selected from the group consisting of: "Erk, Erk1, Erk2" and at least one enzyme is selected from the group consisting of: "ATM, ATR, mTOR, DNA-PK , hSMG-
1 ". 1 ".
44. Verwendung gemäß Anspruch 40, wobei mindestens ein Enzym ausgewählt ist aus der Gruppe bestehend aus: "Jnk, Jnk1 , Jnk2, Jnk3, p38, p38alpha, p38beta, p38gamma, p38delta" und mindestens ein Enzym ausgewählt ist aus der Gruppe bestehend aus: „ATM, ATR, mTOR, DNA-PK, hSMG-1".44. Use according to claim 40, wherein at least one enzyme is selected from the group consisting of: "Jnk, Jnk1, Jnk2, Jnk3, p38, p38alpha, p38beta, p38gamma, p38delta" and at least one enzyme is selected from the group consisting of: "ATM, ATR, mTOR, DNA-PK, hSMG-1".
45. Verwendung gemäß Anspruch 40, wobei mindestens ein Enzym ausgewählt ist aus der Gruppe bestehend aus: „PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34p" und mindestens ein Enzym ausgewählt ist aus der Gruppe bestehend aus: „ATM, ATR, mTOR, DNA-PK, hSMG-1 ".45. Use according to claim 40, wherein at least one enzyme is selected from the group consisting of: "PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34p" and at least one enzyme is selected from Group consisting of: "ATM, ATR, mTOR, DNA-PK, hSMG-1".
46. Verwendung gemäß einem der Ansprüche 1 bis 20, 25 bis 45, wobei die Modulation eine Inhibition ist.Use according to any one of claims 1 to 20, 25 to 45, wherein the modulation is an inhibition.
47. Verwendung gemäß einem der Ansprüche 1 bis 20, 26 bis 46, wobei das Säugetier ausgewählt ist aus der Gruppe bestehend aus: „Mensch, Nutztier, Vieh, Haustier, Rind, Kuh, Schaf, Schwein, Ziege, Pferd, Pony, Esel, Maulesel, Maultier, Hase, Kaninchen, Katze, Hund, Meerschweinchen, Hamster, Ratte, Maus" und bevorzugt ein Mensch ist.Use according to any one of claims 1 to 20, 26 to 46, wherein the mammal is selected from the group consisting of: "human, farm animal, livestock, domestic animal, bovine, cow, sheep, pig, goat, horse, pony, donkey , Mule, mule, rabbit, rabbit, cat, dog, guinea pig, hamster, rat, mouse "and prefers a human being.
48. Verwendung gemäß einem der Ansprüche 1 bis 20, 26 bis 47, wobei die physiologischen und/oder pathophysiologischen Zustände ausgewählt sind aus der Gruppe bestehend aus: „maligne Tumore, benigne Tumore, entzündliche Erkrankungen, Entzündungen, Schmerzen, rheumatische Erkrankungen, arthritische Erkrankungen, HIV Infektionen, neurologische oder neurodegenerative Erkrankungen, Rheuma,48. Use according to any one of claims 1 to 20, 26 to 47, wherein the physiological and / or pathophysiological conditions are selected from the group consisting of: "malignant tumors, benign tumors, inflammatory diseases, inflammation, pain, rheumatic diseases, arthritic diseases , HIV infections, neurological or neurodegenerative diseases, rheumatism,
Arthritis, AIDS, ARC (AIDS related complex), Kaposi-Sarkom, Tumore ausgehend vom Hirn und/oder Nervensystem und/oder Hirnhäuten, Demenz, Alzheimer, hyperproliferative Erkrankungen, Psoriasis, Endometriose, Narbenbildung, benigne Prostatahyperplasie (BPH), Erkrankungen des Immunsystems, Autoimmunerkran- kungen, Immundefizienzerkrankungen, Kolontumor, Magentumor, Darmtumor, Lungentumor, Pankreastumor, Ovarialtumor, Prostatatumor, Leukämie, Melanom, Lebertumor, Nierentumor, Kopftumor, Halstumor, Gliom, Brust-Tumor, Gebärmutterkrebs, Endometriumkrebs, Gebärmutterhalskrebs, Hirntumor, Adenokanthom, Blasenkrebs, Magentumor, Kolorectalrumor, Speiseröhrenkrebs, gynokologischer Tu- mor, Ovartumor, Schilddrüsenkrebs, Lymphom, chronische Leukämie, akute Leukämie, Restenose, Diabetis, diabetische Nephropathie, fibrotische Erkrankungen, cystische Fibrose, maligne Nephrosklerose, thrombotische Microangiopathie Syndrom, Organtransplantat-Abstoßung, Glomerulpathien, Erkrankungen des Stoffwechsels, solide/feste Tumore, rheumatische Arthritis, diabetische Retinopathie, Asthma, Allergien, allergische Erkrankungen, chronische obstruktive pulmonare Erkrankungen, inflammatorische Bowel-Erkrankung, Fibrose, Atheriosklerose, Herzerkrankungen, car- diovaskuläre Erkrankungen, Erkrankungen des Herzmuskels, vaskuläre Erkrankungen, angiogenetische Erkrankungen, Nierenerkrankungen, Rhinitis, Grave Erkran- kung, fokale Ischemie, Herzversagen, Ischemie, kardische Hypertrophie, Nierenversagen, kardische Myozyten Fehlfunktion, Bluthochdruck, Vasoconstriktion, Schlaganfall, anaphylaktischer Schock, Blutplättchen-Verklumpung, Skelettmuskelatrophie, Fettleibigkeit, Übergewicht, Glukose Homeostase, kongestive Herzinsuffizienz, Angina, Herzanfall, Herzinfarkt, Hyperglykämie, Hypoglykämie, Hypertension".Arthritis, AIDS, ARC (AIDS related complex), Kaposi's sarcoma, tumors from the brain and / or nervous system and / or meninges, dementia, Alzheimer's disease, hyperproliferative disorders, psoriasis, endometriosis, scarring, benign prostate hyperplasia (BPH), immune system disorders , Autoimmune diseases, immunodeficiency diseases, colon tumor, gastric tumor, colon tumor, lung tumor, pancreatic tumor, ovarian tumor, prostate tumor, leukemia, melanoma, liver tumor, kidney tumor, head tumor, cervical tumor, glioma, breast tumor, uterine cancer, endometrial cancer, cervix cancer, brain tumor, adenocanthoma, bladder cancer , Gastric tumor, colorectal rumenor, esophageal cancer, gynocological tumor mor, ovarian tumor, thyroid cancer, lymphoma, chronic leukemia, acute leukemia, restenosis, diabetes, diabetic nephropathy, fibrotic diseases, cystic fibrosis, malignant nephrosclerosis, thrombotic microangiopathy syndrome, organ transplant rejection, glomerulopathies, metabolic disorders, solid / solid tumors, rheumatic Arthritis, diabetic retinopathy, asthma, allergies, allergic diseases, chronic obstructive pulmonary diseases, inflammatory bowel disease, fibrosis, atherosclerosis, heart diseases, cariodovascular diseases, diseases of the heart muscle, vascular diseases, angiogenic diseases, kidney diseases, rhinitis, Grave Disease kung, focal ischemia, heart failure, ischaemia, cardiac hypertrophy, renal failure, cardiac myocyte dysfunction, hypertension, vasoconstriction, stroke, anaphylactic shock, platelet aggregation, skeletal muscle atrophy, obesity, obesity, gluc Homeostasis, Congestive Heart Failure, Angina, Heart Attack, Heart Attack, Hyperglycemia, Hypoglycemia, Hypertension ".
49. Verwendung gemäß einem der Ansprüche 1 bis 22, 24, 26 bis 48, wobei das Arzneimittel mindestens eine weitere pharmakologisch aktive Substanz umfasst.49. Use according to any one of claims 1 to 22, 24, 26 to 48, wherein the medicament comprises at least one further pharmacologically active substance.
50. Verwendung gemäß einem der Ansprüche 1 bis 22, 24, 26 bis 48, wobei das Arz- neimittel vor und/oder während und/oder nach der Behandlung mit mindestens einer weiteren pharmakologisch aktiven Substanz verabreicht wird.50. Use according to any one of claims 1 to 22, 24, 26 to 48, wherein the medicament is administered before and / or during and / or after the treatment with at least one further pharmacologically active substance.
51. Verwendung gemäß einem der Ansprüche 1 bis 22, 24, 26 bis 48, wobei das Arzneimittel vor und/oder während und/oder nach der Behandlung mit Strahlenthera- pie und/oder Chirurgie verabreicht wird.51. Use according to any one of claims 1 to 22, 24, 26 to 48, wherein the drug is administered before and / or during and / or after treatment with radiation therapy and / or surgery.
52. Verwendung gemäß einem der Ansprüche 49 bis 50, wobei die weitere pharmakologisch aktive Substanz ausgewählt ist aus der Gruppe bestehend aus: "DNA To- poisomerase I und/oder Il Inhibitoren, DNA Interkalatoren, alkylierende Agentien, Microtubuli Destabilisatoren, Hormon- und/oder Wachstumsfaktor-Rezeptor-52. Use according to any one of claims 49 to 50, wherein the further pharmacologically active substance is selected from the group consisting of: "DNA to poisomerase I and / or II inhibitors, DNA intercalators, alkylating agents, microtubule destabilizers, hormone and / or growth factor receptor
Agonisten und/oder -Antagonisten, Antikörper gegen Wachstumsfaktoren und deren Rezeptoren, Kinase Inhibitoren, Antimetabolite". Agonists and / or antagonists, antibodies against growth factors and their receptors, kinase inhibitors, antimetabolites ".
53. Verwendung gemäß einem der Ansprüche 49, 50, 52, wobei die weitere pharmakologisch aktive Substanz ausgewählt ist aus der Gruppe bestehend aus: "Aspara- ginase, Bleomycin, Carboplatin, Carmustin, Chlorambucil, Cisplatin, Colaspase, Cyclophosphamid, Cytarabin, Dacarbazin, Dactinomycin, Daunorubicin, Doxorubi- cin(Adriamycin), Epirubicin, Etoposide, 5-Fluorouracil, Hexamethylmelamin,53. Use according to any one of claims 49, 50, 52, wherein the further pharmacologically active substance is selected from the group consisting of: "asparaginase, bleomycin, carboplatin, carmustine, chlorambucil, cisplatin, colaspase, cyclophosphamide, cytarabine, dacarbazine, Dactinomycin, daunorubicin, doxorubicin (adriamycin), epirubicin, etoposide, 5-fluorouracil, hexamethylmelamine,
Hydroxharnstoff, Ifosfamid, Irinotecan, Leucovorin, Lomustin, Mechlorethamin,6- Mercaptopurin, Mesna, Methotrexat, Mitomycin C, Mitoxantrone, Prednisolon, Prednison, Procarbazin, Raloxifen, Streptozocin, Tamoxifen, Thioguanin, Topote- can, Vinblastin, Vincristin, Vindesin, Aminoglutethimid, L-Asparaginase, Azathi- oprin, 5-Azacytidin cladribin, Busulfan, Diethylstilbestrol, 2', 2'-Difluorodeoxycytidin,Hydroxurea, ifosfamide, irinotecan, leucovorin, lomustine, mechlorethamine, 6-mercaptopurine, mesna, methotrexate, mitomycin C, mitoxantrone, prednisolone, prednisone, procarbazine, raloxifene, streptozocin, tamoxifen, thioguanine, topotecan, vinblastine, vincristine, vindesine, aminoglutethimide , L-asparaginase, azathioprine, 5-azacytidine cladribine, busulfan, diethylstilbestrol, 2 ', 2'-difluorodeoxycytidine,
Docetaxel, Erythrohydroxynonyladenin, Ethinylestradiol, 5-Fluorodeoxyuridin, 5- Fluorodeoxyuridin Monophosphat, Fludarabin Phosphate, Fluoxymesteron, Fluta- mid, Hydroxyprogesteron Caproat, Idarubicin, Interferon, Medroxyprogesteron Ace- tat, Megestrol Acetat, Melphalan, Mitotan, Paclitaxel, Oxaliplatin, Pentostatin, N- Phosphonoacetyl-L-aspartat (PALA), Plicamycin, Semustin, Teniposide, Testosteron Propionat, Thiotepa, Trimethylmelamin, Uridine, Vinorelbin, Epothilon, Gemcitabin, Taxotere, BCNU, CCNU, DTIC, 5-Fluorouarcil, Herceptin, Avastin, Erbitux, Sorafenib, Gleevec, Iressa, Tarceva, Rapamycin, Actinomycin D".Docetaxel, erythrohydroxynonyladenine, ethinyl estradiol, 5-fluorodeoxyuridine, 5-fluorodeoxyuridine monophosphate, fludarabine phosphates, fluoxymesterone, flutamide, hydroxyprogesterone caproate, idarubicin, interferon, medroxyprogesterone acetate, megestrol acetate, melphalan, mitotane, paclitaxel, oxaliplatin, pentostatin, N - phosphonoacetyl-L-aspartate (PALA), plicamycin, semustine, teniposide, testosterone propionate, thiotepa, trimethylmelamine, uridines, vinorelbine, epothilone, gemcitabine, taxotere, BCNU, CCNU, DTIC, 5-fluorouracil, Herceptin, Avastin, Erbitux, sorafenib , Gleevec, Iressa, Tarceva, Rapamycin, Actinomycin D ".
54. Pharmazeutische Zusammensetzung, die eine pharmakologisch aktive Menge mindestens einer Verbindung gemäß einem der Ansprüche 1 bis 20 umfasst.54. A pharmaceutical composition comprising a pharmacologically active amount of at least one compound according to any one of claims 1 to 20.
55. Pharmazeutische Zusammensetzung gemäß Anspruch 54, wobei der Wirkstoff in einer Einheitsdosis von 0,001 mg bis 100 mg pro kg Körpergewicht eines Patienten vorliegt.55. The pharmaceutical composition according to claim 54, wherein the active ingredient is present in a unit dose of 0.001 mg to 100 mg per kg body weight of a patient.
56. Pharmazeutische Zusammensetzung gemäß einem der Ansprüche 54 bis 55, wobei die Zusammensetzung weiterhin mindestens einen pharmazeutisch verträglichen Trägerstoff und/oder Hilfsstoff enthält.56. The pharmaceutical composition according to any one of claims 54 to 55, wherein the composition further contains at least one pharmaceutically acceptable carrier and / or excipient.
57. Pharmazeutische Zusammensetzung gemäß einem der Ansprüche 54 bis 56, wobei die Zusammensetzung mindestens einen weiteren pharmakologisch aktiven Wirkstoff enthält. 57. The pharmaceutical composition according to any one of claims 54 to 56, wherein the composition contains at least one further pharmacologically active ingredient.
58. Pharmazeutische Zusammensetzung gemäß Anspruch 57, wobei die weitere pharmakologisch aktive Substanz ausgewählt ist aus der Gruppe bestehend aus: "DNA Topoisomerase I und/oder Il Inhibitoren, DNA Interkalatoren, alkylierende Agen- tien, Microtubuli Destabilisatoren, Hormon- und/oder Wachstumsfaktor-Rezeptor- Agonisten und/oder -Antagonisten, Antikörper gegen Wachstumsfaktoren und deren Rezeptoren, Kinase Inhibitoren, Antimetabolite".58. The pharmaceutical composition according to claim 57, wherein the further pharmacologically active substance is selected from the group consisting of: "DNA topoisomerase I and / or II inhibitors, DNA intercalators, alkylating agents, microtubule destabilizers, hormone and / or growth factor Receptor agonists and / or antagonists, antibodies to growth factors and their receptors, kinase inhibitors, antimetabolites ".
59. Pharmazeutische Zusammensetzung gemäß einem der Ansprüche 57 bis 58, wobei der weitere pharmakologisch aktive Wirkstoff ausgewählt ist aus der Gruppe bestehend aus: „Asparaginase, Bleomycin, Carboplatin, Carmustin, Chlorambucil,59. A pharmaceutical composition according to any one of claims 57 to 58, wherein the further pharmacologically active ingredient is selected from the group consisting of: "asparaginase, bleomycin, carboplatin, carmustine, chlorambucil,
Cisplatin, Colaspase, Cyclophosphamid, Cytarabin, Dacarbazin, Dactinomycin, Daunorubicin, Doxorubicin(Adriamycin), Epirubicin, Etoposide, 5-Fluorouracil, He- xamethylmelamin, Hydroxharnstoff, Ifosfamid, Irinotecan, Leucovorin, Lomustin, Mechlorethamin,6-Mercaptopurin, Mesna, Methotrexat, Mitomycin C, Mitoxantrone, Prednisolon, Prednison, Procarbazin, Raloxifen, Streptozocin, Tamoxifen, Thiogu- anin, Topotecan, Vinblastin, Vincristin, Vindesin, Aminoglutethimid, L- Asparaginase, Azathioprin, 5-Azacytidin cladribin, Busulfan, Diethylstilbestrol, 2', 2'-Difluorodeoxycytidin, Docetaxel, Erythrohydroxynonyladenin, Ethinylestradiol, 5- Fluorodeoxyuridin, 5- Fluorodeoxyuridin Monophosphat, Fludarabin Phosphate, Fluoxymesteron, Flutamid, Hydroxyprogesteron Caproat, Idarubicin, Interferon,Cisplatin, colaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, doxorubicin (adriamycin), epirubicin, etoposide, 5-fluorouracil, hexamethylmelamine, hydroxurea, ifosfamide, irinotecan, leucovorin, lomustine, mechlorethamine, 6-mercaptopurine, mesna, methotrexate , Mitomycin C, mitoxantrone, prednisolone, prednisone, procarbazine, raloxifene, streptozocin, tamoxifen, thioguanine, topotecan, vinblastine, vincristine, vindesine, aminoglutethimide, L-asparaginase, azathioprine, 5-azacytidine cladribine, busulfan, diethylstilbestrol, 2 ', 2'-Difluorodeoxycytidine, docetaxel, erythrohydroxynonyladenine, ethinylestradiol, 5-fluorodeoxyuridine, 5-fluorodeoxyuridine monophosphate, fludarabine phosphates, fluoxymesterone, flutamide, hydroxyprogesterone caproate, idarubicin, interferon,
Medroxyprogesteron Acetat, Megestrol Acetat, Melphalan, Mitotan, Paclitaxel, Oxaliplatin, Pentostatin, N-Phosphonoacetyl-L-aspartat (PALA), Plicamycin, Se- mustin, Teniposide, Testosteron Propionat, Thiotepa, Trimethylmelamin, Uridine, Vinorelbin, Epothilon, Gemcitabin, Taxotere, BCNU, CCNU, DTIC, 5-Fluorouarcil, Herceptin, Avastin, Erbitux, Sorafenib, Gleevec, Iressa, Tarceva, Rapamycin, Acti- nomycin D".Medroxyprogesterone Acetate, Megestrol Acetate, Melphalan, Mitotane, Paclitaxel, Oxaliplatin, Pentostatin, N-Phosphonoacetyl-L-Aspartate (PALA), Plicamycin, Sextin, Teniposide, Testosterone Propionate, Thiotepa, Trimethylmelamine, Uridines, Vinorelbine, Epothilone, Gemcitabine, Taxotere, BCNU, CCNU, DTIC, 5-Fluorouracil, Herceptin, Avastin, Erbitux, Sorafenib, Gleevec, Iressa, Tarceva, Rapamycin, Actinomycin D ".
60. Kit umfassend eine pharmakologisch aktive Menge mindestens einer Verbindung gemäß einem der Ansprüche 1 bis 20 und eine pharmakologisch aktive Menge mindestens eines weiteren pharmakologisch aktiven Wirkstoffs gemäß einem der60. A kit comprising a pharmacologically active amount of at least one compound according to any one of claims 1 to 20 and a pharmacologically active amount of at least one further pharmacologically active ingredient according to one of
Ansprüche 57 bis 59. Claims 57 to 59.
EP06819385A 2005-11-11 2006-11-10 Novel pyridopyrazines and their use as modulators of kinases Withdrawn EP1957487A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06819385A EP1957487A1 (en) 2005-11-11 2006-11-10 Novel pyridopyrazines and their use as modulators of kinases

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US73569805P 2005-11-11 2005-11-11
EP05024693A EP1785423A1 (en) 2005-11-11 2005-11-11 Pyridopyrazine derivatives and their use as kinase modulators
US84976106P 2006-10-06 2006-10-06
PCT/EP2006/068322 WO2007054556A1 (en) 2005-11-11 2006-11-10 Novel pyridopyrazines and their use as modulators of kinases
EP06819385A EP1957487A1 (en) 2005-11-11 2006-11-10 Novel pyridopyrazines and their use as modulators of kinases

Publications (1)

Publication Number Publication Date
EP1957487A1 true EP1957487A1 (en) 2008-08-20

Family

ID=37654792

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06819385A Withdrawn EP1957487A1 (en) 2005-11-11 2006-11-10 Novel pyridopyrazines and their use as modulators of kinases

Country Status (10)

Country Link
EP (1) EP1957487A1 (en)
JP (1) JP5527972B2 (en)
KR (1) KR101400905B1 (en)
AR (1) AR060010A1 (en)
AU (1) AU2006313701B2 (en)
CA (1) CA2628039A1 (en)
HK (1) HK1126474A1 (en)
IL (1) IL191139A0 (en)
NO (1) NO20082511L (en)
WO (1) WO2007054556A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790342A1 (en) * 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazine derivatives and their use as signal transduction modulators
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
EP1990342A1 (en) * 2007-05-10 2008-11-12 AEterna Zentaris GmbH Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
WO2009008991A2 (en) * 2007-07-06 2009-01-15 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Dna-pkcs modulates energy regulation and brain function
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
US8846723B2 (en) 2010-07-29 2014-09-30 Eastman Chemical Company Esters of O-substituted hydroxy carboxylic acids and preparations thereof
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2508184A1 (en) 2011-04-06 2012-10-10 Æterna Zentaris GmbH Pyridopyrazine derivatives and their use
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
JO3512B1 (en) 2014-03-26 2020-07-05 Astex Therapeutics Ltd Quinoxaline derivatives useful as fgfr kinase modulators
LT3122358T (en) 2014-03-26 2021-04-12 Astex Therapeutics Ltd. Combinations of fgfr- and cmet-inhibitors for the treatment of cancer
US10736900B2 (en) 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
JOP20200201A1 (en) 2015-02-10 2017-06-16 Astex Therapeutics Ltd Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
LT3353177T (en) 2015-09-23 2020-08-25 Janssen Pharmaceutica Nv Tricyclic heterocycles for the treatment of cancer
CA2996989C (en) 2015-09-23 2023-10-03 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007079999A2 (en) * 2005-11-11 2007-07-19 Æterna Zentaris Gmbh Pyridopyrazine derivatives and use thereof as modulators of the signal transduction paths

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3809695A (en) 1967-04-19 1974-05-07 Degussa 2,6-dichloro-3-nitro-pyridine
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
EP0735025B1 (en) 1995-03-28 1998-07-01 Sumitomo Chemical Company Limited Process for producing aminonitropyridines
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
ATE529109T1 (en) 1997-12-22 2011-11-15 Bayer Healthcare Llc INHIBITION OF P38 KINASE ACTIVITY BY SUBSTITUTED HETEROCYCLIC UREAS
HUP0104607A3 (en) 1998-12-15 2002-12-28 Warner Lambert Co Use of a mek inhibitor for preventing transplant rejection
AP2001002175A0 (en) 1998-12-22 2001-06-21 Warner Lambert Co Combination chemotherapy.
GEP20084317B (en) 2000-04-25 2008-02-25 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
IL153817A0 (en) 2000-07-19 2003-07-31 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
JP3795044B2 (en) 2001-09-14 2006-07-12 メシルジーン、インコーポレイテッド Inhibitors of histone deacetylase
AU2003210969A1 (en) 2002-02-11 2003-09-04 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
EP1496906A4 (en) 2002-04-08 2006-05-03 Merck & Co Inc Inhibitors of akt activity
EP1496981A2 (en) 2002-04-08 2005-01-19 Merck & Co., Inc. Method of treating cancer
AU2003223467B2 (en) 2002-04-08 2007-10-04 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US7718651B2 (en) 2002-07-02 2010-05-18 Southern Research Institute Inhibitors of FtsZ and uses thereof
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
ATE411992T1 (en) * 2003-05-23 2008-11-15 Fterna Zentaris Gmbh NEW PYRIDOPYRAZINE AND THEIR USE AS MODULATORS OF KINASES
DE10323345A1 (en) * 2003-05-23 2004-12-16 Zentaris Gmbh New pyridopyrazines and their use as kinase inhibitors
CA2526663C (en) * 2003-06-05 2011-07-19 Zentaris Gmbh Indole derivatives with apoptosis-inducing effect
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
AU2004297235A1 (en) 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007079999A2 (en) * 2005-11-11 2007-07-19 Æterna Zentaris Gmbh Pyridopyrazine derivatives and use thereof as modulators of the signal transduction paths

Also Published As

Publication number Publication date
JP5527972B2 (en) 2014-06-25
HK1126474A1 (en) 2009-09-04
CA2628039A1 (en) 2007-05-18
WO2007054556A1 (en) 2007-05-18
KR20080068117A (en) 2008-07-22
IL191139A0 (en) 2008-12-29
AU2006313701B2 (en) 2012-05-31
KR101400905B1 (en) 2014-05-29
AR060010A1 (en) 2008-05-21
JP2009515853A (en) 2009-04-16
AU2006313701A1 (en) 2007-05-18
NO20082511L (en) 2008-06-24

Similar Documents

Publication Publication Date Title
WO2007054556A1 (en) Novel pyridopyrazines and their use as modulators of kinases
US8217042B2 (en) Pyridopyrazines and their use as modulators of kinases
US11655246B2 (en) Aminothiazole compounds as inhibitors of CTPS1
JP6997766B2 (en) Modulator of integrated stress pathway
JP5805763B2 (en) Hepatitis C virus inhibitor
EP2504336B1 (en) Novel naphthyridine derivatives and the use thereof as kinase inhibitors
JP6145179B2 (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of Janus related kinase (JAK)
TWI475019B (en) Hepatitis c virus inhibitors
EP2788000B1 (en) Pyrrolopyrimidines as janus kinase inhibitors
JP6585158B2 (en) Pyrrolo [2,3-d] pyrimidine derivatives useful for the inhibition of Janus kinase
JP2021523225A (en) RIP1 inhibitor compound and methods for producing and using it
WO2018052967A1 (en) Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same
UA120382C2 (en) 1,3-thiazol-2-yl substituted benzamides
JP2022522526A (en) Protein tyrosine phosphatase inhibitor and its usage
TW200938549A (en) Compounds
KR20190026731A (en) A modulator of beta-3 adrenergic receptors useful for the treatment or prevention of disorders associated with beta-3 adrenergic receptors
JP2013515733A (en) Indolyl-piperidinylbenzylamine as a β-tryptase inhibitor
CN101356173B (en) Novel pyridopyrazines and their use as modulators of kinases
EP3328859B1 (en) 3-((4-isoquinolin-3-yl)methyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one derivatives and related compounds as inhibitors of replication of the respiratory syncytial virus (rsv)
EP3512849B1 (en) 7-substituted 1-aryl-naphthyridin-3-carboxamides and their use
RU2515944C9 (en) PYRIDOPYRAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING OR PREVENTING PHYSIOLOGICAL AND/OR PATHOPHYSIOLOGICAL CONDITIONS BY INHIBITION OF ENZYMES ERK, ERK1, ERK2, PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34p (VERSIONS)
TWI392675B (en) Novel pyridopyrazines and the use thereof as kinase modulators
TW202112773A (en) Compounds
MX2008006066A (en) Novel pyridopyrazines and their use as modulators of kinases
JP2012501993A (en) 6-Substituted benzoxazines as 5-TH-5A receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080506

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17Q First examination report despatched

Effective date: 20110913

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20150202